

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10011085	C4591001 1001 10011085	16-55	28JUL2020	40018	BNT162b2 (30 µg)	28JUL2020/ BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)		
10011086	C4591001 1001 10011086	16-55	28JUL2020	40021	Placebo	28JUL2020/ Placebo	18AUG2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10011087	C4591001 1001 10011087	16-55	28JUL2020	40032	BNT162b2 (30 µg)	28JUL2020/ BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)		
10011088	C4591001 1001 10011088	16-55	28JUL2020	40047	BNT162b2 (30 µg)	28JUL2020/ BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)		
10011089	C4591001 1001 10011089	16-55	28JUL2020	40070	BNT162b2 (30 µg)	28JUL2020/ BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)		
10011091	C4591001 1001 10011091	16-55	29JUL2020	40171	BNT162b2 (30 µg)	29JUL2020/ BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)		
10011092	C4591001 1001 10011092	16-55	29JUL2020	40172	Placebo	29JUL2020/ Placebo	19AUG2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10011095	C4591001 1001 10011095	16-55	29JUL2020	40178	BNT162b2 (30 µg)	29JUL2020/ BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)		
10011101	C4591001 1001 10011101	16-55	30JUL2020	40180	Placebo	30JUL2020/ Placebo	20AUG2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10011102	C4591001 1001 10011102	16-55	30JUL2020	40541	Placebo	30JUL2020/ Placebo	20AUG2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10031088	C4591001 1003 10031088	16-55	27JUL2020	40003	Placebo	27JUL2020/ Placebo	17AUG2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
10031090	C4591001 1003 10031090	16-55	27JUL2020	40006	BNT162b2 (30 µg)	27JUL2020/ BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)		
10031094	C4591001 1003 10031094	16-55	28JUL2020	40009	BNT162b2 (30 µg)	28JUL2020/ BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)		
10031096	C4591001 1003 10031096	16-55	28JUL2020	40013	BNT162b2 (30 µg)	28JUL2020/ BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)		
10031097	C4591001 1003 10031097	16-55	28JUL2020	40017	Placebo	28JUL2020/ Placebo	18AUG2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
10031100	C4591001 1003 10031100	16-55	28JUL2020	40037	Placebo	28JUL2020/ Placebo	18AUG2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10031101	C4591001 1003 10031101	16-55	28JUL2020	40043	Placebo	28JUL2020/ Placebo	18AUG2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
10031104	C4591001 1003 10031104	16-55	29JUL2020	40145	BNT162b2 (30 µg)	29JUL2020/ BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)		
10031111	C4591001 1003 10031111	16-55	30JUL2020	40149	Placebo	30JUL2020/ Placebo	20AUG2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10031115	C4591001 1003 10031115	16-55	30JUL2020	40151	BNT162b2 (30 µg)	30JUL2020/ BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10071080	C4591001 1007 10071080	16-55	28JUL2020	40012	Placebo	28JUL2020/ Placebo	19AUG2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
10071082	C4591001 1007 10071082	16-55	28JUL2020	40035	Placebo	28JUL2020/ Placebo	19AUG2020/ Placebo		
10071083	C4591001 1007 10071083	16-55	28JUL2020	40026	Placebo	28JUL2020/ Placebo	17AUG2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
10071087	C4591001 1007 10071087	16-55	29JUL2020	40111	Placebo	29JUL2020/ Placebo	19AUG2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
10071089	C4591001 1007 10071089	16-55	29JUL2020	40113	Placebo	29JUL2020/ Placebo	17AUG2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
10071092	C4591001 1007 10071092	16-55	29JUL2020	40117	BNT162b2 (30 µg)	29JUL2020/ BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)		
10071093	C4591001 1007 10071093	16-55	29JUL2020	40120	BNT162b2 (30 µg)	29JUL2020/ BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)		
10071095	C4591001 1007 10071095	16-55	30JUL2020	40422	Placebo	30JUL2020/ Placebo	17AUG2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
10071096	C4591001 1007 10071096	16-55	30JUL2020	40425	Placebo	30JUL2020/ Placebo	20AUG2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10071097	C4591001 1007 10071097	16-55	30JUL2020	40427	BNT162b2 (30 µg)	30JUL2020/ BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10071100	C4591001 1007 10071100	16-55	30JUL2020	40430	BNT162b2 (30 µg)	30JUL2020/ BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)		
10071102	C4591001 1007 10071102	16-55	30JUL2020	40639	Placebo	30JUL2020/ Placebo	20AUG2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
10131002	C4591001 1013 10131002	16-55	28JUL2020	40033	BNT162b2 (30 µg)	28JUL2020/ BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)		
10131003	C4591001 1013 10131003	16-55	28JUL2020	40056	BNT162b2 (30 µg)	28JUL2020/ BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)		
10131005	C4591001 1013 10131005	16-55	28JUL2020	40063	Placebo	28JUL2020/ Placebo	19AUG2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
10131006	C4591001 1013 10131006	16-55	28JUL2020	40057	Placebo	28JUL2020/ Placebo	19AUG2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
10131007	C4591001 1013 10131007	16-55	28JUL2020	40044	BNT162b2 (30 µg)	28JUL2020/ BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)		
10131008	C4591001 1013 10131008	16-55	28JUL2020	40060	BNT162b2 (30 µg)	28JUL2020/ BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)		
10131009	C4591001 1013 10131009	16-55	28JUL2020	40050	Placebo	28JUL2020/ Placebo	17AUG2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
10131010	C4591001 1013 10131010	16-55	29JUL2020	40087	BNT162b2 (30 µg)	29JUL2020/ BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10131011	C4591001 1013 10131011	16-55	29JUL2020	40085	Placebo	29JUL2020/ Placebo	17AUG2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
10131012	C4591001 1013 10131012	16-55	29JUL2020	40129	BNT162b2 (30 µg)	29JUL2020/ BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)		
10131013	C4591001 1013 10131013	16-55	29JUL2020	40123	BNT162b2 (30 µg)	29JUL2020/ BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)		
10131014	C4591001 1013 10131014	16-55	29JUL2020	40092	Placebo	29JUL2020/ Placebo	21AUG2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
10131015	C4591001 1013 10131015	16-55	29JUL2020	40124	Placebo	29JUL2020/ Placebo	20AUG2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
10131016	C4591001 1013 10131016	16-55	29JUL2020	40094	BNT162b2 (30 µg)	29JUL2020/ BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)		
10131018	C4591001 1013 10131018	16-55	30JUL2020	40402	BNT162b2 (30 µg)	30JUL2020/ BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)		
10131019	C4591001 1013 10131019	16-55	30JUL2020	40398	Placebo	30JUL2020/ Placebo	18AUG2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10131020	C4591001 1013 10131020	16-55	30JUL2020	40404	Placebo	30JUL2020/ Placebo	19AUG2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
10131021	C4591001 1013 10131021	16-55	30JUL2020	40407	BNT162b2 (30 µg)	30JUL2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10131022	C4591001 1013 10131022	16-55	30JUL2020	40417	BNT162b2 (30 µg)	30JUL2020/ BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)		
10131023	C4591001 1013 10131023	16-55	30JUL2020	40413	BNT162b2 (30 µg)	30JUL2020/ BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)		
10131024	C4591001 1013 10131024	16-55	30JUL2020	40416	Placebo	30JUL2020/ Placebo	18AUG2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10131025	C4591001 1013 10131025	16-55	30JUL2020	40419	Placebo	30JUL2020/ Placebo	18AUG2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10131026	C4591001 1013 10131026	16-55	30JUL2020	40493	BNT162b2 (30 µg)	30JUL2020/ BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)		
10131030	C4591001 1013 10131030	16-55	30JUL2020	40497	BNT162b2 (30 µg)	30JUL2020/ BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)		
10131031	C4591001 1013 10131031	16-55	30JUL2020	40500	Placebo	30JUL2020/ Placebo	18AUG2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	21JAN2021/ BNT162b2 (30 µg)
10131032	C4591001 1013 10131032	16-55	30JUL2020	40504	Placebo	30JUL2020/ Placebo	19AUG2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	20JAN2021/ BNT162b2 (30 µg)
10161003	C4591001 1016 10161003	16-55	29JUL2020	40137	Placebo	29JUL2020/ Placebo	19AUG2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10161004	C4591001 1016 10161004	16-55	29JUL2020	40139	BNT162b2 (30 µg)	29JUL2020/ BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10161005	C4591001 1016 10161005	16-55	29JUL2020	40142	Placebo	29JUL2020/ Placebo	17AUG2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
10161006	C4591001 1016 10161006	16-55	29JUL2020	40144	BNT162b2 (30 µg)	29JUL2020/ BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)		
10161009	C4591001 1016 10161009	16-55	30JUL2020	40433	BNT162b2 (30 µg)	30JUL2020/ BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)		
10161010	C4591001 1016 10161010	16-55	30JUL2020	40434	BNT162b2 (30 µg)	30JUL2020/ BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)		
10161014	C4591001 1016 10161014	16-55	30JUL2020	40440	Placebo	30JUL2020/ Placebo	19AUG2020/ Placebo		
10181001	C4591001 1018 10181001	16-55	29JUL2020	40193	BNT162b2 (30 µg)	29JUL2020/ BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)		
10181003	C4591001 1018 10181003	16-55	29JUL2020	40194	Placebo	29JUL2020/ Placebo	19AUG2020/ Placebo	23JAN2021/ BNT162b2 (30 µg)	
10181007	C4591001 1018 10181007	16-55	29JUL2020	40199	BNT162b2 (30 µg)	29JUL2020/ BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)		
10421001	C4591001 1042 10421001	16-55	29JUL2020	40290	Placebo	29JUL2020/ Placebo	19AUG2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10421003	C4591001 1042 10421003	16-55	29JUL2020	40293	Placebo	29JUL2020/ Placebo	17AUG2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10421004	C4591001 1042 10421004	16-55	29JUL2020	40295	BNT162b2 (30 µg)	29JUL2020/ BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)		
10421008	C4591001 1042 10421008	16-55	30JUL2020	40296	BNT162b2 (30 µg)	30JUL2020/ BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)		
10731006	C4591001 1073 10731006	16-55	30JUL2020	40529	BNT162b2 (30 µg)	30JUL2020/ BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)		
10731008	C4591001 1073 10731008	16-55	30JUL2020	40530	Placebo	30JUL2020/ Placebo	20AUG2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)
10731009	C4591001 1073 10731009	16-55	30JUL2020	40535	Placebo	30JUL2020/ Placebo	24AUG2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10731012	C4591001 1073 10731012	16-55	30JUL2020	40537	BNT162b2 (30 µg)	30JUL2020/ BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)		
10731013	C4591001 1073 10731013	16-55	30JUL2020	40722	Placebo	30JUL2020/ Placebo	20AUG2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
10791002	C4591001 1079 10791002	16-55	29JUL2020	40279	Placebo	29JUL2020/ Placebo	19AUG2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
10791003	C4591001 1079 10791003	16-55	29JUL2020	40282	BNT162b2 (30 µg)	29JUL2020/ BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)		
10791004	C4591001 1079 10791004	16-55	29JUL2020	40283	BNT162b2 (30 µg)	29JUL2020/ BNT162b2 (30 µg)			

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10791007	C4591001 1079 10791007	16-55	29JUL2020	40285	Placebo	29JUL2020/ Placebo	17AUG2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
10791008	C4591001 1079 10791008	16-55	29JUL2020	40301	BNT162b2 (30 µg)	29JUL2020/ BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)		
10791010	C4591001 1079 10791010	16-55	30JUL2020	40303	Placebo	30JUL2020/ Placebo	20AUG2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10791013	C4591001 1079 10791013	16-55	30JUL2020	40306	Placebo	30JUL2020/ Placebo	19AUG2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10821003	C4591001 1082 10821003	16-55	30JUL2020	40519	BNT162b2 (30 µg)	30JUL2020/ BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)		
10821004	C4591001 1082 10821004	16-55	30JUL2020	40521	BNT162b2 (30 µg)	30JUL2020/ BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)		
10831001	C4591001 1083 10831001	16-55	29JUL2020	40326	Placebo	29JUL2020/ Placebo	21AUG2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
10831002	C4591001 1083 10831002	16-55	29JUL2020	40331	BNT162b2 (30 µg)	29JUL2020/ BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)		
10831004	C4591001 1083 10831004	16-55	29JUL2020	40333	BNT162b2 (30 µg)	29JUL2020/ BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)		
10831005	C4591001 1083 10831005	16-55	29JUL2020	40336	Placebo	29JUL2020/ Placebo	21AUG2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10831006	C4591001 1083 10831006	16-55	29JUL2020	40362	Placebo	29JUL2020/ Placebo	21AUG2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
10841001	C4591001 1084 10841001	16-55	30JUL2020	40590	BNT162b2 (30 µg)	30JUL2020/ BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)		
10841003	C4591001 1084 10841003	16-55	30JUL2020	40591	Placebo	30JUL2020/ Placebo	21AUG2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10851003	C4591001 1085 10851003	16-55	30JUL2020	40554	Placebo	30JUL2020/ Placebo	21AUG2020/ Placebo		
10851004	C4591001 1085 10851004	16-55	30JUL2020	40555	Placebo	30JUL2020/ Placebo	20AUG2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10891011	C4591001 1089 10891011	16-55	30JUL2020	40567	BNT162b2 (30 µg)	30JUL2020/ BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)		
10891013	C4591001 1089 10891013	16-55	30JUL2020	40569	Placebo	30JUL2020/ Placebo	18AUG2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
10891015	C4591001 1089 10891015	16-55	30JUL2020	40572	Placebo	30JUL2020/ Placebo	18AUG2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
10951001	C4591001 1095 10951001	16-55	30JUL2020	40449	BNT162b2 (30 µg)	30JUL2020/ BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)		
10951002	C4591001 1095 10951002	16-55	30JUL2020	40445	Placebo	30JUL2020/ Placebo	21AUG2020/ Placebo	12MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10951005	C4591001 1095 10951005	16-55	30JUL2020	40452	BNT162b2 (30 µg)	30JUL2020/ BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)		
10951006	C4591001 1095 10951006	16-55	30JUL2020	40455	Placebo	30JUL2020/ Placebo	20AUG2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
10951007	C4591001 1095 10951007	16-55	30JUL2020	40697	Placebo	30JUL2020/ Placebo	18AUG2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
11071003	C4591001 1107 11071003	16-55	29JUL2020	40317	Placebo	29JUL2020/ Placebo	18AUG2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
11071006	C4591001 1107 11071006	16-55	30JUL2020	40319	BNT162b2 (30 µg)	30JUL2020/ BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)		
11071010	C4591001 1107 11071010	16-55	30JUL2020	40320	Placebo	30JUL2020/ Placebo	18AUG2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	
11091001	C4591001 1109 11091001	16-55	29JUL2020	40243	Placebo	29JUL2020/ Placebo	17AUG2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
11091002	C4591001 1109 11091002	16-55	29JUL2020	40249	BNT162b2 (30 µg)	29JUL2020/ BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)		
11091003	C4591001 1109 11091003	16-55	29JUL2020	40244	Placebo	29JUL2020/ Placebo	18AUG2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
11091004	C4591001 1109 11091004	16-55	29JUL2020	40266	Placebo	29JUL2020/ Placebo	17AUG2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11091006	C4591001 1109 11091006	16-55	29JUL2020	40251	BNT162b2 (30 µg)	29JUL2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
11091007	C4591001 1109 11091007	16-55	29JUL2020	40267	BNT162b2 (30 µg)	29JUL2020/ BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)		
11091010	C4591001 1109 11091010	16-55	29JUL2020	40271	BNT162b2 (30 µg)	29JUL2020/ BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)		
11091011	C4591001 1109 11091011	16-55	29JUL2020	40270	Placebo	29JUL2020/ Placebo	17AUG2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
11091013	C4591001 1109 11091013	16-55	29JUL2020	40339	Placebo	29JUL2020/ Placebo	17AUG2020/ Placebo	23JAN2021/ BNT162b2 (30 µg)	13FEB2021/ BNT162b2 (30 µg)
11091014	C4591001 1109 11091014	16-55	29JUL2020	40343	BNT162b2 (30 µg)	29JUL2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
11091015	C4591001 1109 11091015	16-55	29JUL2020	40346	Placebo	29JUL2020/ Placebo	18AUG2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
11091016	C4591001 1109 11091016	16-55	30JUL2020	40382	Placebo	30JUL2020/ Placebo	18AUG2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
11091017	C4591001 1109 11091017	16-55	30JUL2020	40348	BNT162b2 (30 µg)	30JUL2020/ BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)		
11091018	C4591001 1109 11091018	16-55	30JUL2020	40373	Placebo	30JUL2020/ Placebo	18AUG2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11091019	C4591001 1109 11091019	16-55	30JUL2020	40377	BNT162b2 (30 µg)	30JUL2020/ BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)		
11091020	C4591001 1109 11091020	16-55	30JUL2020	40384	BNT162b2 (30 µg)	30JUL2020/ BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)		
11091021	C4591001 1109 11091021	16-55	30JUL2020	40387	Placebo	30JUL2020/ Placebo	21AUG2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
11091022	C4591001 1109 11091022	16-55	30JUL2020	40388	Placebo	30JUL2020/ Placebo	18AUG2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
11091023	C4591001 1109 11091023	16-55	30JUL2020	40394	BNT162b2 (30 µg)	30JUL2020/ BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)		
11091024	C4591001 1109 11091024	16-55	30JUL2020	40396	BNT162b2 (30 µg)	30JUL2020/ BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)		
11091027	C4591001 1109 11091027	16-55	30JUL2020	40505	BNT162b2 (30 µg)	30JUL2020/ BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)		
11091028	C4591001 1109 11091028	16-55	30JUL2020	40506	Placebo	30JUL2020/ Placebo	21AUG2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
11091030	C4591001 1109 11091030	16-55	30JUL2020	40507	Placebo	30JUL2020/ Placebo	18AUG2020/ Placebo		
11091033	C4591001 1109 11091033	16-55	30JUL2020	40515	BNT162b2 (30 µg)	30JUL2020/ BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11111001	C4591001 1111 11111001	16-55	30JUL2020	40473	BNT162b2 (30 µg)	30JUL2020/ BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)		
11121004	C4591001 1112 11121004	16-55	29JUL2020	40208	Placebo	29JUL2020/ Placebo	19AUG2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
11121006	C4591001 1112 11121006	16-55	29JUL2020	40214	BNT162b2 (30 µg)	29JUL2020/ BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)		
11121008	C4591001 1112 11121008	16-55	29JUL2020	40215	Placebo	29JUL2020/ Placebo	19AUG2020/ Placebo		
11121009	C4591001 1112 11121009	16-55	30JUL2020	40216	BNT162b2 (30 µg)	30JUL2020/ BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)		
11121011	C4591001 1112 11121011	16-55	30JUL2020	40482	Placebo	30JUL2020/ Placebo	20AUG2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
11121012	C4591001 1112 11121012	16-55	30JUL2020	40485	Placebo	30JUL2020/ Placebo	21AUG2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11121013	C4591001 1112 11121013	16-55	30JUL2020	40486	BNT162b2 (30 µg)	30JUL2020/ BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)		
11121015	C4591001 1112 11121015	16-55	30JUL2020	40674	BNT162b2 (30 µg)	30JUL2020/ BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)		
11121016	C4591001 1112 11121016	16-55	30JUL2020	40487	BNT162b2 (30 µg)	30JUL2020/ BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11201001	C4591001 1120 11201001	16-55	29JUL2020	40349	BNT162b2 (30 µg)	29JUL2020/ BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)		
11231001	C4591001 1123 11231001	16-55	29JUL2020	40221	BNT162b2 (30 µg)	29JUL2020/ BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)		
11231002	C4591001 1123 11231002	16-55	30JUL2020	40223	Placebo	30JUL2020/ Placebo	18AUG2020/ Placebo		
11231003	C4591001 1123 11231003	16-55	30JUL2020	40225	BNT162b2 (30 µg)	30JUL2020/ BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)		
11271004	C4591001 1127 11271004	16-55	29JUL2020	40230	Placebo	29JUL2020/ Placebo	17AUG2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
11271011	C4591001 1127 11271011	16-55	30JUL2020	40234	BNT162b2 (30 µg)	30JUL2020/ BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)		
11271014	C4591001 1127 11271014	16-55	30JUL2020	40613	BNT162b2 (30 µg)	30JUL2020/ BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)		
11271015	C4591001 1127 11271015	16-55	30JUL2020	40235	BNT162b2 (30 µg)	30JUL2020/ BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)		
11271016	C4591001 1127 11271016	16-55	30JUL2020	40238	Placebo	30JUL2020/ Placebo	18AUG2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	27FEB2021/ BNT162b2 (30 µg)
11271017	C4591001 1127 11271017	16-55	30JUL2020	40619	Placebo	30JUL2020/ Placebo	18AUG2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	27FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11291001	C4591001 1129 11291001	16-55	29JUL2020	40183	Placebo	29JUL2020/ Placebo	19AUG2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11291005	C4591001 1129 11291005	16-55	29JUL2020	40184	BNT162b2 (30 µg)	29JUL2020/ BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)		
11291006	C4591001 1129 11291006	16-55	29JUL2020	40188	BNT162b2 (30 µg)	29JUL2020/ BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)		
11291010	C4591001 1129 11291010	16-55	30JUL2020	40192	Placebo	30JUL2020/ Placebo	19AUG2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
11291014	C4591001 1129 11291014	16-55	30JUL2020	40626	BNT162b2 (30 µg)	30JUL2020/ BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)		
11331001	C4591001 1133 11331001	16-55	30JUL2020	40463	BNT162b2 (30 µg)	30JUL2020/ BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)		
11331003	C4591001 1133 11331003	16-55	30JUL2020	40466	BNT162b2 (30 µg)	30JUL2020/ BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)		
11331004	C4591001 1133 11331004	16-55	30JUL2020	40465	Placebo	30JUL2020/ Placebo	21AUG2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
11331011	C4591001 1133 11331011	16-55	30JUL2020	40467	Placebo	30JUL2020/ Placebo	21AUG2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
11331014	C4591001 1133 11331014	16-55	30JUL2020	40650	Placebo	30JUL2020/ Placebo	21AUG2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11331016	C4591001 1133 11331016	16-55	30JUL2020	40651	Placebo	30JUL2020/ Placebo	24AUG2020/ Placebo		
11391001	C4591001 1139 11391001	16-55	29JUL2020	40075	Placebo	29JUL2020/ Placebo	20AUG2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
11391007	C4591001 1139 11391007	16-55	29JUL2020	40076	BNT162b2 (30 µg)	29JUL2020/ BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)		
11391010	C4591001 1139 11391010	16-55	29JUL2020	40078	Placebo	29JUL2020/ Placebo	20AUG2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
11391015	C4591001 1139 11391015	16-55	30JUL2020	40084	BNT162b2 (30 µg)	30JUL2020/ BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)		
11401001	C4591001 1140 11401001	16-55	29JUL2020	40099	Placebo	29JUL2020/ Placebo	19AUG2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
11401006	C4591001 1140 11401006	16-55	30JUL2020	40103	BNT162b2 (30 µg)	30JUL2020/ BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)		
11421001	C4591001 1142 11421001	16-55	29JUL2020	40157	BNT162b2 (30 µg)	29JUL2020/ BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)		
11421002	C4591001 1142 11421002	16-55	29JUL2020	40160	Placebo	29JUL2020/ Placebo	19AUG2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)
11421004	C4591001 1142 11421004	16-55	29JUL2020	40167	BNT162b2 (30 µg)	29JUL2020/ BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11421007	C4591001 1142 11421007	16-55	29JUL2020	40168	Placebo	29JUL2020/ Placebo	17AUG2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	20JAN2021/ BNT162b2 (30 µg)
11421008	C4591001 1142 11421008	16-55	29JUL2020	40254	Placebo	29JUL2020/ Placebo	17AUG2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
11421010	C4591001 1142 11421010	16-55	30JUL2020	40259	Placebo	30JUL2020/ Placebo	18AUG2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11421011	C4591001 1142 11421011	16-55	30JUL2020	40261	BNT162b2 (30 µg)	30JUL2020/ BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)		
11421014	C4591001 1142 11421014	16-55	30JUL2020	40264	BNT162b2 (30 µg)	30JUL2020/ BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)		
11421015	C4591001 1142 11421015	16-55	30JUL2020	40607	BNT162b2 (30 µg)	30JUL2020/ BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)		
11421016	C4591001 1142 11421016	16-55	30JUL2020	40610	Placebo	30JUL2020/ Placebo	18AUG2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
11471001	C4591001 1147 11471001	16-55	30JUL2020	40577	Placebo	30JUL2020/ Placebo	21AUG2020/ Placebo		
10011083	C4591001 1001 10011083	16-55	31JUL2020	40545	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)		
10011105	C4591001 1001 10011105	16-55	31JUL2020	40547	Placebo	31JUL2020/ Placebo	21AUG2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10011106	C4591001 1001 10011106	16-55	31JUL2020	40552	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)		
10011107	C4591001 1001 10011107	16-55	31JUL2020	41035	Placebo	31JUL2020/ Placebo	21AUG2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
10011113	C4591001 1001 10011113	16-55	03AUG2020	41039	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
10011125	C4591001 1001 10011125	16-55	04AUG2020	41040	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)			
10011126	C4591001 1001 10011126	16-55	04AUG2020	41042	Placebo	04AUG2020/ Placebo	24AUG2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
10011129	C4591001 1001 10011129	16-55	05AUG2020	42967	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
10011130	C4591001 1001 10011130	16-55	05AUG2020	42969	Placebo	05AUG2020/ Placebo	26AUG2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10011131	C4591001 1001 10011131	16-55	05AUG2020	42976	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
10011132	C4591001 1001 10011132	16-55	05AUG2020	42973	Placebo	05AUG2020/ Placebo	26AUG2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10011135	C4591001 1001 10011135	16-55	05AUG2020	43218	Placebo	05AUG2020/ Placebo	24AUG2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10011136	C4591001 1001 10011136	16-55	06AUG2020	43219	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)		
10011138	C4591001 1001 10011138	16-55	06AUG2020	43225	Placebo	06AUG2020/ Placebo	27AUG2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
10011143	C4591001 1001 10011143	16-55	06AUG2020	43877	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)		
10011145	C4591001 1001 10011145	16-55	07AUG2020	43878	Placebo	07AUG2020/ Placebo	28AUG2020/ Placebo	06JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
10011146	C4591001 1001 10011146	16-55	07AUG2020	43882	Placebo	07AUG2020/ Placebo	28AUG2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10011149	C4591001 1001 10011149	16-55	07AUG2020	43887	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
10031116	C4591001 1003 10031116	16-55	30JUL2020	40153	Placebo	30JUL2020/ Placebo	21AUG2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
10031122	C4591001 1003 10031122	16-55	31JUL2020	40819	Placebo	31JUL2020/ Placebo	21AUG2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10031124	C4591001 1003 10031124	16-55	31JUL2020	40820	Placebo	31JUL2020/ Placebo	21AUG2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)
10031125	C4591001 1003 10031125	16-55	31JUL2020	40823	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10031137	C4591001 1003 10031137	16-55	04AUG2020	40828	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
10031138	C4591001 1003 10031138	16-55	04AUG2020	42130	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
10031141	C4591001 1003 10031141	16-55	04AUG2020	42133	Placebo	04AUG2020/ Placebo	25AUG2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
10031144	C4591001 1003 10031144	16-55	04AUG2020	42522	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
10031146	C4591001 1003 10031146	16-55	05AUG2020	42524	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
10031147	C4591001 1003 10031147	16-55	05AUG2020	42526	Placebo	05AUG2020/ Placebo	26AUG2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
10031151	C4591001 1003 10031151	16-55	05AUG2020	42529	Placebo	05AUG2020/ Placebo	26AUG2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	27JAN2021/ BNT162b2 (30 µg)
10031155	C4591001 1003 10031155	16-55	06AUG2020	43470	Placebo	06AUG2020/ Placebo	27AUG2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
10031156	C4591001 1003 10031156	16-55	06AUG2020	43474	Placebo	06AUG2020/ Placebo	27AUG2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
10031158	C4591001 1003 10031158	16-55	06AUG2020	43479	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10031160	C4591001 1003 10031160	16-55	06AUG2020	43480	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)		
10031161	C4591001 1003 10031161	16-55	07AUG2020	44214	Placebo	07AUG2020/ Placebo	28AUG2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
10031162	C4591001 1003 10031162	16-55	07AUG2020	44217	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
10031166	C4591001 1003 10031166	16-55	07AUG2020	44221	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
10031170	C4591001 1003 10031170	16-55	10AUG2020	44224	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
10031171	C4591001 1003 10031171	16-55	10AUG2020	45113	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10031174	C4591001 1003 10031174	16-55	10AUG2020	45115	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
10031175	C4591001 1003 10031175	16-55	10AUG2020	45118	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)
10031177	C4591001 1003 10031177	16-55	10AUG2020	45122	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10031179	C4591001 1003 10031179	16-55	11AUG2020	46111	Placebo	11AUG2020/ Placebo	01SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10031180	C4591001 1003 10031180	16-55	11AUG2020	46116	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
10031183	C4591001 1003 10031183	16-55	11AUG2020	46117	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
10031184	C4591001 1003 10031184	16-55	11AUG2020	46119	Placebo	11AUG2020/ Placebo	01SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
10031186	C4591001 1003 10031186	16-55	12AUG2020	47001	Placebo	12AUG2020/ Placebo	03SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10031187	C4591001 1003 10031187	16-55	12AUG2020	47003	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
10031190	C4591001 1003 10031190	16-55	12AUG2020	47004	Placebo	12AUG2020/ Placebo	01SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
10031191	C4591001 1003 10031191	16-55	12AUG2020	47008	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
10031194	C4591001 1003 10031194	16-55	13AUG2020	48774	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
10031196	C4591001 1003 10031196	16-55	13AUG2020	48776	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
10031197	C4591001 1003 10031197	16-55	13AUG2020	48777	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10031198	C4591001 1003 10031198	16-55	13AUG2020	48779	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
10031199	C4591001 1003 10031199	16-55	13AUG2020	49242	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
10031201	C4591001 1003 10031201	16-55	13AUG2020	49250	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
10031203	C4591001 1003 10031203	16-55	14AUG2020	49251	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
10031204	C4591001 1003 10031204	16-55	14AUG2020	49252	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
10031205	C4591001 1003 10031205	16-55	14AUG2020	49868	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
10031206	C4591001 1003 10031206	16-55	14AUG2020	49870	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
10031207	C4591001 1003 10031207	16-55	14AUG2020	49872	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
10051002	C4591001 1005 10051002	16-55	07AUG2020	44385	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
10051003	C4591001 1005 10051003	16-55	07AUG2020	44387	Placebo	07AUG2020/ Placebo	30AUG2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10051004	C4591001 1005 10051004	16-55	10AUG2020	44389	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10051007	C4591001 1005 10051007	16-55	10AUG2020	44392	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
10051008	C4591001 1005 10051008	16-55	10AUG2020	45368	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
10051015	C4591001 1005 10051015	16-55	10AUG2020	45372	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
10051016	C4591001 1005 10051016	16-55	11AUG2020	45373	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10051017	C4591001 1005 10051017	16-55	11AUG2020	45374	Placebo	11AUG2020/ Placebo	01SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10051024	C4591001 1005 10051024	16-55	11AUG2020	46639	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10051026	C4591001 1005 10051026	16-55	11AUG2020	46641	Placebo	11AUG2020/ Placebo	02SEP2020/ Placebo		
10051027	C4591001 1005 10051027	16-55	11AUG2020	46642	Placebo	11AUG2020/ Placebo	31AUG2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
10051028	C4591001 1005 10051028	16-55	12AUG2020	47011	Placebo	12AUG2020/ Placebo	01SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10051029	C4591001 1005 10051029	16-55	12AUG2020	46647	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
10051030	C4591001 1005 10051030	16-55	12AUG2020	47015	Placebo	12AUG2020/ Placebo	01SEP2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
10051031	C4591001 1005 10051031	16-55	12AUG2020	47019	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
10051035	C4591001 1005 10051035	16-55	12AUG2020	47020	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
10051036	C4591001 1005 10051036	16-55	12AUG2020	47597	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
10051041	C4591001 1005 10051041	16-55	12AUG2020	47921	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
10051048	C4591001 1005 10051048	16-55	13AUG2020	47924	Placebo	13AUG2020/ Placebo	02SEP2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
10051051	C4591001 1005 10051051	16-55	13AUG2020	47932	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
10051052	C4591001 1005 10051052	16-55	13AUG2020	47929	Placebo	13AUG2020/ Placebo	02SEP2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10051054	C4591001 1005 10051054	16-55	13AUG2020	48727	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10051055	C4591001 1005 10051055	16-55	13AUG2020	48728	Placebo	13AUG2020/ Placebo	01SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
10051057	C4591001 1005 10051057	16-55	13AUG2020	48729	Placebo	13AUG2020/ Placebo	02SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10051059	C4591001 1005 10051059	16-55	13AUG2020	48733	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
10051066	C4591001 1005 10051066	16-55	13AUG2020	49457	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
10051067	C4591001 1005 10051067	16-55	13AUG2020	49463	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
10051070	C4591001 1005 10051070	16-55	14AUG2020	49464	Placebo	14AUG2020/ Placebo	02SEP2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
10051071	C4591001 1005 10051071	16-55	14AUG2020	49468	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10051073	C4591001 1005 10051073	16-55	14AUG2020	49998	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
10051075	C4591001 1005 10051075	16-55	14AUG2020	50002	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10061005	C4591001 1006 10061005	16-55	10AUG2020	45485	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	20JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10061007	C4591001 1006 10061007	16-55	10AUG2020	45487	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10061008	C4591001 1006 10061008	16-55	10AUG2020	45490	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
10061009	C4591001 1006 10061009	16-55	10AUG2020	45495	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
10061011	C4591001 1006 10061011	16-55	11AUG2020	46289	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10061012	C4591001 1006 10061012	16-55	11AUG2020	46292	Placebo	11AUG2020/ Placebo	31AUG2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
10061013	C4591001 1006 10061013	16-55	11AUG2020	46294	Placebo	11AUG2020/ Placebo	31AUG2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
10061014	C4591001 1006 10061014	16-55	11AUG2020	46296	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10061015	C4591001 1006 10061015	16-55	11AUG2020	46865	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
10061018	C4591001 1006 10061018	16-55	11AUG2020	46868	Placebo	11AUG2020/ Placebo	31AUG2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
10061019	C4591001 1006 10061019	16-55	12AUG2020	46869	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10061021	C4591001 1006 10061021	16-55	12AUG2020	46874	Placebo	12AUG2020/ Placebo	01SEP2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
10061022	C4591001 1006 10061022	16-55	12AUG2020	47813	Placebo	12AUG2020/ Placebo	31AUG2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
10061023	C4591001 1006 10061023	16-55	12AUG2020	47819	Placebo	12AUG2020/ Placebo	31AUG2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
10061024	C4591001 1006 10061024	16-55	12AUG2020	47820	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10061028	C4591001 1006 10061028	16-55	13AUG2020	47823	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
10061031	C4591001 1006 10061031	16-55	13AUG2020	49714	Placebo	13AUG2020/ Placebo	04SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
10061032	C4591001 1006 10061032	16-55	13AUG2020	49718	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
10061033	C4591001 1006 10061033	16-55	13AUG2020	49712	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
10061036	C4591001 1006 10061036	16-55	14AUG2020	49719	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10061037	C4591001 1006 10061037	16-55	14AUG2020	50868	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10071106	C4591001 1007 10071106	16-55	03AUG2020	40640	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
10071107	C4591001 1007 10071107	16-55	03AUG2020	40643	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
10071108	C4591001 1007 10071108	16-55	03AUG2020	40648	Placebo	03AUG2020/ Placebo	27AUG2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
10071109	C4591001 1007 10071109	16-55	03AUG2020	41642	Placebo	03AUG2020/ Placebo	24AUG2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
10071110	C4591001 1007 10071110	16-55	03AUG2020	41636	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
10071111	C4591001 1007 10071111	16-55	03AUG2020	41643	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
10071112	C4591001 1007 10071112	16-55	03AUG2020	41644	Placebo	03AUG2020/ Placebo	24AUG2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
10071117	C4591001 1007 10071117	16-55	03AUG2020	41898	Placebo	03AUG2020/ Placebo	24AUG2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
10071118	C4591001 1007 10071118	16-55	03AUG2020	41901	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
10071119	C4591001 1007 10071119	16-55	05AUG2020	41902	Placebo	05AUG2020/ Placebo	26AUG2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10071123	C4591001 1007 10071123	16-55	05AUG2020	41903	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
10071125	C4591001 1007 10071125	16-55	05AUG2020	42920	Placebo	05AUG2020/ Placebo	24AUG2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
10071129	C4591001 1007 10071129	16-55	05AUG2020	42924	Placebo	05AUG2020/ Placebo	26AUG2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
10071130	C4591001 1007 10071130	16-55	05AUG2020	42921	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
10071131	C4591001 1007 10071131	16-55	05AUG2020	42926	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)		
10071132	C4591001 1007 10071132	16-55	05AUG2020	43159	Placebo	05AUG2020/ Placebo	27AUG2020/ Placebo	06JAN2021/ BNT162b2 (30 µg)	27JAN2021/ BNT162b2 (30 µg)
10071133	C4591001 1007 10071133	16-55	05AUG2020	43163	Placebo	05AUG2020/ Placebo	31AUG2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
10071137	C4591001 1007 10071137	16-55	06AUG2020	43164	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)		
10071138	C4591001 1007 10071138	16-55	06AUG2020	43165	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)		
10071143	C4591001 1007 10071143	16-55	06AUG2020	43834	Placebo	06AUG2020/ Placebo	27AUG2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10071145	C4591001 1007 10071145	16-55	06AUG2020	43832	Placebo	06AUG2020/ Placebo	27AUG2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	28JAN2021/ BNT162b2 (30 µg)
10071146	C4591001 1007 10071146	16-55	06AUG2020	43838	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)		
10071148	C4591001 1007 10071148	16-55	06AUG2020	43839	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)		
10071150	C4591001 1007 10071150	16-55	10AUG2020	45188	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
10071151	C4591001 1007 10071151	16-55	10AUG2020	45186	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10071152	C4591001 1007 10071152	16-55	10AUG2020	45191	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
10071153	C4591001 1007 10071153	16-55	10AUG2020	45270	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10071154	C4591001 1007 10071154	16-55	10AUG2020	45272	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)
10071155	C4591001 1007 10071155	16-55	10AUG2020	45189	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
10071157	C4591001 1007 10071157	16-55	10AUG2020	45273	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10071158	C4591001 1007 10071158	16-55	10AUG2020	45280	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
10071159	C4591001 1007 10071159	16-55	10AUG2020	45643	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10071162	C4591001 1007 10071162	16-55	10AUG2020	45644	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
10071171	C4591001 1007 10071171	16-55	12AUG2020	45645	Placebo	12AUG2020/ Placebo	02SEP2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
10071172	C4591001 1007 10071172	16-55	12AUG2020	45647	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
10071175	C4591001 1007 10071175	16-55	12AUG2020	47633	Placebo	12AUG2020/ Placebo	03SEP2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
10071178	C4591001 1007 10071178	16-55	12AUG2020	47644	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
10071179	C4591001 1007 10071179	16-55	12AUG2020	47634	Placebo	12AUG2020/ Placebo	03SEP2020/ Placebo		
10071181	C4591001 1007 10071181	16-55	12AUG2020	47640	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
10071184	C4591001 1007 10071184	16-55	13AUG2020	48452	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10071185	C4591001 1007 10071185	16-55	13AUG2020	48455	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
10071186	C4591001 1007 10071186	16-55	13AUG2020	48459	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo		
10071193	C4591001 1007 10071193	16-55	13AUG2020	49097	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
10071194	C4591001 1007 10071194	16-55	13AUG2020	49099	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)
10071195	C4591001 1007 10071195	16-55	13AUG2020	49098	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
10071196	C4591001 1007 10071196	16-55	13AUG2020	49103	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
10071197	C4591001 1007 10071197	16-55	13AUG2020	49338	Placebo	13AUG2020/ Placebo	02SEP2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	27JAN2021/ BNT162b2 (30 µg)
10081006	C4591001 1008 10081006	16-55	10AUG2020	45761	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10081007	C4591001 1008 10081007	16-55	10AUG2020	45762	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)
10081011	C4591001 1008 10081011	16-55	11AUG2020	45768	Placebo	11AUG2020/ Placebo	01SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10081013	C4591001 1008 10081013	16-55	11AUG2020	45771	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
10081015	C4591001 1008 10081015	16-55	11AUG2020	46721	Placebo	11AUG2020/ Placebo	02SEP2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
10081018	C4591001 1008 10081018	16-55	12AUG2020	46722	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
10081019	C4591001 1008 10081019	16-55	12AUG2020	46728	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
10081022	C4591001 1008 10081022	16-55	12AUG2020	46730	Placebo	12AUG2020/ Placebo	02SEP2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
10081024	C4591001 1008 10081024	16-55	12AUG2020	48101	Placebo	12AUG2020/ Placebo	02SEP2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
10081025	C4591001 1008 10081025	16-55	13AUG2020	48109	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
10081028	C4591001 1008 10081028	16-55	13AUG2020	48110	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
10081029	C4591001 1008 10081029	16-55	13AUG2020	48112	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
10081030	C4591001 1008 10081030	16-55	13AUG2020	49435	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10081031	C4591001 1008 10081031	16-55	13AUG2020	49441	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10081033	C4591001 1008 10081033	16-55	14AUG2020	49443	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
10081036	C4591001 1008 10081036	16-55	14AUG2020	49444	Placebo	14AUG2020/ Placebo	03SEP2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
10081037	C4591001 1008 10081037	16-55	14AUG2020	50633	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
10081040	C4591001 1008 10081040	16-55	14AUG2020	50634	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
10091002	C4591001 1009 10091002	16-55	07AUG2020	44552	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)		
10091005	C4591001 1009 10091005	16-55	10AUG2020	44556	Placebo	10AUG2020/ Placebo	02SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10091006	C4591001 1009 10091006	16-55	10AUG2020	44558	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10091012	C4591001 1009 10091012	16-55	10AUG2020	44559	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
10091021	C4591001 1009 10091021	16-55	11AUG2020	46841	Placebo	11AUG2020/ Placebo	02SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10091023	C4591001 1009 10091023	16-55	11AUG2020	46842	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
10091028	C4591001 1009 10091028	16-55	12AUG2020	46847	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10091031	C4591001 1009 10091031	16-55	12AUG2020	46850	Placebo	12AUG2020/ Placebo	01SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
10091032	C4591001 1009 10091032	16-55	12AUG2020	48235	Placebo	12AUG2020/ Placebo	02SEP2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10091042	C4591001 1009 10091042	16-55	14AUG2020	48238	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
10091045	C4591001 1009 10091045	16-55	14AUG2020	48240	Placebo	14AUG2020/ Placebo	03SEP2020/ Placebo	31DEC2020/ BNT162b2 (30 µg)	22JAN2021/ BNT162b2 (30 µg)
10091049	C4591001 1009 10091049	16-55	14AUG2020	50934	Placebo	14AUG2020/ Placebo	02SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
10091050	C4591001 1009 10091050	16-55	14AUG2020	50936	Placebo	14AUG2020/ Placebo	02SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
10111001	C4591001 1011 10111001	16-55	11AUG2020	46499	Placebo	11AUG2020/ Placebo	01SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10111004	C4591001 1011 10111004	16-55	12AUG2020	46500	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10111005	C4591001 1011 10111005	16-55	12AUG2020	46501	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
10111006	C4591001 1011 10111006	16-55	12AUG2020	47094	Placebo	12AUG2020/ Placebo	03SEP2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)
10111008	C4591001 1011 10111008	16-55	12AUG2020	47095	Placebo	12AUG2020/ Placebo	01SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
10111009	C4591001 1011 10111009	16-55	12AUG2020	47103	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
10111013	C4591001 1011 10111013	16-55	12AUG2020	47104	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
10111016	C4591001 1011 10111016	16-55	13AUG2020	48308	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10111017	C4591001 1011 10111017	16-55	13AUG2020	48313	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
10111021	C4591001 1011 10111021	16-55	13AUG2020	48314	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10111024	C4591001 1011 10111024	16-55	13AUG2020	48315	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
10111031	C4591001 1011 10111031	16-55	13AUG2020	49649	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10111032	C4591001 1011 10111032	16-55	13AUG2020	49651	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
10111034	C4591001 1011 10111034	16-55	14AUG2020	49652	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
10111035	C4591001 1011 10111035	16-55	14AUG2020	49653	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
10111038	C4591001 1011 10111038	16-55	14AUG2020	50273	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
10111039	C4591001 1011 10111039	16-55	14AUG2020	50274	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
10121001	C4591001 1012 10121001	16-55	03AUG2020	41719	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)			
10121003	C4591001 1012 10121003	16-55	03AUG2020	41723	Placebo	03AUG2020/ Placebo	24AUG2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10121005	C4591001 1012 10121005	16-55	03AUG2020	41725	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
10121006	C4591001 1012 10121006	16-55	03AUG2020	41728	Placebo	03AUG2020/ Placebo	28AUG2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
10121013	C4591001 1012 10121013	16-55	05AUG2020	43014	Placebo	05AUG2020/ Placebo	26AUG2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10121014	C4591001 1012 10121014	16-55	05AUG2020	43017	Placebo	05AUG2020/ Placebo	26AUG2020/ Placebo	30JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
10121016	C4591001 1012 10121016	16-55	06AUG2020	43018	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
10121020	C4591001 1012 10121020	16-55	07AUG2020	44658	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)		
10121021	C4591001 1012 10121021	16-55	07AUG2020	43021	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
10121022	C4591001 1012 10121022	16-55	10AUG2020	44659	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
10121024	C4591001 1012 10121024	16-55	10AUG2020	44664	Placebo	10AUG2020/ Placebo	02SEP2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
10121025	C4591001 1012 10121025	16-55	10AUG2020	44666	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	30JAN2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
10121027	C4591001 1012 10121027	16-55	11AUG2020	46506	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10121030	C4591001 1012 10121030	16-55	12AUG2020	46509	Placebo	12AUG2020/ Placebo	31AUG2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
10121032	C4591001 1012 10121032	16-55	12AUG2020	46512	Placebo	12AUG2020/ Placebo	31AUG2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10121036	C4591001 1012 10121036	16-55	14AUG2020	46516	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
10121037	C4591001 1012 10121037	16-55	14AUG2020	51058	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
10131033	C4591001 1013 10131033	16-55	31JUL2020	40835	Placebo	31JUL2020/ Placebo	19AUG2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
10131034	C4591001 1013 10131034	16-55	31JUL2020	40829	Placebo	31JUL2020/ Placebo	18AUG2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
10131035	C4591001 1013 10131035	16-55	31JUL2020	40833	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)		
10131036	C4591001 1013 10131036	16-55	31JUL2020	40836	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)		
10131038	C4591001 1013 10131038	16-55	31JUL2020	40842	Placebo	31JUL2020/ Placebo	19AUG2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
10131039	C4591001 1013 10131039	16-55	31JUL2020	40848	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)		
10131040	C4591001 1013 10131040	16-55	31JUL2020	40849	Placebo	31JUL2020/ Placebo	18AUG2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
10131042	C4591001 1013 10131042	16-55	31JUL2020	40851	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10131044	C4591001 1013 10131044	16-55	31JUL2020	40937	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)		
10131045	C4591001 1013 10131045	16-55	31JUL2020	40940	Placebo	31JUL2020/ Placebo	19AUG2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10131046	C4591001 1013 10131046	16-55	31JUL2020	40943	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)		
10131047	C4591001 1013 10131047	16-55	31JUL2020	40942	Placebo	31JUL2020/ Placebo	20AUG2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
10131048	C4591001 1013 10131048	16-55	31JUL2020	41000	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)		
10131049	C4591001 1013 10131049	16-55	31JUL2020	41006	Placebo	31JUL2020/ Placebo	20AUG2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
10131050	C4591001 1013 10131050	16-55	31JUL2020	41003	Placebo	31JUL2020/ Placebo	20AUG2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
10131051	C4591001 1013 10131051	16-55	03AUG2020	41007	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
10131052	C4591001 1013 10131052	16-55	03AUG2020	41462	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
10131054	C4591001 1013 10131054	16-55	03AUG2020	41456	Placebo	03AUG2020/ Placebo	24AUG2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10131055	C4591001 1013 10131055	16-55	03AUG2020	41455	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
10131056	C4591001 1013 10131056	16-55	03AUG2020	41463	Placebo	03AUG2020/ Placebo	26AUG2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
10131057	C4591001 1013 10131057	16-55	03AUG2020	41537	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
10131058	C4591001 1013 10131058	16-55	03AUG2020	41542	Placebo	03AUG2020/ Placebo	24AUG2020/ Placebo	02MAR2021/ BNT162b2 (30 µg)	
10131059	C4591001 1013 10131059	16-55	03AUG2020	41544	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
10131060	C4591001 1013 10131060	16-55	03AUG2020	41547	Placebo	03AUG2020/ Placebo	24AUG2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
10131062	C4591001 1013 10131062	16-55	04AUG2020	42203	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
10131063	C4591001 1013 10131063	16-55	04AUG2020	42114	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
10131064	C4591001 1013 10131064	16-55	04AUG2020	42205	Placebo	04AUG2020/ Placebo	24AUG2020/ Placebo		
10131066	C4591001 1013 10131066	16-55	04AUG2020	42115	Placebo	04AUG2020/ Placebo	27AUG2020/ Placebo	15DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10131067	C4591001 1013 10131067	16-55	04AUG2020	42119	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
10131068	C4591001 1013 10131068	16-55	04AUG2020	42116	Placebo	04AUG2020/ Placebo	26AUG2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
10131071	C4591001 1013 10131071	16-55	04AUG2020	42206	Placebo	04AUG2020/ Placebo	25AUG2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
10131072	C4591001 1013 10131072	16-55	04AUG2020	42207	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
10131074	C4591001 1013 10131074	16-55	04AUG2020	42309	Placebo	04AUG2020/ Placebo	26AUG2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
10131076	C4591001 1013 10131076	16-55	04AUG2020	42305	Placebo	04AUG2020/ Placebo	25AUG2020/ Placebo		
10131077	C4591001 1013 10131077	16-55	04AUG2020	42311	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
10131078	C4591001 1013 10131078	16-55	04AUG2020	42314	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
10131079	C4591001 1013 10131079	16-55	04AUG2020	42473	Placebo	04AUG2020/ Placebo	25AUG2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
10131081	C4591001 1013 10131081	16-55	05AUG2020	42476	Placebo	05AUG2020/ Placebo	25AUG2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10131082	C4591001 1013 10131082	16-55	05AUG2020	42478	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)		
10131083	C4591001 1013 10131083	16-55	05AUG2020	42484	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
10131084	C4591001 1013 10131084	16-55	05AUG2020	42812	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
10131087	C4591001 1013 10131087	16-55	06AUG2020	42813	Placebo	06AUG2020/ Placebo	26AUG2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	
10131089	C4591001 1013 10131089	16-55	06AUG2020	42820	Placebo	06AUG2020/ Placebo	27AUG2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10131090	C4591001 1013 10131090	16-55	06AUG2020	42815	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)		
10131093	C4591001 1013 10131093	16-55	06AUG2020	43639	Placebo	06AUG2020/ Placebo	27AUG2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
10131094	C4591001 1013 10131094	16-55	06AUG2020	43637	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
10131098	C4591001 1013 10131098	16-55	06AUG2020	43645	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
10131102	C4591001 1013 10131102	16-55	06AUG2020	43647	Placebo	06AUG2020/ Placebo	27AUG2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10131103	C4591001 1013 10131103	16-55	06AUG2020	44014	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)		
10131105	C4591001 1013 10131105	16-55	10AUG2020	44017	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10131106	C4591001 1013 10131106	16-55	10AUG2020	44018	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10131107	C4591001 1013 10131107	16-55	10AUG2020	45343	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
10131108	C4591001 1013 10131108	16-55	10AUG2020	44019	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10131109	C4591001 1013 10131109	16-55	10AUG2020	45349	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10131111	C4591001 1013 10131111	16-55	10AUG2020	45348	Placebo	10AUG2020/ Placebo	01SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
10131113	C4591001 1013 10131113	16-55	10AUG2020	45351	Placebo	10AUG2020/ Placebo	01SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
10131115	C4591001 1013 10131115	16-55	10AUG2020	45534	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10131116	C4591001 1013 10131116	16-55	10AUG2020	45533	Placebo	10AUG2020/ Placebo	02SEP2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10131117	C4591001 1013 10131117	16-55	10AUG2020	45542	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10131118	C4591001 1013 10131118	16-55	10AUG2020	45541	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
10131119	C4591001 1013 10131119	16-55	10AUG2020	45606	Placebo	10AUG2020/ Placebo	01SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10131120	C4591001 1013 10131120	16-55	10AUG2020	45607	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10131121	C4591001 1013 10131121	16-55	10AUG2020	45611	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10131122	C4591001 1013 10131122	16-55	10AUG2020	45614	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
10131124	C4591001 1013 10131124	16-55	11AUG2020	46088	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
10131125	C4591001 1013 10131125	16-55	11AUG2020	46085	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
10131126	C4591001 1013 10131126	16-55	11AUG2020	46090	Placebo	11AUG2020/ Placebo	01SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
10131127	C4591001 1013 10131127	16-55	11AUG2020	46092	Placebo	11AUG2020/ Placebo	02SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10131128	C4591001 1013 10131128	16-55	11AUG2020	46146	Placebo	11AUG2020/ Placebo	02SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10131131	C4591001 1013 10131131	16-55	11AUG2020	46148	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
10131132	C4591001 1013 10131132	16-55	11AUG2020	46147	Placebo	11AUG2020/ Placebo	03SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
10131135	C4591001 1013 10131135	16-55	11AUG2020	46154	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
10131136	C4591001 1013 10131136	16-55	11AUG2020	46459	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
10131137	C4591001 1013 10131137	16-55	11AUG2020	46460	Placebo	11AUG2020/ Placebo	01SEP2020/ Placebo		
10131138	C4591001 1013 10131138	16-55	11AUG2020	46461	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)			
10131139	C4591001 1013 10131139	16-55	11AUG2020	46465	Placebo	11AUG2020/ Placebo	01SEP2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
10131143	C4591001 1013 10131143	16-55	12AUG2020	47033	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
10131145	C4591001 1013 10131145	16-55	12AUG2020	47035	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10131146	C4591001 1013 10131146	16-55	12AUG2020	47129	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
10131147	C4591001 1013 10131147	16-55	12AUG2020	47130	Placebo	12AUG2020/ Placebo	03SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
10131148	C4591001 1013 10131148	16-55	12AUG2020	47036	Placebo	12AUG2020/ Placebo	02SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
10131149	C4591001 1013 10131149	16-55	12AUG2020	47039	Placebo	12AUG2020/ Placebo	03SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10131155	C4591001 1013 10131155	16-55	12AUG2020	47134	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
10131156	C4591001 1013 10131156	16-55	12AUG2020	47132	Placebo	12AUG2020/ Placebo	03SEP2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
10131158	C4591001 1013 10131158	16-55	12AUG2020	47347	Placebo	12AUG2020/ Placebo	03SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
10131159	C4591001 1013 10131159	16-55	12AUG2020	47349	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
10131163	C4591001 1013 10131163	16-55	13AUG2020	47355	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
10131165	C4591001 1013 10131165	16-55	13AUG2020	48413	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10131166	C4591001 1013 10131166	16-55	13AUG2020	48419	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
10131167	C4591001 1013 10131167	16-55	13AUG2020	48415	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
10131169	C4591001 1013 10131169	16-55	13AUG2020	48420	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
10131171	C4591001 1013 10131171	16-55	13AUG2020	48549	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
10131172	C4591001 1013 10131172	16-55	13AUG2020	48552	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
10131173	C4591001 1013 10131173	16-55	13AUG2020	48555	Placebo	13AUG2020/ Placebo	01SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10131174	C4591001 1013 10131174	16-55	13AUG2020	48556	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
10131177	C4591001 1013 10131177	16-55	13AUG2020	48718	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
10131179	C4591001 1013 10131179	16-55	13AUG2020	48716	Placebo	13AUG2020/ Placebo	02SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
10131180	C4591001 1013 10131180	16-55	13AUG2020	48722	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10131182	C4591001 1013 10131182	16-55	13AUG2020	48717	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
10131185	C4591001 1013 10131185	16-55	13AUG2020	49013	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
10151001	C4591001 1015 10151001	16-55	10AUG2020	45329	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10151005	C4591001 1015 10151005	16-55	12AUG2020	45331	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
10151006	C4591001 1015 10151006	16-55	12AUG2020	45333	Placebo	12AUG2020/ Placebo	03SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
10151009	C4591001 1015 10151009	16-55	13AUG2020	45339	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
10151010	C4591001 1015 10151010	16-55	13AUG2020	48846	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
10151011	C4591001 1015 10151011	16-55	13AUG2020	48847	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
10151013	C4591001 1015 10151013	16-55	13AUG2020	48853	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
10151014	C4591001 1015 10151014	16-55	13AUG2020	48856	Placebo	13AUG2020/ Placebo	02SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10151015	C4591001 1015 10151015	16-55	14AUG2020	49890	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
10151017	C4591001 1015 10151017	16-55	14AUG2020	49892	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo		
10151018	C4591001 1015 10151018	16-55	14AUG2020	49895	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
10151021	C4591001 1015 10151021	16-55	14AUG2020	50793	Placebo	14AUG2020/ Placebo	02SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
10151023	C4591001 1015 10151023	16-55	14AUG2020	50790	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
10151026	C4591001 1015 10151026	16-55	15AUG2020	50800	Placebo	15AUG2020/ Placebo	03SEP2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
10151027	C4591001 1015 10151027	16-55	15AUG2020	51187	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
10161017	C4591001 1016 10161017	16-55	31JUL2020	40441	Placebo	31JUL2020/ Placebo	20AUG2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
10161018	C4591001 1016 10161018	16-55	31JUL2020	40901	Placebo	31JUL2020/ Placebo	20AUG2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
10161019	C4591001 1016 10161019	16-55	31JUL2020	40909	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10161020	C4591001 1016 10161020	16-55	31JUL2020	40908	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)		
10161021	C4591001 1016 10161021	16-55	31JUL2020	40912	Placebo	31JUL2020/ Placebo	20AUG2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
10161028	C4591001 1016 10161028	16-55	03AUG2020	41590	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10161029	C4591001 1016 10161029	16-55	03AUG2020	41592	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
10161030	C4591001 1016 10161030	16-55	03AUG2020	41587	Placebo	03AUG2020/ Placebo	25AUG2020/ Placebo	15DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
10161031	C4591001 1016 10161031	16-55	03AUG2020	41594	Placebo	03AUG2020/ Placebo	24AUG2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
10161038	C4591001 1016 10161038	16-55	04AUG2020	42174	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
10161043	C4591001 1016 10161043	16-55	04AUG2020	42176	Placebo	04AUG2020/ Placebo	25AUG2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10161045	C4591001 1016 10161045	16-55	04AUG2020	42182	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)		
10161046	C4591001 1016 10161046	16-55	04AUG2020	42184	Placebo	04AUG2020/ Placebo	28AUG2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10161047	C4591001 1016 10161047	16-55	04AUG2020	42612	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)			
10161048	C4591001 1016 10161048	16-55	04AUG2020	42614	Placebo	04AUG2020/ Placebo	24AUG2020/ Placebo	06JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
10161049	C4591001 1016 10161049	16-55	04AUG2020	42615	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
10161051	C4591001 1016 10161051	16-55	05AUG2020	42616	Placebo	05AUG2020/ Placebo	26AUG2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	20JAN2021/ BNT162b2 (30 µg)
10161054	C4591001 1016 10161054	16-55	05AUG2020	42823	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
10161057	C4591001 1016 10161057	16-55	05AUG2020	42824	Placebo	05AUG2020/ Placebo	27AUG2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
10161058	C4591001 1016 10161058	16-55	05AUG2020	42828	Placebo	05AUG2020/ Placebo	25AUG2020/ Placebo		
10161060	C4591001 1016 10161060	16-55	06AUG2020	43553	Placebo	06AUG2020/ Placebo	27AUG2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
10161064	C4591001 1016 10161064	16-55	06AUG2020	43554	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
10161065	C4591001 1016 10161065	16-55	06AUG2020	43561	Placebo	06AUG2020/ Placebo	27AUG2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10161069	C4591001 1016 10161069	16-55	06AUG2020	43562	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
10161071	C4591001 1016 10161071	16-55	06AUG2020	44022	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
10161073	C4591001 1016 10161073	16-55	06AUG2020	44023	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
10161076	C4591001 1016 10161076	16-55	06AUG2020	44025	Placebo	06AUG2020/ Placebo	28AUG2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
10161077	C4591001 1016 10161077	16-55	07AUG2020	44028	Placebo	07AUG2020/ Placebo	28AUG2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
10161078	C4591001 1016 10161078	16-55	07AUG2020	44280	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
10161080	C4591001 1016 10161080	16-55	07AUG2020	44282	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)		
10161081	C4591001 1016 10161081	16-55	07AUG2020	44281	Placebo	07AUG2020/ Placebo	28AUG2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
10161082	C4591001 1016 10161082	16-55	07AUG2020	44283	Placebo	07AUG2020/ Placebo	28AUG2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
10161084	C4591001 1016 10161084	16-55	07AUG2020	44491	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10161085	C4591001 1016 10161085	16-55	10AUG2020	44492	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
10161087	C4591001 1016 10161087	16-55	10AUG2020	44493	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)			
10161091	C4591001 1016 10161091	16-55	10AUG2020	44495	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo		
10161092	C4591001 1016 10161092	16-55	10AUG2020	45455	Placebo	10AUG2020/ Placebo	01SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
10161093	C4591001 1016 10161093	16-55	11AUG2020	45457	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
10161094	C4591001 1016 10161094	16-55	11AUG2020	45460	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10161095	C4591001 1016 10161095	16-55	11AUG2020	45458	Placebo	11AUG2020/ Placebo	01SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10161097	C4591001 1016 10161097	16-55	11AUG2020	46229	Placebo	11AUG2020/ Placebo	02SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
10161101	C4591001 1016 10161101	16-55	11AUG2020	46230	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10161102	C4591001 1016 10161102	16-55	12AUG2020	46234	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10161103	C4591001 1016 10161103	16-55	12AUG2020	46237	Placebo	12AUG2020/ Placebo	02SEP2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
10161105	C4591001 1016 10161105	16-55	12AUG2020	47441	Placebo	12AUG2020/ Placebo	01SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10161106	C4591001 1016 10161106	16-55	12AUG2020	47442	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
10161107	C4591001 1016 10161107	16-55	12AUG2020	47444	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
10161109	C4591001 1016 10161109	16-55	12AUG2020	47448	Placebo	12AUG2020/ Placebo	03SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10161114	C4591001 1016 10161114	16-55	13AUG2020	48605	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
10161117	C4591001 1016 10161117	16-55	13AUG2020	48606	Placebo	13AUG2020/ Placebo	02SEP2020/ Placebo		
10161118	C4591001 1016 10161118	16-55	13AUG2020	48607	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
10161119	C4591001 1016 10161119	16-55	14AUG2020	48615	Placebo	14AUG2020/ Placebo	02SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10161120	C4591001 1016 10161120	16-55	14AUG2020	50034	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10161122	C4591001 1016 10161122	16-55	14AUG2020	50036	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
10161123	C4591001 1016 10161123	16-55	14AUG2020	50038	Placebo	14AUG2020/ Placebo	03SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10161125	C4591001 1016 10161125	16-55	14AUG2020	50042	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
10181009	C4591001 1018 10181009	16-55	30JUL2020	40200	Placebo	30JUL2020/ Placebo	22AUG2020/ Placebo		
10181010	C4591001 1018 10181010	16-55	30JUL2020	40781	Placebo	30JUL2020/ Placebo	20AUG2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10181011	C4591001 1018 10181011	16-55	30JUL2020	40783	BNT162b2 (30 µg)	30JUL2020/ BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)		
10181012	C4591001 1018 10181012	16-55	30JUL2020	40790	BNT162b2 (30 µg)	30JUL2020/ BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)		
10181013	C4591001 1018 10181013	16-55	30JUL2020	40792	Placebo	30JUL2020/ Placebo	20AUG2020/ Placebo	16JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
10181014	C4591001 1018 10181014	16-55	30JUL2020	40799	Placebo	30JUL2020/ Placebo	20AUG2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)
10181015	C4591001 1018 10181015	16-55	31JUL2020	40800	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10181016	C4591001 1018 10181016	16-55	31JUL2020	41014	Placebo	31JUL2020/ Placebo	21AUG2020/ Placebo	09JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)
10181017	C4591001 1018 10181017	16-55	31JUL2020	40804	Placebo	31JUL2020/ Placebo	22AUG2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
10181018	C4591001 1018 10181018	16-55	31JUL2020	40802	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)		
10181019	C4591001 1018 10181019	16-55	31JUL2020	41010	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)		
10181020	C4591001 1018 10181020	16-55	31JUL2020	41015	Placebo	31JUL2020/ Placebo	21AUG2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10181021	C4591001 1018 10181021	16-55	31JUL2020	41013	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)		
10181022	C4591001 1018 10181022	16-55	31JUL2020	41117	Placebo	31JUL2020/ Placebo	21AUG2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
10181024	C4591001 1018 10181024	16-55	03AUG2020	41121	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)		
10181025	C4591001 1018 10181025	16-55	03AUG2020	41125	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)			
10181026	C4591001 1018 10181026	16-55	03AUG2020	41694	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10181027	C4591001 1018 10181027	16-55	03AUG2020	41127	Placebo	03AUG2020/ Placebo	24AUG2020/ Placebo		
10181028	C4591001 1018 10181028	16-55	03AUG2020	41765	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10181029	C4591001 1018 10181029	16-55	03AUG2020	41701	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
10181030	C4591001 1018 10181030	16-55	03AUG2020	41695	Placebo	03AUG2020/ Placebo	22AUG2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10181031	C4591001 1018 10181031	16-55	03AUG2020	41766	Placebo	03AUG2020/ Placebo	24AUG2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10181032	C4591001 1018 10181032	16-55	03AUG2020	41702	Placebo	03AUG2020/ Placebo	24AUG2020/ Placebo		
10181033	C4591001 1018 10181033	16-55	03AUG2020	41768	Placebo	03AUG2020/ Placebo	24AUG2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
10181034	C4591001 1018 10181034	16-55	03AUG2020	41776	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
10181036	C4591001 1018 10181036	16-55	03AUG2020	41959	Placebo	03AUG2020/ Placebo			
10181037	C4591001 1018 10181037	16-55	03AUG2020	41961	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10181038	C4591001 1018 10181038	16-55	03AUG2020	41964	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
10181039	C4591001 1018 10181039	16-55	03AUG2020	41994	Placebo	03AUG2020/ Placebo	22AUG2020/ Placebo		
10181040	C4591001 1018 10181040	16-55	03AUG2020	41965	Placebo	03AUG2020/ Placebo	24AUG2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
10181042	C4591001 1018 10181042	16-55	03AUG2020	41997	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
10181045	C4591001 1018 10181045	16-55	03AUG2020	42000	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10181046	C4591001 1018 10181046	16-55	03AUG2020	42004	Placebo	03AUG2020/ Placebo	24AUG2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10181047	C4591001 1018 10181047	16-55	04AUG2020	42252	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
10181048	C4591001 1018 10181048	16-55	04AUG2020	42254	Placebo	04AUG2020/ Placebo	25AUG2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
10181049	C4591001 1018 10181049	16-55	04AUG2020	42256	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
10181050	C4591001 1018 10181050	16-55	04AUG2020	42293	Placebo	04AUG2020/ Placebo	11SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10181051	C4591001 1018 10181051	16-55	04AUG2020	42253	Placebo	04AUG2020/ Placebo	25AUG2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10181052	C4591001 1018 10181052	16-55	04AUG2020	42295	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
10181053	C4591001 1018 10181053	16-55	04AUG2020	42298	Placebo	04AUG2020/ Placebo	25AUG2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
10181054	C4591001 1018 10181054	16-55	04AUG2020	42304	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)			
10181055	C4591001 1018 10181055	16-55	04AUG2020	42582	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
10181056	C4591001 1018 10181056	16-55	04AUG2020	42584	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
10181057	C4591001 1018 10181057	16-55	04AUG2020	42586	Placebo	04AUG2020/ Placebo	25AUG2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
10181058	C4591001 1018 10181058	16-55	04AUG2020	42589	Placebo	04AUG2020/ Placebo	25AUG2020/ Placebo		
10181059	C4591001 1018 10181059	16-55	04AUG2020	42702	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
10181062	C4591001 1018 10181062	16-55	05AUG2020	42703	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10181064	C4591001 1018 10181064	16-55	05AUG2020	42709	Placebo	05AUG2020/ Placebo	29AUG2020/ Placebo	16JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
10181066	C4591001 1018 10181066	16-55	05AUG2020	42711	Placebo	05AUG2020/ Placebo	26AUG2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10181067	C4591001 1018 10181067	16-55	05AUG2020	43098	Placebo	05AUG2020/ Placebo	26AUG2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
10181071	C4591001 1018 10181071	16-55	05AUG2020	43100	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)		
10181072	C4591001 1018 10181072	16-55	05AUG2020	43099	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)		
10181074	C4591001 1018 10181074	16-55	05AUG2020	43101	Placebo	05AUG2020/ Placebo	26AUG2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10181076	C4591001 1018 10181076	16-55	05AUG2020	43289	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
10181077	C4591001 1018 10181077	16-55	05AUG2020	43290	Placebo	05AUG2020/ Placebo	26AUG2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
10181079	C4591001 1018 10181079	16-55	05AUG2020	43291	Placebo	05AUG2020/ Placebo	26AUG2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
10181081	C4591001 1018 10181081	16-55	05AUG2020	43293	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10181083	C4591001 1018 10181083	16-55	06AUG2020	43675	Placebo	06AUG2020/ Placebo	27AUG2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10181084	C4591001 1018 10181084	16-55	06AUG2020	43622	Placebo	06AUG2020/ Placebo	26AUG2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
10181085	C4591001 1018 10181085	16-55	06AUG2020	43613	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)		
10181086	C4591001 1018 10181086	16-55	06AUG2020	43614	Placebo	06AUG2020/ Placebo	27AUG2020/ Placebo	23JAN2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10181088	C4591001 1018 10181088	16-55	06AUG2020	43818	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
10181089	C4591001 1018 10181089	16-55	06AUG2020	43623	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)		
10181090	C4591001 1018 10181090	16-55	06AUG2020	43680	Placebo	06AUG2020/ Placebo	27AUG2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10181091	C4591001 1018 10181091	16-55	06AUG2020	43676	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10181093	C4591001 1018 10181093	16-55	06AUG2020	43678	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
10181094	C4591001 1018 10181094	16-55	07AUG2020	44739	Placebo	07AUG2020/ Placebo	01SEP2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	28JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10181095	C4591001 1018 10181095	16-55	07AUG2020	43821	Placebo	07AUG2020/ Placebo	27AUG2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
10181098	C4591001 1018 10181098	16-55	07AUG2020	43827	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
10181100	C4591001 1018 10181100	16-55	07AUG2020	43824	Placebo	07AUG2020/ Placebo	02SEP2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
10181103	C4591001 1018 10181103	16-55	07AUG2020	44733	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)		
10181104	C4591001 1018 10181104	16-55	07AUG2020	44734	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
10181105	C4591001 1018 10181105	16-55	07AUG2020	44737	Placebo	07AUG2020/ Placebo	26AUG2020/ Placebo		
10181106	C4591001 1018 10181106	16-55	07AUG2020	44901	Placebo	07AUG2020/ Placebo	27AUG2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
10181107	C4591001 1018 10181107	16-55	10AUG2020	44902	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10181108	C4591001 1018 10181108	16-55	10AUG2020	44908	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
10181109	C4591001 1018 10181109	16-55	10AUG2020	44904	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10181111	C4591001 1018 10181111	16-55	10AUG2020	45557	Placebo	10AUG2020/ Placebo	01SEP2020/ Placebo		
10181113	C4591001 1018 10181113	16-55	10AUG2020	45562	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo		
10181114	C4591001 1018 10181114	16-55	10AUG2020	45558	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10181116	C4591001 1018 10181116	16-55	10AUG2020	45858	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10181118	C4591001 1018 10181118	16-55	10AUG2020	45859	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
10181119	C4591001 1018 10181119	16-55	10AUG2020	45564	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10181120	C4591001 1018 10181120	16-55	10AUG2020	45862	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	20JAN2021/ BNT162b2 (30 µg)
10181125	C4591001 1018 10181125	16-55	11AUG2020	45868	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
10181126	C4591001 1018 10181126	16-55	11AUG2020	46853	Placebo	11AUG2020/ Placebo	01SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
10181127	C4591001 1018 10181127	16-55	12AUG2020	46856	Placebo	12AUG2020/ Placebo	12SEP2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10181128	C4591001 1018 10181128	16-55	12AUG2020	46858	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
10181131	C4591001 1018 10181131	16-55	12AUG2020	47429	Placebo	12AUG2020/ Placebo	02SEP2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
10181133	C4591001 1018 10181133	16-55	12AUG2020	46860	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
10181139	C4591001 1018 10181139	16-55	12AUG2020	47435	Placebo	12AUG2020/ Placebo	02SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
10181141	C4591001 1018 10181141	16-55	13AUG2020	49002	Placebo	13AUG2020/ Placebo	02SEP2020/ Placebo		
10181142	C4591001 1018 10181142	16-55	13AUG2020	47439	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)			
10181143	C4591001 1018 10181143	16-55	13AUG2020	48799	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo	09JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)
10181144	C4591001 1018 10181144	16-55	13AUG2020	47440	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10181145	C4591001 1018 10181145	16-55	13AUG2020	49006	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
10181146	C4591001 1018 10181146	16-55	13AUG2020	48802	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10181148	C4591001 1018 10181148	16-55	13AUG2020	48800	Placebo	13AUG2020/ Placebo	01SEP2020/ Placebo	16JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
10181149	C4591001 1018 10181149	16-55	13AUG2020	49003	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
10181150	C4591001 1018 10181150	16-55	13AUG2020	48806	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
10181151	C4591001 1018 10181151	16-55	13AUG2020	49011	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	
10181152	C4591001 1018 10181152	16-55	14AUG2020	50251	Placebo	14AUG2020/ Placebo	02SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10181154	C4591001 1018 10181154	16-55	13AUG2020	49221	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
10181156	C4591001 1018 10181156	16-55	13AUG2020	49227	Placebo	13AUG2020/ Placebo	02SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
10181157	C4591001 1018 10181157	16-55	13AUG2020	49222	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
10181158	C4591001 1018 10181158	16-55	13AUG2020	49223	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
10181159	C4591001 1018 10181159	16-55	14AUG2020	50249	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10181160	C4591001 1018 10181160	16-55	14AUG2020	50254	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
10181162	C4591001 1018 10181162	16-55	14AUG2020	50909	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
10181163	C4591001 1018 10181163	16-55	14AUG2020	50918	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
10181167	C4591001 1018 10181167	16-55	14AUG2020	50919	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
10181186	C4591001 1018 10181186	16-55	19AUG2020	56266	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
10191002	C4591001 1019 10191002	16-55	10AUG2020	45198	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10191005	C4591001 1019 10191005	16-55	10AUG2020	45204	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10191006	C4591001 1019 10191006	16-55	10AUG2020	45205	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10191007	C4591001 1019 10191007	16-55	10AUG2020	45208	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10191015	C4591001 1019 10191015	16-55	11AUG2020	46555	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10191018	C4591001 1019 10191018	16-55	12AUG2020	46556	Placebo	12AUG2020/ Placebo	02SEP2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
10191023	C4591001 1019 10191023	16-55	12AUG2020	46559	Placebo	12AUG2020/ Placebo	02SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
10191027	C4591001 1019 10191027	16-55	13AUG2020	46561	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
10191028	C4591001 1019 10191028	16-55	13AUG2020	227548	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
10191032	C4591001 1019 10191032	16-55	13AUG2020	49054	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
10191034	C4591001 1019 10191034	16-55	13AUG2020	49055	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
10191036	C4591001 1019 10191036	16-55	13AUG2020	49056	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
10191038	C4591001 1019 10191038	16-55	14AUG2020	49060	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10191041	C4591001 1019 10191041	16-55	14AUG2020	50393	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10211011	C4591001 1021 10211011	16-55	11AUG2020	225576	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10211012	C4591001 1021 10211012	16-55	11AUG2020	46484	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10211016	C4591001 1021 10211016	16-55	11AUG2020	46490	Placebo	11AUG2020/ Placebo	02SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
10211032	C4591001 1021 10211032	16-55	13AUG2020	46491	Placebo	13AUG2020/ Placebo	16SEP2020/ Placebo	06JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
10211040	C4591001 1021 10211040	16-55	14AUG2020	46492	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
10221004	C4591001 1022 10221004	16-55	14AUG2020	50525	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
10241001	C4591001 1024 10241001	16-55	12AUG2020	47311	Placebo	12AUG2020/ Placebo	02SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10241002	C4591001 1024 10241002	16-55	12AUG2020	47313	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
10241004	C4591001 1024 10241004	16-55	12AUG2020	47315	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
10241005	C4591001 1024 10241005	16-55	12AUG2020	47316	Placebo	12AUG2020/ Placebo	02SEP2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	28JAN2021/ BNT162b2 (30 µg)
10241006	C4591001 1024 10241006	16-55	12AUG2020	47850	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10241009	C4591001 1024 10241009	16-55	13AUG2020	47851	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
10241011	C4591001 1024 10241011	16-55	13AUG2020	47855	Placebo	13AUG2020/ Placebo	01SEP2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
10241012	C4591001 1024 10241012	16-55	13AUG2020	47858	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
10241014	C4591001 1024 10241014	16-55	13AUG2020	49565	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
10241015	C4591001 1024 10241015	16-55	13AUG2020	49568	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
10241016	C4591001 1024 10241016	16-55	13AUG2020	49573	Placebo	13AUG2020/ Placebo	01SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
10241020	C4591001 1024 10241020	16-55	14AUG2020	49574	Placebo	14AUG2020/ Placebo	03SEP2020/ Placebo	15DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
10241021	C4591001 1024 10241021	16-55	14AUG2020	50345	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
10241023	C4591001 1024 10241023	16-55	14AUG2020	50349	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
10271005	C4591001 1027 10271005	16-55	13AUG2020	48570	Placebo	13AUG2020/ Placebo	04SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10271012	C4591001 1027 10271012	16-55	14AUG2020	48572	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
10271017	C4591001 1027 10271017	16-55	14AUG2020	48574	Placebo	14AUG2020/ Placebo	03SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
10271019	C4591001 1027 10271019	16-55	14AUG2020	48577	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
10271021	C4591001 1027 10271021	16-55	14AUG2020	50599	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
10281001	C4591001 1028 10281001	16-55	13AUG2020	48535	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
10281002	C4591001 1028 10281002	16-55	13AUG2020	48538	Placebo	13AUG2020/ Placebo	02SEP2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
10281003	C4591001 1028 10281003	16-55	14AUG2020	48540	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo		
10421013	C4591001 1042 10421013	16-55	31JUL2020	40877	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
10421014	C4591001 1042 10421014	16-55	31JUL2020	40879	Placebo	31JUL2020/ Placebo	19AUG2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	20JAN2021/ BNT162b2 (30 µg)
10421017	C4591001 1042 10421017	16-55	31JUL2020	40882	Placebo	31JUL2020/ Placebo	19AUG2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10421020	C4591001 1042 10421020	16-55	31JUL2020	40884	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)		
10421021	C4591001 1042 10421021	16-55	03AUG2020	41621	Placebo	03AUG2020/ Placebo	24AUG2020/ Placebo	03MAR2021/ BNT162b2 (30 µg)	
10421022	C4591001 1042 10421022	16-55	03AUG2020	41624	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
10421024	C4591001 1042 10421024	16-55	03AUG2020	41625	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
10421027	C4591001 1042 10421027	16-55	03AUG2020	41950	Placebo	03AUG2020/ Placebo	24AUG2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
10421028	C4591001 1042 10421028	16-55	03AUG2020	41628	Placebo	03AUG2020/ Placebo	26AUG2020/ Placebo		
10421029	C4591001 1042 10421029	16-55	03AUG2020	41951	Placebo	03AUG2020/ Placebo	24AUG2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
10421031	C4591001 1042 10421031	16-55	04AUG2020	41952	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
10421034	C4591001 1042 10421034	16-55	04AUG2020	41955	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
10421035	C4591001 1042 10421035	16-55	04AUG2020	42511	Placebo	04AUG2020/ Placebo	27AUG2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10421039	C4591001 1042 10421039	16-55	04AUG2020	42512	Placebo	04AUG2020/ Placebo	25AUG2020/ Placebo		
10421041	C4591001 1042 10421041	16-55	04AUG2020	42516	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
10421043	C4591001 1042 10421043	16-55	05AUG2020	42941	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
10421044	C4591001 1042 10421044	16-55	05AUG2020	42517	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
10421045	C4591001 1042 10421045	16-55	05AUG2020	42942	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
10421050	C4591001 1042 10421050	16-55	05AUG2020	42949	Placebo	05AUG2020/ Placebo	28AUG2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10421051	C4591001 1042 10421051	16-55	06AUG2020	42951	Placebo	06AUG2020/ Placebo	26AUG2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10421057	C4591001 1042 10421057	16-55	06AUG2020	44082	Placebo	06AUG2020/ Placebo	25AUG2020/ Placebo		
10421059	C4591001 1042 10421059	16-55	07AUG2020	44083	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
10421061	C4591001 1042 10421061	16-55	07AUG2020	44090	Placebo	07AUG2020/ Placebo	28AUG2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10421063	C4591001 1042 10421063	16-55	07AUG2020	44092	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
10421065	C4591001 1042 10421065	16-55	07AUG2020	44838	Placebo	07AUG2020/ Placebo	26AUG2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10421068	C4591001 1042 10421068	16-55	10AUG2020	44840	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10421069	C4591001 1042 10421069	16-55	10AUG2020	44841	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)			
10421070	C4591001 1042 10421070	16-55	10AUG2020	45439	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10421071	C4591001 1042 10421071	16-55	10AUG2020	44848	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
10421073	C4591001 1042 10421073	16-55	10AUG2020	45441	Placebo	10AUG2020/ Placebo	01SEP2020/ Placebo		
10421076	C4591001 1042 10421076	16-55	10AUG2020	45448	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10421077	C4591001 1042 10421077	16-55	10AUG2020	45444	Placebo	10AUG2020/ Placebo	02SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10421079	C4591001 1042 10421079	16-55	10AUG2020	45966	Placebo	10AUG2020/ Placebo	09SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10421080	C4591001 1042 10421080	16-55	10AUG2020	45970	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10421081	C4591001 1042 10421081	16-55	11AUG2020	45972	Placebo	11AUG2020/ Placebo	01SEP2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	20JAN2021/ BNT162b2 (30 µg)
10421082	C4591001 1042 10421082	16-55	11AUG2020	45974	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
10421083	C4591001 1042 10421083	16-55	11AUG2020	46391	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10421085	C4591001 1042 10421085	16-55	11AUG2020	46392	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
10421088	C4591001 1042 10421088	16-55	11AUG2020	46395	Placebo	11AUG2020/ Placebo	01SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
10421092	C4591001 1042 10421092	16-55	11AUG2020	46396	Placebo	11AUG2020/ Placebo	10SEP2020/ Placebo		
10421093	C4591001 1042 10421093	16-55	12AUG2020	47225	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
10421095	C4591001 1042 10421095	16-55	12AUG2020	47233	Placebo	12AUG2020/ Placebo	02SEP2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	20JAN2021/ BNT162b2 (30 µg)
10421100	C4591001 1042 10421100	16-55	12AUG2020	47235	Placebo	12AUG2020/ Placebo	02SEP2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10421103	C4591001 1042 10421103	16-55	12AUG2020	47236	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
10421105	C4591001 1042 10421105	16-55	14AUG2020	50133	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
10421106	C4591001 1042 10421106	16-55	14AUG2020	50134	Placebo	14AUG2020/ Placebo	02SEP2020/ Placebo		
10421108	C4591001 1042 10421108	16-55	14AUG2020	50137	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
10421109	C4591001 1042 10421109	16-55	14AUG2020	50140	Placebo	14AUG2020/ Placebo	02SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
10441001	C4591001 1044 10441001	16-55	14AUG2020	50057	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
10461001	C4591001 1046 10461001	16-55	12AUG2020	47983	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10461002	C4591001 1046 10461002	16-55	12AUG2020	47985	Placebo	12AUG2020/ Placebo	31AUG2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
10461005	C4591001 1046 10461005	16-55	13AUG2020	47987	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
10461006	C4591001 1046 10461006	16-55	13AUG2020	47991	Placebo	13AUG2020/ Placebo	01SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10461010	C4591001 1046 10461010	16-55	13AUG2020	49111	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
10461011	C4591001 1046 10461011	16-55	13AUG2020	49113	Placebo	13AUG2020/ Placebo	01SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
10461014	C4591001 1046 10461014	16-55	13AUG2020	49118	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
10461016	C4591001 1046 10461016	16-55	13AUG2020	49120	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
10461018	C4591001 1046 10461018	16-55	14AUG2020	50081	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
10461020	C4591001 1046 10461020	16-55	14AUG2020	50082	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
10461023	C4591001 1046 10461023	16-55	14AUG2020	50089	Placebo	14AUG2020/ Placebo	02SEP2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10461024	C4591001 1046 10461024	16-55	14AUG2020	50092	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
10461026	C4591001 1046 10461026	16-55	14AUG2020	50801	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
10461027	C4591001 1046 10461027	16-55	14AUG2020	50805	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10461028	C4591001 1046 10461028	16-55	14AUG2020	50806	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
10461029	C4591001 1046 10461029	16-55	14AUG2020	50809	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
10461030	C4591001 1046 10461030	16-55	14AUG2020	51018	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
10461031	C4591001 1046 10461031	16-55	14AUG2020	51019	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
10461039	C4591001 1046 10461039	16-55	15AUG2020	51028	Placebo	15AUG2020/ Placebo	03SEP2020/ Placebo		
10481001	C4591001 1048 10481001	16-55	07AUG2020	44861	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
10481004	C4591001 1048 10481004	16-55	14AUG2020	44866	Placebo	14AUG2020/ Placebo	02SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
10551001	C4591001 1055 10551001	16-55	06AUG2020	43751	Placebo	06AUG2020/ Placebo	26AUG2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10551003	C4591001 1055 10551003	16-55	06AUG2020	43752	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)		
10551007	C4591001 1055 10551007	16-55	07AUG2020	43753	Placebo	07AUG2020/ Placebo	28AUG2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10551012	C4591001 1055 10551012	16-55	10AUG2020	43756	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
10551013	C4591001 1055 10551013	16-55	10AUG2020	45679	Placebo	10AUG2020/ Placebo	01SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
10551016	C4591001 1055 10551016	16-55	10AUG2020	45680	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10551020	C4591001 1055 10551020	16-55	11AUG2020	45681	Placebo	11AUG2020/ Placebo	31AUG2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10551021	C4591001 1055 10551021	16-55	11AUG2020	45684	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10551022	C4591001 1055 10551022	16-55	11AUG2020	46602	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10551025	C4591001 1055 10551025	16-55	11AUG2020	46607	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10551026	C4591001 1055 10551026	16-55	11AUG2020	46608	Placebo	11AUG2020/ Placebo	01SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
10551028	C4591001 1055 10551028	16-55	11AUG2020	46610	Placebo	11AUG2020/ Placebo	02SEP2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
10551029	C4591001 1055 10551029	16-55	12AUG2020	47502	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10551032	C4591001 1055 10551032	16-55	12AUG2020	47504	Placebo	12AUG2020/ Placebo	02SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10551034	C4591001 1055 10551034	16-55	12AUG2020	47505	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
10551037	C4591001 1055 10551037	16-55	12AUG2020	47506	Placebo	12AUG2020/ Placebo	31AUG2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)
10551040	C4591001 1055 10551040	16-55	13AUG2020	49230	Placebo	13AUG2020/ Placebo	02SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10551042	C4591001 1055 10551042	16-55	13AUG2020	49235	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
10551043	C4591001 1055 10551043	16-55	13AUG2020	49238	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
10551045	C4591001 1055 10551045	16-55	13AUG2020	49239	Placebo	13AUG2020/ Placebo	02SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10551046	C4591001 1055 10551046	16-55	13AUG2020	49615	Placebo	13AUG2020/ Placebo	02SEP2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)
10561013	C4591001 1056 10561013	16-55	21AUG2020	60584	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
10571001	C4591001 1057 10571001	16-55	12AUG2020	47742	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10571002	C4591001 1057 10571002	16-55	12AUG2020	47746	Placebo	12AUG2020/ Placebo	02SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
10571005	C4591001 1057 10571005	16-55	13AUG2020	47748	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
10571006	C4591001 1057 10571006	16-55	13AUG2020	48429	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10571007	C4591001 1057 10571007	16-55	13AUG2020	47749	Placebo	13AUG2020/ Placebo	02SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10571008	C4591001 1057 10571008	16-55	13AUG2020	48430	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo		
10571009	C4591001 1057 10571009	16-55	13AUG2020	48431	Placebo	13AUG2020/ Placebo	01SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10571012	C4591001 1057 10571012	16-55	13AUG2020	48435	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
10571013	C4591001 1057 10571013	16-55	13AUG2020	48833	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10571014	C4591001 1057 10571014	16-55	13AUG2020	48839	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
10571015	C4591001 1057 10571015	16-55	13AUG2020	48841	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10571016	C4591001 1057 10571016	16-55	14AUG2020	48844	Placebo	14AUG2020/ Placebo	02SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
10571017	C4591001 1057 10571017	16-55	14AUG2020	49880	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
10571018	C4591001 1057 10571018	16-55	14AUG2020	49884	Placebo	14AUG2020/ Placebo	03SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10571019	C4591001 1057 10571019	16-55	14AUG2020	49887	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10571024	C4591001 1057 10571024	16-55	14AUG2020	49888	Placebo	14AUG2020/ Placebo	02SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10661002	C4591001 1066 10661002	16-55	11AUG2020	46697	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
10661015	C4591001 1066 10661015	16-55	12AUG2020	46702	Placebo	12AUG2020/ Placebo	03SEP2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
10661019	C4591001 1066 10661019	16-55	12AUG2020	46705	Placebo	12AUG2020/ Placebo	01SEP2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
10661020	C4591001 1066 10661020	16-55	12AUG2020	46708	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
10661022	C4591001 1066 10661022	16-55	13AUG2020	48786	Placebo	13AUG2020/ Placebo	02SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10661025	C4591001 1066 10661025	16-55	13AUG2020	48789	Placebo	13AUG2020/ Placebo	04SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
10661026	C4591001 1066 10661026	16-55	13AUG2020	48790	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
10661027	C4591001 1066 10661027	16-55	13AUG2020	48791	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
10661028	C4591001 1066 10661028	16-55	13AUG2020	49470	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo	02MAR2021/ BNT162b2 (30 µg)	
10711004	C4591001 1071 10711004	16-55	10AUG2020	45871	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
10711005	C4591001 1071 10711005	16-55	10AUG2020	45876	Placebo	10AUG2020/ Placebo	01SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10711006	C4591001 1071 10711006	16-55	10AUG2020	45877	Placebo	10AUG2020/ Placebo	01SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10711008	C4591001 1071 10711008	16-55	10AUG2020	45880	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10711019	C4591001 1071 10711019	16-55	11AUG2020	46916	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
10711020	C4591001 1071 10711020	16-55	12AUG2020	46918	Placebo	12AUG2020/ Placebo	02SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10711021	C4591001 1071 10711021	16-55	12AUG2020	46917	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10711022	C4591001 1071 10711022	16-55	12AUG2020	46922	Placebo	12AUG2020/ Placebo	31AUG2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10711026	C4591001 1071 10711026	16-55	12AUG2020	47933	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
10711027	C4591001 1071 10711027	16-55	12AUG2020	47934	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
10711028	C4591001 1071 10711028	16-55	12AUG2020	47936	Placebo	12AUG2020/ Placebo	02SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10711030	C4591001 1071 10711030	16-55	13AUG2020	47943	Placebo	13AUG2020/ Placebo	02SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
10711034	C4591001 1071 10711034	16-55	13AUG2020	49680	Placebo	13AUG2020/ Placebo	01SEP2020/ Placebo		
10711036	C4591001 1071 10711036	16-55	13AUG2020	49682	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
10711037	C4591001 1071 10711037	16-55	14AUG2020	49683	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
10711039	C4591001 1071 10711039	16-55	14AUG2020	49684	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10711040	C4591001 1071 10711040	16-55	14AUG2020	50417	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10711041	C4591001 1071 10711041	16-55	14AUG2020	50418	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
10711042	C4591001 1071 10711042	16-55	14AUG2020	50424	Placebo	14AUG2020/ Placebo	02SEP2020/ Placebo	24JAN2021/ BNT162b2 (30 µg)	14FEB2021/ BNT162b2 (30 µg)
10711045	C4591001 1071 10711045	16-55	14AUG2020	50425	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
10711047	C4591001 1071 10711047	16-55	14AUG2020	51042	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
10731016	C4591001 1073 10731016	16-55	31JUL2020	40728	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
10731020	C4591001 1073 10731020	16-55	31JUL2020	40730	Placebo	31JUL2020/ Placebo	27AUG2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
10731021	C4591001 1073 10731021	16-55	31JUL2020	40732	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
10731022	C4591001 1073 10731022	16-55	03AUG2020	41657	Placebo	03AUG2020/ Placebo	25AUG2020/ Placebo		
10731027	C4591001 1073 10731027	16-55	03AUG2020	41660	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10731028	C4591001 1073 10731028	16-55	04AUG2020	41664	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)		
10731029	C4591001 1073 10731029	16-55	04AUG2020	41665	Placebo	04AUG2020/ Placebo	26AUG2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10731032	C4591001 1073 10731032	16-55	04AUG2020	42463	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
10731034	C4591001 1073 10731034	16-55	04AUG2020	42464	Placebo	04AUG2020/ Placebo	26AUG2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10731036	C4591001 1073 10731036	16-55	05AUG2020	42465	Placebo	05AUG2020/ Placebo	28AUG2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
10731038	C4591001 1073 10731038	16-55	05AUG2020	42468	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)			
10731045	C4591001 1073 10731045	16-55	06AUG2020	43739	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
10731048	C4591001 1073 10731048	16-55	06AUG2020	43741	Placebo	06AUG2020/ Placebo	28AUG2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
10731050	C4591001 1073 10731050	16-55	06AUG2020	43740	Placebo	06AUG2020/ Placebo	03SEP2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	28JAN2021/ BNT162b2 (30 µg)
10731056	C4591001 1073 10731056	16-55	10AUG2020	45655	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10731057	C4591001 1073 10731057	16-55	10AUG2020	43742	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10731059	C4591001 1073 10731059	16-55	10AUG2020	45656	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
10731062	C4591001 1073 10731062	16-55	11AUG2020	45660	Placebo	11AUG2020/ Placebo	01SEP2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)
10731063	C4591001 1073 10731063	16-55	11AUG2020	45662	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
10731064	C4591001 1073 10731064	16-55	11AUG2020	46350	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
10731065	C4591001 1073 10731065	16-55	11AUG2020	46352	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
10731067	C4591001 1073 10731067	16-55	11AUG2020	46353	Placebo	11AUG2020/ Placebo	02SEP2020/ Placebo		
10731068	C4591001 1073 10731068	16-55	11AUG2020	46360	Placebo	11AUG2020/ Placebo	02SEP2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
10731077	C4591001 1073 10731077	16-55	12AUG2020	47537	Placebo	12AUG2020/ Placebo	03SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
10731079	C4591001 1073 10731079	16-55	12AUG2020	47538	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10731081	C4591001 1073 10731081	16-55	12AUG2020	47541	Placebo	12AUG2020/ Placebo	03SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10731083	C4591001 1073 10731083	16-55	13AUG2020	47545	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
10731084	C4591001 1073 10731084	16-55	13AUG2020	48812	Placebo	13AUG2020/ Placebo	02SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
10731085	C4591001 1073 10731085	16-55	13AUG2020	48813	Placebo	13AUG2020/ Placebo	01SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10771001	C4591001 1077 10771001	16-55	10AUG2020	45162	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10771002	C4591001 1077 10771002	16-55	10AUG2020	45164	Placebo	10AUG2020/ Placebo	02SEP2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
10771003	C4591001 1077 10771003	16-55	10AUG2020	45165	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10771004	C4591001 1077 10771004	16-55	10AUG2020	45170	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
10771007	C4591001 1077 10771007	16-55	10AUG2020	45356	Placebo	10AUG2020/ Placebo	04SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10771008	C4591001 1077 10771008	16-55	10AUG2020	45358	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10771009	C4591001 1077 10771009	16-55	10AUG2020	45361	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10771010	C4591001 1077 10771010	16-55	10AUG2020	45363	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10771013	C4591001 1077 10771013	16-55	10AUG2020	45801	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10771014	C4591001 1077 10771014	16-55	10AUG2020	45802	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
10771015	C4591001 1077 10771015	16-55	11AUG2020	45807	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10771018	C4591001 1077 10771018	16-55	11AUG2020	45808	Placebo	11AUG2020/ Placebo	31AUG2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
10771019	C4591001 1077 10771019	16-55	11AUG2020	46193	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10771020	C4591001 1077 10771020	16-55	11AUG2020	46194	Placebo	11AUG2020/ Placebo	01SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
10771023	C4591001 1077 10771023	16-55	11AUG2020	46197	Placebo	11AUG2020/ Placebo	01SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10771027	C4591001 1077 10771027	16-55	11AUG2020	46201	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10771028	C4591001 1077 10771028	16-55	11AUG2020	46788	Placebo	11AUG2020/ Placebo	31AUG2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
10771029	C4591001 1077 10771029	16-55	11AUG2020	46782	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10771030	C4591001 1077 10771030	16-55	12AUG2020	46791	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
10771031	C4591001 1077 10771031	16-55	12AUG2020	46792	Placebo	12AUG2020/ Placebo	04SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
10771035	C4591001 1077 10771035	16-55	12AUG2020	47197	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
10771036	C4591001 1077 10771036	16-55	12AUG2020	47198	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
10771037	C4591001 1077 10771037	16-55	12AUG2020	47200	Placebo	12AUG2020/ Placebo	04SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
10771038	C4591001 1077 10771038	16-55	12AUG2020	47577	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
10791017	C4591001 1079 10791017	16-55	31JUL2020	40307	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)		
10791018	C4591001 1079 10791018	16-55	31JUL2020	41145	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10791021	C4591001 1079 10791021	16-55	31JUL2020	41148	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)		
10791022	C4591001 1079 10791022	16-55	31JUL2020	41150	Placebo	31JUL2020/ Placebo	19AUG2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
10791037	C4591001 1079 10791037	16-55	03AUG2020	41151	Placebo	03AUG2020/ Placebo	26AUG2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
10791039	C4591001 1079 10791039	16-55	03AUG2020	41729	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
10791040	C4591001 1079 10791040	16-55	03AUG2020	41732	Placebo	03AUG2020/ Placebo	24AUG2020/ Placebo		
10791046	C4591001 1079 10791046	16-55	04AUG2020	41733	Placebo	04AUG2020/ Placebo	26AUG2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
10791047	C4591001 1079 10791047	16-55	04AUG2020	41734	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
10791048	C4591001 1079 10791048	16-55	04AUG2020	42320	Placebo	04AUG2020/ Placebo	25AUG2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
10791050	C4591001 1079 10791050	16-55	04AUG2020	42323	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
10791053	C4591001 1079 10791053	16-55	05AUG2020	42325	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10791054	C4591001 1079 10791054	16-55	05AUG2020	42327	Placebo	05AUG2020/ Placebo	28AUG2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
10791058	C4591001 1079 10791058	16-55	05AUG2020	42978	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)		
10791059	C4591001 1079 10791059	16-55	05AUG2020	42979	Placebo	05AUG2020/ Placebo	26AUG2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
10791060	C4591001 1079 10791060	16-55	05AUG2020	42984	Placebo	05AUG2020/ Placebo	27AUG2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
10791061	C4591001 1079 10791061	16-55	05AUG2020	222967	Placebo	05AUG2020/ Placebo	25AUG2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	15JAN2021/ BNT162b2 (30 µg)
10791062	C4591001 1079 10791062	16-55	05AUG2020	222972	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
10791063	C4591001 1079 10791063	16-55	05AUG2020	42985	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
10791072	C4591001 1079 10791072	16-55	06AUG2020	43939	Placebo	06AUG2020/ Placebo	27AUG2020/ Placebo		
10791073	C4591001 1079 10791073	16-55	06AUG2020	43941	Placebo	06AUG2020/ Placebo	27AUG2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
10791075	C4591001 1079 10791075	16-55	07AUG2020	43944	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10791077	C4591001 1079 10791077	16-55	07AUG2020	43948	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
10791079	C4591001 1079 10791079	16-55	07AUG2020	44431	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
10791082	C4591001 1079 10791082	16-55	07AUG2020	44432	Placebo	07AUG2020/ Placebo	24AUG2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
10791086	C4591001 1079 10791086	16-55	10AUG2020	44439	Placebo	10AUG2020/ Placebo	02SEP2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10791087	C4591001 1079 10791087	16-55	10AUG2020	45461	Placebo	10AUG2020/ Placebo	01SEP2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	
10791089	C4591001 1079 10791089	16-55	10AUG2020	45467	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
10791090	C4591001 1079 10791090	16-55	10AUG2020	45468	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
10791091	C4591001 1079 10791091	16-55	10AUG2020	45472	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10791096	C4591001 1079 10791096	16-55	11AUG2020	46421	Placebo	11AUG2020/ Placebo	01SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
10791097	C4591001 1079 10791097	16-55	11AUG2020	46423	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10791098	C4591001 1079 10791098	16-55	11AUG2020	46428	Placebo	11AUG2020/ Placebo	03SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10791099	C4591001 1079 10791099	16-55	11AUG2020	46432	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
10791102	C4591001 1079 10791102	16-55	12AUG2020	47179	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
10791106	C4591001 1079 10791106	16-55	12AUG2020	47181	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
10791107	C4591001 1079 10791107	16-55	12AUG2020	47182	Placebo	12AUG2020/ Placebo	02SEP2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
10791109	C4591001 1079 10791109	16-55	12AUG2020	47188	Placebo	12AUG2020/ Placebo	03SEP2020/ Placebo		
10791110	C4591001 1079 10791110	16-55	12AUG2020	47609	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
10791112	C4591001 1079 10791112	16-55	12AUG2020	47610	Placebo	12AUG2020/ Placebo	04SEP2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
10791113	C4591001 1079 10791113	16-55	12AUG2020	47611	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
10791114	C4591001 1079 10791114	16-55	12AUG2020	47613	Placebo	12AUG2020/ Placebo	02SEP2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10791115	C4591001 1079 10791115	16-55	12AUG2020	48000	Placebo	12AUG2020/ Placebo	02SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
10791116	C4591001 1079 10791116	16-55	12AUG2020	47996	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
10791117	C4591001 1079 10791117	16-55	13AUG2020	48002	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10791118	C4591001 1079 10791118	16-55	13AUG2020	48003	Placebo	13AUG2020/ Placebo	01SEP2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
10791120	C4591001 1079 10791120	16-55	13AUG2020	48658	Placebo	13AUG2020/ Placebo	09SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
10791124	C4591001 1079 10791124	16-55	13AUG2020	48660	Placebo	13AUG2020/ Placebo	01SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
10791125	C4591001 1079 10791125	16-55	13AUG2020	48663	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
10791126	C4591001 1079 10791126	16-55	13AUG2020	48662	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
10791127	C4591001 1079 10791127	16-55	13AUG2020	49410	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
10791162	C4591001 1079 10791162	16-55	20AUG2020	56939	Placebo	20AUG2020/ Placebo	26AUG2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10801001	C4591001 1080 10801001	16-55	10AUG2020	45173	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
10801002	C4591001 1080 10801002	16-55	10AUG2020	45174	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10801003	C4591001 1080 10801003	16-55	10AUG2020	45176	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10801004	C4591001 1080 10801004	16-55	10AUG2020	45182	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
10801009	C4591001 1080 10801009	16-55	11AUG2020	46038	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
10801010	C4591001 1080 10801010	16-55	11AUG2020	46044	Placebo	11AUG2020/ Placebo	02SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
10801017	C4591001 1080 10801017	16-55	12AUG2020	46045	Placebo	12AUG2020/ Placebo	02SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
10801018	C4591001 1080 10801018	16-55	12AUG2020	46048	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
10801019	C4591001 1080 10801019	16-55	12AUG2020	47382	Placebo	12AUG2020/ Placebo	31AUG2020/ Placebo		
10801022	C4591001 1080 10801022	16-55	12AUG2020	47389	Placebo	12AUG2020/ Placebo	02SEP2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10801023	C4591001 1080 10801023	16-55	13AUG2020	47391	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
10801026	C4591001 1080 10801026	16-55	13AUG2020	47392	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
10801027	C4591001 1080 10801027	16-55	13AUG2020	48666	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
10801032	C4591001 1080 10801032	16-55	14AUG2020	48667	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
10801033	C4591001 1080 10801033	16-55	14AUG2020	48670	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
10811001	C4591001 1081 10811001	16-55	10AUG2020	45066	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10811003	C4591001 1081 10811003	16-55	10AUG2020	45072	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
10811006	C4591001 1081 10811006	16-55	10AUG2020	45073	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo		
10811008	C4591001 1081 10811008	16-55	10AUG2020	45076	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10811009	C4591001 1081 10811009	16-55	10AUG2020	45596	Placebo	10AUG2020/ Placebo	02SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10811010	C4591001 1081 10811010	16-55	10AUG2020	45598	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10811012	C4591001 1081 10811012	16-55	10AUG2020	45602	Placebo	10AUG2020/ Placebo	01SEP2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
10811013	C4591001 1081 10811013	16-55	11AUG2020	45604	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
10811018	C4591001 1081 10811018	16-55	11AUG2020	46652	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
10811020	C4591001 1081 10811020	16-55	11AUG2020	46655	Placebo	11AUG2020/ Placebo	03SEP2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
10811023	C4591001 1081 10811023	16-55	12AUG2020	46657	Placebo	12AUG2020/ Placebo	03SEP2020/ Placebo		
10811025	C4591001 1081 10811025	16-55	12AUG2020	46660	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
10811032	C4591001 1081 10811032	16-55	12AUG2020	47782	Placebo	12AUG2020/ Placebo	02SEP2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
10811033	C4591001 1081 10811033	16-55	12AUG2020	47785	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
10811036	C4591001 1081 10811036	16-55	13AUG2020	47787	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10811038	C4591001 1081 10811038	16-55	13AUG2020	47788	Placebo	13AUG2020/ Placebo	01SEP2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
10821006	C4591001 1082 10821006	16-55	31JUL2020	40523	Placebo	31JUL2020/ Placebo	21AUG2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
10821008	C4591001 1082 10821008	16-55	31JUL2020	40526	Placebo	31JUL2020/ Placebo	21AUG2020/ Placebo	06JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
10821009	C4591001 1082 10821009	16-55	03AUG2020	41489	Placebo	03AUG2020/ Placebo	24AUG2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10821011	C4591001 1082 10821011	16-55	03AUG2020	41493	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
10821014	C4591001 1082 10821014	16-55	03AUG2020	41495	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
10821015	C4591001 1082 10821015	16-55	03AUG2020	41741	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
10821016	C4591001 1082 10821016	16-55	03AUG2020	41743	Placebo	03AUG2020/ Placebo	24AUG2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
10821018	C4591001 1082 10821018	16-55	03AUG2020	41744	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
10821019	C4591001 1082 10821019	16-55	03AUG2020	41749	Placebo	03AUG2020/ Placebo	24AUG2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	28JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10821020	C4591001 1082 10821020	16-55	03AUG2020	41861	Placebo	03AUG2020/ Placebo	24AUG2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	04JAN2021/ BNT162b2 (30 µg)
10821021	C4591001 1082 10821021	16-55	04AUG2020	41868	Placebo	04AUG2020/ Placebo	25AUG2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10821022	C4591001 1082 10821022	16-55	04AUG2020	41865	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)		
10821023	C4591001 1082 10821023	16-55	04AUG2020	41866	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
10821024	C4591001 1082 10821024	16-55	04AUG2020	42209	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
10821025	C4591001 1082 10821025	16-55	04AUG2020	42217	Placebo	04AUG2020/ Placebo	25AUG2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
10821026	C4591001 1082 10821026	16-55	04AUG2020	42213	Placebo	04AUG2020/ Placebo	25AUG2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10821027	C4591001 1082 10821027	16-55	04AUG2020	42218	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
10821028	C4591001 1082 10821028	16-55	04AUG2020	42354	Placebo	04AUG2020/ Placebo	25AUG2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10821031	C4591001 1082 10821031	16-55	04AUG2020	42357	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10821034	C4591001 1082 10821034	16-55	04AUG2020	42362	Placebo	04AUG2020/ Placebo	25AUG2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
10821035	C4591001 1082 10821035	16-55	04AUG2020	42363	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
10821036	C4591001 1082 10821036	16-55	04AUG2020	42550	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
10821037	C4591001 1082 10821037	16-55	04AUG2020	42551	Placebo	04AUG2020/ Placebo	25AUG2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10821038	C4591001 1082 10821038	16-55	05AUG2020	42555	Placebo	05AUG2020/ Placebo	26AUG2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
10821039	C4591001 1082 10821039	16-55	05AUG2020	42870	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
10821041	C4591001 1082 10821041	16-55	05AUG2020	42556	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
10821043	C4591001 1082 10821043	16-55	05AUG2020	42875	Placebo	05AUG2020/ Placebo	26AUG2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	04JAN2021/ BNT162b2 (30 µg)
10821044	C4591001 1082 10821044	16-55	05AUG2020	42877	Placebo	05AUG2020/ Placebo	26AUG2020/ Placebo		
10821045	C4591001 1082 10821045	16-55	05AUG2020	42880	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10821047	C4591001 1082 10821047	16-55	05AUG2020	43040	Placebo	05AUG2020/ Placebo	26AUG2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10821049	C4591001 1082 10821049	16-55	05AUG2020	43044	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
10821050	C4591001 1082 10821050	16-55	05AUG2020	43046	Placebo	05AUG2020/ Placebo	26AUG2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
10821053	C4591001 1082 10821053	16-55	05AUG2020	43047	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)		
10821054	C4591001 1082 10821054	16-55	05AUG2020	43181	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
10821056	C4591001 1082 10821056	16-55	06AUG2020	43183	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)		
10821060	C4591001 1082 10821060	16-55	06AUG2020	43188	Placebo	06AUG2020/ Placebo	27AUG2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
10821064	C4591001 1082 10821064	16-55	06AUG2020	43191	Placebo	06AUG2020/ Placebo	28AUG2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10821065	C4591001 1082 10821065	16-55	06AUG2020	43705	Placebo	06AUG2020/ Placebo	27AUG2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
10821066	C4591001 1082 10821066	16-55	06AUG2020	43698	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10821067	C4591001 1082 10821067	16-55	06AUG2020	43707	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
10821069	C4591001 1082 10821069	16-55	06AUG2020	43708	Placebo	06AUG2020/ Placebo	27AUG2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
10821070	C4591001 1082 10821070	16-55	06AUG2020	43902	Placebo	06AUG2020/ Placebo	28AUG2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
10821071	C4591001 1082 10821071	16-55	07AUG2020	43905	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
10821072	C4591001 1082 10821072	16-55	07AUG2020	43907	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
10821073	C4591001 1082 10821073	16-55	07AUG2020	43910	Placebo	07AUG2020/ Placebo	28AUG2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
10821077	C4591001 1082 10821077	16-55	07AUG2020	44469	Placebo	07AUG2020/ Placebo			
10821078	C4591001 1082 10821078	16-55	07AUG2020	44468	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)			
10821080	C4591001 1082 10821080	16-55	07AUG2020	44474	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
10821081	C4591001 1082 10821081	16-55	07AUG2020	44476	Placebo	07AUG2020/ Placebo	28AUG2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10821082	C4591001 1082 10821082	16-55	07AUG2020	44621	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
10821083	C4591001 1082 10821083	16-55	07AUG2020	44629	Placebo	07AUG2020/ Placebo	28AUG2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
10821084	C4591001 1082 10821084	16-55	07AUG2020	44623	Placebo	07AUG2020/ Placebo	28AUG2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	04JAN2021/ BNT162b2 (30 µg)
10821085	C4591001 1082 10821085	16-55	07AUG2020	44632	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
10821088	C4591001 1082 10821088	16-55	10AUG2020	45636	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
10821089	C4591001 1082 10821089	16-55	10AUG2020	45638	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10821090	C4591001 1082 10821090	16-55	10AUG2020	45632	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10821095	C4591001 1082 10821095	16-55	11AUG2020	226245	Placebo	11AUG2020/ Placebo	01SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
10821100	C4591001 1082 10821100	16-55	12AUG2020	45639	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
10821102	C4591001 1082 10821102	16-55	13AUG2020	48870	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10821104	C4591001 1082 10821104	16-55	14AUG2020	48876	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10821105	C4591001 1082 10821105	16-55	14AUG2020	48880	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
10821106	C4591001 1082 10821106	16-55	14AUG2020	50238	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
10821107	C4591001 1082 10821107	16-55	14AUG2020	48879	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo		
10821109	C4591001 1082 10821109	16-55	14AUG2020	50239	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
10831007	C4591001 1083 10831007	16-55	30JUL2020	40367	BNT162b2 (30 µg)	30JUL2020/ BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)		
10831009	C4591001 1083 10831009	16-55	30JUL2020	40368	BNT162b2 (30 µg)	30JUL2020/ BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)		
10831011	C4591001 1083 10831011	16-55	30JUL2020	40369	Placebo	30JUL2020/ Placebo	20AUG2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10831013	C4591001 1083 10831013	16-55	30JUL2020	40761	Placebo	30JUL2020/ Placebo	20AUG2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
10831015	C4591001 1083 10831015	16-55	31JUL2020	40764	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10831017	C4591001 1083 10831017	16-55	31JUL2020	40765	Placebo	31JUL2020/ Placebo	19AUG2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
10831018	C4591001 1083 10831018	16-55	31JUL2020	40766	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)		
10831020	C4591001 1083 10831020	16-55	03AUG2020	41602	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
10831025	C4591001 1083 10831025	16-55	04AUG2020	41605	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
10831026	C4591001 1083 10831026	16-55	04AUG2020	41604	Placebo	04AUG2020/ Placebo	24AUG2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
10831029	C4591001 1083 10831029	16-55	04AUG2020	41608	Placebo	04AUG2020/ Placebo			
10831032	C4591001 1083 10831032	16-55	04AUG2020	42503	Placebo	04AUG2020/ Placebo	24AUG2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
10831033	C4591001 1083 10831033	16-55	04AUG2020	42497	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
10831034	C4591001 1083 10831034	16-55	04AUG2020	42499	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
10831040	C4591001 1083 10831040	16-55	04AUG2020	42508	Placebo	04AUG2020/ Placebo	25AUG2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10831043	C4591001 1083 10831043	16-55	04AUG2020	42713	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
10831044	C4591001 1083 10831044	16-55	05AUG2020	42714	Placebo	05AUG2020/ Placebo	25AUG2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
10831045	C4591001 1083 10831045	16-55	05AUG2020	42722	Placebo	05AUG2020/ Placebo	25AUG2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
10831046	C4591001 1083 10831046	16-55	05AUG2020	42715	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
10831047	C4591001 1083 10831047	16-55	05AUG2020	43073	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
10831052	C4591001 1083 10831052	16-55	05AUG2020	43077	Placebo	05AUG2020/ Placebo	26AUG2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	06MAR2021/ BNT162b2 (30 µg)
10831054	C4591001 1083 10831054	16-55	05AUG2020	43079	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
10831055	C4591001 1083 10831055	16-55	05AUG2020	43082	Placebo	05AUG2020/ Placebo	27AUG2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
10831057	C4591001 1083 10831057	16-55	05AUG2020	43385	Placebo	05AUG2020/ Placebo	26AUG2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)
10831060	C4591001 1083 10831060	16-55	06AUG2020	43386	Placebo	06AUG2020/ Placebo		06MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10831061	C4591001 1083 10831061	16-55	07AUG2020	43392	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
10831062	C4591001 1083 10831062	16-55	07AUG2020	43395	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
10831065	C4591001 1083 10831065	16-55	07AUG2020	44922	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
10831067	C4591001 1083 10831067	16-55	07AUG2020	44923	Placebo	07AUG2020/ Placebo	28AUG2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
10831068	C4591001 1083 10831068	16-55	10AUG2020	44924	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo		
10831069	C4591001 1083 10831069	16-55	10AUG2020	44930	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10831070	C4591001 1083 10831070	16-55	10AUG2020	45389	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	11MAR2021/ BNT162b2 (30 µg)	
10831074	C4591001 1083 10831074	16-55	10AUG2020	45393	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	28JAN2021/ BNT162b2 (30 µg)
10831078	C4591001 1083 10831078	16-55	10AUG2020	45399	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10831081	C4591001 1083 10831081	16-55	10AUG2020	45400	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10831082	C4591001 1083 10831082	16-55	11AUG2020	46171	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10831083	C4591001 1083 10831083	16-55	11AUG2020	46175	Placebo	11AUG2020/ Placebo	01SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
10831084	C4591001 1083 10831084	16-55	11AUG2020	46178	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10831086	C4591001 1083 10831086	16-55	11AUG2020	46179	Placebo	11AUG2020/ Placebo	31AUG2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
10831090	C4591001 1083 10831090	16-55	13AUG2020	48478	Placebo	13AUG2020/ Placebo	01SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
10831091	C4591001 1083 10831091	16-55	13AUG2020	48482	Placebo	13AUG2020/ Placebo	01SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10831093	C4591001 1083 10831093	16-55	13AUG2020	48483	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
10831094	C4591001 1083 10831094	16-55	13AUG2020	48484	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
10831098	C4591001 1083 10831098	16-55	13AUG2020	49062	Placebo	13AUG2020/ Placebo	02SEP2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
10831099	C4591001 1083 10831099	16-55	13AUG2020	49065	Placebo	13AUG2020/ Placebo	01SEP2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10831101	C4591001 1083 10831101	16-55	13AUG2020	49071	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
10831102	C4591001 1083 10831102	16-55	13AUG2020	49072	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
10841004	C4591001 1084 10841004	16-55	07AUG2020	44454	Placebo	07AUG2020/ Placebo	28AUG2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10841008	C4591001 1084 10841008	16-55	30JUL2020	40596	BNT162b2 (30 µg)	30JUL2020/ BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)		
10841009	C4591001 1084 10841009	16-55	30JUL2020	40598	Placebo	30JUL2020/ Placebo	18AUG2020/ Placebo		
10841012	C4591001 1084 10841012	16-55	03AUG2020	41514	Placebo	03AUG2020/ Placebo	24AUG2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10841013	C4591001 1084 10841013	16-55	03AUG2020	41524	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
10841014	C4591001 1084 10841014	16-55	03AUG2020	41520	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
10841015	C4591001 1084 10841015	16-55	03AUG2020	41648	Placebo	03AUG2020/ Placebo	24AUG2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	20JAN2021/ BNT162b2 (30 µg)
10841016	C4591001 1084 10841016	16-55	03AUG2020	41516	Placebo	03AUG2020/ Placebo	24AUG2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10841017	C4591001 1084 10841017	16-55	03AUG2020	41651	Placebo	03AUG2020/ Placebo	24AUG2020/ Placebo		
10841018	C4591001 1084 10841018	16-55	03AUG2020	41652	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
10841023	C4591001 1084 10841023	16-55	03AUG2020	41925	Placebo	03AUG2020/ Placebo	26AUG2020/ Placebo		
10841029	C4591001 1084 10841029	16-55	03AUG2020	41654	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
10841031	C4591001 1084 10841031	16-55	03AUG2020	41930	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
10841033	C4591001 1084 10841033	16-55	03AUG2020	41928	Placebo	03AUG2020/ Placebo	26AUG2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
10841035	C4591001 1084 10841035	16-55	03AUG2020	41931	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)			
10841036	C4591001 1084 10841036	16-55	05AUG2020	42763	Placebo	05AUG2020/ Placebo	26AUG2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
10841038	C4591001 1084 10841038	16-55	05AUG2020	42764	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
10841041	C4591001 1084 10841041	16-55	05AUG2020	42766	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10841042	C4591001 1084 10841042	16-55	05AUG2020	42771	Placebo	05AUG2020/ Placebo	26AUG2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
10841044	C4591001 1084 10841044	16-55	05AUG2020	43086	Placebo	05AUG2020/ Placebo	26AUG2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10841047	C4591001 1084 10841047	16-55	05AUG2020	43092	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
10841054	C4591001 1084 10841054	16-55	05AUG2020	43093	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
10841055	C4591001 1084 10841055	16-55	05AUG2020	43275	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
10841056	C4591001 1084 10841056	16-55	05AUG2020	43095	Placebo	05AUG2020/ Placebo	26AUG2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
10841057	C4591001 1084 10841057	16-55	05AUG2020	43274	Placebo	05AUG2020/ Placebo			
10841058	C4591001 1084 10841058	16-55	05AUG2020	43273	Placebo	05AUG2020/ Placebo	26AUG2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
10841059	C4591001 1084 10841059	16-55	05AUG2020	43276	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
10841060	C4591001 1084 10841060	16-55	07AUG2020	44334	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10841061	C4591001 1084 10841061	16-55	07AUG2020	44336	Placebo	07AUG2020/ Placebo	28AUG2020/ Placebo		
10841062	C4591001 1084 10841062	16-55	07AUG2020	44463	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10841064	C4591001 1084 10841064	16-55	07AUG2020	44340	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
10841066	C4591001 1084 10841066	16-55	07AUG2020	44544	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
10841068	C4591001 1084 10841068	16-55	07AUG2020	44459	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
10841069	C4591001 1084 10841069	16-55	07AUG2020	44344	Placebo	07AUG2020/ Placebo	28AUG2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
10841071	C4591001 1084 10841071	16-55	07AUG2020	44539	Placebo	07AUG2020/ Placebo	28AUG2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10841072	C4591001 1084 10841072	16-55	07AUG2020	44461	Placebo	07AUG2020/ Placebo	28AUG2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)
10841073	C4591001 1084 10841073	16-55	07AUG2020	44545	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
10841076	C4591001 1084 10841076	16-55	07AUG2020	44646	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10841079	C4591001 1084 10841079	16-55	07AUG2020	44547	Placebo	07AUG2020/ Placebo	28AUG2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10841081	C4591001 1084 10841081	16-55	07AUG2020	44647	Placebo	07AUG2020/ Placebo	31AUG2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10841082	C4591001 1084 10841082	16-55	07AUG2020	44653	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
10841083	C4591001 1084 10841083	16-55	07AUG2020	44652	Placebo	07AUG2020/ Placebo	28AUG2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
10841084	C4591001 1084 10841084	16-55	07AUG2020	44787	Placebo	07AUG2020/ Placebo	28AUG2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
10841085	C4591001 1084 10841085	16-55	07AUG2020	44778	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
10841087	C4591001 1084 10841087	16-55	07AUG2020	44779	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
10841089	C4591001 1084 10841089	16-55	07AUG2020	44790	Placebo	07AUG2020/ Placebo	28AUG2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
10841090	C4591001 1084 10841090	16-55	07AUG2020	44788	Placebo	07AUG2020/ Placebo	28AUG2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10841091	C4591001 1084 10841091	16-55	07AUG2020	44795	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10841092	C4591001 1084 10841092	16-55	07AUG2020	44796	Placebo	07AUG2020/ Placebo	28AUG2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
10841095	C4591001 1084 10841095	16-55	10AUG2020	45305	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10841097	C4591001 1084 10841097	16-55	10AUG2020	44799	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10841098	C4591001 1084 10841098	16-55	10AUG2020	45312	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10841099	C4591001 1084 10841099	16-55	10AUG2020	45309	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10841100	C4591001 1084 10841100	16-55	10AUG2020	45314	Placebo	10AUG2020/ Placebo	02SEP2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
10841101	C4591001 1084 10841101	16-55	10AUG2020	45509	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10841102	C4591001 1084 10841102	16-55	10AUG2020	45511	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10841104	C4591001 1084 10841104	16-55	10AUG2020	45513	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
10841107	C4591001 1084 10841107	16-55	10AUG2020	45515	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10841111	C4591001 1084 10841111	16-55	10AUG2020	45618	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10841113	C4591001 1084 10841113	16-55	10AUG2020	45620	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
10841114	C4591001 1084 10841114	16-55	10AUG2020	45626	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10841115	C4591001 1084 10841115	16-55	10AUG2020	45623	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10841117	C4591001 1084 10841117	16-55	10AUG2020	45821	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
10841118	C4591001 1084 10841118	16-55	10AUG2020	45825	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
10841119	C4591001 1084 10841119	16-55	10AUG2020	45889	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo		
10841120	C4591001 1084 10841120	16-55	10AUG2020	45826	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
10841121	C4591001 1084 10841121	16-55	10AUG2020	45884	Placebo	10AUG2020/ Placebo	04SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10841122	C4591001 1084 10841122	16-55	10AUG2020	45832	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10841123	C4591001 1084 10841123	16-55	10AUG2020	45886	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10841126	C4591001 1084 10841126	16-55	12AUG2020	45891	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
10841129	C4591001 1084 10841129	16-55	12AUG2020	47201	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
10841136	C4591001 1084 10841136	16-55	12AUG2020	47205	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
10841137	C4591001 1084 10841137	16-55	12AUG2020	47208	Placebo	12AUG2020/ Placebo	02SEP2020/ Placebo		
10841138	C4591001 1084 10841138	16-55	12AUG2020	47202	Placebo	12AUG2020/ Placebo	02SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10841141	C4591001 1084 10841141	16-55	12AUG2020	47794	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
10841146	C4591001 1084 10841146	16-55	12AUG2020	47793	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
10841148	C4591001 1084 10841148	16-55	12AUG2020	47797	Placebo	12AUG2020/ Placebo	02SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
10841153	C4591001 1084 10841153	16-55	12AUG2020	48079	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10841154	C4591001 1084 10841154	16-55	12AUG2020	47799	Placebo	12AUG2020/ Placebo	02SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
10841155	C4591001 1084 10841155	16-55	14AUG2020	48088	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10841156	C4591001 1084 10841156	16-55	14AUG2020	48086	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo		
10841159	C4591001 1084 10841159	16-55	14AUG2020	48084	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
10841163	C4591001 1084 10841163	16-55	14AUG2020	50300	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
10841164	C4591001 1084 10841164	16-55	14AUG2020	50303	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
10841181	C4591001 1084 10841181	16-55	14AUG2020	50308	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
10841182	C4591001 1084 10841182	16-55	14AUG2020	50889	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
10841186	C4591001 1084 10841186	16-55	14AUG2020	50895	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10851013	C4591001 1085 10851013	16-55	30JUL2020	40738	BNT162b2 (30 µg)	30JUL2020/ BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10851014	C4591001 1085 10851014	16-55	30JUL2020	40742	Placebo	30JUL2020/ Placebo	20AUG2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
10851015	C4591001 1085 10851015	16-55	30JUL2020	40733	BNT162b2 (30 µg)	30JUL2020/ BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)		
10851016	C4591001 1085 10851016	16-55	01AUG2020	40743	Placebo	01AUG2020/ Placebo	22AUG2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10851018	C4591001 1085 10851018	16-55	01AUG2020	41321	BNT162b2 (30 µg)	01AUG2020/ BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)		
10851019	C4591001 1085 10851019	16-55	01AUG2020	41323	Placebo	01AUG2020/ Placebo	22AUG2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
10851022	C4591001 1085 10851022	16-55	01AUG2020	41330	Placebo	01AUG2020/ Placebo	22AUG2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10851023	C4591001 1085 10851023	16-55	01AUG2020	41328	BNT162b2 (30 µg)	01AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
10851026	C4591001 1085 10851026	16-55	04AUG2020	42284	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)		
10851027	C4591001 1085 10851027	16-55	04AUG2020	42286	Placebo	04AUG2020/ Placebo	24AUG2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
10851029	C4591001 1085 10851029	16-55	04AUG2020	42287	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10851032	C4591001 1085 10851032	16-55	05AUG2020	42290	Placebo	05AUG2020/ Placebo	02SEP2020/ Placebo	06JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
10851033	C4591001 1085 10851033	16-55	05AUG2020	43206	Placebo	05AUG2020/ Placebo	26AUG2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
10851034	C4591001 1085 10851034	16-55	05AUG2020	43210	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
10851035	C4591001 1085 10851035	16-55	05AUG2020	43214	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)		
10851039	C4591001 1085 10851039	16-55	05AUG2020	43216	Placebo	05AUG2020/ Placebo	25AUG2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
10851041	C4591001 1085 10851041	16-55	06AUG2020	43628	Placebo	06AUG2020/ Placebo	02SEP2020/ Placebo		
10851047	C4591001 1085 10851047	16-55	06AUG2020	43629	Placebo	06AUG2020/ Placebo	01SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10851048	C4591001 1085 10851048	16-55	06AUG2020	43631	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
10851049	C4591001 1085 10851049	16-55	06AUG2020	44156	Placebo	06AUG2020/ Placebo	02SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
10851050	C4591001 1085 10851050	16-55	06AUG2020	43636	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10851051	C4591001 1085 10851051	16-55	07AUG2020	44159	Placebo	07AUG2020/ Placebo	01SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
10851058	C4591001 1085 10851058	16-55	07AUG2020	44160	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
10851062	C4591001 1085 10851062	16-55	07AUG2020	44874	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10851063	C4591001 1085 10851063	16-55	07AUG2020	44162	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)		
10851064	C4591001 1085 10851064	16-55	08AUG2020	44875	Placebo	08AUG2020/ Placebo	03SEP2020/ Placebo		
10851067	C4591001 1085 10851067	16-55	08AUG2020	44884	BNT162b2 (30 µg)	08AUG2020/ BNT162b2 (30 µg)	05SEP2020/ BNT162b2 (30 µg)		
10851068	C4591001 1085 10851068	16-55	08AUG2020	44879	Placebo	08AUG2020/ Placebo	05SEP2020/ Placebo	03MAR2021/ BNT162b2 (30 µg)	
10851069	C4591001 1085 10851069	16-55	08AUG2020	44986	Placebo	08AUG2020/ Placebo	03SEP2020/ Placebo		
10851070	C4591001 1085 10851070	16-55	08AUG2020	44990	BNT162b2 (30 µg)	08AUG2020/ BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)		
10851075	C4591001 1085 10851075	16-55	08AUG2020	44991	BNT162b2 (30 µg)	08AUG2020/ BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10851079	C4591001 1085 10851079	16-55	10AUG2020	44992	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo		
10851081	C4591001 1085 10851081	16-55	10AUG2020	45896	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	05SEP2020/ BNT162b2 (30 µg)		
10851090	C4591001 1085 10851090	16-55	12AUG2020	45898	Placebo	12AUG2020/ Placebo	03SEP2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
10851098	C4591001 1085 10851098	16-55	13AUG2020	45900	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo	02MAR2021/ BNT162b2 (30 µg)	
10851099	C4591001 1085 10851099	16-55	13AUG2020	45902	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
10871007	C4591001 1087 10871007	16-55	07AUG2020	44230	Placebo	07AUG2020/ Placebo	26AUG2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10871010	C4591001 1087 10871010	16-55	07AUG2020	44231	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)		
10871020	C4591001 1087 10871020	16-55	07AUG2020	44235	Placebo	07AUG2020/ Placebo	27AUG2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10871021	C4591001 1087 10871021	16-55	07AUG2020	44233	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)		
10871028	C4591001 1087 10871028	16-55	07AUG2020	44766	Placebo	07AUG2020/ Placebo	28AUG2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10871035	C4591001 1087 10871035	16-55	08AUG2020	44770	BNT162b2 (30 µg)	08AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
10871041	C4591001 1087 10871041	16-55	10AUG2020	44772	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10871042	C4591001 1087 10871042	16-55	10AUG2020	44776	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
10871045	C4591001 1087 10871045	16-55	10AUG2020	45401	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
10871046	C4591001 1087 10871046	16-55	10AUG2020	45404	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10871052	C4591001 1087 10871052	16-55	10AUG2020	45406	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10871053	C4591001 1087 10871053	16-55	11AUG2020	45412	Placebo	11AUG2020/ Placebo	01SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
10871059	C4591001 1087 10871059	16-55	11AUG2020	46278	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10871060	C4591001 1087 10871060	16-55	11AUG2020	46284	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
10871061	C4591001 1087 10871061	16-55	11AUG2020	46286	Placebo	11AUG2020/ Placebo	01SEP2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10871062	C4591001 1087 10871062	16-55	11AUG2020	46281	Placebo	11AUG2020/ Placebo	02SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
10871064	C4591001 1087 10871064	16-55	11AUG2020	46400	Placebo	11AUG2020/ Placebo	02SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10871065	C4591001 1087 10871065	16-55	11AUG2020	46402	Placebo	11AUG2020/ Placebo	31AUG2020/ Placebo	06JAN2021/ BNT162b2 (30 µg)	27JAN2021/ BNT162b2 (30 µg)
10871066	C4591001 1087 10871066	16-55	11AUG2020	46405	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10871067	C4591001 1087 10871067	16-55	11AUG2020	46407	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
10871068	C4591001 1087 10871068	16-55	11AUG2020	46570	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10871074	C4591001 1087 10871074	16-55	11AUG2020	46576	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
10871076	C4591001 1087 10871076	16-55	11AUG2020	46879	Placebo	11AUG2020/ Placebo	31AUG2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
10871078	C4591001 1087 10871078	16-55	12AUG2020	46883	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10881005	C4591001 1088 10881005	16-55	12AUG2020	47047	Placebo	12AUG2020/ Placebo	03SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10881009	C4591001 1088 10881009	16-55	12AUG2020	47051	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
10881010	C4591001 1088 10881010	16-55	12AUG2020	47053	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10881011	C4591001 1088 10881011	16-55	12AUG2020	47056	Placebo	12AUG2020/ Placebo	31AUG2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
10881012	C4591001 1088 10881012	16-55	12AUG2020	47945	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
10881016	C4591001 1088 10881016	16-55	13AUG2020	47948	Placebo	13AUG2020/ Placebo	01SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
10881017	C4591001 1088 10881017	16-55	13AUG2020	47951	Placebo	13AUG2020/ Placebo	02SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10881019	C4591001 1088 10881019	16-55	13AUG2020	47952	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
10881021	C4591001 1088 10881021	16-55	13AUG2020	49386	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
10881024	C4591001 1088 10881024	16-55	13AUG2020	49389	Placebo	13AUG2020/ Placebo	02SEP2020/ Placebo	06JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
10881025	C4591001 1088 10881025	16-55	14AUG2020	49391	Placebo	14AUG2020/ Placebo	02SEP2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10881036	C4591001 1088 10881036	16-55	14AUG2020	50683	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
10881037	C4591001 1088 10881037	16-55	15AUG2020	50684	Placebo	15AUG2020/ Placebo	03SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10881038	C4591001 1088 10881038	16-55	15AUG2020	50691	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
10881039	C4591001 1088 10881039	16-55	15AUG2020	51276	Placebo	15AUG2020/ Placebo	03SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10881040	C4591001 1088 10881040	16-55	15AUG2020	51270	Placebo	15AUG2020/ Placebo	03SEP2020/ Placebo	06JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)
10881128	C4591001 1088 10881128	16-55	01SEP2020	75393	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10891020	C4591001 1089 10891020	16-55	31JUL2020	40576	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)		
10891022	C4591001 1089 10891022	16-55	31JUL2020	41059	Placebo	31JUL2020/ Placebo	20AUG2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
10891025	C4591001 1089 10891025	16-55	31JUL2020	41061	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)		
10891027	C4591001 1089 10891027	16-55	31JUL2020	41067	Placebo	31JUL2020/ Placebo	25AUG2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10891029	C4591001 1089 10891029	16-55	03AUG2020	41068	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
10891049	C4591001 1089 10891049	16-55	04AUG2020	42413	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
10891050	C4591001 1089 10891050	16-55	04AUG2020	42419	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
10891054	C4591001 1089 10891054	16-55	04AUG2020	42416	Placebo	04AUG2020/ Placebo	25AUG2020/ Placebo		
10891055	C4591001 1089 10891055	16-55	04AUG2020	42422	Placebo	04AUG2020/ Placebo	24AUG2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10891056	C4591001 1089 10891056	16-55	04AUG2020	42561	Placebo	04AUG2020/ Placebo	24AUG2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
10891057	C4591001 1089 10891057	16-55	04AUG2020	42562	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
10891058	C4591001 1089 10891058	16-55	05AUG2020	42564	Placebo	05AUG2020/ Placebo	25AUG2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)
10891059	C4591001 1089 10891059	16-55	05AUG2020	42566	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
10891061	C4591001 1089 10891061	16-55	05AUG2020	42894	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10891062	C4591001 1089 10891062	16-55	05AUG2020	42895	Placebo	05AUG2020/ Placebo	27AUG2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10891064	C4591001 1089 10891064	16-55	05AUG2020	42897	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)		
10891065	C4591001 1089 10891065	16-55	05AUG2020	42901	Placebo	05AUG2020/ Placebo	27AUG2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
10891067	C4591001 1089 10891067	16-55	06AUG2020	43508	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
10891070	C4591001 1089 10891070	16-55	06AUG2020	43509	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)		
10891072	C4591001 1089 10891072	16-55	06AUG2020	43513	Placebo	06AUG2020/ Placebo	27AUG2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
10891074	C4591001 1089 10891074	16-55	06AUG2020	43515	Placebo	06AUG2020/ Placebo	27AUG2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
10891076	C4591001 1089 10891076	16-55	06AUG2020	43844	Placebo	06AUG2020/ Placebo			
10891077	C4591001 1089 10891077	16-55	06AUG2020	43845	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
10891078	C4591001 1089 10891078	16-55	06AUG2020	43849	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10891079	C4591001 1089 10891079	16-55	06AUG2020	43850	Placebo	06AUG2020/ Placebo	27AUG2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
10891080	C4591001 1089 10891080	16-55	06AUG2020	44057	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
10891082	C4591001 1089 10891082	16-55	07AUG2020	44058	Placebo	07AUG2020/ Placebo	28AUG2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
10891084	C4591001 1089 10891084	16-55	07AUG2020	44060	Placebo	07AUG2020/ Placebo	28AUG2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	27JAN2021/ BNT162b2 (30 µg)
10891091	C4591001 1089 10891091	16-55	10AUG2020	44062	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10891100	C4591001 1089 10891100	16-55	11AUG2020	46242	Placebo	11AUG2020/ Placebo	01SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10891101	C4591001 1089 10891101	16-55	11AUG2020	46245	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
10891103	C4591001 1089 10891103	16-55	11AUG2020	46247	Placebo	11AUG2020/ Placebo	31AUG2020/ Placebo		
10891105	C4591001 1089 10891105	16-55	11AUG2020	46250	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10891106	C4591001 1089 10891106	16-55	11AUG2020	46794	Placebo	11AUG2020/ Placebo	01SEP2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10891107	C4591001 1089 10891107	16-55	12AUG2020	46796	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
10891111	C4591001 1089 10891111	16-55	12AUG2020	46803	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
10891113	C4591001 1089 10891113	16-55	12AUG2020	47861	Placebo	12AUG2020/ Placebo	03SEP2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
10891114	C4591001 1089 10891114	16-55	12AUG2020	47862	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
10891115	C4591001 1089 10891115	16-55	13AUG2020	47863	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
10891116	C4591001 1089 10891116	16-55	13AUG2020	47869	Placebo	13AUG2020/ Placebo	02SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
10891119	C4591001 1089 10891119	16-55	13AUG2020	49027	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
10891120	C4591001 1089 10891120	16-55	13AUG2020	49030	Placebo	13AUG2020/ Placebo	02SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10891121	C4591001 1089 10891121	16-55	13AUG2020	49031	Placebo	13AUG2020/ Placebo	01SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
10891123	C4591001 1089 10891123	16-55	14AUG2020	49036	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10891130	C4591001 1089 10891130	16-55	14AUG2020	50622	Placebo	14AUG2020/ Placebo	03SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
10901001	C4591001 1090 10901001	16-55	31JUL2020	41045	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)		
10901002	C4591001 1090 10901002	16-55	31JUL2020	41051	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)		
10901005	C4591001 1090 10901005	16-55	31JUL2020	41189	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)		
10901006	C4591001 1090 10901006	16-55	31JUL2020	41052	Placebo	31JUL2020/ Placebo	21AUG2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
10901007	C4591001 1090 10901007	16-55	31JUL2020	41053	Placebo	31JUL2020/ Placebo	21AUG2020/ Placebo		
10901008	C4591001 1090 10901008	16-55	31JUL2020	41192	Placebo	31JUL2020/ Placebo	21AUG2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
10901009	C4591001 1090 10901009	16-55	31JUL2020	41199	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)		
10901012	C4591001 1090 10901012	16-55	31JUL2020	41200	Placebo	31JUL2020/ Placebo	21AUG2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
10901014	C4591001 1090 10901014	16-55	03AUG2020	41501	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10901015	C4591001 1090 10901015	16-55	03AUG2020	41503	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
10901016	C4591001 1090 10901016	16-55	03AUG2020	41507	Placebo	03AUG2020/ Placebo	24AUG2020/ Placebo		
10901020	C4591001 1090 10901020	16-55	03AUG2020	41509	Placebo	03AUG2020/ Placebo	28AUG2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
10901021	C4591001 1090 10901021	16-55	03AUG2020	41683	Placebo	03AUG2020/ Placebo	24AUG2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
10901022	C4591001 1090 10901022	16-55	03AUG2020	41682	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
10901023	C4591001 1090 10901023	16-55	03AUG2020	41691	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
10901024	C4591001 1090 10901024	16-55	03AUG2020	41684	Placebo	03AUG2020/ Placebo	24AUG2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
10901029	C4591001 1090 10901029	16-55	03AUG2020	41934	Placebo	03AUG2020/ Placebo	24AUG2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
10901031	C4591001 1090 10901031	16-55	03AUG2020	41935	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
10901034	C4591001 1090 10901034	16-55	04AUG2020	41936	Placebo	04AUG2020/ Placebo	28AUG2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10901035	C4591001 1090 10901035	16-55	04AUG2020	41942	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
10901037	C4591001 1090 10901037	16-55	04AUG2020	42236	Placebo	04AUG2020/ Placebo	24AUG2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
10901038	C4591001 1090 10901038	16-55	04AUG2020	42238	Placebo	04AUG2020/ Placebo	28AUG2020/ Placebo	02MAR2021/ BNT162b2 (30 µg)	
10901039	C4591001 1090 10901039	16-55	04AUG2020	42239	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
10901043	C4591001 1090 10901043	16-55	04AUG2020	42533	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
10901044	C4591001 1090 10901044	16-55	04AUG2020	42544	Placebo	04AUG2020/ Placebo	24AUG2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
10901045	C4591001 1090 10901045	16-55	04AUG2020	42244	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
10901046	C4591001 1090 10901046	16-55	04AUG2020	42541	Placebo	04AUG2020/ Placebo	31AUG2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
10901047	C4591001 1090 10901047	16-55	04AUG2020	42539	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
10901049	C4591001 1090 10901049	16-55	04AUG2020	42596	Placebo	04AUG2020/ Placebo	28AUG2020/ Placebo	06JAN2021/ BNT162b2 (30 µg)	27JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10901050	C4591001 1090 10901050	16-55	04AUG2020	42593	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
10901051	C4591001 1090 10901051	16-55	04AUG2020	42600	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
10901052	C4591001 1090 10901052	16-55	04AUG2020	42597	Placebo	04AUG2020/ Placebo	24AUG2020/ Placebo		
10901058	C4591001 1090 10901058	16-55	05AUG2020	43049	Placebo	05AUG2020/ Placebo	24AUG2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
10901061	C4591001 1090 10901061	16-55	05AUG2020	43057	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
10901065	C4591001 1090 10901065	16-55	05AUG2020	43060	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
10901067	C4591001 1090 10901067	16-55	05AUG2020	43059	Placebo	05AUG2020/ Placebo	24AUG2020/ Placebo		
10901068	C4591001 1090 10901068	16-55	05AUG2020	43301	Placebo	05AUG2020/ Placebo			
10901070	C4591001 1090 10901070	16-55	05AUG2020	43305	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
10901072	C4591001 1090 10901072	16-55	05AUG2020	43307	Placebo	05AUG2020/ Placebo	24AUG2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10901073	C4591001 1090 10901073	16-55	05AUG2020	43312	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
10901074	C4591001 1090 10901074	16-55	05AUG2020	43397	Placebo	05AUG2020/ Placebo	24AUG2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10901076	C4591001 1090 10901076	16-55	06AUG2020	43403	Placebo	06AUG2020/ Placebo	28AUG2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
10901079	C4591001 1090 10901079	16-55	06AUG2020	43405	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
10901081	C4591001 1090 10901081	16-55	06AUG2020	43406	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
10901086	C4591001 1090 10901086	16-55	06AUG2020	43949	Placebo	06AUG2020/ Placebo	28AUG2020/ Placebo		
10901088	C4591001 1090 10901088	16-55	06AUG2020	43954	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
10901090	C4591001 1090 10901090	16-55	06AUG2020	43951	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
10901094	C4591001 1090 10901094	16-55	07AUG2020	43955	Placebo	07AUG2020/ Placebo	28AUG2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
10901095	C4591001 1090 10901095	16-55	07AUG2020	44503	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10901096	C4591001 1090 10901096	16-55	07AUG2020	44504	Placebo	07AUG2020/ Placebo	28AUG2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
10901097	C4591001 1090 10901097	16-55	07AUG2020	44510	Placebo	07AUG2020/ Placebo	28AUG2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
10901099	C4591001 1090 10901099	16-55	07AUG2020	44706	Placebo	07AUG2020/ Placebo	28AUG2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)
10901101	C4591001 1090 10901101	16-55	07AUG2020	44505	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
10901103	C4591001 1090 10901103	16-55	07AUG2020	44713	Placebo	07AUG2020/ Placebo	28AUG2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
10901104	C4591001 1090 10901104	16-55	07AUG2020	44707	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
10901105	C4591001 1090 10901105	16-55	07AUG2020	44802	Placebo	07AUG2020/ Placebo	28AUG2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
10901106	C4591001 1090 10901106	16-55	07AUG2020	44936	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
10901109	C4591001 1090 10901109	16-55	07AUG2020	44710	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
10901111	C4591001 1090 10901111	16-55	07AUG2020	44803	Placebo	07AUG2020/ Placebo	28AUG2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10901112	C4591001 1090 10901112	16-55	07AUG2020	44806	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
10901114	C4591001 1090 10901114	16-55	07AUG2020	44937	Placebo	07AUG2020/ Placebo	28AUG2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10901115	C4591001 1090 10901115	16-55	07AUG2020	44812	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
10901116	C4591001 1090 10901116	16-55	10AUG2020	44939	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
10901125	C4591001 1090 10901125	16-55	10AUG2020	44941	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10901131	C4591001 1090 10901131	16-55	11AUG2020	46217	Placebo	11AUG2020/ Placebo	31AUG2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
10901132	C4591001 1090 10901132	16-55	11AUG2020	46218	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10901133	C4591001 1090 10901133	16-55	11AUG2020	46221	Placebo	11AUG2020/ Placebo	31AUG2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
10901135	C4591001 1090 10901135	16-55	11AUG2020	46225	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10901136	C4591001 1090 10901136	16-55	11AUG2020	46469	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10901139	C4591001 1090 10901139	16-55	11AUG2020	46472	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10901140	C4591001 1090 10901140	16-55	11AUG2020	46471	Placebo	11AUG2020/ Placebo	31AUG2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
10901147	C4591001 1090 10901147	16-55	12AUG2020	46478	Placebo	12AUG2020/ Placebo	31AUG2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10901154	C4591001 1090 10901154	16-55	12AUG2020	47958	Placebo	12AUG2020/ Placebo	31AUG2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10901156	C4591001 1090 10901156	16-55	12AUG2020	47966	Placebo	12AUG2020/ Placebo	31AUG2020/ Placebo		
10901157	C4591001 1090 10901157	16-55	12AUG2020	47967	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10901160	C4591001 1090 10901160	16-55	13AUG2020	47968	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
10901161	C4591001 1090 10901161	16-55	13AUG2020	48559	Placebo	13AUG2020/ Placebo	04SEP2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
10901163	C4591001 1090 10901163	16-55	13AUG2020	48561	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
10901167	C4591001 1090 10901167	16-55	13AUG2020	48565	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10901169	C4591001 1090 10901169	16-55	13AUG2020	48568	Placebo	13AUG2020/ Placebo	04SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
10901172	C4591001 1090 10901172	16-55	13AUG2020	49282	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
10901174	C4591001 1090 10901174	16-55	13AUG2020	49285	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
10901177	C4591001 1090 10901177	16-55	13AUG2020	49287	Placebo	13AUG2020/ Placebo	04SEP2020/ Placebo	12MAR2021/ BNT162b2 (30 µg)	
10901178	C4591001 1090 10901178	16-55	13AUG2020	49286	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
10901185	C4591001 1090 10901185	16-55	14AUG2020	50227	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
10901193	C4591001 1090 10901193	16-55	14AUG2020	50234	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10901197	C4591001 1090 10901197	16-55	14AUG2020	50231	Placebo	14AUG2020/ Placebo	03SEP2020/ Placebo	02MAR2021/ BNT162b2 (30 µg)	
10901200	C4591001 1090 10901200	16-55	14AUG2020	50814	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
10901201	C4591001 1090 10901201	16-55	14AUG2020	50815	Placebo	14AUG2020/ Placebo	03SEP2020/ Placebo	03MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10901245	C4591001 1090 10901245	16-55	18AUG2020	54088	Placebo	18AUG2020/ Placebo	04SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10911005	C4591001 1091 10911005	16-55	30JUL2020	40686	BNT162b2 (30 µg)	30JUL2020/ BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)		
10911008	C4591001 1091 10911008	16-55	31JUL2020	40687	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)		
10911011	C4591001 1091 10911011	16-55	31JUL2020	40688	Placebo	31JUL2020/ Placebo	20AUG2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
10911013	C4591001 1091 10911013	16-55	31JUL2020	40689	Placebo	31JUL2020/ Placebo	20AUG2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10911014	C4591001 1091 10911014	16-55	31JUL2020	40896	Placebo	31JUL2020/ Placebo	20AUG2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
10911015	C4591001 1091 10911015	16-55	31JUL2020	40891	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)		
10911017	C4591001 1091 10911017	16-55	03AUG2020	40898	Placebo	03AUG2020/ Placebo	24AUG2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
10911019	C4591001 1091 10911019	16-55	03AUG2020	41673	Placebo	03AUG2020/ Placebo	24AUG2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
10911020	C4591001 1091 10911020	16-55	03AUG2020	40897	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10911022	C4591001 1091 10911022	16-55	03AUG2020	41679	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
10911025	C4591001 1091 10911025	16-55	03AUG2020	41680	Placebo	03AUG2020/ Placebo	24AUG2020/ Placebo		
10911027	C4591001 1091 10911027	16-55	04AUG2020	42059	Placebo	04AUG2020/ Placebo	24AUG2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
10911032	C4591001 1091 10911032	16-55	04AUG2020	42056	Placebo	04AUG2020/ Placebo	24AUG2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
10911033	C4591001 1091 10911033	16-55	04AUG2020	42053	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
10911037	C4591001 1091 10911037	16-55	04AUG2020	42063	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
10911038	C4591001 1091 10911038	16-55	04AUG2020	42341	Placebo	04AUG2020/ Placebo	25AUG2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
10911039	C4591001 1091 10911039	16-55	04AUG2020	42348	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)			
10911042	C4591001 1091 10911042	16-55	04AUG2020	42346	Placebo	04AUG2020/ Placebo	27AUG2020/ Placebo		
10911043	C4591001 1091 10911043	16-55	04AUG2020	42452	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10911046	C4591001 1091 10911046	16-55	04AUG2020	42349	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
10911051	C4591001 1091 10911051	16-55	05AUG2020	42456	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
10911052	C4591001 1091 10911052	16-55	05AUG2020	42458	Placebo	05AUG2020/ Placebo	25AUG2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
10911053	C4591001 1091 10911053	16-55	05AUG2020	43133	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
10911054	C4591001 1091 10911054	16-55	05AUG2020	42459	Placebo	05AUG2020/ Placebo	24AUG2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10911057	C4591001 1091 10911057	16-55	05AUG2020	43135	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
10911058	C4591001 1091 10911058	16-55	05AUG2020	43138	Placebo	05AUG2020/ Placebo	26AUG2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
10911061	C4591001 1091 10911061	16-55	05AUG2020	43316	Placebo	05AUG2020/ Placebo	27AUG2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)
10911062	C4591001 1091 10911062	16-55	05AUG2020	43144	Placebo	05AUG2020/ Placebo	24AUG2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
10911065	C4591001 1091 10911065	16-55	05AUG2020	43319	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10911066	C4591001 1091 10911066	16-55	06AUG2020	43320	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)		
10911067	C4591001 1091 10911067	16-55	06AUG2020	43324	Placebo	06AUG2020/ Placebo	27AUG2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)
10911069	C4591001 1091 10911069	16-55	06AUG2020	43497	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)		
10911070	C4591001 1091 10911070	16-55	06AUG2020	43495	Placebo	06AUG2020/ Placebo	25AUG2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
10911072	C4591001 1091 10911072	16-55	06AUG2020	43496	Placebo	06AUG2020/ Placebo	25AUG2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10911075	C4591001 1091 10911075	16-55	06AUG2020	43499	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
10911077	C4591001 1091 10911077	16-55	06AUG2020	43723	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)			
10911078	C4591001 1091 10911078	16-55	06AUG2020	43724	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
10911079	C4591001 1091 10911079	16-55	06AUG2020	43727	Placebo	06AUG2020/ Placebo	27AUG2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
10911082	C4591001 1091 10911082	16-55	06AUG2020	43729	Placebo	06AUG2020/ Placebo	27AUG2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10911083	C4591001 1091 10911083	16-55	06AUG2020	43855	Placebo	06AUG2020/ Placebo			
10911085	C4591001 1091 10911085	16-55	06AUG2020	43853	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
10911087	C4591001 1091 10911087	16-55	10AUG2020	43861	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
10911088	C4591001 1091 10911088	16-55	10AUG2020	43862	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
10911090	C4591001 1091 10911090	16-55	10AUG2020	45693	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10911091	C4591001 1091 10911091	16-55	10AUG2020	45698	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo		
10911093	C4591001 1091 10911093	16-55	10AUG2020	45700	Placebo	10AUG2020/ Placebo	02SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
10911095	C4591001 1091 10911095	16-55	11AUG2020	46184	Placebo	11AUG2020/ Placebo	02SEP2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)
10911096	C4591001 1091 10911096	16-55	11AUG2020	46183	Placebo	11AUG2020/ Placebo	01SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
10911098	C4591001 1091 10911098	16-55	11AUG2020	46186	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10911099	C4591001 1091 10911099	16-55	11AUG2020	46192	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10911103	C4591001 1091 10911103	16-55	11AUG2020	46675	Placebo	11AUG2020/ Placebo	01SEP2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
10911104	C4591001 1091 10911104	16-55	12AUG2020	46677	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
10911106	C4591001 1091 10911106	16-55	12AUG2020	46680	Placebo	12AUG2020/ Placebo	31AUG2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10911107	C4591001 1091 10911107	16-55	12AUG2020	47266	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
10911108	C4591001 1091 10911108	16-55	12AUG2020	46682	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
10911111	C4591001 1091 10911111	16-55	12AUG2020	47268	Placebo	12AUG2020/ Placebo	02SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10911113	C4591001 1091 10911113	16-55	13AUG2020	47269	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10911116	C4591001 1091 10911116	16-55	13AUG2020	47272	Placebo	13AUG2020/ Placebo	01SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
10911118	C4591001 1091 10911118	16-55	13AUG2020	48678	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10911119	C4591001 1091 10911119	16-55	13AUG2020	48686	Placebo	13AUG2020/ Placebo	02SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10911120	C4591001 1091 10911120	16-55	13AUG2020	48681	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
10911121	C4591001 1091 10911121	16-55	13AUG2020	49362	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
10911122	C4591001 1091 10911122	16-55	13AUG2020	48683	Placebo	13AUG2020/ Placebo	01SEP2020/ Placebo		
10931001	C4591001 1093 10931001	16-55	15AUG2020	51223	Placebo	15AUG2020/ Placebo	03SEP2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)
10931002	C4591001 1093 10931002	16-55	15AUG2020	51226	Placebo	15AUG2020/ Placebo	04SEP2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
10931003	C4591001 1093 10931003	16-55	15AUG2020	51229	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
10931006	C4591001 1093 10931006	16-55	15AUG2020	51232	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
10931007	C4591001 1093 10931007	16-55	15AUG2020	51438	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
10941004	C4591001 1094 10941004	16-55	12AUG2020	48018	Placebo	12AUG2020/ Placebo	03SEP2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10941010	C4591001 1094 10941010	16-55	13AUG2020	48020	Placebo	13AUG2020/ Placebo	01SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
10941016	C4591001 1094 10941016	16-55	14AUG2020	48026	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
10941017	C4591001 1094 10941017	16-55	14AUG2020	48028	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
10951008	C4591001 1095 10951008	16-55	30JUL2020	40703	BNT162b2 (30 µg)	30JUL2020/ BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)		
10951009	C4591001 1095 10951009	16-55	31JUL2020	40705	Placebo	31JUL2020/ Placebo	21AUG2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10951011	C4591001 1095 10951011	16-55	31JUL2020	40708	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)		
10951014	C4591001 1095 10951014	16-55	31JUL2020	41177	Placebo	31JUL2020/ Placebo	21AUG2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10951018	C4591001 1095 10951018	16-55	31JUL2020	41178	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)		
10951021	C4591001 1095 10951021	16-55	03AUG2020	41184	Placebo	03AUG2020/ Placebo	24AUG2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
10951022	C4591001 1095 10951022	16-55	03AUG2020	41550	Placebo	03AUG2020/ Placebo	24AUG2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10951023	C4591001 1095 10951023	16-55	03AUG2020	41179	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
10951024	C4591001 1095 10951024	16-55	03AUG2020	41551	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
10951025	C4591001 1095 10951025	16-55	03AUG2020	41552	Placebo	03AUG2020/ Placebo	24AUG2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10951026	C4591001 1095 10951026	16-55	03AUG2020	41754	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
10951028	C4591001 1095 10951028	16-55	03AUG2020	41553	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
10951029	C4591001 1095 10951029	16-55	03AUG2020	41759	Placebo	03AUG2020/ Placebo	24AUG2020/ Placebo	12MAR2021/ BNT162b2 (30 µg)	
10951030	C4591001 1095 10951030	16-55	03AUG2020	41756	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
10951031	C4591001 1095 10951031	16-55	03AUG2020	41764	Placebo	03AUG2020/ Placebo	24AUG2020/ Placebo		
10951033	C4591001 1095 10951033	16-55	03AUG2020	41910	Placebo	03AUG2020/ Placebo	24AUG2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
10951034	C4591001 1095 10951034	16-55	03AUG2020	41909	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10951036	C4591001 1095 10951036	16-55	03AUG2020	41914	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
10951038	C4591001 1095 10951038	16-55	03AUG2020	41918	Placebo	03AUG2020/ Placebo	24AUG2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	
10951039	C4591001 1095 10951039	16-55	03AUG2020	42021	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
10951040	C4591001 1095 10951040	16-55	04AUG2020	42026	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
10951042	C4591001 1095 10951042	16-55	04AUG2020	42027	Placebo	04AUG2020/ Placebo	25AUG2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
10951044	C4591001 1095 10951044	16-55	04AUG2020	42028	Placebo	04AUG2020/ Placebo	25AUG2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
10951045	C4591001 1095 10951045	16-55	04AUG2020	42377	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
10951046	C4591001 1095 10951046	16-55	04AUG2020	42379	Placebo	04AUG2020/ Placebo	25AUG2020/ Placebo		
10951047	C4591001 1095 10951047	16-55	04AUG2020	42385	Placebo	04AUG2020/ Placebo	25AUG2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
10951055	C4591001 1095 10951055	16-55	04AUG2020	42388	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10951056	C4591001 1095 10951056	16-55	05AUG2020	42774	Placebo	05AUG2020/ Placebo			
10951057	C4591001 1095 10951057	16-55	05AUG2020	42780	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
10951058	C4591001 1095 10951058	16-55	05AUG2020	42782	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
10951059	C4591001 1095 10951059	16-55	05AUG2020	42781	Placebo	05AUG2020/ Placebo	26AUG2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
10951060	C4591001 1095 10951060	16-55	05AUG2020	42989	Placebo	05AUG2020/ Placebo	27AUG2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
10951061	C4591001 1095 10951061	16-55	05AUG2020	42992	Placebo	05AUG2020/ Placebo	27AUG2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
10951062	C4591001 1095 10951062	16-55	05AUG2020	42994	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
10951066	C4591001 1095 10951066	16-55	05AUG2020	42997	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
10951069	C4591001 1095 10951069	16-55	06AUG2020	43543	Placebo	06AUG2020/ Placebo	27AUG2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
10951070	C4591001 1095 10951070	16-55	06AUG2020	43546	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10951073	C4591001 1095 10951073	16-55	06AUG2020	43550	Placebo	06AUG2020/ Placebo	27AUG2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
10951074	C4591001 1095 10951074	16-55	06AUG2020	43551	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)		
10951076	C4591001 1095 10951076	16-55	06AUG2020	43793	Placebo	06AUG2020/ Placebo	28AUG2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
10951083	C4591001 1095 10951083	16-55	06AUG2020	43797	Placebo	06AUG2020/ Placebo	28AUG2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
10951084	C4591001 1095 10951084	16-55	06AUG2020	43802	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)		
10951087	C4591001 1095 10951087	16-55	06AUG2020	43804	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
10951089	C4591001 1095 10951089	16-55	06AUG2020	44203	Placebo	06AUG2020/ Placebo	25AUG2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
10951090	C4591001 1095 10951090	16-55	06AUG2020	44202	Placebo	06AUG2020/ Placebo	27AUG2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10951091	C4591001 1095 10951091	16-55	06AUG2020	44207	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
10951092	C4591001 1095 10951092	16-55	06AUG2020	44211	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10951093	C4591001 1095 10951093	16-55	07AUG2020	44290	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
10951094	C4591001 1095 10951094	16-55	07AUG2020	44294	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
10951095	C4591001 1095 10951095	16-55	07AUG2020	44291	Placebo	07AUG2020/ Placebo	28AUG2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
10951096	C4591001 1095 10951096	16-55	07AUG2020	44295	Placebo	07AUG2020/ Placebo	28AUG2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
10951106	C4591001 1095 10951106	16-55	07AUG2020	44850	Placebo	07AUG2020/ Placebo	28AUG2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
10961007	C4591001 1096 10961007	16-55	13AUG2020	48881	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
10961010	C4591001 1096 10961010	16-55	13AUG2020	48883	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
10961011	C4591001 1096 10961011	16-55	13AUG2020	48888	Placebo	13AUG2020/ Placebo	04SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
10961012	C4591001 1096 10961012	16-55	13AUG2020	48892	Placebo	13AUG2020/ Placebo	10SEP2020/ Placebo		
10961013	C4591001 1096 10961013	16-55	13AUG2020	49555	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10961018	C4591001 1096 10961018	16-55	13AUG2020	49558	Placebo	13AUG2020/ Placebo	15SEP2020/ Placebo		
10961022	C4591001 1096 10961022	16-55	14AUG2020	49559	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
10961023	C4591001 1096 10961023	16-55	14AUG2020	49564	Placebo	14AUG2020/ Placebo	03SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
10961029	C4591001 1096 10961029	16-55	14AUG2020	50905	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
10961030	C4591001 1096 10961030	16-55	14AUG2020	50907	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
11071012	C4591001 1107 11071012	16-55	03AUG2020	40321	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
11071013	C4591001 1107 11071013	16-55	03AUG2020	41443	Placebo	03AUG2020/ Placebo	24AUG2020/ Placebo		
11071015	C4591001 1107 11071015	16-55	03AUG2020	41445	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
11071016	C4591001 1107 11071016	16-55	03AUG2020	41449	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
11071018	C4591001 1107 11071018	16-55	03AUG2020	41789	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11071019	C4591001 1107 11071019	16-55	03AUG2020	41791	Placebo	03AUG2020/ Placebo	24AUG2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
11071020	C4591001 1107 11071020	16-55	03AUG2020	41452	Placebo	03AUG2020/ Placebo	24AUG2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
11071022	C4591001 1107 11071022	16-55	03AUG2020	41794	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
11071025	C4591001 1107 11071025	16-55	03AUG2020	41795	Placebo	03AUG2020/ Placebo	25AUG2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
11071026	C4591001 1107 11071026	16-55	04AUG2020	42098	Placebo	04AUG2020/ Placebo	25AUG2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
11071027	C4591001 1107 11071027	16-55	04AUG2020	42089	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
11071028	C4591001 1107 11071028	16-55	04AUG2020	42091	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
11071031	C4591001 1107 11071031	16-55	04AUG2020	42374	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11071032	C4591001 1107 11071032	16-55	04AUG2020	42099	Placebo	04AUG2020/ Placebo	25AUG2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
11071033	C4591001 1107 11071033	16-55	04AUG2020	42367	Placebo	04AUG2020/ Placebo	25AUG2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11071034	C4591001 1107 11071034	16-55	04AUG2020	42373	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
11071039	C4591001 1107 11071039	16-55	05AUG2020	42376	Placebo	05AUG2020/ Placebo	26AUG2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
11071046	C4591001 1107 11071046	16-55	05AUG2020	43029	Placebo	05AUG2020/ Placebo	26AUG2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
11071049	C4591001 1107 11071049	16-55	05AUG2020	43031	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
11071052	C4591001 1107 11071052	16-55	05AUG2020	43032	Placebo	05AUG2020/ Placebo	27AUG2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
11071054	C4591001 1107 11071054	16-55	06AUG2020	43034	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)		
11071055	C4591001 1107 11071055	16-55	06AUG2020	43566	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)		
11071056	C4591001 1107 11071056	16-55	06AUG2020	43569	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)		
11071057	C4591001 1107 11071057	16-55	06AUG2020	43964	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)		
11071059	C4591001 1107 11071059	16-55	06AUG2020	43962	Placebo	06AUG2020/ Placebo	27AUG2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11071063	C4591001 1107 11071063	16-55	06AUG2020	43571	Placebo	06AUG2020/ Placebo	26AUG2020/ Placebo		
11071065	C4591001 1107 11071065	16-55	06AUG2020	43573	Placebo	06AUG2020/ Placebo	27AUG2020/ Placebo		
11071067	C4591001 1107 11071067	16-55	06AUG2020	43967	Placebo	06AUG2020/ Placebo	27AUG2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
11071069	C4591001 1107 11071069	16-55	06AUG2020	43968	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)		
11071070	C4591001 1107 11071070	16-55	06AUG2020	44045	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)		
11071071	C4591001 1107 11071071	16-55	06AUG2020	44047	Placebo	06AUG2020/ Placebo	27AUG2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	04JAN2021/ BNT162b2 (30 µg)
11071072	C4591001 1107 11071072	16-55	10AUG2020	44049	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
11071074	C4591001 1107 11071074	16-55	10AUG2020	44054	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
11071079	C4591001 1107 11071079	16-55	10AUG2020	45569	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
11071083	C4591001 1107 11071083	16-55	10AUG2020	45572	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11071086	C4591001 1107 11071086	16-55	11AUG2020	45575	Placebo	11AUG2020/ Placebo	14SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
11071087	C4591001 1107 11071087	16-55	11AUG2020	45580	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
11071089	C4591001 1107 11071089	16-55	11AUG2020	46313	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
11071096	C4591001 1107 11071096	16-55	12AUG2020	46317	Placebo	12AUG2020/ Placebo	02SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
11071097	C4591001 1107 11071097	16-55	12AUG2020	46319	Placebo	12AUG2020/ Placebo	02SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
11071098	C4591001 1107 11071098	16-55	12AUG2020	46324	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
11071102	C4591001 1107 11071102	16-55	13AUG2020	48317	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
11071104	C4591001 1107 11071104	16-55	13AUG2020	48319	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
11071105	C4591001 1107 11071105	16-55	13AUG2020	48323	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
11071106	C4591001 1107 11071106	16-55	13AUG2020	48328	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11071109	C4591001 1107 11071109	16-55	13AUG2020	48942	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
11071110	C4591001 1107 11071110	16-55	13AUG2020	48943	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
11071111	C4591001 1107 11071111	16-55	13AUG2020	48946	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
11071112	C4591001 1107 11071112	16-55	13AUG2020	48948	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11091041	C4591001 1109 11091041	16-55	31JUL2020	40805	Placebo	31JUL2020/ Placebo	19AUG2020/ Placebo		
11091043	C4591001 1109 11091043	16-55	31JUL2020	40806	Placebo	31JUL2020/ Placebo	19AUG2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
11091046	C4591001 1109 11091046	16-55	31JUL2020	40808	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)		
11091047	C4591001 1109 11091047	16-55	31JUL2020	40816	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)		
11091048	C4591001 1109 11091048	16-55	31JUL2020	40868	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)		
11091052	C4591001 1109 11091052	16-55	31JUL2020	40872	Placebo	31JUL2020/ Placebo	19AUG2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11091054	C4591001 1109 11091054	16-55	31JUL2020	40873	Placebo	31JUL2020/ Placebo	19AUG2020/ Placebo		
11091055	C4591001 1109 11091055	16-55	31JUL2020	40875	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)		
11091056	C4591001 1109 11091056	16-55	31JUL2020	41027	Placebo	31JUL2020/ Placebo	21AUG2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
11091057	C4591001 1109 11091057	16-55	31JUL2020	41028	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)		
11091058	C4591001 1109 11091058	16-55	31JUL2020	220886	Placebo	31JUL2020/ Placebo	19AUG2020/ Placebo	23JAN2021/ BNT162b2 (30 µg)	13FEB2021/ BNT162b2 (30 µg)
11091059	C4591001 1109 11091059	16-55	31JUL2020	41031	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)			
11091060	C4591001 1109 11091060	16-55	31JUL2020	41032	Placebo	31JUL2020/ Placebo	20AUG2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
11091061	C4591001 1109 11091061	16-55	31JUL2020	41105	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)		
11091062	C4591001 1109 11091062	16-55	31JUL2020	41109	Placebo	31JUL2020/ Placebo	22AUG2020/ Placebo	13FEB2021/ BNT162b2 (30 µg)	06MAR2021/ BNT162b2 (30 µg)
11091063	C4591001 1109 11091063	16-55	31JUL2020	41115	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11091066	C4591001 1109 11091066	16-55	31JUL2020	41116	Placebo	31JUL2020/ Placebo	19AUG2020/ Placebo		
11091067	C4591001 1109 11091067	16-55	31JUL2020	41157	Placebo	31JUL2020/ Placebo	20AUG2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
11091068	C4591001 1109 11091068	16-55	31JUL2020	41153	Placebo	31JUL2020/ Placebo			
11091070	C4591001 1109 11091070	16-55	31JUL2020	41160	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)		
11091071	C4591001 1109 11091071	16-55	31JUL2020	41162	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)		
11091075	C4591001 1109 11091075	16-55	31JUL2020	41213	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)		
11091077	C4591001 1109 11091077	16-55	01AUG2020	41220	Placebo	01AUG2020/ Placebo	20AUG2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
11091078	C4591001 1109 11091078	16-55	01AUG2020	41217	Placebo	01AUG2020/ Placebo	02SEP2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
11091080	C4591001 1109 11091080	16-55	01AUG2020	41221	BNT162b2 (30 µg)	01AUG2020/ BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)		
11091082	C4591001 1109 11091082	16-55	01AUG2020	41297	Placebo	01AUG2020/ Placebo	20AUG2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11091083	C4591001 1109 11091083	16-55	01AUG2020	41299	BNT162b2 (30 µg)	01AUG2020/ BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)		
11091086	C4591001 1109 11091086	16-55	01AUG2020	41303	BNT162b2 (30 µg)	01AUG2020/ BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)		
11091092	C4591001 1109 11091092	16-55	01AUG2020	41308	Placebo	01AUG2020/ Placebo	23AUG2020/ Placebo	27FEB2021/ BNT162b2 (30 µg)	
11091098	C4591001 1109 11091098	16-55	01AUG2020	41347	Placebo	01AUG2020/ Placebo	20AUG2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
11091099	C4591001 1109 11091099	16-55	01AUG2020	41350	Placebo	01AUG2020/ Placebo	21AUG2020/ Placebo	13FEB2021/ BNT162b2 (30 µg)	06MAR2021/ BNT162b2 (30 µg)
11091100	C4591001 1109 11091100	16-55	01AUG2020	41355	BNT162b2 (30 µg)	01AUG2020/ BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)		
11091102	C4591001 1109 11091102	16-55	01AUG2020	41356	BNT162b2 (30 µg)	01AUG2020/ BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)		
11091105	C4591001 1109 11091105	16-55	03AUG2020	41433	Placebo	03AUG2020/ Placebo	23AUG2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
11091106	C4591001 1109 11091106	16-55	03AUG2020	41430	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
11091108	C4591001 1109 11091108	16-55	03AUG2020	41436	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11091109	C4591001 1109 11091109	16-55	03AUG2020	41609	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
11091110	C4591001 1109 11091110	16-55	03AUG2020	41438	Placebo	03AUG2020/ Placebo	23AUG2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
11091112	C4591001 1109 11091112	16-55	03AUG2020	41612	Placebo	03AUG2020/ Placebo	22AUG2020/ Placebo	06JAN2021/ BNT162b2 (30 µg)	27JAN2021/ BNT162b2 (30 µg)
11091115	C4591001 1109 11091115	16-55	03AUG2020	41617	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)		
11091117	C4591001 1109 11091117	16-55	03AUG2020	41802	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
11091122	C4591001 1109 11091122	16-55	03AUG2020	41618	Placebo	03AUG2020/ Placebo	24AUG2020/ Placebo	23JAN2021/ BNT162b2 (30 µg)	13FEB2021/ BNT162b2 (30 µg)
11091126	C4591001 1109 11091126	16-55	03AUG2020	41803	Placebo	03AUG2020/ Placebo	25AUG2020/ Placebo		
11091127	C4591001 1109 11091127	16-55	03AUG2020	41808	Placebo	03AUG2020/ Placebo			
11091132	C4591001 1109 11091132	16-55	03AUG2020	41811	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
11091134	C4591001 1109 11091134	16-55	03AUG2020	41970	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11091136	C4591001 1109 11091136	16-55	04AUG2020	41973	Placebo	04AUG2020/ Placebo	29AUG2020/ Placebo	27FEB2021/ BNT162b2 (30 µg)	
11091145	C4591001 1109 11091145	16-55	04AUG2020	41977	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
11091147	C4591001 1109 11091147	16-55	04AUG2020	41978	Placebo	04AUG2020/ Placebo	23AUG2020/ Placebo	30JAN2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11091148	C4591001 1109 11091148	16-55	04AUG2020	42187	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
11091156	C4591001 1109 11091156	16-55	04AUG2020	42189	Placebo	04AUG2020/ Placebo	25AUG2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
11091158	C4591001 1109 11091158	16-55	04AUG2020	42191	Placebo	04AUG2020/ Placebo	25AUG2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
11091159	C4591001 1109 11091159	16-55	04AUG2020	42196	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)		
11091160	C4591001 1109 11091160	16-55	04AUG2020	42570	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
11091176	C4591001 1109 11091176	16-55	08AUG2020	42576	Placebo	08AUG2020/ Placebo	31AUG2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
11091178	C4591001 1109 11091178	16-55	08AUG2020	42579	BNT162b2 (30 µg)	08AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11091180	C4591001 1109 11091180	16-55	08AUG2020	44958	Placebo	08AUG2020/ Placebo	27AUG2020/ Placebo	23JAN2021/ BNT162b2 (30 µg)	13FEB2021/ BNT162b2 (30 µg)
11091183	C4591001 1109 11091183	16-55	08AUG2020	44961	BNT162b2 (30 µg)	08AUG2020/ BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)		
11091184	C4591001 1109 11091184	16-55	08AUG2020	44966	Placebo	08AUG2020/ Placebo	27AUG2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
11091185	C4591001 1109 11091185	16-55	10AUG2020	44967	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
11091186	C4591001 1109 11091186	16-55	10AUG2020	45077	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
11091187	C4591001 1109 11091187	16-55	10AUG2020	45084	Placebo	10AUG2020/ Placebo	01SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
11091190	C4591001 1109 11091190	16-55	10AUG2020	45086	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
11091197	C4591001 1109 11091197	16-55	10AUG2020	45087	Placebo	10AUG2020/ Placebo	01SEP2020/ Placebo		
11091199	C4591001 1109 11091199	16-55	11AUG2020	46002	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
11091204	C4591001 1109 11091204	16-55	11AUG2020	46006	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11091205	C4591001 1109 11091205	16-55	11AUG2020	46009	Placebo	11AUG2020/ Placebo	04SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
11091211	C4591001 1109 11091211	16-55	13AUG2020	46010	Placebo	13AUG2020/ Placebo	01SEP2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
11091213	C4591001 1109 11091213	16-55	13AUG2020	48299	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
11091214	C4591001 1109 11091214	16-55	13AUG2020	48300	Placebo	13AUG2020/ Placebo	01SEP2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
11091215	C4591001 1109 11091215	16-55	13AUG2020	48301	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
11091216	C4591001 1109 11091216	16-55	14AUG2020	48303	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
11091219	C4591001 1109 11091219	16-55	14AUG2020	49823	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
11091221	C4591001 1109 11091221	16-55	14AUG2020	49824	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
11091223	C4591001 1109 11091223	16-55	14AUG2020	49825	Placebo	14AUG2020/ Placebo	02SEP2020/ Placebo	23JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
11091228	C4591001 1109 11091228	16-55	15AUG2020	51092	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11091230	C4591001 1109 11091230	16-55	15AUG2020	51097	Placebo	15AUG2020/ Placebo	03SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
11091231	C4591001 1109 11091231	16-55	15AUG2020	51098	Placebo	15AUG2020/ Placebo	03SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
11091232	C4591001 1109 11091232	16-55	15AUG2020	51099	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
11091238	C4591001 1109 11091238	16-55	15AUG2020	51339	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
11091260	C4591001 1109 11091260	16-55	16AUG2020	51968	BNT162b2 (30 µg)	16AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
11091266	C4591001 1109 11091266	16-55	16AUG2020	51971	Placebo	16AUG2020/ Placebo	04SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
11101001	C4591001 1110 11101001	16-55	31JUL2020	40856	Placebo	31JUL2020/ Placebo	20AUG2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	
11101002	C4591001 1110 11101002	16-55	31JUL2020	40857	Placebo	31JUL2020/ Placebo	20AUG2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
11101006	C4591001 1110 11101006	16-55	31JUL2020	40859	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)			
11101009	C4591001 1110 11101009	16-55	01AUG2020	40863	BNT162b2 (30 µg)	01AUG2020/ BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11101010	C4591001 1110 11101010	16-55	01AUG2020	41311	Placebo	01AUG2020/ Placebo	21AUG2020/ Placebo		
11101011	C4591001 1110 11101011	16-55	01AUG2020	41314	BNT162b2 (30 µg)	01AUG2020/ BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)		
11101012	C4591001 1110 11101012	16-55	01AUG2020	41318	BNT162b2 (30 µg)	01AUG2020/ BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)		
11101013	C4591001 1110 11101013	16-55	01AUG2020	41320	Placebo	01AUG2020/ Placebo	21AUG2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
11101019	C4591001 1110 11101019	16-55	01AUG2020	41360	BNT162b2 (30 µg)	01AUG2020/ BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)		
11101020	C4591001 1110 11101020	16-55	03AUG2020	41363	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
11101021	C4591001 1110 11101021	16-55	03AUG2020	41364	Placebo	03AUG2020/ Placebo	26AUG2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
11101022	C4591001 1110 11101022	16-55	03AUG2020	41367	Placebo	03AUG2020/ Placebo	24AUG2020/ Placebo	06JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
11101025	C4591001 1110 11101025	16-55	03AUG2020	41887	Placebo	03AUG2020/ Placebo	24AUG2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
11101027	C4591001 1110 11101027	16-55	03AUG2020	41889	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11101028	C4591001 1110 11101028	16-55	03AUG2020	41890	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
11101030	C4591001 1110 11101030	16-55	04AUG2020	41892	Placebo	04AUG2020/ Placebo	25AUG2020/ Placebo		
11101032	C4591001 1110 11101032	16-55	05AUG2020	42860	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
11101033	C4591001 1110 11101033	16-55	05AUG2020	42864	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
11101034	C4591001 1110 11101034	16-55	05AUG2020	42862	Placebo	05AUG2020/ Placebo	25AUG2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
11101035	C4591001 1110 11101035	16-55	05AUG2020	42865	Placebo	05AUG2020/ Placebo	25AUG2020/ Placebo		
11101037	C4591001 1110 11101037	16-55	05AUG2020	43175	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
11101038	C4591001 1110 11101038	16-55	05AUG2020	43169	Placebo	05AUG2020/ Placebo			
11101039	C4591001 1110 11101039	16-55	05AUG2020	43170	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)			
11101040	C4591001 1110 11101040	16-55	05AUG2020	43180	Placebo	05AUG2020/ Placebo	26AUG2020/ Placebo	02MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11101041	C4591001 1110 11101041	16-55	06AUG2020	43484	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
11101042	C4591001 1110 11101042	16-55	06AUG2020	43489	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
11101044	C4591001 1110 11101044	16-55	06AUG2020	43490	Placebo	06AUG2020/ Placebo	26AUG2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
11101045	C4591001 1110 11101045	16-55	06AUG2020	43491	Placebo	06AUG2020/ Placebo	26AUG2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
11101050	C4591001 1110 11101050	16-55	07AUG2020	44393	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)		
11101052	C4591001 1110 11101052	16-55	07AUG2020	44400	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)		
11101053	C4591001 1110 11101053	16-55	07AUG2020	44401	Placebo	07AUG2020/ Placebo	27AUG2020/ Placebo		
11101054	C4591001 1110 11101054	16-55	07AUG2020	44403	Placebo	07AUG2020/ Placebo	27AUG2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
11101057	C4591001 1110 11101057	16-55	07AUG2020	44695	Placebo	07AUG2020/ Placebo	27AUG2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
11101058	C4591001 1110 11101058	16-55	07AUG2020	44699	Placebo	07AUG2020/ Placebo	27AUG2020/ Placebo	02MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11101059	C4591001 1110 11101059	16-55	07AUG2020	44701	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
11101064	C4591001 1110 11101064	16-55	10AUG2020	44703	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
11101065	C4591001 1110 11101065	16-55	10AUG2020	45247	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
11101066	C4591001 1110 11101066	16-55	10AUG2020	45248	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
11101069	C4591001 1110 11101069	16-55	11AUG2020	45249	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)			
11101072	C4591001 1110 11101072	16-55	11AUG2020	45254	Placebo	11AUG2020/ Placebo	25SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
11101075	C4591001 1110 11101075	16-55	12AUG2020	47172	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
11101076	C4591001 1110 11101076	16-55	12AUG2020	47167	Placebo	12AUG2020/ Placebo	02SEP2020/ Placebo	02MAR2021/ BNT162b2 (30 µg)	
11101077	C4591001 1110 11101077	16-55	12AUG2020	47173	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
11101078	C4591001 1110 11101078	16-55	12AUG2020	47176	Placebo	12AUG2020/ Placebo	01SEP2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11101080	C4591001 1110 11101080	16-55	12AUG2020	47658	Placebo	12AUG2020/ Placebo	02SEP2020/ Placebo		
11101081	C4591001 1110 11101081	16-55	12AUG2020	47664	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11101082	C4591001 1110 11101082	16-55	12AUG2020	47668	Placebo	12AUG2020/ Placebo	01SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
11101083	C4591001 1110 11101083	16-55	12AUG2020	47665	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11101084	C4591001 1110 11101084	16-55	12AUG2020	48121	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
11101085	C4591001 1110 11101085	16-55	12AUG2020	48120	Placebo	12AUG2020/ Placebo			
11101086	C4591001 1110 11101086	16-55	13AUG2020	48123	Placebo	13AUG2020/ Placebo	02SEP2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	
11101091	C4591001 1110 11101091	16-55	13AUG2020	48124	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11101092	C4591001 1110 11101092	16-55	13AUG2020	49038	Placebo	13AUG2020/ Placebo	02SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
11101095	C4591001 1110 11101095	16-55	14AUG2020	49041	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11111009	C4591001 1111 11111009	16-55	31JUL2020	40477	Placebo	31JUL2020/ Placebo	20AUG2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
11111012	C4591001 1111 11111012	16-55	03AUG2020	40478	Placebo	03AUG2020/ Placebo	26AUG2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
11111018	C4591001 1111 11111018	16-55	03AUG2020	40479	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
11111022	C4591001 1111 11111022	16-55	04AUG2020	42079	Placebo	04AUG2020/ Placebo	25AUG2020/ Placebo	12MAR2021/ BNT162b2 (30 µg)	
11111023	C4591001 1111 11111023	16-55	04AUG2020	42080	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
11111024	C4591001 1111 11111024	16-55	04AUG2020	42084	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
11111029	C4591001 1111 11111029	16-55	05AUG2020	42088	Placebo	05AUG2020/ Placebo	27AUG2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
11111040	C4591001 1111 11111040	16-55	05AUG2020	43278	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
11111048	C4591001 1111 11111048	16-55	06AUG2020	43283	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
11111050	C4591001 1111 11111050	16-55	06AUG2020	43284	Placebo	06AUG2020/ Placebo	27AUG2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11111051	C4591001 1111 11111051	16-55	06AUG2020	43288	Placebo	06AUG2020/ Placebo	26AUG2020/ Placebo		
11111052	C4591001 1111 11111052	16-55	06AUG2020	44070	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)		
11111053	C4591001 1111 11111053	16-55	06AUG2020	44071	Placebo	06AUG2020/ Placebo	27AUG2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
11111054	C4591001 1111 11111054	16-55	06AUG2020	44076	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
11111057	C4591001 1111 11111057	16-55	07AUG2020	44080	Placebo	07AUG2020/ Placebo	27AUG2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
11111060	C4591001 1111 11111060	16-55	07AUG2020	44346	Placebo	07AUG2020/ Placebo	28AUG2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
11111061	C4591001 1111 11111061	16-55	07AUG2020	44348	Placebo	07AUG2020/ Placebo	28AUG2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
11111064	C4591001 1111 11111064	16-55	07AUG2020	44350	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
11111068	C4591001 1111 11111068	16-55	08AUG2020	44354	BNT162b2 (30 µg)	08AUG2020/ BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)		
11111069	C4591001 1111 11111069	16-55	08AUG2020	44994	Placebo	08AUG2020/ Placebo	29AUG2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11111072	C4591001 1111 11111072	16-55	10AUG2020	44997	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
11111078	C4591001 1111 11111078	16-55	10AUG2020	45002	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
11111079	C4591001 1111 11111079	16-55	10AUG2020	45004	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
11111081	C4591001 1111 11111081	16-55	10AUG2020	45713	Placebo	10AUG2020/ Placebo	29AUG2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
11111082	C4591001 1111 11111082	16-55	10AUG2020	45718	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
11111083	C4591001 1111 11111083	16-55	10AUG2020	45721	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
11111086	C4591001 1111 11111086	16-55	10AUG2020	45722	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
11111087	C4591001 1111 11111087	16-55	10AUG2020	45953	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
11111089	C4591001 1111 11111089	16-55	11AUG2020	45961	Placebo	11AUG2020/ Placebo	01SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
11111090	C4591001 1111 11111090	16-55	11AUG2020	45956	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11111097	C4591001 1111 11111097	16-55	11AUG2020	45964	Placebo	11AUG2020/ Placebo	01SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11111099	C4591001 1111 11111099	16-55	11AUG2020	46829	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)			
11111101	C4591001 1111 11111101	16-55	11AUG2020	46832	Placebo	11AUG2020/ Placebo	01SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
11111104	C4591001 1111 11111104	16-55	14AUG2020	46834	Placebo	14AUG2020/ Placebo	01SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
11111105	C4591001 1111 11111105	16-55	14AUG2020	46838	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
11111113	C4591001 1111 11111113	16-55	14AUG2020	50851	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
11111115	C4591001 1111 11111115	16-55	14AUG2020	50852	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
11121014	C4591001 1112 11121014	16-55	30JUL2020	40675	Placebo	30JUL2020/ Placebo	20AUG2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
11121018	C4591001 1112 11121018	16-55	31JUL2020	40676	Placebo	31JUL2020/ Placebo	21AUG2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
11121019	C4591001 1112 11121019	16-55	31JUL2020	40679	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11121020	C4591001 1112 11121020	16-55	31JUL2020	40974	Placebo	31JUL2020/ Placebo	21AUG2020/ Placebo		
11121021	C4591001 1112 11121021	16-55	31JUL2020	40978	Placebo	31JUL2020/ Placebo	22AUG2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
11121024	C4591001 1112 11121024	16-55	31JUL2020	40979	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)		
11121025	C4591001 1112 11121025	16-55	31JUL2020	40984	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)		
11121026	C4591001 1112 11121026	16-55	31JUL2020	41226	Placebo	31JUL2020/ Placebo	20AUG2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11121027	C4591001 1112 11121027	16-55	31JUL2020	41231	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)		
11121028	C4591001 1112 11121028	16-55	31JUL2020	41233	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)		
11121031	C4591001 1112 11121031	16-55	31JUL2020	41235	Placebo	31JUL2020/ Placebo	21AUG2020/ Placebo		
11121033	C4591001 1112 11121033	16-55	03AUG2020	41467	Placebo	03AUG2020/ Placebo	24AUG2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
11121035	C4591001 1112 11121035	16-55	03AUG2020	41468	Placebo	03AUG2020/ Placebo	24AUG2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11121038	C4591001 1112 11121038	16-55	03AUG2020	41476	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
11121039	C4591001 1112 11121039	16-55	03AUG2020	41472	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)		
11121040	C4591001 1112 11121040	16-55	03AUG2020	41837	Placebo	03AUG2020/ Placebo	24AUG2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
11121042	C4591001 1112 11121042	16-55	03AUG2020	41842	Placebo	03AUG2020/ Placebo	22AUG2020/ Placebo	06JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
11121044	C4591001 1112 11121044	16-55	03AUG2020	41847	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
11121045	C4591001 1112 11121045	16-55	03AUG2020	41848	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
11121046	C4591001 1112 11121046	16-55	03AUG2020	41982	Placebo	03AUG2020/ Placebo	24AUG2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
11121047	C4591001 1112 11121047	16-55	03AUG2020	41984	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)		
11121048	C4591001 1112 11121048	16-55	03AUG2020	41991	Placebo	03AUG2020/ Placebo	24AUG2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
11121049	C4591001 1112 11121049	16-55	03AUG2020	41992	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11121050	C4591001 1112 11121050	16-55	04AUG2020	42067	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
11121053	C4591001 1112 11121053	16-55	04AUG2020	42073	Placebo	04AUG2020/ Placebo	25AUG2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
11121054	C4591001 1112 11121054	16-55	04AUG2020	42074	Placebo	04AUG2020/ Placebo	26AUG2020/ Placebo		
11121055	C4591001 1112 11121055	16-55	04AUG2020	42275	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
11121056	C4591001 1112 11121056	16-55	04AUG2020	42075	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
11121058	C4591001 1112 11121058	16-55	04AUG2020	42276	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)			
11121062	C4591001 1112 11121062	16-55	04AUG2020	42278	Placebo	04AUG2020/ Placebo	25AUG2020/ Placebo		
11121064	C4591001 1112 11121064	16-55	04AUG2020	42279	Placebo	04AUG2020/ Placebo	25AUG2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
11121066	C4591001 1112 11121066	16-55	04AUG2020	42689	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
11121069	C4591001 1112 11121069	16-55	05AUG2020	42696	Placebo	05AUG2020/ Placebo	27AUG2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11121070	C4591001 1112 11121070	16-55	05AUG2020	42699	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
11121071	C4591001 1112 11121071	16-55	05AUG2020	42700	Placebo	05AUG2020/ Placebo	24AUG2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
11121073	C4591001 1112 11121073	16-55	05AUG2020	42883	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)		
11121077	C4591001 1112 11121077	16-55	05AUG2020	42885	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
11121078	C4591001 1112 11121078	16-55	05AUG2020	42884	Placebo	05AUG2020/ Placebo	08SEP2020/ Placebo		
11121082	C4591001 1112 11121082	16-55	05AUG2020	42890	Placebo	05AUG2020/ Placebo	25AUG2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
11121083	C4591001 1112 11121083	16-55	05AUG2020	43363	Placebo	05AUG2020/ Placebo	26AUG2020/ Placebo		
11121085	C4591001 1112 11121085	16-55	10AUG2020	43366	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
11121087	C4591001 1112 11121087	16-55	10AUG2020	43370	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	04JAN2021/ BNT162b2 (30 µg)
11121088	C4591001 1112 11121088	16-55	10AUG2020	43372	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11121090	C4591001 1112 11121090	16-55	10AUG2020	45378	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	04JAN2021/ BNT162b2 (30 µg)
11121091	C4591001 1112 11121091	16-55	10AUG2020	45384	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
11121092	C4591001 1112 11121092	16-55	10AUG2020	45387	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
11121098	C4591001 1112 11121098	16-55	10AUG2020	45388	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
11121100	C4591001 1112 11121100	16-55	10AUG2020	45838	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
11121101	C4591001 1112 11121101	16-55	10AUG2020	45839	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
11121102	C4591001 1112 11121102	16-55	10AUG2020	45844	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11121103	C4591001 1112 11121103	16-55	10AUG2020	45843	Placebo	10AUG2020/ Placebo	01SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
11121104	C4591001 1112 11121104	16-55	10AUG2020	45941	Placebo	10AUG2020/ Placebo	01SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
11121105	C4591001 1112 11121105	16-55	11AUG2020	45942	Placebo	11AUG2020/ Placebo	02SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11121106	C4591001 1112 11121106	16-55	11AUG2020	45951	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
11121107	C4591001 1112 11121107	16-55	11AUG2020	45943	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
11121109	C4591001 1112 11121109	16-55	11AUG2020	46207	Placebo	11AUG2020/ Placebo	01SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11121110	C4591001 1112 11121110	16-55	11AUG2020	46208	Placebo	11AUG2020/ Placebo	02SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
11121114	C4591001 1112 11121114	16-55	11AUG2020	46210	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
11121115	C4591001 1112 11121115	16-55	11AUG2020	46216	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
11121117	C4591001 1112 11121117	16-55	11AUG2020	46628	Placebo	11AUG2020/ Placebo	01SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
11121119	C4591001 1112 11121119	16-55	11AUG2020	46631	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
11121121	C4591001 1112 11121121	16-55	11AUG2020	46635	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11121122	C4591001 1112 11121122	16-55	11AUG2020	46901	Placebo	11AUG2020/ Placebo	01SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11121123	C4591001 1112 11121123	16-55	11AUG2020	46636	Placebo	11AUG2020/ Placebo	02SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11121124	C4591001 1112 11121124	16-55	11AUG2020	46904	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
11141001	C4591001 1114 11141001	16-55	12AUG2020	47149	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
11141002	C4591001 1114 11141002	16-55	12AUG2020	47150	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
11141003	C4591001 1114 11141003	16-55	12AUG2020	47151	Placebo	12AUG2020/ Placebo	01SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
11141007	C4591001 1114 11141007	16-55	12AUG2020	47152	Placebo	12AUG2020/ Placebo	03SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11141008	C4591001 1114 11141008	16-55	12AUG2020	47826	Placebo	12AUG2020/ Placebo	01SEP2020/ Placebo	30JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
11141009	C4591001 1114 11141009	16-55	12AUG2020	47827	Placebo	12AUG2020/ Placebo	01SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
11141010	C4591001 1114 11141010	16-55	12AUG2020	47831	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
11141012	C4591001 1114 11141012	16-55	12AUG2020	48174	Placebo	12AUG2020/ Placebo	02SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11141013	C4591001 1114 11141013	16-55	12AUG2020	47835	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
11141014	C4591001 1114 11141014	16-55	12AUG2020	48182	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
11141015	C4591001 1114 11141015	16-55	12AUG2020	48178	Placebo	12AUG2020/ Placebo	03SEP2020/ Placebo		
11141016	C4591001 1114 11141016	16-55	12AUG2020	48176	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11141021	C4591001 1114 11141021	16-55	13AUG2020	48893	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
11141024	C4591001 1114 11141024	16-55	13AUG2020	48894	Placebo	13AUG2020/ Placebo	04SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
11181001	C4591001 1118 11181001	16-55	10AUG2020	45140	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11181002	C4591001 1118 11181002	16-55	10AUG2020	45144	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
11181003	C4591001 1118 11181003	16-55	10AUG2020	45147	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	30JAN2021/ BNT162b2 (30 µg)	20FEB2021/ BNT162b2 (30 µg)
11181009	C4591001 1118 11181009	16-55	11AUG2020	45148	Placebo	11AUG2020/ Placebo	01SEP2020/ Placebo	30JAN2021/ BNT162b2 (30 µg)	20FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11181014	C4591001 1118 11181014	16-55	11AUG2020	46615	Placebo	11AUG2020/ Placebo	01SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
11181016	C4591001 1118 11181016	16-55	12AUG2020	226194	Placebo	12AUG2020/ Placebo	03SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
11181017	C4591001 1118 11181017	16-55	12AUG2020	46616	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
11181018	C4591001 1118 11181018	16-55	13AUG2020	46621	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
11181019	C4591001 1118 11181019	16-55	12AUG2020	46617	Placebo	12AUG2020/ Placebo	04SEP2020/ Placebo	30JAN2021/ BNT162b2 (30 µg)	20FEB2021/ BNT162b2 (30 µg)
11181021	C4591001 1118 11181021	16-55	13AUG2020	48367	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo	30JAN2021/ BNT162b2 (30 µg)	20FEB2021/ BNT162b2 (30 µg)
11181023	C4591001 1118 11181023	16-55	13AUG2020	48369	Placebo	13AUG2020/ Placebo	01SEP2020/ Placebo	02MAR2021/ BNT162b2 (30 µg)	
11181025	C4591001 1118 11181025	16-55	13AUG2020	48374	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11181026	C4591001 1118 11181026	16-55	13AUG2020	48376	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11181027	C4591001 1118 11181027	16-55	13AUG2020	49265	Placebo	13AUG2020/ Placebo	04SEP2020/ Placebo	31DEC2020/ BNT162b2 (30 µg)	22JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11181028	C4591001 1118 11181028	16-55	13AUG2020	49268	Placebo	13AUG2020/ Placebo	04SEP2020/ Placebo	30JAN2021/ BNT162b2 (30 µg)	20FEB2021/ BNT162b2 (30 µg)
11181030	C4591001 1118 11181030	16-55	14AUG2020	49270	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
11181032	C4591001 1118 11181032	16-55	14AUG2020	49275	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
11181033	C4591001 1118 11181033	16-55	14AUG2020	50110	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	31DEC2020/ BNT162b2 (30 µg)	20JAN2021/ BNT162b2 (30 µg)
11181034	C4591001 1118 11181034	16-55	14AUG2020	50109	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
11181035	C4591001 1118 11181035	16-55	14AUG2020	50112	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
11181099	C4591001 1118 11181099	16-55	29AUG2020	73457	Placebo	29AUG2020/ Placebo	21SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
11201005	C4591001 1120 11201005	16-55	30JUL2020	40351	Placebo	30JUL2020/ Placebo	19AUG2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
11201013	C4591001 1120 11201013	16-55	30JUL2020	40353	Placebo	30JUL2020/ Placebo			
11201014	C4591001 1120 11201014	16-55	31JUL2020	41265	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11201015	C4591001 1120 11201015	16-55	31JUL2020	40355	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)		
11201016	C4591001 1120 11201016	16-55	31JUL2020	41266	Placebo	31JUL2020/ Placebo	19AUG2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
11201023	C4591001 1120 11201023	16-55	03AUG2020	41268	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
11201024	C4591001 1120 11201024	16-55	03AUG2020	42032	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
11201028	C4591001 1120 11201028	16-55	03AUG2020	41271	Placebo	03AUG2020/ Placebo	24AUG2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
11201029	C4591001 1120 11201029	16-55	04AUG2020	42036	Placebo	04AUG2020/ Placebo	25AUG2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
11201034	C4591001 1120 11201034	16-55	04AUG2020	42038	Placebo	04AUG2020/ Placebo	25AUG2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
11201037	C4591001 1120 11201037	16-55	04AUG2020	42040	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
11201039	C4591001 1120 11201039	16-55	04AUG2020	42488	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
11201042	C4591001 1120 11201042	16-55	04AUG2020	42491	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11201044	C4591001 1120 11201044	16-55	06AUG2020	43650	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
11201045	C4591001 1120 11201045	16-55	04AUG2020	42492	Placebo	04AUG2020/ Placebo	26AUG2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
11201053	C4591001 1120 11201053	16-55	05AUG2020	42749	Placebo	05AUG2020/ Placebo	28AUG2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
11201058	C4591001 1120 11201058	16-55	05AUG2020	42752	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)		
11201061	C4591001 1120 11201061	16-55	05AUG2020	42754	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)		
11201062	C4591001 1120 11201062	16-55	05AUG2020	43123	Placebo	05AUG2020/ Placebo	28AUG2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
11201063	C4591001 1120 11201063	16-55	05AUG2020	42757	Placebo	05AUG2020/ Placebo	24AUG2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
11201065	C4591001 1120 11201065	16-55	05AUG2020	43127	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
11201068	C4591001 1120 11201068	16-55	05AUG2020	43129	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
11201076	C4591001 1120 11201076	16-55	05AUG2020	43345	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11201077	C4591001 1120 11201077	16-55	05AUG2020	43130	Placebo	05AUG2020/ Placebo	27AUG2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
11201078	C4591001 1120 11201078	16-55	05AUG2020	43348	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
11201079	C4591001 1120 11201079	16-55	05AUG2020	43346	Placebo	05AUG2020/ Placebo	26AUG2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
11201081	C4591001 1120 11201081	16-55	05AUG2020	43445	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
11201082	C4591001 1120 11201082	16-55	05AUG2020	43347	Placebo	05AUG2020/ Placebo	25AUG2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11201083	C4591001 1120 11201083	16-55	05AUG2020	43448	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
11201084	C4591001 1120 11201084	16-55	06AUG2020	43454	Placebo	06AUG2020/ Placebo	27AUG2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
11201085	C4591001 1120 11201085	16-55	06AUG2020	43456	Placebo	06AUG2020/ Placebo			
11201096	C4591001 1120 11201096	16-55	06AUG2020	43651	Placebo	06AUG2020/ Placebo	25AUG2020/ Placebo		
11201097	C4591001 1120 11201097	16-55	06AUG2020	43656	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11201098	C4591001 1120 11201098	16-55	06AUG2020	43985	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
11201100	C4591001 1120 11201100	16-55	06AUG2020	43988	Placebo	06AUG2020/ Placebo	27AUG2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
11201101	C4591001 1120 11201101	16-55	06AUG2020	43658	Placebo	06AUG2020/ Placebo	25AUG2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
11201103	C4591001 1120 11201103	16-55	06AUG2020	43990	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
11201104	C4591001 1120 11201104	16-55	06AUG2020	43993	Placebo	06AUG2020/ Placebo			
11201105	C4591001 1120 11201105	16-55	06AUG2020	44169	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)		
11201106	C4591001 1120 11201106	16-55	07AUG2020	44170	Placebo	07AUG2020/ Placebo	26AUG2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
11201108	C4591001 1120 11201108	16-55	07AUG2020	44172	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
11201110	C4591001 1120 11201110	16-55	07AUG2020	44174	Placebo	07AUG2020/ Placebo	28AUG2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
11201112	C4591001 1120 11201112	16-55	07AUG2020	44638	Placebo	07AUG2020/ Placebo	27AUG2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11201113	C4591001 1120 11201113	16-55	07AUG2020	44639	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
11201115	C4591001 1120 11201115	16-55	07AUG2020	44641	Placebo	07AUG2020/ Placebo	26AUG2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
11201116	C4591001 1120 11201116	16-55	07AUG2020	44644	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
11201119	C4591001 1120 11201119	16-55	07AUG2020	44815	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)		
11201120	C4591001 1120 11201120	16-55	10AUG2020	44817	Placebo	10AUG2020/ Placebo	03SEP2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
11201130	C4591001 1120 11201130	16-55	11AUG2020	44822	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
11201133	C4591001 1120 11201133	16-55	11AUG2020	44824	Placebo	11AUG2020/ Placebo	08SEP2020/ Placebo		
11201135	C4591001 1120 11201135	16-55	11AUG2020	46735	Placebo	11AUG2020/ Placebo	31AUG2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
11201139	C4591001 1120 11201139	16-55	11AUG2020	46736	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11201142	C4591001 1120 11201142	16-55	12AUG2020	46737	Placebo	12AUG2020/ Placebo	04SEP2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11201144	C4591001 1120 11201144	16-55	12AUG2020	46738	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11201148	C4591001 1120 11201148	16-55	12AUG2020	47393	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
11201149	C4591001 1120 11201149	16-55	12AUG2020	47396	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11201154	C4591001 1120 11201154	16-55	12AUG2020	47399	Placebo	12AUG2020/ Placebo	03SEP2020/ Placebo	03MAR2021/ BNT162b2 (30 µg)	
11201157	C4591001 1120 11201157	16-55	12AUG2020	47401	Placebo	12AUG2020/ Placebo	02SEP2020/ Placebo		
11201161	C4591001 1120 11201161	16-55	12AUG2020	48164	Placebo	12AUG2020/ Placebo	02SEP2020/ Placebo	03MAR2021/ BNT162b2 (30 µg)	
11201165	C4591001 1120 11201165	16-55	13AUG2020	48168	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11201168	C4591001 1120 11201168	16-55	13AUG2020	48170	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
11201171	C4591001 1120 11201171	16-55	13AUG2020	48171	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
11201172	C4591001 1120 11201172	16-55	13AUG2020	48977	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11201176	C4591001 1120 11201176	16-55	13AUG2020	48979	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
11201181	C4591001 1120 11201181	16-55	13AUG2020	48980	Placebo	13AUG2020/ Placebo	02SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
11201191	C4591001 1120 11201191	16-55	14AUG2020	48987	Placebo	14AUG2020/ Placebo	02SEP2020/ Placebo		
11201194	C4591001 1120 11201194	16-55	14AUG2020	50430	Placebo	14AUG2020/ Placebo	02SEP2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
11201195	C4591001 1120 11201195	16-55	14AUG2020	50437	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
11201196	C4591001 1120 11201196	16-55	14AUG2020	50439	Placebo	14AUG2020/ Placebo	02SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
11201197	C4591001 1120 11201197	16-55	14AUG2020	50438	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11201198	C4591001 1120 11201198	16-55	14AUG2020	50574	Placebo	14AUG2020/ Placebo	02SEP2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
11201202	C4591001 1120 11201202	16-55	14AUG2020	50577	Placebo	14AUG2020/ Placebo	02SEP2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
11231005	C4591001 1123 11231005	16-55	30JUL2020	40226	Placebo	30JUL2020/ Placebo	18AUG2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11231007	C4591001 1123 11231007	16-55	30JUL2020	40751	Placebo	30JUL2020/ Placebo	18AUG2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
11231009	C4591001 1123 11231009	16-55	30JUL2020	40752	BNT162b2 (30 µg)	30JUL2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
11231019	C4591001 1123 11231019	16-55	03AUG2020	40754	Placebo	03AUG2020/ Placebo	24AUG2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
11231022	C4591001 1123 11231022	16-55	03AUG2020	40756	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
11231026	C4591001 1123 11231026	16-55	04AUG2020	42617	Placebo	04AUG2020/ Placebo	27AUG2020/ Placebo	12MAR2021/ BNT162b2 (30 µg)	
11231028	C4591001 1123 11231028	16-55	04AUG2020	42654	Placebo	04AUG2020/ Placebo	25AUG2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)
11231029	C4591001 1123 11231029	16-55	04AUG2020	42626	Placebo	04AUG2020/ Placebo	25AUG2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
11231030	C4591001 1123 11231030	16-55	04AUG2020	42623	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
11231031	C4591001 1123 11231031	16-55	04AUG2020	42656	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
11231033	C4591001 1123 11231033	16-55	05AUG2020	43253	Placebo	05AUG2020/ Placebo	24AUG2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11231034	C4591001 1123 11231034	16-55	05AUG2020	42662	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
11231035	C4591001 1123 11231035	16-55	05AUG2020	42661	Placebo	05AUG2020/ Placebo	25AUG2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
11231038	C4591001 1123 11231038	16-55	05AUG2020	43258	Placebo	05AUG2020/ Placebo	27AUG2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
11231041	C4591001 1123 11231041	16-55	05AUG2020	43259	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
11231042	C4591001 1123 11231042	16-55	06AUG2020	43264	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
11231043	C4591001 1123 11231043	16-55	06AUG2020	43975	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
11231044	C4591001 1123 11231044	16-55	06AUG2020	43976	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
11231045	C4591001 1123 11231045	16-55	06AUG2020	43980	Placebo	06AUG2020/ Placebo	25AUG2020/ Placebo		
11231046	C4591001 1123 11231046	16-55	06AUG2020	43984	Placebo	06AUG2020/ Placebo	25AUG2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
11231048	C4591001 1123 11231048	16-55	06AUG2020	44106	Placebo	06AUG2020/ Placebo	26AUG2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11231051	C4591001 1123 11231051	16-55	07AUG2020	44108	Placebo	07AUG2020/ Placebo	27AUG2020/ Placebo		
11231052	C4591001 1123 11231052	16-55	07AUG2020	44111	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
11231055	C4591001 1123 11231055	16-55	07AUG2020	44116	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
11231057	C4591001 1123 11231057	16-55	10AUG2020	45473	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
11231059	C4591001 1123 11231059	16-55	10AUG2020	45475	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
11231060	C4591001 1123 11231060	16-55	10AUG2020	45481	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
11231062	C4591001 1123 11231062	16-55	10AUG2020	45484	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
11231064	C4591001 1123 11231064	16-55	10AUG2020	45906	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
11231067	C4591001 1123 11231067	16-55	11AUG2020	45910	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
11231068	C4591001 1123 11231068	16-55	11AUG2020	45916	Placebo	11AUG2020/ Placebo	01SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11231069	C4591001 1123 11231069	16-55	11AUG2020	45911	Placebo	11AUG2020/ Placebo	01SEP2020/ Placebo		
11231072	C4591001 1123 11231072	16-55	11AUG2020	46822	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
11231073	C4591001 1123 11231073	16-55	11AUG2020	46820	Placebo	11AUG2020/ Placebo	01SEP2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
11231074	C4591001 1123 11231074	16-55	11AUG2020	46827	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
11231075	C4591001 1123 11231075	16-55	11AUG2020	46825	Placebo	11AUG2020/ Placebo	01SEP2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
11231076	C4591001 1123 11231076	16-55	12AUG2020	47801	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11231077	C4591001 1123 11231077	16-55	12AUG2020	47802	Placebo	12AUG2020/ Placebo	02SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
11231078	C4591001 1123 11231078	16-55	12AUG2020	47805	Placebo	12AUG2020/ Placebo	02SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
11231081	C4591001 1123 11231081	16-55	12AUG2020	47808	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
11231082	C4591001 1123 11231082	16-55	12AUG2020	48043	Placebo	12AUG2020/ Placebo	02SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11231083	C4591001 1123 11231083	16-55	12AUG2020	48044	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
11231084	C4591001 1123 11231084	16-55	13AUG2020	48045	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11231085	C4591001 1123 11231085	16-55	13AUG2020	48047	Placebo	13AUG2020/ Placebo	04SEP2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
11231086	C4591001 1123 11231086	16-55	13AUG2020	49327	Placebo	13AUG2020/ Placebo	01SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
11231088	C4591001 1123 11231088	16-55	13AUG2020	49330	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
11231090	C4591001 1123 11231090	16-55	13AUG2020	49333	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
11231091	C4591001 1123 11231091	16-55	13AUG2020	49332	Placebo	13AUG2020/ Placebo	02SEP2020/ Placebo		
11231092	C4591001 1123 11231092	16-55	13AUG2020	49529	Placebo	13AUG2020/ Placebo	02SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
11231094	C4591001 1123 11231094	16-55	13AUG2020	49530	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
11231095	C4591001 1123 11231095	16-55	13AUG2020	49535	Placebo	13AUG2020/ Placebo	02SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11231099	C4591001 1123 11231099	16-55	14AUG2020	50551	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
11231100	C4591001 1123 11231100	16-55	14AUG2020	50549	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11231101	C4591001 1123 11231101	16-55	14AUG2020	50559	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
11231102	C4591001 1123 11231102	16-55	14AUG2020	50555	Placebo	14AUG2020/ Placebo	02SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
11231104	C4591001 1123 11231104	16-55	14AUG2020	50777	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
11241001	C4591001 1124 11241001	16-55	10AUG2020	45127	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo		
11241003	C4591001 1124 11241003	16-55	10AUG2020	45129	Placebo	10AUG2020/ Placebo	08OCT2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
11241005	C4591001 1124 11241005	16-55	10AUG2020	45131	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
11241008	C4591001 1124 11241008	16-55	10AUG2020	45132	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
11241010	C4591001 1124 11241010	16-55	11AUG2020	46013	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11241012	C4591001 1124 11241012	16-55	11AUG2020	46015	Placebo	11AUG2020/ Placebo	31AUG2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11241017	C4591001 1124 11241017	16-55	11AUG2020	46016	Placebo	11AUG2020/ Placebo	01SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
11241018	C4591001 1124 11241018	16-55	11AUG2020	46019	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
11241019	C4591001 1124 11241019	16-55	12AUG2020	46977	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
11241020	C4591001 1124 11241020	16-55	12AUG2020	46978	Placebo	12AUG2020/ Placebo	01SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
11241024	C4591001 1124 11241024	16-55	12AUG2020	46983	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11241025	C4591001 1124 11241025	16-55	12AUG2020	46981	Placebo	12AUG2020/ Placebo	02SEP2020/ Placebo		
11241026	C4591001 1124 11241026	16-55	12AUG2020	47875	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
11241027	C4591001 1124 11241027	16-55	12AUG2020	47878	Placebo	12AUG2020/ Placebo	02SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
11241028	C4591001 1124 11241028	16-55	13AUG2020	47883	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11241030	C4591001 1124 11241030	16-55	13AUG2020	47884	Placebo	13AUG2020/ Placebo	02SEP2020/ Placebo	06JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
11241032	C4591001 1124 11241032	16-55	13AUG2020	48595	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11241036	C4591001 1124 11241036	16-55	13AUG2020	48597	Placebo	13AUG2020/ Placebo	01SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
11241038	C4591001 1124 11241038	16-55	13AUG2020	48599	Placebo	13AUG2020/ Placebo	02SEP2020/ Placebo		
11241039	C4591001 1124 11241039	16-55	13AUG2020	48600	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
11251004	C4591001 1125 11251004	16-55	12AUG2020	47408	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11251005	C4591001 1125 11251005	16-55	12AUG2020	47407	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
11251006	C4591001 1125 11251006	16-55	12AUG2020	47411	Placebo	12AUG2020/ Placebo	31AUG2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
11251007	C4591001 1125 11251007	16-55	12AUG2020	47414	Placebo	12AUG2020/ Placebo	01SEP2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	
11251009	C4591001 1125 11251009	16-55	12AUG2020	47682	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11251010	C4591001 1125 11251010	16-55	12AUG2020	47683	Placebo	12AUG2020/ Placebo	01SEP2020/ Placebo	13FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
11251014	C4591001 1125 11251014	16-55	12AUG2020	47690	Placebo	12AUG2020/ Placebo	02SEP2020/ Placebo		
11251015	C4591001 1125 11251015	16-55	13AUG2020	47691	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
11251017	C4591001 1125 11251017	16-55	13AUG2020	48750	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
11251019	C4591001 1125 11251019	16-55	13AUG2020	48756	Placebo	13AUG2020/ Placebo			
11251020	C4591001 1125 11251020	16-55	13AUG2020	48757	Placebo	13AUG2020/ Placebo	04SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
11251021	C4591001 1125 11251021	16-55	13AUG2020	48760	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
11251022	C4591001 1125 11251022	16-55	13AUG2020	49302	Placebo	13AUG2020/ Placebo	02SEP2020/ Placebo		
11251023	C4591001 1125 11251023	16-55	13AUG2020	49305	Placebo	13AUG2020/ Placebo	02SEP2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
11251024	C4591001 1125 11251024	16-55	13AUG2020	49306	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11251025	C4591001 1125 11251025	16-55	13AUG2020	49307	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
11251027	C4591001 1125 11251027	16-55	13AUG2020	49628	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
11251028	C4591001 1125 11251028	16-55	13AUG2020	49630	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	
11251029	C4591001 1125 11251029	16-55	13AUG2020	49631	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
11251030	C4591001 1125 11251030	16-55	13AUG2020	49633	Placebo	13AUG2020/ Placebo	01SEP2020/ Placebo	13FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
11251031	C4591001 1125 11251031	16-55	13AUG2020	49745	Placebo	13AUG2020/ Placebo	02SEP2020/ Placebo		
11251032	C4591001 1125 11251032	16-55	14AUG2020	49755	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
11251033	C4591001 1125 11251033	16-55	14AUG2020	49751	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11251034	C4591001 1125 11251034	16-55	14AUG2020	49756	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
11251036	C4591001 1125 11251036	16-55	14AUG2020	50264	Placebo	14AUG2020/ Placebo	02SEP2020/ Placebo	27FEB2021/ BNT162b2 (30 µg)	



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11251038	C4591001 1125 11251038	16-55	14AUG2020	50266	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo		
11251039	C4591001 1125 11251039	16-55	14AUG2020	50267	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
11251040	C4591001 1125 11251040	16-55	14AUG2020	50269	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
11251043	C4591001 1125 11251043	16-55	14AUG2020	50732	Placebo	14AUG2020/ Placebo	02SEP2020/ Placebo		
11261002	C4591001 1126 11261002	16-55	10AUG2020	45787	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
11261005	C4591001 1126 11261005	16-55	11AUG2020	45789	Placebo	11AUG2020/ Placebo	31AUG2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
11261006	C4591001 1126 11261006	16-55	11AUG2020	45795	Placebo	11AUG2020/ Placebo	31AUG2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
11261009	C4591001 1126 11261009	16-55	12AUG2020	45796	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11261010	C4591001 1126 11261010	16-55	12AUG2020	47455	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11261011	C4591001 1126 11261011	16-55	12AUG2020	47456	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11261012	C4591001 1126 11261012	16-55	12AUG2020	47457	Placebo	12AUG2020/ Placebo	02SEP2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)
11261013	C4591001 1126 11261013	16-55	12AUG2020	47460	Placebo	12AUG2020/ Placebo	02SEP2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)
11261014	C4591001 1126 11261014	16-55	12AUG2020	48225	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11261017	C4591001 1126 11261017	16-55	13AUG2020	48228	Placebo	13AUG2020/ Placebo	01SEP2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	
11261018	C4591001 1126 11261018	16-55	13AUG2020	48231	Placebo	13AUG2020/ Placebo	01SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
11261019	C4591001 1126 11261019	16-55	13AUG2020	48232	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11261021	C4591001 1126 11261021	16-55	13AUG2020	49734	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11261022	C4591001 1126 11261022	16-55	14AUG2020	49735	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11261024	C4591001 1126 11261024	16-55	14AUG2020	49739	Placebo	14AUG2020/ Placebo	02SEP2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)
11261025	C4591001 1126 11261025	16-55	14AUG2020	49741	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11271021	C4591001 1127 11271021	16-55	30JUL2020	40622	BNT162b2 (30 µg)	30JUL2020/ BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)		
11271022	C4591001 1127 11271022	16-55	30JUL2020	40769	BNT162b2 (30 µg)	30JUL2020/ BNT162b2 (30 µg)			
11271024	C4591001 1127 11271024	16-55	30JUL2020	40624	Placebo	30JUL2020/ Placebo	18AUG2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	27FEB2021/ BNT162b2 (30 µg)
11271025	C4591001 1127 11271025	16-55	30JUL2020	40770	Placebo	30JUL2020/ Placebo	18AUG2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
11271026	C4591001 1127 11271026	16-55	31JUL2020	40772	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)		
11271027	C4591001 1127 11271027	16-55	31JUL2020	40780	Placebo	31JUL2020/ Placebo	21AUG2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	27FEB2021/ BNT162b2 (30 µg)
11271028	C4591001 1127 11271028	16-55	31JUL2020	40925	Placebo	31JUL2020/ Placebo	21AUG2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
11271029	C4591001 1127 11271029	16-55	31JUL2020	40929	Placebo	31JUL2020/ Placebo	19AUG2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
11271030	C4591001 1127 11271030	16-55	31JUL2020	40930	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)		
11271032	C4591001 1127 11271032	16-55	31JUL2020	40932	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11271033	C4591001 1127 11271033	16-55	31JUL2020	41082	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)		
11271036	C4591001 1127 11271036	16-55	31JUL2020	41084	Placebo	31JUL2020/ Placebo	19AUG2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	27FEB2021/ BNT162b2 (30 µg)
11271037	C4591001 1127 11271037	16-55	31JUL2020	41085	Placebo	31JUL2020/ Placebo	19AUG2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
11271040	C4591001 1127 11271040	16-55	31JUL2020	41088	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)		
11271043	C4591001 1127 11271043	16-55	03AUG2020	41708	Placebo	03AUG2020/ Placebo	24AUG2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
11271044	C4591001 1127 11271044	16-55	03AUG2020	41707	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)		
11271047	C4591001 1127 11271047	16-55	03AUG2020	41712	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)		
11271048	C4591001 1127 11271048	16-55	03AUG2020	41709	Placebo	03AUG2020/ Placebo	22AUG2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
11271052	C4591001 1127 11271052	16-55	04AUG2020	42227	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
11271057	C4591001 1127 11271057	16-55	04AUG2020	42230	Placebo	04AUG2020/ Placebo	24AUG2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11271059	C4591001 1127 11271059	16-55	05AUG2020	42231	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
11271068	C4591001 1127 11271068	16-55	05AUG2020	43349	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
11271069	C4591001 1127 11271069	16-55	05AUG2020	42232	Placebo	05AUG2020/ Placebo	24AUG2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	27FEB2021/ BNT162b2 (30 µg)
11271070	C4591001 1127 11271070	16-55	05AUG2020	43352	Placebo	05AUG2020/ Placebo	24AUG2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	27FEB2021/ BNT162b2 (30 µg)
11271072	C4591001 1127 11271072	16-55	06AUG2020	43354	Placebo	06AUG2020/ Placebo	25AUG2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
11271073	C4591001 1127 11271073	16-55	06AUG2020	43356	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
11271076	C4591001 1127 11271076	16-55	06AUG2020	43664	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)		
11271077	C4591001 1127 11271077	16-55	06AUG2020	43666	Placebo	06AUG2020/ Placebo	25AUG2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
11271078	C4591001 1127 11271078	16-55	07AUG2020	43668	Placebo	07AUG2020/ Placebo	28AUG2020/ Placebo		
11271079	C4591001 1127 11271079	16-55	07AUG2020	43670	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11271080	C4591001 1127 11271080	16-55	07AUG2020	44479	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
11271084	C4591001 1127 11271084	16-55	11AUG2020	44483	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
11271085	C4591001 1127 11271085	16-55	11AUG2020	44484	Placebo	11AUG2020/ Placebo	30AUG2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11271086	C4591001 1127 11271086	16-55	11AUG2020	44486	Placebo	11AUG2020/ Placebo	30AUG2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	27FEB2021/ BNT162b2 (30 µg)
11271087	C4591001 1127 11271087	16-55	11AUG2020	46577	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	30AUG2020/ BNT162b2 (30 µg)		
11281001	C4591001 1128 11281001	16-55	31JUL2020	40985	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)		
11281002	C4591001 1128 11281002	16-55	31JUL2020	40990	Placebo	31JUL2020/ Placebo	21AUG2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	27JAN2021/ BNT162b2 (30 µg)
11281005	C4591001 1128 11281005	16-55	31JUL2020	40992	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)		
11281012	C4591001 1128 11281012	16-55	31JUL2020	40995	Placebo	31JUL2020/ Placebo	25SEP2020/ Placebo	06JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)
11281017	C4591001 1128 11281017	16-55	01AUG2020	41334	Placebo	01AUG2020/ Placebo	20AUG2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11281018	C4591001 1128 11281018	16-55	01AUG2020	41335	Placebo	01AUG2020/ Placebo	20AUG2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
11281020	C4591001 1128 11281020	16-55	01AUG2020	41337	BNT162b2 (30 µg)	01AUG2020/ BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)		
11281021	C4591001 1128 11281021	16-55	01AUG2020	41340	BNT162b2 (30 µg)	01AUG2020/ BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)		
11281024	C4591001 1128 11281024	16-55	01AUG2020	41376	BNT162b2 (30 µg)	01AUG2020/ BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)		
11281025	C4591001 1128 11281025	16-55	01AUG2020	41370	BNT162b2 (30 µg)	01AUG2020/ BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)		
11281026	C4591001 1128 11281026	16-55	01AUG2020	41377	Placebo	01AUG2020/ Placebo	20AUG2020/ Placebo		
11281028	C4591001 1128 11281028	16-55	01AUG2020	41380	Placebo	01AUG2020/ Placebo	21AUG2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	27JAN2021/ BNT162b2 (30 µg)
11281029	C4591001 1128 11281029	16-55	01AUG2020	41393	Placebo	01AUG2020/ Placebo	21AUG2020/ Placebo		
11281030	C4591001 1128 11281030	16-55	03AUG2020	41397	Placebo	03AUG2020/ Placebo	24AUG2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
11281031	C4591001 1128 11281031	16-55	03AUG2020	41396	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11281035	C4591001 1128 11281035	16-55	03AUG2020	41398	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
11281038	C4591001 1128 11281038	16-55	05AUG2020	42954	Placebo	05AUG2020/ Placebo	28AUG2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
11281042	C4591001 1128 11281042	16-55	05AUG2020	42957	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
11281045	C4591001 1128 11281045	16-55	05AUG2020	42958	Placebo	05AUG2020/ Placebo	26AUG2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)
11281047	C4591001 1128 11281047	16-55	05AUG2020	42961	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
11281049	C4591001 1128 11281049	16-55	05AUG2020	43242	Placebo	05AUG2020/ Placebo	27AUG2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
11281050	C4591001 1128 11281050	16-55	05AUG2020	43244	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)		
11281054	C4591001 1128 11281054	16-55	05AUG2020	43247	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
11281055	C4591001 1128 11281055	16-55	05AUG2020	43252	Placebo	05AUG2020/ Placebo	26AUG2020/ Placebo		
11281057	C4591001 1128 11281057	16-55	06AUG2020	44177	Placebo	06AUG2020/ Placebo	26AUG2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11281061	C4591001 1128 11281061	16-55	07AUG2020	44181	Placebo	07AUG2020/ Placebo	28AUG2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)
11281062	C4591001 1128 11281062	16-55	07AUG2020	44185	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
11281064	C4591001 1128 11281064	16-55	07AUG2020	44188	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)		
11281067	C4591001 1128 11281067	16-55	07AUG2020	44575	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)		
11281070	C4591001 1128 11281070	16-55	07AUG2020	44578	Placebo	07AUG2020/ Placebo	27AUG2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
11281071	C4591001 1128 11281071	16-55	07AUG2020	44577	Placebo	07AUG2020/ Placebo	31AUG2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
11281073	C4591001 1128 11281073	16-55	07AUG2020	44581	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
11281074	C4591001 1128 11281074	16-55	07AUG2020	44890	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
11281077	C4591001 1128 11281077	16-55	07AUG2020	44891	Placebo	07AUG2020/ Placebo	28AUG2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
11281078	C4591001 1128 11281078	16-55	07AUG2020	44892	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11281080	C4591001 1128 11281080	16-55	10AUG2020	44895	Placebo	10AUG2020/ Placebo	02SEP2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)
11281083	C4591001 1128 11281083	16-55	10AUG2020	45850	Placebo	10AUG2020/ Placebo	01SEP2020/ Placebo		
11281086	C4591001 1128 11281086	16-55	10AUG2020	45852	Placebo	10AUG2020/ Placebo	01SEP2020/ Placebo		
11281092	C4591001 1128 11281092	16-55	11AUG2020	45853	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
11281093	C4591001 1128 11281093	16-55	11AUG2020	46890	Placebo	11AUG2020/ Placebo	28AUG2020/ Placebo		
11281094	C4591001 1128 11281094	16-55	11AUG2020	46896	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
11281095	C4591001 1128 11281095	16-55	11AUG2020	46899	Placebo	11AUG2020/ Placebo	03SEP2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
11281096	C4591001 1128 11281096	16-55	12AUG2020	46900	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
11281098	C4591001 1128 11281098	16-55	12AUG2020	47468	Placebo	12AUG2020/ Placebo	04SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
11281101	C4591001 1128 11281101	16-55	12AUG2020	47471	Placebo	12AUG2020/ Placebo	31AUG2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11281102	C4591001 1128 11281102	16-55	12AUG2020	47474	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
11281103	C4591001 1128 11281103	16-55	12AUG2020	47476	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
11281107	C4591001 1128 11281107	16-55	12AUG2020	48149	Placebo	12AUG2020/ Placebo	04SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
11281112	C4591001 1128 11281112	16-55	12AUG2020	48150	Placebo	12AUG2020/ Placebo	02SEP2020/ Placebo		
11281113	C4591001 1128 11281113	16-55	14AUG2020	48154	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
11281114	C4591001 1128 11281114	16-55	14AUG2020	50336	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
11281115	C4591001 1128 11281115	16-55	14AUG2020	48156	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
11281117	C4591001 1128 11281117	16-55	14AUG2020	50340	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
11281118	C4591001 1128 11281118	16-55	14AUG2020	50343	Placebo	14AUG2020/ Placebo	02SEP2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
11281119	C4591001 1128 11281119	16-55	14AUG2020	50721	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11281120	C4591001 1128 11281120	16-55	14AUG2020	50719	Placebo	14AUG2020/ Placebo	02SEP2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
11291017	C4591001 1129 11291017	16-55	30JUL2020	40628	Placebo	30JUL2020/ Placebo	19AUG2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
11291019	C4591001 1129 11291019	16-55	31JUL2020	40630	Placebo	31JUL2020/ Placebo	19AUG2020/ Placebo	06JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
11291020	C4591001 1129 11291020	16-55	31JUL2020	40635	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)		
11291029	C4591001 1129 11291029	16-55	03AUG2020	41417	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
11291030	C4591001 1129 11291030	16-55	03AUG2020	41420	Placebo	03AUG2020/ Placebo	24AUG2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
11291040	C4591001 1129 11291040	16-55	04AUG2020	41426	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
11291041	C4591001 1129 11291041	16-55	04AUG2020	41428	Placebo	04AUG2020/ Placebo	24AUG2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
11291042	C4591001 1129 11291042	16-55	04AUG2020	42101	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
11291045	C4591001 1129 11291045	16-55	04AUG2020	42102	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11291047	C4591001 1129 11291047	16-55	04AUG2020	42104	Placebo	04AUG2020/ Placebo	24AUG2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11291054	C4591001 1129 11291054	16-55	07AUG2020	44301	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
11291055	C4591001 1129 11291055	16-55	07AUG2020	44298	Placebo	07AUG2020/ Placebo	28AUG2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
11291056	C4591001 1129 11291056	16-55	07AUG2020	44300	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
11291058	C4591001 1129 11291058	16-55	07AUG2020	44308	Placebo	07AUG2020/ Placebo	28AUG2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
11291061	C4591001 1129 11291061	16-55	07AUG2020	44597	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
11291063	C4591001 1129 11291063	16-55	07AUG2020	44598	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
11291064	C4591001 1129 11291064	16-55	07AUG2020	44605	Placebo	07AUG2020/ Placebo	28AUG2020/ Placebo		
11291069	C4591001 1129 11291069	16-55	10AUG2020	44606	Placebo	10AUG2020/ Placebo	01SEP2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
11291070	C4591001 1129 11291070	16-55	10AUG2020	45092	Placebo	10AUG2020/ Placebo	01SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11291071	C4591001 1129 11291071	16-55	10AUG2020	45093	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
11291072	C4591001 1129 11291072	16-55	10AUG2020	45094	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo		
11291073	C4591001 1129 11291073	16-55	10AUG2020	45095	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
11291088	C4591001 1129 11291088	16-55	11AUG2020	46061	Placebo	11AUG2020/ Placebo	01SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
11291089	C4591001 1129 11291089	16-55	11AUG2020	46062	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
11291092	C4591001 1129 11291092	16-55	11AUG2020	46065	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
11291096	C4591001 1129 11291096	16-55	11AUG2020	46066	Placebo	11AUG2020/ Placebo	01SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
11291097	C4591001 1129 11291097	16-55	11AUG2020	46436	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
11291098	C4591001 1129 11291098	16-55	11AUG2020	46439	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
11291104	C4591001 1129 11291104	16-55	11AUG2020	46442	Placebo	11AUG2020/ Placebo	01SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11311002	C4591001 1131 11311002	16-55	13AUG2020	48701	Placebo	13AUG2020/ Placebo	02SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
11311004	C4591001 1131 11311004	16-55	13AUG2020	48702	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
11311011	C4591001 1131 11311011	16-55	14AUG2020	48708	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11311016	C4591001 1131 11311016	16-55	14AUG2020	50562	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
11311020	C4591001 1131 11311020	16-55	14AUG2020	50571	Placebo	14AUG2020/ Placebo	02SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	
11331019	C4591001 1133 11331019	16-55	30JUL2020	40653	BNT162b2 (30 µg)	30JUL2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
11331023	C4591001 1133 11331023	16-55	31JUL2020	40654	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)		
11331028	C4591001 1133 11331028	16-55	31JUL2020	40949	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)		
11331030	C4591001 1133 11331030	16-55	31JUL2020	40953	Placebo	31JUL2020/ Placebo	21AUG2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
11331037	C4591001 1133 11331037	16-55	31JUL2020	40958	Placebo	31JUL2020/ Placebo			

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11331041	C4591001 1133 11331041	16-55	31JUL2020	40960	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)		
11331042	C4591001 1133 11331042	16-55	31JUL2020	41165	Placebo	31JUL2020/ Placebo			
11331043	C4591001 1133 11331043	16-55	31JUL2020	41166	Placebo	31JUL2020/ Placebo	21AUG2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11331044	C4591001 1133 11331044	16-55	31JUL2020	41168	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)		
11331045	C4591001 1133 11331045	16-55	31JUL2020	41176	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)		
11331047	C4591001 1133 11331047	16-55	03AUG2020	41485	Placebo	03AUG2020/ Placebo	24AUG2020/ Placebo		
11331048	C4591001 1133 11331048	16-55	03AUG2020	41482	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
11331050	C4591001 1133 11331050	16-55	03AUG2020	41479	Placebo	03AUG2020/ Placebo	24AUG2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
11331051	C4591001 1133 11331051	16-55	03AUG2020	41562	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
11331052	C4591001 1133 11331052	16-55	03AUG2020	41486	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)			



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11331054	C4591001 1133 11331054	16-55	03AUG2020	41567	Placebo	03AUG2020/ Placebo	24AUG2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
11331058	C4591001 1133 11331058	16-55	03AUG2020	41572	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
11331059	C4591001 1133 11331059	16-55	03AUG2020	41568	Placebo	03AUG2020/ Placebo	16SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
11331060	C4591001 1133 11331060	16-55	03AUG2020	41875	Placebo	03AUG2020/ Placebo	24AUG2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11331062	C4591001 1133 11331062	16-55	03AUG2020	41876	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
11331063	C4591001 1133 11331063	16-55	03AUG2020	41877	Placebo	03AUG2020/ Placebo	24AUG2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
11331066	C4591001 1133 11331066	16-55	07AUG2020	41884	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
11331069	C4591001 1133 11331069	16-55	07AUG2020	44358	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
11331070	C4591001 1133 11331070	16-55	07AUG2020	44360	Placebo	07AUG2020/ Placebo	28AUG2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
11331072	C4591001 1133 11331072	16-55	07AUG2020	44361	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11331074	C4591001 1133 11331074	16-55	07AUG2020	44362	Placebo	07AUG2020/ Placebo	28AUG2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
11331079	C4591001 1133 11331079	16-55	07AUG2020	44609	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
11331083	C4591001 1133 11331083	16-55	07AUG2020	44612	Placebo	07AUG2020/ Placebo	28AUG2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
11331087	C4591001 1133 11331087	16-55	08AUG2020	44616	Placebo	08AUG2020/ Placebo			
11331088	C4591001 1133 11331088	16-55	08AUG2020	44617	BNT162b2 (30 µg)	08AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11331093	C4591001 1133 11331093	16-55	08AUG2020	44971	BNT162b2 (30 µg)	08AUG2020/ BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)		
11331096	C4591001 1133 11331096	16-55	08AUG2020	44972	Placebo	08AUG2020/ Placebo	29AUG2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
11331097	C4591001 1133 11331097	16-55	08AUG2020	44973	Placebo	08AUG2020/ Placebo	29AUG2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
11331102	C4591001 1133 11331102	16-55	08AUG2020	44975	BNT162b2 (30 µg)	08AUG2020/ BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)		
11331103	C4591001 1133 11331103	16-55	08AUG2020	45010	Placebo	08AUG2020/ Placebo	29AUG2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11331105	C4591001 1133 11331105	16-55	08AUG2020	45009	BNT162b2 (30 µg)	08AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
11331106	C4591001 1133 11331106	16-55	08AUG2020	45012	BNT162b2 (30 µg)	08AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11331108	C4591001 1133 11331108	16-55	08AUG2020	45016	Placebo	08AUG2020/ Placebo	29AUG2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
11331111	C4591001 1133 11331111	16-55	08AUG2020	45019	Placebo	08AUG2020/ Placebo	29AUG2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
11331113	C4591001 1133 11331113	16-55	08AUG2020	45021	BNT162b2 (30 µg)	08AUG2020/ BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)		
11331115	C4591001 1133 11331115	16-55	08AUG2020	45022	Placebo	08AUG2020/ Placebo	29AUG2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
11331117	C4591001 1133 11331117	16-55	08AUG2020	45028	BNT162b2 (30 µg)	08AUG2020/ BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)		
11331119	C4591001 1133 11331119	16-55	12AUG2020	47081	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11331120	C4591001 1133 11331120	16-55	12AUG2020	47086	Placebo	12AUG2020/ Placebo	30SEP2020/ Placebo		
11331121	C4591001 1133 11331121	16-55	12AUG2020	47088	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11331122	C4591001 1133 11331122	16-55	12AUG2020	47285	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)			
11331123	C4591001 1133 11331123	16-55	12AUG2020	47092	Placebo	12AUG2020/ Placebo	04SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
11331125	C4591001 1133 11331125	16-55	12AUG2020	47291	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
11331129	C4591001 1133 11331129	16-55	12AUG2020	47290	Placebo	12AUG2020/ Placebo	04SEP2020/ Placebo		
11331130	C4591001 1133 11331130	16-55	12AUG2020	47287	Placebo	12AUG2020/ Placebo	04SEP2020/ Placebo		
11331131	C4591001 1133 11331131	16-55	12AUG2020	47550	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
11331132	C4591001 1133 11331132	16-55	12AUG2020	47555	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
11331135	C4591001 1133 11331135	16-55	12AUG2020	47556	Placebo	12AUG2020/ Placebo	04SEP2020/ Placebo		
11331138	C4591001 1133 11331138	16-55	12AUG2020	47557	Placebo	12AUG2020/ Placebo			
11331139	C4591001 1133 11331139	16-55	14AUG2020	49962	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
11331140	C4591001 1133 11331140	16-55	14AUG2020	49969	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11331142	C4591001 1133 11331142	16-55	14AUG2020	49964	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
11331144	C4591001 1133 11331144	16-55	14AUG2020	49970	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11331145	C4591001 1133 11331145	16-55	14AUG2020	50070	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11331149	C4591001 1133 11331149	16-55	14AUG2020	50071	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
11331150	C4591001 1133 11331150	16-55	14AUG2020	50073	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
11331151	C4591001 1133 11331151	16-55	14AUG2020	50078	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
11331158	C4591001 1133 11331158	16-55	14AUG2020	50179	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
11331166	C4591001 1133 11331166	16-55	14AUG2020	50188	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
11331175	C4591001 1133 11331175	16-55	14AUG2020	50663	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
11331177	C4591001 1133 11331177	16-55	14AUG2020	50666	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11331178	C4591001 1133 11331178	16-55	14AUG2020	50668	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
11341005	C4591001 1134 11341005	16-55	06AUG2020	44118	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
11341007	C4591001 1134 11341007	16-55	07AUG2020	44121	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)		
11341008	C4591001 1134 11341008	16-55	07AUG2020	44120	Placebo	07AUG2020/ Placebo	28AUG2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11341012	C4591001 1134 11341012	16-55	07AUG2020	44122	Placebo	07AUG2020/ Placebo	28AUG2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
11341013	C4591001 1134 11341013	16-55	07AUG2020	44682	Placebo	07AUG2020/ Placebo	27AUG2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
11341018	C4591001 1134 11341018	16-55	10AUG2020	44685	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
11341028	C4591001 1134 11341028	16-55	11AUG2020	44688	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
11341031	C4591001 1134 11341031	16-55	11AUG2020	44689	Placebo	11AUG2020/ Placebo	31AUG2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11341033	C4591001 1134 11341033	16-55	11AUG2020	46411	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)			

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11341039	C4591001 1134 11341039	16-55	11AUG2020	46412	Placebo	11AUG2020/ Placebo	01SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
11341041	C4591001 1134 11341041	16-55	11AUG2020	46417	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11341046	C4591001 1134 11341046	16-55	12AUG2020	46419	Placebo	12AUG2020/ Placebo	01SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
11341054	C4591001 1134 11341054	16-55	12AUG2020	47585	Placebo	12AUG2020/ Placebo	02SEP2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
11341060	C4591001 1134 11341060	16-55	13AUG2020	47586	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11341068	C4591001 1134 11341068	16-55	13AUG2020	47587	Placebo	13AUG2020/ Placebo	04SEP2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	15JAN2021/ BNT162b2 (30 µg)
11341070	C4591001 1134 11341070	16-55	13AUG2020	47589	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
11341072	C4591001 1134 11341072	16-55	14AUG2020	49949	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
11341077	C4591001 1134 11341077	16-55	14AUG2020	49955	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11351001	C4591001 1135 11351001	16-55	03AUG2020	41781	Placebo	03AUG2020/ Placebo	25AUG2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	20JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11351002	C4591001 1135 11351002	16-55	03AUG2020	41780	Placebo	03AUG2020/ Placebo	25AUG2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
11351004	C4591001 1135 11351004	16-55	03AUG2020	41787	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
11351006	C4591001 1135 11351006	16-55	03AUG2020	41788	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
11351007	C4591001 1135 11351007	16-55	03AUG2020	42041	Placebo	03AUG2020/ Placebo	25AUG2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
11351008	C4591001 1135 11351008	16-55	03AUG2020	42047	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
11351009	C4591001 1135 11351009	16-55	04AUG2020	42048	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
11351011	C4591001 1135 11351011	16-55	04AUG2020	42049	Placebo	04AUG2020/ Placebo	25AUG2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11351016	C4591001 1135 11351016	16-55	04AUG2020	42634	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
11351017	C4591001 1135 11351017	16-55	04AUG2020	42631	Placebo	04AUG2020/ Placebo	25AUG2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
11351018	C4591001 1135 11351018	16-55	04AUG2020	42636	Placebo	04AUG2020/ Placebo	25AUG2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11351020	C4591001 1135 11351020	16-55	04AUG2020	42680	Placebo	04AUG2020/ Placebo	25AUG2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
11351021	C4591001 1135 11351021	16-55	04AUG2020	42638	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
11351022	C4591001 1135 11351022	16-55	04AUG2020	42683	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)		
11351023	C4591001 1135 11351023	16-55	04AUG2020	42677	Placebo	04AUG2020/ Placebo	25AUG2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
11351024	C4591001 1135 11351024	16-55	05AUG2020	42687	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
11351025	C4591001 1135 11351025	16-55	05AUG2020	43064	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
11351026	C4591001 1135 11351026	16-55	05AUG2020	43071	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
11351027	C4591001 1135 11351027	16-55	05AUG2020	43061	Placebo	05AUG2020/ Placebo	26AUG2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
11351029	C4591001 1135 11351029	16-55	05AUG2020	43072	Placebo	05AUG2020/ Placebo	27AUG2020/ Placebo		
11351030	C4591001 1135 11351030	16-55	05AUG2020	43194	Placebo	05AUG2020/ Placebo	27AUG2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11351036	C4591001 1135 11351036	16-55	05AUG2020	43195	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
11351037	C4591001 1135 11351037	16-55	05AUG2020	43200	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
11351038	C4591001 1135 11351038	16-55	05AUG2020	43203	Placebo	05AUG2020/ Placebo	02SEP2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
11351040	C4591001 1135 11351040	16-55	05AUG2020	43434	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)		
11351041	C4591001 1135 11351041	16-55	06AUG2020	43443	Placebo	06AUG2020/ Placebo	28AUG2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
11351042	C4591001 1135 11351042	16-55	06AUG2020	43439	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
11351044	C4591001 1135 11351044	16-55	06AUG2020	43444	Placebo	06AUG2020/ Placebo	27AUG2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
11351050	C4591001 1135 11351050	16-55	06AUG2020	44144	Placebo	06AUG2020/ Placebo	25AUG2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
11351052	C4591001 1135 11351052	16-55	07AUG2020	44761	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)		
11351053	C4591001 1135 11351053	16-55	07AUG2020	44146	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11351054	C4591001 1135 11351054	16-55	07AUG2020	44148	Placebo	07AUG2020/ Placebo	27AUG2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
11351057	C4591001 1135 11351057	16-55	07AUG2020	44755	Placebo	07AUG2020/ Placebo	28AUG2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
11351058	C4591001 1135 11351058	16-55	07AUG2020	44149	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
11351059	C4591001 1135 11351059	16-55	07AUG2020	44757	Placebo	07AUG2020/ Placebo	28AUG2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
11351060	C4591001 1135 11351060	16-55	07AUG2020	44758	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
11351061	C4591001 1135 11351061	16-55	07AUG2020	44909	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)			
11351065	C4591001 1135 11351065	16-55	07AUG2020	44945	Placebo	07AUG2020/ Placebo	28AUG2020/ Placebo		
11351067	C4591001 1135 11351067	16-55	07AUG2020	44911	Placebo	07AUG2020/ Placebo	28AUG2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
11351068	C4591001 1135 11351068	16-55	07AUG2020	44912	Placebo	07AUG2020/ Placebo	28AUG2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
11351069	C4591001 1135 11351069	16-55	07AUG2020	44916	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11351072	C4591001 1135 11351072	16-55	08AUG2020	44946	BNT162b2 (30 µg)	08AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
11351073	C4591001 1135 11351073	16-55	08AUG2020	44950	Placebo	08AUG2020/ Placebo	28AUG2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
11351075	C4591001 1135 11351075	16-55	08AUG2020	44952	BNT162b2 (30 µg)	08AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
11351080	C4591001 1135 11351080	16-55	08AUG2020	45029	BNT162b2 (30 µg)	08AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
11351082	C4591001 1135 11351082	16-55	08AUG2020	45036	Placebo	08AUG2020/ Placebo	28AUG2020/ Placebo		
11351083	C4591001 1135 11351083	16-55	08AUG2020	45030	Placebo	08AUG2020/ Placebo	31AUG2020/ Placebo	02MAR2021/ BNT162b2 (30 µg)	
11351084	C4591001 1135 11351084	16-55	08AUG2020	45037	BNT162b2 (30 µg)	08AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
11351085	C4591001 1135 11351085	16-55	08AUG2020	45047	Placebo	08AUG2020/ Placebo	28AUG2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
11351088	C4591001 1135 11351088	16-55	08AUG2020	45041	BNT162b2 (30 µg)	08AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
11351090	C4591001 1135 11351090	16-55	10AUG2020	45050	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11351091	C4591001 1135 11351091	16-55	10AUG2020	45051	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
11351095	C4591001 1135 11351095	16-55	10AUG2020	45930	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
11351097	C4591001 1135 11351097	16-55	10AUG2020	45935	Placebo	10AUG2020/ Placebo	01SEP2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
11351099	C4591001 1135 11351099	16-55	11AUG2020	45936	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
11351100	C4591001 1135 11351100	16-55	11AUG2020	45937	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
11351103	C4591001 1135 11351103	16-55	12AUG2020	47529	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
11351104	C4591001 1135 11351104	16-55	12AUG2020	47530	Placebo	12AUG2020/ Placebo	31AUG2020/ Placebo		
11351105	C4591001 1135 11351105	16-55	12AUG2020	47532	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
11351109	C4591001 1135 11351109	16-55	12AUG2020	47536	Placebo	12AUG2020/ Placebo	31AUG2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
11351111	C4591001 1135 11351111	16-55	12AUG2020	48189	Placebo	12AUG2020/ Placebo	31AUG2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11351112	C4591001 1135 11351112	16-55	13AUG2020	48190	Placebo	13AUG2020/ Placebo	01SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
11351113	C4591001 1135 11351113	16-55	13AUG2020	48193	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11351114	C4591001 1135 11351114	16-55	13AUG2020	49205	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
11351115	C4591001 1135 11351115	16-55	13AUG2020	48196	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11351119	C4591001 1135 11351119	16-55	13AUG2020	49211	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
11351120	C4591001 1135 11351120	16-55	13AUG2020	49213	Placebo	13AUG2020/ Placebo	01SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
11351121	C4591001 1135 11351121	16-55	13AUG2020	49208	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
11351124	C4591001 1135 11351124	16-55	13AUG2020	49662	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11351126	C4591001 1135 11351126	16-55	13AUG2020	49664	Placebo	13AUG2020/ Placebo	11SEP2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
11351127	C4591001 1135 11351127	16-55	14AUG2020	49667	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11351132	C4591001 1135 11351132	16-55	14AUG2020	50767	Placebo	14AUG2020/ Placebo	01SEP2020/ Placebo		
11351134	C4591001 1135 11351134	16-55	14AUG2020	50771	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11391016	C4591001 1139 11391016	16-55	30JUL2020	40661	BNT162b2 (30 µg)	30JUL2020/ BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)		
11391021	C4591001 1139 11391021	16-55	31JUL2020	40664	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)		
11391023	C4591001 1139 11391023	16-55	31JUL2020	40666	Placebo	31JUL2020/ Placebo	19AUG2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
11391025	C4591001 1139 11391025	16-55	31JUL2020	40672	Placebo	31JUL2020/ Placebo	21AUG2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
11391027	C4591001 1139 11391027	16-55	03AUG2020	41410	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
11391028	C4591001 1139 11391028	16-55	03AUG2020	41406	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
11391029	C4591001 1139 11391029	16-55	06AUG2020	43111	Placebo	06AUG2020/ Placebo	26AUG2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
11391033	C4591001 1139 11391033	16-55	03AUG2020	41412	Placebo	03AUG2020/ Placebo	24AUG2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11391037	C4591001 1139 11391037	16-55	04AUG2020	41415	Placebo	04AUG2020/ Placebo	24AUG2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
11391038	C4591001 1139 11391038	16-55	04AUG2020	42257	Placebo	04AUG2020/ Placebo	26AUG2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
11391041	C4591001 1139 11391041	16-55	04AUG2020	42259	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
11391042	C4591001 1139 11391042	16-55	04AUG2020	42267	Placebo	04AUG2020/ Placebo	27AUG2020/ Placebo		
11391044	C4591001 1139 11391044	16-55	04AUG2020	42268	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)		
11391047	C4591001 1139 11391047	16-55	05AUG2020	42846	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
11391048	C4591001 1139 11391048	16-55	05AUG2020	42851	Placebo	05AUG2020/ Placebo	27AUG2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)
11391049	C4591001 1139 11391049	16-55	05AUG2020	42850	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
11391052	C4591001 1139 11391052	16-55	05AUG2020	42854	Placebo	05AUG2020/ Placebo	26AUG2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
11391053	C4591001 1139 11391053	16-55	05AUG2020	43109	Placebo	05AUG2020/ Placebo	26AUG2020/ Placebo	19DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11391058	C4591001 1139 11391058	16-55	06AUG2020	43115	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
11391062	C4591001 1139 11391062	16-55	06AUG2020	43120	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
11391065	C4591001 1139 11391065	16-55	06AUG2020	43805	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)		
11391070	C4591001 1139 11391070	16-55	07AUG2020	43809	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
11391071	C4591001 1139 11391071	16-55	07AUG2020	43811	Placebo	07AUG2020/ Placebo	28AUG2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
11391072	C4591001 1139 11391072	16-55	07AUG2020	43814	Placebo	07AUG2020/ Placebo	27AUG2020/ Placebo	19DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11391073	C4591001 1139 11391073	16-55	07AUG2020	44441	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)		
11391076	C4591001 1139 11391076	16-55	07AUG2020	44444	Placebo	07AUG2020/ Placebo	28AUG2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
11391081	C4591001 1139 11391081	16-55	10AUG2020	44451	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	
11391083	C4591001 1139 11391083	16-55	10AUG2020	44448	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11391086	C4591001 1139 11391086	16-55	10AUG2020	45729	Placebo	10AUG2020/ Placebo	04SEP2020/ Placebo	19DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
11391087	C4591001 1139 11391087	16-55	12AUG2020	45732	Placebo	12AUG2020/ Placebo	03SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11391089	C4591001 1139 11391089	16-55	12AUG2020	45733	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11391090	C4591001 1139 11391090	16-55	12AUG2020	47765	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
11391091	C4591001 1139 11391091	16-55	12AUG2020	45734	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11401009	C4591001 1140 11401009	16-55	31JUL2020	40104	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)		
11401010	C4591001 1140 11401010	16-55	31JUL2020	40108	Placebo	31JUL2020/ Placebo	19AUG2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
11401011	C4591001 1140 11401011	16-55	31JUL2020	40914	Placebo	31JUL2020/ Placebo	21AUG2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
11401015	C4591001 1140 11401015	16-55	31JUL2020	40917	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)		
11401016	C4591001 1140 11401016	16-55	31JUL2020	40918	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11401017	C4591001 1140 11401017	16-55	31JUL2020	40921	Placebo	31JUL2020/ Placebo	19AUG2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
11401019	C4591001 1140 11401019	16-55	03AUG2020	41573	Placebo	03AUG2020/ Placebo	24AUG2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
11401020	C4591001 1140 11401020	16-55	03AUG2020	41574	Placebo	03AUG2020/ Placebo	25AUG2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
11401021	C4591001 1140 11401021	16-55	03AUG2020	41583	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
11401022	C4591001 1140 11401022	16-55	03AUG2020	41580	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
11401023	C4591001 1140 11401023	16-55	03AUG2020	41815	Placebo	03AUG2020/ Placebo	24AUG2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11401024	C4591001 1140 11401024	16-55	03AUG2020	41816	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
11401025	C4591001 1140 11401025	16-55	03AUG2020	41819	Placebo	03AUG2020/ Placebo	25AUG2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11401027	C4591001 1140 11401027	16-55	04AUG2020	41820	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
11401028	C4591001 1140 11401028	16-55	04AUG2020	42151	Placebo	04AUG2020/ Placebo	10SEP2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	28JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11401030	C4591001 1140 11401030	16-55	04AUG2020	42153	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
11401031	C4591001 1140 11401031	16-55	04AUG2020	42154	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
11401032	C4591001 1140 11401032	16-55	04AUG2020	42157	Placebo	04AUG2020/ Placebo	24AUG2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
11401033	C4591001 1140 11401033	16-55	04AUG2020	42425	Placebo	04AUG2020/ Placebo	27AUG2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
11401037	C4591001 1140 11401037	16-55	04AUG2020	42426	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)		
11401039	C4591001 1140 11401039	16-55	05AUG2020	42436	Placebo	05AUG2020/ Placebo	24AUG2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
11401040	C4591001 1140 11401040	16-55	05AUG2020	42429	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)		
11401044	C4591001 1140 11401044	16-55	05AUG2020	43004	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
11401045	C4591001 1140 11401045	16-55	05AUG2020	43005	Placebo	05AUG2020/ Placebo	24AUG2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
11401046	C4591001 1140 11401046	16-55	05AUG2020	43010	Placebo	05AUG2020/ Placebo	25AUG2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11401048	C4591001 1140 11401048	16-55	05AUG2020	43007	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
11401049	C4591001 1140 11401049	16-55	05AUG2020	43149	Placebo	05AUG2020/ Placebo	27AUG2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
11401050	C4591001 1140 11401050	16-55	05AUG2020	43148	Placebo	05AUG2020/ Placebo	24AUG2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)
11401051	C4591001 1140 11401051	16-55	06AUG2020	43153	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
11401052	C4591001 1140 11401052	16-55	06AUG2020	43150	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
11401053	C4591001 1140 11401053	16-55	06AUG2020	43536	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)		
11401055	C4591001 1140 11401055	16-55	06AUG2020	43532	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
11401057	C4591001 1140 11401057	16-55	06AUG2020	43539	Placebo	06AUG2020/ Placebo	26AUG2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
11401059	C4591001 1140 11401059	16-55	06AUG2020	43540	Placebo	06AUG2020/ Placebo	26AUG2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
11401061	C4591001 1140 11401061	16-55	06AUG2020	43685	Placebo	06AUG2020/ Placebo	28AUG2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11401062	C4591001 1140 11401062	16-55	06AUG2020	43686	Placebo	06AUG2020/ Placebo	27AUG2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
11401063	C4591001 1140 11401063	16-55	06AUG2020	43687	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
11401065	C4591001 1140 11401065	16-55	06AUG2020	43693	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
11401067	C4591001 1140 11401067	16-55	06AUG2020	43915	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
11401068	C4591001 1140 11401068	16-55	06AUG2020	43917	Placebo	06AUG2020/ Placebo	27AUG2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
11401069	C4591001 1140 11401069	16-55	07AUG2020	43924	Placebo	07AUG2020/ Placebo	28AUG2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
11401070	C4591001 1140 11401070	16-55	07AUG2020	43922	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
11401071	C4591001 1140 11401071	16-55	07AUG2020	44250	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
11401072	C4591001 1140 11401072	16-55	07AUG2020	44254	Placebo	07AUG2020/ Placebo	26AUG2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
11401073	C4591001 1140 11401073	16-55	07AUG2020	44258	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11401074	C4591001 1140 11401074	16-55	07AUG2020	44260	Placebo	07AUG2020/ Placebo	26AUG2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
11401079	C4591001 1140 11401079	16-55	07AUG2020	44513	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
11401084	C4591001 1140 11401084	16-55	07AUG2020	44518	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
11401085	C4591001 1140 11401085	16-55	07AUG2020	44521	Placebo	07AUG2020/ Placebo	28AUG2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11401088	C4591001 1140 11401088	16-55	10AUG2020	44523	Placebo	10AUG2020/ Placebo	01SEP2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	20JAN2021/ BNT162b2 (30 µg)
11401091	C4591001 1140 11401091	16-55	10AUG2020	45224	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
11401092	C4591001 1140 11401092	16-55	10AUG2020	45227	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
11401093	C4591001 1140 11401093	16-55	11AUG2020	45231	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
11401094	C4591001 1140 11401094	16-55	11AUG2020	45232	Placebo	11AUG2020/ Placebo	03SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11401097	C4591001 1140 11401097	16-55	13AUG2020	48401	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11401100	C4591001 1140 11401100	16-55	13AUG2020	48405	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
11401101	C4591001 1140 11401101	16-55	13AUG2020	48406	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
11401106	C4591001 1140 11401106	16-55	13AUG2020	48409	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11401108	C4591001 1140 11401108	16-55	13AUG2020	49145	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
11401109	C4591001 1140 11401109	16-55	13AUG2020	49156	Placebo	13AUG2020/ Placebo	04SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
11401110	C4591001 1140 11401110	16-55	13AUG2020	49147	Placebo	13AUG2020/ Placebo	04SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
11401112	C4591001 1140 11401112	16-55	13AUG2020	49148	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
11401115	C4591001 1140 11401115	16-55	14AUG2020	49905	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
11401116	C4591001 1140 11401116	16-55	14AUG2020	49906	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
11401118	C4591001 1140 11401118	16-55	14AUG2020	49908	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11401124	C4591001 1140 11401124	16-55	14AUG2020	49912	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
11401127	C4591001 1140 11401127	16-55	14AUG2020	50489	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
11411003	C4591001 1141 11411003	16-55	30JUL2020	40710	Placebo	30JUL2020/ Placebo	19AUG2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
11411004	C4591001 1141 11411004	16-55	30JUL2020	40717	BNT162b2 (30 µg)	30JUL2020/ BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)		
11411005	C4591001 1141 11411005	16-55	31JUL2020	40719	Placebo	31JUL2020/ Placebo	21AUG2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	20JAN2021/ BNT162b2 (30 µg)
11411006	C4591001 1141 11411006	16-55	31JUL2020	40720	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)		
11411007	C4591001 1141 11411007	16-55	31JUL2020	41070	Placebo	31JUL2020/ Placebo	21AUG2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
11411008	C4591001 1141 11411008	16-55	31JUL2020	41071	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)		
11411010	C4591001 1141 11411010	16-55	31JUL2020	41077	Placebo	31JUL2020/ Placebo	01SEP2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	28JAN2021/ BNT162b2 (30 µg)
11411011	C4591001 1141 11411011	16-55	31JUL2020	41078	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11411012	C4591001 1141 11411012	16-55	31JUL2020	41239	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)		
11411013	C4591001 1141 11411013	16-55	03AUG2020	41240	Placebo	03AUG2020/ Placebo	24AUG2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
11411014	C4591001 1141 11411014	16-55	03AUG2020	41243	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
11411016	C4591001 1141 11411016	16-55	03AUG2020	41244	Placebo	03AUG2020/ Placebo	24AUG2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11411017	C4591001 1141 11411017	16-55	03AUG2020	41828	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
11411018	C4591001 1141 11411018	16-55	03AUG2020	41832	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
11411019	C4591001 1141 11411019	16-55	03AUG2020	41829	Placebo	03AUG2020/ Placebo	25AUG2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	14JAN2021/ BNT162b2 (30 µg)
11411020	C4591001 1141 11411020	16-55	03AUG2020	41833	Placebo	03AUG2020/ Placebo	24AUG2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
11411021	C4591001 1141 11411021	16-55	04AUG2020	42137	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
11411022	C4591001 1141 11411022	16-55	04AUG2020	42142	Placebo	04AUG2020/ Placebo	24AUG2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11411023	C4591001 1141 11411023	16-55	04AUG2020	42144	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
11411024	C4591001 1141 11411024	16-55	04AUG2020	42143	Placebo	04AUG2020/ Placebo	27AUG2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11411025	C4591001 1141 11411025	16-55	04AUG2020	42393	Placebo	04AUG2020/ Placebo	24AUG2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11411026	C4591001 1141 11411026	16-55	04AUG2020	42394	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
11411027	C4591001 1141 11411027	16-55	04AUG2020	42397	Placebo	04AUG2020/ Placebo	03SEP2020/ Placebo		
11411029	C4591001 1141 11411029	16-55	04AUG2020	42399	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
11411030	C4591001 1141 11411030	16-55	05AUG2020	42833	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
11411031	C4591001 1141 11411031	16-55	05AUG2020	42834	Placebo	05AUG2020/ Placebo	28AUG2020/ Placebo		
11411032	C4591001 1141 11411032	16-55	05AUG2020	42836	Placebo	05AUG2020/ Placebo	10SEP2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	28JAN2021/ BNT162b2 (30 µg)
11411033	C4591001 1141 11411033	16-55	05AUG2020	42842	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11411036	C4591001 1141 11411036	16-55	05AUG2020	43229	Placebo	05AUG2020/ Placebo	26AUG2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
11411037	C4591001 1141 11411037	16-55	05AUG2020	43231	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
11411038	C4591001 1141 11411038	16-55	06AUG2020	43233	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
11411041	C4591001 1141 11411041	16-55	06AUG2020	43238	Placebo	06AUG2020/ Placebo	25AUG2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	14JAN2021/ BNT162b2 (30 µg)
11411042	C4591001 1141 11411042	16-55	06AUG2020	43757	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
11411044	C4591001 1141 11411044	16-55	06AUG2020	43758	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
11411045	C4591001 1141 11411045	16-55	06AUG2020	43766	Placebo	06AUG2020/ Placebo	28AUG2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	21JAN2021/ BNT162b2 (30 µg)
11411046	C4591001 1141 11411046	16-55	06AUG2020	43759	Placebo	06AUG2020/ Placebo	26AUG2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
11411048	C4591001 1141 11411048	16-55	07AUG2020	44369	Placebo	07AUG2020/ Placebo	11SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
11411049	C4591001 1141 11411049	16-55	07AUG2020	44371	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11411050	C4591001 1141 11411050	16-55	07AUG2020	44379	Placebo	07AUG2020/ Placebo	27AUG2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
11411051	C4591001 1141 11411051	16-55	07AUG2020	44674	Placebo	07AUG2020/ Placebo	27AUG2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11411052	C4591001 1141 11411052	16-55	07AUG2020	44380	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
11411053	C4591001 1141 11411053	16-55	07AUG2020	44676	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
11411054	C4591001 1141 11411054	16-55	07AUG2020	44677	Placebo	07AUG2020/ Placebo	27AUG2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
11411055	C4591001 1141 11411055	16-55	10AUG2020	44680	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
11411056	C4591001 1141 11411056	16-55	10AUG2020	45282	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11411057	C4591001 1141 11411057	16-55	10AUG2020	45281	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
11411060	C4591001 1141 11411060	16-55	10AUG2020	45287	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
11411061	C4591001 1141 11411061	16-55	11AUG2020	45288	Placebo	11AUG2020/ Placebo	01SEP2020/ Placebo	06JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11411062	C4591001 1141 11411062	16-55	11AUG2020	46715	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
11411064	C4591001 1141 11411064	16-55	12AUG2020	46717	Placebo	12AUG2020/ Placebo	01SEP2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	27JAN2021/ BNT162b2 (30 µg)
11411065	C4591001 1141 11411065	16-55	12AUG2020	46718	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
11411067	C4591001 1141 11411067	16-55	12AUG2020	46719	Placebo	12AUG2020/ Placebo	02SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
11411068	C4591001 1141 11411068	16-55	12AUG2020	47720	Placebo	12AUG2020/ Placebo	04SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
11411070	C4591001 1141 11411070	16-55	12AUG2020	47725	Placebo	12AUG2020/ Placebo	31AUG2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	14JAN2021/ BNT162b2 (30 µg)
11411072	C4591001 1141 11411072	16-55	13AUG2020	47726	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11411073	C4591001 1141 11411073	16-55	13AUG2020	47727	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
11411074	C4591001 1141 11411074	16-55	13AUG2020	48917	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
11411075	C4591001 1141 11411075	16-55	13AUG2020	48921	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11411076	C4591001 1141 11411076	16-55	13AUG2020	48922	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11411078	C4591001 1141 11411078	16-55	13AUG2020	49496	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
11411079	C4591001 1141 11411079	16-55	14AUG2020	49497	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)
11411080	C4591001 1141 11411080	16-55	14AUG2020	49500	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	20JAN2021/ BNT162b2 (30 µg)
11411081	C4591001 1141 11411081	16-55	14AUG2020	49501	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11411084	C4591001 1141 11411084	16-55	14AUG2020	50370	Placebo	14AUG2020/ Placebo	02SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11421018	C4591001 1142 11421018	16-55	31JUL2020	40611	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)		
11421020	C4591001 1142 11421020	16-55	31JUL2020	40612	Placebo	31JUL2020/ Placebo	20AUG2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11421021	C4591001 1142 11421021	16-55	31JUL2020	41101	Placebo	31JUL2020/ Placebo	21AUG2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
11421022	C4591001 1142 11421022	16-55	31JUL2020	41102	Placebo	31JUL2020/ Placebo	20AUG2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11421023	C4591001 1142 11421023	16-55	31JUL2020	41103	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)		
11421025	C4591001 1142 11421025	16-55	03AUG2020	41104	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
11421026	C4591001 1142 11421026	16-55	03AUG2020	41526	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
11421027	C4591001 1142 11421027	16-55	03AUG2020	41532	Placebo	03AUG2020/ Placebo	24AUG2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
11421028	C4591001 1142 11421028	16-55	03AUG2020	41533	Placebo	03AUG2020/ Placebo	24AUG2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
11421033	C4591001 1142 11421033	16-55	04AUG2020	41534	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
11421037	C4591001 1142 11421037	16-55	04AUG2020	42437	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
11421040	C4591001 1142 11421040	16-55	04AUG2020	42438	Placebo	04AUG2020/ Placebo	28AUG2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
11421041	C4591001 1142 11421041	16-55	05AUG2020	42446	Placebo	05AUG2020/ Placebo	29AUG2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
11421042	C4591001 1142 11421042	16-55	05AUG2020	42447	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11421043	C4591001 1142 11421043	16-55	05AUG2020	42785	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
11421045	C4591001 1142 11421045	16-55	05AUG2020	42789	Placebo	05AUG2020/ Placebo	28AUG2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
11421046	C4591001 1142 11421046	16-55	05AUG2020	42790	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
11421049	C4591001 1142 11421049	16-55	06AUG2020	42796	Placebo	06AUG2020/ Placebo	28AUG2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11421050	C4591001 1142 11421050	16-55	06AUG2020	43577	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
11421051	C4591001 1142 11421051	16-55	06AUG2020	43578	Placebo	06AUG2020/ Placebo	28AUG2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)
11421052	C4591001 1142 11421052	16-55	06AUG2020	43580	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
11421056	C4591001 1142 11421056	16-55	06AUG2020	43583	Placebo	06AUG2020/ Placebo	28AUG2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	22JAN2021/ BNT162b2 (30 µg)
11421058	C4591001 1142 11421058	16-55	07AUG2020	44309	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
11421059	C4591001 1142 11421059	16-55	07AUG2020	44311	Placebo	07AUG2020/ Placebo	28AUG2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	21JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11421060	C4591001 1142 11421060	16-55	07AUG2020	44312	Placebo	07AUG2020/ Placebo	28AUG2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
11421062	C4591001 1142 11421062	16-55	07AUG2020	44313	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
11421066	C4591001 1142 11421066	16-55	10AUG2020	45258	Placebo	10AUG2020/ Placebo	01SEP2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
11421067	C4591001 1142 11421067	16-55	10AUG2020	45262	Placebo	10AUG2020/ Placebo	01SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
11421068	C4591001 1142 11421068	16-55	10AUG2020	45263	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
11421070	C4591001 1142 11421070	16-55	10AUG2020	45267	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
11421071	C4591001 1142 11421071	16-55	10AUG2020	45521	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
11421072	C4591001 1142 11421072	16-55	11AUG2020	45523	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11421078	C4591001 1142 11421078	16-55	11AUG2020	45525	Placebo	11AUG2020/ Placebo	31AUG2020/ Placebo	06JAN2021/ BNT162b2 (30 µg)	27JAN2021/ BNT162b2 (30 µg)
11421079	C4591001 1142 11421079	16-55	11AUG2020	45528	Placebo	11AUG2020/ Placebo	31AUG2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	21JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11421081	C4591001 1142 11421081	16-55	12AUG2020	47117	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11421082	C4591001 1142 11421082	16-55	12AUG2020	47120	Placebo	12AUG2020/ Placebo	01SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
11421084	C4591001 1142 11421084	16-55	12AUG2020	47124	Placebo	12AUG2020/ Placebo	04SEP2020/ Placebo		
11421085	C4591001 1142 11421085	16-55	12AUG2020	47127	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
11421089	C4591001 1142 11421089	16-55	13AUG2020	48439	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11421090	C4591001 1142 11421090	16-55	13AUG2020	48441	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11421092	C4591001 1142 11421092	16-55	13AUG2020	48443	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
11421094	C4591001 1142 11421094	16-55	13AUG2020	48444	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11421096	C4591001 1142 11421096	16-55	13AUG2020	49079	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
11421099	C4591001 1142 11421099	16-55	14AUG2020	49081	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11421100	C4591001 1142 11421100	16-55	14AUG2020	49083	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
11421101	C4591001 1142 11421101	16-55	14AUG2020	49084	Placebo	14AUG2020/ Placebo	03SEP2020/ Placebo	31DEC2020/ BNT162b2 (30 µg)	22JAN2021/ BNT162b2 (30 µg)
11451001	C4591001 1145 11451001	16-55	12AUG2020	47374	Placebo	12AUG2020/ Placebo	02SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
11451002	C4591001 1145 11451002	16-55	12AUG2020	47378	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11451003	C4591001 1145 11451003	16-55	13AUG2020	47380	Placebo	13AUG2020/ Placebo	02SEP2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11451004	C4591001 1145 11451004	16-55	13AUG2020	47379	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11451007	C4591001 1145 11451007	16-55	13AUG2020	49134	Placebo	13AUG2020/ Placebo	02SEP2020/ Placebo		
11451010	C4591001 1145 11451010	16-55	14AUG2020	49140	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11451011	C4591001 1145 11451011	16-55	14AUG2020	49142	Placebo	14AUG2020/ Placebo	02SEP2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
11461002	C4591001 1146 11461002	16-55	11AUG2020	46591	Placebo	11AUG2020/ Placebo	01SEP2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11461004	C4591001 1146 11461004	16-55	12AUG2020	46594	Placebo	12AUG2020/ Placebo	02SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
11461007	C4591001 1146 11461007	16-55	12AUG2020	46595	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
11461009	C4591001 1146 11461009	16-55	13AUG2020	46599	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
11461010	C4591001 1146 11461010	16-55	13AUG2020	48353	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
11461011	C4591001 1146 11461011	16-55	13AUG2020	48354	Placebo	13AUG2020/ Placebo	01SEP2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
11461013	C4591001 1146 11461013	16-55	13AUG2020	48361	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
11461020	C4591001 1146 11461020	16-55	14AUG2020	48362	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
11461021	C4591001 1146 11461021	16-55	14AUG2020	49929	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
11461023	C4591001 1146 11461023	16-55	14AUG2020	49931	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
11471003	C4591001 1147 11471003	16-55	30JUL2020	40578	BNT162b2 (30 µg)	30JUL2020/ BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11471007	C4591001 1147 11471007	16-55	03AUG2020	40580	Placebo	03AUG2020/ Placebo	24AUG2020/ Placebo		
11471010	C4591001 1147 11471010	16-55	03AUG2020	40586	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
11471011	C4591001 1147 11471011	16-55	04AUG2020	42162	Placebo	04AUG2020/ Placebo	25AUG2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
11471013	C4591001 1147 11471013	16-55	04AUG2020	42167	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
11471014	C4591001 1147 11471014	16-55	04AUG2020	42169	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
11471016	C4591001 1147 11471016	16-55	04AUG2020	42171	Placebo	04AUG2020/ Placebo	27AUG2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
11471017	C4591001 1147 11471017	16-55	05AUG2020	42935	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
11471019	C4591001 1147 11471019	16-55	05AUG2020	42930	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
11471021	C4591001 1147 11471021	16-55	05AUG2020	42938	Placebo	05AUG2020/ Placebo	28AUG2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
11471025	C4591001 1147 11471025	16-55	05AUG2020	42940	Placebo	05AUG2020/ Placebo	26AUG2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11471026	C4591001 1147 11471026	16-55	05AUG2020	43373	Placebo	05AUG2020/ Placebo	24AUG2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11471027	C4591001 1147 11471027	16-55	05AUG2020	43376	Placebo	05AUG2020/ Placebo	24AUG2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
11471031	C4591001 1147 11471031	16-55	06AUG2020	43382	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
11471033	C4591001 1147 11471033	16-55	06AUG2020	43383	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
11471035	C4591001 1147 11471035	16-55	06AUG2020	43777	Placebo	06AUG2020/ Placebo			
11471038	C4591001 1147 11471038	16-55	06AUG2020	43778	Placebo	06AUG2020/ Placebo	28AUG2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
11471039	C4591001 1147 11471039	16-55	06AUG2020	43780	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
11471041	C4591001 1147 11471041	16-55	06AUG2020	43779	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)		
11471045	C4591001 1147 11471045	16-55	06AUG2020	44190	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)		
11471046	C4591001 1147 11471046	16-55	07AUG2020	44197	Placebo	07AUG2020/ Placebo	26AUG2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11471047	C4591001 1147 11471047	16-55	07AUG2020	44196	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
11471048	C4591001 1147 11471048	16-55	07AUG2020	44198	Placebo	07AUG2020/ Placebo	26AUG2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
11471049	C4591001 1147 11471049	16-55	07AUG2020	44409	Placebo	07AUG2020/ Placebo	28AUG2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
11471051	C4591001 1147 11471051	16-55	07AUG2020	44408	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)		
11471053	C4591001 1147 11471053	16-55	07AUG2020	44411	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
11471054	C4591001 1147 11471054	16-55	07AUG2020	44416	Placebo	07AUG2020/ Placebo	27AUG2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
11471056	C4591001 1147 11471056	16-55	07AUG2020	44562	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
11471059	C4591001 1147 11471059	16-55	07AUG2020	44564	Placebo	07AUG2020/ Placebo	28AUG2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
11471065	C4591001 1147 11471065	16-55	07AUG2020	44566	Placebo	07AUG2020/ Placebo	28AUG2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
11471066	C4591001 1147 11471066	16-55	07AUG2020	44569	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11471070	C4591001 1147 11471070	16-55	10AUG2020	45317	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
11471073	C4591001 1147 11471073	16-55	10AUG2020	45322	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
11471077	C4591001 1147 11471077	16-55	10AUG2020	45324	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
11471078	C4591001 1147 11471078	16-55	10AUG2020	45325	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
11471079	C4591001 1147 11471079	16-55	10AUG2020	45705	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
11471085	C4591001 1147 11471085	16-55	10AUG2020	45706	Placebo	10AUG2020/ Placebo	01SEP2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
11471089	C4591001 1147 11471089	16-55	11AUG2020	45707	Placebo	11AUG2020/ Placebo	01SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
11471092	C4591001 1147 11471092	16-55	11AUG2020	45708	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
11471094	C4591001 1147 11471094	16-55	11AUG2020	46449	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
11471100	C4591001 1147 11471100	16-55	11AUG2020	46452	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11471107	C4591001 1147 11471107	16-55	12AUG2020	46453	Placebo	12AUG2020/ Placebo	03SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11471115	C4591001 1147 11471115	16-55	13AUG2020	46455	Placebo	13AUG2020/ Placebo	04SEP2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
11471118	C4591001 1147 11471118	16-55	13AUG2020	49181	Placebo	13AUG2020/ Placebo	01SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
11471119	C4591001 1147 11471119	16-55	13AUG2020	49183	Placebo	13AUG2020/ Placebo	04SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
11471120	C4591001 1147 11471120	16-55	13AUG2020	49184	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
11471121	C4591001 1147 11471121	16-55	13AUG2020	49185	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
11471122	C4591001 1147 11471122	16-55	13AUG2020	49579	Placebo	13AUG2020/ Placebo	04SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11471123	C4591001 1147 11471123	16-55	13AUG2020	49582	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11471129	C4591001 1147 11471129	16-55	14AUG2020	49586	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
11471131	C4591001 1147 11471131	16-55	14AUG2020	49588	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11471132	C4591001 1147 11471132	16-55	14AUG2020	50501	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
11471133	C4591001 1147 11471133	16-55	14AUG2020	50504	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
11471134	C4591001 1147 11471134	16-55	14AUG2020	50505	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
11471135	C4591001 1147 11471135	16-55	14AUG2020	50509	Placebo	14AUG2020/ Placebo	02SEP2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
11491001	C4591001 1149 11491001	16-55	05AUG2020	43415	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
11491005	C4591001 1149 11491005	16-55	05AUG2020	43417	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)			
11491006	C4591001 1149 11491006	16-55	05AUG2020	43418	Placebo	05AUG2020/ Placebo	25AUG2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
11491007	C4591001 1149 11491007	16-55	06AUG2020	43420	Placebo	06AUG2020/ Placebo	25AUG2020/ Placebo		
11491008	C4591001 1149 11491008	16-55	06AUG2020	44037	Placebo	06AUG2020/ Placebo	25AUG2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
11491011	C4591001 1149 11491011	16-55	06AUG2020	44039	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11491012	C4591001 1149 11491012	16-55	06AUG2020	44008	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
11491013	C4591001 1149 11491013	16-55	06AUG2020	43999	Placebo	06AUG2020/ Placebo	25AUG2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
11491014	C4591001 1149 11491014	16-55	06AUG2020	44002	Placebo	06AUG2020/ Placebo	25AUG2020/ Placebo		
11491015	C4591001 1149 11491015	16-55	06AUG2020	44007	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
11491016	C4591001 1149 11491016	16-55	07AUG2020	44042	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)		
11491020	C4591001 1149 11491020	16-55	07AUG2020	44043	Placebo	07AUG2020/ Placebo	27AUG2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11491021	C4591001 1149 11491021	16-55	07AUG2020	44743	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)		
11491023	C4591001 1149 11491023	16-55	07AUG2020	44745	Placebo	07AUG2020/ Placebo	27AUG2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
11491024	C4591001 1149 11491024	16-55	07AUG2020	44752	Placebo	07AUG2020/ Placebo	27AUG2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
11491025	C4591001 1149 11491025	16-55	07AUG2020	44751	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11491027	C4591001 1149 11491027	16-55	07AUG2020	44828	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)		
11491028	C4591001 1149 11491028	16-55	07AUG2020	44831	Placebo	07AUG2020/ Placebo	27AUG2020/ Placebo		
11491029	C4591001 1149 11491029	16-55	07AUG2020	44829	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
11491030	C4591001 1149 11491030	16-55	10AUG2020	44834	Placebo	10AUG2020/ Placebo	01SEP2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
11491031	C4591001 1149 11491031	16-55	10AUG2020	45753	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)			
11491033	C4591001 1149 11491033	16-55	10AUG2020	45756	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
11491034	C4591001 1149 11491034	16-55	10AUG2020	45759	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo		
11491035	C4591001 1149 11491035	16-55	10AUG2020	45754	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
11491036	C4591001 1149 11491036	16-55	10AUG2020	45775	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11491037	C4591001 1149 11491037	16-55	10AUG2020	45776	Placebo	10AUG2020/ Placebo	01SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11491040	C4591001 1149 11491040	16-55	11AUG2020	45779	Placebo	11AUG2020/ Placebo	01SEP2020/ Placebo		
11491044	C4591001 1149 11491044	16-55	11AUG2020	45783	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
11491045	C4591001 1149 11491045	16-55	11AUG2020	46686	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
11491046	C4591001 1149 11491046	16-55	11AUG2020	46688	Placebo	11AUG2020/ Placebo	01SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
11491047	C4591001 1149 11491047	16-55	11AUG2020	46689	Placebo	11AUG2020/ Placebo	01SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
11491049	C4591001 1149 11491049	16-55	11AUG2020	46691	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
11491050	C4591001 1149 11491050	16-55	11AUG2020	46772	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
11491051	C4591001 1149 11491051	16-55	11AUG2020	46773	Placebo	11AUG2020/ Placebo	01SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
11491054	C4591001 1149 11491054	16-55	12AUG2020	46775	Placebo	12AUG2020/ Placebo	02SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11491055	C4591001 1149 11491055	16-55	12AUG2020	46778	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11491057	C4591001 1149 11491057	16-55	12AUG2020	47899	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11491059	C4591001 1149 11491059	16-55	12AUG2020	47905	Placebo	12AUG2020/ Placebo	02SEP2020/ Placebo		
11491061	C4591001 1149 11491061	16-55	12AUG2020	47906	Placebo	12AUG2020/ Placebo	02SEP2020/ Placebo	11MAR2021/ BNT162b2 (30 µg)	
11491062	C4591001 1149 11491062	16-55	12AUG2020	47908	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11491063	C4591001 1149 11491063	16-55	12AUG2020	48031	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11491065	C4591001 1149 11491065	16-55	12AUG2020	48032	Placebo	12AUG2020/ Placebo			
11491066	C4591001 1149 11491066	16-55	12AUG2020	48033	Placebo	12AUG2020/ Placebo		22FEB2021/ BNT162b2 (30 µg)	
11491067	C4591001 1149 11491067	16-55	12AUG2020	48035	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)			
11491068	C4591001 1149 11491068	16-55	13AUG2020	49169	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
11491069	C4591001 1149 11491069	16-55	13AUG2020	49172	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11491070	C4591001 1149 11491070	16-55	13AUG2020	49174	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
11521001	C4591001 1152 11521001	16-55	12AUG2020	47251	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11521002	C4591001 1152 11521002	16-55	12AUG2020	47253	Placebo	12AUG2020/ Placebo	02SEP2020/ Placebo		
11521003	C4591001 1152 11521003	16-55	12AUG2020	47258	Placebo	12AUG2020/ Placebo	02SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
11521005	C4591001 1152 11521005	16-55	12AUG2020	47260	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11521007	C4591001 1152 11521007	16-55	12AUG2020	47492	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11521008	C4591001 1152 11521008	16-55	12AUG2020	47496	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11521009	C4591001 1152 11521009	16-55	12AUG2020	47497	Placebo	12AUG2020/ Placebo	02SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
11521010	C4591001 1152 11521010	16-55	12AUG2020	47498	Placebo	12AUG2020/ Placebo	02SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
11521011	C4591001 1152 11521011	16-55	12AUG2020	47695	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11521012	C4591001 1152 11521012	16-55	12AUG2020	47698	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11521014	C4591001 1152 11521014	16-55	12AUG2020	47703	Placebo	12AUG2020/ Placebo	02SEP2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
11521015	C4591001 1152 11521015	16-55	12AUG2020	47704	Placebo	12AUG2020/ Placebo	02SEP2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
11521017	C4591001 1152 11521017	16-55	12AUG2020	48140	Placebo	12AUG2020/ Placebo	02SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
11521019	C4591001 1152 11521019	16-55	12AUG2020	48145	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11521020	C4591001 1152 11521020	16-55	12AUG2020	48147	Placebo	12AUG2020/ Placebo	02SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
11521022	C4591001 1152 11521022	16-55	12AUG2020	48148	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11521024	C4591001 1152 11521024	16-55	12AUG2020	48210	Placebo	12AUG2020/ Placebo	02SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
11521029	C4591001 1152 11521029	16-55	12AUG2020	48219	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11521030	C4591001 1152 11521030	16-55	12AUG2020	48217	Placebo	12AUG2020/ Placebo			

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11521031	C4591001 1152 11521031	16-55	12AUG2020	48212	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11521032	C4591001 1152 11521032	16-55	12AUG2020	48245	Placebo	12AUG2020/ Placebo	01SEP2020/ Placebo		
11521034	C4591001 1152 11521034	16-55	12AUG2020	48246	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)			
11521035	C4591001 1152 11521035	16-55	12AUG2020	48254	Placebo	12AUG2020/ Placebo	02SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
11521036	C4591001 1152 11521036	16-55	12AUG2020	48253	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11521038	C4591001 1152 11521038	16-55	13AUG2020	48644	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11521039	C4591001 1152 11521039	16-55	13AUG2020	48642	Placebo	13AUG2020/ Placebo	02SEP2020/ Placebo		
11521042	C4591001 1152 11521042	16-55	13AUG2020	48648	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo		
11521043	C4591001 1152 11521043	16-55	13AUG2020	48652	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
11521044	C4591001 1152 11521044	16-55	13AUG2020	48989	Placebo	13AUG2020/ Placebo	02SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11521045	C4591001 1152 11521045	16-55	13AUG2020	48995	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11521046	C4591001 1152 11521046	16-55	13AUG2020	48996	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
11521048	C4591001 1152 11521048	16-55	13AUG2020	48998	Placebo	13AUG2020/ Placebo	01SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
11521051	C4591001 1152 11521051	16-55	13AUG2020	49399	Placebo	13AUG2020/ Placebo	01SEP2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
11521052	C4591001 1152 11521052	16-55	13AUG2020	49400	Placebo	13AUG2020/ Placebo	01SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
11521053	C4591001 1152 11521053	16-55	13AUG2020	49402	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
11521054	C4591001 1152 11521054	16-55	13AUG2020	49406	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
11521056	C4591001 1152 11521056	16-55	13AUG2020	49517	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
11521058	C4591001 1152 11521058	16-55	13AUG2020	49518	Placebo	13AUG2020/ Placebo	01SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
11521059	C4591001 1152 11521059	16-55	13AUG2020	49519	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11521060	C4591001 1152 11521060	16-55	13AUG2020	49526	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
11521061	C4591001 1152 11521061	16-55	13AUG2020	49640	Placebo	13AUG2020/ Placebo	01SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
11521062	C4591001 1152 11521062	16-55	13AUG2020	49643	Placebo	13AUG2020/ Placebo	01SEP2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
11521063	C4591001 1152 11521063	16-55	13AUG2020	49699	Placebo	13AUG2020/ Placebo	01SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
11521064	C4591001 1152 11521064	16-55	13AUG2020	49647	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
11521065	C4591001 1152 11521065	16-55	13AUG2020	49648	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
11521066	C4591001 1152 11521066	16-55	13AUG2020	49701	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
11521070	C4591001 1152 11521070	16-55	13AUG2020	49704	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
11521071	C4591001 1152 11521071	16-55	13AUG2020	49702	Placebo	13AUG2020/ Placebo	11SEP2020/ Placebo		
11521072	C4591001 1152 11521072	16-55	13AUG2020	49760	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11521073	C4591001 1152 11521073	16-55	13AUG2020	49761	Placebo	13AUG2020/ Placebo	02SEP2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
11521075	C4591001 1152 11521075	16-55	13AUG2020	49766	Placebo	13AUG2020/ Placebo	01SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
11521076	C4591001 1152 11521076	16-55	13AUG2020	49768	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
11521077	C4591001 1152 11521077	16-55	13AUG2020	49782	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
11521078	C4591001 1152 11521078	16-55	14AUG2020	49783	Placebo	14AUG2020/ Placebo	03SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
11521081	C4591001 1152 11521081	16-55	14AUG2020	49784	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11571002	C4591001 1157 11571002	16-55	12AUG2020	48129	Placebo	12AUG2020/ Placebo	04SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
11571003	C4591001 1157 11571003	16-55	12AUG2020	48130	Placebo	12AUG2020/ Placebo			
11571004	C4591001 1157 11571004	16-55	12AUG2020	48131	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
11571006	C4591001 1157 11571006	16-55	12AUG2020	48134	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11571009	C4591001 1157 11571009	16-55	13AUG2020	49481	Placebo	13AUG2020/ Placebo	04SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
11571010	C4591001 1157 11571010	16-55	13AUG2020	49487	Placebo	13AUG2020/ Placebo	04SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11571013	C4591001 1157 11571013	16-55	13AUG2020	49491	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
11571015	C4591001 1157 11571015	16-55	13AUG2020	49492	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
11571017	C4591001 1157 11571017	16-55	13AUG2020	49686	Placebo	13AUG2020/ Placebo	04SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
11571019	C4591001 1157 11571019	16-55	14AUG2020	49687	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
11571020	C4591001 1157 11571020	16-55	14AUG2020	49690	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
11571021	C4591001 1157 11571021	16-55	14AUG2020	49695	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	02MAR2021/ BNT162b2 (30 µg)	
11611001	C4591001 1161 11611001	16-55	31JUL2020	41201	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)		
11611002	C4591001 1161 11611002	16-55	31JUL2020	41202	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)			

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11611004	C4591001 1161 11611004	16-55	31JUL2020	41209	Placebo	31JUL2020/ Placebo	04NOV2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
11611006	C4591001 1161 11611006	16-55	31JUL2020	41279	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)			
11611007	C4591001 1161 11611007	16-55	31JUL2020	41280	Placebo	31JUL2020/ Placebo			
11611008	C4591001 1161 11611008	16-55	31JUL2020	41283	Placebo	31JUL2020/ Placebo			
11611009	C4591001 1161 11611009	16-55	31JUL2020	41284	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)		
11611010	C4591001 1161 11611010	16-55	31JUL2020	41285	Placebo	31JUL2020/ Placebo			
11611011	C4591001 1161 11611011	16-55	01AUG2020	41293	BNT162b2 (30 µg)	01AUG2020/ BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)		
11611014	C4591001 1161 11611014	16-55	01AUG2020	41294	BNT162b2 (30 µg)	01AUG2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		
11611015	C4591001 1161 11611015	16-55	01AUG2020	41296	Placebo	01AUG2020/ Placebo	19NOV2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
11611016	C4591001 1161 11611016	16-55	01AUG2020	41384	Placebo	01AUG2020/ Placebo	19NOV2020/ Placebo		
11611017	C4591001 1161 11611017	16-55	01AUG2020	41390	BNT162b2 (30 µg)	01AUG2020/ BNT162b2 (30 µg)	04DEC2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11611018	C4591001 1161 11611018	16-55	01AUG2020	41386	Placebo	01AUG2020/ Placebo			
11611019	C4591001 1161 11611019	16-55	03AUG2020	41855	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
11611020	C4591001 1161 11611020	16-55	03AUG2020	41392	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	23NOV2020/ BNT162b2 (30 µg)		
11611023	C4591001 1161 11611023	16-55	03AUG2020	41857	Placebo	03AUG2020/ Placebo			
11611024	C4591001 1161 11611024	16-55	03AUG2020	41856	Placebo	03AUG2020/ Placebo			
11611026	C4591001 1161 11611026	16-55	04AUG2020	41859	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		
11611027	C4591001 1161 11611027	16-55	04AUG2020	42404	Placebo	04AUG2020/ Placebo	02NOV2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
11611028	C4591001 1161 11611028	16-55	04AUG2020	42405	Placebo	04AUG2020/ Placebo	12NOV2020/ Placebo		
11611032	C4591001 1161 11611032	16-55	05AUG2020	42408	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		
11611033	C4591001 1161 11611033	16-55	05AUG2020	43326	Placebo	05AUG2020/ Placebo	20NOV2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
11611034	C4591001 1161 11611034	16-55	05AUG2020	42411	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	24NOV2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11611040	C4591001 1161 11611040	16-55	05AUG2020	43335	Placebo	05AUG2020/ Placebo	12NOV2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
11611041	C4591001 1161 11611041	16-55	05AUG2020	43328	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
11621001	C4591001 1162 11621001	16-55	31JUL2020	40962	Placebo	31JUL2020/ Placebo	20AUG2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
11621003	C4591001 1162 11621003	16-55	31JUL2020	40963	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)		
11621004	C4591001 1162 11621004	16-55	31JUL2020	40966	Placebo	31JUL2020/ Placebo	19AUG2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
11621005	C4591001 1162 11621005	16-55	31JUL2020	40972	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)			
11621009	C4591001 1162 11621009	16-55	31JUL2020	41249	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)		
11621010	C4591001 1162 11621010	16-55	03AUG2020	41252	Placebo	03AUG2020/ Placebo	26AUG2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11621018	C4591001 1162 11621018	16-55	03AUG2020	41258	Placebo	03AUG2020/ Placebo	09SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
11621019	C4591001 1162 11621019	16-55	03AUG2020	41260	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11621021	C4591001 1162 11621021	16-55	03AUG2020	42006	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
11621023	C4591001 1162 11621023	16-55	04AUG2020	42016	Placebo	04AUG2020/ Placebo	25AUG2020/ Placebo		
11621025	C4591001 1162 11621025	16-55	04AUG2020	42011	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
11621026	C4591001 1162 11621026	16-55	04AUG2020	42331	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
11621028	C4591001 1162 11621028	16-55	04AUG2020	42335	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
11621031	C4591001 1162 11621031	16-55	04AUG2020	42337	Placebo	04AUG2020/ Placebo	25AUG2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)
11621033	C4591001 1162 11621033	16-55	04AUG2020	42668	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
11621034	C4591001 1162 11621034	16-55	04AUG2020	42666	Placebo	04AUG2020/ Placebo	25AUG2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
11621035	C4591001 1162 11621035	16-55	04AUG2020	42672	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
11621037	C4591001 1162 11621037	16-55	04AUG2020	42340	Placebo	04AUG2020/ Placebo	27AUG2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11621039	C4591001 1162 11621039	16-55	06AUG2020	42673	Placebo	06AUG2020/ Placebo	25AUG2020/ Placebo		
11621041	C4591001 1162 11621041	16-55	06AUG2020	43712	Placebo	06AUG2020/ Placebo	25AUG2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
11621042	C4591001 1162 11621042	16-55	06AUG2020	43714	Placebo	06AUG2020/ Placebo	25AUG2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
11621043	C4591001 1162 11621043	16-55	06AUG2020	43715	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
11621044	C4591001 1162 11621044	16-55	06AUG2020	43713	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
11621051	C4591001 1162 11621051	16-55	06AUG2020	43889	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
11621054	C4591001 1162 11621054	16-55	06AUG2020	43897	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
11621055	C4591001 1162 11621055	16-55	06AUG2020	43896	Placebo	06AUG2020/ Placebo	01SEP2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
11621056	C4591001 1162 11621056	16-55	10AUG2020	43900	Placebo	10AUG2020/ Placebo	01SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
11621061	C4591001 1162 11621061	16-55	10AUG2020	45413	Placebo	10AUG2020/ Placebo	02SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11621062	C4591001 1162 11621062	16-55	10AUG2020	45414	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11621064	C4591001 1162 11621064	16-55	10AUG2020	45419	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11621066	C4591001 1162 11621066	16-55	10AUG2020	45424	Placebo	10AUG2020/ Placebo	01SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11621067	C4591001 1162 11621067	16-55	10AUG2020	45546	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11621070	C4591001 1162 11621070	16-55	10AUG2020	45550	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
11621072	C4591001 1162 11621072	16-55	10AUG2020	45555	Placebo	10AUG2020/ Placebo	01SEP2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
11621074	C4591001 1162 11621074	16-55	11AUG2020	45556	Placebo	11AUG2020/ Placebo	02SEP2020/ Placebo		
11621075	C4591001 1162 11621075	16-55	11AUG2020	46137	Placebo	11AUG2020/ Placebo	01SEP2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	22JAN2021/ BNT162b2 (30 µg)
11621077	C4591001 1162 11621077	16-55	11AUG2020	46138	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
11621080	C4591001 1162 11621080	16-55	11AUG2020	46140	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11621081	C4591001 1162 11621081	16-55	11AUG2020	46141	Placebo	11AUG2020/ Placebo	03SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
11621083	C4591001 1162 11621083	16-55	11AUG2020	46345	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
11621084	C4591001 1162 11621084	16-55	11AUG2020	46337	Placebo	11AUG2020/ Placebo	03SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
11621085	C4591001 1162 11621085	16-55	11AUG2020	46338	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
11621086	C4591001 1162 11621086	16-55	11AUG2020	46342	Placebo	11AUG2020/ Placebo	02SEP2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
11621091	C4591001 1162 11621091	16-55	11AUG2020	46495	Placebo	11AUG2020/ Placebo	18SEP2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
11621093	C4591001 1162 11621093	16-55	11AUG2020	46518	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
11621094	C4591001 1162 11621094	16-55	11AUG2020	46519	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11621096	C4591001 1162 11621096	16-55	13AUG2020	46522	Placebo	13AUG2020/ Placebo	22SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
11621097	C4591001 1162 11621097	16-55	13AUG2020	46526	Placebo	13AUG2020/ Placebo	02SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11621098	C4591001 1162 11621098	16-55	13AUG2020	48509	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11621100	C4591001 1162 11621100	16-55	13AUG2020	48520	Placebo	13AUG2020/ Placebo	04SEP2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
11621101	C4591001 1162 11621101	16-55	13AUG2020	48516	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
11621103	C4591001 1162 11621103	16-55	13AUG2020	48517	Placebo	13AUG2020/ Placebo	04SEP2020/ Placebo		
11621104	C4591001 1162 11621104	16-55	13AUG2020	48618	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11621106	C4591001 1162 11621106	16-55	13AUG2020	48620	Placebo	13AUG2020/ Placebo	02SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
11621107	C4591001 1162 11621107	16-55	13AUG2020	48622	Placebo	13AUG2020/ Placebo	02SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
11621108	C4591001 1162 11621108	16-55	13AUG2020	48865	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
11621110	C4591001 1162 11621110	16-55	13AUG2020	48628	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11621111	C4591001 1162 11621111	16-55	13AUG2020	48858	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11621112	C4591001 1162 11621112	16-55	13AUG2020	48860	Placebo	13AUG2020/ Placebo	02SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
11621114	C4591001 1162 11621114	16-55	13AUG2020	48861	Placebo	13AUG2020/ Placebo	04SEP2020/ Placebo		
11621115	C4591001 1162 11621115	16-55	13AUG2020	48954	Placebo	13AUG2020/ Placebo	01SEP2020/ Placebo	02MAR2021/ BNT162b2 (30 µg)	
11621117	C4591001 1162 11621117	16-55	13AUG2020	48955	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11621118	C4591001 1162 11621118	16-55	13AUG2020	48958	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)			
11621120	C4591001 1162 11621120	16-55	13AUG2020	48963	Placebo	13AUG2020/ Placebo	04SEP2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	
11621121	C4591001 1162 11621121	16-55	13AUG2020	49422	Placebo	13AUG2020/ Placebo	02SEP2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)
11631004	C4591001 1163 11631004	16-55	31JUL2020	41130	Placebo	31JUL2020/ Placebo	19AUG2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
11631006	C4591001 1163 11631006	16-55	31JUL2020	41132	BNT162b2 (30 µg)	31JUL2020/ 			
11631021	C4591001 1163 11631021	16-55	04AUG2020	42642	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11631023	C4591001 1163 11631023	16-55	04AUG2020	41138	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
11631028	C4591001 1163 11631028	16-55	05AUG2020	42645	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
11631029	C4591001 1163 11631029	16-55	05AUG2020	42647	Placebo	05AUG2020/ Placebo	24AUG2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
11631036	C4591001 1163 11631036	16-55	05AUG2020	43421	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
11631037	C4591001 1163 11631037	16-55	05AUG2020	42652	Placebo	05AUG2020/ Placebo	24AUG2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
11631039	C4591001 1163 11631039	16-55	06AUG2020	43422	Placebo	06AUG2020/ Placebo	25AUG2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
11631040	C4591001 1163 11631040	16-55	06AUG2020	43429	Placebo	06AUG2020/ Placebo	25AUG2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
11631042	C4591001 1163 11631042	16-55	06AUG2020	43432	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
11631046	C4591001 1163 11631046	16-55	06AUG2020	43783	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
11631048	C4591001 1163 11631048	16-55	06AUG2020	43787	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11631049	C4591001 1163 11631049	16-55	06AUG2020	43788	Placebo	06AUG2020/ Placebo	25AUG2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
11631050	C4591001 1163 11631050	16-55	06AUG2020	43790	Placebo	06AUG2020/ Placebo	25AUG2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
11631052	C4591001 1163 11631052	16-55	06AUG2020	44131	Placebo	06AUG2020/ Placebo	25AUG2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
11631056	C4591001 1163 11631056	16-55	07AUG2020	44133	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
11631059	C4591001 1163 11631059	16-55	07AUG2020	44137	Placebo	07AUG2020/ Placebo		19JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
11631060	C4591001 1163 11631060	16-55	07AUG2020	44529	Placebo	07AUG2020/ Placebo	26AUG2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
11631061	C4591001 1163 11631061	16-55	07AUG2020	44527	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)		
11631064	C4591001 1163 11631064	16-55	07AUG2020	44532	Placebo	07AUG2020/ Placebo	26AUG2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
11631066	C4591001 1163 11631066	16-55	07AUG2020	44535	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
11631069	C4591001 1163 11631069	16-55	10AUG2020	45427	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)			

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11631072	C4591001 1163 11631072	16-55	10AUG2020	45428	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
11631074	C4591001 1163 11631074	16-55	10AUG2020	45921	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
11631075	C4591001 1163 11631075	16-55	10AUG2020	45435	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
11631076	C4591001 1163 11631076	16-55	10AUG2020	45429	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
11631077	C4591001 1163 11631077	16-55	10AUG2020	45917	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
11631081	C4591001 1163 11631081	16-55	11AUG2020	45923	Placebo	11AUG2020/ Placebo	01SEP2020/ Placebo		
11631087	C4591001 1163 11631087	16-55	11AUG2020	45928	Placebo	11AUG2020/ Placebo	01SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
11631088	C4591001 1163 11631088	16-55	11AUG2020	46760	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
11631093	C4591001 1163 11631093	16-55	12AUG2020	46761	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
11631096	C4591001 1163 11631096	16-55	12AUG2020	46764	Placebo	12AUG2020/ Placebo	02SEP2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11631098	C4591001 1163 11631098	16-55	12AUG2020	46768	Placebo	12AUG2020/ Placebo	31AUG2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
11631102	C4591001 1163 11631102	16-55	12AUG2020	48198	Placebo	12AUG2020/ Placebo	31AUG2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
11631103	C4591001 1163 11631103	16-55	13AUG2020	48206	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
11631104	C4591001 1163 11631104	16-55	13AUG2020	48205	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
11631106	C4591001 1163 11631106	16-55	13AUG2020	49591	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
11631107	C4591001 1163 11631107	16-55	13AUG2020	48204	Placebo	13AUG2020/ Placebo	01SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
11631109	C4591001 1163 11631109	16-55	13AUG2020	49595	Placebo	13AUG2020/ Placebo	01SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
11631110	C4591001 1163 11631110	16-55	14AUG2020	49600	Placebo	14AUG2020/ Placebo	02SEP2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
11631112	C4591001 1163 11631112	16-55	14AUG2020	49597	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
11631113	C4591001 1163 11631113	16-55	14AUG2020	50874	Placebo	14AUG2020/ Placebo	02SEP2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11631114	C4591001 1163 11631114	16-55	14AUG2020	50877	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11631116	C4591001 1163 11631116	16-55	14AUG2020	50878	Placebo	14AUG2020/ Placebo	02SEP2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
11671001	C4591001 1167 11671001	16-55	14AUG2020	49809	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11671002	C4591001 1167 11671002	16-55	14AUG2020	49811	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
11671004	C4591001 1167 11671004	16-55	14AUG2020	49816	Placebo	14AUG2020/ Placebo	02SEP2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
11671005	C4591001 1167 11671005	16-55	14AUG2020	50465	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11671006	C4591001 1167 11671006	16-55	14AUG2020	50466	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11681001	C4591001 1168 11681001	16-55	11AUG2020	46667	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
11681002	C4591001 1168 11681002	16-55	11AUG2020	46668	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
11681003	C4591001 1168 11681003	16-55	12AUG2020	46669	Placebo	12AUG2020/ Placebo	31AUG2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11681004	C4591001 1168 11681004	16-55	12AUG2020	46672	Placebo	12AUG2020/ Placebo	02SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
11681005	C4591001 1168 11681005	16-55	12AUG2020	47567	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11681006	C4591001 1168 11681006	16-55	12AUG2020	47568	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11681007	C4591001 1168 11681007	16-55	12AUG2020	47571	Placebo	12AUG2020/ Placebo	01SEP2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
11681008	C4591001 1168 11681008	16-55	12AUG2020	47572	Placebo	12AUG2020/ Placebo	01SEP2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	20FEB2021/ BNT162b2 (30 µg)
11681009	C4591001 1168 11681009	16-55	12AUG2020	47885	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11681011	C4591001 1168 11681011	16-55	13AUG2020	47886	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
11681013	C4591001 1168 11681013	16-55	13AUG2020	47888	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
11681014	C4591001 1168 11681014	16-55	13AUG2020	47893	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
11681016	C4591001 1168 11681016	16-55	13AUG2020	49374	Placebo	13AUG2020/ Placebo	02SEP2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11681017	C4591001 1168 11681017	16-55	13AUG2020	49376	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
11681018	C4591001 1168 11681018	16-55	13AUG2020	49378	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
11681019	C4591001 1168 11681019	16-55	14AUG2020	49383	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
11681020	C4591001 1168 11681020	16-55	14AUG2020	50194	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11681022	C4591001 1168 11681022	16-55	14AUG2020	50195	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	15DEC2020/ BNT162b2 (30 µg)	04JAN2021/ BNT162b2 (30 µg)
11681023	C4591001 1168 11681023	16-55	14AUG2020	50198	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
11681024	C4591001 1168 11681024	16-55	14AUG2020	50200	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
11681025	C4591001 1168 11681025	16-55	15AUG2020	51173	Placebo	15AUG2020/ Placebo	03SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11681026	C4591001 1168 11681026	16-55	15AUG2020	51174	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
11681031	C4591001 1168 11681031	16-55	15AUG2020	51308	Placebo	15AUG2020/ Placebo	04SEP2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	28JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11701001	C4591001 1170 11701001	16-55	12AUG2020	47242	Placebo	12AUG2020/ Placebo	31AUG2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
11701002	C4591001 1170 11701002	16-55	12AUG2020	47244	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11701003	C4591001 1170 11701003	16-55	12AUG2020	47246	Placebo	12AUG2020/ Placebo	31AUG2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
11701006	C4591001 1170 11701006	16-55	12AUG2020	47247	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
11701007	C4591001 1170 11701007	16-55	12AUG2020	48066	Placebo	12AUG2020/ Placebo	31AUG2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11701009	C4591001 1170 11701009	16-55	13AUG2020	48068	Placebo	13AUG2020/ Placebo	01SEP2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
11701011	C4591001 1170 11701011	16-55	13AUG2020	48070	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
11701012	C4591001 1170 11701012	16-55	13AUG2020	49314	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11701013	C4591001 1170 11701013	16-55	13AUG2020	226982	Placebo	13AUG2020/ Placebo	08SEP2020/ Placebo		
11701014	C4591001 1170 11701014	16-55	13AUG2020	49318	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11701015	C4591001 1170 11701015	16-55	14AUG2020	49321	Placebo	14AUG2020/ Placebo	01SEP2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
11701016	C4591001 1170 11701016	16-55	14AUG2020	49323	Placebo	14AUG2020/ Placebo	03SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
11701018	C4591001 1170 11701018	16-55	14AUG2020	50610	Placebo	14AUG2020/ Placebo	03SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
11701019	C4591001 1170 11701019	16-55	14AUG2020	50611	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
11701023	C4591001 1170 11701023	16-55	17AUG2020	52771	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
11711001	C4591001 1171 11711001	16-55	12AUG2020	47321	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
11711002	C4591001 1171 11711002	16-55	12AUG2020	47322	Placebo	12AUG2020/ Placebo	31AUG2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
11711003	C4591001 1171 11711003	16-55	12AUG2020	47325	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11711004	C4591001 1171 11711004	16-55	12AUG2020	47327	Placebo	12AUG2020/ Placebo	31AUG2020/ Placebo		
11711005	C4591001 1171 11711005	16-55	12AUG2020	47706	Placebo	12AUG2020/ Placebo	31AUG2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11711006	C4591001 1171 11711006	16-55	12AUG2020	47710	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
11711008	C4591001 1171 11711008	16-55	12AUG2020	47713	Placebo	12AUG2020/ Placebo	31AUG2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
11711009	C4591001 1171 11711009	16-55	13AUG2020	47714	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
11711010	C4591001 1171 11711010	16-55	13AUG2020	48826	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
11711011	C4591001 1171 11711011	16-55	13AUG2020	48823	Placebo	13AUG2020/ Placebo	01SEP2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
11711012	C4591001 1171 11711012	16-55	13AUG2020	48827	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
11711013	C4591001 1171 11711013	16-55	13AUG2020	48831	Placebo	13AUG2020/ Placebo	01SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
11711014	C4591001 1171 11711014	16-55	13AUG2020	48965	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
11711016	C4591001 1171 11711016	16-55	13AUG2020	48969	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
11711020	C4591001 1171 11711020	16-55	13AUG2020	48971	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11711021	C4591001 1171 11711021	16-55	13AUG2020	48976	Placebo	13AUG2020/ Placebo	10SEP2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
11711023	C4591001 1171 11711023	16-55	14AUG2020	50045	Placebo	14AUG2020/ Placebo	02SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	
11711024	C4591001 1171 11711024	16-55	14AUG2020	50048	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11711026	C4591001 1171 11711026	16-55	14AUG2020	50052	Placebo	14AUG2020/ Placebo	03SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
11711028	C4591001 1171 11711028	16-55	14AUG2020	50407	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11711029	C4591001 1171 11711029	16-55	14AUG2020	50408	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11711030	C4591001 1171 11711030	16-55	14AUG2020	50414	Placebo	14AUG2020/ Placebo	02SEP2020/ Placebo	03MAR2021/ BNT162b2 (30 µg)	
11711031	C4591001 1171 11711031	16-55	14AUG2020	50415	Placebo	14AUG2020/ Placebo	02SEP2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
11711033	C4591001 1171 11711033	16-55	14AUG2020	50516	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11711034	C4591001 1171 11711034	16-55	14AUG2020	50518	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11711036	C4591001 1171 11711036	16-55	14AUG2020	50521	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
11711037	C4591001 1171 11711037	16-55	14AUG2020	50993	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
11711039	C4591001 1171 11711039	16-55	14AUG2020	50995	Placebo	14AUG2020/ Placebo	02SEP2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
11771001	C4591001 1177 11771001	16-55	12AUG2020	47622	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11771003	C4591001 1177 11771003	16-55	12AUG2020	47627	Placebo	12AUG2020/ Placebo	02SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
11771004	C4591001 1177 11771004	16-55	12AUG2020	47624	Placebo	12AUG2020/ Placebo	01SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
11771005	C4591001 1177 11771005	16-55	12AUG2020	47631	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11771007	C4591001 1177 11771007	16-55	12AUG2020	48090	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11771009	C4591001 1177 11771009	16-55	12AUG2020	48092	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11771010	C4591001 1177 11771010	16-55	12AUG2020	48093	Placebo	12AUG2020/ Placebo	02SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11771013	C4591001 1177 11771013	16-55	13AUG2020	48099	Placebo	13AUG2020/ Placebo	02SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
11771014	C4591001 1177 11771014	16-55	13AUG2020	49158	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11771017	C4591001 1177 11771017	16-55	13AUG2020	49160	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11771018	C4591001 1177 11771018	16-55	13AUG2020	49167	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
11771021	C4591001 1177 11771021	16-55	13AUG2020	49168	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
11771022	C4591001 1177 11771022	16-55	13AUG2020	49546	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
11771023	C4591001 1177 11771023	16-55	13AUG2020	49548	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
11771024	C4591001 1177 11771024	16-55	13AUG2020	49549	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
11771025	C4591001 1177 11771025	16-55	13AUG2020	49551	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11771026	C4591001 1177 11771026	16-55	13AUG2020	49721	Placebo	13AUG2020/ Placebo	10SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11771027	C4591001 1177 11771027	16-55	13AUG2020	49728	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
11771028	C4591001 1177 11771028	16-55	13AUG2020	49729	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
11771030	C4591001 1177 11771030	16-55	13AUG2020	49730	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)
11771032	C4591001 1177 11771032	16-55	13AUG2020	49769	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
11771038	C4591001 1177 11771038	16-55	14AUG2020	49772	Placebo	14AUG2020/ Placebo	25SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
11771039	C4591001 1177 11771039	16-55	14AUG2020	49776	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11771043	C4591001 1177 11771043	16-55	14AUG2020	49778	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	05SEP2020/ BNT162b2 (30 µg)		
11771047	C4591001 1177 11771047	16-55	14AUG2020	51077	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
11791002	C4591001 1179 11791002	16-55	14AUG2020	50213	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
12241005	C4591001 1224 12241005	16-55	12AUG2020	47753	Placebo	12AUG2020/ Placebo	31AUG2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	04JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12241008	C4591001 1224 12241008	16-55	12AUG2020	47755	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
12241009	C4591001 1224 12241009	16-55	13AUG2020	47759	Placebo	13AUG2020/ Placebo			
12241010	C4591001 1224 12241010	16-55	13AUG2020	49085	Placebo	13AUG2020/ Placebo	01SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
12241017	C4591001 1224 12241017	16-55	14AUG2020	49087	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
12241021	C4591001 1224 12241021	16-55	14AUG2020	49091	Placebo	14AUG2020/ Placebo	02SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
12241024	C4591001 1224 12241024	16-55	14AUG2020	49093	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
12241026	C4591001 1224 12241026	16-55	14AUG2020	50971	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
12241027	C4591001 1224 12241027	16-55	14AUG2020	50974	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
12261001	C4591001 1226 12261001	16-55	05AUG2020	42725	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
12261002	C4591001 1226 12261002	16-55	05AUG2020	42729	Placebo	05AUG2020/ Placebo	25AUG2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12261003	C4591001 1226 12261003	16-55	05AUG2020	42731	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
12261004	C4591001 1226 12261004	16-55	05AUG2020	42733	Placebo	05AUG2020/ Placebo	24AUG2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12261005	C4591001 1226 12261005	16-55	05AUG2020	42737	Placebo	05AUG2020/ Placebo	24AUG2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12261006	C4591001 1226 12261006	16-55	05AUG2020	42743	Placebo	05AUG2020/ Placebo	24AUG2020/ Placebo	30JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
12261007	C4591001 1226 12261007	16-55	05AUG2020	42745	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
12261008	C4591001 1226 12261008	16-55	05AUG2020	42803	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
12261010	C4591001 1226 12261010	16-55	05AUG2020	42804	Placebo	05AUG2020/ Placebo	10SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
12261011	C4591001 1226 12261011	16-55	05AUG2020	42748	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
12261012	C4591001 1226 12261012	16-55	05AUG2020	42806	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
12261013	C4591001 1226 12261013	16-55	05AUG2020	42797	Placebo	05AUG2020/ Placebo	26AUG2020/ Placebo	23JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12261014	C4591001 1226 12261014	16-55	05AUG2020	42905	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
12261015	C4591001 1226 12261015	16-55	06AUG2020	42909	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
12261016	C4591001 1226 12261016	16-55	06AUG2020	42911	Placebo	06AUG2020/ Placebo	25AUG2020/ Placebo	30JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
12261017	C4591001 1226 12261017	16-55	06AUG2020	42912	Placebo	06AUG2020/ Placebo	25AUG2020/ Placebo	30JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
12261018	C4591001 1226 12261018	16-55	06AUG2020	43459	Placebo	06AUG2020/ Placebo	26AUG2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12261019	C4591001 1226 12261019	16-55	06AUG2020	43462	Placebo	06AUG2020/ Placebo	26AUG2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12261020	C4591001 1226 12261020	16-55	06AUG2020	43465	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
12261021	C4591001 1226 12261021	16-55	06AUG2020	43468	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
12261022	C4591001 1226 12261022	16-55	06AUG2020	43522	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
12261024	C4591001 1226 12261024	16-55	06AUG2020	43524	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12261025	C4591001 1226 12261025	16-55	06AUG2020	43604	Placebo	06AUG2020/ Placebo	25AUG2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12261026	C4591001 1226 12261026	16-55	06AUG2020	43528	Placebo	06AUG2020/ Placebo	25AUG2020/ Placebo	30JAN2021/ BNT162b2 (30 µg)	20FEB2021/ BNT162b2 (30 µg)
12261027	C4591001 1226 12261027	16-55	06AUG2020	43525	Placebo	06AUG2020/ Placebo	12SEP2020/ Placebo	30JAN2021/ BNT162b2 (30 µg)	20FEB2021/ BNT162b2 (30 µg)
12261029	C4591001 1226 12261029	16-55	06AUG2020	43606	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
12261030	C4591001 1226 12261030	16-55	06AUG2020	43608	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
12261031	C4591001 1226 12261031	16-55	06AUG2020	43611	Placebo	06AUG2020/ Placebo	25AUG2020/ Placebo	30JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
12261032	C4591001 1226 12261032	16-55	06AUG2020	43865	Placebo	06AUG2020/ Placebo	25AUG2020/ Placebo	30JAN2021/ BNT162b2 (30 µg)	20FEB2021/ BNT162b2 (30 µg)
12261036	C4591001 1226 12261036	16-55	07AUG2020	43870	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
12261037	C4591001 1226 12261037	16-55	07AUG2020	43873	Placebo	07AUG2020/ Placebo	26AUG2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
12261038	C4591001 1226 12261038	16-55	07AUG2020	43875	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12261041	C4591001 1226 12261041	16-55	07AUG2020	44237	Placebo	07AUG2020/ Placebo	26AUG2020/ Placebo	30JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
12261043	C4591001 1226 12261043	16-55	07AUG2020	44238	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
12261044	C4591001 1226 12261044	16-55	07AUG2020	44246	Placebo	07AUG2020/ Placebo	26AUG2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12261045	C4591001 1226 12261045	16-55	07AUG2020	44248	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
12261047	C4591001 1226 12261047	16-55	07AUG2020	44263	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
12261048	C4591001 1226 12261048	16-55	07AUG2020	44267	Placebo	07AUG2020/ Placebo	26AUG2020/ Placebo	23JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
12261049	C4591001 1226 12261049	16-55	07AUG2020	44270	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
12261052	C4591001 1226 12261052	16-55	10AUG2020	44271	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
12261054	C4591001 1226 12261054	16-55	10AUG2020	45057	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
12261055	C4591001 1226 12261055	16-55	10AUG2020	45063	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	30JAN2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12261056	C4591001 1226 12261056	16-55	10AUG2020	45059	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	30JAN2021/ BNT162b2 (30 µg)	
12261057	C4591001 1226 12261057	16-55	10AUG2020	45060	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
12261058	C4591001 1226 12261058	16-55	10AUG2020	45103	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	30JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
12261060	C4591001 1226 12261060	16-55	10AUG2020	45105	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
12261061	C4591001 1226 12261061	16-55	10AUG2020	45106	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
12261065	C4591001 1226 12261065	16-55	10AUG2020	45107	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	30JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
12261066	C4591001 1226 12261066	16-55	10AUG2020	45209	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
12261067	C4591001 1226 12261067	16-55	10AUG2020	45215	Placebo	10AUG2020/ Placebo	01SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
12261068	C4591001 1226 12261068	16-55	10AUG2020	45212	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
12261069	C4591001 1226 12261069	16-55	10AUG2020	45217	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	30JAN2021/ BNT162b2 (30 µg)	20FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12261071	C4591001 1226 12261071	16-55	11AUG2020	45981	Placebo	11AUG2020/ Placebo	31AUG2020/ Placebo	23JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
12261072	C4591001 1226 12261072	16-55	11AUG2020	45986	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)			
12261073	C4591001 1226 12261073	16-55	11AUG2020	45982	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
12261074	C4591001 1226 12261074	16-55	11AUG2020	45985	Placebo	11AUG2020/ Placebo	04SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12261075	C4591001 1226 12261075	16-55	11AUG2020	45991	Placebo	11AUG2020/ Placebo	01SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12261076	C4591001 1226 12261076	16-55	11AUG2020	45992	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
12261078	C4591001 1226 12261078	16-55	11AUG2020	45995	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
12261079	C4591001 1226 12261079	16-55	11AUG2020	46000	Placebo	11AUG2020/ Placebo	01SEP2020/ Placebo	30JAN2021/ BNT162b2 (30 µg)	20FEB2021/ BNT162b2 (30 µg)
12261080	C4591001 1226 12261080	16-55	11AUG2020	46049	Placebo	11AUG2020/ Placebo	01SEP2020/ Placebo		
12261081	C4591001 1226 12261081	16-55	11AUG2020	46058	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12261082	C4591001 1226 12261082	16-55	11AUG2020	46059	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
12261083	C4591001 1226 12261083	16-55	11AUG2020	46104	Placebo	11AUG2020/ Placebo	04SEP2020/ Placebo	30JAN2021/ BNT162b2 (30 µg)	20FEB2021/ BNT162b2 (30 µg)
12261084	C4591001 1226 12261084	16-55	11AUG2020	46060	Placebo	11AUG2020/ Placebo	01SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12261085	C4591001 1226 12261085	16-55	11AUG2020	46084	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
12261086	C4591001 1226 12261086	16-55	11AUG2020	46073	Placebo	11AUG2020/ Placebo	01SEP2020/ Placebo	30JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
12261087	C4591001 1226 12261087	16-55	11AUG2020	46078	Placebo	11AUG2020/ Placebo	01SEP2020/ Placebo	30JAN2021/ BNT162b2 (30 µg)	20FEB2021/ BNT162b2 (30 µg)
12261088	C4591001 1226 12261088	16-55	11AUG2020	46082	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
12261089	C4591001 1226 12261089	16-55	11AUG2020	46105	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
12261091	C4591001 1226 12261091	16-55	11AUG2020	46107	Placebo	11AUG2020/ Placebo	03SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12261092	C4591001 1226 12261092	16-55	11AUG2020	46108	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12261093	C4591001 1226 12261093	16-55	11AUG2020	46256	Placebo	11AUG2020/ Placebo	01SEP2020/ Placebo	30JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
12261094	C4591001 1226 12261094	16-55	11AUG2020	46257	Placebo	11AUG2020/ Placebo	01SEP2020/ Placebo	11MAR2021/ BNT162b2 (30 µg)	
12261096	C4591001 1226 12261096	16-55	11AUG2020	46258	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
12261097	C4591001 1226 12261097	16-55	11AUG2020	46261	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
12261100	C4591001 1226 12261100	16-55	11AUG2020	46325	Placebo	11AUG2020/ Placebo	31AUG2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12261102	C4591001 1226 12261102	16-55	11AUG2020	46329	Placebo	11AUG2020/ Placebo	01SEP2020/ Placebo	30JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
12261103	C4591001 1226 12261103	16-55	11AUG2020	46330	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
12261104	C4591001 1226 12261104	16-55	11AUG2020	46374	Placebo	11AUG2020/ Placebo	04SEP2020/ Placebo	30JAN2021/ BNT162b2 (30 µg)	20FEB2021/ BNT162b2 (30 µg)
12261105	C4591001 1226 12261105	16-55	11AUG2020	46332	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
12261106	C4591001 1226 12261106	16-55	11AUG2020	46377	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12261107	C4591001 1226 12261107	16-55	11AUG2020	46378	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
12261108	C4591001 1226 12261108	16-55	11AUG2020	46384	Placebo	11AUG2020/ Placebo	31AUG2020/ Placebo		
12261110	C4591001 1226 12261110	16-55	12AUG2020	46925	Placebo	12AUG2020/ Placebo	05SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12261111	C4591001 1226 12261111	16-55	12AUG2020	46926	Placebo	12AUG2020/ Placebo	03SEP2020/ Placebo	30JAN2021/ BNT162b2 (30 µg)	20FEB2021/ BNT162b2 (30 µg)
12261112	C4591001 1226 12261112	16-55	12AUG2020	46931	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
12261113	C4591001 1226 12261113	16-55	12AUG2020	46942	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
12261114	C4591001 1226 12261114	16-55	12AUG2020	46936	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
12261115	C4591001 1226 12261115	16-55	12AUG2020	46941	Placebo	12AUG2020/ Placebo	03SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12261116	C4591001 1226 12261116	16-55	12AUG2020	46945	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12261117	C4591001 1226 12261117	16-55	12AUG2020	46948	Placebo	12AUG2020/ Placebo	04SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12261118	C4591001 1226 12261118	16-55	12AUG2020	46961	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
12261119	C4591001 1226 12261119	16-55	12AUG2020	46970	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12261120	C4591001 1226 12261120	16-55	12AUG2020	46971	Placebo	12AUG2020/ Placebo	08SEP2020/ Placebo	30JAN2021/ BNT162b2 (30 µg)	20FEB2021/ BNT162b2 (30 µg)
12261121	C4591001 1226 12261121	16-55	12AUG2020	46968	Placebo	12AUG2020/ Placebo	08SEP2020/ Placebo	30JAN2021/ BNT162b2 (30 µg)	20FEB2021/ BNT162b2 (30 µg)
12261122	C4591001 1226 12261122	16-55	12AUG2020	47023	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
12261123	C4591001 1226 12261123	16-55	12AUG2020	46989	Placebo	12AUG2020/ Placebo	04SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12261124	C4591001 1226 12261124	16-55	12AUG2020	46992	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
12261125	C4591001 1226 12261125	16-55	12AUG2020	46995	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
12261126	C4591001 1226 12261126	16-55	12AUG2020	46996	Placebo	12AUG2020/ Placebo	21SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12261127	C4591001 1226 12261127	16-55	12AUG2020	47025	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12261130	C4591001 1226 12261130	16-55	12AUG2020	47105	Placebo	12AUG2020/ Placebo	04SEP2020/ Placebo	23JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
12261132	C4591001 1226 12261132	16-55	12AUG2020	47029	Placebo	12AUG2020/ Placebo	11SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12261133	C4591001 1226 12261133	16-55	12AUG2020	47026	Placebo	12AUG2020/ Placebo	04SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12261134	C4591001 1226 12261134	16-55	12AUG2020	47106	Placebo	12AUG2020/ Placebo	01SEP2020/ Placebo	30JAN2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12261135	C4591001 1226 12261135	16-55	12AUG2020	47223	Placebo	12AUG2020/ Placebo	03SEP2020/ Placebo	30JAN2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12261136	C4591001 1226 12261136	16-55	12AUG2020	47109	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
12261137	C4591001 1226 12261137	16-55	12AUG2020	47218	Placebo	12AUG2020/ Placebo	03SEP2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12261138	C4591001 1226 12261138	16-55	12AUG2020	47108	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
12261139	C4591001 1226 12261139	16-55	12AUG2020	47220	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
12261140	C4591001 1226 12261140	16-55	12AUG2020	47224	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12261144	C4591001 1226 12261144	16-55	12AUG2020	47340	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12261146	C4591001 1226 12261146	16-55	13AUG2020	47342	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
12261147	C4591001 1226 12261147	16-55	13AUG2020	47344	Placebo	13AUG2020/ Placebo	11SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12261148	C4591001 1226 12261148	16-55	13AUG2020	47341	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo	30JAN2021/ BNT162b2 (30 µg)	20FEB2021/ BNT162b2 (30 µg)
12261150	C4591001 1226 12261150	16-55	13AUG2020	48330	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12261151	C4591001 1226 12261151	16-55	13AUG2020	48274	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	27FEB2021/ BNT162b2 (30 µg)
12261152	C4591001 1226 12261152	16-55	13AUG2020	48269	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
12261153	C4591001 1226 12261153	16-55	13AUG2020	48275	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo	30JAN2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
12261154	C4591001 1226 12261154	16-55	13AUG2020	48279	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12261155	C4591001 1226 12261155	16-55	13AUG2020	48336	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12261156	C4591001 1226 12261156	16-55	13AUG2020	48331	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12261157	C4591001 1226 12261157	16-55	13AUG2020	48339	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
12261158	C4591001 1226 12261158	16-55	13AUG2020	48381	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12261159	C4591001 1226 12261159	16-55	13AUG2020	48388	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo	23JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
12261160	C4591001 1226 12261160	16-55	13AUG2020	48383	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
12261161	C4591001 1226 12261161	16-55	13AUG2020	48382	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
12261163	C4591001 1226 12261163	16-55	13AUG2020	48506	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
12261164	C4591001 1226 12261164	16-55	13AUG2020	48497	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
12261165	C4591001 1226 12261165	16-55	13AUG2020	48583	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
12261166	C4591001 1226 12261166	16-55	13AUG2020	48507	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12261167	C4591001 1226 12261167	16-55	13AUG2020	48508	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12261168	C4591001 1226 12261168	16-55	13AUG2020	48589	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12261170	C4591001 1226 12261170	16-55	13AUG2020	48582	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
12261172	C4591001 1226 12261172	16-55	13AUG2020	48691	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo	30JAN2021/ BNT162b2 (30 µg)	20FEB2021/ BNT162b2 (30 µg)
12261174	C4591001 1226 12261174	16-55	13AUG2020	48592	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo	30JAN2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12261175	C4591001 1226 12261175	16-55	13AUG2020	48692	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
12261176	C4591001 1226 12261176	16-55	14AUG2020	48697	Placebo	14AUG2020/ Placebo	03SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12261177	C4591001 1226 12261177	16-55	14AUG2020	49794	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	27FEB2021/ BNT162b2 (30 µg)
12261178	C4591001 1226 12261178	16-55	14AUG2020	48698	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
12261179	C4591001 1226 12261179	16-55	14AUG2020	49798	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12261180	C4591001 1226 12261180	16-55	14AUG2020	49843	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
12261182	C4591001 1226 12261182	16-55	14AUG2020	49803	Placebo	14AUG2020/ Placebo	09SEP2020/ Placebo	30JAN2021/ BNT162b2 (30 µg)	20FEB2021/ BNT162b2 (30 µg)
12261183	C4591001 1226 12261183	16-55	14AUG2020	49804	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
12261184	C4591001 1226 12261184	16-55	14AUG2020	49846	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
12261185	C4591001 1226 12261185	16-55	14AUG2020	49844	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12261186	C4591001 1226 12261186	16-55	14AUG2020	49847	Placebo	14AUG2020/ Placebo	03SEP2020/ Placebo	23JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
12261188	C4591001 1226 12261188	16-55	14AUG2020	49939	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12261189	C4591001 1226 12261189	16-55	14AUG2020	49940	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
12261190	C4591001 1226 12261190	16-55	14AUG2020	50014	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
12261191	C4591001 1226 12261191	16-55	14AUG2020	49941	Placebo	14AUG2020/ Placebo	14SEP2020/ Placebo	30JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12261192	C4591001 1226 12261192	16-55	14AUG2020	49944	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
12261193	C4591001 1226 12261193	16-55	14AUG2020	50093	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12261196	C4591001 1226 12261196	16-55	14AUG2020	50017	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
12261197	C4591001 1226 12261197	16-55	14AUG2020	50099	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
12261199	C4591001 1226 12261199	16-55	14AUG2020	50018	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	23JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
12261200	C4591001 1226 12261200	16-55	14AUG2020	50096	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	30JAN2021/ BNT162b2 (30 µg)	20FEB2021/ BNT162b2 (30 µg)
12261202	C4591001 1226 12261202	16-55	14AUG2020	50102	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
12261203	C4591001 1226 12261203	16-55	14AUG2020	50203	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	30JAN2021/ BNT162b2 (30 µg)	20FEB2021/ BNT162b2 (30 µg)
12311001	C4591001 1231 12311001	16-55	06AUG2020	43590	Placebo	06AUG2020/ Placebo	27AUG2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12311002	C4591001 1231 12311002	16-55	06AUG2020	43596	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12311003	C4591001 1231 12311003	16-55	06AUG2020	43593	Placebo	06AUG2020/ Placebo	27AUG2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12311004	C4591001 1231 12311004	16-55	06AUG2020	43598	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)		
12311005	C4591001 1231 12311005	16-55	06AUG2020	43933	Placebo	06AUG2020/ Placebo	27AUG2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
12311006	C4591001 1231 12311006	16-55	06AUG2020	43928	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
12311008	C4591001 1231 12311008	16-55	06AUG2020	43934	Placebo	06AUG2020/ Placebo	27AUG2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12311009	C4591001 1231 12311009	16-55	06AUG2020	44094	Placebo	06AUG2020/ Placebo	27AUG2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12311010	C4591001 1231 12311010	16-55	06AUG2020	43935	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
12311012	C4591001 1231 12311012	16-55	07AUG2020	44100	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)		
12311013	C4591001 1231 12311013	16-55	07AUG2020	44099	Placebo	07AUG2020/ Placebo	26AUG2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12311018	C4591001 1231 12311018	16-55	07AUG2020	44590	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12311019	C4591001 1231 12311019	16-55	07AUG2020	44101	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
12311021	C4591001 1231 12311021	16-55	07AUG2020	44593	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
12311022	C4591001 1231 12311022	16-55	10AUG2020	44595	Placebo	10AUG2020/ Placebo	02SEP2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
12311023	C4591001 1231 12311023	16-55	10AUG2020	44596	Placebo	10AUG2020/ Placebo	01SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12311024	C4591001 1231 12311024	16-55	10AUG2020	45234	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
12311025	C4591001 1231 12311025	16-55	10AUG2020	45238	Placebo	10AUG2020/ Placebo	01SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12311026	C4591001 1231 12311026	16-55	10AUG2020	45240	Placebo	10AUG2020/ Placebo	01SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12311027	C4591001 1231 12311027	16-55	10AUG2020	45244	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
12311029	C4591001 1231 12311029	16-55	10AUG2020	45499	Placebo	10AUG2020/ Placebo	01SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12311030	C4591001 1231 12311030	16-55	10AUG2020	45508	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12311031	C4591001 1231 12311031	16-55	10AUG2020	45500	Placebo	10AUG2020/ Placebo		01MAR2021/ BNT162b2 (30 µg)	
12311032	C4591001 1231 12311032	16-55	10AUG2020	45502	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
12311033	C4591001 1231 12311033	16-55	10AUG2020	45741	Placebo	10AUG2020/ Placebo	01SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12311034	C4591001 1231 12311034	16-55	10AUG2020	45745	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
12311035	C4591001 1231 12311035	16-55	10AUG2020	45747	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
12311036	C4591001 1231 12311036	16-55	10AUG2020	45748	Placebo	10AUG2020/ Placebo	02SEP2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
12311039	C4591001 1231 12311039	16-55	11AUG2020	46033	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
12311040	C4591001 1231 12311040	16-55	11AUG2020	46027	Placebo	11AUG2020/ Placebo	01SEP2020/ Placebo		
12311041	C4591001 1231 12311041	16-55	11AUG2020	46026	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
12311042	C4591001 1231 12311042	16-55	11AUG2020	46036	Placebo	11AUG2020/ Placebo	02SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12311043	C4591001 1231 12311043	16-55	11AUG2020	46123	Placebo	11AUG2020/ Placebo	01SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12311045	C4591001 1231 12311045	16-55	11AUG2020	46126	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
12311046	C4591001 1231 12311046	16-55	11AUG2020	46131	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
12311047	C4591001 1231 12311047	16-55	11AUG2020	46129	Placebo	11AUG2020/ Placebo	01SEP2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
12311049	C4591001 1231 12311049	16-55	11AUG2020	46363	Placebo	11AUG2020/ Placebo	01SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12311051	C4591001 1231 12311051	16-55	11AUG2020	46301	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
12311052	C4591001 1231 12311052	16-55	11AUG2020	46302	Placebo	11AUG2020/ Placebo	01SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12311053	C4591001 1231 12311053	16-55	11AUG2020	46304	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
12311054	C4591001 1231 12311054	16-55	11AUG2020	46303	Placebo	11AUG2020/ Placebo			
12311055	C4591001 1231 12311055	16-55	11AUG2020	46365	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12311058	C4591001 1231 12311058	16-55	11AUG2020	46370	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
12311062	C4591001 1231 12311062	16-55	11AUG2020	46371	Placebo	11AUG2020/ Placebo	01SEP2020/ Placebo		
12311064	C4591001 1231 12311064	16-55	11AUG2020	46541	Placebo	11AUG2020/ Placebo	01SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12311065	C4591001 1231 12311065	16-55	11AUG2020	46544	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
12311068	C4591001 1231 12311068	16-55	11AUG2020	46549	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
12311069	C4591001 1231 12311069	16-55	11AUG2020	46552	Placebo	11AUG2020/ Placebo	02SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12311070	C4591001 1231 12311070	16-55	11AUG2020	46805	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
12311071	C4591001 1231 12311071	16-55	11AUG2020	46811	Placebo	11AUG2020/ Placebo	01SEP2020/ Placebo		
12311072	C4591001 1231 12311072	16-55	11AUG2020	46815	Placebo	11AUG2020/ Placebo	02SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	13FEB2021/ BNT162b2 (30 µg)
12311073	C4591001 1231 12311073	16-55	12AUG2020	46952	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12311074	C4591001 1231 12311074	16-55	12AUG2020	46816	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
12311076	C4591001 1231 12311076	16-55	12AUG2020	46953	Placebo	12AUG2020/ Placebo	04SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12311077	C4591001 1231 12311077	16-55	12AUG2020	46959	Placebo	12AUG2020/ Placebo	01SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12311078	C4591001 1231 12311078	16-55	12AUG2020	46960	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
12311080	C4591001 1231 12311080	16-55	12AUG2020	47072	Placebo	12AUG2020/ Placebo	03SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12311081	C4591001 1231 12311081	16-55	12AUG2020	47070	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
12311082	C4591001 1231 12311082	16-55	12AUG2020	47077	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
12311083	C4591001 1231 12311083	16-55	12AUG2020	47154	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
12311084	C4591001 1231 12311084	16-55	12AUG2020	47080	Placebo	12AUG2020/ Placebo	01SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12311085	C4591001 1231 12311085	16-55	12AUG2020	47155	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12311087	C4591001 1231 12311087	16-55	12AUG2020	47157	Placebo	12AUG2020/ Placebo		01MAR2021/ BNT162b2 (30 µg)	
12311088	C4591001 1231 12311088	16-55	12AUG2020	47159	Placebo	12AUG2020/ Placebo		01MAR2021/ BNT162b2 (30 µg)	
12311089	C4591001 1231 12311089	16-55	12AUG2020	47275	Placebo	12AUG2020/ Placebo	01SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12311091	C4591001 1231 12311091	16-55	12AUG2020	47283	Placebo	12AUG2020/ Placebo	04SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12311092	C4591001 1231 12311092	16-55	12AUG2020	47277	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
12311093	C4591001 1231 12311093	16-55	12AUG2020	47518	Placebo	12AUG2020/ Placebo	04SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12311094	C4591001 1231 12311094	16-55	12AUG2020	47284	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
12311095	C4591001 1231 12311095	16-55	12AUG2020	47513	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
12311096	C4591001 1231 12311096	16-55	12AUG2020	47521	Placebo	12AUG2020/ Placebo	11SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12311097	C4591001 1231 12311097	16-55	12AUG2020	47516	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12311098	C4591001 1231 12311098	16-55	12AUG2020	47669	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
12311099	C4591001 1231 12311099	16-55	12AUG2020	47842	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
12311100	C4591001 1231 12311100	16-55	12AUG2020	47673	Placebo	12AUG2020/ Placebo	01SEP2020/ Placebo		
12311102	C4591001 1231 12311102	16-55	12AUG2020	47678	Placebo	12AUG2020/ Placebo	01SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12311103	C4591001 1231 12311103	16-55	12AUG2020	47672	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
12311104	C4591001 1231 12311104	16-55	12AUG2020	47841	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
12311105	C4591001 1231 12311105	16-55	12AUG2020	47847	Placebo	12AUG2020/ Placebo	02SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12311107	C4591001 1231 12311107	16-55	12AUG2020	48005	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
12311108	C4591001 1231 12311108	16-55	12AUG2020	47846	Placebo	12AUG2020/ Placebo	01SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12311109	C4591001 1231 12311109	16-55	12AUG2020	48006	Placebo	12AUG2020/ Placebo	03SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12311110	C4591001 1231 12311110	16-55	12AUG2020	48008	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
12311112	C4591001 1231 12311112	16-55	13AUG2020	48010	Placebo	13AUG2020/ Placebo	04SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
12311113	C4591001 1231 12311113	16-55	13AUG2020	48282	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
12311114	C4591001 1231 12311114	16-55	13AUG2020	48342	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
12311115	C4591001 1231 12311115	16-55	13AUG2020	48287	Placebo	13AUG2020/ Placebo	01SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
12311116	C4591001 1231 12311116	16-55	13AUG2020	48341	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
12311117	C4591001 1231 12311117	16-55	13AUG2020	48347	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12311118	C4591001 1231 12311118	16-55	13AUG2020	48284	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
12311119	C4591001 1231 12311119	16-55	13AUG2020	48289	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	13FEB2021/ BNT162b2 (30 µg)
12311120	C4591001 1231 12311120	16-55	13AUG2020	48350	Placebo	13AUG2020/ Placebo	01SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12311121	C4591001 1231 12311121	16-55	13AUG2020	48397	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12311122	C4591001 1231 12311122	16-55	13AUG2020	48390	Placebo	13AUG2020/ Placebo	01SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12311123	C4591001 1231 12311123	16-55	13AUG2020	48487	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
12311124	C4591001 1231 12311124	16-55	13AUG2020	48399	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
12311125	C4591001 1231 12311125	16-55	13AUG2020	48491	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)			
12311126	C4591001 1231 12311126	16-55	13AUG2020	48393	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
12311127	C4591001 1231 12311127	16-55	13AUG2020	48488	Placebo	13AUG2020/ Placebo	04SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
12311128	C4591001 1231 12311128	16-55	13AUG2020	48524	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
12311129	C4591001 1231 12311129	16-55	13AUG2020	48496	Placebo	13AUG2020/ Placebo	02SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12311130	C4591001 1231 12311130	16-55	13AUG2020	48523	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12311131	C4591001 1231 12311131	16-55	13AUG2020	48527	Placebo	13AUG2020/ Placebo	01SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12311134	C4591001 1231 12311134	16-55	13AUG2020	48640	Placebo	13AUG2020/ Placebo	01SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12311135	C4591001 1231 12311135	16-55	13AUG2020	48629	Placebo	13AUG2020/ Placebo	01SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12311136	C4591001 1231 12311136	16-55	13AUG2020	48738	Placebo	13AUG2020/ Placebo	02SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12311137	C4591001 1231 12311137	16-55	13AUG2020	48634	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
12311138	C4591001 1231 12311138	16-55	13AUG2020	48638	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
12311140	C4591001 1231 12311140	16-55	13AUG2020	48741	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
12311141	C4591001 1231 12311141	16-55	13AUG2020	48742	Placebo	13AUG2020/ Placebo	02SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12311142	C4591001 1231 12311142	16-55	13AUG2020	48748	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
12311143	C4591001 1231 12311143	16-55	13AUG2020	48929	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12311144	C4591001 1231 12311144	16-55	13AUG2020	48930	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
12311145	C4591001 1231 12311145	16-55	13AUG2020	48934	Placebo	13AUG2020/ Placebo	01SEP2020/ Placebo		
12311147	C4591001 1231 12311147	16-55	13AUG2020	48940	Placebo	13AUG2020/ Placebo		22FEB2021/ BNT162b2 (30 µg)	
12311151	C4591001 1231 12311151	16-55	13AUG2020	49253	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12311152	C4591001 1231 12311152	16-55	13AUG2020	49255	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
12311153	C4591001 1231 12311153	16-55	13AUG2020	49258	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
12311156	C4591001 1231 12311156	16-55	13AUG2020	49289	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
12311157	C4591001 1231 12311157	16-55	13AUG2020	49260	Placebo	13AUG2020/ Placebo	04SEP2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
12311158	C4591001 1231 12311158	16-55	13AUG2020	49297	Placebo	13AUG2020/ Placebo	01SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12311159	C4591001 1231 12311159	16-55	13AUG2020	49291	Placebo	13AUG2020/ Placebo	04SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12311161	C4591001 1231 12311161	16-55	13AUG2020	49445	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
12311162	C4591001 1231 12311162	16-55	13AUG2020	49299	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
12311164	C4591001 1231 12311164	16-55	13AUG2020	49447	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
12311166	C4591001 1231 12311166	16-55	13AUG2020	49454	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo		
12311167	C4591001 1231 12311167	16-55	13AUG2020	49449	Placebo	13AUG2020/ Placebo	01SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12311168	C4591001 1231 12311168	16-55	13AUG2020	49506	Placebo	13AUG2020/ Placebo	01SEP2020/ Placebo		
12311169	C4591001 1231 12311169	16-55	13AUG2020	49508	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
12311170	C4591001 1231 12311170	16-55	13AUG2020	49510	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
12311171	C4591001 1231 12311171	16-55	13AUG2020	49512	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
12311172	C4591001 1231 12311172	16-55	13AUG2020	49601	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12311175	C4591001 1231 12311175	16-55	13AUG2020	49607	Placebo	13AUG2020/ Placebo	01SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12311176	C4591001 1231 12311176	16-55	14AUG2020	49857	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
12311177	C4591001 1231 12311177	16-55	14AUG2020	49855	Placebo	14AUG2020/ Placebo	03SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12311178	C4591001 1231 12311178	16-55	14AUG2020	49611	Placebo	14AUG2020/ Placebo	03SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12311179	C4591001 1231 12311179	16-55	14AUG2020	49610	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
12311180	C4591001 1231 12311180	16-55	14AUG2020	49916	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12311183	C4591001 1231 12311183	16-55	14AUG2020	49989	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
12311185	C4591001 1231 12311185	16-55	14AUG2020	49919	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
12311186	C4591001 1231 12311186	16-55	14AUG2020	49991	Placebo	14AUG2020/ Placebo	02SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12311187	C4591001 1231 12311187	16-55	14AUG2020	49923	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12311188	C4591001 1231 12311188	16-55	14AUG2020	49913	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12311189	C4591001 1231 12311189	16-55	14AUG2020	49863	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)			
12311190	C4591001 1231 12311190	16-55	14AUG2020	49862	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
12311193	C4591001 1231 12311193	16-55	14AUG2020	49992	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
12311194	C4591001 1231 12311194	16-55	14AUG2020	50166	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
12311196	C4591001 1231 12311196	16-55	14AUG2020	50124	Placebo	14AUG2020/ Placebo	02SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12311198	C4591001 1231 12311198	16-55	14AUG2020	50153	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12311199	C4591001 1231 12311199	16-55	14AUG2020	50126	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
12311202	C4591001 1231 12311202	16-55	14AUG2020	50148	Placebo	14AUG2020/ Placebo	03SEP2020/ Placebo		
12311204	C4591001 1231 12311204	16-55	14AUG2020	50145	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12311205	C4591001 1231 12311205	16-55	14AUG2020	50147	Placebo	14AUG2020/ Placebo	03SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12311206	C4591001 1231 12311206	16-55	14AUG2020	50156	Placebo	14AUG2020/ Placebo	02SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12311207	C4591001 1231 12311207	16-55	14AUG2020	50151	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
12311208	C4591001 1231 12311208	16-55	14AUG2020	50162	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
12311210	C4591001 1231 12311210	16-55	14AUG2020	50296	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
12311212	C4591001 1231 12311212	16-55	14AUG2020	50165	Placebo	14AUG2020/ Placebo	02SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
12311216	C4591001 1231 12311216	16-55	14AUG2020	50295	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12311217	C4591001 1231 12311217	16-55	14AUG2020	50285	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
12311218	C4591001 1231 12311218	16-55	14AUG2020	50317	Placebo	14AUG2020/ Placebo	02SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12311219	C4591001 1231 12311219	16-55	14AUG2020	50294	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12311221	C4591001 1231 12311221	16-55	14AUG2020	50173	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
12311222	C4591001 1231 12311222	16-55	14AUG2020	50315	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
12311224	C4591001 1231 12311224	16-55	14AUG2020	50319	Placebo	14AUG2020/ Placebo	03SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12311226	C4591001 1231 12311226	16-55	14AUG2020	50382	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
12311229	C4591001 1231 12311229	16-55	14AUG2020	50366	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
12311230	C4591001 1231 12311230	16-55	14AUG2020	50357	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo		
12311231	C4591001 1231 12311231	16-55	14AUG2020	50364	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
12311233	C4591001 1231 12311233	16-55	14AUG2020	50385	Placebo	14AUG2020/ Placebo	02SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12311237	C4591001 1231 12311237	16-55	14AUG2020	50392	Placebo	14AUG2020/ Placebo	02SEP2020/ Placebo		
12311238	C4591001 1231 12311238	16-55	14AUG2020	50587	Placebo	14AUG2020/ Placebo	02SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12311239	C4591001 1231 12311239	16-55	14AUG2020	50389	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
12311241	C4591001 1231 12311241	16-55	14AUG2020	50454	Placebo	14AUG2020/ Placebo	02SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12311246	C4591001 1231 12311246	16-55	14AUG2020	50460	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
12311247	C4591001 1231 12311247	16-55	14AUG2020	50589	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12311251	C4591001 1231 12311251	16-55	14AUG2020	50656	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
12311252	C4591001 1231 12311252	16-55	14AUG2020	50596	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
12311256	C4591001 1231 12311256	16-55	14AUG2020	50649	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12311259	C4591001 1231 12311259	16-55	14AUG2020	50707	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
12311263	C4591001 1231 12311263	16-55	14AUG2020	50825	Placebo	14AUG2020/ Placebo	02SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12311266	C4591001 1231 12311266	16-55	14AUG2020	50827	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12311268	C4591001 1231 12311268	16-55	14AUG2020	50754	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
12311272	C4591001 1231 12311272	16-55	14AUG2020	50764	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
12311273	C4591001 1231 12311273	16-55	14AUG2020	50835	Placebo	14AUG2020/ Placebo	02SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12311279	C4591001 1231 12311279	16-55	15AUG2020	51121	Placebo	15AUG2020/ Placebo	04SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12311281	C4591001 1231 12311281	16-55	15AUG2020	51134	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
12311282	C4591001 1231 12311282	16-55	15AUG2020	50984	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
12311283	C4591001 1231 12311283	16-55	15AUG2020	50987	Placebo	15AUG2020/ Placebo	04SEP2020/ Placebo		
12311284	C4591001 1231 12311284	16-55	15AUG2020	51155	Placebo	15AUG2020/ Placebo	03SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12311288	C4591001 1231 12311288	16-55	15AUG2020	51104	Placebo	15AUG2020/ Placebo	04SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12311289	C4591001 1231 12311289	16-55	15AUG2020	51115	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12311290	C4591001 1231 12311290	16-55	15AUG2020	51116	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
12311291	C4591001 1231 12311291	16-55	15AUG2020	51136	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
12311293	C4591001 1231 12311293	16-55	15AUG2020	51146	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
12311295	C4591001 1231 12311295	16-55	15AUG2020	51154	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
12311296	C4591001 1231 12311296	16-55	15AUG2020	51142	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
12311303	C4591001 1231 12311303	16-55	15AUG2020	51161	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
12311307	C4591001 1231 12311307	16-55	15AUG2020	51261	Placebo	15AUG2020/ Placebo	04SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12311308	C4591001 1231 12311308	16-55	15AUG2020	51170	Placebo	15AUG2020/ Placebo	03SEP2020/ Placebo		
12311309	C4591001 1231 12311309	16-55	15AUG2020	51281	Placebo	15AUG2020/ Placebo	03SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12311312	C4591001 1231 12311312	16-55	15AUG2020	51257	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12311315	C4591001 1231 12311315	16-55	15AUG2020	51255	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
12311321	C4591001 1231 12311321	16-55	15AUG2020	51251	Placebo	15AUG2020/ Placebo	03SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12311322	C4591001 1231 12311322	16-55	15AUG2020	51200	Placebo	15AUG2020/ Placebo	04SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
12311327	C4591001 1231 12311327	16-55	15AUG2020	51202	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
12311330	C4591001 1231 12311330	16-55	15AUG2020	51203	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
12311331	C4591001 1231 12311331	16-55	15AUG2020	51301	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
12311333	C4591001 1231 12311333	16-55	15AUG2020	51236	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
12311336	C4591001 1231 12311336	16-55	15AUG2020	51217	Placebo	15AUG2020/ Placebo	03SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12311337	C4591001 1231 12311337	16-55	15AUG2020	51233	Placebo	15AUG2020/ Placebo	03SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12311340	C4591001 1231 12311340	16-55	15AUG2020	51220	Placebo	15AUG2020/ Placebo	03SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12311341	C4591001 1231 12311341	16-55	15AUG2020	51327	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
12311342	C4591001 1231 12311342	16-55	15AUG2020	51267	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
12311343	C4591001 1231 12311343	16-55	15AUG2020	51286	Placebo	15AUG2020/ Placebo	03SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12311344	C4591001 1231 12311344	16-55	15AUG2020	51249	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
12311347	C4591001 1231 12311347	16-55	15AUG2020	51300	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
12311348	C4591001 1231 12311348	16-55	15AUG2020	51292	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
12311349	C4591001 1231 12311349	16-55	15AUG2020	51299	Placebo	15AUG2020/ Placebo	04SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12311350	C4591001 1231 12311350	16-55	15AUG2020	51373	Placebo	15AUG2020/ Placebo	04SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12311358	C4591001 1231 12311358	16-55	15AUG2020	51347	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
12311365	C4591001 1231 12311365	16-55	15AUG2020	51323	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12311366	C4591001 1231 12311366	16-55	15AUG2020	51378	Placebo	15AUG2020/ Placebo	04SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12311368	C4591001 1231 12311368	16-55	15AUG2020	51382	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
12311370	C4591001 1231 12311370	16-55	15AUG2020	51361	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
12311372	C4591001 1231 12311372	16-55	15AUG2020	51389	Placebo	15AUG2020/ Placebo	03SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
12311375	C4591001 1231 12311375	16-55	15AUG2020	51401	Placebo	15AUG2020/ Placebo	03SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12311377	C4591001 1231 12311377	16-55	15AUG2020	51350	Placebo	15AUG2020/ Placebo	03SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12311380	C4591001 1231 12311380	16-55	15AUG2020	51399	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
12311381	C4591001 1231 12311381	16-55	15AUG2020	51358	Placebo	15AUG2020/ Placebo	03SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12311383	C4591001 1231 12311383	16-55	15AUG2020	51403	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
12311384	C4591001 1231 12311384	16-55	15AUG2020	51404	Placebo	15AUG2020/ Placebo	04SEP2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12311386	C4591001 1231 12311386	16-55	15AUG2020	51408	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
12311388	C4591001 1231 12311388	16-55	15AUG2020	51427	Placebo	15AUG2020/ Placebo	03SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12311392	C4591001 1231 12311392	16-55	15AUG2020	51491	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
12311393	C4591001 1231 12311393	16-55	15AUG2020	51436	Placebo	15AUG2020/ Placebo	04SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12311395	C4591001 1231 12311395	16-55	15AUG2020	51485	Placebo	15AUG2020/ Placebo	04SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12311396	C4591001 1231 12311396	16-55	15AUG2020	51508	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
12311397	C4591001 1231 12311397	16-55	15AUG2020	51452	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
12311398	C4591001 1231 12311398	16-55	15AUG2020	51449	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
12311399	C4591001 1231 12311399	16-55	15AUG2020	51471	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
12311401	C4591001 1231 12311401	16-55	15AUG2020	51502	Placebo	15AUG2020/ Placebo	03SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12311411	C4591001 1231 12311411	16-55	15AUG2020	51489	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
12311413	C4591001 1231 12311413	16-55	15AUG2020	51476	Placebo	15AUG2020/ Placebo	03SEP2020/ Placebo		
12311414	C4591001 1231 12311414	16-55	15AUG2020	51478	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
12311418	C4591001 1231 12311418	16-55	15AUG2020	51515	Placebo	15AUG2020/ Placebo	04SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
12311425	C4591001 1231 12311425	16-55	15AUG2020	51511	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
12311427	C4591001 1231 12311427	16-55	15AUG2020	51538	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
12311436	C4591001 1231 12311436	16-55	15AUG2020	51542	Placebo	15AUG2020/ Placebo	03SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12311438	C4591001 1231 12311438	16-55	15AUG2020	51543	Placebo	15AUG2020/ Placebo	03SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12311439	C4591001 1231 12311439	16-55	15AUG2020	51671	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
12311440	C4591001 1231 12311440	16-55	15AUG2020	51564	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12311444	C4591001 1231 12311444	16-55	15AUG2020	51551	Placebo	15AUG2020/ Placebo	03SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12311446	C4591001 1231 12311446	16-55	15AUG2020	51560	Placebo	15AUG2020/ Placebo	03SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12311447	C4591001 1231 12311447	16-55	15AUG2020	51569	Placebo	15AUG2020/ Placebo	04SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12311451	C4591001 1231 12311451	16-55	15AUG2020	51565	Placebo	15AUG2020/ Placebo	03SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12311452	C4591001 1231 12311452	16-55	15AUG2020	51579	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
12311454	C4591001 1231 12311454	16-55	15AUG2020	51583	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
12311457	C4591001 1231 12311457	16-55	15AUG2020	51590	Placebo	15AUG2020/ Placebo	04SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12311458	C4591001 1231 12311458	16-55	15AUG2020	51596	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
12311459	C4591001 1231 12311459	16-55	15AUG2020	51600	Placebo	15AUG2020/ Placebo	03SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12311460	C4591001 1231 12311460	16-55	15AUG2020	51602	Placebo	15AUG2020/ Placebo	04SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12311461	C4591001 1231 12311461	16-55	15AUG2020	51603	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
12311464	C4591001 1231 12311464	16-55	15AUG2020	51612	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
12311465	C4591001 1231 12311465	16-55	15AUG2020	51620	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
12311466	C4591001 1231 12311466	16-55	15AUG2020	51614	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
12311468	C4591001 1231 12311468	16-55	15AUG2020	51661	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
12311474	C4591001 1231 12311474	16-55	15AUG2020	51635	Placebo	15AUG2020/ Placebo	03SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12311475	C4591001 1231 12311475	16-55	15AUG2020	51628	Placebo	15AUG2020/ Placebo	03SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12311479	C4591001 1231 12311479	16-55	15AUG2020	51645	Placebo	15AUG2020/ Placebo	04SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12311480	C4591001 1231 12311480	16-55	15AUG2020	51654	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
12311483	C4591001 1231 12311483	16-55	15AUG2020	51640	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12311484	C4591001 1231 12311484	16-55	15AUG2020	51665	Placebo	15AUG2020/ Placebo	03SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12311485	C4591001 1231 12311485	16-55	15AUG2020	51651	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
12311489	C4591001 1231 12311489	16-55	15AUG2020	51663	Placebo	15AUG2020/ Placebo	04SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	13FEB2021/ BNT162b2 (30 µg)
12311490	C4591001 1231 12311490	16-55	15AUG2020	51666	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
12311544	C4591001 1231 12311544	16-55	16AUG2020	51795	BNT162b2 (30 µg)	16AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
12311560	C4591001 1231 12311560	16-55	16AUG2020	51842	Placebo	16AUG2020/ Placebo	04SEP2020/ Placebo		
12311635	C4591001 1231 12311635	16-55	16AUG2020	52037	BNT162b2 (30 µg)	16AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
12311644	C4591001 1231 12311644	16-55	16AUG2020	52063	Placebo	16AUG2020/ Placebo	04SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12321002	C4591001 1232 12321002	16-55	12AUG2020	47299	Placebo	12AUG2020/ Placebo	02SEP2020/ Placebo		
12321003	C4591001 1232 12321003	16-55	12AUG2020	47303	Placebo	12AUG2020/ Placebo	02SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12321004	C4591001 1232 12321004	16-55	12AUG2020	47306	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
12321005	C4591001 1232 12321005	16-55	12AUG2020	47307	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
12321006	C4591001 1232 12321006	16-55	12AUG2020	47418	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
12321007	C4591001 1232 12321007	16-55	12AUG2020	47419	Placebo	12AUG2020/ Placebo	03SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
12321009	C4591001 1232 12321009	16-55	13AUG2020	47424	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo		
12321010	C4591001 1232 12321010	16-55	13AUG2020	47428	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
12321012	C4591001 1232 12321012	16-55	13AUG2020	48764	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
12321014	C4591001 1232 12321014	16-55	13AUG2020	48766	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
12321015	C4591001 1232 12321015	16-55	13AUG2020	48769	Placebo	13AUG2020/ Placebo			
12321018	C4591001 1232 12321018	16-55	13AUG2020	48770	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12321019	C4591001 1232 12321019	16-55	14AUG2020	50022	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
12321022	C4591001 1232 12321022	16-55	14AUG2020	50024	Placebo	14AUG2020/ Placebo	02SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
12321024	C4591001 1232 12321024	16-55	14AUG2020	50026	Placebo	14AUG2020/ Placebo	02SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
12321025	C4591001 1232 12321025	16-55	14AUG2020	50030	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
12321026	C4591001 1232 12321026	16-55	14AUG2020	50697	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
12411001	C4591001 1241 12411001	16-55	07AUG2020	44322	Placebo	07AUG2020/ Placebo	26AUG2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12411002	C4591001 1241 12411002	16-55	07AUG2020	44325	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
12411003	C4591001 1241 12411003	16-55	07AUG2020	44329	Placebo	07AUG2020/ Placebo	26AUG2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
12411004	C4591001 1241 12411004	16-55	07AUG2020	44331	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
12411005	C4591001 1241 12411005	16-55	07AUG2020	44419	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12411006	C4591001 1241 12411006	16-55	07AUG2020	44421	Placebo	07AUG2020/ Placebo	26AUG2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
12411007	C4591001 1241 12411007	16-55	07AUG2020	44422	Placebo	07AUG2020/ Placebo	26AUG2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
12411009	C4591001 1241 12411009	16-55	07AUG2020	44424	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
12411010	C4591001 1241 12411010	16-55	07AUG2020	44717	Placebo	07AUG2020/ Placebo	26AUG2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
12411011	C4591001 1241 12411011	16-55	07AUG2020	44718	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
12411012	C4591001 1241 12411012	16-55	10AUG2020	44723	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
12411013	C4591001 1241 12411013	16-55	10AUG2020	44726	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
12411014	C4591001 1241 12411014	16-55	10AUG2020	45149	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
12411016	C4591001 1241 12411016	16-55	10AUG2020	45150	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
12411017	C4591001 1241 12411017	16-55	10AUG2020	45154	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12411018	C4591001 1241 12411018	16-55	10AUG2020	45155	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
12411019	C4591001 1241 12411019	16-55	10AUG2020	45297	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
12411020	C4591001 1241 12411020	16-55	10AUG2020	45299	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
12411021	C4591001 1241 12411021	16-55	10AUG2020	45300	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12411022	C4591001 1241 12411022	16-55	10AUG2020	45302	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
12411023	C4591001 1241 12411023	16-55	10AUG2020	45588	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
12411024	C4591001 1241 12411024	16-55	10AUG2020	45589	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
12411025	C4591001 1241 12411025	16-55	10AUG2020	45590	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
12411026	C4591001 1241 12411026	16-55	10AUG2020	45591	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12411027	C4591001 1241 12411027	16-55	10AUG2020	45666	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12411028	C4591001 1241 12411028	16-55	10AUG2020	45667	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
12411029	C4591001 1241 12411029	16-55	10AUG2020	45668	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
12411030	C4591001 1241 12411030	16-55	10AUG2020	45673	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
12411031	C4591001 1241 12411031	16-55	10AUG2020	45812	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
12411032	C4591001 1241 12411032	16-55	11AUG2020	45818	Placebo	11AUG2020/ Placebo	03SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
12411033	C4591001 1241 12411033	16-55	11AUG2020	45819	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
12411034	C4591001 1241 12411034	16-55	11AUG2020	45820	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
12411036	C4591001 1241 12411036	16-55	11AUG2020	46163	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
12411037	C4591001 1241 12411037	16-55	11AUG2020	46158	Placebo	11AUG2020/ Placebo	01SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
12411038	C4591001 1241 12411038	16-55	11AUG2020	46164	Placebo	11AUG2020/ Placebo	01SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12411039	C4591001 1241 12411039	16-55	11AUG2020	46166	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
12411040	C4591001 1241 12411040	16-55	11AUG2020	46265	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
12411041	C4591001 1241 12411041	16-55	11AUG2020	46273	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
12411042	C4591001 1241 12411042	16-55	11AUG2020	46274	Placebo	11AUG2020/ Placebo	01SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
12411043	C4591001 1241 12411043	16-55	11AUG2020	46276	Placebo	11AUG2020/ Placebo	01SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
12411044	C4591001 1241 12411044	16-55	11AUG2020	46530	Placebo	11AUG2020/ Placebo	01SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12411045	C4591001 1241 12411045	16-55	11AUG2020	46533	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
12411046	C4591001 1241 12411046	16-55	11AUG2020	46535	Placebo	11AUG2020/ Placebo	01SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12411047	C4591001 1241 12411047	16-55	11AUG2020	46536	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
12411048	C4591001 1241 12411048	16-55	11AUG2020	46746	Placebo	11AUG2020/ Placebo	01SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12411049	C4591001 1241 12411049	16-55	11AUG2020	46750	Placebo	11AUG2020/ Placebo	01SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12411050	C4591001 1241 12411050	16-55	12AUG2020	46753	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
12411051	C4591001 1241 12411051	16-55	12AUG2020	46755	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
12411053	C4591001 1241 12411053	16-55	12AUG2020	47058	Placebo	12AUG2020/ Placebo	02SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
12411054	C4591001 1241 12411054	16-55	12AUG2020	47063	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
12411055	C4591001 1241 12411055	16-55	12AUG2020	47064	Placebo	12AUG2020/ Placebo	02SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
12411056	C4591001 1241 12411056	16-55	12AUG2020	47068	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
12411057	C4591001 1241 12411057	16-55	12AUG2020	47359	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
12411058	C4591001 1241 12411058	16-55	12AUG2020	47362	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
12411059	C4591001 1241 12411059	16-55	12AUG2020	47364	Placebo	12AUG2020/ Placebo	02SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12411060	C4591001 1241 12411060	16-55	12AUG2020	47367	Placebo	12AUG2020/ Placebo	02SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12411061	C4591001 1241 12411061	16-55	12AUG2020	47478	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
12411062	C4591001 1241 12411062	16-55	12AUG2020	47482	Placebo	12AUG2020/ Placebo	02SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12411063	C4591001 1241 12411063	16-55	12AUG2020	47484	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
12411064	C4591001 1241 12411064	16-55	12AUG2020	47488	Placebo	12AUG2020/ Placebo	02SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12411065	C4591001 1241 12411065	16-55	12AUG2020	47603	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
12411066	C4591001 1241 12411066	16-55	12AUG2020	47604	Placebo	12AUG2020/ Placebo	01SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12411068	C4591001 1241 12411068	16-55	12AUG2020	47605	Placebo	12AUG2020/ Placebo	02SEP2020/ Placebo		
12411069	C4591001 1241 12411069	16-55	12AUG2020	47729	Placebo	12AUG2020/ Placebo	02SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12411070	C4591001 1241 12411070	16-55	12AUG2020	47733	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12411071	C4591001 1241 12411071	16-55	12AUG2020	47734	Placebo	12AUG2020/ Placebo	02SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12411072	C4591001 1241 12411072	16-55	12AUG2020	47736	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
12411073	C4591001 1241 12411073	16-55	12AUG2020	47915	Placebo	12AUG2020/ Placebo	08SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12411074	C4591001 1241 12411074	16-55	12AUG2020	47916	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
12411075	C4591001 1241 12411075	16-55	12AUG2020	47918	Placebo	12AUG2020/ Placebo	02SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12411076	C4591001 1241 12411076	16-55	12AUG2020	47920	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
12411077	C4591001 1241 12411077	16-55	12AUG2020	47973	Placebo	12AUG2020/ Placebo	02SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
12411078	C4591001 1241 12411078	16-55	12AUG2020	47975	Placebo	12AUG2020/ Placebo	02SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12411079	C4591001 1241 12411079	16-55	12AUG2020	47976	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
12411080	C4591001 1241 12411080	16-55	12AUG2020	47979	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12411081	C4591001 1241 12411081	16-55	12AUG2020	48055	Placebo	12AUG2020/ Placebo	02SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12411082	C4591001 1241 12411082	16-55	12AUG2020	48059	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
12411083	C4591001 1241 12411083	16-55	13AUG2020	48063	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
12411084	C4591001 1241 12411084	16-55	13AUG2020	48064	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
12411085	C4591001 1241 12411085	16-55	13AUG2020	48262	Placebo	13AUG2020/ Placebo	01SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12411087	C4591001 1241 12411087	16-55	13AUG2020	48263	Placebo	13AUG2020/ Placebo	01SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12411088	C4591001 1241 12411088	16-55	13AUG2020	48265	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
12411089	C4591001 1241 12411089	16-55	13AUG2020	48267	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
12411090	C4591001 1241 12411090	16-55	13AUG2020	48462	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
12411091	C4591001 1241 12411091	16-55	13AUG2020	48464	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12411093	C4591001 1241 12411093	16-55	13AUG2020	48470	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
12411094	C4591001 1241 12411094	16-55	13AUG2020	48471	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12411095	C4591001 1241 12411095	16-55	13AUG2020	48906	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
12411096	C4591001 1241 12411096	16-55	13AUG2020	48907	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
12411097	C4591001 1241 12411097	16-55	13AUG2020	48910	Placebo	13AUG2020/ Placebo	02SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12411098	C4591001 1241 12411098	16-55	13AUG2020	48911	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
12411099	C4591001 1241 12411099	16-55	13AUG2020	49121	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
12411100	C4591001 1241 12411100	16-55	13AUG2020	49122	Placebo	13AUG2020/ Placebo	01SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12411101	C4591001 1241 12411101	16-55	13AUG2020	49123	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12411102	C4591001 1241 12411102	16-55	13AUG2020	49132	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12411103	C4591001 1241 12411103	16-55	13AUG2020	49195	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
12411106	C4591001 1241 12411106	16-55	13AUG2020	49197	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
12411108	C4591001 1241 12411108	16-55	13AUG2020	49200	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12411109	C4591001 1241 12411109	16-55	13AUG2020	49202	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
12411110	C4591001 1241 12411110	16-55	13AUG2020	49350	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
12411111	C4591001 1241 12411111	16-55	13AUG2020	49353	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
12411112	C4591001 1241 12411112	16-55	14AUG2020	49354	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
12411113	C4591001 1241 12411113	16-55	14AUG2020	49360	Placebo	14AUG2020/ Placebo	03SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12411114	C4591001 1241 12411114	16-55	14AUG2020	49830	Placebo	14AUG2020/ Placebo	03SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
12411116	C4591001 1241 12411116	16-55	14AUG2020	49831	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12411118	C4591001 1241 12411118	16-55	14AUG2020	49834	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12411119	C4591001 1241 12411119	16-55	14AUG2020	49837	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
12411120	C4591001 1241 12411120	16-55	14AUG2020	49973	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
12411122	C4591001 1241 12411122	16-55	14AUG2020	49976	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12411123	C4591001 1241 12411123	16-55	14AUG2020	49979	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
12411124	C4591001 1241 12411124	16-55	14AUG2020	49981	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
12411125	C4591001 1241 12411125	16-55	14AUG2020	50321	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
12411127	C4591001 1241 12411127	16-55	14AUG2020	50329	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12411129	C4591001 1241 12411129	16-55	14AUG2020	50330	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
12411130	C4591001 1241 12411130	16-55	14AUG2020	50479	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12411131	C4591001 1241 12411131	16-55	14AUG2020	50481	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12411133	C4591001 1241 12411133	16-55	14AUG2020	50488	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
12411136	C4591001 1241 12411136	16-55	14AUG2020	50543	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12411137	C4591001 1241 12411137	16-55	14AUG2020	50547	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
12411138	C4591001 1241 12411138	16-55	14AUG2020	50669	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
12411139	C4591001 1241 12411139	16-55	14AUG2020	50670	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
12411141	C4591001 1241 12411141	16-55	14AUG2020	50680	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12521001	C4591001 1252 12521001	16-55	12AUG2020	47646	Placebo	12AUG2020/ Placebo	31AUG2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
12521002	C4591001 1252 12521002	16-55	12AUG2020	47648	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
12521004	C4591001 1252 12521004	16-55	13AUG2020	47652	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10031140	C4591001 1003 10031140	16-55	04AUG2020	42131	Placebo				
10031143	C4591001 1003 10031143	16-55	04AUG2020	42136	BNT162b2 (30 µg)				
10051076	C4591001 1005 10051076	16-55	17AUG2020	50006	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10051077	C4591001 1005 10051077	16-55	17AUG2020	50008	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10051079	C4591001 1005 10051079	16-55	19AUG2020	55901	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
10051081	C4591001 1005 10051081	16-55	19AUG2020	55904	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10051082	C4591001 1005 10051082	16-55	19AUG2020	55905	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10051084	C4591001 1005 10051084	16-55	19AUG2020	55912	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
10051085	C4591001 1005 10051085	16-55	19AUG2020	57222	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
10051087	C4591001 1005 10051087	16-55	20AUG2020	57224	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10051093	C4591001 1005 10051093	16-55	20AUG2020	57225	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10051094	C4591001 1005 10051094	16-55	20AUG2020	57229	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
10051100	C4591001 1005 10051100	16-55	20AUG2020	59217	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10051101	C4591001 1005 10051101	16-55	20AUG2020	59214	Placebo	20AUG2020/ Placebo	08SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
10051105	C4591001 1005 10051105	16-55	21AUG2020	59220	Placebo	21AUG2020/ Placebo	10SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
10051106	C4591001 1005 10051106	16-55	21AUG2020	60019	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
10051107	C4591001 1005 10051107	16-55	21AUG2020	60025	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10051108	C4591001 1005 10051108	16-55	21AUG2020	60024	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
10051115	C4591001 1005 10051115	16-55	21AUG2020	60026	Placebo	21AUG2020/ Placebo	09SEP2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
10051117	C4591001 1005 10051117	16-55	21AUG2020	60516	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10051118	C4591001 1005 10051118	16-55	21AUG2020	60510	Placebo	21AUG2020/ Placebo	10SEP2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
10051119	C4591001 1005 10051119	16-55	24AUG2020	60517	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10051123	C4591001 1005 10051123	16-55	24AUG2020	60518	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10051125	C4591001 1005 10051125	16-55	24AUG2020	63763	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10051129	C4591001 1005 10051129	16-55	24AUG2020	63766	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10051134	C4591001 1005 10051134	16-55	24AUG2020	63769	Placebo	24AUG2020/ Placebo	15SEP2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
10051135	C4591001 1005 10051135	16-55	24AUG2020	63772	Placebo	24AUG2020/ Placebo	16SEP2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
10051142	C4591001 1005 10051142	16-55	25AUG2020	65566	Placebo	25AUG2020/ Placebo	14SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
10051144	C4591001 1005 10051144	16-55	25AUG2020	65570	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10051145	C4591001 1005 10051145	16-55	25AUG2020	65572	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10051146	C4591001 1005 10051146	16-55	25AUG2020	65571	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10051147	C4591001 1005 10051147	16-55	25AUG2020	66642	Placebo	25AUG2020/ Placebo	17SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
10051148	C4591001 1005 10051148	16-55	25AUG2020	66646	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10051150	C4591001 1005 10051150	16-55	26AUG2020	66647	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
10051151	C4591001 1005 10051151	16-55	26AUG2020	66652	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10051153	C4591001 1005 10051153	16-55	26AUG2020	67421	Placebo	26AUG2020/ Placebo	17SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10051161	C4591001 1005 10051161	16-55	26AUG2020	67422	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10051164	C4591001 1005 10051164	16-55	26AUG2020	67425	Placebo	26AUG2020/ Placebo	30SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
10051165	C4591001 1005 10051165	16-55	26AUG2020	67427	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10051166	C4591001 1005 10051166	16-55	26AUG2020	68664	Placebo	26AUG2020/ Placebo	15SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10051167	C4591001 1005 10051167	16-55	26AUG2020	68665	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10051168	C4591001 1005 10051168	16-55	27AUG2020	68666	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10051169	C4591001 1005 10051169	16-55	27AUG2020	68668	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
10051170	C4591001 1005 10051170	16-55	27AUG2020	69678	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
10051171	C4591001 1005 10051171	16-55	27AUG2020	69684	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10051175	C4591001 1005 10051175	16-55	27AUG2020	69686	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	28JAN2021/ BNT162b2 (30 µg)
10051178	C4591001 1005 10051178	16-55	28AUG2020	69688	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
10051179	C4591001 1005 10051179	16-55	28AUG2020	71693	Placebo	28AUG2020/ Placebo	17SEP2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
10051181	C4591001 1005 10051181	16-55	28AUG2020	71695	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
10051182	C4591001 1005 10051182	16-55	28AUG2020	71703	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10051183	C4591001 1005 10051183	16-55	31AUG2020	71704	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10051187	C4591001 1005 10051187	16-55	31AUG2020	76003	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10051188	C4591001 1005 10051188	16-55	01SEP2020	76004	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10051189	C4591001 1005 10051189	16-55	01SEP2020	76005	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
10051192	C4591001 1005 10051192	16-55	02SEP2020	76009	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10051198	C4591001 1005 10051198	16-55	03SEP2020	79548	Placebo	03SEP2020/ Placebo	25SEP2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
10051199	C4591001 1005 10051199	16-55	03SEP2020	79545	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10051200	C4591001 1005 10051200	16-55	03SEP2020	79549	Placebo	03SEP2020/ Placebo	23SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10051203	C4591001 1005 10051203	16-55	03SEP2020	79551	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10051210	C4591001 1005 10051210	16-55	03SEP2020	79914	Placebo	03SEP2020/ Placebo	22SEP2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10051212	C4591001 1005 10051212	16-55	03SEP2020	79915	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10051215	C4591001 1005 10051215	16-55	10SEP2020	80877	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
10051216	C4591001 1005 10051216	16-55	03SEP2020	79923	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
10051217	C4591001 1005 10051217	16-55	03SEP2020	79916	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10051219	C4591001 1005 10051219	16-55	03SEP2020	80873	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10051220	C4591001 1005 10051220	16-55	12OCT2020	80882	Placebo	12OCT2020/ Placebo	02NOV2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10051221	C4591001 1005 10051221	16-55	12OCT2020	106314	Placebo	12OCT2020/ Placebo	03NOV2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
10051222	C4591001 1005 10051222	16-55	12OCT2020	80878	BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		
10051223	C4591001 1005 10051223	16-55	12OCT2020	106316	BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
10051224	C4591001 1005 10051224	16-55	12OCT2020	106315	Placebo	12OCT2020/ Placebo	04NOV2020/ Placebo	06JAN2021/ BNT162b2 (30 µg)	27JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10051225	C4591001 1005 10051225	16-55	12OCT2020	106322	BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		
10051226	C4591001 1005 10051226	16-55	12OCT2020	106409	Placebo	12OCT2020/ Placebo	04NOV2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)
10051228	C4591001 1005 10051228	16-55	12OCT2020	106414	BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		
10051232	C4591001 1005 10051232	16-55	12OCT2020	106416	Placebo	12OCT2020/ Placebo	02NOV2020/ Placebo	02MAR2021/ BNT162b2 (30 µg)	
10051233	C4591001 1005 10051233	16-55	12OCT2020	106418	BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		
10051235	C4591001 1005 10051235	16-55	12OCT2020	106685	Placebo	12OCT2020/ Placebo	02NOV2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
10051236	C4591001 1005 10051236	16-55	13OCT2020	106687	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
10051237	C4591001 1005 10051237	16-55	13OCT2020	106691	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		
10051238	C4591001 1005 10051238	16-55	13OCT2020	106696	Placebo	13OCT2020/ Placebo	03NOV2020/ Placebo		
10051240	C4591001 1005 10051240	16-55	13OCT2020	107157	Placebo	13OCT2020/ Placebo	02NOV2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10051241	C4591001 1005 10051241	16-55	13OCT2020	107153	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
10051242	C4591001 1005 10051242	16-55	13OCT2020	107159	Placebo	13OCT2020/ Placebo	03NOV2020/ Placebo	03MAR2021/ BNT162b2 (30 µg)	
10051243	C4591001 1005 10051243	16-55	13OCT2020	107160	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
10051244	C4591001 1005 10051244	16-55	13OCT2020	107246	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		
10051245	C4591001 1005 10051245	16-55	13OCT2020	107245	Placebo	13OCT2020/ Placebo	03NOV2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
10051246	C4591001 1005 10051246	16-55	13OCT2020	107241	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		
10051248	C4591001 1005 10051248	16-55	14OCT2020	107248	Placebo	14OCT2020/ Placebo	03NOV2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
10051251	C4591001 1005 10051251	16-55	14OCT2020	107406	Placebo	14OCT2020/ Placebo	05NOV2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
10051254	C4591001 1005 10051254	16-55	14OCT2020	107409	Placebo	14OCT2020/ Placebo	05NOV2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
10051257	C4591001 1005 10051257	16-55	14OCT2020	107410	BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10051259	C4591001 1005 10051259	16-55	14OCT2020	107414	BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
10051260	C4591001 1005 10051260	16-55	14OCT2020	107790	BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
10051264	C4591001 1005 10051264	16-55	15OCT2020	107793	Placebo	15OCT2020/ Placebo	04NOV2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
10051267	C4591001 1005 10051267	16-55	15OCT2020	107796	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
10051268	C4591001 1005 10051268	16-55	15OCT2020	107797	Placebo	15OCT2020/ Placebo	05NOV2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
10051270	C4591001 1005 10051270	16-55	15OCT2020	108269	Placebo	15OCT2020/ Placebo	03NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10051273	C4591001 1005 10051273	16-55	15OCT2020	108272	Placebo	15OCT2020/ Placebo	03NOV2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
10051274	C4591001 1005 10051274	16-55	15OCT2020	108277	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
10051276	C4591001 1005 10051276	16-55	15OCT2020	108425	Placebo	15OCT2020/ Placebo	04NOV2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
10051277	C4591001 1005 10051277	16-55	15OCT2020	108278	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10051280	C4591001 1005 10051280	16-55	16OCT2020	108428	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
10051281	C4591001 1005 10051281	16-55	16OCT2020	108429	Placebo	16OCT2020/ Placebo	06NOV2020/ Placebo	03MAR2021/ BNT162b2 (30 µg)	
10051283	C4591001 1005 10051283	16-55	16OCT2020	108430	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
10051285	C4591001 1005 10051285	16-55	16OCT2020	109004	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
10051288	C4591001 1005 10051288	16-55	16OCT2020	109006	Placebo	16OCT2020/ Placebo	06NOV2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10051289	C4591001 1005 10051289	16-55	16OCT2020	109010	Placebo	16OCT2020/ Placebo	04NOV2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
10051290	C4591001 1005 10051290	16-55	16OCT2020	109012	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
10051291	C4591001 1005 10051291	16-55	19OCT2020	109823	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
10051292	C4591001 1005 10051292	16-55	19OCT2020	109825	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
10051294	C4591001 1005 10051294	16-55	19OCT2020	109827	Placebo	19OCT2020/ Placebo	10NOV2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10051295	C4591001 1005 10051295	16-55	19OCT2020	109828	Placebo	19OCT2020/ Placebo	09NOV2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
10051301	C4591001 1005 10051301	16-55	19OCT2020	110106	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
10051302	C4591001 1005 10051302	16-55	19OCT2020	110107	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
10051308	C4591001 1005 10051308	16-55	19OCT2020	110110	Placebo	19OCT2020/ Placebo			
10051310	C4591001 1005 10051310	16-55	19OCT2020	110114	Placebo	19OCT2020/ Placebo	09NOV2020/ Placebo		
10051311	C4591001 1005 10051311	16-55	19OCT2020	110432	Placebo	19OCT2020/ Placebo	09NOV2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
10051314	C4591001 1005 10051314	16-55	19OCT2020	110435	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
10051315	C4591001 1005 10051315	16-55	20OCT2020	110436	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
10051316	C4591001 1005 10051316	16-55	20OCT2020	110440	Placebo	20OCT2020/ Placebo	11NOV2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)
10051318	C4591001 1005 10051318	16-55	20OCT2020	110705	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10051322	C4591001 1005 10051322	16-55	20OCT2020	110707	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		
10051323	C4591001 1005 10051323	16-55	20OCT2020	110712	Placebo	20OCT2020/ Placebo	09NOV2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
10051326	C4591001 1005 10051326	16-55	20OCT2020	110716	Placebo	20OCT2020/ Placebo	10NOV2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)
10051331	C4591001 1005 10051331	16-55	20OCT2020	110911	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		
10051332	C4591001 1005 10051332	16-55	20OCT2020	110913	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		
10051335	C4591001 1005 10051335	16-55	21OCT2020	110915	Placebo	21OCT2020/ Placebo	11NOV2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
10051340	C4591001 1005 10051340	16-55	21OCT2020	110919	Placebo	21OCT2020/ Placebo	11NOV2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
10051341	C4591001 1005 10051341	16-55	21OCT2020	111573	Placebo	21OCT2020/ Placebo		12JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)
10051343	C4591001 1005 10051343	16-55	21OCT2020	111578	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
10051345	C4591001 1005 10051345	16-55	21OCT2020	111579	Placebo	21OCT2020/ Placebo	12NOV2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10051346	C4591001 1005 10051346	16-55	21OCT2020	111580	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
10051349	C4591001 1005 10051349	16-55	22OCT2020	112037	Placebo	22OCT2020/ Placebo	11NOV2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10051350	C4591001 1005 10051350	16-55	22OCT2020	112038	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
10051354	C4591001 1005 10051354	16-55	22OCT2020	112040	Placebo	22OCT2020/ Placebo	12NOV2020/ Placebo	06JAN2021/ BNT162b2 (30 µg)	27JAN2021/ BNT162b2 (30 µg)
10051356	C4591001 1005 10051356	16-55	22OCT2020	112042	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
10051357	C4591001 1005 10051357	16-55	22OCT2020	112290	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
10051358	C4591001 1005 10051358	16-55	22OCT2020	112295	Placebo	22OCT2020/ Placebo	13NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10051361	C4591001 1005 10051361	16-55	22OCT2020	112297	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
10051362	C4591001 1005 10051362	16-55	23OCT2020	112300	Placebo	23OCT2020/ Placebo	13NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10051363	C4591001 1005 10051363	16-55	23OCT2020	112711	Placebo	23OCT2020/ Placebo	13NOV2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10051364	C4591001 1005 10051364	16-55	23OCT2020	112714	Placebo	23OCT2020/ Placebo	13NOV2020/ Placebo	06JAN2021/ BNT162b2 (30 µg)	27JAN2021/ BNT162b2 (30 µg)
10051365	C4591001 1005 10051365	16-55	23OCT2020	112715	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
10051366	C4591001 1005 10051366	16-55	23OCT2020	112717	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
10051368	C4591001 1005 10051368	16-55	23OCT2020	112976	Placebo	23OCT2020/ Placebo	13NOV2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
10051369	C4591001 1005 10051369	16-55	26OCT2020	112979	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	18NOV2020/ BNT162b2 (30 µg)		
10051370	C4591001 1005 10051370	16-55	26OCT2020	112984	Placebo	26OCT2020/ Placebo	16NOV2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
10051371	C4591001 1005 10051371	16-55	26OCT2020	112983	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
10051377	C4591001 1005 10051377	16-55	27OCT2020	113982	Placebo	27OCT2020/ Placebo	17NOV2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
10051378	C4591001 1005 10051378	16-55	27OCT2020	113984	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
10051380	C4591001 1005 10051380	16-55	27OCT2020	113991	Placebo	27OCT2020/ Placebo	17NOV2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10051381	C4591001 1005 10051381	16-55	28OCT2020	113992	BNT162b2 (30 µg)				
10051385	C4591001 1005 10051385	16-55	28OCT2020	114463	BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
10051386	C4591001 1005 10051386	16-55	28OCT2020	114465	Placebo	28OCT2020/ Placebo	17NOV2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
10051390	C4591001 1005 10051390	16-55	30OCT2020	273647	Placebo	30OCT2020/ Placebo	18NOV2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
10051393	C4591001 1005 10051393	16-55	30OCT2020	114466	BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)	20NOV2020/ BNT162b2 (30 µg)		
10051394	C4591001 1005 10051394	16-55	02NOV2020	114472	Placebo	02NOV2020/ Placebo	23NOV2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
10051396	C4591001 1005 10051396	16-55	02NOV2020	115315	BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)	23NOV2020/ BNT162b2 (30 µg)		
10051397	C4591001 1005 10051397	16-55	02NOV2020	115317	Placebo	02NOV2020/ Placebo	23NOV2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10051398	C4591001 1005 10051398	16-55	03NOV2020	115318	Placebo	03NOV2020/ Placebo	24NOV2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
10051400	C4591001 1005 10051400	16-55	03NOV2020	115320	BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)	23NOV2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10051407	C4591001 1005 10051407	16-55	11NOV2020	116093	Placebo	11NOV2020/ Placebo	03DEC2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
10051408	C4591001 1005 10051408	16-55	11NOV2020	116096	BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)	03DEC2020/ BNT162b2 (30 µg)		
10051409	C4591001 1005 10051409	16-55	09DEC2020	116098	Placebo	09DEC2020/ Placebo	29DEC2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
10051411	C4591001 1005 10051411	16-55	08JAN2021	117970	BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)	28JAN2021/ BNT162b2 (30 µg)		
10051416	C4591001 1005 10051416	16-55	16DEC2020	116101	BNT162b2 (30 µg)	16DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)		
10051423	C4591001 1005 10051423	16-55	17DEC2020	117906	Placebo	17DEC2020/ Placebo	07JAN2021/ Placebo	17FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
10051426	C4591001 1005 10051426	16-55	21DEC2020	117907	BNT162b2 (30 µg)	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)		
10051432	C4591001 1005 10051432	16-55	22DEC2020	117910	BNT162b2 (30 µg)	22DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)		
10051433	C4591001 1005 10051433	16-55	22DEC2020	117911	Placebo	22DEC2020/ Placebo	13JAN2021/ Placebo	18FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
10051434	C4591001 1005 10051434	16-55	22DEC2020	117954	BNT162b2 (30 µg)	22DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10051435	C4591001 1005 10051435	16-55	22DEC2020	117955	Placebo	22DEC2020/ Placebo	12JAN2021/ Placebo	15FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
10051442	C4591001 1005 10051442	16-55	22DEC2020	117959	BNT162b2 (30 µg)	22DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)		
10051443	C4591001 1005 10051443	16-55	22DEC2020	117962	Placebo	22DEC2020/ Placebo	13JAN2021/ Placebo		
10051446	C4591001 1005 10051446	16-55	22DEC2020	117967	Placebo	22DEC2020/ Placebo	12JAN2021/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
10061040	C4591001 1006 10061040	16-55	14AUG2020	50870	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
10061041	C4591001 1006 10061041	16-55	14AUG2020	50871	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
10061043	C4591001 1006 10061043	16-55	17AUG2020	50872	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10061050	C4591001 1006 10061050	16-55	17AUG2020	53731	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10061052	C4591001 1006 10061052	16-55	18AUG2020	53735	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
10061053	C4591001 1006 10061053	16-55	18AUG2020	53737	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10061054	C4591001 1006 10061054	16-55	18AUG2020	53738	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
10061055	C4591001 1006 10061055	16-55	18AUG2020	54787	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10061056	C4591001 1006 10061056	16-55	18AUG2020	54791	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
10061057	C4591001 1006 10061057	16-55	18AUG2020	54788	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10061061	C4591001 1006 10061061	16-55	18AUG2020	54792	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
10061062	C4591001 1006 10061062	16-55	18AUG2020	55590	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10061066	C4591001 1006 10061066	16-55	19AUG2020	55592	Placebo	19AUG2020/ Placebo	14SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
10061067	C4591001 1006 10061067	16-55	19AUG2020	55593	Placebo	19AUG2020/ Placebo	08SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
10061068	C4591001 1006 10061068	16-55	19AUG2020	55595	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10061070	C4591001 1006 10061070	16-55	19AUG2020	57392	Placebo	19AUG2020/ Placebo	02OCT2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10061071	C4591001 1006 10061071	16-55	19AUG2020	57393	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10061073	C4591001 1006 10061073	16-55	19AUG2020	57394	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
10061074	C4591001 1006 10061074	16-55	19AUG2020	57395	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10061075	C4591001 1006 10061075	16-55	20AUG2020	58337	Placebo	20AUG2020/ Placebo	09SEP2020/ Placebo		
10061078	C4591001 1006 10061078	16-55	20AUG2020	58342	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo		
10061079	C4591001 1006 10061079	16-55	20AUG2020	58343	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10061081	C4591001 1006 10061081	16-55	20AUG2020	58344	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
10061084	C4591001 1006 10061084	16-55	20AUG2020	59827	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10061088	C4591001 1006 10061088	16-55	21AUG2020	59828	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
10061089	C4591001 1006 10061089	16-55	21AUG2020	59831	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10061090	C4591001 1006 10061090	16-55	21AUG2020	59835	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
10061091	C4591001 1006 10061091	16-55	21AUG2020	61613	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)
10061092	C4591001 1006 10061092	16-55	21AUG2020	61614	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
10061093	C4591001 1006 10061093	16-55	24AUG2020	61616	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
10061094	C4591001 1006 10061094	16-55	24AUG2020	61617	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
10061095	C4591001 1006 10061095	16-55	24AUG2020	63883	Placebo	24AUG2020/ Placebo	15SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10061096	C4591001 1006 10061096	16-55	24AUG2020	63885	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
10061099	C4591001 1006 10061099	16-55	24AUG2020	63886	Placebo	24AUG2020/ Placebo	15SEP2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
10061100	C4591001 1006 10061100	16-55	24AUG2020	63892	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10061102	C4591001 1006 10061102	16-55	24AUG2020	64939	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10061103	C4591001 1006 10061103	16-55	24AUG2020	64940	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10061104	C4591001 1006 10061104	16-55	25AUG2020	64944	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10061106	C4591001 1006 10061106	16-55	25AUG2020	64947	Placebo	25AUG2020/ Placebo	14SEP2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10061107	C4591001 1006 10061107	16-55	25AUG2020	66439	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10061108	C4591001 1006 10061108	16-55	25AUG2020	66442	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
10061109	C4591001 1006 10061109	16-55	25AUG2020	66446	Placebo	25AUG2020/ Placebo	14SEP2020/ Placebo		
10061110	C4591001 1006 10061110	16-55	25AUG2020	66447	Placebo	25AUG2020/ Placebo	17SEP2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
10061112	C4591001 1006 10061112	16-55	26AUG2020	67556	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10061113	C4591001 1006 10061113	16-55	26AUG2020	67557	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10061114	C4591001 1006 10061114	16-55	26AUG2020	67561	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10061116	C4591001 1006 10061116	16-55	26AUG2020	67562	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
10061117	C4591001 1006 10061117	16-55	26AUG2020	69344	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10061118	C4591001 1006 10061118	16-55	27AUG2020	69346	Placebo	27AUG2020/ Placebo	18SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10061122	C4591001 1006 10061122	16-55	27AUG2020	69348	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
10061124	C4591001 1006 10061124	16-55	28AUG2020	69350	Placebo	28AUG2020/ Placebo	21SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10061128	C4591001 1006 10061128	16-55	28AUG2020	73077	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
10061129	C4591001 1006 10061129	16-55	28AUG2020	73076	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10061130	C4591001 1006 10061130	16-55	28AUG2020	73081	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	31DEC2020/ BNT162b2 (30 µg)	20JAN2021/ BNT162b2 (30 µg)
10061131	C4591001 1006 10061131	16-55	28AUG2020	73083	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
10061133	C4591001 1006 10061133	16-55	31AUG2020	74861	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10061134	C4591001 1006 10061134	16-55	01SEP2020	74865	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10061136	C4591001 1006 10061136	16-55	01SEP2020	74866	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10061137	C4591001 1006 10061137	16-55	01SEP2020	74868	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10061138	C4591001 1006 10061138	16-55	02SEP2020	78067	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
10061140	C4591001 1006 10061140	16-55	02SEP2020	78074	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10061141	C4591001 1006 10061141	16-55	03SEP2020	78076	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
10061142	C4591001 1006 10061142	16-55	03SEP2020	80753	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
10061144	C4591001 1006 10061144	16-55	03SEP2020	80757	Placebo	03SEP2020/ Placebo	22SEP2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
10061148	C4591001 1006 10061148	16-55	11SEP2020	80761	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10061151	C4591001 1006 10061151	16-55	22SEP2020	80763	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10061152	C4591001 1006 10061152	16-55	22SEP2020	97097	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
10061153	C4591001 1006 10061153	16-55	23SEP2020	97102	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
10061154	C4591001 1006 10061154	16-55	23SEP2020	97105	Placebo	23SEP2020/ Placebo	12OCT2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
10061155	C4591001 1006 10061155	16-55	29SEP2020	101552	Placebo	29SEP2020/ Placebo	22OCT2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
10061156	C4591001 1006 10061156	16-55	24SEP2020	97108	Placebo	24SEP2020/ Placebo	14OCT2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
10061159	C4591001 1006 10061159	16-55	24SEP2020	99089	Placebo	24SEP2020/ Placebo	16OCT2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
10061160	C4591001 1006 10061160	16-55	25SEP2020	99094	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
10061161	C4591001 1006 10061161	16-55	25SEP2020	99095	Placebo	25SEP2020/ Placebo	17OCT2020/ Placebo		
10061162	C4591001 1006 10061162	16-55	25SEP2020	99100	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
10061163	C4591001 1006 10061163	16-55	25SEP2020	100532	Placebo	25SEP2020/ Placebo	15OCT2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10061164	C4591001 1006 10061164	16-55	25SEP2020	100535	Placebo	25SEP2020/ Placebo	15OCT2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10061165	C4591001 1006 10061165	16-55	25SEP2020	100536	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
10061166	C4591001 1006 10061166	16-55	25SEP2020	100538	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
10061167	C4591001 1006 10061167	16-55	28SEP2020	101549	BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)		
10061169	C4591001 1006 10061169	16-55	02OCT2020	101554	Placebo	02OCT2020/ Placebo	23OCT2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
10061170	C4591001 1006 10061170	16-55	05OCT2020	101559	BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
10061171	C4591001 1006 10061171	16-55	08OCT2020	105593	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		
10061173	C4591001 1006 10061173	16-55	09OCT2020	105598	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)		
10061174	C4591001 1006 10061174	16-55	12OCT2020	105601	Placebo	12OCT2020/ Placebo	02NOV2020/ Placebo		
10061176	C4591001 1006 10061176	16-55	27OCT2020	105602	Placebo	27OCT2020/ Placebo	19NOV2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10061179	C4591001 1006 10061179	16-55	30OCT2020	115137	Placebo	30OCT2020/ Placebo	20NOV2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10061180	C4591001 1006 10061180	16-55	06NOV2020	115140	BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)	25NOV2020/ BNT162b2 (30 µg)		
10061181	C4591001 1006 10061181	16-55	13NOV2020	115141	Placebo	13NOV2020/ Placebo	04DEC2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
10061182	C4591001 1006 10061182	16-55	30NOV2020	115143	BNT162b2 (30 µg)	30NOV2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)		
10061185	C4591001 1006 10061185	16-55	30NOV2020	117101	BNT162b2 (30 µg)	30NOV2020/ BNT162b2 (30 µg)	21DEC2020/ BNT162b2 (30 µg)		
10061186	C4591001 1006 10061186	16-55	01DEC2020	117109	Placebo	01DEC2020/ Placebo	21DEC2020/ Placebo		
10061187	C4591001 1006 10061187	16-55	01DEC2020	117110	Placebo	01DEC2020/ Placebo	28DEC2020/ Placebo	03MAR2021/ BNT162b2 (30 µg)	
10061192	C4591001 1006 10061192	16-55	02DEC2020	117112	BNT162b2 (30 µg)	02DEC2020/ BNT162b2 (30 µg)	22DEC2020/ BNT162b2 (30 µg)		
10061193	C4591001 1006 10061193	16-55	02DEC2020	117245	BNT162b2 (30 µg)	02DEC2020/ BNT162b2 (30 µg)	21DEC2020/ BNT162b2 (30 µg)		
10061194	C4591001 1006 10061194	16-55	02DEC2020	117248	Placebo	02DEC2020/ Placebo	23DEC2020/ Placebo	03MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10061195	C4591001 1006 10061195	16-55	02DEC2020	117251	BNT162b2 (30 µg)	02DEC2020/ BNT162b2 (30 µg)	21DEC2020/ BNT162b2 (30 µg)		
10061197	C4591001 1006 10061197	16-55	03DEC2020	117252	Placebo	03DEC2020/ Placebo	22DEC2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
10061199	C4591001 1006 10061199	16-55	03DEC2020	117378	BNT162b2 (30 µg)	03DEC2020/ BNT162b2 (30 µg)	22DEC2020/ BNT162b2 (30 µg)		
10061202	C4591001 1006 10061202	16-55	03DEC2020	117380	BNT162b2 (30 µg)	03DEC2020/ BNT162b2 (30 µg)	22DEC2020/ BNT162b2 (30 µg)		
10061204	C4591001 1006 10061204	16-55	03DEC2020	117381	Placebo	03DEC2020/ Placebo	22DEC2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
10061205	C4591001 1006 10061205	16-55	03DEC2020	117383	Placebo	03DEC2020/ Placebo	24DEC2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
10061208	C4591001 1006 10061208	16-55	04DEC2020	117557	Placebo	04DEC2020/ Placebo	23DEC2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
10061210	C4591001 1006 10061210	16-55	04DEC2020	117561	BNT162b2 (30 µg)	04DEC2020/ BNT162b2 (30 µg)	23DEC2020/ BNT162b2 (30 µg)		
10061211	C4591001 1006 10061211	16-55	04DEC2020	117562	BNT162b2 (30 µg)	04DEC2020/ BNT162b2 (30 µg)	23DEC2020/ BNT162b2 (30 µg)		
10061215	C4591001 1006 10061215	16-55	04DEC2020	117563	Placebo	04DEC2020/ Placebo	22JAN2021/ Placebo	24FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10061216	C4591001 1006 10061216	16-55	04DEC2020	117629	Placebo	04DEC2020/ Placebo	23DEC2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
10061217	C4591001 1006 10061217	16-55	04DEC2020	117633	Placebo	04DEC2020/ Placebo	24DEC2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
10061218	C4591001 1006 10061218	16-55	07DEC2020	117634	BNT162b2 (30 µg)	07DEC2020/ BNT162b2 (30 µg)	28DEC2020/ BNT162b2 (30 µg)		
10061222	C4591001 1006 10061222	16-55	07DEC2020	117639	BNT162b2 (30 µg)	07DEC2020/ BNT162b2 (30 µg)	30DEC2020/ BNT162b2 (30 µg)		
10061225	C4591001 1006 10061225	16-55	07DEC2020	117713	BNT162b2 (30 µg)	07DEC2020/ BNT162b2 (30 µg)	28DEC2020/ BNT162b2 (30 µg)		
10061238	C4591001 1006 10061238	16-55	09DEC2020	117719	Placebo	09DEC2020/ Placebo	30DEC2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
10061240	C4591001 1006 10061240	16-55	09DEC2020	117722	BNT162b2 (30 µg)	09DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)		
10061246	C4591001 1006 10061246	16-55	10DEC2020	117724	Placebo	10DEC2020/ Placebo	29DEC2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
10061255	C4591001 1006 10061255	16-55	11DEC2020	117895	BNT162b2 (30 µg)	11DEC2020/ BNT162b2 (30 µg)	30DEC2020/ BNT162b2 (30 µg)		
10071203	C4591001 1007 10071203	16-55	17AUG2020	49345	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10071204	C4591001 1007 10071204	16-55	17AUG2020	49347	Placebo	17AUG2020/ Placebo	09SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
10071206	C4591001 1007 10071206	16-55	17AUG2020	49348	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10071207	C4591001 1007 10071207	16-55	17AUG2020	52985	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10071208	C4591001 1007 10071208	16-55	17AUG2020	52986	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10071211	C4591001 1007 10071211	16-55	17AUG2020	52987	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
10071212	C4591001 1007 10071212	16-55	17AUG2020	52994	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo		
10071214	C4591001 1007 10071214	16-55	17AUG2020	53133	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10071217	C4591001 1007 10071217	16-55	19AUG2020	53135	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	27JAN2021/ BNT162b2 (30 µg)
10071218	C4591001 1007 10071218	16-55	19AUG2020	53136	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo		
10071219	C4591001 1007 10071219	16-55	19AUG2020	53139	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10071221	C4591001 1007 10071221	16-55	19AUG2020	56214	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
10071225	C4591001 1007 10071225	16-55	19AUG2020	56220	Placebo	19AUG2020/ Placebo	08SEP2020/ Placebo		
10071227	C4591001 1007 10071227	16-55	19AUG2020	56224	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10071228	C4591001 1007 10071228	16-55	19AUG2020	56853	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
10071229	C4591001 1007 10071229	16-55	19AUG2020	56854	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
10071230	C4591001 1007 10071230	16-55	19AUG2020	56857	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10071231	C4591001 1007 10071231	16-55	19AUG2020	56855	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10071232	C4591001 1007 10071232	16-55	20AUG2020	58098	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10071233	C4591001 1007 10071233	16-55	20AUG2020	58099	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
10071235	C4591001 1007 10071235	16-55	20AUG2020	58101	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10071236	C4591001 1007 10071236	16-55	20AUG2020	58108	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10071238	C4591001 1007 10071238	16-55	20AUG2020	58474	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10071240	C4591001 1007 10071240	16-55	20AUG2020	58478	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10071243	C4591001 1007 10071243	16-55	20AUG2020	58475	Placebo	20AUG2020/ Placebo	09SEP2020/ Placebo		
10071246	C4591001 1007 10071246	16-55	20AUG2020	58480	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
10071250	C4591001 1007 10071250	16-55	24AUG2020	63416	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10071251	C4591001 1007 10071251	16-55	24AUG2020	63418	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10071252	C4591001 1007 10071252	16-55	24AUG2020	63420	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
10071253	C4591001 1007 10071253	16-55	24AUG2020	63422	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)
10071256	C4591001 1007 10071256	16-55	24AUG2020	63989	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10071258	C4591001 1007 10071258	16-55	24AUG2020	63993	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10071264	C4591001 1007 10071264	16-55	26AUG2020	63997	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10071266	C4591001 1007 10071266	16-55	26AUG2020	63999	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo		
10071269	C4591001 1007 10071269	16-55	26AUG2020	67664	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo		
10071270	C4591001 1007 10071270	16-55	26AUG2020	67667	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10071272	C4591001 1007 10071272	16-55	26AUG2020	67668	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
10071275	C4591001 1007 10071275	16-55	26AUG2020	67671	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10071276	C4591001 1007 10071276	16-55	26AUG2020	68489	Placebo	26AUG2020/ Placebo	17SEP2020/ Placebo		
10071278	C4591001 1007 10071278	16-55	26AUG2020	68492	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10071280	C4591001 1007 10071280	16-55	27AUG2020	68493	Placebo	27AUG2020/ Placebo	23SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10071281	C4591001 1007 10071281	16-55	27AUG2020	68495	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10071284	C4591001 1007 10071284	16-55	27AUG2020	69885	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10071285	C4591001 1007 10071285	16-55	27AUG2020	69888	Placebo	27AUG2020/ Placebo	16SEP2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
10071286	C4591001 1007 10071286	16-55	27AUG2020	69889	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo		
10071289	C4591001 1007 10071289	16-55	27AUG2020	69892	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10071295	C4591001 1007 10071295	16-55	27AUG2020	70845	Placebo	27AUG2020/ Placebo	16SEP2020/ Placebo		
10071296	C4591001 1007 10071296	16-55	27AUG2020	70844	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
10071307	C4591001 1007 10071307	16-55	12OCT2020	70846	BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		
10071309	C4591001 1007 10071309	16-55	12OCT2020	70848	BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		
10071334	C4591001 1007 10071334	16-55	14OCT2020	107694	BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10071337	C4591001 1007 10071337	16-55	14OCT2020	107700	Placebo	14OCT2020/ Placebo	04NOV2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
10071339	C4591001 1007 10071339	16-55	14OCT2020	107702	Placebo	14OCT2020/ Placebo	03NOV2020/ Placebo		
10071340	C4591001 1007 10071340	16-55	14OCT2020	107703	BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
10071341	C4591001 1007 10071341	16-55	14OCT2020	107807	Placebo	14OCT2020/ Placebo	04NOV2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
10071342	C4591001 1007 10071342	16-55	15OCT2020	107809	Placebo	15OCT2020/ Placebo	05NOV2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
10071350	C4591001 1007 10071350	16-55	15OCT2020	107810	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
10071352	C4591001 1007 10071352	16-55	15OCT2020	108452	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
10071353	C4591001 1007 10071353	16-55	15OCT2020	107811	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
10071358	C4591001 1007 10071358	16-55	19OCT2020	108457	Placebo	19OCT2020/ Placebo	10NOV2020/ Placebo	06JAN2021/ BNT162b2 (30 µg)	27JAN2021/ BNT162b2 (30 µg)
10071362	C4591001 1007 10071362	16-55	19OCT2020	108459	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10071363	C4591001 1007 10071363	16-55	19OCT2020	108458	Placebo	19OCT2020/ Placebo	09NOV2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	28JAN2021/ BNT162b2 (30 µg)
10071365	C4591001 1007 10071365	16-55	19OCT2020	110369	Placebo	19OCT2020/ Placebo	09NOV2020/ Placebo	03MAR2021/ BNT162b2 (30 µg)	
10071366	C4591001 1007 10071366	16-55	19OCT2020	110371	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
10071367	C4591001 1007 10071367	16-55	19OCT2020	110489	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
10071368	C4591001 1007 10071368	16-55	19OCT2020	110375	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
10071369	C4591001 1007 10071369	16-55	19OCT2020	110377	Placebo	19OCT2020/ Placebo	09NOV2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
10071370	C4591001 1007 10071370	16-55	20OCT2020	110490	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		
10071373	C4591001 1007 10071373	16-55	20OCT2020	110500	Placebo	20OCT2020/ Placebo	10NOV2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
10071374	C4591001 1007 10071374	16-55	20OCT2020	110496	Placebo	20OCT2020/ Placebo	10NOV2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
10071376	C4591001 1007 10071376	16-55	20OCT2020	110825	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10071377	C4591001 1007 10071377	16-55	20OCT2020	110831	Placebo	20OCT2020/ Placebo	10NOV2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
10071378	C4591001 1007 10071378	16-55	20OCT2020	110827	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		
10071380	C4591001 1007 10071380	16-55	20OCT2020	110833	Placebo	20OCT2020/ Placebo	10NOV2020/ Placebo		
10071381	C4591001 1007 10071381	16-55	20OCT2020	111017	Placebo	20OCT2020/ Placebo	09NOV2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
10071382	C4591001 1007 10071382	16-55	20OCT2020	111021	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
10071385	C4591001 1007 10071385	16-55	20OCT2020	111025	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		
10071386	C4591001 1007 10071386	16-55	21OCT2020	111027	Placebo	21OCT2020/ Placebo	11NOV2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
10071387	C4591001 1007 10071387	16-55	21OCT2020	111347	Placebo	21OCT2020/ Placebo	11NOV2020/ Placebo		
10071388	C4591001 1007 10071388	16-55	21OCT2020	111342	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
10071389	C4591001 1007 10071389	16-55	21OCT2020	111350	Placebo	21OCT2020/ Placebo	11NOV2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10071390	C4591001 1007 10071390	16-55	21OCT2020	111351	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
10071391	C4591001 1007 10071391	16-55	21OCT2020	111492	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
10071392	C4591001 1007 10071392	16-55	21OCT2020	111493	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
10071397	C4591001 1007 10071397	16-55	21OCT2020	111494	Placebo	21OCT2020/ Placebo	11NOV2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
10071398	C4591001 1007 10071398	16-55	21OCT2020	111766	Placebo	21OCT2020/ Placebo	11NOV2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
10071399	C4591001 1007 10071399	16-55	21OCT2020	111495	Placebo	21OCT2020/ Placebo	11NOV2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	28JAN2021/ BNT162b2 (30 µg)
10071400	C4591001 1007 10071400	16-55	21OCT2020	111769	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
10071401	C4591001 1007 10071401	16-55	21OCT2020	111812	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
10071402	C4591001 1007 10071402	16-55	21OCT2020	111771	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
10071403	C4591001 1007 10071403	16-55	21OCT2020	111772	Placebo	21OCT2020/ Placebo	11NOV2020/ Placebo	03MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10071404	C4591001 1007 10071404	16-55	21OCT2020	111814	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
10071405	C4591001 1007 10071405	16-55	22OCT2020	111816	Placebo	22OCT2020/ Placebo	12NOV2020/ Placebo		
10071406	C4591001 1007 10071406	16-55	22OCT2020	112064	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
10071407	C4591001 1007 10071407	16-55	22OCT2020	111820	Placebo	22OCT2020/ Placebo		12JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)
10071408	C4591001 1007 10071408	16-55	22OCT2020	112068	Placebo	22OCT2020/ Placebo	03DEC2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
10071410	C4591001 1007 10071410	16-55	22OCT2020	112069	Placebo	22OCT2020/ Placebo	12NOV2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
10071416	C4591001 1007 10071416	16-55	22OCT2020	112072	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
10071418	C4591001 1007 10071418	16-55	22OCT2020	112331	Placebo	22OCT2020/ Placebo	12NOV2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
10071419	C4591001 1007 10071419	16-55	22OCT2020	112326	Placebo	22OCT2020/ Placebo	12NOV2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	20JAN2021/ BNT162b2 (30 µg)
10071420	C4591001 1007 10071420	16-55	22OCT2020	112327	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10071421	C4591001 1007 10071421	16-55	22OCT2020	112336	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
10071422	C4591001 1007 10071422	16-55	22OCT2020	112376	Placebo	22OCT2020/ Placebo	12NOV2020/ Placebo		
10071423	C4591001 1007 10071423	16-55	22OCT2020	112378	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
10071424	C4591001 1007 10071424	16-55	22OCT2020	112379	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
10071425	C4591001 1007 10071425	16-55	22OCT2020	112382	Placebo	22OCT2020/ Placebo	12NOV2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
10071426	C4591001 1007 10071426	16-55	22OCT2020	112535	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
10071427	C4591001 1007 10071427	16-55	22OCT2020	112530	Placebo	22OCT2020/ Placebo	23NOV2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
10071431	C4591001 1007 10071431	16-55	26OCT2020	112537	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
10071433	C4591001 1007 10071433	16-55	27OCT2020	112540	Placebo	27OCT2020/ Placebo	17NOV2020/ Placebo		
10071434	C4591001 1007 10071434	16-55	27OCT2020	114209	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10071435	C4591001 1007 10071435	16-55	28OCT2020	114213	Placebo	28OCT2020/ Placebo	18NOV2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
10071436	C4591001 1007 10071436	16-55	28OCT2020	114214	Placebo	28OCT2020/ Placebo	18NOV2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
10071437	C4591001 1007 10071437	16-55	16NOV2020	116279	Placebo	16NOV2020/ Placebo	22DEC2020/ Placebo		
10071438	C4591001 1007 10071438	16-55	29OCT2020	114220	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)		
10071439	C4591001 1007 10071439	16-55	29OCT2020	114777	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)		
10071440	C4591001 1007 10071440	16-55	29OCT2020	114773	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)		
10071441	C4591001 1007 10071441	16-55	29OCT2020	114775	Placebo	29OCT2020/ Placebo	19NOV2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
10071442	C4591001 1007 10071442	16-55	03NOV2020	114784	Placebo	03NOV2020/ Placebo	23NOV2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
10071443	C4591001 1007 10071443	16-55	04NOV2020	115649	Placebo	04NOV2020/ Placebo	25NOV2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
10071444	C4591001 1007 10071444	16-55	04NOV2020	115652	Placebo	04NOV2020/ Placebo	23NOV2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10071445	C4591001 1007 10071445	16-55	10NOV2020	115654	BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)	01DEC2020/ BNT162b2 (30 µg)		
10071446	C4591001 1007 10071446	16-55	18NOV2020	116405	BNT162b2 (30 µg)	18NOV2020/ BNT162b2 (30 µg)	10DEC2020/ BNT162b2 (30 µg)		
10071447	C4591001 1007 10071447	16-55	11NOV2020	115659	BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)	02DEC2020/ BNT162b2 (30 µg)		
10071448	C4591001 1007 10071448	16-55	11NOV2020	116136	Placebo	11NOV2020/ Placebo	02DEC2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
10071449	C4591001 1007 10071449	16-55	11NOV2020	116137	Placebo	11NOV2020/ Placebo	02DEC2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
10071450	C4591001 1007 10071450	16-55	12NOV2020	116138	BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)	03DEC2020/ BNT162b2 (30 µg)		
10071451	C4591001 1007 10071451	16-55	12NOV2020	116140	BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)	03DEC2020/ BNT162b2 (30 µg)		
10071452	C4591001 1007 10071452	16-55	12NOV2020	116167	BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)	03DEC2020/ BNT162b2 (30 µg)		
10071454	C4591001 1007 10071454	16-55	12NOV2020	116168	BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)	03DEC2020/ BNT162b2 (30 µg)		
10071455	C4591001 1007 10071455	16-55	12NOV2020	116170	Placebo	12NOV2020/ Placebo	09DEC2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10071456	C4591001 1007 10071456	16-55	16NOV2020	116174	Placebo	16NOV2020/ Placebo	07DEC2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
10071457	C4591001 1007 10071457	16-55	16NOV2020	116275	BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)	07DEC2020/ BNT162b2 (30 µg)		
10071458	C4591001 1007 10071458	16-55	16NOV2020	116277	Placebo	16NOV2020/ Placebo	09DEC2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
10071459	C4591001 1007 10071459	16-55	17NOV2020	116281	BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)	08DEC2020/ BNT162b2 (30 µg)		
10071461	C4591001 1007 10071461	16-55	18NOV2020	116406	Placebo	18NOV2020/ Placebo	09DEC2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
10071462	C4591001 1007 10071462	16-55	18NOV2020	116409	Placebo	18NOV2020/ Placebo	09DEC2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
10071463	C4591001 1007 10071463	16-55	18NOV2020	116489	Placebo	18NOV2020/ Placebo	09DEC2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
10071464	C4591001 1007 10071464	16-55	18NOV2020	116415	BNT162b2 (30 µg)	18NOV2020/ BNT162b2 (30 µg)	09DEC2020/ BNT162b2 (30 µg)		
10071465	C4591001 1007 10071465	16-55	19NOV2020	116492	Placebo	19NOV2020/ Placebo	10DEC2020/ Placebo		
10071466	C4591001 1007 10071466	16-55	19NOV2020	116494	BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)	10DEC2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10071468	C4591001 1007 10071468	16-55	30NOV2020	116497	BNT162b2 (30 µg)	30NOV2020/ BNT162b2 (30 µg)	21DEC2020/ BNT162b2 (30 µg)		
10071470	C4591001 1007 10071470	16-55	30NOV2020	117030	Placebo	30NOV2020/ Placebo	21DEC2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
10071473	C4591001 1007 10071473	16-55	07DEC2020	117471	BNT162b2 (30 µg)	07DEC2020/ BNT162b2 (30 µg)	28DEC2020/ BNT162b2 (30 µg)		
10071474	C4591001 1007 10071474	16-55	30NOV2020	117032	BNT162b2 (30 µg)	30NOV2020/ BNT162b2 (30 µg)	21DEC2020/ BNT162b2 (30 µg)		
10071477	C4591001 1007 10071477	16-55	30NOV2020	117036	BNT162b2 (30 µg)	30NOV2020/ BNT162b2 (30 µg)	21DEC2020/ BNT162b2 (30 µg)		
10071479	C4591001 1007 10071479	16-55	30NOV2020	117038	Placebo	30NOV2020/ Placebo	21DEC2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
10071486	C4591001 1007 10071486	16-55	01DEC2020	117126	Placebo	01DEC2020/ Placebo	22DEC2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
10071487	C4591001 1007 10071487	16-55	01DEC2020	117129	BNT162b2 (30 µg)	01DEC2020/ BNT162b2 (30 µg)	22DEC2020/ BNT162b2 (30 µg)		
10071489	C4591001 1007 10071489	16-55	01DEC2020	117130	BNT162b2 (30 µg)	01DEC2020/ BNT162b2 (30 µg)	22DEC2020/ BNT162b2 (30 µg)		
10071491	C4591001 1007 10071491	16-55	01DEC2020	117135	Placebo	01DEC2020/ Placebo	21DEC2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10071493	C4591001 1007 10071493	16-55	01DEC2020	117173	Placebo	01DEC2020/ Placebo	22DEC2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
10071498	C4591001 1007 10071498	16-55	02DEC2020	117175	BNT162b2 (30 µg)	02DEC2020/ BNT162b2 (30 µg)	22DEC2020/ BNT162b2 (30 µg)		
10071501	C4591001 1007 10071501	16-55	03DEC2020	117176	Placebo	03DEC2020/ Placebo	22DEC2020/ Placebo		
10071502	C4591001 1007 10071502	16-55	03DEC2020	117180	BNT162b2 (30 µg)	03DEC2020/ BNT162b2 (30 µg)	22DEC2020/ BNT162b2 (30 µg)		
10071503	C4591001 1007 10071503	16-55	03DEC2020	117464	BNT162b2 (30 µg)	03DEC2020/ BNT162b2 (30 µg)	22DEC2020/ BNT162b2 (30 µg)		
10071510	C4591001 1007 10071510	16-55	07DEC2020	117466	Placebo	07DEC2020/ Placebo	28DEC2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
10071513	C4591001 1007 10071513	16-55	07DEC2020	117472	Placebo	07DEC2020/ Placebo	28DEC2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
10071532	C4591001 1007 10071532	16-55	09DEC2020	117799	BNT162b2 (30 µg)	09DEC2020/ BNT162b2 (30 µg)	29DEC2020/ BNT162b2 (30 µg)		
10071534	C4591001 1007 10071534	16-55	09DEC2020	117805	BNT162b2 (30 µg)	09DEC2020/ BNT162b2 (30 µg)	30DEC2020/ BNT162b2 (30 µg)		
10071538	C4591001 1007 10071538	16-55	09DEC2020	117806	Placebo	09DEC2020/ Placebo	30DEC2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10071548	C4591001 1007 10071548	16-55	10DEC2020	117808	Placebo	10DEC2020/ Placebo	30DEC2020/ Placebo	11MAR2021/ BNT162b2 (30 µg)	
10071549	C4591001 1007 10071549	16-55	10DEC2020	117847	BNT162b2 (30 µg)	10DEC2020/ BNT162b2 (30 µg)	30DEC2020/ BNT162b2 (30 µg)		
10071553	C4591001 1007 10071553	16-55	10DEC2020	117849	Placebo	10DEC2020/ Placebo	29DEC2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
10071556	C4591001 1007 10071556	16-55	10DEC2020	117850	Placebo	10DEC2020/ Placebo	29DEC2020/ Placebo		
10081032	C4591001 1008 10081032	16-55	24AUG2020	63515	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
10081042	C4591001 1008 10081042	16-55	17AUG2020	50636	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10081043	C4591001 1008 10081043	16-55	17AUG2020	50640	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10081046	C4591001 1008 10081046	16-55	17AUG2020	53141	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
10081047	C4591001 1008 10081047	16-55	17AUG2020	53142	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10081048	C4591001 1008 10081048	16-55	17AUG2020	53144	Placebo	17AUG2020/ Placebo	09SEP2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	28JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10081049	C4591001 1008 10081049	16-55	17AUG2020	53151	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10081051	C4591001 1008 10081051	16-55	18AUG2020	54390	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10081052	C4591001 1008 10081052	16-55	18AUG2020	54393	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10081053	C4591001 1008 10081053	16-55	18AUG2020	54398	Placebo	18AUG2020/ Placebo	10SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10081054	C4591001 1008 10081054	16-55	18AUG2020	54400	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
10081059	C4591001 1008 10081059	16-55	18AUG2020	55206	Placebo	18AUG2020/ Placebo	10SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
10081064	C4591001 1008 10081064	16-55	19AUG2020	55210	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
10081065	C4591001 1008 10081065	16-55	19AUG2020	55216	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10081066	C4591001 1008 10081066	16-55	19AUG2020	55213	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	20JAN2021/ BNT162b2 (30 µg)
10081067	C4591001 1008 10081067	16-55	19AUG2020	57176	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10081068	C4591001 1008 10081068	16-55	20AUG2020	57177	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10081071	C4591001 1008 10081071	16-55	20AUG2020	57178	Placebo	20AUG2020/ Placebo	09SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
10081072	C4591001 1008 10081072	16-55	20AUG2020	57184	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
10081077	C4591001 1008 10081077	16-55	21AUG2020	60452	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10081078	C4591001 1008 10081078	16-55	21AUG2020	60453	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
10081079	C4591001 1008 10081079	16-55	21AUG2020	60455	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
10081080	C4591001 1008 10081080	16-55	21AUG2020	60456	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
10081086	C4591001 1008 10081086	16-55	24AUG2020	63518	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
10081087	C4591001 1008 10081087	16-55	24AUG2020	63519	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10081088	C4591001 1008 10081088	16-55	24AUG2020	63520	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10081089	C4591001 1008 10081089	16-55	25AUG2020	65489	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10081091	C4591001 1008 10081091	16-55	25AUG2020	65490	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10081095	C4591001 1008 10081095	16-55	25AUG2020	65495	Placebo	25AUG2020/ Placebo	17SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10081099	C4591001 1008 10081099	16-55	25AUG2020	65498	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10081101	C4591001 1008 10081101	16-55	26AUG2020	67614	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
10081102	C4591001 1008 10081102	16-55	26AUG2020	67615	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10081103	C4591001 1008 10081103	16-55	26AUG2020	67622	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10081113	C4591001 1008 10081113	16-55	26AUG2020	67623	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10081116	C4591001 1008 10081116	16-55	27AUG2020	69968	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
10081121	C4591001 1008 10081121	16-55	27AUG2020	69970	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10081122	C4591001 1008 10081122	16-55	27AUG2020	69975	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10081129	C4591001 1008 10081129	16-55	28AUG2020	69976	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
10081130	C4591001 1008 10081130	16-55	28AUG2020	72020	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo		
10081136	C4591001 1008 10081136	16-55	28AUG2020	72021	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
10081137	C4591001 1008 10081137	16-55	28AUG2020	72027	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
10081138	C4591001 1008 10081138	16-55	28AUG2020	72028	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
10081140	C4591001 1008 10081140	16-55	28AUG2020	72785	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
10081142	C4591001 1008 10081142	16-55	28AUG2020	72788	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10081143	C4591001 1008 10081143	16-55	28AUG2020	72789	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
10081147	C4591001 1008 10081147	16-55	31AUG2020	72790	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10081148	C4591001 1008 10081148	16-55	31AUG2020	75737	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
10081149	C4591001 1008 10081149	16-55	31AUG2020	75738	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10081150	C4591001 1008 10081150	16-55	31AUG2020	75746	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10081151	C4591001 1008 10081151	16-55	31AUG2020	75747	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
10081152	C4591001 1008 10081152	16-55	31AUG2020	75850	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10081153	C4591001 1008 10081153	16-55	01SEP2020	75851	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo		
10081155	C4591001 1008 10081155	16-55	01SEP2020	75853	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10081156	C4591001 1008 10081156	16-55	01SEP2020	75854	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
10081158	C4591001 1008 10081158	16-55	01SEP2020	76685	Placebo	01SEP2020/ Placebo	21SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10081159	C4591001 1008 10081159	16-55	01SEP2020	76689	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10081160	C4591001 1008 10081160	16-55	01SEP2020	76695	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
10081166	C4591001 1008 10081166	16-55	02SEP2020	76696	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10081183	C4591001 1008 10081183	16-55	03SEP2020	80622	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10081187	C4591001 1008 10081187	16-55	03SEP2020	80626	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10081191	C4591001 1008 10081191	16-55	04SEP2020	80628	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
10081193	C4591001 1008 10081193	16-55	04SEP2020	81559	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
10081194	C4591001 1008 10081194	16-55	04SEP2020	80631	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
10081197	C4591001 1008 10081197	16-55	04SEP2020	81565	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
10081198	C4591001 1008 10081198	16-55	04SEP2020	81566	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
10081199	C4591001 1008 10081199	16-55	04SEP2020	81568	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10081200	C4591001 1008 10081200	16-55	04SEP2020	82148	Placebo	04SEP2020/ Placebo	23SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10081202	C4591001 1008 10081202	16-55	04SEP2020	82149	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
10081212	C4591001 1008 10081212	16-55	08SEP2020	82153	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
10081215	C4591001 1008 10081215	16-55	08SEP2020	82155	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
10081217	C4591001 1008 10081217	16-55	08SEP2020	84102	Placebo	08SEP2020/ Placebo	01OCT2020/ Placebo	15DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
10081218	C4591001 1008 10081218	16-55	08SEP2020	84106	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
10081220	C4591001 1008 10081220	16-55	08SEP2020	84109	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
10081221	C4591001 1008 10081221	16-55	08SEP2020	84112	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
10081224	C4591001 1008 10081224	16-55	08SEP2020	84320	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
10081225	C4591001 1008 10081225	16-55	08SEP2020	84317	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10081232	C4591001 1008 10081232	16-55	08SEP2020	84322	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
10081233	C4591001 1008 10081233	16-55	08SEP2020	84326	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10081234	C4591001 1008 10081234	16-55	08SEP2020	84648	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
10081235	C4591001 1008 10081235	16-55	08SEP2020	84647	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
10081238	C4591001 1008 10081238	16-55	09SEP2020	84650	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10081239	C4591001 1008 10081239	16-55	09SEP2020	84652	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10081240	C4591001 1008 10081240	16-55	09SEP2020	85037	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10081244	C4591001 1008 10081244	16-55	09SEP2020	85038	Placebo	09SEP2020/ Placebo	01OCT2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10081251	C4591001 1008 10081251	16-55	09SEP2020	85039	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10081253	C4591001 1008 10081253	16-55	09SEP2020	85043	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10081256	C4591001 1008 10081256	16-55	09SEP2020	86071	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10081257	C4591001 1008 10081257	16-55	09SEP2020	86072	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	31DEC2020/ BNT162b2 (30 µg)	21JAN2021/ BNT162b2 (30 µg)
10081258	C4591001 1008 10081258	16-55	09SEP2020	86075	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
10081260	C4591001 1008 10081260	16-55	09SEP2020	86079	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10081261	C4591001 1008 10081261	16-55	09SEP2020	86166	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
10081263	C4591001 1008 10081263	16-55	09SEP2020	86169	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
10081265	C4591001 1008 10081265	16-55	10SEP2020	86172	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
10081271	C4591001 1008 10081271	16-55	10SEP2020	86175	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
10081274	C4591001 1008 10081274	16-55	10SEP2020	87270	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
10081281	C4591001 1008 10081281	16-55	10SEP2020	87273	Placebo	10SEP2020/ Placebo	30SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10081286	C4591001 1008 10081286	16-55	10SEP2020	87274	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10081289	C4591001 1008 10081289	16-55	10SEP2020	87280	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
10081290	C4591001 1008 10081290	16-55	11SEP2020	87977	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)
10081292	C4591001 1008 10081292	16-55	11SEP2020	87982	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
10081293	C4591001 1008 10081293	16-55	11SEP2020	87983	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
10081295	C4591001 1008 10081295	16-55	11SEP2020	87988	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
10081297	C4591001 1008 10081297	16-55	11SEP2020	88170	Placebo	11SEP2020/ Placebo	30SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
10081300	C4591001 1008 10081300	16-55	11SEP2020	88172	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
10081304	C4591001 1008 10081304	16-55	11SEP2020	88174	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
10081306	C4591001 1008 10081306	16-55	11SEP2020	88177	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10081310	C4591001 1008 10081310	16-55	14SEP2020	89467	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
10081312	C4591001 1008 10081312	16-55	14SEP2020	89469	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
10081313	C4591001 1008 10081313	16-55	14SEP2020	89472	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
10081314	C4591001 1008 10081314	16-55	14SEP2020	89476	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10081315	C4591001 1008 10081315	16-55	14SEP2020	89611	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
10081316	C4591001 1008 10081316	16-55	14SEP2020	89612	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
10081320	C4591001 1008 10081320	16-55	14SEP2020	89615	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
10081321	C4591001 1008 10081321	16-55	14SEP2020	89904	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
10081325	C4591001 1008 10081325	16-55	14SEP2020	89619	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
10081326	C4591001 1008 10081326	16-55	14SEP2020	89898	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10081327	C4591001 1008 10081327	16-55	14SEP2020	89903	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
10081328	C4591001 1008 10081328	16-55	14SEP2020	89905	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
10081333	C4591001 1008 10081333	16-55	15SEP2020	90305	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
10081336	C4591001 1008 10081336	16-55	15SEP2020	90312	Placebo	15SEP2020/ Placebo	06OCT2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
10081337	C4591001 1008 10081337	16-55	15SEP2020	90313	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
10081338	C4591001 1008 10081338	16-55	15SEP2020	90316	Placebo	15SEP2020/ Placebo	06OCT2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
10081341	C4591001 1008 10081341	16-55	15SEP2020	90499	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
10081343	C4591001 1008 10081343	16-55	15SEP2020	90500	Placebo	15SEP2020/ Placebo	06OCT2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
10081344	C4591001 1008 10081344	16-55	15SEP2020	90501	Placebo	15SEP2020/ Placebo	06OCT2020/ Placebo	31DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)
10081346	C4591001 1008 10081346	16-55	15SEP2020	90503	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10081347	C4591001 1008 10081347	16-55	16SEP2020	91051	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
10081348	C4591001 1008 10081348	16-55	16SEP2020	91055	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
10081349	C4591001 1008 10081349	16-55	16SEP2020	91056	Placebo	16SEP2020/ Placebo	07OCT2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
10081350	C4591001 1008 10081350	16-55	16SEP2020	91059	Placebo	16SEP2020/ Placebo	08OCT2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
10081351	C4591001 1008 10081351	16-55	16SEP2020	91277	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
10081352	C4591001 1008 10081352	16-55	16SEP2020	91280	Placebo	16SEP2020/ Placebo	07OCT2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
10081354	C4591001 1008 10081354	16-55	16SEP2020	91282	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
10081357	C4591001 1008 10081357	16-55	16SEP2020	91403	Placebo	16SEP2020/ Placebo	06OCT2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
10081358	C4591001 1008 10081358	16-55	16SEP2020	91397	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
10081359	C4591001 1008 10081359	16-55	16SEP2020	91288	Placebo	16SEP2020/ Placebo	08OCT2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10081360	C4591001 1008 10081360	16-55	16SEP2020	91405	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
10081361	C4591001 1008 10081361	16-55	16SEP2020	91408	Placebo	16SEP2020/ Placebo	07OCT2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
10081364	C4591001 1008 10081364	16-55	16SEP2020	91613	Placebo	16SEP2020/ Placebo	07OCT2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
10081365	C4591001 1008 10081365	16-55	16SEP2020	91618	Placebo	16SEP2020/ Placebo	07OCT2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
10081366	C4591001 1008 10081366	16-55	16SEP2020	91621	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
10081367	C4591001 1008 10081367	16-55	16SEP2020	91622	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
10081368	C4591001 1008 10081368	16-55	16SEP2020	91733	Placebo	16SEP2020/ Placebo	07OCT2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
10081370	C4591001 1008 10081370	16-55	17SEP2020	91735	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
10081372	C4591001 1008 10081372	16-55	17SEP2020	91737	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
10081374	C4591001 1008 10081374	16-55	17SEP2020	91743	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10081379	C4591001 1008 10081379	16-55	17SEP2020	92489	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
10081382	C4591001 1008 10081382	16-55	17SEP2020	92491	Placebo	17SEP2020/ Placebo	09OCT2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
10081383	C4591001 1008 10081383	16-55	17SEP2020	92494	Placebo	17SEP2020/ Placebo	09OCT2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
10081384	C4591001 1008 10081384	16-55	17SEP2020	92497	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
10081385	C4591001 1008 10081385	16-55	17SEP2020	92573	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
10081388	C4591001 1008 10081388	16-55	17SEP2020	92575	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
10081391	C4591001 1008 10081391	16-55	17SEP2020	92578	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
10081392	C4591001 1008 10081392	16-55	18SEP2020	92582	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
10081393	C4591001 1008 10081393	16-55	18SEP2020	93486	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
10081394	C4591001 1008 10081394	16-55	18SEP2020	93487	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10081395	C4591001 1008 10081395	16-55	18SEP2020	93489	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
10081396	C4591001 1008 10081396	16-55	18SEP2020	93493	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
10081397	C4591001 1008 10081397	16-55	18SEP2020	93656	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
10081398	C4591001 1008 10081398	16-55	18SEP2020	93658	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
10081401	C4591001 1008 10081401	16-55	18SEP2020	93659	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
10081402	C4591001 1008 10081402	16-55	18SEP2020	93663	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
10081404	C4591001 1008 10081404	16-55	18SEP2020	93810	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
10081407	C4591001 1008 10081407	16-55	18SEP2020	93815	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
10081408	C4591001 1008 10081408	16-55	18SEP2020	93811	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
10081410	C4591001 1008 10081410	16-55	18SEP2020	93817	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10081411	C4591001 1008 10081411	16-55	18SEP2020	94109	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
10081413	C4591001 1008 10081413	16-55	18SEP2020	94110	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
10081416	C4591001 1008 10081416	16-55	21SEP2020	94115	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
10081418	C4591001 1008 10081418	16-55	21SEP2020	94118	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
10081419	C4591001 1008 10081419	16-55	21SEP2020	94821	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo		
10081420	C4591001 1008 10081420	16-55	21SEP2020	94824	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
10081421	C4591001 1008 10081421	16-55	21SEP2020	94825	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
10081422	C4591001 1008 10081422	16-55	21SEP2020	94826	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
10081423	C4591001 1008 10081423	16-55	21SEP2020	94974	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
10081425	C4591001 1008 10081425	16-55	21SEP2020	94977	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10081426	C4591001 1008 10081426	16-55	21SEP2020	94979	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
10081427	C4591001 1008 10081427	16-55	21SEP2020	94980	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
10081429	C4591001 1008 10081429	16-55	21SEP2020	95129	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
10081430	C4591001 1008 10081430	16-55	21SEP2020	95130	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
10081432	C4591001 1008 10081432	16-55	21SEP2020	95134	Placebo	21SEP2020/ Placebo	14OCT2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
10081433	C4591001 1008 10081433	16-55	21SEP2020	95136	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
10081435	C4591001 1008 10081435	16-55	21SEP2020	95299	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
10081436	C4591001 1008 10081436	16-55	21SEP2020	95301	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
10081437	C4591001 1008 10081437	16-55	21SEP2020	95302	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
10081438	C4591001 1008 10081438	16-55	21SEP2020	262615	Placebo	21SEP2020/ Placebo	13OCT2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10081439	C4591001 1008 10081439	16-55	21SEP2020	95306	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
10081440	C4591001 1008 10081440	16-55	21SEP2020	95513	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
10081441	C4591001 1008 10081441	16-55	21SEP2020	95514	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
10081442	C4591001 1008 10081442	16-55	22SEP2020	95515	Placebo	22SEP2020/ Placebo	13OCT2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)
10081444	C4591001 1008 10081444	16-55	22SEP2020	95521	Placebo	22SEP2020/ Placebo	13OCT2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
10081447	C4591001 1008 10081447	16-55	22SEP2020	96163	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
10081449	C4591001 1008 10081449	16-55	22SEP2020	96167	Placebo	22SEP2020/ Placebo	13OCT2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
10081450	C4591001 1008 10081450	16-55	22SEP2020	96170	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
10081452	C4591001 1008 10081452	16-55	22SEP2020	96171	Placebo	22SEP2020/ Placebo	14OCT2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
10081453	C4591001 1008 10081453	16-55	22SEP2020	96330	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10081456	C4591001 1008 10081456	16-55	22SEP2020	96335	Placebo	22SEP2020/ Placebo	13OCT2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
10081457	C4591001 1008 10081457	16-55	22SEP2020	96331	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
10081462	C4591001 1008 10081462	16-55	22SEP2020	96336	Placebo	22SEP2020/ Placebo	13OCT2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
10081463	C4591001 1008 10081463	16-55	22SEP2020	96571	Placebo	22SEP2020/ Placebo	13OCT2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10081464	C4591001 1008 10081464	16-55	22SEP2020	96573	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
10081466	C4591001 1008 10081466	16-55	22SEP2020	96578	Placebo	22SEP2020/ Placebo	15OCT2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
10081467	C4591001 1008 10081467	16-55	22SEP2020	96580	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
10081468	C4591001 1008 10081468	16-55	22SEP2020	96702	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
10081469	C4591001 1008 10081469	16-55	22SEP2020	96708	Placebo	22SEP2020/ Placebo	13OCT2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
10081470	C4591001 1008 10081470	16-55	22SEP2020	96710	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10081471	C4591001 1008 10081471	16-55	22SEP2020	96711	Placebo	22SEP2020/ Placebo	15OCT2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
10081472	C4591001 1008 10081472	16-55	23SEP2020	97448	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
10081473	C4591001 1008 10081473	16-55	23SEP2020	97449	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
10081474	C4591001 1008 10081474	16-55	23SEP2020	97450	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
10081475	C4591001 1008 10081475	16-55	23SEP2020	97452	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
10081476	C4591001 1008 10081476	16-55	23SEP2020	97567	Placebo	23SEP2020/ Placebo	12OCT2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
10081477	C4591001 1008 10081477	16-55	23SEP2020	97569	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
10081479	C4591001 1008 10081479	16-55	23SEP2020	97572	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
10081480	C4591001 1008 10081480	16-55	23SEP2020	97573	Placebo	23SEP2020/ Placebo	13OCT2020/ Placebo		
10081481	C4591001 1008 10081481	16-55	23SEP2020	97697	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10081485	C4591001 1008 10081485	16-55	23SEP2020	97698	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
10081487	C4591001 1008 10081487	16-55	23SEP2020	97699	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
10081492	C4591001 1008 10081492	16-55	23SEP2020	98011	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
10081493	C4591001 1008 10081493	16-55	23SEP2020	97702	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
10081496	C4591001 1008 10081496	16-55	23SEP2020	98012	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
10081497	C4591001 1008 10081497	16-55	23SEP2020	98018	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
10081499	C4591001 1008 10081499	16-55	24SEP2020	98019	Placebo	24SEP2020/ Placebo	15OCT2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
10081500	C4591001 1008 10081500	16-55	24SEP2020	98672	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
10081504	C4591001 1008 10081504	16-55	24SEP2020	98673	Placebo	24SEP2020/ Placebo	15OCT2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
10081505	C4591001 1008 10081505	16-55	24SEP2020	98677	Placebo	24SEP2020/ Placebo	15OCT2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10081506	C4591001 1008 10081506	16-55	24SEP2020	98680	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
10081507	C4591001 1008 10081507	16-55	24SEP2020	98743	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
10081509	C4591001 1008 10081509	16-55	24SEP2020	98746	Placebo	24SEP2020/ Placebo	15OCT2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
10081512	C4591001 1008 10081512	16-55	24SEP2020	98749	Placebo	24SEP2020/ Placebo	15OCT2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
10081513	C4591001 1008 10081513	16-55	24SEP2020	98752	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
10081514	C4591001 1008 10081514	16-55	24SEP2020	98826	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)		
10081518	C4591001 1008 10081518	16-55	24SEP2020	98827	Placebo	24SEP2020/ Placebo	15OCT2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
10081520	C4591001 1008 10081520	16-55	24SEP2020	98831	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
10081521	C4591001 1008 10081521	16-55	24SEP2020	98832	Placebo	24SEP2020/ Placebo	15OCT2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10081524	C4591001 1008 10081524	16-55	24SEP2020	98949	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10081525	C4591001 1008 10081525	16-55	24SEP2020	98950	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
10081527	C4591001 1008 10081527	16-55	25SEP2020	98953	Placebo	25SEP2020/ Placebo	14OCT2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
10081528	C4591001 1008 10081528	16-55	25SEP2020	98954	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
10081529	C4591001 1008 10081529	16-55	25SEP2020	99584	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)			
10081532	C4591001 1008 10081532	16-55	25SEP2020	99586	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
10081533	C4591001 1008 10081533	16-55	25SEP2020	99588	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
10081534	C4591001 1008 10081534	16-55	25SEP2020	99592	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
10081541	C4591001 1008 10081541	16-55	25SEP2020	100229	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
10081542	C4591001 1008 10081542	16-55	25SEP2020	100230	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo		
10081543	C4591001 1008 10081543	16-55	25SEP2020	100236	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10081544	C4591001 1008 10081544	16-55	25SEP2020	100239	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
10081547	C4591001 1008 10081547	16-55	28SEP2020	101362	Placebo	28SEP2020/ Placebo	19OCT2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10081548	C4591001 1008 10081548	16-55	28SEP2020	101363	BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)		
10081549	C4591001 1008 10081549	16-55	28SEP2020	101364	BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)		
10081551	C4591001 1008 10081551	16-55	30SEP2020	102317	Placebo	30SEP2020/ Placebo	21OCT2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
10081552	C4591001 1008 10081552	16-55	30SEP2020	101367	Placebo	30SEP2020/ Placebo	19OCT2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10081553	C4591001 1008 10081553	16-55	30SEP2020	102318	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		
10081554	C4591001 1008 10081554	16-55	30SEP2020	102322	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		
10081555	C4591001 1008 10081555	16-55	30SEP2020	102323	Placebo	30SEP2020/ Placebo	21OCT2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
10081556	C4591001 1008 10081556	16-55	01OCT2020	102929	BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10081557	C4591001 1008 10081557	16-55	01OCT2020	102930	Placebo	01OCT2020/ Placebo	22OCT2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10081558	C4591001 1008 10081558	16-55	02OCT2020	102932	BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)		
10081559	C4591001 1008 10081559	16-55	02OCT2020	102937	Placebo	02OCT2020/ Placebo	23OCT2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
10081567	C4591001 1008 10081567	16-55	06OCT2020	104406	BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		
10081568	C4591001 1008 10081568	16-55	06OCT2020	104407	Placebo	06OCT2020/ Placebo	28OCT2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
10081572	C4591001 1008 10081572	16-55	07OCT2020	104412	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
10081573	C4591001 1008 10081573	16-55	08OCT2020	104413	Placebo	08OCT2020/ Placebo	30OCT2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
10081574	C4591001 1008 10081574	16-55	09OCT2020	105894	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)		
10081576	C4591001 1008 10081576	16-55	09OCT2020	105895	Placebo	09OCT2020/ Placebo	30OCT2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
10081577	C4591001 1008 10081577	16-55	09OCT2020	105903	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10081578	C4591001 1008 10081578	16-55	09OCT2020	105904	Placebo	09OCT2020/ Placebo	30OCT2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
10081579	C4591001 1008 10081579	16-55	09OCT2020	105991	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)		
10081580	C4591001 1008 10081580	16-55	09OCT2020	105992	Placebo	09OCT2020/ Placebo	28OCT2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	15JAN2021/ BNT162b2 (30 µg)
10081581	C4591001 1008 10081581	16-55	09OCT2020	105996	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)		
10081582	C4591001 1008 10081582	16-55	09OCT2020	105999	Placebo	09OCT2020/ Placebo	30OCT2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
10081583	C4591001 1008 10081583	16-55	09OCT2020	106112	Placebo	09OCT2020/ Placebo	30OCT2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10081584	C4591001 1008 10081584	16-55	12OCT2020	106114	BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		
10081590	C4591001 1008 10081590	16-55	13OCT2020	106115	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
10081594	C4591001 1008 10081594	16-55	13OCT2020	106118	Placebo	13OCT2020/ Placebo	02NOV2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
10081595	C4591001 1008 10081595	16-55	13OCT2020	107166	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10081596	C4591001 1008 10081596	16-55	13OCT2020	107167	Placebo	13OCT2020/ Placebo	03NOV2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10081598	C4591001 1008 10081598	16-55	13OCT2020	107170	Placebo	13OCT2020/ Placebo	04NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10081600	C4591001 1008 10081600	16-55	14OCT2020	107174	BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
10081604	C4591001 1008 10081604	16-55	14OCT2020	107717	Placebo	14OCT2020/ Placebo	04NOV2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
10081605	C4591001 1008 10081605	16-55	14OCT2020	107719	BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
10081606	C4591001 1008 10081606	16-55	14OCT2020	107721	BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
10081607	C4591001 1008 10081607	16-55	14OCT2020	107727	Placebo	14OCT2020/ Placebo	04NOV2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
10081608	C4591001 1008 10081608	16-55	14OCT2020	107777	BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		
10081611	C4591001 1008 10081611	16-55	15OCT2020	107785	Placebo	15OCT2020/ Placebo	04NOV2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
10081612	C4591001 1008 10081612	16-55	15OCT2020	107784	Placebo	15OCT2020/ Placebo	04NOV2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10081617	C4591001 1008 10081617	16-55	15OCT2020	107787	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
10081618	C4591001 1008 10081618	16-55	15OCT2020	108535	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
10081620	C4591001 1008 10081620	16-55	16OCT2020	108540	Placebo	16OCT2020/ Placebo	06NOV2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10081623	C4591001 1008 10081623	16-55	16OCT2020	108542	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
10081628	C4591001 1008 10081628	16-55	16OCT2020	108544	Placebo	16OCT2020/ Placebo	06NOV2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
10081629	C4591001 1008 10081629	16-55	16OCT2020	109281	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	24NOV2020/ BNT162b2 (30 µg)		
10081630	C4591001 1008 10081630	16-55	16OCT2020	109279	Placebo	16OCT2020/ Placebo	06NOV2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
10081631	C4591001 1008 10081631	16-55	16OCT2020	109284	Placebo	16OCT2020/ Placebo	06NOV2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
10081632	C4591001 1008 10081632	16-55	19OCT2020	109285	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
10081633	C4591001 1008 10081633	16-55	19OCT2020	110083	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10081637	C4591001 1008 10081637	16-55	19OCT2020	110089	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
10081638	C4591001 1008 10081638	16-55	19OCT2020	110090	Placebo	19OCT2020/ Placebo	09NOV2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
10081643	C4591001 1008 10081643	16-55	20OCT2020	110092	Placebo	20OCT2020/ Placebo	10NOV2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10081647	C4591001 1008 10081647	16-55	20OCT2020	111080	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		
10081648	C4591001 1008 10081648	16-55	20OCT2020	111081	Placebo	20OCT2020/ Placebo	10NOV2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10081649	C4591001 1008 10081649	16-55	20OCT2020	111082	Placebo	20OCT2020/ Placebo	10NOV2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)
10081653	C4591001 1008 10081653	16-55	21OCT2020	111550	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
10081654	C4591001 1008 10081654	16-55	21OCT2020	111087	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
10081655	C4591001 1008 10081655	16-55	21OCT2020	111551	Placebo	21OCT2020/ Placebo	11NOV2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10081657	C4591001 1008 10081657	16-55	21OCT2020	111555	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10081659	C4591001 1008 10081659	16-55	21OCT2020	111556	Placebo	21OCT2020/ Placebo	11NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10081663	C4591001 1008 10081663	16-55	21OCT2020	111821	Placebo	21OCT2020/ Placebo	11NOV2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10081664	C4591001 1008 10081664	16-55	22OCT2020	111825	Placebo	22OCT2020/ Placebo	11NOV2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	28JAN2021/ BNT162b2 (30 µg)
10081665	C4591001 1008 10081665	16-55	22OCT2020	111826	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
10081668	C4591001 1008 10081668	16-55	22OCT2020	111829	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		
10081669	C4591001 1008 10081669	16-55	22OCT2020	112458	Placebo	22OCT2020/ Placebo	12NOV2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10081670	C4591001 1008 10081670	16-55	22OCT2020	112459	Placebo	22OCT2020/ Placebo	12NOV2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
10081672	C4591001 1008 10081672	16-55	22OCT2020	112465	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
10081673	C4591001 1008 10081673	16-55	22OCT2020	112464	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
10081674	C4591001 1008 10081674	16-55	22OCT2020	112567	Placebo	22OCT2020/ Placebo	12NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10081675	C4591001 1008 10081675	16-55	23OCT2020	112569	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
10081676	C4591001 1008 10081676	16-55	23OCT2020	112572	Placebo	23OCT2020/ Placebo	12NOV2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
10081677	C4591001 1008 10081677	16-55	23OCT2020	112576	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
10081678	C4591001 1008 10081678	16-55	23OCT2020	112890	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
10081680	C4591001 1008 10081680	16-55	23OCT2020	112895	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
10081682	C4591001 1008 10081682	16-55	23OCT2020	112897	Placebo	23OCT2020/ Placebo	11DEC2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
10081683	C4591001 1008 10081683	16-55	23OCT2020	112899	Placebo	23OCT2020/ Placebo	13NOV2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
10081688	C4591001 1008 10081688	16-55	26OCT2020	113587	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
10081692	C4591001 1008 10081692	16-55	26OCT2020	113590	Placebo	26OCT2020/ Placebo	16NOV2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
10081693	C4591001 1008 10081693	16-55	26OCT2020	113591	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10081695	C4591001 1008 10081695	16-55	26OCT2020	113765	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
10081696	C4591001 1008 10081696	16-55	26OCT2020	113593	Placebo	26OCT2020/ Placebo	16NOV2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10081698	C4591001 1008 10081698	16-55	27OCT2020	113768	Placebo	27OCT2020/ Placebo	18NOV2020/ Placebo		
10081700	C4591001 1008 10081700	16-55	27OCT2020	113773	Placebo	27OCT2020/ Placebo	17NOV2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
10081703	C4591001 1008 10081703	16-55	27OCT2020	113774	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
10081704	C4591001 1008 10081704	16-55	27OCT2020	114152	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
10081706	C4591001 1008 10081706	16-55	27OCT2020	114155	Placebo	27OCT2020/ Placebo	17NOV2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
10081710	C4591001 1008 10081710	16-55	28OCT2020	114159	BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)	18NOV2020/ BNT162b2 (30 µg)		
10081712	C4591001 1008 10081712	16-55	28OCT2020	114160	Placebo	28OCT2020/ Placebo	16NOV2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10081713	C4591001 1008 10081713	16-55	28OCT2020	114403	Placebo	28OCT2020/ Placebo	18NOV2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10081715	C4591001 1008 10081715	16-55	28OCT2020	114405	BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)	18NOV2020/ BNT162b2 (30 µg)		
10081716	C4591001 1008 10081716	16-55	28OCT2020	114409	Placebo	28OCT2020/ Placebo	18NOV2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
10081717	C4591001 1008 10081717	16-55	28OCT2020	114412	BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)		
10081719	C4591001 1008 10081719	16-55	28OCT2020	114509	BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
10081720	C4591001 1008 10081720	16-55	28OCT2020	114512	Placebo	28OCT2020/ Placebo	17NOV2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
10081721	C4591001 1008 10081721	16-55	29OCT2020	114513	Placebo	29OCT2020/ Placebo		01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10081722	C4591001 1008 10081722	16-55	29OCT2020	114514	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)		
10081727	C4591001 1008 10081727	16-55	29OCT2020	114798	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)		
10081728	C4591001 1008 10081728	16-55	29OCT2020	114801	Placebo	29OCT2020/ Placebo	19NOV2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10081731	C4591001 1008 10081731	16-55	30OCT2020	114804	BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)	20NOV2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10081733	C4591001 1008 10081733	16-55	30OCT2020	114807	Placebo	30OCT2020/ Placebo	20NOV2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10081736	C4591001 1008 10081736	16-55	30OCT2020	115099	BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)	20NOV2020/ BNT162b2 (30 µg)		
10081737	C4591001 1008 10081737	16-55	30OCT2020	115106	BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)	20NOV2020/ BNT162b2 (30 µg)		
10081738	C4591001 1008 10081738	16-55	30OCT2020	115100	Placebo	30OCT2020/ Placebo	20NOV2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10081739	C4591001 1008 10081739	16-55	30OCT2020	115107	Placebo	30OCT2020/ Placebo	20NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10081741	C4591001 1008 10081741	16-55	02NOV2020	115277	BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)	25NOV2020/ BNT162b2 (30 µg)		
10081742	C4591001 1008 10081742	16-55	03NOV2020	115279	Placebo	03NOV2020/ Placebo	25NOV2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
10081743	C4591001 1008 10081743	16-55	04NOV2020	115283	BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)	24NOV2020/ BNT162b2 (30 µg)		
10081744	C4591001 1008 10081744	16-55	04NOV2020	115288	Placebo	04NOV2020/ Placebo	25NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10081745	C4591001 1008 10081745	16-55	12NOV2020	116194	BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)	03DEC2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10081746	C4591001 1008 10081746	16-55	13NOV2020	116195	Placebo	13NOV2020/ Placebo	04DEC2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
10081747	C4591001 1008 10081747	16-55	20NOV2020	116197	BNT162b2 (30 µg)	20NOV2020/ BNT162b2 (30 µg)	11DEC2020/ BNT162b2 (30 µg)		
10081748	C4591001 1008 10081748	16-55	20NOV2020	116199	Placebo	20NOV2020/ Placebo	10DEC2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
10081749	C4591001 1008 10081749	16-55	24NOV2020	116818	BNT162b2 (30 µg)	24NOV2020/ BNT162b2 (30 µg)	14DEC2020/ BNT162b2 (30 µg)		
10081750	C4591001 1008 10081750	16-55	24NOV2020	116821	Placebo	24NOV2020/ Placebo	15DEC2020/ Placebo		
10081762	C4591001 1008 10081762	16-55	07DEC2020	116822	Placebo	07DEC2020/ Placebo	30DEC2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
10081765	C4591001 1008 10081765	16-55	08DEC2020	116823	BNT162b2 (30 µg)	08DEC2020/ BNT162b2 (30 µg)	29DEC2020/ BNT162b2 (30 µg)		
10081766	C4591001 1008 10081766	16-55	08DEC2020	117763	Placebo	08DEC2020/ Placebo	29DEC2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
10081772	C4591001 1008 10081772	16-55	09DEC2020	117765	BNT162b2 (30 µg)	09DEC2020/ BNT162b2 (30 µg)	30DEC2020/ BNT162b2 (30 µg)		
10081776	C4591001 1008 10081776	16-55	09DEC2020	117767	Placebo	09DEC2020/ Placebo	30DEC2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10081778	C4591001 1008 10081778	16-55	10DEC2020	117771	BNT162b2 (30 µg)	10DEC2020/ BNT162b2 (30 µg)	31DEC2020/ BNT162b2 (30 µg)		
10081779	C4591001 1008 10081779	16-55	10DEC2020	117857	Placebo	10DEC2020/ Placebo	29DEC2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10081782	C4591001 1008 10081782	16-55	11DEC2020	117858	BNT162b2 (30 µg)	11DEC2020/ BNT162b2 (30 µg)	30DEC2020/ BNT162b2 (30 µg)		
10081783	C4591001 1008 10081783	16-55	11DEC2020	117864	Placebo	11DEC2020/ Placebo	30DEC2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10081784	C4591001 1008 10081784	16-55	11DEC2020	117868	BNT162b2 (30 µg)	11DEC2020/ BNT162b2 (30 µg)	31DEC2020/ BNT162b2 (30 µg)		
10081786	C4591001 1008 10081786	16-55	11DEC2020	117882	Placebo	11DEC2020/ Placebo	30DEC2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
10091030	C4591001 1009 10091030	16-55	02SEP2020	76250	Placebo	02SEP2020/ Placebo	21SEP2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
10091046	C4591001 1009 10091046	16-55	14AUG2020	48242	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
10091053	C4591001 1009 10091053	16-55	14AUG2020	50938	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
10091056	C4591001 1009 10091056	16-55	17AUG2020	50939	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10091058	C4591001 1009 10091058	16-55	17AUG2020	53621	Placebo	17AUG2020/ Placebo	09SEP2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
10091059	C4591001 1009 10091059	16-55	17AUG2020	53625	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10091061	C4591001 1009 10091061	16-55	17AUG2020	53628	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
10091063	C4591001 1009 10091063	16-55	18AUG2020	53631	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10091066	C4591001 1009 10091066	16-55	18AUG2020	55508	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
10091068	C4591001 1009 10091068	16-55	18AUG2020	55512	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
10091070	C4591001 1009 10091070	16-55	19AUG2020	55515	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10091073	C4591001 1009 10091073	16-55	19AUG2020	55516	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
10091075	C4591001 1009 10091075	16-55	19AUG2020	57658	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	15JAN2021/ BNT162b2 (30 µg)
10091079	C4591001 1009 10091079	16-55	20AUG2020	57660	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10091080	C4591001 1009 10091080	16-55	20AUG2020	57661	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10091081	C4591001 1009 10091081	16-55	20AUG2020	57662	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10091082	C4591001 1009 10091082	16-55	20AUG2020	58649	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
10091084	C4591001 1009 10091084	16-55	20AUG2020	58650	Placebo	20AUG2020/ Placebo	11SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
10091085	C4591001 1009 10091085	16-55	20AUG2020	58657	Placebo	20AUG2020/ Placebo	08SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
10091086	C4591001 1009 10091086	16-55	20AUG2020	58659	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10091088	C4591001 1009 10091088	16-55	20AUG2020	59553	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
10091091	C4591001 1009 10091091	16-55	21AUG2020	59555	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10091092	C4591001 1009 10091092	16-55	21AUG2020	59558	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
10091095	C4591001 1009 10091095	16-55	21AUG2020	59559	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10091097	C4591001 1009 10091097	16-55	24AUG2020	63810	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
10091098	C4591001 1009 10091098	16-55	24AUG2020	63811	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10091102	C4591001 1009 10091102	16-55	24AUG2020	63814	Placebo	24AUG2020/ Placebo	16SEP2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
10091103	C4591001 1009 10091103	16-55	24AUG2020	63819	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10091105	C4591001 1009 10091105	16-55	25AUG2020	66044	Placebo	25AUG2020/ Placebo	17SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
10091106	C4591001 1009 10091106	16-55	25AUG2020	66046	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10091108	C4591001 1009 10091108	16-55	25AUG2020	66050	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10091109	C4591001 1009 10091109	16-55	25AUG2020	66051	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)
10091110	C4591001 1009 10091110	16-55	25AUG2020	67052	Placebo	25AUG2020/ Placebo	14SEP2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
10091112	C4591001 1009 10091112	16-55	26AUG2020	67053	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10091113	C4591001 1009 10091113	16-55	26AUG2020	67054	Placebo	26AUG2020/ Placebo	17SEP2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)
10091116	C4591001 1009 10091116	16-55	26AUG2020	67060	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10091117	C4591001 1009 10091117	16-55	26AUG2020	69306	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10091118	C4591001 1009 10091118	16-55	27AUG2020	69307	Placebo	27AUG2020/ Placebo	18SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
10091124	C4591001 1009 10091124	16-55	27AUG2020	69315	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10091128	C4591001 1009 10091128	16-55	28AUG2020	69316	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
10091129	C4591001 1009 10091129	16-55	28AUG2020	72716	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10091131	C4591001 1009 10091131	16-55	28AUG2020	72717	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
10091133	C4591001 1009 10091133	16-55	28AUG2020	72718	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo		
10091134	C4591001 1009 10091134	16-55	31AUG2020	72724	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10091138	C4591001 1009 10091138	16-55	31AUG2020	76244	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10091140	C4591001 1009 10091140	16-55	01SEP2020	76246	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10091142	C4591001 1009 10091142	16-55	01SEP2020	76247	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10091147	C4591001 1009 10091147	16-55	02SEP2020	79001	Placebo	02SEP2020/ Placebo	25SEP2020/ Placebo		
10091158	C4591001 1009 10091158	16-55	08SEP2020	79002	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
10091159	C4591001 1009 10091159	16-55	08SEP2020	79005	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10091163	C4591001 1009 10091163	16-55	09SEP2020	79006	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10091164	C4591001 1009 10091164	16-55	10SEP2020	86589	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
10091166	C4591001 1009 10091166	16-55	10SEP2020	86590	Placebo	10SEP2020/ Placebo	30SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
10091171	C4591001 1009 10091171	16-55	11SEP2020	86595	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10091172	C4591001 1009 10091172	16-55	11SEP2020	86596	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10091174	C4591001 1009 10091174	16-55	14SEP2020	89841	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
10091175	C4591001 1009 10091175	16-55	14SEP2020	89846	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
10091177	C4591001 1009 10091177	16-55	15SEP2020	89847	Placebo	15SEP2020/ Placebo	06OCT2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
10091178	C4591001 1009 10091178	16-55	15SEP2020	89848	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
10091183	C4591001 1009 10091183	16-55	17SEP2020	92897	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
10091184	C4591001 1009 10091184	16-55	18SEP2020	92898	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
10091185	C4591001 1009 10091185	16-55	18SEP2020	92902	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo		
10091186	C4591001 1009 10091186	16-55	21SEP2020	92908	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
10091187	C4591001 1009 10091187	16-55	21SEP2020	95765	Placebo	21SEP2020/ Placebo	13OCT2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10091188	C4591001 1009 10091188	16-55	21SEP2020	95767	Placebo	21SEP2020/ Placebo	13OCT2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
10091192	C4591001 1009 10091192	16-55	24SEP2020	95769	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
10091194	C4591001 1009 10091194	16-55	24SEP2020	95775	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
10091197	C4591001 1009 10091197	16-55	28SEP2020	101600	Placebo	28SEP2020/ Placebo	19OCT2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
10091198	C4591001 1009 10091198	16-55	28SEP2020	101601	BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)		
10091200	C4591001 1009 10091200	16-55	29SEP2020	101604	BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)		
10091201	C4591001 1009 10091201	16-55	13OCT2020	101607	Placebo	13OCT2020/ Placebo	02NOV2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
10091202	C4591001 1009 10091202	16-55	13OCT2020	107262	Placebo	13OCT2020/ Placebo	02NOV2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
10091203	C4591001 1009 10091203	16-55	15OCT2020	107269	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
10091206	C4591001 1009 10091206	16-55	15OCT2020	107270	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10091207	C4591001 1009 10091207	16-55	15OCT2020	107271	Placebo	15OCT2020/ Placebo	06NOV2020/ Placebo		
10091210	C4591001 1009 10091210	16-55	16OCT2020	108980	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
10091211	C4591001 1009 10091211	16-55	16OCT2020	108983	Placebo	16OCT2020/ Placebo		24FEB2021/ BNT162b2 (30 µg)	
10091214	C4591001 1009 10091214	16-55	16OCT2020	108984	Placebo	16OCT2020/ Placebo	04NOV2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	04JAN2021/ BNT162b2 (30 µg)
10091217	C4591001 1009 10091217	16-55	16OCT2020	108985	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
10091219	C4591001 1009 10091219	16-55	16OCT2020	109074	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
10091222	C4591001 1009 10091222	16-55	19OCT2020	109075	Placebo	19OCT2020/ Placebo	07NOV2020/ Placebo		
10091224	C4591001 1009 10091224	16-55	19OCT2020	109076	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		
10091225	C4591001 1009 10091225	16-55	20OCT2020	109081	Placebo	20OCT2020/ Placebo	10NOV2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
10091228	C4591001 1009 10091228	16-55	20OCT2020	111210	Placebo	20OCT2020/ Placebo	10NOV2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10091230	C4591001 1009 10091230	16-55	20OCT2020	111213	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	23NOV2020/ BNT162b2 (30 µg)		
10091232	C4591001 1009 10091232	16-55	21OCT2020	111216	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
10091235	C4591001 1009 10091235	16-55	21OCT2020	111217	Placebo	21OCT2020/ Placebo	11NOV2020/ Placebo		
10091236	C4591001 1009 10091236	16-55	21OCT2020	111799	Placebo	21OCT2020/ Placebo	11NOV2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
10091239	C4591001 1009 10091239	16-55	21OCT2020	111803	Placebo	21OCT2020/ Placebo	10NOV2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
10091241	C4591001 1009 10091241	16-55	21OCT2020	111805	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
10091242	C4591001 1009 10091242	16-55	22OCT2020	111807	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
10091243	C4591001 1009 10091243	16-55	22OCT2020	112520	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		
10091244	C4591001 1009 10091244	16-55	22OCT2020	112521	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	18NOV2020/ BNT162b2 (30 µg)		
10091252	C4591001 1009 10091252	16-55	23OCT2020	112522	Placebo	23OCT2020/ Placebo	11NOV2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10091253	C4591001 1009 10091253	16-55	26OCT2020	112525	Placebo	26OCT2020/ Placebo	16NOV2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
10091254	C4591001 1009 10091254	16-55	26OCT2020	113802	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
10091255	C4591001 1009 10091255	16-55	26OCT2020	113805	Placebo	26OCT2020/ Placebo	23NOV2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
10091256	C4591001 1009 10091256	16-55	27OCT2020	113808	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)		
10091257	C4591001 1009 10091257	16-55	27OCT2020	113810	Placebo	27OCT2020/ Placebo		02MAR2021/ BNT162b2 (30 µg)	
10091258	C4591001 1009 10091258	16-55	03NOV2020	115462	BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)	25NOV2020/ BNT162b2 (30 µg)		
10091259	C4591001 1009 10091259	16-55	03NOV2020	115463	Placebo	03NOV2020/ Placebo	25NOV2020/ Placebo	02MAR2021/ BNT162b2 (30 µg)	
10091260	C4591001 1009 10091260	16-55	11NOV2020	115465	BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)	02DEC2020/ BNT162b2 (30 µg)		
10091261	C4591001 1009 10091261	16-55	11NOV2020	115467	Placebo	11NOV2020/ Placebo	02DEC2020/ Placebo		
10091262	C4591001 1009 10091262	16-55	13NOV2020	116238	Placebo	13NOV2020/ Placebo	04DEC2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10091263	C4591001 1009 10091263	16-55	30NOV2020	116242	Placebo	30NOV2020/ Placebo	22DEC2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
10091264	C4591001 1009 10091264	16-55	30NOV2020	116243	BNT162b2 (30 µg)	30NOV2020/ BNT162b2 (30 µg)	21DEC2020/ BNT162b2 (30 µg)		
10091271	C4591001 1009 10091271	16-55	01DEC2020	116248	BNT162b2 (30 µg)	01DEC2020/ BNT162b2 (30 µg)	23DEC2020/ BNT162b2 (30 µg)		
10091276	C4591001 1009 10091276	16-55	03DEC2020	117306	BNT162b2 (30 µg)	03DEC2020/ BNT162b2 (30 µg)	22DEC2020/ BNT162b2 (30 µg)		
10091278	C4591001 1009 10091278	16-55	03DEC2020	117308	Placebo	03DEC2020/ Placebo	22DEC2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
10091279	C4591001 1009 10091279	16-55	03DEC2020	117310	BNT162b2 (30 µg)	03DEC2020/ BNT162b2 (30 µg)	22DEC2020/ BNT162b2 (30 µg)		
10091285	C4591001 1009 10091285	16-55	03DEC2020	117313	Placebo	03DEC2020/ Placebo	22DEC2020/ Placebo		
10091286	C4591001 1009 10091286	16-55	04DEC2020	117510	Placebo	04DEC2020/ Placebo	23DEC2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
10091290	C4591001 1009 10091290	16-55	04DEC2020	117513	BNT162b2 (30 µg)	04DEC2020/ BNT162b2 (30 µg)	23DEC2020/ BNT162b2 (30 µg)		
10091291	C4591001 1009 10091291	16-55	04DEC2020	117517	Placebo	04DEC2020/ Placebo	23DEC2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10091299	C4591001 1009 10091299	16-55	07DEC2020	117520	BNT162b2 (30 µg)	07DEC2020/ BNT162b2 (30 µg)	28DEC2020/ BNT162b2 (30 µg)		
10111042	C4591001 1011 10111042	16-55	14AUG2020	50282	Placebo	14AUG2020/ Placebo	08SEP2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
10111043	C4591001 1011 10111043	16-55	17AUG2020	50284	Placebo	17AUG2020/ Placebo	09SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
10111044	C4591001 1011 10111044	16-55	17AUG2020	52421	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10111046	C4591001 1011 10111046	16-55	17AUG2020	52425	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10111052	C4591001 1011 10111052	16-55	18AUG2020	52428	Placebo	18AUG2020/ Placebo	18SEP2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
10111053	C4591001 1011 10111053	16-55	18AUG2020	52432	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10111070	C4591001 1011 10111070	16-55	19AUG2020	56777	Placebo	19AUG2020/ Placebo	01OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
10111071	C4591001 1011 10111071	16-55	20AUG2020	56778	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
10111072	C4591001 1011 10111072	16-55	20AUG2020	56784	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10111074	C4591001 1011 10111074	16-55	20AUG2020	56787	Placebo	20AUG2020/ Placebo	08SEP2020/ Placebo		
10111077	C4591001 1011 10111077	16-55	20AUG2020	59742	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10111078	C4591001 1011 10111078	16-55	20AUG2020	59744	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10111079	C4591001 1011 10111079	16-55	20AUG2020	59746	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10111082	C4591001 1011 10111082	16-55	21AUG2020	59747	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10111087	C4591001 1011 10111087	16-55	24AUG2020	63546	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
10111088	C4591001 1011 10111088	16-55	24AUG2020	63547	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10111089	C4591001 1011 10111089	16-55	24AUG2020	63551	Placebo	24AUG2020/ Placebo	15SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
10111090	C4591001 1011 10111090	16-55	24AUG2020	63554	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10111091	C4591001 1011 10111091	16-55	25AUG2020	65145	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10111092	C4591001 1011 10111092	16-55	25AUG2020	65146	Placebo	25AUG2020/ Placebo	16SEP2020/ Placebo		
10111093	C4591001 1011 10111093	16-55	25AUG2020	65151	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10111094	C4591001 1011 10111094	16-55	25AUG2020	65152	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
10111095	C4591001 1011 10111095	16-55	25AUG2020	66281	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10111097	C4591001 1011 10111097	16-55	25AUG2020	66283	Placebo	25AUG2020/ Placebo	17SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10111098	C4591001 1011 10111098	16-55	26AUG2020	66289	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10111102	C4591001 1011 10111102	16-55	26AUG2020	66292	Placebo	26AUG2020/ Placebo	15SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
10111104	C4591001 1011 10111104	16-55	26AUG2020	68070	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10111106	C4591001 1011 10111106	16-55	27AUG2020	68073	Placebo	27AUG2020/ Placebo	18SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10111107	C4591001 1011 10111107	16-55	27AUG2020	68075	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10111111	C4591001 1011 10111111	16-55	27AUG2020	68078	Placebo	27AUG2020/ Placebo	18SEP2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
10111115	C4591001 1011 10111115	16-55	27AUG2020	71009	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
10111116	C4591001 1011 10111116	16-55	27AUG2020	71014	Placebo	27AUG2020/ Placebo	01OCT2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10111117	C4591001 1011 10111117	16-55	27AUG2020	71016	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10111118	C4591001 1011 10111118	16-55	28AUG2020	71017	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
10111119	C4591001 1011 10111119	16-55	28AUG2020	71561	Placebo	28AUG2020/ Placebo	17SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
10111122	C4591001 1011 10111122	16-55	28AUG2020	71565	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
10111123	C4591001 1011 10111123	16-55	28AUG2020	71566	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
10111124	C4591001 1011 10111124	16-55	28AUG2020	71571	Placebo	28AUG2020/ Placebo	17SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
10111125	C4591001 1011 10111125	16-55	28AUG2020	72355	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10111129	C4591001 1011 10111129	16-55	31AUG2020	72356	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10111130	C4591001 1011 10111130	16-55	31AUG2020	72357	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
10111134	C4591001 1011 10111134	16-55	01SEP2020	72363	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
10111135	C4591001 1011 10111135	16-55	01SEP2020	76374	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10111141	C4591001 1011 10111141	16-55	01SEP2020	76376	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
10111142	C4591001 1011 10111142	16-55	01SEP2020	76378	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10111143	C4591001 1011 10111143	16-55	02SEP2020	76379	Placebo	02SEP2020/ Placebo	24SEP2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)
10111144	C4591001 1011 10111144	16-55	02SEP2020	77864	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10111148	C4591001 1011 10111148	16-55	02SEP2020	77867	Placebo	02SEP2020/ Placebo	01OCT2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10111150	C4591001 1011 10111150	16-55	02SEP2020	77869	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10111151	C4591001 1011 10111151	16-55	02SEP2020	77871	Placebo	02SEP2020/ Placebo	24SEP2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
10111154	C4591001 1011 10111154	16-55	03SEP2020	79578	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10111159	C4591001 1011 10111159	16-55	03SEP2020	79581	Placebo	03SEP2020/ Placebo	23SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10111164	C4591001 1011 10111164	16-55	03SEP2020	79586	Placebo	03SEP2020/ Placebo	01OCT2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
10111166	C4591001 1011 10111166	16-55	03SEP2020	79588	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10111168	C4591001 1011 10111168	16-55	16SEP2020	91495	Placebo	16SEP2020/ Placebo	07OCT2020/ Placebo	24DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
10111169	C4591001 1011 10111169	16-55	06OCT2020	91500	BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		
10111170	C4591001 1011 10111170	16-55	06OCT2020	91502	BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)		
10111173	C4591001 1011 10111173	16-55	07OCT2020	91503	Placebo	07OCT2020/ Placebo	29OCT2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10111174	C4591001 1011 10111174	16-55	07OCT2020	104711	Placebo	07OCT2020/ Placebo	29OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10111175	C4591001 1011 10111175	16-55	13OCT2020	105540	Placebo	13OCT2020/ Placebo	30OCT2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10111176	C4591001 1011 10111176	16-55	07OCT2020	104712	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)		
10111179	C4591001 1011 10111179	16-55	08OCT2020	104714	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		
10111182	C4591001 1011 10111182	16-55	08OCT2020	104716	Placebo	08OCT2020/ Placebo	29OCT2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10111183	C4591001 1011 10111183	16-55	08OCT2020	105533	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)		
10111184	C4591001 1011 10111184	16-55	08OCT2020	105536	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
10111186	C4591001 1011 10111186	16-55	27OCT2020	112924	Placebo	27OCT2020/ Placebo	16NOV2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
10111190	C4591001 1011 10111190	16-55	13OCT2020	105542	Placebo	13OCT2020/ Placebo	06NOV2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)
10111193	C4591001 1011 10111193	16-55	14OCT2020	107442	BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
10111195	C4591001 1011 10111195	16-55	14OCT2020	107444	Placebo	14OCT2020/ Placebo	05NOV2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10111197	C4591001 1011 10111197	16-55	14OCT2020	107450	BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
10111199	C4591001 1011 10111199	16-55	15OCT2020	107452	Placebo	15OCT2020/ Placebo	12NOV2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	14JAN2021/ BNT162b2 (30 µg)
10111203	C4591001 1011 10111203	16-55	15OCT2020	108137	Placebo	15OCT2020/ Placebo	05NOV2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
10111210	C4591001 1011 10111210	16-55	15OCT2020	108138	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
10111211	C4591001 1011 10111211	16-55	26OCT2020	112915	Placebo	26OCT2020/ Placebo	16NOV2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
10111212	C4591001 1011 10111212	16-55	16OCT2020	108141	Placebo	16OCT2020/ Placebo	06NOV2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
10111213	C4591001 1011 10111213	16-55	16OCT2020	108143	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
10111214	C4591001 1011 10111214	16-55	19OCT2020	110096	Placebo	19OCT2020/ Placebo	13NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10111215	C4591001 1011 10111215	16-55	19OCT2020	110094	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
10111216	C4591001 1011 10111216	16-55	19OCT2020	110098	Placebo	19OCT2020/ Placebo	11NOV2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10111219	C4591001 1011 10111219	16-55	20OCT2020	110099	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
10111220	C4591001 1011 10111220	16-55	20OCT2020	111221	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
10111222	C4591001 1011 10111222	16-55	21OCT2020	111226	Placebo	21OCT2020/ Placebo	11NOV2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10111224	C4591001 1011 10111224	16-55	21OCT2020	111227	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
10111227	C4591001 1011 10111227	16-55	23OCT2020	112913	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
10111228	C4591001 1011 10111228	16-55	23OCT2020	111231	Placebo	23OCT2020/ Placebo	13NOV2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10111232	C4591001 1011 10111232	16-55	27OCT2020	112916	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	20NOV2020/ BNT162b2 (30 µg)		
10111233	C4591001 1011 10111233	16-55	29OCT2020	114594	Placebo	29OCT2020/ Placebo	19NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10111234	C4591001 1011 10111234	16-55	29OCT2020	114597	Placebo	29OCT2020/ Placebo	19NOV2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)
10111235	C4591001 1011 10111235	16-55	30OCT2020	114601	BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)	20NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10111236	C4591001 1011 10111236	16-55	30OCT2020	114604	BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)	20NOV2020/ BNT162b2 (30 µg)		
10111237	C4591001 1011 10111237	16-55	30OCT2020	115027	BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)	20NOV2020/ BNT162b2 (30 µg)		
10121043	C4591001 1012 10121043	16-55	18AUG2020	51059	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
10121046	C4591001 1012 10121046	16-55	19AUG2020	51061	Placebo	19AUG2020/ Placebo	08SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
10121051	C4591001 1012 10121051	16-55	20AUG2020	51062	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10121053	C4591001 1012 10121053	16-55	20AUG2020	58915	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10121055	C4591001 1012 10121055	16-55	20AUG2020	58918	Placebo	20AUG2020/ Placebo	09SEP2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	23JAN2021/ BNT162b2 (30 µg)
10121058	C4591001 1012 10121058	16-55	21AUG2020	58919	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10121059	C4591001 1012 10121059	16-55	21AUG2020	58924	Placebo	21AUG2020/ Placebo	10SEP2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
10121061	C4591001 1012 10121061	16-55	24AUG2020	63906	Placebo	24AUG2020/ Placebo	15SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10121065	C4591001 1012 10121065	16-55	24AUG2020	63910	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
10121066	C4591001 1012 10121066	16-55	25AUG2020	63914	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10121072	C4591001 1012 10121072	16-55	26AUG2020	63916	Placebo	26AUG2020/ Placebo	17SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	
10121073	C4591001 1012 10121073	16-55	26AUG2020	68274	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10121074	C4591001 1012 10121074	16-55	26AUG2020	68277	Placebo	26AUG2020/ Placebo	15SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10121076	C4591001 1012 10121076	16-55	26AUG2020	68280	Placebo	26AUG2020/ Placebo	15SEP2020/ Placebo	30JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
10121078	C4591001 1012 10121078	16-55	27AUG2020	68281	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10121079	C4591001 1012 10121079	16-55	27AUG2020	70481	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10121082	C4591001 1012 10121082	16-55	27AUG2020	70486	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10121083	C4591001 1012 10121083	16-55	27AUG2020	70487	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10121085	C4591001 1012 10121085	16-55	28AUG2020	70492	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
10121087	C4591001 1012 10121087	16-55	28AUG2020	72953	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10121089	C4591001 1012 10121089	16-55	28AUG2020	72957	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
10121090	C4591001 1012 10121090	16-55	28AUG2020	72959	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
10121091	C4591001 1012 10121091	16-55	31AUG2020	72964	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10121092	C4591001 1012 10121092	16-55	31AUG2020	75138	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10121095	C4591001 1012 10121095	16-55	31AUG2020	75144	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo		
10121096	C4591001 1012 10121096	16-55	31AUG2020	75145	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo		
10121101	C4591001 1012 10121101	16-55	01SEP2020	75146	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10121102	C4591001 1012 10121102	16-55	01SEP2020	76842	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10121103	C4591001 1012 10121103	16-55	01SEP2020	76845	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ Placebo		
10121104	C4591001 1012 10121104	16-55	01SEP2020	76849	Placebo	01SEP2020/ Placebo	02OCT2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
10121105	C4591001 1012 10121105	16-55	01SEP2020	76848	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10121107	C4591001 1012 10121107	16-55	01SEP2020	77444	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	28JAN2021/ BNT162b2 (30 µg)
10121108	C4591001 1012 10121108	16-55	01SEP2020	77446	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10121110	C4591001 1012 10121110	16-55	01SEP2020	77450	Placebo	01SEP2020/ Placebo	23SEP2020/ Placebo		
10121111	C4591001 1012 10121111	16-55	02SEP2020	77452	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10121116	C4591001 1012 10121116	16-55	02SEP2020	79291	Placebo	02SEP2020/ Placebo	24SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
10121117	C4591001 1012 10121117	16-55	02SEP2020	79290	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10121118	C4591001 1012 10121118	16-55	02SEP2020	79296	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10121119	C4591001 1012 10121119	16-55	02SEP2020	79300	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo		
10121121	C4591001 1012 10121121	16-55	02SEP2020	79471	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10121124	C4591001 1012 10121124	16-55	03SEP2020	79472	Placebo	03SEP2020/ Placebo	25SEP2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
10121130	C4591001 1012 10121130	16-55	03SEP2020	79477	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	23JAN2021/ BNT162b2 (30 µg)
10121131	C4591001 1012 10121131	16-55	04SEP2020	79478	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
10121132	C4591001 1012 10121132	16-55	04SEP2020	81703	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10121133	C4591001 1012 10121133	16-55	04SEP2020	81706	Placebo	04SEP2020/ Placebo	23SEP2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10121134	C4591001 1012 10121134	16-55	04SEP2020	81707	Placebo	04SEP2020/ Placebo	23SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
10121136	C4591001 1012 10121136	16-55	04SEP2020	81709	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
10121137	C4591001 1012 10121137	16-55	04SEP2020	82553	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10121138	C4591001 1012 10121138	16-55	05SEP2020	82559	Placebo	05SEP2020/ Placebo	25SEP2020/ Placebo		
10121141	C4591001 1012 10121141	16-55	05SEP2020	82560	Placebo	05SEP2020/ Placebo	25SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
10121143	C4591001 1012 10121143	16-55	05SEP2020	82563	BNT162b2 (30 µg)	05SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10121144	C4591001 1012 10121144	16-55	05SEP2020	82878	Placebo	05SEP2020/ Placebo	28SEP2020/ Placebo	23JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
10121145	C4591001 1012 10121145	16-55	05SEP2020	82881	BNT162b2 (30 µg)	05SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
10121146	C4591001 1012 10121146	16-55	05SEP2020	82883	BNT162b2 (30 µg)	05SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
10121151	C4591001 1012 10121151	16-55	08SEP2020	83975	Placebo	08SEP2020/ Placebo	02OCT2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	
10121153	C4591001 1012 10121153	16-55	08SEP2020	84197	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
10121154	C4591001 1012 10121154	16-55	08SEP2020	84198	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
10121155	C4591001 1012 10121155	16-55	08SEP2020	84202	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10121156	C4591001 1012 10121156	16-55	09SEP2020	84203	Placebo	09SEP2020/ Placebo	08OCT2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
10121157	C4591001 1012 10121157	16-55	11SEP2020	88155	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
10121158	C4591001 1012 10121158	16-55	09SEP2020	85506	Placebo	09SEP2020/ Placebo	28SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10121162	C4591001 1012 10121162	16-55	09SEP2020	85509	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
10121163	C4591001 1012 10121163	16-55	09SEP2020	85512	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)			
10121164	C4591001 1012 10121164	16-55	10SEP2020	85515	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
10121166	C4591001 1012 10121166	16-55	10SEP2020	86849	Placebo	10SEP2020/ Placebo	30SEP2020/ Placebo		
10121172	C4591001 1012 10121172	16-55	10SEP2020	86852	Placebo	10SEP2020/ Placebo	02OCT2020/ Placebo	23JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
10121173	C4591001 1012 10121173	16-55	10SEP2020	86850	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
10121174	C4591001 1012 10121174	16-55	10SEP2020	86859	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10121178	C4591001 1012 10121178	16-55	11SEP2020	88145	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
10121180	C4591001 1012 10121180	16-55	11SEP2020	88146	Placebo	11SEP2020/ Placebo	30SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
10121181	C4591001 1012 10121181	16-55	11SEP2020	88147	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
10121182	C4591001 1012 10121182	16-55	11SEP2020	88517	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
10121183	C4591001 1012 10121183	16-55	11SEP2020	88519	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
10121185	C4591001 1012 10121185	16-55	11SEP2020	88521	Placebo	11SEP2020/ Placebo	30SEP2020/ Placebo		
10121187	C4591001 1012 10121187	16-55	11SEP2020	88525	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10121188	C4591001 1012 10121188	16-55	11SEP2020	88926	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
10131017	C4591001 1013 10131017	16-55	30JUL2020	40132	Placebo				
10131027	C4591001 1013 10131027	16-55	17AUG2020	52443	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10131112	C4591001 1013 10131112	16-55	02SEP2020	76876	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10131134	C4591001 1013 10131134	16-55	18AUG2020	52895	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10131187	C4591001 1013 10131187	16-55	17AUG2020	49015	Placebo	17AUG2020/ Placebo	09SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
10131188	C4591001 1013 10131188	16-55	17AUG2020	49017	Placebo	17AUG2020/ Placebo	09SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10131190	C4591001 1013 10131190	16-55	17AUG2020	49018	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10131195	C4591001 1013 10131195	16-55	17AUG2020	52439	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10131196	C4591001 1013 10131196	16-55	17AUG2020	52435	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10131197	C4591001 1013 10131197	16-55	17AUG2020	52437	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
10131199	C4591001 1013 10131199	16-55	17AUG2020	52613	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10131200	C4591001 1013 10131200	16-55	17AUG2020	52614	Placebo	17AUG2020/ Placebo	09SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10131204	C4591001 1013 10131204	16-55	17AUG2020	52622	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10131205	C4591001 1013 10131205	16-55	17AUG2020	52620	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
10131207	C4591001 1013 10131207	16-55	17AUG2020	52890	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10131209	C4591001 1013 10131209	16-55	18AUG2020	54017	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10131210	C4591001 1013 10131210	16-55	18AUG2020	54020	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
10131211	C4591001 1013 10131211	16-55	18AUG2020	52898	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10131214	C4591001 1013 10131214	16-55	18AUG2020	54022	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10131215	C4591001 1013 10131215	16-55	18AUG2020	54026	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
10131216	C4591001 1013 10131216	16-55	18AUG2020	52900	Placebo	18AUG2020/ Placebo			
10131218	C4591001 1013 10131218	16-55	18AUG2020	54118	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10131219	C4591001 1013 10131219	16-55	18AUG2020	54116	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
10131220	C4591001 1013 10131220	16-55	18AUG2020	54114	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
10131221	C4591001 1013 10131221	16-55	18AUG2020	54117	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10131223	C4591001 1013 10131223	16-55	18AUG2020	54281	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10131224	C4591001 1013 10131224	16-55	18AUG2020	54289	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo		
10131225	C4591001 1013 10131225	16-55	18AUG2020	54288	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10131228	C4591001 1013 10131228	16-55	19AUG2020	54292	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
10131229	C4591001 1013 10131229	16-55	19AUG2020	55842	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo		
10131231	C4591001 1013 10131231	16-55	19AUG2020	55845	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10131237	C4591001 1013 10131237	16-55	19AUG2020	55849	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10131238	C4591001 1013 10131238	16-55	19AUG2020	55846	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo		
10131239	C4591001 1013 10131239	16-55	19AUG2020	56085	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10131241	C4591001 1013 10131241	16-55	19AUG2020	56086	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
10131245	C4591001 1013 10131245	16-55	19AUG2020	56088	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10131246	C4591001 1013 10131246	16-55	19AUG2020	56092	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
10131250	C4591001 1013 10131250	16-55	20AUG2020	58019	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10131251	C4591001 1013 10131251	16-55	20AUG2020	58014	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10131252	C4591001 1013 10131252	16-55	20AUG2020	58018	Placebo	20AUG2020/ Placebo	08SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
10131254	C4591001 1013 10131254	16-55	20AUG2020	58021	Placebo	20AUG2020/ Placebo	16SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
10131255	C4591001 1013 10131255	16-55	20AUG2020	58170	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10131256	C4591001 1013 10131256	16-55	20AUG2020	58172	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
10131258	C4591001 1013 10131258	16-55	20AUG2020	58177	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10131259	C4591001 1013 10131259	16-55	20AUG2020	58179	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10131263	C4591001 1013 10131263	16-55	20AUG2020	58558	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10131264	C4591001 1013 10131264	16-55	20AUG2020	58563	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
10131266	C4591001 1013 10131266	16-55	20AUG2020	58561	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10131267	C4591001 1013 10131267	16-55	20AUG2020	58688	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
10131268	C4591001 1013 10131268	16-55	20AUG2020	58690	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
10131269	C4591001 1013 10131269	16-55	20AUG2020	58564	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
10131271	C4591001 1013 10131271	16-55	24AUG2020	58691	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10131275	C4591001 1013 10131275	16-55	24AUG2020	63462	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
10131276	C4591001 1013 10131276	16-55	24AUG2020	58695	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10131280	C4591001 1013 10131280	16-55	24AUG2020	63464	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10131281	C4591001 1013 10131281	16-55	24AUG2020	63467	Placebo	24AUG2020/ Placebo	15SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
10131283	C4591001 1013 10131283	16-55	24AUG2020	63465	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10131285	C4591001 1013 10131285	16-55	24AUG2020	63617	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10131287	C4591001 1013 10131287	16-55	24AUG2020	63618	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10131288	C4591001 1013 10131288	16-55	24AUG2020	63624	Placebo	24AUG2020/ Placebo	15SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10131290	C4591001 1013 10131290	16-55	24AUG2020	63626	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
10131291	C4591001 1013 10131291	16-55	24AUG2020	63801	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10131292	C4591001 1013 10131292	16-55	25AUG2020	63802	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10131293	C4591001 1013 10131293	16-55	25AUG2020	63804	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10131296	C4591001 1013 10131296	16-55	25AUG2020	63808	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
10131299	C4591001 1013 10131299	16-55	25AUG2020	65537	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10131302	C4591001 1013 10131302	16-55	25AUG2020	65547	Placebo	25AUG2020/ Placebo	14SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10131303	C4591001 1013 10131303	16-55	25AUG2020	65804	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10131304	C4591001 1013 10131304	16-55	25AUG2020	65543	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10131305	C4591001 1013 10131305	16-55	25AUG2020	65548	Placebo	25AUG2020/ Placebo	17SEP2020/ Placebo		
10131307	C4591001 1013 10131307	16-55	25AUG2020	65899	Placebo	25AUG2020/ Placebo	16SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	
10131308	C4591001 1013 10131308	16-55	25AUG2020	65839	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10131309	C4591001 1013 10131309	16-55	25AUG2020	65900	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10131311	C4591001 1013 10131311	16-55	25AUG2020	65903	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10131312	C4591001 1013 10131312	16-55	25AUG2020	65904	Placebo	25AUG2020/ Placebo	17SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10131313	C4591001 1013 10131313	16-55	26AUG2020	67248	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10131315	C4591001 1013 10131315	16-55	26AUG2020	67244	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10131316	C4591001 1013 10131316	16-55	26AUG2020	67242	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10131317	C4591001 1013 10131317	16-55	26AUG2020	67321	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10131318	C4591001 1013 10131318	16-55	26AUG2020	67316	Placebo	26AUG2020/ Placebo	15SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10131319	C4591001 1013 10131319	16-55	26AUG2020	67251	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
10131321	C4591001 1013 10131321	16-55	26AUG2020	67323	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10131322	C4591001 1013 10131322	16-55	26AUG2020	67322	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
10131325	C4591001 1013 10131325	16-55	26AUG2020	67505	Placebo	26AUG2020/ Placebo	17SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
10131332	C4591001 1013 10131332	16-55	26AUG2020	67506	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10131338	C4591001 1013 10131338	16-55	27AUG2020	67514	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10131339	C4591001 1013 10131339	16-55	27AUG2020	67516	Placebo	27AUG2020/ Placebo	16SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10131340	C4591001 1013 10131340	16-55	27AUG2020	69813	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10131343	C4591001 1013 10131343	16-55	27AUG2020	69815	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10131348	C4591001 1013 10131348	16-55	27AUG2020	69818	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10131349	C4591001 1013 10131349	16-55	27AUG2020	70088	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10131351	C4591001 1013 10131351	16-55	27AUG2020	69819	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10131352	C4591001 1013 10131352	16-55	27AUG2020	70089	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10131353	C4591001 1013 10131353	16-55	27AUG2020	70093	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
10131355	C4591001 1013 10131355	16-55	31AUG2020	70096	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10131357	C4591001 1013 10131357	16-55	31AUG2020	74730	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10131361	C4591001 1013 10131361	16-55	31AUG2020	74731	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10131364	C4591001 1013 10131364	16-55	31AUG2020	74739	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	04JAN2021/ BNT162b2 (30 µg)
10131365	C4591001 1013 10131365	16-55	31AUG2020	74921	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10131366	C4591001 1013 10131366	16-55	31AUG2020	74737	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
10131370	C4591001 1013 10131370	16-55	31AUG2020	74925	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10131371	C4591001 1013 10131371	16-55	31AUG2020	74926	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10131373	C4591001 1013 10131373	16-55	31AUG2020	75188	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo		
10131375	C4591001 1013 10131375	16-55	31AUG2020	74931	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
10131376	C4591001 1013 10131376	16-55	09SEP2020	84956	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
10131377	C4591001 1013 10131377	16-55	31AUG2020	75191	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10131379	C4591001 1013 10131379	16-55	01SEP2020	75194	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10131381	C4591001 1013 10131381	16-55	01SEP2020	75195	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
10131383	C4591001 1013 10131383	16-55	01SEP2020	76399	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
10131385	C4591001 1013 10131385	16-55	01SEP2020	76400	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10131388	C4591001 1013 10131388	16-55	01SEP2020	76403	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	02MAR2021/ BNT162b2 (30 µg)	
10131389	C4591001 1013 10131389	16-55	01SEP2020	76717	Placebo	01SEP2020/ Placebo	21SEP2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10131391	C4591001 1013 10131391	16-55	01SEP2020	76404	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10131394	C4591001 1013 10131394	16-55	01SEP2020	76718	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10131395	C4591001 1013 10131395	16-55	01SEP2020	76719	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10131396	C4591001 1013 10131396	16-55	01SEP2020	76720	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10131397	C4591001 1013 10131397	16-55	01SEP2020	76865	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10131398	C4591001 1013 10131398	16-55	02SEP2020	76867	Placebo	02SEP2020/ Placebo	22SEP2020/ Placebo		
10131400	C4591001 1013 10131400	16-55	02SEP2020	77937	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10131401	C4591001 1013 10131401	16-55	02SEP2020	76875	Placebo	02SEP2020/ Placebo	24SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
10131403	C4591001 1013 10131403	16-55	02SEP2020	77941	Placebo	02SEP2020/ Placebo	22SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
10131405	C4591001 1013 10131405	16-55	02SEP2020	77944	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10131406	C4591001 1013 10131406	16-55	02SEP2020	77942	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
10131407	C4591001 1013 10131407	16-55	02SEP2020	78185	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10131408	C4591001 1013 10131408	16-55	02SEP2020	78193	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10131409	C4591001 1013 10131409	16-55	02SEP2020	78187	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
10131411	C4591001 1013 10131411	16-55	02SEP2020	78269	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10131412	C4591001 1013 10131412	16-55	02SEP2020	78272	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10131413	C4591001 1013 10131413	16-55	02SEP2020	78196	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10131416	C4591001 1013 10131416	16-55	02SEP2020	78347	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10131417	C4591001 1013 10131417	16-55	02SEP2020	78275	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
10131418	C4591001 1013 10131418	16-55	02SEP2020	78276	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10131419	C4591001 1013 10131419	16-55	02SEP2020	78349	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10131420	C4591001 1013 10131420	16-55	02SEP2020	78343	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
10131421	C4591001 1013 10131421	16-55	02SEP2020	78345	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10131422	C4591001 1013 10131422	16-55	03SEP2020	79590	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10131423	C4591001 1013 10131423	16-55	03SEP2020	79597	Placebo	03SEP2020/ Placebo	23SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10131424	C4591001 1013 10131424	16-55	03SEP2020	79593	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10131425	C4591001 1013 10131425	16-55	03SEP2020	79641	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10131426	C4591001 1013 10131426	16-55	03SEP2020	79595	Placebo	03SEP2020/ Placebo			
10131427	C4591001 1013 10131427	16-55	03SEP2020	79645	Placebo	03SEP2020/ Placebo	22SEP2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
10131430	C4591001 1013 10131430	16-55	03SEP2020	79646	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10131432	C4591001 1013 10131432	16-55	03SEP2020	79648	Placebo	03SEP2020/ Placebo	23SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
10131436	C4591001 1013 10131436	16-55	03SEP2020	79856	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10131437	C4591001 1013 10131437	16-55	03SEP2020	79859	Placebo	03SEP2020/ Placebo	22SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
10131438	C4591001 1013 10131438	16-55	03SEP2020	79864	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10131439	C4591001 1013 10131439	16-55	03SEP2020	79860	Placebo	03SEP2020/ Placebo	22SEP2020/ Placebo		
10131440	C4591001 1013 10131440	16-55	03SEP2020	80011	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10131441	C4591001 1013 10131441	16-55	03SEP2020	80014	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
10131442	C4591001 1013 10131442	16-55	03SEP2020	80015	Placebo	03SEP2020/ Placebo	23SEP2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)
10131444	C4591001 1013 10131444	16-55	03SEP2020	80020	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10131445	C4591001 1013 10131445	16-55	08SEP2020	83393	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10131446	C4591001 1013 10131446	16-55	08SEP2020	83311	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
10131447	C4591001 1013 10131447	16-55	08SEP2020	83315	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
10131448	C4591001 1013 10131448	16-55	08SEP2020	83318	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
10131449	C4591001 1013 10131449	16-55	08SEP2020	83317	Placebo	08SEP2020/ Placebo	30SEP2020/ Placebo	02MAR2021/ BNT162b2 (30 µg)	
10131451	C4591001 1013 10131451	16-55	08SEP2020	83403	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
10131452	C4591001 1013 10131452	16-55	08SEP2020	83402	Placebo	08SEP2020/ Placebo	01OCT2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
10131454	C4591001 1013 10131454	16-55	08SEP2020	83397	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
10131458	C4591001 1013 10131458	16-55	08SEP2020	83516	Placebo	08SEP2020/ Placebo	01OCT2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
10131459	C4591001 1013 10131459	16-55	08SEP2020	83515	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
10131463	C4591001 1013 10131463	16-55	08SEP2020	83518	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10131464	C4591001 1013 10131464	16-55	08SEP2020	83520	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
10131467	C4591001 1013 10131467	16-55	08SEP2020	83711	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
10131468	C4591001 1013 10131468	16-55	08SEP2020	83714	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
10131469	C4591001 1013 10131469	16-55	08SEP2020	83715	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
10131470	C4591001 1013 10131470	16-55	08SEP2020	83709	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo		
10131471	C4591001 1013 10131471	16-55	08SEP2020	83790	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
10131472	C4591001 1013 10131472	16-55	09SEP2020	83798	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10131473	C4591001 1013 10131473	16-55	09SEP2020	83799	Placebo	09SEP2020/ Placebo	01OCT2020/ Placebo	03MAR2021/ BNT162b2 (30 µg)	
10131474	C4591001 1013 10131474	16-55	09SEP2020	83795	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10131475	C4591001 1013 10131475	16-55	09SEP2020	84846	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10131476	C4591001 1013 10131476	16-55	09SEP2020	84852	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
10131477	C4591001 1013 10131477	16-55	09SEP2020	84850	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
10131478	C4591001 1013 10131478	16-55	09SEP2020	84849	Placebo	09SEP2020/ Placebo	28SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
10131484	C4591001 1013 10131484	16-55	09SEP2020	84955	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
10131486	C4591001 1013 10131486	16-55	09SEP2020	84959	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10131487	C4591001 1013 10131487	16-55	09SEP2020	84957	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	03MAR2021/ BNT162b2 (30 µg)	
10131492	C4591001 1013 10131492	16-55	09SEP2020	85230	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
10131493	C4591001 1013 10131493	16-55	09SEP2020	85233	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
10131498	C4591001 1013 10131498	16-55	09SEP2020	85235	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
10131499	C4591001 1013 10131499	16-55	10SEP2020	86408	Placebo	10SEP2020/ Placebo	30SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10131500	C4591001 1013 10131500	16-55	10SEP2020	86405	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
10131501	C4591001 1013 10131501	16-55	10SEP2020	85240	Placebo	10SEP2020/ Placebo	29SEP2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
10131502	C4591001 1013 10131502	16-55	10SEP2020	86409	Placebo	10SEP2020/ Placebo	30SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
10131503	C4591001 1013 10131503	16-55	10SEP2020	86477	Placebo	10SEP2020/ Placebo	29SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10131504	C4591001 1013 10131504	16-55	10SEP2020	86416	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
10131507	C4591001 1013 10131507	16-55	10SEP2020	86480	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
10131513	C4591001 1013 10131513	16-55	10SEP2020	86487	Placebo	10SEP2020/ Placebo	30SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10131514	C4591001 1013 10131514	16-55	10SEP2020	86488	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10131515	C4591001 1013 10131515	16-55	10SEP2020	86813	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
10131518	C4591001 1013 10131518	16-55	10SEP2020	86820	Placebo	10SEP2020/ Placebo	30SEP2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10131522	C4591001 1013 10131522	16-55	14SEP2020	86821	Placebo	14SEP2020/ Placebo	07OCT2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
10131524	C4591001 1013 10131524	16-55	14SEP2020	86824	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
10131526	C4591001 1013 10131526	16-55	14SEP2020	89601	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
10131529	C4591001 1013 10131529	16-55	14SEP2020	89604	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
10131530	C4591001 1013 10131530	16-55	15SEP2020	89607	Placebo	15SEP2020/ Placebo	05OCT2020/ Placebo		
10131531	C4591001 1013 10131531	16-55	15SEP2020	89605	Placebo	15SEP2020/ Placebo	08OCT2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
10131532	C4591001 1013 10131532	16-55	15SEP2020	90155	Placebo	15SEP2020/ Placebo	05OCT2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
10131533	C4591001 1013 10131533	16-55	15SEP2020	90153	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
10131534	C4591001 1013 10131534	16-55	15SEP2020	90149	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
10131535	C4591001 1013 10131535	16-55	15SEP2020	90152	Placebo	15SEP2020/ Placebo	07OCT2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10131538	C4591001 1013 10131538	16-55	15SEP2020	90213	Placebo	15SEP2020/ Placebo	06OCT2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
10131541	C4591001 1013 10131541	16-55	15SEP2020	90218	Placebo	15SEP2020/ Placebo	06OCT2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
10131542	C4591001 1013 10131542	16-55	15SEP2020	90214	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
10131544	C4591001 1013 10131544	16-55	15SEP2020	90437	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
10131545	C4591001 1013 10131545	16-55	15SEP2020	90440	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
10131546	C4591001 1013 10131546	16-55	15SEP2020	90220	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
10131550	C4591001 1013 10131550	16-55	16SEP2020	90446	Placebo	16SEP2020/ Placebo	05OCT2020/ Placebo		
10131552	C4591001 1013 10131552	16-55	16SEP2020	90992	Placebo	16SEP2020/ Placebo	05OCT2020/ Placebo		
10131553	C4591001 1013 10131553	16-55	16SEP2020	90448	Placebo	16SEP2020/ Placebo	06OCT2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
10131556	C4591001 1013 10131556	16-55	16SEP2020	90997	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10131557	C4591001 1013 10131557	16-55	16SEP2020	90998	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
10131559	C4591001 1013 10131559	16-55	16SEP2020	91000	Placebo	16SEP2020/ Placebo	06OCT2020/ Placebo	31DEC2020/ BNT162b2 (30 µg)	22JAN2021/ BNT162b2 (30 µg)
10131562	C4591001 1013 10131562	16-55	16SEP2020	91220	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
10131563	C4591001 1013 10131563	16-55	16SEP2020	91223	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
10131564	C4591001 1013 10131564	16-55	16SEP2020	91222	Placebo	16SEP2020/ Placebo	06OCT2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
10131565	C4591001 1013 10131565	16-55	16SEP2020	91226	Placebo	16SEP2020/ Placebo	07OCT2020/ Placebo	03MAR2021/ BNT162b2 (30 µg)	
10131567	C4591001 1013 10131567	16-55	17SEP2020	92030	Placebo	17SEP2020/ Placebo	07OCT2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10131568	C4591001 1013 10131568	16-55	17SEP2020	92021	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
10131569	C4591001 1013 10131569	16-55	17SEP2020	92022	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
10131570	C4591001 1013 10131570	16-55	17SEP2020	92023	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10131571	C4591001 1013 10131571†	16-55	17SEP2020	92110	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
10131572	C4591001 1013 10131572†	16-55	17SEP2020	92111	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
10131573	C4591001 1013 10131573	16-55	17SEP2020	92112	Placebo	17SEP2020/ Placebo	07OCT2020/ Placebo		
10131575	C4591001 1013 10131575	16-55	17SEP2020	92321	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
10131576	C4591001 1013 10131576	16-55	17SEP2020	92114	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo		
10131580	C4591001 1013 10131580	16-55	17SEP2020	92325	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
10131581	C4591001 1013 10131581	16-55	17SEP2020	92329	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
10131582	C4591001 1013 10131582	16-55	17SEP2020	92331	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10131585	C4591001 1013 10131585	16-55	17SEP2020	92465	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
10131586	C4591001 1013 10131586	16-55	17SEP2020	92468	Placebo	17SEP2020/ Placebo	07OCT2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10131587	C4591001 1013 10131587	16-55	21SEP2020	94689	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
10131588	C4591001 1013 10131588	16-55	21SEP2020	92470	Placebo	21SEP2020/ Placebo	15OCT2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
10131589	C4591001 1013 10131589	16-55	21SEP2020	92476	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
10131591	C4591001 1013 10131591	16-55	21SEP2020	94688	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
10131592	C4591001 1013 10131592	16-55	21SEP2020	94693	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo		
10131593	C4591001 1013 10131593	16-55	21SEP2020	94762	Placebo	21SEP2020/ Placebo	14OCT2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
10131594	C4591001 1013 10131594	16-55	21SEP2020	94760	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
10131595	C4591001 1013 10131595	16-55	21SEP2020	94696	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	02MAR2021/ BNT162b2 (30 µg)	
10131597	C4591001 1013 10131597	16-55	21SEP2020	94764	Placebo	21SEP2020/ Placebo	14OCT2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
10131598	C4591001 1013 10131598	16-55	21SEP2020	94944	Placebo	21SEP2020/ Placebo	13OCT2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10131599	C4591001 1013 10131599	16-55	21SEP2020	94768	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
10131600	C4591001 1013 10131600	16-55	21SEP2020	94943	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
10131601	C4591001 1013 10131601	16-55	21SEP2020	94937	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
10131603	C4591001 1013 10131603	16-55	22SEP2020	94948	Placebo	22SEP2020/ Placebo	13OCT2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10131605	C4591001 1013 10131605	16-55	22SEP2020	96234	Placebo	22SEP2020/ Placebo	15OCT2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
10131606	C4591001 1013 10131606	16-55	22SEP2020	96241	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
10131607	C4591001 1013 10131607	16-55	22SEP2020	96240	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
10131608	C4591001 1013 10131608	16-55	22SEP2020	96236	Placebo	22SEP2020/ Placebo	13OCT2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
10131611	C4591001 1013 10131611	16-55	22SEP2020	96368	Placebo	22SEP2020/ Placebo	12OCT2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
10131612	C4591001 1013 10131612	16-55	22SEP2020	96370	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10131613	C4591001 1013 10131613	16-55	23SEP2020	96373	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
10131614	C4591001 1013 10131614†	16-55	23SEP2020	97433	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
10131616	C4591001 1013 10131616	16-55	23SEP2020	96375	Placebo	23SEP2020/ Placebo	15OCT2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10131619	C4591001 1013 10131619	16-55	23SEP2020	97435	Placebo	23SEP2020/ Placebo	13OCT2020/ Placebo		
10131621	C4591001 1013 10131621	16-55	24SEP2020	97442	Placebo	24SEP2020/ Placebo	19OCT2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
10131622	C4591001 1013 10131622	16-55	24SEP2020	97443	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
10131624	C4591001 1013 10131624	16-55	24SEP2020	98729	Placebo	24SEP2020/ Placebo	14OCT2020/ Placebo	03MAR2021/ BNT162b2 (30 µg)	
10131625	C4591001 1013 10131625	16-55	24SEP2020	98730	Placebo	24SEP2020/ Placebo	14OCT2020/ Placebo	02MAR2021/ BNT162b2 (30 µg)	
10131626	C4591001 1013 10131626	16-55	24SEP2020	98731	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
10131628	C4591001 1013 10131628	16-55	05OCT2020	103712	Placebo	05OCT2020/ Placebo	26OCT2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10131629	C4591001 1013 10131629	16-55	05OCT2020	98739	BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		
10131630	C4591001 1013 10131630	16-55	05OCT2020	103716	BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
10131632	C4591001 1013 10131632	16-55	05OCT2020	103714	Placebo	05OCT2020/ Placebo	26OCT2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
10131633	C4591001 1013 10131633	16-55	05OCT2020	103717	BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		
10131634	C4591001 1013 10131634	16-55	05OCT2020	103781	Placebo	05OCT2020/ Placebo	27OCT2020/ Placebo		
10131635	C4591001 1013 10131635	16-55	06OCT2020	103783	BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)		
10131636	C4591001 1013 10131636	16-55	06OCT2020	103782	Placebo	06OCT2020/ Placebo	28OCT2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
10131637	C4591001 1013 10131637	16-55	06OCT2020	103787	BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
10131638	C4591001 1013 10131638	16-55	06OCT2020	104185	Placebo	06OCT2020/ Placebo	29OCT2020/ Placebo	03MAR2021/ BNT162b2 (30 µg)	
10131639	C4591001 1013 10131639	16-55	06OCT2020	104186	BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10131642	C4591001 1013 10131642	16-55	06OCT2020	104178	Placebo	06OCT2020/ Placebo	26OCT2020/ Placebo		
10131643	C4591001 1013 10131643	16-55	06OCT2020	104188	BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
10131644	C4591001 1013 10131644	16-55	06OCT2020	104302	Placebo	06OCT2020/ Placebo	26OCT2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
10131645	C4591001 1013 10131645	16-55	06OCT2020	104303	BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
10131647	C4591001 1013 10131647	16-55	06OCT2020	104304	BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		
10131651	C4591001 1013 10131651	16-55	07OCT2020	104305	Placebo	07OCT2020/ Placebo	28OCT2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
10131652	C4591001 1013 10131652	16-55	07OCT2020	104645	Placebo	07OCT2020/ Placebo	28OCT2020/ Placebo	02MAR2021/ BNT162b2 (30 µg)	
10131653	C4591001 1013 10131653	16-55	07OCT2020	104654	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		
10131654	C4591001 1013 10131654	16-55	07OCT2020	104756	Placebo	07OCT2020/ Placebo	27OCT2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
10131656	C4591001 1013 10131656	16-55	07OCT2020	104650	Placebo	07OCT2020/ Placebo	27OCT2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10131657	C4591001 1013 10131657	16-55	07OCT2020	104758	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
10131658	C4591001 1013 10131658	16-55	07OCT2020	104653	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		
10131660	C4591001 1013 10131660	16-55	07OCT2020	104762	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
10131663	C4591001 1013 10131663	16-55	08OCT2020	104764	Placebo	08OCT2020/ Placebo	27OCT2020/ Placebo		
10131664	C4591001 1013 10131664	16-55	08OCT2020	105199	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)		
10131665	C4591001 1013 10131665	16-55	08OCT2020	105197	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)		
10131666	C4591001 1013 10131666	16-55	08OCT2020	105202	Placebo	08OCT2020/ Placebo	28OCT2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
10131667	C4591001 1013 10131667	16-55	08OCT2020	105205	Placebo	08OCT2020/ Placebo	28OCT2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
10131668	C4591001 1013 10131668	16-55	08OCT2020	105224	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		
10131669	C4591001 1013 10131669	16-55	08OCT2020	105226	Placebo	08OCT2020/ Placebo	27OCT2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10131670	C4591001 1013 10131670†	16-55	08OCT2020	105229	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)			
10131671	C4591001 1013 10131671	16-55	08OCT2020	105231	Placebo	08OCT2020/ Placebo	29OCT2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10131673	C4591001 1013 10131673†	16-55	08OCT2020	105308	Placebo	08OCT2020/ Placebo	29OCT2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
10131675	C4591001 1013 10131675	16-55	08OCT2020	105310	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		
10131676	C4591001 1013 10131676	16-55	12OCT2020	105312	Placebo	12OCT2020/ Placebo	02NOV2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
10131677	C4591001 1013 10131677	16-55	12OCT2020	106349	Placebo	12OCT2020/ Placebo	04NOV2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
10131678	C4591001 1013 10131678	16-55	12OCT2020	105314	BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		
10131680	C4591001 1013 10131680	16-55	12OCT2020	106353	BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
10131681	C4591001 1013 10131681	16-55	12OCT2020	106359	BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
10131682	C4591001 1013 10131682	16-55	12OCT2020	106360	Placebo	12OCT2020/ Placebo	04NOV2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	20JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10131683	C4591001 1013 10131683	16-55	12OCT2020	106402	Placebo	12OCT2020/ Placebo	02NOV2020/ Placebo		
10131685	C4591001 1013 10131685	16-55	12OCT2020	106404	BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
10131688	C4591001 1013 10131688	16-55	12OCT2020	106407	Placebo	12OCT2020/ Placebo	03NOV2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
10131689	C4591001 1013 10131689	16-55	12OCT2020	106507	Placebo	12OCT2020/ Placebo	02NOV2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
10131691	C4591001 1013 10131691	16-55	12OCT2020	106408	BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		
10131693	C4591001 1013 10131693	16-55	13OCT2020	106512	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
10131696	C4591001 1013 10131696	16-55	13OCT2020	106515	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
10131697	C4591001 1013 10131697	16-55	13OCT2020	106509	Placebo	13OCT2020/ Placebo	02NOV2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
10131700	C4591001 1013 10131700	16-55	13OCT2020	106926	Placebo	13OCT2020/ Placebo	03NOV2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10131701	C4591001 1013 10131701	16-55	13OCT2020	106933	Placebo	13OCT2020/ Placebo	03NOV2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10131703	C4591001 1013 10131703	16-55	13OCT2020	106934	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
10131708	C4591001 1013 10131708	16-55	13OCT2020	106935	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
10131709	C4591001 1013 10131709	16-55	14OCT2020	107371	BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
10131710	C4591001 1013 10131710	16-55	14OCT2020	107376	BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
10131713	C4591001 1013 10131713	16-55	14OCT2020	107372	Placebo	14OCT2020/ Placebo	04NOV2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
10131716	C4591001 1013 10131716	16-55	14OCT2020	107377	Placebo	14OCT2020/ Placebo	05NOV2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
10131717	C4591001 1013 10131717	16-55	14OCT2020	107469	Placebo	14OCT2020/ Placebo	03NOV2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10131718	C4591001 1013 10131718	16-55	14OCT2020	107472	Placebo	14OCT2020/ Placebo	02NOV2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
10131720	C4591001 1013 10131720	16-55	14OCT2020	107539	BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
10131721	C4591001 1013 10131721	16-55	14OCT2020	107473	BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10131722	C4591001 1013 10131722	16-55	14OCT2020	107537	Placebo	14OCT2020/ Placebo	04NOV2020/ Placebo	03MAR2021/ BNT162b2 (30 µg)	
10131723	C4591001 1013 10131723	16-55	14OCT2020	107474	BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
10131724	C4591001 1013 10131724	16-55	14OCT2020	107546	BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
10131729	C4591001 1013 10131729	16-55	15OCT2020	107951	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
10131730	C4591001 1013 10131730	16-55	15OCT2020	107548	Placebo	15OCT2020/ Placebo	03NOV2020/ Placebo	02MAR2021/ BNT162b2 (30 µg)	
10131731	C4591001 1013 10131731	16-55	15OCT2020	107948	Placebo	15OCT2020/ Placebo	03NOV2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10131733	C4591001 1013 10131733	16-55	15OCT2020	107954	Placebo	15OCT2020/ Placebo	09NOV2020/ Placebo	02MAR2021/ BNT162b2 (30 µg)	
10131734	C4591001 1013 10131734	16-55	15OCT2020	107956	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
10131736	C4591001 1013 10131736	16-55	15OCT2020	108024	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
10131737	C4591001 1013 10131737	16-55	15OCT2020	108021	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10131738	C4591001 1013 10131738	16-55	15OCT2020	108197	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
10131739	C4591001 1013 10131739	16-55	15OCT2020	108025	Placebo	15OCT2020/ Placebo	05NOV2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
10131740	C4591001 1013 10131740	16-55	15OCT2020	108026	Placebo				
10131744	C4591001 1013 10131744	16-55	19OCT2020	108204	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
10131745	C4591001 1013 10131745	16-55	19OCT2020	108205	Placebo	19OCT2020/ Placebo	09NOV2020/ Placebo	15DEC2020/ BNT162b2 (30 µg)	04JAN2021/ BNT162b2 (30 µg)
10131746	C4591001 1013 10131746	16-55	19OCT2020	108207	Placebo	19OCT2020/ Placebo			
10131748	C4591001 1013 10131748	16-55	19OCT2020	109961	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
10131749	C4591001 1013 10131749	16-55	19OCT2020	109966	Placebo	19OCT2020/ Placebo	09NOV2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
10131752	C4591001 1013 10131752	16-55	19OCT2020	109970	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
10131756	C4591001 1013 10131756	16-55	19OCT2020	109972	Placebo	19OCT2020/ Placebo	12NOV2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10131757	C4591001 1013 10131757	16-55	19OCT2020	110154	Placebo	19OCT2020/ Placebo	11NOV2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
10131759	C4591001 1013 10131759	16-55	19OCT2020	110156	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
10131760	C4591001 1013 10131760	16-55	20OCT2020	110733	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
10131761	C4591001 1013 10131761	16-55	20OCT2020	110730	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
10131762	C4591001 1013 10131762	16-55	20OCT2020	110162	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
10131763	C4591001 1013 10131763	16-55	20OCT2020	110163	Placebo	20OCT2020/ Placebo	12NOV2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10131767	C4591001 1013 10131767	16-55	20OCT2020	110736	Placebo	20OCT2020/ Placebo	09NOV2020/ Placebo		
10131769	C4591001 1013 10131769	16-55	20OCT2020	110740	Placebo	20OCT2020/ Placebo	12NOV2020/ Placebo	03MAR2021/ BNT162b2 (30 µg)	
10131770	C4591001 1013 10131770	16-55	20OCT2020	110804	Placebo	20OCT2020/ Placebo	12NOV2020/ Placebo	03MAR2021/ BNT162b2 (30 µg)	
10131771	C4591001 1013 10131771	16-55	20OCT2020	110802	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10131772	C4591001 1013 10131772	16-55	20OCT2020	110808	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
10131774	C4591001 1013 10131774	16-55	20OCT2020	110807	Placebo	20OCT2020/ Placebo	10NOV2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
10131777	C4591001 1013 10131777	16-55	20OCT2020	110866	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
10131778	C4591001 1013 10131778	16-55	20OCT2020	110861	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
10131779	C4591001 1013 10131779	16-55	20OCT2020	110867	Placebo	20OCT2020/ Placebo	12NOV2020/ Placebo		
10131780	C4591001 1013 10131780	16-55	20OCT2020	110870	Placebo	20OCT2020/ Placebo	12NOV2020/ Placebo		
10131783	C4591001 1013 10131783	16-55	21OCT2020	111330	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		
10131785	C4591001 1013 10131785	16-55	21OCT2020	111334	Placebo	21OCT2020/ Placebo	11NOV2020/ Placebo	03MAR2021/ BNT162b2 (30 µg)	
10131790	C4591001 1013 10131790	16-55	21OCT2020	111338	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
10131791	C4591001 1013 10131791	16-55	21OCT2020	111339	Placebo	21OCT2020/ Placebo	11NOV2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10131792	C4591001 1013 10131792	16-55	21OCT2020	111438	Placebo	21OCT2020/ Placebo	11NOV2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10131793	C4591001 1013 10131793	16-55	21OCT2020	111441	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
10131794	C4591001 1013 10131794	16-55	21OCT2020	111444	Placebo	21OCT2020/ Placebo	10NOV2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
10131796	C4591001 1013 10131796	16-55	21OCT2020	111447	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
10131797	C4591001 1013 10131797	16-55	22OCT2020	112049	Placebo	22OCT2020/ Placebo	12NOV2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
10131800	C4591001 1013 10131800	16-55	22OCT2020	112050	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
10131801	C4591001 1013 10131801	16-55	22OCT2020	112052	Placebo	22OCT2020/ Placebo	10NOV2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
10131802	C4591001 1013 10131802	16-55	22OCT2020	112058	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
10131803	C4591001 1013 10131803	16-55	22OCT2020	112086	Placebo	22OCT2020/ Placebo	10NOV2020/ Placebo		
10131804	C4591001 1013 10131804	16-55	22OCT2020	112096	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10131806	C4591001 1013 10131806	16-55	22OCT2020	112085	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
10131807	C4591001 1013 10131807	16-55	22OCT2020	112174	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		
10131808	C4591001 1013 10131808	16-55	22OCT2020	112091	Placebo	22OCT2020/ Placebo	12NOV2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10131809	C4591001 1013 10131809	16-55	22OCT2020	112172	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
10131810	C4591001 1013 10131810	16-55	22OCT2020	112245	Placebo	22OCT2020/ Placebo	12NOV2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10131811	C4591001 1013 10131811	16-55	22OCT2020	112171	Placebo	22OCT2020/ Placebo	11NOV2020/ Placebo		
10131813	C4591001 1013 10131813	16-55	22OCT2020	112177	Placebo	22OCT2020/ Placebo	12NOV2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
10131815	C4591001 1013 10131815	16-55	22OCT2020	112250	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
10131817	C4591001 1013 10131817	16-55	22OCT2020	112251	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
10131818	C4591001 1013 10131818	16-55	30NOV2020	112252	Placebo	30NOV2020/ Placebo	21DEC2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10131819	C4591001 1013 10131819	16-55	30NOV2020	117007	Placebo	30NOV2020/ Placebo	21DEC2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
10131820	C4591001 1013 10131820	16-55	30NOV2020	20327	Placebo	30NOV2020/ Placebo	22DEC2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
10131825	C4591001 1013 10131825	16-55	01DEC2020	117009	Placebo	01DEC2020/ Placebo	23DEC2020/ Placebo		
10131829	C4591001 1013 10131829	16-55	02DEC2020	117010	BNT162b2 (30 µg)	02DEC2020/ BNT162b2 (30 µg)	23DEC2020/ BNT162b2 (30 µg)		
10131831	C4591001 1013 10131831	16-55	02DEC2020	117199	Placebo	02DEC2020/ Placebo	23DEC2020/ Placebo		
10131832	C4591001 1013 10131832	16-55	02DEC2020	117198	Placebo	02DEC2020/ Placebo	23JAN2021/ Placebo		
10131833	C4591001 1013 10131833	16-55	02DEC2020	117207	BNT162b2 (30 µg)	02DEC2020/ BNT162b2 (30 µg)	21DEC2020/ BNT162b2 (30 µg)		
10131834	C4591001 1013 10131834	16-55	02DEC2020	117016	BNT162b2 (30 µg)	02DEC2020/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)		
10131837	C4591001 1013 10131837	16-55	02DEC2020	117200	BNT162b2 (30 µg)	02DEC2020/ BNT162b2 (30 µg)	21DEC2020/ BNT162b2 (30 µg)		
10131838	C4591001 1013 10131838	16-55	02DEC2020	117222	BNT162b2 (30 µg)	02DEC2020/ BNT162b2 (30 µg)	23DEC2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10131840	C4591001 1013 10131840	16-55	02DEC2020	117224	BNT162b2 (30 µg)	02DEC2020/ BNT162b2 (30 µg)	21DEC2020/ BNT162b2 (30 µg)		
10131847	C4591001 1013 10131847	16-55	03DEC2020	117226	Placebo	03DEC2020/ Placebo	22DEC2020/ Placebo		
10131849	C4591001 1013 10131849	16-55	03DEC2020	117231	Placebo	03DEC2020/ Placebo	23DEC2020/ Placebo		
10131853	C4591001 1013 10131853	16-55	07DEC2020	117701	Placebo	07DEC2020/ Placebo	28DEC2020/ Placebo		
10131854	C4591001 1013 10131854	16-55	08DEC2020	117705	BNT162b2 (30 µg)	08DEC2020/ BNT162b2 (30 µg)	29DEC2020/ BNT162b2 (30 µg)		
10131857	C4591001 1013 10131857	16-55	09DEC2020	117707	Placebo	09DEC2020/ Placebo	30DEC2020/ Placebo		
10131864	C4591001 1013 10131864	16-55	10DEC2020	117710	BNT162b2 (30 µg)	10DEC2020/ BNT162b2 (30 µg)	30DEC2020/ BNT162b2 (30 µg)		
10151020	C4591001 1015 10151020	16-55	14AUG2020	49898	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
10151022	C4591001 1015 10151022	16-55	14AUG2020	50795	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
10151028	C4591001 1015 10151028	16-55	15AUG2020	51188	Placebo	15AUG2020/ Placebo	04SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
10151029	C4591001 1015 10151029	16-55	15AUG2020	51189	Placebo	15AUG2020/ Placebo	04SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10151030	C4591001 1015 10151030	16-55	15AUG2020	51193	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
10151031	C4591001 1015 10151031	16-55	15AUG2020	51416	Placebo	15AUG2020/ Placebo	07SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
10151034	C4591001 1015 10151034	16-55	16AUG2020	51422	Placebo	16AUG2020/ Placebo	07SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
10151035	C4591001 1015 10151035	16-55	16AUG2020	51423	BNT162b2 (30 µg)	16AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
10151038	C4591001 1015 10151038	16-55	17AUG2020	51424	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10151039	C4591001 1015 10151039	16-55	17AUG2020	52343	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
10151041	C4591001 1015 10151041	16-55	17AUG2020	52344	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10151044	C4591001 1015 10151044	16-55	17AUG2020	52348	Placebo	17AUG2020/ Placebo	07SEP2020/ Placebo		
10151045	C4591001 1015 10151045	16-55	17AUG2020	52346	Placebo	17AUG2020/ Placebo	07SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
10151046	C4591001 1015 10151046	16-55	17AUG2020	53299	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10151047	C4591001 1015 10151047	16-55	17AUG2020	53307	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10151048	C4591001 1015 10151048	16-55	17AUG2020	53308	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10151049	C4591001 1015 10151049	16-55	18AUG2020	53999	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	14JAN2021/ BNT162b2 (30 µg)
10151050	C4591001 1015 10151050	16-55	18AUG2020	53996	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10151051	C4591001 1015 10151051	16-55	18AUG2020	54004	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10151052	C4591001 1015 10151052	16-55	18AUG2020	54000	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10151053	C4591001 1015 10151053	16-55	18AUG2020	54740	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10151054	C4591001 1015 10151054	16-55	18AUG2020	54741	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10151055	C4591001 1015 10151055	16-55	18AUG2020	54744	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10151056	C4591001 1015 10151056	16-55	18AUG2020	54746	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10151058	C4591001 1015 10151058	16-55	19AUG2020	55998	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10151061	C4591001 1015 10151061	16-55	19AUG2020	56000	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
10151062	C4591001 1015 10151062	16-55	19AUG2020	56006	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10151063	C4591001 1015 10151063	16-55	19AUG2020	56002	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10151064	C4591001 1015 10151064	16-55	19AUG2020	56898	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10151066	C4591001 1015 10151066	16-55	19AUG2020	56901	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10151067	C4591001 1015 10151067	16-55	19AUG2020	56904	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
10151068	C4591001 1015 10151068	16-55	19AUG2020	56907	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
10151069	C4591001 1015 10151069	16-55	20AUG2020	57967	Placebo	20AUG2020/ Placebo	08SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
10151070	C4591001 1015 10151070	16-55	20AUG2020	57972	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10151071	C4591001 1015 10151071	16-55	20AUG2020	57976	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
10151072	C4591001 1015 10151072	16-55	20AUG2020	57974	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10151073	C4591001 1015 10151073	16-55	20AUG2020	58505	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
10151074	C4591001 1015 10151074	16-55	20AUG2020	58513	Placebo	20AUG2020/ Placebo	08SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
10151075	C4591001 1015 10151075	16-55	20AUG2020	58508	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10151076	C4591001 1015 10151076	16-55	20AUG2020	58515	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10151077	C4591001 1015 10151077	16-55	20AUG2020	59096	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10151080	C4591001 1015 10151080	16-55	20AUG2020	59099	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
10151081	C4591001 1015 10151081	16-55	21AUG2020	59103	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
10151082	C4591001 1015 10151082	16-55	21AUG2020	59104	Placebo	21AUG2020/ Placebo	09SEP2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10151083	C4591001 1015 10151083	16-55	21AUG2020	60281	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
10151084	C4591001 1015 10151084	16-55	21AUG2020	60282	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
10151085	C4591001 1015 10151085	16-55	21AUG2020	60285	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
10151086	C4591001 1015 10151086	16-55	21AUG2020	60291	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
10151087	C4591001 1015 10151087	16-55	24AUG2020	61315	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10151088	C4591001 1015 10151088	16-55	21AUG2020	60864	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
10151089	C4591001 1015 10151089	16-55	21AUG2020	60865	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
10151092	C4591001 1015 10151092	16-55	21AUG2020	60867	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10151093	C4591001 1015 10151093	16-55	21AUG2020	61314	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
10151094	C4591001 1015 10151094	16-55	24AUG2020	61319	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10151097	C4591001 1015 10151097	16-55	24AUG2020	61320	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10151098	C4591001 1015 10151098	16-55	24AUG2020	63919	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10151099	C4591001 1015 10151099	16-55	24AUG2020	63921	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
10151100	C4591001 1015 10151100	16-55	24AUG2020	63922	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10151101	C4591001 1015 10151101	16-55	25AUG2020	66729	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10151102	C4591001 1015 10151102	16-55	24AUG2020	63923	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10151103	C4591001 1015 10151103	16-55	24AUG2020	64518	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10151104	C4591001 1015 10151104	16-55	24AUG2020	64517	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
10151105	C4591001 1015 10151105	16-55	24AUG2020	64522	Placebo	24AUG2020/ Placebo	16SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
10151107	C4591001 1015 10151107	16-55	26AUG2020	66731	Placebo	26AUG2020/ Placebo	18SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10151108	C4591001 1015 10151108	16-55	01SEP2020	75460	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
10151112	C4591001 1015 10151112	16-55	25AUG2020	66726	Placebo	25AUG2020/ Placebo	16SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
10151113	C4591001 1015 10151113	16-55	25AUG2020	64525	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10151115	C4591001 1015 10151115	16-55	26AUG2020	66733	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10151116	C4591001 1015 10151116	16-55	26AUG2020	67301	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10151117	C4591001 1015 10151117	16-55	26AUG2020	67303	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10151118	C4591001 1015 10151118	16-55	26AUG2020	67308	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10151119	C4591001 1015 10151119	16-55	26AUG2020	67307	Placebo	26AUG2020/ Placebo	18SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
10151120	C4591001 1015 10151120	16-55	26AUG2020	68310	Placebo	26AUG2020/ Placebo	17SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
10151121	C4591001 1015 10151121	16-55	24SEP2020	97608	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10151122	C4591001 1015 10151122	16-55	26AUG2020	68314	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10151123	C4591001 1015 10151123	16-55	26AUG2020	68315	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10151124	C4591001 1015 10151124	16-55	26AUG2020	68318	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10151125	C4591001 1015 10151125	16-55	27AUG2020	69557	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10151126	C4591001 1015 10151126	16-55	27AUG2020	69560	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
10151128	C4591001 1015 10151128	16-55	27AUG2020	69561	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
10151130	C4591001 1015 10151130	16-55	27AUG2020	69568	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10151131	C4591001 1015 10151131	16-55	27AUG2020	70270	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
10151132	C4591001 1015 10151132	16-55	27AUG2020	70272	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10151133	C4591001 1015 10151133	16-55	27AUG2020	70273	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10151134	C4591001 1015 10151134	16-55	27AUG2020	70275	Placebo	27AUG2020/ Placebo		21DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
10151135	C4591001 1015 10151135	16-55	27AUG2020	70709	Placebo	27AUG2020/ Placebo	16SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	14JAN2021/ BNT162b2 (30 µg)
10151136	C4591001 1015 10151136	16-55	27AUG2020	70715	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
10151137	C4591001 1015 10151137	16-55	27AUG2020	70714	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
10151138	C4591001 1015 10151138	16-55	28AUG2020	70719	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
10151139	C4591001 1015 10151139	16-55	28AUG2020	71729	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10151143	C4591001 1015 10151143	16-55	28AUG2020	71731	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10151146	C4591001 1015 10151146	16-55	31AUG2020	71733	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
10151147	C4591001 1015 10151147	16-55	31AUG2020	71732	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10151148	C4591001 1015 10151148	16-55	31AUG2020	75018	Placebo	31AUG2020/ Placebo	22SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10151149	C4591001 1015 10151149	16-55	31AUG2020	75017	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10151150	C4591001 1015 10151150	16-55	31AUG2020	75023	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10151151	C4591001 1015 10151151	16-55	31AUG2020	75451	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10151152	C4591001 1015 10151152	16-55	31AUG2020	75028	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10151153	C4591001 1015 10151153	16-55	31AUG2020	75453	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
10151154	C4591001 1015 10151154	16-55	31AUG2020	75454	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10151157	C4591001 1015 10151157	16-55	01SEP2020	76697	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10151159	C4591001 1015 10151159	16-55	01SEP2020	76700	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10151160	C4591001 1015 10151160	16-55	01SEP2020	76701	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo		
10151161	C4591001 1015 10151161	16-55	01SEP2020	76705	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10151162	C4591001 1015 10151162	16-55	01SEP2020	77186	Placebo	01SEP2020/ Placebo	23SEP2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
10151163	C4591001 1015 10151163	16-55	01SEP2020	77187	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
10151164	C4591001 1015 10151164	16-55	01SEP2020	77188	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10151165	C4591001 1015 10151165	16-55	02SEP2020	77875	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
10151166	C4591001 1015 10151166	16-55	02SEP2020	77877	Placebo	02SEP2020/ Placebo	21SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
10151167	C4591001 1015 10151167	16-55	02SEP2020	77879	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10151170	C4591001 1015 10151170	16-55	02SEP2020	77882	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10151171	C4591001 1015 10151171	16-55	03SEP2020	79530	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10151172	C4591001 1015 10151172	16-55	03SEP2020	79533	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
10151174	C4591001 1015 10151174	16-55	03SEP2020	79537	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10151175	C4591001 1015 10151175	16-55	03SEP2020	79540	Placebo	03SEP2020/ Placebo	22SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
10151176	C4591001 1015 10151176	16-55	03SEP2020	80694	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10151177	C4591001 1015 10151177	16-55	03SEP2020	80695	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
10151179	C4591001 1015 10151179	16-55	04SEP2020	80703	Placebo	04SEP2020/ Placebo	28SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
10151180	C4591001 1015 10151180	16-55	04SEP2020	80700	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	15JAN2021/ BNT162b2 (30 µg)
10151182	C4591001 1015 10151182	16-55	04SEP2020	81766	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10151183	C4591001 1015 10151183	16-55	04SEP2020	81768	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
10151184	C4591001 1015 10151184	16-55	04SEP2020	81770	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
10151185	C4591001 1015 10151185	16-55	04SEP2020	81772	Placebo	04SEP2020/ Placebo	23SEP2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	15JAN2021/ BNT162b2 (30 µg)
10151187	C4591001 1015 10151187	16-55	07SEP2020	83060	Placebo	07SEP2020/ Placebo	28SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10151188	C4591001 1015 10151188	16-55	07SEP2020	83061	BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
10151189	C4591001 1015 10151189	16-55	07SEP2020	83065	BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10151191	C4591001 1015 10151191	16-55	07SEP2020	83066	Placebo	07SEP2020/ Placebo	28SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10151192	C4591001 1015 10151192	16-55	07SEP2020	83168	BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
10151193	C4591001 1015 10151193	16-55	07SEP2020	83169	Placebo	07SEP2020/ Placebo	29SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
10151196	C4591001 1015 10151196	16-55	08SEP2020	83171	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10151197	C4591001 1015 10151197	16-55	08SEP2020	83172	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
10151198	C4591001 1015 10151198	16-55	08SEP2020	84029	Placebo	08SEP2020/ Placebo	30SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
10151199	C4591001 1015 10151199	16-55	08SEP2020	84031	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)			
10151200	C4591001 1015 10151200	16-55	08SEP2020	84033	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10151201	C4591001 1015 10151201	16-55	08SEP2020	84034	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
10151202	C4591001 1015 10151202	16-55	09SEP2020	84824	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
10151203	C4591001 1015 10151203	16-55	09SEP2020	84827	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10151204	C4591001 1015 10151204	16-55	09SEP2020	84830	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10151205	C4591001 1015 10151205	16-55	09SEP2020	84832	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
10151206	C4591001 1015 10151206	16-55	09SEP2020	85679	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10151207	C4591001 1015 10151207	16-55	10SEP2020	85680	Placebo	10SEP2020/ Placebo	29SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
10151208	C4591001 1015 10151208	16-55	10SEP2020	85681	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
10151209	C4591001 1015 10151209	16-55	10SEP2020	86780	Placebo	10SEP2020/ Placebo	29SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
10151210	C4591001 1015 10151210	16-55	10SEP2020	85682	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10151211	C4591001 1015 10151211	16-55	10SEP2020	86781	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
10151212	C4591001 1015 10151212	16-55	10SEP2020	86784	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
10151214	C4591001 1015 10151214	16-55	11SEP2020	86787	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
10151217	C4591001 1015 10151217	16-55	11SEP2020	88544	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10151218	C4591001 1015 10151218	16-55	11SEP2020	88541	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
10151220	C4591001 1015 10151220	16-55	11SEP2020	88546	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
10151221	C4591001 1015 10151221	16-55	11SEP2020	88552	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
10151222	C4591001 1015 10151222	16-55	14SEP2020	89717	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
10151223	C4591001 1015 10151223	16-55	14SEP2020	89726	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10151224	C4591001 1015 10151224	16-55	23SEP2020	97605	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10151225	C4591001 1015 10151225	16-55	15SEP2020	89727	Placebo	15SEP2020/ Placebo	08OCT2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	14JAN2021/ BNT162b2 (30 µg)
10151226	C4591001 1015 10151226	16-55	16SEP2020	89728	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
10151227	C4591001 1015 10151227	16-55	17SEP2020	92862	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
10151228	C4591001 1015 10151228	16-55	17SEP2020	92866	Placebo	17SEP2020/ Placebo	07OCT2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
10151229	C4591001 1015 10151229	16-55	18SEP2020	92868	Placebo	18SEP2020/ Placebo	07OCT2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10151230	C4591001 1015 10151230	16-55	21SEP2020	92872	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
10151231	C4591001 1015 10151231	16-55	23SEP2020	97603	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10151232	C4591001 1015 10151232	16-55	23SEP2020	97606	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
10151233	C4591001 1015 10151233	16-55	24SEP2020	98599	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
10151234	C4591001 1015 10151234	16-55	25SEP2020	98601	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10151235	C4591001 1015 10151235	16-55	30SEP2020	98603	Placebo	30SEP2020/ Placebo	20OCT2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
10151236	C4591001 1015 10151236	16-55	01OCT2020	98608	Placebo	01OCT2020/ Placebo	22OCT2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
10151239	C4591001 1015 10151239	16-55	02OCT2020	103282	BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)		
10151240	C4591001 1015 10151240	16-55	07OCT2020	103284	Placebo	07OCT2020/ Placebo	30OCT2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
10151241	C4591001 1015 10151241	16-55	07OCT2020	103286	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
10151242	C4591001 1015 10151242	16-55	08OCT2020	103288	Placebo	08OCT2020/ Placebo	29OCT2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
10151243	C4591001 1015 10151243	16-55	08OCT2020	105475	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		
10151245	C4591001 1015 10151245	16-55	14OCT2020	105479	Placebo	14OCT2020/ Placebo	04NOV2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
10151246	C4591001 1015 10151246	16-55	15OCT2020	105480	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
10151248	C4591001 1015 10151248	16-55	16OCT2020	105482	Placebo	16OCT2020/ Placebo	06NOV2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	14JAN2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10151249	C4591001 1015 10151249	16-55	19OCT2020	109913	Placebo	19OCT2020/ Placebo	09NOV2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	15JAN2021/ BNT162b2 (30 µg)
10151250	C4591001 1015 10151250	16-55	20OCT2020	109914	Placebo	20OCT2020/ Placebo	10NOV2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
10151252	C4591001 1015 10151252	16-55	21OCT2020	109922	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
10151254	C4591001 1015 10151254	16-55	22OCT2020	109923	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
10151255	C4591001 1015 10151255	16-55	23OCT2020	112763	Placebo	23OCT2020/ Placebo	13NOV2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
10151256	C4591001 1015 10151256	16-55	23OCT2020	112757	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
10151257	C4591001 1015 10151257	16-55	26OCT2020	112764	Placebo	26OCT2020/ Placebo	17NOV2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10151259	C4591001 1015 10151259	16-55	27OCT2020	112766	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
10151260	C4591001 1015 10151260	16-55	27OCT2020	114067	Placebo	27OCT2020/ Placebo	18NOV2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
10151261	C4591001 1015 10151261	16-55	27OCT2020	114070	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10151262	C4591001 1015 10151262	16-55	28OCT2020	114071	BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
10151263	C4591001 1015 10151263	16-55	28OCT2020	114076	Placebo	28OCT2020/ Placebo	18NOV2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10151265	C4591001 1015 10151265	16-55	29OCT2020	114633	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	20NOV2020/ BNT162b2 (30 µg)		
10151266	C4591001 1015 10151266	16-55	29OCT2020	114634	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)		
10151267	C4591001 1015 10151267	16-55	30OCT2020	114636	Placebo	30OCT2020/ Placebo	20NOV2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10151268	C4591001 1015 10151268	16-55	30OCT2020	114639	Placebo	30OCT2020/ Placebo	20NOV2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
10161126	C4591001 1016 10161126	16-55	14AUG2020	50442	Placebo	14AUG2020/ Placebo			
10161128	C4591001 1016 10161128	16-55	17AUG2020	50444	Placebo	17AUG2020/ Placebo	09SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
10161130	C4591001 1016 10161130	16-55	17AUG2020	50447	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10161133	C4591001 1016 10161133	16-55	17AUG2020	50451	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10161136	C4591001 1016 10161136	16-55	18AUG2020	54138	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
10161139	C4591001 1016 10161139	16-55	18AUG2020	54140	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10161140	C4591001 1016 10161140	16-55	18AUG2020	54144	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	21JAN2021/ BNT162b2 (30 µg)
10161143	C4591001 1016 10161143	16-55	19AUG2020	54147	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10161144	C4591001 1016 10161144	16-55	19AUG2020	56069	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10161145	C4591001 1016 10161145	16-55	19AUG2020	56072	Placebo	19AUG2020/ Placebo	08SEP2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	20JAN2021/ BNT162b2 (30 µg)
10161147	C4591001 1016 10161147	16-55	19AUG2020	56079	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10161148	C4591001 1016 10161148	16-55	19AUG2020	56080	Placebo	19AUG2020/ Placebo	08SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10161152	C4591001 1016 10161152	16-55	20AUG2020	58085	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10161154	C4591001 1016 10161154	16-55	20AUG2020	58086	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10161155	C4591001 1016 10161155	16-55	20AUG2020	58088	Placebo	20AUG2020/ Placebo	11SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
10161156	C4591001 1016 10161156	16-55	20AUG2020	58095	Placebo	20AUG2020/ Placebo	09SEP2020/ Placebo		
10161159	C4591001 1016 10161159	16-55	20AUG2020	59430	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
10161160	C4591001 1016 10161160	16-55	21AUG2020	59432	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10161163	C4591001 1016 10161163	16-55	21AUG2020	59434	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
10161164	C4591001 1016 10161164	16-55	21AUG2020	59438	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
10161167	C4591001 1016 10161167	16-55	21AUG2020	61289	Placebo	21AUG2020/ Placebo	08SEP2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
10161168	C4591001 1016 10161168	16-55	24AUG2020	61291	Placebo	24AUG2020/ Placebo	15SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
10161170	C4591001 1016 10161170	16-55	24AUG2020	61296	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10161171	C4591001 1016 10161171	16-55	24AUG2020	219978	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10161172	C4591001 1016 10161172	16-55	24AUG2020	61299	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10161176	C4591001 1016 10161176	16-55	25AUG2020	65717	Placebo	25AUG2020/ Placebo	14SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
10161177	C4591001 1016 10161177	16-55	25AUG2020	65721	Placebo	25AUG2020/ Placebo	14SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	
10161178	C4591001 1016 10161178	16-55	25AUG2020	65719	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10161181	C4591001 1016 10161181	16-55	25AUG2020	65725	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10161183	C4591001 1016 10161183	16-55	25AUG2020	66690	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
10161184	C4591001 1016 10161184	16-55	26AUG2020	66695	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10161185	C4591001 1016 10161185	16-55	26AUG2020	66697	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10161186	C4591001 1016 10161186	16-55	26AUG2020	66699	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10161189	C4591001 1016 10161189	16-55	26AUG2020	68553	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10161190	C4591001 1016 10161190	16-55	26AUG2020	68554	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10161192	C4591001 1016 10161192	16-55	27AUG2020	68556	Placebo	27AUG2020/ Placebo	16SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10161193	C4591001 1016 10161193	16-55	27AUG2020	68560	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10161196	C4591001 1016 10161196	16-55	27AUG2020	70015	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10161204	C4591001 1016 10161204	16-55	28AUG2020	70018	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10161205	C4591001 1016 10161205	16-55	28AUG2020	70021	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
10161206	C4591001 1016 10161206	16-55	28AUG2020	70023	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10161208	C4591001 1016 10161208	16-55	31AUG2020	74694	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10161209	C4591001 1016 10161209	16-55	31AUG2020	74697	Placebo	31AUG2020/ Placebo	22SEP2020/ Placebo		
10161210	C4591001 1016 10161210	16-55	31AUG2020	74700	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10161213	C4591001 1016 10161213	16-55	31AUG2020	74703	Placebo	31AUG2020/ Placebo	29SEP2020/ Placebo		
10161215	C4591001 1016 10161215	16-55	31AUG2020	75727	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10161216	C4591001 1016 10161216	16-55	01SEP2020	75733	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
10161217	C4591001 1016 10161217	16-55	01SEP2020	75731	Placebo	01SEP2020/ Placebo	23SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
10161218	C4591001 1016 10161218	16-55	01SEP2020	75736	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10161223	C4591001 1016 10161223	16-55	01SEP2020	77397	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
10161225	C4591001 1016 10161225	16-55	02SEP2020	77398	Placebo	02SEP2020/ Placebo	22SEP2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)
10161226	C4591001 1016 10161226	16-55	02SEP2020	77400	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10161228	C4591001 1016 10161228	16-55	02SEP2020	77401	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10161229	C4591001 1016 10161229	16-55	02SEP2020	78221	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10161230	C4591001 1016 10161230	16-55	02SEP2020	78654	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10161231	C4591001 1016 10161231	16-55	02SEP2020	78656	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
10161232	C4591001 1016 10161232	16-55	02SEP2020	78661	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10161233	C4591001 1016 10161233	16-55	02SEP2020	78662	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
10161234	C4591001 1016 10161234	16-55	02SEP2020	79025	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10161235	C4591001 1016 10161235	16-55	03SEP2020	79031	Placebo	03SEP2020/ Placebo	25SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10161237	C4591001 1016 10161237	16-55	03SEP2020	79032	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10161242	C4591001 1016 10161242	16-55	03SEP2020	79036	Placebo	03SEP2020/ Placebo	23SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10161243	C4591001 1016 10161243	16-55	03SEP2020	80657	Placebo	03SEP2020/ Placebo	23SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
10161244	C4591001 1016 10161244	16-55	03SEP2020	80666	Placebo	03SEP2020/ Placebo	23SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10161245	C4591001 1016 10161245	16-55	04SEP2020	80667	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10161248	C4591001 1016 10161248	16-55	04SEP2020	80668	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
10161249	C4591001 1016 10161249	16-55	04SEP2020	82121	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
10161252	C4591001 1016 10161252	16-55	08SEP2020	82129	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
10161253	C4591001 1016 10161253	16-55	08SEP2020	82130	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
10161255	C4591001 1016 10161255	16-55	08SEP2020	82131	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10161258	C4591001 1016 10161258	16-55	09SEP2020	219977	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10161259	C4591001 1016 10161259	16-55	09SEP2020	219987	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
10161261	C4591001 1016 10161261	16-55	09SEP2020	219988	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
10161265	C4591001 1016 10161265	16-55	09SEP2020	85158	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10161268	C4591001 1016 10161268	16-55	10SEP2020	85163	Placebo	10SEP2020/ Placebo	29SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
10161269	C4591001 1016 10161269	16-55	10SEP2020	85166	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
10161272	C4591001 1016 10161272	16-55	10SEP2020	85168	Placebo	10SEP2020/ Placebo	30SEP2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
10161273	C4591001 1016 10161273	16-55	10SEP2020	87177	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
10161275	C4591001 1016 10161275	16-55	10SEP2020	87178	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
10161276	C4591001 1016 10161276	16-55	10SEP2020	87179	Placebo	10SEP2020/ Placebo	29SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
10161277	C4591001 1016 10161277	16-55	11SEP2020	87181	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
10161279	C4591001 1016 10161279	16-55	11SEP2020	88016	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
10161280	C4591001 1016 10161280	16-55	11SEP2020	88015	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo		
10161281	C4591001 1016 10161281	16-55	11SEP2020	88020	Placebo	11SEP2020/ Placebo	01OCT2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10161284	C4591001 1016 10161284	16-55	11SEP2020	88023	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10161285	C4591001 1016 10161285	16-55	17SEP2020	92153	Placebo	17SEP2020/ Placebo	07OCT2020/ Placebo		
10161286	C4591001 1016 10161286	16-55	17SEP2020	92160	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
10161287	C4591001 1016 10161287	16-55	17SEP2020	92163	Placebo	17SEP2020/ Placebo	09OCT2020/ Placebo		
10161288	C4591001 1016 10161288	16-55	17SEP2020	92164	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
10161289	C4591001 1016 10161289	16-55	18SEP2020	93329	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
10161290	C4591001 1016 10161290	16-55	18SEP2020	93331	Placebo	18SEP2020/ Placebo	07OCT2020/ Placebo		
10161291	C4591001 1016 10161291	16-55	18SEP2020	93334	Placebo	18SEP2020/ Placebo	07OCT2020/ Placebo		
10161292	C4591001 1016 10161292	16-55	18SEP2020	93336	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
10161293	C4591001 1016 10161293	16-55	21SEP2020	94675	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
10161294	C4591001 1016 10161294	16-55	21SEP2020	94679	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10161295	C4591001 1016 10161295	16-55	22SEP2020	94681	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
10161296	C4591001 1016 10161296	16-55	22SEP2020	94684	Placebo	22SEP2020/ Placebo	13OCT2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
10161297	C4591001 1016 10161297	16-55	22SEP2020	96606	Placebo	22SEP2020/ Placebo	14OCT2020/ Placebo		
10161298	C4591001 1016 10161298	16-55	22SEP2020	96611	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
10161299	C4591001 1016 10161299	16-55	23SEP2020	96613	Placebo	23SEP2020/ Placebo	15OCT2020/ Placebo		
10161300	C4591001 1016 10161300	16-55	23SEP2020	96615	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
10161301	C4591001 1016 10161301	16-55	24SEP2020	98576	Placebo	24SEP2020/ Placebo	15OCT2020/ Placebo		
10161302	C4591001 1016 10161302	16-55	24SEP2020	98577	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
10161303	C4591001 1016 10161303	16-55	07OCT2020	98580	Placebo	07OCT2020/ Placebo	28OCT2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10161304	C4591001 1016 10161304	16-55	12OCT2020	98583	BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10161305	C4591001 1016 10161305	16-55	13OCT2020	106865	Placebo	13OCT2020/ Placebo	02NOV2020/ Placebo	03MAR2021/ BNT162b2 (30 µg)	
10161306	C4591001 1016 10161306	16-55	13OCT2020	106871	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
10161312	C4591001 1016 10161312	16-55	15OCT2020	106873	Placebo	15OCT2020/ Placebo	04NOV2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
10161313	C4591001 1016 10161313	16-55	16OCT2020	106874	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
10161317	C4591001 1016 10161317	16-55	16OCT2020	109196	Placebo	16OCT2020/ Placebo	06NOV2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10161321	C4591001 1016 10161321	16-55	19OCT2020	109199	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
10161328	C4591001 1016 10161328	16-55	20OCT2020	109202	Placebo	20OCT2020/ Placebo	10NOV2020/ Placebo		
10161333	C4591001 1016 10161333	16-55	21OCT2020	109203	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		
10161341	C4591001 1016 10161341	16-55	22OCT2020	112505	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)			
10161342	C4591001 1016 10161342	16-55	22OCT2020	112506	Placebo	22OCT2020/ Placebo	12NOV2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10161345	C4591001 1016 10161345	16-55	28OCT2020	112513	BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
10161346	C4591001 1016 10161346	16-55	28OCT2020	112515	Placebo	28OCT2020/ Placebo	20NOV2020/ Placebo		
10161347	C4591001 1016 10161347	16-55	02NOV2020	115301	BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)	23NOV2020/ BNT162b2 (30 µg)		
10161348	C4591001 1016 10161348	16-55	05NOV2020	115302	Placebo	05NOV2020/ Placebo		11MAR2021/ BNT162b2 (30 µg)	
10161349	C4591001 1016 10161349	16-55	06NOV2020	115304	BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)	25NOV2020/ BNT162b2 (30 µg)		
10161355	C4591001 1016 10161355	16-55	02DEC2020	115310	Placebo	02DEC2020/ Placebo	04JAN2021/ Placebo		
10161359	C4591001 1016 10161359	16-55	03DEC2020	117322	Placebo	03DEC2020/ Placebo	22DEC2020/ Placebo		
10161360	C4591001 1016 10161360	16-55	04DEC2020	117323	Placebo	04DEC2020/ Placebo	23DEC2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	07MAR2021/ BNT162b2 (30 µg)
10181161	C4591001 1018 10181161	16-55	14AUG2020	50259	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	16JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
10181164	C4591001 1018 10181164	16-55	14AUG2020	50916	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo		
10181165	C4591001 1018 10181165	16-55	14AUG2020	50960	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10181166	C4591001 1018 10181166	16-55	14AUG2020	50961	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
10181170	C4591001 1018 10181170	16-55	17AUG2020	50964	Placebo	17AUG2020/ Placebo	11SEP2020/ Placebo		
10181171	C4591001 1018 10181171	16-55	17AUG2020	50966	Placebo	17AUG2020/ Placebo	14SEP2020/ Placebo	09JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)
10181173	C4591001 1018 10181173	16-55	17AUG2020	53393	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10181174	C4591001 1018 10181174	16-55	17AUG2020	53397	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10181176	C4591001 1018 10181176	16-55	17AUG2020	53402	Placebo	17AUG2020/ Placebo	09SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
10181178	C4591001 1018 10181178	16-55	18AUG2020	53404	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
10181180	C4591001 1018 10181180	16-55	18AUG2020	54881	Placebo	18AUG2020/ Placebo	12SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
10181181	C4591001 1018 10181181	16-55	18AUG2020	54884	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
10181182	C4591001 1018 10181182	16-55	18AUG2020	54892	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10181183	C4591001 1018 10181183	16-55	18AUG2020	54887	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
10181184	C4591001 1018 10181184	16-55	19AUG2020	56261	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
10181185	C4591001 1018 10181185	16-55	19AUG2020	56262	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10181187	C4591001 1018 10181187	16-55	19AUG2020	56269	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)
10181188	C4591001 1018 10181188	16-55	19AUG2020	57498	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10181189	C4591001 1018 10181189	16-55	19AUG2020	57503	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10181191	C4591001 1018 10181191	16-55	20AUG2020	57505	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo		
10181193	C4591001 1018 10181193	16-55	20AUG2020	59684	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10181194	C4591001 1018 10181194	16-55	20AUG2020	57506	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10181195	C4591001 1018 10181195	16-55	21AUG2020	59685	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10181196	C4591001 1018 10181196	16-55	21AUG2020	59689	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
10181197	C4591001 1018 10181197	16-55	21AUG2020	59690	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10181198	C4591001 1018 10181198	16-55	21AUG2020	60977	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	16JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10181199	C4591001 1018 10181199	16-55	21AUG2020	60980	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10181200	C4591001 1018 10181200	16-55	21AUG2020	60986	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10181201	C4591001 1018 10181201	16-55	21AUG2020	60981	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
10181202	C4591001 1018 10181202	16-55	21AUG2020	61447	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
10181204	C4591001 1018 10181204	16-55	22AUG2020	61450	Placebo	22AUG2020/ Placebo	11SEP2020/ Placebo		
10181205	C4591001 1018 10181205	16-55	22AUG2020	61452	Placebo	22AUG2020/ Placebo	14SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
10181206	C4591001 1018 10181206	16-55	22AUG2020	61453	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	12SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10181207	C4591001 1018 10181207	16-55	22AUG2020	62277	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
10181208	C4591001 1018 10181208	16-55	22AUG2020	62279	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
10181211	C4591001 1018 10181211	16-55	24AUG2020	62280	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
10181214	C4591001 1018 10181214	16-55	24AUG2020	62283	Placebo	24AUG2020/ Placebo	15SEP2020/ Placebo		
10181215	C4591001 1018 10181215	16-55	24AUG2020	64808	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10181216	C4591001 1018 10181216	16-55	25AUG2020	64809	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10181218	C4591001 1018 10181218	16-55	26AUG2020	64810	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
10181219	C4591001 1018 10181219	16-55	26AUG2020	64811	Placebo	26AUG2020/ Placebo	17SEP2020/ Placebo	16JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
10181221	C4591001 1018 10181221	16-55	29AUG2020	73698	Placebo	29AUG2020/ Placebo	25SEP2020/ Placebo		
10181222	C4591001 1018 10181222	16-55	29AUG2020	73700	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10181223	C4591001 1018 10181223	16-55	29AUG2020	73704	Placebo	29AUG2020/ Placebo	25SEP2020/ Placebo		
10181224	C4591001 1018 10181224	16-55	29AUG2020	73708	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
10181225	C4591001 1018 10181225	16-55	29AUG2020	74081	Placebo	29AUG2020/ Placebo	18SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
10181226	C4591001 1018 10181226	16-55	29AUG2020	74084	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
10181227	C4591001 1018 10181227	16-55	29AUG2020	74082	Placebo	29AUG2020/ Placebo	25SEP2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
10181228	C4591001 1018 10181228	16-55	31AUG2020	74090	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10181230	C4591001 1018 10181230	16-55	31AUG2020	75067	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10181232	C4591001 1018 10181232	16-55	31AUG2020	75071	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
10181233	C4591001 1018 10181233	16-55	31AUG2020	75073	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10181234	C4591001 1018 10181234	16-55	01SEP2020	76600	Placebo	01SEP2020/ Placebo	24SEP2020/ Placebo	06JAN2021/ BNT162b2 (30 µg)	27JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10181235	C4591001 1018 10181235	16-55	01SEP2020	76593	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10181236	C4591001 1018 10181236	16-55	01SEP2020	76591	Placebo	01SEP2020/ Placebo	28SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10181237	C4591001 1018 10181237	16-55	01SEP2020	75074	Placebo	01SEP2020/ Placebo	24SEP2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
10181238	C4591001 1018 10181238	16-55	01SEP2020	76598	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10181240	C4591001 1018 10181240	16-55	01SEP2020	76997	Placebo	01SEP2020/ Placebo	24SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
10181241	C4591001 1018 10181241	16-55	01SEP2020	77001	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10181242	C4591001 1018 10181242	16-55	01SEP2020	77004	Placebo	01SEP2020/ Placebo	23SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
10181244	C4591001 1018 10181244	16-55	01SEP2020	77006	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10181245	C4591001 1018 10181245	16-55	01SEP2020	77734	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10181246	C4591001 1018 10181246	16-55	01SEP2020	77738	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10181247	C4591001 1018 10181247	16-55	01SEP2020	77736	Placebo	01SEP2020/ Placebo	25SEP2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
10181251	C4591001 1018 10181251	16-55	02SEP2020	78390	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
10181252	C4591001 1018 10181252	16-55	02SEP2020	77740	Placebo	02SEP2020/ Placebo	24SEP2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	28JAN2021/ BNT162b2 (30 µg)
10181254	C4591001 1018 10181254	16-55	02SEP2020	78391	Placebo	02SEP2020/ Placebo	24SEP2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
10181255	C4591001 1018 10181255	16-55	02SEP2020	78393	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10181256	C4591001 1018 10181256	16-55	02SEP2020	78399	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10181257	C4591001 1018 10181257	16-55	03SEP2020	79758	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
10181259	C4591001 1018 10181259	16-55	03SEP2020	79759	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
10181260	C4591001 1018 10181260	16-55	03SEP2020	79762	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10181261	C4591001 1018 10181261	16-55	03SEP2020	79766	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10181262	C4591001 1018 10181262	16-55	04SEP2020	81443	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	23JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
10181263	C4591001 1018 10181263	16-55	04SEP2020	81440	Placebo	04SEP2020/ Placebo	24SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
10181264	C4591001 1018 10181264	16-55	04SEP2020	81444	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
10181266	C4591001 1018 10181266	16-55	04SEP2020	81445	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)			
10181267	C4591001 1018 10181267	16-55	04SEP2020	81967	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
10181268	C4591001 1018 10181268	16-55	04SEP2020	81968	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
10181269	C4591001 1018 10181269	16-55	04SEP2020	81971	Placebo	04SEP2020/ Placebo	28SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
10181272	C4591001 1018 10181272	16-55	09SEP2020	81974	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
10181275	C4591001 1018 10181275	16-55	09SEP2020	86046	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	09JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
10181276	C4591001 1018 10181276	16-55	10SEP2020	86047	Placebo	10SEP2020/ Placebo	30SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10181277	C4591001 1018 10181277	16-55	10SEP2020	86050	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
10181279	C4591001 1018 10181279	16-55	11SEP2020	86052	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
10181282	C4591001 1018 10181282	16-55	12SEP2020	89144	Placebo	12SEP2020/ Placebo	07OCT2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
10181283	C4591001 1018 10181283	16-55	12SEP2020	89149	BNT162b2 (30 µg)	12SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
10181284	C4591001 1018 10181284	16-55	12SEP2020	89150	BNT162b2 (30 µg)	12SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
10181286	C4591001 1018 10181286	16-55	12SEP2020	89152	Placebo	12SEP2020/ Placebo	02OCT2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
10181287	C4591001 1018 10181287	16-55	14SEP2020	89789	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
10181288	C4591001 1018 10181288	16-55	14SEP2020	89793	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
10181289	C4591001 1018 10181289	16-55	14SEP2020	89794	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
10181290	C4591001 1018 10181290	16-55	15SEP2020	89796	Placebo	15SEP2020/ Placebo	06OCT2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10181292	C4591001 1018 10181292	16-55	15SEP2020	90678	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
10181293	C4591001 1018 10181293	16-55	15SEP2020	90686	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
10181294	C4591001 1018 10181294	16-55	15SEP2020	90679	Placebo	15SEP2020/ Placebo	06OCT2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
10181295	C4591001 1018 10181295	16-55	16SEP2020	90687	Placebo	16SEP2020/ Placebo	07OCT2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
10181298	C4591001 1018 10181298	16-55	17SEP2020	92333	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
10181299	C4591001 1018 10181299	16-55	17SEP2020	92335	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
10181301	C4591001 1018 10181301	16-55	18SEP2020	92344	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	16JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10181302	C4591001 1018 10181302	16-55	18SEP2020	92342	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
10181304	C4591001 1018 10181304	16-55	21SEP2020	95275	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
10181305	C4591001 1018 10181305	16-55	21SEP2020	95279	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10181306	C4591001 1018 10181306	16-55	21SEP2020	95280	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo		
10181307	C4591001 1018 10181307	16-55	23SEP2020	95284	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
10181309	C4591001 1018 10181309	16-55	25SEP2020	100313	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
10181310	C4591001 1018 10181310	16-55	12OCT2020	100320	BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)			
10181311	C4591001 1018 10181311	16-55	12OCT2020	100321	BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)			
10181313	C4591001 1018 10181313	16-55	12OCT2020	100324	Placebo	12OCT2020/ Placebo			
10181314	C4591001 1018 10181314	16-55	13OCT2020	106949	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
10181315	C4591001 1018 10181315	16-55	13OCT2020	106952	Placebo	13OCT2020/ Placebo	04NOV2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10181316	C4591001 1018 10181316	16-55	13OCT2020	106953	Placebo	13OCT2020/ Placebo	03NOV2020/ Placebo	16JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
10181317	C4591001 1018 10181317	16-55	13OCT2020	106957	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10181319	C4591001 1018 10181319	16-55	13OCT2020	107109	Placebo	13OCT2020/ Placebo	03NOV2020/ Placebo		
10181320	C4591001 1018 10181320	16-55	13OCT2020	107111	Placebo	13OCT2020/ Placebo	06NOV2020/ Placebo	06JAN2021/ BNT162b2 (30 µg)	27JAN2021/ BNT162b2 (30 µg)
10181321	C4591001 1018 10181321	16-55	13OCT2020	107114	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
10181322	C4591001 1018 10181322	16-55	13OCT2020	107116	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
10181323	C4591001 1018 10181323	16-55	14OCT2020	107549	Placebo	14OCT2020/ Placebo	04NOV2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10181324	C4591001 1018 10181324	16-55	14OCT2020	107552	BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
10181326	C4591001 1018 10181326	16-55	14OCT2020	107556	BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
10181327	C4591001 1018 10181327	16-55	14OCT2020	107559	Placebo	14OCT2020/ Placebo	04NOV2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
10181329	C4591001 1018 10181329	16-55	14OCT2020	107741	Placebo	14OCT2020/ Placebo	04NOV2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10181333	C4591001 1018 10181333	16-55	15OCT2020	107742	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10181334	C4591001 1018 10181334	16-55	15OCT2020	107743	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
10181335	C4591001 1018 10181335	16-55	15OCT2020	107748	Placebo	15OCT2020/ Placebo	13NOV2020/ Placebo		
10181336	C4591001 1018 10181336	16-55	19OCT2020	110309	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
10181337	C4591001 1018 10181337	16-55	19OCT2020	110311	Placebo	19OCT2020/ Placebo	11NOV2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10181338	C4591001 1018 10181338	16-55	19OCT2020	110318	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
10181340	C4591001 1018 10181340	16-55	19OCT2020	110320	Placebo	19OCT2020/ Placebo	16NOV2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10181341	C4591001 1018 10181341	16-55	19OCT2020	110502	Placebo	19OCT2020/ Placebo	11NOV2020/ Placebo	23JAN2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10181342	C4591001 1018 10181342	16-55	20OCT2020	110503	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
10181344	C4591001 1018 10181344	16-55	20OCT2020	110506	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
10181345	C4591001 1018 10181345	16-55	30OCT2020	111875	Placebo	30OCT2020/ Placebo	20NOV2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10181346	C4591001 1018 10181346	16-55	20OCT2020	110510	Placebo	20OCT2020/ Placebo	11NOV2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
10181347	C4591001 1018 10181347	16-55	20OCT2020	111127	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
10181349	C4591001 1018 10181349	16-55	21OCT2020	111129	Placebo	21OCT2020/ Placebo	11NOV2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	28JAN2021/ BNT162b2 (30 µg)
10181351	C4591001 1018 10181351	16-55	21OCT2020	111130	Placebo	21OCT2020/ Placebo	11NOV2020/ Placebo	23JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
10181352	C4591001 1018 10181352	16-55	21OCT2020	111135	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
10181353	C4591001 1018 10181353	16-55	21OCT2020	111870	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	18NOV2020/ BNT162b2 (30 µg)		
10191044	C4591001 1019 10191044	16-55	17AUG2020	50396	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10191047	C4591001 1019 10191047	16-55	17AUG2020	50398	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10191050	C4591001 1019 10191050	16-55	17AUG2020	50403	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	06JAN2021/ BNT162b2 (30 µg)	27JAN2021/ BNT162b2 (30 µg)
10191056	C4591001 1019 10191056	16-55	18AUG2020	54466	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10191058	C4591001 1019 10191058	16-55	18AUG2020	54461	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10191059	C4591001 1019 10191059	16-55	18AUG2020	54469	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
10191063	C4591001 1019 10191063	16-55	19AUG2020	54471	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo		
10191068	C4591001 1019 10191068	16-55	19AUG2020	57077	Placebo	19AUG2020/ Placebo	11SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
10191073	C4591001 1019 10191073	16-55	20AUG2020	58221	Placebo	20AUG2020/ Placebo	23SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
10191074	C4591001 1019 10191074	16-55	20AUG2020	58223	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)
10191076	C4591001 1019 10191076	16-55	20AUG2020	58226	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10191077	C4591001 1019 10191077	16-55	20AUG2020	58228	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10191081	C4591001 1019 10191081	16-55	21AUG2020	60049	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10191083	C4591001 1019 10191083	16-55	21AUG2020	60050	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	06JAN2021/ BNT162b2 (30 µg)	27JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10191085	C4591001 1019 10191085	16-55	21AUG2020	60051	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
10191090	C4591001 1019 10191090	16-55	24AUG2020	60052	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10191098	C4591001 1019 10191098	16-55	25AUG2020	65807	Placebo	25AUG2020/ Placebo			
10191100	C4591001 1019 10191100	16-55	25AUG2020	65811	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10191101	C4591001 1019 10191101	16-55	25AUG2020	65812	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo		
10191102	C4591001 1019 10191102	16-55	25AUG2020	66478	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10191106	C4591001 1019 10191106	16-55	26AUG2020	66480	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
10191108	C4591001 1019 10191108	16-55	26AUG2020	66483	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10191110	C4591001 1019 10191110	16-55	26AUG2020	66484	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)
10191113	C4591001 1019 10191113	16-55	26AUG2020	68562	Placebo	26AUG2020/ Placebo	15SEP2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10191116	C4591001 1019 10191116	16-55	26AUG2020	68563	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10191123	C4591001 1019 10191123	16-55	27AUG2020	68565	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10191124	C4591001 1019 10191124	16-55	27AUG2020	68572	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)
10191125	C4591001 1019 10191125	16-55	27AUG2020	71250	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10191127	C4591001 1019 10191127	16-55	27AUG2020	71251	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10191128	C4591001 1019 10191128	16-55	27AUG2020	71258	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
10191129	C4591001 1019 10191129	16-55	27AUG2020	71260	Placebo	27AUG2020/ Placebo	16SEP2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
10191133	C4591001 1019 10191133	16-55	28AUG2020	71911	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10191137	C4591001 1019 10191137	16-55	28AUG2020	71912	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10191138	C4591001 1019 10191138	16-55	28AUG2020	71914	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10191140	C4591001 1019 10191140	16-55	31AUG2020	71915	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
10191141	C4591001 1019 10191141	16-55	31AUG2020	75485	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10191145	C4591001 1019 10191145	16-55	01SEP2020	75488	Placebo	01SEP2020/ Placebo	23SEP2020/ Placebo		
10191147	C4591001 1019 10191147	16-55	01SEP2020	75489	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	28JAN2021/ BNT162b2 (30 µg)
10191154	C4591001 1019 10191154	16-55	03SEP2020	75495	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10191156	C4591001 1019 10191156	16-55	03SEP2020	80933	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
10191157	C4591001 1019 10191157	16-55	03SEP2020	80936	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
10191159	C4591001 1019 10191159	16-55	04SEP2020	80943	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
10191161	C4591001 1019 10191161	16-55	04SEP2020	80944	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
10191164	C4591001 1019 10191164	16-55	04SEP2020	81862	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10191165	C4591001 1019 10191165	16-55	04SEP2020	81866	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10191166	C4591001 1019 10191166	16-55	04SEP2020	81867	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)			
10191168	C4591001 1019 10191168	16-55	08SEP2020	81868	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
10191171	C4591001 1019 10191171	16-55	08SEP2020	84138	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
10191172	C4591001 1019 10191172	16-55	08SEP2020	84141	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10191173	C4591001 1019 10191173	16-55	08SEP2020	84142	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
10191174	C4591001 1019 10191174	16-55	09SEP2020	84145	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
10191175	C4591001 1019 10191175	16-55	09SEP2020	84941	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10191181	C4591001 1019 10191181	16-55	09SEP2020	84948	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10191184	C4591001 1019 10191184	16-55	10SEP2020	84951	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10191186	C4591001 1019 10191186	16-55	10SEP2020	86962	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo		
10191187	C4591001 1019 10191187	16-55	10SEP2020	84952	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
10191188	C4591001 1019 10191188	16-55	10SEP2020	86965	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
10191189	C4591001 1019 10191189	16-55	10SEP2020	86967	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10191192	C4591001 1019 10191192	16-55	10SEP2020	86968	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
10191193	C4591001 1019 10191193	16-55	11SEP2020	87809	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
10191194	C4591001 1019 10191194	16-55	11SEP2020	87810	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
10191195	C4591001 1019 10191195	16-55	11SEP2020	87815	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10191196	C4591001 1019 10191196	16-55	11SEP2020	87820	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
10191197	C4591001 1019 10191197	16-55	11SEP2020	88097	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10191198	C4591001 1019 10191198	16-55	11SEP2020	88098	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	20JAN2021/ BNT162b2 (30 µg)
10191205	C4591001 1019 10191205	16-55	14SEP2020	88101	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
10191206	C4591001 1019 10191206	16-55	14SEP2020	88105	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
10191208	C4591001 1019 10191208	16-55	14SEP2020	89935	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
10191209	C4591001 1019 10191209	16-55	15SEP2020	89936	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
10191211	C4591001 1019 10191211	16-55	15SEP2020	89938	Placebo	15SEP2020/ Placebo	07OCT2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
10191212	C4591001 1019 10191212	16-55	15SEP2020	89944	Placebo	15SEP2020/ Placebo	06OCT2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
10191213	C4591001 1019 10191213	16-55	15SEP2020	90765	Placebo	15SEP2020/ Placebo	06OCT2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
10191214	C4591001 1019 10191214	16-55	16SEP2020	90766	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
10191215	C4591001 1019 10191215	16-55	02OCT2020	103238	BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10191216	C4591001 1019 10191216	16-55	16SEP2020	90767	Placebo	16SEP2020/ Placebo	07OCT2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
10191217	C4591001 1019 10191217	16-55	18SEP2020	90770	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
10191218	C4591001 1019 10191218	16-55	18SEP2020	93537	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
10191220	C4591001 1019 10191220	16-55	21SEP2020	93539	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
10191222	C4591001 1019 10191222	16-55	22SEP2020	93541	Placebo	22SEP2020/ Placebo	15OCT2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)
10191225	C4591001 1019 10191225	16-55	23SEP2020	93543	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
10191226	C4591001 1019 10191226	16-55	23SEP2020	97847	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
10191227	C4591001 1019 10191227	16-55	24SEP2020	97848	Placebo	24SEP2020/ Placebo	23OCT2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
10191230	C4591001 1019 10191230	16-55	24SEP2020	97849	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
10191232	C4591001 1019 10191232	16-55	25SEP2020	97850	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10191234	C4591001 1019 10191234	16-55	25SEP2020	99848	Placebo	25SEP2020/ Placebo	15OCT2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
10191235	C4591001 1019 10191235	16-55	25SEP2020	99849	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
10191236	C4591001 1019 10191236	16-55	25SEP2020	99850	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	28JAN2021/ BNT162b2 (30 µg)
10191238	C4591001 1019 10191238	16-55	25SEP2020	99854	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
10191242	C4591001 1019 10191242	16-55	30SEP2020	102245	Placebo	30SEP2020/ Placebo	21OCT2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10191245	C4591001 1019 10191245	16-55	01OCT2020	102251	Placebo	01OCT2020/ Placebo	22OCT2020/ Placebo		
10191246	C4591001 1019 10191246	16-55	01OCT2020	102254	BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)		
10191247	C4591001 1019 10191247	16-55	01OCT2020	102255	BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)		
10191249	C4591001 1019 10191249	16-55	02OCT2020	103231	BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)		
10191251	C4591001 1019 10191251	16-55	02OCT2020	103236	Placebo	02OCT2020/ Placebo	23OCT2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10191252	C4591001 1019 10191252	16-55	02OCT2020	103237	Placebo	02OCT2020/ Placebo	23OCT2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
10191254	C4591001 1019 10191254	16-55	05OCT2020	103925	BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
10191255	C4591001 1019 10191255	16-55	06OCT2020	103927	Placebo	06OCT2020/ Placebo	27OCT2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10191256	C4591001 1019 10191256	16-55	08OCT2020	103931	Placebo	08OCT2020/ Placebo	29OCT2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)
10191257	C4591001 1019 10191257	16-55	09OCT2020	103936	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)		
10191260	C4591001 1019 10191260	16-55	12OCT2020	106363	Placebo	12OCT2020/ Placebo	02NOV2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
10191262	C4591001 1019 10191262	16-55	12OCT2020	106364	Placebo	12OCT2020/ Placebo	02NOV2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)
10191264	C4591001 1019 10191264	16-55	12OCT2020	106370	BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		
10191265	C4591001 1019 10191265	16-55	13OCT2020	106371	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
10191267	C4591001 1019 10191267	16-55	13OCT2020	107143	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10191268	C4591001 1019 10191268	16-55	13OCT2020	107144	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
10191269	C4591001 1019 10191269	16-55	13OCT2020	107145	Placebo	13OCT2020/ Placebo	03NOV2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10191270	C4591001 1019 10191270	16-55	13OCT2020	107149	Placebo	13OCT2020/ Placebo	03NOV2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10191273	C4591001 1019 10191273	16-55	14OCT2020	107574	BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
10191276	C4591001 1019 10191276	16-55	14OCT2020	107575	BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
10191279	C4591001 1019 10191279	16-55	15OCT2020	107579	Placebo	15OCT2020/ Placebo	05NOV2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
10191280	C4591001 1019 10191280	16-55	15OCT2020	107581	Placebo	15OCT2020/ Placebo	05NOV2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	20JAN2021/ BNT162b2 (30 µg)
10191281	C4591001 1019 10191281	16-55	15OCT2020	108329	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
10191288	C4591001 1019 10191288	16-55	20OCT2020	108332	Placebo	20OCT2020/ Placebo	09NOV2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)
10191289	C4591001 1019 10191289	16-55	20OCT2020	108334	Placebo	20OCT2020/ Placebo	09NOV2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10191290	C4591001 1019 10191290	16-55	20OCT2020	108340	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
10191292	C4591001 1019 10191292	16-55	21OCT2020	111401	Placebo	21OCT2020/ Placebo	12NOV2020/ Placebo	06JAN2021/ BNT162b2 (30 µg)	28JAN2021/ BNT162b2 (30 µg)
10191293	C4591001 1019 10191293	16-55	21OCT2020	111402	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
10191295	C4591001 1019 10191295	16-55	21OCT2020	111404	Placebo	21OCT2020/ Placebo	11NOV2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
10191296	C4591001 1019 10191296	16-55	21OCT2020	111411	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
10191301	C4591001 1019 10191301	16-55	23OCT2020	112775	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
10191304	C4591001 1019 10191304	16-55	23OCT2020	112776	Placebo	23OCT2020/ Placebo	13NOV2020/ Placebo		
10191305	C4591001 1019 10191305	16-55	23OCT2020	112777	Placebo	23OCT2020/ Placebo	13NOV2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
10191306	C4591001 1019 10191306	16-55	23OCT2020	112778	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
10191312	C4591001 1019 10191312	16-55	27OCT2020	113994	Placebo	27OCT2020/ Placebo	17NOV2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10191315	C4591001 1019 10191315	16-55	28OCT2020	113996	Placebo	28OCT2020/ Placebo	18NOV2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
10191318	C4591001 1019 10191318	16-55	29OCT2020	113999	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)		
10191321	C4591001 1019 10191321	16-55	30OCT2020	114001	BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)	20NOV2020/ BNT162b2 (30 µg)		
10211042	C4591001 1021 10211042	16-55	17AUG2020	52374	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10211061	C4591001 1021 10211061	16-55	19AUG2020	52377	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
10211066	C4591001 1021 10211066	16-55	20AUG2020	52379	Placebo	20AUG2020/ Placebo	08SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	04JAN2021/ BNT162b2 (30 µg)
10211069	C4591001 1021 10211069	16-55	20AUG2020	52381	Placebo	20AUG2020/ Placebo	08SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	04JAN2021/ BNT162b2 (30 µg)
10211083	C4591001 1021 10211083	16-55	24AUG2020	63329	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10211092	C4591001 1021 10211092	16-55	25AUG2020	63332	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10211097	C4591001 1021 10211097	16-55	26AUG2020	63336	Placebo	26AUG2020/ Placebo	18SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10211099	C4591001 1021 10211099	16-55	26AUG2020	63337	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
10211101	C4591001 1021 10211101	16-55	26AUG2020	68058	Placebo	26AUG2020/ Placebo	18SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
10211104	C4591001 1021 10211104	16-55	26AUG2020	68065	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10211112	C4591001 1021 10211112	16-55	27AUG2020	68067	Placebo	27AUG2020/ Placebo	16SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10211117	C4591001 1021 10211117	16-55	28AUG2020	68068	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
10211119	C4591001 1021 10211119	16-55	28AUG2020	72762	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
10211123	C4591001 1021 10211123	16-55	31AUG2020	72764	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
10211127	C4591001 1021 10211127	16-55	31AUG2020	72769	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10211130	C4591001 1021 10211130	16-55	01SEP2020	72770	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10211137	C4591001 1021 10211137	16-55	02SEP2020	77921	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10211142	C4591001 1021 10211142	16-55	02SEP2020	77923	Placebo	02SEP2020/ Placebo	21SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
10211146	C4591001 1021 10211146	16-55	03SEP2020	77929	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10211147	C4591001 1021 10211147	16-55	03SEP2020	77930	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
10211149	C4591001 1021 10211149	16-55	03SEP2020	79949	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10211152	C4591001 1021 10211152	16-55	03SEP2020	79950	Placebo	03SEP2020/ Placebo	22SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
10211154	C4591001 1021 10211154	16-55	04SEP2020	79957	Placebo	04SEP2020/ Placebo	24SEP2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10211156	C4591001 1021 10211156	16-55	04SEP2020	81500	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10211157	C4591001 1021 10211157	16-55	04SEP2020	79960	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
10211158	C4591001 1021 10211158	16-55	04SEP2020	81501	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
10211168	C4591001 1021 10211168	16-55	08SEP2020	81503	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10211182	C4591001 1021 10211182	16-55	10SEP2020	81504	Placebo	10SEP2020/ Placebo	30SEP2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10211185	C4591001 1021 10211185	16-55	10SEP2020	86949	Placebo	10SEP2020/ Placebo	29SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
10211202	C4591001 1021 10211202	16-55	14SEP2020	86951	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
10211210	C4591001 1021 10211210	16-55	15SEP2020	86954	Placebo	15SEP2020/ Placebo	06OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
10211211	C4591001 1021 10211211	16-55	15SEP2020	90162	Placebo	15SEP2020/ Placebo	05OCT2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
10211212	C4591001 1021 10211212	16-55	15SEP2020	86956	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
10211213	C4591001 1021 10211213	16-55	15SEP2020	90165	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
10211216	C4591001 1021 10211216	16-55	15SEP2020	90166	Placebo	15SEP2020/ Placebo	09OCT2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
10211219	C4591001 1021 10211219	16-55	16SEP2020	90172	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
10211220	C4591001 1021 10211220	16-55	16SEP2020	91073	Placebo	16SEP2020/ Placebo	05OCT2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	04JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10211223	C4591001 1021 10211223	16-55	16SEP2020	91075	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
10211224	C4591001 1021 10211224	16-55	17SEP2020	91079	Placebo	17SEP2020/ Placebo	09OCT2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)
10211230	C4591001 1021 10211230	16-55	17SEP2020	91080	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
10211235	C4591001 1021 10211235	16-55	18SEP2020	93677	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
10211239	C4591001 1021 10211239	16-55	21SEP2020	93679	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
10211240	C4591001 1021 10211240	16-55	21SEP2020	93681	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
10211242	C4591001 1021 10211242	16-55	21SEP2020	93682	Placebo	21SEP2020/ Placebo	13OCT2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
10211244	C4591001 1021 10211244	16-55	21SEP2020	95504	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
10211245	C4591001 1021 10211245	16-55	22SEP2020	95507	Placebo	22SEP2020/ Placebo	14OCT2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
10211246	C4591001 1021 10211246	16-55	22SEP2020	95510	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10211247	C4591001 1021 10211247	16-55	22SEP2020	95511	Placebo	22SEP2020/ Placebo	12OCT2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
10211248	C4591001 1021 10211248	16-55	22SEP2020	96451	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
10211252	C4591001 1021 10211252	16-55	21OCT2020	96453	Placebo	21OCT2020/ Placebo	09NOV2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10221010	C4591001 1022 10221010	16-55	17AUG2020	50526	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
10221013	C4591001 1022 10221013	16-55	17AUG2020	50532	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	04JAN2021/ BNT162b2 (30 µg)
10221017	C4591001 1022 10221017	16-55	17AUG2020	50535	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10221018	C4591001 1022 10221018	16-55	17AUG2020	53407	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10221019	C4591001 1022 10221019	16-55	18AUG2020	53409	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
10221020	C4591001 1022 10221020	16-55	18AUG2020	53410	Placebo	18AUG2020/ Placebo	11SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10221023	C4591001 1022 10221023	16-55	18AUG2020	53416	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10221024	C4591001 1022 10221024	16-55	18AUG2020	54833	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
10221025	C4591001 1022 10221025	16-55	18AUG2020	54839	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10221027	C4591001 1022 10221027	16-55	18AUG2020	54841	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
10221028	C4591001 1022 10221028	16-55	19AUG2020	54843	Placebo	19AUG2020/ Placebo	11SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
10221030	C4591001 1022 10221030	16-55	19AUG2020	56599	Placebo	19AUG2020/ Placebo	11SEP2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
10221031	C4591001 1022 10221031	16-55	19AUG2020	56602	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
10221033	C4591001 1022 10221033	16-55	20AUG2020	56603	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10221035	C4591001 1022 10221035	16-55	20AUG2020	56606	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
10221040	C4591001 1022 10221040	16-55	21AUG2020	60682	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10221043	C4591001 1022 10221043	16-55	11SEP2020	88893	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10221048	C4591001 1022 10221048	16-55	21AUG2020	60683	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10221049	C4591001 1022 10221049	16-55	21AUG2020	60685	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10221051	C4591001 1022 10221051	16-55	24AUG2020	60687	Placebo	24AUG2020/ Placebo	16SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
10221052	C4591001 1022 10221052	16-55	24AUG2020	63954	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
10221054	C4591001 1022 10221054	16-55	24AUG2020	63955	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10221055	C4591001 1022 10221055	16-55	24AUG2020	63958	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10221062	C4591001 1022 10221062	16-55	25AUG2020	63962	Placebo	25AUG2020/ Placebo	16SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
10221064	C4591001 1022 10221064	16-55	25AUG2020	66786	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10221066	C4591001 1022 10221066	16-55	26AUG2020	66787	Placebo	26AUG2020/ Placebo	24SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	04JAN2021/ BNT162b2 (30 µg)
10221069	C4591001 1022 10221069	16-55	26AUG2020	66794	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10221070	C4591001 1022 10221070	16-55	26AUG2020	66796	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10221074	C4591001 1022 10221074	16-55	26AUG2020	68969	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10221076	C4591001 1022 10221076	16-55	27AUG2020	68970	Placebo	27AUG2020/ Placebo	16SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
10221078	C4591001 1022 10221078	16-55	27AUG2020	68971	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
10221080	C4591001 1022 10221080	16-55	27AUG2020	68972	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10221081	C4591001 1022 10221081	16-55	27AUG2020	70626	Placebo	27AUG2020/ Placebo	18SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
10221083	C4591001 1022 10221083	16-55	27AUG2020	70628	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10221084	C4591001 1022 10221084	16-55	27AUG2020	70630	Placebo	27AUG2020/ Placebo	18SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
10221087	C4591001 1022 10221087	16-55	28AUG2020	72389	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
10221088	C4591001 1022 10221088	16-55	28AUG2020	70634	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10221093	C4591001 1022 10221093	16-55	31AUG2020	72390	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10221094	C4591001 1022 10221094	16-55	31AUG2020	72397	Placebo	31AUG2020/ Placebo	22SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	04JAN2021/ BNT162b2 (30 µg)
10221098	C4591001 1022 10221098	16-55	31AUG2020	72399	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
10221100	C4591001 1022 10221100	16-55	31AUG2020	76113	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10221101	C4591001 1022 10221101	16-55	01SEP2020	76114	Placebo	01SEP2020/ Placebo	23SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
10221105	C4591001 1022 10221105	16-55	01SEP2020	76115	Placebo	01SEP2020/ Placebo	24SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
10221106	C4591001 1022 10221106	16-55	01SEP2020	76120	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10221108	C4591001 1022 10221108	16-55	02SEP2020	78321	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10221110	C4591001 1022 10221110	16-55	02SEP2020	78324	Placebo	02SEP2020/ Placebo	22SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
10221111	C4591001 1022 10221111	16-55	02SEP2020	78325	Placebo	02SEP2020/ Placebo	24SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10221112	C4591001 1022 10221112	16-55	02SEP2020	78328	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10221115	C4591001 1022 10221115	16-55	02SEP2020	79062	Placebo	02SEP2020/ Placebo	24SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
10221117	C4591001 1022 10221117	16-55	02SEP2020	79063	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10221120	C4591001 1022 10221120	16-55	03SEP2020	79068	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10221122	C4591001 1022 10221122	16-55	03SEP2020	79070	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	14JAN2021/ BNT162b2 (30 µg)
10221123	C4591001 1022 10221123	16-55	03SEP2020	80333	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10221125	C4591001 1022 10221125	16-55	03SEP2020	80334	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
10221126	C4591001 1022 10221126	16-55	03SEP2020	80335	Placebo	03SEP2020/ Placebo	25SEP2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
10221127	C4591001 1022 10221127	16-55	03SEP2020	80341	Placebo	03SEP2020/ Placebo	22SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
10221128	C4591001 1022 10221128	16-55	04SEP2020	81461	Placebo	04SEP2020/ Placebo	24SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10221129	C4591001 1022 10221129	16-55	04SEP2020	81463	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10221131	C4591001 1022 10221131	16-55	04SEP2020	81466	Placebo	04SEP2020/ Placebo	24SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
10221133	C4591001 1022 10221133	16-55	04SEP2020	81471	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10221134	C4591001 1022 10221134	16-55	04SEP2020	82319	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10221136	C4591001 1022 10221136	16-55	08SEP2020	82320	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
10221137	C4591001 1022 10221137	16-55	08SEP2020	82322	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
10221138	C4591001 1022 10221138	16-55	08SEP2020	82324	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10221139	C4591001 1022 10221139	16-55	08SEP2020	84175	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
10221142	C4591001 1022 10221142	16-55	08SEP2020	84176	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10221143	C4591001 1022 10221143	16-55	08SEP2020	254977	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10221144	C4591001 1022 10221144	16-55	09SEP2020	84181	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
10221147	C4591001 1022 10221147	16-55	09SEP2020	84183	Placebo	09SEP2020/ Placebo	29SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10221156	C4591001 1022 10221156	16-55	15SEP2020	88897	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
10221164	C4591001 1022 10221164	16-55	17SEP2020	88898	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
10221179	C4591001 1022 10221179	16-55	28SEP2020	88900	Placebo	28SEP2020/ Placebo	21OCT2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	15JAN2021/ BNT162b2 (30 µg)
10241026	C4591001 1024 10241026	16-55	17AUG2020	50352	Placebo	17AUG2020/ Placebo	09SEP2020/ Placebo		
10241027	C4591001 1024 10241027	16-55	17AUG2020	50356	Placebo	17AUG2020/ Placebo	09SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
10241029	C4591001 1024 10241029	16-55	17AUG2020	52674	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	03MAR2021/ BNT162b2 (30 µg)	
10241030	C4591001 1024 10241030	16-55	17AUG2020	52679	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
10241032	C4591001 1024 10241032	16-55	17AUG2020	52681	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10241033	C4591001 1024 10241033	16-55	18AUG2020	52684	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10241036	C4591001 1024 10241036	16-55	18AUG2020	54929	Placebo	18AUG2020/ Placebo	10SEP2020/ Placebo		
10241038	C4591001 1024 10241038	16-55	18AUG2020	54934	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
10241039	C4591001 1024 10241039	16-55	18AUG2020	54935	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10241040	C4591001 1024 10241040	16-55	18AUG2020	54939	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10241042	C4591001 1024 10241042	16-55	19AUG2020	55793	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10241043	C4591001 1024 10241043	16-55	19AUG2020	55797	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
10241044	C4591001 1024 10241044	16-55	19AUG2020	55799	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
10241045	C4591001 1024 10241045	16-55	19AUG2020	55804	Placebo	19AUG2020/ Placebo	11SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
10241046	C4591001 1024 10241046	16-55	19AUG2020	56813	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10241051	C4591001 1024 10241051	16-55	20AUG2020	56815	Placebo	20AUG2020/ Placebo	09SEP2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
10241052	C4591001 1024 10241052	16-55	20AUG2020	56820	Placebo	20AUG2020/ Placebo	09SEP2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
10241054	C4591001 1024 10241054	16-55	20AUG2020	56822	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
10241055	C4591001 1024 10241055	16-55	20AUG2020	59717	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
10241056	C4591001 1024 10241056	16-55	20AUG2020	59721	Placebo	20AUG2020/ Placebo	11SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
10241058	C4591001 1024 10241058	16-55	21AUG2020	59722	Placebo	21AUG2020/ Placebo	10SEP2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
10241061	C4591001 1024 10241061	16-55	21AUG2020	59726	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10241063	C4591001 1024 10241063	16-55	24AUG2020	63257	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	04JAN2021/ BNT162b2 (30 µg)
10241064	C4591001 1024 10241064	16-55	24AUG2020	63258	Placebo	24AUG2020/ Placebo	15SEP2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
10241066	C4591001 1024 10241066	16-55	24AUG2020	63264	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10241067	C4591001 1024 10241067	16-55	24AUG2020	63266	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10241070	C4591001 1024 10241070	16-55	24AUG2020	64604	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
10241071	C4591001 1024 10241071	16-55	24AUG2020	64605	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10241072	C4591001 1024 10241072	16-55	25AUG2020	64608	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
10241073	C4591001 1024 10241073	16-55	25AUG2020	64609	Placebo	25AUG2020/ Placebo	16SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
10241074	C4591001 1024 10241074	16-55	25AUG2020	65466	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10241075	C4591001 1024 10241075	16-55	25AUG2020	65468	Placebo	25AUG2020/ Placebo	16SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
10241078	C4591001 1024 10241078	16-55	26AUG2020	65471	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
10241080	C4591001 1024 10241080	16-55	26AUG2020	65476	Placebo	26AUG2020/ Placebo	15SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
10241084	C4591001 1024 10241084	16-55	27AUG2020	69761	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10241085	C4591001 1024 10241085	16-55	27AUG2020	69765	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10241086	C4591001 1024 10241086	16-55	27AUG2020	69767	Placebo	27AUG2020/ Placebo	16SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
10241088	C4591001 1024 10241088	16-55	27AUG2020	69772	Placebo	27AUG2020/ Placebo	18SEP2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
10241090	C4591001 1024 10241090	16-55	28AUG2020	244293	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
10241091	C4591001 1024 10241091	16-55	28AUG2020	71777	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
10241092	C4591001 1024 10241092	16-55	28AUG2020	71781	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)
10241094	C4591001 1024 10241094	16-55	28AUG2020	71782	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10241095	C4591001 1024 10241095	16-55	28AUG2020	71784	Placebo	28AUG2020/ Placebo	17SEP2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
10241098	C4591001 1024 10241098	16-55	28AUG2020	72618	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
10241100	C4591001 1024 10241100	16-55	31AUG2020	72619	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10241101	C4591001 1024 10241101	16-55	31AUG2020	72622	Placebo	31AUG2020/ Placebo	23SEP2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	
10241102	C4591001 1024 10241102	16-55	31AUG2020	72624	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10241104	C4591001 1024 10241104	16-55	01SEP2020	76387	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10241106	C4591001 1024 10241106	16-55	01SEP2020	76388	Placebo	01SEP2020/ Placebo	21SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10241107	C4591001 1024 10241107	16-55	02SEP2020	76390	Placebo	02SEP2020/ Placebo	24SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
10241108	C4591001 1024 10241108	16-55	02SEP2020	76391	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10241109	C4591001 1024 10241109	16-55	02SEP2020	79399	Placebo	02SEP2020/ Placebo	24SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	04JAN2021/ BNT162b2 (30 µg)
10241112	C4591001 1024 10241112	16-55	03SEP2020	79401	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10241114	C4591001 1024 10241114	16-55	08SEP2020	79406	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
10241117	C4591001 1024 10241117	16-55	16SEP2020	79407	Placebo	16SEP2020/ Placebo	16OCT2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10241118	C4591001 1024 10241118†	16-55	21SEP2020	95073	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
10241121	C4591001 1024 10241121†	16-55	08OCT2020	95074	Placebo	08OCT2020/ Placebo	28OCT2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
10241123	C4591001 1024 10241123†	16-55	14OCT2020	95075	Placebo	14OCT2020/ Placebo	03NOV2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10241124	C4591001 1024 10241124†	16-55	14OCT2020	95077	BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
10241129	C4591001 1024 10241129	16-55	19OCT2020	108549	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
10241131	C4591001 1024 10241131	16-55	20OCT2020	108552	Placebo	20OCT2020/ Placebo	11NOV2020/ Placebo	15DEC2020/ BNT162b2 (30 µg)	04JAN2021/ BNT162b2 (30 µg)
10241132	C4591001 1024 10241132	16-55	26OCT2020	108553	Placebo	26OCT2020/ Placebo	16NOV2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
10271026	C4591001 1027 10271026	16-55	17AUG2020	50601	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
10271028	C4591001 1027 10271028	16-55	17AUG2020	50607	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
10271029	C4591001 1027 10271029	16-55	17AUG2020	50608	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10271032	C4591001 1027 10271032	16-55	18AUG2020	54164	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
10271033	C4591001 1027 10271033	16-55	18AUG2020	54166	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10271037	C4591001 1027 10271037	16-55	18AUG2020	54168	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10271040	C4591001 1027 10271040	16-55	19AUG2020	54172	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	04JAN2021/ BNT162b2 (30 µg)
10271041	C4591001 1027 10271041	16-55	19AUG2020	56489	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
10271046	C4591001 1027 10271046	16-55	19AUG2020	56495	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
10271049	C4591001 1027 10271049	16-55	20AUG2020	56499	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
10271058	C4591001 1027 10271058	16-55	21AUG2020	56500	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
10271059	C4591001 1027 10271059	16-55	21AUG2020	60234	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
10271061	C4591001 1027 10271061	16-55	21AUG2020	60237	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	12SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10271079	C4591001 1027 10271079	16-55	25AUG2020	60240	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10271083	C4591001 1027 10271083	16-55	26AUG2020	60243	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10271086	C4591001 1027 10271086	16-55	26AUG2020	67817	Placebo	26AUG2020/ Placebo	18SEP2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	28JAN2021/ BNT162b2 (30 µg)
10271091	C4591001 1027 10271091	16-55	26AUG2020	67819	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10271094	C4591001 1027 10271094	16-55	27AUG2020	67823	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
10271104	C4591001 1027 10271104	16-55	28AUG2020	67825	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10271105	C4591001 1027 10271105	16-55	28AUG2020	72609	Placebo	28AUG2020/ Placebo			
10271107	C4591001 1027 10271107	16-55	31AUG2020	72611	Placebo	31AUG2020/ Placebo	22SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10271108	C4591001 1027 10271108	16-55	31AUG2020	72612	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10271119	C4591001 1027 10271119	16-55	01SEP2020	72614	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10271126	C4591001 1027 10271126	16-55	01SEP2020	77239	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10271127	C4591001 1027 10271127	16-55	01SEP2020	77240	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10271129	C4591001 1027 10271129	16-55	02SEP2020	77243	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
10271145	C4591001 1027 10271145	16-55	03SEP2020	77248	Placebo	03SEP2020/ Placebo	22SEP2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
10271152	C4591001 1027 10271152	16-55	04SEP2020	82098	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10271155	C4591001 1027 10271155	16-55	08SEP2020	82100	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
10271157	C4591001 1027 10271157	16-55	08SEP2020	82103	Placebo	08SEP2020/ Placebo	30SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
10271158	C4591001 1027 10271158	16-55	08SEP2020	82104	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10271162	C4591001 1027 10271162	16-55	09SEP2020	84761	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10271163	C4591001 1027 10271163	16-55	09SEP2020	84762	Placebo	09SEP2020/ Placebo	29SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10271172	C4591001 1027 10271172	16-55	09SEP2020	84763	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10271173	C4591001 1027 10271173	16-55	10SEP2020	84765	Placebo	10SEP2020/ Placebo	30SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
10271182	C4591001 1027 10271182	16-55	10SEP2020	87209	Placebo	10SEP2020/ Placebo	30SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
10271183	C4591001 1027 10271183	16-55	10SEP2020	87215	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10271192	C4591001 1027 10271192	16-55	11SEP2020	87216	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10271193	C4591001 1027 10271193	16-55	11SEP2020	87219	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10271197	C4591001 1027 10271197	16-55	16SEP2020	91457	Placebo	16SEP2020/ Placebo	05OCT2020/ Placebo	06JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
10271199	C4591001 1027 10271199	16-55	22SEP2020	91459	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
10271203	C4591001 1027 10271203	16-55	24SEP2020	91462	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
10271207	C4591001 1027 10271207†	16-55	01OCT2020	91468	Placebo	01OCT2020/ Placebo	22OCT2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10271208	C4591001 1027 10271208†	16-55	01OCT2020	102790	Placebo	01OCT2020/ Placebo	20OCT2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10271212	C4591001 1027 10271212†	16-55	08OCT2020	102791	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
10271214	C4591001 1027 10271214	16-55	14OCT2020	102792	BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		
10271215	C4591001 1027 10271215	16-55	15OCT2020	102794	Placebo	15OCT2020/ Placebo	05NOV2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
10271216	C4591001 1027 10271216	16-55	15OCT2020	108306	Placebo	15OCT2020/ Placebo	05NOV2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
10281005	C4591001 1028 10281005	16-55	17AUG2020	48543	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10281007	C4591001 1028 10281007	16-55	17AUG2020	53349	Placebo	17AUG2020/ Placebo	09SEP2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
10281009	C4591001 1028 10281009	16-55	17AUG2020	53298	Placebo	17AUG2020/ Placebo	09SEP2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	
10281010	C4591001 1028 10281010	16-55	18AUG2020	53350	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10281013	C4591001 1028 10281013	16-55	18AUG2020	53354	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10281017	C4591001 1028 10281017	16-55	18AUG2020	53355	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10281018	C4591001 1028 10281018	16-55	19AUG2020	55987	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10281019	C4591001 1028 10281019	16-55	19AUG2020	55990	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10281022	C4591001 1028 10281022	16-55	19AUG2020	55995	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10281023	C4591001 1028 10281023	16-55	19AUG2020	55991	Placebo	19AUG2020/ Placebo	17SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
10281024	C4591001 1028 10281024	16-55	19AUG2020	57006	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
10281025	C4591001 1028 10281025	16-55	19AUG2020	57005	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10281026	C4591001 1028 10281026	16-55	20AUG2020	57011	Placebo	20AUG2020/ Placebo	11SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
10281027	C4591001 1028 10281027	16-55	20AUG2020	57015	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
10281028	C4591001 1028 10281028	16-55	20AUG2020	58265	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10281029	C4591001 1028 10281029	16-55	20AUG2020	58266	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10281030	C4591001 1028 10281030	16-55	20AUG2020	58272	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
10281031	C4591001 1028 10281031	16-55	20AUG2020	58267	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10281033	C4591001 1028 10281033	16-55	20AUG2020	59313	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
10281035	C4591001 1028 10281035	16-55	21AUG2020	59317	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
10281036	C4591001 1028 10281036	16-55	21AUG2020	59315	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
10281038	C4591001 1028 10281038	16-55	21AUG2020	59319	Placebo	21AUG2020/ Placebo	10SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
10281043	C4591001 1028 10281043	16-55	24AUG2020	63378	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
10281044	C4591001 1028 10281044	16-55	24AUG2020	63384	Placebo	24AUG2020/ Placebo	15SEP2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
10281047	C4591001 1028 10281047	16-55	24AUG2020	63387	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10281048	C4591001 1028 10281048	16-55	24AUG2020	63385	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10281049	C4591001 1028 10281049	16-55	24AUG2020	64301	Placebo	24AUG2020/ Placebo	15SEP2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)
10281050	C4591001 1028 10281050	16-55	24AUG2020	64302	Placebo	24AUG2020/ Placebo	16SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
10281052	C4591001 1028 10281052	16-55	25AUG2020	64304	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10281053	C4591001 1028 10281053	16-55	25AUG2020	64310	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10281054	C4591001 1028 10281054	16-55	25AUG2020	66521	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo		
10281055	C4591001 1028 10281055	16-55	25AUG2020	66522	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10281059	C4591001 1028 10281059	16-55	26AUG2020	66525	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo		
10281060	C4591001 1028 10281060	16-55	26AUG2020	66529	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10281061	C4591001 1028 10281061	16-55	26AUG2020	68681	Placebo	26AUG2020/ Placebo	17SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10281062	C4591001 1028 10281062	16-55	26AUG2020	68684	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
10281065	C4591001 1028 10281065	16-55	27AUG2020	68690	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10281066	C4591001 1028 10281066	16-55	27AUG2020	68691	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10281069	C4591001 1028 10281069	16-55	27AUG2020	70343	Placebo	27AUG2020/ Placebo	18SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
10281070	C4591001 1028 10281070	16-55	27AUG2020	70344	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
10281072	C4591001 1028 10281072	16-55	27AUG2020	70345	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)			
10281075	C4591001 1028 10281075	16-55	28AUG2020	70348	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
10281077	C4591001 1028 10281077	16-55	28AUG2020	71898	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
10281078	C4591001 1028 10281078	16-55	28AUG2020	71903	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
10281079	C4591001 1028 10281079	16-55	28AUG2020	71906	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10281080	C4591001 1028 10281080	16-55	28AUG2020	71907	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
10281085	C4591001 1028 10281085	16-55	31AUG2020	75029	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
10281086	C4591001 1028 10281086	16-55	31AUG2020	75035	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
10281087	C4591001 1028 10281087	16-55	31AUG2020	75037	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10281088	C4591001 1028 10281088	16-55	31AUG2020	75036	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10281089	C4591001 1028 10281089	16-55	31AUG2020	75809	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10281090	C4591001 1028 10281090	16-55	01SEP2020	75811	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10281094	C4591001 1028 10281094	16-55	01SEP2020	75817	Placebo	01SEP2020/ Placebo	24SEP2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
10281095	C4591001 1028 10281095	16-55	01SEP2020	75820	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo		
10281096	C4591001 1028 10281096	16-55	01SEP2020	77288	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10281097	C4591001 1028 10281097	16-55	01SEP2020	77286	Placebo	01SEP2020/ Placebo	21SEP2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
10281098	C4591001 1028 10281098	16-55	01SEP2020	77293	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10281100	C4591001 1028 10281100	16-55	02SEP2020	77295	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
10281101	C4591001 1028 10281101	16-55	02SEP2020	78055	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
10281103	C4591001 1028 10281103	16-55	02SEP2020	78057	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10281104	C4591001 1028 10281104	16-55	02SEP2020	78060	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10281105	C4591001 1028 10281105	16-55	02SEP2020	78931	Placebo	02SEP2020/ Placebo	24SEP2020/ Placebo	06JAN2021/ BNT162b2 (30 µg)	28JAN2021/ BNT162b2 (30 µg)
10281106	C4591001 1028 10281106	16-55	02SEP2020	78063	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
10281110	C4591001 1028 10281110	16-55	03SEP2020	78934	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10281112	C4591001 1028 10281112	16-55	03SEP2020	78932	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10281114	C4591001 1028 10281114	16-55	03SEP2020	78935	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
10281116	C4591001 1028 10281116	16-55	03SEP2020	80705	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10281118	C4591001 1028 10281118	16-55	03SEP2020	80706	Placebo	03SEP2020/ Placebo	23SEP2020/ Placebo		
10281119	C4591001 1028 10281119	16-55	04SEP2020	80709	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10281120	C4591001 1028 10281120	16-55	04SEP2020	80707	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
10281121	C4591001 1028 10281121	16-55	04SEP2020	81283	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10281122	C4591001 1028 10281122	16-55	04SEP2020	81287	Placebo	04SEP2020/ Placebo	24SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	04JAN2021/ BNT162b2 (30 µg)
10281124	C4591001 1028 10281124	16-55	04SEP2020	81288	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10281125	C4591001 1028 10281125	16-55	04SEP2020	81291	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
10281126	C4591001 1028 10281126	16-55	04SEP2020	81750	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10281130	C4591001 1028 10281130	16-55	05SEP2020	81751	Placebo	05SEP2020/ Placebo	24SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
10281131	C4591001 1028 10281131	16-55	05SEP2020	81754	BNT162b2 (30 µg)	05SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
10281133	C4591001 1028 10281133	16-55	05SEP2020	82782	Placebo	05SEP2020/ Placebo	24SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
10281134	C4591001 1028 10281134	16-55	05SEP2020	82784	BNT162b2 (30 µg)	05SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
10281135	C4591001 1028 10281135	16-55	05SEP2020	81759	Placebo	05SEP2020/ Placebo	25SEP2020/ Placebo		
10281138	C4591001 1028 10281138	16-55	07SEP2020	82789	Placebo	07SEP2020/ Placebo	29SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
10281141	C4591001 1028 10281141	16-55	07SEP2020	82790	BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
10281143	C4591001 1028 10281143	16-55	08SEP2020	83357	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
10281144	C4591001 1028 10281144	16-55	08SEP2020	83360	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
10281146	C4591001 1028 10281146	16-55	08SEP2020	83361	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10281150	C4591001 1028 10281150	16-55	10SEP2020	86390	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	28JAN2021/ BNT162b2 (30 µg)
10281152	C4591001 1028 10281152	16-55	09SEP2020	83362	Placebo	09SEP2020/ Placebo	28SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10281153	C4591001 1028 10281153	16-55	09SEP2020	84965	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
10281154	C4591001 1028 10281154	16-55	09SEP2020	84971	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
10281155	C4591001 1028 10281155	16-55	09SEP2020	84966	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
10281156	C4591001 1028 10281156	16-55	09SEP2020	84974	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10281158	C4591001 1028 10281158	16-55	10SEP2020	86381	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
10281159	C4591001 1028 10281159	16-55	10SEP2020	86387	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
10281161	C4591001 1028 10281161	16-55	10SEP2020	86392	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
10281162	C4591001 1028 10281162	16-55	10SEP2020	87162	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10281165	C4591001 1028 10281165	16-55	10SEP2020	87164	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
10281167	C4591001 1028 10281167	16-55	11SEP2020	87165	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
10281170	C4591001 1028 10281170	16-55	11SEP2020	87168	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10281172	C4591001 1028 10281172	16-55	11SEP2020	88410	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
10281174	C4591001 1028 10281174	16-55	14SEP2020	88416	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
10281176	C4591001 1028 10281176	16-55	14SEP2020	88417	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
10281177	C4591001 1028 10281177	16-55	14SEP2020	88420	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
10281183	C4591001 1028 10281183	16-55	15SEP2020	90620	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
10281184	C4591001 1028 10281184	16-55	15SEP2020	90622	Placebo	15SEP2020/ Placebo	06OCT2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
10281186	C4591001 1028 10281186	16-55	15SEP2020	90625	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10281188	C4591001 1028 10281188	16-55	16SEP2020	90628	Placebo	16SEP2020/ Placebo	07OCT2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
10281190	C4591001 1028 10281190	16-55	16SEP2020	91208	Placebo	16SEP2020/ Placebo	07OCT2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
10281191	C4591001 1028 10281191	16-55	16SEP2020	91212	Placebo	16SEP2020/ Placebo	16OCT2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
10281192	C4591001 1028 10281192	16-55	16SEP2020	91214	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
10281197	C4591001 1028 10281197	16-55	17SEP2020	91216	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
10281198	C4591001 1028 10281198	16-55	17SEP2020	92240	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
10281200	C4591001 1028 10281200	16-55	17SEP2020	92244	Placebo	17SEP2020/ Placebo	06OCT2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	28JAN2021/ BNT162b2 (30 µg)
10281202	C4591001 1028 10281202	16-55	18SEP2020	92245	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	27JAN2021/ BNT162b2 (30 µg)
10281203	C4591001 1028 10281203	16-55	18SEP2020	92247	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
10281205	C4591001 1028 10281205	16-55	18SEP2020	93797	Placebo	18SEP2020/ Placebo	08OCT2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10281207	C4591001 1028 10281207	16-55	18SEP2020	93804	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
10281208	C4591001 1028 10281208	16-55	21SEP2020	93806	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10281209	C4591001 1028 10281209	16-55	21SEP2020	93807	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
10281211	C4591001 1028 10281211	16-55	21SEP2020	94841	Placebo	21SEP2020/ Placebo	15OCT2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
10281213	C4591001 1028 10281213	16-55	30SEP2020	99755	Placebo	30SEP2020/ Placebo	30OCT2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
10281216	C4591001 1028 10281216	16-55	22SEP2020	94843	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
10281221	C4591001 1028 10281221	16-55	22SEP2020	94845	Placebo	22SEP2020/ Placebo	15OCT2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
10281222	C4591001 1028 10281222	16-55	23SEP2020	94851	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)		
10281223	C4591001 1028 10281223	16-55	23SEP2020	97338	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
10281224	C4591001 1028 10281224	16-55	23SEP2020	97343	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10281225	C4591001 1028 10281225	16-55	23SEP2020	97347	Placebo	23SEP2020/ Placebo	12OCT2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
10281226	C4591001 1028 10281226	16-55	23SEP2020	97344	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
10281227	C4591001 1028 10281227	16-55	23SEP2020	98021	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
10281228	C4591001 1028 10281228	16-55	23SEP2020	98177	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
10281229	C4591001 1028 10281229	16-55	24SEP2020	98183	Placebo	24SEP2020/ Placebo	15OCT2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
10281231	C4591001 1028 10281231	16-55	24SEP2020	98184	Placebo	24SEP2020/ Placebo	26OCT2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
10281236	C4591001 1028 10281236	16-55	25SEP2020	98186	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
10281237	C4591001 1028 10281237	16-55	25SEP2020	99751	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)		
10281240	C4591001 1028 10281240	16-55	30SEP2020	99752	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		
10281241	C4591001 1028 10281241	16-55	01OCT2020	99758	Placebo	01OCT2020/ Placebo	29OCT2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10281242	C4591001 1028 10281242	16-55	01OCT2020	102919	BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)		
10281243	C4591001 1028 10281243	16-55	02OCT2020	102922	BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)		
10281244	C4591001 1028 10281244	16-55	05OCT2020	102924	Placebo	05OCT2020/ Placebo	26OCT2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
10281246	C4591001 1028 10281246	16-55	06OCT2020	102927	Placebo	06OCT2020/ Placebo	27OCT2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
10281247	C4591001 1028 10281247	16-55	07OCT2020	104634	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
10281248	C4591001 1028 10281248	16-55	07OCT2020	104639	Placebo	07OCT2020/ Placebo	26OCT2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
10281249	C4591001 1028 10281249	16-55	07OCT2020	104642	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		
10281250	C4591001 1028 10281250	16-55	08OCT2020	104644	Placebo	08OCT2020/ Placebo	03NOV2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
10281251	C4591001 1028 10281251	16-55	09OCT2020	105800	Placebo	09OCT2020/ Placebo	28OCT2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10281253	C4591001 1028 10281253	16-55	13OCT2020	105803	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10281254	C4591001 1028 10281254	16-55	14OCT2020	105805	BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
10281255	C4591001 1028 10281255	16-55	14OCT2020	105806	Placebo	14OCT2020/ Placebo	04NOV2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
10281256	C4591001 1028 10281256	16-55	14OCT2020	107659	BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
10281257	C4591001 1028 10281257	16-55	14OCT2020	107661	BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
10281258	C4591001 1028 10281258	16-55	14OCT2020	107664	Placebo	14OCT2020/ Placebo	04NOV2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
10281259	C4591001 1028 10281259	16-55	15OCT2020	107665	Placebo	15OCT2020/ Placebo	06NOV2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
10281261	C4591001 1028 10281261	16-55	19OCT2020	109975	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
10281262	C4591001 1028 10281262	16-55	19OCT2020	109977	Placebo	19OCT2020/ Placebo	12NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10281265	C4591001 1028 10281265	16-55	20OCT2020	109979	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
10281267	C4591001 1028 10281267	16-55	21OCT2020	111318	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	07DEC2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10281269	C4591001 1028 10281269	16-55	20OCT2020	109980	Placebo	20OCT2020/ Placebo	11NOV2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
10281271	C4591001 1028 10281271	16-55	21OCT2020	111320	Placebo	21OCT2020/ Placebo	13NOV2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
10281274	C4591001 1028 10281274	16-55	22OCT2020	111327	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
10281275	C4591001 1028 10281275	16-55	22OCT2020	111324	Placebo	22OCT2020/ Placebo	12NOV2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
10281276	C4591001 1028 10281276	16-55	22OCT2020	112447	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
10281279	C4591001 1028 10281279	16-55	26OCT2020	112448	Placebo	26OCT2020/ Placebo	19NOV2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
10281280	C4591001 1028 10281280	16-55	26OCT2020	112453	Placebo	26OCT2020/ Placebo	17NOV2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10281282	C4591001 1028 10281282	16-55	27OCT2020	112455	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
10281284	C4591001 1028 10281284	16-55	27OCT2020	114162	Placebo	27OCT2020/ Placebo	17NOV2020/ Placebo		
10281285	C4591001 1028 10281285	16-55	27OCT2020	114164	Placebo	27OCT2020/ Placebo		17FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10281286	C4591001 1028 10281286	16-55	27OCT2020	114169	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
10281287	C4591001 1028 10281287	16-55	28OCT2020	114171	BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
10281290	C4591001 1028 10281290	16-55	28OCT2020	114497	Placebo	28OCT2020/ Placebo	19NOV2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
10281291	C4591001 1028 10281291	16-55	28OCT2020	114502	BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)	18NOV2020/ BNT162b2 (30 µg)		
10281294	C4591001 1028 10281294	16-55	29OCT2020	114504	Placebo	29OCT2020/ Placebo		02FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10301001	C4591001 1030 10301001	16-55	26AUG2020	67361	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
10301002	C4591001 1030 10301002	16-55	26AUG2020	67362	Placebo	26AUG2020/ Placebo	15SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
10301003	C4591001 1030 10301003	16-55	26AUG2020	67369	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10301004	C4591001 1030 10301004	16-55	27AUG2020	67372	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10301005	C4591001 1030 10301005	16-55	27AUG2020	69500	Placebo	27AUG2020/ Placebo	16SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10301008	C4591001 1030 10301008	16-55	27AUG2020	69502	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10301010	C4591001 1030 10301010	16-55	28AUG2020	69503	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
10301011	C4591001 1030 10301011	16-55	28AUG2020	69505	Placebo	28AUG2020/ Placebo	17SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
10301012	C4591001 1030 10301012	16-55	28AUG2020	72558	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10301013	C4591001 1030 10301013	16-55	28AUG2020	72559	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
10301014	C4591001 1030 10301014	16-55	28AUG2020	72564	Placebo	28AUG2020/ Placebo	28SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
10301015	C4591001 1030 10301015	16-55	28AUG2020	72568	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
10301018	C4591001 1030 10301018	16-55	31AUG2020	74886	Placebo	31AUG2020/ Placebo	22SEP2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)
10301019	C4591001 1030 10301019	16-55	31AUG2020	74887	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10301021	C4591001 1030 10301021	16-55	31AUG2020	74890	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10301022	C4591001 1030 10301022	16-55	31AUG2020	74893	Placebo	31AUG2020/ Placebo	22SEP2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	14JAN2021/ BNT162b2 (30 µg)
10301023	C4591001 1030 10301023	16-55	31AUG2020	75909	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10301026	C4591001 1030 10301026	16-55	01SEP2020	75913	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)
10301027	C4591001 1030 10301027	16-55	01SEP2020	75914	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10301028	C4591001 1030 10301028	16-55	01SEP2020	77072	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10301029	C4591001 1030 10301029	16-55	01SEP2020	77074	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10301030	C4591001 1030 10301030	16-55	01SEP2020	77075	Placebo	01SEP2020/ Placebo	21SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
10301032	C4591001 1030 10301032	16-55	02SEP2020	77080	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
10301038	C4591001 1030 10301038	16-55	03SEP2020	78774	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10301039	C4591001 1030 10301039	16-55	03SEP2020	78777	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10301040	C4591001 1030 10301040	16-55	03SEP2020	78782	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
10301041	C4591001 1030 10301041	16-55	03SEP2020	79877	Placebo	03SEP2020/ Placebo	22SEP2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)
10301042	C4591001 1030 10301042	16-55	03SEP2020	79880	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
10301043	C4591001 1030 10301043	16-55	03SEP2020	79886	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10301044	C4591001 1030 10301044	16-55	03SEP2020	79888	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
10301045	C4591001 1030 10301045	16-55	04SEP2020	81245	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
10301048	C4591001 1030 10301048	16-55	04SEP2020	81247	Placebo	04SEP2020/ Placebo	23SEP2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
10301049	C4591001 1030 10301049	16-55	04SEP2020	81251	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
10301050	C4591001 1030 10301050	16-55	08SEP2020	81252	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
10301053	C4591001 1030 10301053	16-55	08SEP2020	83946	Placebo	08SEP2020/ Placebo	01OCT2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10301054	C4591001 1030 10301054	16-55	08SEP2020	83948	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
10301055	C4591001 1030 10301055	16-55	08SEP2020	83950	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
10301056	C4591001 1030 10301056	16-55	08SEP2020	83956	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
10301057	C4591001 1030 10301057	16-55	09SEP2020	84857	Placebo	09SEP2020/ Placebo	05OCT2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
10301060	C4591001 1030 10301060	16-55	09SEP2020	84862	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
10301061	C4591001 1030 10301061	16-55	09SEP2020	84863	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
10301063	C4591001 1030 10301063	16-55	10SEP2020	84867	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
10301065	C4591001 1030 10301065	16-55	10SEP2020	86669	Placebo	10SEP2020/ Placebo	02OCT2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
10301069	C4591001 1030 10301069	16-55	10SEP2020	86673	Placebo	10SEP2020/ Placebo	02OCT2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
10301070	C4591001 1030 10301070	16-55	11SEP2020	86674	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10301071	C4591001 1030 10301071	16-55	11SEP2020	86677	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
10301072	C4591001 1030 10301072	16-55	11SEP2020	87751	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
10301075	C4591001 1030 10301075	16-55	11SEP2020	87752	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
10301077	C4591001 1030 10301077	16-55	11SEP2020	87753	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
10301080	C4591001 1030 10301080	16-55	11SEP2020	87758	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
10301081	C4591001 1030 10301081	16-55	14SEP2020	89315	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
10301082	C4591001 1030 10301082	16-55	14SEP2020	89317	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
10301083	C4591001 1030 10301083	16-55	14SEP2020	89318	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
10301087	C4591001 1030 10301087	16-55	15SEP2020	89319	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
10301088	C4591001 1030 10301088	16-55	15SEP2020	90115	Placebo	15SEP2020/ Placebo	05OCT2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10301093	C4591001 1030 10301093	16-55	15SEP2020	90116	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
10301095	C4591001 1030 10301095	16-55	15SEP2020	90119	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
10301097	C4591001 1030 10301097	16-55	16SEP2020	90122	Placebo	16SEP2020/ Placebo	08OCT2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
10301099	C4591001 1030 10301099	16-55	16SEP2020	91328	Placebo	16SEP2020/ Placebo	08OCT2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
10301100	C4591001 1030 10301100	16-55	16SEP2020	91331	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
10301101	C4591001 1030 10301101	16-55	17SEP2020	91332	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
10301102	C4591001 1030 10301102	16-55	17SEP2020	91334	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
10301104	C4591001 1030 10301104	16-55	17SEP2020	92825	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
10301106	C4591001 1030 10301106	16-55	18SEP2020	92827	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
10301107	C4591001 1030 10301107	16-55	18SEP2020	92829	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10301110	C4591001 1030 10301110	16-55	18SEP2020	92835	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
10301113	C4591001 1030 10301113	16-55	18SEP2020	94050	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	22JAN2021/ BNT162b2 (30 µg)
10301120	C4591001 1030 10301120	16-55	22SEP2020	94053	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
10301122	C4591001 1030 10301122	16-55	22SEP2020	94054	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
10301123	C4591001 1030 10301123	16-55	22SEP2020	94055	Placebo	22SEP2020/ Placebo	13OCT2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10301124	C4591001 1030 10301124	16-55	22SEP2020	96821	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
10301127	C4591001 1030 10301127	16-55	23SEP2020	96824	Placebo	23SEP2020/ Placebo	15OCT2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
10301128	C4591001 1030 10301128	16-55	23SEP2020	96827	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
10301130	C4591001 1030 10301130	16-55	24SEP2020	96832	Placebo	24SEP2020/ Placebo	15OCT2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
10301134	C4591001 1030 10301134	16-55	24SEP2020	98897	Placebo	24SEP2020/ Placebo	13OCT2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10301136	C4591001 1030 10301136	16-55	25SEP2020	98901	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	28JAN2021/ BNT162b2 (30 µg)
10301137	C4591001 1030 10301137	16-55	25SEP2020	98903	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
10301139	C4591001 1030 10301139	16-55	25SEP2020	98904	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
10301142	C4591001 1030 10301142	16-55	06OCT2020	104144	BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
10301143	C4591001 1030 10301143	16-55	07OCT2020	104145	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
10301145	C4591001 1030 10301145	16-55	09OCT2020	104147	Placebo	09OCT2020/ Placebo	30OCT2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
10301146	C4591001 1030 10301146	16-55	12OCT2020	104152	Placebo	12OCT2020/ Placebo	02NOV2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
10301148	C4591001 1030 10301148	16-55	12OCT2020	106493	Placebo	12OCT2020/ Placebo	02NOV2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
10301152	C4591001 1030 10301152	16-55	15OCT2020	106497	Placebo	15OCT2020/ Placebo	05NOV2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10301153	C4591001 1030 10301153	16-55	16OCT2020	106500	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10301154	C4591001 1030 10301154	16-55	19OCT2020	106501	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
10301155	C4591001 1030 10301155	16-55	19OCT2020	110120	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
10361004	C4591001 1036 10361004	16-55	19AUG2020	56323	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
10361006	C4591001 1036 10361006	16-55	19AUG2020	56327	Placebo	19AUG2020/ Placebo	08SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
10361009	C4591001 1036 10361009	16-55	19AUG2020	56328	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10361011	C4591001 1036 10361011	16-55	20AUG2020	56329	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)			
10361012	C4591001 1036 10361012	16-55	20AUG2020	58902	Placebo	20AUG2020/ Placebo	09SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10361014	C4591001 1036 10361014	16-55	20AUG2020	58903	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10361017	C4591001 1036 10361017	16-55	21AUG2020	58908	Placebo	21AUG2020/ Placebo	09SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
10361018	C4591001 1036 10361018	16-55	21AUG2020	58910	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10361020	C4591001 1036 10361020	16-55	21AUG2020	61075	Placebo	21AUG2020/ Placebo	10SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
10361021	C4591001 1036 10361021	16-55	21AUG2020	61078	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
10361022	C4591001 1036 10361022	16-55	24AUG2020	61079	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10361023	C4591001 1036 10361023	16-55	25AUG2020	61084	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
10361026	C4591001 1036 10361026	16-55	25AUG2020	66606	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10361027	C4591001 1036 10361027	16-55	25AUG2020	66608	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
10361029	C4591001 1036 10361029	16-55	25AUG2020	66612	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10361030	C4591001 1036 10361030	16-55	25AUG2020	66613	Placebo	25AUG2020/ Placebo	14SEP2020/ Placebo		
10361032	C4591001 1036 10361032	16-55	26AUG2020	68384	Placebo	26AUG2020/ Placebo	17SEP2020/ Placebo		
10361033	C4591001 1036 10361033	16-55	26AUG2020	68389	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10361038	C4591001 1036 10361038	16-55	27AUG2020	68391	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10361039	C4591001 1036 10361039	16-55	27AUG2020	68392	Placebo	27AUG2020/ Placebo	16SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10361040	C4591001 1036 10361040	16-55	27AUG2020	70831	Placebo	27AUG2020/ Placebo	16SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
10361042	C4591001 1036 10361042	16-55	28AUG2020	70832	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10361043	C4591001 1036 10361043	16-55	28AUG2020	70834	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10361047	C4591001 1036 10361047	16-55	29AUG2020	70837	Placebo	29AUG2020/ Placebo	22SEP2020/ Placebo	27FEB2021/ BNT162b2 (30 µg)	
10361048	C4591001 1036 10361048	16-55	29AUG2020	73867	Placebo	29AUG2020/ Placebo	19SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
10361050	C4591001 1036 10361050	16-55	31AUG2020	73868	BNT162b2 (30 µg)				
10361053	C4591001 1036 10361053	16-55	31AUG2020	73871	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10361055	C4591001 1036 10361055	16-55	31AUG2020	75823	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10361056	C4591001 1036 10361056	16-55	31AUG2020	75828	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
10361060	C4591001 1036 10361060	16-55	01SEP2020	75829	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10361061	C4591001 1036 10361061	16-55	01SEP2020	75832	Placebo	01SEP2020/ Placebo	21SEP2020/ Placebo		
10361062	C4591001 1036 10361062	16-55	01SEP2020	76949	Placebo	01SEP2020/ Placebo	21SEP2020/ Placebo		
10361064	C4591001 1036 10361064	16-55	02SEP2020	76951	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10361065	C4591001 1036 10361065	16-55	02SEP2020	76959	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10361068	C4591001 1036 10361068	16-55	02SEP2020	76960	Placebo	02SEP2020/ Placebo	21SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10361069	C4591001 1036 10361069	16-55	02SEP2020	79221	Placebo	02SEP2020/ Placebo	22SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10361070	C4591001 1036 10361070	16-55	02SEP2020	79223	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10361072	C4591001 1036 10361072	16-55	03SEP2020	79224	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10361073	C4591001 1036 10361073	16-55	04SEP2020	79227	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo		
10361074	C4591001 1036 10361074	16-55	04SEP2020	81619	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
10361075	C4591001 1036 10361075	16-55	04SEP2020	81622	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
10361076	C4591001 1036 10361076	16-55	04SEP2020	81623	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
10361078	C4591001 1036 10361078	16-55	08SEP2020	81628	Placebo	08SEP2020/ Placebo	30SEP2020/ Placebo		
10361084	C4591001 1036 10361084	16-55	09SEP2020	86084	Placebo	09SEP2020/ Placebo	01OCT2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	28JAN2021/ BNT162b2 (30 µg)
10361086	C4591001 1036 10361086	16-55	10SEP2020	86085	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)
10361088	C4591001 1036 10361088	16-55	11SEP2020	86086	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
10361093	C4591001 1036 10361093	16-55	12SEP2020	86091	BNT162b2 (30 µg)	12SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
10361094	C4591001 1036 10361094	16-55	12SEP2020	89192	BNT162b2 (30 µg)	12SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10361095	C4591001 1036 10361095	16-55	12SEP2020	89197	Placebo	12SEP2020/ Placebo	02OCT2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10361096	C4591001 1036 10361096	16-55	12SEP2020	89199	Placebo	12SEP2020/ Placebo	05OCT2020/ Placebo		
10361097	C4591001 1036 10361097	16-55	12SEP2020	89200	BNT162b2 (30 µg)	12SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
10361098	C4591001 1036 10361098	16-55	12SEP2020	89214	BNT162b2 (30 µg)	12SEP2020/ BNT162b2 (30 µg)	03OCT2020/ BNT162b2 (30 µg)		
10361099	C4591001 1036 10361099	16-55	12SEP2020	89217	BNT162b2 (30 µg)	12SEP2020/ BNT162b2 (30 µg)	03OCT2020/ BNT162b2 (30 µg)		
10361100	C4591001 1036 10361100	16-55	12SEP2020	89219	Placebo	12SEP2020/ Placebo	03OCT2020/ Placebo		
10361102	C4591001 1036 10361102	16-55	15SEP2020	89221	Placebo	15SEP2020/ Placebo	05OCT2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10361103	C4591001 1036 10361103	16-55	19SEP2020	94446	Placebo	19SEP2020/ Placebo	10OCT2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10361104	C4591001 1036 10361104	16-55	19SEP2020	94447	BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)	10OCT2020/ BNT162b2 (30 µg)		
10361105	C4591001 1036 10361105	16-55	28SEP2020	94451	Placebo	28SEP2020/ Placebo	19OCT2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10361107	C4591001 1036 10361107	16-55	24SEP2020	264862	BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)		
10361110	C4591001 1036 10361110	16-55	02OCT2020	94454	BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)		
10361112	C4591001 1036 10361112	16-55	05OCT2020	103733	BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
10361117	C4591001 1036 10361117	16-55	16OCT2020	108965	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
10361118	C4591001 1036 10361118	16-55	10OCT2020	103735	Placebo	10OCT2020/ Placebo	02NOV2020/ Placebo		
10361119	C4591001 1036 10361119	16-55	10OCT2020	103736	BNT162b2 (30 µg)	10OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		
10361125	C4591001 1036 10361125	16-55	13OCT2020	103741	Placebo	13OCT2020/ Placebo	04NOV2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
10361126	C4591001 1036 10361126	16-55	16OCT2020	108967	Placebo	16OCT2020/ Placebo	06NOV2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
10361127	C4591001 1036 10361127	16-55	16OCT2020	108974	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)			
10361128	C4591001 1036 10361128	16-55	16OCT2020	108975	Placebo	16OCT2020/ Placebo			



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10361129	C4591001 1036 10361129	16-55	16OCT2020	109145	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
10361131	C4591001 1036 10361131	16-55	16OCT2020	109146	Placebo	16OCT2020/ Placebo	06NOV2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
10361135	C4591001 1036 10361135	16-55	19OCT2020	109147	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
10361137	C4591001 1036 10361137	16-55	20OCT2020	109154	Placebo	20OCT2020/ Placebo	12NOV2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
10361141	C4591001 1036 10361141	16-55	23OCT2020	112988	Placebo	23OCT2020/ Placebo	12NOV2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10361144	C4591001 1036 10361144	16-55	26OCT2020	112989	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
10361145	C4591001 1036 10361145	16-55	26OCT2020	112990	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
10371007	C4591001 1037 10371007	16-55	18AUG2020	54153	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10371008	C4591001 1037 10371008	16-55	18AUG2020	54154	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10371010	C4591001 1037 10371010	16-55	18AUG2020	54157	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10371017	C4591001 1037 10371017	16-55	19AUG2020	56129	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10371018	C4591001 1037 10371018	16-55	19AUG2020	54158	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
10371024	C4591001 1037 10371024	16-55	19AUG2020	56133	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
10371026	C4591001 1037 10371026	16-55	20AUG2020	56138	Placebo	20AUG2020/ Placebo	09SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10371028	C4591001 1037 10371028	16-55	20AUG2020	58301	Placebo	20AUG2020/ Placebo	09SEP2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
10371029	C4591001 1037 10371029	16-55	20AUG2020	56140	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10371037	C4591001 1037 10371037	16-55	21AUG2020	58304	Placebo	21AUG2020/ Placebo	15SEP2020/ Placebo		
10371038	C4591001 1037 10371038	16-55	21AUG2020	58308	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10371041	C4591001 1037 10371041	16-55	21AUG2020	58311	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
10371042	C4591001 1037 10371042	16-55	21AUG2020	60773	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10371043	C4591001 1037 10371043	16-55	21AUG2020	60775	Placebo	21AUG2020/ Placebo	09SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
10371044	C4591001 1037 10371044	16-55	21AUG2020	60778	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10371045	C4591001 1037 10371045	16-55	21AUG2020	60784	Placebo	21AUG2020/ Placebo	10SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
10371046	C4591001 1037 10371046	16-55	21AUG2020	60990	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10371047	C4591001 1037 10371047	16-55	21AUG2020	60992	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10371050	C4591001 1037 10371050	16-55	24AUG2020	60994	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo		
10371051	C4591001 1037 10371051	16-55	24AUG2020	60996	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
10371052	C4591001 1037 10371052	16-55	24AUG2020	63425	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10371054	C4591001 1037 10371054	16-55	24AUG2020	63426	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	03MAR2021/ BNT162b2 (30 µg)	
10371056	C4591001 1037 10371056	16-55	24AUG2020	63428	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10371058	C4591001 1037 10371058	16-55	24AUG2020	63435	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
10371060	C4591001 1037 10371060	16-55	24AUG2020	64662	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10371061	C4591001 1037 10371061	16-55	25AUG2020	64665	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10371065	C4591001 1037 10371065	16-55	25AUG2020	64668	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10371067	C4591001 1037 10371067	16-55	25AUG2020	64669	Placebo	25AUG2020/ Placebo	14SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10371068	C4591001 1037 10371068	16-55	25AUG2020	65705	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)			
10371072	C4591001 1037 10371072	16-55	26AUG2020	65709	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10371073	C4591001 1037 10371073	16-55	26AUG2020	65713	Placebo	26AUG2020/ Placebo	15SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
10371074	C4591001 1037 10371074	16-55	26AUG2020	65716	Placebo	26AUG2020/ Placebo	15SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
10371076	C4591001 1037 10371076	16-55	26AUG2020	67686	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10371077	C4591001 1037 10371077	16-55	26AUG2020	67689	Placebo	26AUG2020/ Placebo			
10371078	C4591001 1037 10371078	16-55	26AUG2020	67690	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)			
10371081	C4591001 1037 10371081	16-55	27AUG2020	67692	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
10371082	C4591001 1037 10371082	16-55	27AUG2020	70037	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10371083	C4591001 1037 10371083	16-55	28AUG2020	70041	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10371087	C4591001 1037 10371087	16-55	31AUG2020	70046	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	04JAN2021/ BNT162b2 (30 µg)
10371088	C4591001 1037 10371088	16-55	31AUG2020	70042	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	15DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
10371092	C4591001 1037 10371092	16-55	31AUG2020	74962	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10371096	C4591001 1037 10371096	16-55	31AUG2020	74964	Placebo	31AUG2020/ Placebo	22SEP2020/ Placebo		
10371097	C4591001 1037 10371097	16-55	01SEP2020	74966	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10371104	C4591001 1037 10371104	16-55	01SEP2020	76601	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10371109	C4591001 1037 10371109	16-55	01SEP2020	76605	Placebo	01SEP2020/ Placebo	21SEP2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
10371110	C4591001 1037 10371110	16-55	01SEP2020	76608	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10371115	C4591001 1037 10371115	16-55	02SEP2020	76612	Placebo	02SEP2020/ Placebo	22SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
10371116	C4591001 1037 10371116	16-55	02SEP2020	78079	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10371124	C4591001 1037 10371124	16-55	02SEP2020	78081	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10371125	C4591001 1037 10371125	16-55	02SEP2020	78085	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10371126	C4591001 1037 10371126	16-55	03SEP2020	78088	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
10371130	C4591001 1037 10371130	16-55	03SEP2020	79628	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10371131	C4591001 1037 10371131	16-55	03SEP2020	79630	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10371138	C4591001 1037 10371138	16-55	03SEP2020	79631	Placebo	03SEP2020/ Placebo	22SEP2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
10371140	C4591001 1037 10371140	16-55	03SEP2020	79636	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
10371142	C4591001 1037 10371142	16-55	04SEP2020	81833	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
10371145	C4591001 1037 10371145	16-55	04SEP2020	81836	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
10371148	C4591001 1037 10371148	16-55	04SEP2020	81838	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10371152	C4591001 1037 10371152	16-55	04SEP2020	81841	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)
10371154	C4591001 1037 10371154	16-55	15SEP2020	90249	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
10371155	C4591001 1037 10371155	16-55	08SEP2020	83297	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10371157	C4591001 1037 10371157	16-55	08SEP2020	83298	Placebo	08SEP2020/ Placebo	01OCT2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
10371168	C4591001 1037 10371168	16-55	09SEP2020	83301	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10371169	C4591001 1037 10371169	16-55	09SEP2020	84905	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
10371170	C4591001 1037 10371170	16-55	09SEP2020	83305	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
10371172	C4591001 1037 10371172	16-55	09SEP2020	84907	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10371176	C4591001 1037 10371176	16-55	09SEP2020	84909	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10371179	C4591001 1037 10371179	16-55	10SEP2020	84911	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
10371180	C4591001 1037 10371180	16-55	10SEP2020	86360	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
10371183	C4591001 1037 10371183	16-55	10SEP2020	86363	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
10371192	C4591001 1037 10371192	16-55	11SEP2020	86365	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10371198	C4591001 1037 10371198	16-55	11SEP2020	86368	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
10371199	C4591001 1037 10371199	16-55	14SEP2020	89339	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10371200	C4591001 1037 10371200	16-55	14SEP2020	89334	Placebo	14SEP2020/ Placebo	07OCT2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
10371201	C4591001 1037 10371201	16-55	14SEP2020	89340	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
10371202	C4591001 1037 10371202	16-55	14SEP2020	89342	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
10371208	C4591001 1037 10371208	16-55	14SEP2020	89622	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
10371209	C4591001 1037 10371209	16-55	14SEP2020	89623	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
10371210	C4591001 1037 10371210	16-55	15SEP2020	89624	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
10371214	C4591001 1037 10371214	16-55	15SEP2020	89626	Placebo	15SEP2020/ Placebo	05OCT2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
10371215	C4591001 1037 10371215	16-55	15SEP2020	90252	Placebo	15SEP2020/ Placebo	05OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10371216	C4591001 1037 10371216	16-55	15SEP2020	90255	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
10371219	C4591001 1037 10371219	16-55	16SEP2020	90256	Placebo	16SEP2020/ Placebo	05OCT2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10371220	C4591001 1037 10371220	16-55	16SEP2020	90965	Placebo	16SEP2020/ Placebo	05OCT2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
10371221	C4591001 1037 10371221	16-55	16SEP2020	90971	Placebo	16SEP2020/ Placebo	05OCT2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
10371222	C4591001 1037 10371222	16-55	16SEP2020	90973	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
10371223	C4591001 1037 10371223	16-55	16SEP2020	90976	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
10371230	C4591001 1037 10371230	16-55	17SEP2020	92045	Placebo	17SEP2020/ Placebo	07OCT2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
10371231	C4591001 1037 10371231	16-55	17SEP2020	92046	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
10371232	C4591001 1037 10371232	16-55	17SEP2020	92052	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
10371236	C4591001 1037 10371236	16-55	18SEP2020	92053	Placebo	18SEP2020/ Placebo	08OCT2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
10371237	C4591001 1037 10371237	16-55	18SEP2020	93714	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
10371238	C4591001 1037 10371238	16-55	18SEP2020	93715	Placebo	18SEP2020/ Placebo	08OCT2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10371240	C4591001 1037 10371240	16-55	18SEP2020	93713	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
10371241	C4591001 1037 10371241	16-55	18SEP2020	93720	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
10371245	C4591001 1037 10371245	16-55	21SEP2020	94662	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
10371246	C4591001 1037 10371246	16-55	21SEP2020	94667	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
10371249	C4591001 1037 10371249	16-55	05OCT2020	103687	BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
10371250	C4591001 1037 10371250	16-55	21SEP2020	94668	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
10371253	C4591001 1037 10371253	16-55	21SEP2020	94669	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)		
10371254	C4591001 1037 10371254	16-55	21SEP2020	95167	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
10371255	C4591001 1037 10371255	16-55	22SEP2020	95169	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
10371256	C4591001 1037 10371256	16-55	22SEP2020	95173	Placebo	22SEP2020/ Placebo	13OCT2020/ Placebo	15DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10371257	C4591001 1037 10371257	16-55	22SEP2020	95175	Placebo	22SEP2020/ Placebo	15OCT2020/ Placebo		
10371258	C4591001 1037 10371258	16-55	22SEP2020	96113	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
10371259	C4591001 1037 10371259	16-55	22SEP2020	96117	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
10371262	C4591001 1037 10371262	16-55	22SEP2020	96120	Placebo	22SEP2020/ Placebo	12OCT2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
10371265	C4591001 1037 10371265	16-55	22SEP2020	96123	Placebo	22SEP2020/ Placebo	16OCT2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
10371266	C4591001 1037 10371266	16-55	22SEP2020	96415	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
10371269	C4591001 1037 10371269	16-55	23SEP2020	96417	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10371271	C4591001 1037 10371271	16-55	23SEP2020	96419	Placebo	23SEP2020/ Placebo	15OCT2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
10371272	C4591001 1037 10371272	16-55	23SEP2020	96420	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
10371277	C4591001 1037 10371277	16-55	23SEP2020	97483	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10371284	C4591001 1037 10371284	16-55	24SEP2020	97489	Placebo	24SEP2020/ Placebo	15OCT2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10371285	C4591001 1037 10371285	16-55	24SEP2020	97484	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
10371286	C4591001 1037 10371286	16-55	24SEP2020	97487	Placebo	24SEP2020/ Placebo	13OCT2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
10371287	C4591001 1037 10371287	16-55	24SEP2020	98648	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
10371288	C4591001 1037 10371288	16-55	24SEP2020	98649	Placebo	24SEP2020/ Placebo	22OCT2020/ Placebo	03MAR2021/ BNT162b2 (30 µg)	
10371290	C4591001 1037 10371290	16-55	25SEP2020	98651	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
10371291	C4591001 1037 10371291	16-55	25SEP2020	98652	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10371296	C4591001 1037 10371296	16-55	25SEP2020	100075	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
10371298	C4591001 1037 10371298	16-55	29SEP2020	100077	Placebo	29SEP2020/ Placebo	19OCT2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
10371300	C4591001 1037 10371300	16-55	29SEP2020	100083	Placebo	29SEP2020/ Placebo	19OCT2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10371301	C4591001 1037 10371301	16-55	29SEP2020	100084	BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		
10371302	C4591001 1037 10371302	16-55	29SEP2020	101850	Placebo	29SEP2020/ Placebo	19OCT2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
10371306	C4591001 1037 10371306	16-55	30SEP2020	101851	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		
10371307	C4591001 1037 10371307	16-55	30SEP2020	101853	Placebo	30SEP2020/ Placebo	19OCT2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
10371308	C4591001 1037 10371308	16-55	30SEP2020	101858	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)		
10371309	C4591001 1037 10371309	16-55	30SEP2020	102521	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		
10371310	C4591001 1037 10371310	16-55	01OCT2020	102524	Placebo	01OCT2020/ Placebo	20OCT2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
10371312	C4591001 1037 10371312	16-55	01OCT2020	102527	BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)		
10371313	C4591001 1037 10371313	16-55	01OCT2020	102810	BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)		
10371314	C4591001 1037 10371314	16-55	01OCT2020	102528	Placebo	01OCT2020/ Placebo	22OCT2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10371315	C4591001 1037 10371315	16-55	02OCT2020	102814	BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)		
10371316	C4591001 1037 10371316	16-55	02OCT2020	102817	Placebo	02OCT2020/ Placebo	23OCT2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
10371317	C4591001 1037 10371317	16-55	02OCT2020	102820	Placebo	02OCT2020/ Placebo	22OCT2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
10371319	C4591001 1037 10371319	16-55	05OCT2020	103689	Placebo	05OCT2020/ Placebo	09NOV2020/ Placebo	12MAR2021/ BNT162b2 (30 µg)	
10371321	C4591001 1037 10371321	16-55	07OCT2020	103691	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
10371323	C4591001 1037 10371323	16-55	07OCT2020	103694	Placebo	07OCT2020/ Placebo	28OCT2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
10371324	C4591001 1037 10371324	16-55	07OCT2020	104744	Placebo	07OCT2020/ Placebo	26OCT2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
10371325	C4591001 1037 10371325	16-55	08OCT2020	104749	Placebo	08OCT2020/ Placebo	29OCT2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
10371327	C4591001 1037 10371327	16-55	08OCT2020	104750	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
10371328	C4591001 1037 10371328	16-55	08OCT2020	104752	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10371330	C4591001 1037 10371330	16-55	08OCT2020	105437	Placebo	08OCT2020/ Placebo	27OCT2020/ Placebo		
10371331	C4591001 1037 10371331	16-55	08OCT2020	105444	Placebo	08OCT2020/ Placebo	27OCT2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
10371332	C4591001 1037 10371332	16-55	09OCT2020	105446	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)		
10371336	C4591001 1037 10371336	16-55	13OCT2020	105447	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		
10371337	C4591001 1037 10371337	16-55	02NOV2020	115266	BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)	24NOV2020/ BNT162b2 (30 µg)		
10371340	C4591001 1037 10371340	16-55	13OCT2020	107189	Placebo	13OCT2020/ Placebo	03NOV2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
10371341	C4591001 1037 10371341	16-55	13OCT2020	107194	Placebo	13OCT2020/ Placebo	03NOV2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10371342	C4591001 1037 10371342	16-55	14OCT2020	107196	BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
10371343	C4591001 1037 10371343	16-55	14OCT2020	107198	BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
10371344	C4591001 1037 10371344	16-55	14OCT2020	107599	Placebo	14OCT2020/ Placebo	03NOV2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10371347	C4591001 1037 10371347	16-55	15OCT2020	107600	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
10371349	C4591001 1037 10371349	16-55	15OCT2020	107602	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
10371350	C4591001 1037 10371350	16-55	15OCT2020	107605	Placebo	15OCT2020/ Placebo	05NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
10371351	C4591001 1037 10371351	16-55	16OCT2020	109085	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
10371352	C4591001 1037 10371352	16-55	19OCT2020	109086	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
10371353	C4591001 1037 10371353	16-55	19OCT2020	109090	Placebo	19OCT2020/ Placebo	11NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10371355	C4591001 1037 10371355	16-55	19OCT2020	109093	Placebo	19OCT2020/ Placebo	11NOV2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
10371357	C4591001 1037 10371357	16-55	20OCT2020	111161	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
10371358	C4591001 1037 10371358	16-55	20OCT2020	111164	Placebo	20OCT2020/ Placebo	09NOV2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
10371359	C4591001 1037 10371359	16-55	21OCT2020	111165	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10371360	C4591001 1037 10371360	16-55	23OCT2020	111172	Placebo	23OCT2020/ Placebo	13NOV2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
10381001	C4591001 1038 10381001	16-55	18AUG2020	54797	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
10381002	C4591001 1038 10381002	16-55	18AUG2020	54798	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10381003	C4591001 1038 10381003	16-55	18AUG2020	54806	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10381004	C4591001 1038 10381004	16-55	19AUG2020	54808	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
10381005	C4591001 1038 10381005	16-55	19AUG2020	55869	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10381006	C4591001 1038 10381006	16-55	19AUG2020	55870	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10381008	C4591001 1038 10381008	16-55	19AUG2020	55873	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
10381010	C4591001 1038 10381010	16-55	19AUG2020	55876	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)
10381012	C4591001 1038 10381012	16-55	20AUG2020	57954	Placebo	20AUG2020/ Placebo	09SEP2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	20JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10381013	C4591001 1038 10381013	16-55	20AUG2020	57956	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10381014	C4591001 1038 10381014	16-55	20AUG2020	57959	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10381016	C4591001 1038 10381016	16-55	20AUG2020	57960	Placebo	20AUG2020/ Placebo	09SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
10381018	C4591001 1038 10381018	16-55	20AUG2020	59325	Placebo	20AUG2020/ Placebo	09SEP2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
10381020	C4591001 1038 10381020	16-55	21AUG2020	59327	Placebo	21AUG2020/ Placebo	09SEP2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
10381022	C4591001 1038 10381022	16-55	21AUG2020	59328	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10381023	C4591001 1038 10381023	16-55	21AUG2020	61193	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10381024	C4591001 1038 10381024	16-55	21AUG2020	59330	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10381027	C4591001 1038 10381027	16-55	24AUG2020	61197	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10381028	C4591001 1038 10381028	16-55	24AUG2020	61198	Placebo	24AUG2020/ Placebo	18SEP2020/ Placebo	06JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10381029	C4591001 1038 10381029	16-55	24AUG2020	61201	Placebo	24AUG2020/ Placebo	15SEP2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	20JAN2021/ BNT162b2 (30 µg)
10381036	C4591001 1038 10381036	16-55	25AUG2020	66130	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)
10381038	C4591001 1038 10381038	16-55	25AUG2020	66133	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo		
10381042	C4591001 1038 10381042	16-55	26AUG2020	66134	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10381043	C4591001 1038 10381043	16-55	26AUG2020	66136	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10381044	C4591001 1038 10381044	16-55	26AUG2020	68789	Placebo	26AUG2020/ Placebo	15SEP2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
10381045	C4591001 1038 10381045	16-55	27AUG2020	68790	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
10381048	C4591001 1038 10381048	16-55	27AUG2020	68792	Placebo	27AUG2020/ Placebo	22SEP2020/ Placebo	06JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
10381049	C4591001 1038 10381049	16-55	27AUG2020	68796	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10381052	C4591001 1038 10381052	16-55	27AUG2020	71069	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10381053	C4591001 1038 10381053	16-55	28AUG2020	71070	Placebo	28AUG2020/ Placebo	17SEP2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
10381057	C4591001 1038 10381057	16-55	28AUG2020	71074	Placebo	28AUG2020/ Placebo	15SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
10381059	C4591001 1038 10381059	16-55	28AUG2020	71075	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
10381061	C4591001 1038 10381061	16-55	31AUG2020	74658	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
10381063	C4591001 1038 10381063	16-55	21SEP2020	93518	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
10381065	C4591001 1038 10381065	16-55	31AUG2020	74659	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10381067	C4591001 1038 10381067	16-55	31AUG2020	74661	Placebo	31AUG2020/ Placebo	22SEP2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
10381069	C4591001 1038 10381069	16-55	01SEP2020	74665	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10381070	C4591001 1038 10381070	16-55	01SEP2020	76325	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10381075	C4591001 1038 10381075	16-55	01SEP2020	76333	Placebo	01SEP2020/ Placebo	23SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10381076	C4591001 1038 10381076	16-55	01SEP2020	76334	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10381077	C4591001 1038 10381077	16-55	02SEP2020	76335	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10381078	C4591001 1038 10381078	16-55	02SEP2020	77825	Placebo	02SEP2020/ Placebo	22SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10381079	C4591001 1038 10381079	16-55	02SEP2020	77827	Placebo	02SEP2020/ Placebo	21SEP2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
10381080	C4591001 1038 10381080	16-55	02SEP2020	77829	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10381082	C4591001 1038 10381082	16-55	02SEP2020	77833	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10381083	C4591001 1038 10381083	16-55	02SEP2020	78691	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
10381085	C4591001 1038 10381085	16-55	02SEP2020	78692	Placebo	02SEP2020/ Placebo	21SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10381088	C4591001 1038 10381088	16-55	03SEP2020	78694	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10381091	C4591001 1038 10381091	16-55	03SEP2020	78695	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10381093	C4591001 1038 10381093	16-55	03SEP2020	80863	Placebo	03SEP2020/ Placebo	23SEP2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)
10381094	C4591001 1038 10381094	16-55	03SEP2020	80867	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10381095	C4591001 1038 10381095	16-55	04SEP2020	80868	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10381096	C4591001 1038 10381096	16-55	04SEP2020	80870	Placebo	04SEP2020/ Placebo	23SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
10381097	C4591001 1038 10381097	16-55	04SEP2020	81570	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
10381098	C4591001 1038 10381098	16-55	04SEP2020	81571	Placebo	04SEP2020/ Placebo	23SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
10381102	C4591001 1038 10381102	16-55	08SEP2020	81573	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10381103	C4591001 1038 10381103	16-55	08SEP2020	81577	Placebo	08SEP2020/ Placebo	30SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
10381105	C4591001 1038 10381105	16-55	08SEP2020	84342	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
10381109	C4591001 1038 10381109	16-55	10SEP2020	84343	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10381111	C4591001 1038 10381111	16-55	10SEP2020	84344	Placebo	10SEP2020/ Placebo	29SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
10381112	C4591001 1038 10381112	16-55	10SEP2020	84352	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
10381115	C4591001 1038 10381115	16-55	11SEP2020	88003	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
10381116	C4591001 1038 10381116	16-55	11SEP2020	88009	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10381117	C4591001 1038 10381117	16-55	11SEP2020	88010	Placebo	11SEP2020/ Placebo	01OCT2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
10381118	C4591001 1038 10381118	16-55	11SEP2020	88012	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10381119	C4591001 1038 10381119	16-55	11SEP2020	88674	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
10381120	C4591001 1038 10381120	16-55	11SEP2020	88675	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
10381121	C4591001 1038 10381121	16-55	14SEP2020	88676	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
10381127	C4591001 1038 10381127	16-55	17SEP2020	88679	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10381128	C4591001 1038 10381128	16-55	17SEP2020	92874	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
10381129	C4591001 1038 10381129	16-55	17SEP2020	92878	Placebo	17SEP2020/ Placebo	07OCT2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
10381130	C4591001 1038 10381130	16-55	18SEP2020	92881	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
10381131	C4591001 1038 10381131	16-55	18SEP2020	92884	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
10381133	C4591001 1038 10381133	16-55	18SEP2020	93509	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
10381136	C4591001 1038 10381136	16-55	21SEP2020	93510	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
10381137	C4591001 1038 10381137	16-55	21SEP2020	93519	Placebo	21SEP2020/ Placebo	14OCT2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
10381138	C4591001 1038 10381138	16-55	23SEP2020	97902	Placebo	23SEP2020/ Placebo	16OCT2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
10381140	C4591001 1038 10381140	16-55	24SEP2020	97907	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
10381141	C4591001 1038 10381141	16-55	25SEP2020	97909	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10391002	C4591001 1039 10391002	16-55	20AUG2020	58061	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10391003	C4591001 1039 10391003	16-55	09SEP2020	85376	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10391004	C4591001 1039 10391004	16-55	20AUG2020	58063	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
10391009	C4591001 1039 10391009	16-55	21AUG2020	58071	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10391011	C4591001 1039 10391011	16-55	21AUG2020	58072	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
10391014	C4591001 1039 10391014	16-55	15SEP2020	89808	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
10391016	C4591001 1039 10391016	16-55	24AUG2020	63593	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10391017	C4591001 1039 10391017	16-55	24AUG2020	63594	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10391021	C4591001 1039 10391021	16-55	25AUG2020	63599	Placebo	25AUG2020/ Placebo			
10391022	C4591001 1039 10391022	16-55	25AUG2020	63602	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10391025	C4591001 1039 10391025	16-55	25AUG2020	66174	Placebo	25AUG2020/ Placebo	16SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10391026	C4591001 1039 10391026	16-55	25AUG2020	66177	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10391036	C4591001 1039 10391036	16-55	26AUG2020	66181	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10391045	C4591001 1039 10391045	16-55	28AUG2020	66182	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
10391057	C4591001 1039 10391057	16-55	31AUG2020	75533	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10391058	C4591001 1039 10391058	16-55	31AUG2020	75534	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10391065	C4591001 1039 10391065	16-55	01SEP2020	75537	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	28JAN2021/ BNT162b2 (30 µg)
10391067	C4591001 1039 10391067	16-55	01SEP2020	75544	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10391068	C4591001 1039 10391068	16-55	02SEP2020	77900	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10391071	C4591001 1039 10391071	16-55	02SEP2020	77902	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10391076	C4591001 1039 10391076	16-55	02SEP2020	77904	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
10391080	C4591001 1039 10391080	16-55	03SEP2020	77906	Placebo	03SEP2020/ Placebo			
10391085	C4591001 1039 10391085	16-55	03SEP2020	80477	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
10391086	C4591001 1039 10391086	16-55	03SEP2020	80478	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	14JAN2021/ BNT162b2 (30 µg)
10391087	C4591001 1039 10391087	16-55	03SEP2020	80484	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
10391088	C4591001 1039 10391088	16-55	04SEP2020	251445	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
10391090	C4591001 1039 10391090	16-55	04SEP2020	252354	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
10391091	C4591001 1039 10391091	16-55	04SEP2020	80485	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
10391093	C4591001 1039 10391093	16-55	04SEP2020	81822	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo		
10391096	C4591001 1039 10391096	16-55	04SEP2020	81826	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10391097	C4591001 1039 10391097	16-55	04SEP2020	81829	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
10391099	C4591001 1039 10391099	16-55	08SEP2020	81831	Placebo	08SEP2020/ Placebo	30SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10391104	C4591001 1039 10391104	16-55	08SEP2020	84065	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
10391108	C4591001 1039 10391108	16-55	09SEP2020	84068	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10391109	C4591001 1039 10391109	16-55	09SEP2020	84069	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10391110	C4591001 1039 10391110	16-55	09SEP2020	84933	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10391112	C4591001 1039 10391112	16-55	09SEP2020	84938	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10391114	C4591001 1039 10391114	16-55	09SEP2020	84940	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
10391115	C4591001 1039 10391115	16-55	09SEP2020	84939	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10391118	C4591001 1039 10391118	16-55	09SEP2020	85380	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10391119	C4591001 1039 10391119	16-55	10SEP2020	85382	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
10391120	C4591001 1039 10391120	16-55	15SEP2020	89807	Placebo	15SEP2020/ Placebo	06OCT2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10391124	C4591001 1039 10391124	16-55	10SEP2020	85383	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo		
10391127	C4591001 1039 10391127	16-55	10SEP2020	87282	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
10391128	C4591001 1039 10391128	16-55	10SEP2020	87283	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
10391133	C4591001 1039 10391133	16-55	11SEP2020	87286	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
10391134	C4591001 1039 10391134	16-55	11SEP2020	257764	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	27JAN2021/ BNT162b2 (30 µg)
10391136	C4591001 1039 10391136	16-55	11SEP2020	87290	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10391140	C4591001 1039 10391140	16-55	14SEP2020	89801	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10391145	C4591001 1039 10391145	16-55	17SEP2020	89809	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10391150	C4591001 1039 10391150	16-55	18SEP2020	93377	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
10391151	C4591001 1039 10391151	16-55	18SEP2020	93380	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
10391152	C4591001 1039 10391152	16-55	18SEP2020	93381	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
10391153	C4591001 1039 10391153	16-55	21SEP2020	93384	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo		
10391156	C4591001 1039 10391156	16-55	25SEP2020	99727	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10391157	C4591001 1039 10391157	16-55	25SEP2020	99728	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
10391162	C4591001 1039 10391162	16-55	29SEP2020	99731	Placebo	29SEP2020/ Placebo	20OCT2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10391165	C4591001 1039 10391165	16-55	30SEP2020	99732	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		
10391166	C4591001 1039 10391166	16-55	30SEP2020	102366	Placebo	30SEP2020/ Placebo	23OCT2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10391167	C4591001 1039 10391167	16-55	30SEP2020	102371	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10391168	C4591001 1039 10391168	16-55	01OCT2020	102373	Placebo	01OCT2020/ Placebo	22OCT2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10391171	C4591001 1039 10391171	16-55	01OCT2020	102374	BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		
10391172	C4591001 1039 10391172	16-55	02OCT2020	103135	BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)		
10391175	C4591001 1039 10391175	16-55	05OCT2020	103136	Placebo	05OCT2020/ Placebo	26OCT2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10391176	C4591001 1039 10391176	16-55	05OCT2020	103138	Placebo	05OCT2020/ Placebo	26OCT2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10391177	C4591001 1039 10391177	16-55	05OCT2020	103142	BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
10391178	C4591001 1039 10391178	16-55	05OCT2020	103891	Placebo	05OCT2020/ Placebo	10NOV2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
10391179	C4591001 1039 10391179	16-55	06OCT2020	103892	BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		
10391180	C4591001 1039 10391180	16-55	07OCT2020	103894	Placebo	07OCT2020/ Placebo	28OCT2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10391181	C4591001 1039 10391181	16-55	07OCT2020	103895	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10391182	C4591001 1039 10391182	16-55	07OCT2020	104874	Placebo	07OCT2020/ Placebo	28OCT2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10391183	C4591001 1039 10391183	16-55	08OCT2020	104876	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)		
10391185	C4591001 1039 10391185	16-55	08OCT2020	104883	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)		
10391186	C4591001 1039 10391186	16-55	09OCT2020	104884	Placebo	09OCT2020/ Placebo	28OCT2020/ Placebo		
10391187	C4591001 1039 10391187	16-55	09OCT2020	106085	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)		
10391190	C4591001 1039 10391190	16-55	12OCT2020	106088	BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		
10391196	C4591001 1039 10391196	16-55	15OCT2020	106091	Placebo	15OCT2020/ Placebo	05NOV2020/ Placebo		
10391198	C4591001 1039 10391198	16-55	16OCT2020	106094	Placebo	16OCT2020/ Placebo	06NOV2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10391199	C4591001 1039 10391199	16-55	16OCT2020	109157	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
10391200	C4591001 1039 10391200	16-55	16OCT2020	109164	Placebo	16OCT2020/ Placebo	06NOV2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10391203	C4591001 1039 10391203	16-55	19OCT2020	109166	Placebo	19OCT2020/ Placebo	09NOV2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
10391205	C4591001 1039 10391205	16-55	20OCT2020	109167	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		
10391207	C4591001 1039 10391207	16-55	20OCT2020	110838	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
10391208	C4591001 1039 10391208	16-55	20OCT2020	110841	Placebo	20OCT2020/ Placebo	10NOV2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10391209	C4591001 1039 10391209	16-55	20OCT2020	110840	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		
10391212	C4591001 1039 10391212	16-55	21OCT2020	110844	Placebo	21OCT2020/ Placebo	09NOV2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
10391214	C4591001 1039 10391214	16-55	21OCT2020	111715	Placebo	21OCT2020/ Placebo	11NOV2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10391218	C4591001 1039 10391218†	16-55	22OCT2020	111717	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		
10391220	C4591001 1039 10391220	16-55	23OCT2020	111719	Placebo	23OCT2020/ Placebo	16NOV2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
10391222	C4591001 1039 10391222	16-55	23OCT2020	111722	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10391224	C4591001 1039 10391224	16-55	26OCT2020	113466	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)		
10391225	C4591001 1039 10391225	16-55	26OCT2020	113468	Placebo	26OCT2020/ Placebo	16NOV2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	27JAN2021/ BNT162b2 (30 µg)
10391226	C4591001 1039 10391226	16-55	26OCT2020	113470	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)		
10391232	C4591001 1039 10391232	16-55	27OCT2020	113471	Placebo	27OCT2020/ Placebo	02DEC2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10391233	C4591001 1039 10391233	16-55	28OCT2020	114317	BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)	20NOV2020/ BNT162b2 (30 µg)		
10391234	C4591001 1039 10391234†	16-55	28OCT2020	114319	BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)		
10391235	C4591001 1039 10391235	16-55	29OCT2020	114323	Placebo	29OCT2020/ Placebo	19NOV2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10391237	C4591001 1039 10391237	16-55	29OCT2020	114326	Placebo	29OCT2020/ Placebo	30NOV2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
10391239	C4591001 1039 10391239	16-55	29OCT2020	114704	Placebo	29OCT2020/ Placebo	19NOV2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10391240	C4591001 1039 10391240	16-55	30OCT2020	114707	BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)	23NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10391241	C4591001 1039 10391241	16-55	02NOV2020	114708	BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)	23NOV2020/ BNT162b2 (30 µg)		
10391242	C4591001 1039 10391242	16-55	02NOV2020	114711	Placebo	02NOV2020/ Placebo	23NOV2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
10391243	C4591001 1039 10391243	16-55	09NOV2020	116010	Placebo	09NOV2020/ Placebo	30NOV2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10391244	C4591001 1039 10391244	16-55	11NOV2020	116012	Placebo	11NOV2020/ Placebo		29JAN2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10391245	C4591001 1039 10391245	16-55	30NOV2020	116013	BNT162b2 (30 µg)	30NOV2020/ BNT162b2 (30 µg)	21DEC2020/ BNT162b2 (30 µg)		
10391248	C4591001 1039 10391248	16-55	01DEC2020	116020	BNT162b2 (30 µg)	01DEC2020/ BNT162b2 (30 µg)	21DEC2020/ BNT162b2 (30 µg)		
10391249	C4591001 1039 10391249	16-55	04DEC2020	117535	Placebo	04DEC2020/ Placebo	28DEC2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10391254	C4591001 1039 10391254	16-55	07DEC2020	117538	Placebo	07DEC2020/ Placebo	29DEC2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10391257	C4591001 1039 10391257	16-55	07DEC2020	117542	BNT162b2 (30 µg)	07DEC2020/ BNT162b2 (30 µg)	29DEC2020/ BNT162b2 (30 µg)		
10391261	C4591001 1039 10391261	16-55	07DEC2020	117543	BNT162b2 (30 µg)	07DEC2020/ BNT162b2 (30 µg)	28DEC2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10421111	C4591001 1042 10421111	16-55	17AUG2020	52517	Placebo	17AUG2020/ Placebo	09SEP2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
10421112	C4591001 1042 10421112	16-55	17AUG2020	52520	Placebo	17AUG2020/ Placebo	09SEP2020/ Placebo		
10421114	C4591001 1042 10421114	16-55	17AUG2020	52522	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10421115	C4591001 1042 10421115	16-55	17AUG2020	52523	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10421120	C4591001 1042 10421120	16-55	17AUG2020	53515	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10421121	C4591001 1042 10421121	16-55	17AUG2020	53519	Placebo	17AUG2020/ Placebo	09SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10421123	C4591001 1042 10421123	16-55	17AUG2020	53523	Placebo	17AUG2020/ Placebo	09SEP2020/ Placebo		
10421124	C4591001 1042 10421124	16-55	18AUG2020	53524	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10421125	C4591001 1042 10421125	16-55	18AUG2020	54990	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
10421126	C4591001 1042 10421126	16-55	18AUG2020	54995	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10421128	C4591001 1042 10421128	16-55	19AUG2020	54999	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	03MAR2021/ BNT162b2 (30 µg)	
10421129	C4591001 1042 10421129	16-55	19AUG2020	55000	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10421130	C4591001 1042 10421130	16-55	19AUG2020	56456	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10421131	C4591001 1042 10421131	16-55	19AUG2020	56459	Placebo	19AUG2020/ Placebo	08SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
10421140	C4591001 1042 10421140	16-55	19AUG2020	56461	Placebo	19AUG2020/ Placebo	08SEP2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10421142	C4591001 1042 10421142	16-55	19AUG2020	57677	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10421143	C4591001 1042 10421143	16-55	19AUG2020	56464	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10421144	C4591001 1042 10421144	16-55	24AUG2020	57681	Placebo	24AUG2020/ Placebo	15SEP2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	20JAN2021/ BNT162b2 (30 µg)
10421148	C4591001 1042 10421148	16-55	24AUG2020	57682	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10421151	C4591001 1042 10421151	16-55	24AUG2020	57683	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10421155	C4591001 1042 10421155	16-55	24AUG2020	64890	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
10421157	C4591001 1042 10421157	16-55	26AUG2020	64893	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10421158	C4591001 1042 10421158	16-55	26AUG2020	64896	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10421161	C4591001 1042 10421161	16-55	26AUG2020	64900	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10421162	C4591001 1042 10421162	16-55	26AUG2020	68155	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10421163	C4591001 1042 10421163	16-55	26AUG2020	68157	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10421165	C4591001 1042 10421165	16-55	26AUG2020	68161	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10421169	C4591001 1042 10421169	16-55	27AUG2020	68163	Placebo	27AUG2020/ Placebo	16SEP2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
10421170	C4591001 1042 10421170	16-55	28AUG2020	72930	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10421175	C4591001 1042 10421175	16-55	31AUG2020	72931	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10421176	C4591001 1042 10421176	16-55	31AUG2020	72935	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
10421177	C4591001 1042 10421177	16-55	31AUG2020	72939	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
10421180	C4591001 1042 10421180	16-55	31AUG2020	76173	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10421181	C4591001 1042 10421181	16-55	01SEP2020	76174	Placebo	01SEP2020/ Placebo	21SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
10421185	C4591001 1042 10421185	16-55	02SEP2020	76175	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
10421188	C4591001 1042 10421188	16-55	02SEP2020	76180	Placebo	02SEP2020/ Placebo	21SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
10421190	C4591001 1042 10421190	16-55	02SEP2020	79339	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10421193	C4591001 1042 10421193	16-55	08SEP2020	79341	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
10421194	C4591001 1042 10421194	16-55	08SEP2020	79346	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
10421196	C4591001 1042 10421196	16-55	08SEP2020	79348	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10421197	C4591001 1042 10421197	16-55	08SEP2020	83825	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
10421198	C4591001 1042 10421198	16-55	08SEP2020	83828	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo	02MAR2021/ BNT162b2 (30 µg)	
10421204	C4591001 1042 10421204	16-55	08SEP2020	83833	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10421205	C4591001 1042 10421205	16-55	08SEP2020	83836	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
10421206	C4591001 1042 10421206	16-55	08SEP2020	84608	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
10421207	C4591001 1042 10421207	16-55	08SEP2020	84612	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10421209	C4591001 1042 10421209	16-55	09SEP2020	84615	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10421210	C4591001 1042 10421210	16-55	09SEP2020	84616	Placebo	09SEP2020/ Placebo	28SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10421213	C4591001 1042 10421213	16-55	09SEP2020	85784	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10421216	C4591001 1042 10421216	16-55	10SEP2020	85786	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10421217	C4591001 1042 10421217	16-55	10SEP2020	85789	Placebo	10SEP2020/ Placebo	29SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10421219	C4591001 1042 10421219	16-55	10SEP2020	85791	Placebo	10SEP2020/ Placebo	05OCT2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
10421222	C4591001 1042 10421222	16-55	10SEP2020	87293	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
10421228	C4591001 1042 10421228	16-55	10SEP2020	87294	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
10421229	C4591001 1042 10421229	16-55	10SEP2020	87295	Placebo	10SEP2020/ Placebo	29SEP2020/ Placebo	06JAN2021/ BNT162b2 (30 µg)	
10421231	C4591001 1042 10421231	16-55	11SEP2020	87298	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
10421232	C4591001 1042 10421232	16-55	11SEP2020	87908	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10421233	C4591001 1042 10421233	16-55	11SEP2020	87912	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10421234	C4591001 1042 10421234	16-55	11SEP2020	87913	Placebo	11SEP2020/ Placebo	30SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
10421235	C4591001 1042 10421235	16-55	11SEP2020	87916	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10421237	C4591001 1042 10421237	16-55	11SEP2020	88337	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
10421238	C4591001 1042 10421238	16-55	11SEP2020	88338	Placebo	11SEP2020/ Placebo	30SEP2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
10421239	C4591001 1042 10421239	16-55	11SEP2020	88340	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10421243	C4591001 1042 10421243	16-55	11SEP2020	88344	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10421245	C4591001 1042 10421245	16-55	11SEP2020	88844	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10421246	C4591001 1042 10421246	16-55	11SEP2020	88847	Placebo	11SEP2020/ Placebo	30SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
10421247	C4591001 1042 10421247	16-55	11SEP2020	88849	Placebo	11SEP2020/ Placebo	30SEP2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10421249	C4591001 1042 10421249	16-55	17SEP2020	88850	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
10421250	C4591001 1042 10421250	16-55	17SEP2020	92301	Placebo	17SEP2020/ Placebo			
10421251	C4591001 1042 10421251	16-55	17SEP2020	92302	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)			

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10421252	C4591001 1042 10421252	16-55	18SEP2020	92306	Placebo	18SEP2020/ Placebo	07OCT2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10421253	C4591001 1042 10421253	16-55	18SEP2020	92307	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)		
10421255	C4591001 1042 10421255	16-55	18SEP2020	94385	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
10421256	C4591001 1042 10421256	16-55	22SEP2020	94391	Placebo	22SEP2020/ Placebo	12OCT2020/ Placebo	12MAR2021/ BNT162b2 (30 µg)	
10421259	C4591001 1042 10421259	16-55	05OCT2020	94394	BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
10421260	C4591001 1042 10421260	16-55	05OCT2020	94395	Placebo	05OCT2020/ Placebo	26OCT2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10421261	C4591001 1042 10421261	16-55	07OCT2020	104816	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		
10421262	C4591001 1042 10421262	16-55	14OCT2020	104821	Placebo	14OCT2020/ Placebo	02NOV2020/ Placebo		
10421264	C4591001 1042 10421264	16-55	16OCT2020	104822	Placebo	16OCT2020/ Placebo	13NOV2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
10421265	C4591001 1042 10421265	16-55	20OCT2020	104823	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10421266	C4591001 1042 10421266	16-55	20OCT2020	110789	Placebo	20OCT2020/ Placebo	11NOV2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10421267	C4591001 1042 10421267	16-55	20OCT2020	110792	Placebo	20OCT2020/ Placebo	09NOV2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
10441009	C4591001 1044 10441009	16-55	17AUG2020	50058	Placebo	17AUG2020/ Placebo	06SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
10441011	C4591001 1044 10441011	16-55	18AUG2020	50064	Placebo	18AUG2020/ Placebo	10SEP2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)
10441015	C4591001 1044 10441015	16-55	19AUG2020	50067	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10441019	C4591001 1044 10441019	16-55	20AUG2020	59285	Placebo	20AUG2020/ Placebo	08SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10441021	C4591001 1044 10441021	16-55	21AUG2020	59286	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
10441024	C4591001 1044 10441024	16-55	21AUG2020	59293	Placebo	21AUG2020/ Placebo	10SEP2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)
10441028	C4591001 1044 10441028	16-55	25AUG2020	65391	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10441029	C4591001 1044 10441029	16-55	25AUG2020	59294	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10441030	C4591001 1044 10441030	16-55	25AUG2020	65383	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
10441031	C4591001 1044 10441031	16-55	25AUG2020	65390	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10441034	C4591001 1044 10441034	16-55	26AUG2020	67918	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10441035	C4591001 1044 10441035	16-55	26AUG2020	65392	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
10441037	C4591001 1044 10441037	16-55	26AUG2020	67915	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10441038	C4591001 1044 10441038	16-55	26AUG2020	67919	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
10441042	C4591001 1044 10441042	16-55	26AUG2020	67923	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	06JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
10441043	C4591001 1044 10441043	16-55	27AUG2020	69653	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
10441044	C4591001 1044 10441044	16-55	27AUG2020	69655	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10441045	C4591001 1044 10441045	16-55	27AUG2020	69663	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10441048	C4591001 1044 10441048	16-55	28AUG2020	72641	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10441050	C4591001 1044 10441050	16-55	27AUG2020	69664	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10441051	C4591001 1044 10441051	16-55	28AUG2020	71705	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	14JAN2021/ BNT162b2 (30 µg)
10441052	C4591001 1044 10441052	16-55	28AUG2020	71708	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10441053	C4591001 1044 10441053	16-55	28AUG2020	71709	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	12MAR2021/ BNT162b2 (30 µg)	
10441054	C4591001 1044 10441054	16-55	28AUG2020	71716	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10441056	C4591001 1044 10441056	16-55	29AUG2020	72644	Placebo	29AUG2020/ Placebo	21SEP2020/ Placebo		
10441057	C4591001 1044 10441057	16-55	29AUG2020	72645	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10441058	C4591001 1044 10441058	16-55	29AUG2020	72649	Placebo	11SEP2020/ Placebo	05OCT2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10441059	C4591001 1044 10441059	16-55	29AUG2020	73879	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10441060	C4591001 1044 10441060	16-55	31AUG2020	73885	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10441061	C4591001 1044 10441061	16-55	31AUG2020	73887	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10441063	C4591001 1044 10441063	16-55	01SEP2020	73888	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10441065	C4591001 1044 10441065	16-55	01SEP2020	76568	Placebo	01SEP2020/ Placebo	21SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
10441068	C4591001 1044 10441068	16-55	01SEP2020	76571	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10441069	C4591001 1044 10441069	16-55	02SEP2020	76573	Placebo	02SEP2020/ Placebo	25SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
10441071	C4591001 1044 10441071	16-55	02SEP2020	76575	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10441076	C4591001 1044 10441076	16-55	03SEP2020	80255	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10441077	C4591001 1044 10441077	16-55	03SEP2020	80256	Placebo	03SEP2020/ Placebo	22SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10441079	C4591001 1044 10441079	16-55	04SEP2020	80257	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10441081	C4591001 1044 10441081	16-55	04SEP2020	80260	Placebo	04SEP2020/ Placebo	23SEP2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	14JAN2021/ BNT162b2 (30 µg)
10441084	C4591001 1044 10441084	16-55	05SEP2020	82650	Placebo	05SEP2020/ Placebo	24SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
10441086	C4591001 1044 10441086	16-55	05SEP2020	82651	Placebo	05SEP2020/ Placebo	24SEP2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
10441088	C4591001 1044 10441088	16-55	06SEP2020	82653	BNT162b2 (30 µg)	06SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
10441089	C4591001 1044 10441089	16-55	06SEP2020	82657	BNT162b2 (30 µg)	06SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
10441099	C4591001 1044 10441099	16-55	09SEP2020	85554	Placebo	10SEP2020/ Placebo	29SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10441101	C4591001 1044 10441101	16-55	09SEP2020	85558	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
10441102	C4591001 1044 10441102	16-55	09SEP2020	85561	Placebo	10SEP2020/ Placebo	29SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10441103	C4591001 1044 10441103	16-55	10SEP2020	85564	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
10441107	C4591001 1044 10441107	16-55	10SEP2020	86865	Placebo	10SEP2020/ Placebo	06OCT2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10441112	C4591001 1044 10441112	16-55	11SEP2020	86866	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10441119	C4591001 1044 10441119	16-55	21SEP2020	86867	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
10441121	C4591001 1044 10441121	16-55	22SEP2020	86870	Placebo	22SEP2020/ Placebo	13OCT2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
10441122	C4591001 1044 10441122	16-55	22SEP2020	96066	Placebo	22SEP2020/ Placebo	13OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10441123	C4591001 1044 10441123	16-55	22SEP2020	96070	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
10441126	C4591001 1044 10441126	16-55	22SEP2020	96072	Placebo	22SEP2020/ Placebo	13OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
10441127	C4591001 1044 10441127	16-55	22SEP2020	96074	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
10441129	C4591001 1044 10441129	16-55	22SEP2020	97062	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
10441132	C4591001 1044 10441132	16-55	23SEP2020	97063	Placebo	23SEP2020/ Placebo	13OCT2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
10441133	C4591001 1044 10441133	16-55	23SEP2020	97068	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10441136	C4591001 1044 10441136	16-55	23SEP2020	97070	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10441137	C4591001 1044 10441137	16-55	23SEP2020	98394	Placebo	23SEP2020/ Placebo	13OCT2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10441139	C4591001 1044 10441139	16-55	23SEP2020	98399	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
10441140	C4591001 1044 10441140	16-55	24SEP2020	98403	Placebo	24SEP2020/ Placebo	14OCT2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
10441141	C4591001 1044 10441141	16-55	24SEP2020	98404	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
10441142	C4591001 1044 10441142	16-55	24SEP2020	98754	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
10441143	C4591001 1044 10441143	16-55	24SEP2020	98755	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
10441144	C4591001 1044 10441144	16-55	24SEP2020	98757	Placebo	24SEP2020/ Placebo	14OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10441146	C4591001 1044 10441146	16-55	24SEP2020	98759	Placebo	24SEP2020/ Placebo	15OCT2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
10441151	C4591001 1044 10441151	16-55	25SEP2020	100148	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10441152	C4591001 1044 10441152†	16-55	28SEP2020	100149	Placebo	28SEP2020/ Placebo	19OCT2020/ Placebo		
10441153	C4591001 1044 10441153	16-55	30SEP2020	100151	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)		
10441155	C4591001 1044 10441155	16-55	01OCT2020	100155	BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		
10441156	C4591001 1044 10441156	16-55	01OCT2020	102776	Placebo	01OCT2020/ Placebo	20OCT2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
10441157	C4591001 1044 10441157	16-55	01OCT2020	102777	BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		
10441158	C4591001 1044 10441158	16-55	01OCT2020	102780	Placebo	01OCT2020/ Placebo	20OCT2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
10441159	C4591001 1044 10441159	16-55	02OCT2020	102782	BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
10441162	C4591001 1044 10441162	16-55	05OCT2020	103878	Placebo	05OCT2020/ Placebo	27OCT2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
10441163	C4591001 1044 10441163	16-55	05OCT2020	103880	Placebo	05OCT2020/ Placebo	26OCT2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
10441164	C4591001 1044 10441164	16-55	06OCT2020	103884	BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10441165	C4591001 1044 10441165	16-55	06OCT2020	104394	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
10441166	C4591001 1044 10441166	16-55	06OCT2020	103885	BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		
10441167	C4591001 1044 10441167	16-55	06OCT2020	104393	Placebo	06OCT2020/ Placebo	26OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
10441168	C4591001 1044 10441168	16-55	07OCT2020	104400	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
10441170	C4591001 1044 10441170	16-55	07OCT2020	104404	Placebo	07OCT2020/ Placebo	28OCT2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
10441171	C4591001 1044 10441171	16-55	07OCT2020	104889	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
10441173	C4591001 1044 10441173	16-55	08OCT2020	104893	Placebo	08OCT2020/ Placebo	28OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
10441174	C4591001 1044 10441174	16-55	08OCT2020	104895	Placebo	08OCT2020/ Placebo	28OCT2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
10441176	C4591001 1044 10441176	16-55	08OCT2020	104896	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
10441177	C4591001 1044 10441177	16-55	08OCT2020	105497	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10441181	C4591001 1044 10441181	16-55	16OCT2020	105500	Placebo	16OCT2020/ Placebo	04NOV2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
10441185	C4591001 1044 10441185	16-55	17OCT2020	105503	BNT162b2 (30 µg)	17OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
10441186	C4591001 1044 10441186	16-55	17OCT2020	109555	Placebo	17OCT2020/ Placebo	06NOV2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
10441187	C4591001 1044 10441187	16-55	17OCT2020	105504	Placebo	17OCT2020/ Placebo	05NOV2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10441188	C4591001 1044 10441188	16-55	17OCT2020	109559	Placebo	26OCT2020/ Placebo	16NOV2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
10441190	C4591001 1044 10441190	16-55	17OCT2020	109557	BNT162b2 (30 µg)	17OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
10441191	C4591001 1044 10441191	16-55	17OCT2020	109665	BNT162b2 (30 µg)	17OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
10441192	C4591001 1044 10441192	16-55	17OCT2020	109662	BNT162b2 (30 µg)	17OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
10441193	C4591001 1044 10441193	16-55	17OCT2020	109563	BNT162b2 (30 µg)	17OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
10441197	C4591001 1044 10441197	16-55	18OCT2020	109667	Placebo	18OCT2020/ Placebo	10NOV2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10441198	C4591001 1044 10441198	16-55	18OCT2020	109672	Placebo	18OCT2020/ Placebo	09NOV2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
10441199	C4591001 1044 10441199	16-55	19OCT2020	110381	Placebo	19OCT2020/ Placebo	09NOV2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
10441200	C4591001 1044 10441200	16-55	20OCT2020	110385	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
10441203	C4591001 1044 10441203	16-55	20OCT2020	110386	Placebo	20OCT2020/ Placebo	09NOV2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
10441204	C4591001 1044 10441204	16-55	20OCT2020	110389	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		
10441207	C4591001 1044 10441207	16-55	21OCT2020	111353	Placebo	21OCT2020/ Placebo	11NOV2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
10441210	C4591001 1044 10441210	16-55	21OCT2020	111356	Placebo	21OCT2020/ Placebo	11NOV2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
10441211	C4591001 1044 10441211	16-55	21OCT2020	111357	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
10441212	C4591001 1044 10441212	16-55	21OCT2020	111361	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		
10441213	C4591001 1044 10441213	16-55	22OCT2020	112077	Placebo	22OCT2020/ Placebo	13NOV2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10441215	C4591001 1044 10441215	16-55	22OCT2020	112078	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
10441218	C4591001 1044 10441218	16-55	22OCT2020	112082	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
10441219	C4591001 1044 10441219	16-55	22OCT2020	112083	Placebo	22OCT2020/ Placebo	13NOV2020/ Placebo	31DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)
10441224	C4591001 1044 10441224	16-55	23OCT2020	112999	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
10441227	C4591001 1044 10441227	16-55	23OCT2020	113000	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
10441228	C4591001 1044 10441228	16-55	16NOV2020	113002	Placebo	16NOV2020/ Placebo	07DEC2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
10441229	C4591001 1044 10441229	16-55	17NOV2020	113007	Placebo	17NOV2020/ Placebo	07DEC2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
10441230	C4591001 1044 10441230	16-55	18NOV2020	116384	BNT162b2 (30 µg)	18NOV2020/ BNT162b2 (30 µg)	07DEC2020/ BNT162b2 (30 µg)		
10441231	C4591001 1044 10441231	16-55	18NOV2020	116387	BNT162b2 (30 µg)	18NOV2020/ BNT162b2 (30 µg)	08DEC2020/ BNT162b2 (30 µg)		
10441232	C4591001 1044 10441232	16-55	18NOV2020	116389	Placebo	18NOV2020/ Placebo	09DEC2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10441233	C4591001 1044 10441233	16-55	18NOV2020	116390	Placebo	18NOV2020/ Placebo	07DEC2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	
10441234	C4591001 1044 10441234	16-55	19NOV2020	116517	Placebo	19NOV2020/ Placebo	08DEC2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
10441235	C4591001 1044 10441235	16-55	19NOV2020	116523	BNT162b2 (30 µg)	25NOV2020/ BNT162b2 (30 µg)	17DEC2020/ BNT162b2 (30 µg)		
10441236	C4591001 1044 10441236	16-55	19NOV2020	116522	BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)	08DEC2020/ BNT162b2 (30 µg)		
10441237	C4591001 1044 10441237	16-55	20NOV2020	116524	Placebo	20NOV2020/ Placebo	09DEC2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
10441238	C4591001 1044 10441238	16-55	20NOV2020	116574	Placebo	20NOV2020/ Placebo	09DEC2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
10441239	C4591001 1044 10441239	16-55	20NOV2020	116577	BNT162b2 (30 µg)	20NOV2020/ BNT162b2 (30 µg)	09DEC2020/ BNT162b2 (30 µg)		
10441240	C4591001 1044 10441240	16-55	23NOV2020	116579	Placebo	23NOV2020/ Placebo	16DEC2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
10441241	C4591001 1044 10441241	16-55	23NOV2020	116582	BNT162b2 (30 µg)	23NOV2020/ BNT162b2 (30 µg)	15DEC2020/ BNT162b2 (30 µg)		
10441242	C4591001 1044 10441242	16-55	24NOV2020	116825	Placebo	24NOV2020/ Placebo	15DEC2020/ Placebo	03MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10441243	C4591001 1044 10441243	16-55	24NOV2020	116827	Placebo	24NOV2020/ Placebo	15DEC2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
10441244	C4591001 1044 10441244	16-55	24NOV2020	116832	BNT162b2 (30 µg)	24NOV2020/ BNT162b2 (30 µg)	14DEC2020/ BNT162b2 (30 µg)		
10441245	C4591001 1044 10441245	16-55	24NOV2020	116828	BNT162b2 (30 µg)	24NOV2020/ BNT162b2 (30 µg)	14DEC2020/ BNT162b2 (30 µg)		
10441246	C4591001 1044 10441246	16-55	25NOV2020	116925	BNT162b2 (30 µg)	28DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)		
10441247	C4591001 1044 10441247	16-55	25NOV2020	116922	Placebo	25NOV2020/ Placebo	14DEC2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
10441248	C4591001 1044 10441248	16-55	25NOV2020	116923	BNT162b2 (30 µg)	25NOV2020/ BNT162b2 (30 µg)	16DEC2020/ BNT162b2 (30 µg)		
10441249	C4591001 1044 10441249	16-55	30NOV2020	20352	BNT162b2 (30 µg)	30NOV2020/ BNT162b2 (30 µg)	21DEC2020/ BNT162b2 (30 µg)		
10441250	C4591001 1044 10441250	16-55	30NOV2020	20353	Placebo	30NOV2020/ Placebo	21DEC2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	
10441254	C4591001 1044 10441254	16-55	30NOV2020	20437	Placebo	30NOV2020/ Placebo	21DEC2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
10441258	C4591001 1044 10441258	16-55	01DEC2020	20568	Placebo	01DEC2020/ Placebo	21DEC2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10441262	C4591001 1044 10441262	16-55	07DEC2020	20620	BNT162b2 (30 µg)	07DEC2020/ BNT162b2 (30 µg)	28DEC2020/ BNT162b2 (30 µg)		
10441269	C4591001 1044 10441269	16-55	08DEC2020	116927	Placebo	08DEC2020/ Placebo	30DEC2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
10441272	C4591001 1044 10441272	16-55	08DEC2020	117787	BNT162b2 (30 µg)	08DEC2020/ BNT162b2 (30 µg)	28DEC2020/ BNT162b2 (30 µg)		
10441287	C4591001 1044 10441287	16-55	11DEC2020	117788	Placebo	11DEC2020/ Placebo		30DEC2020/ BNT162b2 (30 µg)	20JAN2021/ BNT162b2 (30 µg)
10461034	C4591001 1046 10461034	16-55	15AUG2020	51027	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	05SEP2020/ BNT162b2 (30 µg)		
10461040	C4591001 1046 10461040	16-55	17AUG2020	52544	Placebo	17AUG2020/ Placebo			
10461042	C4591001 1046 10461042	16-55	17AUG2020	52548	Placebo	17AUG2020/ Placebo	09SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	04JAN2021/ BNT162b2 (30 µg)
10461043	C4591001 1046 10461043	16-55	17AUG2020	52549	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10461044	C4591001 1046 10461044	16-55	17AUG2020	52551	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10461046	C4591001 1046 10461046	16-55	17AUG2020	53287	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10461049	C4591001 1046 10461049	16-55	18AUG2020	53291	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo		
10461050	C4591001 1046 10461050	16-55	18AUG2020	53292	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo		
10461051	C4591001 1046 10461051	16-55	18AUG2020	53296	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10461052	C4591001 1046 10461052	16-55	18AUG2020	54970	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10461053	C4591001 1046 10461053	16-55	18AUG2020	54973	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
10461054	C4591001 1046 10461054	16-55	18AUG2020	54974	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10461055	C4591001 1046 10461055	16-55	18AUG2020	54976	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10461058	C4591001 1046 10461058	16-55	19AUG2020	56981	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10461063	C4591001 1046 10461063	16-55	19AUG2020	56990	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10461066	C4591001 1046 10461066	16-55	20AUG2020	56991	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10461067	C4591001 1046 10461067	16-55	20AUG2020	56992	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10461068	C4591001 1046 10461068	16-55	20AUG2020	59638	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10461069	C4591001 1046 10461069	16-55	20AUG2020	59639	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10461070	C4591001 1046 10461070	16-55	20AUG2020	59640	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10461071	C4591001 1046 10461071	16-55	20AUG2020	59644	Placebo	20AUG2020/ Placebo	08SEP2020/ Placebo		
10461072	C4591001 1046 10461072	16-55	21AUG2020	60381	Placebo	21AUG2020/ Placebo	09SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
10461081	C4591001 1046 10461081	16-55	24AUG2020	60383	Placebo	24AUG2020/ Placebo	16SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
10461089	C4591001 1046 10461089	16-55	24AUG2020	60388	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10461091	C4591001 1046 10461091	16-55	25AUG2020	65358	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10461092	C4591001 1046 10461092	16-55	25AUG2020	65360	Placebo	25AUG2020/ Placebo	14SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10461093	C4591001 1046 10461093	16-55	25AUG2020	65366	Placebo	25AUG2020/ Placebo	09SEP2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
10461097	C4591001 1046 10461097	16-55	25AUG2020	65368	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10461098	C4591001 1046 10461098	16-55	25AUG2020	66797	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10461099	C4591001 1046 10461099	16-55	25AUG2020	66798	Placebo	25AUG2020/ Placebo			
10461100	C4591001 1046 10461100	16-55	25AUG2020	66801	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10461101	C4591001 1046 10461101	16-55	26AUG2020	66802	Placebo	26AUG2020/ Placebo	15SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10461102	C4591001 1046 10461102	16-55	26AUG2020	67410	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10461104	C4591001 1046 10461104	16-55	26AUG2020	67413	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10461105	C4591001 1046 10461105	16-55	26AUG2020	67414	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10461107	C4591001 1046 10461107	16-55	26AUG2020	67417	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10461108	C4591001 1046 10461108	16-55	26AUG2020	68525	Placebo	26AUG2020/ Placebo	17SEP2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10461109	C4591001 1046 10461109	16-55	26AUG2020	68528	Placebo	26AUG2020/ Placebo	17SEP2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10461111	C4591001 1046 10461111	16-55	26AUG2020	68530	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
10461112	C4591001 1046 10461112	16-55	27AUG2020	68535	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
10461113	C4591001 1046 10461113	16-55	27AUG2020	69725	Placebo	27AUG2020/ Placebo	18SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10461115	C4591001 1046 10461115	16-55	27AUG2020	69729	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10461116	C4591001 1046 10461116	16-55	27AUG2020	69731	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
10461117	C4591001 1046 10461117	16-55	27AUG2020	69733	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
10461118	C4591001 1046 10461118	16-55	27AUG2020	70566	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
10461119	C4591001 1046 10461119	16-55	27AUG2020	70567	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10461120	C4591001 1046 10461120	16-55	27AUG2020	70568	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10461123	C4591001 1046 10461123	16-55	27AUG2020	70569	Placebo	27AUG2020/ Placebo	16SEP2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)
10461124	C4591001 1046 10461124	16-55	27AUG2020	71394	Placebo	27AUG2020/ Placebo	16SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
10461125	C4591001 1046 10461125	16-55	27AUG2020	71397	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10461127	C4591001 1046 10461127	16-55	28AUG2020	71402	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10461130	C4591001 1046 10461130	16-55	28AUG2020	71404	Placebo	28AUG2020/ Placebo	19SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
10461131	C4591001 1046 10461131	16-55	28AUG2020	72329	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10461133	C4591001 1046 10461133	16-55	28AUG2020	72334	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
10461134	C4591001 1046 10461134	16-55	28AUG2020	72336	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10461135	C4591001 1046 10461135	16-55	28AUG2020	72338	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10461137	C4591001 1046 10461137	16-55	29AUG2020	73410	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		
10461139	C4591001 1046 10461139	16-55	29AUG2020	73416	Placebo	29AUG2020/ Placebo	19SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
10461140	C4591001 1046 10461140	16-55	29AUG2020	73417	Placebo	29AUG2020/ Placebo			
10461142	C4591001 1046 10461142	16-55	31AUG2020	73420	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10461143	C4591001 1046 10461143	16-55	31AUG2020	74790	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10461145	C4591001 1046 10461145	16-55	31AUG2020	74791	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
10461146	C4591001 1046 10461146	16-55	31AUG2020	74793	Placebo	31AUG2020/ Placebo	19SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
10461147	C4591001 1046 10461147	16-55	31AUG2020	74797	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10461148	C4591001 1046 10461148	16-55	31AUG2020	76025	Placebo	31AUG2020/ Placebo	22SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10461149	C4591001 1046 10461149	16-55	31AUG2020	76026	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10461150	C4591001 1046 10461150	16-55	31AUG2020	245714	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10461151	C4591001 1046 10461151	16-55	01SEP2020	76028	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo		
10461152	C4591001 1046 10461152	16-55	01SEP2020	76031	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10461153	C4591001 1046 10461153	16-55	01SEP2020	76507	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10461154	C4591001 1046 10461154	16-55	01SEP2020	76509	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10461155	C4591001 1046 10461155	16-55	01SEP2020	76511	Placebo	01SEP2020/ Placebo	23SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10461159	C4591001 1046 10461159	16-55	01SEP2020	77417	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
10461162	C4591001 1046 10461162	16-55	02SEP2020	77419	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10461163	C4591001 1046 10461163	16-55	02SEP2020	77421	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10461164	C4591001 1046 10461164	16-55	02SEP2020	77428	Placebo	02SEP2020/ Placebo	24SEP2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10461167	C4591001 1046 10461167	16-55	02SEP2020	78308	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10461168	C4591001 1046 10461168	16-55	02SEP2020	78310	Placebo	02SEP2020/ Placebo	25SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
10461170	C4591001 1046 10461170	16-55	02SEP2020	78312	Placebo	02SEP2020/ Placebo	21SEP2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
10461171	C4591001 1046 10461171	16-55	02SEP2020	78316	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10461172	C4591001 1046 10461172	16-55	02SEP2020	79253	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10461174	C4591001 1046 10461174	16-55	03SEP2020	79257	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
10461175	C4591001 1046 10461175	16-55	03SEP2020	79261	Placebo	03SEP2020/ Placebo	22SEP2020/ Placebo		
10461176	C4591001 1046 10461176	16-55	03SEP2020	79263	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
10461177	C4591001 1046 10461177	16-55	03SEP2020	79865	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10461186	C4591001 1046 10461186	16-55	04SEP2020	79867	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10461188	C4591001 1046 10461188	16-55	04SEP2020	79870	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
10461191	C4591001 1046 10461191	16-55	04SEP2020	79874	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10461192	C4591001 1046 10461192	16-55	04SEP2020	82387	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
10461193	C4591001 1046 10461193	16-55	04SEP2020	82388	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
10461194	C4591001 1046 10461194	16-55	04SEP2020	82390	Placebo	04SEP2020/ Placebo	24SEP2020/ Placebo	27FEB2021/ BNT162b2 (30 µg)	
10461196	C4591001 1046 10461196	16-55	04SEP2020	82394	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
10461197	C4591001 1046 10461197	16-55	05SEP2020	82675	Placebo	05SEP2020/ Placebo	25SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
10461198	C4591001 1046 10461198	16-55	05SEP2020	82676	Placebo	05SEP2020/ Placebo	26SEP2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
10461199	C4591001 1046 10461199	16-55	05SEP2020	82677	BNT162b2 (30 µg)	05SEP2020/ BNT162b2 (30 µg)	26SEP2020/ BNT162b2 (30 µg)		
10461200	C4591001 1046 10461200	16-55	05SEP2020	82678	BNT162b2 (30 µg)	05SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10461201	C4591001 1046 10461201	16-55	05SEP2020	82854	BNT162b2 (30 µg)	05SEP2020/ BNT162b2 (30 µg)	26SEP2020/ BNT162b2 (30 µg)		
10461202	C4591001 1046 10461202	16-55	07SEP2020	82857	BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
10461203	C4591001 1046 10461203	16-55	07SEP2020	82859	Placebo	07SEP2020/ Placebo	02OCT2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10461204	C4591001 1046 10461204	16-55	07SEP2020	82861	Placebo	07SEP2020/ Placebo	30SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
10461209	C4591001 1046 10461209	16-55	08SEP2020	83646	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
10461210	C4591001 1046 10461210	16-55	08SEP2020	83649	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
10461211	C4591001 1046 10461211	16-55	08SEP2020	83651	Placebo	08SEP2020/ Placebo	30SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10461217	C4591001 1046 10461217	16-55	08SEP2020	83656	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
10461218	C4591001 1046 10461218	16-55	08SEP2020	84560	Placebo	08SEP2020/ Placebo	01OCT2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
10461219	C4591001 1046 10461219	16-55	08SEP2020	84563	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10461221	C4591001 1046 10461221	16-55	09SEP2020	84564	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
10461223	C4591001 1046 10461223	16-55	09SEP2020	84568	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
10461224	C4591001 1046 10461224	16-55	09SEP2020	85101	Placebo	09SEP2020/ Placebo	29SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
10461227	C4591001 1046 10461227	16-55	09SEP2020	85105	Placebo	09SEP2020/ Placebo	28SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
10461232	C4591001 1046 10461232	16-55	09SEP2020	85107	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
10461233	C4591001 1046 10461233	16-55	09SEP2020	85108	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10461234	C4591001 1046 10461234	16-55	09SEP2020	86093	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
10461236	C4591001 1046 10461236	16-55	10SEP2020	86097	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
10461237	C4591001 1046 10461237	16-55	10SEP2020	86099	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
10461240	C4591001 1046 10461240	16-55	10SEP2020	86104	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo	27FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10461242	C4591001 1046 10461242	16-55	10SEP2020	87152	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
10461246	C4591001 1046 10461246	16-55	11SEP2020	87156	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
10461247	C4591001 1046 10461247	16-55	11SEP2020	87157	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
10461248	C4591001 1046 10461248	16-55	11SEP2020	87158	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
10461252	C4591001 1046 10461252	16-55	11SEP2020	88733	Placebo	11SEP2020/ Placebo	05OCT2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
10461254	C4591001 1046 10461254	16-55	11SEP2020	88734	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
10461255	C4591001 1046 10461255	16-55	12SEP2020	88737	BNT162b2 (30 µg)	12SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
10461256	C4591001 1046 10461256	16-55	12SEP2020	88740	Placebo	12SEP2020/ Placebo	01OCT2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
10461257	C4591001 1046 10461257	16-55	12SEP2020	89153	BNT162b2 (30 µg)	12SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
10461261	C4591001 1046 10461261	16-55	16SEP2020	89155	Placebo	16SEP2020/ Placebo	06OCT2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10461263	C4591001 1046 10461263	16-55	18SEP2020	89162	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo		
10461265	C4591001 1046 10461265	16-55	19SEP2020	89163	BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
10461266	C4591001 1046 10461266	16-55	21SEP2020	94879	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
10461268	C4591001 1046 10461268	16-55	23SEP2020	94883	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10461269	C4591001 1046 10461269	16-55	24SEP2020	94884	Placebo	24SEP2020/ Placebo	16OCT2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
10461270	C4591001 1046 10461270	16-55	24SEP2020	94886	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	17OCT2020/ BNT162b2 (30 µg)		
10461271	C4591001 1046 10461271	16-55	24SEP2020	98922	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
10461272	C4591001 1046 10461272	16-55	25SEP2020	98926	Placebo	25SEP2020/ Placebo	14OCT2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10461273	C4591001 1046 10461273	16-55	25SEP2020	98932	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	14JAN2021/ BNT162b2 (30 µg)
10461274	C4591001 1046 10461274	16-55	25SEP2020	98927	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10461275	C4591001 1046 10461275	16-55	29SEP2020	101958	BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)		
10461276	C4591001 1046 10461276	16-55	02OCT2020	101963	BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)		
10461280	C4591001 1046 10461280	16-55	06OCT2020	101967	Placebo	06OCT2020/ Placebo	03NOV2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10461281	C4591001 1046 10461281	16-55	06OCT2020	101968	Placebo	06OCT2020/ Placebo	03NOV2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
10461284	C4591001 1046 10461284	16-55	08OCT2020	105365	Placebo	08OCT2020/ Placebo	28OCT2020/ Placebo	12MAR2021/ BNT162b2 (30 µg)	
10461285	C4591001 1046 10461285	16-55	08OCT2020	105369	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
10461287	C4591001 1046 10461287	16-55	09OCT2020	105374	Placebo	09OCT2020/ Placebo	03NOV2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
10461288	C4591001 1046 10461288	16-55	09OCT2020	105375	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)		
10461289	C4591001 1046 10461289	16-55	09OCT2020	106049	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)		
10461290	C4591001 1046 10461290	16-55	09OCT2020	106053	Placebo	09OCT2020/ Placebo	30OCT2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10461291	C4591001 1046 10461291	16-55	09OCT2020	106058	Placebo	09OCT2020/ Placebo	30OCT2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
10461292	C4591001 1046 10461292	16-55	12OCT2020	267853	Placebo	12OCT2020/ Placebo	03NOV2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10461294	C4591001 1046 10461294	16-55	12OCT2020	106059	BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
10461295	C4591001 1046 10461295	16-55	13OCT2020	106901	Placebo	13OCT2020/ Placebo	04NOV2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
10461297	C4591001 1046 10461297	16-55	14OCT2020	106905	BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
10461298	C4591001 1046 10461298	16-55	14OCT2020	106906	Placebo	14OCT2020/ Placebo	04NOV2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
10461300	C4591001 1046 10461300	16-55	14OCT2020	106912	BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
10461302	C4591001 1046 10461302	16-55	15OCT2020	108150	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
10461303	C4591001 1046 10461303	16-55	15OCT2020	108151	Placebo	15OCT2020/ Placebo	05NOV2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
10461304	C4591001 1046 10461304	16-55	15OCT2020	108153	Placebo	15OCT2020/ Placebo	05NOV2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10461306	C4591001 1046 10461306	16-55	16OCT2020	108154	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
10461307	C4591001 1046 10461307	16-55	16OCT2020	108943	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
10461308	C4591001 1046 10461308	16-55	16OCT2020	108944	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
10461311	C4591001 1046 10461311	16-55	17OCT2020	108947	Placebo	17OCT2020/ Placebo	06NOV2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
10461312	C4591001 1046 10461312	16-55	17OCT2020	108950	Placebo	17OCT2020/ Placebo	07NOV2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
10461313	C4591001 1046 10461313	16-55	17OCT2020	109625	BNT162b2 (30 µg)	17OCT2020/ BNT162b2 (30 µg)	07NOV2020/ BNT162b2 (30 µg)		
10461314	C4591001 1046 10461314	16-55	17OCT2020	109626	BNT162b2 (30 µg)	17OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
10461315	C4591001 1046 10461315	16-55	17OCT2020	109629	Placebo	17OCT2020/ Placebo	07NOV2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
10461318	C4591001 1046 10461318	16-55	19OCT2020	109636	Placebo	19OCT2020/ Placebo	03NOV2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
10461319	C4591001 1046 10461319	16-55	26OCT2020	113489	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10461321	C4591001 1046 10461321	16-55	26OCT2020	113493	Placebo	26OCT2020/ Placebo	19NOV2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
10461323	C4591001 1046 10461323	16-55	26OCT2020	113495	Placebo	26OCT2020/ Placebo	17NOV2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
10461324	C4591001 1046 10461324	16-55	26OCT2020	113500	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
10461325	C4591001 1046 10461325	16-55	27OCT2020	114006	Placebo	27OCT2020/ Placebo	17NOV2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10461327	C4591001 1046 10461327	16-55	28OCT2020	114008	BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
10461329	C4591001 1046 10461329	16-55	28OCT2020	114011	BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)	18NOV2020/ BNT162b2 (30 µg)		
10461330	C4591001 1046 10461330	16-55	29OCT2020	114015	Placebo	29OCT2020/ Placebo	19NOV2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
10461331	C4591001 1046 10461331	16-55	29OCT2020	114653	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	18NOV2020/ BNT162b2 (30 µg)		
10461332	C4591001 1046 10461332	16-55	29OCT2020	114654	Placebo	29OCT2020/ Placebo	19NOV2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
10461333	C4591001 1046 10461333	16-55	29OCT2020	114659	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10461334	C4591001 1046 10461334	16-55	29OCT2020	114660	Placebo	29OCT2020/ Placebo	19NOV2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	28JAN2021/ BNT162b2 (30 µg)
10461336	C4591001 1046 10461336	16-55	30OCT2020	114992	Placebo	30OCT2020/ Placebo	18NOV2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10461337	C4591001 1046 10461337	16-55	30OCT2020	114993	BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)	20NOV2020/ BNT162b2 (30 µg)		
10461338	C4591001 1046 10461338	16-55	30OCT2020	114995	BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)	20NOV2020/ BNT162b2 (30 µg)		
10461339	C4591001 1046 10461339	16-55	30OCT2020	114996	Placebo	30OCT2020/ Placebo	20NOV2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
10461340	C4591001 1046 10461340	16-55	30OCT2020	115110	Placebo	30OCT2020/ Placebo	20NOV2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10461341	C4591001 1046 10461341	16-55	19NOV2020	115114	Placebo	19NOV2020/ Placebo	08DEC2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
10461342	C4591001 1046 10461342	16-55	19NOV2020	115115	BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)	08DEC2020/ BNT162b2 (30 µg)		
10461343	C4591001 1046 10461343	16-55	20NOV2020	115118	BNT162b2 (30 µg)	20NOV2020/ BNT162b2 (30 µg)	21DEC2020/ BNT162b2 (30 µg)		
10461344	C4591001 1046 10461344	16-55	20NOV2020	116609	Placebo	20NOV2020/ Placebo	21DEC2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10461345	C4591001 1046 10461345	16-55	24NOV2020	116614	Placebo	24NOV2020/ Placebo	17DEC2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
10461346	C4591001 1046 10461346	16-55	01DEC2020	116615	BNT162b2 (30 µg)	01DEC2020/ BNT162b2 (30 µg)	21DEC2020/ BNT162b2 (30 µg)		
10461347	C4591001 1046 10461347	16-55	03DEC2020	116617	BNT162b2 (30 µg)	03DEC2020/ BNT162b2 (30 µg)	22DEC2020/ BNT162b2 (30 µg)		
10461348	C4591001 1046 10461348	16-55	04DEC2020	117595	BNT162b2 (30 µg)	04DEC2020/ BNT162b2 (30 µg)	22DEC2020/ BNT162b2 (30 µg)		
10471009	C4591001 1047 10471009	16-55	20AUG2020	58289	Placebo	20AUG2020/ Placebo	08SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10471010	C4591001 1047 10471010	16-55	20AUG2020	58290	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10471015	C4591001 1047 10471015	16-55	20AUG2020	58297	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10471017	C4591001 1047 10471017	16-55	21AUG2020	58299	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
10471018	C4591001 1047 10471018	16-55	21AUG2020	60642	Placebo	21AUG2020/ Placebo	09SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10471020	C4591001 1047 10471020	16-55	21AUG2020	60644	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10471021	C4591001 1047 10471021	16-55	21AUG2020	60647	Placebo	21AUG2020/ Placebo	09SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10471025	C4591001 1047 10471025	16-55	21AUG2020	60652	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
10471028	C4591001 1047 10471028	16-55	22AUG2020	61891	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
10471029	C4591001 1047 10471029	16-55	22AUG2020	61898	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
10471030	C4591001 1047 10471030	16-55	22AUG2020	61899	Placebo	22AUG2020/ Placebo	10SEP2020/ Placebo		
10471033	C4591001 1047 10471033	16-55	22AUG2020	62393	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	12SEP2020/ BNT162b2 (30 µg)		
10471034	C4591001 1047 10471034	16-55	22AUG2020	61900	Placebo	22AUG2020/ Placebo	12SEP2020/ Placebo		
10471035	C4591001 1047 10471035	16-55	24AUG2020	62396	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo		
10471036	C4591001 1047 10471036	16-55	24AUG2020	62397	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo		
10471037	C4591001 1047 10471037	16-55	24AUG2020	62403	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10471038	C4591001 1047 10471038	16-55	24AUG2020	64253	Placebo	24AUG2020/ Placebo	16SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10471040	C4591001 1047 10471040	16-55	24AUG2020	64258	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10471041	C4591001 1047 10471041	16-55	25AUG2020	64264	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10471042	C4591001 1047 10471042	16-55	25AUG2020	64263	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
10471046	C4591001 1047 10471046	16-55	25AUG2020	66077	Placebo	25AUG2020/ Placebo	14SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
10471047	C4591001 1047 10471047	16-55	25AUG2020	66082	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10471048	C4591001 1047 10471048	16-55	25AUG2020	66085	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10471049	C4591001 1047 10471049	16-55	25AUG2020	66087	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10471051	C4591001 1047 10471051	16-55	25AUG2020	66906	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10471052	C4591001 1047 10471052	16-55	26AUG2020	66909	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
10471053	C4591001 1047 10471053	16-55	26AUG2020	66912	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10471054	C4591001 1047 10471054	16-55	26AUG2020	66914	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo		
10471056	C4591001 1047 10471056	16-55	26AUG2020	68340	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
10471057	C4591001 1047 10471057	16-55	26AUG2020	68336	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
10471058	C4591001 1047 10471058	16-55	26AUG2020	68342	Placebo	26AUG2020/ Placebo	15SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10471059	C4591001 1047 10471059	16-55	26AUG2020	68344	Placebo	26AUG2020/ Placebo	15SEP2020/ Placebo		
10471061	C4591001 1047 10471061	16-55	27AUG2020	69835	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10471064	C4591001 1047 10471064	16-55	27AUG2020	69837	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10471065	C4591001 1047 10471065	16-55	27AUG2020	69843	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	28JAN2021/ BNT162b2 (30 µg)
10471067	C4591001 1047 10471067	16-55	27AUG2020	69844	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
10471068	C4591001 1047 10471068	16-55	27AUG2020	71047	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10471069	C4591001 1047 10471069	16-55	27AUG2020	71051	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10471070	C4591001 1047 10471070	16-55	27AUG2020	243124	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10471071	C4591001 1047 10471071	16-55	27AUG2020	71048	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10471074	C4591001 1047 10471074	16-55	28AUG2020	71055	Placebo	28AUG2020/ Placebo	17SEP2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
10471075	C4591001 1047 10471075	16-55	28AUG2020	72161	Placebo	28AUG2020/ Placebo	17SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10471076	C4591001 1047 10471076	16-55	28AUG2020	72166	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10471077	C4591001 1047 10471077	16-55	28AUG2020	72168	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
10471078	C4591001 1047 10471078	16-55	28AUG2020	72171	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
10471079	C4591001 1047 10471079	16-55	28AUG2020	72653	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)
10471080	C4591001 1047 10471080	16-55	28AUG2020	72654	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10471081	C4591001 1047 10471081	16-55	28AUG2020	72658	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10471082	C4591001 1047 10471082	16-55	28AUG2020	72656	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
10471083	C4591001 1047 10471083	16-55	28AUG2020	73170	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10471084	C4591001 1047 10471084	16-55	28AUG2020	73172	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10471085	C4591001 1047 10471085	16-55	31AUG2020	73178	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
10471086	C4591001 1047 10471086	16-55	31AUG2020	73179	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10471087	C4591001 1047 10471087	16-55	31AUG2020	75149	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
10471088	C4591001 1047 10471088	16-55	31AUG2020	75151	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10471089	C4591001 1047 10471089	16-55	31AUG2020	75154	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo		
10471093	C4591001 1047 10471093	16-55	31AUG2020	75157	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10471094	C4591001 1047 10471094	16-55	01SEP2020	76484	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10471095	C4591001 1047 10471095	16-55	01SEP2020	76486	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10471100	C4591001 1047 10471100	16-55	01SEP2020	76487	Placebo	01SEP2020/ Placebo	23SEP2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
10471106	C4591001 1047 10471106	16-55	02SEP2020	76490	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10471107	C4591001 1047 10471107	16-55	02SEP2020	78065	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10471109	C4591001 1047 10471109	16-55	02SEP2020	78236	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10471111	C4591001 1047 10471111	16-55	02SEP2020	78237	Placebo	02SEP2020/ Placebo	21SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
10471112	C4591001 1047 10471112	16-55	02SEP2020	78238	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
10471115	C4591001 1047 10471115	16-55	02SEP2020	78239	Placebo	02SEP2020/ Placebo	25SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
10471116	C4591001 1047 10471116	16-55	02SEP2020	79265	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10471117	C4591001 1047 10471117	16-55	03SEP2020	79268	Placebo	04SEP2020/ Placebo	24SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
10471118	C4591001 1047 10471118	16-55	03SEP2020	79269	Placebo	03SEP2020/ Placebo	25SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
10471119	C4591001 1047 10471119	16-55	03SEP2020	79273	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10471120	C4591001 1047 10471120	16-55	03SEP2020	80166	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10471124	C4591001 1047 10471124	16-55	03SEP2020	80171	Placebo	03SEP2020/ Placebo	22SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
10471125	C4591001 1047 10471125	16-55	03SEP2020	80172	Placebo	03SEP2020/ Placebo	23SEP2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
10471126	C4591001 1047 10471126	16-55	03SEP2020	80921	Placebo	03SEP2020/ Placebo	25SEP2020/ Placebo		
10471127	C4591001 1047 10471127	16-55	03SEP2020	80175	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10471128	C4591001 1047 10471128	16-55	03SEP2020	80922	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10471129	C4591001 1047 10471129	16-55	03SEP2020	80927	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10471131	C4591001 1047 10471131	16-55	04SEP2020	80929	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
10471133	C4591001 1047 10471133	16-55	04SEP2020	81401	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
10471134	C4591001 1047 10471134	16-55	04SEP2020	81406	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10471143	C4591001 1047 10471143	16-55	04SEP2020	81409	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
10471144	C4591001 1047 10471144	16-55	04SEP2020	81410	Placebo	04SEP2020/ Placebo	23SEP2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
10471146	C4591001 1047 10471146	16-55	07SEP2020	83146	Placebo	07SEP2020/ Placebo	28SEP2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
10471147	C4591001 1047 10471147	16-55	07SEP2020	83141	BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
10471148	C4591001 1047 10471148	16-55	07SEP2020	83147	Placebo	07SEP2020/ Placebo	29SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
10471149	C4591001 1047 10471149	16-55	07SEP2020	83149	BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
10471150	C4591001 1047 10471150	16-55	07SEP2020	83214	Placebo	07SEP2020/ Placebo	28SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10471151	C4591001 1047 10471151	16-55	07SEP2020	83216	BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10471153	C4591001 1047 10471153	16-55	08SEP2020	83219	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
10471155	C4591001 1047 10471155	16-55	08SEP2020	83221	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
10471159	C4591001 1047 10471159	16-55	08SEP2020	84307	Placebo	08SEP2020/ Placebo	30SEP2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
10471162	C4591001 1047 10471162	16-55	08SEP2020	84311	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
10471163	C4591001 1047 10471163	16-55	09SEP2020	84314	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	02MAR2021/ BNT162b2 (30 µg)	
10471164	C4591001 1047 10471164	16-55	09SEP2020	84316	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10471166	C4591001 1047 10471166	16-55	09SEP2020	85172	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10471167	C4591001 1047 10471167	16-55	09SEP2020	85173	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
10471168	C4591001 1047 10471168	16-55	09SEP2020	85176	Placebo	09SEP2020/ Placebo	02OCT2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10471171	C4591001 1047 10471171	16-55	09SEP2020	85179	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	28JAN2021/ BNT162b2 (30 µg)
10471172	C4591001 1047 10471172	16-55	10SEP2020	86508	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10471174	C4591001 1047 10471174	16-55	10SEP2020	86510	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
10471176	C4591001 1047 10471176	16-55	10SEP2020	86511	Placebo	10SEP2020/ Placebo	23OCT2020/ Placebo	03MAR2021/ BNT162b2 (30 µg)	
10471179	C4591001 1047 10471179	16-55	10SEP2020	86512	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
10471180	C4591001 1047 10471180	16-55	10SEP2020	87526	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10471181	C4591001 1047 10471181	16-55	10SEP2020	87528	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo		
10471186	C4591001 1047 10471186	16-55	11SEP2020	87529	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
10471189	C4591001 1047 10471189	16-55	11SEP2020	87532	Placebo	11SEP2020/ Placebo	01OCT2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
10471192	C4591001 1047 10471192	16-55	11SEP2020	88797	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10471198	C4591001 1047 10471198	16-55	12SEP2020	88799	Placebo	12SEP2020/ Placebo	01OCT2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
10471199	C4591001 1047 10471199	16-55	12SEP2020	88801	BNT162b2 (30 µg)	12SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
10471201	C4591001 1047 10471201	16-55	12SEP2020	89237	BNT162b2 (30 µg)	12SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
10471202	C4591001 1047 10471202	16-55	12SEP2020	88804	Placebo	12SEP2020/ Placebo	05OCT2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
10471203	C4591001 1047 10471203	16-55	14SEP2020	89242	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
10471207	C4591001 1047 10471207	16-55	14SEP2020	89247	Placebo	14SEP2020/ Placebo	06OCT2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
10471210	C4591001 1047 10471210	16-55	15SEP2020	89248	Placebo	15SEP2020/ Placebo	06OCT2020/ Placebo		
10471211	C4591001 1047 10471211	16-55	15SEP2020	90377	Placebo	15SEP2020/ Placebo	05OCT2020/ Placebo		
10471212	C4591001 1047 10471212	16-55	15SEP2020	90378	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		
10471217	C4591001 1047 10471217	16-55	16SEP2020	90379	Placebo	16SEP2020/ Placebo	09OCT2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10471219	C4591001 1047 10471219	16-55	16SEP2020	90382	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		
10471220	C4591001 1047 10471220	16-55	16SEP2020	91193	Placebo	16SEP2020/ Placebo	20OCT2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
10471221	C4591001 1047 10471221	16-55	16SEP2020	91195	Placebo	16SEP2020/ Placebo			
10471223	C4591001 1047 10471223	16-55	16SEP2020	91198	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
10471225	C4591001 1047 10471225	16-55	16SEP2020	91199	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
10471226	C4591001 1047 10471226	16-55	16SEP2020	91687	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
10471227	C4591001 1047 10471227	16-55	16SEP2020	91691	Placebo	16SEP2020/ Placebo	08OCT2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
10471229	C4591001 1047 10471229	16-55	17SEP2020	91693	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
10471231	C4591001 1047 10471231	16-55	17SEP2020	91696	Placebo	17SEP2020/ Placebo	09OCT2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
10471232	C4591001 1047 10471232	16-55	17SEP2020	92454	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10471233	C4591001 1047 10471233	16-55	17SEP2020	92459	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
10471234	C4591001 1047 10471234	16-55	17SEP2020	92461	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo		
10471236	C4591001 1047 10471236	16-55	17SEP2020	92462	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
10471237	C4591001 1047 10471237	16-55	17SEP2020	92970	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
10471238	C4591001 1047 10471238	16-55	18SEP2020	92971	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
10471240	C4591001 1047 10471240	16-55	18SEP2020	92976	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
10471241	C4591001 1047 10471241	16-55	18SEP2020	92979	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
10471243	C4591001 1047 10471243	16-55	18SEP2020	94198	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10471244	C4591001 1047 10471244	16-55	18SEP2020	94200	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
10471245	C4591001 1047 10471245	16-55	21SEP2020	94201	Placebo	21SEP2020/ Placebo	14OCT2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10471246	C4591001 1047 10471246	16-55	21SEP2020	94203	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
10471251	C4591001 1047 10471251	16-55	21SEP2020	95311	Placebo	21SEP2020/ Placebo	13OCT2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10471253	C4591001 1047 10471253	16-55	21SEP2020	95312	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
10471254	C4591001 1047 10471254	16-55	21SEP2020	95316	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
10471255	C4591001 1047 10471255	16-55	21SEP2020	95318	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
10471256	C4591001 1047 10471256	16-55	21SEP2020	95494	Placebo	21SEP2020/ Placebo	14OCT2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
10471257	C4591001 1047 10471257	16-55	21SEP2020	95496	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
10471258	C4591001 1047 10471258	16-55	22SEP2020	95498	Placebo	22SEP2020/ Placebo	13OCT2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
10471259	C4591001 1047 10471259	16-55	22SEP2020	95500	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
10471262	C4591001 1047 10471262	16-55	22SEP2020	96390	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10471264	C4591001 1047 10471264	16-55	22SEP2020	96391	Placebo	22SEP2020/ Placebo	13OCT2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
10471266	C4591001 1047 10471266	16-55	22SEP2020	96392	Placebo	22SEP2020/ Placebo	15OCT2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
10471267	C4591001 1047 10471267	16-55	22SEP2020	96400	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
10471270	C4591001 1047 10471270	16-55	22SEP2020	96930	Placebo	22SEP2020/ Placebo	15OCT2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
10471271	C4591001 1047 10471271	16-55	23SEP2020	96934	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
10471275	C4591001 1047 10471275	16-55	23SEP2020	96936	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
10471278	C4591001 1047 10471278	16-55	23SEP2020	98285	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
10471279	C4591001 1047 10471279	16-55	23SEP2020	96937	Placebo	23SEP2020/ Placebo	16OCT2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
10471284	C4591001 1047 10471284	16-55	24SEP2020	98286	Placebo	24SEP2020/ Placebo	13OCT2020/ Placebo		
10471285	C4591001 1047 10471285	16-55	24SEP2020	98287	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10471286	C4591001 1047 10471286	16-55	24SEP2020	98296	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
10471287	C4591001 1047 10471287	16-55	24SEP2020	98765	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
10471288	C4591001 1047 10471288	16-55	24SEP2020	98767	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
10471289	C4591001 1047 10471289	16-55	24SEP2020	98774	Placebo	24SEP2020/ Placebo	14OCT2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10471291	C4591001 1047 10471291	16-55	24SEP2020	98776	Placebo	24SEP2020/ Placebo	13OCT2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
10471292	C4591001 1047 10471292	16-55	24SEP2020	98985	Placebo	24SEP2020/ Placebo	15OCT2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
10471293	C4591001 1047 10471293	16-55	25SEP2020	98991	Placebo	25SEP2020/ Placebo	15OCT2020/ Placebo		
10471294	C4591001 1047 10471294	16-55	25SEP2020	98987	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
10471295	C4591001 1047 10471295	16-55	25SEP2020	98992	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
10471296	C4591001 1047 10471296	16-55	25SEP2020	99983	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10471297	C4591001 1047 10471297	16-55	25SEP2020	99984	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
10471301	C4591001 1047 10471301	16-55	28SEP2020	99985	Placebo	28SEP2020/ Placebo	19OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	
10471303	C4591001 1047 10471303	16-55	29SEP2020	99986	Placebo	29SEP2020/ Placebo	19OCT2020/ Placebo		
10471304	C4591001 1047 10471304	16-55	30SEP2020	102341	Placebo	30SEP2020/ Placebo	21OCT2020/ Placebo		
10471305	C4591001 1047 10471305	16-55	30SEP2020	102342	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)		
10471306	C4591001 1047 10471306	16-55	02OCT2020	102349	BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)		
10471307	C4591001 1047 10471307	16-55	05OCT2020	102352	Placebo	05OCT2020/ Placebo	28OCT2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
10471308	C4591001 1047 10471308	16-55	05OCT2020	103868	BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		
10471310	C4591001 1047 10471310	16-55	07OCT2020	103874	Placebo	07OCT2020/ Placebo	26OCT2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
10471312	C4591001 1047 10471312	16-55	09OCT2020	103875	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10471314	C4591001 1047 10471314	16-55	12OCT2020	103876	Placebo	12OCT2020/ Placebo			
10471316	C4591001 1047 10471316	16-55	13OCT2020	107229	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
10471317	C4591001 1047 10471317	16-55	13OCT2020	107232	Placebo	13OCT2020/ Placebo	03NOV2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10471318	C4591001 1047 10471318	16-55	14OCT2020	107233	Placebo	14OCT2020/ Placebo	02NOV2020/ Placebo		
10471319	C4591001 1047 10471319	16-55	15OCT2020	107236	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
10471321	C4591001 1047 10471321	16-55	19OCT2020	110057	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
10471322	C4591001 1047 10471322	16-55	19OCT2020	110059	Placebo	19OCT2020/ Placebo	13NOV2020/ Placebo		
10471325	C4591001 1047 10471325	16-55	20OCT2020	110065	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
10471326	C4591001 1047 10471326	16-55	21OCT2020	110068	Placebo	21OCT2020/ Placebo	10NOV2020/ Placebo		
10471327	C4591001 1047 10471327	16-55	21OCT2020	111725	Placebo	21OCT2020/ Placebo	12NOV2020/ Placebo		
10471328	C4591001 1047 10471328	16-55	21OCT2020	111730	Placebo	21OCT2020/ Placebo	11NOV2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10471329	C4591001 1047 10471329	16-55	21OCT2020	111731	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
10471331	C4591001 1047 10471331	16-55	22OCT2020	111736	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
10471332	C4591001 1047 10471332	16-55	23OCT2020	112865	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
10481011	C4591001 1048 10481011	16-55	17AUG2020	44867	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10481017	C4591001 1048 10481017	16-55	18AUG2020	44870	Placebo	18AUG2020/ Placebo	10SEP2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)
10481019	C4591001 1048 10481019	16-55	18AUG2020	55289	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
10481020	C4591001 1048 10481020	16-55	18AUG2020	55290	Placebo	18AUG2020/ Placebo	10SEP2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
10481021	C4591001 1048 10481021	16-55	24AUG2020	55292	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10481024	C4591001 1048 10481024	16-55	24AUG2020	55299	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10481025	C4591001 1048 10481025	16-55	24AUG2020	64818	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10481027	C4591001 1048 10481027	16-55	25AUG2020	64819	Placebo	25AUG2020/ Placebo	16SEP2020/ Placebo		
10481030	C4591001 1048 10481030	16-55	25AUG2020	64821	Placebo	25AUG2020/ Placebo	16SEP2020/ Placebo		
10481032	C4591001 1048 10481032	16-55	25AUG2020	64823	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10481035	C4591001 1048 10481035	16-55	26AUG2020	67949	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10481037	C4591001 1048 10481037	16-55	26AUG2020	67952	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
10481040	C4591001 1048 10481040	16-55	27AUG2020	67953	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	21JAN2021/ BNT162b2 (30 µg)
10481044	C4591001 1048 10481044	16-55	27AUG2020	67955	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10481046	C4591001 1048 10481046	16-55	27AUG2020	71310	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10481048	C4591001 1048 10481048	16-55	28AUG2020	71312	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
10481052	C4591001 1048 10481052	16-55	28AUG2020	71317	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10481054	C4591001 1048 10481054	16-55	28AUG2020	71319	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10481055	C4591001 1048 10481055	16-55	31AUG2020	74945	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10481056	C4591001 1048 10481056	16-55	31AUG2020	74951	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10481057	C4591001 1048 10481057	16-55	31AUG2020	74953	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10481061	C4591001 1048 10481061	16-55	01SEP2020	74956	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10481064	C4591001 1048 10481064	16-55	01SEP2020	77409	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
10481065	C4591001 1048 10481065	16-55	01SEP2020	77405	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10481070	C4591001 1048 10481070	16-55	02SEP2020	77410	Placebo	02SEP2020/ Placebo	21SEP2020/ Placebo		
10481075	C4591001 1048 10481075	16-55	02SEP2020	77416	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10481079	C4591001 1048 10481079	16-55	03SEP2020	80287	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10481080	C4591001 1048 10481080	16-55	03SEP2020	80289	Placebo	03SEP2020/ Placebo	25SEP2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
10481083	C4591001 1048 10481083	16-55	03SEP2020	80291	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10481085	C4591001 1048 10481085	16-55	03SEP2020	80295	Placebo	03SEP2020/ Placebo	25SEP2020/ Placebo		
10481086	C4591001 1048 10481086	16-55	03SEP2020	81140	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10481088	C4591001 1048 10481088	16-55	04SEP2020	81142	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
10481092	C4591001 1048 10481092	16-55	04SEP2020	81143	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
10481094	C4591001 1048 10481094	16-55	04SEP2020	81144	Placebo	04SEP2020/ Placebo	23SEP2020/ Placebo		
10481095	C4591001 1048 10481095	16-55	08SEP2020	83853	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
10481097	C4591001 1048 10481097	16-55	08SEP2020	83858	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10481098	C4591001 1048 10481098	16-55	08SEP2020	83859	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10481101	C4591001 1048 10481101	16-55	08SEP2020	83860	Placebo	08SEP2020/ Placebo	01OCT2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10481103	C4591001 1048 10481103	16-55	08SEP2020	84670	Placebo	08SEP2020/ Placebo	01OCT2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
10481106	C4591001 1048 10481106	16-55	09SEP2020	84671	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
10481107	C4591001 1048 10481107	16-55	09SEP2020	84672	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
10481108	C4591001 1048 10481108	16-55	09SEP2020	84674	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo		
10481109	C4591001 1048 10481109	16-55	09SEP2020	86193	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10481110	C4591001 1048 10481110	16-55	09SEP2020	86195	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
10481114	C4591001 1048 10481114	16-55	10SEP2020	86197	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10481116	C4591001 1048 10481116	16-55	10SEP2020	86200	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
10481125	C4591001 1048 10481125	16-55	11SEP2020	88230	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10481126	C4591001 1048 10481126	16-55	11SEP2020	88235	Placebo	11SEP2020/ Placebo	30SEP2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
10481131	C4591001 1048 10481131	16-55	11SEP2020	88238	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
10481132	C4591001 1048 10481132	16-55	11SEP2020	88937	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
10521003	C4591001 1052 10521003	16-55	18AUG2020	232263	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
10521004	C4591001 1052 10521004	16-55	19AUG2020	56720	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10521005	C4591001 1052 10521005	16-55	19AUG2020	56721	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10521006	C4591001 1052 10521006	16-55	19AUG2020	56722	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
10521007	C4591001 1052 10521007	16-55	19AUG2020	56724	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10521011	C4591001 1052 10521011	16-55	19AUG2020	57569	Placebo	19AUG2020/ Placebo	08SEP2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
10521013	C4591001 1052 10521013	16-55	20AUG2020	57572	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10521015	C4591001 1052 10521015	16-55	20AUG2020	57573	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
10521016	C4591001 1052 10521016	16-55	20AUG2020	57574	Placebo	20AUG2020/ Placebo	11SEP2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	
10521017	C4591001 1052 10521017	16-55	21AUG2020	61042	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10521021	C4591001 1052 10521021	16-55	21AUG2020	61043	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10521022	C4591001 1052 10521022	16-55	21AUG2020	61045	Placebo	21AUG2020/ Placebo	10SEP2020/ Placebo		
10521026	C4591001 1052 10521026	16-55	24AUG2020	61046	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
10521028	C4591001 1052 10521028	16-55	25AUG2020	66490	Placebo	25AUG2020/ Placebo	14SEP2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
10521030	C4591001 1052 10521030	16-55	25AUG2020	66492	Placebo	25AUG2020/ Placebo	14SEP2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10521031	C4591001 1052 10521031	16-55	26AUG2020	66494	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10521032	C4591001 1052 10521032	16-55	26AUG2020	66496	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10521035	C4591001 1052 10521035	16-55	26AUG2020	68623	Placebo	26AUG2020/ Placebo	15SEP2020/ Placebo		
10521036	C4591001 1052 10521036	16-55	26AUG2020	68626	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10521040	C4591001 1052 10521040	16-55	26AUG2020	68630	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10521041	C4591001 1052 10521041	16-55	26AUG2020	69078	Placebo	26AUG2020/ Placebo	15SEP2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)
10521043	C4591001 1052 10521043	16-55	27AUG2020	69082	Placebo	27AUG2020/ Placebo	16SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10521044	C4591001 1052 10521044	16-55	27AUG2020	69084	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10521046	C4591001 1052 10521046	16-55	27AUG2020	69087	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10521049	C4591001 1052 10521049	16-55	27AUG2020	71185	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10521051	C4591001 1052 10521051	16-55	28AUG2020	71186	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10521052	C4591001 1052 10521052	16-55	28AUG2020	71187	Placebo	28AUG2020/ Placebo	17SEP2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10521053	C4591001 1052 10521053	16-55	28AUG2020	71188	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
10521054	C4591001 1052 10521054	16-55	28AUG2020	72584	Placebo	28AUG2020/ Placebo			
10521055	C4591001 1052 10521055	16-55	28AUG2020	72585	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
10521056	C4591001 1052 10521056	16-55	28AUG2020	72587	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
10521057	C4591001 1052 10521057	16-55	28AUG2020	72591	Placebo	28AUG2020/ Placebo			
10521058	C4591001 1052 10521058	16-55	28AUG2020	73110	Placebo	28AUG2020/ Placebo			
10521063	C4591001 1052 10521063	16-55	31AUG2020	73112	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)
10521064	C4591001 1052 10521064	16-55	31AUG2020	73115	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)			
10521065	C4591001 1052 10521065	16-55	31AUG2020	73119	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10521066	C4591001 1052 10521066	16-55	31AUG2020	76126	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10521068	C4591001 1052 10521068	16-55	01SEP2020	76127	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10521070	C4591001 1052 10521070	16-55	01SEP2020	76128	Placebo	01SEP2020/ Placebo	21SEP2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
10521071	C4591001 1052 10521071	16-55	01SEP2020	76131	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10521073	C4591001 1052 10521073	16-55	01SEP2020	77374	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10521075	C4591001 1052 10521075	16-55	01SEP2020	77370	Placebo	01SEP2020/ Placebo	21SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
10521076	C4591001 1052 10521076	16-55	02SEP2020	77377	Placebo	02SEP2020/ Placebo	21SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10521079	C4591001 1052 10521079	16-55	02SEP2020	77378	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10521080	C4591001 1052 10521080	16-55	02SEP2020	78907	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)			
10521081	C4591001 1052 10521081	16-55	02SEP2020	78909	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10521082	C4591001 1052 10521082	16-55	02SEP2020	78913	Placebo	02SEP2020/ Placebo	22SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10521083	C4591001 1052 10521083	16-55	03SEP2020	80370	Placebo	03SEP2020/ Placebo	23SEP2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)
10521084	C4591001 1052 10521084	16-55	03SEP2020	78915	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
10521086	C4591001 1052 10521086	16-55	03SEP2020	80373	Placebo	03SEP2020/ Placebo	25SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10521087	C4591001 1052 10521087	16-55	03SEP2020	80376	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10521090	C4591001 1052 10521090	16-55	03SEP2020	80377	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10521091	C4591001 1052 10521091	16-55	03SEP2020	81030	Placebo	03SEP2020/ Placebo	23SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10521092	C4591001 1052 10521092	16-55	04SEP2020	81034	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10521093	C4591001 1052 10521093	16-55	04SEP2020	81035	Placebo	04SEP2020/ Placebo	24SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
10521096	C4591001 1052 10521096	16-55	04SEP2020	81038	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10521100	C4591001 1052 10521100	16-55	04SEP2020	82054	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10521101	C4591001 1052 10521101	16-55	04SEP2020	82055	Placebo	04SEP2020/ Placebo	24SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
10521104	C4591001 1052 10521104	16-55	04SEP2020	82056	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10521105	C4591001 1052 10521105	16-55	04SEP2020	82057	Placebo	04SEP2020/ Placebo	24SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10521106	C4591001 1052 10521106	16-55	04SEP2020	82410	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10521109	C4591001 1052 10521109	16-55	04SEP2020	82413	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10521110	C4591001 1052 10521110	16-55	04SEP2020	82415	Placebo	04SEP2020/ Placebo	24SEP2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	
10521111	C4591001 1052 10521111	16-55	04SEP2020	82420	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo		
10521113	C4591001 1052 10521113	16-55	04SEP2020	82581	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10521114	C4591001 1052 10521114	16-55	16SEP2020	82585	Placebo	16SEP2020/ Placebo	05OCT2020/ Placebo		
10521116	C4591001 1052 10521116	16-55	16SEP2020	82586	Placebo	16SEP2020/ Placebo	05OCT2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10521117	C4591001 1052 10521117	16-55	16SEP2020	82587	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
10521120	C4591001 1052 10521120	16-55	17SEP2020	92816	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
10521121	C4591001 1052 10521121	16-55	17SEP2020	92815	Placebo	17SEP2020/ Placebo	06OCT2020/ Placebo		
10521123	C4591001 1052 10521123	16-55	18SEP2020	92823	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
10521125	C4591001 1052 10521125	16-55	18SEP2020	93966	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
10521126	C4591001 1052 10521126	16-55	18SEP2020	92824	Placebo	18SEP2020/ Placebo	07OCT2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
10521129	C4591001 1052 10521129	16-55	18SEP2020	93971	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
10521131	C4591001 1052 10521131	16-55	19SEP2020	93972	Placebo	19SEP2020/ Placebo	08OCT2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10521132	C4591001 1052 10521132	16-55	19SEP2020	93974	Placebo	19SEP2020/ Placebo	08OCT2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
10521133	C4591001 1052 10521133	16-55	19SEP2020	94506	BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10521134	C4591001 1052 10521134	16-55	19SEP2020	94510	Placebo	19SEP2020/ Placebo	08OCT2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
10521135	C4591001 1052 10521135	16-55	19SEP2020	94511	Placebo	19SEP2020/ Placebo	08OCT2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
10521139	C4591001 1052 10521139	16-55	19SEP2020	94515	BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)			
10521140	C4591001 1052 10521140	16-55	19SEP2020	94555	BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
10521141	C4591001 1052 10521141	16-55	21SEP2020	94559	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
10521143	C4591001 1052 10521143	16-55	21SEP2020	94563	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
10521145	C4591001 1052 10521145	16-55	22SEP2020	94564	Placebo	22SEP2020/ Placebo	13OCT2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10521148	C4591001 1052 10521148	16-55	22SEP2020	96735	Placebo	22SEP2020/ Placebo	12OCT2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
10521149	C4591001 1052 10521149	16-55	22SEP2020	96728	Placebo	22SEP2020/ Placebo	12OCT2020/ Placebo	06JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
10521150	C4591001 1052 10521150	16-55	22SEP2020	96729	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10521152	C4591001 1052 10521152	16-55	22SEP2020	96736	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
10521154	C4591001 1052 10521154	16-55	23SEP2020	97769	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
10521155	C4591001 1052 10521155	16-55	23SEP2020	97770	Placebo	23SEP2020/ Placebo	12OCT2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	
10521157	C4591001 1052 10521157	16-55	23SEP2020	97771	Placebo	23SEP2020/ Placebo	13OCT2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	28JAN2021/ BNT162b2 (30 µg)
10521158	C4591001 1052 10521158	16-55	23SEP2020	97779	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
10521159	C4591001 1052 10521159	16-55	23SEP2020	97865	Placebo	23SEP2020/ Placebo	13OCT2020/ Placebo		
10521160	C4591001 1052 10521160	16-55	23SEP2020	97870	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
10521161	C4591001 1052 10521161	16-55	23SEP2020	97872	Placebo	23SEP2020/ Placebo	12OCT2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
10521162	C4591001 1052 10521162	16-55	23SEP2020	97873	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
10521163	C4591001 1052 10521163	16-55	23SEP2020	98240	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10521164	C4591001 1052 10521164	16-55	23SEP2020	98241	Placebo	23SEP2020/ Placebo	13OCT2020/ Placebo		
10521165	C4591001 1052 10521165	16-55	23SEP2020	98243	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
10521166	C4591001 1052 10521166	16-55	23SEP2020	98246	Placebo	23SEP2020/ Placebo	13OCT2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
10521167	C4591001 1052 10521167	16-55	24SEP2020	99067	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
10521168	C4591001 1052 10521168	16-55	25SEP2020	99069	Placebo	25SEP2020/ Placebo	19OCT2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
10521169	C4591001 1052 10521169	16-55	25SEP2020	99070	Placebo	25SEP2020/ Placebo	14OCT2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10521170	C4591001 1052 10521170	16-55	25SEP2020	99074	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
10521172	C4591001 1052 10521172	16-55	25SEP2020	100135	Placebo	25SEP2020/ Placebo	14OCT2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
10521173	C4591001 1052 10521173	16-55	25SEP2020	100137	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
10521174	C4591001 1052 10521174	16-55	25SEP2020	100139	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10521175	C4591001 1052 10521175	16-55	25SEP2020	100142	Placebo	25SEP2020/ Placebo	14OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10521176	C4591001 1052 10521176	16-55	25SEP2020	100409	Placebo	25SEP2020/ Placebo	14OCT2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
10521177	C4591001 1052 10521177	16-55	25SEP2020	100417	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)		
10521178	C4591001 1052 10521178	16-55	25SEP2020	100418	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
10541001	C4591001 1054 10541001	16-55	19AUG2020	56513	Placebo	19AUG2020/ Placebo	08SEP2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
10541002	C4591001 1054 10541002	16-55	19AUG2020	56515	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10541003	C4591001 1054 10541003	16-55	19AUG2020	56518	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10541005	C4591001 1054 10541005	16-55	19AUG2020	56523	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
10541006	C4591001 1054 10541006	16-55	19AUG2020	57210	Placebo	19AUG2020/ Placebo	17SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
10541007	C4591001 1054 10541007	16-55	19AUG2020	57209	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10541008	C4591001 1054 10541008	16-55	19AUG2020	57211	Placebo	19AUG2020/ Placebo	08SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
10541011	C4591001 1054 10541011	16-55	20AUG2020	57213	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10541012	C4591001 1054 10541012	16-55	20AUG2020	58541	Placebo	20AUG2020/ Placebo	11SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10541013	C4591001 1054 10541013	16-55	20AUG2020	58543	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
10541014	C4591001 1054 10541014	16-55	20AUG2020	58549	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10541016	C4591001 1054 10541016	16-55	20AUG2020	58551	Placebo	20AUG2020/ Placebo	09SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	
10541017	C4591001 1054 10541017	16-55	20AUG2020	59071	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10541018	C4591001 1054 10541018	16-55	20AUG2020	59075	Placebo	20AUG2020/ Placebo	09SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10541019	C4591001 1054 10541019	16-55	20AUG2020	59076	Placebo	20AUG2020/ Placebo	09SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10541022	C4591001 1054 10541022	16-55	21AUG2020	59079	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)			

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10541023	C4591001 1054 10541023	16-55	21AUG2020	60741	Placebo	21AUG2020/ Placebo			
10541025	C4591001 1054 10541025	16-55	21AUG2020	60743	Placebo	21AUG2020/ Placebo	10SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10541026	C4591001 1054 10541026	16-55	21AUG2020	60744	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10541027	C4591001 1054 10541027	16-55	21AUG2020	60746	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10541028	C4591001 1054 10541028	16-55	21AUG2020	61206	Placebo	21AUG2020/ Placebo	10SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
10541032	C4591001 1054 10541032	16-55	22AUG2020	61213	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
10541033	C4591001 1054 10541033	16-55	22AUG2020	61214	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)			
10541034	C4591001 1054 10541034	16-55	22AUG2020	61215	Placebo	22AUG2020/ Placebo	15SEP2020/ Placebo		
10541035	C4591001 1054 10541035	16-55	22AUG2020	62370	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10541037	C4591001 1054 10541037	16-55	24AUG2020	62375	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10541038	C4591001 1054 10541038	16-55	24AUG2020	62377	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
10541039	C4591001 1054 10541039	16-55	24AUG2020	62378	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10541041	C4591001 1054 10541041	16-55	24AUG2020	64111	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10541042	C4591001 1054 10541042	16-55	24AUG2020	64110	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10541043	C4591001 1054 10541043	16-55	24AUG2020	64112	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10541044	C4591001 1054 10541044	16-55	25AUG2020	64116	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10541047	C4591001 1054 10541047	16-55	25AUG2020	65888	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
10541048	C4591001 1054 10541048	16-55	25AUG2020	65891	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10541049	C4591001 1054 10541049	16-55	25AUG2020	65893	Placebo	25AUG2020/ Placebo	16SEP2020/ Placebo		
10541050	C4591001 1054 10541050	16-55	26AUG2020	65894	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10541051	C4591001 1054 10541051	16-55	26AUG2020	67810	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10541052	C4591001 1054 10541052	16-55	26AUG2020	67814	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo		
10541053	C4591001 1054 10541053	16-55	26AUG2020	67815	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10541054	C4591001 1054 10541054	16-55	26AUG2020	67901	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10541055	C4591001 1054 10541055	16-55	26AUG2020	67903	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)			
10541057	C4591001 1054 10541057	16-55	26AUG2020	67908	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
10541058	C4591001 1054 10541058	16-55	26AUG2020	67912	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10541060	C4591001 1054 10541060	16-55	27AUG2020	69992	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10541061	C4591001 1054 10541061	16-55	27AUG2020	69993	Placebo	27AUG2020/ Placebo	28SEP2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	20JAN2021/ BNT162b2 (30 µg)
10541064	C4591001 1054 10541064	16-55	27AUG2020	69994	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)			

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10541065	C4591001 1054 10541065	16-55	27AUG2020	69996	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
10541066	C4591001 1054 10541066	16-55	28AUG2020	71998	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
10541067	C4591001 1054 10541067	16-55	28AUG2020	71999	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
10541068	C4591001 1054 10541068	16-55	28AUG2020	72001	Placebo	28AUG2020/ Placebo	23SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10541069	C4591001 1054 10541069	16-55	28AUG2020	72004	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
10541070	C4591001 1054 10541070	16-55	28AUG2020	72197	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
10541073	C4591001 1054 10541073	16-55	28AUG2020	72204	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10541074	C4591001 1054 10541074	16-55	28AUG2020	72198	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo		
10541076	C4591001 1054 10541076	16-55	31AUG2020	72207	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10541078	C4591001 1054 10541078	16-55	31AUG2020	75116	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10541080	C4591001 1054 10541080	16-55	31AUG2020	75114	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10541081	C4591001 1054 10541081	16-55	31AUG2020	75117	Placebo	31AUG2020/ Placebo	02OCT2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10541084	C4591001 1054 10541084	16-55	31AUG2020	75557	Placebo	31AUG2020/ Placebo	22SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
10541085	C4591001 1054 10541085	16-55	31AUG2020	75122	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	24DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
10541086	C4591001 1054 10541086	16-55	31AUG2020	75561	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
10541087	C4591001 1054 10541087	16-55	01SEP2020	75566	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10541088	C4591001 1054 10541088	16-55	01SEP2020	75568	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10541089	C4591001 1054 10541089	16-55	01SEP2020	76785	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10541090	C4591001 1054 10541090	16-55	01SEP2020	76786	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10541091	C4591001 1054 10541091	16-55	01SEP2020	76788	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10541092	C4591001 1054 10541092	16-55	01SEP2020	76791	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
10541094	C4591001 1054 10541094	16-55	02SEP2020	77386	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
10541096	C4591001 1054 10541096	16-55	02SEP2020	77389	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10541097	C4591001 1054 10541097	16-55	02SEP2020	77391	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10541098	C4591001 1054 10541098	16-55	02SEP2020	78666	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10541100	C4591001 1054 10541100	16-55	02SEP2020	78669	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
10541101	C4591001 1054 10541101	16-55	02SEP2020	78671	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10541104	C4591001 1054 10541104	16-55	03SEP2020	78672	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10541106	C4591001 1054 10541106	16-55	03SEP2020	79939	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10541107	C4591001 1054 10541107	16-55	03SEP2020	79941	Placebo	03SEP2020/ Placebo	05OCT2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10541108	C4591001 1054 10541108	16-55	03SEP2020	79946	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10541109	C4591001 1054 10541109	16-55	03SEP2020	80563	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
10541110	C4591001 1054 10541110	16-55	03SEP2020	80567	Placebo	03SEP2020/ Placebo	25SEP2020/ Placebo		
10541111	C4591001 1054 10541111	16-55	03SEP2020	80570	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10541113	C4591001 1054 10541113	16-55	03SEP2020	80571	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10541115	C4591001 1054 10541115	16-55	04SEP2020	81608	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
10541119	C4591001 1054 10541119	16-55	04SEP2020	81610	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
10541120	C4591001 1054 10541120	16-55	04SEP2020	81611	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
10541121	C4591001 1054 10541121	16-55	04SEP2020	81614	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
10541122	C4591001 1054 10541122	16-55	08SEP2020	83657	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10541123	C4591001 1054 10541123	16-55	08SEP2020	83659	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
10541125	C4591001 1054 10541125	16-55	08SEP2020	83660	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
10541130	C4591001 1054 10541130	16-55	09SEP2020	83663	Placebo	09SEP2020/ Placebo	29SEP2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	
10541131	C4591001 1054 10541131	16-55	09SEP2020	85293	Placebo	09SEP2020/ Placebo	29SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10541135	C4591001 1054 10541135	16-55	09SEP2020	85294	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
10541137	C4591001 1054 10541137	16-55	10SEP2020	85295	Placebo	10SEP2020/ Placebo	30SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10541138	C4591001 1054 10541138	16-55	10SEP2020	85298	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)			
10541140	C4591001 1054 10541140	16-55	10SEP2020	87234	Placebo	10SEP2020/ Placebo	30SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10541141	C4591001 1054 10541141	16-55	10SEP2020	87235	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10541144	C4591001 1054 10541144	16-55	11SEP2020	87238	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10541145	C4591001 1054 10541145	16-55	11SEP2020	87244	Placebo	11SEP2020/ Placebo	01OCT2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
10541148	C4591001 1054 10541148	16-55	11SEP2020	88506	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
10541150	C4591001 1054 10541150	16-55	14SEP2020	88510	Placebo	14SEP2020/ Placebo			
10541152	C4591001 1054 10541152	16-55	14SEP2020	88513	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
10541153	C4591001 1054 10541153	16-55	15SEP2020	88516	Placebo	15SEP2020/ Placebo	06OCT2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
10541154	C4591001 1054 10541154	16-55	15SEP2020	90414	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
10541155	C4591001 1054 10541155	16-55	15SEP2020	90415	Placebo	15SEP2020/ Placebo	06OCT2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10541157	C4591001 1054 10541157	16-55	15SEP2020	90423	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
10541158	C4591001 1054 10541158	16-55	15SEP2020	90424	Placebo	15SEP2020/ Placebo	06OCT2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
10541160	C4591001 1054 10541160	16-55	16SEP2020	91158	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10541161	C4591001 1054 10541161	16-55	16SEP2020	91161	Placebo	16SEP2020/ Placebo	07OCT2020/ Placebo		
10541165	C4591001 1054 10541165	16-55	17SEP2020	91164	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
10541170	C4591001 1054 10541170	16-55	18SEP2020	91168	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
10541171	C4591001 1054 10541171	16-55	18SEP2020	93762	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10541174	C4591001 1054 10541174	16-55	18SEP2020	93766	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
10541176	C4591001 1054 10541176	16-55	21SEP2020	93770	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
10541178	C4591001 1054 10541178	16-55	22SEP2020	93771	Placebo	22SEP2020/ Placebo	13OCT2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
10541179	C4591001 1054 10541179	16-55	22SEP2020	96751	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
10541182	C4591001 1054 10541182	16-55	23SEP2020	96752	Placebo	23SEP2020/ Placebo	15OCT2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
10541184	C4591001 1054 10541184	16-55	23SEP2020	96758	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10541190	C4591001 1054 10541190	16-55	12OCT2020	106543	Placebo	12OCT2020/ Placebo	04NOV2020/ Placebo		
10541191	C4591001 1054 10541191	16-55	13OCT2020	106544	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
10541192	C4591001 1054 10541192	16-55	13OCT2020	106548	Placebo	13OCT2020/ Placebo	20NOV2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10541193	C4591001 1054 10541193	16-55	14OCT2020	106550	BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
10541197	C4591001 1054 10541197	16-55	19OCT2020	110408	Placebo	19OCT2020/ Placebo	09NOV2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10541200	C4591001 1054 10541200	16-55	22OCT2020	110411	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
10541201	C4591001 1054 10541201	16-55	22OCT2020	110412	Placebo	22OCT2020/ Placebo	20NOV2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
10541203	C4591001 1054 10541203	16-55	23OCT2020	110415	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
10541204	C4591001 1054 10541204†	16-55	26OCT2020	113637	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	03DEC2020/ BNT162b2 (30 µg)		
10541206	C4591001 1054 10541206	16-55	26OCT2020	113743	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10541207	C4591001 1054 10541207	16-55	27OCT2020	113745	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
10541208	C4591001 1054 10541208	16-55	28OCT2020	113750	Placebo	28OCT2020/ Placebo	23NOV2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
10541212	C4591001 1054 10541212†	16-55	29OCT2020	113751	Placebo	29OCT2020/ Placebo	17NOV2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
10541214	C4591001 1054 10541214	16-55	29OCT2020	114749	Placebo	29OCT2020/ Placebo	17NOV2020/ Placebo		
10541215	C4591001 1054 10541215	16-55	29OCT2020	114750	Placebo	29OCT2020/ Placebo	17NOV2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
10551050	C4591001 1055 10551050	16-55	17AUG2020	49616	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10551051	C4591001 1055 10551051	16-55	17AUG2020	49617	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10551054	C4591001 1055 10551054	16-55	17AUG2020	49620	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)
10551056	C4591001 1055 10551056	16-55	17AUG2020	53153	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10551057	C4591001 1055 10551057	16-55	17AUG2020	53157	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10551058	C4591001 1055 10551058	16-55	17AUG2020	53162	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10551061	C4591001 1055 10551061	16-55	18AUG2020	53164	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
10551063	C4591001 1055 10551063	16-55	18AUG2020	55051	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
10551067	C4591001 1055 10551067	16-55	18AUG2020	55055	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10551071	C4591001 1055 10551071	16-55	19AUG2020	55056	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10551072	C4591001 1055 10551072	16-55	19AUG2020	55060	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
10551073	C4591001 1055 10551073	16-55	19AUG2020	56970	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
10551074	C4591001 1055 10551074	16-55	19AUG2020	56974	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
10551075	C4591001 1055 10551075	16-55	19AUG2020	56976	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10551076	C4591001 1055 10551076	16-55	19AUG2020	56979	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10551077	C4591001 1055 10551077	16-55	19AUG2020	57509	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10551078	C4591001 1055 10551078	16-55	19AUG2020	57511	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
10551080	C4591001 1055 10551080	16-55	20AUG2020	57518	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10551082	C4591001 1055 10551082	16-55	20AUG2020	57520	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
10551084	C4591001 1055 10551084	16-55	20AUG2020	59409	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10551085	C4591001 1055 10551085	16-55	20AUG2020	59413	Placebo	20AUG2020/ Placebo	09SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
10551086	C4591001 1055 10551086	16-55	20AUG2020	59415	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10551087	C4591001 1055 10551087	16-55	21AUG2020	59416	Placebo	21AUG2020/ Placebo	10SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
10551089	C4591001 1055 10551089	16-55	21AUG2020	61278	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10551090	C4591001 1055 10551090	16-55	24AUG2020	61279	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10551092	C4591001 1055 10551092	16-55	24AUG2020	61282	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10551097	C4591001 1055 10551097	16-55	24AUG2020	61284	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	22JAN2021/ BNT162b2 (30 µg)
10551099	C4591001 1055 10551099	16-55	24AUG2020	64697	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
10551103	C4591001 1055 10551103	16-55	25AUG2020	64702	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10551104	C4591001 1055 10551104	16-55	25AUG2020	64703	Placebo	25AUG2020/ Placebo	16SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10551105	C4591001 1055 10551105	16-55	25AUG2020	64707	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10551115	C4591001 1055 10551115	16-55	26AUG2020	68226	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10551116	C4591001 1055 10551116	16-55	26AUG2020	68227	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10551117	C4591001 1055 10551117	16-55	26AUG2020	68229	Placebo	26AUG2020/ Placebo	22SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10551118	C4591001 1055 10551118	16-55	26AUG2020	68235	Placebo	26AUG2020/ Placebo	15SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10551121	C4591001 1055 10551121	16-55	26AUG2020	69055	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
10551125	C4591001 1055 10551125	16-55	27AUG2020	69058	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
10551128	C4591001 1055 10551128	16-55	27AUG2020	69060	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10551131	C4591001 1055 10551131	16-55	27AUG2020	69063	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
10551133	C4591001 1055 10551133	16-55	27AUG2020	71302	Placebo	27AUG2020/ Placebo	18SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
10551134	C4591001 1055 10551134	16-55	27AUG2020	71305	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10551135	C4591001 1055 10551135	16-55	28AUG2020	71306	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
10551136	C4591001 1055 10551136	16-55	28AUG2020	71308	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10551138	C4591001 1055 10551138	16-55	28AUG2020	72365	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)
10551139	C4591001 1055 10551139	16-55	28AUG2020	72367	Placebo	28AUG2020/ Placebo	17SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10551143	C4591001 1055 10551143	16-55	28AUG2020	72373	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
10551144	C4591001 1055 10551144	16-55	28AUG2020	72372	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
10551145	C4591001 1055 10551145	16-55	28AUG2020	73002	Placebo	28AUG2020/ Placebo			
10551146	C4591001 1055 10551146	16-55	28AUG2020	73004	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10551151	C4591001 1055 10551151	16-55	31AUG2020	73006	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10551152	C4591001 1055 10551152	16-55	31AUG2020	73011	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	
10551157	C4591001 1055 10551157	16-55	01SEP2020	76985	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
10551161	C4591001 1055 10551161	16-55	01SEP2020	76986	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10551162	C4591001 1055 10551162	16-55	01SEP2020	76991	Placebo	01SEP2020/ Placebo	24SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10551165	C4591001 1055 10551165	16-55	02SEP2020	76992	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10551168	C4591001 1055 10551168	16-55	02SEP2020	78858	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10551169	C4591001 1055 10551169	16-55	02SEP2020	78857	Placebo	02SEP2020/ Placebo	24SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
10551171	C4591001 1055 10551171	16-55	02SEP2020	78859	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10551173	C4591001 1055 10551173	16-55	03SEP2020	78861	Placebo	03SEP2020/ Placebo	23SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
10551174	C4591001 1055 10551174	16-55	03SEP2020	80226	Placebo	03SEP2020/ Placebo	25SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
10551175	C4591001 1055 10551175	16-55	03SEP2020	80231	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10551176	C4591001 1055 10551176	16-55	03SEP2020	80233	Placebo	03SEP2020/ Placebo	23SEP2020/ Placebo		
10551177	C4591001 1055 10551177	16-55	03SEP2020	80236	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10551179	C4591001 1055 10551179	16-55	03SEP2020	80805	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10551181	C4591001 1055 10551181	16-55	03SEP2020	80807	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10551184	C4591001 1055 10551184	16-55	03SEP2020	80808	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10551186	C4591001 1055 10551186	16-55	04SEP2020	80810	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
10551190	C4591001 1055 10551190	16-55	04SEP2020	82172	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
10551193	C4591001 1055 10551193	16-55	04SEP2020	82173	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
10551195	C4591001 1055 10551195	16-55	04SEP2020	82176	Placebo	04SEP2020/ Placebo	23SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
10551198	C4591001 1055 10551198	16-55	08SEP2020	82179	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
10551200	C4591001 1055 10551200	16-55	08SEP2020	84618	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
10551202	C4591001 1055 10551202	16-55	09SEP2020	84623	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	20JAN2021/ BNT162b2 (30 µg)
10551203	C4591001 1055 10551203	16-55	09SEP2020	84625	Placebo	09SEP2020/ Placebo	01OCT2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
10551204	C4591001 1055 10551204	16-55	09SEP2020	84627	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10551206	C4591001 1055 10551206	16-55	09SEP2020	85901	Placebo	09SEP2020/ Placebo	28SEP2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
10551207	C4591001 1055 10551207	16-55	09SEP2020	85906	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
10551208	C4591001 1055 10551208	16-55	09SEP2020	85907	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
10551211	C4591001 1055 10551211	16-55	10SEP2020	85912	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
10551215	C4591001 1055 10551215	16-55	10SEP2020	87558	Placebo	10SEP2020/ Placebo	29SEP2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)
10551219	C4591001 1055 10551219	16-55	11SEP2020	87562	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
10551220	C4591001 1055 10551220	16-55	11SEP2020	87564	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
10551221	C4591001 1055 10551221	16-55	11SEP2020	87566	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
10551222	C4591001 1055 10551222	16-55	11SEP2020	88589	Placebo	11SEP2020/ Placebo	30SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10551223	C4591001 1055 10551223	16-55	11SEP2020	88591	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10551224	C4591001 1055 10551224	16-55	11SEP2020	88594	Placebo	11SEP2020/ Placebo	30SEP2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)
10551225	C4591001 1055 10551225	16-55	11SEP2020	88598	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10551226	C4591001 1055 10551226	16-55	11SEP2020	88855	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	20JAN2021/ BNT162b2 (30 µg)
10551228	C4591001 1055 10551228	16-55	14SEP2020	88856	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
10551229	C4591001 1055 10551229	16-55	14SEP2020	88858	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
10551230	C4591001 1055 10551230	16-55	14SEP2020	88861	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
10551231	C4591001 1055 10551231	16-55	15SEP2020	90450	Placebo	15SEP2020/ Placebo	06OCT2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
10551232	C4591001 1055 10551232	16-55	15SEP2020	90452	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
10551233	C4591001 1055 10551233	16-55	15SEP2020	90455	Placebo	15SEP2020/ Placebo	08OCT2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
10551234	C4591001 1055 10551234	16-55	15SEP2020	90456	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10551235	C4591001 1055 10551235	16-55	15SEP2020	90749	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
10551237	C4591001 1055 10551237	16-55	16SEP2020	90753	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
10551238	C4591001 1055 10551238	16-55	17SEP2020	90754	Placebo	17SEP2020/ Placebo	07OCT2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
10551239	C4591001 1055 10551239	16-55	17SEP2020	90760	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
10551240	C4591001 1055 10551240	16-55	17SEP2020	92744	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
10551243	C4591001 1055 10551243	16-55	24SEP2020	92745	Placebo	24SEP2020/ Placebo	15OCT2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10551244	C4591001 1055 10551244	16-55	19OCT2020	92748	Placebo	19OCT2020/ Placebo	11NOV2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10551245	C4591001 1055 10551245	16-55	21OCT2020	92750	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
10551246	C4591001 1055 10551246	16-55	21OCT2020	111749	Placebo	21OCT2020/ Placebo	11NOV2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
10551247	C4591001 1055 10551247	16-55	21OCT2020	111750	Placebo	21OCT2020/ Placebo	11NOV2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10551249	C4591001 1055 10551249	16-55	21OCT2020	111755	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
10561001	C4591001 1056 10561001	16-55	19AUG2020	57139	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10561002	C4591001 1056 10561002	16-55	19AUG2020	57141	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10561003	C4591001 1056 10561003	16-55	19AUG2020	57143	Placebo	19AUG2020/ Placebo	08SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10561004	C4591001 1056 10561004	16-55	19AUG2020	57145	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
10561006	C4591001 1056 10561006	16-55	20AUG2020	58629	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10561007	C4591001 1056 10561007	16-55	20AUG2020	58632	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10561009	C4591001 1056 10561009	16-55	20AUG2020	58634	Placebo	20AUG2020/ Placebo	08SEP2020/ Placebo		
10561010	C4591001 1056 10561010	16-55	20AUG2020	58636	Placebo	20AUG2020/ Placebo	08SEP2020/ Placebo		
10561016	C4591001 1056 10561016	16-55	21AUG2020	60588	Placebo	21AUG2020/ Placebo	09SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10561019	C4591001 1056 10561019	16-55	22AUG2020	62107	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
10561020	C4591001 1056 10561020	16-55	22AUG2020	60591	Placebo	22AUG2020/ Placebo	10SEP2020/ Placebo		
10561021	C4591001 1056 10561021	16-55	22AUG2020	60592	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10561022	C4591001 1056 10561022	16-55	22AUG2020	62110	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
10561025	C4591001 1056 10561025	16-55	22AUG2020	62112	Placebo	22AUG2020/ Placebo	10SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
10561026	C4591001 1056 10561026	16-55	22AUG2020	62116	Placebo	22AUG2020/ Placebo	10SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
10561027	C4591001 1056 10561027	16-55	22AUG2020	62310	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)			
10561028	C4591001 1056 10561028	16-55	24AUG2020	62316	Placebo	24AUG2020/ Placebo	21SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10561029	C4591001 1056 10561029	16-55	24AUG2020	62319	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10561031	C4591001 1056 10561031	16-55	24AUG2020	62320	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10561039	C4591001 1056 10561039	16-55	25AUG2020	65347	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10561041	C4591001 1056 10561041	16-55	25AUG2020	65351	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10561042	C4591001 1056 10561042	16-55	25AUG2020	65353	Placebo	25AUG2020/ Placebo	17SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
10561046	C4591001 1056 10561046	16-55	25AUG2020	65355	Placebo	25AUG2020/ Placebo	14SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
10561050	C4591001 1056 10561050	16-55	26AUG2020	67985	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo		
10561053	C4591001 1056 10561053	16-55	27AUG2020	67986	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
10561058	C4591001 1056 10561058	16-55	27AUG2020	67990	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10561059	C4591001 1056 10561059	16-55	27AUG2020	67994	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10561060	C4591001 1056 10561060	16-55	27AUG2020	70723	Placebo	27AUG2020/ Placebo	02OCT2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
10561061	C4591001 1056 10561061	16-55	27AUG2020	70724	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10561065	C4591001 1056 10561065	16-55	27AUG2020	70725	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10561069	C4591001 1056 10561069	16-55	28AUG2020	70729	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
10561071	C4591001 1056 10561071	16-55	28AUG2020	71826	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
10561072	C4591001 1056 10561072	16-55	28AUG2020	71829	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
10561073	C4591001 1056 10561073	16-55	28AUG2020	71831	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10561076	C4591001 1056 10561076	16-55	28AUG2020	71834	Placebo	28AUG2020/ Placebo	17SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
10561077	C4591001 1056 10561077	16-55	28AUG2020	72678	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10561081	C4591001 1056 10561081	16-55	28AUG2020	72683	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
10561082	C4591001 1056 10561082	16-55	28AUG2020	72687	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10561087	C4591001 1056 10561087	16-55	29AUG2020	73555	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10561088	C4591001 1056 10561088	16-55	29AUG2020	73559	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10561089	C4591001 1056 10561089	16-55	29AUG2020	73562	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10561090	C4591001 1056 10561090	16-55	29AUG2020	73783	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo		
10561092	C4591001 1056 10561092	16-55	29AUG2020	73564	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo		
10561097	C4591001 1056 10561097	16-55	31AUG2020	73789	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		
10561098	C4591001 1056 10561098	16-55	31AUG2020	73790	Placebo	31AUG2020/ Placebo	18SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
10561100	C4591001 1056 10561100	16-55	31AUG2020	73791	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
10561102	C4591001 1056 10561102	16-55	31AUG2020	75609	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo		
10561103	C4591001 1056 10561103	16-55	31AUG2020	75610	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10561108	C4591001 1056 10561108	16-55	01SEP2020	75615	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10561110	C4591001 1056 10561110	16-55	01SEP2020	76494	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
10561111	C4591001 1056 10561111	16-55	01SEP2020	76498	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10561112	C4591001 1056 10561112	16-55	01SEP2020	76503	Placebo	01SEP2020/ Placebo	21SEP2020/ Placebo		
10561113	C4591001 1056 10561113	16-55	01SEP2020	76504	Placebo	01SEP2020/ Placebo	21SEP2020/ Placebo		
10561115	C4591001 1056 10561115	16-55	01SEP2020	76637	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo		
10561116	C4591001 1056 10561116	16-55	01SEP2020	76638	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10561118	C4591001 1056 10561118	16-55	01SEP2020	76640	Placebo	01SEP2020/ Placebo	23SEP2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
10561119	C4591001 1056 10561119	16-55	01SEP2020	76642	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10561121	C4591001 1056 10561121	16-55	01SEP2020	77249	Placebo	01SEP2020/ Placebo	21SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10561126	C4591001 1056 10561126	16-55	02SEP2020	78102	Placebo	02SEP2020/ Placebo	21SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10561129	C4591001 1056 10561129	16-55	02SEP2020	78106	Placebo	02SEP2020/ Placebo			

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10561130	C4591001 1056 10561130	16-55	02SEP2020	78107	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10561131	C4591001 1056 10561131	16-55	02SEP2020	78109	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10561132	C4591001 1056 10561132	16-55	02SEP2020	78836	Placebo	02SEP2020/ Placebo	21SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10561135	C4591001 1056 10561135	16-55	03SEP2020	78837	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo		
10561145	C4591001 1056 10561145	16-55	03SEP2020	78841	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10561146	C4591001 1056 10561146	16-55	03SEP2020	78844	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		
10561147	C4591001 1056 10561147	16-55	03SEP2020	80442	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
10561149	C4591001 1056 10561149	16-55	03SEP2020	80444	Placebo	03SEP2020/ Placebo	22SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10561152	C4591001 1056 10561152	16-55	03SEP2020	80890	Placebo	03SEP2020/ Placebo			
10561153	C4591001 1056 10561153	16-55	03SEP2020	80895	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10561154	C4591001 1056 10561154	16-55	03SEP2020	81069	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10561155	C4591001 1056 10561155	16-55	03SEP2020	80449	Placebo	03SEP2020/ Placebo	22SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
10561156	C4591001 1056 10561156	16-55	03SEP2020	80452	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10561157	C4591001 1056 10561157	16-55	03SEP2020	80886	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10561158	C4591001 1056 10561158	16-55	03SEP2020	80889	Placebo	03SEP2020/ Placebo	22SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10561160	C4591001 1056 10561160	16-55	04SEP2020	81070	Placebo	04SEP2020/ Placebo	23SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10561161	C4591001 1056 10561161	16-55	04SEP2020	81074	Placebo	04SEP2020/ Placebo	23SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10561165	C4591001 1056 10561165	16-55	04SEP2020	81076	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10561169	C4591001 1056 10561169	16-55	04SEP2020	82182	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10561170	C4591001 1056 10561170	16-55	04SEP2020	82183	Placebo	04SEP2020/ Placebo	23SEP2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10561171	C4591001 1056 10561171	16-55	04SEP2020	82188	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10561172	C4591001 1056 10561172	16-55	04SEP2020	82191	Placebo	04SEP2020/ Placebo	23SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10561173	C4591001 1056 10561173	16-55	04SEP2020	82351	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
10561174	C4591001 1056 10561174	16-55	04SEP2020	82352	Placebo	04SEP2020/ Placebo	30SEP2020/ Placebo		
10561177	C4591001 1056 10561177	16-55	08SEP2020	82354	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
10561178	C4591001 1056 10561178	16-55	08SEP2020	82356	Placebo	08SEP2020/ Placebo	30SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
10561182	C4591001 1056 10561182	16-55	08SEP2020	84389	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10561185	C4591001 1056 10561185	16-55	08SEP2020	84395	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
10561186	C4591001 1056 10561186	16-55	09SEP2020	84396	Placebo	09SEP2020/ Placebo	28SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10561187	C4591001 1056 10561187	16-55	09SEP2020	84400	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10561188	C4591001 1056 10561188	16-55	09SEP2020	85051	Placebo	09SEP2020/ Placebo	28SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10561189	C4591001 1056 10561189	16-55	09SEP2020	85052	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
10561190	C4591001 1056 10561190	16-55	09SEP2020	85055	Placebo	09SEP2020/ Placebo	01OCT2020/ Placebo		
10561191	C4591001 1056 10561191	16-55	09SEP2020	85059	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
10561192	C4591001 1056 10561192	16-55	09SEP2020	85281	Placebo	09SEP2020/ Placebo	25SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10561193	C4591001 1056 10561193	16-55	09SEP2020	85282	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
10561194	C4591001 1056 10561194	16-55	09SEP2020	85284	Placebo	09SEP2020/ Placebo	25SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10561195	C4591001 1056 10561195	16-55	09SEP2020	85287	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
10561196	C4591001 1056 10561196	16-55	09SEP2020	85493	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
10561197	C4591001 1056 10561197	16-55	09SEP2020	85500	Placebo	09SEP2020/ Placebo	28SEP2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10561203	C4591001 1056 10561203	16-55	09SEP2020	85501	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10561205	C4591001 1056 10561205	16-55	09SEP2020	86012	Placebo	09SEP2020/ Placebo	29SEP2020/ Placebo		
10561206	C4591001 1056 10561206	16-55	09SEP2020	85502	Placebo	09SEP2020/ Placebo	29SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10561208	C4591001 1056 10561208	16-55	10SEP2020	86013	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
10561210	C4591001 1056 10561210	16-55	10SEP2020	86015	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
10561212	C4591001 1056 10561212	16-55	10SEP2020	86017	Placebo	10SEP2020/ Placebo	29SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10561213	C4591001 1056 10561213	16-55	10SEP2020	86915	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10561214	C4591001 1056 10561214	16-55	10SEP2020	86916	Placebo	10SEP2020/ Placebo	29SEP2020/ Placebo		
10561215	C4591001 1056 10561215	16-55	10SEP2020	86918	Placebo	10SEP2020/ Placebo	29SEP2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10561217	C4591001 1056 10561217	16-55	11SEP2020	86920	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10561218	C4591001 1056 10561218	16-55	11SEP2020	88253	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10561219	C4591001 1056 10561219	16-55	11SEP2020	88259	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10561226	C4591001 1056 10561226	16-55	11SEP2020	88261	Placebo	11SEP2020/ Placebo	28SEP2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
10561227	C4591001 1056 10561227	16-55	14SEP2020	88262	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10561228	C4591001 1056 10561228	16-55	14SEP2020	89429	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10561230	C4591001 1056 10561230	16-55	14SEP2020	89431	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
10561233	C4591001 1056 10561233	16-55	14SEP2020	89434	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
10561234	C4591001 1056 10561234	16-55	14SEP2020	89437	Placebo	14SEP2020/ Placebo	09OCT2020/ Placebo		
10561235	C4591001 1056 10561235	16-55	14SEP2020	89994	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
10561240	C4591001 1056 10561240	16-55	15SEP2020	89997	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10561241	C4591001 1056 10561241	16-55	15SEP2020	90001	Placebo	15SEP2020/ Placebo	08OCT2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10561243	C4591001 1056 10561243	16-55	15SEP2020	90002	Placebo	15SEP2020/ Placebo	08OCT2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	
10561244	C4591001 1056 10561244	16-55	15SEP2020	90475	Placebo	15SEP2020/ Placebo	08OCT2020/ Placebo		
10561245	C4591001 1056 10561245	16-55	15SEP2020	90480	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
10561246	C4591001 1056 10561246	16-55	15SEP2020	90482	Placebo	15SEP2020/ Placebo	06OCT2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10561251	C4591001 1056 10561251	16-55	16SEP2020	90483	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
10561252	C4591001 1056 10561252	16-55	16SEP2020	91241	Placebo	16SEP2020/ Placebo	05OCT2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10561253	C4591001 1056 10561253	16-55	16SEP2020	91243	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
10561255	C4591001 1056 10561255	16-55	16SEP2020	91250	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
10561256	C4591001 1056 10561256	16-55	16SEP2020	91248	Placebo	16SEP2020/ Placebo	05OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10561262	C4591001 1056 10561262	16-55	16SEP2020	91769	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
10561263	C4591001 1056 10561263	16-55	16SEP2020	91770	Placebo	16SEP2020/ Placebo	05OCT2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10561264	C4591001 1056 10561264	16-55	16SEP2020	91775	Placebo	16SEP2020/ Placebo	07OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
10561268	C4591001 1056 10561268	16-55	17SEP2020	91777	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
10561271	C4591001 1056 10561271	16-55	17SEP2020	92405	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
10561272	C4591001 1056 10561272	16-55	17SEP2020	92407	Placebo	17SEP2020/ Placebo	06OCT2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
10561273	C4591001 1056 10561273	16-55	17SEP2020	92412	Placebo	17SEP2020/ Placebo	06OCT2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10561274	C4591001 1056 10561274	16-55	17SEP2020	92414	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
10561277	C4591001 1056 10561277	16-55	18SEP2020	93455	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
10561278	C4591001 1056 10561278	16-55	18SEP2020	93456	Placebo	18SEP2020/ Placebo	07OCT2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10561282	C4591001 1056 10561282	16-55	18SEP2020	93457	Placebo	18SEP2020/ Placebo	07OCT2020/ Placebo		
10561284	C4591001 1056 10561284	16-55	18SEP2020	93460	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
10561286	C4591001 1056 10561286	16-55	18SEP2020	93835	Placebo	18SEP2020/ Placebo	07OCT2020/ Placebo		
10561288	C4591001 1056 10561288	16-55	18SEP2020	93839	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
10561289	C4591001 1056 10561289	16-55	18SEP2020	93840	Placebo	18SEP2020/ Placebo	07OCT2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10561290	C4591001 1056 10561290	16-55	18SEP2020	93842	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
10561291	C4591001 1056 10561291	16-55	18SEP2020	93941	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
10561292	C4591001 1056 10561292	16-55	18SEP2020	93942	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo		
10561293	C4591001 1056 10561293	16-55	18SEP2020	93950	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)			
10561295	C4591001 1056 10561295	16-55	18SEP2020	93951	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo		
10561299	C4591001 1056 10561299	16-55	18SEP2020	94244	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10561300	C4591001 1056 10561300	16-55	21SEP2020	94247	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
10561304	C4591001 1056 10561304	16-55	21SEP2020	94249	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
10561307	C4591001 1056 10561307	16-55	21SEP2020	94250	Placebo	21SEP2020/ Placebo	27OCT2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10561308	C4591001 1056 10561308	16-55	21SEP2020	95058	Placebo	21SEP2020/ Placebo	15OCT2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10561309	C4591001 1056 10561309	16-55	21SEP2020	95059	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
10561312	C4591001 1056 10561312	16-55	21SEP2020	95061	Placebo	21SEP2020/ Placebo	13OCT2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
10561313	C4591001 1056 10561313	16-55	22SEP2020	95066	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
10561314	C4591001 1056 10561314	16-55	22SEP2020	96475	Placebo	22SEP2020/ Placebo	16OCT2020/ Placebo		
10561315	C4591001 1056 10561315	16-55	22SEP2020	96477	Placebo	22SEP2020/ Placebo	12OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10561316	C4591001 1056 10561316	16-55	22SEP2020	96480	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10561317	C4591001 1056 10561317	16-55	22SEP2020	96483	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
10561319	C4591001 1056 10561319	16-55	22SEP2020	96968	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
10561320	C4591001 1056 10561320	16-55	22SEP2020	96972	Placebo	22SEP2020/ Placebo	09OCT2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
10561321	C4591001 1056 10561321	16-55	22SEP2020	96973	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
10561322	C4591001 1056 10561322	16-55	23SEP2020	96974	Placebo	23SEP2020/ Placebo	12OCT2020/ Placebo		
10561325	C4591001 1056 10561325	16-55	23SEP2020	97817	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
10561327	C4591001 1056 10561327	16-55	24SEP2020	97825	Placebo	24SEP2020/ Placebo	13OCT2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10561330	C4591001 1056 10561330	16-55	24SEP2020	97826	Placebo	24SEP2020/ Placebo	13OCT2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
10561331	C4591001 1056 10561331	16-55	24SEP2020	97827	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
10561332	C4591001 1056 10561332	16-55	24SEP2020	98706	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10561333	C4591001 1056 10561333	16-55	24SEP2020	98707	Placebo	24SEP2020/ Placebo	28OCT2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	
10561335	C4591001 1056 10561335	16-55	24SEP2020	98709	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
10561336	C4591001 1056 10561336	16-55	24SEP2020	98715	Placebo	24SEP2020/ Placebo	13OCT2020/ Placebo		
10561338	C4591001 1056 10561338	16-55	25SEP2020	99451	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
10561340	C4591001 1056 10561340	16-55	25SEP2020	99456	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
10561341	C4591001 1056 10561341	16-55	25SEP2020	99457	Placebo	25SEP2020/ Placebo	14OCT2020/ Placebo	03MAR2021/ BNT162b2 (30 µg)	
10561344	C4591001 1056 10561344	16-55	25SEP2020	99458	Placebo	25SEP2020/ Placebo	15OCT2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10561345	C4591001 1056 10561345	16-55	25SEP2020	100013	Placebo	25SEP2020/ Placebo	14OCT2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10561347	C4591001 1056 10561347	16-55	28SEP2020	100014	Placebo	28SEP2020/ Placebo	19OCT2020/ Placebo		
10561348	C4591001 1056 10561348	16-55	28SEP2020	100017	BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10561350	C4591001 1056 10561350	16-55	28SEP2020	100024	BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		
10561352	C4591001 1056 10561352	16-55	28SEP2020	101465	BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
10561354	C4591001 1056 10561354	16-55	28SEP2020	101466	Placebo	28SEP2020/ Placebo	16OCT2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10561358	C4591001 1056 10561358	16-55	28SEP2020	101468	Placebo	28SEP2020/ Placebo	29OCT2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10561359	C4591001 1056 10561359	16-55	29SEP2020	101814	Placebo	29SEP2020/ Placebo	19OCT2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10561360	C4591001 1056 10561360	16-55	29SEP2020	101470	BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)		
10561361	C4591001 1056 10561361	16-55	29SEP2020	101819	BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)			
10561363	C4591001 1056 10561363	16-55	29SEP2020	101823	BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)		
10561364	C4591001 1056 10561364	16-55	29SEP2020	101824	Placebo	29SEP2020/ Placebo	20OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
10561365	C4591001 1056 10561365	16-55	29SEP2020	101948	BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10561366	C4591001 1056 10561366	16-55	29SEP2020	101949	Placebo	29SEP2020/ Placebo	20OCT2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
10561367	C4591001 1056 10561367	16-55	29SEP2020	101952	BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		
10561369	C4591001 1056 10561369	16-55	30SEP2020	101954	Placebo	30SEP2020/ Placebo	19OCT2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10561372	C4591001 1056 10561372	16-55	30SEP2020	102329	Placebo	30SEP2020/ Placebo			
10561373	C4591001 1056 10561373	16-55	30SEP2020	102330	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)		
10561375	C4591001 1056 10561375	16-55	30SEP2020	102334	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)		
10561376	C4591001 1056 10561376	16-55	30SEP2020	102339	Placebo	30SEP2020/ Placebo	19OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
10561377	C4591001 1056 10561377	16-55	30SEP2020	102465	Placebo	30SEP2020/ Placebo	20OCT2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10561378	C4591001 1056 10561378	16-55	30SEP2020	102467	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)		
10561383	C4591001 1056 10561383	16-55	02OCT2020	102471	BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10561384	C4591001 1056 10561384	16-55	02OCT2020	102472	Placebo	02OCT2020/ Placebo	02DEC2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
10561385	C4591001 1056 10561385	16-55	02OCT2020	103266	Placebo	02OCT2020/ Placebo	21OCT2020/ Placebo		
10561386	C4591001 1056 10561386	16-55	02OCT2020	103267	Placebo	02OCT2020/ Placebo	21OCT2020/ Placebo		
10561388	C4591001 1056 10561388	16-55	02OCT2020	103272	BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		
10561391	C4591001 1056 10561391	16-55	02OCT2020	103274	BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)		
10561392	C4591001 1056 10561392	16-55	02OCT2020	103362	BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		
10561393	C4591001 1056 10561393	16-55	05OCT2020	103367	BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
10561394	C4591001 1056 10561394	16-55	05OCT2020	103369	Placebo	05OCT2020/ Placebo	03NOV2020/ Placebo		
10561395	C4591001 1056 10561395	16-55	05OCT2020	103372	Placebo	05OCT2020/ Placebo			
10561396	C4591001 1056 10561396	16-55	05OCT2020	103818	Placebo	05OCT2020/ Placebo	23OCT2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10561397	C4591001 1056 10561397	16-55	05OCT2020	103819	BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10561398	C4591001 1056 10561398	16-55	05OCT2020	103820	BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		
10561400	C4591001 1056 10561400	16-55	05OCT2020	103826	Placebo	05OCT2020/ Placebo	23OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
10561401	C4591001 1056 10561401	16-55	05OCT2020	103961	Placebo	05OCT2020/ Placebo	27OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
10561402	C4591001 1056 10561402	16-55	05OCT2020	103938	BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)		
10561403	C4591001 1056 10561403	16-55	05OCT2020	103939	Placebo	05OCT2020/ Placebo	23OCT2020/ Placebo		
10561405	C4591001 1056 10561405	16-55	05OCT2020	103947	BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
10561406	C4591001 1056 10561406	16-55	05OCT2020	103941	Placebo	05OCT2020/ Placebo	29OCT2020/ Placebo		
10561407	C4591001 1056 10561407	16-55	05OCT2020	103965	BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
10561408	C4591001 1056 10561408	16-55	06OCT2020	103970	BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
10561411	C4591001 1056 10561411	16-55	06OCT2020	103972	Placebo	06OCT2020/ Placebo	26OCT2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10561413	C4591001 1056 10561413	16-55	06OCT2020	104226	BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
10561414	C4591001 1056 10561414	16-55	06OCT2020	104231	Placebo	06OCT2020/ Placebo			
10561417	C4591001 1056 10561417	16-55	06OCT2020	104235	BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
10561419	C4591001 1056 10561419	16-55	06OCT2020	104236	Placebo	06OCT2020/ Placebo	26OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10561421	C4591001 1056 10561421	16-55	06OCT2020	104417	BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
10561422	C4591001 1056 10561422	16-55	06OCT2020	104419	BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
10561425	C4591001 1056 10561425	16-55	06OCT2020	104421	Placebo	06OCT2020/ Placebo	26OCT2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
10561427	C4591001 1056 10561427	16-55	07OCT2020	104426	Placebo	07OCT2020/ Placebo	26OCT2020/ Placebo		
10561432	C4591001 1056 10561432	16-55	07OCT2020	104792	Placebo	07OCT2020/ Placebo	26OCT2020/ Placebo		
10561434	C4591001 1056 10561434	16-55	07OCT2020	104797	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10561437	C4591001 1056 10561437	16-55	08OCT2020	104798	Placebo	08OCT2020/ Placebo	27OCT2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
10561440	C4591001 1056 10561440	16-55	08OCT2020	104800	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		
10561441	C4591001 1056 10561441	16-55	08OCT2020	105415	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		
10561442	C4591001 1056 10561442	16-55	08OCT2020	105417	Placebo	08OCT2020/ Placebo	27OCT2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
10561443	C4591001 1056 10561443	16-55	08OCT2020	105423	Placebo	08OCT2020/ Placebo	27OCT2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	
10561444	C4591001 1056 10561444	16-55	08OCT2020	105424	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		
10561445	C4591001 1056 10561445	16-55	08OCT2020	105450	Placebo	08OCT2020/ Placebo	27OCT2020/ Placebo		
10561448	C4591001 1056 10561448	16-55	08OCT2020	105452	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		
10561451	C4591001 1056 10561451	16-55	08OCT2020	105456	Placebo	08OCT2020/ Placebo	27OCT2020/ Placebo		
10561452	C4591001 1056 10561452	16-55	08OCT2020	105457	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)			



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10561453	C4591001 1056 10561453	16-55	09OCT2020	105857	Placebo	09OCT2020/ Placebo	28OCT2020/ Placebo		
10561456	C4591001 1056 10561456	16-55	09OCT2020	105859	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
10561466	C4591001 1056 10561466	16-55	09OCT2020	105865	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
10561467	C4591001 1056 10561467	16-55	09OCT2020	105868	Placebo	09OCT2020/ Placebo	05NOV2020/ Placebo		
10561468	C4591001 1056 10561468	16-55	09OCT2020	106169	Placebo	09OCT2020/ Placebo	03NOV2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
10561469	C4591001 1056 10561469	16-55	09OCT2020	106173	Placebo	09OCT2020/ Placebo	28OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
10561471	C4591001 1056 10561471	16-55	09OCT2020	106180	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
10561472	C4591001 1056 10561472	16-55	09OCT2020	106193	Placebo	09OCT2020/ Placebo	28OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
10561473	C4591001 1056 10561473	16-55	09OCT2020	106176	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)		
10561474	C4591001 1056 10561474	16-55	12OCT2020	106197	BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10561475	C4591001 1056 10561475	16-55	12OCT2020	106201	Placebo	12OCT2020/ Placebo	02NOV2020/ Placebo		
10561476	C4591001 1056 10561476	16-55	12OCT2020	106203	BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		
10561477	C4591001 1056 10561477	16-55	12OCT2020	106472	Placebo	12OCT2020/ Placebo	02NOV2020/ Placebo		
10561480	C4591001 1056 10561480	16-55	12OCT2020	106473	BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
10561482	C4591001 1056 10561482	16-55	12OCT2020	106475	Placebo	12OCT2020/ Placebo	04NOV2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
10561484	C4591001 1056 10561484	16-55	12OCT2020	106478	BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
10561488	C4591001 1056 10561488	16-55	12OCT2020	106601	Placebo	12OCT2020/ Placebo	02NOV2020/ Placebo		
10561489	C4591001 1056 10561489	16-55	12OCT2020	106602	Placebo	12OCT2020/ Placebo	02NOV2020/ Placebo	03MAR2021/ BNT162b2 (30 µg)	
10561490	C4591001 1056 10561490	16-55	12OCT2020	106607	BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		
10561491	C4591001 1056 10561491	16-55	12OCT2020	106610	BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10561493	C4591001 1056 10561493	16-55	12OCT2020	106663	Placebo	12OCT2020/ Placebo	03NOV2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
10561494	C4591001 1056 10561494	16-55	13OCT2020	106664	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		
10561495	C4591001 1056 10561495	16-55	13OCT2020	106667	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		
10561499	C4591001 1056 10561499	16-55	13OCT2020	107009	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		
10561503	C4591001 1056 10561503	16-55	13OCT2020	106668	Placebo	13OCT2020/ Placebo	02NOV2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
10561505	C4591001 1056 10561505	16-55	13OCT2020	107010	Placebo	13OCT2020/ Placebo	02NOV2020/ Placebo		
10561506	C4591001 1056 10561506	16-55	13OCT2020	107011	Placebo	13OCT2020/ Placebo	02NOV2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
10561507	C4591001 1056 10561507	16-55	13OCT2020	107020	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		
10561508	C4591001 1056 10561508	16-55	14OCT2020	107478	Placebo	14OCT2020/ Placebo	02NOV2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10561510	C4591001 1056 10561510	16-55	14OCT2020	107480	BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10561511	C4591001 1056 10561511	16-55	14OCT2020	107485	Placebo	14OCT2020/ Placebo	02NOV2020/ Placebo		
10561512	C4591001 1056 10561512	16-55	14OCT2020	107487	BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
10561513	C4591001 1056 10561513	16-55	14OCT2020	107684	BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
10561514	C4591001 1056 10561514	16-55	14OCT2020	107688	Placebo	14OCT2020/ Placebo	05NOV2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
10561516	C4591001 1056 10561516	16-55	14OCT2020	107691	BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)			
10561517	C4591001 1056 10561517	16-55	15OCT2020	107692	Placebo	15OCT2020/ Placebo	03NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
10561518	C4591001 1056 10561518	16-55	15OCT2020	108090	Placebo	15OCT2020/ Placebo	03NOV2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10561519	C4591001 1056 10561519	16-55	15OCT2020	108091	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
10561520	C4591001 1056 10561520	16-55	15OCT2020	108092	Placebo	15OCT2020/ Placebo	03NOV2020/ Placebo		
10561521	C4591001 1056 10561521	16-55	15OCT2020	108096	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10561525	C4591001 1056 10561525	16-55	16OCT2020	108989	Placebo	16OCT2020/ Placebo	09NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10561526	C4591001 1056 10561526	16-55	16OCT2020	108990	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
10561528	C4591001 1056 10561528	16-55	16OCT2020	108995	Placebo	16OCT2020/ Placebo	05NOV2020/ Placebo		
10561529	C4591001 1056 10561529	16-55	16OCT2020	108997	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
10561531	C4591001 1056 10561531	16-55	16OCT2020	109169	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
10561532	C4591001 1056 10561532	16-55	16OCT2020	109172	Placebo	16OCT2020/ Placebo	04NOV2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
10561533	C4591001 1056 10561533	16-55	16OCT2020	109174	Placebo	16OCT2020/ Placebo	04NOV2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
10561534	C4591001 1056 10561534	16-55	16OCT2020	109179	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
10561539	C4591001 1056 10561539	16-55	19OCT2020	110201	Placebo	19OCT2020/ Placebo	11NOV2020/ Placebo		
10561540	C4591001 1056 10561540	16-55	19OCT2020	110203	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10561541	C4591001 1056 10561541	16-55	19OCT2020	110204	Placebo	19OCT2020/ Placebo	09NOV2020/ Placebo		
10561542	C4591001 1056 10561542	16-55	19OCT2020	110212	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		
10561543	C4591001 1056 10561543	16-55	19OCT2020	110334	Placebo	19OCT2020/ Placebo	10NOV2020/ Placebo		
10561544	C4591001 1056 10561544	16-55	19OCT2020	110336	Placebo	19OCT2020/ Placebo	09NOV2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10561545	C4591001 1056 10561545	16-55	19OCT2020	110339	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		
10561547	C4591001 1056 10561547	16-55	19OCT2020	110344	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
10561548	C4591001 1056 10561548	16-55	20OCT2020	110770	Placebo	20OCT2020/ Placebo	09NOV2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10561549	C4591001 1056 10561549	16-55	20OCT2020	110772	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		
10561550	C4591001 1056 10561550	16-55	20OCT2020	110774	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)			
10561553	C4591001 1056 10561553	16-55	20OCT2020	110775	Placebo	20OCT2020/ Placebo	10NOV2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10561554	C4591001 1056 10561554	16-55	20OCT2020	110969	Placebo	20OCT2020/ Placebo			
10561555	C4591001 1056 10561555	16-55	20OCT2020	110972	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
10561558	C4591001 1056 10561558	16-55	20OCT2020	110980	Placebo	20OCT2020/ Placebo	10NOV2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10561559	C4591001 1056 10561559	16-55	20OCT2020	111189	Placebo	20OCT2020/ Placebo	13NOV2020/ Placebo		
10561560	C4591001 1056 10561560	16-55	20OCT2020	111190	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
10561562	C4591001 1056 10561562	16-55	21OCT2020	111192	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
10561563	C4591001 1056 10561563	16-55	21OCT2020	111196	Placebo	21OCT2020/ Placebo	09NOV2020/ Placebo		
10561564	C4591001 1056 10561564	16-55	21OCT2020	111692	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
10561565	C4591001 1056 10561565	16-55	21OCT2020	111693	Placebo	21OCT2020/ Placebo	09NOV2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10561566	C4591001 1056 10561566	16-55	21OCT2020	111697	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10561567	C4591001 1056 10561567	16-55	21OCT2020	111698	Placebo	21OCT2020/ Placebo	13NOV2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
10561569	C4591001 1056 10561569	16-55	21OCT2020	111833	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)			
10561570	C4591001 1056 10561570	16-55	21OCT2020	111835	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
10561572	C4591001 1056 10561572	16-55	22OCT2020	111837	Placebo	22OCT2020/ Placebo	13NOV2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	
10561575	C4591001 1056 10561575	16-55	22OCT2020	111843	Placebo	22OCT2020/ Placebo	10NOV2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10561576	C4591001 1056 10561576	16-55	22OCT2020	112362	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
10561579	C4591001 1056 10561579	16-55	22OCT2020	112363	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	09DEC2020/ BNT162b2 (30 µg)		
10561581	C4591001 1056 10561581	16-55	23OCT2020	112878	Placebo	23OCT2020/ Placebo	11NOV2020/ Placebo		
10561582	C4591001 1056 10561582	16-55	23OCT2020	112366	Placebo	23OCT2020/ Placebo	11NOV2020/ Placebo		
10561583	C4591001 1056 10561583	16-55	23OCT2020	112364	Placebo	23OCT2020/ Placebo	11NOV2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10561585	C4591001 1056 10561585	16-55	23OCT2020	112880	Placebo	23OCT2020/ Placebo	11NOV2020/ Placebo		
10561586	C4591001 1056 10561586	16-55	23OCT2020	112884	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
10561587	C4591001 1056 10561587	16-55	26OCT2020	112886	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
10561588	C4591001 1056 10561588	16-55	26OCT2020	113672	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
10561590	C4591001 1056 10561590	16-55	26OCT2020	113678	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
10561591	C4591001 1056 10561591	16-55	26OCT2020	113679	Placebo	26OCT2020/ Placebo			
10561592	C4591001 1056 10561592	16-55	26OCT2020	113680	Placebo	26OCT2020/ Placebo	30NOV2020/ Placebo		
10561593	C4591001 1056 10561593	16-55	26OCT2020	113682	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
10561594	C4591001 1056 10561594	16-55	26OCT2020	113683	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
10561595	C4591001 1056 10561595	16-55	26OCT2020	113691	Placebo	26OCT2020/ Placebo	16NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10561596	C4591001 1056 10561596	16-55	26OCT2020	113692	Placebo	26OCT2020/ Placebo	16NOV2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10561599	C4591001 1056 10561599	16-55	27OCT2020	114018	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
10561600	C4591001 1056 10561600	16-55	27OCT2020	114020	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
10561601	C4591001 1056 10561601	16-55	27OCT2020	114023	Placebo	27OCT2020/ Placebo	16NOV2020/ Placebo		
10561602	C4591001 1056 10561602	16-55	27OCT2020	114027	Placebo	27OCT2020/ Placebo	16NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
10561606	C4591001 1056 10561606	16-55	27OCT2020	114107	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
10561608	C4591001 1056 10561608	16-55	27OCT2020	114110	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)		
10561609	C4591001 1056 10561609	16-55	27OCT2020	114112	Placebo	27OCT2020/ Placebo	16NOV2020/ Placebo		
10561610	C4591001 1056 10561610	16-55	27OCT2020	114191	Placebo	27OCT2020/ Placebo	18NOV2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
10561611	C4591001 1056 10561611	16-55	27OCT2020	114194	Placebo	27OCT2020/ Placebo	16NOV2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
10561612	C4591001 1056 10561612	16-55	27OCT2020	114195	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10561613	C4591001 1056 10561613	16-55	27OCT2020	114196	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	20NOV2020/ BNT162b2 (30 µg)		
10561614	C4591001 1056 10561614	16-55	27OCT2020	114234	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
10561617	C4591001 1056 10561617	16-55	27OCT2020	114238	Placebo	27OCT2020/ Placebo	17NOV2020/ Placebo		
10561618	C4591001 1056 10561618	16-55	28OCT2020	114241	BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
10561621	C4591001 1056 10561621	16-55	28OCT2020	114244	Placebo	28OCT2020/ Placebo	16NOV2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
10561622	C4591001 1056 10561622	16-55	28OCT2020	114394	BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)		
10561623	C4591001 1056 10561623	16-55	28OCT2020	114395	Placebo	28OCT2020/ Placebo	16NOV2020/ Placebo		
10561626	C4591001 1056 10561626	16-55	28OCT2020	114398	BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)	18NOV2020/ BNT162b2 (30 µg)		
10561627	C4591001 1056 10561627	16-55	28OCT2020	114400	Placebo	28OCT2020/ Placebo	17NOV2020/ Placebo		
10561629	C4591001 1056 10561629	16-55	28OCT2020	114521	Placebo	28OCT2020/ Placebo	17NOV2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10561632	C4591001 1056 10561632	16-55	28OCT2020	114524	Placebo	28OCT2020/ Placebo	17NOV2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
10561633	C4591001 1056 10561633	16-55	28OCT2020	114528	BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
10561634	C4591001 1056 10561634	16-55	29OCT2020	114530	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	18NOV2020/ BNT162b2 (30 µg)		
10561635	C4591001 1056 10561635	16-55	29OCT2020	114642	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)		
10561636	C4591001 1056 10561636	16-55	29OCT2020	114644	Placebo	29OCT2020/ Placebo		11FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10561638	C4591001 1056 10561638	16-55	29OCT2020	114647	Placebo	29OCT2020/ Placebo	17NOV2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10561639	C4591001 1056 10561639	16-55	29OCT2020	114652	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
10561642	C4591001 1056 10561642	16-55	29OCT2020	114809	Placebo	29OCT2020/ Placebo	17NOV2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	
10561643	C4591001 1056 10561643	16-55	30OCT2020	114815	BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)	14DEC2020/ BNT162b2 (30 µg)		
10571025	C4591001 1057 10571025	16-55	17AUG2020	52289	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10571027	C4591001 1057 10571027	16-55	17AUG2020	52292	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
10571028	C4591001 1057 10571028	16-55	17AUG2020	52294	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10571030	C4591001 1057 10571030	16-55	17AUG2020	52297	Placebo	17AUG2020/ Placebo	09SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10571031	C4591001 1057 10571031	16-55	18AUG2020	53876	Placebo				
10571032	C4591001 1057 10571032	16-55	18AUG2020	53878	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10571033	C4591001 1057 10571033	16-55	18AUG2020	53879	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10571035	C4591001 1057 10571035	16-55	18AUG2020	53884	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10571036	C4591001 1057 10571036	16-55	18AUG2020	54041	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10571037	C4591001 1057 10571037	16-55	18AUG2020	54047	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10571042	C4591001 1057 10571042	16-55	19AUG2020	54048	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10571043	C4591001 1057 10571043	16-55	19AUG2020	54052	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10571044	C4591001 1057 10571044	16-55	19AUG2020	55856	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10571045	C4591001 1057 10571045	16-55	19AUG2020	55853	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
10571046	C4591001 1057 10571046	16-55	19AUG2020	55860	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10571048	C4591001 1057 10571048	16-55	19AUG2020	233180	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10571049	C4591001 1057 10571049	16-55	19AUG2020	55862	Placebo	19AUG2020/ Placebo	08SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10571050	C4591001 1057 10571050	16-55	19AUG2020	56352	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo		
10571051	C4591001 1057 10571051	16-55	19AUG2020	56354	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10571054	C4591001 1057 10571054	16-55	20AUG2020	56355	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10571056	C4591001 1057 10571056	16-55	20AUG2020	56356	Placebo	20AUG2020/ Placebo	09SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10571058	C4591001 1057 10571058	16-55	20AUG2020	58399	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10571059	C4591001 1057 10571059	16-55	20AUG2020	58403	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
10571060	C4591001 1057 10571060	16-55	20AUG2020	58405	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
10571065	C4591001 1057 10571065	16-55	21AUG2020	58406	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10571067	C4591001 1057 10571067	16-55	21AUG2020	60461	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10571068	C4591001 1057 10571068	16-55	21AUG2020	60463	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10571070	C4591001 1057 10571070	16-55	21AUG2020	60468	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
10571071	C4591001 1057 10571071	16-55	24AUG2020	60472	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10571074	C4591001 1057 10571074	16-55	24AUG2020	63498	Placebo	24AUG2020/ Placebo	15SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
10571075	C4591001 1057 10571075	16-55	24AUG2020	63506	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10571078	C4591001 1057 10571078	16-55	24AUG2020	63507	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10571079	C4591001 1057 10571079	16-55	24AUG2020	63508	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10571080	C4591001 1057 10571080	16-55	24AUG2020	64121	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
10571081	C4591001 1057 10571081	16-55	24AUG2020	64125	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10571082	C4591001 1057 10571082	16-55	25AUG2020	64127	Placebo	25AUG2020/ Placebo	14SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
10571083	C4591001 1057 10571083	16-55	25AUG2020	64129	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10571085	C4591001 1057 10571085	16-55	25AUG2020	65585	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10571088	C4591001 1057 10571088	16-55	25AUG2020	65587	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
10571089	C4591001 1057 10571089	16-55	25AUG2020	65594	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
10571090	C4591001 1057 10571090	16-55	25AUG2020	65595	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10571091	C4591001 1057 10571091	16-55	25AUG2020	66137	Placebo	25AUG2020/ Placebo	16SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10571092	C4591001 1057 10571092	16-55	26AUG2020	66138	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10571093	C4591001 1057 10571093	16-55	26AUG2020	66145	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10571095	C4591001 1057 10571095	16-55	26AUG2020	66147	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo		
10571100	C4591001 1057 10571100	16-55	26AUG2020	68454	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10571103	C4591001 1057 10571103	16-55	27AUG2020	68455	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10571104	C4591001 1057 10571104	16-55	27AUG2020	68461	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10571106	C4591001 1057 10571106	16-55	27AUG2020	68463	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10571109	C4591001 1057 10571109	16-55	27AUG2020	69907	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
10571111	C4591001 1057 10571111	16-55	27AUG2020	69909	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10571113	C4591001 1057 10571113	16-55	28AUG2020	69911	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
10571117	C4591001 1057 10571117	16-55	28AUG2020	69915	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10571118	C4591001 1057 10571118	16-55	28AUG2020	71659	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10571120	C4591001 1057 10571120	16-55	28AUG2020	71660	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
10571121	C4591001 1057 10571121	16-55	28AUG2020	71662	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
10571122	C4591001 1057 10571122	16-55	28AUG2020	71666	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10571123	C4591001 1057 10571123	16-55	31AUG2020	74669	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10571124	C4591001 1057 10571124	16-55	31AUG2020	74671	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10571125	C4591001 1057 10571125	16-55	31AUG2020	74673	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
10571127	C4591001 1057 10571127	16-55	31AUG2020	74677	Placebo	31AUG2020/ Placebo	23SEP2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10571129	C4591001 1057 10571129	16-55	31AUG2020	74969	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
10571132	C4591001 1057 10571132	16-55	01SEP2020	74970	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10571136	C4591001 1057 10571136	16-55	01SEP2020	74979	Placebo	01SEP2020/ Placebo	21SEP2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
10571137	C4591001 1057 10571137	16-55	01SEP2020	74980	Placebo	01SEP2020/ Placebo	01OCT2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10571139	C4591001 1057 10571139	16-55	02SEP2020	78126	Placebo	02SEP2020/ Placebo	21SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10571140	C4591001 1057 10571140	16-55	02SEP2020	78130	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10571142	C4591001 1057 10571142	16-55	03SEP2020	78135	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10571144	C4591001 1057 10571144	16-55	03SEP2020	78136	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
10571145	C4591001 1057 10571145	16-55	03SEP2020	79565	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
10571146	C4591001 1057 10571146	16-55	03SEP2020	79566	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10571147	C4591001 1057 10571147	16-55	03SEP2020	79572	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10571148	C4591001 1057 10571148	16-55	03SEP2020	79573	Placebo	03SEP2020/ Placebo	22SEP2020/ Placebo		
10571152	C4591001 1057 10571152	16-55	03SEP2020	80430	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10571153	C4591001 1057 10571153	16-55	04SEP2020	80433	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
10571154	C4591001 1057 10571154	16-55	04SEP2020	80435	Placebo	04SEP2020/ Placebo	24SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
10571155	C4591001 1057 10571155	16-55	04SEP2020	81269	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10571156	C4591001 1057 10571156	16-55	04SEP2020	80439	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10571158	C4591001 1057 10571158	16-55	04SEP2020	81273	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10571160	C4591001 1057 10571160	16-55	08SEP2020	81274	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10571161	C4591001 1057 10571161	16-55	08SEP2020	81280	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	28JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10571162	C4591001 1057 10571162	16-55	08SEP2020	83288	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10571163	C4591001 1057 10571163	16-55	08SEP2020	83290	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
10571164	C4591001 1057 10571164	16-55	08SEP2020	83292	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
10571165	C4591001 1057 10571165	16-55	08SEP2020	83294	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
10571169	C4591001 1057 10571169	16-55	09SEP2020	85112	Placebo	09SEP2020/ Placebo	01OCT2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10571170	C4591001 1057 10571170	16-55	09SEP2020	85116	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10571171	C4591001 1057 10571171	16-55	09SEP2020	85117	Placebo	09SEP2020/ Placebo	29SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
10571173	C4591001 1057 10571173	16-55	10SEP2020	85120	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10571176	C4591001 1057 10571176	16-55	10SEP2020	86659	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
10571177	C4591001 1057 10571177	16-55	10SEP2020	86660	Placebo	10SEP2020/ Placebo	05OCT2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10571182	C4591001 1057 10571182	16-55	11SEP2020	86665	Placebo	11SEP2020/ Placebo	30SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
10571185	C4591001 1057 10571185	16-55	14SEP2020	86667	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
10571186	C4591001 1057 10571186	16-55	14SEP2020	89514	Placebo	14SEP2020/ Placebo	06OCT2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
10571187	C4591001 1057 10571187	16-55	14SEP2020	89515	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
10571188	C4591001 1057 10571188	16-55	14SEP2020	89518	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
10571191	C4591001 1057 10571191	16-55	15SEP2020	89523	Placebo	15SEP2020/ Placebo	07OCT2020/ Placebo		
10571193	C4591001 1057 10571193	16-55	15SEP2020	90331	Placebo	15SEP2020/ Placebo	08OCT2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10571194	C4591001 1057 10571194	16-55	15SEP2020	90332	Placebo	15SEP2020/ Placebo	08OCT2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10571195	C4591001 1057 10571195	16-55	16SEP2020	90336	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
10571198	C4591001 1057 10571198	16-55	17SEP2020	92206	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10571200	C4591001 1057 10571200	16-55	17SEP2020	90340	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
10571201	C4591001 1057 10571201	16-55	17SEP2020	92207	Placebo	17SEP2020/ Placebo	14OCT2020/ Placebo		
10571202	C4591001 1057 10571202	16-55	17SEP2020	92208	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
10571203	C4591001 1057 10571203	16-55	17SEP2020	92211	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
10571204	C4591001 1057 10571204	16-55	17SEP2020	92538	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
10571205	C4591001 1057 10571205	16-55	17SEP2020	92543	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10571206	C4591001 1057 10571206	16-55	17SEP2020	92545	Placebo	17SEP2020/ Placebo	06OCT2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
10571207	C4591001 1057 10571207	16-55	17SEP2020	92548	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
10571208	C4591001 1057 10571208	16-55	18SEP2020	93235	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
10571210	C4591001 1057 10571210	16-55	18SEP2020	93239	Placebo	18SEP2020/ Placebo	08OCT2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10571211	C4591001 1057 10571211	16-55	18SEP2020	93241	Placebo				
10571212	C4591001 1057 10571212	16-55	18SEP2020	93242	BNT162b2 (30 µg)				
10571215	C4591001 1057 10571215	16-55	18SEP2020	93703	Placebo				
10571216	C4591001 1057 10571216	16-55	21SEP2020	93709	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo		
10571217	C4591001 1057 10571217	16-55	21SEP2020	93710	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
10571218	C4591001 1057 10571218	16-55	21SEP2020	93711	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
10571219	C4591001 1057 10571219	16-55	21SEP2020	95322	Placebo	21SEP2020/ Placebo	13OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10571220	C4591001 1057 10571220	16-55	21SEP2020	95328	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
10571222	C4591001 1057 10571222	16-55	22SEP2020	95329	Placebo	22SEP2020/ Placebo	13OCT2020/ Placebo		
10571223	C4591001 1057 10571223	16-55	22SEP2020	95330	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
10571226	C4591001 1057 10571226	16-55	22SEP2020	96769	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10571227	C4591001 1057 10571227	16-55	22SEP2020	96766	Placebo	22SEP2020/ Placebo	12OCT2020/ Placebo		
10571229	C4591001 1057 10571229	16-55	23SEP2020	96770	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10571230	C4591001 1057 10571230	16-55	23SEP2020	96772	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)		
10571232	C4591001 1057 10571232	16-55	23SEP2020	97531	Placebo	23SEP2020/ Placebo	13OCT2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
10571233	C4591001 1057 10571233	16-55	23SEP2020	97536	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
10571234	C4591001 1057 10571234	16-55	23SEP2020	97538	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
10571235	C4591001 1057 10571235	16-55	23SEP2020	97540	Placebo	23SEP2020/ Placebo	15OCT2020/ Placebo		
10571236	C4591001 1057 10571236	16-55	23SEP2020	97877	Placebo	23SEP2020/ Placebo	13OCT2020/ Placebo		
10571238	C4591001 1057 10571238	16-55	24SEP2020	97878	Placebo	24SEP2020/ Placebo	15OCT2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)
10571239	C4591001 1057 10571239	16-55	24SEP2020	97883	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10571240	C4591001 1057 10571240	16-55	24SEP2020	98658	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
10571241	C4591001 1057 10571241	16-55	24SEP2020	97885	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
10571243	C4591001 1057 10571243	16-55	24SEP2020	98665	Placebo	24SEP2020/ Placebo	15OCT2020/ Placebo		
10571244	C4591001 1057 10571244	16-55	25SEP2020	98666	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
10571245	C4591001 1057 10571245	16-55	25SEP2020	98668	Placebo	25SEP2020/ Placebo	15OCT2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
10571246	C4591001 1057 10571246	16-55	25SEP2020	99557	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
10571247	C4591001 1057 10571247	16-55	25SEP2020	99560	Placebo	25SEP2020/ Placebo	14OCT2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
10571248	C4591001 1057 10571248	16-55	25SEP2020	99562	Placebo	25SEP2020/ Placebo			
10571249	C4591001 1057 10571249	16-55	25SEP2020	99567	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		
10571252	C4591001 1057 10571252	16-55	28SEP2020	101336	BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10571253	C4591001 1057 10571253	16-55	28SEP2020	101339	Placebo	28SEP2020/ Placebo	19OCT2020/ Placebo		
10571257	C4591001 1057 10571257	16-55	01OCT2020	101340	Placebo	01OCT2020/ Placebo	20OCT2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
10571258	C4591001 1057 10571258	16-55	01OCT2020	101343	BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		
10571259	C4591001 1057 10571259	16-55	01OCT2020	102885	Placebo	01OCT2020/ Placebo	22OCT2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
10571261	C4591001 1057 10571261	16-55	02OCT2020	102888	BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)		
10571262	C4591001 1057 10571262	16-55	02OCT2020	266890	BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
10571263	C4591001 1057 10571263	16-55	02OCT2020	102889	Placebo	02OCT2020/ Placebo	23OCT2020/ Placebo		
10571265	C4591001 1057 10571265	16-55	02OCT2020	102890	BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)		
10571266	C4591001 1057 10571266	16-55	05OCT2020	103843	BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
10571267	C4591001 1057 10571267	16-55	05OCT2020	103845	Placebo	05OCT2020/ Placebo	27OCT2020/ Placebo		
10571268	C4591001 1057 10571268	16-55	06OCT2020	103848	Placebo				

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10571269	C4591001 1057 10571269	16-55	06OCT2020	103851	BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
10571270	C4591001 1057 10571270	16-55	06OCT2020	104207	Placebo	06OCT2020/ Placebo	26OCT2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
10571271	C4591001 1057 10571271	16-55	06OCT2020	104208	Placebo	06OCT2020/ Placebo	26OCT2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	
10571272	C4591001 1057 10571272	16-55	06OCT2020	104209	BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
10571273	C4591001 1057 10571273	16-55	07OCT2020	104211	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)		
10571274	C4591001 1057 10571274	16-55	07OCT2020	104693	Placebo	07OCT2020/ Placebo	27OCT2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10571276	C4591001 1057 10571276	16-55	08OCT2020	104694	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		
10571277	C4591001 1057 10571277	16-55	08OCT2020	104696	Placebo	08OCT2020/ Placebo	27OCT2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
10571278	C4591001 1057 10571278	16-55	08OCT2020	104700	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		
10571279	C4591001 1057 10571279	16-55	08OCT2020	105297	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10571280	C4591001 1057 10571280	16-55	08OCT2020	105299	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
10571281	C4591001 1057 10571281	16-55	08OCT2020	105301	Placebo	08OCT2020/ Placebo	02NOV2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
10571282	C4591001 1057 10571282	16-55	08OCT2020	105304	Placebo	08OCT2020/ Placebo	30OCT2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
10571283	C4591001 1057 10571283	16-55	09OCT2020	105750	Placebo	09OCT2020/ Placebo	29OCT2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
10571284	C4591001 1057 10571284	16-55	09OCT2020	105753	Placebo	09OCT2020/ Placebo	28OCT2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
10571286	C4591001 1057 10571286	16-55	09OCT2020	105754	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
10571287	C4591001 1057 10571287	16-55	09OCT2020	105756	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
10571288	C4591001 1057 10571288	16-55	09OCT2020	105920	Placebo	09OCT2020/ Placebo	04NOV2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
10571291	C4591001 1057 10571291	16-55	09OCT2020	105921	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)		
10571293	C4591001 1057 10571293	16-55	12OCT2020	105923	BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10571294	C4591001 1057 10571294	16-55	12OCT2020	105927	Placebo	12OCT2020/ Placebo	02NOV2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10571295	C4591001 1057 10571295	16-55	12OCT2020	106421	Placebo	12OCT2020/ Placebo	03NOV2020/ Placebo		
10571298	C4591001 1057 10571298	16-55	12OCT2020	106424	BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		
10571299	C4591001 1057 10571299	16-55	12OCT2020	106429	BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		
10571301	C4591001 1057 10571301	16-55	13OCT2020	106430	Placebo	13OCT2020/ Placebo	03NOV2020/ Placebo		
10571304	C4591001 1057 10571304	16-55	13OCT2020	107201	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
10571305	C4591001 1057 10571305	16-55	14OCT2020	107206	BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
10571309	C4591001 1057 10571309	16-55	14OCT2020	107207	Placebo	14OCT2020/ Placebo	02NOV2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
10571311	C4591001 1057 10571311	16-55	14OCT2020	107210	Placebo	14OCT2020/ Placebo	02NOV2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
10571312	C4591001 1057 10571312	16-55	14OCT2020	107648	BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10571313	C4591001 1057 10571313	16-55	14OCT2020	107649	Placebo	14OCT2020/ Placebo	02NOV2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
10571314	C4591001 1057 10571314	16-55	14OCT2020	107652	Placebo	14OCT2020/ Placebo	04NOV2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10571315	C4591001 1057 10571315	16-55	14OCT2020	107653	BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
10571316	C4591001 1057 10571316	16-55	15OCT2020	107897	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
10571317	C4591001 1057 10571317	16-55	15OCT2020	107898	Placebo	15OCT2020/ Placebo	04NOV2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10571318	C4591001 1057 10571318	16-55	15OCT2020	107901	Placebo	15OCT2020/ Placebo	10NOV2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
10571319	C4591001 1057 10571319	16-55	15OCT2020	107902	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
10571320	C4591001 1057 10571320	16-55	15OCT2020	108054	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
10571322	C4591001 1057 10571322	16-55	15OCT2020	108057	Placebo	15OCT2020/ Placebo	06NOV2020/ Placebo		
10571324	C4591001 1057 10571324	16-55	15OCT2020	108062	Placebo	15OCT2020/ Placebo	04NOV2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10571325	C4591001 1057 10571325	16-55	16OCT2020	108063	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
10571326	C4591001 1057 10571326	16-55	16OCT2020	108761	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
10571328	C4591001 1057 10571328	16-55	19OCT2020	108764	Placebo	19OCT2020/ Placebo	11NOV2020/ Placebo		
10571329	C4591001 1057 10571329	16-55	19OCT2020	108769	Placebo	19OCT2020/ Placebo	11NOV2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
10571331	C4591001 1057 10571331	16-55	20OCT2020	108770	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
10571332	C4591001 1057 10571332†	16-55	20OCT2020	110721	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
10571333	C4591001 1057 10571333	16-55	20OCT2020	110722	Placebo	20OCT2020/ Placebo	09NOV2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10571336	C4591001 1057 10571336	16-55	20OCT2020	110726	Placebo	20OCT2020/ Placebo	09NOV2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	
10571337	C4591001 1057 10571337	16-55	20OCT2020	110728	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
10571338	C4591001 1057 10571338	16-55	20OCT2020	110982	Placebo	20OCT2020/ Placebo	10NOV2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10571339	C4591001 1057 10571339	16-55	20OCT2020	110985	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
10571340	C4591001 1057 10571340	16-55	20OCT2020	110986	Placebo	20OCT2020/ Placebo	09NOV2020/ Placebo		
10571341	C4591001 1057 10571341	16-55	21OCT2020	110989	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
10571342	C4591001 1057 10571342	16-55	21OCT2020	111451	Placebo	21OCT2020/ Placebo	11NOV2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
10571343	C4591001 1057 10571343	16-55	21OCT2020	111454	Placebo	21OCT2020/ Placebo	11NOV2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
10571344	C4591001 1057 10571344†	16-55	21OCT2020	111457	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		
10571345	C4591001 1057 10571345†	16-55	21OCT2020	111458	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
10571347	C4591001 1057 10571347†	16-55	21OCT2020	111742	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		
10571348	C4591001 1057 10571348†	16-55	21OCT2020	111743	Placebo	21OCT2020/ Placebo	09NOV2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10571352	C4591001 1057 10571352†	16-55	22OCT2020	111744	Placebo	22OCT2020/ Placebo	10NOV2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10571353	C4591001 1057 10571353	16-55	22OCT2020	111745	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		
10571355	C4591001 1057 10571355†	16-55	23OCT2020	112829	Placebo	23OCT2020/ Placebo	11NOV2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
10571356	C4591001 1057 10571356	16-55	23OCT2020	112831	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
10571357	C4591001 1057 10571357	16-55	26OCT2020	112834	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
10571358	C4591001 1057 10571358	16-55	26OCT2020	112835	Placebo	26OCT2020/ Placebo	17NOV2020/ Placebo		
10571362	C4591001 1057 10571362†	16-55	30OCT2020	115015	Placebo	30OCT2020/ Placebo	18NOV2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
10571363	C4591001 1057 10571363	16-55	18NOV2020	115021	Placebo	18NOV2020/ Placebo	08DEC2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
10571364	C4591001 1057 10571364	16-55	18NOV2020	115022	BNT162b2 (30 µg)	18NOV2020/ BNT162b2 (30 µg)	11DEC2020/ BNT162b2 (30 µg)		
10571365	C4591001 1057 10571365	16-55	23NOV2020	116717	Placebo	23NOV2020/ Placebo	16DEC2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
10571366	C4591001 1057 10571366	16-55	23NOV2020	115024	BNT162b2 (30 µg)	23NOV2020/ BNT162b2 (30 µg)	16DEC2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10571367	C4591001 1057 10571367	16-55	23NOV2020	116721	BNT162b2 (30 µg)	23NOV2020/ BNT162b2 (30 µg)	16DEC2020/ BNT162b2 (30 µg)		
10571368	C4591001 1057 10571368	16-55	23NOV2020	116723	BNT162b2 (30 µg)	23NOV2020/ BNT162b2 (30 µg)	14DEC2020/ BNT162b2 (30 µg)		
10571369	C4591001 1057 10571369	16-55	30NOV2020	116727	Placebo	30NOV2020/ Placebo	22DEC2020/ Placebo	11MAR2021/ BNT162b2 (30 µg)	
10571370	C4591001 1057 10571370	16-55	30NOV2020	117053	BNT162b2 (30 µg)	30NOV2020/ BNT162b2 (30 µg)	21DEC2020/ BNT162b2 (30 µg)		
10571371	C4591001 1057 10571371	16-55	30NOV2020	117056	BNT162b2 (30 µg)	30NOV2020/ BNT162b2 (30 µg)	21DEC2020/ BNT162b2 (30 µg)		
10571372	C4591001 1057 10571372	16-55	02DEC2020	117060	Placebo	02DEC2020/ Placebo	23DEC2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10571373	C4591001 1057 10571373	16-55	02DEC2020	117063	Placebo	02DEC2020/ Placebo	21DEC2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
10571374	C4591001 1057 10571374	16-55	03DEC2020	117354	BNT162b2 (30 µg)	03DEC2020/ BNT162b2 (30 µg)	22DEC2020/ BNT162b2 (30 µg)		
10571375	C4591001 1057 10571375	16-55	03DEC2020	117358	Placebo	03DEC2020/ Placebo	22DEC2020/ Placebo		
10571381	C4591001 1057 10571381	16-55	08DEC2020	117359	Placebo	08DEC2020/ Placebo	28DEC2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10661035	C4591001 1066 10661035	16-55	17AUG2020	49472	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10661036	C4591001 1066 10661036	16-55	17AUG2020	49475	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10661037	C4591001 1066 10661037	16-55	17AUG2020	49478	Placebo	17AUG2020/ Placebo	09SEP2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)
10661044	C4591001 1066 10661044	16-55	18AUG2020	54875	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
10661059	C4591001 1066 10661059	16-55	19AUG2020	54876	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
10661060	C4591001 1066 10661060	16-55	19AUG2020	54877	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
10661062	C4591001 1066 10661062	16-55	19AUG2020	54878	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
10661064	C4591001 1066 10661064	16-55	20AUG2020	58193	Placebo	20AUG2020/ Placebo	09SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
10661071	C4591001 1066 10661071	16-55	20AUG2020	58196	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
10661072	C4591001 1066 10661072	16-55	20AUG2020	58198	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10661073	C4591001 1066 10661073	16-55	20AUG2020	58199	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10661075	C4591001 1066 10661075	16-55	20AUG2020	59853	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
10661078	C4591001 1066 10661078	16-55	21AUG2020	59854	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10661081	C4591001 1066 10661081	16-55	24AUG2020	59856	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
10661082	C4591001 1066 10661082	16-55	24AUG2020	59858	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10661085	C4591001 1066 10661085	16-55	24AUG2020	64205	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10661086	C4591001 1066 10661086	16-55	24AUG2020	64211	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
10661090	C4591001 1066 10661090	16-55	24AUG2020	64214	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10661095	C4591001 1066 10661095	16-55	25AUG2020	64215	Placebo	25AUG2020/ Placebo	14SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	04JAN2021/ BNT162b2 (30 µg)
10661097	C4591001 1066 10661097	16-55	25AUG2020	66548	Placebo	25AUG2020/ Placebo	14SEP2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10661098	C4591001 1066 10661098	16-55	25AUG2020	66549	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10661101	C4591001 1066 10661101	16-55	25AUG2020	66550	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10661106	C4591001 1066 10661106	16-55	26AUG2020	66552	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
10661115	C4591001 1066 10661115	16-55	26AUG2020	69317	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10661116	C4591001 1066 10661116	16-55	26AUG2020	69321	Placebo	26AUG2020/ Placebo	18SEP2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10661121	C4591001 1066 10661121	16-55	27AUG2020	69325	Placebo	27AUG2020/ Placebo	18SEP2020/ Placebo		
10661123	C4591001 1066 10661123	16-55	27AUG2020	69327	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10661129	C4591001 1066 10661129	16-55	28AUG2020	71969	Placebo	28AUG2020/ Placebo	17SEP2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
10661130	C4591001 1066 10661130	16-55	28AUG2020	71975	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
10661132	C4591001 1066 10661132	16-55	28AUG2020	71978	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10661133	C4591001 1066 10661133	16-55	28AUG2020	71979	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
10661136	C4591001 1066 10661136	16-55	28AUG2020	72774	Placebo	28AUG2020/ Placebo	17SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
10661137	C4591001 1066 10661137	16-55	28AUG2020	72781	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
10661138	C4591001 1066 10661138	16-55	28AUG2020	72783	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)
10661139	C4591001 1066 10661139	16-55	28AUG2020	72784	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10661142	C4591001 1066 10661142	16-55	31AUG2020	74779	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10661147	C4591001 1066 10661147	16-55	31AUG2020	74784	Placebo	31AUG2020/ Placebo	22SEP2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
10661149	C4591001 1066 10661149	16-55	31AUG2020	74786	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
10661151	C4591001 1066 10661151	16-55	31AUG2020	74787	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10661152	C4591001 1066 10661152	16-55	01SEP2020	76433	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10661160	C4591001 1066 10661160	16-55	01SEP2020	76436	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10661163	C4591001 1066 10661163	16-55	01SEP2020	76438	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
10661166	C4591001 1066 10661166	16-55	02SEP2020	76441	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10661167	C4591001 1066 10661167	16-55	02SEP2020	78512	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
10661168	C4591001 1066 10661168	16-55	02SEP2020	78514	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
10661173	C4591001 1066 10661173	16-55	03SEP2020	78517	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10661178	C4591001 1066 10661178	16-55	03SEP2020	78518	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10661182	C4591001 1066 10661182	16-55	03SEP2020	81007	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10661183	C4591001 1066 10661183	16-55	03SEP2020	81008	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10661184	C4591001 1066 10661184	16-55	04SEP2020	81012	Placebo	04SEP2020/ Placebo	13OCT2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10661185	C4591001 1066 10661185	16-55	04SEP2020	81016	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
10661186	C4591001 1066 10661186	16-55	04SEP2020	81414	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
10661187	C4591001 1066 10661187	16-55	04SEP2020	81417	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
10661190	C4591001 1066 10661190	16-55	04SEP2020	81419	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	04JAN2021/ BNT162b2 (30 µg)
10661192	C4591001 1066 10661192	16-55	04SEP2020	81421	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
10661193	C4591001 1066 10661193	16-55	04SEP2020	82206	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
10661194	C4591001 1066 10661194	16-55	04SEP2020	82210	Placebo	04SEP2020/ Placebo	23SEP2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10661195	C4591001 1066 10661195	16-55	04SEP2020	82211	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
10661197	C4591001 1066 10661197	16-55	07SEP2020	82212	BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
10661198	C4591001 1066 10661198	16-55	07SEP2020	83095	BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)			

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10661202	C4591001 1066 10661202	16-55	07SEP2020	83098	Placebo	07SEP2020/ Placebo	30SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
10661203	C4591001 1066 10661203	16-55	07SEP2020	83101	BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)	18NOV2020/ BNT162b2 (30 µg)		
10661214	C4591001 1066 10661214	16-55	08SEP2020	83103	Placebo	08SEP2020/ Placebo	30SEP2020/ Placebo	02MAR2021/ BNT162b2 (30 µg)	
10661217	C4591001 1066 10661217	16-55	09SEP2020	85148	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
10661219	C4591001 1066 10661219	16-55	09SEP2020	85150	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
10661226	C4591001 1066 10661226	16-55	09SEP2020	85153	Placebo	09SEP2020/ Placebo	02OCT2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10661233	C4591001 1066 10661233	16-55	10SEP2020	87619	Placebo	10SEP2020/ Placebo	29SEP2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
10661235	C4591001 1066 10661235	16-55	11SEP2020	87622	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
10661242	C4591001 1066 10661242	16-55	11SEP2020	87623	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10661243	C4591001 1066 10661243	16-55	11SEP2020	87627	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10661246	C4591001 1066 10661246	16-55	14SEP2020	90090	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10661247	C4591001 1066 10661247	16-55	14SEP2020	90089	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
10661251	C4591001 1066 10661251	16-55	15SEP2020	90093	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
10661253	C4591001 1066 10661253	16-55	15SEP2020	90098	Placebo	15SEP2020/ Placebo	05OCT2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
10661259	C4591001 1066 10661259	16-55	16SEP2020	91758	Placebo	16SEP2020/ Placebo	06OCT2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
10661260	C4591001 1066 10661260	16-55	16SEP2020	91761	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
10661261	C4591001 1066 10661261	16-55	16SEP2020	91762	Placebo	16SEP2020/ Placebo	07OCT2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	04JAN2021/ BNT162b2 (30 µg)
10661262	C4591001 1066 10661262	16-55	16SEP2020	91764	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
10661264	C4591001 1066 10661264	16-55	17SEP2020	92442	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
10661265	C4591001 1066 10661265	16-55	17SEP2020	92443	Placebo	17SEP2020/ Placebo	09OCT2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10661267	C4591001 1066 10661267	16-55	17SEP2020	92448	Placebo	17SEP2020/ Placebo	06OCT2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
10661270	C4591001 1066 10661270	16-55	17SEP2020	92451	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
10661272	C4591001 1066 10661272	16-55	18SEP2020	93641	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
10661273	C4591001 1066 10661273	16-55	18SEP2020	93644	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10661275	C4591001 1066 10661275	16-55	18SEP2020	93646	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
10661276	C4591001 1066 10661276	16-55	18SEP2020	93647	Placebo	18SEP2020/ Placebo	27OCT2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
10661277	C4591001 1066 10661277	16-55	18SEP2020	94326	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	15DEC2020/ BNT162b2 (30 µg)	04JAN2021/ BNT162b2 (30 µg)
10661278	C4591001 1066 10661278	16-55	21SEP2020	94327	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
10661279	C4591001 1066 10661279	16-55	21SEP2020	94332	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
10661280	C4591001 1066 10661280	16-55	21SEP2020	94336	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10661282	C4591001 1066 10661282	16-55	21SEP2020	95801	Placebo	21SEP2020/ Placebo	14OCT2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
10661284	C4591001 1066 10661284	16-55	22SEP2020	95803	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
10661285	C4591001 1066 10661285	16-55	22SEP2020	95806	Placebo	22SEP2020/ Placebo	13OCT2020/ Placebo	03MAR2021/ BNT162b2 (30 µg)	
10661287	C4591001 1066 10661287	16-55	22SEP2020	95808	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
10661289	C4591001 1066 10661289	16-55	22SEP2020	97025	Placebo	22SEP2020/ Placebo	14OCT2020/ Placebo		
10661290	C4591001 1066 10661290	16-55	22SEP2020	97029	Placebo	22SEP2020/ Placebo	12OCT2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
10661291	C4591001 1066 10661291	16-55	23SEP2020	97032	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
10661293	C4591001 1066 10661293	16-55	23SEP2020	97034	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
10661294	C4591001 1066 10661294	16-55	23SEP2020	98312	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
10661295	C4591001 1066 10661295	16-55	23SEP2020	98316	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10661296	C4591001 1066 10661296	16-55	23SEP2020	98318	Placebo	23SEP2020/ Placebo	12OCT2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
10661299	C4591001 1066 10661299	16-55	24SEP2020	98320	Placebo	24SEP2020/ Placebo	16OCT2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
10661300	C4591001 1066 10661300	16-55	24SEP2020	98624	Placebo	24SEP2020/ Placebo	15OCT2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
10661301	C4591001 1066 10661301	16-55	24SEP2020	98627	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
10661305	C4591001 1066 10661305	16-55	24SEP2020	98629	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
10661307	C4591001 1066 10661307	16-55	06OCT2020	99995	Placebo	06OCT2020/ Placebo	27OCT2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
10661308	C4591001 1066 10661308	16-55	01OCT2020	99991	BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)		
10661309	C4591001 1066 10661309	16-55	25SEP2020	98631	Placebo	25SEP2020/ Placebo	15OCT2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
10661310	C4591001 1066 10661310	16-55	25SEP2020	265017	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
10661312	C4591001 1066 10661312	16-55	25SEP2020	99989	Placebo	25SEP2020/ Placebo	15OCT2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10661315	C4591001 1066 10661315	16-55	05OCT2020	99992	BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
10661317	C4591001 1066 10661317	16-55	08OCT2020	105213	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)		
10661321	C4591001 1066 10661321	16-55	09OCT2020	105215	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		
10661322	C4591001 1066 10661322	16-55	12OCT2020	105218	Placebo	12OCT2020/ Placebo	16NOV2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
10661323	C4591001 1066 10661323	16-55	12OCT2020	105219	Placebo	12OCT2020/ Placebo	02NOV2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
10661324	C4591001 1066 10661324	16-55	12OCT2020	106722	Placebo	12OCT2020/ Placebo	02NOV2020/ Placebo	03MAR2021/ BNT162b2 (30 µg)	
10661330	C4591001 1066 10661330	16-55	13OCT2020	106723	Placebo	13OCT2020/ Placebo	02NOV2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
10661331	C4591001 1066 10661331	16-55	14OCT2020	106726	BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
10661332	C4591001 1066 10661332	16-55	14OCT2020	106732	BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)			
10661333	C4591001 1066 10661333	16-55	20OCT2020	111036	Placebo	20OCT2020/ Placebo	10NOV2020/ Placebo	03MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10661335	C4591001 1066 10661335	16-55	14OCT2020	107674	BNT162b2 (30 µg)				
10661336	C4591001 1066 10661336	16-55	14OCT2020	107676	Placebo	14OCT2020/ Placebo	02NOV2020/ Placebo	02MAR2021/ BNT162b2 (30 µg)	
10661337	C4591001 1066 10661337	16-55	19OCT2020	109368	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
10661338	C4591001 1066 10661338	16-55	15OCT2020	107677	Placebo	15OCT2020/ Placebo	06NOV2020/ Placebo		
10661340	C4591001 1066 10661340	16-55	15OCT2020	107680	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
10661341	C4591001 1066 10661341	16-55	15OCT2020	108581	Placebo	15OCT2020/ Placebo	03NOV2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
10661342	C4591001 1066 10661342	16-55	16OCT2020	108582	Placebo	16OCT2020/ Placebo	06NOV2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10661344	C4591001 1066 10661344	16-55	16OCT2020	108586	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
10661345	C4591001 1066 10661345	16-55	16OCT2020	108591	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
10661346	C4591001 1066 10661346	16-55	16OCT2020	109365	Placebo	16OCT2020/ Placebo	06NOV2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10661348	C4591001 1066 10661348	16-55	19OCT2020	109367	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
10661355	C4591001 1066 10661355	16-55	20OCT2020	109372	Placebo	20OCT2020/ Placebo	10NOV2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
10661358	C4591001 1066 10661358	16-55	04NOV2020	113704	BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)	23NOV2020/ BNT162b2 (30 µg)		
10661360	C4591001 1066 10661360	16-55	20OCT2020	111038	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		
10661363	C4591001 1066 10661363	16-55	21OCT2020	111039	Placebo	21OCT2020/ Placebo	13NOV2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
10661364	C4591001 1066 10661364	16-55	21OCT2020	111040	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
10661366	C4591001 1066 10661366	16-55	22OCT2020	112109	Placebo	22OCT2020/ Placebo	12NOV2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
10661372	C4591001 1066 10661372	16-55	22OCT2020	112112	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
10661379	C4591001 1066 10661379	16-55	23OCT2020	112113	Placebo	23OCT2020/ Placebo	12NOV2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
10661386	C4591001 1066 10661386	16-55	26OCT2020	112116	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10661388	C4591001 1066 10661388	16-55	26OCT2020	113695	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
10661389	C4591001 1066 10661389	16-55	26OCT2020	113698	Placebo	26OCT2020/ Placebo	16NOV2020/ Placebo	15DEC2020/ BNT162b2 (30 µg)	04JAN2021/ BNT162b2 (30 µg)
10661390	C4591001 1066 10661390	16-55	30OCT2020	113701	Placebo	30OCT2020/ Placebo	20NOV2020/ Placebo	03MAR2021/ BNT162b2 (30 µg)	
10661391	C4591001 1066 10661391	16-55	04NOV2020	115688	BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)	30NOV2020/ BNT162b2 (30 µg)		
10661392	C4591001 1066 10661392	16-55	19NOV2020	115689	Placebo	19NOV2020/ Placebo	09DEC2020/ Placebo		
10661393	C4591001 1066 10661393	16-55	24NOV2020	115691	BNT162b2 (30 µg)	24NOV2020/ BNT162b2 (30 µg)	15DEC2020/ BNT162b2 (30 µg)		
10661396	C4591001 1066 10661396	16-55	01DEC2020	115695	Placebo	01DEC2020/ Placebo		22DEC2020/ BNT162b2 (30 µg)	14JAN2021/ BNT162b2 (30 µg)
10661398	C4591001 1066 10661398	16-55	02DEC2020	117187	Placebo	02DEC2020/ Placebo	21DEC2020/ Placebo		
10661399	C4591001 1066 10661399	16-55	02DEC2020	117188	Placebo	02DEC2020/ Placebo	21DEC2020/ Placebo		
10661400	C4591001 1066 10661400	16-55	02DEC2020	117189	BNT162b2 (30 µg)	02DEC2020/ BNT162b2 (30 µg)	21DEC2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10661406	C4591001 1066 10661406	16-55	04DEC2020	117194	BNT162b2 (30 µg)	04DEC2020/ BNT162b2 (30 µg)	22DEC2020/ BNT162b2 (30 µg)		
10661413	C4591001 1066 10661413	16-55	10DEC2020	117836	Placebo	10DEC2020/ Placebo	29DEC2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
10681002	C4591001 1068 10681002	16-55	18AUG2020	55553	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10681003	C4591001 1068 10681003	16-55	19AUG2020	55554	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
10681006	C4591001 1068 10681006	16-55	19AUG2020	55557	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10681010	C4591001 1068 10681010	16-55	19AUG2020	55560	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
10681011	C4591001 1068 10681011	16-55	19AUG2020	57666	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10681012	C4591001 1068 10681012	16-55	20AUG2020	57670	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10681013	C4591001 1068 10681013	16-55	20AUG2020	57674	Placebo	20AUG2020/ Placebo	11SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
10681016	C4591001 1068 10681016	16-55	20AUG2020	57675	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10681017	C4591001 1068 10681017	16-55	20AUG2020	59480	Placebo	20AUG2020/ Placebo	09SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
10681018	C4591001 1068 10681018	16-55	20AUG2020	59485	Placebo	20AUG2020/ Placebo	11SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
10681021	C4591001 1068 10681021	16-55	21AUG2020	59486	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
10681024	C4591001 1068 10681024	16-55	21AUG2020	59488	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10681025	C4591001 1068 10681025	16-55	21AUG2020	61244	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
10681026	C4591001 1068 10681026	16-55	21AUG2020	61248	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
10681027	C4591001 1068 10681027	16-55	21AUG2020	61249	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
10681028	C4591001 1068 10681028	16-55	24AUG2020	61252	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
10681031	C4591001 1068 10681031	16-55	24AUG2020	63728	Placebo	24AUG2020/ Placebo	16SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
10681034	C4591001 1068 10681034	16-55	24AUG2020	63733	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10681035	C4591001 1068 10681035	16-55	24AUG2020	63732	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10681036	C4591001 1068 10681036	16-55	24AUG2020	63734	Placebo	24AUG2020/ Placebo	16SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
10681037	C4591001 1068 10681037	16-55	24AUG2020	64962	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
10681038	C4591001 1068 10681038	16-55	26AUG2020	64964	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
10681042	C4591001 1068 10681042	16-55	26AUG2020	64967	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10681046	C4591001 1068 10681046	16-55	26AUG2020	64972	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10681047	C4591001 1068 10681047	16-55	26AUG2020	69285	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10681052	C4591001 1068 10681052	16-55	27AUG2020	69288	Placebo	27AUG2020/ Placebo	18SEP2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
10681053	C4591001 1068 10681053	16-55	27AUG2020	69289	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
10681058	C4591001 1068 10681058	16-55	27AUG2020	69291	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10681060	C4591001 1068 10681060	16-55	28AUG2020	71717	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10681061	C4591001 1068 10681061	16-55	28AUG2020	71718	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10681064	C4591001 1068 10681064	16-55	28AUG2020	71719	Placebo	28AUG2020/ Placebo	21SEP2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
10681066	C4591001 1068 10681066	16-55	28AUG2020	71724	Placebo	28AUG2020/ Placebo	17SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
10681071	C4591001 1068 10681071	16-55	31AUG2020	74766	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
10681072	C4591001 1068 10681072	16-55	31AUG2020	74769	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10681073	C4591001 1068 10681073	16-55	31AUG2020	74770	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10681074	C4591001 1068 10681074	16-55	31AUG2020	74775	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
10681076	C4591001 1068 10681076	16-55	31AUG2020	75368	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
10681077	C4591001 1068 10681077	16-55	31AUG2020	75370	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10681080	C4591001 1068 10681080	16-55	31AUG2020	75371	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
10681081	C4591001 1068 10681081	16-55	31AUG2020	75372	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10681083	C4591001 1068 10681083	16-55	01SEP2020	76421	Placebo	01SEP2020/ Placebo	21SEP2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
10681086	C4591001 1068 10681086	16-55	01SEP2020	76424	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10681087	C4591001 1068 10681087	16-55	02SEP2020	76426	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
10681089	C4591001 1068 10681089	16-55	02SEP2020	76431	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10681097	C4591001 1068 10681097	16-55	03SEP2020	79661	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
10681098	C4591001 1068 10681098	16-55	03SEP2020	79662	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10681099	C4591001 1068 10681099	16-55	03SEP2020	79667	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10681100	C4591001 1068 10681100	16-55	03SEP2020	79670	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10681102	C4591001 1068 10681102	16-55	03SEP2020	80898	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
10681106	C4591001 1068 10681106	16-55	04SEP2020	80902	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
10681109	C4591001 1068 10681109	16-55	04SEP2020	80904	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
10681110	C4591001 1068 10681110	16-55	04SEP2020	80907	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
10681112	C4591001 1068 10681112	16-55	04SEP2020	82571	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
10681113	C4591001 1068 10681113	16-55	08SEP2020	82573	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
10681114	C4591001 1068 10681114	16-55	08SEP2020	82574	Placebo	08SEP2020/ Placebo	05OCT2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
10681115	C4591001 1068 10681115	16-55	08SEP2020	82575	Placebo	08SEP2020/ Placebo	30SEP2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
10681116	C4591001 1068 10681116	16-55	10SEP2020	86793	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)
10681117	C4591001 1068 10681117	16-55	10SEP2020	86797	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10681119	C4591001 1068 10681119	16-55	10SEP2020	86799	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
10681121	C4591001 1068 10681121	16-55	23SEP2020	86800	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		
10711018	C4591001 1071 10711018	16-55	04SEP2020	81555	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
10711055	C4591001 1071 10711055	16-55	17AUG2020	51049	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
10711056	C4591001 1071 10711056	16-55	18AUG2020	51050	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10711057	C4591001 1071 10711057	16-55	18AUG2020	54629	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	14FEB2021/ BNT162b2 (30 µg)
10711061	C4591001 1071 10711061	16-55	18AUG2020	54630	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10711062	C4591001 1071 10711062	16-55	18AUG2020	54633	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo		
10711065	C4591001 1071 10711065	16-55	19AUG2020	54635	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10711079	C4591001 1071 10711079	16-55	22AUG2020	62083	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10711080	C4591001 1071 10711080	16-55	22AUG2020	62086	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	12SEP2020/ BNT162b2 (30 µg)		
10711081	C4591001 1071 10711081	16-55	23AUG2020	62090	Placebo	23AUG2020/ Placebo	14SEP2020/ Placebo		
10711082	C4591001 1071 10711082	16-55	23AUG2020	62091	Placebo	23AUG2020/ Placebo	12SEP2020/ Placebo		
10711083	C4591001 1071 10711083	16-55	24AUG2020	63705	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10711086	C4591001 1071 10711086	16-55	24AUG2020	63706	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo		
10711087	C4591001 1071 10711087	16-55	24AUG2020	63707	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10711092	C4591001 1071 10711092	16-55	25AUG2020	63712	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10711094	C4591001 1071 10711094	16-55	25AUG2020	67042	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10711095	C4591001 1071 10711095	16-55	25AUG2020	67045	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)			
10711097	C4591001 1071 10711097	16-55	26AUG2020	67047	Placebo	26AUG2020/ Placebo	15SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10711098	C4591001 1071 10711098	16-55	26AUG2020	67048	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	30JAN2021/ BNT162b2 (30 µg)	20FEB2021/ BNT162b2 (30 µg)
10711100	C4591001 1071 10711100	16-55	26AUG2020	69222	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	30JAN2021/ BNT162b2 (30 µg)	20FEB2021/ BNT162b2 (30 µg)
10711102	C4591001 1071 10711102	16-55	27AUG2020	69227	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10711107	C4591001 1071 10711107	16-55	27AUG2020	69231	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
10711113	C4591001 1071 10711113	16-55	29AUG2020	69232	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo	30JAN2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10711114	C4591001 1071 10711114	16-55	29AUG2020	73844	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		
10711115	C4591001 1071 10711115	16-55	29AUG2020	73847	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		
10711116	C4591001 1071 10711116	16-55	29AUG2020	73850	Placebo	29AUG2020/ Placebo	18SEP2020/ Placebo	30JAN2021/ BNT162b2 (30 µg)	20FEB2021/ BNT162b2 (30 µg)
10711118	C4591001 1071 10711118	16-55	31AUG2020	73851	Placebo	31AUG2020/ Placebo	22SEP2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
10711119	C4591001 1071 10711119	16-55	01SEP2020	77742	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10711124	C4591001 1071 10711124	16-55	03SEP2020	77749	Placebo	03SEP2020/ Placebo	22SEP2020/ Placebo	30JAN2021/ BNT162b2 (30 µg)	20FEB2021/ BNT162b2 (30 µg)
10711125	C4591001 1071 10711125	16-55	03SEP2020	77744	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10711127	C4591001 1071 10711127	16-55	03SEP2020	77750	Placebo	03SEP2020/ Placebo	22SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10711128	C4591001 1071 10711128	16-55	04SEP2020	81547	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
10711131	C4591001 1071 10711131	16-55	04SEP2020	81548	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	30JAN2021/ BNT162b2 (30 µg)	20FEB2021/ BNT162b2 (30 µg)
10711133	C4591001 1071 10711133	16-55	04SEP2020	81554	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
10711136	C4591001 1071 10711136	16-55	04SEP2020	82592	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10711137	C4591001 1071 10711137	16-55	04SEP2020	82594	Placebo	04SEP2020/ Placebo	24SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10711138	C4591001 1071 10711138	16-55	08SEP2020	82595	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
10711140	C4591001 1071 10711140	16-55	08SEP2020	82596	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10711148	C4591001 1071 10711148	16-55	09SEP2020	86177	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10711149	C4591001 1071 10711149	16-55	09SEP2020	86179	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	16JAN2021/ BNT162b2 (30 µg)
10711150	C4591001 1071 10711150	16-55	10SEP2020	86180	Placebo	10SEP2020/ Placebo	30SEP2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
10711151	C4591001 1071 10711151	16-55	10SEP2020	86188	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
10711152	C4591001 1071 10711152	16-55	10SEP2020	87380	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10711153	C4591001 1071 10711153	16-55	10SEP2020	87383	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
10711156	C4591001 1071 10711156	16-55	10SEP2020	87384	Placebo	10SEP2020/ Placebo	29SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	13MAR2021/ BNT162b2 (30 µg)
10711157	C4591001 1071 10711157	16-55	10SEP2020	87388	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
10711159	C4591001 1071 10711159	16-55	11SEP2020	88350	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
10711160	C4591001 1071 10711160	16-55	11SEP2020	88351	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10711161	C4591001 1071 10711161	16-55	11SEP2020	88352	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
10711162	C4591001 1071 10711162	16-55	11SEP2020	88357	Placebo				
10711164	C4591001 1071 10711164	16-55	14SEP2020	89777	Placebo	14SEP2020/ Placebo	06OCT2020/ Placebo		
10711166	C4591001 1071 10711166	16-55	15SEP2020	89784	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
10711167	C4591001 1071 10711167	16-55	15SEP2020	89785	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
10711170	C4591001 1071 10711170	16-55	15SEP2020	89786	Placebo	15SEP2020/ Placebo	13OCT2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10711171	C4591001 1071 10711171	16-55	15SEP2020	90848	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
10711173	C4591001 1071 10711173	16-55	16SEP2020	90850	Placebo	16SEP2020/ Placebo	05OCT2020/ Placebo		
10711175	C4591001 1071 10711175	16-55	17SEP2020	90851	Placebo	17SEP2020/ Placebo	07OCT2020/ Placebo		
10711176	C4591001 1071 10711176	16-55	17SEP2020	90855	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
10711182	C4591001 1071 10711182	16-55	17SEP2020	93115	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10711183	C4591001 1071 10711183	16-55	17SEP2020	93120	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
10711185	C4591001 1071 10711185	16-55	18SEP2020	93122	Placebo	18SEP2020/ Placebo			
10711189	C4591001 1071 10711189	16-55	21SEP2020	93124	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
10711193	C4591001 1071 10711193	16-55	23SEP2020	97738	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
10711194	C4591001 1071 10711194	16-55	23SEP2020	97739	Placebo	23SEP2020/ Placebo	13OCT2020/ Placebo	30JAN2021/ BNT162b2 (30 µg)	20FEB2021/ BNT162b2 (30 µg)
10711198	C4591001 1071 10711198	16-55	24SEP2020	97743	Placebo	24SEP2020/ Placebo	14OCT2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10711199	C4591001 1071 10711199	16-55	24SEP2020	97744	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
10711200	C4591001 1071 10711200	16-55	24SEP2020	99042	Placebo	24SEP2020/ Placebo	14OCT2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
10711202	C4591001 1071 10711202	16-55	26SEP2020	99045	Placebo	26SEP2020/ Placebo	16OCT2020/ Placebo	30JAN2021/ BNT162b2 (30 µg)	20FEB2021/ BNT162b2 (30 µg)
10711203	C4591001 1071 10711203	16-55	26SEP2020	99047	BNT162b2 (30 µg)	26SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10711204	C4591001 1071 10711204	16-55	26SEP2020	99050	BNT162b2 (30 µg)	26SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
10711205	C4591001 1071 10711205	16-55	26SEP2020	100602	BNT162b2 (30 µg)	26SEP2020/ BNT162b2 (30 µg)	17OCT2020/ BNT162b2 (30 µg)		
10711206	C4591001 1071 10711206	16-55	26SEP2020	100604	Placebo	26SEP2020/ Placebo	17OCT2020/ Placebo	24JAN2021/ BNT162b2 (30 µg)	14FEB2021/ BNT162b2 (30 µg)
10711208	C4591001 1071 10711208	16-55	02OCT2020	100606	Placebo	02OCT2020/ Placebo	22OCT2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	20FEB2021/ BNT162b2 (30 µg)
10711209	C4591001 1071 10711209	16-55	02OCT2020	100607	BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)		
10711210	C4591001 1071 10711210	16-55	05OCT2020	103793	BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
10711211	C4591001 1071 10711211	16-55	05OCT2020	103796	Placebo	05OCT2020/ Placebo			
10711212	C4591001 1071 10711212	16-55	05OCT2020	103799	BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)	24OCT2020/ BNT162b2 (30 µg)		
10711215	C4591001 1071 10711215	16-55	09OCT2020	105845	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	31OCT2020/ BNT162b2 (30 µg)		
10711217	C4591001 1071 10711217	16-55	09OCT2020	105847	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	31OCT2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10711218	C4591001 1071 10711218	16-55	09OCT2020	105853	Placebo	09OCT2020/ Placebo	30OCT2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
10711219	C4591001 1071 10711219	16-55	12OCT2020	105855	Placebo	12OCT2020/ Placebo	02NOV2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	
10711222	C4591001 1071 10711222	16-55	14OCT2020	107627	BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		
10711223	C4591001 1071 10711223	16-55	14OCT2020	107630	Placebo	14OCT2020/ Placebo	02NOV2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	13MAR2021/ BNT162b2 (30 µg)
10711224	C4591001 1071 10711224	16-55	15OCT2020	107631	Placebo	15OCT2020/ Placebo	04NOV2020/ Placebo		
10711225	C4591001 1071 10711225	16-55	15OCT2020	107632	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
10711227	C4591001 1071 10711227	16-55	15OCT2020	108498	Placebo	15OCT2020/ Placebo	06NOV2020/ Placebo	30JAN2021/ BNT162b2 (30 µg)	20FEB2021/ BNT162b2 (30 µg)
10711229	C4591001 1071 10711229	16-55	16OCT2020	108505	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
10711230	C4591001 1071 10711230	16-55	16OCT2020	108506	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
10711231	C4591001 1071 10711231	16-55	16OCT2020	108507	Placebo	16OCT2020/ Placebo	04NOV2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10711232	C4591001 1071 10711232	16-55	19OCT2020	110191	Placebo	19OCT2020/ Placebo	12NOV2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10711233	C4591001 1071 10711233	16-55	19OCT2020	110195	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
10711234	C4591001 1071 10711234	16-55	19OCT2020	110198	Placebo	19OCT2020/ Placebo	11NOV2020/ Placebo		
10711235	C4591001 1071 10711235	16-55	20OCT2020	110199	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)			
10711236	C4591001 1071 10711236	16-55	20OCT2020	110851	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
10711237	C4591001 1071 10711237	16-55	23OCT2020	110853	Placebo	23OCT2020/ Placebo			
10711239	C4591001 1071 10711239	16-55	24OCT2020	110855	Placebo	24OCT2020/ Placebo	14NOV2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	16JAN2021/ BNT162b2 (30 µg)
10711241	C4591001 1071 10711241	16-55	24OCT2020	110858	BNT162b2 (30 µg)	24OCT2020/ BNT162b2 (30 µg)	14NOV2020/ BNT162b2 (30 µg)		
10711242	C4591001 1071 10711242	16-55	24OCT2020	113292	BNT162b2 (30 µg)	24OCT2020/ BNT162b2 (30 µg)	14NOV2020/ BNT162b2 (30 µg)		
10711244	C4591001 1071 10711244	16-55	27OCT2020	113293	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10711246	C4591001 1071 10711246	16-55	27OCT2020	113294	Placebo	27OCT2020/ Placebo	17NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10711247	C4591001 1071 10711247	16-55	27OCT2020	113296	Placebo	27OCT2020/ Placebo	17NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10711249	C4591001 1071 10711249	16-55	30OCT2020	115122	Placebo	30OCT2020/ Placebo	18NOV2020/ Placebo		
10711250	C4591001 1071 10711250	16-55	30OCT2020	115123	BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)	18NOV2020/ BNT162b2 (30 µg)		
10721001	C4591001 1072 10721001	16-55	17AUG2020	52445	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
10721008	C4591001 1072 10721008	16-55	17AUG2020	52446	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10721009	C4591001 1072 10721009	16-55	18AUG2020	52448	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10721012	C4591001 1072 10721012	16-55	18AUG2020	52453	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo		
10721013	C4591001 1072 10721013	16-55	19AUG2020	56791	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
10721022	C4591001 1072 10721022	16-55	20AUG2020	56796	Placebo	20AUG2020/ Placebo	11SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10721023	C4591001 1072 10721023	16-55	20AUG2020	56797	Placebo	20AUG2020/ Placebo	11SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
10721024	C4591001 1072 10721024	16-55	21AUG2020	56798	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
10721029	C4591001 1072 10721029	16-55	21AUG2020	61412	Placebo	21AUG2020/ Placebo	14SEP2020/ Placebo		
10721030	C4591001 1072 10721030	16-55	22AUG2020	61413	Placebo	22AUG2020/ Placebo	14SEP2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
10721031	C4591001 1072 10721031	16-55	22AUG2020	61417	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10721033	C4591001 1072 10721033	16-55	22AUG2020	61418	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10721034	C4591001 1072 10721034	16-55	22AUG2020	62347	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10721035	C4591001 1072 10721035	16-55	24AUG2020	62348	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10721040	C4591001 1072 10721040	16-55	24AUG2020	62352	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo		
10721046	C4591001 1072 10721046	16-55	25AUG2020	62353	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10721047	C4591001 1072 10721047	16-55	25AUG2020	66835	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
10721049	C4591001 1072 10721049	16-55	26AUG2020	66836	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10721050	C4591001 1072 10721050	16-55	26AUG2020	66839	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10721051	C4591001 1072 10721051	16-55	26AUG2020	66840	Placebo	26AUG2020/ Placebo		08MAR2021/ BNT162b2 (30 µg)	
10721052	C4591001 1072 10721052	16-55	26AUG2020	68202	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10721058	C4591001 1072 10721058	16-55	27AUG2020	68203	Placebo	27AUG2020/ Placebo	25SEP2020/ Placebo		
10721063	C4591001 1072 10721063	16-55	28AUG2020	68205	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10721069	C4591001 1072 10721069	16-55	31AUG2020	68212	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
10721070	C4591001 1072 10721070	16-55	31AUG2020	75882	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10721071	C4591001 1072 10721071	16-55	01SEP2020	75887	Placebo	01SEP2020/ Placebo	21SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10721072	C4591001 1072 10721072	16-55	01SEP2020	75888	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10721074	C4591001 1072 10721074	16-55	01SEP2020	75890	Placebo	01SEP2020/ Placebo	21SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
10721077	C4591001 1072 10721077	16-55	02SEP2020	78920	Placebo	02SEP2020/ Placebo	25SEP2020/ Placebo		
10721083	C4591001 1072 10721083	16-55	03SEP2020	78921	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10721084	C4591001 1072 10721084	16-55	03SEP2020	78924	Placebo	03SEP2020/ Placebo	23SEP2020/ Placebo		
10721085	C4591001 1072 10721085	16-55	04SEP2020	78925	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10721086	C4591001 1072 10721086	16-55	04SEP2020	81426	Placebo	04SEP2020/ Placebo	24SEP2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
10721087	C4591001 1072 10721087	16-55	04SEP2020	81430	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10721089	C4591001 1072 10721089	16-55	04SEP2020	81432	Placebo	04SEP2020/ Placebo	23SEP2020/ Placebo		
10721090	C4591001 1072 10721090	16-55	04SEP2020	81436	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10721091	C4591001 1072 10721091	16-55	08SEP2020	83539	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
10721093	C4591001 1072 10721093	16-55	08SEP2020	83542	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
10721094	C4591001 1072 10721094	16-55	08SEP2020	83543	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
10721099	C4591001 1072 10721099	16-55	10SEP2020	83548	Placebo	10SEP2020/ Placebo	29SEP2020/ Placebo		
10721100	C4591001 1072 10721100	16-55	11SEP2020	88289	Placebo	11SEP2020/ Placebo	30SEP2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
10731091	C4591001 1073 10731091	16-55	19AUG2020	48816	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10731093	C4591001 1073 10731093	16-55	19AUG2020	48818	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10731101	C4591001 1073 10731101	16-55	20AUG2020	58710	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10731103	C4591001 1073 10731103	16-55	20AUG2020	58713	Placebo	20AUG2020/ Placebo	08SEP2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10731106	C4591001 1073 10731106	16-55	24AUG2020	58714	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10731109	C4591001 1073 10731109	16-55	24AUG2020	58716	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10731110	C4591001 1073 10731110	16-55	24AUG2020	64133	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10731112	C4591001 1073 10731112	16-55	25AUG2020	64137	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10731113	C4591001 1073 10731113	16-55	25AUG2020	64140	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10731114	C4591001 1073 10731114	16-55	25AUG2020	64143	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10731116	C4591001 1073 10731116	16-55	25AUG2020	66222	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
10731117	C4591001 1073 10731117	16-55	25AUG2020	66227	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10731120	C4591001 1073 10731120	16-55	26AUG2020	66228	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo		
10771041	C4591001 1077 10771041	16-55	17AUG2020	47579	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10771042	C4591001 1077 10771042	16-55	17AUG2020	226551	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10771044	C4591001 1077 10771044	16-55	17AUG2020	47580	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
10771045	C4591001 1077 10771045	16-55	17AUG2020	47584	Placebo	17AUG2020/ Placebo	10SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
10771054	C4591001 1077 10771054	16-55	17AUG2020	53201	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10771058	C4591001 1077 10771058	16-55	17AUG2020	53205	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
10771061	C4591001 1077 10771061	16-55	18AUG2020	53210	Placebo	18AUG2020/ Placebo	10SEP2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)
10771067	C4591001 1077 10771067	16-55	18AUG2020	53211	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10771068	C4591001 1077 10771068	16-55	18AUG2020	54473	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10771069	C4591001 1077 10771069	16-55	18AUG2020	54474	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
10771071	C4591001 1077 10771071	16-55	18AUG2020	54478	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10771073	C4591001 1077 10771073	16-55	18AUG2020	54479	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10771074	C4591001 1077 10771074	16-55	18AUG2020	55217	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10771076	C4591001 1077 10771076	16-55	19AUG2020	55219	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10771077	C4591001 1077 10771077	16-55	19AUG2020	55221	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10771079	C4591001 1077 10771079	16-55	19AUG2020	55224	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
10771080	C4591001 1077 10771080	16-55	19AUG2020	56241	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
10771082	C4591001 1077 10771082	16-55	19AUG2020	56242	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
10771083	C4591001 1077 10771083	16-55	24AUG2020	56244	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10771084	C4591001 1077 10771084	16-55	24AUG2020	56245	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10771085	C4591001 1077 10771085	16-55	24AUG2020	63301	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10771086	C4591001 1077 10771086	16-55	24AUG2020	63303	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10771087	C4591001 1077 10771087	16-55	24AUG2020	63302	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10771089	C4591001 1077 10771089	16-55	24AUG2020	63582	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10771096	C4591001 1077 10771096	16-55	24AUG2020	63586	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
10771097	C4591001 1077 10771097	16-55	24AUG2020	63589	Placebo	24AUG2020/ Placebo	16SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
10771100	C4591001 1077 10771100	16-55	25AUG2020	63592	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10771108	C4591001 1077 10771108	16-55	25AUG2020	65923	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo		
10771114	C4591001 1077 10771114	16-55	25AUG2020	65926	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10771117	C4591001 1077 10771117	16-55	26AUG2020	65928	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10771118	C4591001 1077 10771118	16-55	26AUG2020	65932	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10771120	C4591001 1077 10771120	16-55	26AUG2020	67495	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10771122	C4591001 1077 10771122	16-55	26AUG2020	67493	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
10771123	C4591001 1077 10771123	16-55	26AUG2020	67496	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
10771124	C4591001 1077 10771124	16-55	26AUG2020	67999	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10771125	C4591001 1077 10771125	16-55	26AUG2020	67501	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10771126	C4591001 1077 10771126	16-55	26AUG2020	68002	Placebo	26AUG2020/ Placebo	15SEP2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	22JAN2021/ BNT162b2 (30 µg)
10771128	C4591001 1077 10771128	16-55	26AUG2020	68006	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10771129	C4591001 1077 10771129	16-55	26AUG2020	68008	Placebo	26AUG2020/ Placebo	18SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
10771131	C4591001 1077 10771131	16-55	26AUG2020	69113	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10771132	C4591001 1077 10771132	16-55	27AUG2020	69117	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10771133	C4591001 1077 10771133	16-55	27AUG2020	69118	Placebo	27AUG2020/ Placebo	18SEP2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10771134	C4591001 1077 10771134	16-55	27AUG2020	69124	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)
10771136	C4591001 1077 10771136	16-55	27AUG2020	69584	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10771137	C4591001 1077 10771137	16-55	27AUG2020	69585	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10771138	C4591001 1077 10771138	16-55	27AUG2020	69587	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10771139	C4591001 1077 10771139	16-55	27AUG2020	69592	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
10771140	C4591001 1077 10771140	16-55	27AUG2020	70218	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
10771142	C4591001 1077 10771142	16-55	27AUG2020	70220	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10771150	C4591001 1077 10771150	16-55	01SEP2020	70224	Placebo	01SEP2020/ Placebo	21SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10771152	C4591001 1077 10771152	16-55	01SEP2020	70227	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10771153	C4591001 1077 10771153	16-55	01SEP2020	76679	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10771156	C4591001 1077 10771156	16-55	01SEP2020	76680	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10771157	C4591001 1077 10771157	16-55	01SEP2020	76682	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	22JAN2021/ BNT162b2 (30 µg)
10771158	C4591001 1077 10771158	16-55	01SEP2020	76683	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10771159	C4591001 1077 10771159	16-55	01SEP2020	77587	Placebo	01SEP2020/ Placebo	21SEP2020/ Placebo		
10771165	C4591001 1077 10771165	16-55	02SEP2020	77590	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
10771166	C4591001 1077 10771166	16-55	02SEP2020	77593	Placebo	02SEP2020/ Placebo	24SEP2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	21JAN2021/ BNT162b2 (30 µg)
10771169	C4591001 1077 10771169	16-55	02SEP2020	77594	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10771171	C4591001 1077 10771171	16-55	02SEP2020	79147	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
10771178	C4591001 1077 10771178	16-55	03SEP2020	79148	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10771181	C4591001 1077 10771181	16-55	03SEP2020	79149	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10771183	C4591001 1077 10771183	16-55	03SEP2020	79152	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10771184	C4591001 1077 10771184	16-55	03SEP2020	80501	Placebo	03SEP2020/ Placebo	25SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
10771186	C4591001 1077 10771186	16-55	03SEP2020	80505	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10771188	C4591001 1077 10771188	16-55	03SEP2020	80510	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10771189	C4591001 1077 10771189	16-55	03SEP2020	80511	Placebo	03SEP2020/ Placebo	22SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10771190	C4591001 1077 10771190	16-55	03SEP2020	80945	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10771192	C4591001 1077 10771192	16-55	03SEP2020	80950	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10771193	C4591001 1077 10771193	16-55	04SEP2020	80952	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
10771198	C4591001 1077 10771198	16-55	04SEP2020	80955	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
10771200	C4591001 1077 10771200	16-55	04SEP2020	81810	Placebo	04SEP2020/ Placebo	23SEP2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	21JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10771201	C4591001 1077 10771201	16-55	04SEP2020	81812	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10771202	C4591001 1077 10771202	16-55	08SEP2020	81813	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
10771203	C4591001 1077 10771203	16-55	08SEP2020	81820	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
10771204	C4591001 1077 10771204	16-55	08SEP2020	83333	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
10771209	C4591001 1077 10771209	16-55	08SEP2020	83334	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
10771212	C4591001 1077 10771212	16-55	08SEP2020	83336	Placebo	08SEP2020/ Placebo	30SEP2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
10771213	C4591001 1077 10771213	16-55	08SEP2020	83343	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
10771214	C4591001 1077 10771214	16-55	09SEP2020	84775	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10771218	C4591001 1077 10771218	16-55	09SEP2020	84779	Placebo	09SEP2020/ Placebo	01OCT2020/ Placebo		
10771222	C4591001 1077 10771222	16-55	10SEP2020	84780	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10771234	C4591001 1077 10771234	16-55	17SEP2020	84782	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
10771235	C4591001 1077 10771235	16-55	17SEP2020	92250	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
10771236	C4591001 1077 10771236	16-55	18SEP2020	92253	Placebo	18SEP2020/ Placebo	08OCT2020/ Placebo	06JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
10771237	C4591001 1077 10771237	16-55	18SEP2020	92259	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
10771238	C4591001 1077 10771238	16-55	18SEP2020	92260	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
10771240	C4591001 1077 10771240	16-55	18SEP2020	93608	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
10771242	C4591001 1077 10771242	16-55	12OCT2020	93609	BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		
10771243	C4591001 1077 10771243	16-55	13OCT2020	93612	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
10771244	C4591001 1077 10771244	16-55	14OCT2020	93615	Placebo	14OCT2020/ Placebo	02NOV2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10771245	C4591001 1077 10771245	16-55	15OCT2020	107983	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10771246	C4591001 1077 10771246	16-55	19OCT2020	107985	Placebo	19OCT2020/ Placebo	09NOV2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
10771247	C4591001 1077 10771247	16-55	19OCT2020	107989	Placebo	19OCT2020/ Placebo	09NOV2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
10771248	C4591001 1077 10771248	16-55	19OCT2020	107991	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
10771250	C4591001 1077 10771250	16-55	19OCT2020	110276	Placebo	19OCT2020/ Placebo	09NOV2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
10771253	C4591001 1077 10771253	16-55	20OCT2020	110278	Placebo	20OCT2020/ Placebo	09NOV2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
10771254	C4591001 1077 10771254	16-55	20OCT2020	110280	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		
10771258	C4591001 1077 10771258	16-55	20OCT2020	110281	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		
10771260	C4591001 1077 10771260	16-55	20OCT2020	110957	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		
10771261	C4591001 1077 10771261	16-55	20OCT2020	110958	Placebo	20OCT2020/ Placebo	10NOV2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10771262	C4591001 1077 10771262	16-55	20OCT2020	110961	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10771268	C4591001 1077 10771268	16-55	22OCT2020	110965	Placebo	22OCT2020/ Placebo	10NOV2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
10771269	C4591001 1077 10771269	16-55	22OCT2020	112339	Placebo	22OCT2020/ Placebo	12NOV2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
10771272	C4591001 1077 10771272	16-55	29OCT2020	112340	Placebo	29OCT2020/ Placebo	20NOV2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
10771273	C4591001 1077 10771273	16-55	02DEC2020	112345	BNT162b2 (30 µg)	02DEC2020/ BNT162b2 (30 µg)	22DEC2020/ BNT162b2 (30 µg)		
10771276	C4591001 1077 10771276	16-55	04DEC2020	112346	BNT162b2 (30 µg)	04DEC2020/ BNT162b2 (30 µg)	23DEC2020/ BNT162b2 (30 µg)		
10791129	C4591001 1079 10791129	16-55	17AUG2020	49412	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10791130	C4591001 1079 10791130	16-55	17AUG2020	49417	Placebo	17AUG2020/ BNT162b2 (30 µg)			
10791133	C4591001 1079 10791133	16-55	17AUG2020	49420	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
10791134	C4591001 1079 10791134	16-55	17AUG2020	53213	Placebo	17AUG2020/ Placebo	09SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)
10791135	C4591001 1079 10791135	16-55	17AUG2020	53215	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10791137	C4591001 1079 10791137	16-55	18AUG2020	53221	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10791142	C4591001 1079 10791142	16-55	18AUG2020	55158	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
10791143	C4591001 1079 10791143	16-55	18AUG2020	53224	Placebo	18AUG2020/ Placebo	06NOV2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
10791144	C4591001 1079 10791144	16-55	19AUG2020	55162	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10791146	C4591001 1079 10791146	16-55	19AUG2020	55163	Placebo	19AUG2020/ Placebo	11SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
10791147	C4591001 1079 10791147	16-55	19AUG2020	55168	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
10791153	C4591001 1079 10791153	16-55	19AUG2020	56933	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
10791154	C4591001 1079 10791154	16-55	19AUG2020	56937	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
10791157	C4591001 1079 10791157	16-55	20AUG2020	56938	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
10791164	C4591001 1079 10791164	16-55	20AUG2020	59273	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10791166	C4591001 1079 10791166	16-55	21AUG2020	59279	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	20JAN2021/ BNT162b2 (30 µg)
10791169	C4591001 1079 10791169	16-55	21AUG2020	59280	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
10791170	C4591001 1079 10791170	16-55	24AUG2020	59283	Placebo	24AUG2020/ Placebo	15SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
10791171	C4591001 1079 10791171	16-55	24AUG2020	63929	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10791172	C4591001 1079 10791172	16-55	24AUG2020	63936	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
10791173	C4591001 1079 10791173	16-55	24AUG2020	63938	Placebo	24AUG2020/ Placebo	15SEP2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
10791174	C4591001 1079 10791174	16-55	25AUG2020	63939	Placebo	25AUG2020/ Placebo	16SEP2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
10791175	C4591001 1079 10791175	16-55	25AUG2020	65418	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10791176	C4591001 1079 10791176	16-55	25AUG2020	65421	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
10791177	C4591001 1079 10791177	16-55	25AUG2020	65425	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10791178	C4591001 1079 10791178	16-55	25AUG2020	65428	Placebo	25AUG2020/ Placebo	16SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
10791179	C4591001 1079 10791179	16-55	25AUG2020	66030	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10791181	C4591001 1079 10791181	16-55	25AUG2020	66039	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10791182	C4591001 1079 10791182	16-55	25AUG2020	66035	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10791184	C4591001 1079 10791184	16-55	26AUG2020	66040	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
10791186	C4591001 1079 10791186	16-55	26AUG2020	68107	Placebo	26AUG2020/ Placebo	15SEP2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
10791187	C4591001 1079 10791187	16-55	26AUG2020	68108	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10791188	C4591001 1079 10791188	16-55	26AUG2020	68110	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10791192	C4591001 1079 10791192	16-55	27AUG2020	68116	Placebo	27AUG2020/ Placebo	16SEP2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
10791195	C4591001 1079 10791195	16-55	27AUG2020	70446	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10791197	C4591001 1079 10791197	16-55	27AUG2020	70450	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
10791199	C4591001 1079 10791199	16-55	27AUG2020	70454	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10791202	C4591001 1079 10791202	16-55	28AUG2020	70455	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
10791203	C4591001 1079 10791203	16-55	28AUG2020	72103	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
10791205	C4591001 1079 10791205	16-55	28AUG2020	72105	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10791206	C4591001 1079 10791206	16-55	28AUG2020	72107	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10791211	C4591001 1079 10791211	16-55	31AUG2020	72111	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
10791224	C4591001 1079 10791224	16-55	01SEP2020	77157	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
10791230	C4591001 1079 10791230	16-55	02SEP2020	77158	Placebo	02SEP2020/ Placebo	22SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	
10791232	C4591001 1079 10791232	16-55	03SEP2020	77164	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10791235	C4591001 1079 10791235	16-55	03SEP2020	80201	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10791238	C4591001 1079 10791238	16-55	03SEP2020	80202	Placebo	03SEP2020/ Placebo	23SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10791239	C4591001 1079 10791239	16-55	03SEP2020	80203	Placebo	03SEP2020/ Placebo	28SEP2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
10791241	C4591001 1079 10791241	16-55	04SEP2020	80209	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
10791244	C4591001 1079 10791244	16-55	04SEP2020	82013	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
10791245	C4591001 1079 10791245	16-55	04SEP2020	82017	Placebo	04SEP2020/ Placebo	23SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
10791249	C4591001 1079 10791249	16-55	08SEP2020	84209	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
10791250	C4591001 1079 10791250	16-55	08SEP2020	82023	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
10791251	C4591001 1079 10791251	16-55	08SEP2020	82022	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
10791252	C4591001 1079 10791252	16-55	08SEP2020	84212	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10791253	C4591001 1079 10791253	16-55	08SEP2020	84216	Placebo	08SEP2020/ Placebo			
10791256	C4591001 1079 10791256	16-55	09SEP2020	84219	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
10791257	C4591001 1079 10791257	16-55	09SEP2020	85413	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
10791262	C4591001 1079 10791262	16-55	09SEP2020	85415	Placebo	09SEP2020/ Placebo	29SEP2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
10791263	C4591001 1079 10791263	16-55	09SEP2020	85414	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
10791265	C4591001 1079 10791265	16-55	09SEP2020	85420	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
10791267	C4591001 1079 10791267	16-55	10SEP2020	86611	Placebo	11SEP2020/ Placebo	29SEP2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
10791272	C4591001 1079 10791272	16-55	11SEP2020	86612	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
10791275	C4591001 1079 10791275	16-55	11SEP2020	86617	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10791277	C4591001 1079 10791277	16-55	11SEP2020	86620	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10791281	C4591001 1079 10791281	16-55	15SEP2020	90177	Placebo	15SEP2020/ Placebo	06OCT2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
10791288	C4591001 1079 10791288	16-55	16SEP2020	90180	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
10791289	C4591001 1079 10791289	16-55	16SEP2020	90182	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
10791290	C4591001 1079 10791290	16-55	16SEP2020	90184	Placebo	16SEP2020/ Placebo	05OCT2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
10791291	C4591001 1079 10791291	16-55	16SEP2020	91505	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
10791293	C4591001 1079 10791293	16-55	21SEP2020	91506	Placebo	21SEP2020/ Placebo	14OCT2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
10791294	C4591001 1079 10791294	16-55	21SEP2020	91507	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
10791296	C4591001 1079 10791296	16-55	09OCT2020	106039	Placebo	09OCT2020/ Placebo	29OCT2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	15JAN2021/ BNT162b2 (30 µg)
10791297	C4591001 1079 10791297	16-55	22SEP2020	91515	Placebo	22SEP2020/ Placebo	14OCT2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
10791298	C4591001 1079 10791298	16-55	22SEP2020	96441	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10791300	C4591001 1079 10791300	16-55	05OCT2020	96442	BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
10791303	C4591001 1079 10791303	16-55	07OCT2020	96444	Placebo	07OCT2020/ Placebo	26OCT2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
10791304	C4591001 1079 10791304	16-55	09OCT2020	96446	Placebo	09OCT2020/ Placebo	30OCT2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
10791305	C4591001 1079 10791305	16-55	12OCT2020	106042	Placebo	12OCT2020/ Placebo	04NOV2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
10791311	C4591001 1079 10791311	16-55	14OCT2020	106045	BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		
10791313	C4591001 1079 10791313	16-55	16OCT2020	106047	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
10791315	C4591001 1079 10791315	16-55	20OCT2020	110933	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
10791316	C4591001 1079 10791316	16-55	23OCT2020	110934	Placebo	23OCT2020/ Placebo	12NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10801036	C4591001 1080 10801036	16-55	14AUG2020	48674	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
10801040	C4591001 1080 10801040	16-55	14AUG2020	50746	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10801041	C4591001 1080 10801041	16-55	14AUG2020	50748	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
10801042	C4591001 1080 10801042	16-55	17AUG2020	50749	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	11MAR2021/ BNT162b2 (30 µg)	
10801043	C4591001 1080 10801043	16-55	17AUG2020	50752	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	11MAR2021/ BNT162b2 (30 µg)	
10801045	C4591001 1080 10801045	16-55	17AUG2020	52829	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10801050	C4591001 1080 10801050	16-55	17AUG2020	52834	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10801051	C4591001 1080 10801051	16-55	17AUG2020	52838	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
10801053	C4591001 1080 10801053	16-55	18AUG2020	52839	Placebo	18AUG2020/ Placebo	10SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10801054	C4591001 1080 10801054	16-55	18AUG2020	54237	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
10801055	C4591001 1080 10801055	16-55	18AUG2020	54240	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo		
10801057	C4591001 1080 10801057	16-55	18AUG2020	54241	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10801058	C4591001 1080 10801058	16-55	19AUG2020	54243	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10801059	C4591001 1080 10801059	16-55	19AUG2020	55829	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10801065	C4591001 1080 10801065	16-55	19AUG2020	55832	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10801068	C4591001 1080 10801068	16-55	20AUG2020	55837	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10801072	C4591001 1080 10801072	16-55	20AUG2020	55838	Placebo	20AUG2020/ Placebo	11SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
10801078	C4591001 1080 10801078	16-55	21AUG2020	60665	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10801079	C4591001 1080 10801079	16-55	21AUG2020	60670	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
10801081	C4591001 1080 10801081	16-55	21AUG2020	60666	Placebo	21AUG2020/ Placebo	10SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
10801082	C4591001 1080 10801082	16-55	24AUG2020	60672	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10801087	C4591001 1080 10801087	16-55	24AUG2020	64361	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10801089	C4591001 1080 10801089	16-55	25AUG2020	64363	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
10801092	C4591001 1080 10801092	16-55	25AUG2020	64365	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10801096	C4591001 1080 10801096	16-55	26AUG2020	64368	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10801100	C4591001 1080 10801100	16-55	26AUG2020	67781	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10801102	C4591001 1080 10801102	16-55	26AUG2020	67782	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
10801104	C4591001 1080 10801104	16-55	27AUG2020	67784	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10801107	C4591001 1080 10801107	16-55	27AUG2020	70901	Placebo	27AUG2020/ Placebo	16SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
10801108	C4591001 1080 10801108	16-55	27AUG2020	67787	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10801109	C4591001 1080 10801109	16-55	28AUG2020	70902	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
10801111	C4591001 1080 10801111	16-55	28AUG2020	70904	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10801114	C4591001 1080 10801114	16-55	28AUG2020	70905	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
10801115	C4591001 1080 10801115	16-55	28AUG2020	72224	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10801117	C4591001 1080 10801117	16-55	28AUG2020	72225	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
10801119	C4591001 1080 10801119	16-55	28AUG2020	72230	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
10801120	C4591001 1080 10801120	16-55	28AUG2020	72845	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10801122	C4591001 1080 10801122	16-55	28AUG2020	72232	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
10801131	C4591001 1080 10801131	16-55	01SEP2020	72852	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
10801132	C4591001 1080 10801132	16-55	02SEP2020	72853	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10801135	C4591001 1080 10801135	16-55	02SEP2020	72855	Placebo	02SEP2020/ Placebo	25SEP2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
10801136	C4591001 1080 10801136	16-55	02SEP2020	78799	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10801137	C4591001 1080 10801137	16-55	02SEP2020	78800	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10801140	C4591001 1080 10801140	16-55	03SEP2020	78808	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10801141	C4591001 1080 10801141	16-55	03SEP2020	78801	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10801142	C4591001 1080 10801142	16-55	03SEP2020	79721	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10801144	C4591001 1080 10801144	16-55	03SEP2020	79723	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10801145	C4591001 1080 10801145	16-55	03SEP2020	79729	Placebo	03SEP2020/ Placebo	23SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
10801149	C4591001 1080 10801149	16-55	03SEP2020	79732	Placebo	03SEP2020/ Placebo	22SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
10801151	C4591001 1080 10801151	16-55	04SEP2020	81257	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10801153	C4591001 1080 10801153	16-55	04SEP2020	81259	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
10801155	C4591001 1080 10801155	16-55	04SEP2020	81261	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10801159	C4591001 1080 10801159	16-55	04SEP2020	81264	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
10801160	C4591001 1080 10801160	16-55	04SEP2020	82306	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10801162	C4591001 1080 10801162	16-55	04SEP2020	82307	Placebo	04SEP2020/ Placebo	24SEP2020/ Placebo		
10801163	C4591001 1080 10801163	16-55	08SEP2020	82310	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
10801179	C4591001 1080 10801179	16-55	11SEP2020	82311	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10801180	C4591001 1080 10801180	16-55	11SEP2020	87835	Placebo	11SEP2020/ Placebo	01OCT2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10801182	C4591001 1080 10801182	16-55	11SEP2020	87837	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10801183	C4591001 1080 10801183	16-55	11SEP2020	87838	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
10801185	C4591001 1080 10801185	16-55	14SEP2020	87841	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
10801187	C4591001 1080 10801187	16-55	14SEP2020	89924	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10801192	C4591001 1080 10801192	16-55	15SEP2020	89926	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
10801193	C4591001 1080 10801193	16-55	16SEP2020	89927	Placebo	16SEP2020/ Placebo	06OCT2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10801194	C4591001 1080 10801194	16-55	16SEP2020	89932	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
10801195	C4591001 1080 10801195	16-55	16SEP2020	91481	Placebo	16SEP2020/ Placebo	14OCT2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
10801196	C4591001 1080 10801196	16-55	17SEP2020	91488	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
10801197	C4591001 1080 10801197	16-55	17SEP2020	91483	Placebo	17SEP2020/ Placebo	06OCT2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10801201	C4591001 1080 10801201	16-55	17SEP2020	91489	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
10801202	C4591001 1080 10801202	16-55	17SEP2020	92588	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
10801205	C4591001 1080 10801205	16-55	18SEP2020	92589	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo		
10801212	C4591001 1080 10801212	16-55	18SEP2020	92591	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10801213	C4591001 1080 10801213	16-55	21SEP2020	92592	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
10801214	C4591001 1080 10801214	16-55	21SEP2020	94713	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
10801219	C4591001 1080 10801219	16-55	21SEP2020	94716	Placebo	21SEP2020/ Placebo	14OCT2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
10801221	C4591001 1080 10801221	16-55	22SEP2020	94719	Placebo	22SEP2020/ Placebo	13OCT2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10811042	C4591001 1081 10811042	16-55	17AUG2020	52194	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo		
10811044	C4591001 1081 10811044	16-55	17AUG2020	52197	Placebo	17AUG2020/ Placebo	09SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10811046	C4591001 1081 10811046	16-55	17AUG2020	52203	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10811047	C4591001 1081 10811047	16-55	17AUG2020	52204	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10811062	C4591001 1081 10811062	16-55	19AUG2020	55650	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10811066	C4591001 1081 10811066	16-55	19AUG2020	55652	Placebo	19AUG2020/ Placebo	08SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10811067	C4591001 1081 10811067	16-55	19AUG2020	55659	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10811070	C4591001 1081 10811070	16-55	19AUG2020	55660	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10811071	C4591001 1081 10811071	16-55	19AUG2020	56839	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)			
10811074	C4591001 1081 10811074	16-55	20AUG2020	56844	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10811075	C4591001 1081 10811075	16-55	20AUG2020	56848	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
10811077	C4591001 1081 10811077	16-55	20AUG2020	59034	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
10811079	C4591001 1081 10811079	16-55	21AUG2020	59037	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10811081	C4591001 1081 10811081	16-55	24AUG2020	59040	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10811085	C4591001 1081 10811085	16-55	24AUG2020	59043	Placebo	24AUG2020/ Placebo	15SEP2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
10811086	C4591001 1081 10811086	16-55	24AUG2020	63523	Placebo	24AUG2020/ Placebo	15SEP2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10811087	C4591001 1081 10811087	16-55	24AUG2020	63524	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10811089	C4591001 1081 10811089	16-55	24AUG2020	63528	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
10811092	C4591001 1081 10811092	16-55	24AUG2020	63532	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10811094	C4591001 1081 10811094	16-55	25AUG2020	65573	Placebo	25AUG2020/ Placebo	14SEP2020/ Placebo		
10811095	C4591001 1081 10811095	16-55	25AUG2020	65575	Placebo	25AUG2020/ Placebo	14SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
10811096	C4591001 1081 10811096	16-55	25AUG2020	65582	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10811098	C4591001 1081 10811098	16-55	25AUG2020	66161	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo		
10811104	C4591001 1081 10811104	16-55	26AUG2020	66163	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
10811105	C4591001 1081 10811105	16-55	26AUG2020	66167	BNT162b2 (30 µg)				
10811106	C4591001 1081 10811106	16-55	26AUG2020	67267	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10811108	C4591001 1081 10811108	16-55	26AUG2020	67269	Placebo	26AUG2020/ Placebo	17SEP2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10811109	C4591001 1081 10811109	16-55	26AUG2020	67274	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10811114	C4591001 1081 10811114	16-55	26AUG2020	67275	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo		
10811118	C4591001 1081 10811118	16-55	26AUG2020	68758	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10811119	C4591001 1081 10811119	16-55	26AUG2020	68759	Placebo	26AUG2020/ Placebo	15SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
10811121	C4591001 1081 10811121	16-55	27AUG2020	68760	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
10811126	C4591001 1081 10811126	16-55	27AUG2020	68763	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10811127	C4591001 1081 10811127	16-55	27AUG2020	70542	Placebo	27AUG2020/ Placebo	16SEP2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
10811130	C4591001 1081 10811130	16-55	27AUG2020	70545	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10811131	C4591001 1081 10811131	16-55	27AUG2020	70546	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10811133	C4591001 1081 10811133	16-55	31AUG2020	70547	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10811134	C4591001 1081 10811134	16-55	31AUG2020	75005	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10811135	C4591001 1081 10811135	16-55	31AUG2020	75008	Placebo	31AUG2020/ Placebo	22SEP2020/ Placebo		
10811141	C4591001 1081 10811141	16-55	01SEP2020	75010	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
10811143	C4591001 1081 10811143	16-55	01SEP2020	75012	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10811145	C4591001 1081 10811145	16-55	01SEP2020	76361	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
10811146	C4591001 1081 10811146	16-55	01SEP2020	76362	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
10811147	C4591001 1081 10811147	16-55	01SEP2020	76367	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10811148	C4591001 1081 10811148	16-55	01SEP2020	76369	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
10811160	C4591001 1081 10811160	16-55	02SEP2020	78498	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10811161	C4591001 1081 10811161	16-55	02SEP2020	78499	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10811164	C4591001 1081 10811164	16-55	02SEP2020	78507	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10811172	C4591001 1081 10811172	16-55	03SEP2020	78508	Placebo	03SEP2020/ Placebo	23SEP2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
10811185	C4591001 1081 10811185	16-55	08SEP2020	83671	Placebo	08SEP2020/ Placebo	30SEP2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10811186	C4591001 1081 10811186	16-55	08SEP2020	83673	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
10811187	C4591001 1081 10811187	16-55	09SEP2020	83674	Placebo	09SEP2020/ Placebo	29SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10811190	C4591001 1081 10811190	16-55	10SEP2020	83675	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
10811192	C4591001 1081 10811192	16-55	10SEP2020	86540	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
10811193	C4591001 1081 10811193	16-55	10SEP2020	86542	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
10811194	C4591001 1081 10811194	16-55	10SEP2020	86545	Placebo	10SEP2020/ Placebo	29SEP2020/ Placebo		
10811196	C4591001 1081 10811196	16-55	10SEP2020	86546	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10811197	C4591001 1081 10811197	16-55	11SEP2020	87714	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10811198	C4591001 1081 10811198	16-55	14SEP2020	87716	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
10811199	C4591001 1081 10811199	16-55	14SEP2020	87722	Placebo	14SEP2020/ Placebo	06OCT2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
10811200	C4591001 1081 10811200	16-55	15SEP2020	87723	Placebo	15SEP2020/ Placebo	07OCT2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
10811206	C4591001 1081 10811206	16-55	17SEP2020	92214	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
10811207	C4591001 1081 10811207	16-55	17SEP2020	92218	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
10811209	C4591001 1081 10811209	16-55	17SEP2020	92220	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
10811210	C4591001 1081 10811210	16-55	17SEP2020	92222	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
10821013	C4591001 1082 10821013	16-55	03AUG2020	41498	Placebo				
10821111	C4591001 1082 10821111	16-55	17AUG2020	50247	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10821113	C4591001 1082 10821113	16-55	17AUG2020	50248	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
10821115	C4591001 1082 10821115	16-55	18AUG2020	54595	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
10821116	C4591001 1082 10821116	16-55	18AUG2020	54596	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10821120	C4591001 1082 10821120	16-55	20AUG2020	54600	Placebo	20AUG2020/ Placebo	08SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10821123	C4591001 1082 10821123	16-55	21AUG2020	54604	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10821127	C4591001 1082 10821127	16-55	24AUG2020	63453	Placebo	24AUG2020/ Placebo	17SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
10821128	C4591001 1082 10821128	16-55	24AUG2020	63454	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10821129	C4591001 1082 10821129	16-55	24AUG2020	63455	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10821130	C4591001 1082 10821130	16-55	24AUG2020	63459	Placebo	24AUG2020/ Placebo	16SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
10821136	C4591001 1082 10821136	16-55	27AUG2020	70399	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10821139	C4591001 1082 10821139	16-55	28AUG2020	70400	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
10821140	C4591001 1082 10821140	16-55	28AUG2020	70402	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10821143	C4591001 1082 10821143	16-55	01SEP2020	70407	Placebo	01SEP2020/ Placebo	25SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
10821145	C4591001 1082 10821145	16-55	02SEP2020	78007	Placebo	02SEP2020/ Placebo	24SEP2020/ Placebo		
10821148	C4591001 1082 10821148	16-55	03SEP2020	78009	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10821149	C4591001 1082 10821149	16-55	03SEP2020	78011	Placebo	03SEP2020/ Placebo	23SEP2020/ Placebo		
10821150	C4591001 1082 10821150	16-55	03SEP2020	80552	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10821151	C4591001 1082 10821151	16-55	03SEP2020	78012	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10821154	C4591001 1082 10821154	16-55	08SEP2020	80554	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
10821156	C4591001 1082 10821156	16-55	10SEP2020	80557	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10821158	C4591001 1082 10821158	16-55	14SEP2020	80560	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
10821161	C4591001 1082 10821161	16-55	18SEP2020	93425	Placebo	18SEP2020/ Placebo	07OCT2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
10821163	C4591001 1082 10821163	16-55	18SEP2020	93426	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
10821168	C4591001 1082 10821168	16-55	21SEP2020	93431	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
10821171	C4591001 1082 10821171	16-55	21SEP2020	93435	Placebo	21SEP2020/ Placebo	14OCT2020/ Placebo		
10821172	C4591001 1082 10821172	16-55	22SEP2020	96090	Placebo	22SEP2020/ Placebo	15OCT2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
10821175	C4591001 1082 10821175	16-55	23SEP2020	96093	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
10821178	C4591001 1082 10821178	16-55	24SEP2020	96095	Placebo	24SEP2020/ Placebo	16OCT2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)
10821180	C4591001 1082 10821180	16-55	24SEP2020	96100	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
10821183	C4591001 1082 10821183	16-55	25SEP2020	99631	Placebo	25SEP2020/ Placebo	19OCT2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10821185	C4591001 1082 10821185	16-55	25SEP2020	99633	Placebo	25SEP2020/ Placebo	14OCT2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
10821186	C4591001 1082 10821186	16-55	25SEP2020	99635	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
10821187	C4591001 1082 10821187	16-55	25SEP2020	99640	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
10821188	C4591001 1082 10821188	16-55	08OCT2020	105281	Placebo	08OCT2020/ Placebo	30OCT2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
10821194	C4591001 1082 10821194	16-55	09OCT2020	106025	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)		
10821195	C4591001 1082 10821195	16-55	09OCT2020	105284	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)		
10821196	C4591001 1082 10821196	16-55	09OCT2020	105290	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
10821197	C4591001 1082 10821197	16-55	12OCT2020	106026	BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
10821198	C4591001 1082 10821198	16-55	14OCT2020	106032	Placebo	14OCT2020/ Placebo	02NOV2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
10821199	C4591001 1082 10821199	16-55	15OCT2020	106036	Placebo	15OCT2020/ Placebo	05NOV2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10821201	C4591001 1082 10821201	16-55	19OCT2020	110299	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
10821202	C4591001 1082 10821202	16-55	19OCT2020	110297	Placebo	19OCT2020/ Placebo	11NOV2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
10821203	C4591001 1082 10821203	16-55	20OCT2020	110304	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
10821204	C4591001 1082 10821204	16-55	20OCT2020	110306	Placebo	20OCT2020/ Placebo	11NOV2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	04JAN2021/ BNT162b2 (30 µg)
10821207	C4591001 1082 10821207	16-55	20OCT2020	111089	Placebo	20OCT2020/ Placebo	12NOV2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
10821208	C4591001 1082 10821208	16-55	21OCT2020	111092	Placebo	21OCT2020/ Placebo	12NOV2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
10821210	C4591001 1082 10821210	16-55	22OCT2020	111095	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
10821211	C4591001 1082 10821211	16-55	27OCT2020	111097	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
10821212	C4591001 1082 10821212	16-55	28OCT2020	114332	Placebo	28OCT2020/ Placebo	18NOV2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
10821215	C4591001 1082 10821215	16-55	29OCT2020	114336	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	18NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10821216	C4591001 1082 10821216	16-55	29OCT2020	114338	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
10821217	C4591001 1082 10821217	16-55	30OCT2020	114340	Placebo	30OCT2020/ Placebo	18NOV2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
10821218	C4591001 1082 10821218	16-55	30OCT2020	115038	BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)		
10821220	C4591001 1082 10821220	16-55	30OCT2020	115040	BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)	20NOV2020/ BNT162b2 (30 µg)		
10821221	C4591001 1082 10821221	16-55	30OCT2020	115044	Placebo	30OCT2020/ Placebo		12FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
10821224	C4591001 1082 10821224	16-55	30OCT2020	115046	Placebo	30OCT2020/ Placebo	20NOV2020/ Placebo		
10831105	C4591001 1083 10831105	16-55	17AUG2020	52365	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
10831106	C4591001 1083 10831106	16-55	17AUG2020	52368	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10831112	C4591001 1083 10831112	16-55	17AUG2020	52369	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10831113	C4591001 1083 10831113	16-55	18AUG2020	52371	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	02MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10831118	C4591001 1083 10831118	16-55	18AUG2020	54641	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10831119	C4591001 1083 10831119	16-55	18AUG2020	54642	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10831122	C4591001 1083 10831122	16-55	19AUG2020	54650	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
10831123	C4591001 1083 10831123	16-55	19AUG2020	54652	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10831124	C4591001 1083 10831124	16-55	19AUG2020	57487	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
10831127	C4591001 1083 10831127	16-55	20AUG2020	57494	Placebo	20AUG2020/ Placebo	11SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
10831128	C4591001 1083 10831128	16-55	20AUG2020	57495	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10831130	C4591001 1083 10831130	16-55	20AUG2020	57496	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10831132	C4591001 1083 10831132	16-55	20AUG2020	58577	Placebo	20AUG2020/ Placebo	09SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
10831133	C4591001 1083 10831133	16-55	20AUG2020	58584	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10831136	C4591001 1083 10831136	16-55	20AUG2020	58585	Placebo	20AUG2020/ Placebo	09SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
10831139	C4591001 1083 10831139	16-55	21AUG2020	61233	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10831140	C4591001 1083 10831140	16-55	21AUG2020	58587	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10831141	C4591001 1083 10831141	16-55	21AUG2020	61236	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)			
10831142	C4591001 1083 10831142	16-55	24AUG2020	61238	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
10831143	C4591001 1083 10831143	16-55	24AUG2020	61240	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
10831145	C4591001 1083 10831145	16-55	24AUG2020	64061	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
10831148	C4591001 1083 10831148	16-55	24AUG2020	64066	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
10831152	C4591001 1083 10831152	16-55	25AUG2020	64067	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
10831153	C4591001 1083 10831153	16-55	25AUG2020	64069	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10831154	C4591001 1083 10831154	16-55	25AUG2020	66297	Placebo	25AUG2020/ Placebo	14SEP2020/ Placebo		
10831160	C4591001 1083 10831160	16-55	26AUG2020	66298	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10831161	C4591001 1083 10831161	16-55	26AUG2020	66301	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
10831162	C4591001 1083 10831162	16-55	26AUG2020	66304	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10831163	C4591001 1083 10831163	16-55	26AUG2020	68505	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
10831164	C4591001 1083 10831164	16-55	26AUG2020	68508	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10831166	C4591001 1083 10831166	16-55	26AUG2020	68510	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo		
10831169	C4591001 1083 10831169	16-55	27AUG2020	68512	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
10831170	C4591001 1083 10831170	16-55	27AUG2020	70457	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	31DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)
10831171	C4591001 1083 10831171	16-55	27AUG2020	70464	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10831174	C4591001 1083 10831174	16-55	27AUG2020	70466	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10831178	C4591001 1083 10831178	16-55	31AUG2020	70468	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
10831179	C4591001 1083 10831179	16-55	31AUG2020	75463	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10831181	C4591001 1083 10831181	16-55	31AUG2020	75465	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	12MAR2021/ BNT162b2 (30 µg)	
10831183	C4591001 1083 10831183	16-55	01SEP2020	75466	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10831185	C4591001 1083 10831185	16-55	01SEP2020	75467	Placebo	01SEP2020/ Placebo	21SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
10831186	C4591001 1083 10831186	16-55	02SEP2020	77957	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10831187	C4591001 1083 10831187	16-55	02SEP2020	77963	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
10831188	C4591001 1083 10831188	16-55	03SEP2020	77965	Placebo	03SEP2020/ Placebo	23SEP2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
10831191	C4591001 1083 10831191	16-55	04SEP2020	77967	Placebo	04SEP2020/ Placebo	23SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10831194	C4591001 1083 10831194	16-55	04SEP2020	81918	Placebo	04SEP2020/ Placebo	23SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
10831197	C4591001 1083 10831197	16-55	04SEP2020	81921	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)		
10831198	C4591001 1083 10831198	16-55	09SEP2020	81922	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
10831201	C4591001 1083 10831201	16-55	09SEP2020	81928	Placebo	09SEP2020/ Placebo	01OCT2020/ Placebo		
10831203	C4591001 1083 10831203	16-55	09SEP2020	86153	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
10831205	C4591001 1083 10831205	16-55	09SEP2020	86158	Placebo	09SEP2020/ Placebo	01OCT2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
10831207	C4591001 1083 10831207	16-55	10SEP2020	86161	Placebo	10SEP2020/ Placebo	29SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
10831210	C4591001 1083 10831210	16-55	10SEP2020	86164	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
10831212	C4591001 1083 10831212	16-55	10SEP2020	87069	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
10831214	C4591001 1083 10831214	16-55	10SEP2020	87072	Placebo	10SEP2020/ Placebo	02OCT2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10831219	C4591001 1083 10831219	16-55	10SEP2020	87074	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10831221	C4591001 1083 10831221	16-55	10SEP2020	87076	Placebo	10SEP2020/ Placebo	29SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
10831222	C4591001 1083 10831222	16-55	10SEP2020	87701	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10831223	C4591001 1083 10831223	16-55	10SEP2020	87705	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
10831227	C4591001 1083 10831227	16-55	11SEP2020	87707	Placebo	11SEP2020/ Placebo	30SEP2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
10831232	C4591001 1083 10831232	16-55	11SEP2020	87712	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10831235	C4591001 1083 10831235	16-55	11SEP2020	88709	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
10831240	C4591001 1083 10831240	16-55	11SEP2020	88711	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10831241	C4591001 1083 10831241	16-55	11SEP2020	88717	Placebo	11SEP2020/ Placebo	30SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
10831242	C4591001 1083 10831242	16-55	11SEP2020	88714	Placebo	11SEP2020/ Placebo	30SEP2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10831244	C4591001 1083 10831244	16-55	11SEP2020	88954	Placebo	11SEP2020/ Placebo	30SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
10831245	C4591001 1083 10831245	16-55	11SEP2020	88953	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10831247	C4591001 1083 10831247	16-55	11SEP2020	88957	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
10831249	C4591001 1083 10831249	16-55	11SEP2020	88959	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
10831250	C4591001 1083 10831250	16-55	11SEP2020	89009	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
10831252	C4591001 1083 10831252	16-55	22SEP2020	89016	Placebo	22SEP2020/ Placebo	13OCT2020/ Placebo		
10831253	C4591001 1083 10831253	16-55	22SEP2020	89011	Placebo	22SEP2020/ Placebo	13OCT2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
10831254	C4591001 1083 10831254	16-55	22SEP2020	89017	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
10831255	C4591001 1083 10831255	16-55	22SEP2020	97039	Placebo	22SEP2020/ Placebo	13OCT2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10831256	C4591001 1083 10831256	16-55	23SEP2020	97040	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10831259	C4591001 1083 10831259	16-55	24SEP2020	97042	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
10831262	C4591001 1083 10831262	16-55	24SEP2020	97045	Placebo	24SEP2020/ Placebo	15OCT2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	21JAN2021/ BNT162b2 (30 µg)
10831264	C4591001 1083 10831264	16-55	24SEP2020	99114	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
10831265	C4591001 1083 10831265	16-55	24SEP2020	99115	Placebo	24SEP2020/ Placebo	13OCT2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
10831266	C4591001 1083 10831266	16-55	25SEP2020	99117	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
10831267	C4591001 1083 10831267	16-55	25SEP2020	99122	Placebo	25SEP2020/ Placebo	14OCT2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
10831268	C4591001 1083 10831268	16-55	25SEP2020	100422	Placebo	25SEP2020/ Placebo	15OCT2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10831270	C4591001 1083 10831270	16-55	21OCT2020	100424	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
10831271	C4591001 1083 10831271	16-55	21OCT2020	100431	Placebo	21OCT2020/ Placebo	12NOV2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
10831272	C4591001 1083 10831272	16-55	21OCT2020	100429	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10831273	C4591001 1083 10831273	16-55	21OCT2020	111657	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
10831276	C4591001 1083 10831276	16-55	21OCT2020	111658	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
10831278	C4591001 1083 10831278	16-55	21OCT2020	111659	Placebo	21OCT2020/ Placebo	11NOV2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
10831279	C4591001 1083 10831279	16-55	22OCT2020	111660	Placebo	22OCT2020/ Placebo	11NOV2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
10831281	C4591001 1083 10831281	16-55	22OCT2020	112399	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
10831282	C4591001 1083 10831282	16-55	22OCT2020	112400	Placebo	22OCT2020/ Placebo	12NOV2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	14JAN2021/ BNT162b2 (30 µg)
10831284	C4591001 1083 10831284	16-55	22OCT2020	112402	Placebo	22OCT2020/ Placebo	12NOV2020/ Placebo	02MAR2021/ BNT162b2 (30 µg)	
10841170	C4591001 1084 10841170	16-55	14AUG2020	50306	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
10841185	C4591001 1084 10841185	16-55	14AUG2020	50886	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	
10841187	C4591001 1084 10841187	16-55	14AUG2020	50894	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10841188	C4591001 1084 10841188	16-55	14AUG2020	50948	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10841189	C4591001 1084 10841189	16-55	17AUG2020	50952	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10841197	C4591001 1084 10841197	16-55	17AUG2020	50955	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10841199	C4591001 1084 10841199	16-55	17AUG2020	52687	Placebo	17AUG2020/ Placebo	09SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
10841200	C4591001 1084 10841200	16-55	17AUG2020	50956	Placebo	17AUG2020/ Placebo	11SEP2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
10841201	C4591001 1084 10841201	16-55	17AUG2020	52689	Placebo	17AUG2020/ Placebo	09SEP2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
10841208	C4591001 1084 10841208	16-55	17AUG2020	52693	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10841209	C4591001 1084 10841209	16-55	17AUG2020	52692	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10841214	C4591001 1084 10841214	16-55	17AUG2020	53277	Placebo	17AUG2020/ Placebo	09SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10841215	C4591001 1084 10841215	16-55	17AUG2020	53274	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10841220	C4591001 1084 10841220	16-55	17AUG2020	53278	Placebo	17AUG2020/ Placebo	09SEP2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
10841222	C4591001 1084 10841222	16-55	19AUG2020	53282	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
10841223	C4591001 1084 10841223	16-55	19AUG2020	56166	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
10841228	C4591001 1084 10841228	16-55	19AUG2020	56167	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10841234	C4591001 1084 10841234	16-55	19AUG2020	56170	Placebo	19AUG2020/ Placebo	11SEP2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
10841241	C4591001 1084 10841241	16-55	19AUG2020	56173	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo		
10841249	C4591001 1084 10841249	16-55	22AUG2020	61857	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10841251	C4591001 1084 10841251	16-55	22AUG2020	61858	Placebo	22AUG2020/ Placebo	14SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
10841254	C4591001 1084 10841254	16-55	22AUG2020	61864	Placebo	22AUG2020/ Placebo	11SEP2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
10841255	C4591001 1084 10841255	16-55	22AUG2020	61855	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10841259	C4591001 1084 10841259	16-55	22AUG2020	61999	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
10841262	C4591001 1084 10841262	16-55	22AUG2020	62001	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
10841267	C4591001 1084 10841267	16-55	22AUG2020	62178	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10841268	C4591001 1084 10841268	16-55	22AUG2020	62006	Placebo	22AUG2020/ Placebo	11SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
10841269	C4591001 1084 10841269	16-55	22AUG2020	62002	Placebo	22AUG2020/ Placebo	11SEP2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
10841270	C4591001 1084 10841270	16-55	22AUG2020	62184	Placebo	22AUG2020/ Placebo	18SEP2020/ Placebo		
10841272	C4591001 1084 10841272	16-55	22AUG2020	62337	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)			
10841273	C4591001 1084 10841273	16-55	22AUG2020	62185	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10841274	C4591001 1084 10841274	16-55	22AUG2020	62340	Placebo	22AUG2020/ Placebo	11SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10841275	C4591001 1084 10841275	16-55	22AUG2020	62339	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10841277	C4591001 1084 10841277	16-55	22AUG2020	62187	Placebo	22AUG2020/ Placebo	14SEP2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10841279	C4591001 1084 10841279	16-55	24AUG2020	63822	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
10841280	C4591001 1084 10841280	16-55	24AUG2020	62344	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
10841281	C4591001 1084 10841281	16-55	24AUG2020	63828	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10841283	C4591001 1084 10841283	16-55	24AUG2020	63830	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
10841285	C4591001 1084 10841285	16-55	24AUG2020	64505	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10841286	C4591001 1084 10841286	16-55	24AUG2020	64631	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10841287	C4591001 1084 10841287	16-55	24AUG2020	64506	Placebo	24AUG2020/ Placebo	18SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10841288	C4591001 1084 10841288	16-55	24AUG2020	64513	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10841290	C4591001 1084 10841290	16-55	24AUG2020	63832	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10841291	C4591001 1084 10841291	16-55	24AUG2020	64509	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10841292	C4591001 1084 10841292	16-55	24AUG2020	64627	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10841294	C4591001 1084 10841294	16-55	26AUG2020	64633	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
10841301	C4591001 1084 10841301	16-55	26AUG2020	64635	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10841303	C4591001 1084 10841303	16-55	26AUG2020	68873	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
10841306	C4591001 1084 10841306	16-55	26AUG2020	68882	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo		
10841307	C4591001 1084 10841307	16-55	26AUG2020	68877	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10841308	C4591001 1084 10841308	16-55	28AUG2020	72057	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
10841309	C4591001 1084 10841309	16-55	28AUG2020	68883	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
10841311	C4591001 1084 10841311	16-55	28AUG2020	72058	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10841312	C4591001 1084 10841312	16-55	28AUG2020	72062	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
10841315	C4591001 1084 10841315	16-55	28AUG2020	72473	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
10841316	C4591001 1084 10841316	16-55	28AUG2020	72064	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10841317	C4591001 1084 10841317	16-55	28AUG2020	72478	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
10841318	C4591001 1084 10841318	16-55	28AUG2020	72481	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
10841321	C4591001 1084 10841321	16-55	31AUG2020	72482	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10841322	C4591001 1084 10841322	16-55	31AUG2020	74911	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)
10841324	C4591001 1084 10841324	16-55	31AUG2020	74912	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10841327	C4591001 1084 10841327	16-55	31AUG2020	74913	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10841328	C4591001 1084 10841328	16-55	31AUG2020	74916	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10841330	C4591001 1084 10841330	16-55	31AUG2020	75527	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10841333	C4591001 1084 10841333	16-55	31AUG2020	75528	Placebo	31AUG2020/ Placebo	02OCT2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10841334	C4591001 1084 10841334	16-55	31AUG2020	75529	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
10841338	C4591001 1084 10841338	16-55	02SEP2020	78426	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
10841339	C4591001 1084 10841339	16-55	02SEP2020	75530	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10841342	C4591001 1084 10841342	16-55	02SEP2020	78429	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10841344	C4591001 1084 10841344	16-55	02SEP2020	78430	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10841346	C4591001 1084 10841346	16-55	04SEP2020	78436	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10841348	C4591001 1084 10841348	16-55	04SEP2020	81773	Placebo	04SEP2020/ Placebo	23SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10841350	C4591001 1084 10841350	16-55	04SEP2020	81774	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10841351	C4591001 1084 10841351	16-55	04SEP2020	81784	Placebo	04SEP2020/ Placebo	23SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
10841352	C4591001 1084 10841352	16-55	04SEP2020	81778	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
10841353	C4591001 1084 10841353	16-55	04SEP2020	82266	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
10841355	C4591001 1084 10841355	16-55	04SEP2020	82272	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
10841356	C4591001 1084 10841356	16-55	04SEP2020	82269	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
10841358	C4591001 1084 10841358	16-55	09SEP2020	82276	Placebo	09SEP2020/ Placebo	28SEP2020/ Placebo		
10841359	C4591001 1084 10841359	16-55	09SEP2020	85013	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
10841365	C4591001 1084 10841365	16-55	09SEP2020	85017	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10841371	C4591001 1084 10841371	16-55	09SEP2020	85020	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo		
10841372	C4591001 1084 10841372	16-55	11SEP2020	85023	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10841373	C4591001 1084 10841373	16-55	11SEP2020	88044	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
10841374	C4591001 1084 10841374	16-55	11SEP2020	88041	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10841375	C4591001 1084 10841375	16-55	11SEP2020	88046	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
10841376	C4591001 1084 10841376	16-55	11SEP2020	88048	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
10841378	C4591001 1084 10841378	16-55	11SEP2020	88325	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10841381	C4591001 1084 10841381	16-55	11SEP2020	88336	Placebo	11SEP2020/ Placebo	30SEP2020/ Placebo	31DEC2020/ BNT162b2 (30 µg)	20JAN2021/ BNT162b2 (30 µg)
10841382	C4591001 1084 10841382	16-55	11SEP2020	88329	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo		
10841384	C4591001 1084 10841384	16-55	11SEP2020	88331	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
10841385	C4591001 1084 10841385	16-55	11SEP2020	88722	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
10841386	C4591001 1084 10841386	16-55	11SEP2020	88727	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10841388	C4591001 1084 10841388	16-55	11SEP2020	88729	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10841390	C4591001 1084 10841390	16-55	14SEP2020	88732	Placebo	14SEP2020/ Placebo	07OCT2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
10841391	C4591001 1084 10841391	16-55	14SEP2020	89525	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
10841393	C4591001 1084 10841393	16-55	14SEP2020	89528	Placebo	14SEP2020/ Placebo	07OCT2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10841394	C4591001 1084 10841394	16-55	14SEP2020	89534	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
10841396	C4591001 1084 10841396	16-55	14SEP2020	89536	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
10841402	C4591001 1084 10841402	16-55	14SEP2020	89969	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
10841404	C4591001 1084 10841404	16-55	14SEP2020	89971	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10841405	C4591001 1084 10841405	16-55	23SEP2020	97472	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	27JAN2021/ BNT162b2 (30 µg)
10841407	C4591001 1084 10841407	16-55	16SEP2020	89975	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10841409	C4591001 1084 10841409	16-55	16SEP2020	89977	Placebo	16SEP2020/ Placebo	07OCT2020/ Placebo		
10841410	C4591001 1084 10841410	16-55	16SEP2020	91409	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
10841413	C4591001 1084 10841413	16-55	16SEP2020	91414	Placebo	16SEP2020/ Placebo	07OCT2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)
10841416	C4591001 1084 10841416	16-55	18SEP2020	91419	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10841417	C4591001 1084 10841417	16-55	18SEP2020	93633	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo		
10841418	C4591001 1084 10841418	16-55	18SEP2020	91420	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
10841420	C4591001 1084 10841420	16-55	18SEP2020	93634	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
10841422	C4591001 1084 10841422	16-55	18SEP2020	93635	Placebo	18SEP2020/ Placebo	21OCT2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10841423	C4591001 1084 10841423	16-55	18SEP2020	93977	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
10841425	C4591001 1084 10841425	16-55	18SEP2020	93639	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10841426	C4591001 1084 10841426	16-55	18SEP2020	93982	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
10841428	C4591001 1084 10841428	16-55	18SEP2020	93984	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
10841429	C4591001 1084 10841429	16-55	21SEP2020	93985	Placebo	21SEP2020/ Placebo	14OCT2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10841431	C4591001 1084 10841431	16-55	21SEP2020	95121	Placebo	21SEP2020/ Placebo	14OCT2020/ Placebo	31DEC2020/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
10841432	C4591001 1084 10841432	16-55	21SEP2020	95120	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
10841433	C4591001 1084 10841433	16-55	21SEP2020	95433	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
10841434	C4591001 1084 10841434	16-55	21SEP2020	95126	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
10841435	C4591001 1084 10841435	16-55	21SEP2020	95124	Placebo	21SEP2020/ Placebo	14OCT2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
10841436	C4591001 1084 10841436	16-55	21SEP2020	95435	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
10841437	C4591001 1084 10841437	16-55	21SEP2020	95438	Placebo	21SEP2020/ Placebo	14OCT2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10841438	C4591001 1084 10841438	16-55	21SEP2020	95440	Placebo	21SEP2020/ Placebo	14OCT2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
10841439	C4591001 1084 10841439	16-55	23SEP2020	97469	Placebo	23SEP2020/ Placebo	12OCT2020/ Placebo		
10841441	C4591001 1084 10841441	16-55	23SEP2020	97473	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
10841442	C4591001 1084 10841442	16-55	23SEP2020	97476	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
10841448	C4591001 1084 10841448	16-55	23SEP2020	98156	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
10841449	C4591001 1084 10841449	16-55	23SEP2020	98153	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
10841450	C4591001 1084 10841450	16-55	25SEP2020	98164	Placebo	25SEP2020/ Placebo	14OCT2020/ Placebo		
10841452	C4591001 1084 10841452	16-55	25SEP2020	98157	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
10841454	C4591001 1084 10841454	16-55	25SEP2020	99941	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10841456	C4591001 1084 10841456	16-55	25SEP2020	99945	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10841457	C4591001 1084 10841457	16-55	25SEP2020	99943	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
10841458	C4591001 1084 10841458	16-55	25SEP2020	99950	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
10841461	C4591001 1084 10841461	16-55	25SEP2020	100508	Placebo	25SEP2020/ Placebo	14OCT2020/ Placebo		
10841462	C4591001 1084 10841462	16-55	28SEP2020	100509	BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)		
10841464	C4591001 1084 10841464	16-55	28SEP2020	100515	Placebo	28SEP2020/ Placebo	19OCT2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10841465	C4591001 1084 10841465	16-55	28SEP2020	100511	BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)		
10841466	C4591001 1084 10841466	16-55	28SEP2020	101479	BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		
10841468	C4591001 1084 10841468	16-55	28SEP2020	101482	BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)		
10841469	C4591001 1084 10841469	16-55	28SEP2020	101486	Placebo	28SEP2020/ Placebo	19OCT2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
10841474	C4591001 1084 10841474	16-55	12OCT2020	101487	Placebo	12OCT2020/ Placebo	02NOV2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10841479	C4591001 1084 10841479	16-55	14OCT2020	107513	BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
10841480	C4591001 1084 10841480	16-55	14OCT2020	107519	Placebo	14OCT2020/ Placebo	02NOV2020/ Placebo		
10841481	C4591001 1084 10841481	16-55	14OCT2020	107514	Placebo	14OCT2020/ Placebo	02NOV2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
10841484	C4591001 1084 10841484	16-55	14OCT2020	107730	Placebo	14OCT2020/ Placebo	04NOV2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10841486	C4591001 1084 10841486	16-55	14OCT2020	107522	BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
10841488	C4591001 1084 10841488	16-55	16OCT2020	107734	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
10841489	C4591001 1084 10841489	16-55	16OCT2020	107736	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
10841492	C4591001 1084 10841492	16-55	16OCT2020	109184	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
10841493	C4591001 1084 10841493	16-55	16OCT2020	109192	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
10841494	C4591001 1084 10841494	16-55	16OCT2020	107740	Placebo	16OCT2020/ Placebo	06NOV2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10841495	C4591001 1084 10841495	16-55	16OCT2020	109187	Placebo	16OCT2020/ Placebo	04NOV2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
10841496	C4591001 1084 10841496	16-55	16OCT2020	109186	Placebo	16OCT2020/ Placebo	04NOV2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
10841499	C4591001 1084 10841499	16-55	16OCT2020	109307	Placebo	16OCT2020/ Placebo	04NOV2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
10841500	C4591001 1084 10841500	16-55	16OCT2020	109308	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
10841502	C4591001 1084 10841502	16-55	19OCT2020	109309	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
10841503	C4591001 1084 10841503	16-55	19OCT2020	109312	Placebo	19OCT2020/ Placebo	16NOV2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10841506	C4591001 1084 10841506	16-55	19OCT2020	110550	Placebo	19OCT2020/ Placebo	11NOV2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10841509	C4591001 1084 10841509	16-55	19OCT2020	110558	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
10841511	C4591001 1084 10841511	16-55	19OCT2020	110551	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
10841512	C4591001 1084 10841512	16-55	21OCT2020	110560	Placebo	21OCT2020/ Placebo	11NOV2020/ Placebo		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10841513	C4591001 1084 10841513	16-55	21OCT2020	111510	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
10841514	C4591001 1084 10841514	16-55	21OCT2020	111515	Placebo	21OCT2020/ Placebo	11NOV2020/ Placebo	31DEC2020/ BNT162b2 (30 µg)	22JAN2021/ BNT162b2 (30 µg)
10841517	C4591001 1084 10841517	16-55	21OCT2020	111516	Placebo	21OCT2020/ Placebo	11NOV2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10841518	C4591001 1084 10841518	16-55	21OCT2020	111629	Placebo	21OCT2020/ Placebo	13NOV2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
10841519	C4591001 1084 10841519	16-55	21OCT2020	111518	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
10841520	C4591001 1084 10841520	16-55	23OCT2020	111630	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
10841521	C4591001 1084 10841521	16-55	23OCT2020	111631	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
10841522	C4591001 1084 10841522	16-55	19NOV2020	272881	Placebo	19NOV2020/ Placebo	10DEC2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
10841526	C4591001 1084 10841526	16-55	23OCT2020	111633	Placebo	23OCT2020/ Placebo	11NOV2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
10841530	C4591001 1084 10841530	16-55	23OCT2020	113219	Placebo	23OCT2020/ Placebo	13NOV2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10841532	C4591001 1084 10841532	16-55	23OCT2020	113221	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
10841533	C4591001 1084 10841533	16-55	26OCT2020	113222	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
10841535	C4591001 1084 10841535	16-55	26OCT2020	113223	Placebo	26OCT2020/ Placebo	16NOV2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10841536	C4591001 1084 10841536	16-55	28OCT2020	114546	Placebo	28OCT2020/ Placebo	18NOV2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
10841537	C4591001 1084 10841537	16-55	30OCT2020	114549	BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)	18NOV2020/ BNT162b2 (30 µg)		
10841538	C4591001 1084 10841538	16-55	06NOV2020	114554	BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)	30NOV2020/ BNT162b2 (30 µg)		
10841539	C4591001 1084 10841539	16-55	11NOV2020	114555	Placebo	11NOV2020/ Placebo	02DEC2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10841540	C4591001 1084 10841540	16-55	20NOV2020	116598	BNT162b2 (30 µg)	20NOV2020/ BNT162b2 (30 µg)	10DEC2020/ BNT162b2 (30 µg)		
10851104	C4591001 1085 10851104	16-55	17AUG2020	52866	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	28JAN2021/ BNT162b2 (30 µg)
10851108	C4591001 1085 10851108	16-55	17AUG2020	52875	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10851109	C4591001 1085 10851109	16-55	17AUG2020	52874	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10851110	C4591001 1085 10851110	16-55	17AUG2020	52876	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10851112	C4591001 1085 10851112	16-55	17AUG2020	53586	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10851114	C4591001 1085 10851114	16-55	18AUG2020	53588	Placebo	18AUG2020/ Placebo	10SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
10851124	C4591001 1085 10851124	16-55	18AUG2020	53592	Placebo	18AUG2020/ Placebo	10SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
10851125	C4591001 1085 10851125	16-55	18AUG2020	55269	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10851127	C4591001 1085 10851127	16-55	18AUG2020	55270	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10851128	C4591001 1085 10851128	16-55	18AUG2020	53596	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10851129	C4591001 1085 10851129	16-55	18AUG2020	55274	Placebo	18AUG2020/ Placebo	10SEP2020/ Placebo		
10851132	C4591001 1085 10851132	16-55	20AUG2020	55276	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10851136	C4591001 1085 10851136	16-55	21AUG2020	60488	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
10851137	C4591001 1085 10851137	16-55	21AUG2020	60493	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo		
10851140	C4591001 1085 10851140	16-55	24AUG2020	60495	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10851141	C4591001 1085 10851141	16-55	24AUG2020	60496	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)
10851142	C4591001 1085 10851142	16-55	24AUG2020	63643	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10851143	C4591001 1085 10851143	16-55	24AUG2020	63642	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10851153	C4591001 1085 10851153	16-55	10SEP2020	87009	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
10851155	C4591001 1085 10851155	16-55	24AUG2020	63646	Placebo	24AUG2020/ Placebo	16SEP2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)
10851157	C4591001 1085 10851157	16-55	24AUG2020	64770	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10851158	C4591001 1085 10851158	16-55	24AUG2020	64771	Placebo	24AUG2020/ Placebo	15SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10851159	C4591001 1085 10851159	16-55	25AUG2020	64775	Placebo	25AUG2020/ Placebo	17SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10851163	C4591001 1085 10851163	16-55	25AUG2020	65971	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10851164	C4591001 1085 10851164	16-55	25AUG2020	64777	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10851165	C4591001 1085 10851165	16-55	25AUG2020	65972	Placebo	25AUG2020/ Placebo	17SEP2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
10851170	C4591001 1085 10851170	16-55	25AUG2020	65976	Placebo	25AUG2020/ Placebo	17SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10851175	C4591001 1085 10851175	16-55	25AUG2020	66848	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10851178	C4591001 1085 10851178	16-55	26AUG2020	66849	Placebo	26AUG2020/ Placebo	18SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	
10851179	C4591001 1085 10851179	16-55	26AUG2020	66850	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10851180	C4591001 1085 10851180	16-55	26AUG2020	66854	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10851188	C4591001 1085 10851188	16-55	26AUG2020	69103	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10851189	C4591001 1085 10851189	16-55	26AUG2020	69101	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
10851191	C4591001 1085 10851191	16-55	26AUG2020	69105	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10851193	C4591001 1085 10851193	16-55	27AUG2020	69111	Placebo	27AUG2020/ Placebo	18SEP2020/ Placebo	06JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
10851195	C4591001 1085 10851195	16-55	27AUG2020	70651	Placebo	27AUG2020/ Placebo	18SEP2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
10851196	C4591001 1085 10851196	16-55	27AUG2020	70653	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10851200	C4591001 1085 10851200	16-55	29AUG2020	70659	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10851203	C4591001 1085 10851203	16-55	29AUG2020	73855	Placebo	29AUG2020/ Placebo	21SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
10851206	C4591001 1085 10851206	16-55	31AUG2020	73857	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10851210	C4591001 1085 10851210	16-55	31AUG2020	73858	Placebo	31AUG2020/ Placebo	23SEP2020/ Placebo		
10851211	C4591001 1085 10851211	16-55	31AUG2020	73861	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10851212	C4591001 1085 10851212	16-55	31AUG2020	75317	Placebo	31AUG2020/ Placebo	23SEP2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)
10851217	C4591001 1085 10851217	16-55	31AUG2020	75318	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	27JAN2021/ BNT162b2 (30 µg)
10851219	C4591001 1085 10851219	16-55	31AUG2020	75325	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10851221	C4591001 1085 10851221	16-55	01SEP2020	75327	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10851225	C4591001 1085 10851225	16-55	01SEP2020	76891	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10851229	C4591001 1085 10851229	16-55	01SEP2020	76892	Placebo	01SEP2020/ Placebo	24SEP2020/ Placebo		
10851231	C4591001 1085 10851231	16-55	01SEP2020	76893	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10851236	C4591001 1085 10851236	16-55	01SEP2020	76897	Placebo	01SEP2020/ Placebo	24SEP2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10851237	C4591001 1085 10851237	16-55	01SEP2020	77709	Placebo	01SEP2020/ Placebo	24SEP2020/ Placebo		
10851238	C4591001 1085 10851238	16-55	02SEP2020	77710	Placebo	02SEP2020/ Placebo	25SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10851239	C4591001 1085 10851239	16-55	02SEP2020	77712	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
10851240	C4591001 1085 10851240	16-55	02SEP2020	77713	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
10851242	C4591001 1085 10851242	16-55	02SEP2020	78295	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
10851244	C4591001 1085 10851244	16-55	02SEP2020	78298	Placebo	02SEP2020/ Placebo	25SEP2020/ Placebo		
10851245	C4591001 1085 10851245	16-55	02SEP2020	78301	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
10851246	C4591001 1085 10851246	16-55	02SEP2020	78304	Placebo	02SEP2020/ Placebo	25SEP2020/ Placebo		
10851248	C4591001 1085 10851248	16-55	02SEP2020	79207	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10851249	C4591001 1085 10851249	16-55	02SEP2020	79213	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	06JAN2021/ BNT162b2 (30 µg)	27JAN2021/ BNT162b2 (30 µg)
10851250	C4591001 1085 10851250	16-55	03SEP2020	79214	Placebo	03SEP2020/ Placebo	25SEP2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)
10851252	C4591001 1085 10851252	16-55	03SEP2020	79215	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10851253	C4591001 1085 10851253	16-55	03SEP2020	80491	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10851256	C4591001 1085 10851256	16-55	03SEP2020	80493	Placebo	03SEP2020/ Placebo	25SEP2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	28JAN2021/ BNT162b2 (30 µg)
10851259	C4591001 1085 10851259	16-55	03SEP2020	80496	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
10851261	C4591001 1085 10851261	16-55	04SEP2020	80499	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10851264	C4591001 1085 10851264	16-55	08SEP2020	83477	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
10851265	C4591001 1085 10851265	16-55	08SEP2020	83478	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10851269	C4591001 1085 10851269	16-55	08SEP2020	83482	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
10851270	C4591001 1085 10851270	16-55	08SEP2020	83485	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
10851276	C4591001 1085 10851276	16-55	08SEP2020	84047	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
10851277	C4591001 1085 10851277	16-55	08SEP2020	84048	Placebo	08SEP2020/ Placebo	01OCT2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10851280	C4591001 1085 10851280	16-55	08SEP2020	84595	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
10851281	C4591001 1085 10851281	16-55	08SEP2020	84052	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
10851283	C4591001 1085 10851283	16-55	09SEP2020	84596	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
10851284	C4591001 1085 10851284	16-55	09SEP2020	84602	Placebo	09SEP2020/ Placebo	02OCT2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10851285	C4591001 1085 10851285	16-55	09SEP2020	84604	Placebo	09SEP2020/ Placebo	02OCT2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
10851286	C4591001 1085 10851286	16-55	09SEP2020	85518	Placebo	09SEP2020/ Placebo			
10851287	C4591001 1085 10851287	16-55	09SEP2020	85520	Placebo	09SEP2020/ Placebo	02OCT2020/ Placebo		
10851290	C4591001 1085 10851290	16-55	09SEP2020	85522	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10851291	C4591001 1085 10851291	16-55	09SEP2020	85528	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
10851294	C4591001 1085 10851294	16-55	09SEP2020	86021	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10851296	C4591001 1085 10851296	16-55	09SEP2020	86024	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
10851298	C4591001 1085 10851298	16-55	10SEP2020	86027	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10851299	C4591001 1085 10851299	16-55	10SEP2020	86031	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo	06JAN2021/ BNT162b2 (30 µg)	27JAN2021/ BNT162b2 (30 µg)
10851300	C4591001 1085 10851300	16-55	10SEP2020	87007	Placebo	10SEP2020/ Placebo	12OCT2020/ Placebo		
10851302	C4591001 1085 10851302	16-55	10SEP2020	87011	Placebo	10SEP2020/ Placebo	02OCT2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
10851304	C4591001 1085 10851304	16-55	10SEP2020	87014	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
10851305	C4591001 1085 10851305	16-55	10SEP2020	87583	Placebo	10SEP2020/ Placebo	02OCT2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
10851307	C4591001 1085 10851307	16-55	10SEP2020	87586	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo		
10851308	C4591001 1085 10851308	16-55	11SEP2020	87587	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10851309	C4591001 1085 10851309	16-55	11SEP2020	87930	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10851310	C4591001 1085 10851310	16-55	11SEP2020	87589	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
10851312	C4591001 1085 10851312	16-55	11SEP2020	87931	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10851314	C4591001 1085 10851314	16-55	11SEP2020	87937	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
10851316	C4591001 1085 10851316	16-55	11SEP2020	87935	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10851320	C4591001 1085 10851320	16-55	11SEP2020	88702	Placebo	11SEP2020/ Placebo	30SEP2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	28JAN2021/ BNT162b2 (30 µg)
10851321	C4591001 1085 10851321	16-55	11SEP2020	88703	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
10851323	C4591001 1085 10851323	16-55	11SEP2020	88704	Placebo	11SEP2020/ Placebo	30SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
10851325	C4591001 1085 10851325	16-55	14SEP2020	88707	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
10851327	C4591001 1085 10851327	16-55	14SEP2020	89741	Placebo	14SEP2020/ Placebo	07OCT2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10851328	C4591001 1085 10851328	16-55	14SEP2020	89744	Placebo	14SEP2020/ Placebo	06OCT2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10851330	C4591001 1085 10851330	16-55	14SEP2020	89745	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
10851332	C4591001 1085 10851332	16-55	14SEP2020	89750	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)			
10851336	C4591001 1085 10851336	16-55	15SEP2020	90432	Placebo	15SEP2020/ Placebo	07OCT2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10851337	C4591001 1085 10851337	16-55	15SEP2020	90426	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
10851339	C4591001 1085 10851339	16-55	15SEP2020	90435	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
10851341	C4591001 1085 10851341	16-55	15SEP2020	90436	Placebo	15SEP2020/ Placebo	07OCT2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10851342	C4591001 1085 10851342	16-55	15SEP2020	90836	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
10851343	C4591001 1085 10851343	16-55	15SEP2020	90838	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
10851344	C4591001 1085 10851344	16-55	16SEP2020	90842	Placebo	16SEP2020/ Placebo	09OCT2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10851345	C4591001 1085 10851345	16-55	16SEP2020	90843	Placebo	16SEP2020/ Placebo	14OCT2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10851346	C4591001 1085 10851346	16-55	16SEP2020	91579	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
10851349	C4591001 1085 10851349	16-55	16SEP2020	91583	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
10851350	C4591001 1085 10851350	16-55	16SEP2020	91584	Placebo	16SEP2020/ Placebo	19OCT2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
10851352	C4591001 1085 10851352	16-55	17SEP2020	91585	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
10851354	C4591001 1085 10851354	16-55	28SEP2020	101430	Placebo	28SEP2020/ Placebo	19OCT2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10851355	C4591001 1085 10851355	16-55	29SEP2020	101432	BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)		
10851356	C4591001 1085 10851356	16-55	29SEP2020	101436	Placebo	29SEP2020/ Placebo	20OCT2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10851357	C4591001 1085 10851357	16-55	30SEP2020	101437	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)		
10851358	C4591001 1085 10851358	16-55	05OCT2020	103747	Placebo	05OCT2020/ Placebo	26OCT2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)
10851359	C4591001 1085 10851359	16-55	05OCT2020	103752	BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10851361	C4591001 1085 10851361	16-55	05OCT2020	103753	Placebo	05OCT2020/ Placebo	27OCT2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
10851362	C4591001 1085 10851362	16-55	05OCT2020	103756	BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		
10851363	C4591001 1085 10851363	16-55	06OCT2020	104357	BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)		
10851364	C4591001 1085 10851364	16-55	06OCT2020	104361	BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)		
10851365	C4591001 1085 10851365	16-55	06OCT2020	104363	Placebo	06OCT2020/ Placebo	29OCT2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
10851366	C4591001 1085 10851366	16-55	08OCT2020	104365	Placebo	08OCT2020/ Placebo	30OCT2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10851367	C4591001 1085 10851367	16-55	08OCT2020	105557	Placebo	08OCT2020/ Placebo	30OCT2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
10851368	C4591001 1085 10851368	16-55	12OCT2020	105558	Placebo	12OCT2020/ Placebo	02NOV2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
10851369	C4591001 1085 10851369	16-55	12OCT2020	105563	BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
10851370	C4591001 1085 10851370	16-55	12OCT2020	105566	BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10851371	C4591001 1085 10851371	16-55	13OCT2020	107034	Placebo	13OCT2020/ Placebo	02NOV2020/ Placebo		
10851372	C4591001 1085 10851372	16-55	13OCT2020	107037	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
10851373	C4591001 1085 10851373	16-55	29OCT2020	107039	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
10851374	C4591001 1085 10851374	16-55	29OCT2020	107041	Placebo	29OCT2020/ Placebo	17NOV2020/ Placebo		
10851375	C4591001 1085 10851375	16-55	29OCT2020	114857	Placebo	29OCT2020/ Placebo	20NOV2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
10871083	C4591001 1087 10871083	16-55	17AUG2020	46887	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
10871084	C4591001 1087 10871084	16-55	17AUG2020	46886	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10871085	C4591001 1087 10871085	16-55	17AUG2020	52403	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo		
10871086	C4591001 1087 10871086	16-55	17AUG2020	52407	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10871087	C4591001 1087 10871087	16-55	17AUG2020	52408	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10871088	C4591001 1087 10871088	16-55	17AUG2020	52406	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10871089	C4591001 1087 10871089	16-55	17AUG2020	52589	Placebo	17AUG2020/ Placebo			
10871092	C4591001 1087 10871092	16-55	17AUG2020	52590	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10871094	C4591001 1087 10871094	16-55	18AUG2020	52599	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10871095	C4591001 1087 10871095	16-55	18AUG2020	52597	Placebo	18AUG2020/ Placebo	17SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10871096	C4591001 1087 10871096	16-55	18AUG2020	53837	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
10871102	C4591001 1087 10871102	16-55	18AUG2020	53840	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10871103	C4591001 1087 10871103	16-55	18AUG2020	53841	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
10871104	C4591001 1087 10871104	16-55	18AUG2020	53842	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10871107	C4591001 1087 10871107	16-55	18AUG2020	54655	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10871108	C4591001 1087 10871108	16-55	18AUG2020	54654	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo		
10871109	C4591001 1087 10871109	16-55	18AUG2020	54657	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10871110	C4591001 1087 10871110	16-55	18AUG2020	54659	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10871111	C4591001 1087 10871111	16-55	18AUG2020	54954	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	22JAN2021/ BNT162b2 (30 µg)
10871113	C4591001 1087 10871113	16-55	18AUG2020	54956	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
10871114	C4591001 1087 10871114	16-55	19AUG2020	54957	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10871118	C4591001 1087 10871118	16-55	19AUG2020	54961	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10871119	C4591001 1087 10871119	16-55	19AUG2020	56576	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
10871120	C4591001 1087 10871120	16-55	19AUG2020	56574	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10871127	C4591001 1087 10871127	16-55	20AUG2020	56577	Placebo	20AUG2020/ Placebo	08SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10871135	C4591001 1087 10871135	16-55	20AUG2020	56583	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10871138	C4591001 1087 10871138	16-55	20AUG2020	58613	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
10871146	C4591001 1087 10871146	16-55	20AUG2020	58614	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10871148	C4591001 1087 10871148	16-55	20AUG2020	58618	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	28JAN2021/ BNT162b2 (30 µg)
10871149	C4591001 1087 10871149	16-55	21AUG2020	58622	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
10871151	C4591001 1087 10871151	16-55	21AUG2020	60319	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10871152	C4591001 1087 10871152	16-55	21AUG2020	60317	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
10871153	C4591001 1087 10871153	16-55	21AUG2020	60318	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
10871160	C4591001 1087 10871160	16-55	21AUG2020	60321	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10871166	C4591001 1087 10871166	16-55	24AUG2020	63318	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10871171	C4591001 1087 10871171	16-55	24AUG2020	63321	Placebo	24AUG2020/ Placebo	18SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
10871172	C4591001 1087 10871172	16-55	24AUG2020	63322	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10871179	C4591001 1087 10871179	16-55	24AUG2020	63328	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10871180	C4591001 1087 10871180	16-55	24AUG2020	64399	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10871181	C4591001 1087 10871181	16-55	24AUG2020	64402	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10871182	C4591001 1087 10871182	16-55	24AUG2020	64403	Placebo	24AUG2020/ Placebo	17SEP2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
10871186	C4591001 1087 10871186	16-55	25AUG2020	64407	Placebo	25AUG2020/ Placebo	09OCT2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
10871189	C4591001 1087 10871189	16-55	25AUG2020	65288	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10871191	C4591001 1087 10871191	16-55	25AUG2020	65289	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10871194	C4591001 1087 10871194	16-55	25AUG2020	65295	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10871195	C4591001 1087 10871195	16-55	25AUG2020	65293	Placebo	25AUG2020/ Placebo	16SEP2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
10871196	C4591001 1087 10871196	16-55	25AUG2020	65768	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10871201	C4591001 1087 10871201	16-55	25AUG2020	65770	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10871205	C4591001 1087 10871205	16-55	25AUG2020	65772	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
10871209	C4591001 1087 10871209	16-55	25AUG2020	66389	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)			
10871212	C4591001 1087 10871212	16-55	25AUG2020	66391	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
10871213	C4591001 1087 10871213	16-55	26AUG2020	66394	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
10871214	C4591001 1087 10871214	16-55	26AUG2020	66396	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10871215	C4591001 1087 10871215	16-55	26AUG2020	67256	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
10871225	C4591001 1087 10871225	16-55	26AUG2020	67260	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10871230	C4591001 1087 10871230	16-55	26AUG2020	67261	Placebo	26AUG2020/ Placebo	15SEP2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10871231	C4591001 1087 10871231	16-55	26AUG2020	67264	Placebo	26AUG2020/ Placebo	15SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
10871235	C4591001 1087 10871235	16-55	26AUG2020	68298	Placebo	26AUG2020/ Placebo	15SEP2020/ Placebo		
10871239	C4591001 1087 10871239	16-55	26AUG2020	68302	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10871241	C4591001 1087 10871241	16-55	26AUG2020	68305	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
10871243	C4591001 1087 10871243	16-55	26AUG2020	68308	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10871244	C4591001 1087 10871244	16-55	26AUG2020	68993	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
10871247	C4591001 1087 10871247	16-55	27AUG2020	68996	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10871248	C4591001 1087 10871248	16-55	27AUG2020	69001	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10871252	C4591001 1087 10871252	16-55	28AUG2020	69003	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10871265	C4591001 1087 10871265	16-55	31AUG2020	75992	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10871267	C4591001 1087 10871267	16-55	31AUG2020	75993	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10871276	C4591001 1087 10871276	16-55	01SEP2020	75994	Placebo	01SEP2020/ Placebo	29SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10871279	C4591001 1087 10871279	16-55	01SEP2020	75995	Placebo	01SEP2020/ Placebo	21SEP2020/ Placebo		
10871282	C4591001 1087 10871282	16-55	01SEP2020	76759	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10871285	C4591001 1087 10871285	16-55	01SEP2020	76763	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	04JAN2021/ BNT162b2 (30 µg)
10871293	C4591001 1087 10871293	16-55	01SEP2020	76765	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10871296	C4591001 1087 10871296	16-55	01SEP2020	249020	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	20JAN2021/ BNT162b2 (30 µg)
10871297	C4591001 1087 10871297	16-55	02SEP2020	76766	Placebo	02SEP2020/ Placebo	21SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10871299	C4591001 1087 10871299	16-55	02SEP2020	77802	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10871301	C4591001 1087 10871301	16-55	02SEP2020	77803	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10871308	C4591001 1087 10871308	16-55	02SEP2020	77809	Placebo	02SEP2020/ Placebo	28SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
10871310	C4591001 1087 10871310	16-55	02SEP2020	77812	Placebo	02SEP2020/ Placebo	24SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
10871314	C4591001 1087 10871314	16-55	02SEP2020	79038	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10871316	C4591001 1087 10871316	16-55	02SEP2020	79041	Placebo	02SEP2020/ Placebo	24SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10871323	C4591001 1087 10871323	16-55	03SEP2020	79044	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10871325	C4591001 1087 10871325	16-55	03SEP2020	79046	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo		
10871330	C4591001 1087 10871330	16-55	03SEP2020	79986	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	04JAN2021/ BNT162b2 (30 µg)
10871332	C4591001 1087 10871332	16-55	03SEP2020	79993	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
10871333	C4591001 1087 10871333	16-55	03SEP2020	79994	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10871336	C4591001 1087 10871336	16-55	03SEP2020	79996	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)			
10871338	C4591001 1087 10871338	16-55	04SEP2020	81377	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10871342	C4591001 1087 10871342	16-55	04SEP2020	81380	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10871343	C4591001 1087 10871343	16-55	08SEP2020	81382	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
10871348	C4591001 1087 10871348	16-55	08SEP2020	83466	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
10871349	C4591001 1087 10871349	16-55	08SEP2020	81383	Placebo	08SEP2020/ Placebo	30SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
10871354	C4591001 1087 10871354	16-55	08SEP2020	83469	Placebo	08SEP2020/ Placebo			
10871355	C4591001 1087 10871355	16-55	08SEP2020	83474	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
10871356	C4591001 1087 10871356	16-55	08SEP2020	83475	Placebo	08SEP2020/ Placebo			
10871357	C4591001 1087 10871357	16-55	08SEP2020	83878	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10871359	C4591001 1087 10871359	16-55	08SEP2020	83879	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
10871360	C4591001 1087 10871360	16-55	08SEP2020	83881	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
10871361	C4591001 1087 10871361	16-55	08SEP2020	83883	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
10871363	C4591001 1087 10871363	16-55	08SEP2020	84246	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo		
10871372	C4591001 1087 10871372	16-55	09SEP2020	84247	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10871377	C4591001 1087 10871377	16-55	09SEP2020	84254	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10871378	C4591001 1087 10871378	16-55	09SEP2020	84255	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
10871387	C4591001 1087 10871387	16-55	09SEP2020	85873	Placebo	09SEP2020/ Placebo	28SEP2020/ Placebo		
10871389	C4591001 1087 10871389	16-55	09SEP2020	85866	Placebo	09SEP2020/ Placebo	29SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10871391	C4591001 1087 10871391	16-55	09SEP2020	85872	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10871393	C4591001 1087 10871393	16-55	09SEP2020	85871	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
10871394	C4591001 1087 10871394	16-55	10SEP2020	86253	Placebo	10SEP2020/ Placebo	29SEP2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
10871395	C4591001 1087 10871395	16-55	10SEP2020	86250	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
10871398	C4591001 1087 10871398	16-55	10SEP2020	86252	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
10871399	C4591001 1087 10871399	16-55	10SEP2020	86259	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
10871401	C4591001 1087 10871401	16-55	10SEP2020	86552	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
10871404	C4591001 1087 10871404	16-55	10SEP2020	86554	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
10871412	C4591001 1087 10871412	16-55	10SEP2020	86556	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
10871414	C4591001 1087 10871414	16-55	10SEP2020	87438	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
10871415	C4591001 1087 10871415	16-55	10SEP2020	87444	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10871420	C4591001 1087 10871420	16-55	11SEP2020	87446	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
10871426	C4591001 1087 10871426	16-55	11SEP2020	87447	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
10871427	C4591001 1087 10871427	16-55	11SEP2020	88195	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
10871435	C4591001 1087 10871435	16-55	11SEP2020	88197	Placebo	11SEP2020/ Placebo	01OCT2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
10871436	C4591001 1087 10871436	16-55	11SEP2020	88201	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
10871443	C4591001 1087 10871443	16-55	14SEP2020	88204	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
10871454	C4591001 1087 10871454	16-55	15SEP2020	90776	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
10871457	C4591001 1087 10871457	16-55	16SEP2020	90778	Placebo	16SEP2020/ Placebo	07OCT2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
10871468	C4591001 1087 10871468	16-55	16SEP2020	90780	Placebo	16SEP2020/ Placebo	07OCT2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
10871469	C4591001 1087 10871469	16-55	16SEP2020	90783	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10871471	C4591001 1087 10871471	16-55	17SEP2020	91975	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
10871473	C4591001 1087 10871473	16-55	17SEP2020	91979	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
10871474	C4591001 1087 10871474	16-55	17SEP2020	91980	Placebo	17SEP2020/ Placebo	07OCT2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10871480	C4591001 1087 10871480	16-55	17SEP2020	91981	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
10871484	C4591001 1087 10871484	16-55	18SEP2020	93200	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
10871486	C4591001 1087 10871486	16-55	18SEP2020	93204	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
10871487	C4591001 1087 10871487	16-55	18SEP2020	93201	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
10871490	C4591001 1087 10871490	16-55	18SEP2020	93207	Placebo	18SEP2020/ Placebo	08OCT2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
10871491	C4591001 1087 10871491	16-55	18SEP2020	93917	Placebo	18SEP2020/ Placebo	07OCT2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
10871493	C4591001 1087 10871493	16-55	18SEP2020	93923	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10871494	C4591001 1087 10871494	16-55	18SEP2020	93924	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)
10871499	C4591001 1087 10871499	16-55	21SEP2020	93927	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
10871504	C4591001 1087 10871504	16-55	21SEP2020	95370	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
10871506	C4591001 1087 10871506	16-55	21SEP2020	95371	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
10871510	C4591001 1087 10871510	16-55	22SEP2020	95375	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
10871513	C4591001 1087 10871513	16-55	22SEP2020	95376	Placebo	22SEP2020/ Placebo	14OCT2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
10871520	C4591001 1087 10871520	16-55	25SEP2020	99681	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
10871525	C4591001 1087 10871525	16-55	25SEP2020	99684	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo		
10871527	C4591001 1087 10871527	16-55	28SEP2020	99685	BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)		
10871529	C4591001 1087 10871529	16-55	29SEP2020	99688	BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10871530	C4591001 1087 10871530	16-55	01OCT2020	102847	BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)		
10871531	C4591001 1087 10871531	16-55	06OCT2020	102851	Placebo	06OCT2020/ Placebo	27OCT2020/ Placebo		
10871533	C4591001 1087 10871533	16-55	08OCT2020	102852	Placebo	08OCT2020/ Placebo	28OCT2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
10871535	C4591001 1087 10871535	16-55	09OCT2020	102854	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
10871541	C4591001 1087 10871541	16-55	12OCT2020	106637	BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
10871543	C4591001 1087 10871543	16-55	12OCT2020	106638	Placebo	12OCT2020/ Placebo	09NOV2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	
10871544	C4591001 1087 10871544	16-55	13OCT2020	106640	Placebo	13OCT2020/ Placebo	03NOV2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
10871545	C4591001 1087 10871545	16-55	13OCT2020	106793	Placebo	13OCT2020/ Placebo	03NOV2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
10871546	C4591001 1087 10871546	16-55	13OCT2020	106643	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
10871550	C4591001 1087 10871550	16-55	13OCT2020	106799	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10871551	C4591001 1087 10871551	16-55	13OCT2020	106797	Placebo	13OCT2020/ Placebo	02NOV2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
10871552	C4591001 1087 10871552	16-55	13OCT2020	106801	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
10871553	C4591001 1087 10871553	16-55	14OCT2020	107346	Placebo	14OCT2020/ Placebo	03NOV2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	14JAN2021/ BNT162b2 (30 µg)
10871554	C4591001 1087 10871554	16-55	14OCT2020	107350	BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
10871555	C4591001 1087 10871555	16-55	14OCT2020	107353	BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
10871556	C4591001 1087 10871556	16-55	14OCT2020	107355	Placebo	14OCT2020/ Placebo	04NOV2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
10871557	C4591001 1087 10871557	16-55	14OCT2020	107612	BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)			
10871558	C4591001 1087 10871558	16-55	14OCT2020	107613	Placebo	14OCT2020/ Placebo	04NOV2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
10871562	C4591001 1087 10871562	16-55	14OCT2020	107614	BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)			
10871563	C4591001 1087 10871563	16-55	15OCT2020	107620	Placebo	15OCT2020/ Placebo	03NOV2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10871565	C4591001 1087 10871565	16-55	15OCT2020	107921	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
10871568	C4591001 1087 10871568	16-55	15OCT2020	107923	Placebo	15OCT2020/ Placebo	05NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10871571	C4591001 1087 10871571	16-55	15OCT2020	107927	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
10871572	C4591001 1087 10871572	16-55	15OCT2020	107931	Placebo	15OCT2020/ Placebo	05NOV2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
10871573	C4591001 1087 10871573	16-55	16OCT2020	108739	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
10871576	C4591001 1087 10871576	16-55	21OCT2020	108742	Placebo	21OCT2020/ Placebo	09NOV2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
10871579	C4591001 1087 10871579	16-55	21OCT2020	108744	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
10871581	C4591001 1087 10871581	16-55	22OCT2020	108745	Placebo	22OCT2020/ Placebo	13NOV2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10871582	C4591001 1087 10871582	16-55	26OCT2020	113478	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
10871583	C4591001 1087 10871583	16-55	26OCT2020	113481	Placebo	26OCT2020/ Placebo	16NOV2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10871584	C4591001 1087 10871584	16-55	26OCT2020	113484	Placebo	26OCT2020/ Placebo	16NOV2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
10871586	C4591001 1087 10871586	16-55	26OCT2020	113487	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
10871588	C4591001 1087 10871588	16-55	27OCT2020	113957	Placebo	27OCT2020/ Placebo	16NOV2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10871593	C4591001 1087 10871593	16-55	28OCT2020	113959	Placebo	28OCT2020/ Placebo	18NOV2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
10871594	C4591001 1087 10871594	16-55	28OCT2020	113961	BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
10871595	C4591001 1087 10871595	16-55	28OCT2020	113962	BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
10871596	C4591001 1087 10871596	16-55	28OCT2020	114356	BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)	18NOV2020/ BNT162b2 (30 µg)		
10871597	C4591001 1087 10871597	16-55	28OCT2020	114359	BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
10871599	C4591001 1087 10871599	16-55	29OCT2020	114362	Placebo	29OCT2020/ Placebo	19NOV2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
10871601	C4591001 1087 10871601	16-55	29OCT2020	114364	Placebo	29OCT2020/ Placebo	20NOV2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10881030	C4591001 1088 10881030	16-55	14AUG2020	49396	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
10881033	C4591001 1088 10881033	16-55	14AUG2020	50682	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
10881044	C4591001 1088 10881044	16-55	17AUG2020	51277	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10881045	C4591001 1088 10881045	16-55	17AUG2020	51279	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
10881048	C4591001 1088 10881048	16-55	17AUG2020	53600	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
10881050	C4591001 1088 10881050	16-55	18AUG2020	53604	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10881053	C4591001 1088 10881053	16-55	18AUG2020	53605	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10881054	C4591001 1088 10881054	16-55	18AUG2020	53607	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	06JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
10881059	C4591001 1088 10881059	16-55	19AUG2020	56441	Placebo	19AUG2020/ Placebo	08SEP2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
10881060	C4591001 1088 10881060	16-55	19AUG2020	56446	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10881064	C4591001 1088 10881064	16-55	19AUG2020	56449	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10881065	C4591001 1088 10881065	16-55	20AUG2020	56451	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10881067	C4591001 1088 10881067	16-55	20AUG2020	58699	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10881074	C4591001 1088 10881074	16-55	21AUG2020	58703	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
10881077	C4591001 1088 10881077	16-55	21AUG2020	58705	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ Placebo		
10881079	C4591001 1088 10881079	16-55	21AUG2020	58707	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10881080	C4591001 1088 10881080	16-55	21AUG2020	61253	Placebo	21AUG2020/ Placebo	12OCT2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
10881081	C4591001 1088 10881081	16-55	24AUG2020	61258	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10881082	C4591001 1088 10881082	16-55	24AUG2020	61263	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10881084	C4591001 1088 10881084	16-55	24AUG2020	61264	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10881087	C4591001 1088 10881087	16-55	24AUG2020	64470	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
10881094	C4591001 1088 10881094	16-55	25AUG2020	64474	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10881095	C4591001 1088 10881095	16-55	25AUG2020	64475	Placebo	25AUG2020/ Placebo	17SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
10881098	C4591001 1088 10881098	16-55	26AUG2020	64479	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10881100	C4591001 1088 10881100	16-55	26AUG2020	68285	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10881101	C4591001 1088 10881101	16-55	26AUG2020	68286	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
10881102	C4591001 1088 10881102	16-55	26AUG2020	68293	Placebo	26AUG2020/ Placebo	15SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
10881103	C4591001 1088 10881103	16-55	26AUG2020	68295	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10881107	C4591001 1088 10881107	16-55	27AUG2020	69953	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
10881109	C4591001 1088 10881109	16-55	27AUG2020	69958	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10881111	C4591001 1088 10881111	16-55	27AUG2020	69960	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10881112	C4591001 1088 10881112	16-55	27AUG2020	69962	Placebo	27AUG2020/ Placebo	16SEP2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
10881114	C4591001 1088 10881114	16-55	28AUG2020	72011	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10881116	C4591001 1088 10881116	16-55	28AUG2020	72012	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10881117	C4591001 1088 10881117	16-55	28AUG2020	72014	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo		
10881123	C4591001 1088 10881123	16-55	31AUG2020	72015	Placebo	31AUG2020/ Placebo	23SEP2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	28JAN2021/ BNT162b2 (30 µg)
10881125	C4591001 1088 10881125	16-55	31AUG2020	75389	Placebo	31AUG2020/ Placebo	22SEP2020/ Placebo	12MAR2021/ BNT162b2 (30 µg)	
10881130	C4591001 1088 10881130	16-55	01SEP2020	75397	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10881134	C4591001 1088 10881134	16-55	01SEP2020	75400	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10881137	C4591001 1088 10881137	16-55	02SEP2020	78608	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10881143	C4591001 1088 10881143	16-55	03SEP2020	78612	Placebo	03SEP2020/ Placebo	22SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10881148	C4591001 1088 10881148	16-55	03SEP2020	78615	Placebo	03SEP2020/ Placebo	23SEP2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
10881151	C4591001 1088 10881151	16-55	04SEP2020	78616	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10881153	C4591001 1088 10881153	16-55	04SEP2020	81595	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
10881158	C4591001 1088 10881158	16-55	04SEP2020	81596	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10881159	C4591001 1088 10881159	16-55	04SEP2020	81598	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
10881160	C4591001 1088 10881160	16-55	04SEP2020	81600	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
10881161	C4591001 1088 10881161	16-55	04SEP2020	82362	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10881162	C4591001 1088 10881162	16-55	04SEP2020	82364	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
10881166	C4591001 1088 10881166	16-55	08SEP2020	82369	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10881169	C4591001 1088 10881169	16-55	08SEP2020	82370	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
10881171	C4591001 1088 10881171	16-55	08SEP2020	84509	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10881175	C4591001 1088 10881175	16-55	09SEP2020	84513	Placebo	09SEP2020/ Placebo	01OCT2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
10881176	C4591001 1088 10881176	16-55	09SEP2020	84514	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
10881177	C4591001 1088 10881177	16-55	09SEP2020	84519	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
10881180	C4591001 1088 10881180	16-55	09SEP2020	85652	Placebo	09SEP2020/ Placebo	28SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10881183	C4591001 1088 10881183	16-55	10SEP2020	85653	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10881185	C4591001 1088 10881185	16-55	10SEP2020	85658	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10881187	C4591001 1088 10881187	16-55	10SEP2020	85660	Placebo	10SEP2020/ Placebo	30SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10881189	C4591001 1088 10881189	16-55	10SEP2020	87511	Placebo	10SEP2020/ Placebo	29SEP2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10881192	C4591001 1088 10881192	16-55	11SEP2020	87514	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10881193	C4591001 1088 10881193	16-55	11SEP2020	87515	Placebo	11SEP2020/ Placebo	01OCT2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10881194	C4591001 1088 10881194	16-55	11SEP2020	87516	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
10881196	C4591001 1088 10881196	16-55	11SEP2020	88559	Placebo	11SEP2020/ Placebo	30SEP2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
10881197	C4591001 1088 10881197	16-55	11SEP2020	88557	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
10881200	C4591001 1088 10881200	16-55	11SEP2020	88560	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10881201	C4591001 1088 10881201	16-55	14SEP2020	88562	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
10881213	C4591001 1088 10881213	16-55	16SEP2020	91745	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
10881214	C4591001 1088 10881214	16-55	17SEP2020	91746	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
10881217	C4591001 1088 10881217	16-55	17SEP2020	91749	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10881218	C4591001 1088 10881218	16-55	17SEP2020	91755	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
10881220	C4591001 1088 10881220	16-55	18SEP2020	93296	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
10881221	C4591001 1088 10881221	16-55	18SEP2020	93294	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
10881222	C4591001 1088 10881222	16-55	18SEP2020	93300	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
10881224	C4591001 1088 10881224	16-55	21SEP2020	93303	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
10881225	C4591001 1088 10881225	16-55	21SEP2020	95191	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
10881227	C4591001 1088 10881227	16-55	21SEP2020	95193	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
10881232	C4591001 1088 10881232	16-55	25SEP2020	95196	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
10881233	C4591001 1088 10881233	16-55	25SEP2020	95199	Placebo	25SEP2020/ Placebo	19OCT2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
10881235	C4591001 1088 10881235	16-55	25SEP2020	99858	Placebo	25SEP2020/ Placebo	15OCT2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10881238	C4591001 1088 10881238	16-55	25SEP2020	99863	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
10881239	C4591001 1088 10881239	16-55	25SEP2020	99866	Placebo	25SEP2020/ Placebo	15OCT2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
10881240	C4591001 1088 10881240	16-55	25SEP2020	99868	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
10881245	C4591001 1088 10881245	16-55	06OCT2020	104429	BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
10881246	C4591001 1088 10881246	16-55	08OCT2020	104430	Placebo	08OCT2020/ Placebo	27OCT2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10881248	C4591001 1088 10881248	16-55	13OCT2020	104432	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
10881251	C4591001 1088 10881251	16-55	13OCT2020	104439	Placebo	13OCT2020/ Placebo	03NOV2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
10881254	C4591001 1088 10881254	16-55	15OCT2020	108185	Placebo	15OCT2020/ Placebo	03NOV2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
10881255	C4591001 1088 10881255	16-55	15OCT2020	108187	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
10881256	C4591001 1088 10881256	16-55	16OCT2020	108195	Placebo	16OCT2020/ Placebo	09NOV2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10881258	C4591001 1088 10881258	16-55	16OCT2020	108196	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
10881259	C4591001 1088 10881259	16-55	19OCT2020	110129	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
10891097	C4591001 1089 10891097	16-55	02SEP2020	77777	Placebo	02SEP2020/ Placebo	28SEP2020/ Placebo		
10891131	C4591001 1089 10891131	16-55	17AUG2020	50626	Placebo	17AUG2020/ Placebo	09SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10891132	C4591001 1089 10891132	16-55	17AUG2020	50627	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10891134	C4591001 1089 10891134	16-55	17AUG2020	50628	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10891135	C4591001 1089 10891135	16-55	17AUG2020	52759	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10891138	C4591001 1089 10891138	16-55	17AUG2020	52761	Placebo	17AUG2020/ Placebo	09SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10891139	C4591001 1089 10891139	16-55	18AUG2020	52762	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
10891140	C4591001 1089 10891140	16-55	18AUG2020	52766	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10891141	C4591001 1089 10891141	16-55	18AUG2020	54188	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10891147	C4591001 1089 10891147	16-55	19AUG2020	54193	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	06JAN2021/ BNT162b2 (30 µg)	27JAN2021/ BNT162b2 (30 µg)
10891149	C4591001 1089 10891149	16-55	19AUG2020	54196	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10891151	C4591001 1089 10891151	16-55	19AUG2020	56058	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10891152	C4591001 1089 10891152	16-55	19AUG2020	56062	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
10891153	C4591001 1089 10891153	16-55	19AUG2020	56064	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10891155	C4591001 1089 10891155	16-55	20AUG2020	56068	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10891156	C4591001 1089 10891156	16-55	20AUG2020	58050	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo		
10891158	C4591001 1089 10891158	16-55	20AUG2020	58055	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)			
10891162	C4591001 1089 10891162	16-55	20AUG2020	58056	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10891165	C4591001 1089 10891165	16-55	21AUG2020	58058	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
10891166	C4591001 1089 10891166	16-55	21AUG2020	60800	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
10891168	C4591001 1089 10891168	16-55	21AUG2020	60804	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)
10891173	C4591001 1089 10891173	16-55	24AUG2020	60807	Placebo	24AUG2020/ Placebo	15SEP2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
10891176	C4591001 1089 10891176	16-55	24AUG2020	60808	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10891179	C4591001 1089 10891179	16-55	25AUG2020	65226	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo		
10891180	C4591001 1089 10891180	16-55	25AUG2020	65229	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10891181	C4591001 1089 10891181	16-55	25AUG2020	65230	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10891182	C4591001 1089 10891182	16-55	25AUG2020	65233	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)			
10891183	C4591001 1089 10891183	16-55	25AUG2020	66248	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10891185	C4591001 1089 10891185	16-55	25AUG2020	66251	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10891186	C4591001 1089 10891186	16-55	25AUG2020	66253	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
10891192	C4591001 1089 10891192	16-55	26AUG2020	66254	Placebo	26AUG2020/ Placebo	17SEP2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
10891193	C4591001 1089 10891193	16-55	26AUG2020	68612	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
10891194	C4591001 1089 10891194	16-55	26AUG2020	68611	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10891196	C4591001 1089 10891196	16-55	27AUG2020	68615	Placebo	27AUG2020/ Placebo	18SEP2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
10891197	C4591001 1089 10891197	16-55	27AUG2020	68617	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10891198	C4591001 1089 10891198	16-55	27AUG2020	70112	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10891199	C4591001 1089 10891199	16-55	27AUG2020	70113	Placebo	27AUG2020/ Placebo	18SEP2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	28JAN2021/ BNT162b2 (30 µg)
10891200	C4591001 1089 10891200	16-55	27AUG2020	70115	Placebo	27AUG2020/ Placebo	18SEP2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10891201	C4591001 1089 10891201	16-55	27AUG2020	70116	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10891204	C4591001 1089 10891204	16-55	27AUG2020	71001	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
10891205	C4591001 1089 10891205	16-55	28AUG2020	71003	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
10891206	C4591001 1089 10891206	16-55	28AUG2020	71007	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
10891207	C4591001 1089 10891207	16-55	28AUG2020	71008	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
10891209	C4591001 1089 10891209	16-55	28AUG2020	72270	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
10891212	C4591001 1089 10891212	16-55	31AUG2020	72275	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10891213	C4591001 1089 10891213	16-55	31AUG2020	72279	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10891215	C4591001 1089 10891215	16-55	31AUG2020	72280	Placebo	31AUG2020/ Placebo	22SEP2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
10891220	C4591001 1089 10891220	16-55	01SEP2020	76338	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10891221	C4591001 1089 10891221	16-55	01SEP2020	76339	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10891225	C4591001 1089 10891225	16-55	01SEP2020	76344	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10891226	C4591001 1089 10891226	16-55	01SEP2020	76348	Placebo	01SEP2020/ Placebo	23SEP2020/ Placebo	12MAR2021/ BNT162b2 (30 µg)	
10891227	C4591001 1089 10891227	16-55	02SEP2020	77782	Placebo	02SEP2020/ Placebo	25SEP2020/ Placebo		
10891228	C4591001 1089 10891228	16-55	02SEP2020	77786	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10891230	C4591001 1089 10891230	16-55	02SEP2020	77788	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10891231	C4591001 1089 10891231	16-55	02SEP2020	78174	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10891232	C4591001 1089 10891232	16-55	02SEP2020	78177	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10891233	C4591001 1089 10891233	16-55	02SEP2020	78180	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10891234	C4591001 1089 10891234	16-55	02SEP2020	78181	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10891235	C4591001 1089 10891235	16-55	02SEP2020	79049	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
10891238	C4591001 1089 10891238	16-55	03SEP2020	79050	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10891239	C4591001 1089 10891239	16-55	03SEP2020	79053	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10891241	C4591001 1089 10891241	16-55	03SEP2020	79060	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
10891246	C4591001 1089 10891246	16-55	04SEP2020	81354	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
10891253	C4591001 1089 10891253	16-55	04SEP2020	81359	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10891257	C4591001 1089 10891257	16-55	08SEP2020	81360	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
10891259	C4591001 1089 10891259	16-55	08SEP2020	81362	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo		
10891261	C4591001 1089 10891261	16-55	08SEP2020	83885	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10891268	C4591001 1089 10891268	16-55	09SEP2020	83888	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10891271	C4591001 1089 10891271	16-55	09SEP2020	83889	Placebo	09SEP2020/ Placebo	28SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
10891272	C4591001 1089 10891272	16-55	09SEP2020	83894	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10891273	C4591001 1089 10891273	16-55	09SEP2020	85566	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
10891275	C4591001 1089 10891275	16-55	09SEP2020	85570	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
10891277	C4591001 1089 10891277	16-55	10SEP2020	85576	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo		
10891278	C4591001 1089 10891278	16-55	10SEP2020	86393	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
10891279	C4591001 1089 10891279	16-55	10SEP2020	85571	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
10891280	C4591001 1089 10891280	16-55	10SEP2020	86400	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
10891283	C4591001 1089 10891283	16-55	10SEP2020	86402	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10891285	C4591001 1089 10891285	16-55	10SEP2020	256802	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10891287	C4591001 1089 10891287	16-55	11SEP2020	86404	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
10891288	C4591001 1089 10891288	16-55	11SEP2020	87738	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
10891289	C4591001 1089 10891289	16-55	11SEP2020	87740	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
10891291	C4591001 1089 10891291	16-55	11SEP2020	87744	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
10891293	C4591001 1089 10891293	16-55	11SEP2020	87747	Placebo	11SEP2020/ Placebo	05OCT2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)
10891294	C4591001 1089 10891294	16-55	11SEP2020	88075	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
10891296	C4591001 1089 10891296	16-55	11SEP2020	88076	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10891299	C4591001 1089 10891299	16-55	14SEP2020	88080	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	27JAN2021/ BNT162b2 (30 µg)
10891306	C4591001 1089 10891306	16-55	14SEP2020	88081	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
10891309	C4591001 1089 10891309	16-55	15SEP2020	90273	Placebo	15SEP2020/ Placebo	07OCT2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10891310	C4591001 1089 10891310	16-55	15SEP2020	90274	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
10891311	C4591001 1089 10891311	16-55	15SEP2020	90275	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
10891313	C4591001 1089 10891313	16-55	15SEP2020	90280	Placebo	15SEP2020/ Placebo	06OCT2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
10891315	C4591001 1089 10891315	16-55	16SEP2020	90929	Placebo	16SEP2020/ Placebo	07OCT2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10891317	C4591001 1089 10891317	16-55	16SEP2020	90933	Placebo	16SEP2020/ Placebo	07OCT2020/ Placebo		
10891318	C4591001 1089 10891318	16-55	16SEP2020	90937	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
10891323	C4591001 1089 10891323	16-55	17SEP2020	90938	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
10891330	C4591001 1089 10891330	16-55	17SEP2020	92982	Placebo	17SEP2020/ Placebo	07OCT2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10891332	C4591001 1089 10891332	16-55	18SEP2020	92985	Placebo	18SEP2020/ Placebo	07OCT2020/ Placebo		
10891334	C4591001 1089 10891334	16-55	18SEP2020	92991	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10891335	C4591001 1089 10891335	16-55	18SEP2020	92987	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
10891336	C4591001 1089 10891336	16-55	18SEP2020	93726	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
10891337	C4591001 1089 10891337	16-55	18SEP2020	93728	Placebo	18SEP2020/ Placebo	07OCT2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10891338	C4591001 1089 10891338	16-55	18SEP2020	93733	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo		
10891339	C4591001 1089 10891339	16-55	21SEP2020	93734	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
10891340	C4591001 1089 10891340	16-55	21SEP2020	94805	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
10891342	C4591001 1089 10891342	16-55	21SEP2020	94808	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
10891343	C4591001 1089 10891343	16-55	21SEP2020	94811	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
10891346	C4591001 1089 10891346	16-55	22SEP2020	94814	BNT162b2 (30 µg)				
10891347	C4591001 1089 10891347	16-55	22SEP2020	96427	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10891348	C4591001 1089 10891348	16-55	22SEP2020	96431	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)		
10891349	C4591001 1089 10891349	16-55	22SEP2020	96433	Placebo	22SEP2020/ Placebo	15OCT2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
10891350	C4591001 1089 10891350	16-55	25SEP2020	96435	Placebo	25SEP2020/ Placebo	15OCT2020/ Placebo		
10891351	C4591001 1089 10891351	16-55	25SEP2020	100061	BNT162b2 (30 µg)				
10891352	C4591001 1089 10891352	16-55	25SEP2020	100069	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
10891353	C4591001 1089 10891353	16-55	25SEP2020	100070	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
10901187	C4591001 1090 10901187	16-55	14AUG2020	50229	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10901206	C4591001 1090 10901206	16-55	17AUG2020	50820	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	02MAR2021/ BNT162b2 (30 µg)	
10901210	C4591001 1090 10901210	16-55	17AUG2020	50824	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10901212	C4591001 1090 10901212	16-55	17AUG2020	52661	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10901216	C4591001 1090 10901216	16-55	17AUG2020	52665	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10901220	C4591001 1090 10901220	16-55	17AUG2020	52669	Placebo	17AUG2020/ Placebo	09SEP2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)
10901222	C4591001 1090 10901222	16-55	17AUG2020	52672	Placebo	17AUG2020/ Placebo	09SEP2020/ Placebo	03MAR2021/ BNT162b2 (30 µg)	
10901226	C4591001 1090 10901226	16-55	18AUG2020	54081	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10901239	C4591001 1090 10901239	16-55	18AUG2020	54086	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10901244	C4591001 1090 10901244	16-55	18AUG2020	54087	Placebo	18AUG2020/ Placebo	10SEP2020/ Placebo		
10901251	C4591001 1090 10901251	16-55	19AUG2020	56143	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
10901253	C4591001 1090 10901253	16-55	19AUG2020	56145	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10901256	C4591001 1090 10901256	16-55	19AUG2020	56150	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10901260	C4591001 1090 10901260	16-55	19AUG2020	56151	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10901262	C4591001 1090 10901262	16-55	19AUG2020	56947	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
10901264	C4591001 1090 10901264	16-55	19AUG2020	57414	Placebo	19AUG2020/ Placebo	08SEP2020/ Placebo	12MAR2021/ BNT162b2 (30 µg)	
10901266	C4591001 1090 10901266	16-55	19AUG2020	56948	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo		
10901267	C4591001 1090 10901267	16-55	19AUG2020	56950	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10901268	C4591001 1090 10901268	16-55	19AUG2020	56954	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10901269	C4591001 1090 10901269	16-55	19AUG2020	57418	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10901270	C4591001 1090 10901270	16-55	19AUG2020	57422	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10901271	C4591001 1090 10901271	16-55	19AUG2020	57423	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
10901277	C4591001 1090 10901277	16-55	01SEP2020	77131	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
10901278	C4591001 1090 10901278	16-55	01SEP2020	77129	Placebo	01SEP2020/ Placebo	21SEP2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10901281	C4591001 1090 10901281	16-55	01SEP2020	77130	Placebo	01SEP2020/ Placebo	21SEP2020/ Placebo		
10901283	C4591001 1090 10901283	16-55	01SEP2020	77133	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10901288	C4591001 1090 10901288	16-55	01SEP2020	77482	Placebo	01SEP2020/ Placebo	24SEP2020/ Placebo		
10901289	C4591001 1090 10901289	16-55	01SEP2020	77483	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10901290	C4591001 1090 10901290	16-55	02SEP2020	77487	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10901291	C4591001 1090 10901291	16-55	02SEP2020	77488	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo		
10901294	C4591001 1090 10901294	16-55	02SEP2020	78115	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10901295	C4591001 1090 10901295	16-55	02SEP2020	78118	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10901297	C4591001 1090 10901297	16-55	02SEP2020	78121	Placebo	02SEP2020/ Placebo	21SEP2020/ Placebo		
10901304	C4591001 1090 10901304	16-55	02SEP2020	78122	Placebo	02SEP2020/ Placebo	24SEP2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	20JAN2021/ BNT162b2 (30 µg)
10901312	C4591001 1090 10901312	16-55	02SEP2020	79125	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10901314	C4591001 1090 10901314	16-55	02SEP2020	79127	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10901315	C4591001 1090 10901315	16-55	02SEP2020	79130	Placebo	02SEP2020/ Placebo	21SEP2020/ Placebo	12MAR2021/ BNT162b2 (30 µg)	
10901316	C4591001 1090 10901316	16-55	03SEP2020	79132	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10901318	C4591001 1090 10901318	16-55	03SEP2020	79781	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10901319	C4591001 1090 10901319	16-55	03SEP2020	79783	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10901320	C4591001 1090 10901320	16-55	03SEP2020	79792	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
10901321	C4591001 1090 10901321	16-55	03SEP2020	79791	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10901323	C4591001 1090 10901323	16-55	03SEP2020	80396	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
10901325	C4591001 1090 10901325	16-55	03SEP2020	80394	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10901326	C4591001 1090 10901326	16-55	03SEP2020	80398	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10901328	C4591001 1090 10901328	16-55	03SEP2020	80915	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10901329	C4591001 1090 10901329	16-55	03SEP2020	80404	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
10901330	C4591001 1090 10901330	16-55	03SEP2020	80909	Placebo	03SEP2020/ Placebo	23SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
10901334	C4591001 1090 10901334	16-55	03SEP2020	80918	Placebo	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10901335	C4591001 1090 10901335	16-55	03SEP2020	80919	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10901336	C4591001 1090 10901336	16-55	08SEP2020	83322	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo	06JAN2021/ BNT162b2 (30 µg)	27JAN2021/ BNT162b2 (30 µg)
10901339	C4591001 1090 10901339	16-55	08SEP2020	83324	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
10901341	C4591001 1090 10901341	16-55	08SEP2020	83327	Placebo	08SEP2020/ Placebo	06OCT2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
10901343	C4591001 1090 10901343	16-55	08SEP2020	83331	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
10901346	C4591001 1090 10901346	16-55	08SEP2020	83721	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10901347	C4591001 1090 10901347	16-55	08SEP2020	83723	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10901348	C4591001 1090 10901348	16-55	08SEP2020	83725	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10901349	C4591001 1090 10901349	16-55	08SEP2020	83728	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo		
10901350	C4591001 1090 10901350	16-55	08SEP2020	84260	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
10901355	C4591001 1090 10901355	16-55	09SEP2020	84262	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10901356	C4591001 1090 10901356	16-55	09SEP2020	84265	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
10901357	C4591001 1090 10901357	16-55	09SEP2020	85085	Placebo	09SEP2020/ Placebo	28SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
10901358	C4591001 1090 10901358	16-55	09SEP2020	84266	Placebo	09SEP2020/ Placebo	01OCT2020/ Placebo	02MAR2021/ BNT162b2 (30 µg)	
10901360	C4591001 1090 10901360	16-55	09SEP2020	85090	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
10901362	C4591001 1090 10901362	16-55	09SEP2020	85094	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10901363	C4591001 1090 10901363	16-55	09SEP2020	85096	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
10901365	C4591001 1090 10901365	16-55	09SEP2020	85625	Placebo	09SEP2020/ Placebo	06OCT2020/ Placebo		
10901366	C4591001 1090 10901366	16-55	09SEP2020	85626	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
10901367	C4591001 1090 10901367	16-55	10SEP2020	85630	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
10901369	C4591001 1090 10901369	16-55	10SEP2020	85632	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
10901370	C4591001 1090 10901370	16-55	10SEP2020	86466	Placebo	10SEP2020/ Placebo	29SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
10901371	C4591001 1090 10901371	16-55	10SEP2020	86468	Placebo	10SEP2020/ Placebo	02OCT2020/ Placebo		
10901372	C4591001 1090 10901372	16-55	10SEP2020	86467	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
10901373	C4591001 1090 10901373	16-55	10SEP2020	86472	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
10901374	C4591001 1090 10901374	16-55	10SEP2020	86741	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10901375	C4591001 1090 10901375	16-55	10SEP2020	86744	Placebo	10SEP2020/ Placebo	30SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10901377	C4591001 1090 10901377	16-55	10SEP2020	86746	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo		
10901378	C4591001 1090 10901378	16-55	10SEP2020	86750	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
10901379	C4591001 1090 10901379	16-55	10SEP2020	87103	Placebo	10SEP2020/ Placebo			
10901380	C4591001 1090 10901380	16-55	10SEP2020	87104	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
10901382	C4591001 1090 10901382	16-55	10SEP2020	87106	Placebo	10SEP2020/ Placebo	29SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
10901383	C4591001 1090 10901383	16-55	14SEP2020	87109	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
10901384	C4591001 1090 10901384	16-55	14SEP2020	89539	Placebo	14SEP2020/ Placebo	06OCT2020/ Placebo		
10901386	C4591001 1090 10901386	16-55	14SEP2020	89542	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
10901387	C4591001 1090 10901387	16-55	14SEP2020	89543	Placebo	14SEP2020/ Placebo	06OCT2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10901391	C4591001 1090 10901391	16-55	15SEP2020	90234	Placebo	15SEP2020/ Placebo	09OCT2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
10901392	C4591001 1090 10901392	16-55	15SEP2020	89545	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
10901393	C4591001 1090 10901393	16-55	15SEP2020	90236	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
10901394	C4591001 1090 10901394	16-55	15SEP2020	90238	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
10901395	C4591001 1090 10901395	16-55	15SEP2020	90239	Placebo	15SEP2020/ Placebo	07OCT2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
10901397	C4591001 1090 10901397	16-55	15SEP2020	90558	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
10901398	C4591001 1090 10901398	16-55	15SEP2020	90560	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
10901399	C4591001 1090 10901399	16-55	16SEP2020	90567	Placebo	16SEP2020/ Placebo	05OCT2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
10901400	C4591001 1090 10901400	16-55	16SEP2020	90568	Placebo	16SEP2020/ Placebo	06OCT2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10901401	C4591001 1090 10901401	16-55	16SEP2020	91145	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10901402	C4591001 1090 10901402	16-55	16SEP2020	91154	Placebo	16SEP2020/ Placebo	07OCT2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
10901407	C4591001 1090 10901407	16-55	16SEP2020	91155	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
10901408	C4591001 1090 10901408	16-55	16SEP2020	91156	Placebo	16SEP2020/ Placebo	07OCT2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
10901410	C4591001 1090 10901410	16-55	17SEP2020	92035	Placebo	17SEP2020/ Placebo	09OCT2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
10901413	C4591001 1090 10901413	16-55	17SEP2020	92041	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
10901416	C4591001 1090 10901416	16-55	17SEP2020	92043	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10901417	C4591001 1090 10901417	16-55	17SEP2020	92044	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
10901418	C4591001 1090 10901418	16-55	17SEP2020	92502	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
10901419	C4591001 1090 10901419	16-55	17SEP2020	92503	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
10901422	C4591001 1090 10901422	16-55	17SEP2020	92505	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10901423	C4591001 1090 10901423	16-55	17SEP2020	92729	Placebo	17SEP2020/ Placebo	09OCT2020/ Placebo		
10901424	C4591001 1090 10901424	16-55	17SEP2020	92507	Placebo	17SEP2020/ Placebo	09OCT2020/ Placebo	02MAR2021/ BNT162b2 (30 µg)	
10901426	C4591001 1090 10901426	16-55	21SEP2020	92731	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10901427	C4591001 1090 10901427	16-55	21SEP2020	92737	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
10901429	C4591001 1090 10901429	16-55	21SEP2020	92740	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
10901431	C4591001 1090 10901431	16-55	21SEP2020	95082	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
10901432	C4591001 1090 10901432	16-55	21SEP2020	95087	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
10901435	C4591001 1090 10901435	16-55	22SEP2020	95088	Placebo	22SEP2020/ Placebo	16OCT2020/ Placebo		
10901437	C4591001 1090 10901437	16-55	22SEP2020	95089	Placebo	22SEP2020/ Placebo	13OCT2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
10901440	C4591001 1090 10901440	16-55	22SEP2020	96344	Placebo	22SEP2020/ Placebo	13OCT2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10901441	C4591001 1090 10901441	16-55	22SEP2020	96346	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
10901443	C4591001 1090 10901443	16-55	22SEP2020	96345	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
10901451	C4591001 1090 10901451	16-55	23SEP2020	96347	Placebo	23SEP2020/ Placebo	15OCT2020/ Placebo		
10901452	C4591001 1090 10901452	16-55	23SEP2020	97675	Placebo	23SEP2020/ Placebo	12OCT2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	28JAN2021/ BNT162b2 (30 µg)
10901457	C4591001 1090 10901457	16-55	23SEP2020	97676	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
10901461	C4591001 1090 10901461	16-55	23SEP2020	97677	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
10901463	C4591001 1090 10901463	16-55	24SEP2020	97684	Placebo	24SEP2020/ Placebo	16OCT2020/ Placebo		
10901464	C4591001 1090 10901464	16-55	24SEP2020	98694	Placebo	24SEP2020/ Placebo	15OCT2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
10901465	C4591001 1090 10901465	16-55	24SEP2020	98695	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
10901470	C4591001 1090 10901470	16-55	25SEP2020	98699	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10901473	C4591001 1090 10901473	16-55	25SEP2020	98703	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
10901474	C4591001 1090 10901474	16-55	25SEP2020	99810	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
10901476	C4591001 1090 10901476	16-55	25SEP2020	99811	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)		
10901477	C4591001 1090 10901477	16-55	25SEP2020	99817	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
10901479	C4591001 1090 10901479	16-55	25SEP2020	99818	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
10901480	C4591001 1090 10901480	16-55	25SEP2020	100122	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
10901481	C4591001 1090 10901481	16-55	25SEP2020	100124	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
10901482	C4591001 1090 10901482	16-55	25SEP2020	100126	Placebo	25SEP2020/ Placebo	14OCT2020/ Placebo		
10901484	C4591001 1090 10901484	16-55	07OCT2020	100132	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
10901489	C4591001 1090 10901489	16-55	09OCT2020	105837	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10901491	C4591001 1090 10901491	16-55	09OCT2020	105839	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		
10901496	C4591001 1090 10901496	16-55	14OCT2020	105841	Placebo	14OCT2020/ Placebo	03NOV2020/ Placebo		
10901497	C4591001 1090 10901497	16-55	14OCT2020	105843	Placebo	14OCT2020/ Placebo	03NOV2020/ Placebo		
10901498	C4591001 1090 10901498	16-55	14OCT2020	107561	Placebo	14OCT2020/ Placebo	04NOV2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
10901502	C4591001 1090 10901502	16-55	15OCT2020	107562	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
10901503	C4591001 1090 10901503	16-55	15OCT2020	107566	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
10901507	C4591001 1090 10901507	16-55	16OCT2020	107570	Placebo	16OCT2020/ Placebo		11MAR2021/ BNT162b2 (30 µg)	
10901508	C4591001 1090 10901508	16-55	16OCT2020	109037	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
10901509	C4591001 1090 10901509	16-55	19OCT2020	109041	Placebo	19OCT2020/ Placebo	11NOV2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
10901510	C4591001 1090 10901510	16-55	19OCT2020	109045	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10901513	C4591001 1090 10901513	16-55	19OCT2020	109046	Placebo	19OCT2020/ Placebo	13NOV2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
10901516	C4591001 1090 10901516	16-55	20OCT2020	110693	Placebo	20OCT2020/ Placebo	06NOV2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10901517	C4591001 1090 10901517	16-55	20OCT2020	110697	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
10901518	C4591001 1090 10901518	16-55	20OCT2020	110699	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
10901520	C4591001 1090 10901520	16-55	20OCT2020	110703	Placebo	20OCT2020/ Placebo	12NOV2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
10901524	C4591001 1090 10901524	16-55	21OCT2020	111431	Placebo	21OCT2020/ Placebo	13NOV2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
10901526	C4591001 1090 10901526	16-55	21OCT2020	111432	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
10901527	C4591001 1090 10901527	16-55	21OCT2020	111433	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
10901528	C4591001 1090 10901528	16-55	22OCT2020	111436	Placebo	22OCT2020/ Placebo	12NOV2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
10901529	C4591001 1090 10901529	16-55	22OCT2020	112152	Placebo	22OCT2020/ Placebo	13NOV2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10901530	C4591001 1090 10901530	16-55	22OCT2020	112150	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
10901535	C4591001 1090 10901535	16-55	23OCT2020	112155	Placebo	23OCT2020/ Placebo	13NOV2020/ Placebo	03MAR2021/ BNT162b2 (30 µg)	
10901536	C4591001 1090 10901536	16-55	23OCT2020	112156	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
10901537	C4591001 1090 10901537	16-55	23OCT2020	112927	Placebo	23OCT2020/ Placebo	11NOV2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10901538	C4591001 1090 10901538	16-55	23OCT2020	112930	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
10901539	C4591001 1090 10901539	16-55	23OCT2020	112933	Placebo	23OCT2020/ Placebo	13NOV2020/ Placebo		
10901540	C4591001 1090 10901540	16-55	23OCT2020	112934	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
10901543	C4591001 1090 10901543	16-55	23OCT2020	113107	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
10901544	C4591001 1090 10901544	16-55	23OCT2020	113109	Placebo	23OCT2020/ Placebo	13NOV2020/ Placebo	03MAR2021/ BNT162b2 (30 µg)	
10901546	C4591001 1090 10901546	16-55	26OCT2020	113113	Placebo	26OCT2020/ Placebo	17NOV2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10901547	C4591001 1090 10901547	16-55	26OCT2020	113116	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
10901548	C4591001 1090 10901548	16-55	26OCT2020	113527	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
10901550	C4591001 1090 10901550	16-55	26OCT2020	113529	Placebo	26OCT2020/ Placebo	16NOV2020/ Placebo	02MAR2021/ BNT162b2 (30 µg)	
10901551	C4591001 1090 10901551	16-55	26OCT2020	113530	Placebo	26OCT2020/ Placebo	17NOV2020/ Placebo		
10901557	C4591001 1090 10901557	16-55	27OCT2020	113535	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
10901558	C4591001 1090 10901558	16-55	27OCT2020	114029	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)		
10901559	C4591001 1090 10901559	16-55	27OCT2020	114032	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
10901565	C4591001 1090 10901565	16-55	29OCT2020	114036	Placebo	29OCT2020/ Placebo	17NOV2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
10901566	C4591001 1090 10901566	16-55	30OCT2020	114040	Placebo	30OCT2020/ Placebo	20NOV2020/ Placebo	03MAR2021/ BNT162b2 (30 µg)	
10911123	C4591001 1091 10911123	16-55	17AUG2020	49366	Placebo	17AUG2020/ Placebo	09SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10911125	C4591001 1091 10911125	16-55	17AUG2020	49370	Placebo	17AUG2020/ Placebo	10SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
10911130	C4591001 1091 10911130	16-55	17AUG2020	49372	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
10911132	C4591001 1091 10911132	16-55	18AUG2020	54223	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10911133	C4591001 1091 10911133	16-55	18AUG2020	54228	Placebo	18AUG2020/ Placebo	15SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10911134	C4591001 1091 10911134	16-55	18AUG2020	54227	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10911137	C4591001 1091 10911137	16-55	18AUG2020	54229	Placebo	18AUG2020/ Placebo	17SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
10911138	C4591001 1091 10911138	16-55	18AUG2020	54977	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10911139	C4591001 1091 10911139	16-55	18AUG2020	54986	Placebo	18AUG2020/ Placebo	10SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10911140	C4591001 1091 10911140	16-55	18AUG2020	54985	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
10911141	C4591001 1091 10911141	16-55	19AUG2020	54988	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10911142	C4591001 1091 10911142	16-55	19AUG2020	56189	Placebo	19AUG2020/ Placebo	16SEP2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)
10911143	C4591001 1091 10911143	16-55	19AUG2020	56199	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
10911144	C4591001 1091 10911144	16-55	19AUG2020	56195	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10911145	C4591001 1091 10911145	16-55	19AUG2020	56289	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
10911146	C4591001 1091 10911146	16-55	19AUG2020	56190	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10911149	C4591001 1091 10911149	16-55	19AUG2020	56290	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10911150	C4591001 1091 10911150	16-55	19AUG2020	56292	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10911151	C4591001 1091 10911151	16-55	19AUG2020	57089	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10911152	C4591001 1091 10911152	16-55	19AUG2020	56296	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
10911156	C4591001 1091 10911156	16-55	20AUG2020	57090	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10911157	C4591001 1091 10911157	16-55	20AUG2020	57095	Placebo	20AUG2020/ Placebo	08SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10911160	C4591001 1091 10911160	16-55	20AUG2020	57096	Placebo	20AUG2020/ Placebo	08SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10911162	C4591001 1091 10911162	16-55	20AUG2020	59154	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10911164	C4591001 1091 10911164	16-55	24AUG2020	59161	Placebo	24AUG2020/ Placebo	16SEP2020/ Placebo	19DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
10911165	C4591001 1091 10911165	16-55	24AUG2020	59162	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10911166	C4591001 1091 10911166	16-55	24AUG2020	59157	Placebo	24AUG2020/ Placebo	17SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
10911169	C4591001 1091 10911169	16-55	25AUG2020	65478	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
10911172	C4591001 1091 10911172	16-55	25AUG2020	65483	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
10911174	C4591001 1091 10911174	16-55	25AUG2020	65485	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10911175	C4591001 1091 10911175	16-55	25AUG2020	65486	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10911176	C4591001 1091 10911176	16-55	26AUG2020	67681	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10911177	C4591001 1091 10911177	16-55	26AUG2020	67675	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
10911179	C4591001 1091 10911179	16-55	26AUG2020	67682	Placebo	26AUG2020/ Placebo	17SEP2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
10911182	C4591001 1091 10911182	16-55	26AUG2020	67684	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10911183	C4591001 1091 10911183	16-55	27AUG2020	69871	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	04JAN2021/ BNT162b2 (30 µg)
10911185	C4591001 1091 10911185	16-55	27AUG2020	69872	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10911186	C4591001 1091 10911186	16-55	27AUG2020	69880	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10911188	C4591001 1091 10911188	16-55	27AUG2020	69877	Placebo	27AUG2020/ Placebo	24SEP2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
10911189	C4591001 1091 10911189	16-55	27AUG2020	70805	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10911192	C4591001 1091 10911192	16-55	28AUG2020	70811	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10911196	C4591001 1091 10911196	16-55	28AUG2020	70812	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10911197	C4591001 1091 10911197	16-55	28AUG2020	71958	Placebo	28AUG2020/ Placebo	17SEP2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
10911198	C4591001 1091 10911198	16-55	28AUG2020	70816	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo		
10911200	C4591001 1091 10911200	16-55	31AUG2020	71968	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10911202	C4591001 1091 10911202	16-55	31AUG2020	71966	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10911203	C4591001 1091 10911203	16-55	31AUG2020	71965	Placebo	31AUG2020/ Placebo	23SEP2020/ Placebo		
10911206	C4591001 1091 10911206	16-55	31AUG2020	75575	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
10911207	C4591001 1091 10911207	16-55	31AUG2020	75578	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10911208	C4591001 1091 10911208	16-55	31AUG2020	75571	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10911210	C4591001 1091 10911210	16-55	01SEP2020	75580	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10911215	C4591001 1091 10911215	16-55	01SEP2020	77189	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo		
10911218	C4591001 1091 10911218	16-55	01SEP2020	77191	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10911219	C4591001 1091 10911219	16-55	01SEP2020	77636	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10911220	C4591001 1091 10911220	16-55	01SEP2020	77196	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10911221	C4591001 1091 10911221	16-55	01SEP2020	77638	Placebo	01SEP2020/ Placebo	23SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
10911223	C4591001 1091 10911223	16-55	01SEP2020	77198	Placebo	01SEP2020/ Placebo	21SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
10911226	C4591001 1091 10911226	16-55	02SEP2020	77641	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
10911229	C4591001 1091 10911229	16-55	02SEP2020	77643	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10911232	C4591001 1091 10911232	16-55	02SEP2020	78881	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10911233	C4591001 1091 10911233	16-55	02SEP2020	78882	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10911236	C4591001 1091 10911236	16-55	02SEP2020	78887	Placebo	02SEP2020/ Placebo	21SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10911237	C4591001 1091 10911237	16-55	02SEP2020	79308	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10911238	C4591001 1091 10911238	16-55	02SEP2020	79301	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo		
10911239	C4591001 1091 10911239	16-55	02SEP2020	78888	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
10911240	C4591001 1091 10911240	16-55	02SEP2020	79311	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10911241	C4591001 1091 10911241	16-55	02SEP2020	79312	Placebo	02SEP2020/ Placebo	21SEP2020/ Placebo		
10911245	C4591001 1091 10911245	16-55	03SEP2020	79776	Placebo	03SEP2020/ Placebo	28SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10911246	C4591001 1091 10911246	16-55	03SEP2020	79771	Placebo	03SEP2020/ Placebo	22SEP2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
10911250	C4591001 1091 10911250	16-55	03SEP2020	79778	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10911252	C4591001 1091 10911252	16-55	08SEP2020	79779	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10911255	C4591001 1091 10911255	16-55	08SEP2020	84165	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
10911256	C4591001 1091 10911256	16-55	08SEP2020	84167	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
10911257	C4591001 1091 10911257	16-55	08SEP2020	84168	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
10911260	C4591001 1091 10911260	16-55	09SEP2020	85326	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
10911261	C4591001 1091 10911261	16-55	09SEP2020	84170	Placebo	09SEP2020/ Placebo	28SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	04JAN2021/ BNT162b2 (30 µg)
10911270	C4591001 1091 10911270	16-55	09SEP2020	85331	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
10911271	C4591001 1091 10911271	16-55	09SEP2020	85327	Placebo	09SEP2020/ Placebo	28SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10911276	C4591001 1091 10911276	16-55	10SEP2020	85336	Placebo	10SEP2020/ Placebo	05OCT2020/ Placebo		
10911277	C4591001 1091 10911277	16-55	10SEP2020	87252	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
10911279	C4591001 1091 10911279	16-55	10SEP2020	87246	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10911281	C4591001 1091 10911281	16-55	10SEP2020	87255	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
10911282	C4591001 1091 10911282	16-55	10SEP2020	87251	Placebo	10SEP2020/ Placebo	29SEP2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
10911283	C4591001 1091 10911283	16-55	10SEP2020	87535	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
10911284	C4591001 1091 10911284	16-55	10SEP2020	87539	Placebo	10SEP2020/ Placebo	29SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
10911286	C4591001 1091 10911286	16-55	11SEP2020	87540	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
10911288	C4591001 1091 10911288	16-55	11SEP2020	87544	Placebo	11SEP2020/ Placebo	01OCT2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
10911289	C4591001 1091 10911289	16-55	11SEP2020	88030	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
10911290	C4591001 1091 10911290	16-55	11SEP2020	88031	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
10911291	C4591001 1091 10911291	16-55	11SEP2020	88028	Placebo	11SEP2020/ Placebo	04NOV2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10911293	C4591001 1091 10911293	16-55	14SEP2020	88034	Placebo	14SEP2020/ Placebo	06OCT2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10911297	C4591001 1091 10911297	16-55	14SEP2020	89862	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
10911298	C4591001 1091 10911298	16-55	14SEP2020	89863	Placebo	14SEP2020/ Placebo	06OCT2020/ Placebo	19DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
10911300	C4591001 1091 10911300	16-55	15SEP2020	89865	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
10911301	C4591001 1091 10911301	16-55	15SEP2020	89870	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
10911302	C4591001 1091 10911302	16-55	15SEP2020	90389	Placebo	15SEP2020/ Placebo	05OCT2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
10911303	C4591001 1091 10911303	16-55	15SEP2020	90391	Placebo	15SEP2020/ Placebo	07OCT2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
10911304	C4591001 1091 10911304	16-55	15SEP2020	90394	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
10911306	C4591001 1091 10911306	16-55	15SEP2020	90399	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
10911309	C4591001 1091 10911309	16-55	16SEP2020	91187	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
10911310	C4591001 1091 10911310	16-55	16SEP2020	91184	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10911311	C4591001 1091 10911311	16-55	16SEP2020	91185	Placebo	16SEP2020/ Placebo	08OCT2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
10911313	C4591001 1091 10911313	16-55	16SEP2020	91565	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
10911314	C4591001 1091 10911314	16-55	16SEP2020	91190	Placebo	16SEP2020/ Placebo	05OCT2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
10911315	C4591001 1091 10911315	16-55	17SEP2020	91570	Placebo	17SEP2020/ Placebo	09OCT2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	04JAN2021/ BNT162b2 (30 µg)
10911317	C4591001 1091 10911317	16-55	17SEP2020	91572	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
10911319	C4591001 1091 10911319	16-55	17SEP2020	91575	Placebo	17SEP2020/ Placebo	07OCT2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
10911320	C4591001 1091 10911320	16-55	17SEP2020	92634	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
10911321	C4591001 1091 10911321	16-55	17SEP2020	92640	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
10911322	C4591001 1091 10911322	16-55	17SEP2020	92635	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
10911324	C4591001 1091 10911324	16-55	17SEP2020	92641	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10911325	C4591001 1091 10911325	16-55	21SEP2020	94832	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
10911327	C4591001 1091 10911327	16-55	21SEP2020	94834	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
10911328	C4591001 1091 10911328	16-55	21SEP2020	94838	Placebo	21SEP2020/ Placebo	15OCT2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
10911331	C4591001 1091 10911331	16-55	22SEP2020	94840	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
10911333	C4591001 1091 10911333	16-55	22SEP2020	97089	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
10911334	C4591001 1091 10911334	16-55	23SEP2020	97091	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
10911336	C4591001 1091 10911336	16-55	23SEP2020	97095	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
10911338	C4591001 1091 10911338	16-55	24SEP2020	97096	Placebo	24SEP2020/ Placebo	13OCT2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
10911339	C4591001 1091 10911339	16-55	25SEP2020	99426	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
10911340	C4591001 1091 10911340	16-55	25SEP2020	99433	Placebo	25SEP2020/ Placebo	15OCT2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10911341	C4591001 1091 10911341	16-55	25SEP2020	99545	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
10911342	C4591001 1091 10911342	16-55	25SEP2020	99430	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
10911343	C4591001 1091 10911343	16-55	25SEP2020	99432	Placebo	25SEP2020/ Placebo	14OCT2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
10911344	C4591001 1091 10911344	16-55	29SEP2020	99549	Placebo	29SEP2020/ Placebo	19OCT2020/ Placebo		
10911348	C4591001 1091 10911348	16-55	01OCT2020	99551	BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		
10911350	C4591001 1091 10911350	16-55	05OCT2020	99554	Placebo	05OCT2020/ Placebo	26OCT2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10911351	C4591001 1091 10911351	16-55	05OCT2020	103902	BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		
10911352	C4591001 1091 10911352	16-55	06OCT2020	103906	Placebo	06OCT2020/ Placebo			
10911353	C4591001 1091 10911353	16-55	06OCT2020	103911	BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
10911355	C4591001 1091 10911355	16-55	08OCT2020	103912	Placebo	08OCT2020/ Placebo	29OCT2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10911356	C4591001 1091 10911356	16-55	08OCT2020	105342	Placebo	08OCT2020/ Placebo	28OCT2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
10911357	C4591001 1091 10911357	16-55	08OCT2020	105345	Placebo	08OCT2020/ Placebo	29OCT2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
10911358	C4591001 1091 10911358	16-55	08OCT2020	105347	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
10911360	C4591001 1091 10911360	16-55	09OCT2020	105351	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
10911361	C4591001 1091 10911361	16-55	12OCT2020	106596	Placebo	12OCT2020/ Placebo	03NOV2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10911362	C4591001 1091 10911362	16-55	12OCT2020	106590	BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		
10911363	C4591001 1091 10911363	16-55	12OCT2020	106593	BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
10911366	C4591001 1091 10911366	16-55	14OCT2020	106600	Placebo	14OCT2020/ Placebo	05NOV2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
10911368	C4591001 1091 10911368	16-55	15OCT2020	108365	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
10911371	C4591001 1091 10911371	16-55	19OCT2020	108366	Placebo	19OCT2020/ Placebo	11NOV2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10911372	C4591001 1091 10911372	16-55	19OCT2020	108368	Placebo	19OCT2020/ Placebo	11NOV2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	04JAN2021/ BNT162b2 (30 µg)
10911373	C4591001 1091 10911373	16-55	20OCT2020	108373	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
10911375	C4591001 1091 10911375	16-55	21OCT2020	111605	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
10911376	C4591001 1091 10911376	16-55	04NOV2020	114763	Placebo	04NOV2020/ Placebo	25NOV2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10911378	C4591001 1091 10911378	16-55	23OCT2020	111607	Placebo	23OCT2020/ Placebo	03DEC2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
10911379	C4591001 1091 10911379	16-55	26OCT2020	111608	Placebo	26OCT2020/ Placebo	17NOV2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
10911380	C4591001 1091 10911380	16-55	26OCT2020	111616	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
10911381	C4591001 1091 10911381	16-55	27OCT2020	114199	Placebo	27OCT2020/ Placebo	16NOV2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10911382	C4591001 1091 10911382	16-55	28OCT2020	114200	BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)	18NOV2020/ BNT162b2 (30 µg)		
10911383	C4591001 1091 10911383	16-55	28OCT2020	114204	Placebo	28OCT2020/ Placebo	18NOV2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10911384	C4591001 1091 10911384	16-55	29OCT2020	114207	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)		
10911385	C4591001 1091 10911385	16-55	29OCT2020	114761	Placebo	29OCT2020/ Placebo	17NOV2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
10911386	C4591001 1091 10911386	16-55	03NOV2020	114762	BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)	23NOV2020/ BNT162b2 (30 µg)		
10911387	C4591001 1091 10911387	16-55	05NOV2020	114767	BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)			
10911388	C4591001 1091 10911388	16-55	16NOV2020	116297	Placebo	16NOV2020/ Placebo	07DEC2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10911389	C4591001 1091 10911389	16-55	18NOV2020	116298	BNT162b2 (30 µg)	18NOV2020/ BNT162b2 (30 µg)	09DEC2020/ BNT162b2 (30 µg)		
10911390	C4591001 1091 10911390	16-55	18NOV2020	116302	Placebo	18NOV2020/ Placebo	09DEC2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
10911391	C4591001 1091 10911391	16-55	25NOV2020	116303	BNT162b2 (30 µg)	25NOV2020/ BNT162b2 (30 µg)	21DEC2020/ BNT162b2 (30 µg)		
10911392	C4591001 1091 10911392	16-55	30NOV2020	117066	Placebo	30NOV2020/ Placebo	22DEC2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
10911393	C4591001 1091 10911393	16-55	01DEC2020	20577	Placebo	01DEC2020/ Placebo	21DEC2020/ Placebo		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10911397	C4591001 1091 10911397	16-55	03DEC2020	117073	Placebo	03DEC2020/ Placebo	22DEC2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
10911398	C4591001 1091 10911398	16-55	03DEC2020	117075	BNT162b2 (30 µg)	03DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)		
10911401	C4591001 1091 10911401	16-55	04DEC2020	117547	BNT162b2 (30 µg)	04DEC2020/ BNT162b2 (30 µg)	29DEC2020/ BNT162b2 (30 µg)		
10921001	C4591001 1092 10921001	16-55	18AUG2020	54917	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10921002	C4591001 1092 10921002	16-55	18AUG2020	54918	Placebo	18AUG2020/ Placebo	10SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
10921003	C4591001 1092 10921003	16-55	18AUG2020	54921	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10921008	C4591001 1092 10921008	16-55	19AUG2020	54922	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10921020	C4591001 1092 10921020	16-55	20AUG2020	57858	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10921024	C4591001 1092 10921024	16-55	20AUG2020	57862	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10921026	C4591001 1092 10921026	16-55	20AUG2020	57863	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10921027	C4591001 1092 10921027	16-55	20AUG2020	57864	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10921029	C4591001 1092 10921029	16-55	20AUG2020	58844	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10921033	C4591001 1092 10921033	16-55	20AUG2020	58847	Placebo	20AUG2020/ Placebo	08SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
10921035	C4591001 1092 10921035	16-55	21AUG2020	58848	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10921036	C4591001 1092 10921036	16-55	21AUG2020	58851	Placebo	21AUG2020/ Placebo	10SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10921042	C4591001 1092 10921042	16-55	24AUG2020	63223	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10921045	C4591001 1092 10921045	16-55	24AUG2020	63226	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
10921053	C4591001 1092 10921053	16-55	24AUG2020	63228	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10921055	C4591001 1092 10921055	16-55	24AUG2020	63229	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo		
10921056	C4591001 1092 10921056	16-55	25AUG2020	65118	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10921064	C4591001 1092 10921064	16-55	25AUG2020	65120	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10921065	C4591001 1092 10921065	16-55	25AUG2020	65121	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10921066	C4591001 1092 10921066	16-55	25AUG2020	65128	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo		
10921075	C4591001 1092 10921075	16-55	26AUG2020	67127	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10921076	C4591001 1092 10921076	16-55	26AUG2020	67128	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10921080	C4591001 1092 10921080	16-55	26AUG2020	67129	Placebo	26AUG2020/ Placebo			
10921081	C4591001 1092 10921081	16-55	26AUG2020	67132	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10921082	C4591001 1092 10921082	16-55	26AUG2020	67627	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10921083	C4591001 1092 10921083	16-55	26AUG2020	67629	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
10921084	C4591001 1092 10921084	16-55	26AUG2020	67631	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10921085	C4591001 1092 10921085	16-55	26AUG2020	67632	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10921091	C4591001 1092 10921091	16-55	26AUG2020	68900	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
10921097	C4591001 1092 10921097	16-55	27AUG2020	68903	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10921098	C4591001 1092 10921098	16-55	27AUG2020	68906	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10921099	C4591001 1092 10921099	16-55	27AUG2020	68907	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10921101	C4591001 1092 10921101	16-55	27AUG2020	71098	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10921106	C4591001 1092 10921106	16-55	31AUG2020	71100	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10921109	C4591001 1092 10921109	16-55	31AUG2020	71103	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo		
10921112	C4591001 1092 10921112	16-55	31AUG2020	71104	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10921113	C4591001 1092 10921113	16-55	31AUG2020	75406	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10921118	C4591001 1092 10921118	16-55	31AUG2020	75408	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
10921122	C4591001 1092 10921122	16-55	01SEP2020	75411	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10921125	C4591001 1092 10921125	16-55	01SEP2020	75412	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10921127	C4591001 1092 10921127	16-55	01SEP2020	76961	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10921128	C4591001 1092 10921128	16-55	01SEP2020	76964	BNT162b2 (30 µg)				
10921130	C4591001 1092 10921130	16-55	01SEP2020	76968	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo		
10921131	C4591001 1092 10921131	16-55	01SEP2020	76970	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10921132	C4591001 1092 10921132	16-55	01SEP2020	77204	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10921133	C4591001 1092 10921133	16-55	01SEP2020	77207	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10921139	C4591001 1092 10921139	16-55	02SEP2020	77209	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10921142	C4591001 1092 10921142	16-55	02SEP2020	77212	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10921143	C4591001 1092 10921143	16-55	02SEP2020	78809	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10921144	C4591001 1092 10921144	16-55	02SEP2020	78814	Placebo	02SEP2020/ Placebo	24SEP2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10921146	C4591001 1092 10921146	16-55	02SEP2020	78815	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10921147	C4591001 1092 10921147	16-55	03SEP2020	78820	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
10921153	C4591001 1092 10921153	16-55	03SEP2020	79901	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10921157	C4591001 1092 10921157	16-55	03SEP2020	79902	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10921158	C4591001 1092 10921158	16-55	03SEP2020	79904	Placebo	03SEP2020/ Placebo	15OCT2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
10921160	C4591001 1092 10921160	16-55	03SEP2020	79908	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10921161	C4591001 1092 10921161	16-55	04SEP2020	81224	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10921162	C4591001 1092 10921162	16-55	04SEP2020	81225	Placebo	04SEP2020/ Placebo	28SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
10921168	C4591001 1092 10921168	16-55	08SEP2020	81231	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
10921175	C4591001 1092 10921175	16-55	09SEP2020	81232	Placebo	09SEP2020/ Placebo	04NOV2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
10921177	C4591001 1092 10921177	16-55	10SEP2020	86239	Placebo	10SEP2020/ Placebo	29SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
10921179	C4591001 1092 10921179	16-55	10SEP2020	86240	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
10921181	C4591001 1092 10921181	16-55	11SEP2020	86244	Placebo	11SEP2020/ Placebo	01OCT2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
10921183	C4591001 1092 10921183	16-55	11SEP2020	86245	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
10921184	C4591001 1092 10921184	16-55	11SEP2020	87893	Placebo	11SEP2020/ Placebo	30SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
10921186	C4591001 1092 10921186	16-55	14SEP2020	87900	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
10921188	C4591001 1092 10921188	16-55	15SEP2020	87903	Placebo	15SEP2020/ Placebo	06OCT2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10921189	C4591001 1092 10921189	16-55	15SEP2020	87904	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
10921192	C4591001 1092 10921192	16-55	16SEP2020	91530	Placebo	16SEP2020/ Placebo	07OCT2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10921197	C4591001 1092 10921197	16-55	05OCT2020	91532	Placebo	05OCT2020/ Placebo	26OCT2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
10921198	C4591001 1092 10921198	16-55	05OCT2020	91535	BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
10921200	C4591001 1092 10921200	16-55	06OCT2020	91540	BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		
10921201	C4591001 1092 10921201	16-55	06OCT2020	104345	Placebo	06OCT2020/ Placebo	27OCT2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10921203	C4591001 1092 10921203	16-55	06OCT2020	104347	BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		
10921204	C4591001 1092 10921204	16-55	06OCT2020	104348	Placebo	06OCT2020/ Placebo	27OCT2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
10921205	C4591001 1092 10921205	16-55	07OCT2020	104349	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
10921208	C4591001 1092 10921208	16-55	07OCT2020	104657	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10921209	C4591001 1092 10921209	16-55	07OCT2020	104658	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)		
10921210	C4591001 1092 10921210	16-55	07OCT2020	104662	Placebo	07OCT2020/ Placebo	28OCT2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
10921211	C4591001 1092 10921211	16-55	07OCT2020	104664	Placebo	07OCT2020/ Placebo	28OCT2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10921218	C4591001 1092 10921218	16-55	09OCT2020	105765	Placebo	09OCT2020/ Placebo	30OCT2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10921219	C4591001 1092 10921219	16-55	09OCT2020	105766	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)		
10921223	C4591001 1092 10921223	16-55	12OCT2020	105769	BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		
10921225	C4591001 1092 10921225	16-55	12OCT2020	105770	Placebo	12OCT2020/ Placebo	02NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10921227	C4591001 1092 10921227	16-55	12OCT2020	106568	Placebo	12OCT2020/ Placebo	02NOV2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
10921228	C4591001 1092 10921228	16-55	12OCT2020	106572	BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		
10921229	C4591001 1092 10921229	16-55	12OCT2020	106573	Placebo	12OCT2020/ Placebo	02NOV2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10921236	C4591001 1092 10921236	16-55	13OCT2020	106575	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
10921237	C4591001 1092 10921237	16-55	13OCT2020	107118	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
10921239	C4591001 1092 10921239	16-55	14OCT2020	107120	Placebo	14OCT2020/ Placebo	04NOV2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10921245	C4591001 1092 10921245	16-55	15OCT2020	107124	Placebo	15OCT2020/ Placebo	05NOV2020/ Placebo		
10921246	C4591001 1092 10921246	16-55	19OCT2020	107128	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
10921247	C4591001 1092 10921247	16-55	19OCT2020	109854	Placebo	19OCT2020/ Placebo	11NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10921248	C4591001 1092 10921248	16-55	19OCT2020	109858	Placebo	19OCT2020/ Placebo	11NOV2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
10921249	C4591001 1092 10921249	16-55	20OCT2020	109859	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)			
10921260	C4591001 1092 10921260	16-55	20OCT2020	109864	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
10921271	C4591001 1092 10921271	16-55	27OCT2020	113924	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10921272	C4591001 1092 10921272	16-55	27OCT2020	113925	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
10921274	C4591001 1092 10921274	16-55	27OCT2020	113929	Placebo	27OCT2020/ Placebo	19NOV2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
10921276	C4591001 1092 10921276	16-55	29OCT2020	113931	Placebo	29OCT2020/ Placebo	19NOV2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10931009	C4591001 1093 10931009	16-55	17AUG2020	51440	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10931011	C4591001 1093 10931011	16-55	17AUG2020	51443	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10931013	C4591001 1093 10931013	16-55	18AUG2020	51448	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
10931017	C4591001 1093 10931017	16-55	18AUG2020	54365	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
10931018	C4591001 1093 10931018	16-55	18AUG2020	54368	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10931019	C4591001 1093 10931019	16-55	18AUG2020	54370	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
10931020	C4591001 1093 10931020	16-55	18AUG2020	54372	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10931022	C4591001 1093 10931022	16-55	19AUG2020	55878	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
10931027	C4591001 1093 10931027	16-55	20AUG2020	55885	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10931028	C4591001 1093 10931028	16-55	20AUG2020	55879	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo		
10931030	C4591001 1093 10931030	16-55	03SEP2020	78898	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
10931031	C4591001 1093 10931031	16-55	21AUG2020	60149	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
10931032	C4591001 1093 10931032	16-55	21AUG2020	55887	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10931033	C4591001 1093 10931033	16-55	21AUG2020	60152	Placebo	21AUG2020/ Placebo	09SEP2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
10931039	C4591001 1093 10931039	16-55	21AUG2020	60155	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
10931040	C4591001 1093 10931040	16-55	21AUG2020	60157	Placebo	21AUG2020/ Placebo	09SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
10931041	C4591001 1093 10931041	16-55	21AUG2020	61577	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10931042	C4591001 1093 10931042	16-55	22AUG2020	61582	Placebo	22AUG2020/ Placebo	02OCT2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10931043	C4591001 1093 10931043	16-55	22AUG2020	61581	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
10931049	C4591001 1093 10931049	16-55	24AUG2020	61587	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
10931052	C4591001 1093 10931052	16-55	25AUG2020	65659	Placebo	25AUG2020/ Placebo	16SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
10931053	C4591001 1093 10931053	16-55	25AUG2020	65660	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10931055	C4591001 1093 10931055	16-55	25AUG2020	65667	BNT162b2 (30 µg)				
10931056	C4591001 1093 10931056	16-55	25AUG2020	65668	Placebo	25AUG2020/ Placebo	22SEP2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
10931058	C4591001 1093 10931058	16-55	25AUG2020	67013	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)			
10931061	C4591001 1093 10931061	16-55	26AUG2020	67017	Placebo	26AUG2020/ Placebo	15SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10931063	C4591001 1093 10931063	16-55	26AUG2020	67019	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10931065	C4591001 1093 10931065	16-55	26AUG2020	67023	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)			
10931066	C4591001 1093 10931066	16-55	26AUG2020	68477	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10931067	C4591001 1093 10931067	16-55	26AUG2020	68478	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10931068	C4591001 1093 10931068	16-55	26AUG2020	68479	Placebo	26AUG2020/ Placebo	15SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10931070	C4591001 1093 10931070	16-55	26AUG2020	68484	Placebo	26AUG2020/ Placebo	17SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10931071	C4591001 1093 10931071	16-55	26AUG2020	69018	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10931072	C4591001 1093 10931072	16-55	26AUG2020	69019	Placebo	26AUG2020/ Placebo			
10931073	C4591001 1093 10931073	16-55	27AUG2020	69021	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
10931074	C4591001 1093 10931074	16-55	27AUG2020	69026	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
10931078	C4591001 1093 10931078	16-55	27AUG2020	71129	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10931084	C4591001 1093 10931084	16-55	28AUG2020	71130	Placebo	28AUG2020/ Placebo	17SEP2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)
10931085	C4591001 1093 10931085	16-55	28AUG2020	71132	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
10931087	C4591001 1093 10931087	16-55	28AUG2020	71137	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	27FEB2021/ BNT162b2 (30 µg)
10931088	C4591001 1093 10931088	16-55	31AUG2020	74722	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10931089	C4591001 1093 10931089	16-55	31AUG2020	74725	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
10931090	C4591001 1093 10931090	16-55	31AUG2020	74726	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10931091	C4591001 1093 10931091	16-55	31AUG2020	74727	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
10931093	C4591001 1093 10931093	16-55	31AUG2020	76073	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10931094	C4591001 1093 10931094	16-55	31AUG2020	76074	Placebo	31AUG2020/ Placebo			
10931095	C4591001 1093 10931095	16-55	31AUG2020	76076	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10931096	C4591001 1093 10931096	16-55	01SEP2020	76082	Placebo	01SEP2020/ Placebo	21SEP2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10931098	C4591001 1093 10931098	16-55	01SEP2020	76829	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10931099	C4591001 1093 10931099	16-55	01SEP2020	76830	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo		
10931100	C4591001 1093 10931100	16-55	01SEP2020	76831	Placebo	01SEP2020/ Placebo	23SEP2020/ Placebo		
10931101	C4591001 1093 10931101	16-55	02SEP2020	76832	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10931103	C4591001 1093 10931103	16-55	02SEP2020	78893	Placebo	02SEP2020/ Placebo	25SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
10931108	C4591001 1093 10931108	16-55	04SEP2020	78901	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
10931111	C4591001 1093 10931111	16-55	08SEP2020	84428	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
10931113	C4591001 1093 10931113	16-55	08SEP2020	84429	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo		
10931115	C4591001 1093 10931115	16-55	10SEP2020	84430	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10931117	C4591001 1093 10931117	16-55	10SEP2020	84431	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	27FEB2021/ BNT162b2 (30 µg)
10931118	C4591001 1093 10931118	16-55	10SEP2020	87629	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10931121	C4591001 1093 10931121	16-55	11SEP2020	87635	Placebo	11SEP2020/ Placebo	05OCT2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
10931123	C4591001 1093 10931123	16-55	11SEP2020	87636	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
10931124	C4591001 1093 10931124	16-55	11SEP2020	87639	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
10931126	C4591001 1093 10931126	16-55	11SEP2020	88626	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
10931127	C4591001 1093 10931127	16-55	11SEP2020	88627	Placebo	11SEP2020/ Placebo	30SEP2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10931129	C4591001 1093 10931129	16-55	15SEP2020	88631	Placebo	15SEP2020/ Placebo	05OCT2020/ Placebo		
10931131	C4591001 1093 10931131	16-55	17SEP2020	88634	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
10931132	C4591001 1093 10931132	16-55	18SEP2020	93260	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10931133	C4591001 1093 10931133	16-55	18SEP2020	93263	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	27FEB2021/ BNT162b2 (30 µg)
10931134	C4591001 1093 10931134	16-55	22SEP2020	93266	Placebo	22SEP2020/ Placebo	14OCT2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10931135	C4591001 1093 10931135	16-55	22SEP2020	93267	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
10931136	C4591001 1093 10931136	16-55	22SEP2020	96199	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
10931137	C4591001 1093 10931137	16-55	22SEP2020	96202	Placebo	22SEP2020/ Placebo	13OCT2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
10931138	C4591001 1093 10931138	16-55	22SEP2020	96203	Placebo	22SEP2020/ Placebo	13OCT2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10931139	C4591001 1093 10931139	16-55	22SEP2020	96204	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
10931145	C4591001 1093 10931145	16-55	22SEP2020	97052	Placebo	22SEP2020/ Placebo	12OCT2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
10931146	C4591001 1093 10931146	16-55	22SEP2020	97053	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
10931147	C4591001 1093 10931147	16-55	22SEP2020	97055	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10931148	C4591001 1093 10931148	16-55	22SEP2020	97109	Placebo	22SEP2020/ Placebo	12OCT2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	27FEB2021/ BNT162b2 (30 µg)
10931149	C4591001 1093 10931149	16-55	22SEP2020	97057	Placebo	22SEP2020/ Placebo	15OCT2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10931150	C4591001 1093 10931150	16-55	22SEP2020	97113	Placebo	22SEP2020/ Placebo	13OCT2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
10931152	C4591001 1093 10931152	16-55	23SEP2020	97115	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
10931155	C4591001 1093 10931155	16-55	23SEP2020	97119	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
10931158	C4591001 1093 10931158	16-55	23SEP2020	97917	Placebo	23SEP2020/ Placebo	13OCT2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
10931168	C4591001 1093 10931168	16-55	02OCT2020	97920	Placebo	02OCT2020/ Placebo	23OCT2020/ Placebo		
10931169	C4591001 1093 10931169	16-55	02OCT2020	97922	BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)		
10931170	C4591001 1093 10931170	16-55	07OCT2020	97924	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
10931171	C4591001 1093 10931171	16-55	07OCT2020	104981	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10931173	C4591001 1093 10931173	16-55	12OCT2020	104984	Placebo	12OCT2020/ Placebo	04NOV2020/ Placebo		
10931174	C4591001 1093 10931174	16-55	12OCT2020	104985	BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
10931175	C4591001 1093 10931175	16-55	14OCT2020	104991	Placebo	14OCT2020/ Placebo	03NOV2020/ Placebo		
10931177	C4591001 1093 10931177	16-55	19OCT2020	109895	Placebo	19OCT2020/ Placebo	09NOV2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10931178	C4591001 1093 10931178	16-55	19OCT2020	109896	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
10931179	C4591001 1093 10931179	16-55	19OCT2020	109897	Placebo	19OCT2020/ Placebo	09NOV2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
10931180	C4591001 1093 10931180	16-55	19OCT2020	109898	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
10931183	C4591001 1093 10931183	16-55	20OCT2020	110876	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
10931185	C4591001 1093 10931185	16-55	20OCT2020	110880	Placebo	20OCT2020/ Placebo	10NOV2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
10931186	C4591001 1093 10931186	16-55	20OCT2020	110878	Placebo	20OCT2020/ Placebo	11NOV2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10931187	C4591001 1093 10931187	16-55	20OCT2020	110881	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		
10931188	C4591001 1093 10931188	16-55	20OCT2020	111233	Placebo	20OCT2020/ Placebo	12NOV2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10931194	C4591001 1093 10931194	16-55	22OCT2020	111241	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
10931195	C4591001 1093 10931195	16-55	22OCT2020	111243	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
10931196	C4591001 1093 10931196	16-55	23OCT2020	111244	Placebo	23OCT2020/ Placebo	13NOV2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
10931197	C4591001 1093 10931197	16-55	23OCT2020	112818	Placebo	23OCT2020/ Placebo	12NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10931199	C4591001 1093 10931199	16-55	23OCT2020	112821	Placebo	23OCT2020/ Placebo	13NOV2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10931200	C4591001 1093 10931200	16-55	23OCT2020	112823	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
10931201	C4591001 1093 10931201	16-55	23OCT2020	112826	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
10931202	C4591001 1093 10931202	16-55	23OCT2020	113167	Placebo	23OCT2020/ Placebo	12NOV2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10931203	C4591001 1093 10931203	16-55	23OCT2020	113171	Placebo	23OCT2020/ Placebo	13NOV2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
10931204	C4591001 1093 10931204	16-55	23OCT2020	113175	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
10931205	C4591001 1093 10931205	16-55	23OCT2020	113176	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
10931208	C4591001 1093 10931208	16-55	26OCT2020	113575	Placebo	26OCT2020/ Placebo	16NOV2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
10931209	C4591001 1093 10931209	16-55	26OCT2020	113583	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
10931210	C4591001 1093 10931210	16-55	26OCT2020	113576	Placebo	26OCT2020/ Placebo	16NOV2020/ Placebo	27FEB2021/ BNT162b2 (30 µg)	
10931211	C4591001 1093 10931211	16-55	26OCT2020	113582	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)			
10931214	C4591001 1093 10931214	16-55	26OCT2020	113721	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
10931215	C4591001 1093 10931215	16-55	26OCT2020	113723	Placebo	26OCT2020/ Placebo	16NOV2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
10931216	C4591001 1093 10931216	16-55	26OCT2020	113726	Placebo	26OCT2020/ Placebo	20NOV2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10931217	C4591001 1093 10931217	16-55	26OCT2020	113780	Placebo	26OCT2020/ Placebo	16NOV2020/ Placebo		
10931218	C4591001 1093 10931218	16-55	26OCT2020	113727	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
10931219	C4591001 1093 10931219	16-55	27OCT2020	113784	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
10931222	C4591001 1093 10931222	16-55	27OCT2020	113785	Placebo	27OCT2020/ Placebo	17NOV2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
10931223	C4591001 1093 10931223	16-55	28OCT2020	113788	BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)	18NOV2020/ BNT162b2 (30 µg)		
10931224	C4591001 1093 10931224	16-55	28OCT2020	114378	BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)	20NOV2020/ BNT162b2 (30 µg)		
10931226	C4591001 1093 10931226	16-55	28OCT2020	114379	Placebo	28OCT2020/ Placebo	18NOV2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
10941025	C4591001 1094 10941025	16-55	18AUG2020	231522	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10941030	C4591001 1094 10941030	16-55	18AUG2020	55259	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
10941031	C4591001 1094 10941031	16-55	18AUG2020	55256	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10941040	C4591001 1094 10941040	16-55	20AUG2020	55260	Placebo	20AUG2020/ Placebo	11SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10941043	C4591001 1094 10941043	16-55	21AUG2020	55264	Placebo	21AUG2020/ Placebo	09SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
10941048	C4591001 1094 10941048	16-55	24AUG2020	64794	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
10941049	C4591001 1094 10941049	16-55	24AUG2020	64793	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
10941055	C4591001 1094 10941055	16-55	25AUG2020	64796	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10941066	C4591001 1094 10941066	16-55	28AUG2020	64798	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
10941067	C4591001 1094 10941067	16-55	28AUG2020	72043	Placebo	28AUG2020/ Placebo	21SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10941068	C4591001 1094 10941068	16-55	28AUG2020	72049	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10941069	C4591001 1094 10941069	16-55	28AUG2020	72051	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10941070	C4591001 1094 10941070	16-55	28AUG2020	72052	Placebo	28AUG2020/ Placebo	28SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10941075	C4591001 1094 10941075	16-55	01SEP2020	77681	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10941076	C4591001 1094 10941076	16-55	01SEP2020	77686	Placebo	01SEP2020/ Placebo	24SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10941077	C4591001 1094 10941077	16-55	01SEP2020	77688	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10941082	C4591001 1094 10941082	16-55	02SEP2020	77690	Placebo	02SEP2020/ Placebo	24SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10941084	C4591001 1094 10941084	16-55	03SEP2020	80180	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10941087	C4591001 1094 10941087	16-55	03SEP2020	80184	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10941090	C4591001 1094 10941090	16-55	03SEP2020	80186	Placebo	03SEP2020/ Placebo	25SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
10941091	C4591001 1094 10941091	16-55	03SEP2020	80188	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10941095	C4591001 1094 10941095	16-55	04SEP2020	82029	Placebo	04SEP2020/ Placebo	23SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
10941098	C4591001 1094 10941098	16-55	04SEP2020	82031	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10941100	C4591001 1094 10941100	16-55	05SEP2020	82034	BNT162b2 (30 µg)	05SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10941104	C4591001 1094 10941104	16-55	07SEP2020	82035	Placebo	07SEP2020/ Placebo	28SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10941107	C4591001 1094 10941107	16-55	07SEP2020	83254	BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
10941108	C4591001 1094 10941108	16-55	07SEP2020	83256	Placebo	07SEP2020/ Placebo	29SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
10941109	C4591001 1094 10941109	16-55	07SEP2020	83258	BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
10941117	C4591001 1094 10941117	16-55	09SEP2020	83259	Placebo	09SEP2020/ Placebo	29SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
10941124	C4591001 1094 10941124	16-55	11SEP2020	88219	Placebo	11SEP2020/ Placebo	30SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
10941129	C4591001 1094 10941129	16-55	15SEP2020	88226	Placebo	15SEP2020/ Placebo	05OCT2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
10941131	C4591001 1094 10941131	16-55	15SEP2020	88227	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
10941132	C4591001 1094 10941132	16-55	15SEP2020	88228	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10941137	C4591001 1094 10941137	16-55	17SEP2020	92708	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	10OCT2020/ BNT162b2 (30 µg)		
10941143	C4591001 1094 10941143	16-55	18SEP2020	262044	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
10941144	C4591001 1094 10941144	16-55	18SEP2020	92709	Placebo	18SEP2020/ Placebo	08OCT2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
10941150	C4591001 1094 10941150	16-55	07OCT2020	103975	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
10941153	C4591001 1094 10941153	16-55	24SEP2020	92711	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
10941155	C4591001 1094 10941155	16-55	25SEP2020	92715	Placebo	25SEP2020/ Placebo	10NOV2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
10941156	C4591001 1094 10941156	16-55	25SEP2020	100025	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
10941163	C4591001 1094 10941163	16-55	01OCT2020	100030	Placebo	01OCT2020/ Placebo	20OCT2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
10941166	C4591001 1094 10941166	16-55	02OCT2020	100031	BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)		
10941167	C4591001 1094 10941167	16-55	02OCT2020	100035	Placebo	02OCT2020/ Placebo	22OCT2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10941169	C4591001 1094 10941169	16-55	05OCT2020	103974	Placebo	05OCT2020/ Placebo	27OCT2020/ Placebo		
10941176	C4591001 1094 10941176	16-55	12OCT2020	103978	BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		
10941179	C4591001 1094 10941179	16-55	19OCT2020	103981	Placebo	19OCT2020/ Placebo	11NOV2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
10941181	C4591001 1094 10941181	16-55	21OCT2020	111463	Placebo	21OCT2020/ Placebo	12NOV2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
10941182	C4591001 1094 10941182	16-55	22OCT2020	111467	Placebo	22OCT2020/ Placebo	12NOV2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
10941186	C4591001 1094 10941186	16-55	29OCT2020	111468	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
10941188	C4591001 1094 10941188	16-55	29OCT2020	111469	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
10941189	C4591001 1094 10941189	16-55	29OCT2020	114821	Placebo	29OCT2020/ Placebo	17NOV2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10941192	C4591001 1094 10941192	16-55	30OCT2020	114825	BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)		
10951110	C4591001 1095 10951110	16-55	19AUG2020	44853	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)			

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10951112	C4591001 1095 10951112	16-55	25AUG2020	65406	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10951114	C4591001 1095 10951114	16-55	20AUG2020	44858	Placebo	20AUG2020/ Placebo	09SEP2020/ Placebo	11MAR2021/ BNT162b2 (30 µg)	
10951116	C4591001 1095 10951116	16-55	21AUG2020	44859	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10951119	C4591001 1095 10951119	16-55	28AUG2020	72343	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	
10951121	C4591001 1095 10951121	16-55	21AUG2020	61398	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	06JAN2021/ BNT162b2 (30 µg)	27JAN2021/ BNT162b2 (30 µg)
10951122	C4591001 1095 10951122	16-55	24AUG2020	61401	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	02MAR2021/ BNT162b2 (30 µg)	
10951124	C4591001 1095 10951124	16-55	24AUG2020	61405	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
10951128	C4591001 1095 10951128	16-55	25AUG2020	65405	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10951129	C4591001 1095 10951129	16-55	25AUG2020	61408	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10951132	C4591001 1095 10951132	16-55	04SEP2020	81485	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10951137	C4591001 1095 10951137	16-55	26AUG2020	65416	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
10951138	C4591001 1095 10951138	16-55	26AUG2020	65414	Placebo	26AUG2020/ Placebo	15SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
10951141	C4591001 1095 10951141	16-55	26AUG2020	68046	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)			
10951142	C4591001 1095 10951142	16-55	26AUG2020	68050	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
10951143	C4591001 1095 10951143	16-55	26AUG2020	68052	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
10951144	C4591001 1095 10951144	16-55	26AUG2020	68053	Placebo	26AUG2020/ Placebo	30NOV2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
10951147	C4591001 1095 10951147	16-55	27AUG2020	69713	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	02MAR2021/ BNT162b2 (30 µg)	
10951148	C4591001 1095 10951148	16-55	27AUG2020	69715	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10951149	C4591001 1095 10951149	16-55	27AUG2020	69717	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10951150	C4591001 1095 10951150	16-55	27AUG2020	69722	Placebo	27AUG2020/ Placebo	24SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10951152	C4591001 1095 10951152	16-55	27AUG2020	71214	Placebo	27AUG2020/ Placebo	18SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
10951153	C4591001 1095 10951153	16-55	28AUG2020	71218	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10951154	C4591001 1095 10951154	16-55	28AUG2020	71222	Placebo	28AUG2020/ Placebo	17SEP2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
10951155	C4591001 1095 10951155	16-55	28AUG2020	72341	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10951156	C4591001 1095 10951156	16-55	28AUG2020	71224	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10951159	C4591001 1095 10951159	16-55	29AUG2020	72345	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
10951160	C4591001 1095 10951160	16-55	29AUG2020	72347	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
10951161	C4591001 1095 10951161	16-55	29AUG2020	73663	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
10951163	C4591001 1095 10951163	16-55	29AUG2020	73666	Placebo	29AUG2020/ Placebo	18SEP2020/ Placebo	02MAR2021/ BNT162b2 (30 µg)	
10951166	C4591001 1095 10951166	16-55	29AUG2020	73668	Placebo	29AUG2020/ Placebo	21SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10951168	C4591001 1095 10951168	16-55	29AUG2020	73669	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)			
10951169	C4591001 1095 10951169	16-55	29AUG2020	74070	Placebo	29AUG2020/ Placebo	21SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
10951170	C4591001 1095 10951170	16-55	29AUG2020	74018	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10951171	C4591001 1095 10951171	16-55	29AUG2020	74015	Placebo	29AUG2020/ Placebo	18SEP2020/ Placebo	02MAR2021/ BNT162b2 (30 µg)	
10951172	C4591001 1095 10951172	16-55	29AUG2020	74012	Placebo	29AUG2020/ Placebo	05OCT2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10951173	C4591001 1095 10951173	16-55	29AUG2020	74020	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)			
10951174	C4591001 1095 10951174	16-55	31AUG2020	74075	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
10951176	C4591001 1095 10951176	16-55	31AUG2020	74072	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10951177	C4591001 1095 10951177	16-55	03SEP2020	79466	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10951178	C4591001 1095 10951178	16-55	31AUG2020	74076	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10951182	C4591001 1095 10951182	16-55	31AUG2020	75221	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10951183	C4591001 1095 10951183	16-55	31AUG2020	75223	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10951184	C4591001 1095 10951184	16-55	31AUG2020	75224	Placebo	31AUG2020/ Placebo	22SEP2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	27JAN2021/ BNT162b2 (30 µg)
10951185	C4591001 1095 10951185	16-55	31AUG2020	75227	Placebo	31AUG2020/ Placebo	22SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
10951186	C4591001 1095 10951186	16-55	31AUG2020	76149	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo		
10951188	C4591001 1095 10951188	16-55	01SEP2020	76150	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10951191	C4591001 1095 10951191	16-55	01SEP2020	76151	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo		
10951194	C4591001 1095 10951194	16-55	01SEP2020	76152	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10951196	C4591001 1095 10951196	16-55	01SEP2020	77333	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	02MAR2021/ BNT162b2 (30 µg)	
10951197	C4591001 1095 10951197	16-55	01SEP2020	77334	Placebo	01SEP2020/ Placebo	19OCT2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10951198	C4591001 1095 10951198	16-55	01SEP2020	77343	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10951199	C4591001 1095 10951199	16-55	01SEP2020	77344	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10951201	C4591001 1095 10951201	16-55	02SEP2020	78091	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10951202	C4591001 1095 10951202	16-55	02SEP2020	78095	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
10951203	C4591001 1095 10951203	16-55	02SEP2020	78099	Placebo	02SEP2020/ Placebo	24SEP2020/ Placebo	03MAR2021/ BNT162b2 (30 µg)	
10951207	C4591001 1095 10951207	16-55	02SEP2020	78100	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
10951208	C4591001 1095 10951208	16-55	02SEP2020	78525	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
10951214	C4591001 1095 10951214	16-55	02SEP2020	78527	Placebo	02SEP2020/ Placebo	24SEP2020/ Placebo	03MAR2021/ BNT162b2 (30 µg)	
10951215	C4591001 1095 10951215	16-55	02SEP2020	78528	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10951216	C4591001 1095 10951216	16-55	02SEP2020	78531	Placebo	02SEP2020/ Placebo	22SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10951217	C4591001 1095 10951217	16-55	02SEP2020	79461	Placebo	02SEP2020/ Placebo	24SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
10951218	C4591001 1095 10951218	16-55	02SEP2020	79465	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10951222	C4591001 1095 10951222	16-55	03SEP2020	79467	Placebo	03SEP2020/ Placebo	25SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
10951223	C4591001 1095 10951223	16-55	04SEP2020	81487	Placebo	04SEP2020/ Placebo	24SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
10951225	C4591001 1095 10951225	16-55	04SEP2020	81488	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
10951231	C4591001 1095 10951231	16-55	25SEP2020	81490	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo		
10951233	C4591001 1095 10951233	16-55	25SEP2020	99896	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
10951236	C4591001 1095 10951236	16-55	25SEP2020	99899	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
10951241	C4591001 1095 10951241	16-55	30SEP2020	102489	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		
10951243	C4591001 1095 10951243	16-55	25SEP2020	99901	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10951244	C4591001 1095 10951244	16-55	28SEP2020	99902	Placebo	28SEP2020/ Placebo	19OCT2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
10951245	C4591001 1095 10951245	16-55	28SEP2020	101369	Placebo	28SEP2020/ Placebo	19OCT2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
10951248	C4591001 1095 10951248	16-55	28SEP2020	101371	BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		
10951250	C4591001 1095 10951250	16-55	28SEP2020	101372	Placebo	28SEP2020/ Placebo	20OCT2020/ Placebo		
10951251	C4591001 1095 10951251	16-55	28SEP2020	101375	BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		
10951253	C4591001 1095 10951253	16-55	28SEP2020	101573	BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		
10951254	C4591001 1095 10951254	16-55	28SEP2020	101577	Placebo	28SEP2020/ Placebo	20OCT2020/ Placebo	11MAR2021/ BNT162b2 (30 µg)	
10951255	C4591001 1095 10951255	16-55	29SEP2020	101579	Placebo	29SEP2020/ Placebo	19OCT2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
10951257	C4591001 1095 10951257	16-55	30SEP2020	101580	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		
10951259	C4591001 1095 10951259	16-55	06OCT2020	102490	Placebo	06OCT2020/ Placebo	27OCT2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10951260	C4591001 1095 10951260	16-55	07OCT2020	102493	Placebo	07OCT2020/ Placebo	28OCT2020/ Placebo	11MAR2021/ BNT162b2 (30 µg)	
10951262	C4591001 1095 10951262	16-55	07OCT2020	102496	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
10951266	C4591001 1095 10951266	16-55	08OCT2020	105333	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
10951267	C4591001 1095 10951267	16-55	08OCT2020	105334	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		
10951268	C4591001 1095 10951268	16-55	08OCT2020	105339	Placebo	08OCT2020/ Placebo	27OCT2020/ Placebo		
10951269	C4591001 1095 10951269	16-55	08OCT2020	105338	Placebo	08OCT2020/ Placebo	27OCT2020/ Placebo		
10951270	C4591001 1095 10951270	16-55	08OCT2020	105512	Placebo	08OCT2020/ Placebo	28OCT2020/ Placebo		
10951271	C4591001 1095 10951271	16-55	08OCT2020	105511	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
10951274	C4591001 1095 10951274	16-55	12OCT2020	105515	BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		
10951277	C4591001 1095 10951277	16-55	12OCT2020	106578	Placebo	12OCT2020/ Placebo	02NOV2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10951278	C4591001 1095 10951278	16-55	12OCT2020	105516	Placebo	12OCT2020/ Placebo	03NOV2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
10951280	C4591001 1095 10951280	16-55	12OCT2020	106587	BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
10951281	C4591001 1095 10951281	16-55	12OCT2020	106581	BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
10951282	C4591001 1095 10951282	16-55	12OCT2020	106585	Placebo	12OCT2020/ Placebo	02NOV2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
10951283	C4591001 1095 10951283	16-55	12OCT2020	106697	Placebo	12OCT2020/ Placebo	02NOV2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10951284	C4591001 1095 10951284	16-55	13OCT2020	106701	Placebo	13OCT2020/ Placebo	04NOV2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
10951285	C4591001 1095 10951285	16-55	13OCT2020	106706	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
10951286	C4591001 1095 10951286	16-55	13OCT2020	106707	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
10951288	C4591001 1095 10951288	16-55	14OCT2020	107754	BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
10951290	C4591001 1095 10951290	16-55	14OCT2020	107756	BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10951291	C4591001 1095 10951291	16-55	14OCT2020	107758	Placebo	14OCT2020/ Placebo	05NOV2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
10951292	C4591001 1095 10951292	16-55	16OCT2020	107762	Placebo	16OCT2020/ Placebo	06NOV2020/ Placebo		
10951293	C4591001 1095 10951293	16-55	16OCT2020	109053	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
10951294	C4591001 1095 10951294	16-55	16OCT2020	109054	Placebo	16OCT2020/ Placebo	04NOV2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)
10951295	C4591001 1095 10951295	16-55	16OCT2020	109058	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
10951296	C4591001 1095 10951296	16-55	19OCT2020	109059	Placebo	19OCT2020/ Placebo	09NOV2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
10951298	C4591001 1095 10951298	16-55	19OCT2020	110561	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
10951299	C4591001 1095 10951299	16-55	20OCT2020	110565	Placebo	20OCT2020/ Placebo	11NOV2020/ Placebo		
10951301	C4591001 1095 10951301	16-55	21OCT2020	110566	Placebo	21OCT2020/ Placebo	11NOV2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
10951304	C4591001 1095 10951304	16-55	22OCT2020	110567	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10951305	C4591001 1095 10951305	16-55	23OCT2020	113201	Placebo	23OCT2020/ Placebo	13NOV2020/ Placebo		
10951306	C4591001 1095 10951306	16-55	23OCT2020	113203	Placebo	23OCT2020/ Placebo	17NOV2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
10951307	C4591001 1095 10951307	16-55	30OCT2020	113207	BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)	20NOV2020/ BNT162b2 (30 µg)		
10951308	C4591001 1095 10951308	16-55	17NOV2020	113212	BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)	10DEC2020/ BNT162b2 (30 µg)		
10951309	C4591001 1095 10951309	16-55	18NOV2020	116456	Placebo	18NOV2020/ Placebo	07DEC2020/ Placebo		
10951310	C4591001 1095 10951310	16-55	19NOV2020	116457	BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)	15DEC2020/ BNT162b2 (30 µg)		
10951311	C4591001 1095 10951311	16-55	19NOV2020	116458	BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)	08DEC2020/ BNT162b2 (30 µg)		
10951312	C4591001 1095 10951312	16-55	20NOV2020	116464	Placebo	20NOV2020/ Placebo	11DEC2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
10951313	C4591001 1095 10951313	16-55	23NOV2020	116671	BNT162b2 (30 µg)	23NOV2020/ BNT162b2 (30 µg)	14DEC2020/ BNT162b2 (30 µg)		
10951314	C4591001 1095 10951314	16-55	23NOV2020	116676	Placebo	23NOV2020/ Placebo	14DEC2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10951315	C4591001 1095 10951315	16-55	23NOV2020	116677	BNT162b2 (30 µg)	23NOV2020/ BNT162b2 (30 µg)	15DEC2020/ BNT162b2 (30 µg)		
10951316	C4591001 1095 10951316	16-55	23NOV2020	116678	Placebo	23NOV2020/ Placebo	15DEC2020/ Placebo	12MAR2021/ BNT162b2 (30 µg)	
10951317	C4591001 1095 10951317	16-55	24NOV2020	116876	Placebo	24NOV2020/ Placebo	15DEC2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
10951318	C4591001 1095 10951318	16-55	30NOV2020	116879	BNT162b2 (30 µg)	30NOV2020/ BNT162b2 (30 µg)	28DEC2020/ BNT162b2 (30 µg)		
10951319	C4591001 1095 10951319	16-55	01DEC2020	116881	BNT162b2 (30 µg)	01DEC2020/ BNT162b2 (30 µg)	28DEC2020/ BNT162b2 (30 µg)		
10961026	C4591001 1096 10961026	16-55	14AUG2020	50902	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo		
10961027	C4591001 1096 10961027	16-55	14AUG2020	50900	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
10961031	C4591001 1096 10961031	16-55	14AUG2020	51006	Placebo	14AUG2020/ Placebo		03MAR2021/ BNT162b2 (30 µg)	
10961032	C4591001 1096 10961032	16-55	14AUG2020	51007	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
10961035	C4591001 1096 10961035	16-55	17AUG2020	51015	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10961036	C4591001 1096 10961036	16-55	17AUG2020	51014	Placebo	17AUG2020/ Placebo	09SEP2020/ Placebo		
10961042	C4591001 1096 10961042	16-55	17AUG2020	53688	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
10961049	C4591001 1096 10961049	16-55	18AUG2020	53689	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
10961052	C4591001 1096 10961052	16-55	18AUG2020	53690	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10961053	C4591001 1096 10961053	16-55	18AUG2020	55568	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10961057	C4591001 1096 10961057	16-55	18AUG2020	53691	Placebo	18AUG2020/ Placebo	10SEP2020/ Placebo		
10961059	C4591001 1096 10961059	16-55	19AUG2020	55573	Placebo	19AUG2020/ Placebo	08SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
10961060	C4591001 1096 10961060	16-55	19AUG2020	55570	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10961061	C4591001 1096 10961061	16-55	19AUG2020	55574	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
10961062	C4591001 1096 10961062	16-55	19AUG2020	56745	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10961063	C4591001 1096 10961063	16-55	19AUG2020	56748	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10961064	C4591001 1096 10961064	16-55	19AUG2020	56749	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
10961067	C4591001 1096 10961067	16-55	19AUG2020	56751	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10961072	C4591001 1096 10961072	16-55	20AUG2020	58782	Placebo	20AUG2020/ Placebo	16SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
10961074	C4591001 1096 10961074	16-55	20AUG2020	58784	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	12SEP2020/ BNT162b2 (30 µg)		
10961075	C4591001 1096 10961075	16-55	20AUG2020	58787	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	12SEP2020/ BNT162b2 (30 µg)		
10961076	C4591001 1096 10961076	16-55	20AUG2020	58785	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo		
10961077	C4591001 1096 10961077	16-55	20AUG2020	58949	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10961078	C4591001 1096 10961078	16-55	20AUG2020	58951	Placebo	20AUG2020/ Placebo	08SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10961081	C4591001 1096 10961081	16-55	20AUG2020	58958	Placebo	20AUG2020/ Placebo			

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10961083	C4591001 1096 10961083	16-55	20AUG2020	59843	Placebo	20AUG2020/ Placebo	11SEP2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
10961084	C4591001 1096 10961084	16-55	20AUG2020	59844	Placebo	20AUG2020/ Placebo	11SEP2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
10961085	C4591001 1096 10961085	16-55	20AUG2020	58960	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
10961087	C4591001 1096 10961087	16-55	21AUG2020	61016	Placebo	21AUG2020/ Placebo	12SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
10961088	C4591001 1096 10961088	16-55	21AUG2020	59846	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
10961089	C4591001 1096 10961089	16-55	21AUG2020	59845	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	12SEP2020/ BNT162b2 (30 µg)		
10961090	C4591001 1096 10961090	16-55	22AUG2020	61019	Placebo	22AUG2020/ Placebo	11SEP2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
10961093	C4591001 1096 10961093	16-55	22AUG2020	61988	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
10961096	C4591001 1096 10961096	16-55	22AUG2020	61024	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10961097	C4591001 1096 10961097	16-55	22AUG2020	61020	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	12SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10961098	C4591001 1096 10961098	16-55	22AUG2020	61991	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	12SEP2020/ BNT162b2 (30 µg)		
10961099	C4591001 1096 10961099	16-55	22AUG2020	61992	Placebo	22AUG2020/ Placebo	19SEP2020/ Placebo		
10961100	C4591001 1096 10961100	16-55	22AUG2020	61996	Placebo	22AUG2020/ Placebo	12SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
10961101	C4591001 1096 10961101	16-55	22AUG2020	62233	Placebo	22AUG2020/ Placebo	12SEP2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
10961102	C4591001 1096 10961102	16-55	22AUG2020	62226	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	12SEP2020/ BNT162b2 (30 µg)		
10961103	C4591001 1096 10961103	16-55	22AUG2020	62225	Placebo	22AUG2020/ Placebo	12SEP2020/ Placebo	06JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
10961105	C4591001 1096 10961105	16-55	22AUG2020	62236	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10961109	C4591001 1096 10961109	16-55	22AUG2020	62291	Placebo	22AUG2020/ Placebo	12SEP2020/ Placebo		
10961110	C4591001 1096 10961110	16-55	22AUG2020	62290	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	12SEP2020/ BNT162b2 (30 µg)		
10961111	C4591001 1096 10961111	16-55	22AUG2020	62288	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	12SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10961112	C4591001 1096 10961112	16-55	22AUG2020	62292	Placebo	22AUG2020/ Placebo	12SEP2020/ Placebo	12MAR2021/ BNT162b2 (30 µg)	
10961113	C4591001 1096 10961113	16-55	22AUG2020	62381	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	12SEP2020/ BNT162b2 (30 µg)		
10961114	C4591001 1096 10961114	16-55	24AUG2020	62384	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
10961115	C4591001 1096 10961115	16-55	24AUG2020	62386	Placebo	24AUG2020/ Placebo	21SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
10961122	C4591001 1096 10961122	16-55	24AUG2020	62391	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10961125	C4591001 1096 10961125	16-55	25AUG2020	66150	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
10961130	C4591001 1096 10961130	16-55	25AUG2020	66152	Placebo	25AUG2020/ Placebo	16SEP2020/ Placebo	11MAR2021/ BNT162b2 (30 µg)	
10961137	C4591001 1096 10961137	16-55	26AUG2020	68095	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10961138	C4591001 1096 10961138	16-55	26AUG2020	68104	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10961139	C4591001 1096 10961139	16-55	26AUG2020	66154	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10961140	C4591001 1096 10961140	16-55	26AUG2020	66159	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10961141	C4591001 1096 10961141	16-55	26AUG2020	68100	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)			
10961142	C4591001 1096 10961142	16-55	26AUG2020	68103	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10961145	C4591001 1096 10961145	16-55	26AUG2020	69029	Placebo	26AUG2020/ Placebo	18SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
10961147	C4591001 1096 10961147	16-55	26AUG2020	69032	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
10961148	C4591001 1096 10961148	16-55	26AUG2020	69031	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
10961150	C4591001 1096 10961150	16-55	27AUG2020	69033	Placebo	27AUG2020/ Placebo	19SEP2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
10961151	C4591001 1096 10961151	16-55	27AUG2020	70443	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10961152	C4591001 1096 10961152	16-55	27AUG2020	70434	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
10961154	C4591001 1096 10961154	16-55	27AUG2020	70442	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10961158	C4591001 1096 10961158	16-55	27AUG2020	70444	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
10961168	C4591001 1096 10961168	16-55	28AUG2020	72569	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10961169	C4591001 1096 10961169	16-55	28AUG2020	72573	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10961170	C4591001 1096 10961170	16-55	29AUG2020	72575	Placebo	29AUG2020/ Placebo	25SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10961172	C4591001 1096 10961172	16-55	29AUG2020	73649	Placebo	29AUG2020/ Placebo	19SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10961173	C4591001 1096 10961173	16-55	29AUG2020	73733	Placebo	29AUG2020/ Placebo	19SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10961175	C4591001 1096 10961175	16-55	29AUG2020	73659	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		
10961176	C4591001 1096 10961176	16-55	29AUG2020	73735	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		
10961177	C4591001 1096 10961177	16-55	29AUG2020	73740	Placebo	29AUG2020/ Placebo	19SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
10961178	C4591001 1096 10961178	16-55	29AUG2020	73739	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10961179	C4591001 1096 10961179	16-55	29AUG2020	73651	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10961180	C4591001 1096 10961180	16-55	29AUG2020	73658	Placebo	29AUG2020/ Placebo	21SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10961185	C4591001 1096 10961185	16-55	29AUG2020	73926	Placebo	29AUG2020/ Placebo	18SEP2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
10961186	C4591001 1096 10961186	16-55	29AUG2020	73930	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
10961187	C4591001 1096 10961187	16-55	29AUG2020	73933	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	26SEP2020/ BNT162b2 (30 µg)		
10961195	C4591001 1096 10961195	16-55	31AUG2020	73936	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo		
10961196	C4591001 1096 10961196	16-55	31AUG2020	75212	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		
10961197	C4591001 1096 10961197	16-55	31AUG2020	75213	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10961199	C4591001 1096 10961199	16-55	31AUG2020	75216	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10961200	C4591001 1096 10961200	16-55	31AUG2020	75218	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10961205	C4591001 1096 10961205	16-55	01SEP2020	77053	Placebo	01SEP2020/ Placebo	24SEP2020/ Placebo		
10961206	C4591001 1096 10961206	16-55	01SEP2020	77045	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10961207	C4591001 1096 10961207	16-55	01SEP2020	77055	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo		
10961208	C4591001 1096 10961208	16-55	01SEP2020	77650	Placebo	01SEP2020/ Placebo	24SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
10961209	C4591001 1096 10961209	16-55	01SEP2020	77645	Placebo	01SEP2020/ Placebo	24SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
10961210	C4591001 1096 10961210	16-55	01SEP2020	77054	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10961211	C4591001 1096 10961211	16-55	01SEP2020	77655	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10961213	C4591001 1096 10961213	16-55	02SEP2020	77656	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10961214	C4591001 1096 10961214	16-55	02SEP2020	78458	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10961215	C4591001 1096 10961215	16-55	02SEP2020	78460	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10961216	C4591001 1096 10961216	16-55	02SEP2020	78452	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo		
10961217	C4591001 1096 10961217	16-55	02SEP2020	78451	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
10961218	C4591001 1096 10961218	16-55	02SEP2020	78643	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
10961219	C4591001 1096 10961219	16-55	02SEP2020	78652	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10961220	C4591001 1096 10961220	16-55	02SEP2020	79363	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
10961222	C4591001 1096 10961222	16-55	02SEP2020	78645	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
10961223	C4591001 1096 10961223	16-55	02SEP2020	78648	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10961225	C4591001 1096 10961225	16-55	03SEP2020	79372	Placebo	03SEP2020/ Placebo	22SEP2020/ Placebo	06JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
10961226	C4591001 1096 10961226	16-55	03SEP2020	79365	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10961227	C4591001 1096 10961227	16-55	03SEP2020	79364	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10961229	C4591001 1096 10961229	16-55	03SEP2020	80405	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
10961230	C4591001 1096 10961230	16-55	03SEP2020	80412	Placebo	03SEP2020/ Placebo	25SEP2020/ Placebo		
10961231	C4591001 1096 10961231	16-55	03SEP2020	80409	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
10961236	C4591001 1096 10961236	16-55	03SEP2020	80416	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	26SEP2020/ BNT162b2 (30 µg)		
10961238	C4591001 1096 10961238	16-55	04SEP2020	81473	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
10961239	C4591001 1096 10961239	16-55	04SEP2020	81474	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
10961240	C4591001 1096 10961240	16-55	04SEP2020	81477	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10961242	C4591001 1096 10961242	16-55	04SEP2020	81478	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10961243	C4591001 1096 10961243	16-55	04SEP2020	81791	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
10961244	C4591001 1096 10961244	16-55	04SEP2020	81796	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10961245	C4591001 1096 10961245	16-55	04SEP2020	81790	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
10961246	C4591001 1096 10961246	16-55	04SEP2020	81788	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
10961249	C4591001 1096 10961249	16-55	04SEP2020	82329	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10961251	C4591001 1096 10961251	16-55	04SEP2020	82330	Placebo	04SEP2020/ Placebo	24SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
10961254	C4591001 1096 10961254	16-55	04SEP2020	82333	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
10961255	C4591001 1096 10961255	16-55	04SEP2020	82334	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10961256	C4591001 1096 10961256	16-55	04SEP2020	82406	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo		
10961257	C4591001 1096 10961257	16-55	04SEP2020	82405	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
10961258	C4591001 1096 10961258	16-55	04SEP2020	82401	Placebo	04SEP2020/ Placebo	28SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10961261	C4591001 1096 10961261	16-55	05SEP2020	82735	Placebo	05SEP2020/ Placebo	26SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10961262	C4591001 1096 10961262	16-55	05SEP2020	82736	BNT162b2 (30 µg)	05SEP2020/ BNT162b2 (30 µg)	26SEP2020/ BNT162b2 (30 µg)		
10961264	C4591001 1096 10961264	16-55	05SEP2020	82737	Placebo	05SEP2020/ Placebo	25SEP2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)
10961265	C4591001 1096 10961265	16-55	05SEP2020	82738	BNT162b2 (30 µg)	05SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10961266	C4591001 1096 10961266	16-55	05SEP2020	82769	Placebo	05SEP2020/ Placebo	24SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10961267	C4591001 1096 10961267	16-55	05SEP2020	82770	BNT162b2 (30 µg)	05SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
10961268	C4591001 1096 10961268	16-55	05SEP2020	82774	Placebo	05SEP2020/ Placebo	24SEP2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	27JAN2021/ BNT162b2 (30 µg)
10961271	C4591001 1096 10961271	16-55	05SEP2020	82775	BNT162b2 (30 µg)	05SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10961275	C4591001 1096 10961275	16-55	05SEP2020	82937	BNT162b2 (30 µg)	05SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
10961276	C4591001 1096 10961276	16-55	05SEP2020	82939	Placebo	05SEP2020/ Placebo			
10961277	C4591001 1096 10961277	16-55	05SEP2020	82938	BNT162b2 (30 µg)	05SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10961278	C4591001 1096 10961278	16-55	05SEP2020	82945	Placebo	05SEP2020/ Placebo	25SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10961279	C4591001 1096 10961279	16-55	05SEP2020	82979	Placebo	05SEP2020/ Placebo	25SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
10961280	C4591001 1096 10961280	16-55	05SEP2020	82976	BNT162b2 (30 µg)	05SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
10961284	C4591001 1096 10961284	16-55	05SEP2020	82991	BNT162b2 (30 µg)	05SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
10961286	C4591001 1096 10961286	16-55	05SEP2020	82982	Placebo	05SEP2020/ Placebo	24SEP2020/ Placebo	06JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
10961287	C4591001 1096 10961287	16-55	05SEP2020	82993	BNT162b2 (30 µg)	05SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10961288	C4591001 1096 10961288	16-55	05SEP2020	82984	BNT162b2 (30 µg)	05SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10961289	C4591001 1096 10961289	16-55	08SEP2020	82995	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
10961291	C4591001 1096 10961291	16-55	08SEP2020	82996	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	20JAN2021/ BNT162b2 (30 µg)
10961293	C4591001 1096 10961293	16-55	08SEP2020	84570	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10961299	C4591001 1096 10961299	16-55	08SEP2020	84574	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
10961301	C4591001 1096 10961301	16-55	08SEP2020	84578	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
10961303	C4591001 1096 10961303	16-55	09SEP2020	84579	Placebo	09SEP2020/ Placebo	02OCT2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
10961305	C4591001 1096 10961305	16-55	09SEP2020	86058	Placebo	09SEP2020/ Placebo	29SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10961306	C4591001 1096 10961306	16-55	10SEP2020	86061	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
10961307	C4591001 1096 10961307	16-55	10SEP2020	86065	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
10961309	C4591001 1096 10961309	16-55	10SEP2020	86066	Placebo	10SEP2020/ Placebo	29SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
10961313	C4591001 1096 10961313	16-55	10SEP2020	87642	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		
10961317	C4591001 1096 10961317	16-55	12SEP2020	87645	Placebo	12SEP2020/ Placebo	05OCT2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
10961318	C4591001 1096 10961318	16-55	12SEP2020	87649	Placebo	12SEP2020/ Placebo	03OCT2020/ Placebo		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10961319	C4591001 1096 10961319	16-55	12SEP2020	87652	BNT162b2 (30 µg)	12SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
10961321	C4591001 1096 10961321	16-55	12SEP2020	89179	Placebo	12SEP2020/ Placebo		01FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
10961322	C4591001 1096 10961322	16-55	14SEP2020	89182	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
10961323	C4591001 1096 10961323	16-55	14SEP2020	89187	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
10961328	C4591001 1096 10961328	16-55	14SEP2020	89188	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	03OCT2020/ BNT162b2 (30 µg)		
10961330	C4591001 1096 10961330	16-55	15SEP2020	90522	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
10961331	C4591001 1096 10961331	16-55	15SEP2020	90523	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
10961335	C4591001 1096 10961335	16-55	15SEP2020	90525	Placebo	15SEP2020/ Placebo	06OCT2020/ Placebo	03MAR2021/ BNT162b2 (30 µg)	
10961336	C4591001 1096 10961336	16-55	15SEP2020	90530	Placebo	15SEP2020/ Placebo	06OCT2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
10961340	C4591001 1096 10961340	16-55	15SEP2020	90810	Placebo	15SEP2020/ Placebo	06OCT2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10961341	C4591001 1096 10961341	16-55	15SEP2020	90814	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		
10961342	C4591001 1096 10961342	16-55	15SEP2020	90816	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
10961343	C4591001 1096 10961343	16-55	16SEP2020	90817	Placebo	16SEP2020/ Placebo	07OCT2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	21JAN2021/ BNT162b2 (30 µg)
10961344	C4591001 1096 10961344	16-55	16SEP2020	91363	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)			
10961345	C4591001 1096 10961345	16-55	16SEP2020	91368	Placebo	16SEP2020/ Placebo	06NOV2020/ Placebo		
10961348	C4591001 1096 10961348	16-55	16SEP2020	91369	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
10961350	C4591001 1096 10961350	16-55	17SEP2020	91371	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)
10961351	C4591001 1096 10961351	16-55	17SEP2020	92671	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
10961357	C4591001 1096 10961357	16-55	17SEP2020	92673	Placebo	17SEP2020/ Placebo	09OCT2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)
10961358	C4591001 1096 10961358	16-55	17SEP2020	92675	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10961359	C4591001 1096 10961359	16-55	17SEP2020	261564	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
10961360	C4591001 1096 10961360	16-55	17SEP2020	92678	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
10961362	C4591001 1096 10961362	16-55	17SEP2020	93108	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
10961366	C4591001 1096 10961366	16-55	28SEP2020	93110	Placebo	28SEP2020/ Placebo	19OCT2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
10961367	C4591001 1096 10961367	16-55	28SEP2020	93111	BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		
10961370	C4591001 1096 10961370	16-55	29SEP2020	93112	Placebo	29SEP2020/ Placebo	19OCT2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10961372	C4591001 1096 10961372	16-55	06OCT2020	104371	Placebo	06OCT2020/ Placebo	27OCT2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
10961373	C4591001 1096 10961373	16-55	06OCT2020	104370	Placebo	06OCT2020/ Placebo	26OCT2020/ Placebo		
10961374	C4591001 1096 10961374	16-55	06OCT2020	104377	BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		
10961375	C4591001 1096 10961375	16-55	07OCT2020	104380	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10961376	C4591001 1096 10961376	16-55	07OCT2020	104950	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
10961378	C4591001 1096 10961378	16-55	08OCT2020	104954	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)		
10961379	C4591001 1096 10961379	16-55	08OCT2020	104953	Placebo	08OCT2020/ Placebo	28OCT2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
10961382	C4591001 1096 10961382	16-55	09OCT2020	104956	Placebo	09OCT2020/ Placebo	29OCT2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
10961385	C4591001 1096 10961385	16-55	09OCT2020	106161	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)		
10961387	C4591001 1096 10961387	16-55	09OCT2020	106163	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
10961388	C4591001 1096 10961388	16-55	09OCT2020	106165	Placebo	09OCT2020/ Placebo		01FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
10961390	C4591001 1096 10961390	16-55	02NOV2020	106167	Placebo	02NOV2020/ Placebo	23NOV2020/ Placebo		
10961391	C4591001 1096 10961391	16-55	05NOV2020	115819	Placebo	05NOV2020/ Placebo	24NOV2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
10961392	C4591001 1096 10961392	16-55	23NOV2020	115821	BNT162b2 (30 µg)	23NOV2020/ BNT162b2 (30 µg)	14DEC2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10961393	C4591001 1096 10961393	16-55	02DEC2020	115827	BNT162b2 (30 µg)	02DEC2020/ BNT162b2 (30 µg)	23DEC2020/ BNT162b2 (30 µg)		
10971007	C4591001 1097 10971007	16-55	20AUG2020	57896	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10971018	C4591001 1097 10971018	16-55	22AUG2020	57898	Placebo	22AUG2020/ Placebo	11SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
10971041	C4591001 1097 10971041	16-55	26AUG2020	57899	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
10971069	C4591001 1097 10971069	16-55	31AUG2020	57900	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10971081	C4591001 1097 10971081	16-55	01SEP2020	248315	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10971083	C4591001 1097 10971083	16-55	01SEP2020	77226	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	
10971085	C4591001 1097 10971085	16-55	01SEP2020	77227	Placebo	01SEP2020/ Placebo	15OCT2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
10971086	C4591001 1097 10971086	16-55	02SEP2020	77228	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10971096	C4591001 1097 10971096	16-55	04SEP2020	77236	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10971116	C4591001 1097 10971116	16-55	18SEP2020	93573	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	15JAN2021/ BNT162b2 (30 µg)
10971117	C4591001 1097 10971117	16-55	21SEP2020	93576	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
10971119	C4591001 1097 10971119	16-55	28SEP2020	93578	BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		
10971120	C4591001 1097 10971120	16-55	15OCT2020	93580	Placebo	15OCT2020/ Placebo	17NOV2020/ Placebo		
10981001	C4591001 1098 10981001	16-55	18AUG2020	54332	Placebo	18AUG2020/ Placebo			
10981004	C4591001 1098 10981004	16-55	18AUG2020	54333	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)
10981006	C4591001 1098 10981006	16-55	18AUG2020	54334	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10981009	C4591001 1098 10981009	16-55	19AUG2020	54338	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10981011	C4591001 1098 10981011	16-55	19AUG2020	56201	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10981014	C4591001 1098 10981014	16-55	19AUG2020	56203	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10981015	C4591001 1098 10981015	16-55	19AUG2020	56209	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10981018	C4591001 1098 10981018	16-55	20AUG2020	56211	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10981020	C4591001 1098 10981020	16-55	20AUG2020	59249	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10981023	C4591001 1098 10981023	16-55	21AUG2020	59257	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10981025	C4591001 1098 10981025	16-55	21AUG2020	59259	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
10981027	C4591001 1098 10981027	16-55	21AUG2020	59260	Placebo	21AUG2020/ Placebo	15SEP2020/ Placebo		
10981029	C4591001 1098 10981029	16-55	21AUG2020	61171	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)			
10981031	C4591001 1098 10981031	16-55	24AUG2020	61173	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10981032	C4591001 1098 10981032	16-55	24AUG2020	61175	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
10981035	C4591001 1098 10981035	16-55	24AUG2020	61180	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10981043	C4591001 1098 10981043	16-55	25AUG2020	66593	Placebo	25AUG2020/ Placebo	16SEP2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
10981048	C4591001 1098 10981048	16-55	26AUG2020	66597	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10981052	C4591001 1098 10981052	16-55	27AUG2020	66599	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10981054	C4591001 1098 10981054	16-55	27AUG2020	66602	Placebo	27AUG2020/ Placebo	16SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
10981055	C4591001 1098 10981055	16-55	27AUG2020	70892	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
10981056	C4591001 1098 10981056	16-55	27AUG2020	70896	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10981057	C4591001 1098 10981057	16-55	28AUG2020	70898	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10981060	C4591001 1098 10981060	16-55	28AUG2020	70900	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10981064	C4591001 1098 10981064	16-55	31AUG2020	74837	Placebo	31AUG2020/ Placebo	22SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10981065	C4591001 1098 10981065	16-55	31AUG2020	74841	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10981067	C4591001 1098 10981067	16-55	31AUG2020	74845	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10981068	C4591001 1098 10981068	16-55	31AUG2020	74848	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10981069	C4591001 1098 10981069	16-55	31AUG2020	75295	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10981073	C4591001 1098 10981073	16-55	01SEP2020	75296	Placebo	01SEP2020/ Placebo	21SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
10981074	C4591001 1098 10981074	16-55	01SEP2020	75301	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10981075	C4591001 1098 10981075	16-55	01SEP2020	75303	Placebo	01SEP2020/ Placebo	23SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10981076	C4591001 1098 10981076	16-55	01SEP2020	77165	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo		
10981077	C4591001 1098 10981077	16-55	02SEP2020	77166	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10981079	C4591001 1098 10981079	16-55	02SEP2020	77169	Placebo	02SEP2020/ Placebo	21SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
10981084	C4591001 1098 10981084	16-55	02SEP2020	77171	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10981085	C4591001 1098 10981085	16-55	02SEP2020	78473	Placebo	02SEP2020/ Placebo	22SEP2020/ Placebo		
10981086	C4591001 1098 10981086	16-55	02SEP2020	78474	Placebo	02SEP2020/ Placebo	29SEP2020/ Placebo	02MAR2021/ BNT162b2 (30 µg)	
10981089	C4591001 1098 10981089	16-55	03SEP2020	78476	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10981091	C4591001 1098 10981091	16-55	03SEP2020	78480	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10981095	C4591001 1098 10981095	16-55	03SEP2020	80221	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10981096	C4591001 1098 10981096	16-55	03SEP2020	80223	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10981097	C4591001 1098 10981097	16-55	03SEP2020	80214	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
10981100	C4591001 1098 10981100	16-55	03SEP2020	80224	Placebo	03SEP2020/ Placebo	22SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
10981101	C4591001 1098 10981101	16-55	03SEP2020	80828	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
10981103	C4591001 1098 10981103	16-55	04SEP2020	80829	Placebo	04SEP2020/ Placebo	24SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10981106	C4591001 1098 10981106	16-55	04SEP2020	80833	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10981111	C4591001 1098 10981111	16-55	05SEP2020	80835	Placebo	05SEP2020/ Placebo	26SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10981117	C4591001 1098 10981117	16-55	05SEP2020	82711	Placebo	05SEP2020/ Placebo	26SEP2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
10981120	C4591001 1098 10981120	16-55	08SEP2020	82712	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
10981121	C4591001 1098 10981121	16-55	08SEP2020	82714	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
10981122	C4591001 1098 10981122	16-55	08SEP2020	82718	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
10981125	C4591001 1098 10981125	16-55	08SEP2020	84269	Placebo	08SEP2020/ Placebo	05OCT2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
10981126	C4591001 1098 10981126	16-55	08SEP2020	84270	Placebo	08SEP2020/ Placebo	30SEP2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
10981129	C4591001 1098 10981129	16-55	09SEP2020	84271	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10981132	C4591001 1098 10981132	16-55	09SEP2020	84276	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10981134	C4591001 1098 10981134	16-55	10SEP2020	86565	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
10981136	C4591001 1098 10981136	16-55	10SEP2020	86567	Placebo	10SEP2020/ Placebo	30SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
10981137	C4591001 1098 10981137	16-55	10SEP2020	86568	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10981138	C4591001 1098 10981138	16-55	10SEP2020	86570	Placebo	10SEP2020/ Placebo	29SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10981140	C4591001 1098 10981140	16-55	10SEP2020	87317	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10981141	C4591001 1098 10981141	16-55	10SEP2020	87319	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10981142	C4591001 1098 10981142	16-55	10SEP2020	87324	Placebo	10SEP2020/ Placebo	30SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
10981143	C4591001 1098 10981143	16-55	11SEP2020	87328	Placebo	11SEP2020/ Placebo	30SEP2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10981144	C4591001 1098 10981144	16-55	11SEP2020	88110	Placebo	11SEP2020/ Placebo	01OCT2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10981145	C4591001 1098 10981145	16-55	11SEP2020	88122	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10981146	C4591001 1098 10981146	16-55	11SEP2020	88124	Placebo	11SEP2020/ Placebo	30SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10981147	C4591001 1098 10981147	16-55	11SEP2020	88130	Placebo	11SEP2020/ Placebo	30SEP2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10981151	C4591001 1098 10981151	16-55	11SEP2020	88132	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10981152	C4591001 1098 10981152	16-55	11SEP2020	88903	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
10981153	C4591001 1098 10981153	16-55	11SEP2020	88908	Placebo	11SEP2020/ Placebo	01OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
10981154	C4591001 1098 10981154	16-55	14SEP2020	88909	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
10981155	C4591001 1098 10981155	16-55	14SEP2020	88911	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo		
10981156	C4591001 1098 10981156	16-55	14SEP2020	89657	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
10981160	C4591001 1098 10981160	16-55	14SEP2020	89660	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10981161	C4591001 1098 10981161	16-55	14SEP2020	89661	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10981163	C4591001 1098 10981163	16-55	14SEP2020	89662	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
10981166	C4591001 1098 10981166	16-55	15SEP2020	90353	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
10981168	C4591001 1098 10981168†	16-55	15SEP2020	90360	Placebo	15SEP2020/ Placebo	06OCT2020/ Placebo		
10981169	C4591001 1098 10981169†	16-55	15SEP2020	90361	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
10981170	C4591001 1098 10981170	16-55	15SEP2020	90362	Placebo	15SEP2020/ Placebo	06OCT2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
10981176	C4591001 1098 10981176	16-55	16SEP2020	91100	Placebo	16SEP2020/ Placebo	06OCT2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10981177	C4591001 1098 10981177	16-55	16SEP2020	91103	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
10981180	C4591001 1098 10981180	16-55	16SEP2020	91106	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
10981181	C4591001 1098 10981181	16-55	16SEP2020	91108	Placebo	16SEP2020/ Placebo	07OCT2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
10981183	C4591001 1098 10981183	16-55	16SEP2020	91795	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10981185	C4591001 1098 10981185	16-55	16SEP2020	91796	Placebo	16SEP2020/ Placebo	07OCT2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10981186	C4591001 1098 10981186	16-55	16SEP2020	91799	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
10981187	C4591001 1098 10981187	16-55	16SEP2020	91803	Placebo	16SEP2020/ Placebo	07OCT2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
10981188	C4591001 1098 10981188	16-55	24SEP2020	98636	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
10981189	C4591001 1098 10981189	16-55	08OCT2020	105245	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	23NOV2020/ BNT162b2 (30 µg)		
10981191	C4591001 1098 10981191	16-55	18SEP2020	93894	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
10981192	C4591001 1098 10981192	16-55	18SEP2020	93896	Placebo	18SEP2020/ Placebo	07OCT2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
10981194	C4591001 1098 10981194	16-55	18SEP2020	93902	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
10981196	C4591001 1098 10981196	16-55	21SEP2020	93903	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10981197	C4591001 1098 10981197	16-55	21SEP2020	94963	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	11MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10981198	C4591001 1098 10981198	16-55	21SEP2020	94965	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	11MAR2021/ BNT162b2 (30 µg)	
10981199	C4591001 1098 10981199	16-55	21SEP2020	94971	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
10981200	C4591001 1098 10981200	16-55	21SEP2020	94970	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)			
10981205	C4591001 1098 10981205	16-55	22SEP2020	96138	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
10981206	C4591001 1098 10981206	16-55	22SEP2020	96144	Placebo	22SEP2020/ Placebo	12OCT2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
10981207	C4591001 1098 10981207	16-55	22SEP2020	96145	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
10981210	C4591001 1098 10981210	16-55	22SEP2020	96146	Placebo	22SEP2020/ Placebo	12OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
10981216	C4591001 1098 10981216	16-55	23SEP2020	97830	Placebo	23SEP2020/ Placebo	13OCT2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
10981217	C4591001 1098 10981217	16-55	23SEP2020	97834	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
10981218	C4591001 1098 10981218	16-55	23SEP2020	97836	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10981219	C4591001 1098 10981219	16-55	24SEP2020	97839	Placebo	24SEP2020/ Placebo			
10981220	C4591001 1098 10981220	16-55	24SEP2020	98635	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
10981224	C4591001 1098 10981224	16-55	25SEP2020	98638	Placebo	25SEP2020/ Placebo	15OCT2020/ Placebo		
10981226	C4591001 1098 10981226	16-55	25SEP2020	98640	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
10981229	C4591001 1098 10981229	16-55	25SEP2020	99953	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
10981230	C4591001 1098 10981230	16-55	25SEP2020	99960	Placebo	25SEP2020/ Placebo	15OCT2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
10981231	C4591001 1098 10981231	16-55	25SEP2020	99961	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
10981232	C4591001 1098 10981232	16-55	25SEP2020	99964	Placebo	25SEP2020/ Placebo	15OCT2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
10981234	C4591001 1098 10981234	16-55	28SEP2020	101443	BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)		
10981235	C4591001 1098 10981235	16-55	28SEP2020	101444	BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10981236	C4591001 1098 10981236	16-55	29SEP2020	101449	Placebo	29SEP2020/ Placebo	19OCT2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
10981238	C4591001 1098 10981238	16-55	29SEP2020	101452	Placebo	29SEP2020/ Placebo	20OCT2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10981240	C4591001 1098 10981240	16-55	30SEP2020	102509	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)		
10981241	C4591001 1098 10981241	16-55	01OCT2020	102510	Placebo	01OCT2020/ Placebo	20OCT2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
10981243	C4591001 1098 10981243	16-55	02OCT2020	102511	BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		
10981244	C4591001 1098 10981244	16-55	02OCT2020	102512	Placebo	02OCT2020/ Placebo	21OCT2020/ Placebo		
10981246	C4591001 1098 10981246	16-55	02OCT2020	103207	Placebo	02OCT2020/ Placebo	21OCT2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10981247	C4591001 1098 10981247	16-55	02OCT2020	103208	BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		
10981251	C4591001 1098 10981251	16-55	07OCT2020	103213	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)		
10981252	C4591001 1098 10981252	16-55	07OCT2020	103215	Placebo	07OCT2020/ Placebo	30OCT2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10981253	C4591001 1098 10981253	16-55	08OCT2020	105249	Placebo	08OCT2020/ Placebo	30OCT2020/ Placebo		
10981254	C4591001 1098 10981254	16-55	09OCT2020	105252	Placebo	09OCT2020/ Placebo	30OCT2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
10981258	C4591001 1098 10981258	16-55	16OCT2020	105253	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
10981259	C4591001 1098 10981259	16-55	16OCT2020	109241	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
10981260	C4591001 1098 10981260	16-55	16OCT2020	109247	Placebo	16OCT2020/ Placebo	04NOV2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
10981262	C4591001 1098 10981262	16-55	20OCT2020	109248	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
10981263	C4591001 1098 10981263	16-55	22OCT2020	109250	Placebo	22OCT2020/ Placebo	11NOV2020/ Placebo	12MAR2021/ BNT162b2 (30 µg)	
10981265	C4591001 1098 10981265	16-55	23OCT2020	112853	Placebo	23OCT2020/ Placebo	11NOV2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
10981266	C4591001 1098 10981266	16-55	23OCT2020	112858	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
11011001	C4591001 1101 11011001	16-55	28AUG2020	71947	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11011004	C4591001 1101 11011004	16-55	01SEP2020	71950	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11011005	C4591001 1101 11011005	16-55	02SEP2020	71952	Placebo	02SEP2020/ Placebo	22SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
11011007	C4591001 1101 11011007	16-55	02SEP2020	71956	Placebo	02SEP2020/ Placebo	22SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
11011010	C4591001 1101 11011010	16-55	02SEP2020	78705	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
11011012	C4591001 1101 11011012	16-55	03SEP2020	78708	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
11011013	C4591001 1101 11011013	16-55	03SEP2020	78711	Placebo	03SEP2020/ Placebo	22SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
11011014	C4591001 1101 11011014	16-55	03SEP2020	78712	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11011015	C4591001 1101 11011015	16-55	04SEP2020	82338	Placebo	04SEP2020/ Placebo	23SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
11011016	C4591001 1101 11011016	16-55	04SEP2020	82342	Placebo	04SEP2020/ Placebo	23SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
11011018	C4591001 1101 11011018	16-55	08SEP2020	82343	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11011020	C4591001 1101 11011020	16-55	08SEP2020	82344	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11011021	C4591001 1101 11011021	16-55	08SEP2020	84536	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
11011022	C4591001 1101 11011022	16-55	09SEP2020	84539	Placebo	09SEP2020/ Placebo	28SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
11011024	C4591001 1101 11011024	16-55	09SEP2020	84540	Placebo	09SEP2020/ Placebo		28DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
11011026	C4591001 1101 11011026	16-55	09SEP2020	84543	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
11011028	C4591001 1101 11011028	16-55	09SEP2020	85843	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
11011029	C4591001 1101 11011029	16-55	09SEP2020	85846	Placebo	09SEP2020/ Placebo	01OCT2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
11011030	C4591001 1101 11011030	16-55	10SEP2020	85847	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
11011033	C4591001 1101 11011033	16-55	10SEP2020	85852	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
11011034	C4591001 1101 11011034	16-55	10SEP2020	86923	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11011038	C4591001 1101 11011038	16-55	10SEP2020	86925	Placebo	10SEP2020/ Placebo	29SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
11011039	C4591001 1101 11011039	16-55	10SEP2020	86926	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
11011040	C4591001 1101 11011040	16-55	10SEP2020	86927	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
11011041	C4591001 1101 11011041	16-55	10SEP2020	87666	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
11011042	C4591001 1101 11011042	16-55	11SEP2020	87667	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
11011044	C4591001 1101 11011044	16-55	11SEP2020	87674	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
11011045	C4591001 1101 11011045	16-55	11SEP2020	87676	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
11011046	C4591001 1101 11011046	16-55	14SEP2020	89407	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
11011048	C4591001 1101 11011048	16-55	14SEP2020	89408	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
11011051	C4591001 1101 11011051	16-55	14SEP2020	89410	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11011052	C4591001 1101 11011052	16-55	14SEP2020	89412	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
11011053	C4591001 1101 11011053	16-55	14SEP2020	90065	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
11011056	C4591001 1101 11011056	16-55	15SEP2020	90068	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
11011057	C4591001 1101 11011057	16-55	15SEP2020	90067	Placebo	15SEP2020/ Placebo	06OCT2020/ Placebo		
11011058	C4591001 1101 11011058	16-55	15SEP2020	90074	Placebo	15SEP2020/ Placebo	05OCT2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
11011059	C4591001 1101 11011059	16-55	15SEP2020	90730	Placebo	15SEP2020/ Placebo	06OCT2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
11011060	C4591001 1101 11011060	16-55	15SEP2020	90732	Placebo	15SEP2020/ Placebo	06OCT2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
11011061	C4591001 1101 11011061	16-55	15SEP2020	90733	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
11011062	C4591001 1101 11011062	16-55	16SEP2020	90735	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
11011065	C4591001 1101 11011065	16-55	16SEP2020	91301	Placebo	16SEP2020/ Placebo	07OCT2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11011067	C4591001 1101 11011067	16-55	16SEP2020	91304	Placebo	16SEP2020/ Placebo	07OCT2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
11011069	C4591001 1101 11011069	16-55	16SEP2020	91306	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
11011070	C4591001 1101 11011070	16-55	16SEP2020	91308	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
11011071	C4591001 1101 11011071	16-55	16SEP2020	91841	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
11011072	C4591001 1101 11011072	16-55	16SEP2020	91846	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
11011073	C4591001 1101 11011073	16-55	17SEP2020	91847	Placebo	17SEP2020/ Placebo	09OCT2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	27JAN2021/ BNT162b2 (30 µg)
11011074	C4591001 1101 11011074	16-55	17SEP2020	91851	Placebo	17SEP2020/ Placebo	07OCT2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
11011075	C4591001 1101 11011075	16-55	17SEP2020	93042	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
11011076	C4591001 1101 11011076	16-55	18SEP2020	93044	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
11011079	C4591001 1101 11011079	16-55	18SEP2020	93050	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11011080	C4591001 1101 11011080	16-55	18SEP2020	93051	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)
11011084	C4591001 1101 11011084	16-55	21SEP2020	95334	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
11011085	C4591001 1101 11011085	16-55	21SEP2020	95336	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
11011087	C4591001 1101 11011087	16-55	22SEP2020	95340	Placebo	22SEP2020/ Placebo	12OCT2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
11011088	C4591001 1101 11011088	16-55	22SEP2020	95344	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
11011089	C4591001 1101 11011089	16-55	23SEP2020	97329	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
11011090	C4591001 1101 11011090	16-55	23SEP2020	97331	Placebo	23SEP2020/ Placebo	16OCT2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
11011091	C4591001 1101 11011091	16-55	23SEP2020	97333	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
11011094	C4591001 1101 11011094	16-55	24SEP2020	97336	Placebo	24SEP2020/ Placebo	13OCT2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
11011096	C4591001 1101 11011096	16-55	24SEP2020	99053	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11011097	C4591001 1101 11011097	16-55	24SEP2020	99054	Placebo	24SEP2020/ Placebo	14OCT2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
11011100	C4591001 1101 11011100	16-55	01OCT2020	99056	Placebo	01OCT2020/ Placebo	20OCT2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
11011101	C4591001 1101 11011101	16-55	07OCT2020	99062	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		
11011105	C4591001 1101 11011105	16-55	12OCT2020	106460	Placebo	12OCT2020/ Placebo	02NOV2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
11011106	C4591001 1101 11011106	16-55	12OCT2020	106463	Placebo	12OCT2020/ Placebo	02NOV2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
11011107	C4591001 1101 11011107	16-55	13OCT2020	106464	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		
11011108	C4591001 1101 11011108	16-55	13OCT2020	106467	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		
11011110	C4591001 1101 11011110	16-55	17NOV2020	113542	BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)	07DEC2020/ BNT162b2 (30 µg)		
11011111	C4591001 1101 11011111	16-55	19OCT2020	110264	Placebo	19OCT2020/ Placebo	11NOV2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
11011113	C4591001 1101 11011113	16-55	20OCT2020	110265	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11011114	C4591001 1101 11011114	16-55	20OCT2020	110267	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
11011115	C4591001 1101 11011115	16-55	20OCT2020	110270	Placebo	20OCT2020/ Placebo	12NOV2020/ Placebo		
11011118	C4591001 1101 11011118	16-55	26OCT2020	113537	Placebo	26OCT2020/ Placebo	16NOV2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
11071114	C4591001 1107 11071114	16-55	17AUG2020	52787	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
11071118	C4591001 1107 11071118	16-55	17AUG2020	52786	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
11071122	C4591001 1107 11071122	16-55	17AUG2020	52781	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11071123	C4591001 1107 11071123	16-55	18AUG2020	53949	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11071124	C4591001 1107 11071124	16-55	17AUG2020	52792	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11071125	C4591001 1107 11071125	16-55	18AUG2020	53951	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11071126	C4591001 1107 11071126	16-55	18AUG2020	53952	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11071129	C4591001 1107 11071129	16-55	18AUG2020	53956	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11071130	C4591001 1107 11071130	16-55	18AUG2020	54509	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
11071134	C4591001 1107 11071134	16-55	18AUG2020	54510	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo		
11071136	C4591001 1107 11071136	16-55	18AUG2020	54515	Placebo	18AUG2020/ Placebo	14SEP2020/ Placebo		
11071138	C4591001 1107 11071138	16-55	19AUG2020	54519	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11071139	C4591001 1107 11071139	16-55	19AUG2020	56022	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11071144	C4591001 1107 11071144	16-55	02SEP2020	78420	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11071145	C4591001 1107 11071145	16-55	20AUG2020	56026	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	04JAN2021/ BNT162b2 (30 µg)
11071146	C4591001 1107 11071146	16-55	20AUG2020	56030	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
11071151	C4591001 1107 11071151	16-55	20AUG2020	56031	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11071154	C4591001 1107 11071154	16-55	20AUG2020	58929	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo		
11071155	C4591001 1107 11071155	16-55	20AUG2020	58931	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
11071156	C4591001 1107 11071156	16-55	20AUG2020	58934	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
11071157	C4591001 1107 11071157	16-55	20AUG2020	58933	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
11071160	C4591001 1107 11071160	16-55	24AUG2020	63390	Placebo	24AUG2020/ Placebo	11SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
11071162	C4591001 1107 11071162	16-55	24AUG2020	63394	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
11071163	C4591001 1107 11071163	16-55	24AUG2020	63396	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
11071164	C4591001 1107 11071164	16-55	24AUG2020	63397	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11071165	C4591001 1107 11071165	16-55	24AUG2020	64241	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11071168	C4591001 1107 11071168	16-55	25AUG2020	64248	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11071171	C4591001 1107 11071171	16-55	25AUG2020	64250	Placebo	25AUG2020/ Placebo	14SEP2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
11071174	C4591001 1107 11071174	16-55	26AUG2020	64252	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
11071178	C4591001 1107 11071178	16-55	27AUG2020	69774	Placebo	27AUG2020/ Placebo	12OCT2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11071179	C4591001 1107 11071179	16-55	27AUG2020	69775	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11071180	C4591001 1107 11071180	16-55	27AUG2020	69779	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11071181	C4591001 1107 11071181	16-55	27AUG2020	69781	Placebo	27AUG2020/ Placebo	21SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
11071184	C4591001 1107 11071184	16-55	31AUG2020	74854	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11071186	C4591001 1107 11071186	16-55	31AUG2020	74856	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11071188	C4591001 1107 11071188	16-55	01SEP2020	74858	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
11071190	C4591001 1107 11071190	16-55	02SEP2020	74860	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11071193	C4591001 1107 11071193	16-55	02SEP2020	78419	Placebo	02SEP2020/ Placebo	28SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
11071195	C4591001 1107 11071195	16-55	03SEP2020	78423	Placebo	03SEP2020/ Placebo	23SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	04JAN2021/ BNT162b2 (30 µg)
11071200	C4591001 1107 11071200	16-55	03SEP2020	78424	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
11071203	C4591001 1107 11071203	16-55	03SEP2020	80688	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11071204	C4591001 1107 11071204	16-55	08SEP2020	80689	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
11071209	C4591001 1107 11071209	16-55	08SEP2020	80690	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
11071211	C4591001 1107 11071211	16-55	10SEP2020	80692	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	20JAN2021/ BNT162b2 (30 µg)
11071212	C4591001 1107 11071212	16-55	10SEP2020	87452	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
11071213	C4591001 1107 11071213	16-55	14SEP2020	87454	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
11071215	C4591001 1107 11071215	16-55	14SEP2020	87457	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	04JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11071222	C4591001 1107 11071222	16-55	13OCT2020	87460	Placebo	13OCT2020/ Placebo	02NOV2020/ Placebo		
11091226	C4591001 1109 11091226	16-55	15AUG2020	49827	Placebo	15AUG2020/ Placebo	08SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
11091234	C4591001 1109 11091234	16-55	15AUG2020	51329	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)			
11091236	C4591001 1109 11091236	16-55	15AUG2020	51336	Placebo	15AUG2020/ Placebo	12SEP2020/ Placebo	27FEB2021/ BNT162b2 (30 µg)	
11091242	C4591001 1109 11091242	16-55	16AUG2020	51340	Placebo	16AUG2020/ Placebo	06SEP2020/ Placebo	23JAN2021/ BNT162b2 (30 µg)	13FEB2021/ BNT162b2 (30 µg)
11091245	C4591001 1109 11091245	16-55	16AUG2020	51691	Placebo	16AUG2020/ Placebo	06SEP2020/ Placebo		
11091246	C4591001 1109 11091246	16-55	16AUG2020	51693	BNT162b2 (30 µg)	16AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11091249	C4591001 1109 11091249	16-55	16AUG2020	51695	Placebo	16AUG2020/ Placebo	07SEP2020/ Placebo	31DEC2020/ BNT162b2 (30 µg)	22JAN2021/ BNT162b2 (30 µg)
11091250	C4591001 1109 11091250	16-55	16AUG2020	51699	BNT162b2 (30 µg)	16AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11091251	C4591001 1109 11091251	16-55	16AUG2020	51813	BNT162b2 (30 µg)	16AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11091252	C4591001 1109 11091252	16-55	16AUG2020	51810	BNT162b2 (30 µg)	16AUG2020/ BNT162b2 (30 µg)	06SEP2020/ BNT162b2 (30 µg)		
11091256	C4591001 1109 11091256	16-55	16AUG2020	51814	Placebo	16AUG2020/ Placebo	04SEP2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
11091258	C4591001 1109 11091258	16-55	16AUG2020	51819	Placebo	16AUG2020/ Placebo	08SEP2020/ Placebo	02MAR2021/ BNT162b2 (30 µg)	
11091261	C4591001 1109 11091261	16-55	16AUG2020	51969	BNT162b2 (30 µg)	16AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11091267	C4591001 1109 11091267	16-55	16AUG2020	51976	Placebo	16AUG2020/ Placebo	08SEP2020/ Placebo		
11091275	C4591001 1109 11091275	16-55	21AUG2020	60006	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11091278	C4591001 1109 11091278	16-55	21AUG2020	60008	Placebo	21AUG2020/ Placebo	18SEP2020/ Placebo	13FEB2021/ BNT162b2 (30 µg)	06MAR2021/ BNT162b2 (30 µg)
11091287	C4591001 1109 11091287	16-55	21AUG2020	60012	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11091288	C4591001 1109 11091288	16-55	21AUG2020	60014	Placebo	21AUG2020/ Placebo	09SEP2020/ Placebo	03MAR2021/ BNT162b2 (30 µg)	
11091303	C4591001 1109 11091303	16-55	22AUG2020	61877	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	12SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11091304	C4591001 1109 11091304	16-55	22AUG2020	61882	Placebo	22AUG2020/ Placebo	12SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
11091308	C4591001 1109 11091308	16-55	22AUG2020	61883	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
11091309	C4591001 1109 11091309	16-55	22AUG2020	61887	Placebo	22AUG2020/ Placebo	10SEP2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
11091311	C4591001 1109 11091311	16-55	23AUG2020	62732	Placebo	23AUG2020/ Placebo	13SEP2020/ Placebo	27FEB2021/ BNT162b2 (30 µg)	
11091314	C4591001 1109 11091314	16-55	23AUG2020	62733	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
11091315	C4591001 1109 11091315	16-55	23AUG2020	62737	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)	12SEP2020/ BNT162b2 (30 µg)		
11091316	C4591001 1109 11091316	16-55	23AUG2020	62740	Placebo	23AUG2020/ Placebo	13SEP2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
11091319	C4591001 1109 11091319	16-55	23AUG2020	62933	Placebo	23AUG2020/ Placebo	11SEP2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
11091320	C4591001 1109 11091320	16-55	23AUG2020	62939	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11091321	C4591001 1109 11091321	16-55	25AUG2020	62941	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11091324	C4591001 1109 11091324	16-55	25AUG2020	62942	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
11091326	C4591001 1109 11091326	16-55	25AUG2020	66211	Placebo	25AUG2020/ Placebo	14SEP2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
11091329	C4591001 1109 11091329	16-55	26AUG2020	66218	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
11091330	C4591001 1109 11091330	16-55	26AUG2020	66219	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
11091331	C4591001 1109 11091331	16-55	26AUG2020	66220	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11091332	C4591001 1109 11091332	16-55	26AUG2020	67831	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11091333	C4591001 1109 11091333	16-55	26AUG2020	67835	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11091335	C4591001 1109 11091335	16-55	26AUG2020	67839	Placebo	26AUG2020/ Placebo			
11091337	C4591001 1109 11091337	16-55	27AUG2020	67840	Placebo	27AUG2020/ Placebo	18SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
11091338	C4591001 1109 11091338	16-55	27AUG2020	69521	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11091340	C4591001 1109 11091340	16-55	27AUG2020	69525	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
11091343	C4591001 1109 11091343	16-55	28AUG2020	69530	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	23JAN2021/ BNT162b2 (30 µg)	13FEB2021/ BNT162b2 (30 µg)
11091349	C4591001 1109 11091349	16-55	28AUG2020	69532	BNT162b2 (30 µg)				
11091350	C4591001 1109 11091350	16-55	28AUG2020	72895	Placebo	28AUG2020/ Placebo	19SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
11091352	C4591001 1109 11091352	16-55	29AUG2020	72896	Placebo	29AUG2020/ Placebo	19SEP2020/ Placebo		
11091353	C4591001 1109 11091353	16-55	29AUG2020	72904	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		
11091355	C4591001 1109 11091355	16-55	29AUG2020	72898	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
11091361	C4591001 1109 11091361	16-55	29AUG2020	73964	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11091362	C4591001 1109 11091362	16-55	29AUG2020	73965	Placebo	29AUG2020/ Placebo	18SEP2020/ Placebo	23JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
11091370	C4591001 1109 11091370	16-55	29AUG2020	73972	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11091372	C4591001 1109 11091372	16-55	29AUG2020	74142	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
11091373	C4591001 1109 11091373	16-55	29AUG2020	73969	Placebo	29AUG2020/ Placebo	19SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
11091375	C4591001 1109 11091375	16-55	29AUG2020	74143	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		
11091378	C4591001 1109 11091378	16-55	31AUG2020	74149	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo		
11091382	C4591001 1109 11091382	16-55	31AUG2020	74150	Placebo	31AUG2020/ Placebo	25SEP2020/ Placebo	02MAR2021/ BNT162b2 (30 µg)	
11091383	C4591001 1109 11091383	16-55	31AUG2020	75862	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo		
11091391	C4591001 1109 11091391	16-55	01SEP2020	75866	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
11091392	C4591001 1109 11091392	16-55	01SEP2020	75865	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11091393	C4591001 1109 11091393	16-55	01SEP2020	75868	Placebo	01SEP2020/ Placebo	29SEP2020/ Placebo		
11091395	C4591001 1109 11091395	16-55	02SEP2020	78792	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11091396	C4591001 1109 11091396	16-55	02SEP2020	78788	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
11091397	C4591001 1109 11091397	16-55	02SEP2020	78794	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
11091400	C4591001 1109 11091400	16-55	02SEP2020	78795	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
11091403	C4591001 1109 11091403	16-55	02SEP2020	79170	Placebo	02SEP2020/ Placebo	21SEP2020/ Placebo		
11091406	C4591001 1109 11091406	16-55	03SEP2020	79171	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11091412	C4591001 1109 11091412	16-55	05SEP2020	79172	Placebo	05SEP2020/ Placebo	05OCT2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
11091414	C4591001 1109 11091414	16-55	05SEP2020	79177	BNT162b2 (30 µg)	05SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11091415	C4591001 1109 11091415	16-55	05SEP2020	82829	Placebo	05SEP2020/ Placebo	26SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
11091416	C4591001 1109 11091416	16-55	05SEP2020	82830	Placebo	05SEP2020/ Placebo	24SEP2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
11091417	C4591001 1109 11091417	16-55	05SEP2020	82833	BNT162b2 (30 µg)	05SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11091418	C4591001 1109 11091418	16-55	05SEP2020	82839	BNT162b2 (30 µg)	05SEP2020/ BNT162b2 (30 µg)	26SEP2020/ BNT162b2 (30 µg)		
11091419	C4591001 1109 11091419	16-55	05SEP2020	82930	Placebo	05SEP2020/ Placebo	28SEP2020/ Placebo		
11091422	C4591001 1109 11091422	16-55	05SEP2020	82928	BNT162b2 (30 µg)	05SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11091424	C4591001 1109 11091424	16-55	05SEP2020	82933	BNT162b2 (30 µg)	05SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
11091425	C4591001 1109 11091425	16-55	05SEP2020	82936	Placebo	05SEP2020/ Placebo	07OCT2020/ Placebo	27FEB2021/ BNT162b2 (30 µg)	
11091426	C4591001 1109 11091426	16-55	05SEP2020	82951	Placebo	05SEP2020/ Placebo	01OCT2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
11091427	C4591001 1109 11091427	16-55	06SEP2020	82956	Placebo	06SEP2020/ Placebo	26SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
11091428	C4591001 1109 11091428	16-55	06SEP2020	82958	BNT162b2 (30 µg)	06SEP2020/ BNT162b2 (30 µg)	04OCT2020/ BNT162b2 (30 µg)		
11091432	C4591001 1109 11091432	16-55	06SEP2020	82959	BNT162b2 (30 µg)	06SEP2020/ BNT162b2 (30 µg)	26SEP2020/ BNT162b2 (30 µg)		
11091434	C4591001 1109 11091434	16-55	07SEP2020	83201	Placebo	07SEP2020/ Placebo	26SEP2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11091435	C4591001 1109 11091435	16-55	07SEP2020	83204	BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)	03OCT2020/ BNT162b2 (30 µg)		
11091436	C4591001 1109 11091436	16-55	07SEP2020	83207	BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)	10OCT2020/ BNT162b2 (30 µg)		
11091439	C4591001 1109 11091439	16-55	07SEP2020	83210	Placebo	07SEP2020/ Placebo	01OCT2020/ Placebo	27FEB2021/ BNT162b2 (30 µg)	
11091440	C4591001 1109 11091440	16-55	07SEP2020	83239	BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
11091441	C4591001 1109 11091441	16-55	07SEP2020	83242	Placebo	07SEP2020/ Placebo	03OCT2020/ Placebo		
11091442	C4591001 1109 11091442	16-55	07SEP2020	83244	BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11091444	C4591001 1109 11091444	16-55	08SEP2020	253742	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11091448	C4591001 1109 11091448	16-55	08SEP2020	84116	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo		
11091450	C4591001 1109 11091450	16-55	08SEP2020	83246	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
11091453	C4591001 1109 11091453	16-55	08SEP2020	84120	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11091455	C4591001 1109 11091455	16-55	08SEP2020	84123	Placebo	08SEP2020/ Placebo	06OCT2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
11091457	C4591001 1109 11091457	16-55	08SEP2020	84124	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11091459	C4591001 1109 11091459	16-55	08SEP2020	84463	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
11091465	C4591001 1109 11091465	16-55	09SEP2020	84472	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
11091466	C4591001 1109 11091466	16-55	09SEP2020	84466	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo		
11091467	C4591001 1109 11091467	16-55	09SEP2020	84470	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
11091468	C4591001 1109 11091468	16-55	09SEP2020	85640	Placebo	09SEP2020/ Placebo	29SEP2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
11091472	C4591001 1109 11091472	16-55	09SEP2020	85641	Placebo	09SEP2020/ Placebo	28SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
11091473	C4591001 1109 11091473	16-55	09SEP2020	85645	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11091476	C4591001 1109 11091476	16-55	09SEP2020	85648	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11091477	C4591001 1109 11091477	16-55	09SEP2020	85973	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
11091478	C4591001 1109 11091478	16-55	09SEP2020	85976	Placebo	09SEP2020/ Placebo			
11091479	C4591001 1109 11091479	16-55	09SEP2020	85977	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
11091483	C4591001 1109 11091483	16-55	10SEP2020	85981	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11091484	C4591001 1109 11091484	16-55	10SEP2020	86998	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
11091485	C4591001 1109 11091485	16-55	10SEP2020	87000	Placebo	10SEP2020/ Placebo	30SEP2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
11091488	C4591001 1109 11091488	16-55	10SEP2020	87002	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	03OCT2020/ BNT162b2 (30 µg)		
11091489	C4591001 1109 11091489	16-55	10SEP2020	87003	Placebo	10SEP2020/ Placebo	06OCT2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
11091492	C4591001 1109 11091492	16-55	10SEP2020	87427	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
11091495	C4591001 1109 11091495	16-55	11SEP2020	87429	Placebo	11SEP2020/ Placebo	30SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11091496	C4591001 1109 11091496	16-55	11SEP2020	87431	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo		
11091497	C4591001 1109 11091497	16-55	11SEP2020	87433	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
11091498	C4591001 1109 11091498	16-55	11SEP2020	88745	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
11091499	C4591001 1109 11091499	16-55	11SEP2020	88749	Placebo	11SEP2020/ Placebo	01OCT2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
11091502	C4591001 1109 11091502	16-55	11SEP2020	88750	Placebo	11SEP2020/ Placebo	01OCT2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
11091506	C4591001 1109 11091506	16-55	12SEP2020	88752	BNT162b2 (30 µg)	12SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
11091507	C4591001 1109 11091507	16-55	12SEP2020	89201	Placebo	12SEP2020/ Placebo	02OCT2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
11091508	C4591001 1109 11091508	16-55	12SEP2020	89202	BNT162b2 (30 µg)	12SEP2020/ BNT162b2 (30 µg)	03OCT2020/ BNT162b2 (30 µg)		
11091511	C4591001 1109 11091511	16-55	13SEP2020	89203	BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)	04OCT2020/ BNT162b2 (30 µg)		
11091512	C4591001 1109 11091512	16-55	13SEP2020	89209	Placebo	13SEP2020/ Placebo	06OCT2020/ Placebo	27FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11091513	C4591001 1109 11091513	16-55	13SEP2020	89285	Placebo	13SEP2020/ Placebo	06OCT2020/ Placebo	27FEB2021/ BNT162b2 (30 µg)	
11091514	C4591001 1109 11091514	16-55	13SEP2020	89286	BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
11091515	C4591001 1109 11091515	16-55	15SEP2020	89287	Placebo	15SEP2020/ Placebo			
11091516	C4591001 1109 11091516	16-55	15SEP2020	89290	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
11091517	C4591001 1109 11091517	16-55	15SEP2020	90701	Placebo	15SEP2020/ Placebo	06OCT2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
11091518	C4591001 1109 11091518	16-55	16SEP2020	90702	Placebo	16SEP2020/ Placebo	03OCT2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
11091520	C4591001 1109 11091520	16-55	17SEP2020	90710	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)		
11091521	C4591001 1109 11091521	16-55	18SEP2020	90711	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
11091522	C4591001 1109 11091522	16-55	18SEP2020	94098	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
11091523	C4591001 1109 11091523	16-55	18SEP2020	94099	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11091524	C4591001 1109 11091524	16-55	18SEP2020	94103	Placebo	18SEP2020/ Placebo	10OCT2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
11091525	C4591001 1109 11091525	16-55	18SEP2020	94108	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	10OCT2020/ BNT162b2 (30 µg)		
11091526	C4591001 1109 11091526	16-55	18SEP2020	94158	Placebo	18SEP2020/ Placebo	05OCT2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
11091528	C4591001 1109 11091528	16-55	19SEP2020	94161	Placebo	19SEP2020/ Placebo	08OCT2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
11091529	C4591001 1109 11091529	16-55	19SEP2020	94159	BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)	24OCT2020/ BNT162b2 (30 µg)		
11091530	C4591001 1109 11091530	16-55	21SEP2020	94890	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
11091531	C4591001 1109 11091531	16-55	21SEP2020	94163	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
11091532	C4591001 1109 11091532	16-55	21SEP2020	94893	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
11091534	C4591001 1109 11091534	16-55	21SEP2020	94894	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)		
11091535	C4591001 1109 11091535	16-55	22SEP2020	94900	Placebo	22SEP2020/ Placebo	12OCT2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11091536	C4591001 1109 11091536	16-55	22SEP2020	96788	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
11091539	C4591001 1109 11091539	16-55	23SEP2020	96790	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
11091540	C4591001 1109 11091540	16-55	23SEP2020	96793	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo		
11091541	C4591001 1109 11091541	16-55	24SEP2020	96795	Placebo	24SEP2020/ Placebo	15OCT2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
11091545	C4591001 1109 11091545	16-55	29SEP2020	101971	BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)		
11091546	C4591001 1109 11091546	16-55	30SEP2020	101974	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)		
11091547	C4591001 1109 11091547	16-55	30SEP2020	101976	Placebo	30SEP2020/ Placebo			
11091548	C4591001 1109 11091548	16-55	01OCT2020	101978	Placebo	01OCT2020/ Placebo	24OCT2020/ Placebo		
11091549	C4591001 1109 11091549	16-55	01OCT2020	102896	Placebo	01OCT2020/ Placebo	24OCT2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
11091550	C4591001 1109 11091550	16-55	01OCT2020	102897	BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11091553	C4591001 1109 11091553	16-55	02OCT2020	102899	BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)		
11091554	C4591001 1109 11091554	16-55	02OCT2020	102903	Placebo	02OCT2020/ Placebo	26OCT2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
11091555	C4591001 1109 11091555	16-55	04OCT2020	103517	BNT162b2 (30 µg)	04OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
11091556	C4591001 1109 11091556	16-55	04OCT2020	103522	Placebo	04OCT2020/ Placebo		02MAR2021/ BNT162b2 (30 µg)	
11091557	C4591001 1109 11091557	16-55	05OCT2020	103525	BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)	24OCT2020/ BNT162b2 (30 µg)		
11091563	C4591001 1109 11091563	16-55	06OCT2020	103528	Placebo	06OCT2020/ Placebo	29OCT2020/ Placebo		
11101096	C4591001 1110 11101096	16-55	14AUG2020	49043	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11101099	C4591001 1110 11101099	16-55	17AUG2020	49046	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11101100	C4591001 1110 11101100	16-55	17AUG2020	53181	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11101102	C4591001 1110 11101102	16-55	18AUG2020	53185	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11101106	C4591001 1110 11101106	16-55	18AUG2020	53187	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	
11101110	C4591001 1110 11101110	16-55	18AUG2020	53188	Placebo	18AUG2020/ Placebo			
11101111	C4591001 1110 11101111	16-55	18AUG2020	55362	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo		
11101113	C4591001 1110 11101113	16-55	19AUG2020	55364	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11101116	C4591001 1110 11101116	16-55	19AUG2020	55365	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo		
11101117	C4591001 1110 11101117	16-55	19AUG2020	55370	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11101122	C4591001 1110 11101122	16-55	20AUG2020	59142	Placebo	20AUG2020/ Placebo	09SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
11101125	C4591001 1110 11101125	16-55	21AUG2020	59147	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
11101126	C4591001 1110 11101126	16-55	21AUG2020	59151	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
11101127	C4591001 1110 11101127	16-55	21AUG2020	60569	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11101131	C4591001 1110 11101131	16-55	24AUG2020	60571	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11101132	C4591001 1110 11101132	16-55	24AUG2020	60573	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11101139	C4591001 1110 11101139	16-55	25AUG2020	60580	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo		
11101141	C4591001 1110 11101141	16-55	26AUG2020	67709	Placebo	26AUG2020/ Placebo	18SEP2020/ Placebo		
11101144	C4591001 1110 11101144	16-55	27AUG2020	67713	Placebo	27AUG2020/ Placebo	16SEP2020/ Placebo		
11101145	C4591001 1110 11101145	16-55	27AUG2020	67714	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11101148	C4591001 1110 11101148	16-55	27AUG2020	67717	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11101149	C4591001 1110 11101149	16-55	27AUG2020	70772	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11101151	C4591001 1110 11101151	16-55	28AUG2020	70775	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
11101154	C4591001 1110 11101154	16-55	28AUG2020	72377	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)			
11101155	C4591001 1110 11101155	16-55	28AUG2020	70779	Placebo	28AUG2020/ Placebo			

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11101156	C4591001 1110 11101156	16-55	28AUG2020	70776	Placebo	28AUG2020/ Placebo			
11101157	C4591001 1110 11101157	16-55	28AUG2020	72379	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo		
11101158	C4591001 1110 11101158	16-55	29AUG2020	72380	Placebo	29AUG2020/ Placebo	21SEP2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
11101161	C4591001 1110 11101161	16-55	29AUG2020	72386	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11101162	C4591001 1110 11101162	16-55	29AUG2020	73631	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11101163	C4591001 1110 11101163	16-55	29AUG2020	73630	Placebo	29AUG2020/ Placebo	21SEP2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
11101164	C4591001 1110 11101164	16-55	29AUG2020	73633	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
11101165	C4591001 1110 11101165	16-55	29AUG2020	73635	Placebo	29AUG2020/ Placebo	18SEP2020/ Placebo	12MAR2021/ BNT162b2 (30 µg)	
11101167	C4591001 1110 11101167	16-55	29AUG2020	73817	Placebo	29AUG2020/ Placebo	18SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
11101168	C4591001 1110 11101168	16-55	29AUG2020	73821	Placebo	29AUG2020/ Placebo	18SEP2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11101174	C4591001 1110 11101174	16-55	29AUG2020	73823	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11101175	C4591001 1110 11101175	16-55	31AUG2020	73828	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11101177	C4591001 1110 11101177	16-55	31AUG2020	75246	Placebo	31AUG2020/ Placebo	22SEP2020/ Placebo		
11101180	C4591001 1110 11101180	16-55	31AUG2020	75252	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11101181	C4591001 1110 11101181	16-55	01SEP2020	75253	Placebo	01SEP2020/ Placebo	08OCT2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
11101182	C4591001 1110 11101182	16-55	01SEP2020	76913	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11101183	C4591001 1110 11101183	16-55	01SEP2020	75255	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11101186	C4591001 1110 11101186	16-55	01SEP2020	76917	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
11101187	C4591001 1110 11101187	16-55	01SEP2020	76918	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
11101189	C4591001 1110 11101189	16-55	11SEP2020	87971	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11101194	C4591001 1110 11101194	16-55	02SEP2020	76921	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11101196	C4591001 1110 11101196	16-55	02SEP2020	79157	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11101198	C4591001 1110 11101198	16-55	02SEP2020	79163	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
11101199	C4591001 1110 11101199	16-55	02SEP2020	79166	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
11101200	C4591001 1110 11101200	16-55	03SEP2020	79167	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11101203	C4591001 1110 11101203	16-55	03SEP2020	80765	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
11101204	C4591001 1110 11101204	16-55	03SEP2020	80775	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
11101205	C4591001 1110 11101205	16-55	03SEP2020	80773	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11101211	C4591001 1110 11101211	16-55	04SEP2020	80776	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
11101212	C4591001 1110 11101212	16-55	04SEP2020	81738	Placebo	04SEP2020/ Placebo	24SEP2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11101213	C4591001 1110 11101213	16-55	04SEP2020	81744	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
11101214	C4591001 1110 11101214	16-55	04SEP2020	81745	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
11101217	C4591001 1110 11101217	16-55	04SEP2020	81748	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
11101219	C4591001 1110 11101219	16-55	04SEP2020	82243	Placebo	04SEP2020/ Placebo	24SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
11101220	C4591001 1110 11101220	16-55	04SEP2020	82241	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
11101221	C4591001 1110 11101221	16-55	04SEP2020	82247	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11101223	C4591001 1110 11101223	16-55	08SEP2020	82248	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo		
11101224	C4591001 1110 11101224	16-55	08SEP2020	84402	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
11101226	C4591001 1110 11101226	16-55	09SEP2020	84403	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
11101227	C4591001 1110 11101227	16-55	09SEP2020	84406	Placebo	09SEP2020/ Placebo	29SEP2020/ Placebo	02MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11101229	C4591001 1110 11101229	16-55	10SEP2020	84410	Placebo	10SEP2020/ Placebo		23FEB2021/ BNT162b2 (30 µg)	
11101231	C4591001 1110 11101231	16-55	11SEP2020	87966	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo		
11101234	C4591001 1110 11101234	16-55	15SEP2020	89760	Placebo	15SEP2020/ Placebo	06OCT2020/ Placebo		
11101235	C4591001 1110 11101235	16-55	11SEP2020	87972	Placebo	11SEP2020/ Placebo	01OCT2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
11101236	C4591001 1110 11101236	16-55	11SEP2020	87974	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
11101237	C4591001 1110 11101237	16-55	14SEP2020	89393	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
11101238	C4591001 1110 11101238	16-55	14SEP2020	89399	Placebo	14SEP2020/ Placebo	07OCT2020/ Placebo		
11101240	C4591001 1110 11101240	16-55	14SEP2020	89395	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo		
11101242	C4591001 1110 11101242	16-55	14SEP2020	89402	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
11101243	C4591001 1110 11101243	16-55	14SEP2020	89753	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
11101244	C4591001 1110 11101244	16-55	14SEP2020	89758	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11101246	C4591001 1110 11101246	16-55	15SEP2020	89761	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
11101247	C4591001 1110 11101247	16-55	15SEP2020	90293	Placebo	15SEP2020/ Placebo			
11101250	C4591001 1110 11101250	16-55	15SEP2020	90296	Placebo	15SEP2020/ Placebo			
11101261	C4591001 1110 11101261	16-55	15SEP2020	90299	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
11101264	C4591001 1110 11101264	16-55	16SEP2020	90302	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
11101266	C4591001 1110 11101266	16-55	16SEP2020	91376	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
11101268	C4591001 1110 11101268	16-55	16SEP2020	91649	Placebo	16SEP2020/ Placebo	06OCT2020/ Placebo	11MAR2021/ BNT162b2 (30 µg)	
11101269	C4591001 1110 11101269	16-55	17SEP2020	91651	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
11101271	C4591001 1110 11101271	16-55	29SEP2020	101399	Placebo	29SEP2020/ Placebo	20OCT2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
11101273	C4591001 1110 11101273	16-55	17SEP2020	91658	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11101274	C4591001 1110 11101274	16-55	17SEP2020	91660	Placebo	17SEP2020/ Placebo	07OCT2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
11101275	C4591001 1110 11101275	16-55	18SEP2020	93318	Placebo	18SEP2020/ Placebo	08OCT2020/ Placebo	03MAR2021/ BNT162b2 (30 µg)	
11101278	C4591001 1110 11101278	16-55	18SEP2020	93322	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
11101282	C4591001 1110 11101282	16-55	21SEP2020	93324	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
11101283	C4591001 1110 11101283	16-55	12OCT2020	105556	BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
11101286	C4591001 1110 11101286	16-55	21SEP2020	95477	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
11101287	C4591001 1110 11101287	16-55	21SEP2020	93328	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo		
11101290	C4591001 1110 11101290	16-55	13OCT2020	107084	Placebo	13OCT2020/ Placebo	04NOV2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
11101292	C4591001 1110 11101292	16-55	22SEP2020	95478	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
11101293	C4591001 1110 11101293	16-55	23SEP2020	95480	Placebo	23SEP2020/ Placebo	13OCT2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11101294	C4591001 1110 11101294	16-55	23SEP2020	95487	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
11101298	C4591001 1110 11101298	16-55	23SEP2020	98225	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
11101300	C4591001 1110 11101300	16-55	24SEP2020	98229	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
11101305	C4591001 1110 11101305	16-55	24SEP2020	98233	Placebo	24SEP2020/ Placebo	14OCT2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
11101308	C4591001 1110 11101308	16-55	25SEP2020	98235	Placebo	25SEP2020/ Placebo	15OCT2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11101311	C4591001 1110 11101311	16-55	28SEP2020	101393	Placebo	28SEP2020/ Placebo	19OCT2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
11101313	C4591001 1110 11101313	16-55	28SEP2020	101394	BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)		
11101314	C4591001 1110 11101314	16-55	29SEP2020	101403	BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)		
11101316	C4591001 1110 11101316	16-55	29SEP2020	101931	BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		
11101317	C4591001 1110 11101317	16-55	29SEP2020	101928	Placebo	29SEP2020/ Placebo	20OCT2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11101318	C4591001 1110 11101318	16-55	29SEP2020	101929	BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)		
11101319	C4591001 1110 11101319	16-55	29SEP2020	101932	Placebo	29SEP2020/ Placebo	19OCT2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
11101320	C4591001 1110 11101320	16-55	30SEP2020	102235	Placebo	30SEP2020/ Placebo	20OCT2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11101321	C4591001 1110 11101321	16-55	30SEP2020	102238	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		
11101322	C4591001 1110 11101322	16-55	30SEP2020	102241	Placebo	30SEP2020/ Placebo	20OCT2020/ Placebo		
11101323	C4591001 1110 11101323	16-55	30SEP2020	102243	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		
11101325	C4591001 1110 11101325	16-55	01OCT2020	102705	Placebo	01OCT2020/ Placebo	22OCT2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
11101326	C4591001 1110 11101326	16-55	01OCT2020	102707	Placebo	01OCT2020/ Placebo	22OCT2020/ Placebo		
11101327	C4591001 1110 11101327	16-55	01OCT2020	102711	BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		
11101328	C4591001 1110 11101328	16-55	01OCT2020	102712	BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11101329	C4591001 1110 11101329	16-55	02OCT2020	103193	Placebo	02OCT2020/ Placebo	22OCT2020/ Placebo	03MAR2021/ BNT162b2 (30 µg)	
11101330	C4591001 1110 11101330	16-55	02OCT2020	103201	Placebo	02OCT2020/ Placebo	26OCT2020/ Placebo		
11101331	C4591001 1110 11101331	16-55	02OCT2020	103195	BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)		
11101333	C4591001 1110 11101333	16-55	02OCT2020	103202	BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)			
11101337	C4591001 1110 11101337	16-55	02OCT2020	103326	Placebo	02OCT2020/ Placebo	22OCT2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
11101338	C4591001 1110 11101338	16-55	02OCT2020	103327	BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)		
11101341	C4591001 1110 11101341	16-55	05OCT2020	103330	BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
11101342	C4591001 1110 11101342	16-55	06OCT2020	103332	Placebo	06OCT2020/ Placebo			
11101343	C4591001 1110 11101343	16-55	06OCT2020	104321	BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		
11101344	C4591001 1110 11101344	16-55	08OCT2020	104331	Placebo	08OCT2020/ Placebo	28OCT2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11101345	C4591001 1110 11101345	16-55	08OCT2020	104322	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)		
11101346	C4591001 1110 11101346	16-55	08OCT2020	104326	Placebo	08OCT2020/ Placebo	30OCT2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
11101347	C4591001 1110 11101347	16-55	08OCT2020	105547	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)		
11101348	C4591001 1110 11101348	16-55	09OCT2020	105548	Placebo	09OCT2020/ Placebo	30OCT2020/ Placebo		
11101349	C4591001 1110 11101349	16-55	09OCT2020	105551	Placebo	09OCT2020/ Placebo	30OCT2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11101350	C4591001 1110 11101350	16-55	13OCT2020	107081	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
11101352	C4591001 1110 11101352	16-55	14OCT2020	107091	Placebo	14OCT2020/ Placebo	03NOV2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
11101354	C4591001 1110 11101354	16-55	15OCT2020	107092	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
11101356	C4591001 1110 11101356	16-55	15OCT2020	108379	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
11101360	C4591001 1110 11101360	16-55	19OCT2020	108382	Placebo	19OCT2020/ Placebo	11NOV2020/ Placebo	11MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11101361	C4591001 1110 11101361	16-55	19OCT2020	108387	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		
11101365	C4591001 1110 11101365	16-55	21OCT2020	108388	Placebo	21OCT2020/ Placebo	09NOV2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
11101371	C4591001 1110 11101371	16-55	26OCT2020	113638	Placebo	26OCT2020/ Placebo	16NOV2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
11101372	C4591001 1110 11101372	16-55	27OCT2020	113641	Placebo	27OCT2020/ Placebo	17NOV2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
11101374	C4591001 1110 11101374	16-55	28OCT2020	113644	BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)	18NOV2020/ BNT162b2 (30 µg)		
11101375	C4591001 1110 11101375	16-55	28OCT2020	114417	Placebo	28OCT2020/ Placebo	17NOV2020/ Placebo		
11101377	C4591001 1110 11101377	16-55	29OCT2020	114420	Placebo	29OCT2020/ Placebo	18NOV2020/ Placebo		
11101379	C4591001 1110 11101379	16-55	13NOV2020	114421	BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)	04DEC2020/ BNT162b2 (30 µg)		
11101380	C4591001 1110 11101380	16-55	04DEC2020	114422	BNT162b2 (30 µg)	04DEC2020/ BNT162b2 (30 µg)	23DEC2020/ BNT162b2 (30 µg)		
11111117	C4591001 1111 11111117	16-55	17AUG2020	50855	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11111121	C4591001 1111 11111121	16-55	17AUG2020	50856	Placebo	17AUG2020/ Placebo	21SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
11111130	C4591001 1111 11111130	16-55	18AUG2020	55002	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
11111132	C4591001 1111 11111132	16-55	19AUG2020	55003	Placebo	19AUG2020/ Placebo	08SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
11111138	C4591001 1111 11111138	16-55	20AUG2020	55008	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11111139	C4591001 1111 11111139	16-55	21AUG2020	55011	Placebo	21AUG2020/ Placebo	08SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11111142	C4591001 1111 11111142	16-55	27AUG2020	70076	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
11111143	C4591001 1111 11111143	16-55	27AUG2020	70081	Placebo	27AUG2020/ Placebo	18SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11111144	C4591001 1111 11111144	16-55	28AUG2020	72437	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11111145	C4591001 1111 11111145	16-55	28AUG2020	70082	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11111146	C4591001 1111 11111146	16-55	28AUG2020	70083	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11111148	C4591001 1111 11111148	16-55	28AUG2020	72438	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
11111151	C4591001 1111 11111151	16-55	28AUG2020	72440	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
11111155	C4591001 1111 11111155	16-55	02SEP2020	77789	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
11111156	C4591001 1111 11111156	16-55	02SEP2020	72442	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
11111159	C4591001 1111 11111159	16-55	02SEP2020	77790	Placebo	02SEP2020/ Placebo	24SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11111166	C4591001 1111 11111166	16-55	02SEP2020	77794	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
11111169	C4591001 1111 11111169	16-55	02SEP2020	77795	Placebo	02SEP2020/ Placebo	12OCT2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
11111170	C4591001 1111 11111170	16-55	02SEP2020	79352	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
11111171	C4591001 1111 11111171	16-55	04SEP2020	79353	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
11111172	C4591001 1111 11111172	16-55	04SEP2020	79356	Placebo	04SEP2020/ Placebo	02OCT2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11111176	C4591001 1111 11111176	16-55	08SEP2020	79357	Placebo	08SEP2020/ Placebo	30SEP2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
11111177	C4591001 1111 11111177	16-55	08SEP2020	83976	Placebo	08SEP2020/ Placebo	30SEP2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
11111179	C4591001 1111 11111179	16-55	09SEP2020	83978	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
11111180	C4591001 1111 11111180	16-55	09SEP2020	83979	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
11111183	C4591001 1111 11111183	16-55	21SEP2020	94626	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
11111184	C4591001 1111 11111184	16-55	21SEP2020	94628	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
11111188	C4591001 1111 11111188	16-55	21SEP2020	94629	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
11111189	C4591001 1111 11111189	16-55	21SEP2020	94630	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
11111191	C4591001 1111 11111191	16-55	30SEP2020	102440	Placebo	30SEP2020/ Placebo	21OCT2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
11111192	C4591001 1111 11111192	16-55	15OCT2020	102442	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11111200	C4591001 1111 11111200	16-55	21OCT2020	102447	Placebo	21OCT2020/ Placebo	11NOV2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
11111203	C4591001 1111 11111203	16-55	21OCT2020	102448	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
11121081	C4591001 1112 11121081	16-55	02SEP2020	78848	Placebo	02SEP2020/ Placebo	22SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
11121125	C4591001 1112 11121125	16-55	17AUG2020	46906	Placebo	17AUG2020/ Placebo	09SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
11121126	C4591001 1112 11121126	16-55	17AUG2020	46911	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11121127	C4591001 1112 11121127	16-55	17AUG2020	52937	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11121128	C4591001 1112 11121128	16-55	17AUG2020	52944	Placebo	17AUG2020/ Placebo	09SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
11121130	C4591001 1112 11121130	16-55	18AUG2020	52945	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11121132	C4591001 1112 11121132	16-55	18AUG2020	52948	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
11121135	C4591001 1112 11121135	16-55	18AUG2020	55086	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11121136	C4591001 1112 11121136	16-55	18AUG2020	55088	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11121137	C4591001 1112 11121137	16-55	18AUG2020	55092	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11121138	C4591001 1112 11121138	16-55	18AUG2020	55093	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
11121139	C4591001 1112 11121139	16-55	19AUG2020	56047	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11121146	C4591001 1112 11121146	16-55	20AUG2020	56049	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
11121147	C4591001 1112 11121147	16-55	20AUG2020	56050	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11121148	C4591001 1112 11121148	16-55	20AUG2020	56052	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
11121151	C4591001 1112 11121151	16-55	20AUG2020	59457	Placebo	20AUG2020/ Placebo	09SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
11121152	C4591001 1112 11121152	16-55	20AUG2020	59458	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
11121154	C4591001 1112 11121154	16-55	21AUG2020	59459	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11121155	C4591001 1112 11121155	16-55	21AUG2020	59462	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11121156	C4591001 1112 11121156	16-55	21AUG2020	60933	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
11121157	C4591001 1112 11121157	16-55	21AUG2020	60934	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
11121158	C4591001 1112 11121158	16-55	21AUG2020	60937	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11121159	C4591001 1112 11121159	16-55	24AUG2020	60938	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11121160	C4591001 1112 11121160	16-55	24AUG2020	63738	Placebo	24AUG2020/ Placebo	16SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
11121161	C4591001 1112 11121161	16-55	24AUG2020	63742	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11121162	C4591001 1112 11121162	16-55	24AUG2020	63743	Placebo	24AUG2020/ Placebo	16SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
11121163	C4591001 1112 11121163	16-55	24AUG2020	63746	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11121165	C4591001 1112 11121165	16-55	24AUG2020	64547	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11121169	C4591001 1112 11121169	16-55	25AUG2020	64550	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
11121171	C4591001 1112 11121171	16-55	25AUG2020	64551	Placebo	25AUG2020/ Placebo	17SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11121173	C4591001 1112 11121173	16-55	25AUG2020	64552	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
11121174	C4591001 1112 11121174	16-55	25AUG2020	66809	Placebo	25AUG2020/ Placebo	14SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
11121175	C4591001 1112 11121175	16-55	26AUG2020	66817	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11121177	C4591001 1112 11121177	16-55	26AUG2020	66818	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
11121180	C4591001 1112 11121180	16-55	26AUG2020	66819	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
11121183	C4591001 1112 11121183	16-55	27AUG2020	70149	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
11121184	C4591001 1112 11121184	16-55	27AUG2020	70152	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
11121185	C4591001 1112 11121185	16-55	27AUG2020	70151	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11121187	C4591001 1112 11121187	16-55	27AUG2020	70156	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
11121188	C4591001 1112 11121188	16-55	27AUG2020	71273	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11121189	C4591001 1112 11121189	16-55	28AUG2020	71277	Placebo	28AUG2020/ Placebo	17SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11121190	C4591001 1112 11121190	16-55	28AUG2020	71278	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11121191	C4591001 1112 11121191	16-55	28AUG2020	71280	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
11121192	C4591001 1112 11121192	16-55	28AUG2020	72740	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)			
11121193	C4591001 1112 11121193	16-55	28AUG2020	72739	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
11121194	C4591001 1112 11121194	16-55	28AUG2020	72745	Placebo	28AUG2020/ Placebo	17SEP2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
11121197	C4591001 1112 11121197	16-55	31AUG2020	72747	Placebo	31AUG2020/ Placebo	23SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
11121198	C4591001 1112 11121198	16-55	31AUG2020	75334	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11121199	C4591001 1112 11121199	16-55	31AUG2020	75335	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
11121200	C4591001 1112 11121200	16-55	31AUG2020	75336	Placebo	31AUG2020/ Placebo	23SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
11121201	C4591001 1112 11121201	16-55	31AUG2020	75337	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11121204	C4591001 1112 11121204	16-55	01SEP2020	76661	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11121207	C4591001 1112 11121207	16-55	01SEP2020	76663	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
11121208	C4591001 1112 11121208	16-55	01SEP2020	76664	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11121213	C4591001 1112 11121213	16-55	02SEP2020	76672	Placebo	02SEP2020/ Placebo	24SEP2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
11121214	C4591001 1112 11121214	16-55	02SEP2020	78845	Placebo	02SEP2020/ Placebo	24SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
11121215	C4591001 1112 11121215	16-55	02SEP2020	78854	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11121216	C4591001 1112 11121216	16-55	02SEP2020	78856	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11121217	C4591001 1112 11121217	16-55	03SEP2020	79604	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11121218	C4591001 1112 11121218	16-55	03SEP2020	79608	Placebo	03SEP2020/ Placebo	23SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11121224	C4591001 1112 11121224	16-55	03SEP2020	79609	Placebo	03SEP2020/ Placebo	23SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
11121225	C4591001 1112 11121225	16-55	04SEP2020	79611	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11121226	C4591001 1112 11121226	16-55	04SEP2020	81668	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
11121228	C4591001 1112 11121228	16-55	04SEP2020	81670	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	
11121229	C4591001 1112 11121229	16-55	04SEP2020	81671	BNT162b2 (30 µg)				
11121231	C4591001 1112 11121231	16-55	08SEP2020	81673	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
11121234	C4591001 1112 11121234	16-55	08SEP2020	84476	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
11121237	C4591001 1112 11121237	16-55	09SEP2020	84478	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11121239	C4591001 1112 11121239	16-55	09SEP2020	84482	Placebo	09SEP2020/ Placebo	29SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
11121240	C4591001 1112 11121240	16-55	09SEP2020	84483	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
11121242	C4591001 1112 11121242	16-55	10SEP2020	86445	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
11121243	C4591001 1112 11121243	16-55	10SEP2020	86448	Placebo	10SEP2020/ Placebo	02OCT2020/ Placebo		
11121244	C4591001 1112 11121244	16-55	10SEP2020	86446	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
11121245	C4591001 1112 11121245	16-55	10SEP2020	86451	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11121246	C4591001 1112 11121246	16-55	10SEP2020	87595	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
11121249	C4591001 1112 11121249	16-55	11SEP2020	87596	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
11121250	C4591001 1112 11121250	16-55	11SEP2020	87599	Placebo	11SEP2020/ Placebo	30SEP2020/ Placebo	06JAN2021/ BNT162b2 (30 µg)	27JAN2021/ BNT162b2 (30 µg)
11121253	C4591001 1112 11121253	16-55	11SEP2020	87604	Placebo	11SEP2020/ Placebo	30SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11121254	C4591001 1112 11121254	16-55	06OCT2020	104155	BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
11121256	C4591001 1112 11121256	16-55	06OCT2020	104156	BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
11121258	C4591001 1112 11121258	16-55	06OCT2020	104160	Placebo	06OCT2020/ Placebo	27OCT2020/ Placebo		
11121259	C4591001 1112 11121259	16-55	06OCT2020	104161	Placebo	06OCT2020/ Placebo	27OCT2020/ Placebo		
11121260	C4591001 1112 11121260	16-55	06OCT2020	104441	Placebo	06OCT2020/ Placebo	26OCT2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
11121261	C4591001 1112 11121261	16-55	07OCT2020	104444	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
11121263	C4591001 1112 11121263	16-55	07OCT2020	104448	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
11121264	C4591001 1112 11121264	16-55	07OCT2020	104452	Placebo	07OCT2020/ Placebo	26OCT2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
11121265	C4591001 1112 11121265†	16-55	07OCT2020	104960	Placebo	07OCT2020/ Placebo	26OCT2020/ Placebo		
11121266	C4591001 1112 11121266	16-55	19OCT2020	107464	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11121268	C4591001 1112 11121268	16-55	08OCT2020	104961	Placebo	08OCT2020/ Placebo	02NOV2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	04JAN2021/ BNT162b2 (30 µg)
11121269	C4591001 1112 11121269	16-55	08OCT2020	104967	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
11121270	C4591001 1112 11121270†	16-55	08OCT2020	104968	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)			
11121271	C4591001 1112 11121271	16-55	08OCT2020	105401	Placebo	08OCT2020/ Placebo	28OCT2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
11121272	C4591001 1112 11121272	16-55	08OCT2020	105405	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
11121273	C4591001 1112 11121273	16-55	08OCT2020	105406	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		
11121275	C4591001 1112 11121275	16-55	08OCT2020	105408	Placebo	08OCT2020/ Placebo	27OCT2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
11121281	C4591001 1112 11121281	16-55	09OCT2020	105966	Placebo	09OCT2020/ Placebo	02NOV2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
11121282	C4591001 1112 11121282	16-55	09OCT2020	105972	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
11121283	C4591001 1112 11121283	16-55	09OCT2020	105974	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11121284	C4591001 1112 11121284	16-55	09OCT2020	105975	Placebo	09OCT2020/ Placebo	02NOV2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	04JAN2021/ BNT162b2 (30 µg)
11121286	C4591001 1112 11121286	16-55	09OCT2020	106148	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
11121289	C4591001 1112 11121289	16-55	09OCT2020	106149	Placebo	09OCT2020/ Placebo	29OCT2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11121290	C4591001 1112 11121290	16-55	12OCT2020	106151	BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		
11121291	C4591001 1112 11121291	16-55	12OCT2020	106156	Placebo	12OCT2020/ Placebo	02NOV2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
11121293	C4591001 1112 11121293	16-55	12OCT2020	106530	Placebo	12OCT2020/ Placebo	03NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
11121296	C4591001 1112 11121296	16-55	12OCT2020	106533	Placebo	12OCT2020/ Placebo	02NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
11121297	C4591001 1112 11121297	16-55	12OCT2020	106538	BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		
11121298	C4591001 1112 11121298	16-55	12OCT2020	106535	BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		
11121299	C4591001 1112 11121299	16-55	12OCT2020	106674	BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11121300	C4591001 1112 11121300	16-55	12OCT2020	106679	BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		
11121301	C4591001 1112 11121301	16-55	12OCT2020	106682	Placebo	12OCT2020/ Placebo	02NOV2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
11121303	C4591001 1112 11121303	16-55	13OCT2020	106683	Placebo	13OCT2020/ Placebo	03NOV2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
11121304	C4591001 1112 11121304	16-55	13OCT2020	106853	Placebo	13OCT2020/ Placebo	03NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
11121305	C4591001 1112 11121305	16-55	13OCT2020	106854	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
11121307	C4591001 1112 11121307	16-55	13OCT2020	106856	Placebo	13OCT2020/ Placebo	04NOV2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11121308	C4591001 1112 11121308	16-55	13OCT2020	106858	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
11121310	C4591001 1112 11121310	16-55	14OCT2020	107457	Placebo	14OCT2020/ Placebo	05NOV2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
11121313	C4591001 1112 11121313	16-55	19OCT2020	107460	Placebo	19OCT2020/ Placebo	11NOV2020/ Placebo		
11121315	C4591001 1112 11121315	16-55	19OCT2020	107462	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11121317	C4591001 1112 11121317	16-55	19OCT2020	110465	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
11121318	C4591001 1112 11121318†	16-55	19OCT2020	110474	Placebo	19OCT2020/ Placebo	11NOV2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
11121319	C4591001 1112 11121319	16-55	19OCT2020	110466	Placebo	19OCT2020/ Placebo	11NOV2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
11121322	C4591001 1112 11121322	16-55	19OCT2020	110475	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
11121323	C4591001 1112 11121323	16-55	20OCT2020	110753	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
11121324	C4591001 1112 11121324	16-55	20OCT2020	110754	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
11121326	C4591001 1112 11121326	16-55	20OCT2020	110760	Placebo	20OCT2020/ Placebo	11NOV2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
11121328	C4591001 1112 11121328	16-55	20OCT2020	110763	Placebo	20OCT2020/ Placebo	11NOV2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
11121331	C4591001 1112 11121331	16-55	20OCT2020	111139	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
11121332	C4591001 1112 11121332	16-55	20OCT2020	111141	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11121333	C4591001 1112 11121333	16-55	21OCT2020	111143	Placebo	21OCT2020/ Placebo	12NOV2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
11121335	C4591001 1112 11121335	16-55	21OCT2020	111148	Placebo	21OCT2020/ Placebo	12NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
11121339	C4591001 1112 11121339	16-55	21OCT2020	111857	Placebo	21OCT2020/ Placebo	11NOV2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
11121341	C4591001 1112 11121341	16-55	22OCT2020	111862	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
11121342	C4591001 1112 11121342	16-55	22OCT2020	111868	Placebo	22OCT2020/ Placebo	12NOV2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
11121343	C4591001 1112 11121343	16-55	22OCT2020	111864	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
11121345	C4591001 1112 11121345	16-55	22OCT2020	112218	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
11121346	C4591001 1112 11121346	16-55	22OCT2020	112219	Placebo	22OCT2020/ Placebo	12NOV2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
11121351	C4591001 1112 11121351	16-55	22OCT2020	112225	Placebo	22OCT2020/ Placebo	12NOV2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
11141027	C4591001 1114 11141027	16-55	17AUG2020	48900	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11141029	C4591001 1114 11141029	16-55	17AUG2020	48903	Placebo	17AUG2020/ Placebo	15SEP2020/ Placebo		
11141033	C4591001 1114 11141033	16-55	17AUG2020	53432	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11141034	C4591001 1114 11141034	16-55	17AUG2020	53435	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
11141037	C4591001 1114 11141037	16-55	17AUG2020	53437	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)			
11141038	C4591001 1114 11141038	16-55	17AUG2020	53705	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
11141039	C4591001 1114 11141039	16-55	17AUG2020	53438	Placebo	17AUG2020/ Placebo	09SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11141040	C4591001 1114 11141040	16-55	17AUG2020	53711	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11141041	C4591001 1114 11141041	16-55	18AUG2020	53715	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11141042	C4591001 1114 11141042	16-55	18AUG2020	53714	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
11141051	C4591001 1114 11141051	16-55	18AUG2020	55449	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11141053	C4591001 1114 11141053	16-55	18AUG2020	55453	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
11141054	C4591001 1114 11141054	16-55	19AUG2020	55454	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo		
11141061	C4591001 1114 11141061	16-55	19AUG2020	55455	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo		
11141062	C4591001 1114 11141062	16-55	19AUG2020	57427	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
11141063	C4591001 1114 11141063	16-55	19AUG2020	57429	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
11141064	C4591001 1114 11141064	16-55	20AUG2020	57430	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
11141065	C4591001 1114 11141065	16-55	20AUG2020	57436	Placebo	20AUG2020/ Placebo	22OCT2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
11141068	C4591001 1114 11141068	16-55	21AUG2020	60222	Placebo	21AUG2020/ Placebo	10SEP2020/ Placebo	30JAN2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11141069	C4591001 1114 11141069	16-55	21AUG2020	60223	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
11141070	C4591001 1114 11141070	16-55	21AUG2020	60229	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11141072	C4591001 1114 11141072	16-55	21AUG2020	60232	Placebo	21AUG2020/ Placebo	10SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
11141074	C4591001 1114 11141074	16-55	21AUG2020	61497	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
11141075	C4591001 1114 11141075	16-55	21AUG2020	61498	Placebo	21AUG2020/ Placebo	10SEP2020/ Placebo		
11141076	C4591001 1114 11141076	16-55	24AUG2020	61499	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
11141079	C4591001 1114 11141079	16-55	24AUG2020	61504	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11141081	C4591001 1114 11141081	16-55	24AUG2020	64349	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11141083	C4591001 1114 11141083	16-55	24AUG2020	64351	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11141084	C4591001 1114 11141084	16-55	24AUG2020	64358	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11141085	C4591001 1114 11141085	16-55	24AUG2020	64359	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
11141087	C4591001 1114 11141087	16-55	25AUG2020	65309	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11141089	C4591001 1114 11141089	16-55	25AUG2020	65313	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
11141093	C4591001 1114 11141093	16-55	25AUG2020	65318	Placebo	25AUG2020/ Placebo	14SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11141095	C4591001 1114 11141095	16-55	25AUG2020	65320	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
11141096	C4591001 1114 11141096	16-55	25AUG2020	66714	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
11141097	C4591001 1114 11141097	16-55	25AUG2020	66718	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
11141098	C4591001 1114 11141098	16-55	25AUG2020	66721	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11141100	C4591001 1114 11141100	16-55	25AUG2020	66723	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11141103	C4591001 1114 11141103	16-55	26AUG2020	68777	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11141105	C4591001 1114 11141105	16-55	26AUG2020	68781	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
11141106	C4591001 1114 11141106	16-55	27AUG2020	68782	Placebo	27AUG2020/ Placebo	16SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11141109	C4591001 1114 11141109	16-55	29AUG2020	68784	Placebo	29AUG2020/ Placebo	26SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
11141111	C4591001 1114 11141111	16-55	29AUG2020	74037	Placebo	29AUG2020/ Placebo	18SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
11141113	C4591001 1114 11141113	16-55	29AUG2020	74039	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
11141115	C4591001 1114 11141115	16-55	29AUG2020	74042	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
11141117	C4591001 1114 11141117	16-55	29AUG2020	74044	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
11141118	C4591001 1114 11141118	16-55	29AUG2020	74277	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
11141119	C4591001 1114 11141119	16-55	31AUG2020	74279	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	30JAN2021/ BNT162b2 (30 µg)	
11141121	C4591001 1114 11141121	16-55	03SEP2020	74281	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11141123	C4591001 1114 11141123	16-55	11SEP2020	74283	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
11161002	C4591001 1116 11161002	16-55	25AUG2020	65946	Placebo	25AUG2020/ Placebo	17SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11161003	C4591001 1116 11161003	16-55	25AUG2020	65950	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11161006	C4591001 1116 11161006	16-55	25AUG2020	65951	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11161007	C4591001 1116 11161007	16-55	25AUG2020	66368	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11161008	C4591001 1116 11161008	16-55	25AUG2020	65953	Placebo	25AUG2020/ Placebo	17SEP2020/ Placebo		
11161009	C4591001 1116 11161009	16-55	25AUG2020	66369	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
11161012	C4591001 1116 11161012	16-55	25AUG2020	66370	Placebo	25AUG2020/ Placebo	17SEP2020/ Placebo		
11161014	C4591001 1116 11161014	16-55	26AUG2020	66372	Placebo	26AUG2020/ Placebo	17SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
11161015	C4591001 1116 11161015	16-55	26AUG2020	67973	BNT162b2 (30 µg)				
11161022	C4591001 1116 11161022	16-55	26AUG2020	67976	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11161023	C4591001 1116 11161023	16-55	26AUG2020	67978	Placebo	26AUG2020/ Placebo	18SEP2020/ Placebo		
11161029	C4591001 1116 11161029	16-55	27AUG2020	67983	Placebo	27AUG2020/ Placebo	18SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11161036	C4591001 1116 11161036	16-55	27AUG2020	71407	Placebo	27AUG2020/ Placebo	18SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
11161041	C4591001 1116 11161041	16-55	28AUG2020	71413	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
11161043	C4591001 1116 11161043	16-55	28AUG2020	71415	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
11161044	C4591001 1116 11161044	16-55	28AUG2020	71416	Placebo	28AUG2020/ Placebo	17SEP2020/ Placebo	12MAR2021/ BNT162b2 (30 µg)	
11161047	C4591001 1116 11161047	16-55	28AUG2020	72463	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
11161049	C4591001 1116 11161049	16-55	28AUG2020	72464	Placebo	28AUG2020/ Placebo	17SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
11161053	C4591001 1116 11161053	16-55	28AUG2020	72467	Placebo	28AUG2020/ Placebo	17SEP2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
11161054	C4591001 1116 11161054	16-55	28AUG2020	72469	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
11161058	C4591001 1116 11161058	16-55	31AUG2020	75041	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
11161059	C4591001 1116 11161059	16-55	31AUG2020	75043	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11161065	C4591001 1116 11161065	16-55	31AUG2020	75044	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo		
11161066	C4591001 1116 11161066	16-55	31AUG2020	75046	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11161068	C4591001 1116 11161068	16-55	31AUG2020	75776	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11161071	C4591001 1116 11161071	16-55	31AUG2020	75777	Placebo	31AUG2020/ Placebo	22SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
11161072	C4591001 1116 11161072	16-55	31AUG2020	75778	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
11161076	C4591001 1116 11161076	16-55	01SEP2020	75784	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11161082	C4591001 1116 11161082	16-55	01SEP2020	77577	Placebo	01SEP2020/ Placebo	24SEP2020/ Placebo	03MAR2021/ BNT162b2 (30 µg)	
11161083	C4591001 1116 11161083	16-55	01SEP2020	77578	Placebo	01SEP2020/ Placebo	24SEP2020/ Placebo	03MAR2021/ BNT162b2 (30 µg)	
11161085	C4591001 1116 11161085	16-55	01SEP2020	77581	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11161091	C4591001 1116 11161091	16-55	02SEP2020	77582	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11161099	C4591001 1116 11161099	16-55	02SEP2020	79016	Placebo	02SEP2020/ Placebo	25SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
11161100	C4591001 1116 11161100	16-55	02SEP2020	79018	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11161101	C4591001 1116 11161101	16-55	02SEP2020	79022	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11161103	C4591001 1116 11161103	16-55	02SEP2020	79024	Placebo	02SEP2020/ Placebo	22SEP2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
11161104	C4591001 1116 11161104	16-55	02SEP2020	79409	Placebo	02SEP2020/ Placebo	21SEP2020/ Placebo		
11161105	C4591001 1116 11161105	16-55	03SEP2020	79411	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
11161107	C4591001 1116 11161107	16-55	03SEP2020	79414	Placebo	03SEP2020/ Placebo	22SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
11161108	C4591001 1116 11161108	16-55	03SEP2020	79416	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11161110	C4591001 1116 11161110	16-55	03SEP2020	80095	Placebo	03SEP2020/ Placebo	23SEP2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
11161113	C4591001 1116 11161113	16-55	03SEP2020	80099	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11161115	C4591001 1116 11161115	16-55	03SEP2020	80100	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
11161119	C4591001 1116 11161119	16-55	03SEP2020	80103	Placebo	03SEP2020/ Placebo	22SEP2020/ Placebo	03MAR2021/ BNT162b2 (30 µg)	
11161129	C4591001 1116 11161129	16-55	04SEP2020	81942	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
11161138	C4591001 1116 11161138	16-55	04SEP2020	81944	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
11161139	C4591001 1116 11161139	16-55	04SEP2020	81946	Placebo	04SEP2020/ Placebo	24SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
11161140	C4591001 1116 11161140	16-55	04SEP2020	81952	Placebo	04SEP2020/ Placebo	23SEP2020/ Placebo		
11161143	C4591001 1116 11161143	16-55	08SEP2020	83586	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)			
11161148	C4591001 1116 11161148	16-55	08SEP2020	83587	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
11161154	C4591001 1116 11161154	16-55	08SEP2020	83593	Placebo	08SEP2020/ Placebo	30SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
11161157	C4591001 1116 11161157	16-55	08SEP2020	83594	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11161158	C4591001 1116 11161158	16-55	09SEP2020	84917	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
11161159	C4591001 1116 11161159	16-55	09SEP2020	84918	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
11161160	C4591001 1116 11161160	16-55	09SEP2020	84922	Placebo	09SEP2020/ Placebo	28SEP2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
11161164	C4591001 1116 11161164	16-55	09SEP2020	255639	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
11161171	C4591001 1116 11161171	16-55	09SEP2020	85950	Placebo	09SEP2020/ Placebo	28SEP2020/ Placebo	27FEB2021/ BNT162b2 (30 µg)	
11161172	C4591001 1116 11161172	16-55	09SEP2020	84924	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)			
11161175	C4591001 1116 11161175	16-55	09SEP2020	85951	Placebo	09SEP2020/ Placebo	28SEP2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
11161176	C4591001 1116 11161176	16-55	09SEP2020	85952	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
11161178	C4591001 1116 11161178	16-55	10SEP2020	85958	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11161179	C4591001 1116 11161179	16-55	10SEP2020	86515	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11161180	C4591001 1116 11161180	16-55	10SEP2020	86516	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11161185	C4591001 1116 11161185	16-55	10SEP2020	86519	Placebo	10SEP2020/ Placebo	29SEP2020/ Placebo	27FEB2021/ BNT162b2 (30 µg)	
11161186	C4591001 1116 11161186	16-55	10SEP2020	86522	Placebo	10SEP2020/ Placebo	29SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
11161196	C4591001 1116 11161196	16-55	10SEP2020	87545	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11161200	C4591001 1116 11161200	16-55	11SEP2020	87550	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
11161203	C4591001 1116 11161203	16-55	11SEP2020	87553	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	27FEB2021/ BNT162b2 (30 µg)	
11161204	C4591001 1116 11161204	16-55	11SEP2020	87556	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
11161205	C4591001 1116 11161205	16-55	11SEP2020	88065	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
11161206	C4591001 1116 11161206	16-55	11SEP2020	88063	Placebo	11SEP2020/ Placebo	30SEP2020/ Placebo		
11161214	C4591001 1116 11161214	16-55	11SEP2020	88069	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11161216	C4591001 1116 11161216	16-55	11SEP2020	88070	Placebo	11SEP2020/ Placebo	30SEP2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
11161217	C4591001 1116 11161217	16-55	11SEP2020	88692	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo		
11161220	C4591001 1116 11161220	16-55	11SEP2020	88694	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
11161224	C4591001 1116 11161224	16-55	11SEP2020	88695	Placebo	11SEP2020/ Placebo	30SEP2020/ Placebo	03MAR2021/ BNT162b2 (30 µg)	
11161225	C4591001 1116 11161225	16-55	11SEP2020	88917	Placebo	11SEP2020/ Placebo	30SEP2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
11161226	C4591001 1116 11161226	16-55	11SEP2020	88696	BNT162b2 (30 µg)	11SEP2020/ Placebo	02OCT2020/ Placebo		
11161228	C4591001 1116 11161228	16-55	17SEP2020	88918	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	27FEB2021/ BNT162b2 (30 µg)	
11161230	C4591001 1116 11161230	16-55	17SEP2020	88919	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
11161235	C4591001 1116 11161235	16-55	17SEP2020	88923	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
11161239	C4591001 1116 11161239	16-55	18SEP2020	93404	Placebo	18SEP2020/ Placebo	08OCT2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11161240	C4591001 1116 11161240	16-55	18SEP2020	93405	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
11161245	C4591001 1116 11161245	16-55	18SEP2020	93406	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
11161249	C4591001 1116 11161249	16-55	18SEP2020	93411	Placebo	18SEP2020/ Placebo	08OCT2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
11161252	C4591001 1116 11161252	16-55	18SEP2020	94253	Placebo	18SEP2020/ Placebo	08OCT2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	27JAN2021/ BNT162b2 (30 µg)
11161256	C4591001 1116 11161256	16-55	19SEP2020	94255	BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
11161259	C4591001 1116 11161259	16-55	19SEP2020	94260	BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
11161260	C4591001 1116 11161260	16-55	19SEP2020	94261	Placebo	19SEP2020/ Placebo	12OCT2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)
11161261	C4591001 1116 11161261	16-55	19SEP2020	94518	Placebo	19SEP2020/ Placebo	12OCT2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
11161268	C4591001 1116 11161268	16-55	22SEP2020	94522	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
11161274	C4591001 1116 11161274	16-55	22SEP2020	94526	Placebo	22SEP2020/ Placebo	13OCT2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11161276	C4591001 1116 11161276	16-55	23SEP2020	94527	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
11161277	C4591001 1116 11161277	16-55	23SEP2020	97589	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
11161284	C4591001 1116 11161284	16-55	23SEP2020	97590	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo		
11161286	C4591001 1116 11161286	16-55	23SEP2020	97593	Placebo	23SEP2020/ Placebo	16OCT2020/ Placebo	27FEB2021/ BNT162b2 (30 µg)	
11161288	C4591001 1116 11161288	16-55	24SEP2020	97596	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
11161292	C4591001 1116 11161292	16-55	24SEP2020	98815	Placebo	24SEP2020/ Placebo			
11161293	C4591001 1116 11161293	16-55	24SEP2020	98817	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
11161299	C4591001 1116 11161299	16-55	24SEP2020	98822	Placebo	24SEP2020/ Placebo	15OCT2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
11161301	C4591001 1116 11161301	16-55	24SEP2020	98823	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
11161305	C4591001 1116 11161305	16-55	25SEP2020	99500	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11161307	C4591001 1116 11161307	16-55	25SEP2020	99501	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
11161308	C4591001 1116 11161308	16-55	25SEP2020	99504	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
11161309	C4591001 1116 11161309	16-55	25SEP2020	99505	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
11161310	C4591001 1116 11161310	16-55	25SEP2020	99653	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
11161312	C4591001 1116 11161312	16-55	25SEP2020	99654	Placebo	25SEP2020/ Placebo	14OCT2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
11161315	C4591001 1116 11161315	16-55	25SEP2020	99655	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
11161317	C4591001 1116 11161317	16-55	25SEP2020	100295	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
11161318	C4591001 1116 11161318	16-55	25SEP2020	99661	Placebo	25SEP2020/ Placebo	14OCT2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
11161320	C4591001 1116 11161320	16-55	25SEP2020	100296	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
11161321	C4591001 1116 11161321	16-55	25SEP2020	100300	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11161322	C4591001 1116 11161322	16-55	25SEP2020	100297	Placebo	25SEP2020/ Placebo	14OCT2020/ Placebo		
11161323	C4591001 1116 11161323	16-55	25SEP2020	100517	Placebo	25SEP2020/ Placebo	14OCT2020/ Placebo		
11161324	C4591001 1116 11161324	16-55	09OCT2020	100522	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
11161326	C4591001 1116 11161326	16-55	09OCT2020	100525	Placebo	09OCT2020/ Placebo	28OCT2020/ Placebo		
11161329	C4591001 1116 11161329	16-55	09OCT2020	100527	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
11171011	C4591001 1117 11171011	16-55	17AUG2020	53717	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
11171014	C4591001 1117 11171014	16-55	18AUG2020	53720	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo		
11171015	C4591001 1117 11171015	16-55	18AUG2020	53722	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11171017	C4591001 1117 11171017	16-55	18AUG2020	53725	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11171021	C4591001 1117 11171021	16-55	19AUG2020	57114	Placebo	19AUG2020/ Placebo	08SEP2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)
11171029	C4591001 1117 11171029	16-55	19AUG2020	57115	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11171030	C4591001 1117 11171030	16-55	19AUG2020	57119	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
11171035	C4591001 1117 11171035	16-55	20AUG2020	59601	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11171036	C4591001 1117 11171036	16-55	20AUG2020	57122	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo		
11171038	C4591001 1117 11171038	16-55	20AUG2020	59602	Placebo	20AUG2020/ Placebo	11SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11171045	C4591001 1117 11171045	16-55	24AUG2020	59608	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11171050	C4591001 1117 11171050	16-55	24AUG2020	64842	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)
11171053	C4591001 1117 11171053	16-55	25AUG2020	64844	Placebo	25AUG2020/ Placebo	14SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
11171058	C4591001 1117 11171058	16-55	25AUG2020	64846	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
11171061	C4591001 1117 11171061	16-55	25AUG2020	64847	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11171062	C4591001 1117 11171062	16-55	26AUG2020	68406	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11171063	C4591001 1117 11171063	16-55	26AUG2020	68407	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
11171064	C4591001 1117 11171064	16-55	26AUG2020	68412	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
11171065	C4591001 1117 11171065	16-55	26AUG2020	68405	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11171066	C4591001 1117 11171066	16-55	26AUG2020	68922	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
11171067	C4591001 1117 11171067	16-55	26AUG2020	68927	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
11171068	C4591001 1117 11171068	16-55	26AUG2020	68925	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11171069	C4591001 1117 11171069	16-55	26AUG2020	68928	Placebo	26AUG2020/ Placebo	18SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
11171070	C4591001 1117 11171070	16-55	26AUG2020	69274	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
11171073	C4591001 1117 11171073	16-55	27AUG2020	69277	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
11171074	C4591001 1117 11171074	16-55	27AUG2020	69279	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11171075	C4591001 1117 11171075	16-55	27AUG2020	71141	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
11171077	C4591001 1117 11171077	16-55	27AUG2020	69280	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
11171078	C4591001 1117 11171078	16-55	27AUG2020	71142	Placebo	27AUG2020/ Placebo	21SEP2020/ Placebo		
11171083	C4591001 1117 11171083	16-55	02SEP2020	71145	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11171084	C4591001 1117 11171084	16-55	02SEP2020	71148	Placebo	02SEP2020/ Placebo	21SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
11171085	C4591001 1117 11171085	16-55	02SEP2020	79387	Placebo	02SEP2020/ Placebo	21SEP2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
11171087	C4591001 1117 11171087	16-55	03SEP2020	79389	Placebo	03SEP2020/ Placebo	23SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
11171089	C4591001 1117 11171089	16-55	03SEP2020	79391	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11171090	C4591001 1117 11171090	16-55	03SEP2020	79393	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11171091	C4591001 1117 11171091	16-55	03SEP2020	81089	Placebo	03SEP2020/ Placebo	25SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11171093	C4591001 1117 11171093	16-55	04SEP2020	81092	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11171095	C4591001 1117 11171095	16-55	04SEP2020	81095	Placebo	04SEP2020/ Placebo	23SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
11171096	C4591001 1117 11171096	16-55	04SEP2020	81090	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
11171099	C4591001 1117 11171099	16-55	04SEP2020	81368	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11171100	C4591001 1117 11171100	16-55	04SEP2020	81372	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
11171101	C4591001 1117 11171101	16-55	04SEP2020	81373	Placebo	04SEP2020/ Placebo	24SEP2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	14JAN2021/ BNT162b2 (30 µg)
11171102	C4591001 1117 11171102	16-55	04SEP2020	81374	Placebo	04SEP2020/ Placebo	02OCT2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
11171103	C4591001 1117 11171103	16-55	10SEP2020	87221	Placebo	10SEP2020/ Placebo	02OCT2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
11171107	C4591001 1117 11171107	16-55	10SEP2020	87227	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
11171108	C4591001 1117 11171108	16-55	10SEP2020	87228	Placebo	10SEP2020/ Placebo	30SEP2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11171109	C4591001 1117 11171109	16-55	11SEP2020	87230	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
11171111	C4591001 1117 11171111	16-55	11SEP2020	88134	Placebo	11SEP2020/ Placebo	01OCT2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
11171113	C4591001 1117 11171113	16-55	14SEP2020	88140	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
11171119	C4591001 1117 11171119	16-55	15SEP2020	88143	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
11171121	C4591001 1117 11171121	16-55	15SEP2020	88144	Placebo	15SEP2020/ Placebo	06OCT2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
11171126	C4591001 1117 11171126	16-55	16SEP2020	91807	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
11171127	C4591001 1117 11171127	16-55	17SEP2020	91809	Placebo	17SEP2020/ Placebo	06OCT2020/ Placebo		
11171129	C4591001 1117 11171129	16-55	17SEP2020	91811	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11171131	C4591001 1117 11171131	16-55	17SEP2020	91816	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
11171132	C4591001 1117 11171132	16-55	21SEP2020	95034	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11171134	C4591001 1117 11171134	16-55	21SEP2020	95037	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
11171137	C4591001 1117 11171137	16-55	21SEP2020	95041	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
11171138	C4591001 1117 11171138	16-55	15OCT2020	108571	Placebo	15OCT2020/ Placebo	17NOV2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
11171140	C4591001 1117 11171140	16-55	22SEP2020	95042	Placebo	22SEP2020/ Placebo	15OCT2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11171143	C4591001 1117 11171143	16-55	22SEP2020	96379	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
11171144	C4591001 1117 11171144	16-55	22SEP2020	96378	Placebo	22SEP2020/ Placebo	13OCT2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
11171145	C4591001 1117 11171145	16-55	22SEP2020	96381	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
11171150	C4591001 1117 11171150	16-55	23SEP2020	96386	Placebo	23SEP2020/ Placebo	12OCT2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11171154	C4591001 1117 11171154	16-55	23SEP2020	98141	Placebo	23SEP2020/ Placebo	16OCT2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
11171156	C4591001 1117 11171156	16-55	24SEP2020	98144	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11171158	C4591001 1117 11171158	16-55	24SEP2020	98148	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
11171161	C4591001 1117 11171161	16-55	29SEP2020	101278	Placebo	29SEP2020/ Placebo	21OCT2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
11171169	C4591001 1117 11171169	16-55	25SEP2020	98149	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11171170	C4591001 1117 11171170	16-55	25SEP2020	100327	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
11171171	C4591001 1117 11171171	16-55	25SEP2020	100332	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
11171172	C4591001 1117 11171172	16-55	25SEP2020	100329	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
11171174	C4591001 1117 11171174	16-55	25SEP2020	100335	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
11171178	C4591001 1117 11171178	16-55	28SEP2020	101273	BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		
11171180	C4591001 1117 11171180	16-55	29SEP2020	101276	BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		
11171181	C4591001 1117 11171181	16-55	29SEP2020	101280	Placebo	29SEP2020/ Placebo	19OCT2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11171183	C4591001 1117 11171183	16-55	29SEP2020	101912	BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)		
11171184	C4591001 1117 11171184	16-55	30SEP2020	101913	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)		
11171186	C4591001 1117 11171186	16-55	06OCT2020	101915	Placebo	06OCT2020/ Placebo			
11171187	C4591001 1117 11171187	16-55	06OCT2020	101919	Placebo	06OCT2020/ Placebo	27OCT2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
11171189	C4591001 1117 11171189	16-55	07OCT2020	104898	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		
11171190	C4591001 1117 11171190	16-55	08OCT2020	104899	Placebo	08OCT2020/ Placebo		11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
11171192	C4591001 1117 11171192	16-55	09OCT2020	104900	Placebo	09OCT2020/ Placebo	28OCT2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
11171196	C4591001 1117 11171196	16-55	15OCT2020	104907	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
11171197	C4591001 1117 11171197	16-55	20OCT2020	108572	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
11181040	C4591001 1118 11181040	16-55	17AUG2020	50116	Placebo	17AUG2020/ Placebo	09SEP2020/ Placebo	30JAN2021/ BNT162b2 (30 µg)	20FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11181042	C4591001 1118 11181042	16-55	17AUG2020	52709	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11181046	C4591001 1118 11181046	16-55	17AUG2020	52712	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11181047	C4591001 1118 11181047	16-55	18AUG2020	52715	Placebo	18AUG2020/ Placebo	10SEP2020/ Placebo	30JAN2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11181048	C4591001 1118 11181048	16-55	18AUG2020	52720	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
11181049	C4591001 1118 11181049	16-55	18AUG2020	53935	Placebo	18AUG2020/ Placebo	10SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
11181054	C4591001 1118 11181054	16-55	18AUG2020	53936	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
11181059	C4591001 1118 11181059	16-55	19AUG2020	53942	Placebo	19AUG2020/ Placebo	11SEP2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	22JAN2021/ BNT162b2 (30 µg)
11181060	C4591001 1118 11181060	16-55	19AUG2020	53944	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
11181061	C4591001 1118 11181061	16-55	19AUG2020	55965	Placebo	19AUG2020/ Placebo	11SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
11181062	C4591001 1118 11181062	16-55	19AUG2020	55962	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11181063	C4591001 1118 11181063	16-55	19AUG2020	55967	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
11181064	C4591001 1118 11181064	16-55	19AUG2020	55971	Placebo	19AUG2020/ Placebo	11SEP2020/ Placebo		
11181070	C4591001 1118 11181070	16-55	20AUG2020	58258	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
11181076	C4591001 1118 11181076	16-55	20AUG2020	58259	Placebo	20AUG2020/ Placebo	09SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	20FEB2021/ BNT162b2 (30 µg)
11181079	C4591001 1118 11181079	16-55	20AUG2020	58262	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
11181080	C4591001 1118 11181080	16-55	20AUG2020	59239	Placebo	20AUG2020/ Placebo	09SEP2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	27JAN2021/ BNT162b2 (30 µg)
11181081	C4591001 1118 11181081	16-55	20AUG2020	58263	Placebo	20AUG2020/ Placebo	11SEP2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
11181082	C4591001 1118 11181082	16-55	25AUG2020	65695	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
11181083	C4591001 1118 11181083	16-55	25AUG2020	65699	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
11181084	C4591001 1118 11181084	16-55	25AUG2020	65702	Placebo	25AUG2020/ Placebo	16SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11181085	C4591001 1118 11181085	16-55	26AUG2020	65703	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11181086	C4591001 1118 11181086	16-55	26AUG2020	68601	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
11181089	C4591001 1118 11181089	16-55	27AUG2020	68603	Placebo	27AUG2020/ Placebo	18SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
11181096	C4591001 1118 11181096	16-55	29AUG2020	68604	Placebo	29AUG2020/ Placebo	18SEP2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	20JAN2021/ BNT162b2 (30 µg)
11181097	C4591001 1118 11181097	16-55	29AUG2020	68607	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
11181100	C4591001 1118 11181100	16-55	29AUG2020	73459	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo	30JAN2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
11181101	C4591001 1118 11181101	16-55	29AUG2020	73461	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
11181103	C4591001 1118 11181103	16-55	09SEP2020	73462	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
11181104	C4591001 1118 11181104	16-55	10SEP2020	86309	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
11181106	C4591001 1118 11181106	16-55	11SEP2020	86311	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11181107	C4591001 1118 11181107	16-55	11SEP2020	86316	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
11181108	C4591001 1118 11181108	16-55	17SEP2020	86317	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	30JAN2021/ BNT162b2 (30 µg)	20FEB2021/ BNT162b2 (30 µg)
11181109	C4591001 1118 11181109	16-55	13OCT2020	107022	Placebo	13OCT2020/ Placebo	03NOV2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
11181110	C4591001 1118 11181110	16-55	19OCT2020	107026	Placebo	19OCT2020/ Placebo	11NOV2020/ Placebo		
11181111	C4591001 1118 11181111	16-55	20OCT2020	107029	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
11181112	C4591001 1118 11181112	16-55	20OCT2020	107030	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
11181115	C4591001 1118 11181115	16-55	21OCT2020	111309	Placebo	21OCT2020/ Placebo	13NOV2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
11181116	C4591001 1118 11181116	16-55	21OCT2020	111312	Placebo	21OCT2020/ Placebo	12NOV2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
11181117	C4591001 1118 11181117	16-55	21OCT2020	111314	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
11181121	C4591001 1118 11181121	16-55	22OCT2020	111315	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11181122	C4591001 1118 11181122	16-55	22OCT2020	112206	Placebo	22OCT2020/ Placebo	11NOV2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	27JAN2021/ BNT162b2 (30 µg)
11201038	C4591001 1120 11201038	16-55	04AUG2020	42486	Placebo				
11201203	C4591001 1120 11201203	16-55	17AUG2020	50579	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11201205	C4591001 1120 11201205	16-55	17AUG2020	50583	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11201207	C4591001 1120 11201207	16-55	17AUG2020	52956	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
11201220	C4591001 1120 11201220	16-55	18AUG2020	52957	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11201223	C4591001 1120 11201223	16-55	18AUG2020	52959	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo		
11201230	C4591001 1120 11201230	16-55	18AUG2020	52960	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11201231	C4591001 1120 11201231	16-55	18AUG2020	55376	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11201234	C4591001 1120 11201234	16-55	19AUG2020	55377	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11201236	C4591001 1120 11201236	16-55	21AUG2020	55384	Placebo	21AUG2020/ Placebo	14SEP2020/ Placebo		
11201237	C4591001 1120 11201237	16-55	21AUG2020	55380	Placebo	21AUG2020/ Placebo	09SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
11201238	C4591001 1120 11201238	16-55	21AUG2020	60353	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11201240	C4591001 1120 11201240	16-55	21AUG2020	60354	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo		
11201241	C4591001 1120 11201241	16-55	21AUG2020	60359	Placebo	21AUG2020/ Placebo	09SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
11201244	C4591001 1120 11201244	16-55	21AUG2020	60363	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11201249	C4591001 1120 11201249	16-55	21AUG2020	60811	Placebo	21AUG2020/ Placebo			
11201250	C4591001 1120 11201250	16-55	21AUG2020	60812	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
11201252	C4591001 1120 11201252	16-55	09SEP2020	60814	Placebo				
11201259	C4591001 1120 11201259	16-55	09SEP2020	60818	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
11201261	C4591001 1120 11201261	16-55	10SEP2020	86578	Placebo	10SEP2020/ Placebo	29SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11201265	C4591001 1120 11201265	16-55	10SEP2020	86584	Placebo	10SEP2020/ Placebo	29SEP2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
11201266	C4591001 1120 11201266	16-55	10SEP2020	86582	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11201270	C4591001 1120 11201270	16-55	11SEP2020	88088	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
11201274	C4591001 1120 11201274	16-55	11SEP2020	88092	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
11201275	C4591001 1120 11201275	16-55	11SEP2020	88091	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
11201277	C4591001 1120 11201277	16-55	11SEP2020	88096	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
11201278	C4591001 1120 11201278	16-55	11SEP2020	88832	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
11201279	C4591001 1120 11201279	16-55	11SEP2020	88837	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
11201280	C4591001 1120 11201280	16-55	11SEP2020	88835	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo		
11201281	C4591001 1120 11201281	16-55	21SEP2020	88839	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11201284	C4591001 1120 11201284	16-55	21SEP2020	95814	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
11201286	C4591001 1120 11201286	16-55	22SEP2020	95817	Placebo	22SEP2020/ Placebo	12OCT2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
11201288	C4591001 1120 11201288	16-55	22SEP2020	95822	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
11201289	C4591001 1120 11201289	16-55	22SEP2020	95824	Placebo	22SEP2020/ Placebo	13OCT2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
11201291	C4591001 1120 11201291	16-55	22SEP2020	96678	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
11201293	C4591001 1120 11201293	16-55	22SEP2020	96681	Placebo	22SEP2020/ Placebo	13OCT2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
11201297	C4591001 1120 11201297	16-55	23SEP2020	96685	Placebo	23SEP2020/ Placebo	12OCT2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11201298	C4591001 1120 11201298	16-55	23SEP2020	96687	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
11201299	C4591001 1120 11201299	16-55	23SEP2020	97508	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)		
11201300	C4591001 1120 11201300	16-55	23SEP2020	97509	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11201303	C4591001 1120 11201303	16-55	23SEP2020	97513	Placebo	23SEP2020/ Placebo	19OCT2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
11201305	C4591001 1120 11201305	16-55	23SEP2020	97514	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	
11201306	C4591001 1120 11201306	16-55	23SEP2020	97987	Placebo	23SEP2020/ Placebo	13OCT2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
11201311	C4591001 1120 11201311	16-55	14OCT2020	97991	BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		
11201315	C4591001 1120 11201315	16-55	14OCT2020	97992	Placebo	14OCT2020/ Placebo	06NOV2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
11201318	C4591001 1120 11201318	16-55	15OCT2020	97995	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
11201320	C4591001 1120 11201320	16-55	15OCT2020	108066	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
11201322	C4591001 1120 11201322	16-55	15OCT2020	108075	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
11201323	C4591001 1120 11201323	16-55	15OCT2020	108068	Placebo	15OCT2020/ Placebo	04NOV2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
11201325	C4591001 1120 11201325	16-55	15OCT2020	108076	Placebo	15OCT2020/ Placebo	04NOV2020/ Placebo		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11201326	C4591001 1120 11201326	16-55	15OCT2020	108320	Placebo	15OCT2020/ Placebo	05NOV2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
11201331	C4591001 1120 11201331	16-55	16OCT2020	108321	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
11201334	C4591001 1120 11201334	16-55	16OCT2020	108325	Placebo	16OCT2020/ Placebo	10NOV2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
11201337	C4591001 1120 11201337	16-55	16OCT2020	108328	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
11201339	C4591001 1120 11201339	16-55	16OCT2020	109205	Placebo	16OCT2020/ Placebo	04NOV2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
11201340	C4591001 1120 11201340	16-55	19OCT2020	109207	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
11201342	C4591001 1120 11201342	16-55	20OCT2020	109209	Placebo	20OCT2020/ Placebo	09NOV2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	20JAN2021/ BNT162b2 (30 µg)
11201343	C4591001 1120 11201343	16-55	20OCT2020	109208	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
11201346	C4591001 1120 11201346	16-55	20OCT2020	111009	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		
11201348	C4591001 1120 11201348	16-55	20OCT2020	111012	Placebo	20OCT2020/ Placebo	09NOV2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11201352	C4591001 1120 11201352	16-55	21OCT2020	111014	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
11201356	C4591001 1120 11201356	16-55	21OCT2020	111015	Placebo	21OCT2020/ Placebo	11NOV2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
11201357	C4591001 1120 11201357	16-55	21OCT2020	111533	Placebo	21OCT2020/ Placebo	10NOV2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
11201363	C4591001 1120 11201363	16-55	21OCT2020	111538	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
11201364	C4591001 1120 11201364	16-55	21OCT2020	111542	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
11201367	C4591001 1120 11201367	16-55	21OCT2020	111544	Placebo	21OCT2020/ Placebo	13NOV2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
11201371	C4591001 1120 11201371	16-55	22OCT2020	112138	Placebo	22OCT2020/ Placebo	11NOV2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
11201386	C4591001 1120 11201386	16-55	22OCT2020	112140	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		
11201388	C4591001 1120 11201388	16-55	23OCT2020	112141	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
11201392	C4591001 1120 11201392	16-55	23OCT2020	113047	Placebo	23OCT2020/ Placebo	01DEC2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11201393	C4591001 1120 11201393	16-55	23OCT2020	112143	Placebo	23OCT2020/ Placebo	11NOV2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
11201395	C4591001 1120 11201395	16-55	23OCT2020	113051	Placebo	23OCT2020/ Placebo	12NOV2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
11201398	C4591001 1120 11201398	16-55	27OCT2020	113053	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
11201404	C4591001 1120 11201404	16-55	28OCT2020	113056	BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
11201405	C4591001 1120 11201405	16-55	28OCT2020	114368	Placebo	28OCT2020/ Placebo	19NOV2020/ Placebo		
11201406	C4591001 1120 11201406	16-55	28OCT2020	114369	Placebo	28OCT2020/ Placebo	16NOV2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
11201407	C4591001 1120 11201407	16-55	28OCT2020	114373	BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
11201409	C4591001 1120 11201409	16-55	28OCT2020	114370	BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
11201416	C4591001 1120 11201416	16-55	28OCT2020	114557	Placebo	28OCT2020/ Placebo	19NOV2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
11201417	C4591001 1120 11201417	16-55	29OCT2020	114562	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11201418	C4591001 1120 11201418	16-55	29OCT2020	114567	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
11201420	C4591001 1120 11201420	16-55	29OCT2020	114564	Placebo	29OCT2020/ Placebo	17NOV2020/ Placebo		
11201425	C4591001 1120 11201425	16-55	29OCT2020	114738	Placebo	29OCT2020/ Placebo	17NOV2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
11201427	C4591001 1120 11201427	16-55	29OCT2020	114741	Placebo	29OCT2020/ Placebo	18NOV2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
11201430	C4591001 1120 11201430	16-55	29OCT2020	114746	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
11201431	C4591001 1120 11201431	16-55	29OCT2020	114747	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	18NOV2020/ BNT162b2 (30 µg)		
11201433	C4591001 1120 11201433	16-55	30OCT2020	115085	Placebo	30OCT2020/ Placebo	20NOV2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
11211001	C4591001 1121 11211001	16-55	24AUG2020	63486	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
11211002	C4591001 1121 11211002	16-55	24AUG2020	63490	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
11211003	C4591001 1121 11211003	16-55	24AUG2020	63493	Placebo	24AUG2020/ Placebo	13SEP2020/ Placebo	11MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11211004	C4591001 1121 11211004	16-55	24AUG2020	63496	Placebo	24AUG2020/ Placebo	13SEP2020/ Placebo		
11211005	C4591001 1121 11211005	16-55	24AUG2020	63689	Placebo	24AUG2020/ Placebo	13SEP2020/ Placebo	11MAR2021/ BNT162b2 (30 µg)	
11211006	C4591001 1121 11211006	16-55	24AUG2020	63694	Placebo	24AUG2020/ Placebo	13SEP2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
11211008	C4591001 1121 11211008	16-55	24AUG2020	63699	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
11211009	C4591001 1121 11211009	16-55	24AUG2020	63700	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
11211010	C4591001 1121 11211010	16-55	24AUG2020	63944	Placebo	24AUG2020/ Placebo	13SEP2020/ Placebo		
11211012	C4591001 1121 11211012	16-55	24AUG2020	63948	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
11211013	C4591001 1121 11211013	16-55	24AUG2020	63951	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
11211014	C4591001 1121 11211014	16-55	25AUG2020	63952	Placebo	25AUG2020/ Placebo	13SEP2020/ Placebo	12MAR2021/ BNT162b2 (30 µg)	
11211015	C4591001 1121 11211015	16-55	25AUG2020	65454	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11211018	C4591001 1121 11211018	16-55	26AUG2020	65455	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo		
11211022	C4591001 1121 11211022	16-55	26AUG2020	65457	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
11211023	C4591001 1121 11211023	16-55	26AUG2020	65463	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11211024	C4591001 1121 11211024	16-55	26AUG2020	67883	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
11211025	C4591001 1121 11211025	16-55	26AUG2020	67885	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)			
11211026	C4591001 1121 11211026	16-55	26AUG2020	67886	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	11MAR2021/ BNT162b2 (30 µg)	
11211027	C4591001 1121 11211027	16-55	27AUG2020	67887	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
11211028	C4591001 1121 11211028	16-55	27AUG2020	69630	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
11211029	C4591001 1121 11211029	16-55	27AUG2020	69632	Placebo	27AUG2020/ Placebo	18SEP2020/ Placebo		
11211030	C4591001 1121 11211030	16-55	27AUG2020	69637	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11211033	C4591001 1121 11211033	16-55	27AUG2020	69640	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
11211034	C4591001 1121 11211034	16-55	27AUG2020	70173	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
11211035	C4591001 1121 11211035	16-55	27AUG2020	70176	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	11MAR2021/ BNT162b2 (30 µg)	
11211036	C4591001 1121 11211036	16-55	27AUG2020	70178	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	12MAR2021/ BNT162b2 (30 µg)	
11211038	C4591001 1121 11211038	16-55	27AUG2020	70180	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
11211039	C4591001 1121 11211039	16-55	27AUG2020	70506	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	12MAR2021/ BNT162b2 (30 µg)	
11211041	C4591001 1121 11211041	16-55	27AUG2020	70510	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	12MAR2021/ BNT162b2 (30 µg)	
11211044	C4591001 1121 11211044	16-55	31AUG2020	70513	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	20SEP2020/ BNT162b2 (30 µg)		
11211050	C4591001 1121 11211050	16-55	01SEP2020	70516	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	20SEP2020/ BNT162b2 (30 µg)		
11211052	C4591001 1121 11211052	16-55	01SEP2020	76577	Placebo	01SEP2020/ Placebo	20SEP2020/ Placebo	12MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11211053	C4591001 1121 11211053	16-55	01SEP2020	76578	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	20SEP2020/ BNT162b2 (30 µg)		
11211054	C4591001 1121 11211054	16-55	01SEP2020	76581	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	20SEP2020/ BNT162b2 (30 µg)		
11211057	C4591001 1121 11211057	16-55	02SEP2020	76587	Placebo	02SEP2020/ Placebo	22SEP2020/ Placebo		
11211059	C4591001 1121 11211059	16-55	02SEP2020	78247	Placebo	02SEP2020/ Placebo	22SEP2020/ Placebo		
11211060	C4591001 1121 11211060	16-55	02SEP2020	78249	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11211061	C4591001 1121 11211061	16-55	02SEP2020	78251	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11211064	C4591001 1121 11211064	16-55	02SEP2020	78255	Placebo	02SEP2020/ Placebo	22SEP2020/ Placebo		
11211065	C4591001 1121 11211065	16-55	02SEP2020	78533	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11211066	C4591001 1121 11211066	16-55	03SEP2020	78534	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11211067	C4591001 1121 11211067	16-55	03SEP2020	78535	Placebo	03SEP2020/ Placebo	22SEP2020/ Placebo		
11211069	C4591001 1121 11211069	16-55	03SEP2020	78540	Placebo	03SEP2020/ Placebo	22SEP2020/ Placebo	12MAR2021/ BNT162b2 (30 µg)	



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11211070	C4591001 1121 11211070	16-55	03SEP2020	79697	Placebo	03SEP2020/ Placebo	22SEP2020/ Placebo	12MAR2021/ BNT162b2 (30 µg)	
11211076	C4591001 1121 11211076	16-55	03SEP2020	79698	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11211078	C4591001 1121 11211078	16-55	03SEP2020	79699	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11211080	C4591001 1121 11211080	16-55	03SEP2020	251734	Placebo	03SEP2020/ Placebo	22SEP2020/ Placebo		
11211081	C4591001 1121 11211081	16-55	04SEP2020	79706	Placebo	04SEP2020/ Placebo	23SEP2020/ Placebo	11MAR2021/ BNT162b2 (30 µg)	
11211082	C4591001 1121 11211082	16-55	04SEP2020	81534	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11211084	C4591001 1121 11211084	16-55	04SEP2020	81537	Placebo	04SEP2020/ Placebo	23SEP2020/ Placebo	11MAR2021/ BNT162b2 (30 µg)	
11211085	C4591001 1121 11211085	16-55	04SEP2020	81541	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11211087	C4591001 1121 11211087	16-55	08SEP2020	81542	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo		
11211091	C4591001 1121 11211091	16-55	08SEP2020	83635	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11211093	C4591001 1121 11211093	16-55	08SEP2020	83636	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
11211094	C4591001 1121 11211094	16-55	08SEP2020	83640	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo		
11211095	C4591001 1121 11211095	16-55	08SEP2020	83643	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo	11MAR2021/ BNT162b2 (30 µg)	
11211096	C4591001 1121 11211096	16-55	08SEP2020	83862	Placebo	08SEP2020/ Placebo	30SEP2020/ Placebo		
11211097	C4591001 1121 11211097	16-55	08SEP2020	83863	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
11211099	C4591001 1121 11211099	16-55	09SEP2020	83864	Placebo	09SEP2020/ Placebo	28SEP2020/ Placebo	12MAR2021/ BNT162b2 (30 µg)	
11211100	C4591001 1121 11211100	16-55	09SEP2020	83867	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
11211105	C4591001 1121 11211105	16-55	09SEP2020	85337	Placebo	09SEP2020/ Placebo	28SEP2020/ Placebo		
11211106	C4591001 1121 11211106	16-55	09SEP2020	85338	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
11211108	C4591001 1121 11211108	16-55	09SEP2020	85341	Placebo	09SEP2020/ Placebo	28SEP2020/ Placebo		
11211109	C4591001 1121 11211109	16-55	09SEP2020	85342	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11211110	C4591001 1121 11211110	16-55	09SEP2020	85589	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
11211111	C4591001 1121 11211111	16-55	10SEP2020	85590	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11211112	C4591001 1121 11211112	16-55	10SEP2020	85592	Placebo	10SEP2020/ Placebo	29SEP2020/ Placebo		
11211113	C4591001 1121 11211113	16-55	10SEP2020	85600	Placebo	10SEP2020/ Placebo	29SEP2020/ Placebo	12MAR2021/ BNT162b2 (30 µg)	
11211114	C4591001 1121 11211114	16-55	10SEP2020	86681	Placebo	10SEP2020/ Placebo	29SEP2020/ Placebo	11MAR2021/ BNT162b2 (30 µg)	
11211115	C4591001 1121 11211115	16-55	10SEP2020	86684	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11211116	C4591001 1121 11211116	16-55	10SEP2020	86685	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11211117	C4591001 1121 11211117	16-55	10SEP2020	86692	Placebo	10SEP2020/ Placebo	29SEP2020/ Placebo	12MAR2021/ BNT162b2 (30 µg)	
11211118	C4591001 1121 11211118	16-55	10SEP2020	86891	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11211121	C4591001 1121 11211121	16-55	10SEP2020	86892	Placebo	10SEP2020/ Placebo	30SEP2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11211123	C4591001 1121 11211123	16-55	10SEP2020	86893	Placebo	10SEP2020/ Placebo	30SEP2020/ Placebo	12MAR2021/ BNT162b2 (30 µg)	
11221001	C4591001 1122 11221001	16-55	31AUG2020	75270	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
11221003	C4591001 1122 11221003	16-55	02SEP2020	75278	Placebo	02SEP2020/ Placebo	29SEP2020/ Placebo		
11221004	C4591001 1122 11221004	16-55	02SEP2020	75279	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11221005	C4591001 1122 11221005	16-55	03SEP2020	75280	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
11221006	C4591001 1122 11221006	16-55	03SEP2020	79925	Placebo				
11221008	C4591001 1122 11221008	16-55	03SEP2020	79929	Placebo	03SEP2020/ Placebo	25SEP2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	14JAN2021/ BNT162b2 (30 µg)
11221009	C4591001 1122 11221009	16-55	04SEP2020	79931	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11221012	C4591001 1122 11221012	16-55	08SEP2020	79936	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
11221014	C4591001 1122 11221014	16-55	09SEP2020	84234	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	28JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11221016	C4591001 1122 11221016	16-55	08SEP2020	84233	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
11221023	C4591001 1122 11221023	16-55	10SEP2020	84240	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
11221024	C4591001 1122 11221024	16-55	10SEP2020	84242	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11221025	C4591001 1122 11221025	16-55	10SEP2020	87402	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11221026	C4591001 1122 11221026	16-55	11SEP2020	87404	BNT162b2 (30 µg)				
11221027	C4591001 1122 11221027	16-55	11SEP2020	87406	Placebo	11SEP2020/ Placebo	01OCT2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11221028	C4591001 1122 11221028	16-55	11SEP2020	87408	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
11221030	C4591001 1122 11221030	16-55	11SEP2020	88472	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
11221031	C4591001 1122 11221031	16-55	11SEP2020	88475	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
11221032	C4591001 1122 11221032	16-55	14SEP2020	88477	Placebo	14SEP2020/ Placebo	23OCT2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11221033	C4591001 1122 11221033	16-55	15SEP2020	88479	Placebo	15SEP2020/ Placebo	06OCT2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
11221038	C4591001 1122 11221038	16-55	25SEP2020	100373	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo		
11221040	C4591001 1122 11221040	16-55	05OCT2020	100376	Placebo	05OCT2020/ Placebo	27OCT2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
11221041	C4591001 1122 11221041	16-55	07OCT2020	100378	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		
11221042	C4591001 1122 11221042	16-55	07OCT2020	100381	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)		
11221045	C4591001 1122 11221045	16-55	08OCT2020	266907	Placebo	08OCT2020/ Placebo	28OCT2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
11221047	C4591001 1122 11221047	16-55	08OCT2020	105237	Placebo	08OCT2020/ Placebo	29OCT2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11221048	C4591001 1122 11221048	16-55	08OCT2020	105239	Placebo	08OCT2020/ Placebo	28OCT2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
11221051	C4591001 1122 11221051	16-55	09OCT2020	105243	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
11221052	C4591001 1122 11221052	16-55	09OCT2020	106121	Placebo	09OCT2020/ Placebo	13NOV2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11221053	C4591001 1122 11221053	16-55	13OCT2020	106126	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
11221054	C4591001 1122 11221054	16-55	15OCT2020	106127	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
11221059	C4591001 1122 11221059	16-55	22OCT2020	106132	Placebo	22OCT2020/ Placebo	10NOV2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11231027	C4591001 1123 11231027	16-55	04AUG2020	42620	BNT162b2 (30 µg)				
11231098	C4591001 1123 11231098	16-55	14AUG2020	49536	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
11231106	C4591001 1123 11231106	16-55	17AUG2020	50783	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
11231108	C4591001 1123 11231108	16-55	17AUG2020	50785	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11231109	C4591001 1123 11231109	16-55	17AUG2020	52966	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11231114	C4591001 1123 11231114	16-55	17AUG2020	52968	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
11231115	C4591001 1123 11231115	16-55	17AUG2020	52970	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11231116	C4591001 1123 11231116	16-55	17AUG2020	52972	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11231117	C4591001 1123 11231117	16-55	18AUG2020	54500	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
11231118	C4591001 1123 11231118	16-55	18AUG2020	54503	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
11231119	C4591001 1123 11231119	16-55	18AUG2020	54504	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11231120	C4591001 1123 11231120	16-55	18AUG2020	54506	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11231121	C4591001 1123 11231121	16-55	18AUG2020	55078	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11231122	C4591001 1123 11231122	16-55	18AUG2020	55080	Placebo	18AUG2020/ Placebo	10SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
11231123	C4591001 1123 11231123	16-55	19AUG2020	55081	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	06JAN2021/ BNT162b2 (30 µg)	27JAN2021/ BNT162b2 (30 µg)
11231124	C4591001 1123 11231124	16-55	19AUG2020	55082	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11231127	C4591001 1123 11231127	16-55	19AUG2020	57037	Placebo	19AUG2020/ Placebo	08SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11231128	C4591001 1123 11231128	16-55	19AUG2020	57038	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11231130	C4591001 1123 11231130	16-55	19AUG2020	57039	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11231132	C4591001 1123 11231132	16-55	20AUG2020	57040	Placebo	20AUG2020/ Placebo	08SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
11231134	C4591001 1123 11231134	16-55	20AUG2020	58817	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11231135	C4591001 1123 11231135	16-55	20AUG2020	58822	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
11231136	C4591001 1123 11231136	16-55	20AUG2020	58825	Placebo	20AUG2020/ Placebo	09SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
11231137	C4591001 1123 11231137	16-55	20AUG2020	58828	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11231138	C4591001 1123 11231138	16-55	20AUG2020	59003	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	02MAR2021/ BNT162b2 (30 µg)	
11231142	C4591001 1123 11231142	16-55	20AUG2020	59005	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	28JAN2021/ BNT162b2 (30 µg)
11231143	C4591001 1123 11231143	16-55	20AUG2020	59008	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11231144	C4591001 1123 11231144	16-55	20AUG2020	59658	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)			
11231145	C4591001 1123 11231145	16-55	24AUG2020	59663	Placebo	24AUG2020/ Placebo	15SEP2020/ Placebo		
11231151	C4591001 1123 11231151	16-55	24AUG2020	59668	Placebo	24AUG2020/ Placebo	15SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
11231152	C4591001 1123 11231152	16-55	24AUG2020	64050	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11231153	C4591001 1123 11231153	16-55	24AUG2020	59665	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11231154	C4591001 1123 11231154	16-55	24AUG2020	64052	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)			
11231155	C4591001 1123 11231155	16-55	24AUG2020	64055	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
11231156	C4591001 1123 11231156	16-55	24AUG2020	64056	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
11231157	C4591001 1123 11231157	16-55	24AUG2020	64386	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
11231159	C4591001 1123 11231159	16-55	24AUG2020	64387	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11231160	C4591001 1123 11231160	16-55	25AUG2020	64394	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11231161	C4591001 1123 11231161	16-55	25AUG2020	64391	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11231162	C4591001 1123 11231162	16-55	25AUG2020	66269	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
11231163	C4591001 1123 11231163	16-55	25AUG2020	66271	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11231164	C4591001 1123 11231164	16-55	25AUG2020	66278	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	27JAN2021/ BNT162b2 (30 µg)
11231165	C4591001 1123 11231165	16-55	25AUG2020	66280	Placebo	25AUG2020/ Placebo	14SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
11231168	C4591001 1123 11231168	16-55	25AUG2020	66666	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)			
11231170	C4591001 1123 11231170	16-55	25AUG2020	66668	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	06JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)
11231171	C4591001 1123 11231171	16-55	25AUG2020	66670	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
11231172	C4591001 1123 11231172	16-55	25AUG2020	66676	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11231173	C4591001 1123 11231173	16-55	25AUG2020	66965	Placebo	25AUG2020/ Placebo	17SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
11231175	C4591001 1123 11231175	16-55	26AUG2020	66966	Placebo	26AUG2020/ Placebo	15SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	
11231176	C4591001 1123 11231176	16-55	26AUG2020	66967	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11231177	C4591001 1123 11231177	16-55	26AUG2020	66970	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
11231178	C4591001 1123 11231178	16-55	26AUG2020	68168	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
11231179	C4591001 1123 11231179	16-55	26AUG2020	68169	Placebo	26AUG2020/ Placebo	15SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
11231183	C4591001 1123 11231183	16-55	26AUG2020	68176	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)
11231184	C4591001 1123 11231184	16-55	26AUG2020	68173	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
11231187	C4591001 1123 11231187	16-55	26AUG2020	68741	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11231188	C4591001 1123 11231188	16-55	26AUG2020	68742	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11231189	C4591001 1123 11231189	16-55	26AUG2020	68745	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
11231190	C4591001 1123 11231190	16-55	26AUG2020	68748	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11231191	C4591001 1123 11231191	16-55	26AUG2020	69089	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
11231194	C4591001 1123 11231194	16-55	27AUG2020	69091	Placebo	27AUG2020/ Placebo	16SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
11231195	C4591001 1123 11231195	16-55	27AUG2020	69096	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
11231197	C4591001 1123 11231197	16-55	27AUG2020	69098	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11231199	C4591001 1123 11231199	16-55	27AUG2020	71057	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
11231200	C4591001 1123 11231200	16-55	27AUG2020	71066	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11231201	C4591001 1123 11231201	16-55	27AUG2020	71065	Placebo	27AUG2020/ Placebo	01OCT2020/ Placebo		
11231202	C4591001 1123 11231202	16-55	27AUG2020	71068	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11231204	C4591001 1123 11231204	16-55	27AUG2020	71165	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
11231207	C4591001 1123 11231207	16-55	27AUG2020	71170	Placebo	27AUG2020/ Placebo	16SEP2020/ Placebo		
11231208	C4591001 1123 11231208	16-55	28AUG2020	71175	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		
11231209	C4591001 1123 11231209	16-55	04SEP2020	71176	Placebo	04SEP2020/ Placebo	23SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
11231210	C4591001 1123 11231210	16-55	04SEP2020	81846	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
11231212	C4591001 1123 11231212	16-55	04SEP2020	81849	Placebo	04SEP2020/ Placebo	23SEP2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
11231215	C4591001 1123 11231215	16-55	08SEP2020	81851	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11231216	C4591001 1123 11231216	16-55	08SEP2020	81852	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11231217	C4591001 1123 11231217	16-55	09SEP2020	84882	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
11231218	C4591001 1123 11231218	16-55	09SEP2020	84885	Placebo	09SEP2020/ Placebo	28SEP2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11231220	C4591001 1123 11231220	16-55	09SEP2020	84890	Placebo	09SEP2020/ Placebo	01OCT2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
11231221	C4591001 1123 11231221	16-55	09SEP2020	84892	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11231222	C4591001 1123 11231222	16-55	09SEP2020	85830	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
11231228	C4591001 1123 11231228	16-55	10SEP2020	85831	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
11231229	C4591001 1123 11231229	16-55	10SEP2020	85833	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
11231230	C4591001 1123 11231230	16-55	10SEP2020	85839	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
11231232	C4591001 1123 11231232	16-55	10SEP2020	87497	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
11231233	C4591001 1123 11231233	16-55	10SEP2020	87504	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11231234	C4591001 1123 11231234	16-55	11SEP2020	87506	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
11231235	C4591001 1123 11231235	16-55	11SEP2020	87507	Placebo	11SEP2020/ Placebo	30SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11231236	C4591001 1123 11231236	16-55	11SEP2020	88054	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
11231237	C4591001 1123 11231237	16-55	11SEP2020	88050	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo		
11231238	C4591001 1123 11231238	16-55	11SEP2020	88057	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
11231239	C4591001 1123 11231239	16-55	11SEP2020	88059	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo		
11231240	C4591001 1123 11231240	16-55	11SEP2020	88426	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
11231243	C4591001 1123 11231243	16-55	14SEP2020	88428	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
11231245	C4591001 1123 11231245	16-55	14SEP2020	88431	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
11231246	C4591001 1123 11231246	16-55	14SEP2020	88432	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
11231248	C4591001 1123 11231248	16-55	15SEP2020	90595	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
11231249	C4591001 1123 11231249	16-55	15SEP2020	90596	Placebo	15SEP2020/ Placebo	07OCT2020/ Placebo		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11231251	C4591001 1123 11231251	16-55	15SEP2020	90598	Placebo	15SEP2020/ Placebo	05OCT2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
11231252	C4591001 1123 11231252	16-55	15SEP2020	90604	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
11231253	C4591001 1123 11231253	16-55	16SEP2020	91256	Placebo	16SEP2020/ Placebo	07OCT2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
11231260	C4591001 1123 11231260	16-55	16SEP2020	91259	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
11231261	C4591001 1123 11231261	16-55	16SEP2020	91262	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
11231262	C4591001 1123 11231262	16-55	17SEP2020	91264	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11231263	C4591001 1123 11231263	16-55	17SEP2020	92553	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	23NOV2020/ BNT162b2 (30 µg)		
11231264	C4591001 1123 11231264	16-55	17SEP2020	92554	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
11231265	C4591001 1123 11231265	16-55	17SEP2020	92556	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
11231266	C4591001 1123 11231266	16-55	17SEP2020	92560	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11231267	C4591001 1123 11231267	16-55	17SEP2020	92720	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
11231268	C4591001 1123 11231268	16-55	17SEP2020	92719	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
11231269	C4591001 1123 11231269	16-55	17SEP2020	92721	Placebo	17SEP2020/ Placebo	09OCT2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
11231272	C4591001 1123 11231272	16-55	18SEP2020	93884	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
11231275	C4591001 1123 11231275	16-55	18SEP2020	92724	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
11231276	C4591001 1123 11231276	16-55	18SEP2020	93887	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
11231280	C4591001 1123 11231280	16-55	21SEP2020	93888	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
11231281	C4591001 1123 11231281	16-55	22SEP2020	93890	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
11231283	C4591001 1123 11231283	16-55	22SEP2020	96353	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
11231286	C4591001 1123 11231286	16-55	23SEP2020	96356	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11231287	C4591001 1123 11231287	16-55	23SEP2020	96359	Placebo	23SEP2020/ Placebo	12OCT2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
11231289	C4591001 1123 11231289	16-55	23SEP2020	97783	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
11231290	C4591001 1123 11231290	16-55	23SEP2020	96360	Placebo	23SEP2020/ Placebo			
11231291	C4591001 1123 11231291	16-55	23SEP2020	97787	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
11231292	C4591001 1123 11231292	16-55	23SEP2020	97789	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
11231293	C4591001 1123 11231293	16-55	23SEP2020	97791	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
11231294	C4591001 1123 11231294	16-55	23SEP2020	97997	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
11231295	C4591001 1123 11231295	16-55	23SEP2020	98003	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
11231298	C4591001 1123 11231298	16-55	23SEP2020	98004	Placebo	23SEP2020/ Placebo	15OCT2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
11231299	C4591001 1123 11231299	16-55	23SEP2020	98006	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11231300	C4591001 1123 11231300	16-55	24SEP2020	98585	Placebo	24SEP2020/ Placebo	13OCT2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
11231301	C4591001 1123 11231301	16-55	24SEP2020	98586	BNT162b2 (30 µg)				
11231302	C4591001 1123 11231302	16-55	24SEP2020	98588	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
11231303	C4591001 1123 11231303	16-55	24SEP2020	98589	Placebo	24SEP2020/ Placebo	14OCT2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
11231304	C4591001 1123 11231304	16-55	24SEP2020	98838	Placebo	24SEP2020/ Placebo	15OCT2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
11231305	C4591001 1123 11231305	16-55	24SEP2020	98845	Placebo	24SEP2020/ Placebo	15OCT2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
11231306	C4591001 1123 11231306	16-55	24SEP2020	98848	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
11231307	C4591001 1123 11231307	16-55	24SEP2020	98847	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
11231308	C4591001 1123 11231308	16-55	24SEP2020	98888	Placebo	24SEP2020/ Placebo	13OCT2020/ Placebo		
11231309	C4591001 1123 11231309	16-55	24SEP2020	98891	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11231313	C4591001 1123 11231313	16-55	24SEP2020	98894	Placebo	24SEP2020/ Placebo		12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
11231317	C4591001 1123 11231317	16-55	24SEP2020	98896	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
11231320	C4591001 1123 11231320	16-55	24SEP2020	99130	Placebo	24SEP2020/ Placebo	16OCT2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	14JAN2021/ BNT162b2 (30 µg)
11231321	C4591001 1123 11231321	16-55	25SEP2020	99132	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
11231322	C4591001 1123 11231322	16-55	25SEP2020	99134	Placebo	25SEP2020/ Placebo	15OCT2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
11231323	C4591001 1123 11231323	16-55	25SEP2020	99135	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
11231324	C4591001 1123 11231324	16-55	25SEP2020	99869	Placebo	25SEP2020/ Placebo	15OCT2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11231325	C4591001 1123 11231325	16-55	25SEP2020	99870	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
11231326	C4591001 1123 11231326	16-55	25SEP2020	99871	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
11231327	C4591001 1123 11231327	16-55	25SEP2020	99879	Placebo	25SEP2020/ Placebo	14OCT2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11231328	C4591001 1123 11231328	16-55	25SEP2020	100001	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
11231329	C4591001 1123 11231329	16-55	25SEP2020	100004	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
11231330	C4591001 1123 11231330	16-55	25SEP2020	100005	Placebo	25SEP2020/ Placebo	14OCT2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
11231334	C4591001 1123 11231334	16-55	25SEP2020	100012	Placebo	25SEP2020/ Placebo	15OCT2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
11231336	C4591001 1123 11231336	16-55	02OCT2020	103313	BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)		
11231337	C4591001 1123 11231337	16-55	02OCT2020	103314	Placebo	02OCT2020/ Placebo	23OCT2020/ Placebo		
11231338	C4591001 1123 11231338	16-55	06OCT2020	103316	BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
11231339	C4591001 1123 11231339	16-55	06OCT2020	103317	Placebo	06OCT2020/ Placebo	26OCT2020/ Placebo		
11231346	C4591001 1123 11231346	16-55	07OCT2020	104969	Placebo	07OCT2020/ Placebo	27OCT2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
11231350	C4591001 1123 11231350	16-55	08OCT2020	104971	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11231351	C4591001 1123 11231351	16-55	08OCT2020	104978	Placebo	08OCT2020/ Placebo	27OCT2020/ Placebo		
11231352	C4591001 1123 11231352	16-55	08OCT2020	104980	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)		
11231353	C4591001 1123 11231353	16-55	08OCT2020	105583	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)		
11231357	C4591001 1123 11231357	16-55	09OCT2020	105585	Placebo	09OCT2020/ Placebo	29OCT2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
11231358	C4591001 1123 11231358	16-55	09OCT2020	105587	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)		
11231359	C4591001 1123 11231359	16-55	12OCT2020	105588	Placebo	12OCT2020/ Placebo	02NOV2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
11231360	C4591001 1123 11231360	16-55	12OCT2020	106375	Placebo	12OCT2020/ Placebo	02NOV2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
11231361	C4591001 1123 11231361	16-55	12OCT2020	106377	BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
11231362	C4591001 1123 11231362	16-55	12OCT2020	106378	Placebo	12OCT2020/ Placebo	03NOV2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
11231364	C4591001 1123 11231364	16-55	12OCT2020	106384	BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11231365	C4591001 1123 11231365	16-55	12OCT2020	106522	BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		
11231366	C4591001 1123 11231366	16-55	12OCT2020	106523	BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
11231369	C4591001 1123 11231369	16-55	12OCT2020	106526	Placebo	12OCT2020/ Placebo	02NOV2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
11231372	C4591001 1123 11231372	16-55	13OCT2020	106528	Placebo	13OCT2020/ Placebo	02NOV2020/ Placebo		
11231375	C4591001 1123 11231375	16-55	13OCT2020	107058	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		
11231377	C4591001 1123 11231377	16-55	14OCT2020	107060	Placebo	14OCT2020/ Placebo	04NOV2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
11231381	C4591001 1123 11231381	16-55	15OCT2020	107068	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
11231382	C4591001 1123 11231382	16-55	15OCT2020	108486	Placebo	15OCT2020/ Placebo	06NOV2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
11231383	C4591001 1123 11231383	16-55	15OCT2020	108488	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
11231384	C4591001 1123 11231384	16-55	15OCT2020	108487	Placebo	15OCT2020/ Placebo	05NOV2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11231386	C4591001 1123 11231386	16-55	19OCT2020	108491	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)			
11231387	C4591001 1123 11231387	16-55	19OCT2020	110526	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
11231389	C4591001 1123 11231389	16-55	20OCT2020	110531	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		
11231392	C4591001 1123 11231392	16-55	21OCT2020	110533	Placebo	21OCT2020/ Placebo	09NOV2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
11231395	C4591001 1123 11231395	16-55	22OCT2020	110535	Placebo	22OCT2020/ Placebo	10NOV2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
11231397	C4591001 1123 11231397	16-55	22OCT2020	112304	Placebo	22OCT2020/ Placebo	13NOV2020/ Placebo		
11231398	C4591001 1123 11231398	16-55	22OCT2020	112305	Placebo	22OCT2020/ Placebo	10NOV2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
11231399	C4591001 1123 11231399	16-55	23OCT2020	112307	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
11231403	C4591001 1123 11231403	16-55	26OCT2020	112312	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
11231404	C4591001 1123 11231404	16-55	26OCT2020	113645	Placebo	26OCT2020/ Placebo	16NOV2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11231405	C4591001 1123 11231405	16-55	26OCT2020	113647	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
11231407	C4591001 1123 11231407	16-55	28OCT2020	113649	Placebo	28OCT2020/ Placebo	16NOV2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
11231408	C4591001 1123 11231408	16-55	28OCT2020	113656	BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
11231409	C4591001 1123 11231409	16-55	29OCT2020	114716	Placebo	29OCT2020/ Placebo	18NOV2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
11231410	C4591001 1123 11231410	16-55	29OCT2020	114718	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)		
11231411	C4591001 1123 11231411	16-55	30OCT2020	114722	BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)	18NOV2020/ BNT162b2 (30 µg)		
11231412	C4591001 1123 11231412	16-55	17NOV2020	114724	Placebo	17NOV2020/ Placebo	09DEC2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
11231413	C4591001 1123 11231413	16-55	18NOV2020	116442	BNT162b2 (30 µg)	18NOV2020/ BNT162b2 (30 µg)	09DEC2020/ BNT162b2 (30 µg)		
11231414	C4591001 1123 11231414	16-55	19NOV2020	116445	BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)	10DEC2020/ BNT162b2 (30 µg)		
11231415	C4591001 1123 11231415	16-55	19NOV2020	116446	Placebo	19NOV2020/ Placebo	10DEC2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11231416	C4591001 1123 11231416	16-55	19NOV2020	116452	Placebo	19NOV2020/ Placebo	10DEC2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
11231417	C4591001 1123 11231417	16-55	23NOV2020	116684	BNT162b2 (30 µg)	23NOV2020/ BNT162b2 (30 µg)	16DEC2020/ BNT162b2 (30 µg)		
11231418	C4591001 1123 11231418	16-55	23NOV2020	116687	Placebo	23NOV2020/ Placebo	14DEC2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
11231419	C4591001 1123 11231419	16-55	24NOV2020	116688	Placebo	24NOV2020/ Placebo	14DEC2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
11231420	C4591001 1123 11231420	16-55	25NOV2020	116692	BNT162b2 (30 µg)	25NOV2020/ BNT162b2 (30 µg)	18DEC2020/ BNT162b2 (30 µg)		
11231421	C4591001 1123 11231421	16-55	30NOV2020	117017	BNT162b2 (30 µg)	30NOV2020/ BNT162b2 (30 µg)	22DEC2020/ BNT162b2 (30 µg)		
11231423	C4591001 1123 11231423	16-55	01DEC2020	117018	BNT162b2 (30 µg)	01DEC2020/ BNT162b2 (30 µg)	21DEC2020/ BNT162b2 (30 µg)		
11231426	C4591001 1123 11231426	16-55	03DEC2020	117024	Placebo	03DEC2020/ Placebo	23DEC2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
11231427	C4591001 1123 11231427	16-55	03DEC2020	117028	Placebo	03DEC2020/ Placebo	23DEC2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	
11231429	C4591001 1123 11231429	16-55	03DEC2020	117450	BNT162b2 (30 µg)	03DEC2020/ BNT162b2 (30 µg)	22DEC2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11231430	C4591001 1123 11231430	16-55	03DEC2020	117451	Placebo	03DEC2020/ Placebo	22DEC2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
11231433	C4591001 1123 11231433	16-55	07DEC2020	117455	Placebo	07DEC2020/ Placebo	28DEC2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
11231435	C4591001 1123 11231435	16-55	07DEC2020	117459	BNT162b2 (30 µg)	07DEC2020/ BNT162b2 (30 µg)	30DEC2020/ BNT162b2 (30 µg)		
11231436	C4591001 1123 11231436	16-55	07DEC2020	117665	BNT162b2 (30 µg)	07DEC2020/ BNT162b2 (30 µg)	30DEC2020/ BNT162b2 (30 µg)		
11231437	C4591001 1123 11231437	16-55	08DEC2020	117669	BNT162b2 (30 µg)	08DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)		
11231464	C4591001 1123 11231464	16-55	18DEC2020	117672	Placebo	18DEC2020/ Placebo	07JAN2021/ Placebo	18FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
11231471	C4591001 1123 11231471	16-55	21DEC2020	117673	Placebo	21DEC2020/ Placebo	12JAN2021/ Placebo	16FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
11231480	C4591001 1123 11231480	16-55	21DEC2020	117943	BNT162b2 (30 µg)	21DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)		
11231490	C4591001 1123 11231490	16-55	22DEC2020	117945	BNT162b2 (30 µg)	22DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)		
11231498	C4591001 1123 11231498	16-55	23DEC2020	117950	Placebo	23DEC2020/ Placebo	20JAN2021/ Placebo	26FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11241041	C4591001 1124 11241041	16-55	17AUG2020	52243	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo		
11241042	C4591001 1124 11241042	16-55	17AUG2020	52246	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
11241043	C4591001 1124 11241043	16-55	17AUG2020	52248	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11241047	C4591001 1124 11241047	16-55	17AUG2020	52251	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
11241049	C4591001 1124 11241049	16-55	17AUG2020	53046	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)			
11241050	C4591001 1124 11241050	16-55	17AUG2020	53051	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
11241052	C4591001 1124 11241052	16-55	18AUG2020	53054	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo		
11241053	C4591001 1124 11241053	16-55	18AUG2020	53055	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11241054	C4591001 1124 11241054	16-55	18AUG2020	54005	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
11241055	C4591001 1124 11241055	16-55	18AUG2020	54009	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11241057	C4591001 1124 11241057	16-55	18AUG2020	54010	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
11241058	C4591001 1124 11241058	16-55	18AUG2020	54016	Placebo	18AUG2020/ Placebo	10SEP2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
11241059	C4591001 1124 11241059	16-55	18AUG2020	54893	Placebo	18AUG2020/ Placebo	10SEP2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
11241060	C4591001 1124 11241060	16-55	18AUG2020	54894	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
11241061	C4591001 1124 11241061	16-55	19AUG2020	54896	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11241065	C4591001 1124 11241065	16-55	19AUG2020	54902	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11241066	C4591001 1124 11241066	16-55	19AUG2020	57019	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11241067	C4591001 1124 11241067	16-55	19AUG2020	57020	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11241068	C4591001 1124 11241068	16-55	19AUG2020	57028	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	21JAN2021/ BNT162b2 (30 µg)
11241069	C4591001 1124 11241069	16-55	19AUG2020	57021	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	20JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11241071	C4591001 1124 11241071	16-55	19AUG2020	57450	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
11241072	C4591001 1124 11241072	16-55	19AUG2020	57452	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo		
11241075	C4591001 1124 11241075	16-55	20AUG2020	57453	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
11241076	C4591001 1124 11241076	16-55	20AUG2020	58877	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
11241077	C4591001 1124 11241077	16-55	20AUG2020	57459	Placebo	20AUG2020/ Placebo	11SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
11241078	C4591001 1124 11241078	16-55	20AUG2020	58881	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
11241081	C4591001 1124 11241081	16-55	24AUG2020	58887	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
11241083	C4591001 1124 11241083	16-55	24AUG2020	58888	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11241084	C4591001 1124 11241084	16-55	24AUG2020	63665	Placebo	24AUG2020/ Placebo			
11241086	C4591001 1124 11241086	16-55	24AUG2020	63667	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11241087	C4591001 1124 11241087	16-55	24AUG2020	63671	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11241090	C4591001 1124 11241090	16-55	25AUG2020	63675	Placebo	25AUG2020/ Placebo	14SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
11241092	C4591001 1124 11241092	16-55	25AUG2020	65442	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11241093	C4591001 1124 11241093	16-55	25AUG2020	65444	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	15DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
11241094	C4591001 1124 11241094	16-55	25AUG2020	65450	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
11241095	C4591001 1124 11241095	16-55	25AUG2020	65452	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11241096	C4591001 1124 11241096	16-55	25AUG2020	66257	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
11241097	C4591001 1124 11241097	16-55	25AUG2020	66260	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
11241099	C4591001 1124 11241099	16-55	26AUG2020	66267	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11241100	C4591001 1124 11241100	16-55	26AUG2020	67338	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11241102	C4591001 1124 11241102	16-55	26AUG2020	67340	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11241103	C4591001 1124 11241103	16-55	26AUG2020	67347	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo		
11241104	C4591001 1124 11241104	16-55	26AUG2020	67348	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11241105	C4591001 1124 11241105	16-55	26AUG2020	68359	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
11241106	C4591001 1124 11241106	16-55	26AUG2020	68357	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11241108	C4591001 1124 11241108	16-55	26AUG2020	68364	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
11241109	C4591001 1124 11241109	16-55	26AUG2020	68365	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
11241111	C4591001 1124 11241111	16-55	26AUG2020	69163	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	15DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
11241112	C4591001 1124 11241112	16-55	27AUG2020	69168	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11241113	C4591001 1124 11241113	16-55	27AUG2020	69169	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11241118	C4591001 1124 11241118	16-55	27AUG2020	69172	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11241120	C4591001 1124 11241120	16-55	27AUG2020	70821	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo		
11241122	C4591001 1124 11241122	16-55	27AUG2020	70822	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
11241125	C4591001 1124 11241125	16-55	31AUG2020	70824	Placebo	31AUG2020/ Placebo	22SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
11241127	C4591001 1124 11241127	16-55	31AUG2020	70825	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11241129	C4591001 1124 11241129	16-55	31AUG2020	75356	Placebo	31AUG2020/ Placebo	23SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	04JAN2021/ BNT162b2 (30 µg)
11241137	C4591001 1124 11241137	16-55	01SEP2020	75357	Placebo	01SEP2020/ Placebo	24SEP2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
11241141	C4591001 1124 11241141	16-55	01SEP2020	75361	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11241142	C4591001 1124 11241142	16-55	02SEP2020	75364	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11241149	C4591001 1124 11241149	16-55	02SEP2020	78979	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11241152	C4591001 1124 11241152	16-55	02SEP2020	78985	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11241153	C4591001 1124 11241153	16-55	02SEP2020	78986	Placebo	02SEP2020/ Placebo	21SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11241167	C4591001 1124 11241167	16-55	03SEP2020	78988	Placebo	03SEP2020/ Placebo	22SEP2020/ Placebo		
11241168	C4591001 1124 11241168	16-55	03SEP2020	80959	Placebo	03SEP2020/ Placebo	23SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
11241170	C4591001 1124 11241170	16-55	04SEP2020	80962	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
11241174	C4591001 1124 11241174	16-55	04SEP2020	80963	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
11241176	C4591001 1124 11241176	16-55	04SEP2020	80967	Placebo	04SEP2020/ Placebo	23SEP2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
11241178	C4591001 1124 11241178	16-55	08SEP2020	83274	Placebo	08SEP2020/ Placebo	01OCT2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
11241179	C4591001 1124 11241179	16-55	08SEP2020	83277	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11241180	C4591001 1124 11241180	16-55	08SEP2020	83280	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11241183	C4591001 1124 11241183	16-55	08SEP2020	83284	Placebo	08SEP2020/ Placebo	01OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
11241184	C4591001 1124 11241184	16-55	08SEP2020	83957	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
11241185	C4591001 1124 11241185	16-55	08SEP2020	83961	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
11241186	C4591001 1124 11241186	16-55	08SEP2020	83963	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
11241187	C4591001 1124 11241187	16-55	08SEP2020	83964	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
11241188	C4591001 1124 11241188	16-55	09SEP2020	84786	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11241189	C4591001 1124 11241189	16-55	09SEP2020	84787	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
11241190	C4591001 1124 11241190	16-55	09SEP2020	84793	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
11241194	C4591001 1124 11241194	16-55	09SEP2020	84794	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
11241195	C4591001 1124 11241195	16-55	09SEP2020	85435	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11241196	C4591001 1124 11241196	16-55	10SEP2020	86374	Placebo	10SEP2020/ Placebo	30SEP2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
11241197	C4591001 1124 11241197	16-55	09SEP2020	85439	Placebo	09SEP2020/ Placebo	28SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
11241198	C4591001 1124 11241198	16-55	09SEP2020	85440	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
11241199	C4591001 1124 11241199	16-55	10SEP2020	85442	Placebo	10SEP2020/ Placebo	29SEP2020/ Placebo		
11241200	C4591001 1124 11241200	16-55	10SEP2020	86370	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
11241202	C4591001 1124 11241202	16-55	10SEP2020	86373	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
11241207	C4591001 1124 11241207	16-55	10SEP2020	87187	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
11241208	C4591001 1124 11241208	16-55	10SEP2020	86378	Placebo	10SEP2020/ Placebo	02OCT2020/ Placebo		
11241212	C4591001 1124 11241212	16-55	11SEP2020	87189	Placebo	11SEP2020/ Placebo	30SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
11241213	C4591001 1124 11241213	16-55	11SEP2020	87192	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11241214	C4591001 1124 11241214	16-55	11SEP2020	87196	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
11241216	C4591001 1124 11241216	16-55	11SEP2020	87959	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
11241217	C4591001 1124 11241217	16-55	11SEP2020	87958	Placebo	11SEP2020/ Placebo	30SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
11241218	C4591001 1124 11241218	16-55	11SEP2020	87961	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
11241219	C4591001 1124 11241219	16-55	11SEP2020	87963	Placebo	11SEP2020/ Placebo	30SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
11241222	C4591001 1124 11241222	16-55	11SEP2020	88313	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
11241223	C4591001 1124 11241223	16-55	14SEP2020	88314	Placebo	14SEP2020/ Placebo	07OCT2020/ Placebo		
11241224	C4591001 1124 11241224	16-55	14SEP2020	88316	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
11241225	C4591001 1124 11241225	16-55	16SEP2020	88323	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
11241226	C4591001 1124 11241226	16-55	16SEP2020	91270	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11241227	C4591001 1124 11241227	16-55	17SEP2020	91271	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
11241228	C4591001 1124 11241228	16-55	17SEP2020	91274	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo		
11241232	C4591001 1124 11241232	16-55	23SEP2020	91276	Placebo	23SEP2020/ Placebo	13OCT2020/ Placebo	02MAR2021/ BNT162b2 (30 µg)	
11241233	C4591001 1124 11241233	16-55	30SEP2020	98977	Placebo	30SEP2020/ Placebo	20OCT2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
11241234	C4591001 1124 11241234	16-55	24SEP2020	98969	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
11241235	C4591001 1124 11241235	16-55	24SEP2020	98972	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
11251044	C4591001 1125 11251044	16-55	17AUG2020	50737	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11251045	C4591001 1125 11251045	16-55	17AUG2020	50734	Placebo	17AUG2020/ Placebo	09SEP2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
11251049	C4591001 1125 11251049	16-55	17AUG2020	53081	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
11251050	C4591001 1125 11251050	16-55	17AUG2020	50739	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11251051	C4591001 1125 11251051	16-55	17AUG2020	53083	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11251053	C4591001 1125 11251053	16-55	18AUG2020	53087	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
11251058	C4591001 1125 11251058	16-55	18AUG2020	53091	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
11251059	C4591001 1125 11251059	16-55	18AUG2020	55115	Placebo	18AUG2020/ Placebo	10SEP2020/ Placebo		
11251061	C4591001 1125 11251061	16-55	18AUG2020	55116	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	11MAR2021/ BNT162b2 (30 µg)	
11251062	C4591001 1125 11251062	16-55	21AUG2020	55118	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11251067	C4591001 1125 11251067	16-55	21AUG2020	55120	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11251075	C4591001 1125 11251075	16-55	22AUG2020	61774	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11251078	C4591001 1125 11251078	16-55	22AUG2020	61777	Placebo	22AUG2020/ Placebo	14SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
11251080	C4591001 1125 11251080	16-55	22AUG2020	61778	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11251081	C4591001 1125 11251081	16-55	22AUG2020	61780	Placebo	22AUG2020/ Placebo	10SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
11251086	C4591001 1125 11251086	16-55	24AUG2020	64183	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo		
11251087	C4591001 1125 11251087	16-55	24AUG2020	64185	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11251091	C4591001 1125 11251091	16-55	25AUG2020	64186	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11251094	C4591001 1125 11251094	16-55	25AUG2020	64191	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	27FEB2021/ BNT162b2 (30 µg)	
11251095	C4591001 1125 11251095	16-55	25AUG2020	66405	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11251096	C4591001 1125 11251096	16-55	25AUG2020	66406	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
11251097	C4591001 1125 11251097	16-55	25AUG2020	66411	Placebo	25AUG2020/ Placebo	14SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
11251098	C4591001 1125 11251098	16-55	25AUG2020	66412	Placebo	25AUG2020/ Placebo	16SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
11251099	C4591001 1125 11251099	16-55	26AUG2020	67470	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11251101	C4591001 1125 11251101	16-55	26AUG2020	67471	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
11251102	C4591001 1125 11251102	16-55	26AUG2020	67472	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
11251105	C4591001 1125 11251105	16-55	26AUG2020	67474	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
11251106	C4591001 1125 11251106	16-55	26AUG2020	69245	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
11251108	C4591001 1125 11251108	16-55	27AUG2020	69246	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
11251109	C4591001 1125 11251109	16-55	27AUG2020	69249	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
11251112	C4591001 1125 11251112	16-55	27AUG2020	69253	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
11251117	C4591001 1125 11251117	16-55	27AUG2020	71333	Placebo	27AUG2020/ Placebo	16SEP2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
11251119	C4591001 1125 11251119	16-55	28AUG2020	71334	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11251124	C4591001 1125 11251124	16-55	28AUG2020	71338	Placebo	28AUG2020/ Placebo	17SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11251126	C4591001 1125 11251126	16-55	28AUG2020	71341	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11251127	C4591001 1125 11251127	16-55	28AUG2020	72884	Placebo	28AUG2020/ Placebo	17SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
11251128	C4591001 1125 11251128	16-55	31AUG2020	72885	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11251131	C4591001 1125 11251131	16-55	31AUG2020	72887	Placebo	31AUG2020/ Placebo	22SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
11251132	C4591001 1125 11251132	16-55	31AUG2020	72888	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11251134	C4591001 1125 11251134	16-55	31AUG2020	75677	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	27FEB2021/ BNT162b2 (30 µg)	
11251135	C4591001 1125 11251135	16-55	31AUG2020	75680	Placebo	31AUG2020/ Placebo	28SEP2020/ Placebo		
11251136	C4591001 1125 11251136	16-55	31AUG2020	75682	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11251138	C4591001 1125 11251138	16-55	01SEP2020	75683	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
11251139	C4591001 1125 11251139	16-55	01SEP2020	76811	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11251140	C4591001 1125 11251140	16-55	01SEP2020	76812	Placebo	01SEP2020/ Placebo	21SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
11251142	C4591001 1125 11251142	16-55	01SEP2020	76813	Placebo	01SEP2020/ Placebo	24SEP2020/ Placebo		
11251144	C4591001 1125 11251144	16-55	02SEP2020	76816	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11251146	C4591001 1125 11251146	16-55	02SEP2020	78211	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
11251148	C4591001 1125 11251148	16-55	02SEP2020	78213	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)			
11251149	C4591001 1125 11251149	16-55	02SEP2020	78216	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
11251150	C4591001 1125 11251150	16-55	02SEP2020	78220	Placebo	02SEP2020/ Placebo	24SEP2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
11251151	C4591001 1125 11251151	16-55	02SEP2020	79483	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11251152	C4591001 1125 11251152	16-55	02SEP2020	79484	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
11251155	C4591001 1125 11251155	16-55	03SEP2020	79487	Placebo	03SEP2020/ Placebo	22SEP2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11251156	C4591001 1125 11251156	16-55	03SEP2020	80021	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
11251158	C4591001 1125 11251158	16-55	03SEP2020	79488	Placebo	03SEP2020/ Placebo	25SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
11251159	C4591001 1125 11251159	16-55	03SEP2020	80023	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)			
11251160	C4591001 1125 11251160	16-55	03SEP2020	80026	Placebo	03SEP2020/ Placebo			
11251162	C4591001 1125 11251162	16-55	03SEP2020	80032	Placebo	03SEP2020/ Placebo	28SEP2020/ Placebo		
11251166	C4591001 1125 11251166	16-55	04SEP2020	81318	Placebo	04SEP2020/ Placebo	24SEP2020/ Placebo		
11251167	C4591001 1125 11251167	16-55	04SEP2020	81319	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
11251168	C4591001 1125 11251168	16-55	04SEP2020	81320	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
11251169	C4591001 1125 11251169	16-55	04SEP2020	81321	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	13FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
11251170	C4591001 1125 11251170	16-55	04SEP2020	81581	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	22JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11251173	C4591001 1125 11251173	16-55	04SEP2020	81583	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
11251174	C4591001 1125 11251174	16-55	04SEP2020	81585	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11251175	C4591001 1125 11251175	16-55	04SEP2020	81588	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11251176	C4591001 1125 11251176	16-55	04SEP2020	82159	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
11251177	C4591001 1125 11251177	16-55	04SEP2020	82161	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11251178	C4591001 1125 11251178	16-55	04SEP2020	82165	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11251179	C4591001 1125 11251179	16-55	04SEP2020	82166	Placebo	04SEP2020/ Placebo	24SEP2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)
11251180	C4591001 1125 11251180	16-55	04SEP2020	82434	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
11251181	C4591001 1125 11251181	16-55	08SEP2020	82437	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	
11251182	C4591001 1125 11251182	16-55	08SEP2020	82438	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo	27FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11251183	C4591001 1125 11251183	16-55	08SEP2020	82440	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11251184	C4591001 1125 11251184	16-55	08SEP2020	83574	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
11251193	C4591001 1125 11251193	16-55	09SEP2020	83576	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
11251194	C4591001 1125 11251194	16-55	09SEP2020	83582	Placebo	09SEP2020/ Placebo	28SEP2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
11251195	C4591001 1125 11251195	16-55	09SEP2020	83583	Placebo	09SEP2020/ Placebo	29SEP2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11251197	C4591001 1125 11251197	16-55	10SEP2020	86599	Placebo	10SEP2020/ Placebo	02OCT2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	28JAN2021/ BNT162b2 (30 µg)
11251198	C4591001 1125 11251198	16-55	10SEP2020	86600	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11251200	C4591001 1125 11251200	16-55	10SEP2020	86602	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
11251201	C4591001 1125 11251201	16-55	10SEP2020	86607	Placebo	10SEP2020/ Placebo	02OCT2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	
11251202	C4591001 1125 11251202	16-55	10SEP2020	87032	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11251203	C4591001 1125 11251203	16-55	10SEP2020	87038	Placebo	10SEP2020/ Placebo	29SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
11251207	C4591001 1125 11251207	16-55	10SEP2020	87039	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
11251208	C4591001 1125 11251208	16-55	11SEP2020	87040	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
11251212	C4591001 1125 11251212	16-55	11SEP2020	88566	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
11251213	C4591001 1125 11251213	16-55	16SEP2020	88569	Placebo	16SEP2020/ Placebo	08OCT2020/ Placebo		
11251214	C4591001 1125 11251214	16-55	17SEP2020	88572	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
11251215	C4591001 1125 11251215	16-55	22SEP2020	88574	Placebo	22SEP2020/ Placebo	13OCT2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)
11251218	C4591001 1125 11251218	16-55	24SEP2020	98684	Placebo	24SEP2020/ Placebo	15OCT2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
11251219	C4591001 1125 11251219	16-55	24SEP2020	98685	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
11251221	C4591001 1125 11251221	16-55	24SEP2020	98689	Placebo	24SEP2020/ Placebo	16OCT2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11251237	C4591001 1125 11251237	16-55	21OCT2020	98690	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
11251238	C4591001 1125 11251238	16-55	22OCT2020	112414	Placebo	22OCT2020/ Placebo			
11251239	C4591001 1125 11251239	16-55	18NOV2020	112418	Placebo	18NOV2020/ Placebo	09DEC2020/ Placebo		
11251240	C4591001 1125 11251240	16-55	20NOV2020	112419	BNT162b2 (30 µg)	20NOV2020/ BNT162b2 (30 µg)	11DEC2020/ BNT162b2 (30 µg)		
11251243	C4591001 1125 11251243	16-55	08DEC2020	112420	BNT162b2 (30 µg)	08DEC2020/ BNT162b2 (30 µg)			
11251247	C4591001 1125 11251247	16-55	11DEC2020	117872	BNT162b2 (30 µg)	11DEC2020/ BNT162b2 (30 µg)	30DEC2020/ BNT162b2 (30 µg)		
11261028	C4591001 1126 11261028	16-55	14AUG2020	51029	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
11261029	C4591001 1126 11261029	16-55	17AUG2020	51030	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11261030	C4591001 1126 11261030	16-55	17AUG2020	51032	Placebo	17AUG2020/ Placebo	17SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
11261033	C4591001 1126 11261033	16-55	17AUG2020	51035	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11261034	C4591001 1126 11261034	16-55	17AUG2020	53743	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11261035	C4591001 1126 11261035	16-55	18AUG2020	53745	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)
11261037	C4591001 1126 11261037	16-55	18AUG2020	53749	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)
11261039	C4591001 1126 11261039	16-55	18AUG2020	53751	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
11261040	C4591001 1126 11261040	16-55	18AUG2020	55614	Placebo	18AUG2020/ Placebo	10SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
11261041	C4591001 1126 11261041	16-55	19AUG2020	55616	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
11261043	C4591001 1126 11261043	16-55	19AUG2020	55618	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11261044	C4591001 1126 11261044	16-55	19AUG2020	55623	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11261045	C4591001 1126 11261045	16-55	19AUG2020	57618	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
11261046	C4591001 1126 11261046	16-55	19AUG2020	57690	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11261047	C4591001 1126 11261047	16-55	19AUG2020	57695	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
11261048	C4591001 1126 11261048	16-55	20AUG2020	57698	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11261053	C4591001 1126 11261053	16-55	20AUG2020	57700	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11261055	C4591001 1126 11261055	16-55	21AUG2020	60419	Placebo	21AUG2020/ Placebo	10SEP2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
11261056	C4591001 1126 11261056	16-55	21AUG2020	60421	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
11261060	C4591001 1126 11261060	16-55	21AUG2020	60422	Placebo	21AUG2020/ Placebo	10SEP2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
11261061	C4591001 1126 11261061	16-55	21AUG2020	60424	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
11261062	C4591001 1126 11261062	16-55	21AUG2020	61589	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
11261063	C4591001 1126 11261063	16-55	24AUG2020	61594	Placebo	24AUG2020/ Placebo	16SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
11261064	C4591001 1126 11261064	16-55	24AUG2020	61596	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11261068	C4591001 1126 11261068	16-55	24AUG2020	61598	Placebo	24AUG2020/ Placebo	15SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
11261074	C4591001 1126 11261074	16-55	25AUG2020	67065	Placebo				
11261075	C4591001 1126 11261075	16-55	25AUG2020	67063	Placebo	25AUG2020/ Placebo	17SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
11261076	C4591001 1126 11261076	16-55	26AUG2020	67066	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11261078	C4591001 1126 11261078	16-55	26AUG2020	67071	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11261080	C4591001 1126 11261080	16-55	26AUG2020	68981	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo		
11261081	C4591001 1126 11261081	16-55	26AUG2020	68986	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	20JAN2021/ BNT162b2 (30 µg)
11261082	C4591001 1126 11261082	16-55	26AUG2020	68990	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11261083	C4591001 1126 11261083	16-55	26AUG2020	68992	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
11261085	C4591001 1126 11261085	16-55	27AUG2020	70361	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11261086	C4591001 1126 11261086	16-55	27AUG2020	70362	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
11261092	C4591001 1126 11261092	16-55	27AUG2020	70371	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
11261093	C4591001 1126 11261093	16-55	28AUG2020	70372	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
11261099	C4591001 1126 11261099	16-55	28AUG2020	73085	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11261101	C4591001 1126 11261101	16-55	28AUG2020	73207	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11261103	C4591001 1126 11261103	16-55	31AUG2020	73208	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11261104	C4591001 1126 11261104	16-55	31AUG2020	73212	Placebo	31AUG2020/ Placebo	22SEP2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)
11261105	C4591001 1126 11261105	16-55	31AUG2020	73209	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	27JAN2021/ BNT162b2 (30 µg)
11261109	C4591001 1126 11261109	16-55	31AUG2020	76181	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11261111	C4591001 1126 11261111	16-55	01SEP2020	76182	Placebo	01SEP2020/ Placebo	21SEP2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	22JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11261113	C4591001 1126 11261113	16-55	01SEP2020	77108	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	21JAN2021/ BNT162b2 (30 µg)
11261114	C4591001 1126 11261114	16-55	01SEP2020	76185	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
11261115	C4591001 1126 11261115	16-55	01SEP2020	76190	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11261116	C4591001 1126 11261116	16-55	01SEP2020	77112	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
11261121	C4591001 1126 11261121	16-55	02SEP2020	77113	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11261122	C4591001 1126 11261122	16-55	02SEP2020	77116	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11261124	C4591001 1126 11261124	16-55	02SEP2020	79314	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11261126	C4591001 1126 11261126	16-55	03SEP2020	79323	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
11261128	C4591001 1126 11261128	16-55	03SEP2020	79315	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
11261131	C4591001 1126 11261131	16-55	03SEP2020	79320	Placebo	03SEP2020/ Placebo	23SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11261134	C4591001 1126 11261134	16-55	03SEP2020	81174	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11261135	C4591001 1126 11261135	16-55	03SEP2020	81175	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo		
11261141	C4591001 1126 11261141	16-55	04SEP2020	81177	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
11261142	C4591001 1126 11261142	16-55	04SEP2020	81184	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
11261143	C4591001 1126 11261143	16-55	08SEP2020	83609	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	22JAN2021/ BNT162b2 (30 µg)
11261144	C4591001 1126 11261144	16-55	08SEP2020	83610	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
11261145	C4591001 1126 11261145	16-55	08SEP2020	83611	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
11261148	C4591001 1126 11261148	16-55	08SEP2020	83612	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
11261149	C4591001 1126 11261149	16-55	09SEP2020	85302	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	21JAN2021/ BNT162b2 (30 µg)
11261150	C4591001 1126 11261150	16-55	09SEP2020	85307	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11261151	C4591001 1126 11261151	16-55	09SEP2020	85308	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo		
11261157	C4591001 1126 11261157	16-55	09SEP2020	85309	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
11261158	C4591001 1126 11261158	16-55	10SEP2020	86838	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
11261161	C4591001 1126 11261161	16-55	10SEP2020	86841	Placebo	10SEP2020/ Placebo	29SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
11261166	C4591001 1126 11261166	16-55	11SEP2020	86844	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
11261170	C4591001 1126 11261170	16-55	11SEP2020	88640	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	22JAN2021/ BNT162b2 (30 µg)
11261171	C4591001 1126 11261171	16-55	11SEP2020	86847	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
11261172	C4591001 1126 11261172	16-55	11SEP2020	88639	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
11261173	C4591001 1126 11261173	16-55	11SEP2020	88645	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
11261177	C4591001 1126 11261177	16-55	11SEP2020	88646	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11261178	C4591001 1126 11261178	16-55	15SEP2020	90799	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
11261182	C4591001 1126 11261182	16-55	16SEP2020	90800	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
11261183	C4591001 1126 11261183	16-55	16SEP2020	90801	Placebo	16SEP2020/ Placebo	07OCT2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)
11261184	C4591001 1126 11261184	16-55	16SEP2020	90805	Placebo	16SEP2020/ Placebo	07OCT2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	22JAN2021/ BNT162b2 (30 µg)
11261185	C4591001 1126 11261185	16-55	17SEP2020	92561	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
11261186	C4591001 1126 11261186	16-55	17SEP2020	92564	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
11261187	C4591001 1126 11261187	16-55	17SEP2020	92565	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
11261189	C4591001 1126 11261189	16-55	18SEP2020	92570	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
11261190	C4591001 1126 11261190	16-55	18SEP2020	93991	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
11261191	C4591001 1126 11261191	16-55	18SEP2020	93995	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11261192	C4591001 1126 11261192	16-55	18SEP2020	93998	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
11261193	C4591001 1126 11261193	16-55	18SEP2020	93999	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
11261194	C4591001 1126 11261194	16-55	18SEP2020	94402	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
11261195	C4591001 1126 11261195	16-55	18SEP2020	94404	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
11261196	C4591001 1126 11261196	16-55	21SEP2020	94405	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
11261197	C4591001 1126 11261197	16-55	21SEP2020	94407	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
11261198	C4591001 1126 11261198	16-55	21SEP2020	95358	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)
11261199	C4591001 1126 11261199	16-55	21SEP2020	95360	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
11261200	C4591001 1126 11261200	16-55	29OCT2020	95364	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	20NOV2020/ BNT162b2 (30 µg)		
11261201	C4591001 1126 11261201	16-55	30OCT2020	95368	Placebo	30OCT2020/ Placebo	18NOV2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11261202	C4591001 1126 11261202	16-55	30OCT2020	115150	BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)	20NOV2020/ BNT162b2 (30 µg)		
11261203	C4591001 1126 11261203	16-55	02NOV2020	115153	Placebo	02NOV2020/ Placebo	23NOV2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
11261204	C4591001 1126 11261204	16-55	04NOV2020	115154	Placebo	04NOV2020/ Placebo	23NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
11261205	C4591001 1126 11261205	16-55	11NOV2020	115156	BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)	02DEC2020/ BNT162b2 (30 µg)		
11261206	C4591001 1126 11261206	16-55	11NOV2020	116141	Placebo	11NOV2020/ Placebo	02DEC2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
11261207	C4591001 1126 11261207	16-55	13NOV2020	116145	Placebo	13NOV2020/ Placebo	04DEC2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
11261208	C4591001 1126 11261208	16-55	13NOV2020	116147	BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)	04DEC2020/ BNT162b2 (30 µg)		
11261209	C4591001 1126 11261209	16-55	16NOV2020	116152	BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)	07DEC2020/ BNT162b2 (30 µg)		
11261210	C4591001 1126 11261210	16-55	16NOV2020	116324	Placebo	16NOV2020/ Placebo	07DEC2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
11261211	C4591001 1126 11261211	16-55	17NOV2020	116326	Placebo	17NOV2020/ Placebo	09DEC2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11261212	C4591001 1126 11261212	16-55	18NOV2020	116329	BNT162b2 (30 µg)	18NOV2020/ BNT162b2 (30 µg)	08DEC2020/ BNT162b2 (30 µg)		
11261213	C4591001 1126 11261213	16-55	18NOV2020	116331	BNT162b2 (30 µg)	18NOV2020/ BNT162b2 (30 µg)	09DEC2020/ BNT162b2 (30 µg)		
11261214	C4591001 1126 11261214	16-55	20NOV2020	116623	Placebo	20NOV2020/ Placebo	10DEC2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
11261215	C4591001 1126 11261215	16-55	20NOV2020	116626	Placebo	20NOV2020/ Placebo	11DEC2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
11261216	C4591001 1126 11261216	16-55	23NOV2020	116629	BNT162b2 (30 µg)	23NOV2020/ BNT162b2 (30 µg)	15DEC2020/ BNT162b2 (30 µg)		
11261217	C4591001 1126 11261217	16-55	23NOV2020	116630	BNT162b2 (30 µg)	23NOV2020/ BNT162b2 (30 µg)	15DEC2020/ BNT162b2 (30 µg)		
11261218	C4591001 1126 11261218	16-55	23NOV2020	116759	Placebo	23NOV2020/ Placebo	16DEC2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
11261219	C4591001 1126 11261219	16-55	24NOV2020	116760	BNT162b2 (30 µg)	24NOV2020/ BNT162b2 (30 µg)	16DEC2020/ BNT162b2 (30 µg)		
11261220	C4591001 1126 11261220	16-55	24NOV2020	116761	Placebo	24NOV2020/ Placebo	16DEC2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
11261221	C4591001 1126 11261221	16-55	24NOV2020	116764	BNT162b2 (30 µg)	24NOV2020/ BNT162b2 (30 µg)	15DEC2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11261222	C4591001 1126 11261222	16-55	24NOV2020	116897	BNT162b2 (30 µg)	24NOV2020/ BNT162b2 (30 µg)	14DEC2020/ BNT162b2 (30 µg)		
11261223	C4591001 1126 11261223	16-55	25NOV2020	116899	Placebo	25NOV2020/ Placebo	18DEC2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
11261224	C4591001 1126 11261224	16-55	25NOV2020	116900	Placebo	25NOV2020/ Placebo	18DEC2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
11261225	C4591001 1126 11261225	16-55	25NOV2020	116907	BNT162b2 (30 µg)	25NOV2020/ BNT162b2 (30 µg)	17DEC2020/ BNT162b2 (30 µg)		
11261226	C4591001 1126 11261226	16-55	25NOV2020	116957	BNT162b2 (30 µg)	25NOV2020/ BNT162b2 (30 µg)	18DEC2020/ BNT162b2 (30 µg)		
11261227	C4591001 1126 11261227	16-55	25NOV2020	116958	Placebo	25NOV2020/ Placebo	18DEC2020/ Placebo	03MAR2021/ BNT162b2 (30 µg)	
11261228	C4591001 1126 11261228	16-55	25NOV2020	116963	Placebo	25NOV2020/ Placebo	16DEC2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
11261231	C4591001 1126 11261231	16-55	30NOV2020	116968	BNT162b2 (30 µg)	30NOV2020/ BNT162b2 (30 µg)	21DEC2020/ BNT162b2 (30 µg)		
11261232	C4591001 1126 11261232	16-55	01DEC2020	117118	BNT162b2 (30 µg)	01DEC2020/ BNT162b2 (30 µg)	22DEC2020/ BNT162b2 (30 µg)		
11261234	C4591001 1126 11261234	16-55	01DEC2020	117119	BNT162b2 (30 µg)	01DEC2020/ BNT162b2 (30 µg)	21DEC2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11261236	C4591001 1126 11261236	16-55	01DEC2020	117120	Placebo	01DEC2020/ Placebo	21DEC2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
11261237	C4591001 1126 11261237	16-55	01DEC2020	117122	Placebo	01DEC2020/ Placebo	22DEC2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
11261238	C4591001 1126 11261238	16-55	02DEC2020	117211	Placebo	02DEC2020/ Placebo	21DEC2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
11261242	C4591001 1126 11261242	16-55	02DEC2020	117212	BNT162b2 (30 µg)	02DEC2020/ BNT162b2 (30 µg)	21DEC2020/ BNT162b2 (30 µg)		
11261244	C4591001 1126 11261244	16-55	02DEC2020	117216	Placebo	02DEC2020/ Placebo	23DEC2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
11261245	C4591001 1126 11261245	16-55	02DEC2020	117218	BNT162b2 (30 µg)	02DEC2020/ BNT162b2 (30 µg)	23DEC2020/ BNT162b2 (30 µg)		
11261247	C4591001 1126 11261247	16-55	02DEC2020	117283	Placebo	02DEC2020/ Placebo	21DEC2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
11261248	C4591001 1126 11261248	16-55	02DEC2020	117285	Placebo	02DEC2020/ Placebo	21DEC2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
11261252	C4591001 1126 11261252	16-55	03DEC2020	117287	BNT162b2 (30 µg)	03DEC2020/ BNT162b2 (30 µg)	23DEC2020/ BNT162b2 (30 µg)		
11261256	C4591001 1126 11261256	16-55	03DEC2020	117288	BNT162b2 (30 µg)	03DEC2020/ BNT162b2 (30 µg)	22DEC2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11261257	C4591001 1126 11261257	16-55	03DEC2020	117479	BNT162b2 (30 µg)	03DEC2020/ BNT162b2 (30 µg)	22DEC2020/ BNT162b2 (30 µg)		
11261259	C4591001 1126 11261259	16-55	03DEC2020	117481	BNT162b2 (30 µg)	03DEC2020/ BNT162b2 (30 µg)	22DEC2020/ BNT162b2 (30 µg)		
11261260	C4591001 1126 11261260	16-55	04DEC2020	117482	Placebo	04DEC2020/ Placebo	23DEC2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
11261261	C4591001 1126 11261261	16-55	04DEC2020	117484	Placebo	04DEC2020/ Placebo	23DEC2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
11271096	C4591001 1127 11271096	16-55	19AUG2020	46581	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
11271097	C4591001 1127 11271097	16-55	19AUG2020	46585	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11271099	C4591001 1127 11271099	16-55	19AUG2020	46586	Placebo	19AUG2020/ Placebo		03FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
11271101	C4591001 1127 11271101	16-55	20AUG2020	58207	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	27FEB2021/ BNT162b2 (30 µg)
11271102	C4591001 1127 11271102	16-55	20AUG2020	58208	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
11271105	C4591001 1127 11271105	16-55	20AUG2020	58211	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11271106	C4591001 1127 11271106	16-55	20AUG2020	58216	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
11271107	C4591001 1127 11271107	16-55	20AUG2020	58854	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	27FEB2021/ BNT162b2 (30 µg)
11271109	C4591001 1127 11271109	16-55	20AUG2020	58856	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
11271112	C4591001 1127 11271112	16-55	20AUG2020	58862	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
11281116	C4591001 1128 11281116	16-55	14AUG2020	50338	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)
11281123	C4591001 1128 11281123	16-55	17AUG2020	50728	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11281124	C4591001 1128 11281124	16-55	17AUG2020	52809	Placebo	17AUG2020/ Placebo	09SEP2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
11281125	C4591001 1128 11281125	16-55	17AUG2020	50726	Placebo	17AUG2020/ Placebo	09SEP2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
11281126	C4591001 1128 11281126	16-55	17AUG2020	52806	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
11281128	C4591001 1128 11281128	16-55	17AUG2020	52810	Placebo	17AUG2020/ Placebo	09SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11281129	C4591001 1128 11281129	16-55	17AUG2020	52812	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11281132	C4591001 1128 11281132	16-55	17AUG2020	53574	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11281134	C4591001 1128 11281134	16-55	18AUG2020	53575	Placebo	18AUG2020/ Placebo	10SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
11281135	C4591001 1128 11281135	16-55	18AUG2020	53577	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11281137	C4591001 1128 11281137	16-55	18AUG2020	53581	Placebo	18AUG2020/ Placebo	10SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
11281143	C4591001 1128 11281143	16-55	18AUG2020	55327	Placebo	18AUG2020/ Placebo	10SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
11281145	C4591001 1128 11281145	16-55	18AUG2020	55328	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11281146	C4591001 1128 11281146	16-55	19AUG2020	55331	Placebo	19AUG2020/ Placebo			
11281147	C4591001 1128 11281147	16-55	19AUG2020	55336	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11281151	C4591001 1128 11281151	16-55	19AUG2020	57607	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11281152	C4591001 1128 11281152	16-55	19AUG2020	57611	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)
11281153	C4591001 1128 11281153	16-55	19AUG2020	57612	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
11281154	C4591001 1128 11281154	16-55	20AUG2020	57613	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11281155	C4591001 1128 11281155	16-55	20AUG2020	58829	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11281156	C4591001 1128 11281156	16-55	20AUG2020	58837	Placebo	20AUG2020/ Placebo	08SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
11281157	C4591001 1128 11281157	16-55	20AUG2020	58836	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
11281159	C4591001 1128 11281159	16-55	20AUG2020	58840	Placebo	20AUG2020/ Placebo	11SEP2020/ Placebo		
11281162	C4591001 1128 11281162	16-55	20AUG2020	59646	Placebo	20AUG2020/ Placebo	08SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
11281164	C4591001 1128 11281164	16-55	20AUG2020	59655	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
11281165	C4591001 1128 11281165	16-55	24AUG2020	59656	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11281167	C4591001 1128 11281167	16-55	24AUG2020	63870	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11281168	C4591001 1128 11281168	16-55	24AUG2020	63874	Placebo	24AUG2020/ Placebo	15SEP2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
11281169	C4591001 1128 11281169	16-55	24AUG2020	63873	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11281170	C4591001 1128 11281170	16-55	24AUG2020	64169	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
11281171	C4591001 1128 11281171	16-55	24AUG2020	63880	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
11281173	C4591001 1128 11281173	16-55	24AUG2020	64180	Placebo	24AUG2020/ Placebo	30SEP2020/ Placebo		
11281174	C4591001 1128 11281174	16-55	24AUG2020	64171	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	20FEB2021/ BNT162b2 (30 µg)
11281175	C4591001 1128 11281175	16-55	24AUG2020	64170	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11281176	C4591001 1128 11281176	16-55	24AUG2020	64738	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11281177	C4591001 1128 11281177	16-55	24AUG2020	64740	Placebo	24AUG2020/ Placebo	29SEP2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11281178	C4591001 1128 11281178	16-55	24AUG2020	64741	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
11281181	C4591001 1128 11281181	16-55	25AUG2020	64743	Placebo	25AUG2020/ Placebo	14SEP2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	28JAN2021/ BNT162b2 (30 µg)
11281183	C4591001 1128 11281183	16-55	25AUG2020	65982	Placebo	25AUG2020/ Placebo	14SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
11281184	C4591001 1128 11281184	16-55	25AUG2020	65985	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11281187	C4591001 1128 11281187	16-55	25AUG2020	65986	Placebo	25AUG2020/ Placebo	17SEP2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
11281188	C4591001 1128 11281188	16-55	25AUG2020	66895	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
11281190	C4591001 1128 11281190	16-55	25AUG2020	65989	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
11281195	C4591001 1128 11281195	16-55	25AUG2020	66900	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11281196	C4591001 1128 11281196	16-55	25AUG2020	66902	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11281197	C4591001 1128 11281197	16-55	25AUG2020	66903	Placebo	25AUG2020/ Placebo	17SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11281198	C4591001 1128 11281198	16-55	26AUG2020	67721	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11281199	C4591001 1128 11281199	16-55	26AUG2020	67722	Placebo	26AUG2020/ Placebo	17SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11281200	C4591001 1128 11281200	16-55	26AUG2020	68213	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11281201	C4591001 1128 11281201	16-55	26AUG2020	67729	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
11281202	C4591001 1128 11281202	16-55	26AUG2020	67723	Placebo	26AUG2020/ Placebo	17SEP2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
11281204	C4591001 1128 11281204	16-55	26AUG2020	68214	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
11281208	C4591001 1128 11281208	16-55	26AUG2020	68220	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
11281209	C4591001 1128 11281209	16-55	27AUG2020	68224	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)
11281210	C4591001 1128 11281210	16-55	27AUG2020	70157	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
11281216	C4591001 1128 11281216	16-55	27AUG2020	70158	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11281217	C4591001 1128 11281217	16-55	27AUG2020	70167	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	20JAN2021/ BNT162b2 (30 µg)
11281218	C4591001 1128 11281218	16-55	27AUG2020	70163	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
11281219	C4591001 1128 11281219	16-55	28AUG2020	72137	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	20JAN2021/ BNT162b2 (30 µg)
11281220	C4591001 1128 11281220	16-55	28AUG2020	72144	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
11281222	C4591001 1128 11281222	16-55	28AUG2020	72141	Placebo	28AUG2020/ Placebo	17SEP2020/ Placebo		
11281224	C4591001 1128 11281224	16-55	28AUG2020	72665	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
11281225	C4591001 1128 11281225	16-55	28AUG2020	72674	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
11281227	C4591001 1128 11281227	16-55	28AUG2020	72675	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo		
11281228	C4591001 1128 11281228	16-55	31AUG2020	72676	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11281230	C4591001 1128 11281230	16-55	31AUG2020	75104	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11281231	C4591001 1128 11281231	16-55	31AUG2020	75101	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11281232	C4591001 1128 11281232	16-55	31AUG2020	75105	Placebo	31AUG2020/ Placebo	22SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
11281235	C4591001 1128 11281235	16-55	31AUG2020	75112	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11281239	C4591001 1128 11281239	16-55	31AUG2020	75977	Placebo	31AUG2020/ Placebo	22SEP2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)
11281240	C4591001 1128 11281240	16-55	31AUG2020	75980	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11281241	C4591001 1128 11281241	16-55	31AUG2020	75978	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo		
11281243	C4591001 1128 11281243	16-55	31AUG2020	75985	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11281244	C4591001 1128 11281244	16-55	01SEP2020	76625	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11281245	C4591001 1128 11281245	16-55	01SEP2020	76628	Placebo	01SEP2020/ Placebo	23SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
11281246	C4591001 1128 11281246	16-55	02SEP2020	78029	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11281247	C4591001 1128 11281247	16-55	01SEP2020	76632	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11281248	C4591001 1128 11281248	16-55	01SEP2020	76636	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
11281249	C4591001 1128 11281249	16-55	01SEP2020	77179	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11281252	C4591001 1128 11281252	16-55	01SEP2020	77457	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11281255	C4591001 1128 11281255	16-55	01SEP2020	77463	Placebo	01SEP2020/ Placebo	21SEP2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
11281257	C4591001 1128 11281257	16-55	01SEP2020	77462	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11281261	C4591001 1128 11281261	16-55	01SEP2020	77464	Placebo	01SEP2020/ Placebo	24SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11281262	C4591001 1128 11281262	16-55	17SEP2020	91725	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
11281263	C4591001 1128 11281263	16-55	02SEP2020	78032	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
11281265	C4591001 1128 11281265	16-55	02SEP2020	78033	Placebo	02SEP2020/ Placebo	24SEP2020/ Placebo		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11281267	C4591001 1128 11281267	16-55	02SEP2020	78035	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
11281268	C4591001 1128 11281268	16-55	02SEP2020	78821	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11281269	C4591001 1128 11281269	16-55	02SEP2020	78827	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo		
11281272	C4591001 1128 11281272	16-55	02SEP2020	78828	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11281274	C4591001 1128 11281274	16-55	03SEP2020	78830	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
11281275	C4591001 1128 11281275	16-55	03SEP2020	80417	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11281276	C4591001 1128 11281276	16-55	03SEP2020	80422	Placebo	03SEP2020/ Placebo	25SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
11281279	C4591001 1128 11281279	16-55	03SEP2020	80424	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11281281	C4591001 1128 11281281	16-55	03SEP2020	80427	Placebo	03SEP2020/ Placebo	23SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
11281282	C4591001 1128 11281282	16-55	03SEP2020	81129	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11281283	C4591001 1128 11281283	16-55	03SEP2020	81125	Placebo	03SEP2020/ Placebo	25SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
11281285	C4591001 1128 11281285	16-55	04SEP2020	81134	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
11281286	C4591001 1128 11281286	16-55	04SEP2020	81131	Placebo	04SEP2020/ Placebo	24SEP2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
11281287	C4591001 1128 11281287	16-55	02OCT2020	103354	Placebo	02OCT2020/ Placebo	23OCT2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)
11281288	C4591001 1128 11281288	16-55	04SEP2020	81978	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
11281289	C4591001 1128 11281289	16-55	04SEP2020	81983	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11281291	C4591001 1128 11281291	16-55	04SEP2020	81986	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
11281292	C4591001 1128 11281292	16-55	04SEP2020	81987	Placebo	04SEP2020/ Placebo	23SEP2020/ Placebo		
11281294	C4591001 1128 11281294	16-55	08SEP2020	83695	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	03OCT2020/ BNT162b2 (30 µg)		
11281297	C4591001 1128 11281297	16-55	08SEP2020	83697	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11281299	C4591001 1128 11281299	16-55	08SEP2020	83701	Placebo	08SEP2020/ Placebo	07OCT2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
11281300	C4591001 1128 11281300	16-55	08SEP2020	83703	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
11281301	C4591001 1128 11281301	16-55	08SEP2020	84490	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
11281302	C4591001 1128 11281302	16-55	08SEP2020	84492	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
11281304	C4591001 1128 11281304	16-55	08SEP2020	84493	Placebo	08SEP2020/ Placebo	02OCT2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
11281305	C4591001 1128 11281305	16-55	08SEP2020	84496	Placebo	08SEP2020/ Placebo	06OCT2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11281306	C4591001 1128 11281306	16-55	09SEP2020	85265	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
11281309	C4591001 1128 11281309	16-55	09SEP2020	85268	Placebo	09SEP2020/ Placebo	29SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	06MAR2021/ BNT162b2 (30 µg)
11281311	C4591001 1128 11281311	16-55	09SEP2020	85269	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
11281312	C4591001 1128 11281312	16-55	09SEP2020	85273	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11281317	C4591001 1128 11281317	16-55	11SEP2020	87685	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
11281319	C4591001 1128 11281319	16-55	09SEP2020	86213	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
11281323	C4591001 1128 11281323	16-55	10SEP2020	86217	Placebo	10SEP2020/ Placebo	30SEP2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	20JAN2021/ BNT162b2 (30 µg)
11281324	C4591001 1128 11281324	16-55	10SEP2020	86220	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
11281326	C4591001 1128 11281326	16-55	10SEP2020	87682	Placebo	10SEP2020/ Placebo	30SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
11281327	C4591001 1128 11281327	16-55	10SEP2020	86221	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	03OCT2020/ BNT162b2 (30 µg)		
11281328	C4591001 1128 11281328	16-55	10SEP2020	87677	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11281331	C4591001 1128 11281331	16-55	11SEP2020	88386	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)
11281332	C4591001 1128 11281332	16-55	11SEP2020	87686	Placebo	11SEP2020/ Placebo	03OCT2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	28JAN2021/ BNT162b2 (30 µg)
11281334	C4591001 1128 11281334	16-55	11SEP2020	88390	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	03OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11281337	C4591001 1128 11281337	16-55	11SEP2020	88391	Placebo	11SEP2020/ Placebo	30SEP2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
11281338	C4591001 1128 11281338	16-55	11SEP2020	88881	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo		
11281339	C4591001 1128 11281339	16-55	11SEP2020	88394	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
11281341	C4591001 1128 11281341	16-55	11SEP2020	88882	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
11281342	C4591001 1128 11281342	16-55	11SEP2020	88883	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	03OCT2020/ BNT162b2 (30 µg)		
11281343	C4591001 1128 11281343	16-55	12SEP2020	89129	BNT162b2 (30 µg)	12SEP2020/ BNT162b2 (30 µg)	03OCT2020/ BNT162b2 (30 µg)		
11281345	C4591001 1128 11281345	16-55	12SEP2020	88886	BNT162b2 (30 µg)	12SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
11281347	C4591001 1128 11281347	16-55	12SEP2020	89130	Placebo	12SEP2020/ Placebo	03OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
11281352	C4591001 1128 11281352	16-55	12SEP2020	89131	BNT162b2 (30 µg)	12SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
11281355	C4591001 1128 11281355	16-55	14SEP2020	89139	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11281357	C4591001 1128 11281357	16-55	15SEP2020	90282	Placebo	15SEP2020/ Placebo	06OCT2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11281358	C4591001 1128 11281358	16-55	15SEP2020	90288	Placebo	15SEP2020/ Placebo	07OCT2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)
11281359	C4591001 1128 11281359	16-55	15SEP2020	90289	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
11281363	C4591001 1128 11281363	16-55	15SEP2020	90716	Placebo	15SEP2020/ Placebo	05OCT2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	28JAN2021/ BNT162b2 (30 µg)
11281364	C4591001 1128 11281364	16-55	15SEP2020	90292	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
11281366	C4591001 1128 11281366	16-55	15SEP2020	90718	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
11281367	C4591001 1128 11281367	16-55	16SEP2020	90721	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
11281368	C4591001 1128 11281368	16-55	16SEP2020	90719	Placebo	16SEP2020/ Placebo			
11281373	C4591001 1128 11281373	16-55	16SEP2020	91722	Placebo	16SEP2020/ Placebo	07OCT2020/ Placebo		
11281384	C4591001 1128 11281384	16-55	23SEP2020	91726	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11281385	C4591001 1128 11281385	16-55	25SEP2020	91730	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
11291048	C4591001 1129 11291048	16-55	04AUG2020	42108	Placebo				
11291106	C4591001 1129 11291106	16-55	17AUG2020	46444	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
11291120	C4591001 1129 11291120	16-55	18AUG2020	53922	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
11291129	C4591001 1129 11291129	16-55	18AUG2020	53927	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11291135	C4591001 1129 11291135	16-55	25AUG2020	53928	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
11291141	C4591001 1129 11291141	16-55	25AUG2020	53931	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
11291142	C4591001 1129 11291142	16-55	25AUG2020	66185	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11291143	C4591001 1129 11291143	16-55	25AUG2020	66191	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
11291145	C4591001 1129 11291145	16-55	25AUG2020	66193	Placebo	25AUG2020/ Placebo	14SEP2020/ Placebo	24DEC2020/ BNT162b2 (30 µg)	14JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11291148	C4591001 1129 11291148	16-55	25AUG2020	66195	Placebo	25AUG2020/ Placebo	18SEP2020/ Placebo		
11291153	C4591001 1129 11291153	16-55	31AUG2020	75893	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11291157	C4591001 1129 11291157	16-55	01SEP2020	75896	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11291163	C4591001 1129 11291163	16-55	01SEP2020	75898	Placebo	01SEP2020/ Placebo	21SEP2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
11291164	C4591001 1129 11291164	16-55	08SEP2020	83261	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo	24DEC2020/ BNT162b2 (30 µg)	14JAN2021/ BNT162b2 (30 µg)
11291165	C4591001 1129 11291165	16-55	08SEP2020	75901	Placebo	08SEP2020/ Placebo	27OCT2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
11291168	C4591001 1129 11291168	16-55	08SEP2020	83263	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11291171	C4591001 1129 11291171	16-55	14SEP2020	83265	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
11291178	C4591001 1129 11291178	16-55	14SEP2020	83271	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
11291181	C4591001 1129 11291181	16-55	14SEP2020	89981	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11291185	C4591001 1129 11291185	16-55	15SEP2020	89987	Placebo	15SEP2020/ Placebo	06OCT2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
11291187	C4591001 1129 11291187	16-55	15SEP2020	89985	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
11291189	C4591001 1129 11291189	16-55	15SEP2020	89992	Placebo	15SEP2020/ Placebo	06OCT2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
11291190	C4591001 1129 11291190	16-55	21SEP2020	94722	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
11291192	C4591001 1129 11291192	16-55	21SEP2020	94723	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11291193	C4591001 1129 11291193	16-55	21SEP2020	94728	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo		
11291196	C4591001 1129 11291196	16-55	22SEP2020	96018	Placebo	22SEP2020/ Placebo	12OCT2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
11291197	C4591001 1129 11291197	16-55	22SEP2020	94730	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
11291201	C4591001 1129 11291201	16-55	22SEP2020	96019	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
11291202	C4591001 1129 11291202	16-55	22SEP2020	96021	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11291209	C4591001 1129 11291209	16-55	29SEP2020	96022	Placebo	29SEP2020/ Placebo	20OCT2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
11291210	C4591001 1129 11291210	16-55	29SEP2020	101874	BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		
11291211	C4591001 1129 11291211	16-55	29SEP2020	266504	Placebo	29SEP2020/ Placebo	20OCT2020/ Placebo	24DEC2020/ BNT162b2 (30 µg)	14JAN2021/ BNT162b2 (30 µg)
11291212	C4591001 1129 11291212	16-55	29SEP2020	101881	BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		
11291213	C4591001 1129 11291213	16-55	05OCT2020	101882	Placebo	05OCT2020/ Placebo	26OCT2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
11291216	C4591001 1129 11291216	16-55	06OCT2020	101884	Placebo	06OCT2020/ Placebo	26OCT2020/ Placebo	24DEC2020/ BNT162b2 (30 µg)	15JAN2021/ BNT162b2 (30 µg)
11291220	C4591001 1129 11291220	16-55	07OCT2020	104777	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
11291223	C4591001 1129 11291223	16-55	12OCT2020	104778	Placebo	12OCT2020/ Placebo	04NOV2020/ Placebo		
11291224	C4591001 1129 11291224	16-55	12OCT2020	104782	Placebo	12OCT2020/ Placebo	03NOV2020/ Placebo	31DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)
11291228	C4591001 1129 11291228	16-55	13OCT2020	104783	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11291229	C4591001 1129 11291229	16-55	13OCT2020	106817	Placebo	13OCT2020/ Placebo	05NOV2020/ Placebo		
11291238	C4591001 1129 11291238	16-55	19OCT2020	106818	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
11291244	C4591001 1129 11291244	16-55	21OCT2020	106820	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
11291245	C4591001 1129 11291245	16-55	24OCT2020	106823	Placebo	24OCT2020/ Placebo	13NOV2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
11291249	C4591001 1129 11291249	16-55	24OCT2020	113263	BNT162b2 (30 µg)	24OCT2020/ BNT162b2 (30 µg)			
11291252	C4591001 1129 11291252	16-55	24OCT2020	113261	BNT162b2 (30 µg)	24OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
11291255	C4591001 1129 11291255	16-55	13NOV2020	113264	Placebo	13NOV2020/ Placebo	04DEC2020/ Placebo		
11291256	C4591001 1129 11291256	16-55	16NOV2020	113271	Placebo	16NOV2020/ Placebo	23DEC2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
11291257	C4591001 1129 11291257	16-55	18NOV2020	116477	Placebo	18NOV2020/ Placebo	09DEC2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
11291258	C4591001 1129 11291258	16-55	30NOV2020	117080	BNT162b2 (30 µg)	30NOV2020/ BNT162b2 (30 µg)	21DEC2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11291260	C4591001 1129 11291260	16-55	20NOV2020	116482	Placebo	20NOV2020/ Placebo	15DEC2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	
11291261	C4591001 1129 11291261	16-55	23NOV2020	116485	BNT162b2 (30 µg)	23NOV2020/ BNT162b2 (30 µg)	14DEC2020/ BNT162b2 (30 µg)		
11291262	C4591001 1129 11291262	16-55	23NOV2020	116487	BNT162b2 (30 µg)	23NOV2020/ BNT162b2 (30 µg)	14DEC2020/ BNT162b2 (30 µg)		
11291263	C4591001 1129 11291263	16-55	03DEC2020	117081	Placebo	03DEC2020/ Placebo	22DEC2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
11291264	C4591001 1129 11291264	16-55	03DEC2020	117082	BNT162b2 (30 µg)	03DEC2020/ BNT162b2 (30 µg)	28DEC2020/ BNT162b2 (30 µg)		
11291265	C4591001 1129 11291265	16-55	03DEC2020	117087	Placebo	03DEC2020/ Placebo	22DEC2020/ Placebo		
11301001	C4591001 1130 11301001	16-55	24AUG2020	64101	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11301002	C4591001 1130 11301002	16-55	24AUG2020	64103	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11301014	C4591001 1130 11301014	16-55	27AUG2020	64105	Placebo	27AUG2020/ Placebo	18SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
11301015	C4591001 1130 11301015	16-55	27AUG2020	64106	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11301021	C4591001 1130 11301021	16-55	31AUG2020	76210	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
11301026	C4591001 1130 11301026	16-55	01SEP2020	76211	Placebo	01SEP2020/ Placebo	24SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
11301028	C4591001 1130 11301028	16-55	02SEP2020	76214	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11301032	C4591001 1130 11301032	16-55	02SEP2020	76216	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11301033	C4591001 1130 11301033	16-55	02SEP2020	79496	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
11301043	C4591001 1130 11301043	16-55	04SEP2020	79498	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11301044	C4591001 1130 11301044	16-55	04SEP2020	79502	Placebo	04SEP2020/ Placebo	23SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
11301045	C4591001 1130 11301045	16-55	04SEP2020	79503	Placebo	04SEP2020/ Placebo	24SEP2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
11301046	C4591001 1130 11301046	16-55	04SEP2020	82460	Placebo	04SEP2020/ Placebo	23SEP2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)
11301047	C4591001 1130 11301047	16-55	04SEP2020	82464	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11301049	C4591001 1130 11301049	16-55	04SEP2020	82465	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11301051	C4591001 1130 11301051	16-55	08SEP2020	82467	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
11301052	C4591001 1130 11301052	16-55	08SEP2020	83993	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
11301054	C4591001 1130 11301054	16-55	08SEP2020	84000	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
11301056	C4591001 1130 11301056	16-55	08SEP2020	84001	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
11301058	C4591001 1130 11301058	16-55	09SEP2020	84004	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)
11301059	C4591001 1130 11301059	16-55	09SEP2020	85603	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
11301063	C4591001 1130 11301063	16-55	10SEP2020	85605	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
11301064	C4591001 1130 11301064	16-55	10SEP2020	85606	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11301068	C4591001 1130 11301068	16-55	11SEP2020	85611	Placebo	11SEP2020/ Placebo	08OCT2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11301069	C4591001 1130 11301069	16-55	14SEP2020	89706	Placebo	14SEP2020/ Placebo	06OCT2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11301072	C4591001 1130 11301072	16-55	16SEP2020	89708	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
11301073	C4591001 1130 11301073	16-55	17SEP2020	89713	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
11301074	C4591001 1130 11301074	16-55	22SEP2020	89715	Placebo	22SEP2020/ Placebo	13OCT2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)
11301075	C4591001 1130 11301075	16-55	22SEP2020	96618	Placebo	22SEP2020/ Placebo	13OCT2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
11301077	C4591001 1130 11301077	16-55	23SEP2020	96622	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
11301078	C4591001 1130 11301078	16-55	23SEP2020	96623	Placebo	23SEP2020/ Placebo	12OCT2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)
11301079	C4591001 1130 11301079	16-55	24SEP2020	96626	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
11301081	C4591001 1130 11301081	16-55	16OCT2020	109109	Placebo	16OCT2020/ Placebo	06NOV2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
11301082	C4591001 1130 11301082	16-55	16OCT2020	109110	Placebo	16OCT2020/ Placebo	04NOV2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11301083	C4591001 1130 11301083	16-55	16OCT2020	109118	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
11301084	C4591001 1130 11301084	16-55	19OCT2020	109120	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	18NOV2020/ BNT162b2 (30 µg)		
11301085	C4591001 1130 11301085	16-55	20OCT2020	110900	Placebo	20OCT2020/ Placebo	10NOV2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)
11301086	C4591001 1130 11301086	16-55	20OCT2020	110901	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
11301087	C4591001 1130 11301087	16-55	20OCT2020	110902	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
11301088	C4591001 1130 11301088	16-55	21OCT2020	110905	Placebo	21OCT2020/ Placebo	11NOV2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
11301089	C4591001 1130 11301089	16-55	21OCT2020	111669	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
11301090	C4591001 1130 11301090	16-55	22OCT2020	111670	Placebo	22OCT2020/ Placebo	12NOV2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
11301091	C4591001 1130 11301091	16-55	26OCT2020	111671	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
11301092	C4591001 1130 11301092	16-55	26OCT2020	111675	Placebo	26OCT2020/ Placebo	16NOV2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11301093	C4591001 1130 11301093	16-55	26OCT2020	113816	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
11301094	C4591001 1130 11301094	16-55	27OCT2020	260487	Placebo	27OCT2020/ Placebo	03DEC2020/ Placebo		
11301097	C4591001 1130 11301097	16-55	27OCT2020	113820	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
11301099	C4591001 1130 11301099	16-55	30OCT2020	113822	Placebo	30OCT2020/ Placebo	18NOV2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
11311015	C4591001 1131 11311015	16-55	14AUG2020	48710	Placebo	14AUG2020/ Placebo	08SEP2020/ Placebo		
11311017	C4591001 1131 11311017	16-55	14AUG2020	50566	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	02MAR2021/ BNT162b2 (30 µg)	
11311018	C4591001 1131 11311018	16-55	14AUG2020	50569	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
11311024	C4591001 1131 11311024	16-55	17AUG2020	52927	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)			
11311026	C4591001 1131 11311026	16-55	17AUG2020	52928	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
11311031	C4591001 1131 11311031	16-55	18AUG2020	52930	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11311032	C4591001 1131 11311032	16-55	18AUG2020	52936	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
11311035	C4591001 1131 11311035	16-55	18AUG2020	54781	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11311038	C4591001 1131 11311038	16-55	18AUG2020	54782	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
11311041	C4591001 1131 11311041	16-55	19AUG2020	54783	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11311042	C4591001 1131 11311042	16-55	19AUG2020	54784	Placebo	19AUG2020/ Placebo	08SEP2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
11311045	C4591001 1131 11311045	16-55	19AUG2020	57198	Placebo	19AUG2020/ Placebo	11SEP2020/ Placebo		
11311046	C4591001 1131 11311046	16-55	19AUG2020	57199	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
11311048	C4591001 1131 11311048	16-55	19AUG2020	57204	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11311049	C4591001 1131 11311049	16-55	19AUG2020	57208	Placebo	19AUG2020/ Placebo	11SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
11311050	C4591001 1131 11311050	16-55	19AUG2020	57642	Placebo	19AUG2020/ Placebo	11SEP2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11311051	C4591001 1131 11311051	16-55	20AUG2020	57646	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
11311053	C4591001 1131 11311053	16-55	20AUG2020	57647	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
11311061	C4591001 1131 11311061	16-55	20AUG2020	57652	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
11311062	C4591001 1131 11311062	16-55	21AUG2020	60174	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
11311064	C4591001 1131 11311064	16-55	21AUG2020	60176	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
11311065	C4591001 1131 11311065	16-55	21AUG2020	60179	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
11311069	C4591001 1131 11311069	16-55	21AUG2020	60184	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
11311071	C4591001 1131 11311071	16-55	21AUG2020	61351	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11311073	C4591001 1131 11311073	16-55	24AUG2020	61353	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	11MAR2021/ BNT162b2 (30 µg)	
11311076	C4591001 1131 11311076	16-55	24AUG2020	61356	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11311078	C4591001 1131 11311078	16-55	24AUG2020	61359	Placebo	24AUG2020/ Placebo	16SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
11311079	C4591001 1131 11311079	16-55	25AUG2020	65502	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo		
11311080	C4591001 1131 11311080	16-55	25AUG2020	65510	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
11311081	C4591001 1131 11311081	16-55	25AUG2020	65508	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
11311083	C4591001 1131 11311083	16-55	25AUG2020	65512	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
11311085	C4591001 1131 11311085	16-55	25AUG2020	66857	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo		
11311086	C4591001 1131 11311086	16-55	27AUG2020	66859	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11311087	C4591001 1131 11311087	16-55	27AUG2020	66862	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11311090	C4591001 1131 11311090	16-55	27AUG2020	66865	Placebo	27AUG2020/ Placebo	18SEP2020/ Placebo		
11311091	C4591001 1131 11311091	16-55	27AUG2020	70493	Placebo	27AUG2020/ Placebo	16SEP2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11311092	C4591001 1131 11311092	16-55	27AUG2020	70494	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11311093	C4591001 1131 11311093	16-55	27AUG2020	70500	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11311094	C4591001 1131 11311094	16-55	27AUG2020	70504	Placebo	27AUG2020/ Placebo	16SEP2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
11311097	C4591001 1131 11311097	16-55	27AUG2020	71382	Placebo	27AUG2020/ Placebo	18SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
11311099	C4591001 1131 11311099	16-55	28AUG2020	71386	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
11311102	C4591001 1131 11311102	16-55	28AUG2020	71388	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11311103	C4591001 1131 11311103	16-55	28AUG2020	71391	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
11311104	C4591001 1131 11311104	16-55	28AUG2020	72821	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
11311106	C4591001 1131 11311106	16-55	28AUG2020	72823	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
11311107	C4591001 1131 11311107	16-55	31AUG2020	72826	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11311109	C4591001 1131 11311109	16-55	31AUG2020	72827	Placebo	31AUG2020/ Placebo	22SEP2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
11311111	C4591001 1131 11311111	16-55	01SEP2020	76448	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	03MAR2021/ BNT162b2 (30 µg)	
11311112	C4591001 1131 11311112	16-55	01SEP2020	76450	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11311113	C4591001 1131 11311113	16-55	01SEP2020	76451	Placebo	01SEP2020/ Placebo	24SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
11311116	C4591001 1131 11311116	16-55	01SEP2020	76456	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11311117	C4591001 1131 11311117	16-55	01SEP2020	77754	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	21JAN2021/ BNT162b2 (30 µg)
11311124	C4591001 1131 11311124	16-55	02SEP2020	77755	Placebo	02SEP2020/ Placebo	25SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
11311129	C4591001 1131 11311129	16-55	03SEP2020	77759	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
11311131	C4591001 1131 11311131	16-55	03SEP2020	77762	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
11311132	C4591001 1131 11311132	16-55	03SEP2020	80986	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11311134	C4591001 1131 11311134	16-55	03SEP2020	80987	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
11311136	C4591001 1131 11311136	16-55	03SEP2020	80990	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11311138	C4591001 1131 11311138	16-55	04SEP2020	80992	Placebo	04SEP2020/ Placebo	24SEP2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
11311142	C4591001 1131 11311142	16-55	04SEP2020	81899	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
11311143	C4591001 1131 11311143	16-55	04SEP2020	81900	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
11311144	C4591001 1131 11311144	16-55	04SEP2020	81901	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
11311147	C4591001 1131 11311147	16-55	08SEP2020	81902	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
11311148	C4591001 1131 11311148	16-55	08SEP2020	84329	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
11311152	C4591001 1131 11311152	16-55	09SEP2020	84330	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
11311153	C4591001 1131 11311153	16-55	09SEP2020	84337	Placebo	09SEP2020/ Placebo	02OCT2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11311157	C4591001 1131 11311157	16-55	09SEP2020	84338	Placebo	09SEP2020/ Placebo	01OCT2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	28JAN2021/ BNT162b2 (30 µg)
11311158	C4591001 1131 11311158	16-55	09SEP2020	85771	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
11311160	C4591001 1131 11311160	16-55	09SEP2020	85772	Placebo	09SEP2020/ Placebo	28SEP2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
11311161	C4591001 1131 11311161	16-55	09SEP2020	85775	Placebo	09SEP2020/ Placebo	01OCT2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
11311162	C4591001 1131 11311162	16-55	10SEP2020	85776	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
11311167	C4591001 1131 11311167	16-55	10SEP2020	87389	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
11311172	C4591001 1131 11311172	16-55	11SEP2020	87390	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
11311173	C4591001 1131 11311173	16-55	11SEP2020	87392	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
11311178	C4591001 1131 11311178	16-55	15SEP2020	87393	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
11311181	C4591001 1131 11311181	16-55	16SEP2020	91435	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11311182	C4591001 1131 11311182	16-55	16SEP2020	91437	Placebo	16SEP2020/ Placebo	06OCT2020/ Placebo	03MAR2021/ BNT162b2 (30 µg)	
11311183	C4591001 1131 11311183	16-55	16SEP2020	91441	Placebo	16SEP2020/ Placebo	08OCT2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11311184	C4591001 1131 11311184	16-55	16SEP2020	91444	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
11311190	C4591001 1131 11311190	16-55	18SEP2020	93343	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
11311193	C4591001 1131 11311193	16-55	18SEP2020	93346	Placebo	18SEP2020/ Placebo			
11311201	C4591001 1131 11311201	16-55	21SEP2020	93349	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
11311205	C4591001 1131 11311205	16-55	22SEP2020	93351	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
11311209	C4591001 1131 11311209	16-55	24SEP2020	98849	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
11311219	C4591001 1131 11311219	16-55	25SEP2020	98855	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
11311220	C4591001 1131 11311220	16-55	25SEP2020	98857	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11311221	C4591001 1131 11311221	16-55	25SEP2020	98860	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
11311228	C4591001 1131 11311228	16-55	30SEP2020	102356	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)		
11311229	C4591001 1131 11311229	16-55	02OCT2020	102357	Placebo	02OCT2020/ Placebo	23OCT2020/ Placebo		
11311230	C4591001 1131 11311230	16-55	06OCT2020	102361	Placebo	06OCT2020/ Placebo	29OCT2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
11311232	C4591001 1131 11311232	16-55	08OCT2020	102362	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)		
11311233	C4591001 1131 11311233	16-55	09OCT2020	106062	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)		
11311241	C4591001 1131 11311241	16-55	12OCT2020	106063	Placebo	12OCT2020/ Placebo	02NOV2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
11311243	C4591001 1131 11311243	16-55	13OCT2020	106064	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
11311246	C4591001 1131 11311246	16-55	19OCT2020	106065	Placebo	19OCT2020/ Placebo	09NOV2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)
11311252	C4591001 1131 11311252	16-55	23OCT2020	113098	Placebo	23OCT2020/ Placebo	12NOV2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11311253	C4591001 1131 11311253	16-55	23OCT2020	113100	Placebo	23OCT2020/ Placebo	11NOV2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11311254	C4591001 1131 11311254	16-55	23OCT2020	113101	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
11311257	C4591001 1131 11311257	16-55	29OCT2020	113104	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)		
11311260	C4591001 1131 11311260	16-55	29OCT2020	114848	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	18NOV2020/ BNT162b2 (30 µg)		
11311263	C4591001 1131 11311263	16-55	13NOV2020	114849	Placebo	13NOV2020/ Placebo	04DEC2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
11311264	C4591001 1131 11311264	16-55	16NOV2020	114851	BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)	08DEC2020/ BNT162b2 (30 µg)		
11311265	C4591001 1131 11311265	16-55	17NOV2020	114855	Placebo	17NOV2020/ Placebo	08DEC2020/ Placebo	02MAR2021/ BNT162b2 (30 µg)	
11311266	C4591001 1131 11311266	16-55	18NOV2020	116470	BNT162b2 (30 µg)	18NOV2020/ BNT162b2 (30 µg)	08DEC2020/ BNT162b2 (30 µg)		
11311267	C4591001 1131 11311267	16-55	23NOV2020	116472	Placebo	23NOV2020/ Placebo	15DEC2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
11311268	C4591001 1131 11311268	16-55	23NOV2020	116476	BNT162b2 (30 µg)	23NOV2020/ BNT162b2 (30 µg)	15DEC2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11311269	C4591001 1131 11311269	16-55	23NOV2020	116474	Placebo	23NOV2020/ Placebo	15DEC2020/ Placebo	03MAR2021/ BNT162b2 (30 µg)	
11311270	C4591001 1131 11311270	16-55	24NOV2020	116790	Placebo	24NOV2020/ Placebo	15DEC2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
11311271	C4591001 1131 11311271	16-55	24NOV2020	116792	Placebo	24NOV2020/ Placebo	15DEC2020/ Placebo		
11311272	C4591001 1131 11311272	16-55	02DEC2020	116794	BNT162b2 (30 µg)	02DEC2020/ BNT162b2 (30 µg)	22DEC2020/ BNT162b2 (30 µg)		
11311273	C4591001 1131 11311273	16-55	02DEC2020	116795	BNT162b2 (30 µg)	02DEC2020/ BNT162b2 (30 µg)	22DEC2020/ BNT162b2 (30 µg)		
11311274	C4591001 1131 11311274	16-55	04DEC2020	117498	BNT162b2 (30 µg)	04DEC2020/ BNT162b2 (30 µg)	23DEC2020/ BNT162b2 (30 µg)		
11311276	C4591001 1131 11311276	16-55	04DEC2020	117500	Placebo	04DEC2020/ Placebo	23DEC2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
11311279	C4591001 1131 11311279	16-55	21DEC2020	117502	BNT162b2 (30 µg)	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)		
11331152	C4591001 1133 11331152	16-55	14AUG2020	50178	Placebo	14AUG2020/ Placebo	09SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11331162	C4591001 1133 11331162	16-55	14AUG2020	50182	Placebo				

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11331170	C4591001 1133 11331170	16-55	14AUG2020	50660	Placebo	14AUG2020/ Placebo			
11331180	C4591001 1133 11331180	16-55	14AUG2020	50921	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
11331185	C4591001 1133 11331185	16-55	19AUG2020	50927	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11331186	C4591001 1133 11331186	16-55	19AUG2020	50923	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
11331188	C4591001 1133 11331188	16-55	19AUG2020	50929	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo		
11331193	C4591001 1133 11331193	16-55	19AUG2020	56661	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11331195	C4591001 1133 11331195	16-55	19AUG2020	56663	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
11331198	C4591001 1133 11331198	16-55	19AUG2020	56666	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11331202	C4591001 1133 11331202	16-55	19AUG2020	56667	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11331203	C4591001 1133 11331203	16-55	19AUG2020	56912	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11331206	C4591001 1133 11331206	16-55	19AUG2020	56914	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11331207	C4591001 1133 11331207	16-55	19AUG2020	56917	Placebo	19AUG2020/ Placebo			
11331208	C4591001 1133 11331208	16-55	19AUG2020	56916	Placebo	19AUG2020/ Placebo	18SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11331209	C4591001 1133 11331209	16-55	19AUG2020	57522	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo		
11331210	C4591001 1133 11331210	16-55	19AUG2020	57525	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11331216	C4591001 1133 11331216	16-55	24AUG2020	57530	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
11331226	C4591001 1133 11331226	16-55	24AUG2020	64005	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11331228	C4591001 1133 11331228	16-55	24AUG2020	64010	Placebo	24AUG2020/ Placebo	21SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
11331230	C4591001 1133 11331230	16-55	24AUG2020	64009	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11331236	C4591001 1133 11331236	16-55	26AUG2020	64011	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11331240	C4591001 1133 11331240	16-55	26AUG2020	67577	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
11331246	C4591001 1133 11331246	16-55	26AUG2020	67583	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11331248	C4591001 1133 11331248	16-55	26AUG2020	67578	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11331252	C4591001 1133 11331252	16-55	26AUG2020	67579	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11331255	C4591001 1133 11331255	16-55	26AUG2020	67970	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11331256	C4591001 1133 11331256	16-55	26AUG2020	67962	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo		
11331257	C4591001 1133 11331257	16-55	26AUG2020	67966	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
11331258	C4591001 1133 11331258	16-55	26AUG2020	68117	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11331259	C4591001 1133 11331259	16-55	26AUG2020	67969	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11331263	C4591001 1133 11331263	16-55	26AUG2020	68125	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11331264	C4591001 1133 11331264	16-55	26AUG2020	68126	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11331265	C4591001 1133 11331265	16-55	26AUG2020	68128	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
11331266	C4591001 1133 11331266	16-55	26AUG2020	68589	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
11331267	C4591001 1133 11331267	16-55	26AUG2020	68590	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
11331272	C4591001 1133 11331272	16-55	27AUG2020	68596	Placebo	27AUG2020/ Placebo	18SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11331273	C4591001 1133 11331273	16-55	27AUG2020	69787	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
11331274	C4591001 1133 11331274	16-55	27AUG2020	68594	Placebo	27AUG2020/ Placebo	18SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11331275	C4591001 1133 11331275	16-55	27AUG2020	69788	Placebo	27AUG2020/ Placebo	23SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11331276	C4591001 1133 11331276	16-55	27AUG2020	69795	Placebo	27AUG2020/ Placebo	21SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11331278	C4591001 1133 11331278	16-55	27AUG2020	69796	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11331282	C4591001 1133 11331282	16-55	27AUG2020	70315	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
11331283	C4591001 1133 11331283	16-55	27AUG2020	70313	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
11331291	C4591001 1133 11331291	16-55	27AUG2020	70554	Placebo	27AUG2020/ Placebo			
11331292	C4591001 1133 11331292	16-55	27AUG2020	70561	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
11331293	C4591001 1133 11331293	16-55	27AUG2020	70322	Placebo	27AUG2020/ Placebo	18SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
11331294	C4591001 1133 11331294	16-55	27AUG2020	70323	Placebo	27AUG2020/ Placebo	18SEP2020/ Placebo		
11331295	C4591001 1133 11331295	16-55	27AUG2020	70558	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)			
11331296	C4591001 1133 11331296	16-55	27AUG2020	70564	Placebo	27AUG2020/ Placebo	18SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11331301	C4591001 1133 11331301	16-55	27AUG2020	70857	Placebo	27AUG2020/ Placebo	23SEP2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
11331303	C4591001 1133 11331303	16-55	01OCT2020	99918	BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11331307	C4591001 1133 11331307	16-55	28AUG2020	244327	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
11331308	C4591001 1133 11331308	16-55	28AUG2020	70858	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11331313	C4591001 1133 11331313	16-55	28AUG2020	70861	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11331316	C4591001 1133 11331316	16-55	28AUG2020	72320	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
11331317	C4591001 1133 11331317	16-55	28AUG2020	70859	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11331320	C4591001 1133 11331320	16-55	28AUG2020	72323	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
11331321	C4591001 1133 11331321	16-55	28AUG2020	72327	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
11331322	C4591001 1133 11331322	16-55	28AUG2020	72449	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
11331324	C4591001 1133 11331324	16-55	28AUG2020	72451	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
11331328	C4591001 1133 11331328	16-55	29AUG2020	72455	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11331329	C4591001 1133 11331329	16-55	29AUG2020	72458	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11331332	C4591001 1133 11331332	16-55	29AUG2020	73447	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11331333	C4591001 1133 11331333	16-55	29AUG2020	73450	Placebo	29AUG2020/ Placebo	23SEP2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
11331334	C4591001 1133 11331334	16-55	29AUG2020	73452	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11331335	C4591001 1133 11331335	16-55	29AUG2020	73453	Placebo	29AUG2020/ Placebo	23SEP2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
11331336	C4591001 1133 11331336	16-55	29AUG2020	73685	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11331337	C4591001 1133 11331337	16-55	29AUG2020	73689	Placebo	29AUG2020/ Placebo	21SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
11331338	C4591001 1133 11331338	16-55	29AUG2020	73829	Placebo	29AUG2020/ Placebo			
11331340	C4591001 1133 11331340	16-55	29AUG2020	73696	Placebo	29AUG2020/ Placebo	25SEP2020/ Placebo		
11331341	C4591001 1133 11331341	16-55	29AUG2020	73691	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)			

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11331346	C4591001 1133 11331346	16-55	29AUG2020	73831	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		
11331348	C4591001 1133 11331348	16-55	29AUG2020	73834	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11331350	C4591001 1133 11331350	16-55	02SEP2020	73836	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11331351	C4591001 1133 11331351	16-55	02SEP2020	77969	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11331352	C4591001 1133 11331352	16-55	02SEP2020	77970	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11331354	C4591001 1133 11331354	16-55	02SEP2020	77975	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo		
11331355	C4591001 1133 11331355	16-55	02SEP2020	78137	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
11331357	C4591001 1133 11331357	16-55	02SEP2020	77980	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo		
11331360	C4591001 1133 11331360	16-55	02SEP2020	78143	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11331363	C4591001 1133 11331363	16-55	02SEP2020	78138	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11331365	C4591001 1133 11331365	16-55	02SEP2020	78140	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11331367	C4591001 1133 11331367	16-55	02SEP2020	78377	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11331370	C4591001 1133 11331370	16-55	02SEP2020	78379	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
11331374	C4591001 1133 11331374	16-55	02SEP2020	78380	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
11331376	C4591001 1133 11331376	16-55	02SEP2020	78726	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
11331378	C4591001 1133 11331378	16-55	02SEP2020	78727	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo		
11331379	C4591001 1133 11331379	16-55	02SEP2020	78381	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
11331385	C4591001 1133 11331385	16-55	02SEP2020	79078	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11331387	C4591001 1133 11331387	16-55	02SEP2020	78734	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
11331388	C4591001 1133 11331388	16-55	02SEP2020	79077	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11331389	C4591001 1133 11331389	16-55	02SEP2020	79081	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo		
11331393	C4591001 1133 11331393	16-55	02SEP2020	79083	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
11331395	C4591001 1133 11331395	16-55	09SEP2020	84896	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
11331397	C4591001 1133 11331397	16-55	09SEP2020	84898	Placebo	09SEP2020/ Placebo	01OCT2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11331398	C4591001 1133 11331398	16-55	09SEP2020	85062	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
11331401	C4591001 1133 11331401	16-55	09SEP2020	85071	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
11331404	C4591001 1133 11331404	16-55	09SEP2020	84901	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
11331406	C4591001 1133 11331406	16-55	09SEP2020	84900	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
11331408	C4591001 1133 11331408	16-55	09SEP2020	85064	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
11331409	C4591001 1133 11331409	16-55	09SEP2020	85134	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11331410	C4591001 1133 11331410	16-55	09SEP2020	85136	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
11331411	C4591001 1133 11331411	16-55	09SEP2020	85350	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
11331413	C4591001 1133 11331413	16-55	09SEP2020	85143	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11331414	C4591001 1133 11331414	16-55	09SEP2020	85140	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
11331418	C4591001 1133 11331418	16-55	09SEP2020	85352	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo		
11331419	C4591001 1133 11331419	16-55	09SEP2020	85357	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
11331422	C4591001 1133 11331422	16-55	09SEP2020	85358	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
11331423	C4591001 1133 11331423	16-55	09SEP2020	85759	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11331427	C4591001 1133 11331427	16-55	09SEP2020	85765	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
11331428	C4591001 1133 11331428	16-55	09SEP2020	85767	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11331432	C4591001 1133 11331432	16-55	09SEP2020	85768	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
11331435	C4591001 1133 11331435	16-55	09SEP2020	85889	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
11331438	C4591001 1133 11331438	16-55	09SEP2020	85899	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo		
11331439	C4591001 1133 11331439	16-55	09SEP2020	85893	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
11331440	C4591001 1133 11331440	16-55	09SEP2020	85900	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11331441	C4591001 1133 11331441	16-55	09SEP2020	86117	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo		
11331448	C4591001 1133 11331448	16-55	16SEP2020	86118	Placebo	16SEP2020/ Placebo	07OCT2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11331450	C4591001 1133 11331450	16-55	16SEP2020	86121	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
11331456	C4591001 1133 11331456	16-55	16SEP2020	86126	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
11331460	C4591001 1133 11331460	16-55	18SEP2020	93353	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11331461	C4591001 1133 11331461	16-55	18SEP2020	93354	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
11331462	C4591001 1133 11331462	16-55	18SEP2020	93356	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
11331463	C4591001 1133 11331463	16-55	18SEP2020	93363	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
11331465	C4591001 1133 11331465	16-55	18SEP2020	93738	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
11331467	C4591001 1133 11331467	16-55	18SEP2020	93744	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11331468	C4591001 1133 11331468	16-55	18SEP2020	93740	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
11331473	C4591001 1133 11331473	16-55	18SEP2020	93748	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
11331474	C4591001 1133 11331474	16-55	18SEP2020	94077	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
11331475	C4591001 1133 11331475	16-55	21SEP2020	94081	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
11331476	C4591001 1133 11331476	16-55	21SEP2020	94084	Placebo	21SEP2020/ Placebo	14OCT2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11331478	C4591001 1133 11331478	16-55	21SEP2020	94082	Placebo	21SEP2020/ Placebo	14OCT2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11331479	C4591001 1133 11331479	16-55	21SEP2020	94927	Placebo	21SEP2020/ Placebo	14OCT2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11331480	C4591001 1133 11331480	16-55	21SEP2020	94928	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		
11331483	C4591001 1133 11331483	16-55	21SEP2020	94936	Placebo	21SEP2020/ Placebo	14OCT2020/ Placebo		
11331484	C4591001 1133 11331484	16-55	21SEP2020	95285	Placebo	21SEP2020/ Placebo	14OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	
11331485	C4591001 1133 11331485	16-55	21SEP2020	94930	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
11331489	C4591001 1133 11331489	16-55	21SEP2020	95293	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
11331490	C4591001 1133 11331490	16-55	21SEP2020	95292	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
11331491	C4591001 1133 11331491	16-55	21SEP2020	95294	Placebo	21SEP2020/ Placebo	14OCT2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
11331492	C4591001 1133 11331492	16-55	23SEP2020	97388	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11331495	C4591001 1133 11331495	16-55	23SEP2020	97389	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
11331496	C4591001 1133 11331496†	16-55	23SEP2020	97393	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
11331497	C4591001 1133 11331497	16-55	23SEP2020	97390	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
11331498	C4591001 1133 11331498	16-55	23SEP2020	97745	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
11331499	C4591001 1133 11331499	16-55	23SEP2020	97752	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo		
11331501	C4591001 1133 11331501	16-55	23SEP2020	97751	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
11331502	C4591001 1133 11331502	16-55	23SEP2020	97756	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
11331504	C4591001 1133 11331504	16-55	23SEP2020	98058	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
11331505	C4591001 1133 11331505	16-55	23SEP2020	98063	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
11331506	C4591001 1133 11331506	16-55	23SEP2020	98062	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11331508	C4591001 1133 11331508	16-55	25SEP2020	98068	Placebo	25SEP2020/ Placebo	14OCT2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11331509	C4591001 1133 11331509	16-55	25SEP2020	99461	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)			
11331510	C4591001 1133 11331510	16-55	25SEP2020	99464	Placebo	25SEP2020/ Placebo			
11331511	C4591001 1133 11331511	16-55	25SEP2020	99463	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
11331512	C4591001 1133 11331512	16-55	25SEP2020	99468	Placebo	25SEP2020/ Placebo		12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
11331515	C4591001 1133 11331515	16-55	25SEP2020	99917	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
11331521	C4591001 1133 11331521	16-55	23OCT2020	400487	Placebo	23OCT2020/ Placebo	11NOV2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
11331522	C4591001 1133 11331522	16-55	23OCT2020	400484	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
11331523	C4591001 1133 11331523	16-55	23OCT2020	400489	Placebo	23OCT2020/ Placebo	13NOV2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
11331524	C4591001 1133 11331524	16-55	23OCT2020	400491	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11331525	C4591001 1133 11331525	16-55	23OCT2020	400529	Placebo	23OCT2020/ Placebo	11NOV2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
11331526	C4591001 1133 11331526	16-55	23OCT2020	400532	Placebo	23OCT2020/ Placebo	11NOV2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
11331527	C4591001 1133 11331527	16-55	23OCT2020	400538	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
11331528	C4591001 1133 11331528	16-55	23OCT2020	400539	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
11331529	C4591001 1133 11331529	16-55	23OCT2020	400583	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
11331530	C4591001 1133 11331530	16-55	23OCT2020	400584	Placebo	23OCT2020/ Placebo	11NOV2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11331531	C4591001 1133 11331531	16-55	23OCT2020	400588	Placebo	23OCT2020/ Placebo	11NOV2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11331532	C4591001 1133 11331532	16-55	23OCT2020	400606	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
11331533	C4591001 1133 11331533	16-55	23OCT2020	400657	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
11331534	C4591001 1133 11331534	16-55	23OCT2020	400603	Placebo	23OCT2020/ Placebo	11NOV2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11331535	C4591001 1133 11331535	16-55	23OCT2020	400585	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
11331536	C4591001 1133 11331536	16-55	23OCT2020	400655	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
11331537	C4591001 1133 11331537	16-55	23OCT2020	400610	Placebo	23OCT2020/ Placebo	11NOV2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
11331538	C4591001 1133 11331538	16-55	23OCT2020	400609	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
11331539	C4591001 1133 11331539	16-55	23OCT2020	400654	Placebo	23OCT2020/ Placebo	11NOV2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11331540	C4591001 1133 11331540	16-55	26OCT2020	400658	Placebo	26OCT2020/ Placebo	16NOV2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11331541	C4591001 1133 11331541	16-55	26OCT2020	400784	Placebo	26OCT2020/ Placebo	16NOV2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
11331542	C4591001 1133 11331542	16-55	26OCT2020	400799	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	01DEC2020/ BNT162b2 (30 µg)		
11331543	C4591001 1133 11331543	16-55	26OCT2020	400798	Placebo	26OCT2020/ Placebo	18NOV2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11331544	C4591001 1133 11331544	16-55	26OCT2020	400781	Placebo	26OCT2020/ Placebo	16NOV2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11331545	C4591001 1133 11331545	16-55	26OCT2020	400786	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
11331546	C4591001 1133 11331546	16-55	26OCT2020	400792	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
11331547	C4591001 1133 11331547	16-55	26OCT2020	400800	Placebo	26OCT2020/ Placebo	16NOV2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
11331548	C4591001 1133 11331548	16-55	26OCT2020	400803	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
11331549	C4591001 1133 11331549	16-55	26OCT2020	400832	Placebo	26OCT2020/ Placebo	16NOV2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
11331550	C4591001 1133 11331550	16-55	26OCT2020	400835	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
11331551	C4591001 1133 11331551	16-55	26OCT2020	400830	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	18NOV2020/ BNT162b2 (30 µg)		
11331552	C4591001 1133 11331552	16-55	26OCT2020	400847	Placebo	26OCT2020/ Placebo	16NOV2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
11331553	C4591001 1133 11331553	16-55	26OCT2020	400839	Placebo	26OCT2020/ Placebo	16NOV2020/ Placebo		
11331554	C4591001 1133 11331554	16-55	26OCT2020	400850	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11331555	C4591001 1133 11331555	16-55	26OCT2020	400851	Placebo	26OCT2020/ Placebo	16NOV2020/ Placebo		
11331556	C4591001 1133 11331556	16-55	26OCT2020	400852	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
11331557	C4591001 1133 11331557	16-55	26OCT2020	400892	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
11331558	C4591001 1133 11331558	16-55	26OCT2020	400894	Placebo	26OCT2020/ Placebo	16NOV2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
11331559	C4591001 1133 11331559	16-55	26OCT2020	400897	Placebo	26OCT2020/ Placebo	16NOV2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
11331560	C4591001 1133 11331560	16-55	26OCT2020	400899	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
11331561	C4591001 1133 11331561	16-55	26OCT2020	400978	Placebo	26OCT2020/ Placebo	16NOV2020/ Placebo		
11331562	C4591001 1133 11331562	16-55	26OCT2020	400952	Placebo	26OCT2020/ Placebo		05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
11331563	C4591001 1133 11331563	16-55	26OCT2020	400949	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
11331564	C4591001 1133 11331564	16-55	26OCT2020	400951	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11331565	C4591001 1133 11331565	16-55	26OCT2020	400983	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
11331566	C4591001 1133 11331566	16-55	26OCT2020	400989	Placebo	26OCT2020/ Placebo	17NOV2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
11331567	C4591001 1133 11331567	16-55	26OCT2020	400984	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
11331568	C4591001 1133 11331568	16-55	26OCT2020	400960	Placebo	26OCT2020/ Placebo			
11331569	C4591001 1133 11331569	16-55	26OCT2020	400974	Placebo	26OCT2020/ Placebo	16NOV2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11331570	C4591001 1133 11331570	16-55	26OCT2020	400990	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
11331571	C4591001 1133 11331571	16-55	26OCT2020	401012	Placebo	26OCT2020/ Placebo	16NOV2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11331572	C4591001 1133 11331572	16-55	26OCT2020	400995	Placebo	26OCT2020/ Placebo	16NOV2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11331573	C4591001 1133 11331573	16-55	26OCT2020	400993	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
11331574	C4591001 1133 11331574	16-55	26OCT2020	401014	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11331575	C4591001 1133 11331575	16-55	29OCT2020	401015	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)		
11331577	C4591001 1133 11331577	16-55	29OCT2020	401243	Placebo	29OCT2020/ Placebo	19NOV2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
11331578	C4591001 1133 11331578	16-55	29OCT2020	401242	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	18NOV2020/ BNT162b2 (30 µg)		
11331579	C4591001 1133 11331579	16-55	29OCT2020	401020	Placebo	29OCT2020/ Placebo	19NOV2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
11331580	C4591001 1133 11331580	16-55	29OCT2020	401237	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)		
11331581	C4591001 1133 11331581	16-55	29OCT2020	401251	Placebo	29OCT2020/ Placebo	19NOV2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
11331582	C4591001 1133 11331582†	16-55	29OCT2020	401252	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)		
11331583	C4591001 1133 11331583	16-55	29OCT2020	401258	Placebo	29OCT2020/ Placebo			
11331584	C4591001 1133 11331584	16-55	29OCT2020	401247	Placebo	29OCT2020/ Placebo	19NOV2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
11331585	C4591001 1133 11331585	16-55	29OCT2020	401259	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11331586	C4591001 1133 11331586	16-55	29OCT2020	401277	Placebo	29OCT2020/ Placebo	19NOV2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
11331587	C4591001 1133 11331587	16-55	29OCT2020	401280	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)		
11331588	C4591001 1133 11331588	16-55	29OCT2020	401282	Placebo	29OCT2020/ Placebo	19NOV2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
11331589	C4591001 1133 11331589	16-55	29OCT2020	401284	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)		
11331590	C4591001 1133 11331590	16-55	29OCT2020	401289	Placebo	29OCT2020/ Placebo	19NOV2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
11331591	C4591001 1133 11331591	16-55	29OCT2020	401305	Placebo	29OCT2020/ Placebo	19NOV2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
11331592	C4591001 1133 11331592	16-55	29OCT2020	401296	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)		
11331593	C4591001 1133 11331593	16-55	29OCT2020	401293	Placebo	29OCT2020/ Placebo	19NOV2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
11331594	C4591001 1133 11331594	16-55	29OCT2020	401291	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)		
11331595	C4591001 1133 11331595	16-55	29OCT2020	401298	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11331596	C4591001 1133 11331596	16-55	29OCT2020	401309	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)		
11331598	C4591001 1133 11331598	16-55	29OCT2020	401307	Placebo	29OCT2020/ Placebo			
11331600	C4591001 1133 11331600	16-55	29OCT2020	401317	Placebo	29OCT2020/ Placebo	19NOV2020/ Placebo	06JAN2021/ BNT162b2 (30 µg)	27JAN2021/ BNT162b2 (30 µg)
11331601	C4591001 1133 11331601	16-55	29OCT2020	401299	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)		
11331602	C4591001 1133 11331602	16-55	29OCT2020	401315	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)		
11331603	C4591001 1133 11331603	16-55	29OCT2020	401318	Placebo	29OCT2020/ Placebo	19NOV2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
11331604	C4591001 1133 11331604	16-55	29OCT2020	401335	Placebo	29OCT2020/ Placebo	19NOV2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
11331605	C4591001 1133 11331605	16-55	29OCT2020	401336	Placebo	29OCT2020/ Placebo	24NOV2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
11331606	C4591001 1133 11331606	16-55	29OCT2020	401339	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)		
11331609	C4591001 1133 11331609	16-55	29OCT2020	401341	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11331610	C4591001 1133 11331610	16-55	29OCT2020	401358	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
11331612	C4591001 1133 11331612	16-55	29OCT2020	401385	Placebo	29OCT2020/ Placebo	19NOV2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
11331613	C4591001 1133 11331613	16-55	29OCT2020	401362	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)		
11331614	C4591001 1133 11331614	16-55	29OCT2020	401382	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)		
11331615	C4591001 1133 11331615	16-55	29OCT2020	401365	Placebo	29OCT2020/ Placebo	19NOV2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
11331616	C4591001 1133 11331616	16-55	29OCT2020	401388	Placebo	29OCT2020/ Placebo	19NOV2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
11331617	C4591001 1133 11331617	16-55	29OCT2020	401364	Placebo	29OCT2020/ Placebo	19NOV2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
11331618	C4591001 1133 11331618†	16-55	29OCT2020	401390	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)		
11331619	C4591001 1133 11331619	16-55	29OCT2020	401407	Placebo	29OCT2020/ Placebo	19NOV2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
11331621	C4591001 1133 11331621	16-55	29OCT2020	401409	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11331622	C4591001 1133 11331622	16-55	29OCT2020	401413	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)		
11331624	C4591001 1133 11331624	16-55	29OCT2020	401416	Placebo	29OCT2020/ Placebo	19NOV2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
11331625	C4591001 1133 11331625	16-55	29OCT2020	401418	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)		
11331626	C4591001 1133 11331626	16-55	29OCT2020	401419	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)		
11331627	C4591001 1133 11331627	16-55	29OCT2020	401428	Placebo	29OCT2020/ Placebo	19NOV2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
11331628	C4591001 1133 11331628	16-55	29OCT2020	401424	Placebo	29OCT2020/ Placebo	19NOV2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
11331629	C4591001 1133 11331629	16-55	29OCT2020	401445	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)		
11331630	C4591001 1133 11331630	16-55	29OCT2020	401441	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)		
11331631	C4591001 1133 11331631	16-55	29OCT2020	401444	Placebo	29OCT2020/ Placebo	19NOV2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
11331632	C4591001 1133 11331632	16-55	29OCT2020	401456	Placebo	29OCT2020/ Placebo	19NOV2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11331633	C4591001 1133 11331633	16-55	29OCT2020	401453	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	01DEC2020/ BNT162b2 (30 µg)		
11331634	C4591001 1133 11331634	16-55	29OCT2020	401451	Placebo	29OCT2020/ Placebo	19NOV2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
11331635	C4591001 1133 11331635	16-55	30OCT2020	401458	Placebo	30OCT2020/ Placebo			
11331636	C4591001 1133 11331636	16-55	30OCT2020	401460	BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)		
11331637	C4591001 1133 11331637	16-55	30OCT2020	401470	Placebo	30OCT2020/ Placebo	19NOV2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
11331638	C4591001 1133 11331638	16-55	30OCT2020	401468	BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)		
11331639	C4591001 1133 11331639	16-55	30OCT2020	401471	BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)		
11331640	C4591001 1133 11331640	16-55	30OCT2020	401483	BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)		
11331641	C4591001 1133 11331641	16-55	30OCT2020	401473	Placebo	30OCT2020/ Placebo	20NOV2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
11331642	C4591001 1133 11331642	16-55	30OCT2020	401482	BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11331643	C4591001 1133 11331643	16-55	30OCT2020	401486	Placebo	30OCT2020/ Placebo	19NOV2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
11331644	C4591001 1133 11331644	16-55	30OCT2020	401477	Placebo	30OCT2020/ Placebo	19NOV2020/ Placebo		
11331645	C4591001 1133 11331645	16-55	30OCT2020	401490	BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)		
11331646	C4591001 1133 11331646	16-55	02NOV2020	401495	Placebo	02NOV2020/ Placebo	24NOV2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
11331647	C4591001 1133 11331647	16-55	02NOV2020	401497	Placebo	02NOV2020/ Placebo	23NOV2020/ Placebo		
11331648	C4591001 1133 11331648	16-55	02NOV2020	401499	BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)	23NOV2020/ BNT162b2 (30 µg)		
11341086	C4591001 1134 11341086	16-55	17AUG2020	49956	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
11341088	C4591001 1134 11341088	16-55	17AUG2020	49960	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11341089	C4591001 1134 11341089	16-55	17AUG2020	52738	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11341093	C4591001 1134 11341093	16-55	18AUG2020	52740	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	22JAN2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11341102	C4591001 1134 11341102	16-55	18AUG2020	52741	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11341104	C4591001 1134 11341104	16-55	19AUG2020	52744	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo	06JAN2021/ BNT162b2 (30 µg)	27JAN2021/ BNT162b2 (30 µg)
11341106	C4591001 1134 11341106	16-55	20AUG2020	56284	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
11341107	C4591001 1134 11341107	16-55	19AUG2020	56280	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11341111	C4591001 1134 11341111	16-55	19AUG2020	56282	Placebo	19AUG2020/ Placebo	08SEP2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
11341112	C4591001 1134 11341112	16-55	19AUG2020	56281	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11341116	C4591001 1134 11341116	16-55	20AUG2020	57992	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
11341117	C4591001 1134 11341117	16-55	20AUG2020	57993	Placebo	20AUG2020/ Placebo	09SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
11341118	C4591001 1134 11341118	16-55	20AUG2020	57997	Placebo	20AUG2020/ Placebo	08SEP2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
11341129	C4591001 1134 11341129	16-55	20AUG2020	58000	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11341134	C4591001 1134 11341134	16-55	21AUG2020	60293	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
11341147	C4591001 1134 11341147	16-55	24AUG2020	60294	Placebo	24AUG2020/ Placebo	15SEP2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
11341149	C4591001 1134 11341149	16-55	24AUG2020	60298	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11341151	C4591001 1134 11341151	16-55	24AUG2020	60301	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
11341153	C4591001 1134 11341153	16-55	24AUG2020	64342	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)			
11341154	C4591001 1134 11341154	16-55	24AUG2020	64339	Placebo	24AUG2020/ Placebo	16SEP2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
11341157	C4591001 1134 11341157	16-55	24AUG2020	64346	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11341169	C4591001 1134 11341169	16-55	25AUG2020	64348	Placebo	25AUG2020/ Placebo	14SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
11341173	C4591001 1134 11341173	16-55	26AUG2020	67446	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
11341174	C4591001 1134 11341174	16-55	26AUG2020	67450	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)			

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11341176	C4591001 1134 11341176	16-55	26AUG2020	67451	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
11341177	C4591001 1134 11341177	16-55	26AUG2020	67455	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
11341180	C4591001 1134 11341180	16-55	26AUG2020	68181	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
11341183	C4591001 1134 11341183	16-55	26AUG2020	68185	Placebo	26AUG2020/ Placebo	15SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
11341184	C4591001 1134 11341184	16-55	26AUG2020	68186	Placebo	26AUG2020/ Placebo	17SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
11341186	C4591001 1134 11341186	16-55	27AUG2020	68188	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
11341188	C4591001 1134 11341188	16-55	27AUG2020	69594	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
11341190	C4591001 1134 11341190	16-55	27AUG2020	69600	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
11341192	C4591001 1134 11341192	16-55	27AUG2020	69602	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11341195	C4591001 1134 11341195	16-55	27AUG2020	69603	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11341203	C4591001 1134 11341203	16-55	27AUG2020	70987	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
11341204	C4591001 1134 11341204	16-55	27AUG2020	70988	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
11341210	C4591001 1134 11341210	16-55	28AUG2020	70994	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
11341211	C4591001 1134 11341211	16-55	28AUG2020	70995	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
11341213	C4591001 1134 11341213	16-55	28AUG2020	72549	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
11341222	C4591001 1134 11341222	16-55	31AUG2020	72550	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
11341224	C4591001 1134 11341224	16-55	31AUG2020	72553	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
11341225	C4591001 1134 11341225	16-55	31AUG2020	72556	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11341226	C4591001 1134 11341226	16-55	31AUG2020	75874	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
11341228	C4591001 1134 11341228	16-55	01SEP2020	75876	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11341230	C4591001 1134 11341230	16-55	01SEP2020	75877	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
11341232	C4591001 1134 11341232	16-55	01SEP2020	75878	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
11341234	C4591001 1134 11341234	16-55	01SEP2020	77489	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11341235	C4591001 1134 11341235	16-55	01SEP2020	77498	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11341236	C4591001 1134 11341236	16-55	01SEP2020	77490	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo		
11341237	C4591001 1134 11341237	16-55	01SEP2020	77492	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
11341241	C4591001 1134 11341241	16-55	02SEP2020	78021	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11341242	C4591001 1134 11341242	16-55	02SEP2020	78024	Placebo	02SEP2020/ Placebo	30SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11341244	C4591001 1134 11341244	16-55	02SEP2020	78025	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11341247	C4591001 1134 11341247	16-55	02SEP2020	78027	Placebo	02SEP2020/ Placebo	24SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11341248	C4591001 1134 11341248	16-55	02SEP2020	79185	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11341249	C4591001 1134 11341249	16-55	02SEP2020	79186	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
11341253	C4591001 1134 11341253	16-55	03SEP2020	79188	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
11341254	C4591001 1134 11341254	16-55	03SEP2020	79189	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
11341259	C4591001 1134 11341259	16-55	03SEP2020	80782	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
11341260	C4591001 1134 11341260	16-55	03SEP2020	80779	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
11341263	C4591001 1134 11341263	16-55	03SEP2020	80784	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
11341268	C4591001 1134 11341268	16-55	04SEP2020	80785	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11341269	C4591001 1134 11341269	16-55	04SEP2020	81692	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
11341276	C4591001 1134 11341276	16-55	04SEP2020	81696	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11341280	C4591001 1134 11341280	16-55	08SEP2020	81697	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
11341281	C4591001 1134 11341281	16-55	08SEP2020	81699	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11341282	C4591001 1134 11341282	16-55	08SEP2020	83376	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
11341283	C4591001 1134 11341283	16-55	08SEP2020	83373	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11341286	C4591001 1134 11341286	16-55	08SEP2020	83378	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
11341290	C4591001 1134 11341290	16-55	08SEP2020	83380	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11341292	C4591001 1134 11341292	16-55	08SEP2020	84078	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11341295	C4591001 1134 11341295	16-55	08SEP2020	84083	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
11341296	C4591001 1134 11341296	16-55	08SEP2020	84084	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
11341299	C4591001 1134 11341299	16-55	09SEP2020	84087	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11341301	C4591001 1134 11341301	16-55	09SEP2020	85482	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
11341303	C4591001 1134 11341303	16-55	09SEP2020	85490	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11341304	C4591001 1134 11341304	16-55	09SEP2020	85484	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo		
11341308	C4591001 1134 11341308	16-55	09SEP2020	85491	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11341313	C4591001 1134 11341313	16-55	10SEP2020	86286	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
11341314	C4591001 1134 11341314	16-55	10SEP2020	86290	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
11341315	C4591001 1134 11341315	16-55	10SEP2020	86291	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
11341317	C4591001 1134 11341317	16-55	10SEP2020	86295	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11341321	C4591001 1134 11341321	16-55	10SEP2020	86933	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
11341322	C4591001 1134 11341322	16-55	10SEP2020	86935	Placebo	10SEP2020/ Placebo	02OCT2020/ Placebo		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11341323	C4591001 1134 11341323	16-55	10SEP2020	86939	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
11341324	C4591001 1134 11341324	16-55	10SEP2020	86942	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
11341325	C4591001 1134 11341325	16-55	11SEP2020	87725	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
11341326	C4591001 1134 11341326	16-55	11SEP2020	87726	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
11341327	C4591001 1134 11341327	16-55	11SEP2020	87727	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
11341328	C4591001 1134 11341328	16-55	11SEP2020	87728	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
11341330	C4591001 1134 11341330	16-55	11SEP2020	87825	Placebo	11SEP2020/ Placebo	01OCT2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
11341332	C4591001 1134 11341332	16-55	11SEP2020	87826	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo		
11341335	C4591001 1134 11341335	16-55	11SEP2020	87830	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
11341336	C4591001 1134 11341336	16-55	11SEP2020	88608	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11341337	C4591001 1134 11341337	16-55	11SEP2020	88603	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
11341338	C4591001 1134 11341338	16-55	11SEP2020	87832	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
11341340	C4591001 1134 11341340	16-55	14SEP2020	88609	Placebo	14SEP2020/ Placebo	07OCT2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
11341344	C4591001 1134 11341344	16-55	14SEP2020	88611	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
11341348	C4591001 1134 11341348	16-55	14SEP2020	89887	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11341351	C4591001 1134 11341351	16-55	15SEP2020	89890	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
11341352	C4591001 1134 11341352	16-55	15SEP2020	89891	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
11341355	C4591001 1134 11341355	16-55	16SEP2020	89896	Placebo	16SEP2020/ Placebo	05OCT2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
11341356	C4591001 1134 11341356	16-55	16SEP2020	91521	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
11341363	C4591001 1134 11341363	16-55	18SEP2020	91522	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11341364	C4591001 1134 11341364	16-55	18SEP2020	91523	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
11341365	C4591001 1134 11341365	16-55	18SEP2020	91525	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
11341370	C4591001 1134 11341370	16-55	25SEP2020	99716	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
11341372	C4591001 1134 11341372	16-55	25SEP2020	99719	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
11341373	C4591001 1134 11341373	16-55	25SEP2020	99721	Placebo	25SEP2020/ Placebo	14OCT2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
11341378	C4591001 1134 11341378	16-55	06OCT2020	99723	BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		
11341379	C4591001 1134 11341379	16-55	06OCT2020	104273	BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
11341381	C4591001 1134 11341381	16-55	07OCT2020	104274	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
11341385	C4591001 1134 11341385	16-55	08OCT2020	104277	Placebo	08OCT2020/ Placebo	29OCT2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11341389	C4591001 1134 11341389	16-55	08OCT2020	104281	Placebo	08OCT2020/ Placebo	28OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11341392	C4591001 1134 11341392	16-55	09OCT2020	105775	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)		
11341393	C4591001 1134 11341393	16-55	09OCT2020	105776	Placebo	09OCT2020/ Placebo	30OCT2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
11341397	C4591001 1134 11341397	16-55	09OCT2020	105779	Placebo	09OCT2020/ Placebo	06NOV2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
11341399	C4591001 1134 11341399	16-55	09OCT2020	105780	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
11341404	C4591001 1134 11341404	16-55	12OCT2020	106557	BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		
11341406	C4591001 1134 11341406	16-55	12OCT2020	106561	Placebo	12OCT2020/ Placebo	02NOV2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
11341407	C4591001 1134 11341407	16-55	12OCT2020	106562	BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		
11341408	C4591001 1134 11341408	16-55	13OCT2020	106564	Placebo	13OCT2020/ Placebo	03NOV2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
11341413	C4591001 1134 11341413	16-55	14OCT2020	107420	BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
11341416	C4591001 1134 11341416	16-55	15OCT2020	107424	Placebo	15OCT2020/ Placebo	05NOV2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11341417	C4591001 1134 11341417	16-55	15OCT2020	107425	Placebo	15OCT2020/ Placebo	05NOV2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
11341420	C4591001 1134 11341420	16-55	15OCT2020	107428	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
11341421	C4591001 1134 11341421	16-55	15OCT2020	108233	Placebo	15OCT2020/ Placebo	11NOV2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
11341424	C4591001 1134 11341424	16-55	15OCT2020	108242	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
11341425	C4591001 1134 11341425	16-55	15OCT2020	108235	Placebo	15OCT2020/ Placebo	06NOV2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
11341426	C4591001 1134 11341426	16-55	15OCT2020	108243	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
11341428	C4591001 1134 11341428	16-55	16OCT2020	108838	Placebo	16OCT2020/ Placebo	06NOV2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
11341433	C4591001 1134 11341433	16-55	19OCT2020	108840	Placebo	19OCT2020/ Placebo	11NOV2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
11341435	C4591001 1134 11341435	16-55	21OCT2020	108841	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
11341436	C4591001 1134 11341436	16-55	21OCT2020	108843	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11341437	C4591001 1134 11341437	16-55	22OCT2020	112481	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
11341438	C4591001 1134 11341438	16-55	28OCT2020	112482	BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
11351129	C4591001 1135 11351129	16-55	14AUG2020	49669	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
11351136	C4591001 1135 11351136	16-55	17AUG2020	50773	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
11351137	C4591001 1135 11351137	16-55	17AUG2020	50776	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11351139	C4591001 1135 11351139	16-55	17AUG2020	53117	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	02MAR2021/ BNT162b2 (30 µg)	
11351142	C4591001 1135 11351142	16-55	17AUG2020	53120	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	02MAR2021/ BNT162b2 (30 µg)	
11351144	C4591001 1135 11351144	16-55	17AUG2020	53124	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
11351145	C4591001 1135 11351145	16-55	17AUG2020	53125	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11351148	C4591001 1135 11351148	16-55	17AUG2020	53669	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11351151	C4591001 1135 11351151	16-55	18AUG2020	53675	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11351152	C4591001 1135 11351152	16-55	18AUG2020	53677	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11351154	C4591001 1135 11351154	16-55	18AUG2020	53679	Placebo	18AUG2020/ Placebo	10SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
11351155	C4591001 1135 11351155	16-55	18AUG2020	55434	Placebo	18AUG2020/ Placebo	10SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
11351156	C4591001 1135 11351156	16-55	19AUG2020	55437	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11351158	C4591001 1135 11351158	16-55	19AUG2020	55440	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11351163	C4591001 1135 11351163	16-55	19AUG2020	55443	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
11351164	C4591001 1135 11351164	16-55	20AUG2020	58663	Placebo	20AUG2020/ Placebo	11SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
11351165	C4591001 1135 11351165	16-55	20AUG2020	58667	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11351166	C4591001 1135 11351166	16-55	20AUG2020	58669	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11351168	C4591001 1135 11351168	16-55	20AUG2020	59381	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
11351169	C4591001 1135 11351169	16-55	20AUG2020	58671	Placebo	20AUG2020/ Placebo	11SEP2020/ Placebo		
11351170	C4591001 1135 11351170	16-55	20AUG2020	59388	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11351171	C4591001 1135 11351171	16-55	20AUG2020	59386	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11351172	C4591001 1135 11351172	16-55	21AUG2020	59390	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
11351173	C4591001 1135 11351173	16-55	21AUG2020	60766	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
11351175	C4591001 1135 11351175	16-55	21AUG2020	60770	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
11351176	C4591001 1135 11351176	16-55	21AUG2020	61373	Placebo	21AUG2020/ Placebo	10SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
11351177	C4591001 1135 11351177	16-55	21AUG2020	60767	Placebo	21AUG2020/ Placebo	10SEP2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
11351178	C4591001 1135 11351178	16-55	21AUG2020	60772	Placebo	21AUG2020/ Placebo	10SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11351179	C4591001 1135 11351179	16-55	21AUG2020	61377	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
11351184	C4591001 1135 11351184	16-55	24AUG2020	238320	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11351190	C4591001 1135 11351190	16-55	24AUG2020	61383	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11351191	C4591001 1135 11351191	16-55	24AUG2020	61379	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11351194	C4591001 1135 11351194	16-55	24AUG2020	64581	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11351195	C4591001 1135 11351195	16-55	24AUG2020	64580	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
11351198	C4591001 1135 11351198	16-55	24AUG2020	64584	Placebo	24AUG2020/ Placebo	16SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
11351199	C4591001 1135 11351199	16-55	24AUG2020	64585	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)			
11351200	C4591001 1135 11351200	16-55	24AUG2020	64974	Placebo	24AUG2020/ Placebo			
11351201	C4591001 1135 11351201	16-55	25AUG2020	64978	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11351203	C4591001 1135 11351203	16-55	25AUG2020	64979	Placebo	25AUG2020/ Placebo	16SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
11351205	C4591001 1135 11351205	16-55	25AUG2020	64980	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
11351206	C4591001 1135 11351206	16-55	25AUG2020	66425	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
11351207	C4591001 1135 11351207	16-55	25AUG2020	66435	Placebo	25AUG2020/ Placebo	14SEP2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
11351208	C4591001 1135 11351208	16-55	25AUG2020	66427	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11351210	C4591001 1135 11351210	16-55	25AUG2020	66436	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
11351211	C4591001 1135 11351211	16-55	25AUG2020	66958	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
11351212	C4591001 1135 11351212	16-55	25AUG2020	66960	Placebo	25AUG2020/ Placebo			
11351213	C4591001 1135 11351213	16-55	25AUG2020	66954	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11351214	C4591001 1135 11351214	16-55	25AUG2020	66963	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11351216	C4591001 1135 11351216	16-55	26AUG2020	68081	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
11351217	C4591001 1135 11351217	16-55	26AUG2020	68087	Placebo	26AUG2020/ Placebo	17SEP2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
11351220	C4591001 1135 11351220	16-55	27AUG2020	68089	Placebo	27AUG2020/ Placebo	16SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11351221	C4591001 1135 11351221	16-55	28AUG2020	68092	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
11351222	C4591001 1135 11351222	16-55	31AUG2020	75177	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11351225	C4591001 1135 11351225	16-55	31AUG2020	75183	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
11351226	C4591001 1135 11351226	16-55	31AUG2020	75178	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
11351227	C4591001 1135 11351227	16-55	31AUG2020	75179	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11351228	C4591001 1135 11351228	16-55	31AUG2020	75630	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11351229	C4591001 1135 11351229	16-55	31AUG2020	75638	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11351230	C4591001 1135 11351230	16-55	31AUG2020	75635	Placebo	31AUG2020/ Placebo	29SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11351231	C4591001 1135 11351231	16-55	31AUG2020	75639	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
11351234	C4591001 1135 11351234	16-55	31AUG2020	76037	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
11351235	C4591001 1135 11351235	16-55	31AUG2020	76038	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11351239	C4591001 1135 11351239	16-55	01SEP2020	76040	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11351241	C4591001 1135 11351241	16-55	01SEP2020	76048	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo		
11351242	C4591001 1135 11351242	16-55	01SEP2020	76819	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11351243	C4591001 1135 11351243	16-55	01SEP2020	76822	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11351244	C4591001 1135 11351244	16-55	01SEP2020	76825	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
11351245	C4591001 1135 11351245	16-55	01SEP2020	76827	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11351247	C4591001 1135 11351247	16-55	01SEP2020	77363	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
11351248	C4591001 1135 11351248	16-55	01SEP2020	77357	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo		
11351250	C4591001 1135 11351250	16-55	01SEP2020	77361	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11351251	C4591001 1135 11351251	16-55	01SEP2020	77358	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11351253	C4591001 1135 11351253	16-55	01SEP2020	77615	Placebo	01SEP2020/ Placebo	23SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
11351256	C4591001 1135 11351256	16-55	01SEP2020	77617	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11351259	C4591001 1135 11351259	16-55	01SEP2020	77619	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11351262	C4591001 1135 11351262	16-55	02SEP2020	78369	Placebo	02SEP2020/ Placebo	25SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11351263	C4591001 1135 11351263	16-55	02SEP2020	77620	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11351264	C4591001 1135 11351264	16-55	02SEP2020	78373	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11351265	C4591001 1135 11351265	16-55	02SEP2020	78372	Placebo	02SEP2020/ Placebo	25SEP2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
11351267	C4591001 1135 11351267	16-55	02SEP2020	78374	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
11351268	C4591001 1135 11351268	16-55	02SEP2020	78678	Placebo	02SEP2020/ Placebo	25SEP2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
11351269	C4591001 1135 11351269	16-55	02SEP2020	78684	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
11351274	C4591001 1135 11351274	16-55	02SEP2020	78685	Placebo	02SEP2020/ Placebo	24SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
11351276	C4591001 1135 11351276	16-55	03SEP2020	78686	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11351279	C4591001 1135 11351279	16-55	03SEP2020	80241	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
11351281	C4591001 1135 11351281	16-55	03SEP2020	80242	Placebo	03SEP2020/ Placebo	25SEP2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
11351282	C4591001 1135 11351282	16-55	03SEP2020	80243	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
11351284	C4591001 1135 11351284	16-55	03SEP2020	80244	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11351285	C4591001 1135 11351285	16-55	03SEP2020	80844	Placebo	03SEP2020/ Placebo	25SEP2020/ Placebo		
11351286	C4591001 1135 11351286	16-55	03SEP2020	80842	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
11351287	C4591001 1135 11351287	16-55	03SEP2020	80848	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
11351288	C4591001 1135 11351288	16-55	03SEP2020	80837	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
11351290	C4591001 1135 11351290	16-55	03SEP2020	81042	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
11351291	C4591001 1135 11351291	16-55	03SEP2020	81044	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
11351292	C4591001 1135 11351292	16-55	03SEP2020	81045	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
11351293	C4591001 1135 11351293	16-55	04SEP2020	81052	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11351294	C4591001 1135 11351294	16-55	04SEP2020	81653	Placebo	04SEP2020/ Placebo	23SEP2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
11351295	C4591001 1135 11351295	16-55	04SEP2020	81654	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11351297	C4591001 1135 11351297	16-55	04SEP2020	81656	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
11351301	C4591001 1135 11351301	16-55	04SEP2020	81658	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo		
11351304	C4591001 1135 11351304	16-55	04SEP2020	82533	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11351307	C4591001 1135 11351307	16-55	15SEP2020	89961	Placebo	15SEP2020/ Placebo	06OCT2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
11351308	C4591001 1135 11351308	16-55	08SEP2020	82537	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11351310	C4591001 1135 11351310	16-55	08SEP2020	82538	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
11351313	C4591001 1135 11351313	16-55	08SEP2020	82539	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11351315	C4591001 1135 11351315	16-55	08SEP2020	84130	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
11351322	C4591001 1135 11351322	16-55	08SEP2020	84131	Placebo	08SEP2020/ Placebo	01OCT2020/ Placebo		
11351323	C4591001 1135 11351323	16-55	08SEP2020	84133	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11351326	C4591001 1135 11351326	16-55	08SEP2020	84136	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
11351327	C4591001 1135 11351327	16-55	08SEP2020	84583	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
11351328	C4591001 1135 11351328	16-55	08SEP2020	84587	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
11351330	C4591001 1135 11351330	16-55	09SEP2020	84589	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
11351331	C4591001 1135 11351331	16-55	09SEP2020	84591	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11351332	C4591001 1135 11351332	16-55	09SEP2020	85398	Placebo	09SEP2020/ Placebo	28SEP2020/ Placebo		
11351334	C4591001 1135 11351334	16-55	09SEP2020	85406	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
11351335	C4591001 1135 11351335	16-55	09SEP2020	85700	Placebo	09SEP2020/ Placebo	29SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
11351336	C4591001 1135 11351336	16-55	09SEP2020	85401	Placebo	09SEP2020/ Placebo	01OCT2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
11351338	C4591001 1135 11351338	16-55	09SEP2020	85408	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11351341	C4591001 1135 11351341	16-55	09SEP2020	85702	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
11351342	C4591001 1135 11351342	16-55	09SEP2020	85706	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
11351343	C4591001 1135 11351343	16-55	09SEP2020	85708	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
11351346	C4591001 1135 11351346	16-55	09SEP2020	86038	Placebo	09SEP2020/ Placebo	29SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
11351347	C4591001 1135 11351347	16-55	09SEP2020	86034	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
11351349	C4591001 1135 11351349	16-55	11SEP2020	86040	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
11351350	C4591001 1135 11351350	16-55	14SEP2020	86042	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo		
11351351	C4591001 1135 11351351	16-55	14SEP2020	89957	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo		
11351355	C4591001 1135 11351355	16-55	15SEP2020	89962	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
11351356	C4591001 1135 11351356	16-55	16SEP2020	89966	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11351359	C4591001 1135 11351359	16-55	17SEP2020	92514	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
11351360	C4591001 1135 11351360	16-55	17SEP2020	92520	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
11351361	C4591001 1135 11351361	16-55	17SEP2020	92523	Placebo	17SEP2020/ Placebo	07OCT2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
11351362	C4591001 1135 11351362	16-55	17SEP2020	92522	Placebo	17SEP2020/ Placebo	06OCT2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
11351363	C4591001 1135 11351363	16-55	17SEP2020	92794	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
11351365	C4591001 1135 11351365	16-55	17SEP2020	92797	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
11351366	C4591001 1135 11351366	16-55	17SEP2020	92799	Placebo	17SEP2020/ Placebo	06OCT2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
11351367	C4591001 1135 11351367	16-55	17SEP2020	92800	Placebo	17SEP2020/ Placebo	07OCT2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
11351368	C4591001 1135 11351368	16-55	18SEP2020	93670	Placebo	18SEP2020/ Placebo	07OCT2020/ Placebo		
11351369	C4591001 1135 11351369	16-55	18SEP2020	93673	Placebo	18SEP2020/ Placebo	08OCT2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11351370	C4591001 1135 11351370	16-55	18SEP2020	93667	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
11351373	C4591001 1135 11351373	16-55	18SEP2020	93676	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
11351374	C4591001 1135 11351374	16-55	18SEP2020	93908	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11351375	C4591001 1135 11351375	16-55	18SEP2020	93909	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
11351376	C4591001 1135 11351376	16-55	18SEP2020	93910	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	10OCT2020/ BNT162b2 (30 µg)		
11351377	C4591001 1135 11351377	16-55	18SEP2020	93911	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
11351378	C4591001 1135 11351378	16-55	18SEP2020	94316	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
11351379	C4591001 1135 11351379	16-55	18SEP2020	94319	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
11351381	C4591001 1135 11351381	16-55	19SEP2020	94324	BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
11351382	C4591001 1135 11351382	16-55	19SEP2020	94320	Placebo	19SEP2020/ Placebo	12OCT2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11351383	C4591001 1135 11351383	16-55	19SEP2020	94502	BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
11351384	C4591001 1135 11351384	16-55	19SEP2020	94498	Placebo	19SEP2020/ Placebo	09OCT2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
11351387	C4591001 1135 11351387	16-55	19SEP2020	94500	Placebo	19SEP2020/ Placebo	08OCT2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
11351389	C4591001 1135 11351389	16-55	19SEP2020	94503	BNT162b2 (30 µg)				
11351391	C4591001 1135 11351391	16-55	19SEP2020	94547	Placebo	19SEP2020/ Placebo	09OCT2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
11351392	C4591001 1135 11351392	16-55	19SEP2020	94541	BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
11351393	C4591001 1135 11351393	16-55	19SEP2020	94544	BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
11351394	C4591001 1135 11351394	16-55	19SEP2020	94550	Placebo	19SEP2020/ Placebo	09OCT2020/ Placebo		
11351399	C4591001 1135 11351399	16-55	21SEP2020	95550	Placebo	21SEP2020/ Placebo	13OCT2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
11351400	C4591001 1135 11351400	16-55	21SEP2020	95552	Placebo	21SEP2020/ Placebo	13OCT2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11351401	C4591001 1135 11351401	16-55	21SEP2020	95556	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
11351403	C4591001 1135 11351403	16-55	21SEP2020	95676	Placebo	21SEP2020/ Placebo	13OCT2020/ Placebo		
11351404	C4591001 1135 11351404	16-55	21SEP2020	95558	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
11351405	C4591001 1135 11351405	16-55	21SEP2020	95677	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
11351408	C4591001 1135 11351408	16-55	22SEP2020	95679	Placebo	22SEP2020/ Placebo	12OCT2020/ Placebo		
11351410	C4591001 1135 11351410	16-55	22SEP2020	95680	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
11351411	C4591001 1135 11351411	16-55	22SEP2020	96800	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
11351412	C4591001 1135 11351412	16-55	22SEP2020	96797	Placebo	22SEP2020/ Placebo	13OCT2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
11351414	C4591001 1135 11351414	16-55	22SEP2020	96801	Placebo	22SEP2020/ Placebo	13OCT2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
11351415	C4591001 1135 11351415	16-55	22SEP2020	96804	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11351416	C4591001 1135 11351416	16-55	22SEP2020	97016	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
11351417	C4591001 1135 11351417	16-55	23SEP2020	97017	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
11351418	C4591001 1135 11351418	16-55	23SEP2020	97018	Placebo	23SEP2020/ Placebo	12OCT2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
11351420	C4591001 1135 11351420	16-55	23SEP2020	97023	Placebo	23SEP2020/ Placebo			
11351421	C4591001 1135 11351421	16-55	23SEP2020	98070	Placebo	23SEP2020/ Placebo	13OCT2020/ Placebo		
11351422	C4591001 1135 11351422	16-55	23SEP2020	98072	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
11351423	C4591001 1135 11351423	16-55	23SEP2020	98071	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
11351425	C4591001 1135 11351425	16-55	23SEP2020	98077	Placebo	23SEP2020/ Placebo	15OCT2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11351428	C4591001 1135 11351428	16-55	23SEP2020	98406	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)			
11351429	C4591001 1135 11351429	16-55	24SEP2020	98408	Placebo	24SEP2020/ Placebo	15OCT2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11351430	C4591001 1135 11351430	16-55	24SEP2020	98409	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)			
11351431	C4591001 1135 11351431	16-55	24SEP2020	98413	Placebo	24SEP2020/ Placebo	13OCT2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
11351432	C4591001 1135 11351432	16-55	24SEP2020	99020	Placebo	24SEP2020/ Placebo	14OCT2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
11351433	C4591001 1135 11351433	16-55	24SEP2020	99021	Placebo	24SEP2020/ Placebo	14OCT2020/ Placebo		
11351434	C4591001 1135 11351434	16-55	24SEP2020	99022	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
11351435	C4591001 1135 11351435	16-55	24SEP2020	99026	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
11351436	C4591001 1135 11351436	16-55	24SEP2020	99149	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
11351437	C4591001 1135 11351437	16-55	25SEP2020	99150	Placebo	25SEP2020/ Placebo	15OCT2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11351438	C4591001 1135 11351438	16-55	25SEP2020	99155	Placebo	25SEP2020/ Placebo	14OCT2020/ Placebo		
11351439	C4591001 1135 11351439	16-55	25SEP2020	99156	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11351440	C4591001 1135 11351440	16-55	21OCT2020	400193	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
11351441	C4591001 1135 11351441	16-55	21OCT2020	400194	Placebo	21OCT2020/ Placebo	11NOV2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
11351442	C4591001 1135 11351442	16-55	21OCT2020	400202	Placebo	21OCT2020/ Placebo	11NOV2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
11351443	C4591001 1135 11351443	16-55	21OCT2020	400201	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
11351444	C4591001 1135 11351444	16-55	21OCT2020	400221	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
11351445	C4591001 1135 11351445	16-55	21OCT2020	400222	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
11351446	C4591001 1135 11351446	16-55	21OCT2020	400223	Placebo	21OCT2020/ Placebo	11NOV2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
11351448	C4591001 1135 11351448	16-55	21OCT2020	400228	Placebo	21OCT2020/ Placebo	11NOV2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
11351449	C4591001 1135 11351449	16-55	21OCT2020	400257	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
11351450	C4591001 1135 11351450	16-55	21OCT2020	400254	Placebo	21OCT2020/ Placebo	09NOV2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11351451	C4591001 1135 11351451	16-55	21OCT2020	400263	Placebo	21OCT2020/ Placebo	09NOV2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
11351452	C4591001 1135 11351452	16-55	21OCT2020	400264	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
11351453	C4591001 1135 11351453	16-55	21OCT2020	400295	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
11351454	C4591001 1135 11351454	16-55	21OCT2020	400298	Placebo	21OCT2020/ Placebo	11NOV2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
11351455	C4591001 1135 11351455	16-55	21OCT2020	400297	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
11351456	C4591001 1135 11351456	16-55	21OCT2020	400296	Placebo	21OCT2020/ Placebo	11NOV2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
11351457	C4591001 1135 11351457	16-55	21OCT2020	400317	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
11351458	C4591001 1135 11351458	16-55	21OCT2020	400321	Placebo	21OCT2020/ Placebo	11NOV2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
11351459	C4591001 1135 11351459	16-55	21OCT2020	400313	Placebo	21OCT2020/ Placebo	12NOV2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
11351460	C4591001 1135 11351460	16-55	21OCT2020	400326	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11351461	C4591001 1135 11351461	16-55	21OCT2020	400316	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
11351462	C4591001 1135 11351462	16-55	21OCT2020	400327	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
11351463	C4591001 1135 11351463	16-55	21OCT2020	400328	Placebo	21OCT2020/ Placebo	12NOV2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
11351464	C4591001 1135 11351464	16-55	22OCT2020	400329	Placebo	22OCT2020/ Placebo	16NOV2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
11351465	C4591001 1135 11351465	16-55	22OCT2020	400386	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
11351466	C4591001 1135 11351466	16-55	22OCT2020	400388	Placebo	22OCT2020/ Placebo	12NOV2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
11351467	C4591001 1135 11351467	16-55	22OCT2020	400392	Placebo	22OCT2020/ Placebo	12NOV2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11351468	C4591001 1135 11351468	16-55	22OCT2020	400395	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
11351469	C4591001 1135 11351469	16-55	22OCT2020	400411	Placebo	22OCT2020/ Placebo	12NOV2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
11351470	C4591001 1135 11351470	16-55	22OCT2020	400413	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11351471	C4591001 1135 11351471	16-55	22OCT2020	400433	Placebo	22OCT2020/ Placebo	12NOV2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
11351472	C4591001 1135 11351472	16-55	22OCT2020	400414	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
11351473	C4591001 1135 11351473	16-55	22OCT2020	400419	Placebo	22OCT2020/ Placebo	12NOV2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
11351474	C4591001 1135 11351474	16-55	22OCT2020	400435	Placebo	22OCT2020/ Placebo	10NOV2020/ Placebo		
11351475	C4591001 1135 11351475	16-55	22OCT2020	400442	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
11351476	C4591001 1135 11351476	16-55	22OCT2020	400437	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
11351477	C4591001 1135 11351477	16-55	22OCT2020	400459	Placebo	22OCT2020/ Placebo	12NOV2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
11351479	C4591001 1135 11351479	16-55	22OCT2020	400462	Placebo	22OCT2020/ Placebo	12NOV2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
11351480	C4591001 1135 11351480	16-55	22OCT2020	400467	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
11351482	C4591001 1135 11351482	16-55	22OCT2020	400468	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11351483	C4591001 1135 11351483	16-55	23OCT2020	400495	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
11351484	C4591001 1135 11351484	16-55	23OCT2020	400496	Placebo	23OCT2020/ Placebo	13NOV2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
11351485	C4591001 1135 11351485	16-55	23OCT2020	400504	Placebo	23OCT2020/ Placebo	13NOV2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
11351486	C4591001 1135 11351486	16-55	23OCT2020	400499	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
11351487	C4591001 1135 11351487	16-55	23OCT2020	400541	Placebo	23OCT2020/ Placebo	14NOV2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
11351488	C4591001 1135 11351488	16-55	23OCT2020	400546	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
11351489	C4591001 1135 11351489	16-55	23OCT2020	400567	Placebo	23OCT2020/ Placebo	13NOV2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
11351490	C4591001 1135 11351490	16-55	23OCT2020	400551	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
11351491	C4591001 1135 11351491	16-55	23OCT2020	400574	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
11351492	C4591001 1135 11351492	16-55	23OCT2020	400552	Placebo	23OCT2020/ Placebo	13NOV2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11351493	C4591001 1135 11351493	16-55	23OCT2020	400568	Placebo	23OCT2020/ Placebo	13NOV2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
11351494	C4591001 1135 11351494	16-55	23OCT2020	400575	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
11351495	C4591001 1135 11351495	16-55	23OCT2020	400616	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
11351496	C4591001 1135 11351496	16-55	23OCT2020	400614	Placebo	23OCT2020/ Placebo	12NOV2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11351497	C4591001 1135 11351497	16-55	23OCT2020	400640	Placebo	23OCT2020/ Placebo	13NOV2020/ Placebo		
11351498	C4591001 1135 11351498	16-55	23OCT2020	400624	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
11351499	C4591001 1135 11351499	16-55	23OCT2020	400638	Placebo	23OCT2020/ Placebo	13NOV2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
11351500	C4591001 1135 11351500	16-55	23OCT2020	400618	Placebo	23OCT2020/ Placebo	11NOV2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
11351501	C4591001 1135 11351501	16-55	23OCT2020	400696	Placebo	23OCT2020/ Placebo	12NOV2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
11351502	C4591001 1135 11351502	16-55	23OCT2020	400695	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11351503	C4591001 1135 11351503	16-55	23OCT2020	400644	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
11351505	C4591001 1135 11351505	16-55	23OCT2020	400641	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
11351506	C4591001 1135 11351506	16-55	23OCT2020	400689	Placebo	23OCT2020/ Placebo	16NOV2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)
11351508	C4591001 1135 11351508	16-55	23OCT2020	400688	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
11351509	C4591001 1135 11351509	16-55	23OCT2020	400698	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
11351510	C4591001 1135 11351510	16-55	24OCT2020	400704	Placebo	24OCT2020/ Placebo	12NOV2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
11351511	C4591001 1135 11351511	16-55	24OCT2020	400703	Placebo	24OCT2020/ Placebo	12NOV2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
11351512	C4591001 1135 11351512	16-55	24OCT2020	400700	BNT162b2 (30 µg)	24OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
11351513	C4591001 1135 11351513	16-55	24OCT2020	400710	BNT162b2 (30 µg)	24OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
11351514	C4591001 1135 11351514	16-55	24OCT2020	400725	Placebo	24OCT2020/ Placebo	12NOV2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11351516	C4591001 1135 11351516	16-55	24OCT2020	400720	Placebo	24OCT2020/ Placebo	12NOV2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
11351517	C4591001 1135 11351517	16-55	24OCT2020	400716	Placebo	24OCT2020/ Placebo	16NOV2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
11351518	C4591001 1135 11351518	16-55	24OCT2020	400712	BNT162b2 (30 µg)	24OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
11351519	C4591001 1135 11351519	16-55	24OCT2020	400731	Placebo	24OCT2020/ Placebo	12NOV2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11351520	C4591001 1135 11351520	16-55	24OCT2020	400723	BNT162b2 (30 µg)	24OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
11351521	C4591001 1135 11351521	16-55	24OCT2020	400728	BNT162b2 (30 µg)	24OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
11351522	C4591001 1135 11351522	16-55	24OCT2020	400734	BNT162b2 (30 µg)	24OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
11351523	C4591001 1135 11351523	16-55	24OCT2020	400738	BNT162b2 (30 µg)	24OCT2020/ BNT162b2 (30 µg)			
11351524	C4591001 1135 11351524	16-55	24OCT2020	400735	Placebo	24OCT2020/ Placebo	13NOV2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
11351525	C4591001 1135 11351525	16-55	24OCT2020	400742	Placebo	24OCT2020/ Placebo	12NOV2020/ Placebo		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11351526	C4591001 1135 11351526	16-55	24OCT2020	400750	Placebo	24OCT2020/ Placebo	13NOV2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
11351527	C4591001 1135 11351527	16-55	24OCT2020	400751	Placebo	24OCT2020/ Placebo	13NOV2020/ Placebo		
11351528	C4591001 1135 11351528	16-55	24OCT2020	400757	BNT162b2 (30 µg)	24OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
11351529	C4591001 1135 11351529	16-55	24OCT2020	400756	BNT162b2 (30 µg)	24OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
11351530	C4591001 1135 11351530	16-55	24OCT2020	400752	BNT162b2 (30 µg)	24OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
11351531	C4591001 1135 11351531	16-55	24OCT2020	400763	BNT162b2 (30 µg)	24OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
11351532	C4591001 1135 11351532	16-55	24OCT2020	400758	Placebo	24OCT2020/ Placebo	13NOV2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
11351533	C4591001 1135 11351533	16-55	24OCT2020	400768	Placebo	24OCT2020/ Placebo	12NOV2020/ Placebo		
11351534	C4591001 1135 11351534	16-55	26OCT2020	400858	Placebo	26OCT2020/ Placebo	16NOV2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
11351535	C4591001 1135 11351535	16-55	26OCT2020	400854	Placebo	26OCT2020/ Placebo	17NOV2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11351536	C4591001 1135 11351536	16-55	26OCT2020	400859	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
11351537	C4591001 1135 11351537	16-55	26OCT2020	400867	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
11351538	C4591001 1135 11351538	16-55	26OCT2020	400876	Placebo	26OCT2020/ Placebo	16NOV2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11351539	C4591001 1135 11351539	16-55	26OCT2020	400861	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
11351540	C4591001 1135 11351540	16-55	26OCT2020	400902	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
11351541	C4591001 1135 11351541	16-55	26OCT2020	400869	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
11351542	C4591001 1135 11351542	16-55	26OCT2020	400872	Placebo	26OCT2020/ Placebo	17NOV2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	27JAN2021/ BNT162b2 (30 µg)
11351543	C4591001 1135 11351543	16-55	26OCT2020	400903	Placebo	26OCT2020/ Placebo	16NOV2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
11351544	C4591001 1135 11351544	16-55	26OCT2020	400904	Placebo	26OCT2020/ Placebo	16NOV2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
11351545	C4591001 1135 11351545	16-55	26OCT2020	400910	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11351546	C4591001 1135 11351546	16-55	26OCT2020	400998	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
11351547	C4591001 1135 11351547	16-55	26OCT2020	400999	Placebo	26OCT2020/ Placebo	16NOV2020/ Placebo		
11351548	C4591001 1135 11351548	16-55	26OCT2020	401005	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
11351549	C4591001 1135 11351549	16-55	26OCT2020	401000	Placebo	26OCT2020/ Placebo	16NOV2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
11351550	C4591001 1135 11351550	16-55	26OCT2020	401033	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
11351551	C4591001 1135 11351551	16-55	27OCT2020	401035	Placebo	27OCT2020/ Placebo	17NOV2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
11351552	C4591001 1135 11351552	16-55	27OCT2020	401039	Placebo	27OCT2020/ Placebo	17NOV2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
11351553	C4591001 1135 11351553	16-55	27OCT2020	401043	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	18NOV2020/ BNT162b2 (30 µg)		
11351554	C4591001 1135 11351554	16-55	27OCT2020	401073	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
11351555	C4591001 1135 11351555	16-55	27OCT2020	401074	Placebo	27OCT2020/ Placebo	17NOV2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11351556	C4591001 1135 11351556	16-55	27OCT2020	401079	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
11351557	C4591001 1135 11351557	16-55	27OCT2020	401080	Placebo	27OCT2020/ Placebo	17NOV2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
11351558	C4591001 1135 11351558	16-55	27OCT2020	401097	Placebo	27OCT2020/ Placebo	17NOV2020/ Placebo		
11351559	C4591001 1135 11351559	16-55	27OCT2020	401099	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
11351560	C4591001 1135 11351560	16-55	27OCT2020	401101	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
11351561	C4591001 1135 11351561	16-55	27OCT2020	401100	Placebo	27OCT2020/ Placebo	17NOV2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
11351562	C4591001 1135 11351562	16-55	27OCT2020	401105	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
11351563	C4591001 1135 11351563	16-55	27OCT2020	401109	Placebo	27OCT2020/ Placebo	20NOV2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
11351564	C4591001 1135 11351564	16-55	27OCT2020	401110	Placebo	27OCT2020/ Placebo	17NOV2020/ Placebo		
11351565	C4591001 1135 11351565	16-55	27OCT2020	401112	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11351566	C4591001 1135 11351566	16-55	27OCT2020	401146	Placebo	27OCT2020/ Placebo	18NOV2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
11351567	C4591001 1135 11351567	16-55	27OCT2020	401141	Placebo	27OCT2020/ Placebo	17NOV2020/ Placebo	11MAR2021/ BNT162b2 (30 µg)	
11351568	C4591001 1135 11351568	16-55	27OCT2020	401144	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
11351569	C4591001 1135 11351569	16-55	27OCT2020	401147	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
11351571	C4591001 1135 11351571	16-55	27OCT2020	401154	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
11351572	C4591001 1135 11351572	16-55	27OCT2020	401153	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
11351573	C4591001 1135 11351573	16-55	27OCT2020	401158	Placebo	27OCT2020/ Placebo	17NOV2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
11361001	C4591001 1136 11361001	16-55	18AUG2020	54536	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
11361002	C4591001 1136 11361002	16-55	18AUG2020	54540	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11361003	C4591001 1136 11361003	16-55	18AUG2020	54544	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11361004	C4591001 1136 11361004	16-55	18AUG2020	54537	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
11361006	C4591001 1136 11361006	16-55	18AUG2020	54713	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
11361007	C4591001 1136 11361007	16-55	18AUG2020	54717	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
11361010	C4591001 1136 11361010	16-55	18AUG2020	54718	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
11361012	C4591001 1136 11361012	16-55	18AUG2020	54722	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
11361013	C4591001 1136 11361013	16-55	18AUG2020	55304	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	20JAN2021/ BNT162b2 (30 µg)
11361018	C4591001 1136 11361018	16-55	20AUG2020	55305	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
11361020	C4591001 1136 11361020	16-55	20AUG2020	55308	Placebo	20AUG2020/ Placebo	09SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
11361021	C4591001 1136 11361021	16-55	20AUG2020	55309	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11361024	C4591001 1136 11361024	16-55	20AUG2020	59083	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11361026	C4591001 1136 11361026	16-55	20AUG2020	59091	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11361027	C4591001 1136 11361027	16-55	20AUG2020	59092	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
11361028	C4591001 1136 11361028	16-55	20AUG2020	59444	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
11361029	C4591001 1136 11361029	16-55	20AUG2020	59449	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
11361030	C4591001 1136 11361030	16-55	20AUG2020	59450	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
11361031	C4591001 1136 11361031	16-55	20AUG2020	59451	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo		
11361032	C4591001 1136 11361032	16-55	20AUG2020	59778	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo		
11361034	C4591001 1136 11361034	16-55	20AUG2020	59779	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
11361035	C4591001 1136 11361035	16-55	20AUG2020	59781	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
11361036	C4591001 1136 11361036	16-55	21AUG2020	59785	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11361039	C4591001 1136 11361039	16-55	21AUG2020	61602	Placebo	21AUG2020/ Placebo	14SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
11361040	C4591001 1136 11361040	16-55	21AUG2020	61605	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
11361042	C4591001 1136 11361042	16-55	24AUG2020	61609	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11361043	C4591001 1136 11361043	16-55	24AUG2020	61610	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)			
11361045	C4591001 1136 11361045	16-55	24AUG2020	65036	Placebo	24AUG2020/ Placebo			
11361046	C4591001 1136 11361046	16-55	24AUG2020	65033	Placebo	24AUG2020/ Placebo	01OCT2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
11361047	C4591001 1136 11361047	16-55	25AUG2020	65040	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11361048	C4591001 1136 11361048	16-55	25AUG2020	65044	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11361049	C4591001 1136 11361049	16-55	25AUG2020	67073	Placebo	25AUG2020/ Placebo	14SEP2020/ Placebo		
11361054	C4591001 1136 11361054	16-55	28AUG2020	67075	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11361058	C4591001 1136 11361058	16-55	14SEP2020	67077	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	
11361060	C4591001 1136 11361060	16-55	14SEP2020	67084	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
11361062	C4591001 1136 11361062	16-55	14SEP2020	89826	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
11361063	C4591001 1136 11361063	16-55	14SEP2020	89829	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
11361064	C4591001 1136 11361064	16-55	14SEP2020	89831	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
11361065	C4591001 1136 11361065	16-55	14SEP2020	89835	Placebo	14SEP2020/ Placebo	06OCT2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
11361067	C4591001 1136 11361067	16-55	21OCT2020	111560	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
11361072	C4591001 1136 11361072	16-55	21OCT2020	111564	Placebo	21OCT2020/ Placebo	11NOV2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
11361073	C4591001 1136 11361073	16-55	21OCT2020	111562	Placebo	21OCT2020/ Placebo	11NOV2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
11361076	C4591001 1136 11361076	16-55	22OCT2020	111565	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11361082	C4591001 1136 11361082	16-55	27OCT2020	114248	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)		
11361083	C4591001 1136 11361083	16-55	27OCT2020	114249	Placebo	27OCT2020/ Placebo	18NOV2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
11361084	C4591001 1136 11361084	16-55	28OCT2020	114250	Placebo	28OCT2020/ Placebo	16NOV2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
11361086	C4591001 1136 11361086	16-55	28OCT2020	114252	BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)	18NOV2020/ BNT162b2 (30 µg)		
11361087	C4591001 1136 11361087	16-55	28OCT2020	114474	Placebo	28OCT2020/ Placebo	16NOV2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
11361090	C4591001 1136 11361090	16-55	28OCT2020	114476	Placebo	28OCT2020/ Placebo	16NOV2020/ Placebo		
11361091	C4591001 1136 11361091	16-55	28OCT2020	114477	BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
11361092	C4591001 1136 11361092	16-55	28OCT2020	114479	BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
11361094	C4591001 1136 11361094	16-55	29OCT2020	114692	Placebo	29OCT2020/ Placebo	17NOV2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
11361095	C4591001 1136 11361095	16-55	29OCT2020	114696	Placebo	29OCT2020/ Placebo	16NOV2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	22JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11361098	C4591001 1136 11361098	16-55	29OCT2020	114697	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
11361099	C4591001 1136 11361099	16-55	29OCT2020	114700	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
11361100	C4591001 1136 11361100	16-55	29OCT2020	114726	Placebo	29OCT2020/ Placebo	17NOV2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
11361101	C4591001 1136 11361101	16-55	29OCT2020	114728	Placebo	29OCT2020/ Placebo	17NOV2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
11361108	C4591001 1136 11361108	16-55	29OCT2020	114730	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
11361109	C4591001 1136 11361109	16-55	29OCT2020	114834	Placebo	29OCT2020/ Placebo	17NOV2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
11361111	C4591001 1136 11361111	16-55	29OCT2020	114735	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)			
11391094	C4591001 1139 11391094	16-55	06OCT2020	47767	Placebo	06OCT2020/ Placebo	27OCT2020/ Placebo	19DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11391099	C4591001 1139 11391099	16-55	08OCT2020	47771	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)		
11391100	C4591001 1139 11391100	16-55	08OCT2020	47775	Placebo	08OCT2020/ Placebo	30OCT2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11391101	C4591001 1139 11391101	16-55	08OCT2020	105464	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)		
11391102	C4591001 1139 11391102	16-55	15OCT2020	107075	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
11391103	C4591001 1139 11391103	16-55	09OCT2020	105465	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)		
11391105	C4591001 1139 11391105	16-55	13OCT2020	105469	Placebo	13OCT2020/ Placebo	03NOV2020/ Placebo	19DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
11391106	C4591001 1139 11391106	16-55	13OCT2020	107069	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
11391107	C4591001 1139 11391107	16-55	13OCT2020	107072	Placebo	13OCT2020/ Placebo	03NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
11391108	C4591001 1139 11391108	16-55	13OCT2020	105472	Placebo	13OCT2020/ Placebo	03NOV2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
11391109	C4591001 1139 11391109	16-55	15OCT2020	107079	Placebo	15OCT2020/ Placebo	05NOV2020/ Placebo		
11391110	C4591001 1139 11391110	16-55	15OCT2020	108227	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
11391112	C4591001 1139 11391112	16-55	16OCT2020	108228	Placebo	16OCT2020/ Placebo	05NOV2020/ Placebo	19DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11391113	C4591001 1139 11391113	16-55	16OCT2020	108229	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
11391114	C4591001 1139 11391114	16-55	19OCT2020	108230	Placebo	19OCT2020/ Placebo	13NOV2020/ Placebo	19DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
11391116	C4591001 1139 11391116	16-55	20OCT2020	110233	Placebo	20OCT2020/ Placebo	12NOV2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
11391117	C4591001 1139 11391117	16-55	20OCT2020	110235	Placebo	20OCT2020/ Placebo	12NOV2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
11391119	C4591001 1139 11391119	16-55	19OCT2020	110231	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
11391120	C4591001 1139 11391120	16-55	19OCT2020	110225	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
11391125	C4591001 1139 11391125	16-55	22OCT2020	112265	Placebo	22OCT2020/ Placebo	13NOV2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11391127	C4591001 1139 11391127	16-55	23OCT2020	112270	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
11391130	C4591001 1139 11391130	16-55	10NOV2020	112273	BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)	07DEC2020/ BNT162b2 (30 µg)		
11391131	C4591001 1139 11391131	16-55	13NOV2020	112274	Placebo	13NOV2020/ Placebo	04DEC2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11391132	C4591001 1139 11391132	16-55	17NOV2020	116334	BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)	08DEC2020/ BNT162b2 (30 µg)		
11391133	C4591001 1139 11391133	16-55	17NOV2020	116335	Placebo	17NOV2020/ Placebo	08DEC2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
11391134	C4591001 1139 11391134	16-55	17NOV2020	116337	Placebo	17NOV2020/ Placebo	08DEC2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	
11391135	C4591001 1139 11391135	16-55	17NOV2020	116344	BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)	08DEC2020/ BNT162b2 (30 µg)		
11391136	C4591001 1139 11391136	16-55	23NOV2020	116696	BNT162b2 (30 µg)	23NOV2020/ BNT162b2 (30 µg)	15DEC2020/ BNT162b2 (30 µg)		
11391137	C4591001 1139 11391137	16-55	23NOV2020	116697	BNT162b2 (30 µg)	23NOV2020/ BNT162b2 (30 µg)	15DEC2020/ BNT162b2 (30 µg)		
11391138	C4591001 1139 11391138	16-55	24NOV2020	116699	Placebo	24NOV2020/ Placebo	17DEC2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
11391139	C4591001 1139 11391139	16-55	24NOV2020	116704	Placebo	24NOV2020/ Placebo	15DEC2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
11391140	C4591001 1139 11391140	16-55	24NOV2020	116801	Placebo	24NOV2020/ Placebo	18DEC2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
11391141	C4591001 1139 11391141	16-55	24NOV2020	116806	BNT162b2 (30 µg)	24NOV2020/ BNT162b2 (30 µg)	15DEC2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11391142	C4591001 1139 11391142	16-55	24NOV2020	116807	Placebo	24NOV2020/ Placebo	18DEC2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
11391143	C4591001 1139 11391143	16-55	11DEC2020	117758	Placebo	11DEC2020/ Placebo	30DEC2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
11391146	C4591001 1139 11391146	16-55	01DEC2020	116808	BNT162b2 (30 µg)	01DEC2020/ BNT162b2 (30 µg)	21DEC2020/ BNT162b2 (30 µg)		
11391147	C4591001 1139 11391147	16-55	08DEC2020	117376	BNT162b2 (30 µg)	08DEC2020/ BNT162b2 (30 µg)	29DEC2020/ BNT162b2 (30 µg)		
11391148	C4591001 1139 11391148	16-55	18DEC2020	117919	Placebo	18DEC2020/ Placebo	07JAN2021/ Placebo	15FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
11391149	C4591001 1139 11391149	16-55	03DEC2020	117367	BNT162b2 (30 µg)	03DEC2020/ BNT162b2 (30 µg)	28DEC2020/ BNT162b2 (30 µg)		
11391150	C4591001 1139 11391150	16-55	04DEC2020	117369	Placebo	04DEC2020/ Placebo	23DEC2020/ Placebo		
11391153	C4591001 1139 11391153	16-55	04DEC2020	117375	Placebo	04DEC2020/ Placebo	28DEC2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
11391160	C4591001 1139 11391160	16-55	08DEC2020	117750	BNT162b2 (30 µg)	08DEC2020/ BNT162b2 (30 µg)	29DEC2020/ BNT162b2 (30 µg)		
11391164	C4591001 1139 11391164	16-55	11DEC2020	117756	BNT162b2 (30 µg)	11DEC2020/ BNT162b2 (30 µg)	30DEC2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11391167	C4591001 1139 11391167	16-55	11DEC2020	117760	Placebo	11DEC2020/ Placebo	30DEC2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
11401054	C4591001 1140 11401054	16-55	25AUG2020	65613	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	14JAN2021/ BNT162b2 (30 µg)
11401129	C4591001 1140 11401129	16-55	17AUG2020	50495	Placebo	17AUG2020/ Placebo	09SEP2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	20JAN2021/ BNT162b2 (30 µg)
11401130	C4591001 1140 11401130	16-55	17AUG2020	229998	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11401135	C4591001 1140 11401135	16-55	17AUG2020	50497	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
11401136	C4591001 1140 11401136	16-55	17AUG2020	50500	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11401137	C4591001 1140 11401137	16-55	17AUG2020	53003	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11401144	C4591001 1140 11401144	16-55	04SEP2020	80651	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
11401148	C4591001 1140 11401148	16-55	18AUG2020	53004	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo		
11401149	C4591001 1140 11401149	16-55	18AUG2020	53005	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11401150	C4591001 1140 11401150	16-55	18AUG2020	54858	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11401151	C4591001 1140 11401151	16-55	18AUG2020	53008	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11401153	C4591001 1140 11401153	16-55	19AUG2020	54861	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11401154	C4591001 1140 11401154	16-55	19AUG2020	54863	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
11401157	C4591001 1140 11401157	16-55	19AUG2020	54866	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
11401158	C4591001 1140 11401158	16-55	19AUG2020	56731	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11401159	C4591001 1140 11401159	16-55	19AUG2020	56733	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
11401160	C4591001 1140 11401160	16-55	19AUG2020	56736	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11401164	C4591001 1140 11401164	16-55	20AUG2020	56738	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
11401166	C4591001 1140 11401166	16-55	20AUG2020	58433	Placebo	20AUG2020/ Placebo	14SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11401170	C4591001 1140 11401170	16-55	20AUG2020	58436	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11401176	C4591001 1140 11401176	16-55	21AUG2020	58437	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo		
11401177	C4591001 1140 11401177	16-55	21AUG2020	58438	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
11401178	C4591001 1140 11401178	16-55	24AUG2020	63309	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
11401180	C4591001 1140 11401180	16-55	24AUG2020	63310	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
11401184	C4591001 1140 11401184	16-55	24AUG2020	63312	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11401187	C4591001 1140 11401187	16-55	25AUG2020	65611	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
11401188	C4591001 1140 11401188	16-55	25AUG2020	63316	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
11401198	C4591001 1140 11401198	16-55	26AUG2020	65618	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11401201	C4591001 1140 11401201	16-55	27AUG2020	69511	Placebo	27AUG2020/ Placebo	16SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11401202	C4591001 1140 11401202	16-55	27AUG2020	65619	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11401203	C4591001 1140 11401203	16-55	27AUG2020	69509	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
11401206	C4591001 1140 11401206	16-55	27AUG2020	69514	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
11401209	C4591001 1140 11401209	16-55	28AUG2020	69518	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11401210	C4591001 1140 11401210	16-55	28AUG2020	71597	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
11401211	C4591001 1140 11401211	16-55	28AUG2020	71598	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11401214	C4591001 1140 11401214	16-55	28AUG2020	71606	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
11401215	C4591001 1140 11401215	16-55	28AUG2020	71608	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
11401216	C4591001 1140 11401216	16-55	31AUG2020	74621	Placebo	31AUG2020/ Placebo	22SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
11401219	C4591001 1140 11401219	16-55	31AUG2020	74627	Placebo	31AUG2020/ Placebo	22SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11401224	C4591001 1140 11401224	16-55	31AUG2020	74628	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11401231	C4591001 1140 11401231	16-55	01SEP2020	74630	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11401232	C4591001 1140 11401232	16-55	01SEP2020	76740	Placebo	01SEP2020/ Placebo	23SEP2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
11401239	C4591001 1140 11401239	16-55	02SEP2020	76741	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11401240	C4591001 1140 11401240	16-55	02SEP2020	76743	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11401241	C4591001 1140 11401241	16-55	02SEP2020	76744	Placebo	02SEP2020/ Placebo	21SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
11401243	C4591001 1140 11401243	16-55	02SEP2020	78356	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11401246	C4591001 1140 11401246	16-55	02SEP2020	78360	Placebo	02SEP2020/ Placebo	24SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
11401249	C4591001 1140 11401249	16-55	03SEP2020	78361	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11401250	C4591001 1140 11401250	16-55	03SEP2020	78362	Placebo	03SEP2020/ Placebo	23SEP2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11401251	C4591001 1140 11401251	16-55	03SEP2020	80157	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11401252	C4591001 1140 11401252	16-55	03SEP2020	80159	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
11401255	C4591001 1140 11401255	16-55	03SEP2020	80164	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
11401257	C4591001 1140 11401257	16-55	03SEP2020	80645	Placebo	03SEP2020/ Placebo	23SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
11401259	C4591001 1140 11401259	16-55	04SEP2020	80647	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
11401262	C4591001 1140 11401262	16-55	07OCT2020	80653	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
11401264	C4591001 1140 11401264	16-55	07OCT2020	104923	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
11401272	C4591001 1140 11401272	16-55	09OCT2020	104924	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)		
11401279	C4591001 1140 11401279	16-55	13OCT2020	104926	Placebo	13OCT2020/ Placebo	02NOV2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11401281	C4591001 1140 11401281	16-55	13OCT2020	104932	Placebo	13OCT2020/ Placebo	02NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11401282	C4591001 1140 11401282	16-55	13OCT2020	107214	Placebo	13OCT2020/ Placebo	03NOV2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
11401284	C4591001 1140 11401284	16-55	14OCT2020	107215	BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		
11401285	C4591001 1140 11401285	16-55	14OCT2020	107216	Placebo	14OCT2020/ Placebo	04NOV2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
11401290	C4591001 1140 11401290	16-55	15OCT2020	107218	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
11401294	C4591001 1140 11401294	16-55	15OCT2020	108414	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
11401298	C4591001 1140 11401298	16-55	16OCT2020	108417	Placebo	16OCT2020/ Placebo	06NOV2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
11401299	C4591001 1140 11401299	16-55	16OCT2020	108419	Placebo	16OCT2020/ Placebo	06NOV2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
11401301	C4591001 1140 11401301	16-55	19OCT2020	108424	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)			
11401303	C4591001 1140 11401303	16-55	20OCT2020	110681	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
11401304	C4591001 1140 11401304	16-55	20OCT2020	110682	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11401306	C4591001 1140 11401306	16-55	22OCT2020	110686	Placebo	22OCT2020/ Placebo			
11401308	C4591001 1140 11401308	16-55	23OCT2020	110691	Placebo	23OCT2020/ Placebo	11NOV2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	27JAN2021/ BNT162b2 (30 µg)
11401309	C4591001 1140 11401309	16-55	23OCT2020	113082	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
11401310	C4591001 1140 11401310	16-55	23OCT2020	113083	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
11401311	C4591001 1140 11401311	16-55	26OCT2020	113085	Placebo	26OCT2020/ Placebo	16NOV2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)
11401314	C4591001 1140 11401314	16-55	03NOV2020	113086	Placebo	03NOV2020/ Placebo	23NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
11401316	C4591001 1140 11401316	16-55	25NOV2020	116910	BNT162b2 (30 µg)	25NOV2020/ BNT162b2 (30 µg)	14DEC2020/ BNT162b2 (30 µg)		
11401317	C4591001 1140 11401317	16-55	02DEC2020	116913	BNT162b2 (30 µg)	02DEC2020/ BNT162b2 (30 µg)	23DEC2020/ BNT162b2 (30 µg)		
11401318	C4591001 1140 11401318	16-55	03DEC2020	116914	Placebo	03DEC2020/ Placebo	23DEC2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
11401319	C4591001 1140 11401319	16-55	03DEC2020	116915	Placebo	03DEC2020/ Placebo	23DEC2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11401320	C4591001 1140 11401320	16-55	03DEC2020	117330	BNT162b2 (30 µg)	03DEC2020/ BNT162b2 (30 µg)	23DEC2020/ BNT162b2 (30 µg)		
11401321	C4591001 1140 11401321	16-55	04DEC2020	117332	Placebo	04DEC2020/ Placebo	23DEC2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
11401322	C4591001 1140 11401322	16-55	04DEC2020	117334	BNT162b2 (30 µg)	04DEC2020/ BNT162b2 (30 µg)	23DEC2020/ BNT162b2 (30 µg)		
11411077	C4591001 1141 11411077	16-55	13AUG2020	48926	Placebo	17AUG2020/ Placebo	09SEP2020/ Placebo		
11411082	C4591001 1141 11411082	16-55	14AUG2020	50369	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11411085	C4591001 1141 11411085	16-55	14AUG2020	50373	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11411087	C4591001 1141 11411087	16-55	17AUG2020	50380	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11411088	C4591001 1141 11411088	16-55	17AUG2020	52697	Placebo	17AUG2020/ Placebo	09SEP2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	14JAN2021/ BNT162b2 (30 µg)
11411089	C4591001 1141 11411089	16-55	17AUG2020	52701	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11411090	C4591001 1141 11411090	16-55	17AUG2020	52708	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11411091	C4591001 1141 11411091	16-55	17AUG2020	52707	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11411092	C4591001 1141 11411092	16-55	17AUG2020	53334	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11411093	C4591001 1141 11411093	16-55	18AUG2020	53336	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	27JAN2021/ BNT162b2 (30 µg)
11411094	C4591001 1141 11411094	16-55	18AUG2020	53339	Placebo	18AUG2020/ Placebo	10SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
11411096	C4591001 1141 11411096	16-55	18AUG2020	53342	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
11411097	C4591001 1141 11411097	16-55	18AUG2020	54753	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11411098	C4591001 1141 11411098	16-55	18AUG2020	54755	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)
11411099	C4591001 1141 11411099	16-55	19AUG2020	54758	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
11411102	C4591001 1141 11411102	16-55	19AUG2020	54760	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11411103	C4591001 1141 11411103	16-55	19AUG2020	56586	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11411104	C4591001 1141 11411104	16-55	19AUG2020	56590	Placebo	19AUG2020/ Placebo	08SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
11411106	C4591001 1141 11411106	16-55	19AUG2020	56593	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
11411107	C4591001 1141 11411107	16-55	19AUG2020	56594	Placebo	19AUG2020/ Placebo	11SEP2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
11411108	C4591001 1141 11411108	16-55	20AUG2020	58073	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
11411109	C4591001 1141 11411109	16-55	20AUG2020	58076	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
11411110	C4591001 1141 11411110	16-55	20AUG2020	58078	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
11411112	C4591001 1141 11411112	16-55	20AUG2020	58082	Placebo	20AUG2020/ Placebo	09SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
11411113	C4591001 1141 11411113	16-55	20AUG2020	59610	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
11411114	C4591001 1141 11411114	16-55	21AUG2020	59612	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
11411116	C4591001 1141 11411116	16-55	21AUG2020	59613	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11411118	C4591001 1141 11411118	16-55	21AUG2020	59619	Placebo	21AUG2020/ Placebo	16SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
11411119	C4591001 1141 11411119	16-55	21AUG2020	60869	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
11411120	C4591001 1141 11411120	16-55	21AUG2020	60871	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
11411121	C4591001 1141 11411121	16-55	21AUG2020	60872	Placebo	21AUG2020/ Placebo	10SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
11411122	C4591001 1141 11411122	16-55	24AUG2020	60874	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
11411123	C4591001 1141 11411123	16-55	24AUG2020	63719	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11411124	C4591001 1141 11411124	16-55	24AUG2020	63716	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
11411125	C4591001 1141 11411125	16-55	24AUG2020	63721	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11411127	C4591001 1141 11411127	16-55	24AUG2020	63723	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		
11411128	C4591001 1141 11411128	16-55	24AUG2020	64496	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11411129	C4591001 1141 11411129	16-55	25AUG2020	64497	Placebo	25AUG2020/ Placebo	14SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11411130	C4591001 1141 11411130	16-55	25AUG2020	64503	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
11411131	C4591001 1141 11411131	16-55	25AUG2020	64504	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11411132	C4591001 1141 11411132	16-55	25AUG2020	66630	Placebo	25AUG2020/ Placebo	16SEP2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	20JAN2021/ BNT162b2 (30 µg)
11411133	C4591001 1141 11411133	16-55	26AUG2020	66631	Placebo	26AUG2020/ Placebo	25SEP2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
11411135	C4591001 1141 11411135	16-55	26AUG2020	66633	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
11411136	C4591001 1141 11411136	16-55	26AUG2020	68321	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11411137	C4591001 1141 11411137	16-55	26AUG2020	66640	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
11411139	C4591001 1141 11411139	16-55	27AUG2020	68322	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
11411140	C4591001 1141 11411140	16-55	27AUG2020	68326	Placebo	27AUG2020/ Placebo	18SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11411141	C4591001 1141 11411141	16-55	27AUG2020	68327	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
11411142	C4591001 1141 11411142	16-55	27AUG2020	70592	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
11411144	C4591001 1141 11411144	16-55	27AUG2020	70593	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11411146	C4591001 1141 11411146	16-55	28AUG2020	70595	Placebo	28AUG2020/ Placebo		29JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
11411148	C4591001 1141 11411148	16-55	28AUG2020	70597	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
11411149	C4591001 1141 11411149	16-55	28AUG2020	72509	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
11411151	C4591001 1141 11411151	16-55	31AUG2020	72513	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
11411152	C4591001 1141 11411152	16-55	31AUG2020	72512	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
11411153	C4591001 1141 11411153	16-55	31AUG2020	75258	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
11411154	C4591001 1141 11411154	16-55	31AUG2020	72514	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11411156	C4591001 1141 11411156	16-55	31AUG2020	75259	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11411158	C4591001 1141 11411158	16-55	01SEP2020	75260	Placebo	01SEP2020/ Placebo	21SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
11411159	C4591001 1141 11411159	16-55	01SEP2020	75262	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11411161	C4591001 1141 11411161	16-55	02SEP2020	77996	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
11411162	C4591001 1141 11411162	16-55	02SEP2020	78000	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
11411163	C4591001 1141 11411163	16-55	02SEP2020	78001	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
11411164	C4591001 1141 11411164	16-55	02SEP2020	78004	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)			
11411165	C4591001 1141 11411165	16-55	02SEP2020	78956	Placebo	02SEP2020/ Placebo	28SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11411166	C4591001 1141 11411166	16-55	02SEP2020	78957	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
11411167	C4591001 1141 11411167	16-55	03SEP2020	78958	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11411168	C4591001 1141 11411168	16-55	03SEP2020	78962	Placebo	03SEP2020/ Placebo	25SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
11411169	C4591001 1141 11411169	16-55	03SEP2020	79962	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11411170	C4591001 1141 11411170	16-55	03SEP2020	79963	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
11411171	C4591001 1141 11411171	16-55	03SEP2020	79969	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11411172	C4591001 1141 11411172	16-55	03SEP2020	79972	Placebo	03SEP2020/ Placebo	25SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
11411173	C4591001 1141 11411173	16-55	04SEP2020	81305	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11411174	C4591001 1141 11411174	16-55	04SEP2020	81308	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
11411175	C4591001 1141 11411175	16-55	04SEP2020	81310	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)
11411176	C4591001 1141 11411176	16-55	04SEP2020	81309	Placebo	04SEP2020/ Placebo	23SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11411177	C4591001 1141 11411177	16-55	04SEP2020	82085	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11411179	C4591001 1141 11411179	16-55	08SEP2020	82088	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11411181	C4591001 1141 11411181	16-55	08SEP2020	82089	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
11411182	C4591001 1141 11411182	16-55	08SEP2020	82094	Placebo	08SEP2020/ Placebo	01OCT2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
11411184	C4591001 1141 11411184	16-55	09SEP2020	85001	Placebo	09SEP2020/ Placebo	28SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
11411185	C4591001 1141 11411185	16-55	09SEP2020	85007	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
11411186	C4591001 1141 11411186	16-55	09SEP2020	85004	Placebo	09SEP2020/ Placebo	29SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
11411187	C4591001 1141 11411187	16-55	09SEP2020	85010	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
11411188	C4591001 1141 11411188	16-55	09SEP2020	85710	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
11411192	C4591001 1141 11411192	16-55	10SEP2020	85714	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
11411193	C4591001 1141 11411193	16-55	10SEP2020	85717	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11411194	C4591001 1141 11411194	16-55	10SEP2020	85718	Placebo	10SEP2020/ Placebo	02OCT2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11411195	C4591001 1141 11411195	16-55	10SEP2020	87259	Placebo	10SEP2020/ Placebo	14OCT2020/ Placebo	03MAR2021/ BNT162b2 (30 µg)	
11411197	C4591001 1141 11411197	16-55	10SEP2020	87260	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
11411198	C4591001 1141 11411198	16-55	11SEP2020	87262	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
11411199	C4591001 1141 11411199	16-55	11SEP2020	87267	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)
11411201	C4591001 1141 11411201	16-55	11SEP2020	88401	Placebo	11SEP2020/ Placebo	30SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	14JAN2021/ BNT162b2 (30 µg)
11411202	C4591001 1141 11411202	16-55	11SEP2020	88404	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
11411203	C4591001 1141 11411203	16-55	11SEP2020	88405	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
11411204	C4591001 1141 11411204	16-55	11SEP2020	88408	Placebo	11SEP2020/ Placebo	01OCT2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
11411205	C4591001 1141 11411205	16-55	14SEP2020	89357	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11411206	C4591001 1141 11411206	16-55	14SEP2020	89360	Placebo	14SEP2020/ Placebo	08OCT2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
11411208	C4591001 1141 11411208	16-55	14SEP2020	89364	Placebo	14SEP2020/ Placebo	08OCT2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
11411209	C4591001 1141 11411209	16-55	14SEP2020	89365	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
11411211	C4591001 1141 11411211	16-55	15SEP2020	90260	Placebo	15SEP2020/ Placebo	05OCT2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
11411212	C4591001 1141 11411212	16-55	15SEP2020	90261	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
11411213	C4591001 1141 11411213	16-55	15SEP2020	90264	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
11411214	C4591001 1141 11411214	16-55	15SEP2020	90265	Placebo	15SEP2020/ Placebo	07OCT2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
11411215	C4591001 1141 11411215	16-55	16SEP2020	91002	Placebo	16SEP2020/ Placebo	07OCT2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)
11411217	C4591001 1141 11411217	16-55	16SEP2020	91004	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
11411218	C4591001 1141 11411218	16-55	16SEP2020	91005	Placebo	16SEP2020/ Placebo	09OCT2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11411219	C4591001 1141 11411219	16-55	16SEP2020	91010	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
11411220	C4591001 1141 11411220	16-55	16SEP2020	91629	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
11411221	C4591001 1141 11411221	16-55	16SEP2020	91630	Placebo	16SEP2020/ Placebo	07OCT2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
11411222	C4591001 1141 11411222	16-55	16SEP2020	91635	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
11411223	C4591001 1141 11411223	16-55	16SEP2020	91636	Placebo	16SEP2020/ Placebo	05OCT2020/ Placebo		
11411224	C4591001 1141 11411224	16-55	17SEP2020	92383	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
11411226	C4591001 1141 11411226	16-55	17SEP2020	92384	Placebo	17SEP2020/ Placebo	13OCT2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
11411227	C4591001 1141 11411227	16-55	17SEP2020	92389	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
11411228	C4591001 1141 11411228	16-55	17SEP2020	92391	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
11411229	C4591001 1141 11411229	16-55	17SEP2020	92912	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11411230	C4591001 1141 11411230	16-55	18SEP2020	92917	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
11411231	C4591001 1141 11411231	16-55	18SEP2020	92918	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
11411234	C4591001 1141 11411234	16-55	18SEP2020	92919	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
11411235	C4591001 1141 11411235	16-55	18SEP2020	94027	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
11411236	C4591001 1141 11411236	16-55	18SEP2020	94029	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
11411237	C4591001 1141 11411237	16-55	21SEP2020	94032	Placebo	21SEP2020/ Placebo	14OCT2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
11411238	C4591001 1141 11411238	16-55	21SEP2020	94036	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
11411239	C4591001 1141 11411239	16-55	21SEP2020	95597	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)
11411240	C4591001 1141 11411240	16-55	22SEP2020	95600	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
11411241	C4591001 1141 11411241	16-55	22SEP2020	95605	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11411242	C4591001 1141 11411242	16-55	24SEP2020	95608	Placebo	24SEP2020/ Placebo	15OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
11411243	C4591001 1141 11411243	16-55	24SEP2020	98935	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
11411245	C4591001 1141 11411245	16-55	25SEP2020	98938	Placebo	25SEP2020/ Placebo	14OCT2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	04JAN2021/ BNT162b2 (30 µg)
11411246	C4591001 1141 11411246	16-55	25SEP2020	100279	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
11411247	C4591001 1141 11411247	16-55	25SEP2020	98941	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
11411248	C4591001 1141 11411248	16-55	25SEP2020	98943	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
11411249	C4591001 1141 11411249	16-55	25SEP2020	100282	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
11411250	C4591001 1141 11411250	16-55	05OCT2020	100285	Placebo	05OCT2020/ Placebo	26OCT2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
11411251	C4591001 1141 11411251	16-55	06OCT2020	100287	Placebo	06OCT2020/ Placebo	27OCT2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
11411254	C4591001 1141 11411254	16-55	07OCT2020	104841	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11411255	C4591001 1141 11411255	16-55	08OCT2020	104844	Placebo	08OCT2020/ Placebo	29OCT2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
11411256	C4591001 1141 11411256	16-55	04NOV2020	115677	Placebo	04NOV2020/ Placebo	04DEC2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
11411257	C4591001 1141 11411257	16-55	12OCT2020	104846	BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		
11411260	C4591001 1141 11411260	16-55	14OCT2020	104847	Placebo	14OCT2020/ Placebo	11NOV2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
11411262	C4591001 1141 11411262	16-55	16OCT2020	109013	Placebo	16OCT2020/ Placebo	05NOV2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
11411263	C4591001 1141 11411263	16-55	19OCT2020	109014	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
11411264	C4591001 1141 11411264	16-55	20OCT2020	109017	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		
11411265	C4591001 1141 11411265	16-55	20OCT2020	109020	Placebo	20OCT2020/ Placebo	10NOV2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11411266	C4591001 1141 11411266	16-55	21OCT2020	111526	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		
11411267	C4591001 1141 11411267	16-55	23OCT2020	111529	Placebo	23OCT2020/ Placebo	12NOV2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11411269	C4591001 1141 11411269	16-55	27OCT2020	111531	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	18NOV2020/ BNT162b2 (30 µg)		
11411270	C4591001 1141 11411270	16-55	27OCT2020	111532	Placebo	27OCT2020/ Placebo	17NOV2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
11421029	C4591001 1142 11421029	16-55	19AUG2020	56670	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11421063	C4591001 1142 11421063	16-55	01SEP2020	75243	Placebo	01SEP2020/ Placebo	24SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11421106	C4591001 1142 11421106	16-55	17AUG2020	52472	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	15DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
11421107	C4591001 1142 11421107	16-55	17AUG2020	52476	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11421110	C4591001 1142 11421110	16-55	17AUG2020	52477	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11421112	C4591001 1142 11421112	16-55	17AUG2020	52479	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo		
11421113	C4591001 1142 11421113	16-55	18AUG2020	54187	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
11421115	C4591001 1142 11421115	16-55	18AUG2020	54259	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	21JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11421119	C4591001 1142 11421119	16-55	18AUG2020	54260	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
11421123	C4591001 1142 11421123	16-55	19AUG2020	54261	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11421124	C4591001 1142 11421124	16-55	19AUG2020	54267	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11421126	C4591001 1142 11421126	16-55	19AUG2020	56669	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11421129	C4591001 1142 11421129	16-55	20AUG2020	56674	Placebo	20AUG2020/ Placebo	08SEP2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
11421130	C4591001 1142 11421130	16-55	20AUG2020	56680	Placebo	20AUG2020/ Placebo	11SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
11421131	C4591001 1142 11421131	16-55	20AUG2020	58147	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
11421132	C4591001 1142 11421132	16-55	20AUG2020	58151	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
11421138	C4591001 1142 11421138	16-55	21AUG2020	58153	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
11421141	C4591001 1142 11421141	16-55	21AUG2020	58155	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11421142	C4591001 1142 11421142	16-55	21AUG2020	60822	Placebo	21AUG2020/ Placebo	10SEP2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
11421149	C4591001 1142 11421149	16-55	24AUG2020	60823	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
11421150	C4591001 1142 11421150	16-55	24AUG2020	60826	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11421153	C4591001 1142 11421153	16-55	24AUG2020	60830	Placebo	24AUG2020/ Placebo	15SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
11421155	C4591001 1142 11421155	16-55	24AUG2020	63980	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11421157	C4591001 1142 11421157	16-55	31AUG2020	63984	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
11421158	C4591001 1142 11421158	16-55	31AUG2020	63986	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
11421161	C4591001 1142 11421161	16-55	31AUG2020	63987	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11421163	C4591001 1142 11421163	16-55	31AUG2020	75238	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11421164	C4591001 1142 11421164	16-55	01SEP2020	75239	Placebo	01SEP2020/ Placebo	23SEP2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11421166	C4591001 1142 11421166	16-55	01SEP2020	75241	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11421173	C4591001 1142 11421173	16-55	02SEP2020	77982	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11421175	C4591001 1142 11421175	16-55	02SEP2020	77985	Placebo	02SEP2020/ Placebo	22SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
11421178	C4591001 1142 11421178	16-55	10SEP2020	85451	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11421179	C4591001 1142 11421179	16-55	02SEP2020	77991	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
11421181	C4591001 1142 11421181	16-55	03SEP2020	77992	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
11421182	C4591001 1142 11421182	16-55	03SEP2020	79687	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11421183	C4591001 1142 11421183	16-55	03SEP2020	79688	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11421184	C4591001 1142 11421184	16-55	03SEP2020	79690	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
11421185	C4591001 1142 11421185	16-55	03SEP2020	79691	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11421187	C4591001 1142 11421187	16-55	03SEP2020	80322	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
11421188	C4591001 1142 11421188	16-55	04SEP2020	80324	Placebo	04SEP2020/ Placebo	24SEP2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
11421190	C4591001 1142 11421190	16-55	04SEP2020	80328	Placebo	04SEP2020/ Placebo	28SEP2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
11421194	C4591001 1142 11421194	16-55	04SEP2020	80330	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11421197	C4591001 1142 11421197	16-55	08SEP2020	83441	Placebo	08SEP2020/ Placebo	30SEP2020/ Placebo	06JAN2021/ BNT162b2 (30 µg)	27JAN2021/ BNT162b2 (30 µg)
11421198	C4591001 1142 11421198	16-55	08SEP2020	83442	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11421199	C4591001 1142 11421199	16-55	08SEP2020	83445	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
11421200	C4591001 1142 11421200	16-55	08SEP2020	83447	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)
11421202	C4591001 1142 11421202	16-55	08SEP2020	83837	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11421203	C4591001 1142 11421203	16-55	09SEP2020	83842	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11421204	C4591001 1142 11421204	16-55	09SEP2020	83846	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
11421205	C4591001 1142 11421205	16-55	09SEP2020	83847	Placebo	09SEP2020/ Placebo	01OCT2020/ Placebo	31DEC2020/ BNT162b2 (30 µg)	20JAN2021/ BNT162b2 (30 µg)
11421206	C4591001 1142 11421206	16-55	09SEP2020	85450	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)
11421212	C4591001 1142 11421212	16-55	10SEP2020	85454	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11421214	C4591001 1142 11421214	16-55	10SEP2020	85456	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
11421216	C4591001 1142 11421216	16-55	11SEP2020	87919	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
11421218	C4591001 1142 11421218	16-55	11SEP2020	87925	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
11421219	C4591001 1142 11421219	16-55	11SEP2020	87926	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
11421220	C4591001 1142 11421220	16-55	11SEP2020	87927	Placebo	11SEP2020/ Placebo	20OCT2020/ Placebo		
11421222	C4591001 1142 11421222	16-55	14SEP2020	89489	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11421223	C4591001 1142 11421223	16-55	14SEP2020	89491	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
11421229	C4591001 1142 11421229	16-55	14SEP2020	89494	Placebo	14SEP2020/ Placebo	07OCT2020/ Placebo		
11421230	C4591001 1142 11421230	16-55	15SEP2020	89500	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
11421231	C4591001 1142 11421231	16-55	15SEP2020	90221	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
11421233	C4591001 1142 11421233	16-55	15SEP2020	90223	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
11421234	C4591001 1142 11421234	16-55	16SEP2020	90228	Placebo	16SEP2020/ Placebo	06OCT2020/ Placebo	02MAR2021/ BNT162b2 (30 µg)	
11421235	C4591001 1142 11421235	16-55	16SEP2020	90229	Placebo	16SEP2020/ Placebo	12OCT2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
11421239	C4591001 1142 11421239	16-55	17SEP2020	92527	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
11421242	C4591001 1142 11421242	16-55	18SEP2020	92530	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
11421244	C4591001 1142 11421244	16-55	18SEP2020	92533	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11421245	C4591001 1142 11421245	16-55	18SEP2020	92535	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
11421248	C4591001 1142 11421248	16-55	21SEP2020	94769	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
11421250	C4591001 1142 11421250	16-55	21SEP2020	94772	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
11421251	C4591001 1142 11421251	16-55	21SEP2020	94774	Placebo	21SEP2020/ Placebo	14OCT2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11421253	C4591001 1142 11421253	16-55	22SEP2020	94775	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
11421255	C4591001 1142 11421255	16-55	22SEP2020	96509	Placebo	22SEP2020/ Placebo	14OCT2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
11421256	C4591001 1142 11421256	16-55	23SEP2020	96511	Placebo	23SEP2020/ Placebo	12OCT2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
11421258	C4591001 1142 11421258	16-55	23SEP2020	96514	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
11421261	C4591001 1142 11421261	16-55	24SEP2020	96515	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
11421262	C4591001 1142 11421262	16-55	24SEP2020	98801	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11421264	C4591001 1142 11421264	16-55	25SEP2020	98803	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11421265	C4591001 1142 11421265	16-55	25SEP2020	98806	Placebo	25SEP2020/ Placebo	14OCT2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)
11421269	C4591001 1142 11421269	16-55	05OCT2020	98808	BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
11421270	C4591001 1142 11421270	16-55	05OCT2020	103829	BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
11421271	C4591001 1142 11421271	16-55	05OCT2020	103836	Placebo	05OCT2020/ Placebo	26OCT2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	28JAN2021/ BNT162b2 (30 µg)
11421274	C4591001 1142 11421274	16-55	07OCT2020	103837	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
11421275	C4591001 1142 11421275	16-55	07OCT2020	103838	Placebo	07OCT2020/ Placebo	28OCT2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	20JAN2021/ BNT162b2 (30 µg)
11421276	C4591001 1142 11421276	16-55	07OCT2020	104825	Placebo	07OCT2020/ Placebo	28OCT2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	20JAN2021/ BNT162b2 (30 µg)
11421277	C4591001 1142 11421277	16-55	08OCT2020	104828	Placebo	08OCT2020/ Placebo	29OCT2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	21JAN2021/ BNT162b2 (30 µg)
11421280	C4591001 1142 11421280	16-55	09OCT2020	104829	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11421281	C4591001 1142 11421281	16-55	13OCT2020	104832	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
11421282	C4591001 1142 11421282	16-55	15OCT2020	108077	Placebo	15OCT2020/ Placebo	03NOV2020/ Placebo		
11421283	C4591001 1142 11421283	16-55	15OCT2020	108082	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
11421284	C4591001 1142 11421284	16-55	15OCT2020	108086	Placebo	15OCT2020/ Placebo	03NOV2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
11421286	C4591001 1142 11421286	16-55	16OCT2020	108088	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
11421287	C4591001 1142 11421287	16-55	16OCT2020	108870	Placebo	16OCT2020/ Placebo	06NOV2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
11421289	C4591001 1142 11421289	16-55	19OCT2020	108871	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
11421290	C4591001 1142 11421290	16-55	20OCT2020	108878	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
11421292	C4591001 1142 11421292	16-55	20OCT2020	108879	Placebo	20OCT2020/ Placebo	12NOV2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
11421293	C4591001 1142 11421293	16-55	21OCT2020	111392	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11421295	C4591001 1142 11421295	16-55	23OCT2020	111395	Placebo	23OCT2020/ Placebo	12NOV2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	21JAN2021/ BNT162b2 (30 µg)
11421298	C4591001 1142 11421298	16-55	23OCT2020	111396	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
11421299	C4591001 1142 11421299	16-55	26OCT2020	111400	Placebo	26OCT2020/ Placebo	18NOV2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11421300	C4591001 1142 11421300	16-55	26OCT2020	113514	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	18NOV2020/ BNT162b2 (30 µg)		
11421303	C4591001 1142 11421303	16-55	27OCT2020	113520	Placebo	27OCT2020/ Placebo	12NOV2020/ Placebo		
11421306	C4591001 1142 11421306	16-55	28OCT2020	113522	Placebo	28OCT2020/ Placebo	18NOV2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	20JAN2021/ BNT162b2 (30 µg)
11421307	C4591001 1142 11421307	16-55	28OCT2020	113524	BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)	18NOV2020/ BNT162b2 (30 µg)		
11421308	C4591001 1142 11421308	16-55	28OCT2020	114452	BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)	18NOV2020/ BNT162b2 (30 µg)		
11421310	C4591001 1142 11421310	16-55	29OCT2020	114456	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
11421313	C4591001 1142 11421313	16-55	29OCT2020	114458	Placebo	29OCT2020/ Placebo	19NOV2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11421314	C4591001 1142 11421314	16-55	23NOV2020	114459	Placebo	23NOV2020/ Placebo	15DEC2020/ Placebo		
11421315	C4591001 1142 11421315	16-55	24NOV2020	116779	Placebo	24NOV2020/ Placebo	15DEC2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
11421316	C4591001 1142 11421316	16-55	24NOV2020	116782	BNT162b2 (30 µg)	24NOV2020/ BNT162b2 (30 µg)	15DEC2020/ BNT162b2 (30 µg)		
11421317	C4591001 1142 11421317	16-55	25NOV2020	116786	Placebo	25NOV2020/ Placebo	15DEC2020/ Placebo		
11421322	C4591001 1142 11421322	16-55	03DEC2020	116788	BNT162b2 (30 µg)	03DEC2020/ BNT162b2 (30 µg)	22DEC2020/ BNT162b2 (30 µg)		
11421328	C4591001 1142 11421328	16-55	04DEC2020	117521	BNT162b2 (30 µg)	04DEC2020/ BNT162b2 (30 µg)	23DEC2020/ BNT162b2 (30 µg)		
11421331	C4591001 1142 11421331	16-55	04DEC2020	117522	Placebo	04DEC2020/ Placebo	23DEC2020/ Placebo		
11421332	C4591001 1142 11421332	16-55	04DEC2020	117525	BNT162b2 (30 µg)	04DEC2020/ BNT162b2 (30 µg)	23DEC2020/ BNT162b2 (30 µg)		
11421334	C4591001 1142 11421334	16-55	04DEC2020	117527	Placebo	04DEC2020/ Placebo	23DEC2020/ Placebo		
11421336	C4591001 1142 11421336	16-55	04DEC2020	117606	Placebo	04DEC2020/ Placebo	23DEC2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
11421337	C4591001 1142 11421337	16-55	04DEC2020	117609	Placebo	04DEC2020/ Placebo	23DEC2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11421338	C4591001 1142 11421338	16-55	04DEC2020	117612	BNT162b2 (30 µg)	04DEC2020/ BNT162b2 (30 µg)	23DEC2020/ BNT162b2 (30 µg)		
11421339	C4591001 1142 11421339	16-55	04DEC2020	117615	BNT162b2 (30 µg)	04DEC2020/ BNT162b2 (30 µg)	23DEC2020/ BNT162b2 (30 µg)		
11421347	C4591001 1142 11421347	16-55	10DEC2020	117813	BNT162b2 (30 µg)	10DEC2020/ BNT162b2 (30 µg)	29DEC2020/ BNT162b2 (30 µg)		
11451017	C4591001 1145 11451017	16-55	17AUG2020	49143	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11451019	C4591001 1145 11451019	16-55	17AUG2020	53034	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11451020	C4591001 1145 11451020	16-55	17AUG2020	53035	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
11451021	C4591001 1145 11451021	16-55	18AUG2020	53037	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)
11451022	C4591001 1145 11451022	16-55	18AUG2020	53042	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11451025	C4591001 1145 11451025	16-55	18AUG2020	54821	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11451026	C4591001 1145 11451026	16-55	18AUG2020	54823	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11451030	C4591001 1145 11451030	16-55	21AUG2020	54829	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11451031	C4591001 1145 11451031	16-55	21AUG2020	54831	Placebo	21AUG2020/ Placebo	09SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
11451033	C4591001 1145 11451033	16-55	21AUG2020	60881	Placebo	21AUG2020/ Placebo	09SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
11451034	C4591001 1145 11451034	16-55	24AUG2020	60884	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
11451036	C4591001 1145 11451036	16-55	24AUG2020	60891	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
11451037	C4591001 1145 11451037	16-55	24AUG2020	60892	Placebo	24AUG2020/ Placebo	15SEP2020/ Placebo		
11451039	C4591001 1145 11451039	16-55	24AUG2020	64087	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11451042	C4591001 1145 11451042	16-55	25AUG2020	64092	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
11451043	C4591001 1145 11451043	16-55	25AUG2020	64093	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
11451044	C4591001 1145 11451044	16-55	25AUG2020	64094	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11451051	C4591001 1145 11451051	16-55	26AUG2020	68262	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
11451053	C4591001 1145 11451053	16-55	27AUG2020	68265	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
11451054	C4591001 1145 11451054	16-55	27AUG2020	68267	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
11451057	C4591001 1145 11451057	16-55	28AUG2020	68269	Placebo	28AUG2020/ Placebo	17SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
11451059	C4591001 1145 11451059	16-55	28AUG2020	72415	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
11451060	C4591001 1145 11451060	16-55	28AUG2020	72414	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
11451063	C4591001 1145 11451063	16-55	31AUG2020	72416	Placebo	31AUG2020/ Placebo	24NOV2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
11451064	C4591001 1145 11451064	16-55	02SEP2020	72418	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11451067	C4591001 1145 11451067	16-55	03SEP2020	80084	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
11451068	C4591001 1145 11451068	16-55	03SEP2020	80088	Placebo	03SEP2020/ Placebo	22SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11451071	C4591001 1145 11451071	16-55	04SEP2020	80090	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
11451074	C4591001 1145 11451074	16-55	04SEP2020	81713	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
11451075	C4591001 1145 11451075	16-55	04SEP2020	80091	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
11451077	C4591001 1145 11451077	16-55	04SEP2020	81720	Placebo	04SEP2020/ Placebo	24SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11451079	C4591001 1145 11451079	16-55	04SEP2020	81723	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
11451080	C4591001 1145 11451080	16-55	08SEP2020	81724	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
11451081	C4591001 1145 11451081	16-55	09SEP2020	85025	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11451082	C4591001 1145 11451082	16-55	09SEP2020	85033	Placebo	09SEP2020/ Placebo	29SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
11451085	C4591001 1145 11451085	16-55	09SEP2020	85034	Placebo	09SEP2020/ Placebo	29SEP2020/ Placebo		
11451086	C4591001 1145 11451086	16-55	09SEP2020	85036	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11451087	C4591001 1145 11451087	16-55	09SEP2020	85532	Placebo	09SEP2020/ Placebo	29SEP2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
11451088	C4591001 1145 11451088	16-55	09SEP2020	85534	Placebo	09SEP2020/ Placebo	29SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
11451090	C4591001 1145 11451090	16-55	10SEP2020	85540	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11451091	C4591001 1145 11451091	16-55	10SEP2020	85537	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11451093	C4591001 1145 11451093	16-55	10SEP2020	86802	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11451094	C4591001 1145 11451094	16-55	10SEP2020	86804	Placebo	10SEP2020/ Placebo	29SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
11451097	C4591001 1145 11451097	16-55	10SEP2020	86807	Placebo	10SEP2020/ Placebo	29SEP2020/ Placebo	02MAR2021/ BNT162b2 (30 µg)	
11451101	C4591001 1145 11451101	16-55	11SEP2020	86811	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
11451103	C4591001 1145 11451103	16-55	11SEP2020	88582	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
11451104	C4591001 1145 11451104	16-55	11SEP2020	88585	Placebo	11SEP2020/ Placebo	01OCT2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11451106	C4591001 1145 11451106	16-55	18SEP2020	88588	Placebo	18SEP2020/ Placebo	08OCT2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
11451107	C4591001 1145 11451107	16-55	18SEP2020	88586	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
11451108	C4591001 1145 11451108	16-55	13OCT2020	106988	Placebo	13OCT2020/ Placebo	05NOV2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
11451110	C4591001 1145 11451110	16-55	15OCT2020	106989	Placebo	15OCT2020/ Placebo	05NOV2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
11451112	C4591001 1145 11451112	16-55	22OCT2020	106990	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
11451115	C4591001 1145 11451115	16-55	28OCT2020	106992	BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)		
11461028	C4591001 1146 11461028	16-55	17AUG2020	49932	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11461030	C4591001 1146 11461030	16-55	17AUG2020	49935	Placebo	17AUG2020/ Placebo	09SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
11461031	C4591001 1146 11461031	16-55	17AUG2020	52325	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
11461033	C4591001 1146 11461033	16-55	17AUG2020	52327	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11461034	C4591001 1146 11461034	16-55	17AUG2020	52328	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
11461038	C4591001 1146 11461038	16-55	17AUG2020	52330	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11461041	C4591001 1146 11461041	16-55	18AUG2020	53789	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11461043	C4591001 1146 11461043	16-55	18AUG2020	53793	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11461044	C4591001 1146 11461044	16-55	18AUG2020	53794	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
11461046	C4591001 1146 11461046	16-55	18AUG2020	53800	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
11461049	C4591001 1146 11461049	16-55	18AUG2020	54762	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11461050	C4591001 1146 11461050	16-55	19AUG2020	54766	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11461052	C4591001 1146 11461052	16-55	19AUG2020	54767	Placebo	19AUG2020/ Placebo	23SEP2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
11461053	C4591001 1146 11461053	16-55	19AUG2020	54771	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	28JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11461054	C4591001 1146 11461054	16-55	19AUG2020	55950	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
11461055	C4591001 1146 11461055	16-55	19AUG2020	55952	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
11461056	C4591001 1146 11461056	16-55	19AUG2020	55953	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11461058	C4591001 1146 11461058	16-55	19AUG2020	55956	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
11461059	C4591001 1146 11461059	16-55	19AUG2020	56429	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
11461061	C4591001 1146 11461061	16-55	19AUG2020	56430	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11461063	C4591001 1146 11461063	16-55	19AUG2020	56433	Placebo	19AUG2020/ Placebo	08SEP2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
11461069	C4591001 1146 11461069	16-55	20AUG2020	56436	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
11461070	C4591001 1146 11461070	16-55	20AUG2020	58006	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
11461071	C4591001 1146 11461071	16-55	20AUG2020	58007	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11461075	C4591001 1146 11461075	16-55	20AUG2020	58012	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11461076	C4591001 1146 11461076	16-55	20AUG2020	58011	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
11461077	C4591001 1146 11461077	16-55	20AUG2020	58745	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11461078	C4591001 1146 11461078	16-55	20AUG2020	58748	Placebo	20AUG2020/ Placebo	11SEP2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)
11461080	C4591001 1146 11461080	16-55	20AUG2020	58751	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
11461081	C4591001 1146 11461081	16-55	20AUG2020	58756	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
11461082	C4591001 1146 11461082	16-55	21AUG2020	59899	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
11461083	C4591001 1146 11461083	16-55	21AUG2020	59900	Placebo	21AUG2020/ Placebo	10SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
11461084	C4591001 1146 11461084	16-55	21AUG2020	59907	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11461085	C4591001 1146 11461085	16-55	21AUG2020	59903	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11461086	C4591001 1146 11461086	16-55	21AUG2020	60090	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
11461090	C4591001 1146 11461090	16-55	21AUG2020	60093	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11461091	C4591001 1146 11461091	16-55	21AUG2020	60098	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
11461092	C4591001 1146 11461092	16-55	21AUG2020	60100	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
11461093	C4591001 1146 11461093	16-55	21AUG2020	60605	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
11461094	C4591001 1146 11461094	16-55	21AUG2020	60607	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11461096	C4591001 1146 11461096	16-55	21AUG2020	60612	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
11461097	C4591001 1146 11461097	16-55	21AUG2020	60613	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
11461098	C4591001 1146 11461098	16-55	21AUG2020	60849	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
11461100	C4591001 1146 11461100	16-55	24AUG2020	60850	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11461102	C4591001 1146 11461102	16-55	24AUG2020	60852	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	
11461103	C4591001 1146 11461103	16-55	24AUG2020	60854	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11461104	C4591001 1146 11461104	16-55	24AUG2020	63476	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
11461108	C4591001 1146 11461108	16-55	25AUG2020	63478	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
11461110	C4591001 1146 11461110	16-55	25AUG2020	63482	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11461111	C4591001 1146 11461111	16-55	26AUG2020	63483	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
11461112	C4591001 1146 11461112	16-55	26AUG2020	67194	Placebo	26AUG2020/ Placebo	15SEP2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	28JAN2021/ BNT162b2 (30 µg)
11461113	C4591001 1146 11461113	16-55	26AUG2020	67193	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
11461116	C4591001 1146 11461116	16-55	26AUG2020	67199	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
11461117	C4591001 1146 11461117	16-55	26AUG2020	67200	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11461118	C4591001 1146 11461118	16-55	26AUG2020	67757	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
11461119	C4591001 1146 11461119	16-55	26AUG2020	67759	Placebo	26AUG2020/ Placebo	18SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
11461122	C4591001 1146 11461122	16-55	26AUG2020	67766	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
11461123	C4591001 1146 11461123	16-55	26AUG2020	67768	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11461124	C4591001 1146 11461124	16-55	27AUG2020	69398	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
11461125	C4591001 1146 11461125	16-55	27AUG2020	69392	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
11461126	C4591001 1146 11461126	16-55	27AUG2020	69395	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
11461129	C4591001 1146 11461129	16-55	27AUG2020	69703	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
11461130	C4591001 1146 11461130	16-55	27AUG2020	69399	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
11461133	C4591001 1146 11461133	16-55	27AUG2020	69706	Placebo	27AUG2020/ Placebo	18SEP2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11461140	C4591001 1146 11461140	16-55	27AUG2020	69710	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo		
11461141	C4591001 1146 11461141	16-55	28AUG2020	71494	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
11461142	C4591001 1146 11461142	16-55	28AUG2020	71495	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
11461144	C4591001 1146 11461144	16-55	28AUG2020	71496	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
11461145	C4591001 1146 11461145	16-55	28AUG2020	71681	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11461146	C4591001 1146 11461146	16-55	28AUG2020	71497	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
11461147	C4591001 1146 11461147	16-55	28AUG2020	71684	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
11461150	C4591001 1146 11461150	16-55	28AUG2020	71689	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
11461155	C4591001 1146 11461155	16-55	28AUG2020	72500	Placebo	28AUG2020/ Placebo	17SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
11461157	C4591001 1146 11461157	16-55	28AUG2020	71692	Placebo	28AUG2020/ Placebo	17SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11461158	C4591001 1146 11461158	16-55	31AUG2020	72501	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
11461159	C4591001 1146 11461159	16-55	31AUG2020	72507	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11461160	C4591001 1146 11461160	16-55	31AUG2020	72504	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11461163	C4591001 1146 11461163	16-55	31AUG2020	74803	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11461166	C4591001 1146 11461166	16-55	31AUG2020	74804	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11461167	C4591001 1146 11461167	16-55	31AUG2020	74805	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11461168	C4591001 1146 11461168	16-55	01SEP2020	74811	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
11461170	C4591001 1146 11461170	16-55	01SEP2020	76289	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11461172	C4591001 1146 11461172	16-55	01SEP2020	76290	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	27JAN2021/ BNT162b2 (30 µg)
11461176	C4591001 1146 11461176	16-55	01SEP2020	76299	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11461177	C4591001 1146 11461177	16-55	01SEP2020	76298	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
11461179	C4591001 1146 11461179	16-55	01SEP2020	76925	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
11461183	C4591001 1146 11461183	16-55	02SEP2020	76927	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11461184	C4591001 1146 11461184	16-55	02SEP2020	76935	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
11461185	C4591001 1146 11461185	16-55	02SEP2020	76936	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11461186	C4591001 1146 11461186	16-55	02SEP2020	77949	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
11461187	C4591001 1146 11461187	16-55	02SEP2020	77951	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11461190	C4591001 1146 11461190	16-55	02SEP2020	77952	Placebo	02SEP2020/ Placebo	21SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
11461192	C4591001 1146 11461192	16-55	02SEP2020	77954	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11461193	C4591001 1146 11461193	16-55	02SEP2020	78584	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11461195	C4591001 1146 11461195	16-55	03SEP2020	78587	Placebo	03SEP2020/ Placebo	22SEP2020/ Placebo		
11461196	C4591001 1146 11461196	16-55	03SEP2020	78589	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
11461197	C4591001 1146 11461197	16-55	03SEP2020	78592	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
11461198	C4591001 1146 11461198	16-55	03SEP2020	79520	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11461199	C4591001 1146 11461199	16-55	03SEP2020	79517	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
11461200	C4591001 1146 11461200	16-55	03SEP2020	79525	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
11461201	C4591001 1146 11461201	16-55	03SEP2020	79528	Placebo	03SEP2020/ Placebo	25SEP2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
11461202	C4591001 1146 11461202	16-55	03SEP2020	79829	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
11461204	C4591001 1146 11461204	16-55	03SEP2020	79832	Placebo	03SEP2020/ Placebo	22SEP2020/ Placebo	06JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
11461205	C4591001 1146 11461205	16-55	03SEP2020	79838	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11461206	C4591001 1146 11461206	16-55	03SEP2020	79836	Placebo	03SEP2020/ Placebo	23SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
11461207	C4591001 1146 11461207	16-55	03SEP2020	80275	Placebo	03SEP2020/ Placebo	22SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
11461210	C4591001 1146 11461210	16-55	04SEP2020	80282	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
11461211	C4591001 1146 11461211	16-55	04SEP2020	80283	Placebo	04SEP2020/ Placebo	02OCT2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11461212	C4591001 1146 11461212	16-55	04SEP2020	80284	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11461216	C4591001 1146 11461216	16-55	04SEP2020	81330	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
11461218	C4591001 1146 11461218	16-55	04SEP2020	81333	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
11461219	C4591001 1146 11461219	16-55	04SEP2020	81335	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
11461220	C4591001 1146 11461220	16-55	04SEP2020	81340	Placebo	04SEP2020/ Placebo	23SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
11461221	C4591001 1146 11461221	16-55	04SEP2020	81521	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11461225	C4591001 1146 11461225	16-55	04SEP2020	81522	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
11461227	C4591001 1146 11461227	16-55	04SEP2020	81529	Placebo	04SEP2020/ Placebo	23SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
11461229	C4591001 1146 11461229	16-55	11SEP2020	81531	Placebo	11SEP2020/ Placebo	01OCT2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
11461234	C4591001 1146 11461234	16-55	14SEP2020	89586	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
11461236	C4591001 1146 11461236	16-55	14SEP2020	89587	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
11461237	C4591001 1146 11461237	16-55	15SEP2020	89594	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
11461238	C4591001 1146 11461238	16-55	15SEP2020	89596	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
11461239	C4591001 1146 11461239	16-55	15SEP2020	90139	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
11461240	C4591001 1146 11461240	16-55	15SEP2020	90143	Placebo	15SEP2020/ Placebo	06OCT2020/ Placebo		
11461241	C4591001 1146 11461241	16-55	15SEP2020	90147	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11461243	C4591001 1146 11461243	16-55	15SEP2020	90148	Placebo	15SEP2020/ Placebo	06OCT2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
11461245	C4591001 1146 11461245	16-55	15SEP2020	90584	Placebo	15SEP2020/ Placebo	06OCT2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
11461246	C4591001 1146 11461246†	16-55	16SEP2020	90585	Placebo	16SEP2020/ Placebo	06OCT2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
11461248	C4591001 1146 11461248	16-55	16SEP2020	90588	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
11461249	C4591001 1146 11461249	16-55	17SEP2020	90589	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
11461250	C4591001 1146 11461250	16-55	17SEP2020	92172	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
11461251	C4591001 1146 11461251	16-55	17SEP2020	92173	Placebo	17SEP2020/ Placebo	06OCT2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
11461255	C4591001 1146 11461255	16-55	18SEP2020	92175	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
11461258	C4591001 1146 11461258	16-55	18SEP2020	92176	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
11461263	C4591001 1146 11461263	16-55	25SEP2020	99935	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11461265	C4591001 1146 11461265	16-55	25SEP2020	99933	Placebo	25SEP2020/ Placebo	14OCT2020/ Placebo	11MAR2021/ BNT162b2 (30 µg)	
11461267	C4591001 1146 11461267	16-55	19OCT2020	400002	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
11461268	C4591001 1146 11461268	16-55	19OCT2020	400004	Placebo	19OCT2020/ Placebo	09NOV2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
11461269	C4591001 1146 11461269	16-55	19OCT2020	400003	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		
11461270	C4591001 1146 11461270	16-55	19OCT2020	400006	Placebo	19OCT2020/ Placebo	10NOV2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
11461271	C4591001 1146 11461271	16-55	19OCT2020	400015	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
11461272	C4591001 1146 11461272	16-55	19OCT2020	400017	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
11461273	C4591001 1146 11461273	16-55	19OCT2020	400022	Placebo	19OCT2020/ Placebo	13NOV2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
11461274	C4591001 1146 11461274	16-55	19OCT2020	400023	Placebo	19OCT2020/ Placebo	11NOV2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
11461275	C4591001 1146 11461275	16-55	19OCT2020	400026	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11461276	C4591001 1146 11461276	16-55	19OCT2020	400030	Placebo	19OCT2020/ Placebo	09NOV2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
11461277	C4591001 1146 11461277	16-55	19OCT2020	400032	Placebo	19OCT2020/ Placebo	09NOV2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
11461278	C4591001 1146 11461278	16-55	19OCT2020	400033	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
11461279	C4591001 1146 11461279	16-55	20OCT2020	400038	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
11461280	C4591001 1146 11461280	16-55	20OCT2020	400040	Placebo	20OCT2020/ Placebo	10NOV2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
11461281	C4591001 1146 11461281	16-55	20OCT2020	400046	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		
11461282	C4591001 1146 11461282	16-55	20OCT2020	400044	Placebo	20OCT2020/ Placebo	12NOV2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
11461283	C4591001 1146 11461283	16-55	20OCT2020	400065	Placebo	20OCT2020/ Placebo	12NOV2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
11461284	C4591001 1146 11461284	16-55	20OCT2020	400064	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
11461285	C4591001 1146 11461285	16-55	20OCT2020	400066	Placebo	20OCT2020/ Placebo	11NOV2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11461286	C4591001 1146 11461286	16-55	20OCT2020	400085	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
11461287	C4591001 1146 11461287	16-55	20OCT2020	400069	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
11461288	C4591001 1146 11461288	16-55	20OCT2020	400086	Placebo	20OCT2020/ Placebo	19NOV2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
11461289	C4591001 1146 11461289	16-55	20OCT2020	400091	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
11461290	C4591001 1146 11461290	16-55	20OCT2020	400094	Placebo	20OCT2020/ Placebo	11NOV2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
11461291	C4591001 1146 11461291	16-55	20OCT2020	400121	Placebo	20OCT2020/ Placebo	11NOV2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
11461292	C4591001 1146 11461292	16-55	20OCT2020	400128	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
11461293	C4591001 1146 11461293	16-55	20OCT2020	400127	Placebo	20OCT2020/ Placebo	17NOV2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
11461294	C4591001 1146 11461294	16-55	21OCT2020	400131	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
11461295	C4591001 1146 11461295	16-55	21OCT2020	400145	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11461296	C4591001 1146 11461296	16-55	21OCT2020	400150	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
11461297	C4591001 1146 11461297	16-55	21OCT2020	400152	Placebo	21OCT2020/ Placebo	13NOV2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
11461298	C4591001 1146 11461298	16-55	21OCT2020	400153	Placebo	21OCT2020/ Placebo	13NOV2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
11461299	C4591001 1146 11461299	16-55	21OCT2020	400169	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
11461300	C4591001 1146 11461300	16-55	21OCT2020	400179	Placebo	21OCT2020/ Placebo	11NOV2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
11461301	C4591001 1146 11461301	16-55	21OCT2020	400174	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
11461302	C4591001 1146 11461302	16-55	21OCT2020	400180	Placebo	21OCT2020/ Placebo	10NOV2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
11461303	C4591001 1146 11461303	16-55	21OCT2020	400234	Placebo	21OCT2020/ Placebo	11NOV2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
11461304	C4591001 1146 11461304	16-55	21OCT2020	400237	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
11461305	C4591001 1146 11461305	16-55	21OCT2020	400235	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11461306	C4591001 1146 11461306	16-55	21OCT2020	400240	Placebo	21OCT2020/ Placebo	12NOV2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
11461307	C4591001 1146 11461307	16-55	21OCT2020	400279	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
11461308	C4591001 1146 11461308	16-55	22OCT2020	400281	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
11461309	C4591001 1146 11461309	16-55	22OCT2020	400283	Placebo	22OCT2020/ Placebo	12NOV2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	28JAN2021/ BNT162b2 (30 µg)
11461310	C4591001 1146 11461310	16-55	22OCT2020	400282	Placebo	22OCT2020/ Placebo	11NOV2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
11461311	C4591001 1146 11461311	16-55	22OCT2020	400339	Placebo	22OCT2020/ Placebo	13NOV2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11461312	C4591001 1146 11461312	16-55	22OCT2020	400344	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		
11461313	C4591001 1146 11461313	16-55	22OCT2020	400345	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
11461314	C4591001 1146 11461314	16-55	22OCT2020	400348	Placebo	22OCT2020/ Placebo	11NOV2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
11461315	C4591001 1146 11461315	16-55	22OCT2020	400362	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11461316	C4591001 1146 11461316	16-55	22OCT2020	400363	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
11461317	C4591001 1146 11461317	16-55	22OCT2020	400372	Placebo	22OCT2020/ Placebo	12NOV2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
11461318	C4591001 1146 11461318	16-55	22OCT2020	400369	Placebo	22OCT2020/ Placebo	12NOV2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
11461319	C4591001 1146 11461319	16-55	22OCT2020	400399	Placebo	22OCT2020/ Placebo	11NOV2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
11461320	C4591001 1146 11461320	16-55	22OCT2020	400401	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
11461321	C4591001 1146 11461321	16-55	22OCT2020	400403	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
11461322	C4591001 1146 11461322	16-55	22OCT2020	400406	Placebo	22OCT2020/ Placebo	12NOV2020/ Placebo		
11461323	C4591001 1146 11461323	16-55	22OCT2020	400445	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
11461324	C4591001 1146 11461324	16-55	22OCT2020	400446	Placebo	22OCT2020/ Placebo	11NOV2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
11461325	C4591001 1146 11461325	16-55	23OCT2020	400449	Placebo	23OCT2020/ Placebo	13NOV2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11461326	C4591001 1146 11461326	16-55	23OCT2020	400455	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
11461327	C4591001 1146 11461327	16-55	23OCT2020	400469	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
11461328	C4591001 1146 11461328	16-55	23OCT2020	400475	Placebo	23OCT2020/ Placebo	13NOV2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
11461329	C4591001 1146 11461329	16-55	23OCT2020	400471	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
11461331	C4591001 1146 11461331	16-55	23OCT2020	400480	Placebo	23OCT2020/ Placebo	13NOV2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
11461332	C4591001 1146 11461332	16-55	23OCT2020	400517	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
11461333	C4591001 1146 11461333	16-55	23OCT2020	400518	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
11461334	C4591001 1146 11461334	16-55	23OCT2020	400521	Placebo	23OCT2020/ Placebo	11NOV2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
11461335	C4591001 1146 11461335	16-55	23OCT2020	400523	Placebo	23OCT2020/ Placebo	11NOV2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
11461336	C4591001 1146 11461336	16-55	23OCT2020	400627	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11461337	C4591001 1146 11461337	16-55	23OCT2020	400628	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
11461338	C4591001 1146 11461338	16-55	23OCT2020	400630	Placebo	23OCT2020/ Placebo	13NOV2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
11461339	C4591001 1146 11461339	16-55	26OCT2020	400634	Placebo	26OCT2020/ Placebo	16NOV2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
11461340	C4591001 1146 11461340	16-55	26OCT2020	400771	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	04DEC2020/ BNT162b2 (30 µg)		
11461341	C4591001 1146 11461341	16-55	26OCT2020	400773	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
11461342	C4591001 1146 11461342	16-55	26OCT2020	400774	Placebo	26OCT2020/ Placebo	16NOV2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
11461343	C4591001 1146 11461343	16-55	26OCT2020	400777	Placebo	26OCT2020/ Placebo	18NOV2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
11461344	C4591001 1146 11461344	16-55	26OCT2020	400806	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
11461345	C4591001 1146 11461345	16-55	26OCT2020	400807	Placebo	26OCT2020/ Placebo	18NOV2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
11461346	C4591001 1146 11461346	16-55	26OCT2020	400808	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	18NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11461347	C4591001 1146 11461347	16-55	26OCT2020	400812	Placebo	26OCT2020/ Placebo	18NOV2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
11461348	C4591001 1146 11461348	16-55	26OCT2020	400913	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
11461349	C4591001 1146 11461349	16-55	26OCT2020	400914	Placebo	26OCT2020/ Placebo	18NOV2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
11461350	C4591001 1146 11461350	16-55	26OCT2020	400916	Placebo	26OCT2020/ Placebo	17NOV2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
11461351	C4591001 1146 11461351	16-55	26OCT2020	400922	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	18NOV2020/ BNT162b2 (30 µg)		
11461352	C4591001 1146 11461352	16-55	26OCT2020	400942	Placebo	26OCT2020/ Placebo	16NOV2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
11461353	C4591001 1146 11461353	16-55	26OCT2020	400944	Placebo	26OCT2020/ Placebo	18NOV2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
11461354	C4591001 1146 11461354	16-55	26OCT2020	400946	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
11461355	C4591001 1146 11461355	16-55	27OCT2020	400947	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
11461356	C4591001 1146 11461356	16-55	27OCT2020	401045	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11461357	C4591001 1146 11461357	16-55	27OCT2020	401050	Placebo	27OCT2020/ Placebo	17NOV2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
11461358	C4591001 1146 11461358	16-55	27OCT2020	401054	Placebo	27OCT2020/ Placebo	16NOV2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
11461359	C4591001 1146 11461359	16-55	27OCT2020	401055	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	18NOV2020/ BNT162b2 (30 µg)		
11461360	C4591001 1146 11461360	16-55	27OCT2020	401057	Placebo	27OCT2020/ Placebo	16NOV2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
11461361	C4591001 1146 11461361	16-55	27OCT2020	401061	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
11461363	C4591001 1146 11461363	16-55	27OCT2020	401062	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
11461364	C4591001 1146 11461364	16-55	27OCT2020	401118	Placebo	27OCT2020/ Placebo	16NOV2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
11461365	C4591001 1146 11461365	16-55	27OCT2020	401068	Placebo	27OCT2020/ Placebo	16NOV2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
11461366	C4591001 1146 11461366	16-55	28OCT2020	401119	Placebo	28OCT2020/ Placebo	16NOV2020/ Placebo	06JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)
11461367	C4591001 1146 11461367	16-55	28OCT2020	401121	BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)	18NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11461368	C4591001 1146 11461368	16-55	28OCT2020	401124	BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
11461369	C4591001 1146 11461369	16-55	28OCT2020	401165	BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
11461370	C4591001 1146 11461370	16-55	28OCT2020	401168	Placebo	28OCT2020/ Placebo	19NOV2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
11461371	C4591001 1146 11461371	16-55	28OCT2020	401166	BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)		
11461372	C4591001 1146 11461372	16-55	28OCT2020	401178	BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
11461373	C4591001 1146 11461373	16-55	28OCT2020	401174	Placebo	28OCT2020/ Placebo	18NOV2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
11461374	C4591001 1146 11461374	16-55	28OCT2020	401180	BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
11461375	C4591001 1146 11461375	16-55	29OCT2020	401183	Placebo	29OCT2020/ Placebo	19NOV2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
11461376	C4591001 1146 11461376	16-55	29OCT2020	401218	Placebo	29OCT2020/ Placebo	17NOV2020/ Placebo		
11461377	C4591001 1146 11461377	16-55	29OCT2020	401188	Placebo	29OCT2020/ Placebo	19NOV2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11461378	C4591001 1146 11461378	16-55	29OCT2020	401219	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
11461379	C4591001 1146 11461379	16-55	29OCT2020	401221	Placebo	29OCT2020/ Placebo	17NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
11461380	C4591001 1146 11461380	16-55	29OCT2020	401224	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	30NOV2020/ BNT162b2 (30 µg)		
11461381	C4591001 1146 11461381	16-55	29OCT2020	401226	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)		
11461382	C4591001 1146 11461382	16-55	29OCT2020	401232	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
11461384	C4591001 1146 11461384	16-55	29OCT2020	401231	Placebo	29OCT2020/ Placebo	20NOV2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
11461385	C4591001 1146 11461385	16-55	29OCT2020	401234	Placebo	29OCT2020/ Placebo	17NOV2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
11461386	C4591001 1146 11461386	16-55	29OCT2020	401323	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	18NOV2020/ BNT162b2 (30 µg)		
11461387	C4591001 1146 11461387	16-55	29OCT2020	401325	Placebo	29OCT2020/ Placebo	20NOV2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
11461388	C4591001 1146 11461388	16-55	29OCT2020	401332	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11461389	C4591001 1146 11461389	16-55	29OCT2020	401331	Placebo	29OCT2020/ Placebo	18NOV2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
11461390	C4591001 1146 11461390	16-55	29OCT2020	401351	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
11461391	C4591001 1146 11461391	16-55	29OCT2020	401353	Placebo	29OCT2020/ Placebo	17NOV2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
11461393	C4591001 1146 11461393	16-55	29OCT2020	401355	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
11461394	C4591001 1146 11461394	16-55	29OCT2020	401356	Placebo	29OCT2020/ Placebo	17NOV2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
11461395	C4591001 1146 11461395	16-55	29OCT2020	401393	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	18NOV2020/ BNT162b2 (30 µg)		
11461397	C4591001 1146 11461397	16-55	29OCT2020	401404	Placebo	29OCT2020/ Placebo	18NOV2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
11461398	C4591001 1146 11461398	16-55	29OCT2020	401397	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)		
11461399	C4591001 1146 11461399	16-55	29OCT2020	401403	Placebo	29OCT2020/ Placebo	17NOV2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
11471112	C4591001 1147 11471112	16-55	24AUG2020	61112	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11471136	C4591001 1147 11471136	16-55	14AUG2020	50838	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
11471140	C4591001 1147 11471140	16-55	17AUG2020	50839	Placebo	17AUG2020/ Placebo	10SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
11471142	C4591001 1147 11471142	16-55	18AUG2020	50842	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
11471144	C4591001 1147 11471144	16-55	19AUG2020	50847	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
11471145	C4591001 1147 11471145	16-55	19AUG2020	56122	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo		
11471147	C4591001 1147 11471147	16-55	19AUG2020	56123	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
11471149	C4591001 1147 11471149	16-55	19AUG2020	56124	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
11471150	C4591001 1147 11471150	16-55	19AUG2020	56125	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
11471151	C4591001 1147 11471151	16-55	19AUG2020	57043	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
11471152	C4591001 1147 11471152	16-55	19AUG2020	57046	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11471153	C4591001 1147 11471153	16-55	19AUG2020	57047	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
11471160	C4591001 1147 11471160	16-55	20AUG2020	57051	Placebo	20AUG2020/ Placebo	09SEP2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
11471163	C4591001 1147 11471163	16-55	20AUG2020	58964	Placebo	20AUG2020/ Placebo	17SEP2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
11471164	C4591001 1147 11471164	16-55	20AUG2020	58967	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
11471165	C4591001 1147 11471165	16-55	20AUG2020	58971	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
11471166	C4591001 1147 11471166	16-55	20AUG2020	58972	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
11471168	C4591001 1147 11471168	16-55	20AUG2020	59813	Placebo	20AUG2020/ Placebo	09SEP2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
11471171	C4591001 1147 11471171	16-55	21AUG2020	59815	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
11471173	C4591001 1147 11471173	16-55	21AUG2020	59817	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11471174	C4591001 1147 11471174	16-55	21AUG2020	59823	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11471176	C4591001 1147 11471176	16-55	21AUG2020	61110	Placebo	21AUG2020/ Placebo	09SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
11471180	C4591001 1147 11471180	16-55	24AUG2020	61116	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11471182	C4591001 1147 11471182	16-55	24AUG2020	61120	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
11471183	C4591001 1147 11471183	16-55	24AUG2020	64326	Placebo	24AUG2020/ Placebo	18SEP2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
11471184	C4591001 1147 11471184	16-55	24AUG2020	64331	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
11471186	C4591001 1147 11471186	16-55	25AUG2020	64334	Placebo	25AUG2020/ Placebo	14SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
11471188	C4591001 1147 11471188	16-55	25AUG2020	64336	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11471189	C4591001 1147 11471189	16-55	25AUG2020	66463	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11471191	C4591001 1147 11471191	16-55	26AUG2020	66466	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
11471194	C4591001 1147 11471194	16-55	27AUG2020	66469	Placebo	27AUG2020/ Placebo	18SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11471195	C4591001 1147 11471195	16-55	27AUG2020	66472	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)
11471197	C4591001 1147 11471197	16-55	28AUG2020	72030	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
11471201	C4591001 1147 11471201	16-55	28AUG2020	72034	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
11471202	C4591001 1147 11471202	16-55	28AUG2020	72039	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
11471203	C4591001 1147 11471203	16-55	31AUG2020	72040	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
11471204	C4591001 1147 11471204	16-55	31AUG2020	75641	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11471206	C4591001 1147 11471206	16-55	31AUG2020	75643	Placebo	31AUG2020/ Placebo	22SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
11471207	C4591001 1147 11471207	16-55	31AUG2020	75649	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11471209	C4591001 1147 11471209	16-55	01SEP2020	75650	Placebo	01SEP2020/ Placebo	21SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
11471210	C4591001 1147 11471210	16-55	02SEP2020	78437	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11471211	C4591001 1147 11471211	16-55	02SEP2020	78438	Placebo	02SEP2020/ Placebo	02OCT2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
11471212	C4591001 1147 11471212	16-55	03SEP2020	78442	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)			
11471213	C4591001 1147 11471213	16-55	03SEP2020	78443	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
11471216	C4591001 1147 11471216	16-55	03SEP2020	80453	Placebo	03SEP2020/ Placebo	28SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11471217	C4591001 1147 11471217	16-55	03SEP2020	80456	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
11471219	C4591001 1147 11471219	16-55	03SEP2020	80458	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11471220	C4591001 1147 11471220	16-55	03SEP2020	80464	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
11471222	C4591001 1147 11471222	16-55	04SEP2020	81886	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
11471223	C4591001 1147 11471223	16-55	04SEP2020	81887	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
11471225	C4591001 1147 11471225	16-55	09SEP2020	81888	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11471226	C4591001 1147 11471226	16-55	09SEP2020	81889	Placebo	09SEP2020/ Placebo	02OCT2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
11471227	C4591001 1147 11471227	16-55	09SEP2020	85388	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11471231	C4591001 1147 11471231	16-55	09SEP2020	85389	Placebo	09SEP2020/ Placebo	28SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
11471234	C4591001 1147 11471234	16-55	10SEP2020	85392	Placebo	10SEP2020/ Placebo	29SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11471235	C4591001 1147 11471235	16-55	10SEP2020	86648	Placebo	10SEP2020/ Placebo	30SEP2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)
11471236	C4591001 1147 11471236	16-55	10SEP2020	86645	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
11471237	C4591001 1147 11471237	16-55	10SEP2020	85395	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
11471243	C4591001 1147 11471243	16-55	10SEP2020	86649	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
11471245	C4591001 1147 11471245	16-55	11SEP2020	86651	Placebo	11SEP2020/ Placebo	05OCT2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
11471246	C4591001 1147 11471246	16-55	11SEP2020	88244	Placebo	11SEP2020/ Placebo	30SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11471252	C4591001 1147 11471252	16-55	11SEP2020	88249	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
11471253	C4591001 1147 11471253	16-55	11SEP2020	88251	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
11471254	C4591001 1147 11471254	16-55	11SEP2020	88252	Placebo	11SEP2020/ Placebo	30SEP2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	20JAN2021/ BNT162b2 (30 µg)
11471255	C4591001 1147 11471255	16-55	14NOV2020	116261	BNT162b2 (30 µg)	14NOV2020/ BNT162b2 (30 µg)	05DEC2020/ BNT162b2 (30 µg)		
11471256	C4591001 1147 11471256	16-55	14NOV2020	116263	Placebo	14NOV2020/ Placebo	05DEC2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
11471257	C4591001 1147 11471257	16-55	21NOV2020	116269	BNT162b2 (30 µg)	21NOV2020/ BNT162b2 (30 µg)	12DEC2020/ BNT162b2 (30 µg)		
11471258	C4591001 1147 11471258	16-55	21NOV2020	116271	Placebo	21NOV2020/ Placebo	12DEC2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
11471259	C4591001 1147 11471259	16-55	21NOV2020	116650	BNT162b2 (30 µg)	21NOV2020/ BNT162b2 (30 µg)	12DEC2020/ BNT162b2 (30 µg)		
11471260	C4591001 1147 11471260	16-55	21NOV2020	116653	BNT162b2 (30 µg)	21NOV2020/ BNT162b2 (30 µg)	12DEC2020/ BNT162b2 (30 µg)		
11471265	C4591001 1147 11471265	16-55	05DEC2020	116654	Placebo	05DEC2020/ Placebo	28DEC2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11471266	C4591001 1147 11471266	16-55	05DEC2020	116656	Placebo	05DEC2020/ Placebo	28DEC2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
11471267	C4591001 1147 11471267	16-55	05DEC2020	117642	Placebo	05DEC2020/ Placebo	28DEC2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
11471272	C4591001 1147 11471272	16-55	05DEC2020	117644	Placebo	05DEC2020/ Placebo	28DEC2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
11471276	C4591001 1147 11471276	16-55	05DEC2020	117646	BNT162b2 (30 µg)	05DEC2020/ BNT162b2 (30 µg)	28DEC2020/ BNT162b2 (30 µg)		
11491073	C4591001 1149 11491073	16-55	17AUG2020	53237	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11491074	C4591001 1149 11491074	16-55	17AUG2020	53243	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11491075	C4591001 1149 11491075	16-55	17AUG2020	53246	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11491076	C4591001 1149 11491076	16-55	17AUG2020	53247	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	27JAN2021/ BNT162b2 (30 µg)
11491077	C4591001 1149 11491077	16-55	17AUG2020	53381	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11491079	C4591001 1149 11491079	16-55	17AUG2020	53383	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11491083	C4591001 1149 11491083	16-55	18AUG2020	53386	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
11491084	C4591001 1149 11491084	16-55	18AUG2020	53392	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
11491085	C4591001 1149 11491085	16-55	18AUG2020	55025	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11491086	C4591001 1149 11491086	16-55	18AUG2020	55028	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11491087	C4591001 1149 11491087	16-55	18AUG2020	55034	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo		
11491088	C4591001 1149 11491088	16-55	18AUG2020	55035	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
11491089	C4591001 1149 11491089	16-55	19AUG2020	57079	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
11491092	C4591001 1149 11491092	16-55	19AUG2020	57088	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11491093	C4591001 1149 11491093	16-55	19AUG2020	57086	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11491096	C4591001 1149 11491096	16-55	19AUG2020	57326	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11491097	C4591001 1149 11491097	16-55	19AUG2020	57327	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
11491098	C4591001 1149 11491098	16-55	19AUG2020	57319	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11491099	C4591001 1149 11491099	16-55	20AUG2020	57328	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	
11491108	C4591001 1149 11491108	16-55	20AUG2020	59790	Placebo				
11491109	C4591001 1149 11491109	16-55	20AUG2020	59192	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
11491110	C4591001 1149 11491110	16-55	20AUG2020	59194	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
11491114	C4591001 1149 11491114	16-55	20AUG2020	59189	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
11491115	C4591001 1149 11491115	16-55	20AUG2020	59132	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	20JAN2021/ BNT162b2 (30 µg)
11491116	C4591001 1149 11491116	16-55	20AUG2020	59195	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11491119	C4591001 1149 11491119	16-55	21AUG2020	59791	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11491120	C4591001 1149 11491120	16-55	21AUG2020	59795	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
11491121	C4591001 1149 11491121	16-55	21AUG2020	59796	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
11491125	C4591001 1149 11491125	16-55	21AUG2020	61121	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
11491128	C4591001 1149 11491128	16-55	24AUG2020	61129	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11491129	C4591001 1149 11491129	16-55	24AUG2020	61122	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11491133	C4591001 1149 11491133	16-55	24AUG2020	61131	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	28JAN2021/ BNT162b2 (30 µg)
11491136	C4591001 1149 11491136	16-55	25AUG2020	66355	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
11491137	C4591001 1149 11491137	16-55	25AUG2020	66354	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
11491140	C4591001 1149 11491140	16-55	25AUG2020	66534	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
11491141	C4591001 1149 11491141	16-55	25AUG2020	66362	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11491142	C4591001 1149 11491142	16-55	25AUG2020	66363	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
11491145	C4591001 1149 11491145	16-55	26AUG2020	66537	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11491146	C4591001 1149 11491146	16-55	26AUG2020	66538	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
11491147	C4591001 1149 11491147	16-55	26AUG2020	66543	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11491148	C4591001 1149 11491148	16-55	26AUG2020	68839	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11491149	C4591001 1149 11491149	16-55	26AUG2020	68842	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
11491150	C4591001 1149 11491150	16-55	26AUG2020	68846	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
11491151	C4591001 1149 11491151	16-55	26AUG2020	68848	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11491154	C4591001 1149 11491154	16-55	27AUG2020	70745	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
11491155	C4591001 1149 11491155	16-55	27AUG2020	70746	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11491156	C4591001 1149 11491156	16-55	27AUG2020	70747	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
11491157	C4591001 1149 11491157	16-55	27AUG2020	71227	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
11491158	C4591001 1149 11491158	16-55	27AUG2020	70753	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
11491160	C4591001 1149 11491160	16-55	27AUG2020	71226	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
11491162	C4591001 1149 11491162	16-55	27AUG2020	71234	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
11491163	C4591001 1149 11491163	16-55	27AUG2020	71230	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
11491164	C4591001 1149 11491164	16-55	27AUG2020	71346	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo		
11491165	C4591001 1149 11491165	16-55	28AUG2020	71347	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
11491166	C4591001 1149 11491166	16-55	28AUG2020	71352	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
11491169	C4591001 1149 11491169	16-55	28AUG2020	71356	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11491170	C4591001 1149 11491170	16-55	28AUG2020	73017	Placebo	28AUG2020/ Placebo	17SEP2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)
11491172	C4591001 1149 11491172	16-55	28AUG2020	73020	Placebo	28AUG2020/ Placebo	20NOV2020/ Placebo		
11491173	C4591001 1149 11491173	16-55	28AUG2020	73018	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
11491174	C4591001 1149 11491174	16-55	01SEP2020	73021	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11491175	C4591001 1149 11491175	16-55	01SEP2020	77261	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
11491176	C4591001 1149 11491176	16-55	01SEP2020	77263	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11491178	C4591001 1149 11491178	16-55	01SEP2020	77266	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)
11491179	C4591001 1149 11491179	16-55	01SEP2020	77268	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11491180	C4591001 1149 11491180	16-55	01SEP2020	77310	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11491181	C4591001 1149 11491181	16-55	01SEP2020	77312	Placebo	01SEP2020/ Placebo	21SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11491182	C4591001 1149 11491182	16-55	01SEP2020	77314	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11491183	C4591001 1149 11491183	16-55	02SEP2020	77317	Placebo	02SEP2020/ Placebo	22SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
11491186	C4591001 1149 11491186	16-55	02SEP2020	78871	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11491187	C4591001 1149 11491187	16-55	02SEP2020	78869	Placebo	02SEP2020/ Placebo	21SEP2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
11491188	C4591001 1149 11491188	16-55	02SEP2020	78874	Placebo	02SEP2020/ Placebo	22SEP2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
11491191	C4591001 1149 11491191	16-55	02SEP2020	78875	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11491194	C4591001 1149 11491194	16-55	03SEP2020	80721	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
11491197	C4591001 1149 11491197	16-55	03SEP2020	80724	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
11491198	C4591001 1149 11491198	16-55	03SEP2020	80725	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
11491201	C4591001 1149 11491201	16-55	04SEP2020	80728	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11491202	C4591001 1149 11491202	16-55	04SEP2020	82374	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
11491203	C4591001 1149 11491203	16-55	04SEP2020	82381	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
11491204	C4591001 1149 11491204	16-55	04SEP2020	82384	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
11491205	C4591001 1149 11491205	16-55	04SEP2020	82383	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
11491206	C4591001 1149 11491206	16-55	04SEP2020	82470	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
11491207	C4591001 1149 11491207	16-55	04SEP2020	82477	Placebo	04SEP2020/ Placebo	06OCT2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
11491208	C4591001 1149 11491208	16-55	04SEP2020	82480	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	22JAN2021/ BNT162b2 (30 µg)
11491209	C4591001 1149 11491209	16-55	04SEP2020	82479	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
11491210	C4591001 1149 11491210	16-55	04SEP2020	82507	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
11491211	C4591001 1149 11491211	16-55	04SEP2020	82512	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11491212	C4591001 1149 11491212	16-55	04SEP2020	82514	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
11491213	C4591001 1149 11491213	16-55	08SEP2020	82516	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11491215	C4591001 1149 11491215	16-55	08SEP2020	84282	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
11491216	C4591001 1149 11491216	16-55	08SEP2020	84287	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
11491217	C4591001 1149 11491217	16-55	08SEP2020	84289	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11491218	C4591001 1149 11491218	16-55	08SEP2020	84291	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11491219	C4591001 1149 11491219	16-55	08SEP2020	84355	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11491220	C4591001 1149 11491220	16-55	08SEP2020	84357	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
11491221	C4591001 1149 11491221	16-55	10SEP2020	84359	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
11491223	C4591001 1149 11491223	16-55	10SEP2020	84362	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11491227	C4591001 1149 11491227	16-55	10SEP2020	87473	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
11491228	C4591001 1149 11491228	16-55	11SEP2020	87474	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
11491230	C4591001 1149 11491230	16-55	11SEP2020	87475	Placebo	11SEP2020/ Placebo			
11491233	C4591001 1149 11491233	16-55	11SEP2020	87480	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
11491234	C4591001 1149 11491234	16-55	11SEP2020	88781	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
11491235	C4591001 1149 11491235	16-55	11SEP2020	88785	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo		
11491238	C4591001 1149 11491238	16-55	15SEP2020	88788	Placebo	15SEP2020/ Placebo	06OCT2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
11491241	C4591001 1149 11491241	16-55	15SEP2020	88791	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
11491242	C4591001 1149 11491242	16-55	16SEP2020	91558	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
11491246	C4591001 1149 11491246	16-55	16SEP2020	91563	Placebo	16SEP2020/ Placebo	07OCT2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11491247	C4591001 1149 11491247	16-55	16SEP2020	91562	Placebo	16SEP2020/ Placebo	07OCT2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11491248	C4591001 1149 11491248	16-55	17SEP2020	91564	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
11491249	C4591001 1149 11491249	16-55	17SEP2020	92766	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
11491250	C4591001 1149 11491250	16-55	18SEP2020	92768	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
11491252	C4591001 1149 11491252	16-55	18SEP2020	92769	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
11491254	C4591001 1149 11491254	16-55	18SEP2020	94010	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
11491255	C4591001 1149 11491255	16-55	18SEP2020	92774	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
11491256	C4591001 1149 11491256	16-55	18SEP2020	94001	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
11491258	C4591001 1149 11491258	16-55	18SEP2020	94006	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11491259	C4591001 1149 11491259	16-55	18SEP2020	94011	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11491263	C4591001 1149 11491263	16-55	18SEP2020	94291	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
11491266	C4591001 1149 11491266	16-55	21SEP2020	94293	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
11491268	C4591001 1149 11491268	16-55	21SEP2020	94297	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
11491269	C4591001 1149 11491269	16-55	21SEP2020	95456	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
11491270	C4591001 1149 11491270	16-55	21SEP2020	94298	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
11491271	C4591001 1149 11491271	16-55	21SEP2020	95458	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
11491273	C4591001 1149 11491273	16-55	22SEP2020	95463	Placebo	22SEP2020/ Placebo	13OCT2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
11491274	C4591001 1149 11491274	16-55	22SEP2020	95464	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
11491275	C4591001 1149 11491275	16-55	22SEP2020	96857	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
11491276	C4591001 1149 11491276	16-55	22SEP2020	96862	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11491277	C4591001 1149 11491277	16-55	22SEP2020	96865	Placebo	22SEP2020/ Placebo	13OCT2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
11491280	C4591001 1149 11491280	16-55	22SEP2020	96866	Placebo	22SEP2020/ Placebo	13OCT2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
11491281	C4591001 1149 11491281	16-55	22SEP2020	96907	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
11491282	C4591001 1149 11491282	16-55	22SEP2020	96909	Placebo	22SEP2020/ Placebo	14OCT2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
11491284	C4591001 1149 11491284	16-55	23SEP2020	96911	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
11491285	C4591001 1149 11491285	16-55	23SEP2020	96914	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
11491286	C4591001 1149 11491286	16-55	23SEP2020	98105	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
11491289	C4591001 1149 11491289	16-55	23SEP2020	98113	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
11491290	C4591001 1149 11491290	16-55	23SEP2020	98108	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
11491292	C4591001 1149 11491292	16-55	23SEP2020	98115	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11491293	C4591001 1149 11491293	16-55	23SEP2020	98265	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
11491294	C4591001 1149 11491294	16-55	23SEP2020	98266	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)		
11491295	C4591001 1149 11491295	16-55	23SEP2020	98270	Placebo	23SEP2020/ Placebo	15OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
11491302	C4591001 1149 11491302	16-55	24SEP2020	98911	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
11491303	C4591001 1149 11491303	16-55	24SEP2020	98999	Placebo	24SEP2020/ Placebo	16OCT2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
11491304	C4591001 1149 11491304	16-55	24SEP2020	98912	Placebo	24SEP2020/ Placebo	16OCT2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
11491305	C4591001 1149 11491305	16-55	24SEP2020	98272	Placebo	24SEP2020/ Placebo	15OCT2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
11491307	C4591001 1149 11491307	16-55	24SEP2020	99000	Placebo	24SEP2020/ Placebo	15OCT2020/ Placebo		
11491308	C4591001 1149 11491308	16-55	24SEP2020	98916	Placebo	24SEP2020/ Placebo	16OCT2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
11491310	C4591001 1149 11491310	16-55	24SEP2020	98996	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11491311	C4591001 1149 11491311	16-55	24SEP2020	98913	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
11491314	C4591001 1149 11491314	16-55	24SEP2020	99002	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
11491315	C4591001 1149 11491315	16-55	24SEP2020	99079	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
11491316	C4591001 1149 11491316	16-55	24SEP2020	99081	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
11491320	C4591001 1149 11491320	16-55	25SEP2020	99086	Placebo	25SEP2020/ Placebo	14OCT2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
11491321	C4591001 1149 11491321	16-55	25SEP2020	100362	Placebo	25SEP2020/ Placebo	14OCT2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
11491322	C4591001 1149 11491322	16-55	25SEP2020	100364	Placebo	25SEP2020/ Placebo	15OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
11491324	C4591001 1149 11491324	16-55	25SEP2020	99085	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
11491327	C4591001 1149 11491327	16-55	25SEP2020	100367	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
11491328	C4591001 1149 11491328	16-55	19OCT2020	100372	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11491329	C4591001 1149 11491329	16-55	19OCT2020	110441	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
11491331	C4591001 1149 11491331	16-55	20OCT2020	110446	Placebo	20OCT2020/ Placebo	13NOV2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
11491332	C4591001 1149 11491332	16-55	20OCT2020	110449	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
11491334	C4591001 1149 11491334†	16-55	26OCT2020	113729	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
11491335	C4591001 1149 11491335†	16-55	26OCT2020	113731	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
11491337	C4591001 1149 11491337†	16-55	26OCT2020	110451	Placebo	26OCT2020/ Placebo	16NOV2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
11491339	C4591001 1149 11491339†	16-55	26OCT2020	113733	Placebo	26OCT2020/ Placebo	16NOV2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
11491340	C4591001 1149 11491340	16-55	27OCT2020	113735	Placebo	27OCT2020/ Placebo	19NOV2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
11491341	C4591001 1149 11491341	16-55	27OCT2020	114138	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
11491343	C4591001 1149 11491343	16-55	27OCT2020	114139	Placebo	27OCT2020/ Placebo	17NOV2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11491344	C4591001 1149 11491344†	16-55	27OCT2020	114145	Placebo	27OCT2020/ Placebo			
11501001	C4591001 1150 11501001	16-55	17AUG2020	52855	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11501002	C4591001 1150 11501002	16-55	17AUG2020	52856	Placebo	17AUG2020/ Placebo	09SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
11501003	C4591001 1150 11501003	16-55	17AUG2020	52857	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11501004	C4591001 1150 11501004	16-55	17AUG2020	52858	Placebo	17AUG2020/ Placebo	15SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
11501005	C4591001 1150 11501005	16-55	18AUG2020	53887	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11501006	C4591001 1150 11501006	16-55	18AUG2020	53892	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11501007	C4591001 1150 11501007	16-55	18AUG2020	53895	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
11501008	C4591001 1150 11501008	16-55	18AUG2020	53896	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
11501009	C4591001 1150 11501009	16-55	18AUG2020	54678	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11501010	C4591001 1150 11501010	16-55	18AUG2020	54682	Placebo	18AUG2020/ Placebo	10SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
11501011	C4591001 1150 11501011	16-55	18AUG2020	54683	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11501012	C4591001 1150 11501012	16-55	19AUG2020	54684	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11501013	C4591001 1150 11501013	16-55	19AUG2020	55805	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
11501014	C4591001 1150 11501014	16-55	19AUG2020	55807	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
11501015	C4591001 1150 11501015	16-55	19AUG2020	55809	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
11501016	C4591001 1150 11501016	16-55	19AUG2020	55811	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
11501017	C4591001 1150 11501017	16-55	19AUG2020	56405	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
11501018	C4591001 1150 11501018	16-55	19AUG2020	56409	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11501019	C4591001 1150 11501019	16-55	19AUG2020	56413	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11501020	C4591001 1150 11501020	16-55	19AUG2020	57293	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11501021	C4591001 1150 11501021	16-55	19AUG2020	56416	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
11501022	C4591001 1150 11501022	16-55	19AUG2020	57299	Placebo	19AUG2020/ Placebo	08SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
11501023	C4591001 1150 11501023	16-55	20AUG2020	57301	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11501024	C4591001 1150 11501024	16-55	20AUG2020	57304	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11501025	C4591001 1150 11501025	16-55	20AUG2020	58675	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11501026	C4591001 1150 11501026	16-55	20AUG2020	58677	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11501027	C4591001 1150 11501027	16-55	20AUG2020	58680	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11501028	C4591001 1150 11501028	16-55	20AUG2020	58681	Placebo	20AUG2020/ Placebo	09SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
11501029	C4591001 1150 11501029	16-55	21AUG2020	60104	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11501031	C4591001 1150 11501031	16-55	21AUG2020	60105	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11501032	C4591001 1150 11501032	16-55	24AUG2020	60107	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11501033	C4591001 1150 11501033	16-55	24AUG2020	60112	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
11501034	C4591001 1150 11501034	16-55	24AUG2020	63896	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11501035	C4591001 1150 11501035	16-55	24AUG2020	63899	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11501036	C4591001 1150 11501036	16-55	24AUG2020	63900	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
11501037	C4591001 1150 11501037	16-55	24AUG2020	63901	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11501038	C4591001 1150 11501038	16-55	25AUG2020	65165	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11501039	C4591001 1150 11501039	16-55	25AUG2020	65167	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
11501040	C4591001 1150 11501040	16-55	25AUG2020	65172	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11501041	C4591001 1150 11501041	16-55	25AUG2020	65174	Placebo	25AUG2020/ Placebo	17SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
11501043	C4591001 1150 11501043	16-55	25AUG2020	66008	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
11501044	C4591001 1150 11501044	16-55	25AUG2020	66009	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
11501045	C4591001 1150 11501045	16-55	25AUG2020	66011	Placebo	25AUG2020/ Placebo	14SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11501046	C4591001 1150 11501046	16-55	25AUG2020	66012	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
11501047	C4591001 1150 11501047	16-55	25AUG2020	66763	Placebo	25AUG2020/ Placebo	14SEP2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
11501048	C4591001 1150 11501048	16-55	25AUG2020	66764	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11501049	C4591001 1150 11501049	16-55	25AUG2020	66767	Placebo	25AUG2020/ Placebo	16SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
11501050	C4591001 1150 11501050	16-55	26AUG2020	66768	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11501051	C4591001 1150 11501051	16-55	26AUG2020	67569	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11501052	C4591001 1150 11501052	16-55	26AUG2020	67571	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
11501053	C4591001 1150 11501053	16-55	26AUG2020	67573	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
11501054	C4591001 1150 11501054	16-55	26AUG2020	67576	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
11501055	C4591001 1150 11501055	16-55	26AUG2020	68469	Placebo	26AUG2020/ Placebo	15SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
11501056	C4591001 1150 11501056	16-55	26AUG2020	68470	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
11501057	C4591001 1150 11501057	16-55	26AUG2020	68472	Placebo	26AUG2020/ Placebo	17SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11501058	C4591001 1150 11501058	16-55	26AUG2020	68474	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
11501059	C4591001 1150 11501059	16-55	26AUG2020	69197	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
11501060	C4591001 1150 11501060	16-55	27AUG2020	69199	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
11501061	C4591001 1150 11501061	16-55	27AUG2020	69203	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11501062	C4591001 1150 11501062	16-55	27AUG2020	69208	Placebo	27AUG2020/ Placebo	16SEP2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
11501063	C4591001 1150 11501063	16-55	27AUG2020	70424	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11501064	C4591001 1150 11501064	16-55	27AUG2020	70428	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
11501065	C4591001 1150 11501065	16-55	27AUG2020	70431	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
11501067	C4591001 1150 11501067	16-55	27AUG2020	70432	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
11501068	C4591001 1150 11501068	16-55	27AUG2020	71194	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
11501069	C4591001 1150 11501069	16-55	28AUG2020	71195	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
11501070	C4591001 1150 11501070	16-55	28AUG2020	71198	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
11501071	C4591001 1150 11501071	16-55	28AUG2020	71199	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
11501072	C4591001 1150 11501072	16-55	28AUG2020	71887	Placebo	28AUG2020/ Placebo	17SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11501073	C4591001 1150 11501073	16-55	31AUG2020	71888	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11501074	C4591001 1150 11501074	16-55	31AUG2020	71893	Placebo	31AUG2020/ Placebo	22SEP2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
11501075	C4591001 1150 11501075	16-55	31AUG2020	71894	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11501076	C4591001 1150 11501076	16-55	31AUG2020	75920	Placebo	31AUG2020/ Placebo	22SEP2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)
11501077	C4591001 1150 11501077	16-55	01SEP2020	75923	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11501078	C4591001 1150 11501078	16-55	01SEP2020	75924	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
11501079	C4591001 1150 11501079	16-55	01SEP2020	75928	Placebo	01SEP2020/ Placebo	23SEP2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
11501080	C4591001 1150 11501080	16-55	01SEP2020	76976	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
11501081	C4591001 1150 11501081	16-55	01SEP2020	76980	Placebo	01SEP2020/ Placebo	24SEP2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
11501082	C4591001 1150 11501082	16-55	01SEP2020	76981	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11501083	C4591001 1150 11501083	16-55	01SEP2020	76984	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
11501084	C4591001 1150 11501084	16-55	01SEP2020	77669	Placebo	01SEP2020/ Placebo	01OCT2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
11501085	C4591001 1150 11501085	16-55	02SEP2020	77670	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11501086	C4591001 1150 11501086	16-55	02SEP2020	77675	Placebo	02SEP2020/ Placebo	24SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11501087	C4591001 1150 11501087	16-55	02SEP2020	77676	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
11501088	C4591001 1150 11501088	16-55	02SEP2020	78969	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11501089	C4591001 1150 11501089	16-55	02SEP2020	78971	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11501090	C4591001 1150 11501090	16-55	02SEP2020	78973	Placebo	02SEP2020/ Placebo	24SEP2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
11501091	C4591001 1150 11501091	16-55	02SEP2020	78974	Placebo	02SEP2020/ Placebo	24SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
11501092	C4591001 1150 11501092	16-55	02SEP2020	79436	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11501093	C4591001 1150 11501093	16-55	03SEP2020	79438	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
11501094	C4591001 1150 11501094	16-55	03SEP2020	79439	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11501095	C4591001 1150 11501095	16-55	03SEP2020	79441	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
11501096	C4591001 1150 11501096	16-55	03SEP2020	79805	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11501097	C4591001 1150 11501097	16-55	03SEP2020	79809	Placebo	03SEP2020/ Placebo	25SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
11501098	C4591001 1150 11501098	16-55	03SEP2020	79810	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
11501099	C4591001 1150 11501099	16-55	03SEP2020	79814	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
11501100	C4591001 1150 11501100	16-55	03SEP2020	80586	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11501101	C4591001 1150 11501101	16-55	03SEP2020	80587	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11501102	C4591001 1150 11501102	16-55	03SEP2020	80594	Placebo	03SEP2020/ Placebo	23SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11501103	C4591001 1150 11501103	16-55	08SEP2020	80596	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
11501104	C4591001 1150 11501104	16-55	08SEP2020	84545	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11501105	C4591001 1150 11501105	16-55	09SEP2020	84549	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
11501106	C4591001 1150 11501106	16-55	09SEP2020	84550	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
11501107	C4591001 1150 11501107	16-55	10SEP2020	84555	Placebo	10SEP2020/ Placebo	30SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
11501110	C4591001 1150 11501110	16-55	11SEP2020	87845	Placebo	11SEP2020/ Placebo	01OCT2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
11501111	C4591001 1150 11501111	16-55	11SEP2020	87846	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
11501112	C4591001 1150 11501112	16-55	11SEP2020	87852	Placebo	11SEP2020/ Placebo	01OCT2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
11501113	C4591001 1150 11501113	16-55	11SEP2020	87853	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
11501114	C4591001 1150 11501114	16-55	11SEP2020	88485	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11501115	C4591001 1150 11501115	16-55	24SEP2020	88486	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
11501116	C4591001 1150 11501116	16-55	24SEP2020	88488	Placebo	24SEP2020/ Placebo	16OCT2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
11501117	C4591001 1150 11501117	16-55	25SEP2020	88490	Placebo	25SEP2020/ Placebo	14OCT2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
11501122	C4591001 1150 11501122	16-55	15OCT2020	108475	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
11501137	C4591001 1150 11501137	16-55	22OCT2020	108477	Placebo	22OCT2020/ Placebo	12NOV2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
11501138	C4591001 1150 11501138	16-55	26OCT2020	108482	Placebo	26OCT2020/ Placebo	16NOV2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
11501139	C4591001 1150 11501139	16-55	27OCT2020	108484	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
11501140	C4591001 1150 11501140	16-55	27OCT2020	114081	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
11501141	C4591001 1150 11501141	16-55	27OCT2020	114082	Placebo	27OCT2020/ Placebo	17NOV2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
11501142	C4591001 1150 11501142	16-55	28OCT2020	114085	Placebo	28OCT2020/ Placebo	24NOV2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11501144	C4591001 1150 11501144	16-55	29OCT2020	114087	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	18NOV2020/ BNT162b2 (30 µg)		
11501145	C4591001 1150 11501145	16-55	29OCT2020	114786	Placebo	29OCT2020/ Placebo	19NOV2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
11501146	C4591001 1150 11501146	16-55	05NOV2020	114788	BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)	24NOV2020/ BNT162b2 (30 µg)		
11501147	C4591001 1150 11501147	16-55	09NOV2020	114791	BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)	01DEC2020/ BNT162b2 (30 µg)		
11501148	C4591001 1150 11501148	16-55	11NOV2020	114795	Placebo	11NOV2020/ Placebo	03DEC2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
11501149	C4591001 1150 11501149	16-55	12NOV2020	116154	Placebo	12NOV2020/ Placebo	02DEC2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
11501150	C4591001 1150 11501150	16-55	12NOV2020	116156	BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)	04DEC2020/ BNT162b2 (30 µg)		
11501151	C4591001 1150 11501151	16-55	16NOV2020	116160	Placebo	16NOV2020/ Placebo	08DEC2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
11501152	C4591001 1150 11501152	16-55	17NOV2020	116164	BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)	23DEC2020/ BNT162b2 (30 µg)		
11501153	C4591001 1150 11501153	16-55	18NOV2020	116431	Placebo	18NOV2020/ Placebo	11DEC2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11501154	C4591001 1150 11501154	16-55	20NOV2020	116432	BNT162b2 (30 µg)	20NOV2020/ BNT162b2 (30 µg)	09DEC2020/ BNT162b2 (30 µg)		
11501155	C4591001 1150 11501155	16-55	23NOV2020	116433	Placebo	23NOV2020/ Placebo	14DEC2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
11501156	C4591001 1150 11501156	16-55	23NOV2020	116434	BNT162b2 (30 µg)	23NOV2020/ BNT162b2 (30 µg)	14DEC2020/ BNT162b2 (30 µg)		
11501157	C4591001 1150 11501157	16-55	23NOV2020	116733	BNT162b2 (30 µg)	23NOV2020/ BNT162b2 (30 µg)	16DEC2020/ BNT162b2 (30 µg)		
11501158	C4591001 1150 11501158	16-55	23NOV2020	116734	Placebo	23NOV2020/ Placebo	16DEC2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
11501159	C4591001 1150 11501159	16-55	23NOV2020	116737	Placebo	23NOV2020/ Placebo	16DEC2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
11501160	C4591001 1150 11501160	16-55	24NOV2020	116738	BNT162b2 (30 µg)	24NOV2020/ BNT162b2 (30 µg)	15DEC2020/ BNT162b2 (30 µg)		
11501161	C4591001 1150 11501161	16-55	24NOV2020	116768	BNT162b2 (30 µg)	24NOV2020/ BNT162b2 (30 µg)	15DEC2020/ BNT162b2 (30 µg)		
11501162	C4591001 1150 11501162	16-55	24NOV2020	116769	Placebo	24NOV2020/ Placebo	14DEC2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
11501163	C4591001 1150 11501163	16-55	24NOV2020	116772	BNT162b2 (30 µg)	24NOV2020/ BNT162b2 (30 µg)	16DEC2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11501164	C4591001 1150 11501164	16-55	24NOV2020	116776	Placebo	24NOV2020/ Placebo	16DEC2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
11501165	C4591001 1150 11501165	16-55	30NOV2020	116995	BNT162b2 (30 µg)	30NOV2020/ BNT162b2 (30 µg)	22DEC2020/ BNT162b2 (30 µg)		
11501167	C4591001 1150 11501167	16-55	02DEC2020	116998	BNT162b2 (30 µg)	02DEC2020/ BNT162b2 (30 µg)	23DEC2020/ BNT162b2 (30 µg)		
11501169	C4591001 1150 11501169	16-55	02DEC2020	117000	Placebo	02DEC2020/ Placebo	28DEC2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
11501170	C4591001 1150 11501170	16-55	03DEC2020	117004	Placebo	03DEC2020/ Placebo	24DEC2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
11501174	C4591001 1150 11501174	16-55	03DEC2020	117343	Placebo	03DEC2020/ Placebo	23DEC2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
11501175	C4591001 1150 11501175	16-55	03DEC2020	117345	BNT162b2 (30 µg)	03DEC2020/ BNT162b2 (30 µg)	22DEC2020/ BNT162b2 (30 µg)		
11501177	C4591001 1150 11501177	16-55	07DEC2020	117346	Placebo	07DEC2020/ Placebo	28DEC2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
11501181	C4591001 1150 11501181	16-55	08DEC2020	117350	BNT162b2 (30 µg)	08DEC2020/ BNT162b2 (30 µg)	28DEC2020/ BNT162b2 (30 µg)		
11501184	C4591001 1150 11501184	16-55	08DEC2020	117737	Placebo	08DEC2020/ Placebo	30DEC2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11501188	C4591001 1150 11501188	16-55	09DEC2020	117738	BNT162b2 (30 µg)	09DEC2020/ BNT162b2 (30 µg)	29DEC2020/ BNT162b2 (30 µg)		
11521084	C4591001 1152 11521084	16-55	19AUG2020	49788	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
11521085	C4591001 1152 11521085	16-55	19AUG2020	56371	Placebo	19AUG2020/ Placebo			
11521086	C4591001 1152 11521086	16-55	19AUG2020	56375	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
11521089	C4591001 1152 11521089	16-55	19AUG2020	56378	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
11521090	C4591001 1152 11521090	16-55	19AUG2020	56380	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
11521098	C4591001 1152 11521098	16-55	19AUG2020	57355	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
11521100	C4591001 1152 11521100	16-55	19AUG2020	57358	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo		
11521105	C4591001 1152 11521105	16-55	19AUG2020	57363	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
11521108	C4591001 1152 11521108	16-55	19AUG2020	57364	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11521110	C4591001 1152 11521110	16-55	19AUG2020	57716	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11521111	C4591001 1152 11521111	16-55	19AUG2020	57720	Placebo	19AUG2020/ Placebo	11SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
11521112	C4591001 1152 11521112	16-55	19AUG2020	57722	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
11521113	C4591001 1152 11521113	16-55	19AUG2020	57724	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo	12MAR2021/ BNT162b2 (30 µg)	
11521114	C4591001 1152 11521114	16-55	19AUG2020	57728	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
11521115	C4591001 1152 11521115	16-55	19AUG2020	57727	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
11521116	C4591001 1152 11521116	16-55	19AUG2020	57732	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11521117	C4591001 1152 11521117	16-55	19AUG2020	57734	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
11521118	C4591001 1152 11521118	16-55	19AUG2020	57742	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
11521120	C4591001 1152 11521120	16-55	20AUG2020	57743	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11521121	C4591001 1152 11521121	16-55	20AUG2020	57746	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
11521126	C4591001 1152 11521126	16-55	21AUG2020	57747	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
11521129	C4591001 1152 11521129	16-55	21AUG2020	60943	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
11521131	C4591001 1152 11521131	16-55	21AUG2020	60944	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
11521137	C4591001 1152 11521137	16-55	21AUG2020	60945	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo		
11521138	C4591001 1152 11521138	16-55	21AUG2020	60950	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
11521139	C4591001 1152 11521139	16-55	21AUG2020	61530	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo		
11521140	C4591001 1152 11521140	16-55	21AUG2020	61532	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
11521142	C4591001 1152 11521142	16-55	21AUG2020	61534	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
11521143	C4591001 1152 11521143	16-55	21AUG2020	61539	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11521144	C4591001 1152 11521144	16-55	21AUG2020	61570	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
11521145	C4591001 1152 11521145	16-55	21AUG2020	61569	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
11521146	C4591001 1152 11521146	16-55	21AUG2020	61572	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
11521147	C4591001 1152 11521147	16-55	21AUG2020	61575	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
11521148	C4591001 1152 11521148	16-55	21AUG2020	61629	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
11521149	C4591001 1152 11521149	16-55	21AUG2020	61630	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
11521150	C4591001 1152 11521150	16-55	21AUG2020	61631	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11521153	C4591001 1152 11521153	16-55	24AUG2020	61632	Placebo	24AUG2020/ Placebo	15SEP2020/ Placebo		
11521154	C4591001 1152 11521154	16-55	24AUG2020	63846	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11521156	C4591001 1152 11521156	16-55	24AUG2020	63850	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11521157	C4591001 1152 11521157	16-55	24AUG2020	63852	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11521158	C4591001 1152 11521158	16-55	24AUG2020	63851	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
11521159	C4591001 1152 11521159	16-55	24AUG2020	64157	Placebo	24AUG2020/ Placebo	15SEP2020/ Placebo	12MAR2021/ BNT162b2 (30 µg)	
11521164	C4591001 1152 11521164	16-55	24AUG2020	64158	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11521165	C4591001 1152 11521165	16-55	24AUG2020	64160	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11521166	C4591001 1152 11521166	16-55	24AUG2020	64857	Placebo	24AUG2020/ Placebo	16SEP2020/ Placebo		
11521167	C4591001 1152 11521167	16-55	24AUG2020	64165	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
11521168	C4591001 1152 11521168	16-55	24AUG2020	64859	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
11521169	C4591001 1152 11521169	16-55	24AUG2020	64861	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11521173	C4591001 1152 11521173	16-55	24AUG2020	64864	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11521176	C4591001 1152 11521176	16-55	24AUG2020	65022	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11521177	C4591001 1152 11521177	16-55	24AUG2020	65024	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11521180	C4591001 1152 11521180	16-55	24AUG2020	65026	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
11521182	C4591001 1152 11521182	16-55	24AUG2020	65027	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11521183	C4591001 1152 11521183	16-55	24AUG2020	65045	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
11521184	C4591001 1152 11521184	16-55	24AUG2020	65047	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11521185	C4591001 1152 11521185	16-55	25AUG2020	65049	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
11521186	C4591001 1152 11521186	16-55	25AUG2020	65054	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
11521187	C4591001 1152 11521187	16-55	25AUG2020	66235	Placebo	25AUG2020/ Placebo	14SEP2020/ Placebo		
11521188	C4591001 1152 11521188	16-55	25AUG2020	66236	Placebo	25AUG2020/ Placebo	14SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11521189	C4591001 1152 11521189	16-55	25AUG2020	66238	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11521192	C4591001 1152 11521192	16-55	25AUG2020	66244	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11521195	C4591001 1152 11521195	16-55	25AUG2020	66994	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
11521196	C4591001 1152 11521196	16-55	25AUG2020	66992	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
11521197	C4591001 1152 11521197	16-55	25AUG2020	66995	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11521199	C4591001 1152 11521199	16-55	25AUG2020	66998	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11521204	C4591001 1152 11521204	16-55	25AUG2020	67086	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	11MAR2021/ BNT162b2 (30 µg)	
11521205	C4591001 1152 11521205	16-55	25AUG2020	67091	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo		
11521206	C4591001 1152 11521206	16-55	26AUG2020	67095	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11521207	C4591001 1152 11521207	16-55	26AUG2020	67094	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11521208	C4591001 1152 11521208	16-55	26AUG2020	68249	Placebo	26AUG2020/ Placebo	15SEP2020/ Placebo		
11521209	C4591001 1152 11521209	16-55	26AUG2020	68253	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo		
11521211	C4591001 1152 11521211	16-55	26AUG2020	68254	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11521212	C4591001 1152 11521212	16-55	26AUG2020	68258	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11521213	C4591001 1152 11521213	16-55	26AUG2020	68697	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo		
11521214	C4591001 1152 11521214	16-55	26AUG2020	68698	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11521215	C4591001 1152 11521215	16-55	26AUG2020	68699	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
11521216	C4591001 1152 11521216	16-55	26AUG2020	68703	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11521218	C4591001 1152 11521218	16-55	26AUG2020	69294	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
11521219	C4591001 1152 11521219	16-55	26AUG2020	69299	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11521220	C4591001 1152 11521220	16-55	26AUG2020	69303	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
11521221	C4591001 1152 11521221	16-55	26AUG2020	69304	Placebo	26AUG2020/ Placebo	15SEP2020/ Placebo		
11521222	C4591001 1152 11521222	16-55	26AUG2020	69330	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
11521223	C4591001 1152 11521223	16-55	26AUG2020	69334	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11521224	C4591001 1152 11521224	16-55	26AUG2020	69337	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11521225	C4591001 1152 11521225	16-55	26AUG2020	69339	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11521226	C4591001 1152 11521226	16-55	26AUG2020	69378	Placebo	26AUG2020/ Placebo	15SEP2020/ Placebo	12MAR2021/ BNT162b2 (30 µg)	
11521227	C4591001 1152 11521227	16-55	26AUG2020	69380	Placebo	26AUG2020/ Placebo	17SEP2020/ Placebo		
11521228	C4591001 1152 11521228	16-55	27AUG2020	69381	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
11521229	C4591001 1152 11521229	16-55	27AUG2020	69387	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11521231	C4591001 1152 11521231	16-55	27AUG2020	70677	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
11521234	C4591001 1152 11521234	16-55	27AUG2020	70681	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
11521235	C4591001 1152 11521235	16-55	27AUG2020	70682	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
11521236	C4591001 1152 11521236	16-55	27AUG2020	70684	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	11MAR2021/ BNT162b2 (30 µg)	
11521239	C4591001 1152 11521239	16-55	27AUG2020	71034	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
11521240	C4591001 1152 11521240	16-55	27AUG2020	71037	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11521248	C4591001 1152 11521248	16-55	27AUG2020	71038	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
11521249	C4591001 1152 11521249	16-55	27AUG2020	71041	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
11521253	C4591001 1152 11521253	16-55	27AUG2020	71443	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11521254	C4591001 1152 11521254	16-55	27AUG2020	71444	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11521255	C4591001 1152 11521255	16-55	31AUG2020	71447	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
11521256	C4591001 1152 11521256	16-55	31AUG2020	71451	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11521261	C4591001 1152 11521261	16-55	31AUG2020	75282	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11521263	C4591001 1152 11521263	16-55	31AUG2020	75284	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11521264	C4591001 1152 11521264	16-55	31AUG2020	75290	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
11521269	C4591001 1152 11521269	16-55	31AUG2020	75291	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
11521270	C4591001 1152 11521270	16-55	31AUG2020	75766	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
11521271	C4591001 1152 11521271	16-55	31AUG2020	75768	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11521274	C4591001 1152 11521274	16-55	31AUG2020	75769	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
11521275	C4591001 1152 11521275	16-55	31AUG2020	75770	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11521276	C4591001 1152 11521276	16-55	31AUG2020	76098	Placebo	31AUG2020/ Placebo	23SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
11521277	C4591001 1152 11521277	16-55	31AUG2020	76099	Placebo	31AUG2020/ Placebo	22SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
11521282	C4591001 1152 11521282	16-55	31AUG2020	76100	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11521283	C4591001 1152 11521283	16-55	31AUG2020	76104	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11521284	C4591001 1152 11521284	16-55	31AUG2020	76202	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11521285	C4591001 1152 11521285	16-55	31AUG2020	76195	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
11521286	C4591001 1152 11521286	16-55	31AUG2020	76203	Placebo	31AUG2020/ Placebo	22SEP2020/ Placebo		
11521287	C4591001 1152 11521287	16-55	31AUG2020	76204	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11521288	C4591001 1152 11521288	16-55	31AUG2020	76220	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11521289	C4591001 1152 11521289	16-55	31AUG2020	76223	Placebo	31AUG2020/ Placebo	24SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11521291	C4591001 1152 11521291	16-55	31AUG2020	76225	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo		
11521295	C4591001 1152 11521295	16-55	31AUG2020	76226	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11521296	C4591001 1152 11521296	16-55	31AUG2020	76265	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	12MAR2021/ BNT162b2 (30 µg)	
11521297	C4591001 1152 11521297	16-55	31AUG2020	76268	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11521298	C4591001 1152 11521298	16-55	31AUG2020	76274	Placebo	31AUG2020/ Placebo	23SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
11521302	C4591001 1152 11521302	16-55	03SEP2020	76275	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11521308	C4591001 1152 11521308	16-55	03SEP2020	80132	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11521309	C4591001 1152 11521309	16-55	03SEP2020	80133	Placebo	03SEP2020/ Placebo	22SEP2020/ Placebo	11MAR2021/ BNT162b2 (30 µg)	
11521312	C4591001 1152 11521312	16-55	03SEP2020	80139	Placebo	03SEP2020/ Placebo	22SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
11521316	C4591001 1152 11521316	16-55	03SEP2020	80140	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11521318	C4591001 1152 11521318	16-55	03SEP2020	80791	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
11521319	C4591001 1152 11521319	16-55	03SEP2020	80796	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
11521322	C4591001 1152 11521322	16-55	03SEP2020	80797	Placebo	03SEP2020/ Placebo	22SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
11521323	C4591001 1152 11521323	16-55	03SEP2020	81083	Placebo	03SEP2020/ Placebo	22SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
11521325	C4591001 1152 11521325	16-55	03SEP2020	80799	Placebo	03SEP2020/ Placebo	22SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
11521327	C4591001 1152 11521327	16-55	03SEP2020	81086	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
11521328	C4591001 1152 11521328	16-55	03SEP2020	81084	Placebo	03SEP2020/ Placebo	22SEP2020/ Placebo		
11521329	C4591001 1152 11521329	16-55	03SEP2020	81088	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11521332	C4591001 1152 11521332	16-55	03SEP2020	81153	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11521333	C4591001 1152 11521333	16-55	03SEP2020	81154	Placebo	03SEP2020/ Placebo	22SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11521335	C4591001 1152 11521335	16-55	03SEP2020	81159	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11521336	C4591001 1152 11521336	16-55	03SEP2020	81158	Placebo	03SEP2020/ Placebo	22SEP2020/ Placebo		
11521338	C4591001 1152 11521338	16-55	03SEP2020	81188	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11521339	C4591001 1152 11521339	16-55	03SEP2020	81185	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
11521340	C4591001 1152 11521340	16-55	03SEP2020	81191	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11521341	C4591001 1152 11521341	16-55	03SEP2020	81194	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
11521344	C4591001 1152 11521344	16-55	03SEP2020	81197	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
11521345	C4591001 1152 11521345	16-55	03SEP2020	81199	Placebo	03SEP2020/ Placebo	22SEP2020/ Placebo	11MAR2021/ BNT162b2 (30 µg)	
11521346	C4591001 1152 11521346	16-55	03SEP2020	81202	Placebo	03SEP2020/ Placebo	22SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
11521347	C4591001 1152 11521347	16-55	03SEP2020	81206	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11521348	C4591001 1152 11521348	16-55	03SEP2020	81209	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11521352	C4591001 1152 11521352	16-55	04SEP2020	81218	Placebo	04SEP2020/ Placebo	23SEP2020/ Placebo		
11521353	C4591001 1152 11521353	16-55	04SEP2020	81219	Placebo	04SEP2020/ Placebo	23SEP2020/ Placebo		
11521354	C4591001 1152 11521354	16-55	04SEP2020	81220	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
11521355	C4591001 1152 11521355	16-55	04SEP2020	82001	Placebo	04SEP2020/ Placebo	24SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
11521356	C4591001 1152 11521356	16-55	04SEP2020	82007	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11521357	C4591001 1152 11521357	16-55	04SEP2020	82008	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11521361	C4591001 1152 11521361	16-55	08SEP2020	83551	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
11521362	C4591001 1152 11521362	16-55	08SEP2020	83554	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo		
11521363	C4591001 1152 11521363	16-55	08SEP2020	83558	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo		
11521365	C4591001 1152 11521365	16-55	08SEP2020	83560	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11521366	C4591001 1152 11521366	16-55	08SEP2020	83730	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11521367	C4591001 1152 11521367	16-55	08SEP2020	83731	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo	11MAR2021/ BNT162b2 (30 µg)	
11521369	C4591001 1152 11521369	16-55	08SEP2020	83738	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
11521371	C4591001 1152 11521371	16-55	08SEP2020	83740	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
11521372	C4591001 1152 11521372	16-55	08SEP2020	83937	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo		
11521373	C4591001 1152 11521373	16-55	08SEP2020	83936	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
11521374	C4591001 1152 11521374	16-55	08SEP2020	83940	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
11521376	C4591001 1152 11521376	16-55	08SEP2020	83943	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
11521377	C4591001 1152 11521377	16-55	08SEP2020	84150	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
11521378	C4591001 1152 11521378	16-55	08SEP2020	84151	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo	11MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11521379	C4591001 1152 11521379	16-55	08SEP2020	84155	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
11521381	C4591001 1152 11521381	16-55	08SEP2020	84158	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
11521382	C4591001 1152 11521382	16-55	08SEP2020	84451	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
11521383	C4591001 1152 11521383	16-55	08SEP2020	84449	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
11521384	C4591001 1152 11521384	16-55	08SEP2020	84454	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
11521390	C4591001 1152 11521390	16-55	08SEP2020	84455	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo		
11521391	C4591001 1152 11521391	16-55	08SEP2020	84653	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11521393	C4591001 1152 11521393	16-55	08SEP2020	84656	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
11521394	C4591001 1152 11521394	16-55	08SEP2020	84661	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
11521396	C4591001 1152 11521396	16-55	08SEP2020	84663	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11521397	C4591001 1152 11521397	16-55	08SEP2020	84703	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
11521399	C4591001 1152 11521399	16-55	08SEP2020	84704	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
11521400	C4591001 1152 11521400	16-55	08SEP2020	84705	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
11521401	C4591001 1152 11521401	16-55	08SEP2020	84709	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
11521402	C4591001 1152 11521402	16-55	08SEP2020	84722	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
11521403	C4591001 1152 11521403	16-55	08SEP2020	84715	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11521404	C4591001 1152 11521404	16-55	08SEP2020	84724	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
11521405	C4591001 1152 11521405	16-55	08SEP2020	84723	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11521406	C4591001 1152 11521406	16-55	08SEP2020	84725	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
11521407	C4591001 1152 11521407	16-55	08SEP2020	84733	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11521408	C4591001 1152 11521408	16-55	08SEP2020	84734	Placebo	08SEP2020/ Placebo	14OCT2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
11521409	C4591001 1152 11521409	16-55	08SEP2020	84736	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
11521410	C4591001 1152 11521410	16-55	08SEP2020	84737	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
11521412	C4591001 1152 11521412	16-55	09SEP2020	84741	Placebo	09SEP2020/ Placebo	29SEP2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
11521413	C4591001 1152 11521413	16-55	09SEP2020	84744	Placebo	09SEP2020/ Placebo	29SEP2020/ Placebo		
11521414	C4591001 1152 11521414	16-55	09SEP2020	84747	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
11521415	C4591001 1152 11521415	16-55	09SEP2020	85255	Placebo	09SEP2020/ Placebo	29SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
11521416	C4591001 1152 11521416	16-55	09SEP2020	85256	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11521419	C4591001 1152 11521419	16-55	09SEP2020	85258	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11521421	C4591001 1152 11521421	16-55	09SEP2020	85263	Placebo	09SEP2020/ Placebo	29SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11521422	C4591001 1152 11521422	16-55	09SEP2020	85578	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11521423	C4591001 1152 11521423	16-55	09SEP2020	85584	Placebo	09SEP2020/ Placebo	29SEP2020/ Placebo		
11521424	C4591001 1152 11521424	16-55	09SEP2020	85586	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11521426	C4591001 1152 11521426	16-55	09SEP2020	85587	Placebo	09SEP2020/ Placebo	09OCT2020/ Placebo		
11521427	C4591001 1152 11521427	16-55	09SEP2020	85805	Placebo	09SEP2020/ Placebo	29SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
11521429	C4591001 1152 11521429	16-55	09SEP2020	85806	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
11521430	C4591001 1152 11521430	16-55	09SEP2020	85808	Placebo	09SEP2020/ Placebo	28SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
11521431	C4591001 1152 11521431	16-55	09SEP2020	85813	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11521432	C4591001 1152 11521432	16-55	09SEP2020	86105	Placebo	09SEP2020/ Placebo	29SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11521433	C4591001 1152 11521433	16-55	09SEP2020	86107	Placebo	09SEP2020/ Placebo	29SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11521434	C4591001 1152 11521434	16-55	09SEP2020	86113	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11521435	C4591001 1152 11521435	16-55	09SEP2020	86114	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11521436	C4591001 1152 11521436	16-55	09SEP2020	86201	Placebo	09SEP2020/ Placebo	29SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
11521437	C4591001 1152 11521437	16-55	09SEP2020	86202	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11521439	C4591001 1152 11521439	16-55	09SEP2020	86207	Placebo	09SEP2020/ Placebo	29SEP2020/ Placebo		
11521440	C4591001 1152 11521440	16-55	09SEP2020	86208	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
11521441	C4591001 1152 11521441	16-55	09SEP2020	86225	Placebo	09SEP2020/ Placebo	29SEP2020/ Placebo		
11521442	C4591001 1152 11521442	16-55	16SEP2020	86226	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
11521443	C4591001 1152 11521443	16-55	16SEP2020	86231	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
11521444	C4591001 1152 11521444	16-55	16SEP2020	86234	Placebo	16SEP2020/ Placebo	07OCT2020/ Placebo		
11521445	C4591001 1152 11521445	16-55	16SEP2020	91603	Placebo	16SEP2020/ Placebo	07OCT2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11521446	C4591001 1152 11521446	16-55	16SEP2020	91605	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
11521447	C4591001 1152 11521447	16-55	16SEP2020	91606	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
11521449	C4591001 1152 11521449	16-55	16SEP2020	91612	Placebo	16SEP2020/ Placebo	09OCT2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
11521450	C4591001 1152 11521450	16-55	16SEP2020	91854	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
11521451	C4591001 1152 11521451	16-55	16SEP2020	91858	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
11521452	C4591001 1152 11521452	16-55	16SEP2020	91861	Placebo	16SEP2020/ Placebo	07OCT2020/ Placebo		
11521453	C4591001 1152 11521453	16-55	16SEP2020	91862	Placebo	16SEP2020/ Placebo	07OCT2020/ Placebo		
11521454	C4591001 1152 11521454	16-55	17SEP2020	93077	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11521455	C4591001 1152 11521455	16-55	17SEP2020	93080	Placebo	17SEP2020/ Placebo	07OCT2020/ Placebo		
11521456	C4591001 1152 11521456	16-55	17SEP2020	93082	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11521457	C4591001 1152 11521457	16-55	17SEP2020	93087	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
11521459	C4591001 1152 11521459	16-55	18SEP2020	93847	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
11521460	C4591001 1152 11521460	16-55	18SEP2020	93848	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
11521461	C4591001 1152 11521461	16-55	18SEP2020	93850	Placebo	18SEP2020/ Placebo	07OCT2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
11521462	C4591001 1152 11521462	16-55	18SEP2020	93856	Placebo	18SEP2020/ Placebo	07OCT2020/ Placebo		
11521464	C4591001 1152 11521464	16-55	18SEP2020	94040	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
11521465	C4591001 1152 11521465	16-55	18SEP2020	94042	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
11521467	C4591001 1152 11521467	16-55	22SEP2020	94045	Placebo	22SEP2020/ Placebo	12OCT2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
11521468	C4591001 1152 11521468	16-55	22SEP2020	94048	Placebo	22SEP2020/ Placebo	12OCT2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
11521469	C4591001 1152 11521469	16-55	23SEP2020	98023	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11521470	C4591001 1152 11521470	16-55	23SEP2020	98028	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo		
11521472	C4591001 1152 11521472	16-55	24SEP2020	98029	Placebo	24SEP2020/ Placebo	15OCT2020/ Placebo		
11521474	C4591001 1152 11521474	16-55	24SEP2020	99139	Placebo	24SEP2020/ Placebo	15OCT2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
11521475	C4591001 1152 11521475	16-55	24SEP2020	99140	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
11521477	C4591001 1152 11521477	16-55	25SEP2020	99147	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
11521478	C4591001 1152 11521478	16-55	25SEP2020	99148	Placebo	25SEP2020/ Placebo	15OCT2020/ Placebo		
11521479	C4591001 1152 11521479	16-55	25SEP2020	100098	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
11521480	C4591001 1152 11521480	16-55	25SEP2020	100100	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
11521481	C4591001 1152 11521481	16-55	25SEP2020	100099	Placebo	25SEP2020/ Placebo	15OCT2020/ Placebo		
11521482	C4591001 1152 11521482	16-55	25SEP2020	100105	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo		
11521483	C4591001 1152 11521483	16-55	25SEP2020	100542	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11521489	C4591001 1152 11521489	16-55	02OCT2020	100546	Placebo	02OCT2020/ Placebo	21OCT2020/ Placebo		
11521490	C4591001 1152 11521490	16-55	02OCT2020	100549	BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		
11521492	C4591001 1152 11521492	16-55	06OCT2020	100551	BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		
11521493	C4591001 1152 11521493	16-55	06OCT2020	104385	BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		
11521496	C4591001 1152 11521496	16-55	07OCT2020	104386	Placebo	07OCT2020/ Placebo	29OCT2020/ Placebo		
11521498	C4591001 1152 11521498	16-55	07OCT2020	104387	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
11521499	C4591001 1152 11521499	16-55	07OCT2020	104388	Placebo	07OCT2020/ Placebo	06NOV2020/ Placebo		
11521500	C4591001 1152 11521500	16-55	08OCT2020	105522	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)		
11521501	C4591001 1152 11521501	16-55	09OCT2020	105526	Placebo	09OCT2020/ Placebo	29OCT2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11521504	C4591001 1152 11521504	16-55	09OCT2020	105530	Placebo	09OCT2020/ Placebo	30OCT2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11521505	C4591001 1152 11521505	16-55	09OCT2020	105531	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)		
11521506	C4591001 1152 11521506	16-55	09OCT2020	106207	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)		
11521508	C4591001 1152 11521508	16-55	09OCT2020	106211	Placebo	09OCT2020/ Placebo	30OCT2020/ Placebo		
11521509	C4591001 1152 11521509	16-55	09OCT2020	106213	Placebo	09OCT2020/ Placebo	29OCT2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
11521511	C4591001 1152 11521511	16-55	09OCT2020	106215	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
11521512	C4591001 1152 11521512	16-55	12OCT2020	106738	Placebo	12OCT2020/ Placebo	04NOV2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
11521515	C4591001 1152 11521515	16-55	13OCT2020	106739	Placebo	13OCT2020/ Placebo	04NOV2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
11521517	C4591001 1152 11521517	16-55	13OCT2020	106740	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
11521519	C4591001 1152 11521519	16-55	13OCT2020	106743	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
11521520	C4591001 1152 11521520	16-55	14OCT2020	107815	Placebo	14OCT2020/ Placebo	04NOV2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11521521	C4591001 1152 11521521	16-55	15OCT2020	107817	Placebo	15OCT2020/ Placebo	05NOV2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
11521522	C4591001 1152 11521522	16-55	15OCT2020	107819	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
11521529	C4591001 1152 11521529	16-55	15OCT2020	107824	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
11521533	C4591001 1152 11521533	16-55	15OCT2020	108594	Placebo	15OCT2020/ Placebo	04NOV2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
11521534	C4591001 1152 11521534	16-55	16OCT2020	108596	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
11521537	C4591001 1152 11521537	16-55	16OCT2020	108598	Placebo	16OCT2020/ Placebo	04NOV2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
11521541	C4591001 1152 11521541	16-55	19OCT2020	108601	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
11521549	C4591001 1152 11521549	16-55	20OCT2020	111198	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
11521551	C4591001 1152 11521551	16-55	21OCT2020	111199	Placebo	21OCT2020/ Placebo	11NOV2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
11521552	C4591001 1152 11521552	16-55	21OCT2020	111200	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11521557	C4591001 1152 11521557	16-55	22OCT2020	111207	Placebo	22OCT2020/ Placebo	11NOV2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
11521560	C4591001 1152 11521560	16-55	22OCT2020	112589	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
11521566	C4591001 1152 11521566	16-55	26OCT2020	112595	Placebo	26OCT2020/ Placebo	17NOV2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
11521568	C4591001 1152 11521568	16-55	26OCT2020	112598	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
11521569	C4591001 1152 11521569	16-55	26OCT2020	112599	Placebo	26OCT2020/ Placebo	16NOV2020/ Placebo	15DEC2020/ BNT162b2 (30 µg)	04JAN2021/ BNT162b2 (30 µg)
11521570	C4591001 1152 11521570	16-55	26OCT2020	113790	Placebo	26OCT2020/ Placebo	16NOV2020/ Placebo	11MAR2021/ BNT162b2 (30 µg)	
11521571	C4591001 1152 11521571	16-55	26OCT2020	113794	Placebo	26OCT2020/ Placebo	16NOV2020/ Placebo		
11521575	C4591001 1152 11521575	16-55	28OCT2020	113795	BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
11521577	C4591001 1152 11521577	16-55	29OCT2020	113798	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
11521583	C4591001 1152 11521583	16-55	30OCT2020	115063	Placebo	30OCT2020/ Placebo	18NOV2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11521584	C4591001 1152 11521584	16-55	30OCT2020	115065	Placebo	30OCT2020/ Placebo	19NOV2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
11521587	C4591001 1152 11521587	16-55	16NOV2020	115067	BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)	07DEC2020/ BNT162b2 (30 µg)		
11521588	C4591001 1152 11521588	16-55	16NOV2020	115071	BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)	07DEC2020/ BNT162b2 (30 µg)		
11521589	C4591001 1152 11521589	16-55	17NOV2020	116358	BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)	07DEC2020/ BNT162b2 (30 µg)		
11521590	C4591001 1152 11521590	16-55	17NOV2020	116359	Placebo	17NOV2020/ Placebo	07DEC2020/ Placebo		
11521591	C4591001 1152 11521591	16-55	17NOV2020	116366	Placebo	17NOV2020/ Placebo	07DEC2020/ Placebo	11MAR2021/ BNT162b2 (30 µg)	
11521592	C4591001 1152 11521592	16-55	18NOV2020	116368	BNT162b2 (30 µg)	18NOV2020/ BNT162b2 (30 µg)	07DEC2020/ BNT162b2 (30 µg)		
11521593	C4591001 1152 11521593	16-55	18NOV2020	116394	BNT162b2 (30 µg)	18NOV2020/ BNT162b2 (30 µg)	07DEC2020/ BNT162b2 (30 µg)		
11521594	C4591001 1152 11521594	16-55	19NOV2020	116398	Placebo	19NOV2020/ Placebo	08DEC2020/ Placebo		
11521595	C4591001 1152 11521595	16-55	19NOV2020	116399	Placebo	19NOV2020/ Placebo	08DEC2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11521596	C4591001 1152 11521596	16-55	19NOV2020	116402	BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)	10DEC2020/ BNT162b2 (30 µg)		
11521597	C4591001 1152 11521597	16-55	23NOV2020	116742	Placebo	23NOV2020/ Placebo	15DEC2020/ Placebo		
11521598	C4591001 1152 11521598	16-55	23NOV2020	116744	BNT162b2 (30 µg)	23NOV2020/ BNT162b2 (30 µg)	15DEC2020/ BNT162b2 (30 µg)		
11521599	C4591001 1152 11521599	16-55	23NOV2020	116747	Placebo	23NOV2020/ Placebo	14DEC2020/ Placebo		
11521600	C4591001 1152 11521600	16-55	24NOV2020	116748	BNT162b2 (30 µg)	24NOV2020/ BNT162b2 (30 µg)	15DEC2020/ BNT162b2 (30 µg)		
11521601	C4591001 1152 11521601	16-55	24NOV2020	116861	BNT162b2 (30 µg)	24NOV2020/ BNT162b2 (30 µg)	15DEC2020/ BNT162b2 (30 µg)		
11521602	C4591001 1152 11521602	16-55	24NOV2020	116867	Placebo	24NOV2020/ Placebo	14DEC2020/ Placebo	11MAR2021/ BNT162b2 (30 µg)	
11521603	C4591001 1152 11521603	16-55	24NOV2020	116868	BNT162b2 (30 µg)	24NOV2020/ BNT162b2 (30 µg)	14DEC2020/ BNT162b2 (30 µg)		
11521606	C4591001 1152 11521606	16-55	03DEC2020	117419	Placebo	03DEC2020/ Placebo	22DEC2020/ Placebo		
11521609	C4591001 1152 11521609	16-55	03DEC2020	116871	Placebo	03DEC2020/ Placebo	23DEC2020/ Placebo		
11521610	C4591001 1152 11521610	16-55	03DEC2020	117416	BNT162b2 (30 µg)	03DEC2020/ BNT162b2 (30 µg)	22DEC2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11521616	C4591001 1152 11521616	16-55	03DEC2020	117423	Placebo	03DEC2020/ Placebo	23DEC2020/ Placebo		
11521618	C4591001 1152 11521618	16-55	03DEC2020	117424	BNT162b2 (30 µg)	03DEC2020/ BNT162b2 (30 µg)	28DEC2020/ BNT162b2 (30 µg)		
11521620	C4591001 1152 11521620	16-55	03DEC2020	117486	Placebo	03DEC2020/ Placebo	22DEC2020/ Placebo		
11521621	C4591001 1152 11521621	16-55	03DEC2020	117487	BNT162b2 (30 µg)	03DEC2020/ BNT162b2 (30 µg)	22DEC2020/ BNT162b2 (30 µg)		
11521622	C4591001 1152 11521622	16-55	04DEC2020	117492	BNT162b2 (30 µg)	04DEC2020/ BNT162b2 (30 µg)	23DEC2020/ BNT162b2 (30 µg)		
11521623	C4591001 1152 11521623	16-55	04DEC2020	117570	Placebo	04DEC2020/ Placebo	23DEC2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11521624	C4591001 1152 11521624	16-55	04DEC2020	117493	Placebo	04DEC2020/ Placebo	23DEC2020/ Placebo		
11521627	C4591001 1152 11521627	16-55	04DEC2020	117574	Placebo	04DEC2020/ Placebo	23DEC2020/ Placebo		
11521630	C4591001 1152 11521630	16-55	07DEC2020	117578	BNT162b2 (30 µg)	07DEC2020/ BNT162b2 (30 µg)	28DEC2020/ BNT162b2 (30 µg)		
11521631	C4591001 1152 11521631	16-55	07DEC2020	117580	BNT162b2 (30 µg)	07DEC2020/ BNT162b2 (30 µg)	28DEC2020/ BNT162b2 (30 µg)		
11521632	C4591001 1152 11521632	16-55	07DEC2020	117677	BNT162b2 (30 µg)	07DEC2020/ BNT162b2 (30 µg)	28DEC2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11521634	C4591001 1152 11521634	16-55	07DEC2020	117681	BNT162b2 (30 µg)	07DEC2020/ BNT162b2 (30 µg)	28DEC2020/ BNT162b2 (30 µg)		
11521643	C4591001 1152 11521643	16-55	07DEC2020	117687	Placebo	07DEC2020/ Placebo	28DEC2020/ Placebo		
11561002	C4591001 1156 11561002	16-55	19AUG2020	57067	Placebo	19AUG2020/ Placebo	08SEP2020/ Placebo	12MAR2021/ BNT162b2 (30 µg)	
11561003	C4591001 1156 11561003	16-55	19AUG2020	57066	Placebo	19AUG2020/ Placebo	08SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
11561004	C4591001 1156 11561004	16-55	19AUG2020	57071	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11561005	C4591001 1156 11561005	16-55	20AUG2020	57073	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11561006	C4591001 1156 11561006	16-55	20AUG2020	58517	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)			
11561007	C4591001 1156 11561007	16-55	20AUG2020	58521	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo		
11561008	C4591001 1156 11561008	16-55	20AUG2020	58519	Placebo	20AUG2020/ Placebo	08SEP2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)
11561009	C4591001 1156 11561009	16-55	20AUG2020	58522	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11561010	C4591001 1156 11561010	16-55	25AUG2020	64238	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11561011	C4591001 1156 11561011	16-55	21AUG2020	60329	Placebo	21AUG2020/ Placebo	09SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
11561012	C4591001 1156 11561012	16-55	21AUG2020	60332	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11561013	C4591001 1156 11561013	16-55	21AUG2020	60334	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
11561014	C4591001 1156 11561014	16-55	21AUG2020	60337	Placebo	21AUG2020/ Placebo	10SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
11561015	C4591001 1156 11561015	16-55	21AUG2020	61147	Placebo	21AUG2020/ Placebo			
11561016	C4591001 1156 11561016	16-55	21AUG2020	61149	Placebo	21AUG2020/ Placebo	09SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
11561018	C4591001 1156 11561018	16-55	24AUG2020	61150	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
11561019	C4591001 1156 11561019	16-55	24AUG2020	61154	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11561021	C4591001 1156 11561021	16-55	24AUG2020	64234	Placebo	24AUG2020/ Placebo	15SEP2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11561023	C4591001 1156 11561023	16-55	24AUG2020	64229	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo		
11561026	C4591001 1156 11561026	16-55	25AUG2020	64236	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
11561028	C4591001 1156 11561028	16-55	25AUG2020	65598	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11561029	C4591001 1156 11561029	16-55	25AUG2020	65601	Placebo	25AUG2020/ Placebo	14SEP2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
11561030	C4591001 1156 11561030	16-55	25AUG2020	65603	Placebo	25AUG2020/ Placebo	14SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
11561031	C4591001 1156 11561031	16-55	25AUG2020	65602	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
11561032	C4591001 1156 11561032	16-55	25AUG2020	66703	Placebo	25AUG2020/ Placebo	14SEP2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
11561033	C4591001 1156 11561033	16-55	26AUG2020	66704	Placebo	26AUG2020/ Placebo			
11561034	C4591001 1156 11561034	16-55	26AUG2020	66706	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
11561036	C4591001 1156 11561036	16-55	26AUG2020	66711	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11561039	C4591001 1156 11561039	16-55	26AUG2020	68814	Placebo	26AUG2020/ Placebo	17SEP2020/ Placebo		
11561040	C4591001 1156 11561040	16-55	26AUG2020	68815	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
11561041	C4591001 1156 11561041	16-55	26AUG2020	68813	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo		
11561042	C4591001 1156 11561042	16-55	27AUG2020	68820	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
11561043	C4591001 1156 11561043	16-55	27AUG2020	69797	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
11561045	C4591001 1156 11561045	16-55	27AUG2020	69802	Placebo	27AUG2020/ Placebo	18SEP2020/ Placebo		
11561046	C4591001 1156 11561046	16-55	27AUG2020	69807	Placebo	27AUG2020/ Placebo	16SEP2020/ Placebo		
11561048	C4591001 1156 11561048	16-55	27AUG2020	69808	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11561049	C4591001 1156 11561049	16-55	27AUG2020	70878	Placebo	27AUG2020/ Placebo	16SEP2020/ Placebo		
11561050	C4591001 1156 11561050	16-55	27AUG2020	70884	Placebo	27AUG2020/ Placebo	16SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
11561053	C4591001 1156 11561053	16-55	28AUG2020	70888	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11561054	C4591001 1156 11561054	16-55	28AUG2020	71849	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11561055	C4591001 1156 11561055	16-55	28AUG2020	71850	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo		
11561056	C4591001 1156 11561056	16-55	28AUG2020	71856	Placebo	28AUG2020/ Placebo	17SEP2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
11561057	C4591001 1156 11561057	16-55	28AUG2020	71860	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
11561058	C4591001 1156 11561058	16-55	28AUG2020	72523	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
11561060	C4591001 1156 11561060	16-55	29AUG2020	72526	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo		
11561061	C4591001 1156 11561061	16-55	29AUG2020	72529	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
11561062	C4591001 1156 11561062	16-55	29AUG2020	72531	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo		
11561063	C4591001 1156 11561063	16-55	29AUG2020	73473	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
11561064	C4591001 1156 11561064	16-55	29AUG2020	73474	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11561065	C4591001 1156 11561065	16-55	29AUG2020	73475	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11561071	C4591001 1156 11561071	16-55	31AUG2020	73477	Placebo	31AUG2020/ Placebo	22SEP2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
11561072	C4591001 1156 11561072	16-55	01SEP2020	76541	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11561073	C4591001 1156 11561073	16-55	01SEP2020	76544	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
11561074	C4591001 1156 11561074	16-55	01SEP2020	76545	Placebo	01SEP2020/ Placebo	24SEP2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
11561075	C4591001 1156 11561075	16-55	01SEP2020	76549	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
11561076	C4591001 1156 11561076	16-55	01SEP2020	76938	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11561077	C4591001 1156 11561077	16-55	01SEP2020	76941	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	06JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
11561078	C4591001 1156 11561078	16-55	01SEP2020	76942	Placebo	01SEP2020/ Placebo	23SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11561081	C4591001 1156 11561081	16-55	02SEP2020	76947	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11561082	C4591001 1156 11561082	16-55	02SEP2020	78041	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	11MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11561085	C4591001 1156 11561085	16-55	02SEP2020	78046	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11561086	C4591001 1156 11561086	16-55	02SEP2020	78051	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo		
11561087	C4591001 1156 11561087	16-55	02SEP2020	78052	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11561089	C4591001 1156 11561089	16-55	02SEP2020	79133	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11561090	C4591001 1156 11561090	16-55	03SEP2020	79134	Placebo	03SEP2020/ Placebo	02OCT2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
11561093	C4591001 1156 11561093	16-55	03SEP2020	79139	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11561097	C4591001 1156 11561097	16-55	03SEP2020	79141	Placebo	03SEP2020/ Placebo	25SEP2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)
11561105	C4591001 1156 11561105	16-55	04SEP2020	82037	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11561107	C4591001 1156 11561107	16-55	04SEP2020	82042	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11561108	C4591001 1156 11561108	16-55	04SEP2020	82043	Placebo	04SEP2020/ Placebo	24SEP2020/ Placebo		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11561109	C4591001 1156 11561109	16-55	08SEP2020	82045	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11561111	C4591001 1156 11561111	16-55	08SEP2020	83684	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
11561113	C4591001 1156 11561113	16-55	08SEP2020	83685	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo		
11561115	C4591001 1156 11561115	16-55	08SEP2020	83687	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
11561119	C4591001 1156 11561119	16-55	09SEP2020	83692	Placebo	09SEP2020/ Placebo	29SEP2020/ Placebo		
11561120	C4591001 1156 11561120	16-55	09SEP2020	85820	Placebo	09SEP2020/ Placebo	02OCT2020/ Placebo		
11561121	C4591001 1156 11561121	16-55	09SEP2020	85822	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
11561123	C4591001 1156 11561123	16-55	10SEP2020	85825	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11561124	C4591001 1156 11561124	16-55	10SEP2020	85827	Placebo	10SEP2020/ Placebo	02OCT2020/ Placebo		
11561126	C4591001 1156 11561126	16-55	10SEP2020	86976	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
11561128	C4591001 1156 11561128	16-55	10SEP2020	86977	Placebo	10SEP2020/ Placebo	29SEP2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11561129	C4591001 1156 11561129	16-55	11SEP2020	86979	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
11561131	C4591001 1156 11561131	16-55	11SEP2020	86980	Placebo	11SEP2020/ Placebo	30SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
11561132	C4591001 1156 11561132	16-55	11SEP2020	88446	Placebo	11SEP2020/ Placebo	30SEP2020/ Placebo		
11561134	C4591001 1156 11561134	16-55	11SEP2020	88447	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
11561135	C4591001 1156 11561135	16-55	11SEP2020	88453	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
11561136	C4591001 1156 11561136	16-55	11SEP2020	88455	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo		
11561137	C4591001 1156 11561137	16-55	14SEP2020	89477	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo	02MAR2021/ BNT162b2 (30 µg)	
11561145	C4591001 1156 11561145	16-55	15SEP2020	89481	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
11561146	C4591001 1156 11561146	16-55	15SEP2020	89482	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
11561147	C4591001 1156 11561147	16-55	16SEP2020	89487	Placebo	16SEP2020/ Placebo	09OCT2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11561148	C4591001 1156 11561148	16-55	16SEP2020	91133	Placebo	16SEP2020/ Placebo	07OCT2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
11561149	C4591001 1156 11561149	16-55	16SEP2020	91137	Placebo	16SEP2020/ Placebo	06OCT2020/ Placebo		
11561154	C4591001 1156 11561154	16-55	17SEP2020	91140	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
11561155	C4591001 1156 11561155	16-55	18SEP2020	91144	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
11561156	C4591001 1156 11561156	16-55	18SEP2020	93622	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
11561158	C4591001 1156 11561158	16-55	21SEP2020	93624	Placebo	21SEP2020/ Placebo	13OCT2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
11561159	C4591001 1156 11561159	16-55	21SEP2020	93626	Placebo	21SEP2020/ Placebo	13OCT2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
11561161	C4591001 1156 11561161	16-55	21SEP2020	93628	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
11561162	C4591001 1156 11561162	16-55	22SEP2020	96214	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
11561163	C4591001 1156 11561163	16-55	22SEP2020	96215	Placebo	22SEP2020/ Placebo	14OCT2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11561164	C4591001 1156 11561164	16-55	23SEP2020	96218	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
11561165	C4591001 1156 11561165	16-55	23SEP2020	96219	Placebo	23SEP2020/ Placebo	15OCT2020/ Placebo		
11561166	C4591001 1156 11561166	16-55	23SEP2020	98083	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
11561170	C4591001 1156 11561170	16-55	24SEP2020	98085	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
11561172	C4591001 1156 11561172	16-55	25SEP2020	98089	Placebo	25SEP2020/ Placebo	14OCT2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
11561174	C4591001 1156 11561174	16-55	25SEP2020	98092	Placebo	25SEP2020/ Placebo	14OCT2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
11561175	C4591001 1156 11561175	16-55	25SEP2020	99965	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
11561176	C4591001 1156 11561176	16-55	25SEP2020	99973	Placebo	25SEP2020/ Placebo	20OCT2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
11561177	C4591001 1156 11561177	16-55	25SEP2020	99975	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		
11561178	C4591001 1156 11561178	16-55	25SEP2020	99976	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11561179	C4591001 1156 11561179	16-55	28SEP2020	101324	Placebo	28SEP2020/ Placebo	19OCT2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
11561180	C4591001 1156 11561180	16-55	28SEP2020	101325	Placebo	28SEP2020/ Placebo	19OCT2020/ Placebo		
11561185	C4591001 1156 11561185	16-55	30SEP2020	101330	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		
11561186	C4591001 1156 11561186	16-55	30SEP2020	102197	Placebo	30SEP2020/ Placebo	26OCT2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
11561187	C4591001 1156 11561187	16-55	30SEP2020	102203	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
11561188	C4591001 1156 11561188	16-55	30SEP2020	101332	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		
11561189	C4591001 1156 11561189	16-55	30SEP2020	102204	Placebo	30SEP2020/ Placebo	20OCT2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
11561190	C4591001 1156 11561190	16-55	30SEP2020	102207	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		
11561194	C4591001 1156 11561194	16-55	30SEP2020	102535	Placebo	30SEP2020/ Placebo	21OCT2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
11561196	C4591001 1156 11561196	16-55	01OCT2020	102539	BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11561198	C4591001 1156 11561198	16-55	01OCT2020	102540	Placebo	01OCT2020/ Placebo	20OCT2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
11561199	C4591001 1156 11561199	16-55	01OCT2020	102543	BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)		
11561200	C4591001 1156 11561200	16-55	01OCT2020	102989	Placebo	01OCT2020/ Placebo	24NOV2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
11561201	C4591001 1156 11561201	16-55	02OCT2020	102990	BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)		
11561203	C4591001 1156 11561203	16-55	02OCT2020	102993	Placebo	02OCT2020/ Placebo	23OCT2020/ Placebo		
11561205	C4591001 1156 11561205	16-55	02OCT2020	102994	BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)		
11561206	C4591001 1156 11561206	16-55	02OCT2020	103289	BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)		
11561208	C4591001 1156 11561208	16-55	05OCT2020	103292	Placebo	05OCT2020/ Placebo	28OCT2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
11561209	C4591001 1156 11561209	16-55	06OCT2020	103299	BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
11561210	C4591001 1156 11561210	16-55	06OCT2020	103300	Placebo	06OCT2020/ Placebo	26OCT2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11561213	C4591001 1156 11561213	16-55	08OCT2020	105317	Placebo	08OCT2020/ Placebo	28OCT2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
11561214	C4591001 1156 11561214	16-55	08OCT2020	105323	Placebo	08OCT2020/ Placebo	28OCT2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
11561216	C4591001 1156 11561216	16-55	08OCT2020	105324	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)		
11561225	C4591001 1156 11561225	16-55	12OCT2020	105327	BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		
11561226	C4591001 1156 11561226	16-55	12OCT2020	106390	Placebo	12OCT2020/ Placebo	02NOV2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
11561227	C4591001 1156 11561227	16-55	12OCT2020	106391	BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		
11561229	C4591001 1156 11561229	16-55	12OCT2020	106392	BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
11561230	C4591001 1156 11561230	16-55	12OCT2020	106393	Placebo	12OCT2020/ Placebo	04NOV2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
11561231	C4591001 1156 11561231	16-55	12OCT2020	106613	BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
11561233	C4591001 1156 11561233	16-55	12OCT2020	106617	Placebo	12OCT2020/ Placebo	02NOV2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11561234	C4591001 1156 11561234	16-55	12OCT2020	106622	BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		
11561235	C4591001 1156 11561235	16-55	13OCT2020	106624	Placebo	13OCT2020/ Placebo	04NOV2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
11561239	C4591001 1156 11561239	16-55	13OCT2020	107286	Placebo	13OCT2020/ Placebo	04NOV2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
11561251	C4591001 1156 11561251	16-55	16OCT2020	107289	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
11561252	C4591001 1156 11561252	16-55	16OCT2020	107292	Placebo	16OCT2020/ Placebo	04NOV2020/ Placebo		
11561258	C4591001 1156 11561258	16-55	20OCT2020	107294	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
11561268	C4591001 1156 11561268	16-55	23OCT2020	112809	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
11561270	C4591001 1156 11561270	16-55	23OCT2020	112811	Placebo	23OCT2020/ Placebo	11NOV2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
11561272	C4591001 1156 11561272	16-55	26OCT2020	112815	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
11561273	C4591001 1156 11561273	16-55	26OCT2020	112816	Placebo	26OCT2020/ Placebo	16NOV2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11561274	C4591001 1156 11561274	16-55	26OCT2020	113565	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
11561275	C4591001 1156 11561275	16-55	26OCT2020	113566	Placebo	26OCT2020/ Placebo	16NOV2020/ Placebo		
11561276	C4591001 1156 11561276	16-55	27OCT2020	113569	Placebo	27OCT2020/ Placebo	16NOV2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
11561277	C4591001 1156 11561277	16-55	27OCT2020	113572	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
11561281	C4591001 1156 11561281	16-55	28OCT2020	114487	Placebo	28OCT2020/ Placebo	16NOV2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
11561282	C4591001 1156 11561282	16-55	29OCT2020	114488	Placebo	29OCT2020/ Placebo	17NOV2020/ Placebo		
11561283	C4591001 1156 11561283	16-55	29OCT2020	114491	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)		
11561286	C4591001 1156 11561286	16-55	29OCT2020	114492	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	20NOV2020/ BNT162b2 (30 µg)		
11561287	C4591001 1156 11561287	16-55	30OCT2020	114966	Placebo	30OCT2020/ Placebo	19NOV2020/ Placebo		
11561288	C4591001 1156 11561288	16-55	30OCT2020	114969	BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)	20NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11561289	C4591001 1156 11561289	16-55	30OCT2020	114974	Placebo	30OCT2020/ Placebo	19NOV2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
11561290	C4591001 1156 11561290	16-55	30OCT2020	115049	Placebo	30OCT2020/ Placebo	19NOV2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
11561291	C4591001 1156 11561291	16-55	30OCT2020	114975	BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)		
11561292	C4591001 1156 11561292	16-55	30OCT2020	115052	Placebo	30OCT2020/ Placebo	20NOV2020/ Placebo		
11561293	C4591001 1156 11561293	16-55	30OCT2020	115054	BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)		
11561294	C4591001 1156 11561294	16-55	03NOV2020	115059	BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)	23NOV2020/ BNT162b2 (30 µg)		
11561295	C4591001 1156 11561295	16-55	04NOV2020	115615	BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)	27NOV2020/ BNT162b2 (30 µg)		
11561296	C4591001 1156 11561296	16-55	05NOV2020	115618	BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)	24NOV2020/ BNT162b2 (30 µg)		
11561297	C4591001 1156 11561297	16-55	05NOV2020	115623	Placebo	05NOV2020/ Placebo	25NOV2020/ Placebo		
11561298	C4591001 1156 11561298	16-55	11NOV2020	115624	Placebo	11NOV2020/ Placebo	01DEC2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11561299	C4591001 1156 11561299	16-55	11NOV2020	116117	Placebo	11NOV2020/ Placebo	01DEC2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
11561300	C4591001 1156 11561300	16-55	17NOV2020	116122	BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)	07DEC2020/ BNT162b2 (30 µg)		
11561301	C4591001 1156 11561301	16-55	18NOV2020	116125	Placebo	18NOV2020/ Placebo	10DEC2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
11561302	C4591001 1156 11561302	16-55	19NOV2020	116128	BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)	09DEC2020/ BNT162b2 (30 µg)		
11561315	C4591001 1156 11561315	16-55	03DEC2020	117295	Placebo	03DEC2020/ Placebo	23DEC2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
11561326	C4591001 1156 11561326	16-55	10DEC2020	117299	Placebo	10DEC2020/ Placebo	29DEC2020/ Placebo		
11561329	C4591001 1156 11561329	16-55	16DEC2020	117300	BNT162b2 (30 µg)	16DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)		
11571026	C4591001 1157 11571026	16-55	14AUG2020	51069	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
11571034	C4591001 1157 11571034	16-55	17AUG2020	51070	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11571040	C4591001 1157 11571040	16-55	18AUG2020	51071	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11571042	C4591001 1157 11571042	16-55	18AUG2020	51076	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)
11571052	C4591001 1157 11571052	16-55	19AUG2020	57332	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11571054	C4591001 1157 11571054	16-55	19AUG2020	57333	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
11571057	C4591001 1157 11571057	16-55	19AUG2020	57335	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
11571070	C4591001 1157 11571070	16-55	25AUG2020	57338	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)			
11571077	C4591001 1157 11571077	16-55	25AUG2020	66738	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo		
11571081	C4591001 1157 11571081	16-55	25AUG2020	66743	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11571082	C4591001 1157 11571082	16-55	25AUG2020	66746	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11571083	C4591001 1157 11571083	16-55	25AUG2020	66744	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11571088	C4591001 1157 11571088	16-55	26AUG2020	67893	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11571090	C4591001 1157 11571090	16-55	26AUG2020	67894	Placebo	26AUG2020/ Placebo	15SEP2020/ Placebo		
11571092	C4591001 1157 11571092	16-55	26AUG2020	67899	Placebo	26AUG2020/ Placebo	15SEP2020/ Placebo		
11571093	C4591001 1157 11571093	16-55	26AUG2020	67896	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
11571103	C4591001 1157 11571103	16-55	26AUG2020	69257	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
11571106	C4591001 1157 11571106	16-55	27AUG2020	69258	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
11571108	C4591001 1157 11571108	16-55	27AUG2020	69259	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
11571109	C4591001 1157 11571109	16-55	27AUG2020	69264	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo		
11571111	C4591001 1157 11571111	16-55	27AUG2020	70530	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
11571112	C4591001 1157 11571112	16-55	01SEP2020	70532	Placebo	01SEP2020/ Placebo	23SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11571113	C4591001 1157 11571113	16-55	01SEP2020	70539	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11571114	C4591001 1157 11571114	16-55	01SEP2020	70540	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11571115	C4591001 1157 11571115	16-55	01SEP2020	76902	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11571117	C4591001 1157 11571117	16-55	01SEP2020	76903	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11571118	C4591001 1157 11571118	16-55	01SEP2020	76904	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo		
11571121	C4591001 1157 11571121	16-55	01SEP2020	76911	Placebo	01SEP2020/ Placebo	21SEP2020/ Placebo		
11571124	C4591001 1157 11571124	16-55	01SEP2020	77507	Placebo	01SEP2020/ Placebo	23SEP2020/ Placebo		
11571125	C4591001 1157 11571125	16-55	01SEP2020	77510	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
11571126	C4591001 1157 11571126	16-55	01SEP2020	77511	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11571127	C4591001 1157 11571127	16-55	01SEP2020	77512	Placebo	01SEP2020/ Placebo	23SEP2020/ Placebo		
11571130	C4591001 1157 11571130	16-55	01SEP2020	77765	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11571132	C4591001 1157 11571132	16-55	02SEP2020	77773	Placebo	02SEP2020/ Placebo	22SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11571135	C4591001 1157 11571135	16-55	02SEP2020	77774	Placebo	02SEP2020/ Placebo			
11571136	C4591001 1157 11571136	16-55	02SEP2020	77775	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11571137	C4591001 1157 11571137	16-55	02SEP2020	78560	Placebo	02SEP2020/ Placebo	21SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11571140	C4591001 1157 11571140	16-55	02SEP2020	78561	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11571141	C4591001 1157 11571141	16-55	05OCT2020	78565	BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		
11571145	C4591001 1157 11571145	16-55	08OCT2020	78567	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)		
11571154	C4591001 1157 11571154	16-55	10OCT2020	106241	BNT162b2 (30 µg)	10OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		
11571156	C4591001 1157 11571156	16-55	10OCT2020	106247	Placebo	10OCT2020/ Placebo	30NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
11571166	C4591001 1157 11571166	16-55	19OCT2020	106248	Placebo	19OCT2020/ Placebo	11NOV2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
11571168	C4591001 1157 11571168	16-55	19OCT2020	106252	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11571169	C4591001 1157 11571169	16-55	19OCT2020	110573	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	11DEC2020/ BNT162b2 (30 µg)		
11571170	C4591001 1157 11571170	16-55	19OCT2020	110579	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		
11571174	C4591001 1157 11571174	16-55	20OCT2020	110582	Placebo	20OCT2020/ Placebo	12NOV2020/ Placebo		
11571176	C4591001 1157 11571176	16-55	20OCT2020	110584	Placebo	20OCT2020/ Placebo	12NOV2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
11611005	C4591001 1161 11611005	16-55	31JUL2020	41211	Placebo	31JUL2020/ Placebo			
11621024	C4591001 1162 11621024	16-55	04AUG2020	42014	Placebo				
11621124	C4591001 1162 11621124	16-55	17AUG2020	49424	Placebo	17AUG2020/ Placebo	09SEP2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
11621128	C4591001 1162 11621128	16-55	17AUG2020	52825	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11621129	C4591001 1162 11621129	16-55	17AUG2020	49429	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11621130	C4591001 1162 11621130	16-55	17AUG2020	52567	Placebo	17AUG2020/ Placebo	09SEP2020/ Placebo		
11621131	C4591001 1162 11621131	16-55	17AUG2020	49431	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11621132	C4591001 1162 11621132	16-55	17AUG2020	52565	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11621133	C4591001 1162 11621133	16-55	17AUG2020	52569	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11621135	C4591001 1162 11621135	16-55	17AUG2020	52574	Placebo	17AUG2020/ Placebo	09SEP2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
11621137	C4591001 1162 11621137	16-55	17AUG2020	52824	Placebo	17AUG2020/ Placebo	09SEP2020/ Placebo		
11621140	C4591001 1162 11621140	16-55	17AUG2020	52826	Placebo	17AUG2020/ Placebo	09SEP2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
11621141	C4591001 1162 11621141	16-55	17AUG2020	52828	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11621142	C4591001 1162 11621142	16-55	17AUG2020	52902	Placebo	17AUG2020/ Placebo	09SEP2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
11621143	C4591001 1162 11621143	16-55	17AUG2020	52901	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11621144	C4591001 1162 11621144	16-55	17AUG2020	52905	Placebo	17AUG2020/ Placebo	09SEP2020/ Placebo		
11621145	C4591001 1162 11621145	16-55	17AUG2020	52910	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11621146	C4591001 1162 11621146	16-55	18AUG2020	53988	Placebo	18AUG2020/ Placebo	11SEP2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
11621147	C4591001 1162 11621147	16-55	18AUG2020	53983	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
11621150	C4591001 1162 11621150	16-55	18AUG2020	53989	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
11621151	C4591001 1162 11621151	16-55	18AUG2020	53991	Placebo	18AUG2020/ Placebo	10SEP2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
11621152	C4591001 1162 11621152	16-55	18AUG2020	54272	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
11621153	C4591001 1162 11621153	16-55	18AUG2020	54275	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
11621154	C4591001 1162 11621154	16-55	18AUG2020	54273	Placebo	18AUG2020/ Placebo	10SEP2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
11621155	C4591001 1162 11621155	16-55	18AUG2020	54425	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
11621156	C4591001 1162 11621156	16-55	18AUG2020	54428	Placebo	18AUG2020/ Placebo	10SEP2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
11621158	C4591001 1162 11621158	16-55	18AUG2020	54435	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11621159	C4591001 1162 11621159	16-55	18AUG2020	54431	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
11621162	C4591001 1162 11621162	16-55	18AUG2020	54671	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
11621163	C4591001 1162 11621163	16-55	18AUG2020	54669	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
11621164	C4591001 1162 11621164	16-55	18AUG2020	54666	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo		
11621166	C4591001 1162 11621166	16-55	24AUG2020	63401	Placebo	24AUG2020/ Placebo	16SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	15JAN2021/ BNT162b2 (30 µg)
11621168	C4591001 1162 11621168	16-55	24AUG2020	54673	Placebo	24AUG2020/ Placebo	21SEP2020/ Placebo		
11621169	C4591001 1162 11621169	16-55	24AUG2020	63407	Placebo	24AUG2020/ Placebo	16SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
11621170	C4591001 1162 11621170	16-55	24AUG2020	63403	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11621171	C4591001 1162 11621171	16-55	24AUG2020	63412	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11621172	C4591001 1162 11621172	16-55	24AUG2020	63558	Placebo	24AUG2020/ Placebo	16SEP2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11621175	C4591001 1162 11621175	16-55	24AUG2020	63564	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11621177	C4591001 1162 11621177	16-55	24AUG2020	63565	Placebo	24AUG2020/ Placebo	17SEP2020/ Placebo		
11621178	C4591001 1162 11621178	16-55	24AUG2020	63568	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11621180	C4591001 1162 11621180	16-55	24AUG2020	63837	Placebo	24AUG2020/ Placebo	16SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
11621181	C4591001 1162 11621181	16-55	24AUG2020	63840	Placebo	24AUG2020/ Placebo	15SEP2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
11621182	C4591001 1162 11621182	16-55	24AUG2020	63843	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11621183	C4591001 1162 11621183	16-55	24AUG2020	63842	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11621187	C4591001 1162 11621187	16-55	24AUG2020	64040	Placebo	24AUG2020/ Placebo	16SEP2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
11621188	C4591001 1162 11621188	16-55	24AUG2020	64045	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11621190	C4591001 1162 11621190	16-55	24AUG2020	64046	Placebo	24AUG2020/ Placebo	16SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11621193	C4591001 1162 11621193	16-55	25AUG2020	64047	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
11621195	C4591001 1162 11621195	16-55	25AUG2020	65790	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11621202	C4591001 1162 11621202	16-55	25AUG2020	65792	Placebo	25AUG2020/ Placebo	16SEP2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
11621203	C4591001 1162 11621203	16-55	25AUG2020	65794	Placebo	25AUG2020/ Placebo	02OCT2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
11621204	C4591001 1162 11621204	16-55	25AUG2020	65796	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11621205	C4591001 1162 11621205	16-55	27AUG2020	69848	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11621206	C4591001 1162 11621206	16-55	27AUG2020	69853	Placebo	27AUG2020/ Placebo	18SEP2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
11621207	C4591001 1162 11621207	16-55	27AUG2020	69850	Placebo	27AUG2020/ Placebo	18SEP2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
11621208	C4591001 1162 11621208	16-55	27AUG2020	69846	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
11621210	C4591001 1162 11621210	16-55	27AUG2020	70301	Placebo	27AUG2020/ Placebo	18SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11621216	C4591001 1162 11621216	16-55	27AUG2020	70308	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
11621217	C4591001 1162 11621217	16-55	27AUG2020	70303	Placebo	27AUG2020/ Placebo	09OCT2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
11621219	C4591001 1162 11621219	16-55	27AUG2020	70311	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
11621220	C4591001 1162 11621220	16-55	27AUG2020	70519	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
11621222	C4591001 1162 11621222	16-55	27AUG2020	70522	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11621223	C4591001 1162 11621223	16-55	27AUG2020	70528	Placebo	27AUG2020/ Placebo	18SEP2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
11621224	C4591001 1162 11621224	16-55	27AUG2020	70526	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11621226	C4591001 1162 11621226	16-55	31AUG2020	74753	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11621227	C4591001 1162 11621227	16-55	31AUG2020	74755	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
11621234	C4591001 1162 11621234	16-55	31AUG2020	74764	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11621235	C4591001 1162 11621235	16-55	31AUG2020	74761	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11621239	C4591001 1162 11621239	16-55	31AUG2020	75162	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
11621243	C4591001 1162 11621243	16-55	31AUG2020	75166	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11621244	C4591001 1162 11621244	16-55	31AUG2020	75163	Placebo	31AUG2020/ Placebo	23SEP2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
11621245	C4591001 1162 11621245	16-55	31AUG2020	75172	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11621247	C4591001 1162 11621247	16-55	31AUG2020	75618	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
11621249	C4591001 1162 11621249	16-55	01SEP2020	75619	Placebo	01SEP2020/ Placebo	23SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11621251	C4591001 1162 11621251	16-55	01SEP2020	75621	Placebo	01SEP2020/ Placebo	23SEP2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
11621252	C4591001 1162 11621252	16-55	01SEP2020	76615	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11621254	C4591001 1162 11621254	16-55	01SEP2020	75623	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11621255	C4591001 1162 11621255	16-55	01SEP2020	76623	Placebo	01SEP2020/ Placebo	23SEP2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
11621256	C4591001 1162 11621256	16-55	01SEP2020	76617	Placebo	01SEP2020/ Placebo	23SEP2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
11621259	C4591001 1162 11621259	16-55	01SEP2020	76624	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11621260	C4591001 1162 11621260	16-55	01SEP2020	76793	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
11621267	C4591001 1162 11621267	16-55	01SEP2020	76796	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
11621268	C4591001 1162 11621268	16-55	01SEP2020	76803	Placebo	01SEP2020/ Placebo	23SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
11621269	C4591001 1162 11621269	16-55	01SEP2020	76801	Placebo	01SEP2020/ Placebo	23SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
11621273	C4591001 1162 11621273	16-55	03SEP2020	79752	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
11621274	C4591001 1162 11621274	16-55	03SEP2020	79753	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
11621275	C4591001 1162 11621275	16-55	03SEP2020	79747	Placebo	03SEP2020/ Placebo	25SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11621279	C4591001 1162 11621279	16-55	03SEP2020	79754	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
11621282	C4591001 1162 11621282	16-55	03SEP2020	80297	Placebo	03SEP2020/ Placebo	02OCT2020/ Placebo		
11621283	C4591001 1162 11621283	16-55	03SEP2020	80300	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
11621284	C4591001 1162 11621284	16-55	03SEP2020	80301	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
11621285	C4591001 1162 11621285	16-55	03SEP2020	80526	Placebo	03SEP2020/ Placebo	25SEP2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
11621286	C4591001 1162 11621286	16-55	03SEP2020	80307	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
11621287	C4591001 1162 11621287	16-55	03SEP2020	80527	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
11621289	C4591001 1162 11621289	16-55	08SEP2020	83501	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
11621290	C4591001 1162 11621290	16-55	08SEP2020	80528	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
11621291	C4591001 1162 11621291	16-55	08SEP2020	80532	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11621294	C4591001 1162 11621294	16-55	08SEP2020	83508	Placebo	08SEP2020/ Placebo			
11621295	C4591001 1162 11621295	16-55	08SEP2020	83504	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11621296	C4591001 1162 11621296	16-55	08SEP2020	83502	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11621302	C4591001 1162 11621302	16-55	08SEP2020	83741	Placebo	08SEP2020/ Placebo	30SEP2020/ Placebo	03MAR2021/ BNT162b2 (30 µg)	
11621304	C4591001 1162 11621304	16-55	08SEP2020	83748	Placebo	08SEP2020/ Placebo	05OCT2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
11621306	C4591001 1162 11621306	16-55	08SEP2020	83744	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
11621308	C4591001 1162 11621308	16-55	08SEP2020	83752	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11621310	C4591001 1162 11621310	16-55	08SEP2020	84005	Placebo	08SEP2020/ Placebo			
11621311	C4591001 1162 11621311	16-55	08SEP2020	84006	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
11621313	C4591001 1162 11621313	16-55	08SEP2020	84012	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11621314	C4591001 1162 11621314	16-55	08SEP2020	84014	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo		
11621315	C4591001 1162 11621315	16-55	08SEP2020	84366	Placebo	08SEP2020/ Placebo	01OCT2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
11621316	C4591001 1162 11621316	16-55	08SEP2020	84367	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
11621320	C4591001 1162 11621320	16-55	17SEP2020	90026	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
11621321	C4591001 1162 11621321	16-55	10SEP2020	84373	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
11621322	C4591001 1162 11621322	16-55	10SEP2020	86697	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
11621323	C4591001 1162 11621323	16-55	10SEP2020	84375	Placebo	10SEP2020/ Placebo	02OCT2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
11621324	C4591001 1162 11621324	16-55	10SEP2020	86699	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
11621325	C4591001 1162 11621325	16-55	10SEP2020	86702	Placebo	10SEP2020/ Placebo	02OCT2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
11621326	C4591001 1162 11621326	16-55	10SEP2020	87050	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11621328	C4591001 1162 11621328	16-55	10SEP2020	86703	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11621331	C4591001 1162 11621331	16-55	10SEP2020	86873	Placebo	10SEP2020/ Placebo	29SEP2020/ Placebo		
11621334	C4591001 1162 11621334	16-55	10SEP2020	86875	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11621335	C4591001 1162 11621335	16-55	10SEP2020	86876	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
11621336	C4591001 1162 11621336	16-55	10SEP2020	86879	Placebo	10SEP2020/ Placebo	30SEP2020/ Placebo		
11621338	C4591001 1162 11621338	16-55	10SEP2020	87051	Placebo	10SEP2020/ Placebo	30SEP2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
11621339	C4591001 1162 11621339	16-55	10SEP2020	87044	Placebo	10SEP2020/ Placebo	02OCT2020/ Placebo		
11621340	C4591001 1162 11621340	16-55	10SEP2020	87049	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11621344	C4591001 1162 11621344	16-55	10SEP2020	87312	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
11621346	C4591001 1162 11621346	16-55	10SEP2020	87313	Placebo	10SEP2020/ Placebo	29SEP2020/ Placebo		
11621350	C4591001 1162 11621350	16-55	14SEP2020	87315	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11621351	C4591001 1162 11621351	16-55	14SEP2020	89502	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
11621352	C4591001 1162 11621352	16-55	14SEP2020	87316	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
11621354	C4591001 1162 11621354	16-55	14SEP2020	89511	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
11621355	C4591001 1162 11621355	16-55	14SEP2020	89503	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)		
11621356	C4591001 1162 11621356	16-55	14SEP2020	89509	Placebo	14SEP2020/ Placebo			
11621358	C4591001 1162 11621358	16-55	14SEP2020	89555	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo		
11621360	C4591001 1162 11621360	16-55	14SEP2020	89550	Placebo	14SEP2020/ Placebo	22OCT2020/ Placebo		
11621361	C4591001 1162 11621361	16-55	14SEP2020	89558	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
11621362	C4591001 1162 11621362	16-55	14SEP2020	89559	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
11621363	C4591001 1162 11621363	16-55	14SEP2020	89686	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11621366	C4591001 1162 11621366	16-55	14SEP2020	89690	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
11621367	C4591001 1162 11621367	16-55	14SEP2020	89691	Placebo	14SEP2020/ Placebo	07OCT2020/ Placebo		
11621370	C4591001 1162 11621370	16-55	14SEP2020	89692	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
11621372	C4591001 1162 11621372	16-55	14SEP2020	89815	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
11621374	C4591001 1162 11621374	16-55	14SEP2020	89819	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)			
11621375	C4591001 1162 11621375	16-55	14SEP2020	89820	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
11621376	C4591001 1162 11621376	16-55	14SEP2020	89823	Placebo	14SEP2020/ Placebo	07OCT2020/ Placebo		
11621377	C4591001 1162 11621377	16-55	14SEP2020	89873	Placebo	14SEP2020/ Placebo	15OCT2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
11621378	C4591001 1162 11621378	16-55	14SEP2020	89877	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
11621379	C4591001 1162 11621379	16-55	14SEP2020	89880	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11621381	C4591001 1162 11621381	16-55	14SEP2020	90019	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)			
11621382	C4591001 1162 11621382	16-55	14SEP2020	89881	Placebo	14SEP2020/ Placebo	09OCT2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
11621383	C4591001 1162 11621383	16-55	17SEP2020	90027	Placebo	17SEP2020/ Placebo	07OCT2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
11621384	C4591001 1162 11621384	16-55	17SEP2020	90021	Placebo	17SEP2020/ Placebo	06OCT2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
11621386	C4591001 1162 11621386	16-55	17SEP2020	92192	Placebo	17SEP2020/ Placebo	09OCT2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
11621387	C4591001 1162 11621387	16-55	17SEP2020	92194	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
11621388	C4591001 1162 11621388	16-55	17SEP2020	92195	Placebo	17SEP2020/ Placebo	19OCT2020/ Placebo		
11621389	C4591001 1162 11621389	16-55	17SEP2020	92198	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
11621391	C4591001 1162 11621391	16-55	17SEP2020	92345	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)			
11621392	C4591001 1162 11621392	16-55	17SEP2020	92418	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11621393	C4591001 1162 11621393	16-55	17SEP2020	92347	Placebo	17SEP2020/ Placebo	09OCT2020/ Placebo		
11621394	C4591001 1162 11621394	16-55	17SEP2020	92353	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
11621396	C4591001 1162 11621396	16-55	17SEP2020	92354	Placebo	17SEP2020/ Placebo	06OCT2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
11621401	C4591001 1162 11621401	16-55	17SEP2020	92425	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
11621404	C4591001 1162 11621404	16-55	17SEP2020	92427	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
11621405	C4591001 1162 11621405	16-55	17SEP2020	92420	Placebo	17SEP2020/ Placebo	13OCT2020/ Placebo		
11621406	C4591001 1162 11621406	16-55	17SEP2020	92683	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
11621408	C4591001 1162 11621408	16-55	17SEP2020	92684	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
11621410	C4591001 1162 11621410	16-55	17SEP2020	92687	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
11621413	C4591001 1162 11621413	16-55	17SEP2020	92692	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11621414	C4591001 1162 11621414	16-55	17SEP2020	92837	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
11621416	C4591001 1162 11621416	16-55	21SEP2020	92848	Placebo	21SEP2020/ Placebo	14OCT2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
11621417	C4591001 1162 11621417	16-55	21SEP2020	92846	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
11621418	C4591001 1162 11621418	16-55	21SEP2020	92847	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
11621421	C4591001 1162 11621421	16-55	21SEP2020	95097	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
11621422	C4591001 1162 11621422	16-55	21SEP2020	95095	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
11621423	C4591001 1162 11621423	16-55	21SEP2020	95098	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
11621427	C4591001 1162 11621427	16-55	21SEP2020	95104	Placebo	21SEP2020/ Placebo	14OCT2020/ Placebo		
11621429	C4591001 1162 11621429	16-55	22SEP2020	96258	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
11621430	C4591001 1162 11621430	16-55	22SEP2020	96259	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11621434	C4591001 1162 11621434	16-55	28SEP2020	96264	Placebo	28SEP2020/ Placebo	19OCT2020/ Placebo		
11621435	C4591001 1162 11621435	16-55	28SEP2020	101309	BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		
11621436	C4591001 1162 11621436	16-55	28SEP2020	96266	Placebo	28SEP2020/ Placebo	19OCT2020/ Placebo		
11621437	C4591001 1162 11621437	16-55	28SEP2020	101310	Placebo	28SEP2020/ Placebo	19OCT2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
11621439	C4591001 1162 11621439	16-55	28SEP2020	101314	Placebo	28SEP2020/ Placebo	21OCT2020/ Placebo		
11621442	C4591001 1162 11621442	16-55	28SEP2020	101316	BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		
11621443	C4591001 1162 11621443	16-55	28SEP2020	101420	BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		
11621445	C4591001 1162 11621445	16-55	28SEP2020	101419	BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)		
11621446	C4591001 1162 11621446	16-55	28SEP2020	101421	Placebo	28SEP2020/ Placebo	20OCT2020/ Placebo		
11621448	C4591001 1162 11621448	16-55	28SEP2020	101498	BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		
11621450	C4591001 1162 11621450	16-55	28SEP2020	101490	Placebo	28SEP2020/ Placebo	19OCT2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11621451	C4591001 1162 11621451	16-55	28SEP2020	101428	Placebo	28SEP2020/ Placebo	19OCT2020/ Placebo		
11621452	C4591001 1162 11621452	16-55	28SEP2020	101496	BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)		
11621454	C4591001 1162 11621454	16-55	28SEP2020	101548	Placebo	28SEP2020/ Placebo	19OCT2020/ Placebo		
11621455	C4591001 1162 11621455	16-55	28SEP2020	101500	Placebo	28SEP2020/ Placebo	19OCT2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
11621456	C4591001 1162 11621456	16-55	28SEP2020	101537	BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)		
11621457	C4591001 1162 11621457	16-55	28SEP2020	101561	Placebo	28SEP2020/ Placebo	19OCT2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
11621458	C4591001 1162 11621458	16-55	28SEP2020	101544	Placebo	28SEP2020/ Placebo	19OCT2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
11621459	C4591001 1162 11621459	16-55	28SEP2020	101545	BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)		
11621460	C4591001 1162 11621460	16-55	30SEP2020	101564	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)		
11621463	C4591001 1162 11621463	16-55	30SEP2020	101567	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11621464	C4591001 1162 11621464	16-55	30SEP2020	101570	Placebo	30SEP2020/ Placebo	19OCT2020/ Placebo		
11621466	C4591001 1162 11621466	16-55	30SEP2020	102310	Placebo	30SEP2020/ Placebo	19OCT2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
11621467	C4591001 1162 11621467	16-55	30SEP2020	102306	Placebo	30SEP2020/ Placebo	19OCT2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
11621468	C4591001 1162 11621468	16-55	30SEP2020	102313	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		
11621469	C4591001 1162 11621469	16-55	30SEP2020	102309	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)		
11621471	C4591001 1162 11621471	16-55	30SEP2020	102390	Placebo	30SEP2020/ Placebo	19OCT2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
11621472	C4591001 1162 11621472	16-55	30SEP2020	102393	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		
11621476	C4591001 1162 11621476	16-55	30SEP2020	102396	Placebo	30SEP2020/ Placebo	21OCT2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
11621477	C4591001 1162 11621477	16-55	30SEP2020	102398	BNT162b2 (30 µg)				
11621479	C4591001 1162 11621479	16-55	07OCT2020	104672	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11621480	C4591001 1162 11621480	16-55	07OCT2020	104671	Placebo	07OCT2020/ Placebo	28OCT2020/ Placebo		
11621483	C4591001 1162 11621483	16-55	07OCT2020	104673	Placebo	07OCT2020/ Placebo	26OCT2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
11621484	C4591001 1162 11621484	16-55	07OCT2020	104680	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
11621486	C4591001 1162 11621486	16-55	07OCT2020	104803	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
11621488	C4591001 1162 11621488	16-55	07OCT2020	104801	Placebo	07OCT2020/ Placebo	29OCT2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
11621489	C4591001 1162 11621489	16-55	07OCT2020	104806	Placebo	07OCT2020/ Placebo	28OCT2020/ Placebo		
11621490	C4591001 1162 11621490	16-55	07OCT2020	104865	Placebo	07OCT2020/ Placebo	28OCT2020/ Placebo		
11621491	C4591001 1162 11621491	16-55	07OCT2020	104808	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
11621492	C4591001 1162 11621492	16-55	07OCT2020	104867	Placebo	07OCT2020/ Placebo	26OCT2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
11621494	C4591001 1162 11621494	16-55	07OCT2020	104868	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11621496	C4591001 1162 11621496	16-55	13OCT2020	106914	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
11621499	C4591001 1162 11621499	16-55	13OCT2020	106920	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
11621500	C4591001 1162 11621500	16-55	13OCT2020	106924	Placebo	13OCT2020/ Placebo	05NOV2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
11621502	C4591001 1162 11621502	16-55	13OCT2020	106922	Placebo	13OCT2020/ Placebo	02NOV2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
11621504	C4591001 1162 11621504	16-55	13OCT2020	107047	Placebo	13OCT2020/ Placebo	04NOV2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
11621505	C4591001 1162 11621505	16-55	13OCT2020	107046	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		
11621510	C4591001 1162 11621510	16-55	13OCT2020	107052	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
11621513	C4591001 1162 11621513	16-55	15OCT2020	107054	Placebo	15OCT2020/ Placebo	06NOV2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
11621514	C4591001 1162 11621514	16-55	15OCT2020	108029	Placebo	15OCT2020/ Placebo			
11621515	C4591001 1162 11621515	16-55	15OCT2020	108031	Placebo	15OCT2020/ Placebo			

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11621518	C4591001 1162 11621518	16-55	15OCT2020	108033	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
11621519	C4591001 1162 11621519	16-55	15OCT2020	108125	Placebo	15OCT2020/ Placebo	05NOV2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
11621520	C4591001 1162 11621520	16-55	15OCT2020	108034	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
11621522	C4591001 1162 11621522	16-55	15OCT2020	108127	Placebo	15OCT2020/ Placebo	06NOV2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
11621524	C4591001 1162 11621524	16-55	15OCT2020	108132	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)			
11621526	C4591001 1162 11621526	16-55	15OCT2020	108136	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
11621530	C4591001 1162 11621530	16-55	15OCT2020	108346	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
11621532	C4591001 1162 11621532	16-55	15OCT2020	108341	Placebo	15OCT2020/ Placebo	03NOV2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
11621534	C4591001 1162 11621534	16-55	15OCT2020	108347	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
11621535	C4591001 1162 11621535	16-55	15OCT2020	108350	Placebo	15OCT2020/ Placebo	04NOV2020/ Placebo	03MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11621537	C4591001 1162 11621537	16-55	15OCT2020	108509	Placebo	15OCT2020/ Placebo	03NOV2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
11621538	C4591001 1162 11621538	16-55	21OCT2020	108519	Placebo	21OCT2020/ Placebo	12NOV2020/ Placebo		
11621539	C4591001 1162 11621539	16-55	21OCT2020	108516	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
11621540	C4591001 1162 11621540	16-55	21OCT2020	108520	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
11621541	C4591001 1162 11621541	16-55	21OCT2020	111497	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
11621543	C4591001 1162 11621543	16-55	21OCT2020	111501	Placebo	21OCT2020/ Placebo	13NOV2020/ Placebo		
11621545	C4591001 1162 11621545	16-55	21OCT2020	111503	Placebo	21OCT2020/ Placebo	11NOV2020/ Placebo		
11621548	C4591001 1162 11621548	16-55	21OCT2020	111505	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
11621549	C4591001 1162 11621549	16-55	21OCT2020	111644	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
11621551	C4591001 1162 11621551	16-55	21OCT2020	111646	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11621553	C4591001 1162 11621553	16-55	21OCT2020	111648	Placebo	21OCT2020/ Placebo	11NOV2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
11621554	C4591001 1162 11621554	16-55	21OCT2020	111647	Placebo	21OCT2020/ Placebo	11NOV2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
11621559	C4591001 1162 11621559	16-55	22OCT2020	112097	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
11621563	C4591001 1162 11621563	16-55	22OCT2020	112104	Placebo	22OCT2020/ Placebo	11NOV2020/ Placebo		
11621566	C4591001 1162 11621566	16-55	22OCT2020	112102	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)			
11621569	C4591001 1162 11621569	16-55	22OCT2020	112107	Placebo	22OCT2020/ Placebo	12NOV2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
11621570	C4591001 1162 11621570	16-55	22OCT2020	112254	Placebo	22OCT2020/ Placebo	12NOV2020/ Placebo		
11621571	C4591001 1162 11621571	16-55	22OCT2020	112259	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
11621572	C4591001 1162 11621572	16-55	22OCT2020	112256	Placebo	22OCT2020/ Placebo	11NOV2020/ Placebo		
11621573	C4591001 1162 11621573	16-55	22OCT2020	112263	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11621574	C4591001 1162 11621574	16-55	22OCT2020	112354	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
11621576	C4591001 1162 11621576	16-55	22OCT2020	112356	Placebo	22OCT2020/ Placebo	23NOV2020/ Placebo		
11621579	C4591001 1162 11621579	16-55	22OCT2020	112357	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
11621580	C4591001 1162 11621580	16-55	22OCT2020	112358	Placebo	22OCT2020/ Placebo	13NOV2020/ Placebo		
11621582	C4591001 1162 11621582	16-55	22OCT2020	112469	Placebo	22OCT2020/ Placebo	11NOV2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
11621583	C4591001 1162 11621583	16-55	28OCT2020	112471	BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)	18NOV2020/ BNT162b2 (30 µg)		
11621584	C4591001 1162 11621584	16-55	29OCT2020	112478	Placebo	29OCT2020/ Placebo	19NOV2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
11621585	C4591001 1162 11621585	16-55	29OCT2020	112472	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)		
11621586	C4591001 1162 11621586	16-55	04NOV2020	115638	Placebo	04NOV2020/ Placebo	24NOV2020/ Placebo		
11621587	C4591001 1162 11621587	16-55	12NOV2020	115642	BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)	02DEC2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11621588	C4591001 1162 11621588	16-55	17NOV2020	115645	Placebo	17NOV2020/ Placebo	10DEC2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
11621589	C4591001 1162 11621589	16-55	17NOV2020	115644	BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)	10DEC2020/ BNT162b2 (30 µg)		
11631117	C4591001 1163 11631117	16-55	17AUG2020	50881	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11631121	C4591001 1163 11631121	16-55	17AUG2020	53636	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11631122	C4591001 1163 11631122	16-55	17AUG2020	53638	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	02MAR2021/ BNT162b2 (30 µg)	
11631123	C4591001 1163 11631123	16-55	17AUG2020	53640	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo		
11631124	C4591001 1163 11631124	16-55	17AUG2020	53642	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11631127	C4591001 1163 11631127	16-55	18AUG2020	55482	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11631129	C4591001 1163 11631129	16-55	19AUG2020	55488	Placebo	19AUG2020/ Placebo	08SEP2020/ Placebo	02MAR2021/ BNT162b2 (30 µg)	
11631135	C4591001 1163 11631135	16-55	20AUG2020	55491	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11631136	C4591001 1163 11631136	16-55	20AUG2020	55492	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11631138	C4591001 1163 11631138	16-55	20AUG2020	59861	Placebo	20AUG2020/ Placebo	08SEP2020/ Placebo	03MAR2021/ BNT162b2 (30 µg)	
11631142	C4591001 1163 11631142	16-55	21AUG2020	59868	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11631143	C4591001 1163 11631143	16-55	21AUG2020	59867	Placebo	21AUG2020/ Placebo	09SEP2020/ Placebo	03MAR2021/ BNT162b2 (30 µg)	
11631145	C4591001 1163 11631145	16-55	21AUG2020	59871	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11661002	C4591001 1166 11661002	16-55	18AUG2020	54353	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11661003	C4591001 1166 11661003	16-55	18AUG2020	54355	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11661004	C4591001 1166 11661004	16-55	18AUG2020	54357	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
11661005	C4591001 1166 11661005	16-55	18AUG2020	54358	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11661008	C4591001 1166 11661008	16-55	18AUG2020	54845	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11661009	C4591001 1166 11661009	16-55	18AUG2020	54847	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
11661011	C4591001 1166 11661011	16-55	19AUG2020	54848	Placebo	19AUG2020/ Placebo	08SEP2020/ Placebo		
11661014	C4591001 1166 11661014	16-55	19AUG2020	54854	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
11661016	C4591001 1166 11661016	16-55	19AUG2020	56384	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
11661017	C4591001 1166 11661017	16-55	19AUG2020	56386	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
11661019	C4591001 1166 11661019	16-55	19AUG2020	56387	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
11661022	C4591001 1166 11661022	16-55	20AUG2020	56390	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11661023	C4591001 1166 11661023	16-55	20AUG2020	57906	Placebo	20AUG2020/ Placebo	09SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
11661024	C4591001 1166 11661024	16-55	20AUG2020	57911	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11661025	C4591001 1166 11661025	16-55	20AUG2020	57912	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11661028	C4591001 1166 11661028	16-55	20AUG2020	57915	Placebo	20AUG2020/ Placebo	08SEP2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
11661030	C4591001 1166 11661030	16-55	20AUG2020	58482	Placebo	20AUG2020/ Placebo	11SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11661032	C4591001 1166 11661032	16-55	20AUG2020	58484	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
11661033	C4591001 1166 11661033	16-55	20AUG2020	58488	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11661035	C4591001 1166 11661035	16-55	20AUG2020	58490	Placebo	20AUG2020/ Placebo	08SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
11661036	C4591001 1166 11661036	16-55	20AUG2020	59009	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11661037	C4591001 1166 11661037	16-55	20AUG2020	59012	Placebo	20AUG2020/ Placebo	09SEP2020/ Placebo		
11661039	C4591001 1166 11661039	16-55	21AUG2020	59015	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	03MAR2021/ BNT162b2 (30 µg)	
11661041	C4591001 1166 11661041	16-55	21AUG2020	59020	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
11661042	C4591001 1166 11661042	16-55	21AUG2020	60377	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11661044	C4591001 1166 11661044	16-55	31AUG2020	74645	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo		
11661046	C4591001 1166 11661046	16-55	31AUG2020	74646	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11661047	C4591001 1166 11661047	16-55	31AUG2020	74652	Placebo	31AUG2020/ Placebo			
11661048	C4591001 1166 11661048	16-55	31AUG2020	74656	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11661049	C4591001 1166 11661049	16-55	01SEP2020	76301	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11661051	C4591001 1166 11661051	16-55	01SEP2020	76304	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo		
11661052	C4591001 1166 11661052	16-55	01SEP2020	76305	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
11661055	C4591001 1166 11661055	16-55	03SEP2020	76306	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11661056	C4591001 1166 11661056	16-55	03SEP2020	79613	Placebo	03SEP2020/ Placebo	23SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
11661060	C4591001 1166 11661060	16-55	03SEP2020	79616	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11661061	C4591001 1166 11661061	16-55	03SEP2020	79617	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11661062	C4591001 1166 11661062	16-55	03SEP2020	79624	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
11661063	C4591001 1166 11661063	16-55	03SEP2020	80073	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
11661064	C4591001 1166 11661064	16-55	03SEP2020	80074	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
11661065	C4591001 1166 11661065	16-55	03SEP2020	80076	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11661066	C4591001 1166 11661066	16-55	03SEP2020	80078	Placebo	03SEP2020/ Placebo	28SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
11661067	C4591001 1166 11661067	16-55	03SEP2020	80741	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11661068	C4591001 1166 11661068	16-55	04SEP2020	80748	Placebo	04SEP2020/ Placebo	24SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
11661069	C4591001 1166 11661069	16-55	04SEP2020	80749	Placebo	04SEP2020/ Placebo	24SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
11661070	C4591001 1166 11661070	16-55	04SEP2020	80752	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11661071	C4591001 1166 11661071	16-55	10SEP2020	86453	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
11661072	C4591001 1166 11661072	16-55	10SEP2020	86456	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11661073	C4591001 1166 11661073	16-55	11SEP2020	86459	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
11661076	C4591001 1166 11661076	16-55	15SEP2020	86463	Placebo	15SEP2020/ Placebo	05OCT2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
11661077	C4591001 1166 11661077	16-55	15SEP2020	90629	Placebo	15SEP2020/ Placebo	05OCT2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
11661078	C4591001 1166 11661078	16-55	15SEP2020	90631	Placebo	15SEP2020/ Placebo	05OCT2020/ Placebo		
11661079	C4591001 1166 11661079	16-55	16SEP2020	90634	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
11661080	C4591001 1166 11661080	16-55	17SEP2020	90638	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
11661081	C4591001 1166 11661081	16-55	17SEP2020	92058	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
11661082	C4591001 1166 11661082	16-55	17SEP2020	92061	Placebo	17SEP2020/ Placebo	07OCT2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11661083	C4591001 1166 11661083	16-55	17SEP2020	92063	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
11661084	C4591001 1166 11661084	16-55	17SEP2020	92065	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
11661085	C4591001 1166 11661085	16-55	17SEP2020	92658	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
11661086	C4591001 1166 11661086	16-55	18SEP2020	92659	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
11661087	C4591001 1166 11661087	16-55	18SEP2020	92660	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
11661088	C4591001 1166 11661088	16-55	18SEP2020	92664	Placebo	18SEP2020/ Placebo	07OCT2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
11661090	C4591001 1166 11661090	16-55	22SEP2020	96185	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
11661091	C4591001 1166 11661091	16-55	22SEP2020	96186	Placebo	22SEP2020/ Placebo	04NOV2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
11661092	C4591001 1166 11661092	16-55	23SEP2020	96192	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
11661094	C4591001 1166 11661094	16-55	23SEP2020	96194	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11661095	C4591001 1166 11661095	16-55	24SEP2020	98790	Placebo	24SEP2020/ Placebo	13OCT2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
11661096	C4591001 1166 11661096	16-55	24SEP2020	98791	Placebo	24SEP2020/ Placebo	14OCT2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
11661097	C4591001 1166 11661097	16-55	23OCT2020	98793	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	24NOV2020/ BNT162b2 (30 µg)		
11661099	C4591001 1166 11661099	16-55	26OCT2020	98794	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
11661103	C4591001 1166 11661103	16-55	26OCT2020	113706	Placebo	26OCT2020/ Placebo	16NOV2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
11661104	C4591001 1166 11661104	16-55	26OCT2020	113707	Placebo	26OCT2020/ Placebo	16NOV2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
11661106	C4591001 1166 11661106	16-55	29OCT2020	113713	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	24NOV2020/ BNT162b2 (30 µg)		
11661109	C4591001 1166 11661109	16-55	30OCT2020	113715	BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)		
11661110	C4591001 1166 11661110	16-55	30OCT2020	115001	Placebo	30OCT2020/ Placebo	18NOV2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
11661112	C4591001 1166 11661112	16-55	30OCT2020	115004	BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)	18NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11671003	C4591001 1167 11671003	16-55	14AUG2020	49812	Placebo				
11671007	C4591001 1167 11671007	16-55	17AUG2020	50468	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
11671009	C4591001 1167 11671009	16-55	17AUG2020	50474	Placebo	17AUG2020/ Placebo	09SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	04JAN2021/ BNT162b2 (30 µg)
11671010	C4591001 1167 11671010	16-55	17AUG2020	53011	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	15DEC2020/ BNT162b2 (30 µg)	04JAN2021/ BNT162b2 (30 µg)
11671011	C4591001 1167 11671011	16-55	17AUG2020	53017	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11671013	C4591001 1167 11671013	16-55	17AUG2020	53018	Placebo	17AUG2020/ Placebo	09SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
11671017	C4591001 1167 11671017	16-55	18AUG2020	53019	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
11671019	C4591001 1167 11671019	16-55	18AUG2020	55121	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
11671020	C4591001 1167 11671020	16-55	19AUG2020	55123	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11671021	C4591001 1167 11671021	16-55	19AUG2020	55126	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11671023	C4591001 1167 11671023	16-55	19AUG2020	55132	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
11671025	C4591001 1167 11671025	16-55	19AUG2020	57257	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11671026	C4591001 1167 11671026	16-55	20AUG2020	57261	Placebo	20AUG2020/ Placebo	11SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
11671028	C4591001 1167 11671028	16-55	20AUG2020	57263	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
11671029	C4591001 1167 11671029	16-55	20AUG2020	57266	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11671030	C4591001 1167 11671030	16-55	20AUG2020	58327	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11671032	C4591001 1167 11671032	16-55	20AUG2020	58328	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
11671034	C4591001 1167 11671034	16-55	20AUG2020	58333	Placebo	20AUG2020/ Placebo	11SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
11671035	C4591001 1167 11671035	16-55	20AUG2020	58335	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11671036	C4591001 1167 11671036	16-55	21AUG2020	59986	Placebo	21AUG2020/ Placebo	09SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11671038	C4591001 1167 11671038	16-55	21AUG2020	59988	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
11671039	C4591001 1167 11671039	16-55	21AUG2020	59990	Placebo	21AUG2020/ Placebo	10SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
11671040	C4591001 1167 11671040	16-55	21AUG2020	59991	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11671041	C4591001 1167 11671041	16-55	21AUG2020	60534	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
11671044	C4591001 1167 11671044	16-55	21AUG2020	60538	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
11671045	C4591001 1167 11671045	16-55	21AUG2020	60539	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
11671046	C4591001 1167 11671046	16-55	21AUG2020	60541	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
11671050	C4591001 1167 11671050	16-55	24AUG2020	63569	Placebo	24AUG2020/ Placebo	15SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
11671051	C4591001 1167 11671051	16-55	24AUG2020	63570	Placebo	24AUG2020/ Placebo	15SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
11671053	C4591001 1167 11671053	16-55	24AUG2020	63571	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11671054	C4591001 1167 11671054	16-55	24AUG2020	63578	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11671055	C4591001 1167 11671055	16-55	25AUG2020	65214	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11671057	C4591001 1167 11671057	16-55	25AUG2020	65216	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
11671058	C4591001 1167 11671058	16-55	25AUG2020	65217	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11671060	C4591001 1167 11671060	16-55	25AUG2020	65222	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
11671061	C4591001 1167 11671061	16-55	25AUG2020	65840	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
11671065	C4591001 1167 11671065	16-55	25AUG2020	65846	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	15DEC2020/ BNT162b2 (30 µg)	04JAN2021/ BNT162b2 (30 µg)
11671066	C4591001 1167 11671066	16-55	26AUG2020	65848	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
11671070	C4591001 1167 11671070	16-55	26AUG2020	67637	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11671071	C4591001 1167 11671071	16-55	26AUG2020	67645	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11671073	C4591001 1167 11671073	16-55	26AUG2020	67646	Placebo	26AUG2020/ Placebo	17SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11671078	C4591001 1167 11671078	16-55	27AUG2020	67647	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
11671082	C4591001 1167 11671082	16-55	27AUG2020	70937	Placebo	27AUG2020/ Placebo	16SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
11671083	C4591001 1167 11671083	16-55	27AUG2020	70943	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
11671086	C4591001 1167 11671086	16-55	28AUG2020	70946	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11671089	C4591001 1167 11671089	16-55	28AUG2020	70948	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11671092	C4591001 1167 11671092	16-55	28AUG2020	72486	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
11671095	C4591001 1167 11671095	16-55	31AUG2020	72489	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11671096	C4591001 1167 11671096	16-55	31AUG2020	72495	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11671097	C4591001 1167 11671097	16-55	31AUG2020	72496	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11671099	C4591001 1167 11671099	16-55	31AUG2020	74981	Placebo	31AUG2020/ Placebo	23SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
11671102	C4591001 1167 11671102	16-55	31AUG2020	74983	Placebo	31AUG2020/ Placebo	23SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
11671103	C4591001 1167 11671103	16-55	31AUG2020	74986	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11671105	C4591001 1167 11671105	16-55	01SEP2020	74991	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
11671106	C4591001 1167 11671106	16-55	01SEP2020	76277	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
11671111	C4591001 1167 11671111	16-55	01SEP2020	76279	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)			
11671112	C4591001 1167 11671112	16-55	01SEP2020	76282	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
11671113	C4591001 1167 11671113	16-55	01SEP2020	76286	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
11671114	C4591001 1167 11671114	16-55	01SEP2020	77121	Placebo	01SEP2020/ Placebo	24SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
11671117	C4591001 1167 11671117	16-55	02SEP2020	77122	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11671118	C4591001 1167 11671118	16-55	02SEP2020	77123	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
11671119	C4591001 1167 11671119	16-55	02SEP2020	77127	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11671120	C4591001 1167 11671120	16-55	02SEP2020	77885	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11671124	C4591001 1167 11671124	16-55	02SEP2020	77891	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
11671125	C4591001 1167 11671125	16-55	02SEP2020	77893	Placebo	02SEP2020/ Placebo	21SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
11671128	C4591001 1167 11671128	16-55	02SEP2020	77896	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11671129	C4591001 1167 11671129	16-55	02SEP2020	79098	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11671130	C4591001 1167 11671130	16-55	03SEP2020	79101	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11671131	C4591001 1167 11671131	16-55	03SEP2020	79104	Placebo	03SEP2020/ Placebo	22SEP2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
11671132	C4591001 1167 11671132	16-55	03SEP2020	79108	Placebo	03SEP2020/ Placebo	22SEP2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11671134	C4591001 1167 11671134	16-55	03SEP2020	79841	Placebo	03SEP2020/ Placebo	22SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
11671140	C4591001 1167 11671140	16-55	03SEP2020	79842	Placebo	03SEP2020/ Placebo	22SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
11671142	C4591001 1167 11671142	16-55	04SEP2020	79846	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11671144	C4591001 1167 11671144	16-55	04SEP2020	79847	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
11671146	C4591001 1167 11671146	16-55	04SEP2020	81451	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11671149	C4591001 1167 11671149	16-55	04SEP2020	81453	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
11671150	C4591001 1167 11671150	16-55	04SEP2020	81454	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
11671151	C4591001 1167 11671151	16-55	04SEP2020	81458	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
11671152	C4591001 1167 11671152	16-55	04SEP2020	82133	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
11671160	C4591001 1167 11671160	16-55	08SEP2020	82134	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11671162	C4591001 1167 11671162	16-55	09SEP2020	254067	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
11671164	C4591001 1167 11671164	16-55	09SEP2020	82135	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
11671166	C4591001 1167 11671166	16-55	09SEP2020	82143	Placebo	09SEP2020/ Placebo	29SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
11671167	C4591001 1167 11671167	16-55	09SEP2020	85544	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
11671169	C4591001 1167 11671169	16-55	10SEP2020	85545	Placebo	10SEP2020/ Placebo	29SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
11671170	C4591001 1167 11671170	16-55	10SEP2020	85547	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11671173	C4591001 1167 11671173	16-55	10SEP2020	85550	Placebo	10SEP2020/ Placebo	19OCT2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
11671174	C4591001 1167 11671174	16-55	10SEP2020	87079	Placebo	10SEP2020/ Placebo	29SEP2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
11671175	C4591001 1167 11671175	16-55	10SEP2020	87080	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11671178	C4591001 1167 11671178	16-55	11SEP2020	87081	Placebo	11SEP2020/ Placebo	30SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11671179	C4591001 1167 11671179	16-55	11SEP2020	87082	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
11671181	C4591001 1167 11671181	16-55	11SEP2020	88436	Placebo	11SEP2020/ Placebo	30SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
11671185	C4591001 1167 11671185	16-55	14SEP2020	88437	Placebo	14SEP2020/ Placebo	07OCT2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
11671187	C4591001 1167 11671187	16-55	15SEP2020	88438	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
11671188	C4591001 1167 11671188	16-55	15SEP2020	88443	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
11671189	C4591001 1167 11671189	16-55	16SEP2020	90941	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
11671191	C4591001 1167 11671191	16-55	16SEP2020	90946	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
11671192	C4591001 1167 11671192	16-55	16SEP2020	90951	Placebo	16SEP2020/ Placebo	07OCT2020/ Placebo	15DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
11671193	C4591001 1167 11671193	16-55	16SEP2020	90952	Placebo	16SEP2020/ Placebo	07OCT2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
11671194	C4591001 1167 11671194	16-55	16SEP2020	91445	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11671195	C4591001 1167 11671195	16-55	16SEP2020	91449	Placebo	16SEP2020/ Placebo	06OCT2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
11671199	C4591001 1167 11671199	16-55	17SEP2020	91450	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
11671200	C4591001 1167 11671200	16-55	17SEP2020	91452	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
11671201	C4591001 1167 11671201	16-55	17SEP2020	92312	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
11671202	C4591001 1167 11671202	16-55	17SEP2020	92315	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	15DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
11671205	C4591001 1167 11671205	16-55	18SEP2020	92318	Placebo	18SEP2020/ Placebo	07OCT2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
11671206	C4591001 1167 11671206	16-55	18SEP2020	92320	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
11671208	C4591001 1167 11671208	16-55	18SEP2020	94086	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
11671210	C4591001 1167 11671210	16-55	21SEP2020	94087	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
11671211	C4591001 1167 11671211	16-55	21SEP2020	94091	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11671212	C4591001 1167 11671212	16-55	21SEP2020	94092	Placebo	21SEP2020/ Placebo	14OCT2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
11671213	C4591001 1167 11671213	16-55	21SEP2020	95564	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
11671214	C4591001 1167 11671214	16-55	21SEP2020	95561	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
11671216	C4591001 1167 11671216	16-55	22SEP2020	95565	Placebo	22SEP2020/ Placebo	12OCT2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
11671217	C4591001 1167 11671217	16-55	22SEP2020	95572	Placebo	22SEP2020/ Placebo	13OCT2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
11671218	C4591001 1167 11671218	16-55	22SEP2020	96560	Placebo	22SEP2020/ Placebo	15OCT2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
11671219	C4591001 1167 11671219	16-55	22SEP2020	96563	Placebo	22SEP2020/ Placebo	15OCT2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
11671220	C4591001 1167 11671220	16-55	22SEP2020	96566	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
11671222	C4591001 1167 11671222	16-55	23SEP2020	96568	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
11671223	C4591001 1167 11671223	16-55	23SEP2020	98189	Placebo	23SEP2020/ Placebo	12NOV2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11671224	C4591001 1167 11671224	16-55	24SEP2020	98190	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
11671230	C4591001 1167 11671230	16-55	25SEP2020	98196	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)		
11671231	C4591001 1167 11671231	16-55	25SEP2020	98200	Placebo	25SEP2020/ Placebo	19OCT2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
11681027	C4591001 1168 11681027	16-55	15AUG2020	51175	Placebo	15AUG2020/ Placebo	04SEP2020/ Placebo	15DEC2020/ BNT162b2 (30 µg)	04JAN2021/ BNT162b2 (30 µg)
11681028	C4591001 1168 11681028	16-55	15AUG2020	51182	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
11681030	C4591001 1168 11681030	16-55	15AUG2020	51307	BNT162b2 (30 µg)				
11681032	C4591001 1168 11681032	16-55	17AUG2020	51314	Placebo	17AUG2020/ Placebo	09SEP2020/ Placebo		
11681033	C4591001 1168 11681033	16-55	17AUG2020	51316	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11681034	C4591001 1168 11681034	16-55	17AUG2020	53453	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11681035	C4591001 1168 11681035	16-55	17AUG2020	53457	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11681036	C4591001 1168 11681036	16-55	19AUG2020	55342	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
11681038	C4591001 1168 11681038	16-55	18AUG2020	53461	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	28JAN2021/ BNT162b2 (30 µg)
11681039	C4591001 1168 11681039	16-55	18AUG2020	53462	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo		
11681040	C4591001 1168 11681040	16-55	18AUG2020	54617	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11681041	C4591001 1168 11681041	16-55	18AUG2020	54620	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	20FEB2021/ BNT162b2 (30 µg)
11681042	C4591001 1168 11681042	16-55	18AUG2020	54625	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11681045	C4591001 1168 11681045	16-55	18AUG2020	55338	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
11681046	C4591001 1168 11681046	16-55	18AUG2020	54628	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
11681047	C4591001 1168 11681047	16-55	19AUG2020	55343	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
11681048	C4591001 1168 11681048	16-55	19AUG2020	55348	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11681050	C4591001 1168 11681050	16-55	19AUG2020	56637	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
11681052	C4591001 1168 11681052	16-55	19AUG2020	56640	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
11681053	C4591001 1168 11681053	16-55	19AUG2020	56642	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11681054	C4591001 1168 11681054	16-55	20AUG2020	56643	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
11681058	C4591001 1168 11681058	16-55	20AUG2020	59513	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
11681059	C4591001 1168 11681059	16-55	20AUG2020	59518	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11681060	C4591001 1168 11681060	16-55	20AUG2020	59522	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
11681062	C4591001 1168 11681062	16-55	21AUG2020	59523	Placebo	21AUG2020/ Placebo	16SEP2020/ Placebo		
11681063	C4591001 1168 11681063	16-55	21AUG2020	60366	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
11681064	C4591001 1168 11681064	16-55	21AUG2020	60367	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11681065	C4591001 1168 11681065	16-55	21AUG2020	60369	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
11681068	C4591001 1168 11681068	16-55	21AUG2020	60376	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11681069	C4591001 1168 11681069	16-55	21AUG2020	60966	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
11681070	C4591001 1168 11681070	16-55	21AUG2020	60968	Placebo	21AUG2020/ Placebo	05OCT2020/ Placebo		
11681071	C4591001 1168 11681071	16-55	21AUG2020	60971	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
11681072	C4591001 1168 11681072	16-55	21AUG2020	61482	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
11681073	C4591001 1168 11681073	16-55	21AUG2020	60974	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
11681074	C4591001 1168 11681074	16-55	24AUG2020	61484	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
11681076	C4591001 1168 11681076	16-55	24AUG2020	61485	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11681077	C4591001 1168 11681077	16-55	24AUG2020	61487	Placebo	24AUG2020/ Placebo	15SEP2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11681078	C4591001 1168 11681078	16-55	24AUG2020	64746	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
11681079	C4591001 1168 11681079	16-55	25AUG2020	64749	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
11681080	C4591001 1168 11681080	16-55	25AUG2020	64751	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
11681081	C4591001 1168 11681081	16-55	25AUG2020	64755	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
11681084	C4591001 1168 11681084	16-55	25AUG2020	66331	Placebo	25AUG2020/ Placebo	14SEP2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
11681085	C4591001 1168 11681085	16-55	25AUG2020	66338	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11681086	C4591001 1168 11681086	16-55	25AUG2020	66332	Placebo	25AUG2020/ Placebo	14SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11681087	C4591001 1168 11681087	16-55	26AUG2020	66339	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11681088	C4591001 1168 11681088	16-55	26AUG2020	68369	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
11681089	C4591001 1168 11681089	16-55	26AUG2020	68370	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11681090	C4591001 1168 11681090	16-55	27AUG2020	68373	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
11681093	C4591001 1168 11681093	16-55	27AUG2020	68374	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
11681094	C4591001 1168 11681094	16-55	27AUG2020	70637	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo		
11681095	C4591001 1168 11681095	16-55	27AUG2020	70639	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11681096	C4591001 1168 11681096	16-55	27AUG2020	70642	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
11681097	C4591001 1168 11681097	16-55	27AUG2020	70646	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)
11681098	C4591001 1168 11681098	16-55	27AUG2020	71369	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
11681100	C4591001 1168 11681100	16-55	28AUG2020	71372	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
11681101	C4591001 1168 11681101	16-55	28AUG2020	71379	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
11681102	C4591001 1168 11681102	16-55	28AUG2020	71380	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11681103	C4591001 1168 11681103	16-55	28AUG2020	72295	Placebo	28AUG2020/ Placebo	17SEP2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
11681104	C4591001 1168 11681104	16-55	28AUG2020	72297	Placebo	28AUG2020/ Placebo			
11681105	C4591001 1168 11681105	16-55	28AUG2020	72298	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
11681107	C4591001 1168 11681107	16-55	28AUG2020	72299	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
11681109	C4591001 1168 11681109	16-55	28AUG2020	73099	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
11681112	C4591001 1168 11681112	16-55	31AUG2020	73100	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11681114	C4591001 1168 11681114	16-55	31AUG2020	73101	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
11681115	C4591001 1168 11681115	16-55	31AUG2020	73107	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11681116	C4591001 1168 11681116	16-55	31AUG2020	75655	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11681117	C4591001 1168 11681117	16-55	31AUG2020	75656	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	20FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11681118	C4591001 1168 11681118	16-55	01SEP2020	75662	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11681121	C4591001 1168 11681121	16-55	01SEP2020	75663	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
11681125	C4591001 1168 11681125	16-55	01SEP2020	77465	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
11681126	C4591001 1168 11681126	16-55	01SEP2020	77468	Placebo	01SEP2020/ Placebo	21SEP2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	
11681127	C4591001 1168 11681127	16-55	02SEP2020	77473	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11681128	C4591001 1168 11681128	16-55	02SEP2020	77476	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11681130	C4591001 1168 11681130	16-55	03SEP2020	79818	Placebo	03SEP2020/ Placebo	25SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11681132	C4591001 1168 11681132	16-55	03SEP2020	79819	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
11681134	C4591001 1168 11681134	16-55	03SEP2020	79821	Placebo	03SEP2020/ Placebo	22SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	04JAN2021/ BNT162b2 (30 µg)
11681135	C4591001 1168 11681135	16-55	03SEP2020	79823	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11681136	C4591001 1168 11681136	16-55	03SEP2020	81057	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
11681137	C4591001 1168 11681137	16-55	03SEP2020	81059	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
11681138	C4591001 1168 11681138	16-55	03SEP2020	81060	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
11681141	C4591001 1168 11681141	16-55	04SEP2020	81063	Placebo	04SEP2020/ Placebo	24SEP2020/ Placebo	15DEC2020/ BNT162b2 (30 µg)	04JAN2021/ BNT162b2 (30 µg)
11681142	C4591001 1168 11681142	16-55	04SEP2020	82231	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
11681143	C4591001 1168 11681143	16-55	04SEP2020	82232	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
11681145	C4591001 1168 11681145	16-55	08SEP2020	82239	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo	15DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
11681146	C4591001 1168 11681146	16-55	08SEP2020	82240	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
11681148	C4591001 1168 11681148	16-55	09SEP2020	85218	Placebo	09SEP2020/ Placebo	29SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
11681153	C4591001 1168 11681153	16-55	10SEP2020	85221	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	28JAN2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11681154	C4591001 1168 11681154	16-55	10SEP2020	85225	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11681157	C4591001 1168 11681157	16-55	10SEP2020	85228	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
11681158	C4591001 1168 11681158	16-55	11SEP2020	87858	Placebo	11SEP2020/ Placebo	01OCT2020/ Placebo	15DEC2020/ BNT162b2 (30 µg)	04JAN2021/ BNT162b2 (30 µg)
11681159	C4591001 1168 11681159	16-55	11SEP2020	87863	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
11681160	C4591001 1168 11681160	16-55	11SEP2020	87866	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
11681162	C4591001 1168 11681162	16-55	11SEP2020	87868	Placebo	11SEP2020/ Placebo	01OCT2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
11681163	C4591001 1168 11681163	16-55	11SEP2020	88661	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
11681164	C4591001 1168 11681164	16-55	11SEP2020	88662	Placebo	11SEP2020/ Placebo	01OCT2020/ Placebo		
11681166	C4591001 1168 11681166	16-55	14SEP2020	88672	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	20FEB2021/ BNT162b2 (30 µg)
11681167	C4591001 1168 11681167	16-55	14SEP2020	88668	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11681168	C4591001 1168 11681168	16-55	14SEP2020	90077	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
11681169	C4591001 1168 11681169	16-55	15SEP2020	90084	Placebo	15SEP2020/ Placebo	13OCT2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	20FEB2021/ BNT162b2 (30 µg)
11681175	C4591001 1168 11681175	16-55	15SEP2020	90086	Placebo	15SEP2020/ Placebo	05OCT2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
11681176	C4591001 1168 11681176	16-55	16SEP2020	90087	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
11681177	C4591001 1168 11681177	16-55	16SEP2020	91109	Placebo	16SEP2020/ Placebo	07OCT2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
11681178	C4591001 1168 11681178	16-55	16SEP2020	91115	Placebo	16SEP2020/ Placebo	08OCT2020/ Placebo		
11681182	C4591001 1168 11681182	16-55	17SEP2020	91117	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
11681184	C4591001 1168 11681184	16-55	17SEP2020	91119	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
11681185	C4591001 1168 11681185	16-55	17SEP2020	93020	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	15DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11681186	C4591001 1168 11681186	16-55	17SEP2020	93026	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11681187	C4591001 1168 11681187	16-55	18SEP2020	93027	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	20FEB2021/ BNT162b2 (30 µg)
11681188	C4591001 1168 11681188	16-55	18SEP2020	93028	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
11681192	C4591001 1168 11681192	16-55	21SEP2020	95407	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
11681193	C4591001 1168 11681193	16-55	21SEP2020	95411	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
11681194	C4591001 1168 11681194	16-55	22SEP2020	95415	Placebo	22SEP2020/ Placebo	13OCT2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	28JAN2021/ BNT162b2 (30 µg)
11681195	C4591001 1168 11681195	16-55	22SEP2020	95416	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
11681197	C4591001 1168 11681197	16-55	23SEP2020	97494	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
11681198	C4591001 1168 11681198	16-55	23SEP2020	97518	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
11681202	C4591001 1168 11681202	16-55	23SEP2020	97520	Placebo	23SEP2020/ Placebo	13OCT2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
11681203	C4591001 1168 11681203	16-55	23SEP2020	97521	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11681206	C4591001 1168 11681206	16-55	24SEP2020	97526	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
11681207	C4591001 1168 11681207	16-55	25SEP2020	99510	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	28JAN2021/ BNT162b2 (30 µg)
11681210	C4591001 1168 11681210	16-55	25SEP2020	99513	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
11681212	C4591001 1168 11681212	16-55	25SEP2020	99516	Placebo	25SEP2020/ Placebo	15OCT2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
11681213	C4591001 1168 11681213	16-55	25SEP2020	99517	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
11681215	C4591001 1168 11681215	16-55	29SEP2020	102005	BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)		
11681216	C4591001 1168 11681216	16-55	02OCT2020	102008	Placebo	02OCT2020/ Placebo	23OCT2020/ Placebo	15DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
11681217	C4591001 1168 11681217	16-55	05OCT2020	102013	BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
11681218	C4591001 1168 11681218	16-55	05OCT2020	103913	BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)		
11681219	C4591001 1168 11681219	16-55	05OCT2020	103917	BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11681220	C4591001 1168 11681220	16-55	05OCT2020	102016	Placebo	05OCT2020/ Placebo	26OCT2020/ Placebo		
11681221	C4591001 1168 11681221	16-55	06OCT2020	103921	Placebo	06OCT2020/ Placebo	29OCT2020/ Placebo		
11681222	C4591001 1168 11681222	16-55	06OCT2020	103922	Placebo	06OCT2020/ Placebo	26OCT2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
11681223	C4591001 1168 11681223	16-55	07OCT2020	104936	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
11681224	C4591001 1168 11681224	16-55	08OCT2020	104938	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
11681226	C4591001 1168 11681226	16-55	08OCT2020	104939	Placebo	08OCT2020/ Placebo	28OCT2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
11681227	C4591001 1168 11681227	16-55	12OCT2020	104943	Placebo	12OCT2020/ Placebo			
11681228	C4591001 1168 11681228	16-55	13OCT2020	107277	Placebo	13OCT2020/ Placebo	10NOV2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	20FEB2021/ BNT162b2 (30 µg)
11681229	C4591001 1168 11681229	16-55	15OCT2020	107279	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
11681231	C4591001 1168 11681231	16-55	20OCT2020	107280	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11681234	C4591001 1168 11681234	16-55	21OCT2020	107281	Placebo	21OCT2020/ Placebo	02DEC2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	20FEB2021/ BNT162b2 (30 µg)
11681239	C4591001 1168 11681239	16-55	23OCT2020	113022	Placebo	23OCT2020/ Placebo	13NOV2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
11681241	C4591001 1168 11681241	16-55	28OCT2020	113026	Placebo	28OCT2020/ Placebo	16NOV2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
11691001	C4591001 1169 11691001	16-55	01SEP2020	76411	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11691002	C4591001 1169 11691002	16-55	01SEP2020	76413	Placebo	01SEP2020/ Placebo	23SEP2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
11691007	C4591001 1169 11691007	16-55	03SEP2020	76414	Placebo	03SEP2020/ Placebo	23SEP2020/ Placebo	06JAN2021/ BNT162b2 (30 µg)	27JAN2021/ BNT162b2 (30 µg)
11691010	C4591001 1169 11691010	16-55	03SEP2020	76419	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
11691011	C4591001 1169 11691011	16-55	03SEP2020	80106	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11691012	C4591001 1169 11691012	16-55	04SEP2020	80108	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11691014	C4591001 1169 11691014	16-55	04SEP2020	80110	Placebo	04SEP2020/ Placebo	23SEP2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11691017	C4591001 1169 11691017	16-55	08SEP2020	80114	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
11691018	C4591001 1169 11691018	16-55	08SEP2020	83345	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)
11691019	C4591001 1169 11691019	16-55	08SEP2020	83347	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
11691020	C4591001 1169 11691020	16-55	08SEP2020	83348	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
11691021	C4591001 1169 11691021	16-55	08SEP2020	83355	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
11691022	C4591001 1169 11691022	16-55	08SEP2020	83801	Placebo	08SEP2020/ Placebo	01OCT2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
11691023	C4591001 1169 11691023	16-55	08SEP2020	83802	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11691024	C4591001 1169 11691024	16-55	09SEP2020	83807	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11691025	C4591001 1169 11691025	16-55	09SEP2020	83812	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
11691026	C4591001 1169 11691026	16-55	09SEP2020	85125	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11691027	C4591001 1169 11691027	16-55	09SEP2020	85128	Placebo	09SEP2020/ Placebo	28SEP2020/ Placebo	06JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
11691029	C4591001 1169 11691029	16-55	09SEP2020	85130	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
11691030	C4591001 1169 11691030	16-55	10SEP2020	85132	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
11691031	C4591001 1169 11691031	16-55	10SEP2020	86418	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11691033	C4591001 1169 11691033	16-55	10SEP2020	86419	Placebo	10SEP2020/ Placebo	30SEP2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11691034	C4591001 1169 11691034	16-55	10SEP2020	86423	Placebo	10SEP2020/ Placebo	30SEP2020/ Placebo		
11691036	C4591001 1169 11691036	16-55	11SEP2020	86425	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
11691038	C4591001 1169 11691038	16-55	11SEP2020	87943	Placebo	11SEP2020/ Placebo	30SEP2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	28JAN2021/ BNT162b2 (30 µg)
11691039	C4591001 1169 11691039	16-55	11SEP2020	87945	Placebo	11SEP2020/ Placebo	01OCT2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
11691040	C4591001 1169 11691040	16-55	11SEP2020	87951	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11691041	C4591001 1169 11691041	16-55	11SEP2020	87952	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
11691043	C4591001 1169 11691043	16-55	14SEP2020	89346	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
11691044	C4591001 1169 11691044	16-55	14SEP2020	89347	Placebo	14SEP2020/ Placebo	06OCT2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)
11691046	C4591001 1169 11691046	16-55	15SEP2020	89353	Placebo	15SEP2020/ Placebo	06OCT2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
11691047	C4591001 1169 11691047	16-55	15SEP2020	89355	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
11691048	C4591001 1169 11691048	16-55	15SEP2020	90341	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
11691049	C4591001 1169 11691049	16-55	15SEP2020	90342	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
11691053	C4591001 1169 11691053	16-55	16SEP2020	90343	Placebo	16SEP2020/ Placebo	07OCT2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
11691054	C4591001 1169 11691054	16-55	16SEP2020	90346	Placebo	16SEP2020/ Placebo	07OCT2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	27JAN2021/ BNT162b2 (30 µg)
11691055	C4591001 1169 11691055	16-55	16SEP2020	91122	Placebo	16SEP2020/ Placebo	06OCT2020/ Placebo	06JAN2021/ BNT162b2 (30 µg)	27JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11691056	C4591001 1169 11691056	16-55	16SEP2020	91124	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
11691057	C4591001 1169 11691057	16-55	16SEP2020	91127	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
11691058	C4591001 1169 11691058	16-55	16SEP2020	91131	Placebo	16SEP2020/ Placebo		07JAN2021/ BNT162b2 (30 µg)	28JAN2021/ BNT162b2 (30 µg)
11691059	C4591001 1169 11691059	16-55	17SEP2020	92070	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
11691060	C4591001 1169 11691060	16-55	17SEP2020	92071	Placebo	17SEP2020/ Placebo	13OCT2020/ Placebo		
11691062	C4591001 1169 11691062	16-55	17SEP2020	92075	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
11691063	C4591001 1169 11691063	16-55	17SEP2020	92077	Placebo	17SEP2020/ Placebo	06OCT2020/ Placebo	06JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
11691064	C4591001 1169 11691064	16-55	17SEP2020	92597	Placebo	17SEP2020/ Placebo	06OCT2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
11691065	C4591001 1169 11691065	16-55	18SEP2020	92600	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
11691067	C4591001 1169 11691067	16-55	18SEP2020	92602	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11691069	C4591001 1169 11691069	16-55	18SEP2020	92608	Placebo	18SEP2020/ Placebo	07OCT2020/ Placebo		
11691072	C4591001 1169 11691072	16-55	22SEP2020	95983	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
11691073	C4591001 1169 11691073†	16-55	01OCT2020	95984	Placebo	01OCT2020/ Placebo	23OCT2020/ Placebo	06JAN2021/ BNT162b2 (30 µg)	27JAN2021/ BNT162b2 (30 µg)
11691075	C4591001 1169 11691075†	16-55	02OCT2020	95987	Placebo	02OCT2020/ Placebo	23OCT2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
11701020	C4591001 1170 11701020	16-55	17AUG2020	50616	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11701021	C4591001 1170 11701021	16-55	17AUG2020	50617	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11701022	C4591001 1170 11701022	16-55	17AUG2020	52770	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11701024	C4591001 1170 11701024	16-55	17AUG2020	52772	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	15DEC2020/ BNT162b2 (30 µg)	04JAN2021/ BNT162b2 (30 µg)
11701025	C4591001 1170 11701025	16-55	17AUG2020	52780	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11701026	C4591001 1170 11701026	16-55	17AUG2020	53645	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11701029	C4591001 1170 11701029	16-55	18AUG2020	53648	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11701031	C4591001 1170 11701031	16-55	18AUG2020	53649	Placebo	18AUG2020/ Placebo	10SEP2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
11701034	C4591001 1170 11701034	16-55	19AUG2020	53654	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11701035	C4591001 1170 11701035	16-55	19AUG2020	56309	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
11701036	C4591001 1170 11701036	16-55	19AUG2020	56311	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
11701037	C4591001 1170 11701037	16-55	19AUG2020	56316	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)
11701038	C4591001 1170 11701038	16-55	19AUG2020	56317	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11701040	C4591001 1170 11701040	16-55	19AUG2020	57250	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	21JAN2021/ BNT162b2 (30 µg)
11701041	C4591001 1170 11701041	16-55	19AUG2020	57251	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
11701042	C4591001 1170 11701042	16-55	20AUG2020	57252	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11701043	C4591001 1170 11701043	16-55	20AUG2020	57255	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
11701044	C4591001 1170 11701044	16-55	20AUG2020	58446	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
11701045	C4591001 1170 11701045	16-55	20AUG2020	58447	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo		
11701047	C4591001 1170 11701047	16-55	20AUG2020	58450	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
11701048	C4591001 1170 11701048	16-55	20AUG2020	58455	Placebo	20AUG2020/ Placebo	11SEP2020/ Placebo		
11701049	C4591001 1170 11701049	16-55	20AUG2020	59372	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
11701052	C4591001 1170 11701052	16-55	21AUG2020	59375	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
11701054	C4591001 1170 11701054	16-55	21AUG2020	59378	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)
11701055	C4591001 1170 11701055	16-55	21AUG2020	59379	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
11701057	C4591001 1170 11701057	16-55	21AUG2020	60727	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11701059	C4591001 1170 11701059	16-55	21AUG2020	60733	Placebo	21AUG2020/ Placebo	08SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11701060	C4591001 1170 11701060	16-55	21AUG2020	60734	Placebo	21AUG2020/ Placebo	09SEP2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)
11701063	C4591001 1170 11701063	16-55	24AUG2020	60736	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11701064	C4591001 1170 11701064	16-55	24AUG2020	63629	Placebo	24AUG2020/ Placebo	11SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
11701065	C4591001 1170 11701065	16-55	24AUG2020	63630	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11701069	C4591001 1170 11701069	16-55	24AUG2020	63636	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11701072	C4591001 1170 11701072	16-55	25AUG2020	63639	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
11701073	C4591001 1170 11701073	16-55	25AUG2020	65622	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
11701074	C4591001 1170 11701074	16-55	25AUG2020	65623	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)
11701075	C4591001 1170 11701075	16-55	25AUG2020	65625	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11701076	C4591001 1170 11701076	16-55	25AUG2020	65629	Placebo	25AUG2020/ Placebo	14SEP2020/ Placebo		
11701077	C4591001 1170 11701077	16-55	25AUG2020	66102	Placebo	25AUG2020/ Placebo	14SEP2020/ Placebo		
11701079	C4591001 1170 11701079	16-55	25AUG2020	66105	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11701081	C4591001 1170 11701081	16-55	25AUG2020	66106	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo		
11701085	C4591001 1170 11701085	16-55	26AUG2020	66112	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
11701086	C4591001 1170 11701086	16-55	26AUG2020	67535	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
11701087	C4591001 1170 11701087	16-55	26AUG2020	67536	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11701089	C4591001 1170 11701089	16-55	26AUG2020	67538	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo		
11701091	C4591001 1170 11701091	16-55	26AUG2020	67540	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11701092	C4591001 1170 11701092	16-55	26AUG2020	68192	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
11701093	C4591001 1170 11701093	16-55	26AUG2020	68195	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11701094	C4591001 1170 11701094	16-55	26AUG2020	68196	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
11701095	C4591001 1170 11701095	16-55	26AUG2020	68197	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
11701096	C4591001 1170 11701096	16-55	26AUG2020	68948	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11701097	C4591001 1170 11701097	16-55	27AUG2020	68949	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
11701098	C4591001 1170 11701098	16-55	27AUG2020	68950	Placebo	27AUG2020/ Placebo	18SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
11701099	C4591001 1170 11701099	16-55	27AUG2020	68952	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
11701100	C4591001 1170 11701100	16-55	27AUG2020	70330	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11701101	C4591001 1170 11701101	16-55	27AUG2020	70332	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
11701102	C4591001 1170 11701102	16-55	27AUG2020	70335	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
11701103	C4591001 1170 11701103	16-55	27AUG2020	70336	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11701104	C4591001 1170 11701104	16-55	27AUG2020	70601	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
11701105	C4591001 1170 11701105	16-55	27AUG2020	70605	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
11701106	C4591001 1170 11701106	16-55	27AUG2020	70607	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11701107	C4591001 1170 11701107	16-55	27AUG2020	70612	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
11701108	C4591001 1170 11701108	16-55	27AUG2020	70961	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
11701110	C4591001 1170 11701110	16-55	27AUG2020	70964	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo		
11701111	C4591001 1170 11701111	16-55	27AUG2020	70965	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
11701112	C4591001 1170 11701112	16-55	28AUG2020	70967	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
11701115	C4591001 1170 11701115	16-55	28AUG2020	71767	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11701116	C4591001 1170 11701116	16-55	28AUG2020	71771	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11701117	C4591001 1170 11701117	16-55	28AUG2020	71773	Placebo	28AUG2020/ Placebo	15SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
11701118	C4591001 1170 11701118	16-55	28AUG2020	71775	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
11701119	C4591001 1170 11701119	16-55	28AUG2020	71925	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)
11701120	C4591001 1170 11701120	16-55	28AUG2020	71928	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
11701121	C4591001 1170 11701121	16-55	28AUG2020	71930	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	20JAN2021/ BNT162b2 (30 µg)
11701122	C4591001 1170 11701122	16-55	28AUG2020	71931	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
11701123	C4591001 1170 11701123	16-55	28AUG2020	72259	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11701125	C4591001 1170 11701125	16-55	28AUG2020	72261	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
11701126	C4591001 1170 11701126	16-55	28AUG2020	72262	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
11701127	C4591001 1170 11701127	16-55	28AUG2020	72264	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11701128	C4591001 1170 11701128	16-55	28AUG2020	72701	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
11701129	C4591001 1170 11701129	16-55	28AUG2020	72703	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
11701131	C4591001 1170 11701131	16-55	31AUG2020	72704	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11701136	C4591001 1170 11701136	16-55	31AUG2020	72708	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
11701137	C4591001 1170 11701137	16-55	31AUG2020	75092	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
11701138	C4591001 1170 11701138	16-55	31AUG2020	75095	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11701139	C4591001 1170 11701139	16-55	31AUG2020	75097	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
11701143	C4591001 1170 11701143	16-55	31AUG2020	75098	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11701144	C4591001 1170 11701144	16-55	31AUG2020	75690	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11701145	C4591001 1170 11701145	16-55	31AUG2020	75691	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11701146	C4591001 1170 11701146	16-55	31AUG2020	75694	Placebo	31AUG2020/ Placebo	23SEP2020/ Placebo		
11701149	C4591001 1170 11701149	16-55	01SEP2020	75697	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
11701150	C4591001 1170 11701150	16-55	01SEP2020	76316	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
11701151	C4591001 1170 11701151	16-55	01SEP2020	76321	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11701152	C4591001 1170 11701152	16-55	01SEP2020	76322	Placebo	01SEP2020/ Placebo	25SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
11701153	C4591001 1170 11701153	16-55	01SEP2020	76324	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11701154	C4591001 1170 11701154	16-55	01SEP2020	76521	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
11701156	C4591001 1170 11701156	16-55	01SEP2020	76523	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11701158	C4591001 1170 11701158	16-55	01SEP2020	76525	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
11701159	C4591001 1170 11701159	16-55	01SEP2020	76528	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11701162	C4591001 1170 11701162	16-55	01SEP2020	77142	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11701163	C4591001 1170 11701163	16-55	01SEP2020	77146	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
11701164	C4591001 1170 11701164	16-55	01SEP2020	77151	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
11701165	C4591001 1170 11701165	16-55	01SEP2020	77152	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
11701166	C4591001 1170 11701166	16-55	01SEP2020	77347	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11701167	C4591001 1170 11701167	16-55	01SEP2020	77348	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11701170	C4591001 1170 11701170	16-55	02SEP2020	77351	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
11701171	C4591001 1170 11701171	16-55	02SEP2020	77352	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo		
11701174	C4591001 1170 11701174	16-55	02SEP2020	78332	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11701178	C4591001 1170 11701178	16-55	02SEP2020	78333	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11701179	C4591001 1170 11701179	16-55	02SEP2020	78335	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
11701180	C4591001 1170 11701180	16-55	02SEP2020	78340	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
11701181	C4591001 1170 11701181	16-55	02SEP2020	78767	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
11701182	C4591001 1170 11701182	16-55	02SEP2020	78768	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11701183	C4591001 1170 11701183	16-55	02SEP2020	78769	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11701184	C4591001 1170 11701184	16-55	02SEP2020	78770	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
11701185	C4591001 1170 11701185	16-55	02SEP2020	79243	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11701187	C4591001 1170 11701187	16-55	02SEP2020	79247	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11701190	C4591001 1170 11701190	16-55	03SEP2020	79250	Placebo	03SEP2020/ Placebo	28SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	
11701191	C4591001 1170 11701191	16-55	03SEP2020	79251	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11701192	C4591001 1170 11701192	16-55	03SEP2020	79651	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
11701193	C4591001 1170 11701193	16-55	03SEP2020	79653	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
11701195	C4591001 1170 11701195	16-55	03SEP2020	79655	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	20JAN2021/ BNT162b2 (30 µg)
11701196	C4591001 1170 11701196	16-55	03SEP2020	79658	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
11701199	C4591001 1170 11701199	16-55	03SEP2020	80576	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
11701201	C4591001 1170 11701201	16-55	03SEP2020	80578	Placebo	03SEP2020/ Placebo	21SEP2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
11701203	C4591001 1170 11701203	16-55	03SEP2020	80581	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
11701204	C4591001 1170 11701204	16-55	03SEP2020	80582	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
11701205	C4591001 1170 11701205	16-55	03SEP2020	81020	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11701206	C4591001 1170 11701206	16-55	04SEP2020	81021	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11701207	C4591001 1170 11701207	16-55	04SEP2020	81022	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
11701208	C4591001 1170 11701208	16-55	04SEP2020	81024	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
11701209	C4591001 1170 11701209	16-55	04SEP2020	81678	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	
11701210	C4591001 1170 11701210	16-55	08SEP2020	81679	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
11701211	C4591001 1170 11701211	16-55	08SEP2020	81680	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11701212	C4591001 1170 11701212	16-55	08SEP2020	81686	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11701213	C4591001 1170 11701213	16-55	08SEP2020	83419	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11701215	C4591001 1170 11701215	16-55	08SEP2020	83420	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11701221	C4591001 1170 11701221	16-55	08SEP2020	83423	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
11701222	C4591001 1170 11701222	16-55	08SEP2020	83426	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11701223	C4591001 1170 11701223	16-55	08SEP2020	83902	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
11701225	C4591001 1170 11701225	16-55	08SEP2020	83903	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
11701226	C4591001 1170 11701226	16-55	08SEP2020	83906	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
11701227	C4591001 1170 11701227	16-55	08SEP2020	83907	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11701228	C4591001 1170 11701228	16-55	08SEP2020	84225	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11701229	C4591001 1170 11701229	16-55	08SEP2020	84229	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
11701230	C4591001 1170 11701230	16-55	08SEP2020	84231	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11701231	C4591001 1170 11701231	16-55	08SEP2020	84232	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo		
11701232	C4591001 1170 11701232	16-55	08SEP2020	84378	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11701233	C4591001 1170 11701233	16-55	08SEP2020	84380	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11701234	C4591001 1170 11701234	16-55	09SEP2020	84381	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
11701235	C4591001 1170 11701235	16-55	09SEP2020	84388	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
11701236	C4591001 1170 11701236	16-55	09SEP2020	84874	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
11701237	C4591001 1170 11701237	16-55	09SEP2020	84875	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
11701241	C4591001 1170 11701241	16-55	09SEP2020	84877	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
11701243	C4591001 1170 11701243	16-55	09SEP2020	84880	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
11701244	C4591001 1170 11701244	16-55	09SEP2020	85472	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
11701245	C4591001 1170 11701245	16-55	09SEP2020	85473	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
11701249	C4591001 1170 11701249	16-55	09SEP2020	85478	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
11701250	C4591001 1170 11701250	16-55	09SEP2020	85480	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11701251	C4591001 1170 11701251	16-55	09SEP2020	85747	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
11701252	C4591001 1170 11701252	16-55	09SEP2020	85749	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
11701253	C4591001 1170 11701253	16-55	09SEP2020	85751	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)
11701255	C4591001 1170 11701255	16-55	09SEP2020	85755	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
11701256	C4591001 1170 11701256	16-55	09SEP2020	256211	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	15DEC2020/ BNT162b2 (30 µg)	04JAN2021/ BNT162b2 (30 µg)
11701257	C4591001 1170 11701257	16-55	09SEP2020	85961	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
11701258	C4591001 1170 11701258	16-55	09SEP2020	85965	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
11701259	C4591001 1170 11701259	16-55	09SEP2020	85967	Placebo	09SEP2020/ Placebo	29SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
11701260	C4591001 1170 11701260	16-55	09SEP2020	85969	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
11701261	C4591001 1170 11701261	16-55	10SEP2020	86297	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11701262	C4591001 1170 11701262	16-55	10SEP2020	86298	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11701263	C4591001 1170 11701263	16-55	10SEP2020	86300	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
11701264	C4591001 1170 11701264	16-55	10SEP2020	86305	Placebo	10SEP2020/ Placebo	02OCT2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
11701268	C4591001 1170 11701268	16-55	10SEP2020	86768	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
11701269	C4591001 1170 11701269	16-55	10SEP2020	86772	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
11701271	C4591001 1170 11701271	16-55	10SEP2020	86775	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
11701274	C4591001 1170 11701274	16-55	10SEP2020	86776	Placebo	10SEP2020/ Placebo	30SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11701279	C4591001 1170 11701279	16-55	10SEP2020	87332	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
11701280	C4591001 1170 11701280	16-55	10SEP2020	87334	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
11701281	C4591001 1170 11701281	16-55	10SEP2020	87337	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11701283	C4591001 1170 11701283	16-55	10SEP2020	87340	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
11701284	C4591001 1170 11701284	16-55	10SEP2020	87466	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
11701285	C4591001 1170 11701285	16-55	10SEP2020	87467	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
11701286	C4591001 1170 11701286	16-55	10SEP2020	87468	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
11701287	C4591001 1170 11701287	16-55	10SEP2020	87472	Placebo	10SEP2020/ Placebo	02OCT2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	14JAN2021/ BNT162b2 (30 µg)
11701288	C4591001 1170 11701288	16-55	10SEP2020	87569	Placebo	10SEP2020/ Placebo	02OCT2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
11701289	C4591001 1170 11701289	16-55	11SEP2020	87575	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
11701290	C4591001 1170 11701290	16-55	11SEP2020	87576	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
11701291	C4591001 1170 11701291	16-55	11SEP2020	87579	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
11701292	C4591001 1170 11701292	16-55	11SEP2020	87992	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11701293	C4591001 1170 11701293	16-55	11SEP2020	87994	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
11701296	C4591001 1170 11701296	16-55	11SEP2020	87995	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo		
11701297	C4591001 1170 11701297	16-55	11SEP2020	87996	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)
11701298	C4591001 1170 11701298	16-55	11SEP2020	88457	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
11701300	C4591001 1170 11701300	16-55	11SEP2020	88461	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
11701302	C4591001 1170 11701302	16-55	11SEP2020	88463	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
11701303	C4591001 1170 11701303	16-55	11SEP2020	88464	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
11701304	C4591001 1170 11701304	16-55	11SEP2020	88770	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
11701306	C4591001 1170 11701306	16-55	11SEP2020	88774	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
11701307	C4591001 1170 11701307	16-55	11SEP2020	88779	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11701308	C4591001 1170 11701308	16-55	11SEP2020	88780	Placebo	11SEP2020/ Placebo	29SEP2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
11701310	C4591001 1170 11701310	16-55	14SEP2020	89321	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
11701311	C4591001 1170 11701311	16-55	14SEP2020	89324	Placebo	14SEP2020/ Placebo			
11701312	C4591001 1170 11701312	16-55	14SEP2020	89327	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11701313	C4591001 1170 11701313	16-55	14SEP2020	89330	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
11701314	C4591001 1170 11701314	16-55	14SEP2020	89852	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
11701315	C4591001 1170 11701315	16-55	14SEP2020	89853	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
11701316	C4591001 1170 11701316	16-55	14SEP2020	89855	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
11701317	C4591001 1170 11701317	16-55	15SEP2020	89856	Placebo	15SEP2020/ Placebo	06OCT2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
11701318	C4591001 1170 11701318	16-55	15SEP2020	90317	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11701319	C4591001 1170 11701319	16-55	15SEP2020	90321	Placebo	15SEP2020/ Placebo	06OCT2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11701320	C4591001 1170 11701320	16-55	15SEP2020	90322	Placebo	15SEP2020/ Placebo	06OCT2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)
11701321	C4591001 1170 11701321	16-55	15SEP2020	90324	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
11701322	C4591001 1170 11701322	16-55	15SEP2020	90510	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
11701323	C4591001 1170 11701323	16-55	15SEP2020	90511	Placebo	15SEP2020/ Placebo	06OCT2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
11701324	C4591001 1170 11701324	16-55	15SEP2020	90513	Placebo	15SEP2020/ Placebo	06OCT2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
11701325	C4591001 1170 11701325†	16-55	15SEP2020	90517	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
11701326	C4591001 1170 11701326†	16-55	16SEP2020	91019	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
11701334	C4591001 1170 11701334†	16-55	16SEP2020	91021	Placebo	16SEP2020/ Placebo	07OCT2020/ Placebo	06JAN2021/ BNT162b2 (30 µg)	27JAN2021/ BNT162b2 (30 µg)
11701337	C4591001 1170 11701337	16-55	16SEP2020	91022	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11701338	C4591001 1170 11701338	16-55	17SEP2020	91024	Placebo	17SEP2020/ Placebo	15OCT2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
11701340	C4591001 1170 11701340	16-55	17SEP2020	92265	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
11701341	C4591001 1170 11701341	16-55	17SEP2020	92267	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
11701342	C4591001 1170 11701342	16-55	17SEP2020	92270	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
11701343	C4591001 1170 11701343	16-55	17SEP2020	92272	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
11701344	C4591001 1170 11701344†	16-55	17SEP2020	92777	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
11701346	C4591001 1170 11701346	16-55	17SEP2020	92779	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
11701348	C4591001 1170 11701348	16-55	17SEP2020	92780	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
11701349	C4591001 1170 11701349	16-55	17SEP2020	92785	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
11701350	C4591001 1170 11701350	16-55	18SEP2020	93285	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11701352	C4591001 1170 11701352†	16-55	18SEP2020	93286	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
11701355	C4591001 1170 11701355†	16-55	18SEP2020	93287	Placebo	18SEP2020/ Placebo	07OCT2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
11701357	C4591001 1170 11701357	16-55	21SEP2020	94735	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
11701358	C4591001 1170 11701358	16-55	21SEP2020	94736	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
11701359	C4591001 1170 11701359	16-55	21SEP2020	94740	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo		
11701360	C4591001 1170 11701360	16-55	21SEP2020	94744	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)
11701361	C4591001 1170 11701361	16-55	21SEP2020	95623	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
11701362	C4591001 1170 11701362	16-55	22SEP2020	95628	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
11701364	C4591001 1170 11701364	16-55	22SEP2020	95629	Placebo	22SEP2020/ Placebo	17NOV2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)
11701365	C4591001 1170 11701365	16-55	22SEP2020	95630	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11701370	C4591001 1170 11701370	16-55	23SEP2020	97582	Placebo	23SEP2020/ Placebo	13OCT2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)
11701372	C4591001 1170 11701372	16-55	25SEP2020	97585	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	04JAN2021/ BNT162b2 (30 µg)
11701373	C4591001 1170 11701373	16-55	25SEP2020	97587	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
11701374	C4591001 1170 11701374	16-55	20OCT2020	400049	Placebo	20OCT2020/ Placebo	09NOV2020/ Placebo		
11701375	C4591001 1170 11701375	16-55	20OCT2020	400051	Placebo	20OCT2020/ Placebo	11NOV2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
11701376	C4591001 1170 11701376	16-55	20OCT2020	400053	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		
11701377	C4591001 1170 11701377	16-55	20OCT2020	400057	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		
11701378	C4591001 1170 11701378	16-55	20OCT2020	400074	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		
11701379	C4591001 1170 11701379	16-55	20OCT2020	400076	Placebo	20OCT2020/ Placebo	11NOV2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
11701380	C4591001 1170 11701380	16-55	20OCT2020	400081	Placebo	20OCT2020/ Placebo	10NOV2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11701381	C4591001 1170 11701381	16-55	20OCT2020	400083	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		
11701382	C4591001 1170 11701382	16-55	20OCT2020	400100	Placebo	20OCT2020/ Placebo	10NOV2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
11701383	C4591001 1170 11701383	16-55	20OCT2020	400101	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		
11701384	C4591001 1170 11701384	16-55	20OCT2020	400106	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		
11701385	C4591001 1170 11701385†	16-55	20OCT2020	400108	Placebo	20OCT2020/ Placebo	10NOV2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
11701386	C4591001 1170 11701386	16-55	20OCT2020	400109	Placebo	20OCT2020/ Placebo	10NOV2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11701387	C4591001 1170 11701387	16-55	20OCT2020	400111	Placebo	20OCT2020/ Placebo	09NOV2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11701388	C4591001 1170 11701388	16-55	20OCT2020	400115	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		
11701389	C4591001 1170 11701389	16-55	20OCT2020	400117	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
11701390	C4591001 1170 11701390	16-55	20OCT2020	400139	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11701391	C4591001 1170 11701391	16-55	20OCT2020	400140	Placebo	20OCT2020/ Placebo	11NOV2020/ Placebo	15DEC2020/ BNT162b2 (30 µg)	04JAN2021/ BNT162b2 (30 µg)
11701392	C4591001 1170 11701392	16-55	20OCT2020	400141	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
11701393	C4591001 1170 11701393	16-55	21OCT2020	400144	Placebo	21OCT2020/ Placebo	11NOV2020/ Placebo		
11701394	C4591001 1170 11701394†	16-55	21OCT2020	400157	Placebo	21OCT2020/ Placebo	11NOV2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
11701395	C4591001 1170 11701395	16-55	21OCT2020	400159	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
11701396	C4591001 1170 11701396	16-55	21OCT2020	400161	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
11701397	C4591001 1170 11701397	16-55	21OCT2020	400162	Placebo	21OCT2020/ Placebo	11NOV2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
11701398	C4591001 1170 11701398	16-55	21OCT2020	400182	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
11701399	C4591001 1170 11701399	16-55	21OCT2020	400183	Placebo	21OCT2020/ Placebo	11NOV2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
11701400	C4591001 1170 11701400	16-55	21OCT2020	400184	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11701401	C4591001 1170 11701401	16-55	21OCT2020	400189	Placebo	21OCT2020/ Placebo	12NOV2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
11701402	C4591001 1170 11701402	16-55	21OCT2020	400205	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
11701403	C4591001 1170 11701403	16-55	21OCT2020	400211	Placebo	21OCT2020/ Placebo	11NOV2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
11701404	C4591001 1170 11701404	16-55	21OCT2020	400213	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	23NOV2020/ BNT162b2 (30 µg)		
11701405	C4591001 1170 11701405	16-55	21OCT2020	400215	Placebo	21OCT2020/ Placebo	12NOV2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
11701406	C4591001 1170 11701406	16-55	21OCT2020	400243	Placebo	21OCT2020/ Placebo	11NOV2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
11701407	C4591001 1170 11701407	16-55	21OCT2020	400245	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
11701408	C4591001 1170 11701408†	16-55	21OCT2020	400246	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
11701410	C4591001 1170 11701410	16-55	21OCT2020	400265	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
11701411	C4591001 1170 11701411	16-55	21OCT2020	400270	Placebo	21OCT2020/ Placebo	11NOV2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11701412	C4591001 1170 11701412	16-55	21OCT2020	400272	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
11701413	C4591001 1170 11701413	16-55	21OCT2020	400273	Placebo	21OCT2020/ Placebo	11NOV2020/ Placebo		
11701414	C4591001 1170 11701414	16-55	21OCT2020	400304	Placebo	21OCT2020/ Placebo	12NOV2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	14JAN2021/ BNT162b2 (30 µg)
11701416	C4591001 1170 11701416	16-55	22OCT2020	400309	Placebo	22OCT2020/ Placebo	11NOV2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
11701417	C4591001 1170 11701417	16-55	22OCT2020	400311	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
11701418	C4591001 1170 11701418	16-55	22OCT2020	400312	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		
11701419	C4591001 1170 11701419	16-55	22OCT2020	400354	Placebo	22OCT2020/ Placebo	12NOV2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
11701420	C4591001 1170 11701420	16-55	22OCT2020	400355	Placebo	22OCT2020/ Placebo	10NOV2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11701421	C4591001 1170 11701421	16-55	22OCT2020	400356	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
11701422	C4591001 1170 11701422†	16-55	22OCT2020	400358	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11701423	C4591001 1170 11701423	16-55	22OCT2020	400378	Placebo	22OCT2020/ Placebo	10NOV2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
11701424	C4591001 1170 11701424	16-55	22OCT2020	400379	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		
11701425	C4591001 1170 11701425	16-55	22OCT2020	400380	Placebo	22OCT2020/ Placebo	12NOV2020/ Placebo	15DEC2020/ BNT162b2 (30 µg)	04JAN2021/ BNT162b2 (30 µg)
11701426	C4591001 1170 11701426	16-55	22OCT2020	400381	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
11701427	C4591001 1170 11701427†	16-55	22OCT2020	400421	Placebo	22OCT2020/ Placebo			
11701428	C4591001 1170 11701428	16-55	22OCT2020	400426	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
11701429	C4591001 1170 11701429	16-55	22OCT2020	400428	Placebo	22OCT2020/ Placebo	11NOV2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
11701430	C4591001 1170 11701430	16-55	22OCT2020	400431	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
11701431	C4591001 1170 11701431	16-55	23OCT2020	400505	Placebo	23OCT2020/ Placebo	13NOV2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11701432	C4591001 1170 11701432	16-55	23OCT2020	400508	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11701433	C4591001 1170 11701433	16-55	23OCT2020	400511	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
11701434	C4591001 1170 11701434	16-55	23OCT2020	400514	Placebo	23OCT2020/ Placebo	13NOV2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
11701435	C4591001 1170 11701435	16-55	23OCT2020	400554	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		
11701436	C4591001 1170 11701436	16-55	23OCT2020	400555	Placebo	23OCT2020/ Placebo	12NOV2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	27JAN2021/ BNT162b2 (30 µg)
11701437	C4591001 1170 11701437	16-55	23OCT2020	400556	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
11701438	C4591001 1170 11701438	16-55	23OCT2020	400557	Placebo	23OCT2020/ Placebo	13NOV2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	28JAN2021/ BNT162b2 (30 µg)
11701439	C4591001 1170 11701439	16-55	23OCT2020	400594	Placebo	23OCT2020/ Placebo	13NOV2020/ Placebo	15DEC2020/ BNT162b2 (30 µg)	04JAN2021/ BNT162b2 (30 µg)
11701440	C4591001 1170 11701440	16-55	23OCT2020	400595	Placebo	23OCT2020/ Placebo	13NOV2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
11701441	C4591001 1170 11701441	16-55	23OCT2020	400596	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		
11701442	C4591001 1170 11701442	16-55	23OCT2020	400598	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11701443	C4591001 1170 11701443	16-55	23OCT2020	400663	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
11701444	C4591001 1170 11701444	16-55	23OCT2020	400664	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
11701445	C4591001 1170 11701445	16-55	23OCT2020	400669	Placebo	23OCT2020/ Placebo	13NOV2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
11701446	C4591001 1170 11701446	16-55	23OCT2020	400671	Placebo	23OCT2020/ Placebo	13NOV2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
11701447	C4591001 1170 11701447	16-55	23OCT2020	400673	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
11701449	C4591001 1170 11701449	16-55	26OCT2020	400677	Placebo	26OCT2020/ Placebo	16NOV2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11701450	C4591001 1170 11701450	16-55	26OCT2020	400678	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
11701451	C4591001 1170 11701451	16-55	26OCT2020	400818	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
11701452	C4591001 1170 11701452	16-55	26OCT2020	400825	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
11701453	C4591001 1170 11701453	16-55	26OCT2020	400827	Placebo	26OCT2020/ Placebo	13NOV2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11701455	C4591001 1170 11701455	16-55	26OCT2020	400877	Placebo	26OCT2020/ Placebo	16NOV2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
11701456	C4591001 1170 11701456†	16-55	26OCT2020	400879	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
11701457	C4591001 1170 11701457†	16-55	26OCT2020	400880	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
11701458	C4591001 1170 11701458	16-55	26OCT2020	400881	Placebo	26OCT2020/ Placebo	17NOV2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
11701459	C4591001 1170 11701459	16-55	26OCT2020	400928	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
11701460	C4591001 1170 11701460	16-55	26OCT2020	400931	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
11701461	C4591001 1170 11701461	16-55	26OCT2020	400934	Placebo	26OCT2020/ Placebo	17NOV2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
11701462	C4591001 1170 11701462	16-55	26OCT2020	400936	Placebo	26OCT2020/ Placebo	16NOV2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
11701463	C4591001 1170 11701463†	16-55	26OCT2020	400964	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
11701464	C4591001 1170 11701464	16-55	26OCT2020	400965	Placebo	26OCT2020/ Placebo	16NOV2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11701465	C4591001 1170 11701465	16-55	26OCT2020	400968	Placebo	26OCT2020/ Placebo	16NOV2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11701466	C4591001 1170 11701466	16-55	26OCT2020	400969	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
11701467	C4591001 1170 11701467	16-55	26OCT2020	401021	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
11701468	C4591001 1170 11701468	16-55	27OCT2020	401023	Placebo	27OCT2020/ Placebo	17NOV2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
11701469	C4591001 1170 11701469	16-55	27OCT2020	401025	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
11701470	C4591001 1170 11701470	16-55	27OCT2020	401030	Placebo	27OCT2020/ Placebo	18NOV2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
11701471	C4591001 1170 11701471	16-55	27OCT2020	401081	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	18NOV2020/ BNT162b2 (30 µg)		
11701472	C4591001 1170 11701472	16-55	27OCT2020	401084	Placebo	27OCT2020/ Placebo	18NOV2020/ Placebo	06JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
11701473	C4591001 1170 11701473	16-55	27OCT2020	401086	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	18NOV2020/ BNT162b2 (30 µg)		
11701474	C4591001 1170 11701474†	16-55	27OCT2020	401087	Placebo	27OCT2020/ Placebo	17NOV2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11701475	C4591001 1170 11701475	16-55	27OCT2020	401129	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
11701476	C4591001 1170 11701476	16-55	27OCT2020	401133	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
11701477	C4591001 1170 11701477	16-55	28OCT2020	401135	Placebo	28OCT2020/ Placebo	18NOV2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
11701478	C4591001 1170 11701478	16-55	28OCT2020	401139	Placebo	28OCT2020/ Placebo	17NOV2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
11701479	C4591001 1170 11701479	16-55	28OCT2020	401189	Placebo	28OCT2020/ Placebo	17NOV2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
11701480	C4591001 1170 11701480	16-55	28OCT2020	401193	BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
11701481	C4591001 1170 11701481	16-55	28OCT2020	401194	BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)	18NOV2020/ BNT162b2 (30 µg)		
11701482	C4591001 1170 11701482	16-55	28OCT2020	401200	Placebo	28OCT2020/ Placebo	18NOV2020/ Placebo		
11701483	C4591001 1170 11701483	16-55	28OCT2020	401206	BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)		
11701484	C4591001 1170 11701484	16-55	28OCT2020	401209	Placebo	28OCT2020/ Placebo	18NOV2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11701485	C4591001 1170 11701485	16-55	28OCT2020	401210	BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)	24NOV2020/ BNT162b2 (30 µg)		
11701486	C4591001 1170 11701486	16-55	29OCT2020	401211	Placebo	29OCT2020/ Placebo	19NOV2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
11701487	C4591001 1170 11701487	16-55	29OCT2020	401261	Placebo	29OCT2020/ Placebo	17NOV2020/ Placebo		
11701488	C4591001 1170 11701488	16-55	29OCT2020	401266	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
11701489	C4591001 1170 11701489	16-55	29OCT2020	401267	Placebo	29OCT2020/ Placebo	19NOV2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
11701490	C4591001 1170 11701490	16-55	29OCT2020	401271	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)		
11701491	C4591001 1170 11701491	16-55	29OCT2020	401369	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	20NOV2020/ BNT162b2 (30 µg)		
11701492	C4591001 1170 11701492	16-55	29OCT2020	401377	Placebo	29OCT2020/ Placebo	19NOV2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)
11701493	C4591001 1170 11701493	16-55	29OCT2020	401378	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	20NOV2020/ BNT162b2 (30 µg)		
11701494	C4591001 1170 11701494	16-55	29OCT2020	401380	Placebo	29OCT2020/ Placebo	17NOV2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11701495	C4591001 1170 11701495	16-55	29OCT2020	401433	Placebo	29OCT2020/ Placebo	19NOV2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11701496	C4591001 1170 11701496	16-55	30OCT2020	401434	BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)		
11701497	C4591001 1170 11701497†	16-55	30OCT2020	401436	Placebo	30OCT2020/ Placebo	20NOV2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
11701498	C4591001 1170 11701498	16-55	30OCT2020	401440	BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)	20NOV2020/ BNT162b2 (30 µg)		
11701499	C4591001 1170 11701499	16-55	30OCT2020	401504	Placebo	30OCT2020/ Placebo	20NOV2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
11701500	C4591001 1170 11701500	16-55	30OCT2020	401506	BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)	20NOV2020/ BNT162b2 (30 µg)		
11701501	C4591001 1170 11701501	16-55	30OCT2020	401509	BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)	20NOV2020/ BNT162b2 (30 µg)		
11711027	C4591001 1171 11711027	16-55	14AUG2020	50056	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
11711042	C4591001 1171 11711042	16-55	17AUG2020	50996	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)			
11711043	C4591001 1171 11711043	16-55	17AUG2020	53444	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11711044	C4591001 1171 11711044	16-55	17AUG2020	50997	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11711046	C4591001 1171 11711046	16-55	17AUG2020	53447	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo		
11711047	C4591001 1171 11711047	16-55	17AUG2020	53449	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
11711050	C4591001 1171 11711050	16-55	17AUG2020	53450	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11711052	C4591001 1171 11711052	16-55	17AUG2020	53609	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11711053	C4591001 1171 11711053	16-55	18AUG2020	53612	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
11711055	C4591001 1171 11711055	16-55	18AUG2020	53619	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11711056	C4591001 1171 11711056	16-55	18AUG2020	53620	Placebo	18AUG2020/ Placebo	14SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
11711058	C4591001 1171 11711058	16-55	18AUG2020	54546	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
11711060	C4591001 1171 11711060	16-55	18AUG2020	54548	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11711062	C4591001 1171 11711062	16-55	18AUG2020	54553	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
11711065	C4591001 1171 11711065	16-55	18AUG2020	54556	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11711066	C4591001 1171 11711066	16-55	18AUG2020	55315	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11711067	C4591001 1171 11711067	16-55	18AUG2020	55316	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
11711068	C4591001 1171 11711068	16-55	18AUG2020	55320	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
11711069	C4591001 1171 11711069	16-55	18AUG2020	55322	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11711070	C4591001 1171 11711070	16-55	19AUG2020	56334	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
11711071	C4591001 1171 11711071	16-55	19AUG2020	56336	Placebo	19AUG2020/ Placebo	16SEP2020/ Placebo		
11711072	C4591001 1171 11711072	16-55	19AUG2020	56340	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)			
11711073	C4591001 1171 11711073	16-55	19AUG2020	56343	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11711074	C4591001 1171 11711074	16-55	19AUG2020	56825	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
11711076	C4591001 1171 11711076	16-55	19AUG2020	56831	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo	02MAR2021/ BNT162b2 (30 µg)	
11711077	C4591001 1171 11711077	16-55	19AUG2020	56828	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
11711079	C4591001 1171 11711079	16-55	19AUG2020	56836	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11711080	C4591001 1171 11711080	16-55	19AUG2020	57561	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
11711081	C4591001 1171 11711081	16-55	19AUG2020	57562	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
11711082	C4591001 1171 11711082	16-55	20AUG2020	57564	Placebo	20AUG2020/ Placebo	11SEP2020/ Placebo	03MAR2021/ BNT162b2 (30 µg)	
11711083	C4591001 1171 11711083	16-55	20AUG2020	57567	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
11711084	C4591001 1171 11711084	16-55	20AUG2020	58589	Placebo	20AUG2020/ Placebo	11SEP2020/ Placebo	02MAR2021/ BNT162b2 (30 µg)	
11711085	C4591001 1171 11711085	16-55	20AUG2020	58590	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11711087	C4591001 1171 11711087	16-55	20AUG2020	58592	Placebo	20AUG2020/ Placebo	11SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11711088	C4591001 1171 11711088	16-55	20AUG2020	58760	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
11711089	C4591001 1171 11711089	16-55	20AUG2020	58600	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
11711091	C4591001 1171 11711091	16-55	20AUG2020	58765	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11711092	C4591001 1171 11711092	16-55	20AUG2020	58767	Placebo	20AUG2020/ Placebo	11SEP2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)
11711093	C4591001 1171 11711093	16-55	20AUG2020	58768	Placebo	20AUG2020/ Placebo	11SEP2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)
11711095	C4591001 1171 11711095	16-55	20AUG2020	59562	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
11711096	C4591001 1171 11711096	16-55	20AUG2020	59565	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
11711097	C4591001 1171 11711097	16-55	20AUG2020	59567	Placebo	20AUG2020/ Placebo	14SEP2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	27JAN2021/ BNT162b2 (30 µg)
11711100	C4591001 1171 11711100	16-55	24AUG2020	63656	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11711101	C4591001 1171 11711101	16-55	24AUG2020	59570	Placebo	24AUG2020/ Placebo	11SEP2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
11711103	C4591001 1171 11711103	16-55	24AUG2020	63657	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
11711104	C4591001 1171 11711104	16-55	24AUG2020	63660	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11711105	C4591001 1171 11711105	16-55	24AUG2020	63664	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11711106	C4591001 1171 11711106	16-55	24AUG2020	64436	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11711109	C4591001 1171 11711109	16-55	24AUG2020	64437	Placebo	24AUG2020/ Placebo	15SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
11711110	C4591001 1171 11711110	16-55	25AUG2020	65646	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
11711111	C4591001 1171 11711111	16-55	25AUG2020	64438	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	03MAR2021/ BNT162b2 (30 µg)	
11711112	C4591001 1171 11711112	16-55	25AUG2020	64439	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11711113	C4591001 1171 11711113	16-55	25AUG2020	65647	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11711114	C4591001 1171 11711114	16-55	25AUG2020	65649	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
11711115	C4591001 1171 11711115	16-55	25AUG2020	65650	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
11711116	C4591001 1171 11711116	16-55	25AUG2020	65853	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
11711118	C4591001 1171 11711118	16-55	25AUG2020	65856	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
11711119	C4591001 1171 11711119	16-55	25AUG2020	65859	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11711121	C4591001 1171 11711121	16-55	25AUG2020	66574	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
11711122	C4591001 1171 11711122	16-55	25AUG2020	65860	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
11711124	C4591001 1171 11711124	16-55	25AUG2020	66575	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
11711125	C4591001 1171 11711125	16-55	25AUG2020	66578	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
11711126	C4591001 1171 11711126	16-55	25AUG2020	66580	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11711127	C4591001 1171 11711127	16-55	26AUG2020	67770	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11711128	C4591001 1171 11711128	16-55	26AUG2020	67771	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
11711129	C4591001 1171 11711129	16-55	26AUG2020	67775	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
11711130	C4591001 1171 11711130	16-55	26AUG2020	67772	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11711131	C4591001 1171 11711131	16-55	26AUG2020	68013	Placebo	26AUG2020/ Placebo			
11711133	C4591001 1171 11711133	16-55	26AUG2020	68018	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
11711134	C4591001 1171 11711134	16-55	26AUG2020	68015	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11711135	C4591001 1171 11711135	16-55	26AUG2020	68017	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11711136	C4591001 1171 11711136	16-55	26AUG2020	68129	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	20JAN2021/ BNT162b2 (30 µg)
11711137	C4591001 1171 11711137	16-55	26AUG2020	68131	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11711138	C4591001 1171 11711138	16-55	26AUG2020	68136	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
11711139	C4591001 1171 11711139	16-55	26AUG2020	68137	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
11711141	C4591001 1171 11711141	16-55	26AUG2020	68909	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11711142	C4591001 1171 11711142	16-55	26AUG2020	68920	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
11711143	C4591001 1171 11711143	16-55	26AUG2020	68912	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11711144	C4591001 1171 11711144	16-55	26AUG2020	68911	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11711145	C4591001 1171 11711145	16-55	26AUG2020	69237	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
11711146	C4591001 1171 11711146	16-55	26AUG2020	69241	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11711147	C4591001 1171 11711147	16-55	27AUG2020	69243	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
11711151	C4591001 1171 11711151	16-55	31AUG2020	69244	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11711152	C4591001 1171 11711152	16-55	31AUG2020	75057	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo		
11711153	C4591001 1171 11711153	16-55	31AUG2020	75058	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
11711154	C4591001 1171 11711154	16-55	31AUG2020	75061	Placebo	31AUG2020/ Placebo	18SEP2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
11711156	C4591001 1171 11711156	16-55	01SEP2020	75803	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11711158	C4591001 1171 11711158	16-55	31AUG2020	75063	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11711159	C4591001 1171 11711159	16-55	31AUG2020	75799	Placebo	31AUG2020/ Placebo			
11711161	C4591001 1171 11711161	16-55	31AUG2020	75802	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
11711163	C4591001 1171 11711163	16-55	01SEP2020	75807	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11711164	C4591001 1171 11711164	16-55	01SEP2020	76726	Placebo	01SEP2020/ Placebo	23SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
11711166	C4591001 1171 11711166	16-55	01SEP2020	76728	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11711167	C4591001 1171 11711167	16-55	01SEP2020	76727	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11711169	C4591001 1171 11711169	16-55	01SEP2020	76730	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11711171	C4591001 1171 11711171	16-55	01SEP2020	77275	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11711172	C4591001 1171 11711172	16-55	01SEP2020	77279	Placebo	01SEP2020/ Placebo	21SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
11711174	C4591001 1171 11711174	16-55	01SEP2020	77280	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
11711175	C4591001 1171 11711175	16-55	02SEP2020	77284	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11711176	C4591001 1171 11711176	16-55	02SEP2020	78200	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11711177	C4591001 1171 11711177	16-55	02SEP2020	78204	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11711181	C4591001 1171 11711181	16-55	02SEP2020	78205	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo		
11711183	C4591001 1171 11711183	16-55	02SEP2020	78206	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11711184	C4591001 1171 11711184	16-55	02SEP2020	79085	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11711185	C4591001 1171 11711185	16-55	02SEP2020	79090	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
11711186	C4591001 1171 11711186	16-55	02SEP2020	79091	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo		
11711187	C4591001 1171 11711187	16-55	02SEP2020	79096	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11711189	C4591001 1171 11711189	16-55	03SEP2020	79890	Placebo	03SEP2020/ Placebo	21SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
11711191	C4591001 1171 11711191	16-55	08SEP2020	79896	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11711192	C4591001 1171 11711192	16-55	08SEP2020	79897	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
11711194	C4591001 1171 11711194	16-55	08SEP2020	79900	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11711195	C4591001 1171 11711195	16-55	08SEP2020	83925	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11711196	C4591001 1171 11711196	16-55	08SEP2020	83926	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11711198	C4591001 1171 11711198	16-55	08SEP2020	83928	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
11711200	C4591001 1171 11711200	16-55	08SEP2020	83932	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
11711203	C4591001 1171 11711203	16-55	09SEP2020	85195	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11711206	C4591001 1171 11711206	16-55	09SEP2020	85199	Placebo	09SEP2020/ Placebo	28SEP2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
11711207	C4591001 1171 11711207	16-55	09SEP2020	85200	Placebo	09SEP2020/ Placebo	29SEP2020/ Placebo		
11711209	C4591001 1171 11711209	16-55	09SEP2020	85201	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11711210	C4591001 1171 11711210	16-55	09SEP2020	85855	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11711211	C4591001 1171 11711211	16-55	09SEP2020	85856	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11711212	C4591001 1171 11711212	16-55	09SEP2020	85864	Placebo	09SEP2020/ Placebo	16OCT2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
11711213	C4591001 1171 11711213	16-55	09SEP2020	85857	Placebo	09SEP2020/ Placebo	29SEP2020/ Placebo	12MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11711214	C4591001 1171 11711214	16-55	10SEP2020	86636	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
11711216	C4591001 1171 11711216	16-55	10SEP2020	86637	Placebo	10SEP2020/ Placebo	28SEP2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
11711219	C4591001 1171 11711219	16-55	10SEP2020	86638	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
11711221	C4591001 1171 11711221	16-55	10SEP2020	86644	Placebo	10SEP2020/ Placebo	28SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
11711223	C4591001 1171 11711223	16-55	10SEP2020	87019	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
11711224	C4591001 1171 11711224	16-55	10SEP2020	87024	Placebo	10SEP2020/ Placebo	28SEP2020/ Placebo		
11711225	C4591001 1171 11711225	16-55	10SEP2020	87027	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
11711226	C4591001 1171 11711226	16-55	10SEP2020	87026	Placebo	10SEP2020/ Placebo	28SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
11711228	C4591001 1171 11711228	16-55	10SEP2020	87369	Placebo	10SEP2020/ Placebo	28SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
11711229	C4591001 1171 11711229	16-55	10SEP2020	87366	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11711231	C4591001 1171 11711231	16-55	10SEP2020	87373	Placebo	10SEP2020/ Placebo	28SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
11711234	C4591001 1171 11711234	16-55	10SEP2020	87376	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
11711236	C4591001 1171 11711236	16-55	11SEP2020	88111	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11711239	C4591001 1171 11711239	16-55	11SEP2020	88112	Placebo	11SEP2020/ Placebo	01OCT2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)
11711240	C4591001 1171 11711240	16-55	11SEP2020	88115	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
11711241	C4591001 1171 11711241	16-55	11SEP2020	88302	Placebo	11SEP2020/ Placebo	29SEP2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
11711242	C4591001 1171 11711242	16-55	11SEP2020	88303	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11711245	C4591001 1171 11711245	16-55	11SEP2020	88308	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	12MAR2021/ BNT162b2 (30 µg)	
11711246	C4591001 1171 11711246	16-55	11SEP2020	88311	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
11711247	C4591001 1171 11711247	16-55	11SEP2020	88759	Placebo	11SEP2020/ Placebo	29SEP2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11711248	C4591001 1171 11711248	16-55	11SEP2020	88760	Placebo	11SEP2020/ Placebo	29SEP2020/ Placebo	12MAR2021/ BNT162b2 (30 µg)	
11711249	C4591001 1171 11711249	16-55	11SEP2020	88765	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11711250	C4591001 1171 11711250	16-55	11SEP2020	88869	Placebo	11SEP2020/ Placebo	29SEP2020/ Placebo		
11711251	C4591001 1171 11711251	16-55	11SEP2020	88865	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
11711252	C4591001 1171 11711252	16-55	11SEP2020	88768	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
11711256	C4591001 1171 11711256	16-55	15SEP2020	88871	Placebo	15SEP2020/ Placebo	06OCT2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	
11711258	C4591001 1171 11711258	16-55	16SEP2020	88873	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
11711260	C4591001 1171 11711260	16-55	16SEP2020	91314	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
11711261	C4591001 1171 11711261	16-55	17SEP2020	91318	Placebo	17SEP2020/ Placebo	06OCT2020/ Placebo		
11711262	C4591001 1171 11711262	16-55	17SEP2020	91323	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11711263	C4591001 1171 11711263	16-55	17SEP2020	91322	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
11711265	C4591001 1171 11711265	16-55	17SEP2020	92933	Placebo	17SEP2020/ Placebo	07OCT2020/ Placebo	11MAR2021/ BNT162b2 (30 µg)	
11711266	C4591001 1171 11711266	16-55	17SEP2020	92934	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
11711267	C4591001 1171 11711267	16-55	17SEP2020	92938	Placebo	17SEP2020/ Placebo	06OCT2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
11711271	C4591001 1171 11711271	16-55	18SEP2020	92943	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
11711272	C4591001 1171 11711272	16-55	18SEP2020	93790	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
11711273	C4591001 1171 11711273	16-55	18SEP2020	93791	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
11711274	C4591001 1171 11711274	16-55	18SEP2020	93794	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
11711278	C4591001 1171 11711278	16-55	21SEP2020	93795	Placebo	21SEP2020/ Placebo	13OCT2020/ Placebo		
11711279	C4591001 1171 11711279	16-55	21SEP2020	95046	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11711280	C4591001 1171 11711280	16-55	21SEP2020	95047	Placebo	21SEP2020/ Placebo	13OCT2020/ Placebo	12MAR2021/ BNT162b2 (30 µg)	
11711281	C4591001 1171 11711281	16-55	21SEP2020	95050	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
11711286	C4591001 1171 11711286	16-55	22SEP2020	95056	Placebo	22SEP2020/ Placebo	12OCT2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
11711287	C4591001 1171 11711287	16-55	22SEP2020	96296	Placebo	22SEP2020/ Placebo	12OCT2020/ Placebo	11MAR2021/ BNT162b2 (30 µg)	
11711288	C4591001 1171 11711288	16-55	23SEP2020	96298	Placebo	23SEP2020/ Placebo	12OCT2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
11711289	C4591001 1171 11711289	16-55	23SEP2020	96300	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
11711290	C4591001 1171 11711290	16-55	23SEP2020	96304	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
11711292	C4591001 1171 11711292	16-55	23SEP2020	97762	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
11711293	C4591001 1171 11711293	16-55	24SEP2020	97764	Placebo	24SEP2020/ Placebo	13OCT2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
11711294	C4591001 1171 11711294	16-55	24SEP2020	97766	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11711298	C4591001 1171 11711298	16-55	28SEP2020	97767	Placebo	28SEP2020/ Placebo	19OCT2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
11711299	C4591001 1171 11711299	16-55	28SEP2020	101586	Placebo	28SEP2020/ Placebo	19OCT2020/ Placebo		
11711301	C4591001 1171 11711301	16-55	30SEP2020	101592	Placebo	30SEP2020/ Placebo			
11711303	C4591001 1171 11711303	16-55	07OCT2020	101593	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
11711305	C4591001 1171 11711305	16-55	09OCT2020	101595	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)		
11711306	C4591001 1171 11711306	16-55	12OCT2020	106445	BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		
11741003	C4591001 1174 11741003	16-55	31AUG2020	75500	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11741004	C4591001 1174 11741004	16-55	31AUG2020	75501	Placebo	31AUG2020/ Placebo	23SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
11741005	C4591001 1174 11741005	16-55	01SEP2020	75504	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11741006	C4591001 1174 11741006	16-55	01SEP2020	75505	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11741008	C4591001 1174 11741008	16-55	01SEP2020	77082	Placebo	01SEP2020/ Placebo	21SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
11741011	C4591001 1174 11741011	16-55	01SEP2020	77086	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11741013	C4591001 1174 11741013	16-55	02SEP2020	77088	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11741015	C4591001 1174 11741015	16-55	02SEP2020	77089	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
11741020	C4591001 1174 11741020	16-55	03SEP2020	79673	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)
11741023	C4591001 1174 11741023	16-55	03SEP2020	79674	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
11741024	C4591001 1174 11741024	16-55	04SEP2020	79676	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11741026	C4591001 1174 11741026	16-55	04SEP2020	79684	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
11741027	C4591001 1174 11741027	16-55	04SEP2020	81953	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
11741030	C4591001 1174 11741030	16-55	04SEP2020	81959	Placebo	04SEP2020/ Placebo	24SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11741031	C4591001 1174 11741031	16-55	04SEP2020	81955	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
11741032	C4591001 1174 11741032	16-55	04SEP2020	81960	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
11741034	C4591001 1174 11741034	16-55	08SEP2020	83492	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
11741038	C4591001 1174 11741038	16-55	08SEP2020	83494	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
11741045	C4591001 1174 11741045	16-55	09SEP2020	83498	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
11741046	C4591001 1174 11741046	16-55	10SEP2020	86490	Placebo	10SEP2020/ Placebo	30SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
11741049	C4591001 1174 11741049	16-55	10SEP2020	86496	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
11741050	C4591001 1174 11741050	16-55	10SEP2020	86498	Placebo	10SEP2020/ Placebo	29SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
11741051	C4591001 1174 11741051	16-55	10SEP2020	86500	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11741053	C4591001 1174 11741053	16-55	11SEP2020	88205	Placebo	11SEP2020/ Placebo	01OCT2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11741055	C4591001 1174 11741055	16-55	11SEP2020	88206	Placebo	11SEP2020/ Placebo	30SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
11741056	C4591001 1174 11741056	16-55	11SEP2020	88211	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
11741057	C4591001 1174 11741057	16-55	28SEP2020	93420	Placebo	28SEP2020/ Placebo	19OCT2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	28JAN2021/ BNT162b2 (30 µg)
11741058	C4591001 1174 11741058	16-55	15SEP2020	88214	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
11741060	C4591001 1174 11741060	16-55	15SEP2020	90665	Placebo	15SEP2020/ Placebo	06OCT2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11741061	C4591001 1174 11741061	16-55	16SEP2020	90666	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
11741063	C4591001 1174 11741063	16-55	17SEP2020	90669	Placebo	17SEP2020/ Placebo	07OCT2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
11741065	C4591001 1174 11741065	16-55	17SEP2020	90672	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
11741066	C4591001 1174 11741066†	16-55	18SEP2020	93413	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
11741071	C4591001 1174 11741071	16-55	28SEP2020	93414	BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11741072	C4591001 1174 11741072	16-55	28SEP2020	93418	Placebo	28SEP2020/ Placebo	19OCT2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
11771048	C4591001 1177 11771048	16-55	14AUG2020	51080	Placebo	14AUG2020/ Placebo	05SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
11771049	C4591001 1177 11771049	16-55	17AUG2020	51088	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
11771050	C4591001 1177 11771050	16-55	17AUG2020	53057	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11771051	C4591001 1177 11771051	16-55	17AUG2020	51086	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11771054	C4591001 1177 11771054	16-55	17AUG2020	53061	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
11771056	C4591001 1177 11771056	16-55	17AUG2020	53067	Placebo	17AUG2020/ Placebo	09SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
11771057	C4591001 1177 11771057	16-55	17AUG2020	53068	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
11771058	C4591001 1177 11771058	16-55	17AUG2020	53550	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
11771066	C4591001 1177 11771066	16-55	18AUG2020	53555	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11771070	C4591001 1177 11771070	16-55	18AUG2020	53559	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11771075	C4591001 1177 11771075	16-55	19AUG2020	53560	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11771076	C4591001 1177 11771076	16-55	19AUG2020	56804	Placebo	19AUG2020/ Placebo	08SEP2020/ Placebo		
11771078	C4591001 1177 11771078	16-55	19AUG2020	56807	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11771079	C4591001 1177 11771079	16-55	19AUG2020	56811	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11771080	C4591001 1177 11771080	16-55	19AUG2020	56812	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
11771081	C4591001 1177 11771081	16-55	19AUG2020	57370	Placebo	19AUG2020/ Placebo	11SEP2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
11771082	C4591001 1177 11771082	16-55	19AUG2020	57371	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
11771086	C4591001 1177 11771086	16-55	19AUG2020	57374	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
11771087	C4591001 1177 11771087	16-55	19AUG2020	57376	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11771088	C4591001 1177 11771088	16-55	19AUG2020	57703	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11771090	C4591001 1177 11771090	16-55	19AUG2020	57704	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11771092	C4591001 1177 11771092	16-55	20AUG2020	57706	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11771093	C4591001 1177 11771093	16-55	20AUG2020	57708	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
11771095	C4591001 1177 11771095	16-55	20AUG2020	59333	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11771096	C4591001 1177 11771096	16-55	20AUG2020	59340	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
11771097	C4591001 1177 11771097	16-55	20AUG2020	59341	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11771100	C4591001 1177 11771100	16-55	20AUG2020	59344	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
11771101	C4591001 1177 11771101	16-55	20AUG2020	59873	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
11771103	C4591001 1177 11771103	16-55	20AUG2020	59876	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11771105	C4591001 1177 11771105	16-55	21AUG2020	59877	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
11771111	C4591001 1177 11771111	16-55	21AUG2020	61521	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
11771113	C4591001 1177 11771113	16-55	21AUG2020	59878	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
11771114	C4591001 1177 11771114	16-55	21AUG2020	61518	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
11771116	C4591001 1177 11771116	16-55	21AUG2020	61522	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
11771117	C4591001 1177 11771117	16-55	24AUG2020	61526	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11771118	C4591001 1177 11771118	16-55	24AUG2020	64026	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11771119	C4591001 1177 11771119	16-55	24AUG2020	64032	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)
11771122	C4591001 1177 11771122	16-55	24AUG2020	64033	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11771124	C4591001 1177 11771124	16-55	24AUG2020	64035	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11771128	C4591001 1177 11771128	16-55	24AUG2020	65011	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11771134	C4591001 1177 11771134	16-55	25AUG2020	65012	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
11771135	C4591001 1177 11771135	16-55	25AUG2020	65018	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
11771137	C4591001 1177 11771137	16-55	25AUG2020	65020	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)
11771138	C4591001 1177 11771138	16-55	25AUG2020	66881	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
11771139	C4591001 1177 11771139	16-55	25AUG2020	66885	Placebo	25AUG2020/ Placebo		05MAR2021/ BNT162b2 (30 µg)	
11771145	C4591001 1177 11771145	16-55	25AUG2020	66887	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	15DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
11771153	C4591001 1177 11771153	16-55	26AUG2020	66888	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11771154	C4591001 1177 11771154	16-55	26AUG2020	69153	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11771155	C4591001 1177 11771155	16-55	26AUG2020	69154	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11771156	C4591001 1177 11771156	16-55	26AUG2020	69156	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
11771157	C4591001 1177 11771157	16-55	26AUG2020	69158	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo		
11771159	C4591001 1177 11771159	16-55	26AUG2020	69358	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
11771160	C4591001 1177 11771160	16-55	26AUG2020	69359	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
11771161	C4591001 1177 11771161	16-55	26AUG2020	69363	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
11771162	C4591001 1177 11771162	16-55	26AUG2020	69364	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11771163	C4591001 1177 11771163	16-55	26AUG2020	69366	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
11771165	C4591001 1177 11771165	16-55	27AUG2020	69369	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	15DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11771166	C4591001 1177 11771166	16-55	27AUG2020	69371	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
11771167	C4591001 1177 11771167	16-55	27AUG2020	69375	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11771170	C4591001 1177 11771170	16-55	27AUG2020	70698	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
11771171	C4591001 1177 11771171	16-55	27AUG2020	70700	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11771172	C4591001 1177 11771172	16-55	27AUG2020	70706	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
11771173	C4591001 1177 11771173	16-55	27AUG2020	70707	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
11771174	C4591001 1177 11771174	16-55	27AUG2020	71124	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	15DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11771176	C4591001 1177 11771176	16-55	27AUG2020	71126	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
11771177	C4591001 1177 11771177	16-55	27AUG2020	71127	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
11771179	C4591001 1177 11771179	16-55	27AUG2020	71128	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
11771181	C4591001 1177 11771181	16-55	27AUG2020	71419	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
11771182	C4591001 1177 11771182	16-55	27AUG2020	71423	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11771183	C4591001 1177 11771183	16-55	27AUG2020	71424	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	15DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
11771184	C4591001 1177 11771184	16-55	27AUG2020	71428	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
11771185	C4591001 1177 11771185	16-55	27AUG2020	71429	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
11771186	C4591001 1177 11771186	16-55	28AUG2020	71438	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
11771187	C4591001 1177 11771187	16-55	28AUG2020	71431	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
11771192	C4591001 1177 11771192	16-55	28AUG2020	71439	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
11771194	C4591001 1177 11771194	16-55	28AUG2020	73121	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
11771195	C4591001 1177 11771195	16-55	28AUG2020	73127	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
11771196	C4591001 1177 11771196	16-55	28AUG2020	73128	Placebo	28AUG2020/ Placebo	25SEP2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
11771197	C4591001 1177 11771197	16-55	28AUG2020	73130	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11771198	C4591001 1177 11771198	16-55	28AUG2020	73256	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
11771200	C4591001 1177 11771200	16-55	31AUG2020	73259	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11771207	C4591001 1177 11771207	16-55	31AUG2020	73262	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11771209	C4591001 1177 11771209	16-55	31AUG2020	76087	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11771210	C4591001 1177 11771210	16-55	31AUG2020	73263	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11771212	C4591001 1177 11771212	16-55	31AUG2020	76089	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11771216	C4591001 1177 11771216	16-55	31AUG2020	76091	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11771218	C4591001 1177 11771218	16-55	31AUG2020	76093	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
11771219	C4591001 1177 11771219	16-55	31AUG2020	76229	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
11771220	C4591001 1177 11771220	16-55	31AUG2020	76230	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11771221	C4591001 1177 11771221	16-55	31AUG2020	76233	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11771222	C4591001 1177 11771222	16-55	01SEP2020	77093	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11771223	C4591001 1177 11771223	16-55	01SEP2020	76239	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
11771224	C4591001 1177 11771224	16-55	01SEP2020	77096	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
11771225	C4591001 1177 11771225	16-55	01SEP2020	77098	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11771226	C4591001 1177 11771226	16-55	01SEP2020	77102	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
11771228	C4591001 1177 11771228	16-55	01SEP2020	77562	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
11771234	C4591001 1177 11771234	16-55	01SEP2020	77566	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
11771235	C4591001 1177 11771235	16-55	01SEP2020	77570	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11771236	C4591001 1177 11771236	16-55	02SEP2020	77571	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11771237	C4591001 1177 11771237	16-55	02SEP2020	78596	Placebo	02SEP2020/ Placebo	24SEP2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
11771238	C4591001 1177 11771238	16-55	02SEP2020	78600	Placebo	02SEP2020/ Placebo	21SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11771241	C4591001 1177 11771241	16-55	02SEP2020	78601	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11771242	C4591001 1177 11771242	16-55	02SEP2020	250293	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11771245	C4591001 1177 11771245	16-55	02SEP2020	78602	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11771246	C4591001 1177 11771246	16-55	02SEP2020	79423	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11771248	C4591001 1177 11771248	16-55	02SEP2020	79425	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
11771251	C4591001 1177 11771251	16-55	02SEP2020	79426	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11771254	C4591001 1177 11771254	16-55	02SEP2020	79431	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11771257	C4591001 1177 11771257	16-55	03SEP2020	80515	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11771258	C4591001 1177 11771258	16-55	03SEP2020	80518	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
11771259	C4591001 1177 11771259	16-55	03SEP2020	80520	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
11771260	C4591001 1177 11771260	16-55	03SEP2020	80849	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
11771261	C4591001 1177 11771261	16-55	03SEP2020	80524	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
11771262	C4591001 1177 11771262	16-55	03SEP2020	80850	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
11771265	C4591001 1177 11771265	16-55	03SEP2020	80853	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
11771266	C4591001 1177 11771266	16-55	03SEP2020	80857	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	15DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
11771267	C4591001 1177 11771267	16-55	03SEP2020	81161	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
11771270	C4591001 1177 11771270	16-55	03SEP2020	81167	Placebo	03SEP2020/ Placebo	25SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
11771271	C4591001 1177 11771271	16-55	03SEP2020	81169	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11771272	C4591001 1177 11771272	16-55	04SEP2020	81171	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11771278	C4591001 1177 11771278	16-55	04SEP2020	82495	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
11771281	C4591001 1177 11771281	16-55	04SEP2020	82498	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
11771282	C4591001 1177 11771282	16-55	04SEP2020	82601	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
11771283	C4591001 1177 11771283	16-55	04SEP2020	82500	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
11771284	C4591001 1177 11771284	16-55	04SEP2020	82503	Placebo	04SEP2020/ Placebo	24SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
11771285	C4591001 1177 11771285	16-55	04SEP2020	82604	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
11771289	C4591001 1177 11771289	16-55	05SEP2020	82608	Placebo	05SEP2020/ Placebo	25SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
11771292	C4591001 1177 11771292	16-55	05SEP2020	82612	Placebo	05SEP2020/ Placebo	23SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
11771294	C4591001 1177 11771294	16-55	05SEP2020	82902	BNT162b2 (30 µg)	05SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11771295	C4591001 1177 11771295	16-55	05SEP2020	82904	BNT162b2 (30 µg)	05SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
11771296	C4591001 1177 11771296	16-55	05SEP2020	82906	Placebo	05SEP2020/ Placebo	24SEP2020/ Placebo	06JAN2021/ BNT162b2 (30 µg)	27JAN2021/ BNT162b2 (30 µg)
11771297	C4591001 1177 11771297	16-55	05SEP2020	82912	Placebo	05SEP2020/ Placebo	25SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
11771300	C4591001 1177 11771300	16-55	08SEP2020	83981	Placebo	08SEP2020/ Placebo	05OCT2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
11771302	C4591001 1177 11771302	16-55	08SEP2020	83984	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
11771303	C4591001 1177 11771303	16-55	08SEP2020	83986	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11771304	C4591001 1177 11771304	16-55	08SEP2020	83992	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
11771305	C4591001 1177 11771305	16-55	08SEP2020	84631	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
11771306	C4591001 1177 11771306	16-55	08SEP2020	84632	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11771307	C4591001 1177 11771307	16-55	08SEP2020	84630	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11771309	C4591001 1177 11771309	16-55	08SEP2020	84638	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
11771310	C4591001 1177 11771310	16-55	08SEP2020	84691	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11771312	C4591001 1177 11771312	16-55	08SEP2020	84693	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11771313	C4591001 1177 11771313	16-55	09SEP2020	85615	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
11771314	C4591001 1177 11771314	16-55	09SEP2020	84697	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	02MAR2021/ BNT162b2 (30 µg)	
11771315	C4591001 1177 11771315	16-55	09SEP2020	84698	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	02MAR2021/ BNT162b2 (30 µg)	
11771318	C4591001 1177 11771318	16-55	09SEP2020	85618	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
11771319	C4591001 1177 11771319	16-55	09SEP2020	85620	Placebo	09SEP2020/ Placebo	29SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
11771320	C4591001 1177 11771320	16-55	09SEP2020	85624	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
11771321	C4591001 1177 11771321	16-55	09SEP2020	86000	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11771322	C4591001 1177 11771322	16-55	09SEP2020	86005	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
11771323	C4591001 1177 11771323	16-55	09SEP2020	86007	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
11771324	C4591001 1177 11771324	16-55	09SEP2020	86008	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
11771328	C4591001 1177 11771328	16-55	10SEP2020	87342	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
11771329	C4591001 1177 11771329	16-55	10SEP2020	87346	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
11771330	C4591001 1177 11771330	16-55	10SEP2020	87347	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
11771331	C4591001 1177 11771331	16-55	10SEP2020	87348	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
11771332	C4591001 1177 11771332	16-55	10SEP2020	87606	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
11771333	C4591001 1177 11771333	16-55	10SEP2020	87608	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo	12MAR2021/ BNT162b2 (30 µg)	
11771334	C4591001 1177 11771334	16-55	10SEP2020	87609	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11771335	C4591001 1177 11771335	16-55	10SEP2020	87614	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	28JAN2021/ BNT162b2 (30 µg)
11771341	C4591001 1177 11771341	16-55	11SEP2020	88973	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
11771342	C4591001 1177 11771342	16-55	11SEP2020	88979	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
11771343	C4591001 1177 11771343	16-55	11SEP2020	89006	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
11771345	C4591001 1177 11771345	16-55	11SEP2020	88980	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
11771346	C4591001 1177 11771346	16-55	11SEP2020	88982	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
11771347	C4591001 1177 11771347	16-55	11SEP2020	89000	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
11771348	C4591001 1177 11771348	16-55	14SEP2020	89007	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
11771351	C4591001 1177 11771351	16-55	14SEP2020	89008	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
11771354	C4591001 1177 11771354	16-55	14SEP2020	90029	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11771355	C4591001 1177 11771355	16-55	14SEP2020	90031	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
11771357	C4591001 1177 11771357	16-55	14SEP2020	90035	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
11771360	C4591001 1177 11771360	16-55	15SEP2020	90038	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
11771361	C4591001 1177 11771361	16-55	15SEP2020	90605	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
11771366	C4591001 1177 11771366	16-55	15SEP2020	90611	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
11771367	C4591001 1177 11771367	16-55	16SEP2020	90613	Placebo	16SEP2020/ Placebo	07OCT2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
11771368	C4591001 1177 11771368	16-55	16SEP2020	90614	Placebo	16SEP2020/ Placebo	07OCT2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	20JAN2021/ BNT162b2 (30 µg)
11771369	C4591001 1177 11771369	16-55	16SEP2020	91638	Placebo	16SEP2020/ Placebo	07OCT2020/ Placebo		
11771371	C4591001 1177 11771371	16-55	16SEP2020	91639	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
11771374	C4591001 1177 11771374	16-55	16SEP2020	91641	Placebo	16SEP2020/ Placebo	07OCT2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11771375	C4591001 1177 11771375	16-55	16SEP2020	91647	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
11771377	C4591001 1177 11771377	16-55	17SEP2020	92645	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
11771383	C4591001 1177 11771383	16-55	17SEP2020	92650	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
11771385	C4591001 1177 11771385	16-55	18SEP2020	92652	Placebo	18SEP2020/ Placebo	07OCT2020/ Placebo		
11771386	C4591001 1177 11771386	16-55	18SEP2020	92655	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	04JAN2021/ BNT162b2 (30 µg)
11771389	C4591001 1177 11771389	16-55	18SEP2020	94133	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
11771391	C4591001 1177 11771391	16-55	18SEP2020	94139	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11771392	C4591001 1177 11771392	16-55	18SEP2020	94141	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
11771393	C4591001 1177 11771393	16-55	18SEP2020	94142	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
11771394	C4591001 1177 11771394	16-55	18SEP2020	94411	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11771397	C4591001 1177 11771397	16-55	18SEP2020	94412	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
11771400	C4591001 1177 11771400	16-55	21SEP2020	94417	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	02MAR2021/ BNT162b2 (30 µg)	
11771401	C4591001 1177 11771401	16-55	21SEP2020	94420	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
11771402	C4591001 1177 11771402	16-55	21SEP2020	95733	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11771403	C4591001 1177 11771403	16-55	21SEP2020	95737	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
11771404	C4591001 1177 11771404	16-55	21SEP2020	95738	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
11771405	C4591001 1177 11771405	16-55	21SEP2020	95739	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)
11771410	C4591001 1177 11771410	16-55	22SEP2020	96656	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		
11771411	C4591001 1177 11771411	16-55	22SEP2020	96657	Placebo	22SEP2020/ Placebo	13OCT2020/ Placebo	03MAR2021/ BNT162b2 (30 µg)	
11771415	C4591001 1177 11771415	16-55	22SEP2020	96659	Placebo	22SEP2020/ Placebo	20OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11771416	C4591001 1177 11771416	16-55	22SEP2020	96663	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
11771418	C4591001 1177 11771418	16-55	22SEP2020	97125	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
11771420	C4591001 1177 11771420	16-55	22SEP2020	97126	Placebo	22SEP2020/ Placebo	13OCT2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
11771422	C4591001 1177 11771422	16-55	23SEP2020	97127	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
11771423	C4591001 1177 11771423	16-55	23SEP2020	97129	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)
11771424	C4591001 1177 11771424	16-55	23SEP2020	98214	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11771428	C4591001 1177 11771428	16-55	23SEP2020	98219	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
11771429	C4591001 1177 11771429	16-55	23SEP2020	98216	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
11771432	C4591001 1177 11771432	16-55	24SEP2020	98223	Placebo	24SEP2020/ Placebo	15OCT2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
11771433	C4591001 1177 11771433	16-55	24SEP2020	98874	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11771434	C4591001 1177 11771434	16-55	24SEP2020	98878	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)		
11771435	C4591001 1177 11771435	16-55	24SEP2020	98877	Placebo	24SEP2020/ Placebo	15OCT2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11771438	C4591001 1177 11771438	16-55	24SEP2020	98884	Placebo	24SEP2020/ Placebo	15OCT2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
11771439	C4591001 1177 11771439	16-55	24SEP2020	99106	Placebo	24SEP2020/ Placebo	15OCT2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
11771440	C4591001 1177 11771440	16-55	24SEP2020	99107	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
11771441	C4591001 1177 11771441	16-55	24SEP2020	99108	Placebo	24SEP2020/ Placebo	16OCT2020/ Placebo	02MAR2021/ BNT162b2 (30 µg)	
11771442	C4591001 1177 11771442	16-55	24SEP2020	99110	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
11771443	C4591001 1177 11771443	16-55	24SEP2020	99163	Placebo	24SEP2020/ Placebo	16OCT2020/ Placebo	02MAR2021/ BNT162b2 (30 µg)	
11771444	C4591001 1177 11771444	16-55	24SEP2020	99167	Placebo	24SEP2020/ Placebo	15OCT2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
11771445	C4591001 1177 11771445	16-55	24SEP2020	99169	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11771446	C4591001 1177 11771446	16-55	25SEP2020	99171	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		
11771449	C4591001 1177 11771449	16-55	25SEP2020	100458	Placebo	25SEP2020/ Placebo	14OCT2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	
11771450	C4591001 1177 11771450	16-55	25SEP2020	100462	Placebo	25SEP2020/ Placebo	15OCT2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
11771452	C4591001 1177 11771452	16-55	05OCT2020	100465	BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
11771453	C4591001 1177 11771453	16-55	05OCT2020	100467	BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
11771454	C4591001 1177 11771454	16-55	05OCT2020	103954	Placebo	05OCT2020/ Placebo	26OCT2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
11771455	C4591001 1177 11771455	16-55	05OCT2020	103956	BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
11771456	C4591001 1177 11771456	16-55	05OCT2020	103958	Placebo	05OCT2020/ Placebo	26OCT2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
11771458	C4591001 1177 11771458	16-55	05OCT2020	103959	BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
11771463	C4591001 1177 11771463	16-55	06OCT2020	104466	Placebo	06OCT2020/ Placebo	28OCT2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11771464	C4591001 1177 11771464	16-55	07OCT2020	104471	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)		
11771465	C4591001 1177 11771465	16-55	07OCT2020	104473	Placebo	07OCT2020/ Placebo	28OCT2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
11771466	C4591001 1177 11771466	16-55	07OCT2020	104474	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
11771472	C4591001 1177 11771472	16-55	07OCT2020	105031	Placebo	07OCT2020/ Placebo	28OCT2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
11771473	C4591001 1177 11771473	16-55	08OCT2020	105034	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)		
11771475	C4591001 1177 11771475	16-55	08OCT2020	105035	Placebo	08OCT2020/ Placebo	05NOV2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
11771477	C4591001 1177 11771477	16-55	08OCT2020	105039	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		
11771478	C4591001 1177 11771478	16-55	08OCT2020	105571	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)		
11771479	C4591001 1177 11771479	16-55	08OCT2020	105576	Placebo	08OCT2020/ Placebo	29OCT2020/ Placebo	02MAR2021/ BNT162b2 (30 µg)	
11771482	C4591001 1177 11771482	16-55	09OCT2020	105577	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11771484	C4591001 1177 11771484	16-55	09OCT2020	105580	Placebo	09OCT2020/ Placebo	30OCT2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11771485	C4591001 1177 11771485	16-55	09OCT2020	106221	Placebo	09OCT2020/ Placebo	30OCT2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
11771487	C4591001 1177 11771487	16-55	09OCT2020	106222	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)		
11771488	C4591001 1177 11771488	16-55	09OCT2020	106223	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)		
11771490	C4591001 1177 11771490	16-55	12OCT2020	106227	Placebo	12OCT2020/ Placebo	02NOV2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
11771491	C4591001 1177 11771491	16-55	12OCT2020	106653	BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)		
11771493	C4591001 1177 11771493	16-55	12OCT2020	106652	Placebo	12OCT2020/ Placebo	02NOV2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
11771494	C4591001 1177 11771494	16-55	12OCT2020	106656	Placebo	12OCT2020/ Placebo	02NOV2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
11771496	C4591001 1177 11771496	16-55	12OCT2020	106658	BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		
11771497	C4591001 1177 11771497	16-55	12OCT2020	106709	Placebo	12OCT2020/ Placebo	03NOV2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11771499	C4591001 1177 11771499	16-55	12OCT2020	106712	Placebo	12OCT2020/ Placebo	02NOV2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
11771500	C4591001 1177 11771500	16-55	13OCT2020	106714	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
11771501	C4591001 1177 11771501	16-55	13OCT2020	106716	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
11771502	C4591001 1177 11771502	16-55	13OCT2020	107249	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
11771503	C4591001 1177 11771503	16-55	13OCT2020	107250	Placebo	13OCT2020/ Placebo	03NOV2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
11771504	C4591001 1177 11771504	16-55	13OCT2020	107252	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
11771506	C4591001 1177 11771506	16-55	14OCT2020	107254	Placebo	14OCT2020/ Placebo	04NOV2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
11771509	C4591001 1177 11771509	16-55	14OCT2020	107766	BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
11771510	C4591001 1177 11771510	16-55	14OCT2020	107771	BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
11771511	C4591001 1177 11771511	16-55	14OCT2020	107775	Placebo	14OCT2020/ Placebo	04NOV2020/ Placebo	03MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11771513	C4591001 1177 11771513	16-55	14OCT2020	107776	Placebo	14OCT2020/ Placebo	03NOV2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
11771514	C4591001 1177 11771514	16-55	15OCT2020	108294	Placebo	15OCT2020/ Placebo	12NOV2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
11771515	C4591001 1177 11771515	16-55	15OCT2020	108295	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
11771516	C4591001 1177 11771516	16-55	15OCT2020	108302	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
11771517	C4591001 1177 11771517	16-55	15OCT2020	108304	Placebo	15OCT2020/ Placebo	05NOV2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
11771520	C4591001 1177 11771520	16-55	16OCT2020	109313	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
11771521	C4591001 1177 11771521	16-55	16OCT2020	109314	Placebo	16OCT2020/ Placebo	06NOV2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
11771524	C4591001 1177 11771524	16-55	19OCT2020	109316	Placebo	19OCT2020/ Placebo	09NOV2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
11771525	C4591001 1177 11771525	16-55	19OCT2020	109320	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
11771526	C4591001 1177 11771526	16-55	19OCT2020	110537	Placebo	19OCT2020/ Placebo	11NOV2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11771528	C4591001 1177 11771528	16-55	19OCT2020	110538	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
11771529	C4591001 1177 11771529	16-55	19OCT2020	110540	Placebo	19OCT2020/ Placebo	10NOV2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)
11771531	C4591001 1177 11771531	16-55	19OCT2020	110542	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
11771532	C4591001 1177 11771532	16-55	19OCT2020	110611	Placebo	19OCT2020/ Placebo	09NOV2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11771533	C4591001 1177 11771533	16-55	19OCT2020	110612	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
11771534	C4591001 1177 11771534	16-55	20OCT2020	110618	Placebo	20OCT2020/ Placebo	10NOV2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)
11771537	C4591001 1177 11771537	16-55	20OCT2020	110620	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		
11771539	C4591001 1177 11771539	16-55	20OCT2020	111248	Placebo	20OCT2020/ Placebo	10NOV2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
11771540	C4591001 1177 11771540	16-55	20OCT2020	111245	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		
11771541	C4591001 1177 11771541	16-55	21OCT2020	111250	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11771543	C4591001 1177 11771543	16-55	21OCT2020	111255	Placebo	21OCT2020/ Placebo	11NOV2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
11771544	C4591001 1177 11771544	16-55	21OCT2020	111788	Placebo	21OCT2020/ Placebo	12NOV2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
11771548	C4591001 1177 11771548	16-55	21OCT2020	111789	Placebo	21OCT2020/ Placebo	11NOV2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11771549	C4591001 1177 11771549	16-55	21OCT2020	111791	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
11771550	C4591001 1177 11771550	16-55	21OCT2020	111792	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
11771551	C4591001 1177 11771551	16-55	21OCT2020	111882	Placebo	21OCT2020/ Placebo	12NOV2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)
11771552	C4591001 1177 11771552	16-55	21OCT2020	111885	Placebo	21OCT2020/ Placebo	16NOV2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
11771554	C4591001 1177 11771554	16-55	22OCT2020	111887	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
11771555	C4591001 1177 11771555	16-55	22OCT2020	111888	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
11771556	C4591001 1177 11771556	16-55	22OCT2020	112577	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11771557	C4591001 1177 11771557	16-55	22OCT2020	112578	Placebo	22OCT2020/ Placebo	12NOV2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
11771562	C4591001 1177 11771562	16-55	23OCT2020	112580	Placebo	23OCT2020/ Placebo	13NOV2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
11771563	C4591001 1177 11771563	16-55	23OCT2020	112588	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
11771564	C4591001 1177 11771564	16-55	27OCT2020	114259	Placebo	27OCT2020/ Placebo	17NOV2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
11771565	C4591001 1177 11771565	16-55	29OCT2020	114260	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
11781001	C4591001 1178 11781001	16-55	21AUG2020	60245	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11781010	C4591001 1178 11781010	16-55	24AUG2020	60247	Placebo	24AUG2020/ Placebo	15SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
11781014	C4591001 1178 11781014	16-55	25AUG2020	60248	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	06JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
11781019	C4591001 1178 11781019	16-55	25AUG2020	60255	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11781020	C4591001 1178 11781020	16-55	26AUG2020	67375	Placebo	26AUG2020/ Placebo	17SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11781029	C4591001 1178 11781029	16-55	27AUG2020	67378	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
11781030	C4591001 1178 11781030	16-55	27AUG2020	67383	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
11781036	C4591001 1178 11781036	16-55	27AUG2020	67384	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
11781040	C4591001 1178 11781040	16-55	28AUG2020	71838	Placebo	28AUG2020/ Placebo	17SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
11781041	C4591001 1178 11781041	16-55	28AUG2020	71840	Placebo	28AUG2020/ Placebo	17SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
11781043	C4591001 1178 11781043	16-55	28AUG2020	71842	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
11781044	C4591001 1178 11781044	16-55	28AUG2020	71841	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
11781050	C4591001 1178 11781050	16-55	31AUG2020	75515	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11781051	C4591001 1178 11781051	16-55	31AUG2020	75510	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
11781052	C4591001 1178 11781052	16-55	31AUG2020	75511	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11781053	C4591001 1178 11781053	16-55	31AUG2020	75517	Placebo	31AUG2020/ Placebo	23SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
11781054	C4591001 1178 11781054	16-55	31AUG2020	75957	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
11781055	C4591001 1178 11781055	16-55	31AUG2020	75958	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11781058	C4591001 1178 11781058	16-55	01SEP2020	75960	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
11781061	C4591001 1178 11781061	16-55	01SEP2020	75963	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
11781062	C4591001 1178 11781062	16-55	01SEP2020	76651	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
11781065	C4591001 1178 11781065	16-55	01SEP2020	76653	Placebo	01SEP2020/ Placebo	21SEP2020/ Placebo		
11781067	C4591001 1178 11781067	16-55	01SEP2020	76654	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11781069	C4591001 1178 11781069	16-55	01SEP2020	76658	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11781070	C4591001 1178 11781070	16-55	01SEP2020	77538	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11781072	C4591001 1178 11781072	16-55	02SEP2020	77542	Placebo	02SEP2020/ Placebo	22SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11781073	C4591001 1178 11781073	16-55	02SEP2020	77541	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11781074	C4591001 1178 11781074	16-55	02SEP2020	77547	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11781077	C4591001 1178 11781077	16-55	02SEP2020	78714	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11781078	C4591001 1178 11781078	16-55	02SEP2020	78716	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11781079	C4591001 1178 11781079	16-55	02SEP2020	78723	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
11781082	C4591001 1178 11781082	16-55	02SEP2020	78724	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
11781084	C4591001 1178 11781084	16-55	02SEP2020	79277	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11781087	C4591001 1178 11781087	16-55	03SEP2020	79279	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11781089	C4591001 1178 11781089	16-55	03SEP2020	79280	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11781092	C4591001 1178 11781092	16-55	03SEP2020	79282	Placebo	03SEP2020/ Placebo	23SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
11781095	C4591001 1178 11781095	16-55	03SEP2020	80970	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
11781096	C4591001 1178 11781096	16-55	03SEP2020	80971	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
11781097	C4591001 1178 11781097	16-55	04SEP2020	81344	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
11781098	C4591001 1178 11781098	16-55	04SEP2020	80978	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
11781100	C4591001 1178 11781100	16-55	04SEP2020	80979	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
11781104	C4591001 1178 11781104	16-55	04SEP2020	81347	Placebo	04SEP2020/ Placebo	23SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
11781105	C4591001 1178 11781105	16-55	04SEP2020	81349	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
11781106	C4591001 1178 11781106	16-55	04SEP2020	81351	Placebo	04SEP2020/ Placebo	24SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
11781107	C4591001 1178 11781107	16-55	04SEP2020	82074	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)			

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11781110	C4591001 1178 11781110	16-55	08SEP2020	82075	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
11781113	C4591001 1178 11781113	16-55	08SEP2020	82077	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
11781114	C4591001 1178 11781114	16-55	08SEP2020	82080	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
11781120	C4591001 1178 11781120	16-55	08SEP2020	84522	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
11781121	C4591001 1178 11781121	16-55	08SEP2020	84525	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
11781127	C4591001 1178 11781127	16-55	09SEP2020	84529	Placebo	09SEP2020/ Placebo	29SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
11781128	C4591001 1178 11781128	16-55	09SEP2020	84530	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
11781129	C4591001 1178 11781129	16-55	09SEP2020	85692	Placebo	09SEP2020/ Placebo	29SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
11781130	C4591001 1178 11781130	16-55	09SEP2020	85691	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
11781131	C4591001 1178 11781131	16-55	09SEP2020	85685	Placebo	09SEP2020/ Placebo	29SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11781133	C4591001 1178 11781133	16-55	09SEP2020	85693	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11781135	C4591001 1178 11781135	16-55	09SEP2020	85987	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
11781137	C4591001 1178 11781137	16-55	10SEP2020	85988	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
11781144	C4591001 1178 11781144	16-55	10SEP2020	85991	Placebo	10SEP2020/ Placebo	30SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
11781145	C4591001 1178 11781145	16-55	10SEP2020	85993	Placebo	10SEP2020/ Placebo	30SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
11781149	C4591001 1178 11781149	16-55	11SEP2020	87798	Placebo	11SEP2020/ Placebo	30SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
11781150	C4591001 1178 11781150	16-55	11SEP2020	87802	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
11781153	C4591001 1178 11781153	16-55	11SEP2020	87799	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
11781154	C4591001 1178 11781154	16-55	11SEP2020	87804	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
11781155	C4591001 1178 11781155	16-55	11SEP2020	88182	Placebo	11SEP2020/ Placebo	01OCT2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11781156	C4591001 1178 11781156	16-55	11SEP2020	88184	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
11781161	C4591001 1178 11781161	16-55	11SEP2020	88187	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
11781162	C4591001 1178 11781162	16-55	11SEP2020	88188	Placebo	11SEP2020/ Placebo	01OCT2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
11781163	C4591001 1178 11781163	16-55	14SEP2020	89421	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
11781168	C4591001 1178 11781168	16-55	14SEP2020	89426	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
11781170	C4591001 1178 11781170	16-55	14SEP2020	89427	Placebo	14SEP2020/ Placebo	14OCT2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
11781171	C4591001 1178 11781171	16-55	15SEP2020	90189	Placebo	15SEP2020/ Placebo	07OCT2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
11781175	C4591001 1178 11781175	16-55	15SEP2020	90190	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
11781179	C4591001 1178 11781179	16-55	15SEP2020	90191	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
11781181	C4591001 1178 11781181	16-55	15SEP2020	90786	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11781182	C4591001 1178 11781182	16-55	15SEP2020	90196	Placebo	15SEP2020/ Placebo	05OCT2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11781183	C4591001 1178 11781183	16-55	15SEP2020	90788	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
11781185	C4591001 1178 11781185	16-55	16SEP2020	90789	Placebo	16SEP2020/ Placebo	05OCT2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
11781186	C4591001 1178 11781186	16-55	16SEP2020	90796	Placebo	16SEP2020/ Placebo	06OCT2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
11781187	C4591001 1178 11781187	16-55	16SEP2020	91038	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
11781188	C4591001 1178 11781188	16-55	16SEP2020	91043	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
11781189	C4591001 1178 11781189	16-55	16SEP2020	91045	Placebo	16SEP2020/ Placebo	05OCT2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
11781190	C4591001 1178 11781190	16-55	16SEP2020	91047	Placebo	16SEP2020/ Placebo	07OCT2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11781194	C4591001 1178 11781194	16-55	16SEP2020	91661	Placebo	16SEP2020/ Placebo	06OCT2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11781197	C4591001 1178 11781197	16-55	16SEP2020	91665	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11781198	C4591001 1178 11781198	16-55	17SEP2020	91666	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
11781208	C4591001 1178 11781208	16-55	17SEP2020	92993	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
11781209	C4591001 1178 11781209	16-55	17SEP2020	91669	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
11781210	C4591001 1178 11781210	16-55	18SEP2020	92998	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
11781211	C4591001 1178 11781211	16-55	18SEP2020	93001	Placebo	18SEP2020/ Placebo	12OCT2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
11781213	C4591001 1178 11781213	16-55	18SEP2020	93004	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
11781214	C4591001 1178 11781214	16-55	18SEP2020	93822	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
11781216	C4591001 1178 11781216	16-55	21SEP2020	93828	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
11781217	C4591001 1178 11781217	16-55	21SEP2020	93826	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
11781218	C4591001 1178 11781218	16-55	21SEP2020	93832	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11781219	C4591001 1178 11781219	16-55	21SEP2020	94949	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
11781221	C4591001 1178 11781221	16-55	21SEP2020	94950	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
11781222	C4591001 1178 11781222	16-55	21SEP2020	94952	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11781223	C4591001 1178 11781223	16-55	21SEP2020	94953	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
11781224	C4591001 1178 11781224	16-55	21SEP2020	95528	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
11781226	C4591001 1178 11781226	16-55	21SEP2020	95530	Placebo	21SEP2020/ Placebo	13OCT2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
11781227	C4591001 1178 11781227	16-55	22SEP2020	95535	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
11781228	C4591001 1178 11781228	16-55	22SEP2020	95536	Placebo	22SEP2020/ Placebo	12OCT2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
11781230	C4591001 1178 11781230	16-55	22SEP2020	96282	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
11781233	C4591001 1178 11781233	16-55	22SEP2020	96284	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11781234	C4591001 1178 11781234	16-55	22SEP2020	96283	Placebo	22SEP2020/ Placebo	12OCT2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
11781236	C4591001 1178 11781236	16-55	22SEP2020	96291	Placebo	22SEP2020/ Placebo	14OCT2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
11781237	C4591001 1178 11781237	16-55	22SEP2020	96894	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
11781239	C4591001 1178 11781239	16-55	23SEP2020	96896	Placebo	23SEP2020/ Placebo	13OCT2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
11781244	C4591001 1178 11781244	16-55	23SEP2020	96898	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
11781245	C4591001 1178 11781245	16-55	23SEP2020	96899	Placebo	23SEP2020/ Placebo	13OCT2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
11781247	C4591001 1178 11781247	16-55	24SEP2020	98565	Placebo	24SEP2020/ Placebo	14OCT2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	28JAN2021/ BNT162b2 (30 µg)
11781248	C4591001 1178 11781248	16-55	24SEP2020	98569	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
11781249	C4591001 1178 11781249	16-55	24SEP2020	98570	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
11781251	C4591001 1178 11781251	16-55	24SEP2020	98571	Placebo	24SEP2020/ Placebo	15OCT2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11781253	C4591001 1178 11781253	16-55	24SEP2020	99007	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
11781254	C4591001 1178 11781254	16-55	24SEP2020	99008	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
11781257	C4591001 1178 11781257	16-55	25SEP2020	99014	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
11781258	C4591001 1178 11781258	16-55	25SEP2020	99016	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
11781260	C4591001 1178 11781260	16-55	25SEP2020	99773	Placebo	25SEP2020/ Placebo	15OCT2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
11781262	C4591001 1178 11781262	16-55	28SEP2020	99775	Placebo	28SEP2020/ Placebo	19OCT2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
11781263	C4591001 1178 11781263	16-55	28SEP2020	99776	BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		
11781266	C4591001 1178 11781266	16-55	29SEP2020	99782	BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)		
11781267	C4591001 1178 11781267	16-55	29SEP2020	101792	Placebo	29SEP2020/ Placebo	19OCT2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11781268	C4591001 1178 11781268	16-55	29SEP2020	101793	BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11781269	C4591001 1178 11781269	16-55	29SEP2020	101795	Placebo	29SEP2020/ Placebo	19OCT2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
11781270	C4591001 1178 11781270	16-55	29SEP2020	101797	BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		
11781271	C4591001 1178 11781271	16-55	29SEP2020	101994	BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)		
11781275	C4591001 1178 11781275	16-55	01OCT2020	101999	Placebo	01OCT2020/ Placebo	20OCT2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
11781277	C4591001 1178 11781277	16-55	02OCT2020	102002	Placebo	02OCT2020/ Placebo	21OCT2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11781279	C4591001 1178 11781279	16-55	02OCT2020	102000	BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)		
11781284	C4591001 1178 11781284	16-55	06OCT2020	104168	Placebo	06OCT2020/ Placebo	26OCT2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
11781285	C4591001 1178 11781285	16-55	06OCT2020	104169	BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
11781286	C4591001 1178 11781286	16-55	06OCT2020	104171	Placebo	06OCT2020/ Placebo	26OCT2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
11781288	C4591001 1178 11781288	16-55	06OCT2020	104176	BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11781290	C4591001 1178 11781290	16-55	06OCT2020	104455	BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		
11781291	C4591001 1178 11781291	16-55	07OCT2020	104458	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		
11781295	C4591001 1178 11781295	16-55	08OCT2020	104462	Placebo	08OCT2020/ Placebo	29OCT2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
11781296	C4591001 1178 11781296	16-55	12OCT2020	104464	Placebo	12OCT2020/ Placebo	03NOV2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
11781298	C4591001 1178 11781298	16-55	14OCT2020	107525	Placebo	14OCT2020/ Placebo	04NOV2020/ Placebo		
11781300	C4591001 1178 11781300	16-55	14OCT2020	107527	Placebo	14OCT2020/ Placebo	04NOV2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
11781301	C4591001 1178 11781301	16-55	14OCT2020	107532	BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
11781309	C4591001 1178 11781309	16-55	20OCT2020	107534	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
11781310	C4591001 1178 11781310	16-55	20OCT2020	111053	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
11781311	C4591001 1178 11781311	16-55	21OCT2020	111054	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11781312	C4591001 1178 11781312	16-55	21OCT2020	111060	Placebo	21OCT2020/ Placebo	11NOV2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11781314	C4591001 1178 11781314	16-55	22OCT2020	111063	Placebo	22OCT2020/ Placebo	11NOV2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11781316	C4591001 1178 11781316	16-55	26OCT2020	113621	Placebo	26OCT2020/ Placebo	16NOV2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
11791008	C4591001 1179 11791008	16-55	20AUG2020	50214	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11791009	C4591001 1179 11791009	16-55	21AUG2020	50218	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
11791010	C4591001 1179 11791010	16-55	21AUG2020	50219	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
11791014	C4591001 1179 11791014	16-55	27AUG2020	69442	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
11791021	C4591001 1179 11791021	16-55	29AUG2020	69443	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
11791023	C4591001 1179 11791023	16-55	31AUG2020	69444	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11791030	C4591001 1179 11791030	16-55	02SEP2020	69446	Placebo	02SEP2020/ Placebo	21SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11791033	C4591001 1179 11791033	16-55	02SEP2020	77813	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11791050	C4591001 1179 11791050	16-55	05SEP2020	77818	BNT162b2 (30 µg)	05SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
11791054	C4591001 1179 11791054	16-55	05SEP2020	77820	Placebo	05SEP2020/ Placebo	24SEP2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
11791058	C4591001 1179 11791058	16-55	08SEP2020	77823	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo	19DEC2020/ BNT162b2 (30 µg)	09JAN2021/ BNT162b2 (30 µg)
11791061	C4591001 1179 11791061	16-55	08SEP2020	84438	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
11791064	C4591001 1179 11791064	16-55	09SEP2020	84441	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	19DEC2020/ BNT162b2 (30 µg)	09JAN2021/ BNT162b2 (30 µg)
11791066	C4591001 1179 11791066	16-55	09SEP2020	84443	Placebo	09SEP2020/ Placebo	28SEP2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
11791067	C4591001 1179 11791067	16-55	10SEP2020	84444	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
11791069	C4591001 1179 11791069	16-55	10SEP2020	86265	Placebo	10SEP2020/ Placebo	30SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
11791075	C4591001 1179 11791075	16-55	11SEP2020	86266	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11791076	C4591001 1179 11791076	16-55	11SEP2020	86267	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
11791079	C4591001 1179 11791079	16-55	11SEP2020	86268	Placebo	11SEP2020/ Placebo	30SEP2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
11791081	C4591001 1179 11791081	16-55	16SEP2020	90895	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
11791082	C4591001 1179 11791082	16-55	16SEP2020	90896	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
11791083	C4591001 1179 11791083	16-55	16SEP2020	90900	Placebo	16SEP2020/ Placebo	08OCT2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11791085	C4591001 1179 11791085	16-55	17SEP2020	90901	Placebo	17SEP2020/ Placebo	07OCT2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
11791086	C4591001 1179 11791086	16-55	18SEP2020	93559	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
11791087	C4591001 1179 11791087	16-55	18SEP2020	93560	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
11791090	C4591001 1179 11791090	16-55	18SEP2020	93561	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
11791091	C4591001 1179 11791091	16-55	18SEP2020	93566	Placebo	18SEP2020/ Placebo	07OCT2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11791093	C4591001 1179 11791093	16-55	21SEP2020	94700	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
11791098	C4591001 1179 11791098	16-55	25SEP2020	94704	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
11791099	C4591001 1179 11791099	16-55	25SEP2020	94705	Placebo	25SEP2020/ Placebo	14OCT2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
11791100	C4591001 1179 11791100	16-55	25SEP2020	99666	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
11791101	C4591001 1179 11791101	16-55	25SEP2020	99670	Placebo	25SEP2020/ Placebo	14OCT2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
11791104	C4591001 1179 11791104	16-55	26SEP2020	99673	BNT162b2 (30 µg)	26SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
11791106	C4591001 1179 11791106	16-55	26SEP2020	99674	BNT162b2 (30 µg)	26SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
11791107	C4591001 1179 11791107	16-55	01OCT2020	102725	Placebo	01OCT2020/ Placebo	21OCT2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
11791109	C4591001 1179 11791109	16-55	01OCT2020	102726	Placebo	01OCT2020/ Placebo	22OCT2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
11791112	C4591001 1179 11791112	16-55	02OCT2020	102730	BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11791114	C4591001 1179 11791114	16-55	02OCT2020	102736	BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)		
11791115	C4591001 1179 11791115	16-55	07OCT2020	104626	Placebo	07OCT2020/ Placebo	26OCT2020/ Placebo		
11791117	C4591001 1179 11791117	16-55	08OCT2020	104627	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)		
11791118	C4591001 1179 11791118	16-55	08OCT2020	104628	Placebo	08OCT2020/ Placebo	30OCT2020/ Placebo	19DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11791119	C4591001 1179 11791119	16-55	08OCT2020	104629	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
11791122	C4591001 1179 11791122	16-55	09OCT2020	106099	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
11791123	C4591001 1179 11791123	16-55	15OCT2020	106103	Placebo	15OCT2020/ Placebo	04NOV2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
11791125	C4591001 1179 11791125	16-55	16OCT2020	106104	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
11791126	C4591001 1179 11791126	16-55	19OCT2020	106108	Placebo	19OCT2020/ Placebo	09NOV2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
11791130	C4591001 1179 11791130	16-55	21OCT2020	111293	Placebo	21OCT2020/ Placebo	10NOV2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11791131	C4591001 1179 11791131	16-55	21OCT2020	111294	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
11791133	C4591001 1179 11791133	16-55	21OCT2020	111295	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
11791136	C4591001 1179 11791136	16-55	23OCT2020	111304	Placebo	23OCT2020/ Placebo	11NOV2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
11791137	C4591001 1179 11791137	16-55	24OCT2020	113251	BNT162b2 (30 µg)	24OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
11791138	C4591001 1179 11791138	16-55	24OCT2020	113252	BNT162b2 (30 µg)	24OCT2020/ BNT162b2 (30 µg)			
11791139	C4591001 1179 11791139	16-55	24OCT2020	113255	Placebo	24OCT2020/ Placebo	12NOV2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
11791143	C4591001 1179 11791143	16-55	24OCT2020	113258	Placebo	24OCT2020/ Placebo	16NOV2020/ Placebo	19DEC2020/ BNT162b2 (30 µg)	09JAN2021/ BNT162b2 (30 µg)
11791144	C4591001 1179 11791144	16-55	24OCT2020	113277	BNT162b2 (30 µg)	24OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
11791145	C4591001 1179 11791145	16-55	26OCT2020	113278	Placebo	26OCT2020/ Placebo	16NOV2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
11791146	C4591001 1179 11791146	16-55	26OCT2020	113279	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11791147	C4591001 1179 11791147	16-55	26OCT2020	113284	Placebo	26OCT2020/ Placebo	16NOV2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
11791148	C4591001 1179 11791148	16-55	26OCT2020	113552	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
11791149	C4591001 1179 11791149	16-55	26OCT2020	113553	Placebo	26OCT2020/ Placebo	16NOV2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
11791150	C4591001 1179 11791150	16-55	26OCT2020	113554	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
11791152	C4591001 1179 11791152	16-55	26OCT2020	113557	Placebo	26OCT2020/ Placebo	16NOV2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
11791153	C4591001 1179 11791153	16-55	26OCT2020	113658	Placebo	26OCT2020/ Placebo	16NOV2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
11791154	C4591001 1179 11791154	16-55	26OCT2020	113659	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
11791158	C4591001 1179 11791158	16-55	28OCT2020	113662	BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
11791159	C4591001 1179 11791159	16-55	28OCT2020	113667	Placebo	28OCT2020/ Placebo	16NOV2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
11791160	C4591001 1179 11791160	16-55	29OCT2020	114618	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	18NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11791161	C4591001 1179 11791161	16-55	29OCT2020	114621	Placebo	29OCT2020/ Placebo	18NOV2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
11791162	C4591001 1179 11791162	16-55	29OCT2020	114625	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)		
11791165	C4591001 1179 11791165	16-55	30OCT2020	114626	Placebo	30OCT2020/ Placebo	20NOV2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
11791166	C4591001 1179 11791166	16-55	30OCT2020	114981	Placebo	30OCT2020/ Placebo	19NOV2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
11791167	C4591001 1179 11791167	16-55	30OCT2020	114983	BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)	20NOV2020/ BNT162b2 (30 µg)		
11791170	C4591001 1179 11791170	16-55	30OCT2020	114984	Placebo	30OCT2020/ Placebo	20NOV2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
11791173	C4591001 1179 11791173	16-55	30OCT2020	114987	BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)	20NOV2020/ BNT162b2 (30 µg)		
11791174	C4591001 1179 11791174	16-55	30OCT2020	115074	BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)	20NOV2020/ BNT162b2 (30 µg)		
11851002	C4591001 1185 11851002	16-55	26OCT2020	113501	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
11851005	C4591001 1185 11851005	16-55	26OCT2020	113502	Placebo	26OCT2020/ Placebo	16NOV2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11851008	C4591001 1185 11851008	16-55	27OCT2020	113508	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
11851009	C4591001 1185 11851009	16-55	27OCT2020	113512	Placebo	27OCT2020/ Placebo	17NOV2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
11851010	C4591001 1185 11851010	16-55	27OCT2020	113876	Placebo	27OCT2020/ Placebo	17NOV2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
11851011	C4591001 1185 11851011	16-55	27OCT2020	113880	Placebo	27OCT2020/ Placebo	16NOV2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
11851012	C4591001 1185 11851012	16-55	27OCT2020	113873	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
11851013	C4591001 1185 11851013	16-55	27OCT2020	113882	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
11851015	C4591001 1185 11851015	16-55	27OCT2020	113886	Placebo	27OCT2020/ Placebo	17NOV2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
11851017	C4591001 1185 11851017	16-55	27OCT2020	113889	Placebo	27OCT2020/ Placebo	16NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
11851018	C4591001 1185 11851018	16-55	27OCT2020	113891	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
11851021	C4591001 1185 11851021	16-55	27OCT2020	113894	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11851022	C4591001 1185 11851022†	16-55	27OCT2020	113933	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
11851023	C4591001 1185 11851023	16-55	27OCT2020	113938	Placebo	27OCT2020/ Placebo	18NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
11851024	C4591001 1185 11851024	16-55	27OCT2020	113942	Placebo	27OCT2020/ Placebo	16NOV2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
11851025	C4591001 1185 11851025	16-55	27OCT2020	113944	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
11851028	C4591001 1185 11851028	16-55	27OCT2020	113969	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
11851029	C4591001 1185 11851029	16-55	27OCT2020	113972	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
11851030	C4591001 1185 11851030	16-55	27OCT2020	113977	Placebo	27OCT2020/ Placebo	17NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
11851032	C4591001 1185 11851032	16-55	27OCT2020	113980	Placebo	27OCT2020/ Placebo	17NOV2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
11851033	C4591001 1185 11851033	16-55	27OCT2020	114041	Placebo	27OCT2020/ Placebo	17NOV2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
11851036	C4591001 1185 11851036	16-55	27OCT2020	114045	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11851037	C4591001 1185 11851037	16-55	27OCT2020	114052	Placebo	27OCT2020/ Placebo	16NOV2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
11851038	C4591001 1185 11851038	16-55	27OCT2020	114089	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
11851039	C4591001 1185 11851039	16-55	27OCT2020	114091	Placebo	27OCT2020/ Placebo	17NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
11851040	C4591001 1185 11851040	16-55	27OCT2020	114094	Placebo	27OCT2020/ Placebo	16NOV2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
11851041	C4591001 1185 11851041	16-55	29OCT2020	114096	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)		
11851043	C4591001 1185 11851043	16-55	29OCT2020	114572	Placebo	29OCT2020/ Placebo	19NOV2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
11851048	C4591001 1185 11851048	16-55	29OCT2020	114576	Placebo	29OCT2020/ Placebo	18NOV2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
11851049	C4591001 1185 11851049	16-55	29OCT2020	114577	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)		
11851050	C4591001 1185 11851050	16-55	29OCT2020	114580	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	18NOV2020/ BNT162b2 (30 µg)		
11851051	C4591001 1185 11851051	16-55	29OCT2020	114581	Placebo	29OCT2020/ Placebo	18NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11851052	C4591001 1185 11851052	16-55	29OCT2020	114582	Placebo	29OCT2020/ Placebo	18NOV2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
11851053	C4591001 1185 11851053	16-55	29OCT2020	114584	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	18NOV2020/ BNT162b2 (30 µg)		
11851054	C4591001 1185 11851054	16-55	29OCT2020	114587	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)		
11851055	C4591001 1185 11851055	16-55	29OCT2020	114608	Placebo	29OCT2020/ Placebo	19NOV2020/ Placebo		
11851056	C4591001 1185 11851056	16-55	29OCT2020	114609	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)		
11851059	C4591001 1185 11851059	16-55	29OCT2020	114613	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	18NOV2020/ BNT162b2 (30 µg)		
11851060	C4591001 1185 11851060	16-55	29OCT2020	114615	Placebo	29OCT2020/ Placebo	18NOV2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
11851063	C4591001 1185 11851063	16-55	29OCT2020	114667	Placebo	29OCT2020/ Placebo	18NOV2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
11851064	C4591001 1185 11851064	16-55	29OCT2020	114668	Placebo	29OCT2020/ Placebo	19NOV2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
11851066	C4591001 1185 11851066	16-55	29OCT2020	114669	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11851067	C4591001 1185 11851067	16-55	29OCT2020	114674	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	18NOV2020/ BNT162b2 (30 µg)		
11941003	C4591001 1194 11941003	16-55	15OCT2020	107837	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
11941004	C4591001 1194 11941004	16-55	15OCT2020	107838	Placebo	15OCT2020/ Placebo	06NOV2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
11941009	C4591001 1194 11941009	16-55	15OCT2020	107846	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
11941010	C4591001 1194 11941010	16-55	15OCT2020	107847	Placebo	15OCT2020/ Placebo	04NOV2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)
11941012	C4591001 1194 11941012	16-55	15OCT2020	108246	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
11941014	C4591001 1194 11941014	16-55	16OCT2020	108249	Placebo	16OCT2020/ Placebo	06NOV2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
11941016	C4591001 1194 11941016	16-55	16OCT2020	108250	Placebo	16OCT2020/ Placebo	06NOV2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
11941019	C4591001 1194 11941019	16-55	16OCT2020	108254	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
11941020	C4591001 1194 11941020	16-55	16OCT2020	108749	Placebo	16OCT2020/ Placebo	04NOV2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11941023	C4591001 1194 11941023	16-55	16OCT2020	108752	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	07NOV2020/ BNT162b2 (30 µg)		
11941024	C4591001 1194 11941024	16-55	16OCT2020	108755	Placebo	16OCT2020/ Placebo	07NOV2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
11941025	C4591001 1194 11941025	16-55	16OCT2020	108757	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
11941026	C4591001 1194 11941026	16-55	16OCT2020	108893	Placebo	16OCT2020/ Placebo	05NOV2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
11941030	C4591001 1194 11941030	16-55	16OCT2020	108902	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	07NOV2020/ BNT162b2 (30 µg)		
11941031	C4591001 1194 11941031	16-55	16OCT2020	108903	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	07NOV2020/ BNT162b2 (30 µg)		
11941032	C4591001 1194 11941032	16-55	16OCT2020	108904	Placebo	16OCT2020/ Placebo	06NOV2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
11941033	C4591001 1194 11941033	16-55	16OCT2020	109061	Placebo	16OCT2020/ Placebo	06NOV2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)
11941034	C4591001 1194 11941034	16-55	17OCT2020	109064	BNT162b2 (30 µg)	17OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
11941041	C4591001 1194 11941041	16-55	17OCT2020	109071	Placebo	17OCT2020/ Placebo	05NOV2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11941043	C4591001 1194 11941043	16-55	17OCT2020	109437	BNT162b2 (30 µg)	17OCT2020/ BNT162b2 (30 µg)	07NOV2020/ BNT162b2 (30 µg)		
11941044	C4591001 1194 11941044	16-55	17OCT2020	109439	BNT162b2 (30 µg)	17OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
11941045	C4591001 1194 11941045	16-55	17OCT2020	109440	Placebo	17OCT2020/ Placebo	09NOV2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
11941046	C4591001 1194 11941046	16-55	17OCT2020	109442	Placebo	17OCT2020/ Placebo	09NOV2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
11941047	C4591001 1194 11941047	16-55	17OCT2020	109481	Placebo	17OCT2020/ Placebo	09NOV2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
11941048	C4591001 1194 11941048	16-55	17OCT2020	109484	Placebo	17OCT2020/ Placebo	06NOV2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
11941051	C4591001 1194 11941051	16-55	19OCT2020	109485	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
11941052	C4591001 1194 11941052	16-55	19OCT2020	109492	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
11941053	C4591001 1194 11941053	16-55	19OCT2020	109793	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		
11941054	C4591001 1194 11941054	16-55	19OCT2020	109799	Placebo	19OCT2020/ Placebo	10NOV2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11941056	C4591001 1194 11941056	16-55	19OCT2020	109800	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		
11941057	C4591001 1194 11941057	16-55	19OCT2020	109801	Placebo	19OCT2020/ Placebo	09NOV2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)
11941058	C4591001 1194 11941058	16-55	19OCT2020	109925	Placebo	19OCT2020/ Placebo	10NOV2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)
11941061	C4591001 1194 11941061	16-55	19OCT2020	109927	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)			
11941062	C4591001 1194 11941062	16-55	20OCT2020	109932	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
11941066	C4591001 1194 11941066	16-55	20OCT2020	109933	Placebo	20OCT2020/ Placebo	11NOV2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
11941067	C4591001 1194 11941067	16-55	20OCT2020	110634	Placebo	20OCT2020/ Placebo	11NOV2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
11941069	C4591001 1194 11941069	16-55	20OCT2020	110637	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
11941071	C4591001 1194 11941071	16-55	20OCT2020	110639	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
11941072	C4591001 1194 11941072	16-55	20OCT2020	110641	Placebo	20OCT2020/ Placebo	12NOV2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11941080	C4591001 1194 11941080	16-55	21OCT2020	111272	Placebo	21OCT2020/ Placebo	11NOV2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
11941081	C4591001 1194 11941081	16-55	21OCT2020	111273	Placebo	21OCT2020/ Placebo	10NOV2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
11941082	C4591001 1194 11941082	16-55	21OCT2020	111275	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
11941083	C4591001 1194 11941083	16-55	21OCT2020	111279	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
11941086	C4591001 1194 11941086	16-55	21OCT2020	111417	Placebo	21OCT2020/ Placebo	12NOV2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
11941087	C4591001 1194 11941087	16-55	21OCT2020	111418	Placebo	21OCT2020/ Placebo	12NOV2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
11941088	C4591001 1194 11941088	16-55	21OCT2020	111419	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
11941089	C4591001 1194 11941089	16-55	21OCT2020	111421	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
11941090	C4591001 1194 11941090	16-55	22OCT2020	111941	Placebo	22OCT2020/ Placebo	13NOV2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
11941091	C4591001 1194 11941091	16-55	22OCT2020	111945	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11941092	C4591001 1194 11941092	16-55	22OCT2020	111946	Placebo	22OCT2020/ Placebo	12NOV2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
11941093	C4591001 1194 11941093	16-55	22OCT2020	111950	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
11941096	C4591001 1194 11941096	16-55	22OCT2020	111991	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
11941097	C4591001 1194 11941097	16-55	22OCT2020	111993	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
11941098	C4591001 1194 11941098	16-55	22OCT2020	111994	Placebo	22OCT2020/ Placebo	13NOV2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
11941100	C4591001 1194 11941100	16-55	22OCT2020	111999	Placebo	22OCT2020/ Placebo	12NOV2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
11941103	C4591001 1194 11941103	16-55	22OCT2020	112233	Placebo	22OCT2020/ Placebo	12NOV2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
11941105	C4591001 1194 11941105	16-55	22OCT2020	112234	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
11941106	C4591001 1194 11941106	16-55	23OCT2020	112236	Placebo	23OCT2020/ Placebo	13NOV2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11951001	C4591001 1195 11951001	16-55	15OCT2020	107826	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11951002	C4591001 1195 11951002	16-55	15OCT2020	107827	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
11951003	C4591001 1195 11951003	16-55	15OCT2020	107833	Placebo	15OCT2020/ Placebo	05NOV2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
11951004	C4591001 1195 11951004	16-55	15OCT2020	107835	Placebo	15OCT2020/ Placebo	05NOV2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
11951005	C4591001 1195 11951005	16-55	15OCT2020	107851	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
11951008	C4591001 1195 11951008	16-55	15OCT2020	107852	Placebo	15OCT2020/ Placebo	03NOV2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
11951009	C4591001 1195 11951009	16-55	15OCT2020	107855	Placebo	15OCT2020/ Placebo	03NOV2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
11951010	C4591001 1195 11951010	16-55	15OCT2020	107856	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
11951013	C4591001 1195 11951013	16-55	15OCT2020	107909	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
11951015	C4591001 1195 11951015	16-55	15OCT2020	107910	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
11951017	C4591001 1195 11951017	16-55	15OCT2020	107913	Placebo	15OCT2020/ Placebo	03NOV2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11951018	C4591001 1195 11951018	16-55	15OCT2020	107919	Placebo	15OCT2020/ Placebo	05NOV2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
11951019	C4591001 1195 11951019	16-55	15OCT2020	108005	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
11951020	C4591001 1195 11951020	16-55	15OCT2020	108009	Placebo	15OCT2020/ Placebo	03NOV2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
11951021	C4591001 1195 11951021	16-55	15OCT2020	108014	Placebo	15OCT2020/ Placebo	03NOV2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
11951022	C4591001 1195 11951022	16-55	15OCT2020	108015	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
11951023	C4591001 1195 11951023	16-55	16OCT2020	108605	Placebo	16OCT2020/ Placebo	04NOV2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
11951024	C4591001 1195 11951024	16-55	16OCT2020	108610	Placebo	16OCT2020/ Placebo	06NOV2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
11951026	C4591001 1195 11951026	16-55	16OCT2020	108611	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	08NOV2020/ BNT162b2 (30 µg)		
11951027	C4591001 1195 11951027	16-55	16OCT2020	108614	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
11951029	C4591001 1195 11951029	16-55	16OCT2020	108654	Placebo	16OCT2020/ Placebo	04NOV2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11951030	C4591001 1195 11951030	16-55	16OCT2020	108655	Placebo	16OCT2020/ Placebo	04NOV2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
11951032	C4591001 1195 11951032	16-55	16OCT2020	108660	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
11951035	C4591001 1195 11951035	16-55	16OCT2020	108662	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
11951040	C4591001 1195 11951040	16-55	16OCT2020	108704	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
11951041	C4591001 1195 11951041	16-55	16OCT2020	108707	Placebo	16OCT2020/ Placebo	05NOV2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
11951042	C4591001 1195 11951042	16-55	16OCT2020	108710	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
11951043	C4591001 1195 11951043	16-55	16OCT2020	108712	Placebo	16OCT2020/ Placebo	06NOV2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
11951047	C4591001 1195 11951047	16-55	16OCT2020	108917	Placebo	16OCT2020/ Placebo	04NOV2020/ Placebo		
11951048	C4591001 1195 11951048	16-55	16OCT2020	108918	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
11951051	C4591001 1195 11951051	16-55	16OCT2020	108927	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11951053	C4591001 1195 11951053	16-55	17OCT2020	108928	Placebo	17OCT2020/ Placebo	07NOV2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
11951054	C4591001 1195 11951054	16-55	17OCT2020	109374	Placebo	17OCT2020/ Placebo	07NOV2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
11951055	C4591001 1195 11951055	16-55	17OCT2020	109375	BNT162b2 (30 µg)	17OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
11951056	C4591001 1195 11951056	16-55	17OCT2020	109379	Placebo	17OCT2020/ Placebo	07NOV2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
11951060	C4591001 1195 11951060	16-55	17OCT2020	109380	BNT162b2 (30 µg)	17OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
11951061	C4591001 1195 11951061	16-55	17OCT2020	109400	BNT162b2 (30 µg)	17OCT2020/ BNT162b2 (30 µg)			
11951062	C4591001 1195 11951062	16-55	17OCT2020	109401	BNT162b2 (30 µg)	17OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
11951063	C4591001 1195 11951063	16-55	17OCT2020	109402	Placebo	17OCT2020/ Placebo	06NOV2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
11951064	C4591001 1195 11951064	16-55	17OCT2020	109399	Placebo	17OCT2020/ Placebo	07NOV2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
11951065	C4591001 1195 11951065	16-55	17OCT2020	109409	BNT162b2 (30 µg)	17OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11951066	C4591001 1195 11951066	16-55	17OCT2020	109413	Placebo	17OCT2020/ Placebo	05NOV2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
11951067	C4591001 1195 11951067	16-55	17OCT2020	109411	Placebo	17OCT2020/ Placebo	07NOV2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
11951068	C4591001 1195 11951068	16-55	17OCT2020	109415	BNT162b2 (30 µg)	17OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
11951070	C4591001 1195 11951070	16-55	17OCT2020	109427	Placebo	17OCT2020/ Placebo	07NOV2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
11951071	C4591001 1195 11951071	16-55	17OCT2020	109429	BNT162b2 (30 µg)	17OCT2020/ BNT162b2 (30 µg)	07NOV2020/ BNT162b2 (30 µg)		
11951072	C4591001 1195 11951072	16-55	17OCT2020	109430	Placebo	17OCT2020/ Placebo	07NOV2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
11951073	C4591001 1195 11951073	16-55	17OCT2020	109431	BNT162b2 (30 µg)	17OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
11951074	C4591001 1195 11951074	16-55	17OCT2020	109448	BNT162b2 (30 µg)	17OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
11951075	C4591001 1195 11951075	16-55	17OCT2020	109450	Placebo	17OCT2020/ Placebo	05NOV2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
11951076	C4591001 1195 11951076	16-55	17OCT2020	109453	Placebo	17OCT2020/ Placebo	05NOV2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11951077	C4591001 1195 11951077	16-55	17OCT2020	109455	BNT162b2 (30 µg)	17OCT2020/ BNT162b2 (30 µg)	08NOV2020/ BNT162b2 (30 µg)		
11951079	C4591001 1195 11951079	16-55	17OCT2020	109547	BNT162b2 (30 µg)	17OCT2020/ BNT162b2 (30 µg)	07NOV2020/ BNT162b2 (30 µg)		
11951080	C4591001 1195 11951080	16-55	17OCT2020	109548	Placebo	17OCT2020/ Placebo	06NOV2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
11951081	C4591001 1195 11951081	16-55	17OCT2020	109550	BNT162b2 (30 µg)	17OCT2020/ BNT162b2 (30 µg)	07NOV2020/ BNT162b2 (30 µg)		
11951082	C4591001 1195 11951082	16-55	17OCT2020	109552	Placebo	17OCT2020/ Placebo	07NOV2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
11951083	C4591001 1195 11951083	16-55	17OCT2020	109613	BNT162b2 (30 µg)	17OCT2020/ BNT162b2 (30 µg)	07NOV2020/ BNT162b2 (30 µg)		
11951084	C4591001 1195 11951084	16-55	17OCT2020	109615	Placebo	17OCT2020/ Placebo	05NOV2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
11951085	C4591001 1195 11951085	16-55	18OCT2020	109620	BNT162b2 (30 µg)	18OCT2020/ BNT162b2 (30 µg)	08NOV2020/ BNT162b2 (30 µg)		
11951089	C4591001 1195 11951089	16-55	18OCT2020	109622	Placebo	18OCT2020/ Placebo	08NOV2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
11951090	C4591001 1195 11951090	16-55	18OCT2020	109686	Placebo	18OCT2020/ Placebo	08NOV2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11951091	C4591001 1195 11951091	16-55	18OCT2020	109691	BNT162b2 (30 µg)	18OCT2020/ BNT162b2 (30 µg)	08NOV2020/ BNT162b2 (30 µg)		
11951092	C4591001 1195 11951092	16-55	18OCT2020	109692	BNT162b2 (30 µg)	18OCT2020/ BNT162b2 (30 µg)	07NOV2020/ BNT162b2 (30 µg)		
11951093	C4591001 1195 11951093	16-55	18OCT2020	109694	Placebo	18OCT2020/ Placebo	08NOV2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
11951098	C4591001 1195 11951098	16-55	18OCT2020	109712	BNT162b2 (30 µg)	18OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
11951099	C4591001 1195 11951099	16-55	18OCT2020	109716	Placebo	18OCT2020/ Placebo	06NOV2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
11951100	C4591001 1195 11951100	16-55	18OCT2020	109718	Placebo	18OCT2020/ Placebo	06NOV2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
11951101	C4591001 1195 11951101	16-55	18OCT2020	109719	BNT162b2 (30 µg)	18OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
11951104	C4591001 1195 11951104	16-55	18OCT2020	109721	BNT162b2 (30 µg)	18OCT2020/ BNT162b2 (30 µg)	08NOV2020/ BNT162b2 (30 µg)		
11951105	C4591001 1195 11951105	16-55	18OCT2020	109722	Placebo	18OCT2020/ Placebo	08NOV2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
11951106	C4591001 1195 11951106	16-55	18OCT2020	109724	BNT162b2 (30 µg)	18OCT2020/ BNT162b2 (30 µg)	08NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11951107	C4591001 1195 11951107	16-55	18OCT2020	109732	Placebo	18OCT2020/ Placebo	08NOV2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
11951108	C4591001 1195 11951108	16-55	18OCT2020	109733	Placebo	18OCT2020/ Placebo	08NOV2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
11951109	C4591001 1195 11951109	16-55	18OCT2020	109735	BNT162b2 (30 µg)	18OCT2020/ BNT162b2 (30 µg)	08NOV2020/ BNT162b2 (30 µg)		
11951113	C4591001 1195 11951113	16-55	18OCT2020	109739	Placebo	18OCT2020/ Placebo	07NOV2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
11951114	C4591001 1195 11951114	16-55	18OCT2020	109742	BNT162b2 (30 µg)	18OCT2020/ BNT162b2 (30 µg)	08NOV2020/ BNT162b2 (30 µg)		
11951115	C4591001 1195 11951115	16-55	18OCT2020	109759	BNT162b2 (30 µg)	18OCT2020/ BNT162b2 (30 µg)	08NOV2020/ BNT162b2 (30 µg)		
11951116	C4591001 1195 11951116	16-55	18OCT2020	109762	Placebo	18OCT2020/ Placebo	08NOV2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
11951117	C4591001 1195 11951117	16-55	19OCT2020	109763	Placebo	19OCT2020/ Placebo	07NOV2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
11951118	C4591001 1195 11951118	16-55	19OCT2020	109768	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	07NOV2020/ BNT162b2 (30 µg)		
11951119	C4591001 1195 11951119	16-55	19OCT2020	109783	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	08NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11951120	C4591001 1195 11951120	16-55	19OCT2020	109784	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	08NOV2020/ BNT162b2 (30 µg)		
11951123	C4591001 1195 11951123	16-55	19OCT2020	109787	Placebo	19OCT2020/ Placebo	11NOV2020/ Placebo		
11951134	C4591001 1195 11951134	16-55	19OCT2020	109788	Placebo	19OCT2020/ Placebo	11NOV2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
11951135	C4591001 1195 11951135	16-55	19OCT2020	109950	Placebo	19OCT2020/ Placebo	11NOV2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
11951136	C4591001 1195 11951136	16-55	19OCT2020	109956	Placebo	19OCT2020/ Placebo	08NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
11951137	C4591001 1195 11951137	16-55	19OCT2020	109958	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	07NOV2020/ BNT162b2 (30 µg)		
11951138	C4591001 1195 11951138	16-55	19OCT2020	109960	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
11951139	C4591001 1195 11951139	16-55	19OCT2020	110036	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	07NOV2020/ BNT162b2 (30 µg)		
11951140	C4591001 1195 11951140	16-55	19OCT2020	110038	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	07NOV2020/ BNT162b2 (30 µg)		
11951141	C4591001 1195 11951141	16-55	20OCT2020	110043	Placebo	20OCT2020/ Placebo	12NOV2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11951142	C4591001 1195 11951142	16-55	20OCT2020	110044	Placebo	20OCT2020/ Placebo	12NOV2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
11951146	C4591001 1195 11951146	16-55	20OCT2020	110650	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	08NOV2020/ BNT162b2 (30 µg)		
11951147	C4591001 1195 11951147	16-55	20OCT2020	110648	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	08NOV2020/ BNT162b2 (30 µg)		
11951148	C4591001 1195 11951148	16-55	20OCT2020	110649	Placebo	20OCT2020/ Placebo	08NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
11951153	C4591001 1195 11951153	16-55	20OCT2020	110653	Placebo	20OCT2020/ Placebo	08NOV2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
11951154	C4591001 1195 11951154	16-55	20OCT2020	110657	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
11951155	C4591001 1195 11951155	16-55	20OCT2020	110660	Placebo	20OCT2020/ Placebo	11NOV2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
11951157	C4591001 1195 11951157	16-55	20OCT2020	110664	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	08NOV2020/ BNT162b2 (30 µg)		
11951158	C4591001 1195 11951158	16-55	20OCT2020	110665	Placebo	20OCT2020/ Placebo	08NOV2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
11971001	C4591001 1197 11971001	16-55	15OCT2020	107862	Placebo	15OCT2020/ Placebo	04NOV2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	13FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11971003	C4591001 1197 11971003	16-55	15OCT2020	107864	Placebo	15OCT2020/ Placebo	04NOV2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
11971005	C4591001 1197 11971005	16-55	15OCT2020	107866	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
11971007	C4591001 1197 11971007	16-55	15OCT2020	107868	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
11971014	C4591001 1197 11971014	16-55	16OCT2020	108617	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
11971015	C4591001 1197 11971015	16-55	16OCT2020	108620	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
11971017	C4591001 1197 11971017	16-55	16OCT2020	108622	Placebo	16OCT2020/ Placebo	04NOV2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
11971018	C4591001 1197 11971018	16-55	16OCT2020	108628	Placebo	16OCT2020/ Placebo	04NOV2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
11971019	C4591001 1197 11971019	16-55	16OCT2020	108645	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
11971020	C4591001 1197 11971020	16-55	16OCT2020	108641	Placebo	16OCT2020/ Placebo	04NOV2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	13FEB2021/ BNT162b2 (30 µg)
11971026	C4591001 1197 11971026	16-55	16OCT2020	108651	Placebo	16OCT2020/ Placebo	06NOV2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11971028	C4591001 1197 11971028	16-55	16OCT2020	108652	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
11971029	C4591001 1197 11971029	16-55	16OCT2020	108822	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
11971031	C4591001 1197 11971031	16-55	16OCT2020	108823	Placebo	16OCT2020/ Placebo	06NOV2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
11971035	C4591001 1197 11971035	16-55	16OCT2020	108827	Placebo	16OCT2020/ Placebo	06NOV2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
11971039	C4591001 1197 11971039	16-55	17OCT2020	108832	BNT162b2 (30 µg)	17OCT2020/ BNT162b2 (30 µg)	07NOV2020/ BNT162b2 (30 µg)		
11971040	C4591001 1197 11971040	16-55	17OCT2020	109387	Placebo	17OCT2020/ Placebo	04NOV2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
11971041	C4591001 1197 11971041	16-55	17OCT2020	109388	Placebo	17OCT2020/ Placebo	04NOV2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
11971042	C4591001 1197 11971042	16-55	17OCT2020	109389	BNT162b2 (30 µg)	17OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
11971045	C4591001 1197 11971045	16-55	17OCT2020	109390	BNT162b2 (30 µg)	17OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
11971053	C4591001 1197 11971053	16-55	17OCT2020	109519	BNT162b2 (30 µg)	17OCT2020/ BNT162b2 (30 µg)	07NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11971058	C4591001 1197 11971058	16-55	18OCT2020	109520	Placebo	18OCT2020/ Placebo	06NOV2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
11971059	C4591001 1197 11971059	16-55	18OCT2020	109525	BNT162b2 (30 µg)	18OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
11971060	C4591001 1197 11971060	16-55	18OCT2020	109526	Placebo	18OCT2020/ Placebo	06NOV2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
11971064	C4591001 1197 11971064	16-55	18OCT2020	109699	Placebo	18OCT2020/ Placebo	06NOV2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
11971068	C4591001 1197 11971068	16-55	18OCT2020	109702	BNT162b2 (30 µg)	18OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
11971069	C4591001 1197 11971069	16-55	18OCT2020	109703	Placebo	18OCT2020/ Placebo	07NOV2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
11971077	C4591001 1197 11971077	16-55	18OCT2020	109745	Placebo	18OCT2020/ Placebo	06NOV2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
11971078	C4591001 1197 11971078	16-55	18OCT2020	109750	BNT162b2 (30 µg)	18OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
11971079	C4591001 1197 11971079	16-55	18OCT2020	109751	BNT162b2 (30 µg)	18OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
11971088	C4591001 1197 11971088	16-55	19OCT2020	109754	Placebo	19OCT2020/ Placebo	07NOV2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11971092	C4591001 1197 11971092	16-55	19OCT2020	109879	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	07NOV2020/ BNT162b2 (30 µg)		
11971093	C4591001 1197 11971093	16-55	19OCT2020	109880	Placebo	19OCT2020/ Placebo	07NOV2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	13FEB2021/ BNT162b2 (30 µg)
11971094	C4591001 1197 11971094	16-55	19OCT2020	109882	Placebo	19OCT2020/ Placebo	07NOV2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
11971096	C4591001 1197 11971096	16-55	19OCT2020	109883	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	07NOV2020/ BNT162b2 (30 µg)		
12021007	C4591001 1202 12021007	16-55	28OCT2020	114296	Placebo	28OCT2020/ Placebo	17NOV2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12021009	C4591001 1202 12021009	16-55	28OCT2020	114299	Placebo	28OCT2020/ Placebo	17NOV2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12021010	C4591001 1202 12021010	16-55	28OCT2020	114300	BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
12021011	C4591001 1202 12021011	16-55	28OCT2020	114302	BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
12031001	C4591001 1203 12031001	16-55	16OCT2020	108632	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
12031004	C4591001 1203 12031004	16-55	16OCT2020	108634	Placebo	16OCT2020/ Placebo	06NOV2020/ Placebo	03MAR2021/ BNT162b2 (30 µg)	



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12031005	C4591001 1203 12031005	16-55	16OCT2020	108635	Placebo	16OCT2020/ Placebo	06NOV2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
12031008	C4591001 1203 12031008	16-55	16OCT2020	108636	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
12031010	C4591001 1203 12031010	16-55	19OCT2020	109770	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
12031015	C4591001 1203 12031015	16-55	19OCT2020	109771	Placebo	19OCT2020/ Placebo	09NOV2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12031020	C4591001 1203 12031020	16-55	20OCT2020	109773	Placebo	20OCT2020/ Placebo	10NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12031021	C4591001 1203 12031021	16-55	20OCT2020	109780	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		
12031026	C4591001 1203 12031026	16-55	20OCT2020	110623	Placebo	20OCT2020/ Placebo	10NOV2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
12031030	C4591001 1203 12031030	16-55	20OCT2020	110624	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		
12031031	C4591001 1203 12031031	16-55	20OCT2020	110625	Placebo	20OCT2020/ Placebo	10NOV2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12031032	C4591001 1203 12031032	16-55	21OCT2020	111260	Placebo	21OCT2020/ Placebo	11NOV2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12031033	C4591001 1203 12031033	16-55	21OCT2020	110632	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
12031034	C4591001 1203 12031034	16-55	21OCT2020	111261	Placebo	21OCT2020/ Placebo	11NOV2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12031037	C4591001 1203 12031037	16-55	21OCT2020	111265	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)			
12031041	C4591001 1203 12031041	16-55	21OCT2020	111268	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
12031042	C4591001 1203 12031042	16-55	21OCT2020	111281	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
12031044	C4591001 1203 12031044	16-55	21OCT2020	111290	Placebo	21OCT2020/ Placebo	11NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12031045	C4591001 1203 12031045	16-55	21OCT2020	111288	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
12031047	C4591001 1203 12031047	16-55	23OCT2020	111292	Placebo	23OCT2020/ Placebo	13NOV2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12031048	C4591001 1203 12031048	16-55	23OCT2020	112625	Placebo	23OCT2020/ Placebo	13NOV2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12031051	C4591001 1203 12031051	16-55	23OCT2020	112627	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12031053	C4591001 1203 12031053	16-55	23OCT2020	112629	Placebo	23OCT2020/ Placebo	13NOV2020/ Placebo		
12031056	C4591001 1203 12031056	16-55	23OCT2020	112631	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
12031057	C4591001 1203 12031057	16-55	23OCT2020	112673	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
12031058	C4591001 1203 12031058	16-55	23OCT2020	112676	Placebo	23OCT2020/ Placebo	13NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12031059	C4591001 1203 12031059	16-55	23OCT2020	112678	Placebo	23OCT2020/ Placebo	13NOV2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12031060	C4591001 1203 12031060	16-55	23OCT2020	112684	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
12031063	C4591001 1203 12031063	16-55	26OCT2020	113399	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
12031064	C4591001 1203 12031064	16-55	26OCT2020	113394	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
12031066	C4591001 1203 12031066	16-55	26OCT2020	113403	Placebo	26OCT2020/ Placebo	16NOV2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
12031067	C4591001 1203 12031067	16-55	26OCT2020	113404	Placebo	26OCT2020/ Placebo	16NOV2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12031069	C4591001 1203 12031069	16-55	26OCT2020	113432	Placebo	26OCT2020/ Placebo	16NOV2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
12041001	C4591001 1204 12041001	16-55	24AUG2020	63367	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12041004	C4591001 1204 12041004	16-55	24AUG2020	63371	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12041005	C4591001 1204 12041005	16-55	25AUG2020	63376	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12041006	C4591001 1204 12041006	16-55	25AUG2020	66325	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	15DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
12041008	C4591001 1204 12041008	16-55	25AUG2020	66320	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12041009	C4591001 1204 12041009	16-55	26AUG2020	66327	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12041010	C4591001 1204 12041010	16-55	26AUG2020	66328	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	06JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
12041011	C4591001 1204 12041011	16-55	27AUG2020	70205	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
12041012	C4591001 1204 12041012	16-55	28AUG2020	70209	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12041013	C4591001 1204 12041013	16-55	28AUG2020	70210	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12041015	C4591001 1204 12041015	16-55	28AUG2020	70215	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
12041017	C4591001 1204 12041017	16-55	08SEP2020	83388	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
12041018	C4591001 1204 12041018	16-55	08SEP2020	83383	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
12041019	C4591001 1204 12041019	16-55	31AUG2020	75944	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
12041020	C4591001 1204 12041020	16-55	31AUG2020	75946	Placebo	31AUG2020/ Placebo	02OCT2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
12041021	C4591001 1204 12041021	16-55	31AUG2020	75950	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
12041023	C4591001 1204 12041023	16-55	01SEP2020	75951	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
12041025	C4591001 1204 12041025	16-55	01SEP2020	77433	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
12041026	C4591001 1204 12041026	16-55	01SEP2020	77432	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12041027	C4591001 1204 12041027	16-55	02SEP2020	244912	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
12041029	C4591001 1204 12041029	16-55	02SEP2020	77434	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
12041030	C4591001 1204 12041030	16-55	02SEP2020	77435	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12041031	C4591001 1204 12041031	16-55	02SEP2020	78990	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
12041034	C4591001 1204 12041034	16-55	03SEP2020	78992	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12041038	C4591001 1204 12041038	16-55	04SEP2020	78993	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
12041039	C4591001 1204 12041039	16-55	04SEP2020	79000	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
12041040	C4591001 1204 12041040	16-55	04SEP2020	81931	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	28JAN2021/ BNT162b2 (30 µg)
12041041	C4591001 1204 12041041	16-55	04SEP2020	81932	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
12041043	C4591001 1204 12041043	16-55	04SEP2020	81934	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12041044	C4591001 1204 12041044	16-55	04SEP2020	81935	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
12041046	C4591001 1204 12041046	16-55	08SEP2020	83389	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
12041047	C4591001 1204 12041047	16-55	08SEP2020	83391	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12041048	C4591001 1204 12041048	16-55	08SEP2020	83533	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
12041049	C4591001 1204 12041049	16-55	08SEP2020	83530	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
12041051	C4591001 1204 12041051	16-55	08SEP2020	83536	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
12041052	C4591001 1204 12041052	16-55	08SEP2020	83534	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
12041055	C4591001 1204 12041055	16-55	08SEP2020	83909	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
12041058	C4591001 1204 12041058	16-55	08SEP2020	83913	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
12041059	C4591001 1204 12041059	16-55	08SEP2020	84497	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12041060	C4591001 1204 12041060	16-55	08SEP2020	83914	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo		
12041061	C4591001 1204 12041061	16-55	08SEP2020	83915	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12041062	C4591001 1204 12041062	16-55	08SEP2020	84499	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
12041063	C4591001 1204 12041063	16-55	09SEP2020	84500	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
12041064	C4591001 1204 12041064	16-55	09SEP2020	84504	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
12041065	C4591001 1204 12041065	16-55	09SEP2020	84993	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
12041066	C4591001 1204 12041066	16-55	09SEP2020	84998	Placebo	09SEP2020/ Placebo	01OCT2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	04JAN2021/ BNT162b2 (30 µg)
12041067	C4591001 1204 12041067	16-55	09SEP2020	84995	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
12041070	C4591001 1204 12041070	16-55	09SEP2020	84999	Placebo	09SEP2020/ Placebo	14OCT2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
12041071	C4591001 1204 12041071	16-55	09SEP2020	85421	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12041072	C4591001 1204 12041072	16-55	09SEP2020	85426	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
12041073	C4591001 1204 12041073	16-55	09SEP2020	85427	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
12041074	C4591001 1204 12041074	16-55	09SEP2020	85432	Placebo	09SEP2020/ Placebo	29SEP2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
12041075	C4591001 1204 12041075	16-55	09SEP2020	85733	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
12041076	C4591001 1204 12041076	16-55	09SEP2020	85735	Placebo	09SEP2020/ Placebo	29SEP2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12041077	C4591001 1204 12041077	16-55	09SEP2020	85738	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
12041078	C4591001 1204 12041078	16-55	09SEP2020	85740	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
12041079	C4591001 1204 12041079	16-55	10SEP2020	86278	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
12041080	C4591001 1204 12041080	16-55	10SEP2020	86277	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
12041081	C4591001 1204 12041081	16-55	10SEP2020	86280	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12041082	C4591001 1204 12041082	16-55	10SEP2020	86283	Placebo	10SEP2020/ Placebo	02OCT2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
12041084	C4591001 1204 12041084	16-55	10SEP2020	87138	Placebo	10SEP2020/ Placebo	02OCT2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12041086	C4591001 1204 12041086	16-55	10SEP2020	87139	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
12041088	C4591001 1204 12041088	16-55	10SEP2020	87146	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
12041089	C4591001 1204 12041089	16-55	11SEP2020	87148	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
12041090	C4591001 1204 12041090	16-55	11SEP2020	87881	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
12041091	C4591001 1204 12041091	16-55	11SEP2020	87885	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12041092	C4591001 1204 12041092	16-55	11SEP2020	87886	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
12041093	C4591001 1204 12041093	16-55	11SEP2020	87892	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
12041094	C4591001 1204 12041094	16-55	11SEP2020	88362	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12041095	C4591001 1204 12041095	16-55	11SEP2020	88366	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
12041096	C4591001 1204 12041096	16-55	11SEP2020	88368	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
12041097	C4591001 1204 12041097	16-55	11SEP2020	88367	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
12041098	C4591001 1204 12041098	16-55	11SEP2020	88614	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
12041099	C4591001 1204 12041099	16-55	11SEP2020	88617	Placebo	11SEP2020/ Placebo	01OCT2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12041100	C4591001 1204 12041100	16-55	14SEP2020	88620	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
12041101	C4591001 1204 12041101	16-55	14SEP2020	88623	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
12041102	C4591001 1204 12041102	16-55	14SEP2020	90006	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo	15DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
12041103	C4591001 1204 12041103	16-55	14SEP2020	90008	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
12041105	C4591001 1204 12041105	16-55	15SEP2020	90010	Placebo	15SEP2020/ Placebo	06OCT2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12041107	C4591001 1204 12041107	16-55	16SEP2020	90015	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
12041108	C4591001 1204 12041108	16-55	16SEP2020	91025	Placebo	16SEP2020/ Placebo	07OCT2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	27JAN2021/ BNT162b2 (30 µg)
12041110	C4591001 1204 12041110	16-55	16SEP2020	91029	Placebo	16SEP2020/ Placebo	07OCT2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
12041111	C4591001 1204 12041111	16-55	16SEP2020	91033	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
12041112	C4591001 1204 12041112	16-55	16SEP2020	91036	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
12041113	C4591001 1204 12041113	16-55	17SEP2020	92179	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
12041116	C4591001 1204 12041116	16-55	17SEP2020	92180	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	20JAN2021/ BNT162b2 (30 µg)
12041118	C4591001 1204 12041118	16-55	17SEP2020	92181	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
12041120	C4591001 1204 12041120	16-55	18SEP2020	92185	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
12041121	C4591001 1204 12041121	16-55	18SEP2020	93476	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12041122	C4591001 1204 12041122	16-55	18SEP2020	93477	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
12041123	C4591001 1204 12041123	16-55	18SEP2020	93479	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
12041124	C4591001 1204 12041124	16-55	18SEP2020	93481	Placebo	18SEP2020/ Placebo	08OCT2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12041125	C4591001 1204 12041125	16-55	18SEP2020	93750	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
12041127	C4591001 1204 12041127	16-55	18SEP2020	93752	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
12041128	C4591001 1204 12041128	16-55	18SEP2020	93754	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
12041129	C4591001 1204 12041129	16-55	18SEP2020	93760	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)
12041131	C4591001 1204 12041131	16-55	18SEP2020	94062	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12041132	C4591001 1204 12041132	16-55	18SEP2020	94065	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
12041133	C4591001 1204 12041133	16-55	21SEP2020	94067	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12041134	C4591001 1204 12041134	16-55	21SEP2020	94070	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
12041135	C4591001 1204 12041135	16-55	21SEP2020	95009	Placebo	21SEP2020/ Placebo	14OCT2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
12041136	C4591001 1204 12041136	16-55	21SEP2020	95013	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
12041137	C4591001 1204 12041137	16-55	21SEP2020	95014	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
12041138	C4591001 1204 12041138	16-55	21SEP2020	95019	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
12041139	C4591001 1204 12041139	16-55	22SEP2020	96127	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
12041140	C4591001 1204 12041140	16-55	22SEP2020	96129	Placebo	22SEP2020/ Placebo	12OCT2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
12041141	C4591001 1204 12041141	16-55	22SEP2020	96135	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
12041143	C4591001 1204 12041143†	16-55	22SEP2020	96136	Placebo	22SEP2020/ Placebo	12OCT2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12041144	C4591001 1204 12041144	16-55	22SEP2020	96583	Placebo	22SEP2020/ Placebo	14OCT2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12041145	C4591001 1204 12041145	16-55	23SEP2020	96586	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
12041147	C4591001 1204 12041147	16-55	23SEP2020	96588	Placebo	23SEP2020/ Placebo	13OCT2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12041149	C4591001 1204 12041149†	16-55	23SEP2020	96589	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
12041150	C4591001 1204 12041150	16-55	23SEP2020	97793	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
12041152	C4591001 1204 12041152†	16-55	23SEP2020	97796	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
12041153	C4591001 1204 12041153	16-55	23SEP2020	97797	Placebo	23SEP2020/ Placebo	13OCT2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12041154	C4591001 1204 12041154†	16-55	23SEP2020	97798	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
12041155	C4591001 1204 12041155	16-55	23SEP2020	98298	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
12041157	C4591001 1204 12041157	16-55	24SEP2020	98299	Placebo	24SEP2020/ Placebo	16OCT2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
12041161	C4591001 1204 12041161	16-55	24SEP2020	98301	Placebo	24SEP2020/ Placebo	15OCT2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	15JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12041163	C4591001 1204 12041163†	16-55	24SEP2020	98303	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
12041164	C4591001 1204 12041164†	16-55	24SEP2020	98959	Placebo	24SEP2020/ Placebo	14OCT2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
12041165	C4591001 1204 12041165†	16-55	20OCT2020	110894	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
12041167	C4591001 1204 12041167	16-55	25SEP2020	98963	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
12041168	C4591001 1204 12041168	16-55	25SEP2020	98966	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12041170	C4591001 1204 12041170	16-55	25SEP2020	98967	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
12041174	C4591001 1204 12041174	16-55	28SEP2020	101503	BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)		
12041176	C4591001 1204 12041176†	16-55	29SEP2020	101508	BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)		
12041177	C4591001 1204 12041177	16-55	29SEP2020	101510	Placebo	29SEP2020/ Placebo	20OCT2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12041178	C4591001 1204 12041178	16-55	29SEP2020	101983	BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12041179	C4591001 1204 12041179	16-55	29SEP2020	101512	Placebo	29SEP2020/ Placebo	19OCT2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
12041181	C4591001 1204 12041181	16-55	01OCT2020	101984	Placebo	01OCT2020/ Placebo	22OCT2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
12041182	C4591001 1204 12041182†	16-55	09OCT2020	105496	Placebo	09OCT2020/ Placebo	29OCT2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
12041184	C4591001 1204 12041184	16-55	02OCT2020	101986	BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)		
12041185	C4591001 1204 12041185	16-55	02OCT2020	101989	Placebo	02OCT2020/ Placebo	23OCT2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
12041186	C4591001 1204 12041186	16-55	02OCT2020	103338	BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)		
12041187	C4591001 1204 12041187	16-55	05OCT2020	103342	Placebo	05OCT2020/ Placebo	26OCT2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12041188	C4591001 1204 12041188†	16-55	05OCT2020	103345	BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
12041189	C4591001 1204 12041189	16-55	05OCT2020	103347	Placebo	05OCT2020/ Placebo	26OCT2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
12041190	C4591001 1204 12041190	16-55	06OCT2020	104288	Placebo	06OCT2020/ Placebo	27OCT2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12041191	C4591001 1204 12041191	16-55	06OCT2020	104292	Placebo	06OCT2020/ Placebo	26OCT2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12041192	C4591001 1204 12041192	16-55	06OCT2020	104294	BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
12041193	C4591001 1204 12041193†	16-55	07OCT2020	104296	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
12041194	C4591001 1204 12041194†	16-55	07OCT2020	104911	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
12041195	C4591001 1204 12041195	16-55	08OCT2020	104913	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
12041197	C4591001 1204 12041197†	16-55	08OCT2020	104915	Placebo	08OCT2020/ Placebo			
12041199	C4591001 1204 12041199	16-55	08OCT2020	104916	Placebo	08OCT2020/ Placebo	30OCT2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
12041202	C4591001 1204 12041202	16-55	08OCT2020	105487	Placebo	08OCT2020/ Placebo	27OCT2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
12041203	C4591001 1204 12041203	16-55	08OCT2020	105489	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)		
12041204	C4591001 1204 12041204	16-55	09OCT2020	105494	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12041205	C4591001 1204 12041205	16-55	09OCT2020	105941	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)		
12041206	C4591001 1204 12041206	16-55	09OCT2020	105945	Placebo	09OCT2020/ Placebo	02NOV2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
12041208	C4591001 1204 12041208	16-55	09OCT2020	105946	Placebo	09OCT2020/ Placebo	30OCT2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	04JAN2021/ BNT162b2 (30 µg)
12041209	C4591001 1204 12041209	16-55	09OCT2020	105950	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)		
12041210	C4591001 1204 12041210†	16-55	09OCT2020	106134	Placebo	09OCT2020/ Placebo	28OCT2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
12041214	C4591001 1204 12041214	16-55	12OCT2020	106142	BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		
12041215	C4591001 1204 12041215	16-55	12OCT2020	106135	BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		
12041216	C4591001 1204 12041216†	16-55	12OCT2020	106625	BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
12041217	C4591001 1204 12041217	16-55	12OCT2020	106143	Placebo	12OCT2020/ Placebo	03NOV2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
12041218	C4591001 1204 12041218	16-55	12OCT2020	106628	Placebo	12OCT2020/ Placebo	02NOV2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12041220	C4591001 1204 12041220	16-55	12OCT2020	106631	BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		
12041221	C4591001 1204 12041221	16-55	12OCT2020	106634	Placebo	12OCT2020/ Placebo	02NOV2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12041222	C4591001 1204 12041222	16-55	13OCT2020	106880	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		
12041227	C4591001 1204 12041227	16-55	13OCT2020	106881	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
12041228	C4591001 1204 12041228	16-55	13OCT2020	106885	Placebo	13OCT2020/ Placebo	03NOV2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
12041233	C4591001 1204 12041233†	16-55	14OCT2020	106886	Placebo	14OCT2020/ Placebo	06NOV2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
12041234	C4591001 1204 12041234	16-55	14OCT2020	107705	BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
12041235	C4591001 1204 12041235	16-55	14OCT2020	107706	Placebo	14OCT2020/ Placebo	03NOV2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12041236	C4591001 1204 12041236	16-55	15OCT2020	107708	Placebo	15OCT2020/ Placebo	05NOV2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
12041237	C4591001 1204 12041237	16-55	15OCT2020	108041	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12041238	C4591001 1204 12041238	16-55	15OCT2020	108045	Placebo	15OCT2020/ Placebo	05NOV2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12041239	C4591001 1204 12041239	16-55	15OCT2020	107709	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
12041240	C4591001 1204 12041240	16-55	15OCT2020	108046	Placebo	15OCT2020/ Placebo	06NOV2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12041241	C4591001 1204 12041241	16-55	15OCT2020	108173	Placebo	15OCT2020/ Placebo	06NOV2020/ Placebo	03MAR2021/ BNT162b2 (30 µg)	
12041242	C4591001 1204 12041242	16-55	15OCT2020	108179	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
12041243	C4591001 1204 12041243	16-55	15OCT2020	108051	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
12041246	C4591001 1204 12041246	16-55	15OCT2020	108180	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
12041247	C4591001 1204 12041247	16-55	15OCT2020	108182	Placebo	15OCT2020/ Placebo	06NOV2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
12041248	C4591001 1204 12041248	16-55	15OCT2020	108463	Placebo	15OCT2020/ Placebo	05NOV2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
12041252	C4591001 1204 12041252	16-55	16OCT2020	108471	Placebo	16OCT2020/ Placebo	05NOV2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12041253	C4591001 1204 12041253	16-55	16OCT2020	108467	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
12041255	C4591001 1204 12041255	16-55	16OCT2020	108472	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
12041256	C4591001 1204 12041256	16-55	16OCT2020	109121	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
12041257	C4591001 1204 12041257	16-55	16OCT2020	109122	Placebo	16OCT2020/ Placebo	06NOV2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12041258	C4591001 1204 12041258	16-55	16OCT2020	109127	Placebo	16OCT2020/ Placebo	06NOV2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12041259	C4591001 1204 12041259	16-55	16OCT2020	109131	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
12041260	C4591001 1204 12041260	16-55	19OCT2020	110010	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
12041261	C4591001 1204 12041261	16-55	19OCT2020	110009	Placebo	19OCT2020/ Placebo	09NOV2020/ Placebo		
12041262	C4591001 1204 12041262	16-55	19OCT2020	110249	Placebo	19OCT2020/ Placebo	09NOV2020/ Placebo	06JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
12041263	C4591001 1204 12041263	16-55	19OCT2020	110018	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12041264	C4591001 1204 12041264	16-55	19OCT2020	110016	Placebo	19OCT2020/ Placebo	09NOV2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
12041265	C4591001 1204 12041265	16-55	19OCT2020	110250	Placebo	19OCT2020/ Placebo	09NOV2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
12041267	C4591001 1204 12041267	16-55	19OCT2020	110256	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
12041268	C4591001 1204 12041268	16-55	20OCT2020	110258	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		
12041269	C4591001 1204 12041269	16-55	20OCT2020	110887	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		
12041270	C4591001 1204 12041270	16-55	20OCT2020	110889	Placebo	20OCT2020/ Placebo	10NOV2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
12041271	C4591001 1204 12041271	16-55	20OCT2020	110891	Placebo	20OCT2020/ Placebo	10NOV2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
12041272	C4591001 1204 12041272	16-55	21OCT2020	111377	Placebo	21OCT2020/ Placebo	11NOV2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
12041273	C4591001 1204 12041273	16-55	21OCT2020	111378	Placebo	21OCT2020/ Placebo	11NOV2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
12041274	C4591001 1204 12041274	16-55	21OCT2020	111386	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12041275	C4591001 1204 12041275	16-55	21OCT2020	111388	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
12041276	C4591001 1204 12041276	16-55	21OCT2020	111617	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
12041279	C4591001 1204 12041279	16-55	21OCT2020	111625	Placebo	21OCT2020/ Placebo	12NOV2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
12041280	C4591001 1204 12041280	16-55	21OCT2020	111624	Placebo	21OCT2020/ Placebo	13NOV2020/ Placebo		
12041281	C4591001 1204 12041281	16-55	21OCT2020	111627	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
12041283	C4591001 1204 12041283	16-55	23OCT2020	112793	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
12041284	C4591001 1204 12041284	16-55	23OCT2020	112803	Placebo	23OCT2020/ Placebo	11NOV2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
12041285	C4591001 1204 12041285	16-55	23OCT2020	112796	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	18NOV2020/ BNT162b2 (30 µg)		
12041286	C4591001 1204 12041286	16-55	23OCT2020	112804	Placebo	23OCT2020/ Placebo	13NOV2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
12041287	C4591001 1204 12041287	16-55	23OCT2020	112901	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12041288	C4591001 1204 12041288	16-55	23OCT2020	112904	Placebo	23OCT2020/ Placebo	11NOV2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
12041290	C4591001 1204 12041290	16-55	23OCT2020	112911	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
12041292	C4591001 1204 12041292	16-55	23OCT2020	112912	Placebo	23OCT2020/ Placebo	11NOV2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
12041293	C4591001 1204 12041293	16-55	23OCT2020	113195	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
12041294	C4591001 1204 12041294	16-55	23OCT2020	113192	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
12051003	C4591001 1205 12051003	16-55	22OCT2020	111967	Placebo	22OCT2020/ Placebo	13NOV2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
12051004	C4591001 1205 12051004	16-55	22OCT2020	111969	Placebo	22OCT2020/ Placebo	13NOV2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
12051010	C4591001 1205 12051010	16-55	23OCT2020	112687	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
12051011	C4591001 1205 12051011	16-55	27OCT2020	112689	Placebo	27OCT2020/ Placebo	16NOV2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
12051012	C4591001 1205 12051012	16-55	27OCT2020	112690	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12051013	C4591001 1205 12051013	16-55	27OCT2020	112693	Placebo	27OCT2020/ Placebo	16NOV2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
12051014	C4591001 1205 12051014	16-55	27OCT2020	113910	Placebo	27OCT2020/ Placebo	17NOV2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
12051015	C4591001 1205 12051015	16-55	27OCT2020	113912	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
12051017	C4591001 1205 12051017	16-55	27OCT2020	113915	Placebo	27OCT2020/ Placebo	17NOV2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12051021	C4591001 1205 12051021	16-55	28OCT2020	113918	BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
12051022	C4591001 1205 12051022	16-55	30OCT2020	114906	Placebo	30OCT2020/ Placebo	20NOV2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
12051023	C4591001 1205 12051023	16-55	30OCT2020	114913	Placebo	30OCT2020/ Placebo	19NOV2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
12051024	C4591001 1205 12051024	16-55	30OCT2020	114915	BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)	20NOV2020/ BNT162b2 (30 µg)		
12051025	C4591001 1205 12051025	16-55	30OCT2020	114916	BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)		
12051026	C4591001 1205 12051026	16-55	30OCT2020	114954	Placebo	30OCT2020/ Placebo	19NOV2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12051027	C4591001 1205 12051027	16-55	30OCT2020	114955	BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)		
12051028	C4591001 1205 12051028	16-55	30OCT2020	114959	BNT162b2 (30 µg)				
12051029	C4591001 1205 12051029	16-55	02NOV2020	114961	Placebo	02NOV2020/ Placebo	23NOV2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
12051030	C4591001 1205 12051030	16-55	02NOV2020	115243	Placebo	02NOV2020/ Placebo	23NOV2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
12051032	C4591001 1205 12051032	16-55	03NOV2020	115247	BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)	24NOV2020/ BNT162b2 (30 µg)		
12051033	C4591001 1205 12051033	16-55	03NOV2020	115248	Placebo	03NOV2020/ Placebo	24NOV2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)
12051034	C4591001 1205 12051034	16-55	03NOV2020	115252	BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)	24NOV2020/ BNT162b2 (30 µg)		
12051035	C4591001 1205 12051035	16-55	03NOV2020	115362	BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)	24NOV2020/ BNT162b2 (30 µg)		
12051036	C4591001 1205 12051036	16-55	03NOV2020	115364	BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)	24NOV2020/ BNT162b2 (30 µg)		
12051041	C4591001 1205 12051041	16-55	04NOV2020	115371	Placebo	04NOV2020/ Placebo	24NOV2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	28JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12051042	C4591001 1205 12051042	16-55	04NOV2020	115372	Placebo	04NOV2020/ Placebo	25NOV2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12051043	C4591001 1205 12051043	16-55	04NOV2020	115541	BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)	25NOV2020/ BNT162b2 (30 µg)		
12051044	C4591001 1205 12051044	16-55	04NOV2020	115543	BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)	25NOV2020/ BNT162b2 (30 µg)		
12051047	C4591001 1205 12051047	16-55	04NOV2020	115550	Placebo	04NOV2020/ Placebo	26NOV2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)
12051048	C4591001 1205 12051048	16-55	05NOV2020	115552	Placebo	05NOV2020/ Placebo	26NOV2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12051049	C4591001 1205 12051049	16-55	05NOV2020	115723	Placebo	05NOV2020/ Placebo	26NOV2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)
12051050	C4591001 1205 12051050	16-55	05NOV2020	115724	Placebo	05NOV2020/ Placebo	26NOV2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
12051051	C4591001 1205 12051051	16-55	05NOV2020	115726	BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)	26NOV2020/ BNT162b2 (30 µg)		
12051052	C4591001 1205 12051052	16-55	05NOV2020	115730	BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)	26NOV2020/ BNT162b2 (30 µg)		
12051054	C4591001 1205 12051054	16-55	05NOV2020	115807	BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)	26NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12051061	C4591001 1205 12051061	16-55	06NOV2020	115811	Placebo	06NOV2020/ Placebo	27NOV2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
12051062	C4591001 1205 12051062	16-55	06NOV2020	115814	Placebo	06NOV2020/ Placebo	27NOV2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
12051063	C4591001 1205 12051063	16-55	09NOV2020	115816	BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)	30NOV2020/ BNT162b2 (30 µg)		
12051064	C4591001 1205 12051064	16-55	09NOV2020	115975	BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)	30NOV2020/ BNT162b2 (30 µg)		
12051065	C4591001 1205 12051065	16-55	09NOV2020	115978	Placebo	09NOV2020/ Placebo	30NOV2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
12051066	C4591001 1205 12051066	16-55	09NOV2020	115982	Placebo	09NOV2020/ Placebo	30NOV2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
12051067	C4591001 1205 12051067	16-55	09NOV2020	115984	BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)	01DEC2020/ BNT162b2 (30 µg)		
12051068	C4591001 1205 12051068	16-55	09NOV2020	115997	Placebo	09NOV2020/ Placebo	30NOV2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)
12051069	C4591001 1205 12051069	16-55	09NOV2020	116004	BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)	30NOV2020/ BNT162b2 (30 µg)		
12051071	C4591001 1205 12051071	16-55	10NOV2020	116005	BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)	01DEC2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12051073	C4591001 1205 12051073	16-55	10NOV2020	116008	Placebo	10NOV2020/ Placebo	01DEC2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
12051074	C4591001 1205 12051074	16-55	10NOV2020	116058	Placebo	10NOV2020/ Placebo	02DEC2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
12051075	C4591001 1205 12051075	16-55	10NOV2020	116062	BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)	01DEC2020/ BNT162b2 (30 µg)		
12051077	C4591001 1205 12051077	16-55	10NOV2020	116063	BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)	02DEC2020/ BNT162b2 (30 µg)		
12051078	C4591001 1205 12051078	16-55	10NOV2020	116064	Placebo	10NOV2020/ Placebo		28JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12051079	C4591001 1205 12051079	16-55	11NOV2020	116081	BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)	02DEC2020/ BNT162b2 (30 µg)		
12051080	C4591001 1205 12051080	16-55	11NOV2020	116084	BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)	02DEC2020/ BNT162b2 (30 µg)		
12071002	C4591001 1207 12071002	16-55	22OCT2020	111929	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
12071003	C4591001 1207 12071003	16-55	23OCT2020	111934	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
12071005	C4591001 1207 12071005	16-55	23OCT2020	111935	Placebo	23OCT2020/ Placebo	13NOV2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12071006	C4591001 1207 12071006	16-55	23OCT2020	111938	Placebo	23OCT2020/ Placebo	18NOV2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
12071007	C4591001 1207 12071007	16-55	26OCT2020	113345	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
12071008	C4591001 1207 12071008	16-55	26OCT2020	113405	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
12071009	C4591001 1207 12071009	16-55	26OCT2020	113356	Placebo	26OCT2020/ Placebo	16NOV2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12071010	C4591001 1207 12071010	16-55	26OCT2020	113352	Placebo	26OCT2020/ Placebo	16NOV2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
12071011	C4591001 1207 12071011	16-55	26OCT2020	113351	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
12071012	C4591001 1207 12071012	16-55	26OCT2020	113408	Placebo	26OCT2020/ Placebo	16NOV2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
12071013	C4591001 1207 12071013	16-55	26OCT2020	113415	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
12071014	C4591001 1207 12071014	16-55	27OCT2020	113869	Placebo	27OCT2020/ Placebo	17NOV2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
12071016	C4591001 1207 12071016	16-55	27OCT2020	113867	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12071018	C4591001 1207 12071018	16-55	27OCT2020	113861	Placebo	27OCT2020/ Placebo	17NOV2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
12071021	C4591001 1207 12071021	16-55	27OCT2020	113416	Placebo	27OCT2020/ Placebo	17NOV2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	27JAN2021/ BNT162b2 (30 µg)
12071023	C4591001 1207 12071023	16-55	28OCT2020	114282	BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)	20NOV2020/ BNT162b2 (30 µg)		
12071024	C4591001 1207 12071024	16-55	28OCT2020	114287	BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)			
12071025	C4591001 1207 12071025	16-55	30OCT2020	114290	Placebo	30OCT2020/ Placebo	18NOV2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
12071026	C4591001 1207 12071026	16-55	30OCT2020	114292	Placebo	30OCT2020/ Placebo	18NOV2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12071027	C4591001 1207 12071027	16-55	30OCT2020	114882	BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)	18NOV2020/ BNT162b2 (30 µg)		
12071028	C4591001 1207 12071028	16-55	30OCT2020	114883	Placebo	30OCT2020/ Placebo	18NOV2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
12071032	C4591001 1207 12071032	16-55	02NOV2020	114884	Placebo	02NOV2020/ Placebo	23NOV2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)
12071033	C4591001 1207 12071033	16-55	02NOV2020	115182	Placebo	02NOV2020/ Placebo	23NOV2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	27JAN2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12071036	C4591001 1207 12071036	16-55	02NOV2020	115181	BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)	23NOV2020/ BNT162b2 (30 µg)		
12071037	C4591001 1207 12071037	16-55	02NOV2020	114892	BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)	23NOV2020/ BNT162b2 (30 µg)		
12071038	C4591001 1207 12071038	16-55	02NOV2020	115186	Placebo	02NOV2020/ Placebo	23NOV2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12071039	C4591001 1207 12071039	16-55	03NOV2020	115354	BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)	24NOV2020/ BNT162b2 (30 µg)		
12071040	C4591001 1207 12071040	16-55	03NOV2020	115358	BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)	24NOV2020/ BNT162b2 (30 µg)		
12071041	C4591001 1207 12071041	16-55	03NOV2020	115188	BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)	24NOV2020/ BNT162b2 (30 µg)		
12071042	C4591001 1207 12071042	16-55	03NOV2020	115350	Placebo	03NOV2020/ Placebo	24NOV2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12071044	C4591001 1207 12071044	16-55	03NOV2020	115359	Placebo	03NOV2020/ Placebo	24NOV2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
12071045	C4591001 1207 12071045	16-55	03NOV2020	115387	Placebo	03NOV2020/ Placebo	24NOV2020/ Placebo		
12071046	C4591001 1207 12071046	16-55	03NOV2020	115391	BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)	24NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12071047	C4591001 1207 12071047	16-55	04NOV2020	115393	Placebo	04NOV2020/ Placebo	25NOV2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	28JAN2021/ BNT162b2 (30 µg)
12071048	C4591001 1207 12071048	16-55	04NOV2020	115490	Placebo	04NOV2020/ Placebo	25NOV2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
12071049	C4591001 1207 12071049	16-55	04NOV2020	115396	BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)	25NOV2020/ BNT162b2 (30 µg)		
12071050	C4591001 1207 12071050	16-55	04NOV2020	115482	BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)	25NOV2020/ BNT162b2 (30 µg)		
12071051	C4591001 1207 12071051	16-55	04NOV2020	115484	Placebo	04NOV2020/ Placebo	25NOV2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
12071052	C4591001 1207 12071052	16-55	04NOV2020	115487	BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)	25NOV2020/ BNT162b2 (30 µg)		
12071053	C4591001 1207 12071053	16-55	04NOV2020	115510	Placebo	04NOV2020/ Placebo	24NOV2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
12071054	C4591001 1207 12071054	16-55	04NOV2020	115511	Placebo	04NOV2020/ Placebo	25NOV2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
12071057	C4591001 1207 12071057	16-55	05NOV2020	115512	BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)	26NOV2020/ BNT162b2 (30 µg)		
12071058	C4591001 1207 12071058	16-55	05NOV2020	115514	BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)	26NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12071059	C4591001 1207 12071059	16-55	05NOV2020	115709	Placebo	05NOV2020/ Placebo	26NOV2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12071060	C4591001 1207 12071060	16-55	05NOV2020	115711	BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)	27NOV2020/ BNT162b2 (30 µg)		
12071061	C4591001 1207 12071061	16-55	06NOV2020	115868	Placebo	06NOV2020/ Placebo	27NOV2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12071062	C4591001 1207 12071062	16-55	06NOV2020	115719	BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)	27NOV2020/ BNT162b2 (30 µg)		
12071064	C4591001 1207 12071064	16-55	06NOV2020	115869	BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)	26NOV2020/ BNT162b2 (30 µg)		
12071065	C4591001 1207 12071065	16-55	06NOV2020	115716	Placebo	06NOV2020/ Placebo	27NOV2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
12071066	C4591001 1207 12071066	16-55	06NOV2020	115871	BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)	26NOV2020/ BNT162b2 (30 µg)		
12071067	C4591001 1207 12071067	16-55	06NOV2020	115873	Placebo	06NOV2020/ Placebo	26NOV2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
12081001	C4591001 1208 12081001	16-55	22OCT2020	111894	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
12081002	C4591001 1208 12081002	16-55	22OCT2020	111895	Placebo	22OCT2020/ Placebo	13NOV2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12081003	C4591001 1208 12081003	16-55	23OCT2020	111902	Placebo	23OCT2020/ Placebo	13NOV2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
12081004	C4591001 1208 12081004	16-55	23OCT2020	111904	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
12081005	C4591001 1208 12081005	16-55	26OCT2020	113323	Placebo	26OCT2020/ Placebo	18NOV2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
12081007	C4591001 1208 12081007	16-55	26OCT2020	113326	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	18NOV2020/ BNT162b2 (30 µg)		
12081008	C4591001 1208 12081008	16-55	26OCT2020	113327	Placebo	26OCT2020/ Placebo	16NOV2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	27JAN2021/ BNT162b2 (30 µg)
12081009	C4591001 1208 12081009	16-55	26OCT2020	113330	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
12081010	C4591001 1208 12081010	16-55	27OCT2020	113827	Placebo	27OCT2020/ Placebo	17NOV2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	27JAN2021/ BNT162b2 (30 µg)
12081011	C4591001 1208 12081011	16-55	27OCT2020	113829	Placebo	27OCT2020/ Placebo	18NOV2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12081012	C4591001 1208 12081012	16-55	27OCT2020	113835	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
12081013	C4591001 1208 12081013	16-55	27OCT2020	113836	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12081016	C4591001 1208 12081016	16-55	30OCT2020	114893	Placebo	30OCT2020/ Placebo	20NOV2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
12081017	C4591001 1208 12081017	16-55	30OCT2020	114897	BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)	20NOV2020/ BNT162b2 (30 µg)		
12081018	C4591001 1208 12081018	16-55	30OCT2020	114902	BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)			
12081019	C4591001 1208 12081019	16-55	30OCT2020	114904	Placebo	30OCT2020/ Placebo	20NOV2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)
12081020	C4591001 1208 12081020	16-55	02NOV2020	115219	Placebo	02NOV2020/ Placebo	23NOV2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
12081021	C4591001 1208 12081021	16-55	02NOV2020	115221	Placebo	02NOV2020/ Placebo	23NOV2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
12081022	C4591001 1208 12081022	16-55	02NOV2020	115222	BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)	25NOV2020/ BNT162b2 (30 µg)		
12081023	C4591001 1208 12081023	16-55	02NOV2020	115223	BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)	23NOV2020/ BNT162b2 (30 µg)		
12081024	C4591001 1208 12081024	16-55	02NOV2020	115253	BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)	23NOV2020/ BNT162b2 (30 µg)		
12081025	C4591001 1208 12081025	16-55	03NOV2020	115260	Placebo	03NOV2020/ Placebo	24NOV2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12081026	C4591001 1208 12081026	16-55	03NOV2020	115262	BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)	26NOV2020/ BNT162b2 (30 µg)		
12081027	C4591001 1208 12081027	16-55	03NOV2020	115263	Placebo	03NOV2020/ Placebo	24NOV2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
12081028	C4591001 1208 12081028	16-55	03NOV2020	115435	BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)	26NOV2020/ BNT162b2 (30 µg)		
12081029	C4591001 1208 12081029	16-55	03NOV2020	115441	BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)	25NOV2020/ BNT162b2 (30 µg)		
12081030	C4591001 1208 12081030	16-55	04NOV2020	115442	Placebo	04NOV2020/ Placebo	24NOV2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	27JAN2021/ BNT162b2 (30 µg)
12081031	C4591001 1208 12081031	16-55	04NOV2020	115444	Placebo	04NOV2020/ Placebo	24NOV2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	27JAN2021/ BNT162b2 (30 µg)
12081032	C4591001 1208 12081032	16-55	04NOV2020	115519	Placebo	04NOV2020/ Placebo	24NOV2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12081033	C4591001 1208 12081033	16-55	04NOV2020	115522	Placebo	04NOV2020/ Placebo	26NOV2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12081034	C4591001 1208 12081034	16-55	04NOV2020	115523	BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)	26NOV2020/ BNT162b2 (30 µg)		
12081035	C4591001 1208 12081035	16-55	05NOV2020	115528	BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)	26NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12081037	C4591001 1208 12081037	16-55	05NOV2020	115769	Placebo	05NOV2020/ Placebo	24NOV2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
12081038	C4591001 1208 12081038	16-55	05NOV2020	115774	Placebo	05NOV2020/ Placebo	25NOV2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12081039	C4591001 1208 12081039	16-55	05NOV2020	115776	BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)	25NOV2020/ BNT162b2 (30 µg)		
12081040	C4591001 1208 12081040	16-55	06NOV2020	115778	BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)	27NOV2020/ BNT162b2 (30 µg)		
12081042	C4591001 1208 12081042	16-55	06NOV2020	115895	Placebo	06NOV2020/ Placebo	27NOV2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12081043	C4591001 1208 12081043	16-55	06NOV2020	115896	Placebo	06NOV2020/ Placebo	26NOV2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)
12081044	C4591001 1208 12081044	16-55	06NOV2020	115897	BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)	27NOV2020/ BNT162b2 (30 µg)		
12081045	C4591001 1208 12081045	16-55	06NOV2020	115899	BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)	27NOV2020/ BNT162b2 (30 µg)		
12081046	C4591001 1208 12081046	16-55	06NOV2020	115915	BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)	27NOV2020/ BNT162b2 (30 µg)		
12081047	C4591001 1208 12081047	16-55	06NOV2020	115916	BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)	27NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12081048	C4591001 1208 12081048	16-55	09NOV2020	115917	Placebo	09NOV2020/ Placebo	02DEC2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12081049	C4591001 1208 12081049	16-55	09NOV2020	115918	Placebo	09NOV2020/ Placebo	30NOV2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12081050	C4591001 1208 12081050	16-55	10NOV2020	116033	BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)	01DEC2020/ BNT162b2 (30 µg)		
12081051	C4591001 1208 12081051	16-55	10NOV2020	116034	BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)	01DEC2020/ BNT162b2 (30 µg)		
12081052	C4591001 1208 12081052	16-55	10NOV2020	116040	Placebo	10NOV2020/ Placebo	01DEC2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
12081053	C4591001 1208 12081053	16-55	10NOV2020	116043	Placebo	10NOV2020/ Placebo	03DEC2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12081054	C4591001 1208 12081054	16-55	10NOV2020	116069	Placebo	10NOV2020/ Placebo	03DEC2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12091001	C4591001 1209 12091001	16-55	22OCT2020	112015	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
12091002	C4591001 1209 12091002	16-55	23OCT2020	112019	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
12091003	C4591001 1209 12091003	16-55	23OCT2020	112020	Placebo	23OCT2020/ Placebo	13NOV2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12091004	C4591001 1209 12091004	16-55	26OCT2020	112021	Placebo	26OCT2020/ Placebo	18NOV2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
12091006	C4591001 1209 12091006	16-55	28OCT2020	114270	BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)	18NOV2020/ BNT162b2 (30 µg)		
12091007	C4591001 1209 12091007	16-55	28OCT2020	114274	BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)	18NOV2020/ BNT162b2 (30 µg)		
12091008	C4591001 1209 12091008	16-55	30OCT2020	114277	Placebo	30OCT2020/ Placebo	20NOV2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12091009	C4591001 1209 12091009	16-55	30OCT2020	114280	Placebo	30OCT2020/ Placebo	19NOV2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12091010	C4591001 1209 12091010	16-55	02NOV2020	115194	Placebo	02NOV2020/ Placebo	23NOV2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
12091011	C4591001 1209 12091011	16-55	02NOV2020	115196	Placebo	02NOV2020/ Placebo	23NOV2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
12091013	C4591001 1209 12091013	16-55	02NOV2020	115197	BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)			
12091015	C4591001 1209 12091015	16-55	03NOV2020	115203	BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)	24NOV2020/ BNT162b2 (30 µg)		
12091016	C4591001 1209 12091016	16-55	03NOV2020	115339	BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)	24NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12091017	C4591001 1209 12091017	16-55	03NOV2020	115341	Placebo	03NOV2020/ Placebo	25NOV2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
12091018	C4591001 1209 12091018	16-55	04NOV2020	115344	BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)	25NOV2020/ BNT162b2 (30 µg)		
12091019	C4591001 1209 12091019	16-55	04NOV2020	115346	Placebo	04NOV2020/ Placebo	25NOV2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12091020	C4591001 1209 12091020	16-55	04NOV2020	115593	Placebo	04NOV2020/ Placebo	26NOV2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12091021	C4591001 1209 12091021	16-55	05NOV2020	272976	BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)	26NOV2020/ BNT162b2 (30 µg)		
12101001	C4591001 1210 12101001	16-55	22OCT2020	111917	Placebo	22OCT2020/ Placebo	12NOV2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
12101002	C4591001 1210 12101002	16-55	22OCT2020	111919	Placebo	22OCT2020/ Placebo	12NOV2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
12101005	C4591001 1210 12101005	16-55	23OCT2020	111923	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
12101006	C4591001 1210 12101006	16-55	23OCT2020	111927	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
12101007	C4591001 1210 12101007	16-55	23OCT2020	112721	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12101008	C4591001 1210 12101008	16-55	26OCT2020	112724	Placebo	26OCT2020/ Placebo	16NOV2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	20JAN2021/ BNT162b2 (30 µg)
12101009	C4591001 1210 12101009	16-55	26OCT2020	112730	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
12101010	C4591001 1210 12101010	16-55	26OCT2020	112732	Placebo	26OCT2020/ Placebo	16NOV2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	20JAN2021/ BNT162b2 (30 µg)
12101011	C4591001 1210 12101011	16-55	26OCT2020	113443	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
12101012	C4591001 1210 12101012	16-55	26OCT2020	113444	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
12101013	C4591001 1210 12101013	16-55	27OCT2020	113445	Placebo	27OCT2020/ Placebo	16NOV2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)
12101014	C4591001 1210 12101014	16-55	27OCT2020	113450	Placebo	27OCT2020/ Placebo	16NOV2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
12101015	C4591001 1210 12101015	16-55	27OCT2020	113897	Placebo	27OCT2020/ Placebo	17NOV2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
12101016	C4591001 1210 12101016	16-55	27OCT2020	113900	Placebo	27OCT2020/ Placebo	18NOV2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)
12101017	C4591001 1210 12101017	16-55	27OCT2020	113902	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	18NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12101018	C4591001 1210 12101018	16-55	27OCT2020	113908	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	18NOV2020/ BNT162b2 (30 µg)		
12101019	C4591001 1210 12101019	16-55	27OCT2020	113946	Placebo	27OCT2020/ Placebo		05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
12101020	C4591001 1210 12101020	16-55	27OCT2020	113949	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
12101021	C4591001 1210 12101021	16-55	27OCT2020	113951	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
12101022	C4591001 1210 12101022	16-55	28OCT2020	113956	Placebo	28OCT2020/ Placebo	18NOV2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
12101023	C4591001 1210 12101023	16-55	28OCT2020	114305	Placebo	28OCT2020/ Placebo	18NOV2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
12101024	C4591001 1210 12101024	16-55	28OCT2020	114307	BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)	18NOV2020/ BNT162b2 (30 µg)		
12101025	C4591001 1210 12101025	16-55	30OCT2020	114309	BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)	23NOV2020/ BNT162b2 (30 µg)		
12101026	C4591001 1210 12101026	16-55	30OCT2020	114315	Placebo	30OCT2020/ Placebo	11DEC2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
12101027	C4591001 1210 12101027	16-55	30OCT2020	114941	Placebo	30OCT2020/ Placebo	20NOV2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12101028	C4591001 1210 12101028	16-55	30OCT2020	114943	BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)	20NOV2020/ BNT162b2 (30 µg)		
12101029	C4591001 1210 12101029	16-55	30OCT2020	114945	Placebo	30OCT2020/ Placebo	20NOV2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)
12101030	C4591001 1210 12101030	16-55	30OCT2020	114949	BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)	20NOV2020/ BNT162b2 (30 µg)		
12101031	C4591001 1210 12101031	16-55	02NOV2020	115169	Placebo	02NOV2020/ Placebo	23NOV2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
12101032	C4591001 1210 12101032	16-55	02NOV2020	115173	Placebo	02NOV2020/ Placebo	23NOV2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
12101033	C4591001 1210 12101033	16-55	02NOV2020	115175	BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)	23NOV2020/ BNT162b2 (30 µg)		
12101034	C4591001 1210 12101034	16-55	02NOV2020	115179	BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)	23NOV2020/ BNT162b2 (30 µg)		
12101035	C4591001 1210 12101035	16-55	02NOV2020	115229	Placebo	02NOV2020/ Placebo	24NOV2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
12101036	C4591001 1210 12101036	16-55	02NOV2020	115232	BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)	24NOV2020/ BNT162b2 (30 µg)		
12101037	C4591001 1210 12101037	16-55	03NOV2020	115233	Placebo	03NOV2020/ Placebo	23NOV2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12101038	C4591001 1210 12101038	16-55	03NOV2020	115235	BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)	24NOV2020/ BNT162b2 (30 µg)		
12101039	C4591001 1210 12101039	16-55	03NOV2020	115410	BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)	24NOV2020/ BNT162b2 (30 µg)		
12101040	C4591001 1210 12101040	16-55	03NOV2020	115414	Placebo	03NOV2020/ Placebo	23NOV2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)
12101041	C4591001 1210 12101041	16-55	03NOV2020	115416	Placebo	03NOV2020/ Placebo	23NOV2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	20JAN2021/ BNT162b2 (30 µg)
12101045	C4591001 1210 12101045	16-55	04NOV2020	115420	BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)	24NOV2020/ BNT162b2 (30 µg)		
12101046	C4591001 1210 12101046	16-55	04NOV2020	115553	BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)	24NOV2020/ BNT162b2 (30 µg)		
12101047	C4591001 1210 12101047	16-55	04NOV2020	115556	BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)	24NOV2020/ BNT162b2 (30 µg)		
12101048	C4591001 1210 12101048	16-55	04NOV2020	115563	Placebo	04NOV2020/ Placebo	25NOV2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)
12101049	C4591001 1210 12101049	16-55	04NOV2020	115564	Placebo	04NOV2020/ Placebo	25NOV2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	20JAN2021/ BNT162b2 (30 µg)
12101050	C4591001 1210 12101050	16-55	05NOV2020	115735	BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)	26NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12101051	C4591001 1210 12101051	16-55	05NOV2020	115736	BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)	25NOV2020/ BNT162b2 (30 µg)		
12101052	C4591001 1210 12101052	16-55	05NOV2020	115743	Placebo	05NOV2020/ Placebo	25NOV2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	20JAN2021/ BNT162b2 (30 µg)
12101053	C4591001 1210 12101053	16-55	05NOV2020	115744	Placebo	05NOV2020/ Placebo		29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
12101054	C4591001 1210 12101054	16-55	05NOV2020	115793	BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)	26NOV2020/ BNT162b2 (30 µg)		
12101055	C4591001 1210 12101055	16-55	06NOV2020	115800	BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)	26NOV2020/ BNT162b2 (30 µg)		
12101056	C4591001 1210 12101056	16-55	06NOV2020	115802	Placebo	06NOV2020/ Placebo	27NOV2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	
12101057	C4591001 1210 12101057	16-55	06NOV2020	115804	Placebo	06NOV2020/ Placebo	27NOV2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
12101058	C4591001 1210 12101058	16-55	06NOV2020	115902	Placebo	06NOV2020/ Placebo	27NOV2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)
12101059	C4591001 1210 12101059	16-55	06NOV2020	115905	Placebo	06NOV2020/ Placebo	27NOV2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)
12101060	C4591001 1210 12101060	16-55	06NOV2020	115909	BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)	27NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12101061	C4591001 1210 12101061	16-55	09NOV2020	115910	BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)	30NOV2020/ BNT162b2 (30 µg)		
12121001	C4591001 1212 12121001	16-55	22OCT2020	112002	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
12121002	C4591001 1212 12121002	16-55	22OCT2020	112003	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
12121003	C4591001 1212 12121003	16-55	23OCT2020	112005	Placebo	23OCT2020/ Placebo	12NOV2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)
12121004	C4591001 1212 12121004	16-55	23OCT2020	112012	Placebo	23OCT2020/ Placebo	12NOV2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)
12121005	C4591001 1212 12121005	16-55	23OCT2020	112637	Placebo	23OCT2020/ Placebo	12NOV2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12121006	C4591001 1212 12121006	16-55	23OCT2020	112639	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
12121007	C4591001 1212 12121007	16-55	26OCT2020	112641	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
12121008	C4591001 1212 12121008	16-55	26OCT2020	112648	Placebo	26OCT2020/ Placebo	17NOV2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
12121009	C4591001 1212 12121009	16-55	26OCT2020	113372	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12121010	C4591001 1212 12121010	16-55	26OCT2020	113373	Placebo	26OCT2020/ Placebo	18NOV2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
12121011	C4591001 1212 12121011	16-55	26OCT2020	113376	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	18NOV2020/ BNT162b2 (30 µg)		
12121012	C4591001 1212 12121012	16-55	27OCT2020	113379	Placebo	27OCT2020/ Placebo	18NOV2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
12121013	C4591001 1212 12121013	16-55	27OCT2020	113852	Placebo	27OCT2020/ Placebo	18NOV2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
12121014	C4591001 1212 12121014	16-55	27OCT2020	113858	Placebo	27OCT2020/ Placebo	18NOV2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	28JAN2021/ BNT162b2 (30 µg)
12121015	C4591001 1212 12121015	16-55	27OCT2020	113859	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	18NOV2020/ BNT162b2 (30 µg)		
12121016	C4591001 1212 12121016	16-55	27OCT2020	113860	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	18NOV2020/ BNT162b2 (30 µg)		
12121017	C4591001 1212 12121017	16-55	30OCT2020	114870	BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)	20NOV2020/ BNT162b2 (30 µg)		
12121018	C4591001 1212 12121018	16-55	30OCT2020	114871	Placebo	30OCT2020/ Placebo	20NOV2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
12121019	C4591001 1212 12121019	16-55	30OCT2020	114875	Placebo	30OCT2020/ Placebo	20NOV2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12121020	C4591001 1212 12121020†	16-55	03NOV2020	114877	BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)	24NOV2020/ BNT162b2 (30 µg)		
12121022	C4591001 1212 12121022	16-55	03NOV2020	115426	Placebo	03NOV2020/ Placebo	24NOV2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12121023	C4591001 1212 12121023	16-55	03NOV2020	115429	BNT162b2 (30 µg)				
12121024	C4591001 1212 12121024	16-55	04NOV2020	115430	BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)	25NOV2020/ BNT162b2 (30 µg)		
12121025	C4591001 1212 12121025	16-55	04NOV2020	115432	Placebo	04NOV2020/ Placebo	25NOV2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)
12121026	C4591001 1212 12121026	16-55	04NOV2020	115495	BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)	25NOV2020/ BNT162b2 (30 µg)		
12121027	C4591001 1212 12121027	16-55	04NOV2020	115497	Placebo	04NOV2020/ Placebo	24NOV2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	28JAN2021/ BNT162b2 (30 µg)
12121028	C4591001 1212 12121028	16-55	05NOV2020	115500	BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)	26NOV2020/ BNT162b2 (30 µg)		
12121029	C4591001 1212 12121029	16-55	05NOV2020	115502	Placebo	05NOV2020/ Placebo	26NOV2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)
12121031	C4591001 1212 12121031	16-55	05NOV2020	274009	Placebo	05NOV2020/ Placebo	26NOV2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12121032	C4591001 1212 12121032	16-55	05NOV2020	115757	Placebo	05NOV2020/ Placebo	26NOV2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)
12121034	C4591001 1212 12121034	16-55	05NOV2020	115758	BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)	27NOV2020/ BNT162b2 (30 µg)		
12121035	C4591001 1212 12121035	16-55	06NOV2020	115760	Placebo	06NOV2020/ Placebo	26NOV2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	28JAN2021/ BNT162b2 (30 µg)
12121036	C4591001 1212 12121036	16-55	06NOV2020	115764	BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)	26NOV2020/ BNT162b2 (30 µg)		
12131001	C4591001 1213 12131001	16-55	22OCT2020	111955	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
12131002	C4591001 1213 12131002	16-55	22OCT2020	111956	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
12131003	C4591001 1213 12131003	16-55	22OCT2020	111959	Placebo	22OCT2020/ Placebo	12NOV2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)
12131004	C4591001 1213 12131004	16-55	23OCT2020	111964	Placebo	23OCT2020/ Placebo	12NOV2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12131005	C4591001 1213 12131005	16-55	23OCT2020	112662	Placebo	23OCT2020/ Placebo	12NOV2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)
12131006	C4591001 1213 12131006	16-55	23OCT2020	112663	Placebo	23OCT2020/ Placebo	12NOV2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12131008	C4591001 1213 12131008	16-55	23OCT2020	112668	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
12131010	C4591001 1213 12131010	16-55	26OCT2020	113360	Placebo	26OCT2020/ Placebo	17NOV2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	28JAN2021/ BNT162b2 (30 µg)
12131012	C4591001 1213 12131012	16-55	26OCT2020	113362	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
12131013	C4591001 1213 12131013	16-55	26OCT2020	113364	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
12131014	C4591001 1213 12131014	16-55	02NOV2020	113366	Placebo	02NOV2020/ Placebo	23NOV2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	27JAN2021/ BNT162b2 (30 µg)
12131015	C4591001 1213 12131015	16-55	02NOV2020	115159	Placebo	02NOV2020/ Placebo	23NOV2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	27JAN2021/ BNT162b2 (30 µg)
12131016	C4591001 1213 12131016	16-55	02NOV2020	115161	BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)	23NOV2020/ BNT162b2 (30 µg)		
12131018	C4591001 1213 12131018	16-55	02NOV2020	115164	Placebo	02NOV2020/ Placebo	24NOV2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
12131019	C4591001 1213 12131019	16-55	02NOV2020	115168	BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)	23NOV2020/ BNT162b2 (30 µg)		
12131025	C4591001 1213 12131025	16-55	03NOV2020	115373	BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)	25NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12131026	C4591001 1213 12131026	16-55	03NOV2020	115377	Placebo	03NOV2020/ Placebo	24NOV2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12131028	C4591001 1213 12131028	16-55	03NOV2020	115379	BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)	27NOV2020/ BNT162b2 (30 µg)		
12131032	C4591001 1213 12131032	16-55	04NOV2020	115382	Placebo	04NOV2020/ Placebo	24NOV2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
12131033	C4591001 1213 12131033	16-55	04NOV2020	115565	BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)	30NOV2020/ BNT162b2 (30 µg)		
12131034	C4591001 1213 12131034	16-55	04NOV2020	115572	Placebo	04NOV2020/ Placebo	30NOV2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
12131035	C4591001 1213 12131035	16-55	05NOV2020	115574	Placebo	05NOV2020/ Placebo	26NOV2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
12131036	C4591001 1213 12131036	16-55	04NOV2020	115573	BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)	25NOV2020/ BNT162b2 (30 µg)		
12131037	C4591001 1213 12131037	16-55	05NOV2020	115697	BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)	26NOV2020/ BNT162b2 (30 µg)		
12131038	C4591001 1213 12131038	16-55	05NOV2020	115700	BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)	24NOV2020/ BNT162b2 (30 µg)		
12131039	C4591001 1213 12131039	16-55	05NOV2020	115702	Placebo	05NOV2020/ Placebo	25NOV2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12131040	C4591001 1213 12131040	16-55	05NOV2020	115704	Placebo	05NOV2020/ Placebo	27NOV2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)
12131041	C4591001 1213 12131041	16-55	05NOV2020	115748	BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)	26NOV2020/ BNT162b2 (30 µg)		
12131042	C4591001 1213 12131042	16-55	05NOV2020	115750	BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)	27NOV2020/ BNT162b2 (30 µg)		
12131043	C4591001 1213 12131043	16-55	05NOV2020	115752	Placebo	05NOV2020/ Placebo	26NOV2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
12131044	C4591001 1213 12131044	16-55	05NOV2020	115754	Placebo	05NOV2020/ Placebo	26NOV2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12131046	C4591001 1213 12131046	16-55	06NOV2020	115829	Placebo	06NOV2020/ Placebo			
12131050	C4591001 1213 12131050	16-55	06NOV2020	115838	BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)	27NOV2020/ BNT162b2 (30 µg)		
12131052	C4591001 1213 12131052	16-55	09NOV2020	115839	BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)	30NOV2020/ BNT162b2 (30 µg)		
12131053	C4591001 1213 12131053	16-55	09NOV2020	115937	BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)	30NOV2020/ BNT162b2 (30 µg)		
12131054	C4591001 1213 12131054	16-55	09NOV2020	115940	BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)	30NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12131055	C4591001 1213 12131055	16-55	09NOV2020	115942	Placebo	09NOV2020/ Placebo	02DEC2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)
12131056	C4591001 1213 12131056	16-55	09NOV2020	115945	Placebo	09NOV2020/ Placebo	30NOV2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)
12131057	C4591001 1213 12131057	16-55	09NOV2020	115963	Placebo	09NOV2020/ Placebo	01DEC2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
12131059	C4591001 1213 12131059	16-55	09NOV2020	115965	BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)	01DEC2020/ BNT162b2 (30 µg)		
12131060	C4591001 1213 12131060	16-55	09NOV2020	115966	Placebo	09NOV2020/ Placebo	30NOV2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
12141001	C4591001 1214 12141001	16-55	22OCT2020	111905	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
12141004	C4591001 1214 12141004	16-55	23OCT2020	111907	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
12141005	C4591001 1214 12141005	16-55	23OCT2020	111912	Placebo	23OCT2020/ Placebo	13NOV2020/ Placebo	31DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)
12141007	C4591001 1214 12141007	16-55	26OCT2020	111916	Placebo	26OCT2020/ Placebo	17NOV2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12141008	C4591001 1214 12141008	16-55	26OCT2020	113419	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12141009	C4591001 1214 12141009	16-55	26OCT2020	113420	Placebo	26OCT2020/ Placebo	17NOV2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12141012	C4591001 1214 12141012	16-55	30OCT2020	113422	Placebo	30OCT2020/ Placebo	18NOV2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12141013	C4591001 1214 12141013	16-55	30OCT2020	113423	BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)		
12141014	C4591001 1214 12141014	16-55	30OCT2020	114929	Placebo	30OCT2020/ Placebo	19NOV2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12141015	C4591001 1214 12141015	16-55	30OCT2020	114931	Placebo	30OCT2020/ Placebo	19NOV2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12141016	C4591001 1214 12141016	16-55	02NOV2020	114933	BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)	20NOV2020/ BNT162b2 (30 µg)		
12141017	C4591001 1214 12141017	16-55	02NOV2020	114938	BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)	23NOV2020/ BNT162b2 (30 µg)		
12141018	C4591001 1214 12141018	16-55	02NOV2020	115208	BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)	23NOV2020/ BNT162b2 (30 µg)		
12141019	C4591001 1214 12141019	16-55	02NOV2020	115213	BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)	23NOV2020/ BNT162b2 (30 µg)		
12141020	C4591001 1214 12141020	16-55	02NOV2020	115214	Placebo	02NOV2020/ Placebo	20NOV2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12141022	C4591001 1214 12141022	16-55	03NOV2020	115216	Placebo	03NOV2020/ Placebo	25NOV2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12141023	C4591001 1214 12141023	16-55	03NOV2020	115400	BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)	24NOV2020/ BNT162b2 (30 µg)		
12141024	C4591001 1214 12141024	16-55	03NOV2020	115402	Placebo	03NOV2020/ Placebo	24NOV2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12141025	C4591001 1214 12141025	16-55	03NOV2020	115403	BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)	24NOV2020/ BNT162b2 (30 µg)		
12141027	C4591001 1214 12141027	16-55	04NOV2020	115405	Placebo	04NOV2020/ Placebo	25NOV2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12141029	C4591001 1214 12141029	16-55	04NOV2020	115529	BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)	24NOV2020/ BNT162b2 (30 µg)		
12141030	C4591001 1214 12141030	16-55	04NOV2020	115531	Placebo	04NOV2020/ Placebo	25NOV2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12141031	C4591001 1214 12141031	16-55	04NOV2020	115532	Placebo	04NOV2020/ Placebo	25NOV2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12141034	C4591001 1214 12141034	16-55	05NOV2020	115536	BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)	26NOV2020/ BNT162b2 (30 µg)		
12141036	C4591001 1214 12141036	16-55	05NOV2020	115781	BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)			

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12141037	C4591001 1214 12141037	16-55	05NOV2020	115785	BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)	26NOV2020/ BNT162b2 (30 µg)		
12141038	C4591001 1214 12141038	16-55	06NOV2020	115788	Placebo	06NOV2020/ Placebo	24NOV2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
12141039	C4591001 1214 12141039	16-55	06NOV2020	115789	Placebo	06NOV2020/ Placebo	27NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12141040	C4591001 1214 12141040	16-55	06NOV2020	115877	Placebo	06NOV2020/ Placebo	27NOV2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
12141041	C4591001 1214 12141041	16-55	06NOV2020	115879	Placebo	06NOV2020/ Placebo	27NOV2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12141042	C4591001 1214 12141042	16-55	06NOV2020	115881	BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)	26NOV2020/ BNT162b2 (30 µg)		
12141043	C4591001 1214 12141043	16-55	09NOV2020	115888	BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)	30NOV2020/ BNT162b2 (30 µg)		
12141044	C4591001 1214 12141044	16-55	09NOV2020	115951	Placebo	09NOV2020/ Placebo	30NOV2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12141045	C4591001 1214 12141045	16-55	09NOV2020	115954	BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)	30NOV2020/ BNT162b2 (30 µg)		
12141047	C4591001 1214 12141047	16-55	09NOV2020	115957	BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)	01DEC2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12141048	C4591001 1214 12141048	16-55	09NOV2020	115958	Placebo	09NOV2020/ Placebo	27NOV2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
12141049	C4591001 1214 12141049	16-55	10NOV2020	116022	BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)	01DEC2020/ BNT162b2 (30 µg)		
12141051	C4591001 1214 12141051	16-55	10NOV2020	116027	Placebo	10NOV2020/ Placebo	01DEC2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
12141052	C4591001 1214 12141052	16-55	10NOV2020	116031	BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)	01DEC2020/ BNT162b2 (30 µg)		
12141053	C4591001 1214 12141053	16-55	10NOV2020	116032	Placebo	10NOV2020/ Placebo	02DEC2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
12141054	C4591001 1214 12141054	16-55	10NOV2020	116045	Placebo	10NOV2020/ Placebo	02DEC2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
12141055	C4591001 1214 12141055	16-55	10NOV2020	116046	BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)	02DEC2020/ BNT162b2 (30 µg)		
12171002	C4591001 1217 12171002	16-55	22OCT2020	111977	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
12171003	C4591001 1217 12171003	16-55	22OCT2020	111978	Placebo	22OCT2020/ Placebo	12NOV2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
12171005	C4591001 1217 12171005†	16-55	22OCT2020	111983	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12171008	C4591001 1217 12171008	16-55	23OCT2020	111984	Placebo	23OCT2020/ Placebo	13NOV2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
12171009	C4591001 1217 12171009	16-55	23OCT2020	112649	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
12171010	C4591001 1217 12171010	16-55	23OCT2020	112651	Placebo	23OCT2020/ Placebo	13NOV2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12171011	C4591001 1217 12171011	16-55	23OCT2020	112654	Placebo	23OCT2020/ Placebo	13NOV2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
12171012	C4591001 1217 12171012	16-55	23OCT2020	112660	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
12171013	C4591001 1217 12171013	16-55	26OCT2020	113334	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
12171014	C4591001 1217 12171014	16-55	26OCT2020	113336	Placebo	26OCT2020/ Placebo	16NOV2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
12171015	C4591001 1217 12171015†	16-55	26OCT2020	113340	Placebo	26OCT2020/ Placebo	17NOV2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12171016	C4591001 1217 12171016	16-55	26OCT2020	113344	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
12171017	C4591001 1217 12171017	16-55	26OCT2020	113381	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12171018	C4591001 1217 12171018	16-55	27OCT2020	113383	Placebo	27OCT2020/ Placebo	17NOV2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
12171019	C4591001 1217 12171019	16-55	27OCT2020	113385	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
12171020	C4591001 1217 12171020	16-55	27OCT2020	113390	Placebo	27OCT2020/ Placebo	17NOV2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
12171021	C4591001 1217 12171021	16-55	27OCT2020	113837	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
12171022	C4591001 1217 12171022	16-55	27OCT2020	113838	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
12171023	C4591001 1217 12171023	16-55	27OCT2020	113843	Placebo	27OCT2020/ Placebo	17NOV2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)
12171028	C4591001 1217 12171028	16-55	30OCT2020	113848	Placebo	30OCT2020/ Placebo	19NOV2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	28JAN2021/ BNT162b2 (30 µg)
12171030	C4591001 1217 12171030	16-55	30OCT2020	114920	BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)		
12171031	C4591001 1217 12171031	16-55	30OCT2020	114923	Placebo	30OCT2020/ Placebo			
12171032	C4591001 1217 12171032	16-55	02NOV2020	114925	Placebo	02NOV2020/ Placebo	24NOV2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	28JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12171034	C4591001 1217 12171034	16-55	03NOV2020	114927	BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)	24NOV2020/ BNT162b2 (30 µg)		
12171035	C4591001 1217 12171035	16-55	03NOV2020	115328	Placebo	03NOV2020/ Placebo	24NOV2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	28JAN2021/ BNT162b2 (30 µg)
12171037	C4591001 1217 12171037	16-55	03NOV2020	115329	BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)	24NOV2020/ BNT162b2 (30 µg)		
12171038	C4591001 1217 12171038	16-55	03NOV2020	115330	BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)	24NOV2020/ BNT162b2 (30 µg)		
12171039	C4591001 1217 12171039	16-55	04NOV2020	115336	Placebo	04NOV2020/ Placebo	25NOV2020/ Placebo	03MAR2021/ BNT162b2 (30 µg)	
12171040	C4591001 1217 12171040	16-55	04NOV2020	115470	BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)	25NOV2020/ BNT162b2 (30 µg)		
12171041	C4591001 1217 12171041	16-55	04NOV2020	115475	Placebo	04NOV2020/ Placebo	25NOV2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
12171042	C4591001 1217 12171042	16-55	04NOV2020	115476	BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)	25NOV2020/ BNT162b2 (30 µg)		
12171044	C4591001 1217 12171044	16-55	04NOV2020	115479	Placebo	04NOV2020/ Placebo			
12171045	C4591001 1217 12171045	16-55	04NOV2020	115578	BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)	25NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12171046	C4591001 1217 12171046	16-55	05NOV2020	115582	Placebo	05NOV2020/ Placebo	25NOV2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
12171047	C4591001 1217 12171047	16-55	05NOV2020	115583	BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)	26NOV2020/ BNT162b2 (30 µg)		
12171048	C4591001 1217 12171048	16-55	05NOV2020	115588	Placebo	05NOV2020/ Placebo	26NOV2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)
12171049	C4591001 1217 12171049	16-55	06NOV2020	115842	Placebo	06NOV2020/ Placebo	27NOV2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	28JAN2021/ BNT162b2 (30 µg)
12171050	C4591001 1217 12171050	16-55	06NOV2020	115845	BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)	27NOV2020/ BNT162b2 (30 µg)		
12171051	C4591001 1217 12171051	16-55	06NOV2020	115847	Placebo	06NOV2020/ Placebo	27NOV2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
12171052	C4591001 1217 12171052	16-55	06NOV2020	115852	BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)	27NOV2020/ BNT162b2 (30 µg)		
12171053	C4591001 1217 12171053	16-55	06NOV2020	115855	BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)	26NOV2020/ BNT162b2 (30 µg)		
12171054	C4591001 1217 12171054	16-55	06NOV2020	115856	Placebo	06NOV2020/ Placebo	27NOV2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	28JAN2021/ BNT162b2 (30 µg)
12171055	C4591001 1217 12171055	16-55	06NOV2020	115859	Placebo	06NOV2020/ Placebo	27NOV2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	28JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12171056	C4591001 1217 12171056	16-55	06NOV2020	115861	BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)	27NOV2020/ BNT162b2 (30 µg)		
12171059	C4591001 1217 12171059	16-55	09NOV2020	115987	BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)	30NOV2020/ BNT162b2 (30 µg)		
12171061	C4591001 1217 12171061	16-55	09NOV2020	115993	Placebo	09NOV2020/ Placebo	30NOV2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
12171062	C4591001 1217 12171062	16-55	09NOV2020	115995	Placebo	09NOV2020/ Placebo	30NOV2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
12181001	C4591001 1218 12181001	16-55	19OCT2020	110585	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
12181003	C4591001 1218 12181003	16-55	21OCT2020	110589	Placebo	21OCT2020/ Placebo	10NOV2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12181004	C4591001 1218 12181004	16-55	21OCT2020	110593	Placebo	21OCT2020/ Placebo	10NOV2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	27JAN2021/ BNT162b2 (30 µg)
12181005	C4591001 1218 12181005	16-55	23OCT2020	110595	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
12181006	C4591001 1218 12181006	16-55	23OCT2020	113069	Placebo	23OCT2020/ Placebo	12NOV2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12181007	C4591001 1218 12181007	16-55	27OCT2020	113071	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12181008	C4591001 1218 12181008	16-55	28OCT2020	113079	BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
12181009	C4591001 1218 12181009	16-55	02NOV2020	113080	Placebo	02NOV2020/ Placebo	24NOV2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
12181011	C4591001 1218 12181011	16-55	02NOV2020	115290	BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)	24NOV2020/ BNT162b2 (30 µg)		
12181012	C4591001 1218 12181012	16-55	02NOV2020	115291	Placebo	02NOV2020/ Placebo	24NOV2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12181013	C4591001 1218 12181013	16-55	03NOV2020	115296	Placebo	03NOV2020/ Placebo	23NOV2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
12181014	C4591001 1218 12181014	16-55	11NOV2020	115300	BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)	02DEC2020/ BNT162b2 (30 µg)		
12181015	C4591001 1218 12181015	16-55	12NOV2020	116202	Placebo	12NOV2020/ Placebo	03DEC2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	27JAN2021/ BNT162b2 (30 µg)
12181016	C4591001 1218 12181016	16-55	12NOV2020	116205	BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)	03DEC2020/ BNT162b2 (30 µg)		
12181017	C4591001 1218 12181017	16-55	13NOV2020	116206	BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)	04DEC2020/ BNT162b2 (30 µg)		
12181018	C4591001 1218 12181018	16-55	13NOV2020	116209	Placebo	13NOV2020/ Placebo	04DEC2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12181019	C4591001 1218 12181019	16-55	13NOV2020	116225	BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)	04DEC2020/ BNT162b2 (30 µg)		
12181022	C4591001 1218 12181022	16-55	17NOV2020	116233	Placebo	17NOV2020/ Placebo	07DEC2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)
12181023	C4591001 1218 12181023	16-55	17NOV2020	116235	Placebo	17NOV2020/ Placebo	07DEC2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)
12181025	C4591001 1218 12181025	16-55	18NOV2020	116236	BNT162b2 (30 µg)	18NOV2020/ BNT162b2 (30 µg)	09DEC2020/ BNT162b2 (30 µg)		
12181026	C4591001 1218 12181026	16-55	18NOV2020	116506	Placebo	18NOV2020/ Placebo	07DEC2020/ Placebo		
12181027	C4591001 1218 12181027	16-55	19NOV2020	116507	Placebo	19NOV2020/ Placebo	08DEC2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	
12181028	C4591001 1218 12181028	16-55	19NOV2020	116509	BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)	10DEC2020/ BNT162b2 (30 µg)		
12181030	C4591001 1218 12181030	16-55	20NOV2020	116510	BNT162b2 (30 µg)	20NOV2020/ BNT162b2 (30 µg)	09DEC2020/ BNT162b2 (30 µg)		
12181031	C4591001 1218 12181031	16-55	20NOV2020	116587	Placebo	20NOV2020/ Placebo	10DEC2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12181032	C4591001 1218 12181032	16-55	20NOV2020	116592	Placebo	20NOV2020/ Placebo	09DEC2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12181034	C4591001 1218 12181034	16-55	23NOV2020	116593	BNT162b2 (30 µg)	23NOV2020/ BNT162b2 (30 µg)	14DEC2020/ BNT162b2 (30 µg)		
12181035	C4591001 1218 12181035	16-55	24NOV2020	116595	BNT162b2 (30 µg)	24NOV2020/ BNT162b2 (30 µg)	16DEC2020/ BNT162b2 (30 µg)		
12181036	C4591001 1218 12181036	16-55	24NOV2020	116885	Placebo	24NOV2020/ Placebo	14DEC2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
12181037	C4591001 1218 12181037	16-55	30NOV2020	116887	BNT162b2 (30 µg)	30NOV2020/ BNT162b2 (30 µg)	21DEC2020/ BNT162b2 (30 µg)		
12181039	C4591001 1218 12181039	16-55	30NOV2020	116890	BNT162b2 (30 µg)	30NOV2020/ BNT162b2 (30 µg)	21DEC2020/ BNT162b2 (30 µg)		
12181041	C4591001 1218 12181041	16-55	01DEC2020	116895	Placebo	01DEC2020/ Placebo		10FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12181042	C4591001 1218 12181042	16-55	01DEC2020	117162	Placebo	01DEC2020/ Placebo		21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
12181043	C4591001 1218 12181043	16-55	01DEC2020	117166	BNT162b2 (30 µg)	01DEC2020/ BNT162b2 (30 µg)	21DEC2020/ BNT162b2 (30 µg)		
12181044	C4591001 1218 12181044	16-55	02DEC2020	117167	Placebo	02DEC2020/ Placebo	22DEC2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)
12181045	C4591001 1218 12181045	16-55	02DEC2020	117169	BNT162b2 (30 µg)	02DEC2020/ BNT162b2 (30 µg)	22DEC2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12181046	C4591001 1218 12181046	16-55	02DEC2020	117234	BNT162b2 (30 µg)	02DEC2020/ BNT162b2 (30 µg)	28DEC2020/ BNT162b2 (30 µg)		
12181047	C4591001 1218 12181047	16-55	02DEC2020	117236	BNT162b2 (30 µg)	02DEC2020/ BNT162b2 (30 µg)	21DEC2020/ BNT162b2 (30 µg)		
12181048	C4591001 1218 12181048	16-55	03DEC2020	117243	Placebo	03DEC2020/ Placebo		22DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
12181049	C4591001 1218 12181049	16-55	03DEC2020	117244	Placebo	03DEC2020/ Placebo	22DEC2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12181050	C4591001 1218 12181050	16-55	03DEC2020	117428	Placebo	03DEC2020/ Placebo		23DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
12181051	C4591001 1218 12181051	16-55	03DEC2020	117431	BNT162b2 (30 µg)	03DEC2020/ BNT162b2 (30 µg)	23DEC2020/ BNT162b2 (30 µg)		
12181052	C4591001 1218 12181052	16-55	03DEC2020	117432	Placebo	03DEC2020/ Placebo		23DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
12181053	C4591001 1218 12181053	16-55	07DEC2020	117436	BNT162b2 (30 µg)	07DEC2020/ BNT162b2 (30 µg)	28DEC2020/ BNT162b2 (30 µg)		
12181054	C4591001 1218 12181054	16-55	07DEC2020	117694	Placebo	07DEC2020/ Placebo	28DEC2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12181055	C4591001 1218 12181055	16-55	07DEC2020	117697	BNT162b2 (30 µg)	07DEC2020/ BNT162b2 (30 µg)	28DEC2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12181057	C4591001 1218 12181057	16-55	08DEC2020	117698	Placebo	08DEC2020/ Placebo		16FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
12181058	C4591001 1218 12181058	16-55	08DEC2020	117700	BNT162b2 (30 µg)	08DEC2020/ BNT162b2 (30 µg)	28DEC2020/ BNT162b2 (30 µg)		
12181059	C4591001 1218 12181059	16-55	10DEC2020	117826	BNT162b2 (30 µg)	10DEC2020/ BNT162b2 (30 µg)	29DEC2020/ BNT162b2 (30 µg)		
12191001	C4591001 1219 12191001	16-55	25SEP2020	100553	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
12191002	C4591001 1219 12191002	16-55	25SEP2020	100555	Placebo	25SEP2020/ Placebo	14OCT2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
12191003	C4591001 1219 12191003	16-55	01OCT2020	100556	Placebo	01OCT2020/ Placebo	22OCT2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12191004	C4591001 1219 12191004	16-55	01OCT2020	100559	BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
12191013	C4591001 1219 12191013	16-55	08OCT2020	105393	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		
12191014	C4591001 1219 12191014	16-55	08OCT2020	105396	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		
12191016	C4591001 1219 12191016	16-55	09OCT2020	105398	Placebo	09OCT2020/ Placebo	28OCT2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12191017	C4591001 1219 12191017	16-55	13OCT2020	105400	Placebo	13OCT2020/ Placebo	02NOV2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12191022	C4591001 1219 12191022	16-55	20OCT2020	111101	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
12191023	C4591001 1219 12191023	16-55	20OCT2020	111102	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
12191024	C4591001 1219 12191024	16-55	22OCT2020	111110	Placebo	22OCT2020/ Placebo	10NOV2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	
12191026	C4591001 1219 12191026	16-55	26OCT2020	111111	Placebo	26OCT2020/ Placebo	16NOV2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12191028	C4591001 1219 12191028	16-55	27OCT2020	114221	Placebo	27OCT2020/ Placebo	19NOV2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
12191029	C4591001 1219 12191029	16-55	29OCT2020	114225	Placebo	29OCT2020/ Placebo	23NOV2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
12191030	C4591001 1219 12191030	16-55	29OCT2020	114224	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	07DEC2020/ BNT162b2 (30 µg)		
12191033	C4591001 1219 12191033	16-55	12NOV2020	114229	BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)	01DEC2020/ BNT162b2 (30 µg)		
12191034	C4591001 1219 12191034	16-55	12NOV2020	116177	BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)	01DEC2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12191035	C4591001 1219 12191035	16-55	13NOV2020	116184	Placebo	13NOV2020/ Placebo	02DEC2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
12191039	C4591001 1219 12191039	16-55	17NOV2020	116187	Placebo	17NOV2020/ Placebo	07DEC2020/ Placebo	06JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
12191040	C4591001 1219 12191040	16-55	17NOV2020	116188	BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)	07DEC2020/ BNT162b2 (30 µg)		
12191042	C4591001 1219 12191042	16-55	23NOV2020	116706	BNT162b2 (30 µg)	23NOV2020/ BNT162b2 (30 µg)	14DEC2020/ BNT162b2 (30 µg)		
12191044	C4591001 1219 12191044	16-55	23NOV2020	116707	Placebo	23NOV2020/ Placebo	14DEC2020/ Placebo	02MAR2021/ BNT162b2 (30 µg)	
12191047	C4591001 1219 12191047	16-55	25NOV2020	116708	BNT162b2 (30 µg)	25NOV2020/ BNT162b2 (30 µg)	16DEC2020/ BNT162b2 (30 µg)		
12191048	C4591001 1219 12191048	16-55	25NOV2020	116714	Placebo	25NOV2020/ Placebo	16DEC2020/ Placebo	06JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
12191049	C4591001 1219 12191049	16-55	25NOV2020	116970	Placebo	25NOV2020/ Placebo	14DEC2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)
12191050	C4591001 1219 12191050	16-55	30NOV2020	116971	Placebo	30NOV2020/ Placebo	21DEC2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)
12191051	C4591001 1219 12191051	16-55	02DEC2020	116974	BNT162b2 (30 µg)	02DEC2020/ BNT162b2 (30 µg)	21DEC2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12191053	C4591001 1219 12191053	16-55	03DEC2020	117396	Placebo	03DEC2020/ Placebo	22DEC2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
12191054	C4591001 1219 12191054	16-55	03DEC2020	116978	BNT162b2 (30 µg)	03DEC2020/ BNT162b2 (30 µg)	22DEC2020/ BNT162b2 (30 µg)		
12191056	C4591001 1219 12191056	16-55	03DEC2020	117395	Placebo	03DEC2020/ Placebo		22DEC2020/ BNT162b2 (30 µg)	14JAN2021/ BNT162b2 (30 µg)
12191058	C4591001 1219 12191058	16-55	07DEC2020	117397	BNT162b2 (30 µg)	07DEC2020/ BNT162b2 (30 µg)	28DEC2020/ BNT162b2 (30 µg)		
12191059	C4591001 1219 12191059	16-55	08DEC2020	117399	BNT162b2 (30 µg)	08DEC2020/ BNT162b2 (30 µg)	29DEC2020/ BNT162b2 (30 µg)		
12191062	C4591001 1219 12191062	16-55	08DEC2020	117775	Placebo	08DEC2020/ Placebo		18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
12201003	C4591001 1220 12201003	16-55	28SEP2020	101525	BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
12201004	C4591001 1220 12201004	16-55	28SEP2020	101527	Placebo	28SEP2020/ Placebo	19OCT2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12201009	C4591001 1220 12201009	16-55	02OCT2020	101529	Placebo	02OCT2020/ Placebo	22OCT2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12201012	C4591001 1220 12201012	16-55	07OCT2020	101533	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12201013	C4591001 1220 12201013	16-55	08OCT2020	105426	Placebo	08OCT2020/ Placebo	29OCT2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
12201015	C4591001 1220 12201015	16-55	15OCT2020	105431	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
12201017	C4591001 1220 12201017	16-55	15OCT2020	105432	Placebo	15OCT2020/ Placebo	06NOV2020/ Placebo		
12201018	C4591001 1220 12201018	16-55	16OCT2020	105433	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
12201020	C4591001 1220 12201020	16-55	16OCT2020	109218	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
12201021	C4591001 1220 12201021	16-55	20OCT2020	109222	Placebo	20OCT2020/ Placebo	11NOV2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12201022	C4591001 1220 12201022	16-55	20OCT2020	109224	Placebo	20OCT2020/ Placebo	12NOV2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12201024	C4591001 1220 12201024	16-55	21OCT2020	109228	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
12201025	C4591001 1220 12201025	16-55	26OCT2020	113756	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	23NOV2020/ BNT162b2 (30 µg)		
12201026	C4591001 1220 12201026	16-55	27OCT2020	113761	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12201027	C4591001 1220 12201027	16-55	27OCT2020	113762	Placebo	27OCT2020/ Placebo	17NOV2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
12201028	C4591001 1220 12201028	16-55	28OCT2020	113763	Placebo	28OCT2020/ Placebo	18NOV2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
12201029	C4591001 1220 12201029	16-55	28OCT2020	114533	Placebo	28OCT2020/ Placebo	18NOV2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	
12201030	C4591001 1220 12201030	16-55	29OCT2020	114540	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	18NOV2020/ BNT162b2 (30 µg)		
12201031	C4591001 1220 12201031	16-55	30OCT2020	114541	BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)	23NOV2020/ BNT162b2 (30 µg)		
12201032	C4591001 1220 12201032	16-55	02NOV2020	114542	Placebo	02NOV2020/ Placebo	23NOV2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
12201033	C4591001 1220 12201033	16-55	03NOV2020	115445	Placebo	03NOV2020/ Placebo	23NOV2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
12201035	C4591001 1220 12201035	16-55	03NOV2020	115446	BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)	24NOV2020/ BNT162b2 (30 µg)		
12201036	C4591001 1220 12201036	16-55	04NOV2020	115447	BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)			
12201037	C4591001 1220 12201037	16-55	05NOV2020	115451	Placebo	05NOV2020/ Placebo	24NOV2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12201039	C4591001 1220 12201039	16-55	11NOV2020	116105	Placebo	11NOV2020/ Placebo	02DEC2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
12201041	C4591001 1220 12201041	16-55	12NOV2020	116108	Placebo	12NOV2020/ Placebo	30NOV2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
12201042	C4591001 1220 12201042	16-55	13NOV2020	116114	BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)	04DEC2020/ BNT162b2 (30 µg)		
12201043	C4591001 1220 12201043	16-55	13NOV2020	116116	BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)	07DEC2020/ BNT162b2 (30 µg)		
12201044	C4591001 1220 12201044	16-55	13NOV2020	116251	Placebo	13NOV2020/ Placebo	04DEC2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
12201045	C4591001 1220 12201045	16-55	16NOV2020	116256	BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)	09DEC2020/ BNT162b2 (30 µg)		
12201046	C4591001 1220 12201046	16-55	16NOV2020	116257	BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)	07DEC2020/ BNT162b2 (30 µg)		
12201047	C4591001 1220 12201047	16-55	16NOV2020	116260	Placebo	16NOV2020/ Placebo	07DEC2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
12201048	C4591001 1220 12201048	16-55	17NOV2020	116346	BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)	07DEC2020/ BNT162b2 (30 µg)		
12201050	C4591001 1220 12201050	16-55	17NOV2020	116351	Placebo	17NOV2020/ Placebo	08DEC2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12201051	C4591001 1220 12201051	16-55	18NOV2020	116352	Placebo	18NOV2020/ Placebo	11DEC2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
12201052	C4591001 1220 12201052	16-55	18NOV2020	116356	BNT162b2 (30 µg)	18NOV2020/ BNT162b2 (30 µg)	08DEC2020/ BNT162b2 (30 µg)		
12201053	C4591001 1220 12201053	16-55	19NOV2020	116539	Placebo	19NOV2020/ Placebo	09DEC2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
12201056	C4591001 1220 12201056	16-55	20NOV2020	116540	Placebo	20NOV2020/ Placebo	11DEC2020/ Placebo		
12201057	C4591001 1220 12201057	16-55	20NOV2020	116543	BNT162b2 (30 µg)	20NOV2020/ BNT162b2 (30 µg)	11DEC2020/ BNT162b2 (30 µg)		
12201059	C4591001 1220 12201059	16-55	24NOV2020	116544	BNT162b2 (30 µg)	24NOV2020/ BNT162b2 (30 µg)	16DEC2020/ BNT162b2 (30 µg)		
12201061	C4591001 1220 12201061	16-55	25NOV2020	116934	Placebo	25NOV2020/ Placebo	15DEC2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
12201062	C4591001 1220 12201062	16-55	25NOV2020	116938	BNT162b2 (30 µg)	25NOV2020/ BNT162b2 (30 µg)	14DEC2020/ BNT162b2 (30 µg)		
12201063	C4591001 1220 12201063	16-55	25NOV2020	116939	BNT162b2 (30 µg)	25NOV2020/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)		
12201065	C4591001 1220 12201065	16-55	02DEC2020	116941	Placebo	02DEC2020/ Placebo		01MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12211002	C4591001 1221 12211002	16-55	13OCT2020	107094	Placebo	13OCT2020/ Placebo	02NOV2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12211003	C4591001 1221 12211003	16-55	15OCT2020	107095	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
12211005	C4591001 1221 12211005	16-55	15OCT2020	107096	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
12211006	C4591001 1221 12211006	16-55	15OCT2020	107097	Placebo	15OCT2020/ Placebo	04NOV2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12211007	C4591001 1221 12211007	16-55	16OCT2020	109338	Placebo	16OCT2020/ Placebo	07DEC2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
12211010	C4591001 1221 12211010	16-55	20OCT2020	109339	Placebo	20OCT2020/ Placebo	09NOV2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
12211011	C4591001 1221 12211011	16-55	20OCT2020	109343	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
12211012	C4591001 1221 12211012	16-55	22OCT2020	112199	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		
12211013	C4591001 1221 12211013	16-55	22OCT2020	112198	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		
12211014	C4591001 1221 12211014	16-55	22OCT2020	109347	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12211020	C4591001 1221 12211020	16-55	30OCT2020	112201	Placebo	30OCT2020/ Placebo	19NOV2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12211022	C4591001 1221 12211022	16-55	02NOV2020	112203	Placebo	02NOV2020/ Placebo	23NOV2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12211023	C4591001 1221 12211023	16-55	04NOV2020	115604	Placebo	04NOV2020/ Placebo	23NOV2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
12211024	C4591001 1221 12211024	16-55	18NOV2020	116379	BNT162b2 (30 µg)	18NOV2020/ BNT162b2 (30 µg)	10DEC2020/ BNT162b2 (30 µg)		
12211025	C4591001 1221 12211025	16-55	05NOV2020	115608	BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)	24NOV2020/ BNT162b2 (30 µg)		
12211026	C4591001 1221 12211026	16-55	05NOV2020	115606	Placebo	05NOV2020/ Placebo	24NOV2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
12211029	C4591001 1221 12211029	16-55	13NOV2020	116213	BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)	02DEC2020/ BNT162b2 (30 µg)		
12211030	C4591001 1221 12211030	16-55	12NOV2020	115610	BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)	03DEC2020/ BNT162b2 (30 µg)		
12211031	C4591001 1221 12211031	16-55	13NOV2020	116218	Placebo	13NOV2020/ Placebo	03DEC2020/ Placebo		
12211032	C4591001 1221 12211032	16-55	13NOV2020	116217	Placebo	13NOV2020/ Placebo	03DEC2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12211033	C4591001 1221 12211033	16-55	13NOV2020	116221	BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)	03DEC2020/ BNT162b2 (30 µg)		
12211036	C4591001 1221 12211036	16-55	16NOV2020	116287	BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)	07DEC2020/ BNT162b2 (30 µg)		
12211037	C4591001 1221 12211037	16-55	16NOV2020	116290	Placebo	16NOV2020/ Placebo	07DEC2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12211038	C4591001 1221 12211038	16-55	16NOV2020	116292	Placebo	16NOV2020/ Placebo	07DEC2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12211040	C4591001 1221 12211040	16-55	17NOV2020	116294	BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)	09DEC2020/ BNT162b2 (30 µg)		
12211041	C4591001 1221 12211041	16-55	17NOV2020	116371	BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)	07DEC2020/ BNT162b2 (30 µg)		
12211042	C4591001 1221 12211042	16-55	17NOV2020	116373	Placebo	17NOV2020/ Placebo	08DEC2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12211043	C4591001 1221 12211043	16-55	18NOV2020	116380	Placebo	18NOV2020/ Placebo	07DEC2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
12211044	C4591001 1221 12211044	16-55	18NOV2020	116419	BNT162b2 (30 µg)	18NOV2020/ BNT162b2 (30 µg)	08DEC2020/ BNT162b2 (30 µg)		
12211045	C4591001 1221 12211045	16-55	18NOV2020	116420	Placebo	18NOV2020/ Placebo	10DEC2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12211046	C4591001 1221 12211046	16-55	18NOV2020	116423	BNT162b2 (30 µg)	18NOV2020/ BNT162b2 (30 µg)	10DEC2020/ BNT162b2 (30 µg)		
12211047	C4591001 1221 12211047	16-55	23NOV2020	116564	Placebo	23NOV2020/ Placebo	15DEC2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
12211053	C4591001 1221 12211053	16-55	20NOV2020	116428	Placebo	20NOV2020/ Placebo	10DEC2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
12211054	C4591001 1221 12211054	16-55	20NOV2020	116561	BNT162b2 (30 µg)	20NOV2020/ BNT162b2 (30 µg)	09DEC2020/ BNT162b2 (30 µg)		
12211055	C4591001 1221 12211055	16-55	23NOV2020	116562	Placebo	23NOV2020/ Placebo	14DEC2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	27JAN2021/ BNT162b2 (30 µg)
12211056	C4591001 1221 12211056	16-55	23NOV2020	116569	BNT162b2 (30 µg)	23NOV2020/ BNT162b2 (30 µg)	15DEC2020/ BNT162b2 (30 µg)		
12211062	C4591001 1221 12211062	16-55	24NOV2020	116851	Placebo	24NOV2020/ Placebo	14DEC2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
12211064	C4591001 1221 12211064	16-55	25NOV2020	116852	BNT162b2 (30 µg)	25NOV2020/ BNT162b2 (30 µg)	15DEC2020/ BNT162b2 (30 µg)		
12211065	C4591001 1221 12211065	16-55	25NOV2020	116857	Placebo	25NOV2020/ Placebo	14DEC2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
12211067	C4591001 1221 12211067	16-55	30NOV2020	116860	BNT162b2 (30 µg)	30NOV2020/ BNT162b2 (30 µg)	21DEC2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12211068	C4591001 1221 12211068	16-55	30NOV2020	117093	BNT162b2 (30 µg)	30NOV2020/ BNT162b2 (30 µg)	21DEC2020/ BNT162b2 (30 µg)		
12211069	C4591001 1221 12211069	16-55	01DEC2020	117151	Placebo	01DEC2020/ Placebo	22DEC2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12211070	C4591001 1221 12211070	16-55	01DEC2020	117153	BNT162b2 (30 µg)	01DEC2020/ BNT162b2 (30 µg)	23DEC2020/ BNT162b2 (30 µg)		
12211071	C4591001 1221 12211071	16-55	01DEC2020	117154	BNT162b2 (30 µg)	01DEC2020/ BNT162b2 (30 µg)	23DEC2020/ BNT162b2 (30 µg)		
12211072	C4591001 1221 12211072	16-55	01DEC2020	117094	Placebo	01DEC2020/ Placebo	21DEC2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
12211073	C4591001 1221 12211073	16-55	01DEC2020	117099	Placebo	01DEC2020/ Placebo	21DEC2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12211074	C4591001 1221 12211074	16-55	01DEC2020	117100	BNT162b2 (30 µg)	01DEC2020/ BNT162b2 (30 µg)	22DEC2020/ BNT162b2 (30 µg)		
12211078	C4591001 1221 12211078	16-55	02DEC2020	117158	Placebo	02DEC2020/ Placebo		23DEC2020/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)
12211079	C4591001 1221 12211079	16-55	02DEC2020	117260	BNT162b2 (30 µg)	02DEC2020/ BNT162b2 (30 µg)	21DEC2020/ BNT162b2 (30 µg)		
12211080	C4591001 1221 12211080	16-55	02DEC2020	117257	Placebo	02DEC2020/ Placebo	21DEC2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12211081	C4591001 1221 12211081	16-55	02DEC2020	117265	Placebo	02DEC2020/ Placebo	22DEC2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	27JAN2021/ BNT162b2 (30 µg)
12211082	C4591001 1221 12211082	16-55	03DEC2020	117268	BNT162b2 (30 µg)	03DEC2020/ BNT162b2 (30 µg)	22DEC2020/ BNT162b2 (30 µg)		
12211083	C4591001 1221 12211083	16-55	03DEC2020	117438	BNT162b2 (30 µg)	03DEC2020/ BNT162b2 (30 µg)	22DEC2020/ BNT162b2 (30 µg)		
12211087	C4591001 1221 12211087	16-55	07DEC2020	117440	BNT162b2 (30 µg)	07DEC2020/ BNT162b2 (30 µg)	28DEC2020/ BNT162b2 (30 µg)		
12211088	C4591001 1221 12211088	16-55	07DEC2020	117446	Placebo	07DEC2020/ Placebo	28DEC2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12211089	C4591001 1221 12211089	16-55	08DEC2020	117447	Placebo	08DEC2020/ Placebo	28DEC2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
12211090	C4591001 1221 12211090	16-55	08DEC2020	117726	Placebo	08DEC2020/ Placebo	19JAN2021/ Placebo	04FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
12231001	C4591001 1223 12231001	16-55	26AUG2020	68430	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
12231003	C4591001 1223 12231003	16-55	27AUG2020	68434	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12231004	C4591001 1223 12231004	16-55	27AUG2020	68438	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12231005	C4591001 1223 12231005	16-55	27AUG2020	68440	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
12231008	C4591001 1223 12231008	16-55	27AUG2020	70097	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	14JAN2021/ BNT162b2 (30 µg)
12231014	C4591001 1223 12231014	16-55	28AUG2020	70098	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
12231016	C4591001 1223 12231016	16-55	28AUG2020	70104	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
12231022	C4591001 1223 12231022	16-55	28AUG2020	70108	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
12231024	C4591001 1223 12231024	16-55	28AUG2020	72425	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
12231025	C4591001 1223 12231025	16-55	28AUG2020	72426	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12231026	C4591001 1223 12231026	16-55	28AUG2020	72428	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
12231027	C4591001 1223 12231027	16-55	28AUG2020	72431	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12231028	C4591001 1223 12231028	16-55	28AUG2020	72835	Placebo	28AUG2020/ Placebo	17SEP2020/ Placebo	20DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12231030	C4591001 1223 12231030	16-55	29AUG2020	72837	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12231031	C4591001 1223 12231031	16-55	29AUG2020	72839	Placebo	29AUG2020/ Placebo	18SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12231034	C4591001 1223 12231034	16-55	29AUG2020	72843	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
12231035	C4591001 1223 12231035	16-55	29AUG2020	73799	Placebo	29AUG2020/ Placebo	18SEP2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12231036	C4591001 1223 12231036	16-55	31AUG2020	73800	Placebo	31AUG2020/ Placebo	22SEP2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
12231041	C4591001 1223 12231041	16-55	31AUG2020	73801	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
12231044	C4591001 1223 12231044	16-55	31AUG2020	73802	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
12231045	C4591001 1223 12231045	16-55	31AUG2020	75473	Placebo	31AUG2020/ Placebo	22SEP2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
12231050	C4591001 1223 12231050	16-55	31AUG2020	75476	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
12231051	C4591001 1223 12231051	16-55	01SEP2020	75478	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12231053	C4591001 1223 12231053	16-55	01SEP2020	75479	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
12231054	C4591001 1223 12231054	16-55	01SEP2020	76459	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo		
12231055	C4591001 1223 12231055	16-55	01SEP2020	76464	Placebo	01SEP2020/ Placebo	23SEP2020/ Placebo	20DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
12231057	C4591001 1223 12231057	16-55	01SEP2020	76465	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
12231061	C4591001 1223 12231061	16-55	01SEP2020	76466	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
12231062	C4591001 1223 12231062	16-55	01SEP2020	76878	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
12231063	C4591001 1223 12231063	16-55	01SEP2020	76880	Placebo	01SEP2020/ Placebo	23SEP2020/ Placebo		
12231064	C4591001 1223 12231064	16-55	01SEP2020	76885	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
12231066	C4591001 1223 12231066	16-55	01SEP2020	76888	Placebo	01SEP2020/ Placebo	21SEP2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
12231069	C4591001 1223 12231069	16-55	01SEP2020	77297	Placebo	01SEP2020/ Placebo	23SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12231072	C4591001 1223 12231072	16-55	01SEP2020	77302	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
12231073	C4591001 1223 12231073	16-55	01SEP2020	77306	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12231074	C4591001 1223 12231074	16-55	01SEP2020	77308	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
12231075	C4591001 1223 12231075	16-55	02SEP2020	77841	Placebo	02SEP2020/ Placebo	21SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
12231077	C4591001 1223 12231077	16-55	02SEP2020	77842	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
12231079	C4591001 1223 12231079	16-55	02SEP2020	77847	Placebo	02SEP2020/ Placebo	25SEP2020/ Placebo		
12231082	C4591001 1223 12231082	16-55	02SEP2020	77848	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
12231083	C4591001 1223 12231083	16-55	02SEP2020	78166	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
12231084	C4591001 1223 12231084	16-55	02SEP2020	78167	Placebo	02SEP2020/ Placebo	25SEP2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12231086	C4591001 1223 12231086	16-55	02SEP2020	78168	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12231087	C4591001 1223 12231087	16-55	02SEP2020	78169	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
12231090	C4591001 1223 12231090	16-55	02SEP2020	78569	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
12231094	C4591001 1223 12231094	16-55	02SEP2020	78570	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
12231095	C4591001 1223 12231095	16-55	02SEP2020	78577	Placebo	02SEP2020/ Placebo	25SEP2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
12231099	C4591001 1223 12231099	16-55	03SEP2020	78578	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
12231100	C4591001 1223 12231100	16-55	03SEP2020	79977	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
12231101	C4591001 1223 12231101	16-55	03SEP2020	79979	Placebo	03SEP2020/ Placebo	07OCT2020/ Placebo	20DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
12231105	C4591001 1223 12231105	16-55	04SEP2020	79982	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12231111	C4591001 1223 12231111	16-55	05SEP2020	79983	BNT162b2 (30 µg)	05SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
12231112	C4591001 1223 12231112	16-55	05SEP2020	82752	Placebo	05SEP2020/ Placebo	28SEP2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12231113	C4591001 1223 12231113	16-55	05SEP2020	82754	Placebo	05SEP2020/ Placebo	28SEP2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12231117	C4591001 1223 12231117	16-55	05SEP2020	82755	BNT162b2 (30 µg)	05SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
12231118	C4591001 1223 12231118	16-55	05SEP2020	82756	BNT162b2 (30 µg)	05SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
12231119	C4591001 1223 12231119	16-55	05SEP2020	82865	BNT162b2 (30 µg)	05SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
12231120	C4591001 1223 12231120	16-55	05SEP2020	82869	BNT162b2 (30 µg)	05SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
12231121	C4591001 1223 12231121	16-55	08SEP2020	82871	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
12231122	C4591001 1223 12231122	16-55	08SEP2020	82873	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
12231127	C4591001 1223 12231127	16-55	08SEP2020	83598	Placebo	08SEP2020/ Placebo	30SEP2020/ Placebo		
12231128	C4591001 1223 12231128	16-55	08SEP2020	83600	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
12231131	C4591001 1223 12231131	16-55	08SEP2020	83605	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12231133	C4591001 1223 12231133	16-55	08SEP2020	83608	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
12231135	C4591001 1223 12231135	16-55	09SEP2020	84798	Placebo	09SEP2020/ Placebo	01OCT2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12231137	C4591001 1223 12231137	16-55	09SEP2020	84800	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
12231141	C4591001 1223 12231141	16-55	09SEP2020	84805	Placebo	09SEP2020/ Placebo	01OCT2020/ Placebo	20DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
12231144	C4591001 1223 12231144	16-55	09SEP2020	84807	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
12231145	C4591001 1223 12231145	16-55	09SEP2020	85663	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
12231146	C4591001 1223 12231146	16-55	09SEP2020	85666	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
12231147	C4591001 1223 12231147	16-55	09SEP2020	85668	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
12231148	C4591001 1223 12231148	16-55	09SEP2020	85670	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
12231150	C4591001 1223 12231150	16-55	09SEP2020	86129	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12231151	C4591001 1223 12231151	16-55	09SEP2020	86132	Placebo	09SEP2020/ Placebo	02OCT2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12231152	C4591001 1223 12231152	16-55	10SEP2020	86140	Placebo	10SEP2020/ Placebo	02OCT2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
12231153	C4591001 1223 12231153	16-55	10SEP2020	86133	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
12231154	C4591001 1223 12231154	16-55	10SEP2020	86345	Placebo	10SEP2020/ Placebo	29SEP2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
12231157	C4591001 1223 12231157	16-55	10SEP2020	86350	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
12231160	C4591001 1223 12231160	16-55	14SEP2020	89456	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
12231161	C4591001 1223 12231161	16-55	14SEP2020	86353	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
12231162	C4591001 1223 12231162	16-55	14SEP2020	86356	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo		
12231163	C4591001 1223 12231163	16-55	14SEP2020	89419	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12231164	C4591001 1223 12231164	16-55	14SEP2020	89454	Placebo	14SEP2020/ Placebo	06OCT2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12231166	C4591001 1223 12231166	16-55	14SEP2020	89458	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
12231170	C4591001 1223 12231170	16-55	14SEP2020	257124	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
12231171	C4591001 1223 12231171	16-55	14SEP2020	89464	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
12231172	C4591001 1223 12231172	16-55	14SEP2020	89947	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12231173	C4591001 1223 12231173	16-55	14SEP2020	89952	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
12231174	C4591001 1223 12231174	16-55	15SEP2020	89953	Placebo	15SEP2020/ Placebo			
12231175	C4591001 1223 12231175	16-55	15SEP2020	89956	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
12231176	C4591001 1223 12231176	16-55	15SEP2020	90401	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
12231177	C4591001 1223 12231177	16-55	15SEP2020	90402	Placebo	15SEP2020/ Placebo	05OCT2020/ Placebo		
12231179	C4591001 1223 12231179	16-55	16SEP2020	90404	Placebo	16SEP2020/ Placebo	07OCT2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12231180	C4591001 1223 12231180	16-55	16SEP2020	90412	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
12231181	C4591001 1223 12231181	16-55	16SEP2020	91293	Placebo	16SEP2020/ Placebo	07OCT2020/ Placebo	20DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
12231183	C4591001 1223 12231183	16-55	16SEP2020	91294	Placebo	16SEP2020/ Placebo	06OCT2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
12231184	C4591001 1223 12231184	16-55	16SEP2020	91297	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
12231186	C4591001 1223 12231186	16-55	16SEP2020	91298	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
12231187	C4591001 1223 12231187	16-55	16SEP2020	91698	Placebo	16SEP2020/ Placebo	06OCT2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
12231188	C4591001 1223 12231188	16-55	16SEP2020	91700	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
12231189	C4591001 1223 12231189	16-55	17SEP2020	91704	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		
12231190	C4591001 1223 12231190	16-55	20OCT2020	110782	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
12231192	C4591001 1223 12231192	16-55	18SEP2020	91708	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12231195	C4591001 1223 12231195	16-55	21SEP2020	94781	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo		
12231196	C4591001 1223 12231196	16-55	21SEP2020	94784	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
12231197	C4591001 1223 12231197	16-55	21SEP2020	95839	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
12231199	C4591001 1223 12231199	16-55	21SEP2020	94785	Placebo	21SEP2020/ Placebo	15OCT2020/ Placebo		
12231200	C4591001 1223 12231200	16-55	21SEP2020	94790	BNT162b2 (30 µg)				
12231201	C4591001 1223 12231201	16-55	21SEP2020	95842	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
12231202	C4591001 1223 12231202	16-55	21SEP2020	95844	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
12231204	C4591001 1223 12231204	16-55	22SEP2020	95847	Placebo	22SEP2020/ Placebo	13OCT2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
12231205	C4591001 1223 12231205	16-55	22SEP2020	96630	Placebo	22SEP2020/ Placebo	12OCT2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12231210	C4591001 1223 12231210	16-55	29SEP2020	96632	BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12231211	C4591001 1223 12231211	16-55	29SEP2020	96633	BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)		
12231212	C4591001 1223 12231212	16-55	29SEP2020	96640	Placebo	29SEP2020/ Placebo	22OCT2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
12231213	C4591001 1223 12231213	16-55	30SEP2020	102162	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		
12231214	C4591001 1223 12231214	16-55	30SEP2020	102166	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		
12231216	C4591001 1223 12231216	16-55	30SEP2020	102167	Placebo	30SEP2020/ Placebo	30OCT2020/ Placebo		
12231219	C4591001 1223 12231219	16-55	30SEP2020	102169	Placebo	30SEP2020/ Placebo	23OCT2020/ Placebo		
12231220	C4591001 1223 12231220	16-55	01OCT2020	102953	Placebo	01OCT2020/ Placebo	22OCT2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
12231221	C4591001 1223 12231221	16-55	01OCT2020	102957	Placebo	01OCT2020/ Placebo	23OCT2020/ Placebo		
12231222	C4591001 1223 12231222	16-55	01OCT2020	102961	BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)		
12231223	C4591001 1223 12231223	16-55	06OCT2020	102964	BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		
12231224	C4591001 1223 12231224	16-55	06OCT2020	104335	Placebo	06OCT2020/ Placebo	27OCT2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12231225	C4591001 1223 12231225	16-55	06OCT2020	104339	BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
12231226	C4591001 1223 12231226	16-55	07OCT2020	104340	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
12231229	C4591001 1223 12231229	16-55	08OCT2020	104343	Placebo	08OCT2020/ Placebo	27OCT2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
12231230	C4591001 1223 12231230	16-55	08OCT2020	105381	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		
12231231	C4591001 1223 12231231	16-55	08OCT2020	105384	Placebo	08OCT2020/ Placebo	27OCT2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
12231232	C4591001 1223 12231232	16-55	09OCT2020	105387	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)		
12231233	C4591001 1223 12231233	16-55	12OCT2020	105388	Placebo	12OCT2020/ Placebo	04NOV2020/ Placebo		
12231234	C4591001 1223 12231234	16-55	12OCT2020	106482	BNT162b2 (30 µg)				
12231236	C4591001 1223 12231236	16-55	13OCT2020	106485	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		
12231237	C4591001 1223 12231237	16-55	13OCT2020	106487	Placebo	13OCT2020/ Placebo	02NOV2020/ Placebo	02MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12231238	C4591001 1223 12231238	16-55	14OCT2020	106488	Placebo	14OCT2020/ Placebo	02NOV2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
12231239	C4591001 1223 12231239	16-55	14OCT2020	107384	Placebo	14OCT2020/ Placebo	02NOV2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
12231241	C4591001 1223 12231241	16-55	14OCT2020	107386	BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
12231242	C4591001 1223 12231242	16-55	14OCT2020	107389	BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
12231243	C4591001 1223 12231243	16-55	14OCT2020	107390	Placebo	14OCT2020/ Placebo	04NOV2020/ Placebo	20DEC2020/ BNT162b2 (30 µg)	09JAN2021/ BNT162b2 (30 µg)
12231244	C4591001 1223 12231244	16-55	15OCT2020	107957	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
12231245	C4591001 1223 12231245	16-55	15OCT2020	107959	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
12231246	C4591001 1223 12231246	16-55	15OCT2020	107963	Placebo	15OCT2020/ Placebo	05NOV2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12231247	C4591001 1223 12231247†	16-55	15OCT2020	107964	Placebo	15OCT2020/ Placebo	04NOV2020/ Placebo	20DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
12231249	C4591001 1223 12231249	16-55	16OCT2020	108809	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12231251	C4591001 1223 12231251	16-55	16OCT2020	108813	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
12231252	C4591001 1223 12231252	16-55	16OCT2020	108817	Placebo	16OCT2020/ Placebo	04NOV2020/ Placebo		
12231253	C4591001 1223 12231253	16-55	23OCT2020	112183	Placebo	23OCT2020/ Placebo	12NOV2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
12231256	C4591001 1223 12231256	16-55	20OCT2020	108818	Placebo	20OCT2020/ Placebo	09NOV2020/ Placebo	02MAR2021/ BNT162b2 (30 µg)	
12231258	C4591001 1223 12231258	16-55	22OCT2020	110787	Placebo	22OCT2020/ Placebo	12NOV2020/ Placebo	20DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
12231260	C4591001 1223 12231260	16-55	20OCT2020	110785	Placebo	20OCT2020/ Placebo	09NOV2020/ Placebo	20DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
12231264	C4591001 1223 12231264	16-55	21OCT2020	110786	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
12231265	C4591001 1223 12231265	16-55	22OCT2020	112182	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
12241034	C4591001 1224 12241034	16-55	17AUG2020	50976	Placebo	17AUG2020/ Placebo	09SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12241053	C4591001 1224 12241053	16-55	20AUG2020	50978	Placebo	20AUG2020/ Placebo	09SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12241056	C4591001 1224 12241056	16-55	21AUG2020	60704	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12241058	C4591001 1224 12241058	16-55	21AUG2020	60706	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12241060	C4591001 1224 12241060	16-55	21AUG2020	60711	Placebo	21AUG2020/ Placebo	10SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	04JAN2021/ BNT162b2 (30 µg)
12241065	C4591001 1224 12241065	16-55	24AUG2020	60712	Placebo	24AUG2020/ Placebo		01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12241066	C4591001 1224 12241066	16-55	24AUG2020	63754	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12241067	C4591001 1224 12241067	16-55	24AUG2020	63756	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12241068	C4591001 1224 12241068	16-55	24AUG2020	63757	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
12241069	C4591001 1224 12241069	16-55	24AUG2020	63758	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12241072	C4591001 1224 12241072	16-55	24AUG2020	64073	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12241074	C4591001 1224 12241074	16-55	24AUG2020	64077	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12241075	C4591001 1224 12241075	16-55	25AUG2020	64078	Placebo	25AUG2020/ Placebo	14SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12241078	C4591001 1224 12241078	16-55	25AUG2020	64083	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12241079	C4591001 1224 12241079	16-55	25AUG2020	66071	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12241081	C4591001 1224 12241081	16-55	25AUG2020	66072	Placebo	25AUG2020/ Placebo	14SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12241083	C4591001 1224 12241083	16-55	26AUG2020	66075	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12241084	C4591001 1224 12241084	16-55	26AUG2020	67841	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12241085	C4591001 1224 12241085	16-55	26AUG2020	67844	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12241086	C4591001 1224 12241086	16-55	26AUG2020	67848	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12241088	C4591001 1224 12241088	16-55	27AUG2020	67851	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12241090	C4591001 1224 12241090	16-55	27AUG2020	70690	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12241091	C4591001 1224 12241091	16-55	27AUG2020	70691	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12241093	C4591001 1224 12241093	16-55	28AUG2020	70694	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12241096	C4591001 1224 12241096	16-55	28AUG2020	70695	Placebo	28AUG2020/ Placebo	17SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12241098	C4591001 1224 12241098	16-55	31AUG2020	74813	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
12241104	C4591001 1224 12241104	16-55	31AUG2020	74814	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
12241105	C4591001 1224 12241105	16-55	31AUG2020	74815	Placebo	31AUG2020/ Placebo	22SEP2020/ Placebo	06JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
12241114	C4591001 1224 12241114	16-55	01SEP2020	74816	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
12241117	C4591001 1224 12241117	16-55	01SEP2020	77035	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
12241118	C4591001 1224 12241118	16-55	01SEP2020	77037	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
12241119	C4591001 1224 12241119	16-55	01SEP2020	77039	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12241121	C4591001 1224 12241121	16-55	04SEP2020	81392	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
12241123	C4591001 1224 12241123	16-55	01SEP2020	77041	Placebo	01SEP2020/ Placebo	23SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
12241124	C4591001 1224 12241124	16-55	01SEP2020	77621	Placebo	01SEP2020/ Placebo	21SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12241126	C4591001 1224 12241126	16-55	02SEP2020	77625	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
12241128	C4591001 1224 12241128	16-55	02SEP2020	77629	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
12241131	C4591001 1224 12241131	16-55	03SEP2020	77632	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
12241132	C4591001 1224 12241132	16-55	03SEP2020	80141	Placebo	03SEP2020/ Placebo	23SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	04JAN2021/ BNT162b2 (30 µg)
12241133	C4591001 1224 12241133	16-55	03SEP2020	80142	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
12241134	C4591001 1224 12241134	16-55	03SEP2020	80143	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
12241135	C4591001 1224 12241135	16-55	04SEP2020	80152	Placebo	04SEP2020/ Placebo	23SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12241136	C4591001 1224 12241136	16-55	04SEP2020	81391	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
12241137	C4591001 1224 12241137	16-55	04SEP2020	81396	Placebo	04SEP2020/ Placebo	23SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12241138	C4591001 1224 12241138	16-55	04SEP2020	81399	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12241139	C4591001 1224 12241139	16-55	04SEP2020	81726	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
12241141	C4591001 1224 12241141	16-55	04SEP2020	81729	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
12241143	C4591001 1224 12241143	16-55	04SEP2020	81730	Placebo	04SEP2020/ Placebo	24SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
12241144	C4591001 1224 12241144	16-55	04SEP2020	81732	Placebo	04SEP2020/ Placebo	23SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12241146	C4591001 1224 12241146	16-55	04SEP2020	82422	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	27JAN2021/ BNT162b2 (30 µg)
12241147	C4591001 1224 12241147	16-55	08SEP2020	82425	Placebo	08SEP2020/ Placebo	30SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12241150	C4591001 1224 12241150	16-55	08SEP2020	82430	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12241151	C4591001 1224 12241151	16-55	08SEP2020	82431	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
12241152	C4591001 1224 12241152	16-55	08SEP2020	83756	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
12241155	C4591001 1224 12241155	16-55	16SEP2020	83761	Placebo	16SEP2020/ Placebo	05OCT2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12241156	C4591001 1224 12241156	16-55	16SEP2020	83763	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
12241158	C4591001 1224 12241158†	16-55	18SEP2020	83764	Placebo	18SEP2020/ Placebo	08OCT2020/ Placebo		
12241160	C4591001 1224 12241160	16-55	24SEP2020	98778	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
12241161	C4591001 1224 12241161	16-55	24SEP2020	98781	Placebo	24SEP2020/ Placebo	14OCT2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
12241162	C4591001 1224 12241162	16-55	24SEP2020	98784	Placebo	24SEP2020/ Placebo	14OCT2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	04JAN2021/ BNT162b2 (30 µg)
12241165	C4591001 1224 12241165	16-55	19NOV2020	98785	BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)	10DEC2020/ BNT162b2 (30 µg)		
12241166	C4591001 1224 12241166	16-55	20NOV2020	116554	BNT162b2 (30 µg)	20NOV2020/ BNT162b2 (30 µg)	10DEC2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12241167	C4591001 1224 12241167	16-55	20NOV2020	116556	Placebo	20NOV2020/ Placebo		04FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12241168	C4591001 1224 12241168	16-55	20NOV2020	116558	BNT162b2 (30 µg)	20NOV2020/ BNT162b2 (30 µg)	10DEC2020/ BNT162b2 (30 µg)		
12241169	C4591001 1224 12241169	16-55	23NOV2020	116559	Placebo	23NOV2020/ Placebo	15DEC2020/ Placebo	06JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
12241170	C4591001 1224 12241170	16-55	23NOV2020	116661	Placebo				
12241171	C4591001 1224 12241171	16-55	23NOV2020	116663	BNT162b2 (30 µg)	23NOV2020/ BNT162b2 (30 µg)	14DEC2020/ BNT162b2 (30 µg)		
12241172	C4591001 1224 12241172	16-55	23NOV2020	116665	Placebo	23NOV2020/ Placebo	14DEC2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12241173	C4591001 1224 12241173	16-55	30NOV2020	116668	BNT162b2 (30 µg)	30NOV2020/ BNT162b2 (30 µg)	21DEC2020/ BNT162b2 (30 µg)		
12241174	C4591001 1224 12241174	16-55	30NOV2020	116981	BNT162b2 (30 µg)	30NOV2020/ BNT162b2 (30 µg)	21DEC2020/ BNT162b2 (30 µg)		
12241175	C4591001 1224 12241175	16-55	30NOV2020	116983	Placebo	30NOV2020/ Placebo		03FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12241176	C4591001 1224 12241176	16-55	30NOV2020	116985	BNT162b2 (30 µg)	30NOV2020/ BNT162b2 (30 µg)			



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12241177	C4591001 1224 12241177	16-55	30NOV2020	116988	Placebo	30NOV2020/ Placebo	21DEC2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12241178	C4591001 1224 12241178	16-55	30NOV2020	117042	BNT162b2 (30 µg)	30NOV2020/ BNT162b2 (30 µg)	29DEC2020/ BNT162b2 (30 µg)		
12241179	C4591001 1224 12241179	16-55	30NOV2020	117043	Placebo	30NOV2020/ Placebo	29DEC2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12241180	C4591001 1224 12241180	16-55	03DEC2020	117044	BNT162b2 (30 µg)	03DEC2020/ BNT162b2 (30 µg)	22DEC2020/ BNT162b2 (30 µg)		
12241181	C4591001 1224 12241181	16-55	03DEC2020	117048	Placebo	03DEC2020/ Placebo	22DEC2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12241182	C4591001 1224 12241182	16-55	03DEC2020	117401	Placebo	03DEC2020/ Placebo	22DEC2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12241183	C4591001 1224 12241183	16-55	04DEC2020	117403	BNT162b2 (30 µg)	04DEC2020/ BNT162b2 (30 µg)	28DEC2020/ BNT162b2 (30 µg)		
12241184	C4591001 1224 12241184	16-55	04DEC2020	117405	Placebo	04DEC2020/ Placebo	28DEC2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12241185	C4591001 1224 12241185	16-55	04DEC2020	117408	BNT162b2 (30 µg)	04DEC2020/ BNT162b2 (30 µg)	28DEC2020/ BNT162b2 (30 µg)		
12241186	C4591001 1224 12241186	16-55	04DEC2020	117583	BNT162b2 (30 µg)	04DEC2020/ BNT162b2 (30 µg)	28DEC2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12241187	C4591001 1224 12241187	16-55	04DEC2020	117586	BNT162b2 (30 µg)	04DEC2020/ BNT162b2 (30 µg)	28DEC2020/ BNT162b2 (30 µg)		
12261194	C4591001 1226 12261194	16-55	14AUG2020	50013	Placebo	14AUG2020/ Placebo	05SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12261204	C4591001 1226 12261204	16-55	17AUG2020	50204	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12261205	C4591001 1226 12261205	16-55	17AUG2020	50206	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo		
12261206	C4591001 1226 12261206	16-55	17AUG2020	50207	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12261207	C4591001 1226 12261207	16-55	17AUG2020	52148	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	30JAN2021/ BNT162b2 (30 µg)	20FEB2021/ BNT162b2 (30 µg)
12261208	C4591001 1226 12261208	16-55	17AUG2020	52149	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12261210	C4591001 1226 12261210	16-55	17AUG2020	52152	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12261213	C4591001 1226 12261213	16-55	17AUG2020	52151	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	30JAN2021/ BNT162b2 (30 µg)	20FEB2021/ BNT162b2 (30 µg)
12261214	C4591001 1226 12261214	16-55	17AUG2020	52232	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12261215	C4591001 1226 12261215	16-55	17AUG2020	52234	Placebo	17AUG2020/ Placebo	07SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
12261216	C4591001 1226 12261216	16-55	21AUG2020	58574	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
12261217	C4591001 1226 12261217	16-55	17AUG2020	52237	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	30JAN2021/ BNT162b2 (30 µg)	20FEB2021/ BNT162b2 (30 µg)
12261218	C4591001 1226 12261218	16-55	17AUG2020	52239	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12261220	C4591001 1226 12261220	16-55	17AUG2020	52461	Placebo	17AUG2020/ Placebo	10SEP2020/ Placebo	23JAN2021/ BNT162b2 (30 µg)	13FEB2021/ BNT162b2 (30 µg)
12261223	C4591001 1226 12261223	16-55	17AUG2020	52462	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12261226	C4591001 1226 12261226	16-55	17AUG2020	52464	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
12261227	C4591001 1226 12261227	16-55	17AUG2020	52468	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12261228	C4591001 1226 12261228	16-55	17AUG2020	52507	Placebo	17AUG2020/ Placebo	09SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12261229	C4591001 1226 12261229	16-55	17AUG2020	52511	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12261230	C4591001 1226 12261230	16-55	17AUG2020	52508	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12261231	C4591001 1226 12261231	16-55	17AUG2020	52509	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12261232	C4591001 1226 12261232	16-55	17AUG2020	52581	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12261233	C4591001 1226 12261233	16-55	17AUG2020	52584	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12261234	C4591001 1226 12261234	16-55	17AUG2020	52656	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12261235	C4591001 1226 12261235	16-55	17AUG2020	52580	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12261236	C4591001 1226 12261236	16-55	17AUG2020	52654	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12261237	C4591001 1226 12261237	16-55	17AUG2020	52588	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	30JAN2021/ BNT162b2 (30 µg)	20FEB2021/ BNT162b2 (30 µg)
12261238	C4591001 1226 12261238	16-55	18AUG2020	52657	Placebo	18AUG2020/ Placebo	07SEP2020/ Placebo	30JAN2021/ BNT162b2 (30 µg)	20FEB2021/ BNT162b2 (30 µg)
12261239	C4591001 1226 12261239	16-55	18AUG2020	53773	Placebo	18AUG2020/ Placebo	07SEP2020/ Placebo	30JAN2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12261240	C4591001 1226 12261240	16-55	18AUG2020	52660	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12261241	C4591001 1226 12261241	16-55	18AUG2020	53775	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	23JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
12261242	C4591001 1226 12261242	16-55	18AUG2020	53774	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12261243	C4591001 1226 12261243	16-55	18AUG2020	53815	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12261244	C4591001 1226 12261244	16-55	18AUG2020	53816	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	23JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
12261245	C4591001 1226 12261245	16-55	18AUG2020	53819	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12261246	C4591001 1226 12261246	16-55	18AUG2020	53820	Placebo	18AUG2020/ Placebo	07SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12261247	C4591001 1226 12261247	16-55	18AUG2020	53776	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12261248	C4591001 1226 12261248	16-55	18AUG2020	53960	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12261249	C4591001 1226 12261249	16-55	27AUG2020	67932	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12261250	C4591001 1226 12261250	16-55	18AUG2020	53962	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12261251	C4591001 1226 12261251	16-55	18AUG2020	53963	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12261254	C4591001 1226 12261254	16-55	18AUG2020	54104	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12261256	C4591001 1226 12261256	16-55	18AUG2020	54105	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12261257	C4591001 1226 12261257	16-55	18AUG2020	53967	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12261258	C4591001 1226 12261258	16-55	18AUG2020	54108	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12261259	C4591001 1226 12261259	16-55	18AUG2020	54111	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12261261	C4591001 1226 12261261	16-55	18AUG2020	54247	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12261262	C4591001 1226 12261262	16-55	18AUG2020	54250	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12261263	C4591001 1226 12261263	16-55	18AUG2020	54249	Placebo	18AUG2020/ Placebo	07SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12261264	C4591001 1226 12261264	16-55	18AUG2020	54254	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12261266	C4591001 1226 12261266	16-55	18AUG2020	54308	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12261267	C4591001 1226 12261267	16-55	18AUG2020	54311	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12261269	C4591001 1226 12261269	16-55	18AUG2020	54414	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12261270	C4591001 1226 12261270	16-55	18AUG2020	54312	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12261271	C4591001 1226 12261271	16-55	18AUG2020	54315	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12261272	C4591001 1226 12261272	16-55	19AUG2020	54417	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo		
12261273	C4591001 1226 12261273	16-55	19AUG2020	54418	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12261274	C4591001 1226 12261274	16-55	19AUG2020	54424	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12261275	C4591001 1226 12261275	16-55	19AUG2020	55645	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12261276	C4591001 1226 12261276	16-55	19AUG2020	55641	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12261277	C4591001 1226 12261277	16-55	19AUG2020	55644	Placebo	19AUG2020/ Placebo	07SEP2020/ Placebo	23JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
12261278	C4591001 1226 12261278	16-55	19AUG2020	55648	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
12261279	C4591001 1226 12261279	16-55	19AUG2020	55702	Placebo	19AUG2020/ Placebo	14SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
12261280	C4591001 1226 12261280	16-55	19AUG2020	55699	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12261282	C4591001 1226 12261282	16-55	19AUG2020	55707	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12261285	C4591001 1226 12261285	16-55	19AUG2020	55708	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12261287	C4591001 1226 12261287	16-55	19AUG2020	55931	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12261288	C4591001 1226 12261288	16-55	19AUG2020	55932	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12261290	C4591001 1226 12261290	16-55	19AUG2020	55934	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12261291	C4591001 1226 12261291	16-55	19AUG2020	55935	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	27FEB2021/ BNT162b2 (30 µg)
12261292	C4591001 1226 12261292	16-55	19AUG2020	56105	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12261293	C4591001 1226 12261293	16-55	19AUG2020	56357	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12261294	C4591001 1226 12261294	16-55	19AUG2020	56114	Placebo	19AUG2020/ Placebo	07SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12261295	C4591001 1226 12261295	16-55	19AUG2020	56109	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
12261296	C4591001 1226 12261296	16-55	19AUG2020	56108	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12261298	C4591001 1226 12261298	16-55	20AUG2020	56359	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	12SEP2020/ BNT162b2 (30 µg)		
12261299	C4591001 1226 12261299	16-55	20AUG2020	56366	Placebo	20AUG2020/ Placebo	11SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12261300	C4591001 1226 12261300	16-55	20AUG2020	56368	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12261301	C4591001 1226 12261301	16-55	20AUG2020	57799	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12261302	C4591001 1226 12261302	16-55	20AUG2020	57801	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12261303	C4591001 1226 12261303	16-55	20AUG2020	57804	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12261304	C4591001 1226 12261304	16-55	20AUG2020	57870	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12261305	C4591001 1226 12261305	16-55	20AUG2020	57807	Placebo	20AUG2020/ Placebo	11SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12261306	C4591001 1226 12261306	16-55	20AUG2020	57869	Placebo	20AUG2020/ Placebo	11SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12261307	C4591001 1226 12261307	16-55	20AUG2020	57872	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12261308	C4591001 1226 12261308	16-55	20AUG2020	57875	Placebo	20AUG2020/ Placebo	11SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12261312	C4591001 1226 12261312	16-55	20AUG2020	58026	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12261313	C4591001 1226 12261313	16-55	20AUG2020	58029	Placebo	20AUG2020/ Placebo	11SEP2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12261314	C4591001 1226 12261314	16-55	20AUG2020	58033	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12261319	C4591001 1226 12261319	16-55	20AUG2020	58035	Placebo	20AUG2020/ Placebo	11SEP2020/ Placebo	23JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
12261321	C4591001 1226 12261321	16-55	20AUG2020	58313	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12261322	C4591001 1226 12261322	16-55	20AUG2020	58316	Placebo	20AUG2020/ Placebo	11SEP2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12261323	C4591001 1226 12261323	16-55	20AUG2020	58319	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12261324	C4591001 1226 12261324	16-55	20AUG2020	58320	Placebo	20AUG2020/ Placebo	11SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12261325	C4591001 1226 12261325	16-55	20AUG2020	58362	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12261326	C4591001 1226 12261326	16-55	20AUG2020	58363	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12261327	C4591001 1226 12261327	16-55	20AUG2020	58364	Placebo	20AUG2020/ Placebo	11SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12261328	C4591001 1226 12261328	16-55	20AUG2020	58370	Placebo	20AUG2020/ Placebo	11SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12261330	C4591001 1226 12261330	16-55	20AUG2020	58566	Placebo	20AUG2020/ Placebo	12SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12261331	C4591001 1226 12261331	16-55	20AUG2020	58571	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
12261332	C4591001 1226 12261332	16-55	20AUG2020	58572	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
12261336	C4591001 1226 12261336	16-55	21AUG2020	59917	Placebo	21AUG2020/ Placebo	09SEP2020/ Placebo	23JAN2021/ BNT162b2 (30 µg)	13FEB2021/ BNT162b2 (30 µg)
12261337	C4591001 1226 12261337	16-55	21AUG2020	59918	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12261338	C4591001 1226 12261338	16-55	21AUG2020	59919	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12261340	C4591001 1226 12261340	16-55	21AUG2020	59920	Placebo	21AUG2020/ Placebo	09SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12261341	C4591001 1226 12261341	16-55	21AUG2020	59969	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
12261343	C4591001 1226 12261343	16-55	21AUG2020	59970	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12261344	C4591001 1226 12261344	16-55	21AUG2020	59975	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12261345	C4591001 1226 12261345	16-55	21AUG2020	59974	Placebo	21AUG2020/ Placebo	09SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12261347	C4591001 1226 12261347	16-55	21AUG2020	60145	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12261348	C4591001 1226 12261348	16-55	21AUG2020	60140	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12261349	C4591001 1226 12261349	16-55	21AUG2020	60147	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
12261350	C4591001 1226 12261350	16-55	21AUG2020	60148	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
12261351	C4591001 1226 12261351	16-55	21AUG2020	60269	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12261352	C4591001 1226 12261352	16-55	21AUG2020	60438	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
12261354	C4591001 1226 12261354	16-55	21AUG2020	60270	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12261355	C4591001 1226 12261355	16-55	21AUG2020	60276	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12261356	C4591001 1226 12261356	16-55	21AUG2020	60439	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12261357	C4591001 1226 12261357	16-55	21AUG2020	60277	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12261358	C4591001 1226 12261358	16-55	21AUG2020	60445	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12261359	C4591001 1226 12261359	16-55	21AUG2020	60448	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	23JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
12261360	C4591001 1226 12261360	16-55	21AUG2020	60545	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	27FEB2021/ BNT162b2 (30 µg)
12261361	C4591001 1226 12261361	16-55	21AUG2020	60551	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12261362	C4591001 1226 12261362	16-55	21AUG2020	60555	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12261363	C4591001 1226 12261363	16-55	21AUG2020	60556	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12261364	C4591001 1226 12261364	16-55	21AUG2020	60629	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12261365	C4591001 1226 12261365	16-55	21AUG2020	60630	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12261369	C4591001 1226 12261369	16-55	21AUG2020	60632	Placebo	21AUG2020/ Placebo	10SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12261372	C4591001 1226 12261372	16-55	24AUG2020	63233	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12261373	C4591001 1226 12261373	16-55	24AUG2020	60633	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12261375	C4591001 1226 12261375	16-55	24AUG2020	63237	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
12261376	C4591001 1226 12261376	16-55	24AUG2020	63235	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
12261377	C4591001 1226 12261377	16-55	24AUG2020	63241	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12261379	C4591001 1226 12261379	16-55	24AUG2020	63281	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12261380	C4591001 1226 12261380	16-55	24AUG2020	63287	Placebo	24AUG2020/ Placebo	13OCT2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12261382	C4591001 1226 12261382	16-55	24AUG2020	63290	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12261383	C4591001 1226 12261383	16-55	24AUG2020	63291	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12261384	C4591001 1226 12261384	16-55	24AUG2020	63366	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
12261385	C4591001 1226 12261385	16-55	24AUG2020	63445	Placebo	24AUG2020/ Placebo	15SEP2020/ Placebo	23JAN2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12261387	C4591001 1226 12261387	16-55	24AUG2020	63441	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12261390	C4591001 1226 12261390	16-55	24AUG2020	63446	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12261391	C4591001 1226 12261391	16-55	24AUG2020	63448	Placebo	24AUG2020/ Placebo	13OCT2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	27FEB2021/ BNT162b2 (30 µg)
12261392	C4591001 1226 12261392	16-55	24AUG2020	63678	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12261393	C4591001 1226 12261393	16-55	24AUG2020	63685	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12261394	C4591001 1226 12261394	16-55	24AUG2020	63681	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12261395	C4591001 1226 12261395	16-55	24AUG2020	63686	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12261396	C4591001 1226 12261396	16-55	24AUG2020	63785	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12261397	C4591001 1226 12261397	16-55	25AUG2020	63787	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12261399	C4591001 1226 12261399	16-55	25AUG2020	63788	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12261400	C4591001 1226 12261400	16-55	25AUG2020	63793	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
12261403	C4591001 1226 12261403	16-55	25AUG2020	65334	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12261404	C4591001 1226 12261404	16-55	25AUG2020	65336	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12261405	C4591001 1226 12261405	16-55	25AUG2020	65339	Placebo	25AUG2020/ Placebo	14SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12261406	C4591001 1226 12261406	16-55	25AUG2020	65343	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	27FEB2021/ BNT162b2 (30 µg)
12261407	C4591001 1226 12261407	16-55	25AUG2020	65516	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	27FEB2021/ BNT162b2 (30 µg)
12261408	C4591001 1226 12261408	16-55	25AUG2020	65519	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12261409	C4591001 1226 12261409	16-55	25AUG2020	65522	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)			
12261410	C4591001 1226 12261410	16-55	25AUG2020	65523	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
12261411	C4591001 1226 12261411	16-55	25AUG2020	65743	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	23JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12261412	C4591001 1226 12261412	16-55	25AUG2020	65748	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12261413	C4591001 1226 12261413	16-55	25AUG2020	65749	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12261414	C4591001 1226 12261414	16-55	25AUG2020	65752	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12261415	C4591001 1226 12261415	16-55	25AUG2020	65873	Placebo	25AUG2020/ Placebo	22SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
12261416	C4591001 1226 12261416	16-55	25AUG2020	65882	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12261417	C4591001 1226 12261417	16-55	25AUG2020	65883	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12261418	C4591001 1226 12261418	16-55	25AUG2020	65884	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12261420	C4591001 1226 12261420	16-55	26AUG2020	67099	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12261421	C4591001 1226 12261421	16-55	26AUG2020	67101	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12261422	C4591001 1226 12261422	16-55	26AUG2020	67108	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12261423	C4591001 1226 12261423	16-55	26AUG2020	67105	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12261424	C4591001 1226 12261424	16-55	26AUG2020	67208	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
12261425	C4591001 1226 12261425	16-55	26AUG2020	67211	Placebo	26AUG2020/ Placebo	15SEP2020/ Placebo	23JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
12261426	C4591001 1226 12261426	16-55	26AUG2020	67215	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12261427	C4591001 1226 12261427	16-55	26AUG2020	67216	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12261428	C4591001 1226 12261428	16-55	26AUG2020	67352	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12261429	C4591001 1226 12261429	16-55	26AUG2020	67350	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12261430	C4591001 1226 12261430	16-55	26AUG2020	67353	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12261431	C4591001 1226 12261431	16-55	26AUG2020	67356	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	27FEB2021/ BNT162b2 (30 µg)
12261432	C4591001 1226 12261432	16-55	26AUG2020	67604	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12261433	C4591001 1226 12261433	16-55	26AUG2020	67485	Placebo	26AUG2020/ Placebo	19SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
12261434	C4591001 1226 12261434	16-55	26AUG2020	67488	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
12261436	C4591001 1226 12261436	16-55	26AUG2020	67491	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12261437	C4591001 1226 12261437	16-55	26AUG2020	67738	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	23JAN2021/ BNT162b2 (30 µg)	13FEB2021/ BNT162b2 (30 µg)
12261439	C4591001 1226 12261439	16-55	26AUG2020	67492	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12261440	C4591001 1226 12261440	16-55	26AUG2020	67740	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12261441	C4591001 1226 12261441	16-55	26AUG2020	67605	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12261442	C4591001 1226 12261442	16-55	26AUG2020	67606	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12261443	C4591001 1226 12261443	16-55	26AUG2020	67611	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12261444	C4591001 1226 12261444	16-55	26AUG2020	67734	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12261445	C4591001 1226 12261445	16-55	26AUG2020	67742	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12261447	C4591001 1226 12261447	16-55	26AUG2020	67930	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
12261448	C4591001 1226 12261448	16-55	27AUG2020	67936	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		
12261449	C4591001 1226 12261449	16-55	27AUG2020	67934	Placebo	27AUG2020/ Placebo	19SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
12261451	C4591001 1226 12261451	16-55	27AUG2020	69417	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		
12261452	C4591001 1226 12261452	16-55	27AUG2020	69420	Placebo	27AUG2020/ Placebo	22SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12261454	C4591001 1226 12261454	16-55	27AUG2020	69421	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		
12261455	C4591001 1226 12261455	16-55	27AUG2020	69423	Placebo	27AUG2020/ Placebo	19SEP2020/ Placebo		
12261456	C4591001 1226 12261456	16-55	27AUG2020	69541	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		
12261457	C4591001 1226 12261457	16-55	27AUG2020	69544	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12261459	C4591001 1226 12261459	16-55	27AUG2020	69536	Placebo	27AUG2020/ Placebo	21SEP2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12261460	C4591001 1226 12261460	16-55	27AUG2020	69539	Placebo	27AUG2020/ Placebo	19SEP2020/ Placebo	23JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
12261463	C4591001 1226 12261463	16-55	27AUG2020	69689	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		
12261465	C4591001 1226 12261465	16-55	27AUG2020	69692	Placebo	27AUG2020/ Placebo	23SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12261466	C4591001 1226 12261466	16-55	27AUG2020	69941	Placebo	27AUG2020/ Placebo	21SEP2020/ Placebo	23JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
12261468	C4591001 1226 12261468	16-55	27AUG2020	69694	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
12261469	C4591001 1226 12261469	16-55	27AUG2020	69696	Placebo	27AUG2020/ Placebo	21SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12261470	C4591001 1226 12261470	16-55	27AUG2020	70068	Placebo	27AUG2020/ Placebo	19SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12261471	C4591001 1226 12261471	16-55	27AUG2020	69943	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		
12261472	C4591001 1226 12261472	16-55	27AUG2020	69945	Placebo	27AUG2020/ Placebo	21SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12261474	C4591001 1226 12261474	16-55	27AUG2020	69951	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		
12261475	C4591001 1226 12261475	16-55	27AUG2020	70071	Placebo	27AUG2020/ Placebo	19SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12261476	C4591001 1226 12261476	16-55	27AUG2020	70061	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		
12261478	C4591001 1226 12261478	16-55	27AUG2020	70065	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
12261479	C4591001 1226 12261479	16-55	27AUG2020	70233	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		
12261480	C4591001 1226 12261480	16-55	27AUG2020	70231	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		
12261482	C4591001 1226 12261482	16-55	27AUG2020	70234	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12261483	C4591001 1226 12261483	16-55	27AUG2020	70235	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12261484	C4591001 1226 12261484	16-55	31AUG2020	71638	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
12261485	C4591001 1226 12261485	16-55	27AUG2020	70385	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12261486	C4591001 1226 12261486	16-55	27AUG2020	70390	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12261488	C4591001 1226 12261488	16-55	27AUG2020	70392	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12261489	C4591001 1226 12261489	16-55	27AUG2020	70394	Placebo	27AUG2020/ Placebo	21SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12261490	C4591001 1226 12261490	16-55	28AUG2020	71471	Placebo	28AUG2020/ Placebo	21SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
12261491	C4591001 1226 12261491	16-55	28AUG2020	71469	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		
12261492	C4591001 1226 12261492	16-55	28AUG2020	71454	Placebo	28AUG2020/ Placebo	19SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12261493	C4591001 1226 12261493	16-55	28AUG2020	71456	Placebo	28AUG2020/ Placebo	19SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
12261494	C4591001 1226 12261494	16-55	28AUG2020	71457	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		
12261495	C4591001 1226 12261495	16-55	28AUG2020	71476	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		
12261496	C4591001 1226 12261496	16-55	28AUG2020	71460	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12261497	C4591001 1226 12261497	16-55	28AUG2020	71475	Placebo	28AUG2020/ Placebo	19SEP2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	27FEB2021/ BNT162b2 (30 µg)
12261498	C4591001 1226 12261498	16-55	28AUG2020	71538	Placebo	28AUG2020/ Placebo	19SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12261500	C4591001 1226 12261500	16-55	28AUG2020	71542	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		
12261501	C4591001 1226 12261501	16-55	28AUG2020	71543	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		
12261502	C4591001 1226 12261502	16-55	28AUG2020	71548	Placebo	28AUG2020/ Placebo	21SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12261503	C4591001 1226 12261503	16-55	28AUG2020	71637	Placebo	28AUG2020/ Placebo	24SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
12261504	C4591001 1226 12261504	16-55	01SEP2020	76469	Placebo	01SEP2020/ Placebo	21SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12261505	C4591001 1226 12261505	16-55	01SEP2020	76474	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
12261507	C4591001 1226 12261507	16-55	01SEP2020	71644	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
12261508	C4591001 1226 12261508	16-55	01SEP2020	76479	Placebo	01SEP2020/ Placebo	21SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12261509	C4591001 1226 12261509	16-55	01SEP2020	71643	Placebo	01SEP2020/ Placebo	21SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12261511	C4591001 1226 12261511	16-55	01SEP2020	76529	Placebo	01SEP2020/ Placebo	21SEP2020/ Placebo	23JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
12261512	C4591001 1226 12261512	16-55	01SEP2020	76478	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
12261514	C4591001 1226 12261514	16-55	04SEP2020	81295	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
12261515	C4591001 1226 12261515	16-55	04SEP2020	80197	Placebo	04SEP2020/ Placebo	23SEP2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	27FEB2021/ BNT162b2 (30 µg)
12261516	C4591001 1226 12261516	16-55	05SEP2020	82641	BNT162b2 (30 µg)	05SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
12261517	C4591001 1226 12261517	16-55	04SEP2020	81293	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
12261518	C4591001 1226 12261518	16-55	03SEP2020	80194	Placebo	03SEP2020/ Placebo	22SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12261519	C4591001 1226 12261519	16-55	03SEP2020	76532	Placebo	03SEP2020/ Placebo	22SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12261520	C4591001 1226 12261520	16-55	03SEP2020	76538	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12261521	C4591001 1226 12261521	16-55	05SEP2020	81296	Placebo	05SEP2020/ Placebo	24SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12261522	C4591001 1226 12261522	16-55	03SEP2020	76533	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
12261524	C4591001 1226 12261524	16-55	03SEP2020	80189	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
12261525	C4591001 1226 12261525	16-55	03SEP2020	80192	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
12261526	C4591001 1226 12261526	16-55	05SEP2020	81297	Placebo	05SEP2020/ Placebo	24SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12261529	C4591001 1226 12261529	16-55	05SEP2020	82625	Placebo	05SEP2020/ Placebo	28SEP2020/ Placebo	23JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
12261530	C4591001 1226 12261530	16-55	05SEP2020	82628	Placebo	05SEP2020/ Placebo	24SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12261531	C4591001 1226 12261531	16-55	05SEP2020	82631	BNT162b2 (30 µg)	05SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
12261532	C4591001 1226 12261532	16-55	05SEP2020	82643	Placebo	05SEP2020/ Placebo	24SEP2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12261533	C4591001 1226 12261533	16-55	05SEP2020	82636	BNT162b2 (30 µg)	05SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12261535	C4591001 1226 12261535	16-55	05SEP2020	82646	BNT162b2 (30 µg)	05SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
12261538	C4591001 1226 12261538	16-55	08SEP2020	83406	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12261540	C4591001 1226 12261540	16-55	05SEP2020	82648	Placebo	05SEP2020/ Placebo	24SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12261542	C4591001 1226 12261542	16-55	05SEP2020	82668	BNT162b2 (30 µg)	05SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
12261543	C4591001 1226 12261543	16-55	05SEP2020	82665	BNT162b2 (30 µg)	05SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
12261544	C4591001 1226 12261544	16-55	05SEP2020	82670	Placebo	05SEP2020/ Placebo	24SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12261545	C4591001 1226 12261545	16-55	05SEP2020	82687	BNT162b2 (30 µg)	05SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
12261546	C4591001 1226 12261546	16-55	05SEP2020	82672	Placebo	05SEP2020/ Placebo	25SEP2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	27FEB2021/ BNT162b2 (30 µg)
12261547	C4591001 1226 12261547	16-55	07SEP2020	82852	BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
12261548	C4591001 1226 12261548	16-55	05SEP2020	82688	Placebo	05SEP2020/ Placebo	24SEP2020/ Placebo	23JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12261549	C4591001 1226 12261549	16-55	05SEP2020	82693	Placebo	05SEP2020/ Placebo	24SEP2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	27FEB2021/ BNT162b2 (30 µg)
12261551	C4591001 1226 12261551	16-55	05SEP2020	82694	BNT162b2 (30 µg)	05SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
12261553	C4591001 1226 12261553	16-55	05SEP2020	82697	BNT162b2 (30 µg)	05SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
12261554	C4591001 1226 12261554	16-55	05SEP2020	82698	Placebo	05SEP2020/ Placebo	24SEP2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
12261555	C4591001 1226 12261555	16-55	05SEP2020	82706	Placebo	05SEP2020/ Placebo	24SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12261557	C4591001 1226 12261557	16-55	05SEP2020	82724	BNT162b2 (30 µg)	05SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
12261559	C4591001 1226 12261559	16-55	05SEP2020	82722	BNT162b2 (30 µg)	05SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
12261560	C4591001 1226 12261560	16-55	05SEP2020	82707	BNT162b2 (30 µg)	05SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
12261561	C4591001 1226 12261561	16-55	05SEP2020	82727	Placebo	05SEP2020/ Placebo	25SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12261562	C4591001 1226 12261562	16-55	05SEP2020	82730	Placebo	05SEP2020/ Placebo	25SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12261563	C4591001 1226 12261563	16-55	05SEP2020	82761	Placebo	05SEP2020/ Placebo	25SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12261564	C4591001 1226 12261564	16-55	05SEP2020	82762	BNT162b2 (30 µg)	05SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
12261566	C4591001 1226 12261566	16-55	05SEP2020	82767	Placebo	05SEP2020/ Placebo	24SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12261567	C4591001 1226 12261567	16-55	05SEP2020	82768	BNT162b2 (30 µg)	05SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
12261568	C4591001 1226 12261568	16-55	05SEP2020	82800	BNT162b2 (30 µg)	05SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
12261569	C4591001 1226 12261569	16-55	05SEP2020	82793	Placebo	05SEP2020/ Placebo	25SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12261570	C4591001 1226 12261570	16-55	05SEP2020	82801	Placebo	05SEP2020/ Placebo	25SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12261571	C4591001 1226 12261571	16-55	05SEP2020	82803	BNT162b2 (30 µg)	05SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
12261572	C4591001 1226 12261572	16-55	05SEP2020	82807	BNT162b2 (30 µg)	05SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
12261574	C4591001 1226 12261574	16-55	05SEP2020	82809	BNT162b2 (30 µg)	05SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12261575	C4591001 1226 12261575	16-55	05SEP2020	82814	Placebo	05SEP2020/ Placebo	28SEP2020/ Placebo	13FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
12261576	C4591001 1226 12261576	16-55	05SEP2020	82815	Placebo	05SEP2020/ Placebo	28SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12261577	C4591001 1226 12261577	16-55	05SEP2020	82841	BNT162b2 (30 µg)	05SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
12261578	C4591001 1226 12261578	16-55	05SEP2020	82849	Placebo	05SEP2020/ Placebo	24SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	27FEB2021/ BNT162b2 (30 µg)
12261579	C4591001 1226 12261579	16-55	05SEP2020	82851	Placebo	05SEP2020/ Placebo	28SEP2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	27FEB2021/ BNT162b2 (30 µg)
12261581	C4591001 1226 12261581	16-55	07SEP2020	83033	Placebo	07SEP2020/ Placebo	28SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
12261582	C4591001 1226 12261582	16-55	07SEP2020	83037	BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
12261583	C4591001 1226 12261583	16-55	07SEP2020	83035	BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
12261584	C4591001 1226 12261584	16-55	07SEP2020	83039	Placebo	07SEP2020/ Placebo	28SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
12261585	C4591001 1226 12261585	16-55	07SEP2020	83069	Placebo	07SEP2020/ Placebo	30SEP2020/ Placebo	23JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12261586	C4591001 1226 12261586	16-55	07SEP2020	83045	Placebo	07SEP2020/ Placebo	28SEP2020/ Placebo	23JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
12261587	C4591001 1226 12261587	16-55	07SEP2020	83048	Placebo	07SEP2020/ Placebo	28SEP2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	27FEB2021/ BNT162b2 (30 µg)
12261588	C4591001 1226 12261588	16-55	07SEP2020	83070	Placebo	07SEP2020/ Placebo	28SEP2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	27FEB2021/ BNT162b2 (30 µg)
12261590	C4591001 1226 12261590	16-55	07SEP2020	83050	BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
12261591	C4591001 1226 12261591	16-55	07SEP2020	83051	BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
12261592	C4591001 1226 12261592	16-55	07SEP2020	83076	BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
12261593	C4591001 1226 12261593	16-55	07SEP2020	83077	BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
12261594	C4591001 1226 12261594	16-55	07SEP2020	83092	Placebo	07SEP2020/ Placebo	28SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12261595	C4591001 1226 12261595	16-55	07SEP2020	83090	BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
12261596	C4591001 1226 12261596	16-55	07SEP2020	83084	BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12261597	C4591001 1226 12261597	16-55	07SEP2020	83107	Placebo	07SEP2020/ Placebo	30SEP2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	27FEB2021/ BNT162b2 (30 µg)
12261598	C4591001 1226 12261598	16-55	07SEP2020	83113	Placebo	07SEP2020/ Placebo	29SEP2020/ Placebo	23JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
12261599	C4591001 1226 12261599	16-55	07SEP2020	83114	BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
12261600	C4591001 1226 12261600	16-55	07SEP2020	83086	Placebo	07SEP2020/ Placebo	30SEP2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
12261601	C4591001 1226 12261601	16-55	07SEP2020	83116	BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
12261602	C4591001 1226 12261602	16-55	07SEP2020	83118	BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
12261603	C4591001 1226 12261603	16-55	07SEP2020	83121	Placebo	07SEP2020/ Placebo	02OCT2020/ Placebo	23JAN2021/ BNT162b2 (30 µg)	13FEB2021/ BNT162b2 (30 µg)
12261604	C4591001 1226 12261604	16-55	07SEP2020	83127	Placebo	07SEP2020/ Placebo	30SEP2020/ Placebo	23JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
12261606	C4591001 1226 12261606	16-55	07SEP2020	83128	BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
12261607	C4591001 1226 12261607	16-55	07SEP2020	83159	BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12261609	C4591001 1226 12261609	16-55	07SEP2020	83129	BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
12261610	C4591001 1226 12261610	16-55	07SEP2020	83137	Placebo	07SEP2020/ Placebo	28SEP2020/ Placebo	23JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
12261611	C4591001 1226 12261611	16-55	07SEP2020	83138	Placebo	07SEP2020/ Placebo	28SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	27FEB2021/ BNT162b2 (30 µg)
12261612	C4591001 1226 12261612	16-55	07SEP2020	83140	BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
12261614	C4591001 1226 12261614	16-55	07SEP2020	83157	BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
12261615	C4591001 1226 12261615	16-55	07SEP2020	83181	BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
12261616	C4591001 1226 12261616	16-55	07SEP2020	83163	Placebo	07SEP2020/ Placebo	28SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
12261618	C4591001 1226 12261618	16-55	07SEP2020	83187	Placebo	07SEP2020/ Placebo	01OCT2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
12261619	C4591001 1226 12261619	16-55	07SEP2020	83186	BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
12261620	C4591001 1226 12261620	16-55	07SEP2020	83180	Placebo	07SEP2020/ Placebo	30SEP2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	27FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12261621	C4591001 1226 12261621	16-55	07SEP2020	83189	BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
12261622	C4591001 1226 12261622	16-55	08SEP2020	83196	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
12261623	C4591001 1226 12261623	16-55	08SEP2020	83197	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
12261624	C4591001 1226 12261624	16-55	08SEP2020	83198	Placebo	08SEP2020/ Placebo	30SEP2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12261625	C4591001 1226 12261625	16-55	08SEP2020	83412	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo	23JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
12261627	C4591001 1226 12261627	16-55	08SEP2020	83413	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
12261628	C4591001 1226 12261628	16-55	08SEP2020	83415	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
12261629	C4591001 1226 12261629	16-55	08SEP2020	83623	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
12261630	C4591001 1226 12261630	16-55	08SEP2020	83628	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12261631	C4591001 1226 12261631	16-55	08SEP2020	83630	Placebo	08SEP2020/ Placebo	30SEP2020/ Placebo	23JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12261632	C4591001 1226 12261632	16-55	09SEP2020	83632	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
12261633	C4591001 1226 12261633	16-55	09SEP2020	84749	Placebo	09SEP2020/ Placebo	29SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
12261634	C4591001 1226 12261634	16-55	09SEP2020	84750	Placebo	09SEP2020/ Placebo	29SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
12261636	C4591001 1226 12261636	16-55	09SEP2020	84754	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
12261637	C4591001 1226 12261637	16-55	09SEP2020	84759	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
12261641	C4591001 1226 12261641	16-55	09SEP2020	85207	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
12261643	C4591001 1226 12261643	16-55	09SEP2020	85208	Placebo	09SEP2020/ Placebo	29SEP2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	27FEB2021/ BNT162b2 (30 µg)
12261644	C4591001 1226 12261644	16-55	10SEP2020	85209	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
12261646	C4591001 1226 12261646	16-55	10SEP2020	85216	Placebo	10SEP2020/ Placebo	30SEP2020/ Placebo		
12261647	C4591001 1226 12261647	16-55	10SEP2020	86321	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12261648	C4591001 1226 12261648	16-55	10SEP2020	86322	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
12261649	C4591001 1226 12261649	16-55	10SEP2020	86432	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
12261650	C4591001 1226 12261650	16-55	10SEP2020	86326	Placebo	10SEP2020/ Placebo	30SEP2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	27FEB2021/ BNT162b2 (30 µg)
12261651	C4591001 1226 12261651	16-55	10SEP2020	86327	Placebo	10SEP2020/ Placebo	30SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12261653	C4591001 1226 12261653	16-55	10SEP2020	86433	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
12261654	C4591001 1226 12261654	16-55	10SEP2020	86717	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
12261655	C4591001 1226 12261655	16-55	10SEP2020	86719	Placebo	10SEP2020/ Placebo	30SEP2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	27FEB2021/ BNT162b2 (30 µg)
12261656	C4591001 1226 12261656	16-55	10SEP2020	86435	Placebo	10SEP2020/ Placebo	29SEP2020/ Placebo	23JAN2021/ BNT162b2 (30 µg)	13FEB2021/ BNT162b2 (30 µg)
12261657	C4591001 1226 12261657	16-55	10SEP2020	86722	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
12261659	C4591001 1226 12261659	16-55	10SEP2020	86440	Placebo	10SEP2020/ Placebo	29SEP2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12261660	C4591001 1226 12261660	16-55	11SEP2020	86727	Placebo	11SEP2020/ Placebo	30SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12261661	C4591001 1226 12261661	16-55	11SEP2020	87788	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
12261664	C4591001 1226 12261664	16-55	12SEP2020	87791	Placebo	12SEP2020/ Placebo	01OCT2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	27FEB2021/ BNT162b2 (30 µg)
12261665	C4591001 1226 12261665	16-55	12SEP2020	87795	BNT162b2 (30 µg)	12SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
12261666	C4591001 1226 12261666	16-55	12SEP2020	89022	BNT162b2 (30 µg)	12SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
12261667	C4591001 1226 12261667	16-55	12SEP2020	89027	BNT162b2 (30 µg)	12SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
12261668	C4591001 1226 12261668	16-55	12SEP2020	89032	Placebo	12SEP2020/ Placebo	01OCT2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	27FEB2021/ BNT162b2 (30 µg)
12261669	C4591001 1226 12261669	16-55	12SEP2020	89031	Placebo	12SEP2020/ Placebo	01OCT2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	27FEB2021/ BNT162b2 (30 µg)
12261670	C4591001 1226 12261670	16-55	12SEP2020	89034	BNT162b2 (30 µg)	12SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
12261672	C4591001 1226 12261672	16-55	12SEP2020	89053	Placebo	12SEP2020/ Placebo	02OCT2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	27FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12261673	C4591001 1226 12261673	16-55	12SEP2020	89047	BNT162b2 (30 µg)	12SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
12261674	C4591001 1226 12261674	16-55	12SEP2020	89049	Placebo	12SEP2020/ Placebo	02OCT2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	27FEB2021/ BNT162b2 (30 µg)
12261675	C4591001 1226 12261675	16-55	12SEP2020	89040	Placebo	12SEP2020/ Placebo	02OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
12261676	C4591001 1226 12261676	16-55	12SEP2020	89042	Placebo	12SEP2020/ Placebo	02OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
12261677	C4591001 1226 12261677	16-55	12SEP2020	89051	BNT162b2 (30 µg)	12SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
12261679	C4591001 1226 12261679	16-55	12SEP2020	89067	BNT162b2 (30 µg)	12SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
12261680	C4591001 1226 12261680	16-55	12SEP2020	89064	BNT162b2 (30 µg)	12SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
12261681	C4591001 1226 12261681	16-55	12SEP2020	89065	Placebo	12SEP2020/ Placebo	02OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
12261682	C4591001 1226 12261682	16-55	12SEP2020	89068	Placebo	12SEP2020/ Placebo	02OCT2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12261683	C4591001 1226 12261683	16-55	12SEP2020	89071	BNT162b2 (30 µg)	12SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12261684	C4591001 1226 12261684	16-55	12SEP2020	89069	BNT162b2 (30 µg)	12SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
12261685	C4591001 1226 12261685	16-55	12SEP2020	89084	Placebo	12SEP2020/ Placebo	02OCT2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12261686	C4591001 1226 12261686	16-55	12SEP2020	89073	Placebo	12SEP2020/ Placebo	05OCT2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12261687	C4591001 1226 12261687	16-55	12SEP2020	89079	Placebo	12SEP2020/ Placebo	02OCT2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
12261688	C4591001 1226 12261688	16-55	12SEP2020	89087	BNT162b2 (30 µg)	12SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
12261689	C4591001 1226 12261689	16-55	12SEP2020	89090	Placebo	12SEP2020/ Placebo	02OCT2020/ Placebo	23JAN2021/ BNT162b2 (30 µg)	13FEB2021/ BNT162b2 (30 µg)
12261690	C4591001 1226 12261690	16-55	12SEP2020	89091	BNT162b2 (30 µg)	12SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
12261691	C4591001 1226 12261691	16-55	12SEP2020	89105	BNT162b2 (30 µg)	12SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
12261692	C4591001 1226 12261692	16-55	12SEP2020	89107	Placebo	12SEP2020/ Placebo	02OCT2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12261693	C4591001 1226 12261693	16-55	12SEP2020	89110	Placebo	12SEP2020/ Placebo	02OCT2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12261694	C4591001 1226 12261694	16-55	12SEP2020	89119	Placebo	12SEP2020/ Placebo	02OCT2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	27FEB2021/ BNT162b2 (30 µg)
12261695	C4591001 1226 12261695	16-55	12SEP2020	89114	BNT162b2 (30 µg)	12SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
12261696	C4591001 1226 12261696	16-55	12SEP2020	89122	BNT162b2 (30 µg)	12SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
12261697	C4591001 1226 12261697	16-55	12SEP2020	89125	BNT162b2 (30 µg)	12SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
12261698	C4591001 1226 12261698	16-55	14SEP2020	89127	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	27FEB2021/ BNT162b2 (30 µg)
12261699	C4591001 1226 12261699	16-55	14SEP2020	89298	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
12261701	C4591001 1226 12261701	16-55	14SEP2020	89306	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	27FEB2021/ BNT162b2 (30 µg)
12261702	C4591001 1226 12261702	16-55	14SEP2020	89307	Placebo	14SEP2020/ Placebo	06OCT2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12261703	C4591001 1226 12261703	16-55	14SEP2020	89300	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
12261704	C4591001 1226 12261704	16-55	14SEP2020	89385	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12261705	C4591001 1226 12261705	16-55	14SEP2020	89390	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo	23JAN2021/ BNT162b2 (30 µg)	13FEB2021/ BNT162b2 (30 µg)
12261706	C4591001 1226 12261706	16-55	14SEP2020	89386	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
12261707	C4591001 1226 12261707	16-55	14SEP2020	89392	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
12261709	C4591001 1226 12261709	16-55	14SEP2020	89447	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
12261710	C4591001 1226 12261710	16-55	14SEP2020	89583	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12261711	C4591001 1226 12261711	16-55	14SEP2020	89449	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
12261712	C4591001 1226 12261712	16-55	14SEP2020	89579	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
12261713	C4591001 1226 12261713	16-55	14SEP2020	89451	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
12261714	C4591001 1226 12261714	16-55	14SEP2020	89448	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
12261715	C4591001 1226 12261715	16-55	14SEP2020	89636	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12261716	C4591001 1226 12261716	16-55	14SEP2020	89576	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
12261717	C4591001 1226 12261717	16-55	14SEP2020	89584	Placebo	14SEP2020/ Placebo	07OCT2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12261718	C4591001 1226 12261718	16-55	14SEP2020	89641	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo		
12261719	C4591001 1226 12261719	16-55	14SEP2020	89638	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
12261720	C4591001 1226 12261720	16-55	14SEP2020	89643	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
12261721	C4591001 1226 12261721	16-55	14SEP2020	89731	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
12261722	C4591001 1226 12261722	16-55	14SEP2020	89732	Placebo	14SEP2020/ Placebo	07OCT2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
12261723	C4591001 1226 12261723	16-55	15SEP2020	89735	Placebo	15SEP2020/ Placebo	06OCT2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	27FEB2021/ BNT162b2 (30 µg)
12261724	C4591001 1226 12261724	16-55	15SEP2020	90131	Placebo	15SEP2020/ Placebo	05OCT2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
12261725	C4591001 1226 12261725	16-55	15SEP2020	90129	Placebo	15SEP2020/ Placebo	05OCT2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	27FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12261726	C4591001 1226 12261726	16-55	15SEP2020	89737	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
12261728	C4591001 1226 12261728	16-55	15SEP2020	90133	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
12261729	C4591001 1226 12261729	16-55	15SEP2020	90135	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
12261730	C4591001 1226 12261730	16-55	15SEP2020	90199	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
12261731	C4591001 1226 12261731	16-55	15SEP2020	90204	Placebo	15SEP2020/ Placebo	06OCT2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	
12261732	C4591001 1226 12261732	16-55	15SEP2020	90206	Placebo	15SEP2020/ Placebo	06OCT2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
12261733	C4591001 1226 12261733	16-55	15SEP2020	90208	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
12261734	C4591001 1226 12261734	16-55	15SEP2020	90366	Placebo	15SEP2020/ Placebo	06OCT2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	27FEB2021/ BNT162b2 (30 µg)
12261736	C4591001 1226 12261736	16-55	15SEP2020	90370	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
12261737	C4591001 1226 12261737	16-55	15SEP2020	90374	Placebo	15SEP2020/ Placebo	06OCT2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12261738	C4591001 1226 12261738	16-55	15SEP2020	90371	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
12261739	C4591001 1226 12261739	16-55	16SEP2020	90873	Placebo	16SEP2020/ Placebo	08OCT2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	27FEB2021/ BNT162b2 (30 µg)
12261740	C4591001 1226 12261740	16-55	16SEP2020	90874	Placebo	16SEP2020/ Placebo	06OCT2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
12261741	C4591001 1226 12261741	16-55	16SEP2020	90876	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
12261742	C4591001 1226 12261742	16-55	16SEP2020	90875	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
12261743	C4591001 1226 12261743	16-55	16SEP2020	90920	Placebo	16SEP2020/ Placebo	06OCT2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12261745	C4591001 1226 12261745	16-55	16SEP2020	90922	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
12261746	C4591001 1226 12261746	16-55	16SEP2020	90978	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
12261747	C4591001 1226 12261747	16-55	16SEP2020	90923	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
12261748	C4591001 1226 12261748	16-55	16SEP2020	90925	Placebo	16SEP2020/ Placebo	06OCT2020/ Placebo	13FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12261750	C4591001 1226 12261750	16-55	16SEP2020	91089	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
12261751	C4591001 1226 12261751	16-55	16SEP2020	91093	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
12261752	C4591001 1226 12261752	16-55	16SEP2020	90982	Placebo	16SEP2020/ Placebo	09OCT2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	27FEB2021/ BNT162b2 (30 µg)
12261753	C4591001 1226 12261753	16-55	16SEP2020	91094	Placebo	16SEP2020/ Placebo	06OCT2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	27FEB2021/ BNT162b2 (30 µg)
12261754	C4591001 1226 12261754	16-55	16SEP2020	91095	Placebo	16SEP2020/ Placebo	06OCT2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12261756	C4591001 1226 12261756	16-55	16SEP2020	90979	Placebo	16SEP2020/ Placebo	06OCT2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	27FEB2021/ BNT162b2 (30 µg)
12261757	C4591001 1226 12261757	16-55	16SEP2020	90985	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
12261759	C4591001 1226 12261759	16-55	16SEP2020	91172	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
12261760	C4591001 1226 12261760	16-55	16SEP2020	91179	Placebo	16SEP2020/ Placebo	06OCT2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12261761	C4591001 1226 12261761	16-55	16SEP2020	91173	Placebo	16SEP2020/ Placebo	06OCT2020/ Placebo	23JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12261762	C4591001 1226 12261762	16-55	16SEP2020	91176	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
12261763	C4591001 1226 12261763	16-55	17SEP2020	91918	Placebo	17SEP2020/ Placebo	07OCT2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12261764	C4591001 1226 12261764	16-55	17SEP2020	91913	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
12261765	C4591001 1226 12261765	16-55	17SEP2020	91919	Placebo	17SEP2020/ Placebo	07OCT2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12261766	C4591001 1226 12261766	16-55	17SEP2020	91917	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
12261767	C4591001 1226 12261767	16-55	17SEP2020	91937	Placebo	17SEP2020/ Placebo	07OCT2020/ Placebo	23JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
12261768	C4591001 1226 12261768	16-55	17SEP2020	91947	Placebo	17SEP2020/ Placebo	07OCT2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	27FEB2021/ BNT162b2 (30 µg)
12261769	C4591001 1226 12261769	16-55	17SEP2020	91945	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
12261770	C4591001 1226 12261770	16-55	17SEP2020	91941	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
12261771	C4591001 1226 12261771	16-55	17SEP2020	91951	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12261772	C4591001 1226 12261772	16-55	17SEP2020	91952	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
12261773	C4591001 1226 12261773	16-55	17SEP2020	91958	Placebo	17SEP2020/ Placebo	07OCT2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
12261775	C4591001 1226 12261775	16-55	17SEP2020	91960	Placebo	17SEP2020/ Placebo	07OCT2020/ Placebo	13FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
12261776	C4591001 1226 12261776	16-55	17SEP2020	92005	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
12261777	C4591001 1226 12261777	16-55	17SEP2020	91997	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
12261778	C4591001 1226 12261778	16-55	17SEP2020	92014	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
12261779	C4591001 1226 12261779	16-55	17SEP2020	92001	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
12261780	C4591001 1226 12261780	16-55	17SEP2020	92004	Placebo	17SEP2020/ Placebo	07OCT2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
12261781	C4591001 1226 12261781	16-55	17SEP2020	92013	Placebo	17SEP2020/ Placebo	07OCT2020/ Placebo	03MAR2021/ BNT162b2 (30 µg)	
12261784	C4591001 1226 12261784	16-55	17SEP2020	92016	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12261789	C4591001 1226 12261789	16-55	17SEP2020	92018	Placebo	17SEP2020/ Placebo	07OCT2020/ Placebo		
12261790	C4591001 1226 12261790	16-55	17SEP2020	92230	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
12261791	C4591001 1226 12261791	16-55	17SEP2020	92236	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
12261792	C4591001 1226 12261792	16-55	17SEP2020	92287	Placebo	17SEP2020/ Placebo	07OCT2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12261794	C4591001 1226 12261794	16-55	17SEP2020	92227	Placebo	17SEP2020/ Placebo	07OCT2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12261795	C4591001 1226 12261795	16-55	17SEP2020	92292	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
12261796	C4591001 1226 12261796	16-55	17SEP2020	92228	Placebo	17SEP2020/ Placebo	07OCT2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12261797	C4591001 1226 12261797	16-55	17SEP2020	92286	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
12261798	C4591001 1226 12261798	16-55	17SEP2020	92379	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
12261800	C4591001 1226 12261800	16-55	17SEP2020	92369	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12261801	C4591001 1226 12261801	16-55	17SEP2020	92374	Placebo	17SEP2020/ Placebo	07OCT2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	27FEB2021/ BNT162b2 (30 µg)
12261802	C4591001 1226 12261802	16-55	17SEP2020	92377	Placebo	17SEP2020/ Placebo	06OCT2020/ Placebo	23JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
12261803	C4591001 1226 12261803	16-55	17SEP2020	92296	Placebo	17SEP2020/ Placebo	06OCT2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
12261805	C4591001 1226 12261805	16-55	17SEP2020	92429	Placebo	17SEP2020/ Placebo	06OCT2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
12261806	C4591001 1226 12261806	16-55	17SEP2020	92430	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
12261807	C4591001 1226 12261807	16-55	17SEP2020	92434	Placebo	17SEP2020/ Placebo	06OCT2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12261809	C4591001 1226 12261809	16-55	17SEP2020	92438	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
12261810	C4591001 1226 12261810	16-55	18SEP2020	93173	Placebo	18SEP2020/ Placebo	08OCT2020/ Placebo	23JAN2021/ BNT162b2 (30 µg)	13FEB2021/ BNT162b2 (30 µg)
12261811	C4591001 1226 12261811	16-55	18SEP2020	93175	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
12261812	C4591001 1226 12261812	16-55	18SEP2020	93182	Placebo	18SEP2020/ Placebo	08OCT2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12261813	C4591001 1226 12261813	16-55	18SEP2020	93187	Placebo	18SEP2020/ Placebo	08OCT2020/ Placebo	23JAN2021/ BNT162b2 (30 µg)	13FEB2021/ BNT162b2 (30 µg)
12261815	C4591001 1226 12261815	16-55	18SEP2020	93179	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
12261818	C4591001 1226 12261818	16-55	18SEP2020	93196	Placebo	18SEP2020/ Placebo	13OCT2020/ Placebo	30JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12261819	C4591001 1226 12261819	16-55	18SEP2020	93193	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
12261820	C4591001 1226 12261820	16-55	18SEP2020	93195	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
12261821	C4591001 1226 12261821	16-55	18SEP2020	93209	Placebo	18SEP2020/ Placebo	22OCT2020/ Placebo	23JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
12261823	C4591001 1226 12261823	16-55	18SEP2020	93217	Placebo	18SEP2020/ Placebo	08OCT2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	27FEB2021/ BNT162b2 (30 µg)
12261824	C4591001 1226 12261824	16-55	18SEP2020	93220	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
12261826	C4591001 1226 12261826	16-55	18SEP2020	93212	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
12261827	C4591001 1226 12261827	16-55	18SEP2020	93245	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12261828	C4591001 1226 12261828	16-55	18SEP2020	93279	Placebo	18SEP2020/ Placebo	08OCT2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12261830	C4591001 1226 12261830	16-55	18SEP2020	93246	Placebo	18SEP2020/ Placebo	08OCT2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	27FEB2021/ BNT162b2 (30 µg)
12261831	C4591001 1226 12261831	16-55	18SEP2020	93249	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	27FEB2021/ BNT162b2 (30 µg)
12261832	C4591001 1226 12261832	16-55	18SEP2020	93253	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
12261833	C4591001 1226 12261833	16-55	18SEP2020	93277	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
12261834	C4591001 1226 12261834	16-55	18SEP2020	93273	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
12261835	C4591001 1226 12261835	16-55	18SEP2020	93274	Placebo	18SEP2020/ Placebo	08OCT2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12261836	C4591001 1226 12261836	16-55	18SEP2020	93367	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	23JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
12261838	C4591001 1226 12261838	16-55	18SEP2020	93368	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
12261839	C4591001 1226 12261839	16-55	18SEP2020	93374	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12261840	C4591001 1226 12261840	16-55	18SEP2020	93372	Placebo	18SEP2020/ Placebo	08OCT2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
12261841	C4591001 1226 12261841	16-55	18SEP2020	93523	Placebo	18SEP2020/ Placebo	08OCT2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
12261842	C4591001 1226 12261842	16-55	18SEP2020	93463	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
12261843	C4591001 1226 12261843	16-55	18SEP2020	93466	Placebo	18SEP2020/ Placebo	08OCT2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	27FEB2021/ BNT162b2 (30 µg)
12261844	C4591001 1226 12261844	16-55	18SEP2020	93465	Placebo	18SEP2020/ Placebo	08OCT2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12261845	C4591001 1226 12261845	16-55	18SEP2020	93469	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
12261846	C4591001 1226 12261846	16-55	18SEP2020	93584	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
12261847	C4591001 1226 12261847	16-55	18SEP2020	93524	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
12261848	C4591001 1226 12261848	16-55	18SEP2020	93586	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12261849	C4591001 1226 12261849	16-55	18SEP2020	261715	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	27FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12261850	C4591001 1226 12261850	16-55	18SEP2020	93525	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
12261851	C4591001 1226 12261851	16-55	18SEP2020	93526	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	13FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
12261852	C4591001 1226 12261852	16-55	18SEP2020	93582	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	23JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
12261853	C4591001 1226 12261853	16-55	18SEP2020	93690	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
12261854	C4591001 1226 12261854	16-55	18SEP2020	93691	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
12261855	C4591001 1226 12261855	16-55	18SEP2020	93590	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
12261856	C4591001 1226 12261856	16-55	18SEP2020	93695	Placebo	18SEP2020/ Placebo	07OCT2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12261857	C4591001 1226 12261857	16-55	18SEP2020	93699	Placebo	18SEP2020/ Placebo	07OCT2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	27FEB2021/ BNT162b2 (30 µg)
12261858	C4591001 1226 12261858	16-55	19SEP2020	94426	BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
12261859	C4591001 1226 12261859	16-55	19SEP2020	94428	Placebo	19SEP2020/ Placebo	08OCT2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12261860	C4591001 1226 12261860	16-55	19SEP2020	94429	Placebo	19SEP2020/ Placebo	09OCT2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	27FEB2021/ BNT162b2 (30 µg)
12261863	C4591001 1226 12261863	16-55	19SEP2020	94433	BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
12261864	C4591001 1226 12261864	16-55	19SEP2020	94430	BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
12261865	C4591001 1226 12261865	16-55	19SEP2020	94437	Placebo	19SEP2020/ Placebo	09OCT2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	27FEB2021/ BNT162b2 (30 µg)
12261866	C4591001 1226 12261866	16-55	19SEP2020	94438	Placebo	19SEP2020/ Placebo	08OCT2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12261867	C4591001 1226 12261867	16-55	19SEP2020	94442	BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
12261868	C4591001 1226 12261868	16-55	19SEP2020	94457	BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
12261869	C4591001 1226 12261869	16-55	19SEP2020	94459	BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
12261870	C4591001 1226 12261870	16-55	19SEP2020	94462	Placebo	19SEP2020/ Placebo	09OCT2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12261871	C4591001 1226 12261871	16-55	19SEP2020	94468	Placebo	19SEP2020/ Placebo	17OCT2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12261873	C4591001 1226 12261873	16-55	19SEP2020	94471	BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
12261874	C4591001 1226 12261874	16-55	19SEP2020	94475	Placebo	19SEP2020/ Placebo	09OCT2020/ Placebo	23JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
12261875	C4591001 1226 12261875	16-55	19SEP2020	94474	BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
12261876	C4591001 1226 12261876	16-55	19SEP2020	94483	Placebo	19SEP2020/ Placebo	09OCT2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12261877	C4591001 1226 12261877	16-55	19SEP2020	94476	Placebo	19SEP2020/ Placebo	09OCT2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12261878	C4591001 1226 12261878	16-55	19SEP2020	94486	BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
12261879	C4591001 1226 12261879	16-55	19SEP2020	94484	Placebo	19SEP2020/ Placebo	09OCT2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12261880	C4591001 1226 12261880	16-55	25SEP2020	99293	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
12261881	C4591001 1226 12261881	16-55	25SEP2020	94490	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
12261882	C4591001 1226 12261882	16-55	25SEP2020	99295	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12261884	C4591001 1226 12261884	16-55	25SEP2020	99299	Placebo	25SEP2020/ Placebo	15OCT2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12261885	C4591001 1226 12261885	16-55	25SEP2020	99394	Placebo	25SEP2020/ Placebo	17OCT2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12261886	C4591001 1226 12261886	16-55	25SEP2020	99300	Placebo	25SEP2020/ Placebo	14OCT2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12261887	C4591001 1226 12261887	16-55	25SEP2020	99395	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
12261888	C4591001 1226 12261888	16-55	25SEP2020	99398	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
12261889	C4591001 1226 12261889	16-55	25SEP2020	99399	Placebo	25SEP2020/ Placebo	17OCT2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12261890	C4591001 1226 12261890	16-55	25SEP2020	99479	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		
12261892	C4591001 1226 12261892	16-55	25SEP2020	99480	Placebo	25SEP2020/ Placebo	14OCT2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12261893	C4591001 1226 12261893	16-55	25SEP2020	99483	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
12261894	C4591001 1226 12261894	16-55	25SEP2020	99481	Placebo	25SEP2020/ Placebo		19FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12261895	C4591001 1226 12261895	16-55	25SEP2020	99569	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
12261896	C4591001 1226 12261896	16-55	25SEP2020	99572	Placebo	25SEP2020/ Placebo	14OCT2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
12261897	C4591001 1226 12261897	16-55	25SEP2020	99578	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12261898	C4591001 1226 12261898	16-55	25SEP2020	99580	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
12261899	C4591001 1226 12261899	16-55	25SEP2020	99620	Placebo	25SEP2020/ Placebo	14OCT2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12261900	C4591001 1226 12261900	16-55	25SEP2020	99621	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
12261901	C4591001 1226 12261901	16-55	25SEP2020	99624	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		
12261902	C4591001 1226 12261902	16-55	25SEP2020	99788	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
12261904	C4591001 1226 12261904	16-55	25SEP2020	99627	Placebo	25SEP2020/ Placebo	15OCT2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12261905	C4591001 1226 12261905	16-55	25SEP2020	99789	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12261906	C4591001 1226 12261906	16-55	28SEP2020	99792	Placebo	28SEP2020/ Placebo	20OCT2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12261907	C4591001 1226 12261907	16-55	28SEP2020	101238	Placebo	28SEP2020/ Placebo	20OCT2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12261908	C4591001 1226 12261908	16-55	28SEP2020	101237	BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)		
12261909	C4591001 1226 12261909	16-55	28SEP2020	101248	Placebo	28SEP2020/ Placebo	20OCT2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	20FEB2021/ BNT162b2 (30 µg)
12261910	C4591001 1226 12261910	16-55	28SEP2020	101239	BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		
12261911	C4591001 1226 12261911	16-55	28SEP2020	101266	BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		
12261912	C4591001 1226 12261912	16-55	28SEP2020	101269	BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)		
12261914	C4591001 1226 12261914	16-55	28SEP2020	101271	Placebo	28SEP2020/ Placebo	20OCT2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12261917	C4591001 1226 12261917	16-55	28SEP2020	101272	Placebo	28SEP2020/ Placebo	20OCT2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12261918	C4591001 1226 12261918	16-55	28SEP2020	101345	Placebo	28SEP2020/ Placebo	20OCT2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12261919	C4591001 1226 12261919	16-55	28SEP2020	101352	BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)		
12261920	C4591001 1226 12261920	16-55	28SEP2020	101354	Placebo	28SEP2020/ Placebo	20OCT2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
12261922	C4591001 1226 12261922	16-55	28SEP2020	101356	BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		
12261923	C4591001 1226 12261923	16-55	29SEP2020	101753	BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		
12261924	C4591001 1226 12261924	16-55	29SEP2020	101757	BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		
12261925	C4591001 1226 12261925	16-55	29SEP2020	101764	Placebo	29SEP2020/ Placebo	22OCT2020/ Placebo	13FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
12261926	C4591001 1226 12261926	16-55	29SEP2020	101763	Placebo	29SEP2020/ Placebo	20OCT2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	13FEB2021/ BNT162b2 (30 µg)
12261927	C4591001 1226 12261927	16-55	29SEP2020	101765	Placebo	29SEP2020/ Placebo	05NOV2020/ Placebo		
12261928	C4591001 1226 12261928	16-55	29SEP2020	101769	BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		
12261929	C4591001 1226 12261929	16-55	29SEP2020	101775	BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12261930	C4591001 1226 12261930	16-55	29SEP2020	101787	BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)		
12261931	C4591001 1226 12261931	16-55	29SEP2020	101776	Placebo	29SEP2020/ Placebo	21OCT2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
12261932	C4591001 1226 12261932	16-55	29SEP2020	101781	Placebo	29SEP2020/ Placebo	22OCT2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12261933	C4591001 1226 12261933	16-55	29SEP2020	101783	Placebo	29SEP2020/ Placebo	20OCT2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12261934	C4591001 1226 12261934	16-55	29SEP2020	101788	BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		
12261935	C4591001 1226 12261935	16-55	29SEP2020	101831	Placebo	29SEP2020/ Placebo	20OCT2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
12261936	C4591001 1226 12261936	16-55	29SEP2020	101835	BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		
12261937	C4591001 1226 12261937	16-55	29SEP2020	101826	BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		
12261938	C4591001 1226 12261938	16-55	29SEP2020	101842	Placebo	29SEP2020/ Placebo	21OCT2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12261939	C4591001 1226 12261939	16-55	29SEP2020	101843	BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12261940	C4591001 1226 12261940	16-55	29SEP2020	101836	Placebo	29SEP2020/ Placebo	20OCT2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12261941	C4591001 1226 12261941	16-55	29SEP2020	101846	Placebo	29SEP2020/ Placebo	20OCT2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12261942	C4591001 1226 12261942	16-55	29SEP2020	101848	BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		
12261944	C4591001 1226 12261944	16-55	29SEP2020	101862	Placebo	29SEP2020/ Placebo	20OCT2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
12261945	C4591001 1226 12261945	16-55	29SEP2020	101866	Placebo	29SEP2020/ Placebo	19OCT2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
12261946	C4591001 1226 12261946	16-55	29SEP2020	101863	BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		
12261947	C4591001 1226 12261947	16-55	29SEP2020	101872	BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		
12261948	C4591001 1226 12261948	16-55	29SEP2020	101900	Placebo	29SEP2020/ Placebo	20OCT2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
12261950	C4591001 1226 12261950	16-55	29SEP2020	101904	BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		
12261951	C4591001 1226 12261951	16-55	29SEP2020	101906	Placebo	29SEP2020/ Placebo	22OCT2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12261952	C4591001 1226 12261952	16-55	30SEP2020	101907	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
12261953	C4591001 1226 12261953	16-55	30SEP2020	102178	Placebo	30SEP2020/ Placebo	21OCT2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12261954	C4591001 1226 12261954	16-55	30SEP2020	102173	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
12261956	C4591001 1226 12261956	16-55	30SEP2020	102180	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		
12261957	C4591001 1226 12261957	16-55	30SEP2020	102184	Placebo	30SEP2020/ Placebo	21OCT2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
12261958	C4591001 1226 12261958	16-55	30SEP2020	102223	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		
12261959	C4591001 1226 12261959	16-55	30SEP2020	102228	Placebo	30SEP2020/ Placebo	21OCT2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
12261960	C4591001 1226 12261960	16-55	30SEP2020	102232	Placebo	30SEP2020/ Placebo	21OCT2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12261961	C4591001 1226 12261961	16-55	30SEP2020	102231	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		
12261962	C4591001 1226 12261962	16-55	30SEP2020	102282	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12261963	C4591001 1226 12261963	16-55	30SEP2020	102283	Placebo	30SEP2020/ Placebo	21OCT2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
12261964	C4591001 1226 12261964	16-55	30SEP2020	102284	Placebo	30SEP2020/ Placebo	21OCT2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12261966	C4591001 1226 12261966	16-55	30SEP2020	102291	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)		
12261967	C4591001 1226 12261967	16-55	30SEP2020	102377	Placebo	30SEP2020/ Placebo	21OCT2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
12261968	C4591001 1226 12261968	16-55	30SEP2020	102378	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		
12261970	C4591001 1226 12261970	16-55	30SEP2020	102381	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		
12261971	C4591001 1226 12261971	16-55	30SEP2020	102385	Placebo	30SEP2020/ Placebo	03NOV2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12261972	C4591001 1226 12261972	16-55	30SEP2020	102415	Placebo	30SEP2020/ Placebo	21OCT2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12261973	C4591001 1226 12261973	16-55	01OCT2020	102416	Placebo	01OCT2020/ Placebo	22OCT2020/ Placebo	13FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
12261974	C4591001 1226 12261974	16-55	01OCT2020	102658	Placebo	01OCT2020/ Placebo	22OCT2020/ Placebo	13FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12261975	C4591001 1226 12261975	16-55	01OCT2020	102419	BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)		
12261976	C4591001 1226 12261976	16-55	01OCT2020	102420	BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)		
12261978	C4591001 1226 12261978	16-55	01OCT2020	102660	BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)		
12261980	C4591001 1226 12261980	16-55	01OCT2020	102661	Placebo	01OCT2020/ Placebo	21OCT2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12261981	C4591001 1226 12261981	16-55	01OCT2020	102690	Placebo	01OCT2020/ Placebo	23OCT2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12261982	C4591001 1226 12261982	16-55	01OCT2020	102664	BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		
12261983	C4591001 1226 12261983	16-55	01OCT2020	102693	BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)		
12261985	C4591001 1226 12261985	16-55	01OCT2020	102695	Placebo	01OCT2020/ Placebo	23OCT2020/ Placebo	23JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
12261987	C4591001 1226 12261987	16-55	01OCT2020	102751	Placebo	01OCT2020/ Placebo	22OCT2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12261988	C4591001 1226 12261988	16-55	01OCT2020	102700	BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12261989	C4591001 1226 12261989	16-55	01OCT2020	102752	BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
12261992	C4591001 1226 12261992	16-55	01OCT2020	102754	Placebo	01OCT2020/ Placebo	23OCT2020/ Placebo	23JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
12261994	C4591001 1226 12261994	16-55	01OCT2020	102797	Placebo	01OCT2020/ Placebo	23OCT2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12261995	C4591001 1226 12261995	16-55	01OCT2020	102758	BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)		
12261996	C4591001 1226 12261996	16-55	01OCT2020	102798	BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)		
12261997	C4591001 1226 12261997	16-55	01OCT2020	102800	Placebo	01OCT2020/ Placebo	23OCT2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
12261998	C4591001 1226 12261998	16-55	01OCT2020	102807	BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)		
12261999	C4591001 1226 12261999	16-55	01OCT2020	102821	BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)		
12262000	C4591001 1226 12262000	16-55	01OCT2020	102823	Placebo	01OCT2020/ Placebo	22OCT2020/ Placebo		
12262001	C4591001 1226 12262001	16-55	01OCT2020	102832	BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12262002	C4591001 1226 12262002	16-55	01OCT2020	102858	BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)		
12262003	C4591001 1226 12262003	16-55	01OCT2020	102828	Placebo	01OCT2020/ Placebo	23OCT2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12262006	C4591001 1226 12262006	16-55	01OCT2020	102861	Placebo	01OCT2020/ Placebo	21OCT2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12262007	C4591001 1226 12262007	16-55	02OCT2020	102862	BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		
12262008	C4591001 1226 12262008	16-55	02OCT2020	102866	Placebo	02OCT2020/ Placebo	23OCT2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12262010	C4591001 1226 12262010	16-55	02OCT2020	103099	Placebo	02OCT2020/ Placebo	21OCT2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
12262011	C4591001 1226 12262011	16-55	02OCT2020	103100	Placebo	02OCT2020/ Placebo	21OCT2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12262012	C4591001 1226 12262012	16-55	02OCT2020	103103	BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		
12262013	C4591001 1226 12262013	16-55	02OCT2020	103107	BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
12262014	C4591001 1226 12262014	16-55	02OCT2020	103158	Placebo	02OCT2020/ Placebo	21OCT2020/ Placebo	13FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12262015	C4591001 1226 12262015	16-55	02OCT2020	103165	BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)		
12262016	C4591001 1226 12262016	16-55	02OCT2020	103164	Placebo	02OCT2020/ Placebo	21OCT2020/ Placebo	13FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
12262017	C4591001 1226 12262017	16-55	02OCT2020	103166	BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		
12262018	C4591001 1226 12262018	16-55	02OCT2020	103182	BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)		
12262019	C4591001 1226 12262019	16-55	02OCT2020	103181	Placebo	02OCT2020/ Placebo	21OCT2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
12262021	C4591001 1226 12262021	16-55	02OCT2020	103185	Placebo	02OCT2020/ Placebo	21OCT2020/ Placebo	13FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
12262022	C4591001 1226 12262022	16-55	02OCT2020	103184	BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		
12262023	C4591001 1226 12262023	16-55	02OCT2020	103245	Placebo	02OCT2020/ Placebo	21OCT2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12262024	C4591001 1226 12262024	16-55	03OCT2020	103250	Placebo	03OCT2020/ Placebo	22OCT2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12262026	C4591001 1226 12262026	16-55	03OCT2020	103251	BNT162b2 (30 µg)	03OCT2020/ BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12262027	C4591001 1226 12262027	16-55	03OCT2020	103252	BNT162b2 (30 µg)	03OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
12262028	C4591001 1226 12262028	16-55	03OCT2020	103421	Placebo	03OCT2020/ Placebo	22OCT2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
12262029	C4591001 1226 12262029	16-55	03OCT2020	103422	BNT162b2 (30 µg)	03OCT2020/ BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)		
12262030	C4591001 1226 12262030	16-55	03OCT2020	103424	Placebo	03OCT2020/ Placebo	26OCT2020/ Placebo	13FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
12262034	C4591001 1226 12262034	16-55	03OCT2020	103430	BNT162b2 (30 µg)	03OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
12262035	C4591001 1226 12262035	16-55	03OCT2020	103444	Placebo	03OCT2020/ Placebo	29OCT2020/ Placebo	13FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
12262036	C4591001 1226 12262036	16-55	03OCT2020	103434	BNT162b2 (30 µg)	03OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
12262037	C4591001 1226 12262037	16-55	03OCT2020	103438	BNT162b2 (30 µg)	03OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
12262038	C4591001 1226 12262038	16-55	03OCT2020	103451	Placebo	03OCT2020/ Placebo	26OCT2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12262039	C4591001 1226 12262039	16-55	03OCT2020	103439	Placebo	03OCT2020/ Placebo	22OCT2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12262040	C4591001 1226 12262040	16-55	03OCT2020	103450	BNT162b2 (30 µg)	03OCT2020/ BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)		
12262041	C4591001 1226 12262041	16-55	03OCT2020	103445	Placebo	03OCT2020/ Placebo	26OCT2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12262042	C4591001 1226 12262042	16-55	03OCT2020	103452	BNT162b2 (30 µg)	03OCT2020/ BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)		
12262044	C4591001 1226 12262044	16-55	03OCT2020	103461	BNT162b2 (30 µg)	03OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
12262045	C4591001 1226 12262045	16-55	03OCT2020	103467	Placebo	03OCT2020/ Placebo	26OCT2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
12262046	C4591001 1226 12262046	16-55	03OCT2020	103459	BNT162b2 (30 µg)	03OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
12262047	C4591001 1226 12262047	16-55	03OCT2020	103468	Placebo	03OCT2020/ Placebo	27OCT2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
12262048	C4591001 1226 12262048	16-55	03OCT2020	103477	Placebo	03OCT2020/ Placebo	26OCT2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
12262049	C4591001 1226 12262049	16-55	03OCT2020	103469	Placebo	03OCT2020/ Placebo	23OCT2020/ Placebo	13FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
12262050	C4591001 1226 12262050	16-55	03OCT2020	103475	BNT162b2 (30 µg)	03OCT2020/ BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12262051	C4591001 1226 12262051	16-55	03OCT2020	103478	BNT162b2 (30 µg)	03OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
12262052	C4591001 1226 12262052	16-55	03OCT2020	103482	Placebo	03OCT2020/ Placebo	26OCT2020/ Placebo	13FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
12262056	C4591001 1226 12262056	16-55	03OCT2020	103484	Placebo	03OCT2020/ Placebo	26OCT2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12262058	C4591001 1226 12262058	16-55	03OCT2020	103493	BNT162b2 (30 µg)	03OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
12262059	C4591001 1226 12262059	16-55	03OCT2020	103489	BNT162b2 (30 µg)	03OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
12262060	C4591001 1226 12262060	16-55	03OCT2020	103492	BNT162b2 (30 µg)	03OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
12262062	C4591001 1226 12262062	16-55	03OCT2020	103500	Placebo	03OCT2020/ Placebo	26OCT2020/ Placebo	13FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
12262063	C4591001 1226 12262063	16-55	03OCT2020	103502	Placebo	03OCT2020/ Placebo	23NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12262064	C4591001 1226 12262064	16-55	03OCT2020	103503	BNT162b2 (30 µg)	03OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
12262065	C4591001 1226 12262065	16-55	03OCT2020	103506	BNT162b2 (30 µg)	03OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12262067	C4591001 1226 12262067	16-55	03OCT2020	103508	Placebo	03OCT2020/ Placebo	26OCT2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12262068	C4591001 1226 12262068	16-55	05OCT2020	103514	BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
12262070	C4591001 1226 12262070	16-55	05OCT2020	103515	Placebo	05OCT2020/ Placebo	28OCT2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12262071	C4591001 1226 12262071	16-55	05OCT2020	103662	BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
12262072	C4591001 1226 12262072	16-55	05OCT2020	103664	BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		
12262073	C4591001 1226 12262073	16-55	05OCT2020	103671	Placebo	05OCT2020/ Placebo	28OCT2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12262075	C4591001 1226 12262075	16-55	05OCT2020	103669	Placebo	05OCT2020/ Placebo	27OCT2020/ Placebo	13FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
12262076	C4591001 1226 12262076	16-55	05OCT2020	103697	BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
12262078	C4591001 1226 12262078	16-55	05OCT2020	103700	Placebo	05OCT2020/ Placebo	27OCT2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12262079	C4591001 1226 12262079	16-55	05OCT2020	103702	BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12262080	C4591001 1226 12262080	16-55	05OCT2020	103705	Placebo	05OCT2020/ Placebo	30OCT2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12262081	C4591001 1226 12262081	16-55	05OCT2020	103722	BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		
12262083	C4591001 1226 12262083	16-55	05OCT2020	103727	Placebo	05OCT2020/ Placebo	07NOV2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
12262084	C4591001 1226 12262084	16-55	05OCT2020	103729	Placebo	05OCT2020/ Placebo	28OCT2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12262085	C4591001 1226 12262085	16-55	05OCT2020	103731	BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
12262086	C4591001 1226 12262086	16-55	05OCT2020	103775	BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		
12262087	C4591001 1226 12262087	16-55	06OCT2020	103776	Placebo	06OCT2020/ Placebo	28OCT2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
12262089	C4591001 1226 12262089	16-55	06OCT2020	103777	BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
12262090	C4591001 1226 12262090	16-55	06OCT2020	103778	Placebo	06OCT2020/ Placebo	27OCT2020/ Placebo	13FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
12262091	C4591001 1226 12262091	16-55	06OCT2020	104214	Placebo	06OCT2020/ Placebo	27OCT2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12262092	C4591001 1226 12262092	16-55	06OCT2020	104215	Placebo	06OCT2020/ Placebo	26OCT2020/ Placebo	13FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
12262094	C4591001 1226 12262094	16-55	06OCT2020	104216	BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
12262095	C4591001 1226 12262095	16-55	06OCT2020	104222	BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
12262096	C4591001 1226 12262096	16-55	06OCT2020	104309	Placebo	06OCT2020/ Placebo	26OCT2020/ Placebo	13FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
12262097	C4591001 1226 12262097	16-55	07OCT2020	104310	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		
12262099	C4591001 1226 12262099	16-55	07OCT2020	104317	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		
12262103	C4591001 1226 12262103	16-55	07OCT2020	104318	Placebo	07OCT2020/ Placebo	30OCT2020/ Placebo	13FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
12262104	C4591001 1226 12262104	16-55	07OCT2020	104766	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
12262105	C4591001 1226 12262105	16-55	07OCT2020	104769	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)		
12262106	C4591001 1226 12262106	16-55	08OCT2020	104771	Placebo	08OCT2020/ Placebo	28OCT2020/ Placebo	13FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12262107	C4591001 1226 12262107	16-55	08OCT2020	104776	Placebo	08OCT2020/ Placebo	30OCT2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
12262108	C4591001 1226 12262108	16-55	08OCT2020	105258	Placebo	08OCT2020/ Placebo		10FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12262110	C4591001 1226 12262110	16-55	08OCT2020	105260	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)		
12262111	C4591001 1226 12262111	16-55	08OCT2020	105266	Placebo	08OCT2020/ Placebo	30OCT2020/ Placebo	13FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
12262112	C4591001 1226 12262112	16-55	08OCT2020	105267	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
12262113	C4591001 1226 12262113	16-55	08OCT2020	105356	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)		
12262114	C4591001 1226 12262114	16-55	08OCT2020	105359	Placebo	08OCT2020/ Placebo	29OCT2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	13FEB2021/ BNT162b2 (30 µg)
12262115	C4591001 1226 12262115	16-55	08OCT2020	105360	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		
12262116	C4591001 1226 12262116	16-55	08OCT2020	105362	Placebo	08OCT2020/ Placebo	28OCT2020/ Placebo	13FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
12262117	C4591001 1226 12262117	16-55	09OCT2020	105810	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12262119	C4591001 1226 12262119	16-55	09OCT2020	105820	Placebo	09OCT2020/ Placebo	30OCT2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12262120	C4591001 1226 12262120	16-55	09OCT2020	105815	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
12262121	C4591001 1226 12262121	16-55	09OCT2020	105817	Placebo	09OCT2020/ Placebo	30OCT2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12262122	C4591001 1226 12262122	16-55	09OCT2020	105875	Placebo	09OCT2020/ Placebo	29OCT2020/ Placebo	13FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
12262123	C4591001 1226 12262123	16-55	09OCT2020	105871	Placebo	09OCT2020/ Placebo	28OCT2020/ Placebo	13FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
12262124	C4591001 1226 12262124	16-55	09OCT2020	105915	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)		
12262125	C4591001 1226 12262125	16-55	09OCT2020	105916	Placebo	09OCT2020/ Placebo	29OCT2020/ Placebo	13FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
12262126	C4591001 1226 12262126	16-55	09OCT2020	105873	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)		
12262127	C4591001 1226 12262127	16-55	09OCT2020	105914	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)		
12262128	C4591001 1226 12262128	16-55	09OCT2020	105955	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12262129	C4591001 1226 12262129	16-55	09OCT2020	105960	Placebo	09OCT2020/ Placebo	30OCT2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
12262130	C4591001 1226 12262130	16-55	09OCT2020	105878	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)		
12262131	C4591001 1226 12262131	16-55	09OCT2020	105961	Placebo	09OCT2020/ Placebo	04NOV2020/ Placebo	13FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
12262132	C4591001 1226 12262132	16-55	09OCT2020	105910	Placebo	09OCT2020/ Placebo	13NOV2020/ Placebo		
12262133	C4591001 1226 12262133	16-55	09OCT2020	105978	Placebo	09OCT2020/ Placebo	05NOV2020/ Placebo	13FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
12262134	C4591001 1226 12262134	16-55	09OCT2020	105962	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)		
12262135	C4591001 1226 12262135	16-55	09OCT2020	105981	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)		
12262136	C4591001 1226 12262136	16-55	09OCT2020	106004	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	04DEC2020/ BNT162b2 (30 µg)		
12262137	C4591001 1226 12262137	16-55	09OCT2020	105982	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)		
12262138	C4591001 1226 12262138	16-55	09OCT2020	105988	Placebo	09OCT2020/ Placebo	30OCT2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12262140	C4591001 1226 12262140	16-55	13OCT2020	106007	Placebo	13OCT2020/ Placebo	06NOV2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
12262141	C4591001 1226 12262141	16-55	13OCT2020	106009	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
12262143	C4591001 1226 12262143	16-55	13OCT2020	106782	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
12262144	C4591001 1226 12262144	16-55	13OCT2020	106008	Placebo	13OCT2020/ Placebo	03NOV2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
12262145	C4591001 1226 12262145	16-55	13OCT2020	106790	Placebo	13OCT2020/ Placebo	03NOV2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12262146	C4591001 1226 12262146	16-55	13OCT2020	106783	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
12262148	C4591001 1226 12262148	16-55	13OCT2020	106784	Placebo	13OCT2020/ Placebo	03NOV2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
12262149	C4591001 1226 12262149	16-55	13OCT2020	106806	Placebo	13OCT2020/ Placebo	04NOV2020/ Placebo	13FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
12262151	C4591001 1226 12262151	16-55	13OCT2020	106811	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
12262152	C4591001 1226 12262152	16-55	13OCT2020	106814	Placebo	13OCT2020/ Placebo	03NOV2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12262153	C4591001 1226 12262153	16-55	13OCT2020	106816	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
12262154	C4591001 1226 12262154	16-55	13OCT2020	106831	Placebo	13OCT2020/ Placebo	03NOV2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12262157	C4591001 1226 12262157	16-55	13OCT2020	106833	Placebo	13OCT2020/ Placebo	03NOV2020/ Placebo	13FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
12262159	C4591001 1226 12262159	16-55	13OCT2020	106836	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
12262162	C4591001 1226 12262162	16-55	13OCT2020	106837	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
12262163	C4591001 1226 12262163	16-55	13OCT2020	106889	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
12262164	C4591001 1226 12262164	16-55	13OCT2020	106891	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
12262165	C4591001 1226 12262165	16-55	13OCT2020	106895	Placebo	13OCT2020/ Placebo	05NOV2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12262166	C4591001 1226 12262166	16-55	13OCT2020	106893	Placebo	13OCT2020/ Placebo	05NOV2020/ Placebo	13FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
12262167	C4591001 1226 12262167	16-55	13OCT2020	106941	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12262168	C4591001 1226 12262168	16-55	13OCT2020	106942	Placebo	13OCT2020/ Placebo	03NOV2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	
12262169	C4591001 1226 12262169	16-55	13OCT2020	106945	Placebo	13OCT2020/ Placebo	03NOV2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12262170	C4591001 1226 12262170	16-55	13OCT2020	106946	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
12262172	C4591001 1226 12262172	16-55	13OCT2020	106962	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
12262178	C4591001 1226 12262178	16-55	13OCT2020	106964	Placebo	13OCT2020/ Placebo	05NOV2020/ Placebo	13FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
12262179	C4591001 1226 12262179	16-55	13OCT2020	106969	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
12262181	C4591001 1226 12262181	16-55	13OCT2020	106971	Placebo	13OCT2020/ Placebo	03NOV2020/ Placebo	13FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
12262182	C4591001 1226 12262182	16-55	14OCT2020	107321	Placebo	14OCT2020/ Placebo	04NOV2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12262183	C4591001 1226 12262183	16-55	14OCT2020	107322	Placebo	14OCT2020/ Placebo	04NOV2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
12262184	C4591001 1226 12262184	16-55	14OCT2020	107325	BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12262185	C4591001 1226 12262185	16-55	14OCT2020	107330	BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
12262186	C4591001 1226 12262186	16-55	14OCT2020	107359	BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
12262187	C4591001 1226 12262187	16-55	14OCT2020	107361	BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
12262188	C4591001 1226 12262188	16-55	14OCT2020	107362	Placebo	14OCT2020/ Placebo	04NOV2020/ Placebo	13FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
12262189	C4591001 1226 12262189	16-55	14OCT2020	107368	Placebo	14OCT2020/ Placebo		19FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12262190	C4591001 1226 12262190	16-55	14OCT2020	107490	BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
12262191	C4591001 1226 12262191	16-55	14OCT2020	107492	Placebo	14OCT2020/ Placebo	04NOV2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12262192	C4591001 1226 12262192	16-55	15OCT2020	107493	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
12262193	C4591001 1226 12262193	16-55	15OCT2020	107876	Placebo	15OCT2020/ Placebo	04NOV2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12262194	C4591001 1226 12262194	16-55	15OCT2020	107495	Placebo	15OCT2020/ Placebo	05NOV2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12262195	C4591001 1226 12262195	16-55	15OCT2020	107880	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
12262196	C4591001 1226 12262196	16-55	15OCT2020	107881	Placebo	15OCT2020/ Placebo	04NOV2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
12262197	C4591001 1226 12262197	16-55	15OCT2020	107882	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
12262198	C4591001 1226 12262198	16-55	15OCT2020	107885	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
12262199	C4591001 1226 12262199	16-55	15OCT2020	107887	Placebo	15OCT2020/ Placebo	04NOV2020/ Placebo	13FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
12262200	C4591001 1226 12262200	16-55	15OCT2020	107890	Placebo	15OCT2020/ Placebo	04NOV2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
12262201	C4591001 1226 12262201	16-55	15OCT2020	107891	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
12262204	C4591001 1226 12262204	16-55	15OCT2020	107935	Placebo	15OCT2020/ Placebo	04NOV2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12262205	C4591001 1226 12262205	16-55	15OCT2020	107936	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
12262206	C4591001 1226 12262206	16-55	15OCT2020	107940	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12262208	C4591001 1226 12262208	16-55	15OCT2020	107944	Placebo	15OCT2020/ Placebo	05NOV2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
12262209	C4591001 1226 12262209	16-55	15OCT2020	107972	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
12262211	C4591001 1226 12262211	16-55	15OCT2020	107976	Placebo	15OCT2020/ Placebo	06NOV2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12262212	C4591001 1226 12262212	16-55	15OCT2020	107977	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
12262213	C4591001 1226 12262213	16-55	15OCT2020	107979	Placebo	15OCT2020/ Placebo	05NOV2020/ Placebo	13FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
12262216	C4591001 1226 12262216	16-55	15OCT2020	108117	Placebo	15OCT2020/ Placebo	05NOV2020/ Placebo	13FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
12262217	C4591001 1226 12262217	16-55	15OCT2020	108119	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
12262218	C4591001 1226 12262218	16-55	15OCT2020	108121	Placebo	15OCT2020/ Placebo	05NOV2020/ Placebo	13FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
12262219	C4591001 1226 12262219	16-55	15OCT2020	108164	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
12262220	C4591001 1226 12262220	16-55	15OCT2020	108122	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12262221	C4591001 1226 12262221	16-55	15OCT2020	108162	Placebo	15OCT2020/ Placebo	05NOV2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
12262223	C4591001 1226 12262223	16-55	16OCT2020	108170	Placebo	16OCT2020/ Placebo	05NOV2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12262224	C4591001 1226 12262224	16-55	16OCT2020	108689	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
12262225	C4591001 1226 12262225	16-55	16OCT2020	108172	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
12262226	C4591001 1226 12262226	16-55	16OCT2020	108697	Placebo	16OCT2020/ Placebo	07NOV2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12262227	C4591001 1226 12262227	16-55	16OCT2020	108698	Placebo	16OCT2020/ Placebo	06NOV2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12262228	C4591001 1226 12262228	16-55	16OCT2020	108727	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
12262229	C4591001 1226 12262229	16-55	16OCT2020	108700	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	30NOV2020/ BNT162b2 (30 µg)		
12262230	C4591001 1226 12262230	16-55	16OCT2020	108729	Placebo	16OCT2020/ Placebo	04NOV2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
12262231	C4591001 1226 12262231	16-55	16OCT2020	108730	Placebo	16OCT2020/ Placebo	04NOV2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12262232	C4591001 1226 12262232	16-55	16OCT2020	108734	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
12262233	C4591001 1226 12262233	16-55	16OCT2020	108787	Placebo	16OCT2020/ Placebo	04NOV2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
12262234	C4591001 1226 12262234	16-55	16OCT2020	108789	Placebo	16OCT2020/ Placebo	04NOV2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
12262236	C4591001 1226 12262236	16-55	16OCT2020	108791	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
12262237	C4591001 1226 12262237	16-55	16OCT2020	108795	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
12262239	C4591001 1226 12262239	16-55	16OCT2020	108846	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
12262241	C4591001 1226 12262241	16-55	16OCT2020	108848	Placebo	16OCT2020/ Placebo	04NOV2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12262242	C4591001 1226 12262242	16-55	16OCT2020	108849	Placebo	16OCT2020/ Placebo	06NOV2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12262243	C4591001 1226 12262243	16-55	16OCT2020	108953	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
12262244	C4591001 1226 12262244	16-55	16OCT2020	108854	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12262245	C4591001 1226 12262245	16-55	16OCT2020	108957	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
12262246	C4591001 1226 12262246	16-55	16OCT2020	108958	Placebo	16OCT2020/ Placebo	06NOV2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12262247	C4591001 1226 12262247	16-55	16OCT2020	270063	Placebo	16OCT2020/ Placebo	06NOV2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
12262249	C4591001 1226 12262249	16-55	16OCT2020	108963	Placebo	16OCT2020/ Placebo	05NOV2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12262251	C4591001 1226 12262251	16-55	16OCT2020	109027	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
12262252	C4591001 1226 12262252	16-55	16OCT2020	109031	Placebo	16OCT2020/ Placebo	06NOV2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12262255	C4591001 1226 12262255†	16-55	16OCT2020	109029	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
12262256	C4591001 1226 12262256	16-55	16OCT2020	109036	Placebo	16OCT2020/ Placebo	07NOV2020/ Placebo	30JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
12262258	C4591001 1226 12262258	16-55	17OCT2020	109458	BNT162b2 (30 µg)	17OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
12262259	C4591001 1226 12262259	16-55	17OCT2020	109459	Placebo	17OCT2020/ Placebo	07NOV2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12262260	C4591001 1226 12262260	16-55	17OCT2020	109461	BNT162b2 (30 µg)	17OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
12262261	C4591001 1226 12262261	16-55	17OCT2020	109467	Placebo	17OCT2020/ Placebo	07NOV2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12262262	C4591001 1226 12262262	16-55	17OCT2020	109470	BNT162b2 (30 µg)	17OCT2020/ BNT162b2 (30 µg)	07DEC2020/ BNT162b2 (30 µg)		
12262263	C4591001 1226 12262263	16-55	17OCT2020	109469	BNT162b2 (30 µg)	17OCT2020/ BNT162b2 (30 µg)	07NOV2020/ BNT162b2 (30 µg)		
12262267	C4591001 1226 12262267	16-55	17OCT2020	109477	Placebo	17OCT2020/ Placebo		19FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12262268	C4591001 1226 12262268	16-55	17OCT2020	109472	Placebo	17OCT2020/ Placebo	07NOV2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
12262269	C4591001 1226 12262269	16-55	17OCT2020	109493	Placebo	17OCT2020/ Placebo	07NOV2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12262270	C4591001 1226 12262270	16-55	17OCT2020	109500	BNT162b2 (30 µg)	17OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
12262272	C4591001 1226 12262272	16-55	17OCT2020	109494	Placebo	17OCT2020/ Placebo	07NOV2020/ Placebo	23JAN2021/ BNT162b2 (30 µg)	20FEB2021/ BNT162b2 (30 µg)
12262273	C4591001 1226 12262273	16-55	17OCT2020	109504	BNT162b2 (30 µg)	17OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12262274	C4591001 1226 12262274	16-55	17OCT2020	109506	Placebo	17OCT2020/ Placebo	06NOV2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12262275	C4591001 1226 12262275	16-55	17OCT2020	109511	BNT162b2 (30 µg)	17OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
12262276	C4591001 1226 12262276	16-55	17OCT2020	109507	BNT162b2 (30 µg)	17OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
12262278	C4591001 1226 12262278	16-55	17OCT2020	109515	Placebo	17OCT2020/ Placebo	20NOV2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12262279	C4591001 1226 12262279	16-55	17OCT2020	109529	Placebo	17OCT2020/ Placebo	06NOV2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12262280	C4591001 1226 12262280	16-55	17OCT2020	109530	Placebo	17OCT2020/ Placebo	05NOV2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12262282	C4591001 1226 12262282	16-55	17OCT2020	109538	BNT162b2 (30 µg)	17OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
12262283	C4591001 1226 12262283	16-55	17OCT2020	109571	Placebo	17OCT2020/ Placebo	06NOV2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12262284	C4591001 1226 12262284	16-55	17OCT2020	109536	BNT162b2 (30 µg)	17OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
12262285	C4591001 1226 12262285	16-55	17OCT2020	109567	BNT162b2 (30 µg)	17OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12262286	C4591001 1226 12262286	16-55	17OCT2020	109580	BNT162b2 (30 µg)	17OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
12262287	C4591001 1226 12262287	16-55	17OCT2020	109569	Placebo	17OCT2020/ Placebo	09NOV2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12262289	C4591001 1226 12262289	16-55	17OCT2020	109583	Placebo	17OCT2020/ Placebo	07NOV2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12262290	C4591001 1226 12262290	16-55	17OCT2020	109593	BNT162b2 (30 µg)	17OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
12262291	C4591001 1226 12262291	16-55	17OCT2020	109584	BNT162b2 (30 µg)	17OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
12262292	C4591001 1226 12262292	16-55	17OCT2020	109576	BNT162b2 (30 µg)	17OCT2020/ BNT162b2 (30 µg)	07NOV2020/ BNT162b2 (30 µg)		
12262293	C4591001 1226 12262293	16-55	17OCT2020	109591	Placebo	17OCT2020/ Placebo	06NOV2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12262294	C4591001 1226 12262294	16-55	17OCT2020	109585	Placebo	17OCT2020/ Placebo	07NOV2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12262295	C4591001 1226 12262295	16-55	17OCT2020	109601	BNT162b2 (30 µg)	17OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
12262297	C4591001 1226 12262297	16-55	17OCT2020	109596	BNT162b2 (30 µg)	17OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12262298	C4591001 1226 12262298	16-55	17OCT2020	109598	Placebo	17OCT2020/ Placebo	07NOV2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12262299	C4591001 1226 12262299	16-55	17OCT2020	109602	BNT162b2 (30 µg)	17OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
12262300	C4591001 1226 12262300	16-55	17OCT2020	109610	Placebo	17OCT2020/ Placebo	06NOV2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12262301	C4591001 1226 12262301	16-55	17OCT2020	109637	Placebo	17OCT2020/ Placebo	07NOV2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12262303	C4591001 1226 12262303	16-55	17OCT2020	109609	Placebo	17OCT2020/ Placebo	07NOV2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12262304	C4591001 1226 12262304	16-55	17OCT2020	109641	BNT162b2 (30 µg)	17OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
12262307	C4591001 1226 12262307	16-55	17OCT2020	109646	BNT162b2 (30 µg)	17OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
12262309	C4591001 1226 12262309	16-55	17OCT2020	109643	Placebo	17OCT2020/ Placebo	05NOV2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12262311	C4591001 1226 12262311	16-55	17OCT2020	109649	Placebo	17OCT2020/ Placebo	05NOV2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12262313	C4591001 1226 12262313	16-55	19OCT2020	109653	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)			

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12262314	C4591001 1226 12262314	16-55	19OCT2020	109656	Placebo	19OCT2020/ Placebo	11NOV2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
12262315	C4591001 1226 12262315	16-55	19OCT2020	109660	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
12262316	C4591001 1226 12262316	16-55	19OCT2020	109829	Placebo	19OCT2020/ Placebo	13NOV2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
12262317	C4591001 1226 12262317	16-55	19OCT2020	109833	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
12262318	C4591001 1226 12262318	16-55	19OCT2020	109835	Placebo	19OCT2020/ Placebo	07NOV2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
12262319	C4591001 1226 12262319	16-55	19OCT2020	109839	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	07NOV2020/ BNT162b2 (30 µg)		
12262320	C4591001 1226 12262320	16-55	19OCT2020	109866	Placebo	19OCT2020/ Placebo	11NOV2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
12262321	C4591001 1226 12262321	16-55	19OCT2020	109869	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
12262322	C4591001 1226 12262322	16-55	19OCT2020	109870	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
12262326	C4591001 1226 12262326	16-55	19OCT2020	109871	Placebo	19OCT2020/ Placebo	11NOV2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12262327	C4591001 1226 12262327	16-55	19OCT2020	109938	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	07NOV2020/ BNT162b2 (30 µg)		
12262329	C4591001 1226 12262329	16-55	19OCT2020	109940	Placebo	19OCT2020/ Placebo	11NOV2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	
12262330	C4591001 1226 12262330	16-55	19OCT2020	109941	Placebo	19OCT2020/ Placebo	11NOV2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	20FEB2021/ BNT162b2 (30 µg)
12262331	C4591001 1226 12262331	16-55	19OCT2020	109947	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	07NOV2020/ BNT162b2 (30 µg)		
12262334	C4591001 1226 12262334	16-55	19OCT2020	109997	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
12262335	C4591001 1226 12262335	16-55	19OCT2020	110005	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	07NOV2020/ BNT162b2 (30 µg)		
12262337	C4591001 1226 12262337	16-55	19OCT2020	110007	Placebo	19OCT2020/ Placebo	07NOV2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12262338	C4591001 1226 12262338	16-55	19OCT2020	110006	Placebo	19OCT2020/ Placebo	07NOV2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12262339	C4591001 1226 12262339	16-55	19OCT2020	110049	Placebo	19OCT2020/ Placebo	19NOV2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	
12262340	C4591001 1226 12262340	16-55	19OCT2020	110053	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	07NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12262341	C4591001 1226 12262341	16-55	19OCT2020	110055	Placebo	19OCT2020/ Placebo	07NOV2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12262343	C4591001 1226 12262343	16-55	19OCT2020	110056	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
12262346	C4591001 1226 12262346	16-55	19OCT2020	110187	Placebo	19OCT2020/ Placebo	11NOV2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
12262347	C4591001 1226 12262347	16-55	19OCT2020	110239	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
12262348	C4591001 1226 12262348	16-55	19OCT2020	110180	Placebo	19OCT2020/ Placebo	11NOV2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12262350	C4591001 1226 12262350	16-55	19OCT2020	110181	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
12262351	C4591001 1226 12262351	16-55	19OCT2020	110182	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
12262352	C4591001 1226 12262352	16-55	20OCT2020	110241	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
12262353	C4591001 1226 12262353	16-55	20OCT2020	110244	Placebo	23OCT2020/ Placebo	11NOV2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12262354	C4591001 1226 12262354	16-55	20OCT2020	110245	Placebo	20OCT2020/ Placebo	11NOV2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12262356	C4591001 1226 12262356	16-55	20OCT2020	110742	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)		
12262357	C4591001 1226 12262357	16-55	20OCT2020	110743	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
12291001	C4591001 1229 12291001	16-55	22SEP2020	95924	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
12291002	C4591001 1229 12291002	16-55	22SEP2020	95925	Placebo	22SEP2020/ Placebo	14OCT2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12291004	C4591001 1229 12291004	16-55	22SEP2020	95926	Placebo	22SEP2020/ Placebo	14OCT2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12291006	C4591001 1229 12291006	16-55	23SEP2020	95931	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
12291007	C4591001 1229 12291007	16-55	23SEP2020	97153	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
12291008	C4591001 1229 12291008	16-55	23SEP2020	97152	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
12291009	C4591001 1229 12291009	16-55	23SEP2020	97154	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
12291010	C4591001 1229 12291010	16-55	23SEP2020	97178	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12291011	C4591001 1229 12291011	16-55	23SEP2020	97155	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12291012	C4591001 1229 12291012	16-55	23SEP2020	97169	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
12291013	C4591001 1229 12291013	16-55	23SEP2020	97176	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
12291015	C4591001 1229 12291015	16-55	25SEP2020	97180	Placebo	25SEP2020/ Placebo	15OCT2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
12291016	C4591001 1229 12291016	16-55	25SEP2020	99188	Placebo	25SEP2020/ Placebo	15OCT2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12291019	C4591001 1229 12291019	16-55	25SEP2020	99190	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12291020	C4591001 1229 12291020	16-55	25SEP2020	99195	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
12291021	C4591001 1229 12291021	16-55	25SEP2020	99192	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
12291022	C4591001 1229 12291022	16-55	25SEP2020	99227	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
12291024	C4591001 1229 12291024†	16-55	28SEP2020	99232	Placebo	28SEP2020/ Placebo	20OCT2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12291025	C4591001 1229 12291025	16-55	28SEP2020	99230	Placebo	28SEP2020/ Placebo	20OCT2020/ Placebo		
12291027	C4591001 1229 12291027†	16-55	28SEP2020	101177	Placebo	28SEP2020/ Placebo	20OCT2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
12291029	C4591001 1229 12291029	16-55	28SEP2020	99231	BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		
12291030	C4591001 1229 12291030	16-55	28SEP2020	101188	BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		
12291031	C4591001 1229 12291031	16-55	28SEP2020	101180	Placebo	28SEP2020/ Placebo	23OCT2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12291032	C4591001 1229 12291032	16-55	28SEP2020	101185	BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		
12291033	C4591001 1229 12291033	16-55	28SEP2020	101213	BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		
12291035	C4591001 1229 12291035	16-55	28SEP2020	101214	Placebo	28SEP2020/ Placebo	20OCT2020/ Placebo		
12291037	C4591001 1229 12291037	16-55	28SEP2020	101215	Placebo	28SEP2020/ Placebo	20OCT2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12291042	C4591001 1229 12291042†	16-55	29SEP2020	101216	BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12291043	C4591001 1229 12291043	16-55	29SEP2020	101681	Placebo	29SEP2020/ Placebo	20OCT2020/ Placebo		
12291045	C4591001 1229 12291045†	16-55	29SEP2020	101686	Placebo	29SEP2020/ Placebo	20OCT2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12291046	C4591001 1229 12291046	16-55	29SEP2020	101691	BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		
12291047	C4591001 1229 12291047	16-55	29SEP2020	101688	BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		
12291048	C4591001 1229 12291048	16-55	29SEP2020	101722	Placebo	29SEP2020/ Placebo	20OCT2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
12291049	C4591001 1229 12291049	16-55	29SEP2020	101723	BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		
12291051	C4591001 1229 12291051	16-55	29SEP2020	101726	BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)		
12291052	C4591001 1229 12291052†	16-55	30SEP2020	102077	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		
12291055	C4591001 1229 12291055†	16-55	30SEP2020	102111	Placebo	30SEP2020/ Placebo	21OCT2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
12291057	C4591001 1229 12291057	16-55	30SEP2020	101728	Placebo	30SEP2020/ Placebo	21OCT2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12291058	C4591001 1229 12291058†	16-55	30SEP2020	102101	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)		
12291059	C4591001 1229 12291059	16-55	30SEP2020	102083	Placebo	30SEP2020/ Placebo	21OCT2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12291061	C4591001 1229 12291061	16-55	30SEP2020	102102	Placebo	30SEP2020/ Placebo	21OCT2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12291062	C4591001 1229 12291062	16-55	30SEP2020	102084	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		
12291063	C4591001 1229 12291063†	16-55	30SEP2020	102087	Placebo	30SEP2020/ Placebo	21OCT2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
12291064	C4591001 1229 12291064	16-55	30SEP2020	102132	Placebo	30SEP2020/ Placebo	21OCT2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12291065	C4591001 1229 12291065	16-55	30SEP2020	102129	Placebo	30SEP2020/ Placebo	21OCT2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12291066	C4591001 1229 12291066	16-55	30SEP2020	102112	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		
12291070	C4591001 1229 12291070†	16-55	01OCT2020	102609	Placebo	01OCT2020/ Placebo	22OCT2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12291072	C4591001 1229 12291072†	16-55	01OCT2020	102133	BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12291073	C4591001 1229 12291073†	16-55	01OCT2020	102606	Placebo	01OCT2020/ Placebo	22OCT2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
12291077	C4591001 1229 12291077	16-55	01OCT2020	102135	BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
12291078	C4591001 1229 12291078	16-55	01OCT2020	102615	BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)		
12291079	C4591001 1229 12291079	16-55	01OCT2020	102613	BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)		
12291081	C4591001 1229 12291081†	16-55	01OCT2020	102630	Placebo	01OCT2020/ Placebo	22OCT2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
12291082	C4591001 1229 12291082	16-55	01OCT2020	102632	BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)		
12291083	C4591001 1229 12291083†	16-55	01OCT2020	102631	Placebo	01OCT2020/ Placebo	22OCT2020/ Placebo		
12291086	C4591001 1229 12291086†	16-55	02OCT2020	102639	BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)		
12291088	C4591001 1229 12291088	16-55	02OCT2020	103005	Placebo	02OCT2020/ Placebo	23OCT2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	13MAR2021/ BNT162b2 (30 µg)
12291091	C4591001 1229 12291091	16-55	02OCT2020	103040	BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12291092	C4591001 1229 12291092†	16-55	02OCT2020	103001	BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)		
12291093	C4591001 1229 12291093	16-55	02OCT2020	103012	BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)		
12291094	C4591001 1229 12291094	16-55	02OCT2020	103041	Placebo	02OCT2020/ Placebo	23OCT2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
12291095	C4591001 1229 12291095	16-55	02OCT2020	103009	Placebo	02OCT2020/ Placebo	23OCT2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
12291096	C4591001 1229 12291096†	16-55	02OCT2020	103042	BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)		
12291098	C4591001 1229 12291098	16-55	05OCT2020	103043	Placebo	05OCT2020/ Placebo	26OCT2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
12291099	C4591001 1229 12291099	16-55	05OCT2020	103555	Placebo	05OCT2020/ Placebo	26OCT2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12291100	C4591001 1229 12291100	16-55	05OCT2020	103558	BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
12291101	C4591001 1229 12291101	16-55	05OCT2020	103563	Placebo	05OCT2020/ Placebo	26OCT2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12291103	C4591001 1229 12291103	16-55	05OCT2020	103590	BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12291104	C4591001 1229 12291104	16-55	05OCT2020	103591	BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
12291105	C4591001 1229 12291105	16-55	05OCT2020	103562	BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
12291107	C4591001 1229 12291107	16-55	05OCT2020	103595	Placebo	05OCT2020/ Placebo	26OCT2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12291108	C4591001 1229 12291108	16-55	05OCT2020	103598	Placebo	05OCT2020/ Placebo	26OCT2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
12291109	C4591001 1229 12291109	16-55	05OCT2020	103634	BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
12291110	C4591001 1229 12291110	16-55	05OCT2020	103625	Placebo	05OCT2020/ Placebo	28OCT2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
12291112	C4591001 1229 12291112	16-55	05OCT2020	103632	Placebo	05OCT2020/ Placebo	26OCT2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	
12291113	C4591001 1229 12291113†	16-55	06OCT2020	103636	BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		
12291114	C4591001 1229 12291114	16-55	06OCT2020	104029	BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		
12291115	C4591001 1229 12291115	16-55	06OCT2020	104022	Placebo	06OCT2020/ Placebo	28OCT2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12291116	C4591001 1229 12291116	16-55	06OCT2020	104070	Placebo	06OCT2020/ Placebo	27OCT2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12291117	C4591001 1229 12291117†	16-55	06OCT2020	104024	BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		
12291118	C4591001 1229 12291118	16-55	06OCT2020	104028	Placebo	06OCT2020/ Placebo	27OCT2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
12291119	C4591001 1229 12291119	16-55	06OCT2020	104069	Placebo	06OCT2020/ Placebo	27OCT2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12291122	C4591001 1229 12291122	16-55	06OCT2020	104074	BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		
12291124	C4591001 1229 12291124	16-55	06OCT2020	104080	BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		
12291126	C4591001 1229 12291126†	16-55	06OCT2020	104106	Placebo	06OCT2020/ Placebo	27OCT2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12291127	C4591001 1229 12291127	16-55	06OCT2020	104109	BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		
12291130	C4591001 1229 12291130†	16-55	07OCT2020	104567	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
12291131	C4591001 1229 12291131†	16-55	07OCT2020	104110	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12291134	C4591001 1229 12291134†	16-55	07OCT2020	104539	Placebo	07OCT2020/ Placebo	28OCT2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12291135	C4591001 1229 12291135†	16-55	07OCT2020	104116	Placebo	07OCT2020/ Placebo	28OCT2020/ Placebo		
12291136	C4591001 1229 12291136	16-55	07OCT2020	104542	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
12291138	C4591001 1229 12291138	16-55	07OCT2020	104544	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
12291139	C4591001 1229 12291139†	16-55	07OCT2020	104564	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
12291140	C4591001 1229 12291140†	16-55	07OCT2020	104543	Placebo	07OCT2020/ Placebo	28OCT2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12291141	C4591001 1229 12291141	16-55	07OCT2020	104611	Placebo	07OCT2020/ Placebo	28OCT2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
12291142	C4591001 1229 12291142	16-55	07OCT2020	104563	Placebo	07OCT2020/ Placebo	28OCT2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12291143	C4591001 1229 12291143	16-55	07OCT2020	104568	Placebo	07OCT2020/ Placebo	28OCT2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12291145	C4591001 1229 12291145	16-55	08OCT2020	104617	Placebo	08OCT2020/ Placebo	29OCT2020/ Placebo	03MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12291146	C4591001 1229 12291146	16-55	08OCT2020	104614	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
12291149	C4591001 1229 12291149	16-55	08OCT2020	105093	Placebo	08OCT2020/ Placebo	28OCT2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12291151	C4591001 1229 12291151	16-55	08OCT2020	105098	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)		
12291152	C4591001 1229 12291152	16-55	08OCT2020	105133	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
12291153	C4591001 1229 12291153	16-55	08OCT2020	105131	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)		
12291154	C4591001 1229 12291154	16-55	08OCT2020	104619	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)		
12291155	C4591001 1229 12291155	16-55	08OCT2020	105132	Placebo	08OCT2020/ Placebo	28OCT2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12291156	C4591001 1229 12291156	16-55	08OCT2020	105173	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)		
12291157	C4591001 1229 12291157	16-55	08OCT2020	105136	Placebo	08OCT2020/ Placebo	29OCT2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
12291158	C4591001 1229 12291158	16-55	08OCT2020	105096	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12291159	C4591001 1229 12291159	16-55	08OCT2020	105100	Placebo	08OCT2020/ Placebo	29OCT2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12291160	C4591001 1229 12291160	16-55	08OCT2020	105174	Placebo	08OCT2020/ Placebo	29OCT2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
12291165	C4591001 1229 12291165†	16-55	09OCT2020	105181	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)		
12291166	C4591001 1229 12291166†	16-55	09OCT2020	105656	Placebo	09OCT2020/ Placebo	30OCT2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
12291167	C4591001 1229 12291167†	16-55	09OCT2020	105653	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)		
12291168	C4591001 1229 12291168	16-55	09OCT2020	105689	Placebo	09OCT2020/ Placebo	30OCT2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
12291169	C4591001 1229 12291169	16-55	09OCT2020	105663	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)		
12291170	C4591001 1229 12291170†	16-55	09OCT2020	105664	Placebo	09OCT2020/ Placebo	30OCT2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
12291171	C4591001 1229 12291171†	16-55	09OCT2020	105690	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)		
12291172	C4591001 1229 12291172	16-55	09OCT2020	105691	Placebo	09OCT2020/ Placebo	30OCT2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12291173	C4591001 1229 12291173	16-55	09OCT2020	267808	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)		
12291174	C4591001 1229 12291174	16-55	12OCT2020	106265	Placebo	12OCT2020/ Placebo	02NOV2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12291175	C4591001 1229 12291175	16-55	12OCT2020	106276	BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		
12291176	C4591001 1229 12291176	16-55	12OCT2020	105696	BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		
12291177	C4591001 1229 12291177	16-55	12OCT2020	106282	Placebo	12OCT2020/ Placebo	03NOV2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12291178	C4591001 1229 12291178†	16-55	12OCT2020	106278	BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		
12291179	C4591001 1229 12291179	16-55	12OCT2020	106283	BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		
12291180	C4591001 1229 12291180	16-55	12OCT2020	106279	Placebo	12OCT2020/ Placebo	06NOV2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
12291181	C4591001 1229 12291181†	16-55	12OCT2020	106267	BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
12291182	C4591001 1229 12291182	16-55	12OCT2020	106291	Placebo	12OCT2020/ Placebo	02NOV2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12291184	C4591001 1229 12291184	16-55	12OCT2020	106270	Placebo	12OCT2020/ Placebo	04NOV2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12291185	C4591001 1229 12291185	16-55	12OCT2020	106311	BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
12291186	C4591001 1229 12291186	16-55	12OCT2020	106299	BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		
12291187	C4591001 1229 12291187	16-55	12OCT2020	106296	BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		
12291188	C4591001 1229 12291188	16-55	12OCT2020	106308	Placebo	12OCT2020/ Placebo	02NOV2020/ Placebo		
12291189	C4591001 1229 12291189	16-55	12OCT2020	106295	Placebo	12OCT2020/ Placebo	02NOV2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
12291190	C4591001 1229 12291190	16-55	12OCT2020	106307	BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		
12291192	C4591001 1229 12291192	16-55	13OCT2020	106752	Placebo	13OCT2020/ Placebo	03NOV2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
12291193	C4591001 1229 12291193	16-55	13OCT2020	106753	Placebo	13OCT2020/ Placebo	04NOV2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12291194	C4591001 1229 12291194†	16-55	13OCT2020	106312	Placebo	13OCT2020/ Placebo	03NOV2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12291195	C4591001 1229 12291195	16-55	13OCT2020	106745	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
12291196	C4591001 1229 12291196	16-55	13OCT2020	106755	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
12291197	C4591001 1229 12291197	16-55	13OCT2020	106758	Placebo	13OCT2020/ Placebo	06NOV2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12291198	C4591001 1229 12291198	16-55	13OCT2020	106774	Placebo	13OCT2020/ Placebo	05NOV2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12291200	C4591001 1229 12291200	16-55	13OCT2020	106765	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
12291201	C4591001 1229 12291201	16-55	13OCT2020	106778	Placebo	13OCT2020/ Placebo	03NOV2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
12291202	C4591001 1229 12291202	16-55	13OCT2020	106759	Placebo	13OCT2020/ Placebo	03NOV2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12291204	C4591001 1229 12291204	16-55	13OCT2020	106766	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)			
12291205	C4591001 1229 12291205	16-55	13OCT2020	106770	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
12291207	C4591001 1229 12291207	16-55	14OCT2020	107301	Placebo	14OCT2020/ Placebo	04NOV2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12291209	C4591001 1229 12291209	16-55	14OCT2020	107313	Placebo	14OCT2020/ Placebo	04NOV2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12291211	C4591001 1229 12291211†	16-55	14OCT2020	107306	BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
12291212	C4591001 1229 12291212	16-55	14OCT2020	106779	BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
12291213	C4591001 1229 12291213	16-55	14OCT2020	107305	BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
12291214	C4591001 1229 12291214	16-55	14OCT2020	107307	Placebo	14OCT2020/ Placebo	04NOV2020/ Placebo		
12291215	C4591001 1229 12291215†	16-55	14OCT2020	107315	Placebo	14OCT2020/ Placebo	04NOV2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12291216	C4591001 1229 12291216	16-55	14OCT2020	107317	BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
12291217	C4591001 1229 12291217	16-55	15OCT2020	107318	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
12301001	C4591001 1230 12301001	16-55	23SEP2020	97134	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	17OCT2020/ BNT162b2 (30 µg)		
12301002	C4591001 1230 12301002	16-55	23SEP2020	97135	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12301004	C4591001 1230 12301004	16-55	23SEP2020	97139	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12301005	C4591001 1230 12301005	16-55	23SEP2020	97144	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12301006	C4591001 1230 12301006	16-55	23SEP2020	97230	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12301008	C4591001 1230 12301008	16-55	23SEP2020	97231	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12301009	C4591001 1230 12301009	16-55	23SEP2020	97237	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
12301010	C4591001 1230 12301010	16-55	23SEP2020	97232	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
12301011	C4591001 1230 12301011	16-55	23SEP2020	97553	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12301012	C4591001 1230 12301012	16-55	23SEP2020	97556	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
12301015	C4591001 1230 12301015	16-55	24SEP2020	97558	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
12301017	C4591001 1230 12301017	16-55	24SEP2020	97560	Placebo	24SEP2020/ Placebo	15OCT2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12301018	C4591001 1230 12301018	16-55	24SEP2020	98507	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
12301019	C4591001 1230 12301019	16-55	24SEP2020	98509	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
12301020	C4591001 1230 12301020	16-55	24SEP2020	98510	Placebo	24SEP2020/ Placebo	15OCT2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
12301021	C4591001 1230 12301021	16-55	24SEP2020	98512	Placebo	24SEP2020/ Placebo	15OCT2020/ Placebo		
12301022	C4591001 1230 12301022	16-55	24SEP2020	98549	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
12301023	C4591001 1230 12301023	16-55	24SEP2020	98552	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
12301024	C4591001 1230 12301024	16-55	25SEP2020	98553	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12301026	C4591001 1230 12301026	16-55	25SEP2020	98554	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12301028	C4591001 1230 12301028	16-55	25SEP2020	99239	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12301029	C4591001 1230 12301029	16-55	25SEP2020	99235	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12301031	C4591001 1230 12301031	16-55	25SEP2020	99242	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
12301032	C4591001 1230 12301032	16-55	25SEP2020	99244	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
12301033	C4591001 1230 12301033	16-55	25SEP2020	99282	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
12301034	C4591001 1230 12301034	16-55	25SEP2020	99284	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
12301035	C4591001 1230 12301035	16-55	25SEP2020	99283	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
12301036	C4591001 1230 12301036	16-55	25SEP2020	99285	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
12301037	C4591001 1230 12301037	16-55	26SEP2020	100579	BNT162b2 (30 µg)	26SEP2020/ BNT162b2 (30 µg)	17OCT2020/ BNT162b2 (30 µg)		
12301038	C4591001 1230 12301038	16-55	26SEP2020	100580	Placebo	26SEP2020/ Placebo	17OCT2020/ Placebo	13FEB2021/ BNT162b2 (30 µg)	06MAR2021/ BNT162b2 (30 µg)
12301039	C4591001 1230 12301039	16-55	26SEP2020	100588	Placebo	26SEP2020/ Placebo	17OCT2020/ Placebo	13FEB2021/ BNT162b2 (30 µg)	06MAR2021/ BNT162b2 (30 µg)
12301040	C4591001 1230 12301040	16-55	26SEP2020	100595	Placebo	26SEP2020/ Placebo	17OCT2020/ Placebo		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12301041	C4591001 1230 12301041	16-55	26SEP2020	100585	BNT162b2 (30 µg)	26SEP2020/ BNT162b2 (30 µg)	17OCT2020/ BNT162b2 (30 µg)		
12301043	C4591001 1230 12301043	16-55	26SEP2020	100596	BNT162b2 (30 µg)	26SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
12301044	C4591001 1230 12301044	16-55	26SEP2020	100598	BNT162b2 (30 µg)	26SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
12301045	C4591001 1230 12301045†	16-55	29SEP2020	101741	BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)			
12301047	C4591001 1230 12301047	16-55	28SEP2020	100599	Placebo	28SEP2020/ Placebo	20OCT2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12301048	C4591001 1230 12301048	16-55	28SEP2020	101191	BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)		
12301050	C4591001 1230 12301050	16-55	28SEP2020	101192	Placebo	28SEP2020/ Placebo	19OCT2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
12301051	C4591001 1230 12301051	16-55	28SEP2020	101193	BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)		
12301052	C4591001 1230 12301052	16-55	28SEP2020	101225	BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		
12301053	C4591001 1230 12301053	16-55	28SEP2020	101199	Placebo	28SEP2020/ Placebo	19OCT2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12301054	C4591001 1230 12301054	16-55	28SEP2020	101230	Placebo	28SEP2020/ Placebo	19OCT2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
12301055	C4591001 1230 12301055	16-55	28SEP2020	101236	BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)		
12301056	C4591001 1230 12301056	16-55	28SEP2020	101234	Placebo	28SEP2020/ Placebo	20OCT2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12301057	C4591001 1230 12301057	16-55	28SEP2020	101292	Placebo	28SEP2020/ Placebo	19OCT2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12301058	C4591001 1230 12301058	16-55	28SEP2020	101293	BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)		
12301060	C4591001 1230 12301060	16-55	28SEP2020	101294	Placebo	28SEP2020/ Placebo	19OCT2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
12301062	C4591001 1230 12301062	16-55	29SEP2020	101296	BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		
12301063	C4591001 1230 12301063	16-55	29SEP2020	101670	Placebo	29SEP2020/ Placebo	21OCT2020/ Placebo		
12301064	C4591001 1230 12301064	16-55	29SEP2020	101671	BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		
12301065	C4591001 1230 12301065	16-55	29SEP2020	101672	Placebo	29SEP2020/ Placebo	26NOV2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12301066	C4591001 1230 12301066	16-55	29SEP2020	101673	BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		
12301067	C4591001 1230 12301067	16-55	29SEP2020	101693	BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		
12301068	C4591001 1230 12301068	16-55	29SEP2020	101696	Placebo	29SEP2020/ Placebo	20OCT2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
12301069	C4591001 1230 12301069	16-55	29SEP2020	101702	Placebo	29SEP2020/ Placebo	20OCT2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
12301070	C4591001 1230 12301070	16-55	29SEP2020	101742	Placebo	29SEP2020/ Placebo	21OCT2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
12301071	C4591001 1230 12301071	16-55	29SEP2020	101703	BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		
12301072	C4591001 1230 12301072	16-55	29SEP2020	101749	Placebo	29SEP2020/ Placebo	20OCT2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
12301073	C4591001 1230 12301073†	16-55	29SEP2020	101750	BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)		
12301074	C4591001 1230 12301074	16-55	30SEP2020	102018	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		
12301075	C4591001 1230 12301075	16-55	30SEP2020	102118	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12301077	C4591001 1230 12301077	16-55	05OCT2020	103420	Placebo	05OCT2020/ Placebo	24OCT2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
12301078	C4591001 1230 12301078	16-55	30SEP2020	102019	Placebo	30SEP2020/ Placebo	20OCT2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12301079	C4591001 1230 12301079	16-55	30SEP2020	102020	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		
12301080	C4591001 1230 12301080	16-55	30SEP2020	102024	Placebo	30SEP2020/ Placebo	20OCT2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12301082	C4591001 1230 12301082	16-55	30SEP2020	102114	Placebo	30SEP2020/ Placebo	20OCT2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
12301083	C4591001 1230 12301083	16-55	30SEP2020	102121	Placebo	30SEP2020/ Placebo	21OCT2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
12301084	C4591001 1230 12301084	16-55	30SEP2020	102123	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		
12301085	C4591001 1230 12301085	16-55	30SEP2020	102262	Placebo	30SEP2020/ Placebo	21OCT2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12301086	C4591001 1230 12301086†	16-55	30SEP2020	102264	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)		
12301087	C4591001 1230 12301087	16-55	30SEP2020	102266	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12301089	C4591001 1230 12301089	16-55	01OCT2020	102267	Placebo	01OCT2020/ Placebo	20OCT2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12301091	C4591001 1230 12301091	16-55	01OCT2020	102593	BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		
12301092	C4591001 1230 12301092	16-55	01OCT2020	102594	Placebo	01OCT2020/ Placebo	20OCT2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
12301094	C4591001 1230 12301094	16-55	01OCT2020	102602	Placebo	01OCT2020/ Placebo	21OCT2020/ Placebo	13FEB2021/ BNT162b2 (30 µg)	06MAR2021/ BNT162b2 (30 µg)
12301095	C4591001 1230 12301095	16-55	01OCT2020	102603	BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		
12301097	C4591001 1230 12301097	16-55	01OCT2020	102761	Placebo	01OCT2020/ Placebo	20OCT2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
12301099	C4591001 1230 12301099	16-55	02OCT2020	103111	BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)		
12301100	C4591001 1230 12301100	16-55	02OCT2020	102764	BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)		
12301101	C4591001 1230 12301101	16-55	02OCT2020	102765	Placebo	02OCT2020/ Placebo	22OCT2020/ Placebo		
12301102	C4591001 1230 12301102	16-55	02OCT2020	102772	BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12301103	C4591001 1230 12301103	16-55	02OCT2020	103026	BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)		
12301104	C4591001 1230 12301104	16-55	02OCT2020	103030	Placebo	02OCT2020/ Placebo	23OCT2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
12301105	C4591001 1230 12301105	16-55	02OCT2020	103034	BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)		
12301106	C4591001 1230 12301106	16-55	02OCT2020	103035	Placebo	02OCT2020/ Placebo	23OCT2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
12301107	C4591001 1230 12301107	16-55	02OCT2020	103049	Placebo	02OCT2020/ Placebo	23OCT2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
12301108	C4591001 1230 12301108	16-55	02OCT2020	103052	BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)		
12301109	C4591001 1230 12301109	16-55	02OCT2020	103058	Placebo	02OCT2020/ Placebo	23OCT2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
12301110	C4591001 1230 12301110	16-55	02OCT2020	103059	BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)		
12301112	C4591001 1230 12301112	16-55	02OCT2020	103110	Placebo	02OCT2020/ Placebo	23OCT2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12301113	C4591001 1230 12301113	16-55	02OCT2020	103114	BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)			

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12301114	C4591001 1230 12301114	16-55	03OCT2020	103116	Placebo	03OCT2020/ Placebo	26OCT2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12301115	C4591001 1230 12301115	16-55	03OCT2020	103385	BNT162b2 (30 µg)	03OCT2020/ BNT162b2 (30 µg)	24OCT2020/ BNT162b2 (30 µg)		
12301116	C4591001 1230 12301116	16-55	03OCT2020	103387	Placebo	03OCT2020/ Placebo	24OCT2020/ Placebo	13FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
12301117	C4591001 1230 12301117	16-55	03OCT2020	103389	Placebo	03OCT2020/ Placebo	24OCT2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
12301118	C4591001 1230 12301118	16-55	03OCT2020	103393	BNT162b2 (30 µg)	03OCT2020/ BNT162b2 (30 µg)	24OCT2020/ BNT162b2 (30 µg)		
12301121	C4591001 1230 12301121	16-55	03OCT2020	103415	Placebo	03OCT2020/ Placebo	27OCT2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
12301122	C4591001 1230 12301122	16-55	03OCT2020	103416	BNT162b2 (30 µg)	03OCT2020/ BNT162b2 (30 µg)	24OCT2020/ BNT162b2 (30 µg)		
12301123	C4591001 1230 12301123	16-55	03OCT2020	103418	BNT162b2 (30 µg)	03OCT2020/ BNT162b2 (30 µg)	24OCT2020/ BNT162b2 (30 µg)		
12301124	C4591001 1230 12301124	16-55	05OCT2020	103541	Placebo	05OCT2020/ Placebo	27OCT2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12301125	C4591001 1230 12301125	16-55	05OCT2020	103546	Placebo	05OCT2020/ Placebo	26OCT2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12301129	C4591001 1230 12301129	16-55	05OCT2020	103614	Placebo	05OCT2020/ Placebo	28OCT2020/ Placebo		
12301130	C4591001 1230 12301130	16-55	05OCT2020	103619	BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
12301132	C4591001 1230 12301132	16-55	05OCT2020	103621	Placebo	05OCT2020/ Placebo	26OCT2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	
12301133	C4591001 1230 12301133	16-55	05OCT2020	103622	BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
12301134	C4591001 1230 12301134	16-55	05OCT2020	103675	BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
12301135	C4591001 1230 12301135	16-55	05OCT2020	103676	BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
12301136	C4591001 1230 12301136	16-55	05OCT2020	103678	Placebo	05OCT2020/ Placebo	26OCT2020/ Placebo	13FEB2021/ BNT162b2 (30 µg)	06MAR2021/ BNT162b2 (30 µg)
12301137	C4591001 1230 12301137	16-55	05OCT2020	103682	Placebo	05OCT2020/ Placebo	26OCT2020/ Placebo	13FEB2021/ BNT162b2 (30 µg)	06MAR2021/ BNT162b2 (30 µg)
12301138	C4591001 1230 12301138	16-55	06OCT2020	103986	BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		
12301139	C4591001 1230 12301139†	16-55	06OCT2020	103987	Placebo	06OCT2020/ Placebo	27OCT2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12301140	C4591001 1230 12301140†	16-55	06OCT2020	103991	BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		
12301142	C4591001 1230 12301142	16-55	06OCT2020	103996	Placebo	06OCT2020/ Placebo	27OCT2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
12301143	C4591001 1230 12301143	16-55	06OCT2020	104058	Placebo	06OCT2020/ Placebo	27OCT2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
12301144	C4591001 1230 12301144	16-55	06OCT2020	104060	BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		
12301145	C4591001 1230 12301145	16-55	06OCT2020	104059	BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		
12301146	C4591001 1230 12301146	16-55	06OCT2020	104063	Placebo	06OCT2020/ Placebo	26OCT2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12301147	C4591001 1230 12301147	16-55	06OCT2020	104093	Placebo	06OCT2020/ Placebo	27OCT2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
12301148	C4591001 1230 12301148	16-55	06OCT2020	104098	BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)			
12301150	C4591001 1230 12301150	16-55	06OCT2020	104100	Placebo	06OCT2020/ Placebo			
12301151	C4591001 1230 12301151	16-55	06OCT2020	104101	BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12301152	C4591001 1230 12301152	16-55	06OCT2020	104129	Placebo	06OCT2020/ Placebo	27OCT2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12301153	C4591001 1230 12301153	16-55	06OCT2020	104134	BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		
12301154	C4591001 1230 12301154	16-55	06OCT2020	104135	Placebo	06OCT2020/ Placebo	27OCT2020/ Placebo	13FEB2021/ BNT162b2 (30 µg)	06MAR2021/ BNT162b2 (30 µg)
12301157	C4591001 1230 12301157	16-55	06OCT2020	104137	BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
12301158	C4591001 1230 12301158	16-55	06OCT2020	104249	Placebo	06OCT2020/ Placebo	27OCT2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
12301159	C4591001 1230 12301159	16-55	06OCT2020	104254	Placebo	06OCT2020/ Placebo	27OCT2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
12301161	C4591001 1230 12301161	16-55	07OCT2020	104256	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
12301162	C4591001 1230 12301162	16-55	07OCT2020	104259	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
12301163	C4591001 1230 12301163	16-55	07OCT2020	104513	Placebo	07OCT2020/ Placebo	28OCT2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
12301164	C4591001 1230 12301164	16-55	07OCT2020	104521	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12301165	C4591001 1230 12301165	16-55	07OCT2020	104519	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
12301166	C4591001 1230 12301166	16-55	07OCT2020	104522	Placebo	07OCT2020/ Placebo	28OCT2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
12301170	C4591001 1230 12301170	16-55	07OCT2020	104553	Placebo	07OCT2020/ Placebo	28OCT2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
12301171	C4591001 1230 12301171	16-55	07OCT2020	104551	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
12301172	C4591001 1230 12301172	16-55	07OCT2020	104556	Placebo	07OCT2020/ Placebo	28OCT2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
12301173	C4591001 1230 12301173	16-55	07OCT2020	104597	Placebo	07OCT2020/ Placebo	28OCT2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
12301174	C4591001 1230 12301174†	16-55	07OCT2020	104604	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
12301175	C4591001 1230 12301175	16-55	07OCT2020	104607	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
12301176	C4591001 1230 12301176†	16-55	07OCT2020	104608	Placebo	07OCT2020/ Placebo	28OCT2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
12301177	C4591001 1230 12301177	16-55	07OCT2020	104681	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12301181	C4591001 1230 12301181	16-55	08OCT2020	104686	Placebo	08OCT2020/ Placebo	29OCT2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
12301182	C4591001 1230 12301182	16-55	08OCT2020	104690	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)		
12301183	C4591001 1230 12301183	16-55	08OCT2020	104691	Placebo	08OCT2020/ Placebo	29OCT2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12301184	C4591001 1230 12301184†	16-55	08OCT2020	105116	Placebo	08OCT2020/ Placebo	29OCT2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
12301185	C4591001 1230 12301185	16-55	08OCT2020	105115	Placebo	08OCT2020/ Placebo	29OCT2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
12301186	C4591001 1230 12301186	16-55	08OCT2020	105117	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)		
12301187	C4591001 1230 12301187	16-55	08OCT2020	105119	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)		
12301188	C4591001 1230 12301188	16-55	08OCT2020	105153	Placebo	08OCT2020/ Placebo	29OCT2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
12301189	C4591001 1230 12301189	16-55	08OCT2020	105157	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)		
12301190	C4591001 1230 12301190	16-55	08OCT2020	105158	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12301191	C4591001 1230 12301191	16-55	08OCT2020	105160	Placebo	08OCT2020/ Placebo	29OCT2020/ Placebo		
12301192	C4591001 1230 12301192	16-55	08OCT2020	105189	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)		
12301193	C4591001 1230 12301193	16-55	08OCT2020	105194	Placebo	08OCT2020/ Placebo	29OCT2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12301195	C4591001 1230 12301195	16-55	08OCT2020	105195	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)		
12301196	C4591001 1230 12301196	16-55	08OCT2020	105196	Placebo	08OCT2020/ Placebo	29OCT2020/ Placebo		
12301197	C4591001 1230 12301197	16-55	08OCT2020	105270	Placebo	08OCT2020/ Placebo	29OCT2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
12301198	C4591001 1230 12301198	16-55	08OCT2020	105271	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)		
12301199	C4591001 1230 12301199	16-55	09OCT2020	105276	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)		
12301200	C4591001 1230 12301200	16-55	09OCT2020	105630	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)		
12301201	C4591001 1230 12301201	16-55	09OCT2020	105279	Placebo	09OCT2020/ Placebo	29OCT2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12301202	C4591001 1230 12301202	16-55	09OCT2020	105633	Placebo	09OCT2020/ Placebo	28OCT2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
12301203	C4591001 1230 12301203	16-55	09OCT2020	105637	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)		
12301204	C4591001 1230 12301204	16-55	09OCT2020	105635	Placebo	09OCT2020/ Placebo	30OCT2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
12301205	C4591001 1230 12301205	16-55	09OCT2020	105666	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)		
12301206	C4591001 1230 12301206	16-55	09OCT2020	105669	Placebo	09OCT2020/ Placebo	30OCT2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
12301207	C4591001 1230 12301207	16-55	09OCT2020	105727	Placebo	09OCT2020/ Placebo	30OCT2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12301208	C4591001 1230 12301208	16-55	09OCT2020	105672	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)		
12301209	C4591001 1230 12301209	16-55	09OCT2020	105673	Placebo	09OCT2020/ Placebo	30OCT2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
12301210	C4591001 1230 12301210	16-55	09OCT2020	105730	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)		
12301211	C4591001 1230 12301211	16-55	09OCT2020	105732	Placebo	09OCT2020/ Placebo	30OCT2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12301212	C4591001 1230 12301212	16-55	09OCT2020	105733	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)		
12301213	C4591001 1230 12301213	16-55	09OCT2020	105738	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)		
12301214	C4591001 1230 12301214	16-55	09OCT2020	105743	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)		
12301215	C4591001 1230 12301215	16-55	09OCT2020	105739	Placebo	09OCT2020/ Placebo	30OCT2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
12301216	C4591001 1230 12301216	16-55	09OCT2020	105742	Placebo	09OCT2020/ Placebo	30OCT2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
12301217	C4591001 1230 12301217	16-55	09OCT2020	105825	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)		
12301218	C4591001 1230 12301218	16-55	09OCT2020	105822	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)		
12301219	C4591001 1230 12301219	16-55	09OCT2020	105827	Placebo	09OCT2020/ Placebo	30OCT2020/ Placebo	13FEB2021/ BNT162b2 (30 µg)	06MAR2021/ BNT162b2 (30 µg)
12301220	C4591001 1230 12301220	16-55	09OCT2020	105830	Placebo	09OCT2020/ Placebo	30OCT2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
12301222	C4591001 1230 12301222	16-55	09OCT2020	105884	Placebo	09OCT2020/ Placebo	28OCT2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12301223	C4591001 1230 12301223	16-55	09OCT2020	105885	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)		
12301224	C4591001 1230 12301224	16-55	09OCT2020	105888	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)		
12301225	C4591001 1230 12301225	16-55	09OCT2020	106014	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)		
12301226	C4591001 1230 12301226	16-55	09OCT2020	106018	Placebo	09OCT2020/ Placebo	30OCT2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
12311191	C4591001 1231 12311191	16-55	14AUG2020	49988	Placebo	14AUG2020/ Placebo		03MAR2021/ BNT162b2 (30 µg)	
12311195	C4591001 1231 12311195	16-55	14AUG2020	50123	Placebo	14AUG2020/ Placebo		03MAR2021/ BNT162b2 (30 µg)	
12311200	C4591001 1231 12311200	16-55	14AUG2020	50125	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)			
12311211	C4591001 1231 12311211	16-55	14AUG2020	50163	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
12311214	C4591001 1231 12311214	16-55	14AUG2020	50167	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
12311232	C4591001 1231 12311232	16-55	14AUG2020	50359	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12311242	C4591001 1231 12311242	16-55	14AUG2020	50458	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311243	C4591001 1231 12311243	16-55	14AUG2020	50594	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
12311244	C4591001 1231 12311244	16-55	14AUG2020	50457	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo		
12311245	C4591001 1231 12311245	16-55	14AUG2020	50646	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12311248	C4591001 1231 12311248	16-55	14AUG2020	50650	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
12311257	C4591001 1231 12311257	16-55	14AUG2020	50705	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12311261	C4591001 1231 12311261	16-55	14AUG2020	50983	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
12311264	C4591001 1231 12311264	16-55	14AUG2020	50710	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
12311265	C4591001 1231 12311265	16-55	14AUG2020	50712	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
12311269	C4591001 1231 12311269	16-55	14AUG2020	50761	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12311270	C4591001 1231 12311270	16-55	14AUG2020	50759	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12311274	C4591001 1231 12311274	16-55	14AUG2020	50836	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
12311277	C4591001 1231 12311277	16-55	15AUG2020	51118	Placebo	15AUG2020/ Placebo	04SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12311285	C4591001 1231 12311285	16-55	15AUG2020	51137	Placebo	15AUG2020/ Placebo	04SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12311286	C4591001 1231 12311286	16-55	15AUG2020	50990	Placebo	15AUG2020/ Placebo	15SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12311287	C4591001 1231 12311287	16-55	15AUG2020	51101	Placebo	15AUG2020/ Placebo	07SEP2020/ Placebo		
12311294	C4591001 1231 12311294	16-55	15AUG2020	51105	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311297	C4591001 1231 12311297	16-55	15AUG2020	51125	Placebo	15AUG2020/ Placebo	07SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12311298	C4591001 1231 12311298	16-55	15AUG2020	51129	Placebo	15AUG2020/ Placebo	04SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12311301	C4591001 1231 12311301	16-55	15AUG2020	51158	Placebo	15AUG2020/ Placebo	28SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12311302	C4591001 1231 12311302	16-55	15AUG2020	51143	Placebo	15AUG2020/ Placebo	07SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12311304	C4591001 1231 12311304	16-55	15AUG2020	51152	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
12311306	C4591001 1231 12311306	16-55	15AUG2020	51164	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	06SEP2020/ BNT162b2 (30 µg)		
12311311	C4591001 1231 12311311	16-55	15AUG2020	51282	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311314	C4591001 1231 12311314	16-55	15AUG2020	51165	Placebo	15AUG2020/ Placebo	04SEP2020/ Placebo		
12311317	C4591001 1231 12311317	16-55	15AUG2020	51259	Placebo	15AUG2020/ Placebo	07SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12311320	C4591001 1231 12311320	16-55	15AUG2020	51234	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12311328	C4591001 1231 12311328	16-55	15AUG2020	51246	Placebo	15AUG2020/ Placebo	04SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12311334	C4591001 1231 12311334	16-55	15AUG2020	51238	Placebo	15AUG2020/ Placebo	07SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12311335	C4591001 1231 12311335	16-55	15AUG2020	51205	Placebo	15AUG2020/ Placebo	07SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12311338	C4591001 1231 12311338	16-55	15AUG2020	51211	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311339	C4591001 1231 12311339	16-55	15AUG2020	51216	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	06SEP2020/ BNT162b2 (30 µg)		
12311352	C4591001 1231 12311352	16-55	15AUG2020	51324	Placebo	15AUG2020/ Placebo	04SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12311353	C4591001 1231 12311353	16-55	15AUG2020	51364	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311354	C4591001 1231 12311354	16-55	15AUG2020	51343	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311355	C4591001 1231 12311355	16-55	15AUG2020	51304	Placebo	15AUG2020/ Placebo	07SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12311356	C4591001 1231 12311356	16-55	15AUG2020	51354	Placebo	15AUG2020/ Placebo			
12311359	C4591001 1231 12311359	16-55	15AUG2020	51370	Placebo	15AUG2020/ Placebo	07SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
12311360	C4591001 1231 12311360	16-55	15AUG2020	51318	Placebo	15AUG2020/ Placebo	07SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12311361	C4591001 1231 12311361	16-55	15AUG2020	51375	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12311362	C4591001 1231 12311362	16-55	15AUG2020	51344	Placebo	15AUG2020/ Placebo	07SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12311364	C4591001 1231 12311364	16-55	15AUG2020	51377	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
12311367	C4591001 1231 12311367	16-55	15AUG2020	51387	Placebo	15AUG2020/ Placebo	07SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12311371	C4591001 1231 12311371	16-55	15AUG2020	51397	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12311373	C4591001 1231 12311373	16-55	15AUG2020	51453	Placebo	15AUG2020/ Placebo	07SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12311374	C4591001 1231 12311374	16-55	15AUG2020	51394	Placebo	15AUG2020/ Placebo			
12311376	C4591001 1231 12311376	16-55	15AUG2020	51367	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
12311385	C4591001 1231 12311385	16-55	15AUG2020	51426	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311387	C4591001 1231 12311387	16-55	15AUG2020	51509	Placebo	15AUG2020/ Placebo	04SEP2020/ Placebo		
12311389	C4591001 1231 12311389	16-55	15AUG2020	51434	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12311391	C4591001 1231 12311391	16-55	15AUG2020	51486	Placebo	15AUG2020/ Placebo			
12311402	C4591001 1231 12311402	16-55	15AUG2020	51460	Placebo	15AUG2020/ Placebo		22FEB2021/ BNT162b2 (30 µg)	
12311403	C4591001 1231 12311403	16-55	15AUG2020	51462	Placebo	15AUG2020/ Placebo	06SEP2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
12311405	C4591001 1231 12311405	16-55	15AUG2020	51501	Placebo	15AUG2020/ Placebo	04SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12311408	C4591001 1231 12311408	16-55	15AUG2020	51463	Placebo	15AUG2020/ Placebo	07SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12311409	C4591001 1231 12311409	16-55	15AUG2020	51472	BNT162b2 (30 µg)				
12311410	C4591001 1231 12311410	16-55	15AUG2020	51473	Placebo	15AUG2020/ Placebo	06SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12311412	C4591001 1231 12311412	16-55	15AUG2020	51482	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12311417	C4591001 1231 12311417	16-55	15AUG2020	51507	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12311420	C4591001 1231 12311420	16-55	15AUG2020	51532	Placebo	15AUG2020/ Placebo	15OCT2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12311422	C4591001 1231 12311422	16-55	15AUG2020	51547	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
12311423	C4591001 1231 12311423	16-55	15AUG2020	51575	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
12311428	C4591001 1231 12311428	16-55	15AUG2020	51523	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311429	C4591001 1231 12311429	16-55	15AUG2020	51519	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311431	C4591001 1231 12311431	16-55	15AUG2020	51526	Placebo	15AUG2020/ Placebo			
12311432	C4591001 1231 12311432	16-55	15AUG2020	51528	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
12311433	C4591001 1231 12311433	16-55	15AUG2020	51540	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311435	C4591001 1231 12311435	16-55	15AUG2020	51561	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311441	C4591001 1231 12311441	16-55	15AUG2020	51548	Placebo	15AUG2020/ Placebo			
12311443	C4591001 1231 12311443	16-55	15AUG2020	51550	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)			

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12311445	C4591001 1231 12311445	16-55	15AUG2020	51571	Placebo	15AUG2020/ Placebo	04SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12311448	C4591001 1231 12311448	16-55	15AUG2020	51586	Placebo	15AUG2020/ Placebo	07SEP2020/ Placebo		
12311449	C4591001 1231 12311449	16-55	15AUG2020	51588	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
12311462	C4591001 1231 12311462	16-55	15AUG2020	51605	Placebo	15AUG2020/ Placebo	07SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12311463	C4591001 1231 12311463	16-55	15AUG2020	51606	Placebo	15AUG2020/ Placebo	04SEP2020/ Placebo		
12311467	C4591001 1231 12311467	16-55	15AUG2020	51638	Placebo	15AUG2020/ Placebo	04SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12311469	C4591001 1231 12311469	16-55	15AUG2020	51617	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311470	C4591001 1231 12311470	16-55	15AUG2020	51641	Placebo	15AUG2020/ Placebo	04SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12311473	C4591001 1231 12311473	16-55	15AUG2020	51625	Placebo	15AUG2020/ Placebo		02MAR2021/ BNT162b2 (30 µg)	
12311476	C4591001 1231 12311476	16-55	15AUG2020	51636	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12311481	C4591001 1231 12311481	16-55	15AUG2020	51664	Placebo	15AUG2020/ Placebo	07SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
12311486	C4591001 1231 12311486	16-55	15AUG2020	51642	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311491	C4591001 1231 12311491	16-55	16AUG2020	51680	Placebo	16AUG2020/ Placebo	08SEP2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12311492	C4591001 1231 12311492	16-55	16AUG2020	51686	Placebo	16AUG2020/ Placebo	07SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
12311494	C4591001 1231 12311494	16-55	16AUG2020	51681	BNT162b2 (30 µg)	16AUG2020/ BNT162b2 (30 µg)	06SEP2020/ BNT162b2 (30 µg)		
12311495	C4591001 1231 12311495	16-55	16AUG2020	51673	Placebo	16AUG2020/ Placebo	07SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12311496	C4591001 1231 12311496	16-55	16AUG2020	51723	Placebo	16AUG2020/ Placebo	07SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12311497	C4591001 1231 12311497	16-55	16AUG2020	51754	Placebo	16AUG2020/ Placebo	07SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12311499	C4591001 1231 12311499	16-55	16AUG2020	51712	BNT162b2 (30 µg)	16AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
12311502	C4591001 1231 12311502	16-55	16AUG2020	51702	Placebo	16AUG2020/ Placebo	07SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12311503	C4591001 1231 12311503	16-55	16AUG2020	51710	Placebo	16AUG2020/ Placebo	07SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12311504	C4591001 1231 12311504	16-55	16AUG2020	51835	BNT162b2 (30 µg)	16AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311505	C4591001 1231 12311505	16-55	16AUG2020	229684	BNT162b2 (30 µg)	16AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311506	C4591001 1231 12311506	16-55	16AUG2020	51839	Placebo	16AUG2020/ Placebo	07SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12311507	C4591001 1231 12311507	16-55	16AUG2020	51717	BNT162b2 (30 µg)	16AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311508	C4591001 1231 12311508	16-55	16AUG2020	51711	BNT162b2 (30 µg)	16AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311509	C4591001 1231 12311509	16-55	16AUG2020	51685	BNT162b2 (30 µg)	16AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12311513	C4591001 1231 12311513	16-55	16AUG2020	51738	BNT162b2 (30 µg)	16AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12311516	C4591001 1231 12311516	16-55	16AUG2020	51785	Placebo				
12311518	C4591001 1231 12311518	16-55	16AUG2020	51715	Placebo	16AUG2020/ Placebo	07SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12311519	C4591001 1231 12311519	16-55	16AUG2020	51749	BNT162b2 (30 µg)	16AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311520	C4591001 1231 12311520	16-55	16AUG2020	51756	BNT162b2 (30 µg)	16AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311521	C4591001 1231 12311521	16-55	16AUG2020	51753	Placebo	16AUG2020/ Placebo	08SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12311522	C4591001 1231 12311522	16-55	16AUG2020	51728	BNT162b2 (30 µg)	16AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12311523	C4591001 1231 12311523	16-55	16AUG2020	51724	BNT162b2 (30 µg)	16AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12311524	C4591001 1231 12311524	16-55	16AUG2020	51732	Placebo	16AUG2020/ Placebo	08SEP2020/ Placebo		
12311525	C4591001 1231 12311525	16-55	16AUG2020	51748	Placebo	16AUG2020/ Placebo	07SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12311526	C4591001 1231 12311526	16-55	16AUG2020	51735	BNT162b2 (30 µg)	16AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311527	C4591001 1231 12311527	16-55	16AUG2020	51734	Placebo	16AUG2020/ Placebo	08SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12311528	C4591001 1231 12311528	16-55	16AUG2020	51743	Placebo	16AUG2020/ Placebo	07SEP2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12311529	C4591001 1231 12311529	16-55	16AUG2020	51739	BNT162b2 (30 µg)	16AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12311530	C4591001 1231 12311530	16-55	16AUG2020	51764	BNT162b2 (30 µg)	16AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12311531	C4591001 1231 12311531	16-55	16AUG2020	51786	Placebo	16AUG2020/ Placebo	08SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12311532	C4591001 1231 12311532	16-55	16AUG2020	51765	BNT162b2 (30 µg)	16AUG2020/ BNT162b2 (30 µg)			
12311534	C4591001 1231 12311534	16-55	16AUG2020	51768	Placebo	16AUG2020/ Placebo	07SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12311535	C4591001 1231 12311535	16-55	16AUG2020	51773	BNT162b2 (30 µg)	16AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12311538	C4591001 1231 12311538	16-55	16AUG2020	51774	BNT162b2 (30 µg)	16AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311539	C4591001 1231 12311539	16-55	16AUG2020	51777	Placebo	16AUG2020/ Placebo	08SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12311540	C4591001 1231 12311540	16-55	16AUG2020	51767	Placebo	16AUG2020/ Placebo	07SEP2020/ Placebo		
12311541	C4591001 1231 12311541	16-55	16AUG2020	51778	Placebo	16AUG2020/ Placebo	07SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12311543	C4591001 1231 12311543	16-55	16AUG2020	51799	BNT162b2 (30 µg)	16AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311545	C4591001 1231 12311545	16-55	16AUG2020	51865	BNT162b2 (30 µg)	16AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311546	C4591001 1231 12311546	16-55	16AUG2020	51804	Placebo	16AUG2020/ Placebo	07SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12311547	C4591001 1231 12311547	16-55	16AUG2020	51796	BNT162b2 (30 µg)	16AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12311548	C4591001 1231 12311548	16-55	16AUG2020	51871	BNT162b2 (30 µg)	16AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12311550	C4591001 1231 12311550	16-55	16AUG2020	51824	Placebo	16AUG2020/ Placebo	07SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12311551	C4591001 1231 12311551	16-55	16AUG2020	51851	Placebo	16AUG2020/ Placebo	07SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
12311552	C4591001 1231 12311552	16-55	16AUG2020	51850	BNT162b2 (30 µg)	16AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311553	C4591001 1231 12311553	16-55	16AUG2020	51805	BNT162b2 (30 µg)	16AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
12311555	C4591001 1231 12311555	16-55	16AUG2020	51843	BNT162b2 (30 µg)	16AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12311556	C4591001 1231 12311556	16-55	16AUG2020	51808	Placebo	16AUG2020/ Placebo	07SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12311557	C4591001 1231 12311557	16-55	16AUG2020	51825	BNT162b2 (30 µg)	16AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
12311558	C4591001 1231 12311558	16-55	16AUG2020	51827	BNT162b2 (30 µg)	16AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311559	C4591001 1231 12311559	16-55	16AUG2020	51830	Placebo	16AUG2020/ Placebo			
12311565	C4591001 1231 12311565	16-55	16AUG2020	51852	BNT162b2 (30 µg)	16AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12311566	C4591001 1231 12311566	16-55	16AUG2020	51853	Placebo	16AUG2020/ Placebo	07SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12311567	C4591001 1231 12311567	16-55	16AUG2020	51857	BNT162b2 (30 µg)	16AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311568	C4591001 1231 12311568	16-55	16AUG2020	51858	Placebo	16AUG2020/ Placebo		22FEB2021/ BNT162b2 (30 µg)	
12311569	C4591001 1231 12311569	16-55	16AUG2020	51873	Placebo	16AUG2020/ Placebo	08SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12311570	C4591001 1231 12311570	16-55	16AUG2020	51885	Placebo	16AUG2020/ Placebo	07SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12311571	C4591001 1231 12311571	16-55	16AUG2020	51883	Placebo	16AUG2020/ Placebo	07SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
12311572	C4591001 1231 12311572	16-55	16AUG2020	51866	Placebo	16AUG2020/ Placebo	07SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12311573	C4591001 1231 12311573	16-55	16AUG2020	51874	Placebo	16AUG2020/ Placebo	07SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12311575	C4591001 1231 12311575	16-55	16AUG2020	51877	BNT162b2 (30 µg)	16AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12311577	C4591001 1231 12311577	16-55	16AUG2020	51887	BNT162b2 (30 µg)	16AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311580	C4591001 1231 12311580	16-55	16AUG2020	51962	Placebo	16AUG2020/ Placebo	24SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	
12311581	C4591001 1231 12311581	16-55	16AUG2020	51891	BNT162b2 (30 µg)	16AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311582	C4591001 1231 12311582	16-55	16AUG2020	51979	BNT162b2 (30 µg)	16AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12311584	C4591001 1231 12311584	16-55	16AUG2020	51894	Placebo	16AUG2020/ Placebo	08SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12311585	C4591001 1231 12311585	16-55	16AUG2020	51921	BNT162b2 (30 µg)	16AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12311587	C4591001 1231 12311587	16-55	16AUG2020	51905	BNT162b2 (30 µg)	16AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311588	C4591001 1231 12311588	16-55	16AUG2020	51910	Placebo	16AUG2020/ Placebo	08SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12311590	C4591001 1231 12311590	16-55	16AUG2020	51900	BNT162b2 (30 µg)	16AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311591	C4591001 1231 12311591	16-55	16AUG2020	51914	BNT162b2 (30 µg)	16AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311592	C4591001 1231 12311592	16-55	16AUG2020	51919	Placebo	16AUG2020/ Placebo	07SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
12311593	C4591001 1231 12311593	16-55	16AUG2020	51895	BNT162b2 (30 µg)	16AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12311594	C4591001 1231 12311594	16-55	16AUG2020	51903	Placebo	16AUG2020/ Placebo	07SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12311595	C4591001 1231 12311595	16-55	16AUG2020	51907	Placebo	16AUG2020/ Placebo	04SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12311596	C4591001 1231 12311596	16-55	16AUG2020	51986	BNT162b2 (30 µg)	16AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311597	C4591001 1231 12311597	16-55	16AUG2020	51959	BNT162b2 (30 µg)	16AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12311598	C4591001 1231 12311598	16-55	16AUG2020	51936	Placebo	16AUG2020/ Placebo	08SEP2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
12311599	C4591001 1231 12311599	16-55	16AUG2020	51981	Placebo	16AUG2020/ Placebo	07SEP2020/ Placebo	02MAR2021/ BNT162b2 (30 µg)	
12311600	C4591001 1231 12311600	16-55	16AUG2020	51924	Placebo	16AUG2020/ Placebo	07SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12311601	C4591001 1231 12311601	16-55	16AUG2020	51933	Placebo	16AUG2020/ Placebo	07SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12311602	C4591001 1231 12311602	16-55	16AUG2020	51927	BNT162b2 (30 µg)	16AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12311604	C4591001 1231 12311604	16-55	16AUG2020	51949	BNT162b2 (30 µg)	16AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311605	C4591001 1231 12311605	16-55	16AUG2020	51951	Placebo	16AUG2020/ Placebo	08SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12311606	C4591001 1231 12311606	16-55	16AUG2020	51934	BNT162b2 (30 µg)	16AUG2020/ BNT162b2 (30 µg)	06SEP2020/ BNT162b2 (30 µg)		
12311607	C4591001 1231 12311607	16-55	16AUG2020	51964	BNT162b2 (30 µg)	16AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12311608	C4591001 1231 12311608	16-55	16AUG2020	51999	Placebo	16AUG2020/ Placebo	07SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12311609	C4591001 1231 12311609	16-55	16AUG2020	51937	BNT162b2 (30 µg)	16AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311611	C4591001 1231 12311611	16-55	16AUG2020	51942	Placebo	16AUG2020/ Placebo	07SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
12311614	C4591001 1231 12311614	16-55	16AUG2020	51950	BNT162b2 (30 µg)	16AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311615	C4591001 1231 12311615	16-55	16AUG2020	51954	Placebo	16AUG2020/ Placebo	08SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12311616	C4591001 1231 12311616	16-55	16AUG2020	52006	BNT162b2 (30 µg)	16AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311617	C4591001 1231 12311617	16-55	16AUG2020	51987	Placebo	16AUG2020/ Placebo	07SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12311618	C4591001 1231 12311618	16-55	16AUG2020	52016	BNT162b2 (30 µg)	16AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311619	C4591001 1231 12311619	16-55	16AUG2020	51996	Placebo	16AUG2020/ Placebo	07SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12311621	C4591001 1231 12311621	16-55	16AUG2020	52000	BNT162b2 (30 µg)	16AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311623	C4591001 1231 12311623	16-55	16AUG2020	51998	BNT162b2 (30 µg)	16AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12311624	C4591001 1231 12311624	16-55	16AUG2020	52011	Placebo	16AUG2020/ Placebo	08SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12311625	C4591001 1231 12311625	16-55	16AUG2020	52008	BNT162b2 (30 µg)	16AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311626	C4591001 1231 12311626	16-55	16AUG2020	52010	Placebo	16AUG2020/ Placebo	08SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12311627	C4591001 1231 12311627	16-55	16AUG2020	52026	Placebo	16AUG2020/ Placebo	07SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12311628	C4591001 1231 12311628	16-55	16AUG2020	52020	BNT162b2 (30 µg)	16AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12311629	C4591001 1231 12311629	16-55	16AUG2020	52035	BNT162b2 (30 µg)	16AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311630	C4591001 1231 12311630	16-55	16AUG2020	52013	Placebo	16AUG2020/ Placebo	07SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	
12311631	C4591001 1231 12311631	16-55	16AUG2020	52097	BNT162b2 (30 µg)	16AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311633	C4591001 1231 12311633	16-55	16AUG2020	52036	BNT162b2 (30 µg)	16AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311634	C4591001 1231 12311634	16-55	16AUG2020	52022	Placebo	16AUG2020/ Placebo	07SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12311636	C4591001 1231 12311636	16-55	16AUG2020	52029	Placebo	16AUG2020/ Placebo	07SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12311637	C4591001 1231 12311637	16-55	16AUG2020	52038	Placebo	16AUG2020/ Placebo	07SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12311638	C4591001 1231 12311638	16-55	16AUG2020	52045	Placebo	16AUG2020/ Placebo	08SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12311640	C4591001 1231 12311640	16-55	16AUG2020	52059	Placebo	16AUG2020/ Placebo	07SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12311641	C4591001 1231 12311641	16-55	16AUG2020	52068	BNT162b2 (30 µg)	16AUG2020/ BNT162b2 (30 µg)			
12311642	C4591001 1231 12311642	16-55	16AUG2020	52053	Placebo	16AUG2020/ Placebo	08SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12311643	C4591001 1231 12311643	16-55	16AUG2020	52039	BNT162b2 (30 µg)	16AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311645	C4591001 1231 12311645	16-55	16AUG2020	52055	BNT162b2 (30 µg)	16AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311646	C4591001 1231 12311646	16-55	16AUG2020	52106	BNT162b2 (30 µg)	16AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311647	C4591001 1231 12311647	16-55	16AUG2020	52050	BNT162b2 (30 µg)	16AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12311648	C4591001 1231 12311648	16-55	16AUG2020	52072	Placebo	16AUG2020/ Placebo	08SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12311649	C4591001 1231 12311649	16-55	16AUG2020	52078	Placebo	16AUG2020/ Placebo	08SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12311650	C4591001 1231 12311650	16-55	16AUG2020	52069	BNT162b2 (30 µg)	16AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311651	C4591001 1231 12311651	16-55	16AUG2020	52083	Placebo	16AUG2020/ Placebo	07SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12311652	C4591001 1231 12311652	16-55	16AUG2020	52079	BNT162b2 (30 µg)	16AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12311653	C4591001 1231 12311653	16-55	16AUG2020	52093	BNT162b2 (30 µg)	16AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311654	C4591001 1231 12311654	16-55	16AUG2020	52076	BNT162b2 (30 µg)	16AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311655	C4591001 1231 12311655	16-55	16AUG2020	52095	Placebo	16AUG2020/ Placebo	07SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
12311656	C4591001 1231 12311656	16-55	16AUG2020	52092	Placebo	16AUG2020/ Placebo		01MAR2021/ BNT162b2 (30 µg)	
12311658	C4591001 1231 12311658	16-55	16AUG2020	52090	BNT162b2 (30 µg)	16AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12311659	C4591001 1231 12311659	16-55	16AUG2020	52102	Placebo	16AUG2020/ Placebo	07SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12311660	C4591001 1231 12311660	16-55	16AUG2020	52112	Placebo	16AUG2020/ Placebo	07SEP2020/ Placebo		
12311661	C4591001 1231 12311661	16-55	16AUG2020	52108	Placebo	16AUG2020/ Placebo	07SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12311662	C4591001 1231 12311662	16-55	16AUG2020	52113	BNT162b2 (30 µg)	16AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311663	C4591001 1231 12311663	16-55	16AUG2020	52114	BNT162b2 (30 µg)	16AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12311664	C4591001 1231 12311664	16-55	16AUG2020	52115	Placebo	16AUG2020/ Placebo	07SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12311665	C4591001 1231 12311665	16-55	17AUG2020	52158	Placebo	17AUG2020/ Placebo	09SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12311666	C4591001 1231 12311666	16-55	17AUG2020	52161	Placebo	17AUG2020/ Placebo	09SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12311668	C4591001 1231 12311668	16-55	17AUG2020	52164	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12311669	C4591001 1231 12311669	16-55	17AUG2020	52165	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12311671	C4591001 1231 12311671	16-55	17AUG2020	52178	Placebo	17AUG2020/ Placebo	07SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
12311673	C4591001 1231 12311673	16-55	17AUG2020	52169	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
12311676	C4591001 1231 12311676	16-55	17AUG2020	52175	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311678	C4591001 1231 12311678	16-55	17AUG2020	52288	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12311679	C4591001 1231 12311679	16-55	17AUG2020	52221	Placebo	17AUG2020/ Placebo	07SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
12311681	C4591001 1231 12311681	16-55	17AUG2020	52222	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311682	C4591001 1231 12311682	16-55	17AUG2020	52177	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12311683	C4591001 1231 12311683	16-55	17AUG2020	52272	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12311684	C4591001 1231 12311684	16-55	17AUG2020	52219	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311685	C4591001 1231 12311685	16-55	17AUG2020	52215	Placebo	17AUG2020/ Placebo	09SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12311686	C4591001 1231 12311686	16-55	17AUG2020	52303	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12311687	C4591001 1231 12311687	16-55	17AUG2020	52228	Placebo	17AUG2020/ Placebo	07SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12311689	C4591001 1231 12311689	16-55	17AUG2020	52213	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12311690	C4591001 1231 12311690	16-55	17AUG2020	52287	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12311691	C4591001 1231 12311691	16-55	17AUG2020	52301	Placebo	17AUG2020/ Placebo	07SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	13FEB2021/ BNT162b2 (30 µg)
12311692	C4591001 1231 12311692	16-55	17AUG2020	52205	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12311693	C4591001 1231 12311693	16-55	17AUG2020	52214	Placebo	17AUG2020/ Placebo	07SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12311694	C4591001 1231 12311694	16-55	17AUG2020	52271	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12311695	C4591001 1231 12311695	16-55	17AUG2020	52270	Placebo	17AUG2020/ Placebo	07SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12311696	C4591001 1231 12311696	16-55	17AUG2020	52274	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12311697	C4591001 1231 12311697	16-55	17AUG2020	52280	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
12311698	C4591001 1231 12311698	16-55	17AUG2020	52284	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12311701	C4591001 1231 12311701	16-55	17AUG2020	52309	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311702	C4591001 1231 12311702	16-55	17AUG2020	52311	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311704	C4591001 1231 12311704	16-55	17AUG2020	52316	Placebo	17AUG2020/ Placebo	07SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12311705	C4591001 1231 12311705	16-55	17AUG2020	52492	Placebo	17AUG2020/ Placebo	07SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
12311708	C4591001 1231 12311708	16-55	17AUG2020	52317	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311710	C4591001 1231 12311710	16-55	17AUG2020	52320	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311711	C4591001 1231 12311711	16-55	17AUG2020	52313	Placebo	17AUG2020/ Placebo	07SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12311712	C4591001 1231 12311712	16-55	17AUG2020	52350	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12311714	C4591001 1231 12311714	16-55	17AUG2020	52356	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311715	C4591001 1231 12311715	16-55	17AUG2020	52351	Placebo	17AUG2020/ Placebo	07SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12311718	C4591001 1231 12311718	16-55	17AUG2020	52481	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12311719	C4591001 1231 12311719	16-55	17AUG2020	52411	Placebo	17AUG2020/ Placebo	07SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12311721	C4591001 1231 12311721	16-55	17AUG2020	52418	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12311722	C4591001 1231 12311722	16-55	17AUG2020	52358	Placebo	17AUG2020/ Placebo	07SEP2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
12311724	C4591001 1231 12311724	16-55	17AUG2020	52409	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311726	C4591001 1231 12311726	16-55	17AUG2020	52414	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12311730	C4591001 1231 12311730	16-55	17AUG2020	52489	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311731	C4591001 1231 12311731	16-55	17AUG2020	52488	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12311733	C4591001 1231 12311733	16-55	17AUG2020	52501	Placebo	17AUG2020/ Placebo	07SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12311734	C4591001 1231 12311734	16-55	17AUG2020	52494	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311735	C4591001 1231 12311735	16-55	17AUG2020	52504	Placebo	17AUG2020/ Placebo	07SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12311736	C4591001 1231 12311736	16-55	17AUG2020	52497	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311738	C4591001 1231 12311738	16-55	17AUG2020	52531	Placebo	17AUG2020/ Placebo	09SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12311740	C4591001 1231 12311740	16-55	17AUG2020	52534	Placebo	17AUG2020/ Placebo	07SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12311746	C4591001 1231 12311746	16-55	17AUG2020	52557	Placebo	17AUG2020/ Placebo	07SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12311747	C4591001 1231 12311747	16-55	17AUG2020	52558	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311748	C4591001 1231 12311748	16-55	17AUG2020	52561	Placebo	17AUG2020/ Placebo	07SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12311749	C4591001 1231 12311749	16-55	17AUG2020	52540	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12311750	C4591001 1231 12311750	16-55	17AUG2020	52539	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311751	C4591001 1231 12311751	16-55	17AUG2020	52556	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311752	C4591001 1231 12311752	16-55	17AUG2020	52610	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311754	C4591001 1231 12311754	16-55	17AUG2020	52630	Placebo	17AUG2020/ Placebo	07SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12311755	C4591001 1231 12311755	16-55	17AUG2020	52607	Placebo	17AUG2020/ Placebo	07SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12311756	C4591001 1231 12311756	16-55	17AUG2020	52605	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12311759	C4591001 1231 12311759	16-55	17AUG2020	52633	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12311760	C4591001 1231 12311760	16-55	17AUG2020	52608	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
12311761	C4591001 1231 12311761	16-55	17AUG2020	52625	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12311763	C4591001 1231 12311763	16-55	17AUG2020	52636	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12311764	C4591001 1231 12311764	16-55	17AUG2020	52642	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12311765	C4591001 1231 12311765	16-55	17AUG2020	52648	Placebo	17AUG2020/ Placebo	09SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12311766	C4591001 1231 12311766	16-55	17AUG2020	52647	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311768	C4591001 1231 12311768	16-55	17AUG2020	52645	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311769	C4591001 1231 12311769	16-55	17AUG2020	52798	Placebo	17AUG2020/ Placebo	15SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12311770	C4591001 1231 12311770	16-55	17AUG2020	52724	Placebo	17AUG2020/ Placebo	07SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12311773	C4591001 1231 12311773	16-55	17AUG2020	52794	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12311774	C4591001 1231 12311774	16-55	17AUG2020	52722	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311776	C4591001 1231 12311776	16-55	17AUG2020	52725	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311777	C4591001 1231 12311777	16-55	17AUG2020	52729	Placebo	17AUG2020/ Placebo	09SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12311778	C4591001 1231 12311778	16-55	17AUG2020	52802	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12311779	C4591001 1231 12311779	16-55	17AUG2020	52842	Placebo	17AUG2020/ Placebo	07SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12311780	C4591001 1231 12311780	16-55	17AUG2020	52878	Placebo	17AUG2020/ Placebo	07SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12311782	C4591001 1231 12311782	16-55	17AUG2020	52844	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12311783	C4591001 1231 12311783	16-55	17AUG2020	52803	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311784	C4591001 1231 12311784	16-55	17AUG2020	52851	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311786	C4591001 1231 12311786	16-55	17AUG2020	52879	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311787	C4591001 1231 12311787	16-55	17AUG2020	52843	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12311788	C4591001 1231 12311788	16-55	17AUG2020	52917	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12311789	C4591001 1231 12311789	16-55	17AUG2020	52974	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12311790	C4591001 1231 12311790	16-55	17AUG2020	52884	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12311791	C4591001 1231 12311791	16-55	17AUG2020	52924	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	13FEB2021/ BNT162b2 (30 µg)
12311792	C4591001 1231 12311792	16-55	17AUG2020	52921	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311793	C4591001 1231 12311793	16-55	17AUG2020	52888	Placebo	17AUG2020/ Placebo	07SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12311794	C4591001 1231 12311794	16-55	17AUG2020	52915	Placebo	17AUG2020/ Placebo	07SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	13FEB2021/ BNT162b2 (30 µg)
12311795	C4591001 1231 12311795	16-55	17AUG2020	52973	Placebo	17AUG2020/ Placebo	07SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12311797	C4591001 1231 12311797	16-55	17AUG2020	53022	Placebo	17AUG2020/ Placebo	07SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12311799	C4591001 1231 12311799	16-55	17AUG2020	52980	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12311801	C4591001 1231 12311801	16-55	17AUG2020	52977	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
12311802	C4591001 1231 12311802	16-55	17AUG2020	53031	Placebo	17AUG2020/ Placebo	07SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12311804	C4591001 1231 12311804	16-55	17AUG2020	53024	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12311807	C4591001 1231 12311807	16-55	17AUG2020	53093	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12311809	C4591001 1231 12311809	16-55	17AUG2020	53171	Placebo	17AUG2020/ Placebo	07SEP2020/ Placebo		
12311811	C4591001 1231 12311811	16-55	17AUG2020	53028	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12311812	C4591001 1231 12311812	16-55	17AUG2020	53264	Placebo	17AUG2020/ Placebo	07SEP2020/ Placebo		
12311813	C4591001 1231 12311813	16-55	17AUG2020	53098	Placebo	17AUG2020/ Placebo	07SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	13FEB2021/ BNT162b2 (30 µg)
12311816	C4591001 1231 12311816	16-55	17AUG2020	53095	Placebo	17AUG2020/ Placebo			
12311817	C4591001 1231 12311817	16-55	17AUG2020	53309	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311818	C4591001 1231 12311818	16-55	17AUG2020	53170	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311819	C4591001 1231 12311819	16-55	17AUG2020	53106	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12311820	C4591001 1231 12311820	16-55	17AUG2020	53271	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311821	C4591001 1231 12311821	16-55	17AUG2020	53113	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12311823	C4591001 1231 12311823	16-55	17AUG2020	53172	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12311824	C4591001 1231 12311824	16-55	17AUG2020	53167	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12311825	C4591001 1231 12311825	16-55	17AUG2020	53314	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
12311827	C4591001 1231 12311827	16-55	17AUG2020	53112	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12311828	C4591001 1231 12311828	16-55	17AUG2020	53116	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311829	C4591001 1231 12311829	16-55	17AUG2020	53319	Placebo	17AUG2020/ Placebo	09SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12311830	C4591001 1231 12311830	16-55	17AUG2020	53258	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12311831	C4591001 1231 12311831	16-55	17AUG2020	53266	Placebo	17AUG2020/ Placebo	07SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12311833	C4591001 1231 12311833	16-55	17AUG2020	53267	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12311834	C4591001 1231 12311834	16-55	17AUG2020	53315	Placebo	17AUG2020/ Placebo	07SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12311836	C4591001 1231 12311836	16-55	17AUG2020	53260	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
12311837	C4591001 1231 12311837	16-55	17AUG2020	53323	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311838	C4591001 1231 12311838	16-55	17AUG2020	53322	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311839	C4591001 1231 12311839	16-55	17AUG2020	53332	Placebo	17AUG2020/ Placebo	07SEP2020/ Placebo		
12311841	C4591001 1231 12311841	16-55	17AUG2020	53249	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311842	C4591001 1231 12311842	16-55	17AUG2020	53329	Placebo	17AUG2020/ Placebo	07SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12311843	C4591001 1231 12311843	16-55	17AUG2020	53378	Placebo	17AUG2020/ Placebo	07SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
12311844	C4591001 1231 12311844	16-55	17AUG2020	53369	Placebo	17AUG2020/ Placebo	07SEP2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12311845	C4591001 1231 12311845	16-55	17AUG2020	53259	Placebo	17AUG2020/ Placebo	09SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
12311846	C4591001 1231 12311846	16-55	17AUG2020	53379	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311847	C4591001 1231 12311847	16-55	17AUG2020	53380	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311849	C4591001 1231 12311849	16-55	17AUG2020	53421	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	02MAR2021/ BNT162b2 (30 µg)	
12311850	C4591001 1231 12311850	16-55	17AUG2020	53427	Placebo	17AUG2020/ Placebo	07SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
12311851	C4591001 1231 12311851	16-55	17AUG2020	53423	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12311852	C4591001 1231 12311852	16-55	17AUG2020	53422	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311854	C4591001 1231 12311854	16-55	17AUG2020	53467	Placebo	17AUG2020/ Placebo	07SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12311857	C4591001 1231 12311857	16-55	17AUG2020	53497	Placebo	17AUG2020/ Placebo	07SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
12311858	C4591001 1231 12311858	16-55	17AUG2020	53475	Placebo	17AUG2020/ Placebo	16OCT2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12311859	C4591001 1231 12311859	16-55	17AUG2020	53476	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12311860	C4591001 1231 12311860	16-55	17AUG2020	53469	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12311861	C4591001 1231 12311861	16-55	17AUG2020	53498	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311862	C4591001 1231 12311862	16-55	17AUG2020	53495	Placebo	17AUG2020/ Placebo	09SEP2020/ Placebo		
12311863	C4591001 1231 12311863	16-55	17AUG2020	53502	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311865	C4591001 1231 12311865	16-55	17AUG2020	53509	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12311866	C4591001 1231 12311866	16-55	17AUG2020	53503	Placebo	17AUG2020/ Placebo	07SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12311868	C4591001 1231 12311868	16-55	17AUG2020	53511	Placebo	17AUG2020/ Placebo	09SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12311869	C4591001 1231 12311869	16-55	17AUG2020	53525	Placebo	17AUG2020/ Placebo	07SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12311870	C4591001 1231 12311870	16-55	17AUG2020	53499	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12311871	C4591001 1231 12311871	16-55	17AUG2020	53540	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311874	C4591001 1231 12311874	16-55	17AUG2020	53526	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12311875	C4591001 1231 12311875	16-55	17AUG2020	53530	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311876	C4591001 1231 12311876	16-55	17AUG2020	53534	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311877	C4591001 1231 12311877	16-55	17AUG2020	53543	Placebo	17AUG2020/ Placebo	07SEP2020/ Placebo		
12311879	C4591001 1231 12311879	16-55	17AUG2020	53544	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12311881	C4591001 1231 12311881	16-55	22AUG2020	62127	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12311882	C4591001 1231 12311882	16-55	17AUG2020	53548	Placebo	17AUG2020/ Placebo	07SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12311883	C4591001 1231 12311883	16-55	17AUG2020	53693	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12311884	C4591001 1231 12311884	16-55	18AUG2020	53704	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12311885	C4591001 1231 12311885	16-55	18AUG2020	53803	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12311886	C4591001 1231 12311886	16-55	18AUG2020	53703	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311887	C4591001 1231 12311887	16-55	18AUG2020	53698	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12311888	C4591001 1231 12311888	16-55	18AUG2020	53804	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12311889	C4591001 1231 12311889	16-55	18AUG2020	53830	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12311890	C4591001 1231 12311890	16-55	18AUG2020	53870	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311893	C4591001 1231 12311893	16-55	18AUG2020	53849	Placebo	18AUG2020/ Placebo	29SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
12311894	C4591001 1231 12311894	16-55	18AUG2020	53855	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)			
12311896	C4591001 1231 12311896	16-55	18AUG2020	53854	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12311897	C4591001 1231 12311897	16-55	18AUG2020	53865	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12311898	C4591001 1231 12311898	16-55	18AUG2020	53868	Placebo	18AUG2020/ Placebo	10SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12311899	C4591001 1231 12311899	16-55	18AUG2020	53826	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12311900	C4591001 1231 12311900	16-55	18AUG2020	53829	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12311901	C4591001 1231 12311901	16-55	18AUG2020	53835	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo		
12311903	C4591001 1231 12311903	16-55	18AUG2020	53809	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12311905	C4591001 1231 12311905	16-55	18AUG2020	53863	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo		
12311906	C4591001 1231 12311906	16-55	18AUG2020	54407	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12311907	C4591001 1231 12311907	16-55	18AUG2020	53850	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12311908	C4591001 1231 12311908	16-55	18AUG2020	53810	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12311911	C4591001 1231 12311911	16-55	18AUG2020	54091	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)			

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12311913	C4591001 1231 12311913	16-55	18AUG2020	53900	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12311915	C4591001 1231 12311915	16-55	18AUG2020	53897	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12311917	C4591001 1231 12311917	16-55	18AUG2020	54056	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12311920	C4591001 1231 12311920	16-55	18AUG2020	53906	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12311921	C4591001 1231 12311921	16-55	18AUG2020	53908	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12311922	C4591001 1231 12311922	16-55	18AUG2020	53977	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12311923	C4591001 1231 12311923	16-55	18AUG2020	53980	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12311924	C4591001 1231 12311924	16-55	18AUG2020	53972	Placebo	18AUG2020/ Placebo	07SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12311926	C4591001 1231 12311926	16-55	18AUG2020	54038	Placebo				
12311928	C4591001 1231 12311928	16-55	18AUG2020	54053	Placebo	18AUG2020/ Placebo	07SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12311929	C4591001 1231 12311929	16-55	18AUG2020	54094	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
12311930	C4591001 1231 12311930	16-55	18AUG2020	54032	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12311932	C4591001 1231 12311932	16-55	18AUG2020	54097	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12311934	C4591001 1231 12311934	16-55	18AUG2020	53975	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
12311938	C4591001 1231 12311938	16-55	18AUG2020	54125	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12311939	C4591001 1231 12311939	16-55	18AUG2020	54064	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12311940	C4591001 1231 12311940	16-55	18AUG2020	54059	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12311941	C4591001 1231 12311941	16-55	18AUG2020	54034	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12311942	C4591001 1231 12311942	16-55	18AUG2020	54036	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311944	C4591001 1231 12311944	16-55	18AUG2020	54129	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12311945	C4591001 1231 12311945	16-55	18AUG2020	54126	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12311947	C4591001 1231 12311947	16-55	18AUG2020	54131	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12311949	C4591001 1231 12311949	16-55	18AUG2020	54348	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12311950	C4591001 1231 12311950	16-55	18AUG2020	54177	Placebo	18AUG2020/ Placebo	07SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12311951	C4591001 1231 12311951	16-55	18AUG2020	54175	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12311952	C4591001 1231 12311952	16-55	18AUG2020	54184	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12311954	C4591001 1231 12311954	16-55	18AUG2020	54179	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12311955	C4591001 1231 12311955	16-55	18AUG2020	54210	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12311957	C4591001 1231 12311957	16-55	18AUG2020	54209	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12311958	C4591001 1231 12311958	16-55	18AUG2020	54212	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12311961	C4591001 1231 12311961	16-55	18AUG2020	54213	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311962	C4591001 1231 12311962	16-55	18AUG2020	54269	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12311964	C4591001 1231 12311964	16-55	18AUG2020	54304	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311965	C4591001 1231 12311965	16-55	18AUG2020	54454	Placebo	18AUG2020/ Placebo	10SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12311967	C4591001 1231 12311967	16-55	18AUG2020	54317	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12311968	C4591001 1231 12311968	16-55	18AUG2020	54297	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12311969	C4591001 1231 12311969	16-55	18AUG2020	54302	Placebo	18AUG2020/ Placebo	07SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12311971	C4591001 1231 12311971	16-55	18AUG2020	54328	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12311972	C4591001 1231 12311972	16-55	18AUG2020	54322	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12311973	C4591001 1231 12311973	16-55	18AUG2020	54294	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12311974	C4591001 1231 12311974	16-55	18AUG2020	54377	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12311975	C4591001 1231 12311975	16-55	18AUG2020	54439	Placebo	18AUG2020/ Placebo	18SEP2020/ Placebo		
12311976	C4591001 1231 12311976	16-55	18AUG2020	54350	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311980	C4591001 1231 12311980	16-55	18AUG2020	54319	Placebo	18AUG2020/ Placebo	10SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
12311981	C4591001 1231 12311981	16-55	18AUG2020	54401	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12311982	C4591001 1231 12311982	16-55	18AUG2020	54345	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12311983	C4591001 1231 12311983	16-55	18AUG2020	54346	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12311984	C4591001 1231 12311984	16-55	18AUG2020	54453	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12311985	C4591001 1231 12311985	16-55	18AUG2020	54386	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12311986	C4591001 1231 12311986	16-55	18AUG2020	54402	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12311989	C4591001 1231 12311989	16-55	18AUG2020	54405	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311990	C4591001 1231 12311990	16-55	18AUG2020	54388	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12311991	C4591001 1231 12311991	16-55	18AUG2020	54384	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)			
12311994	C4591001 1231 12311994	16-55	18AUG2020	54441	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12311996	C4591001 1231 12311996	16-55	18AUG2020	54448	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo		
12311997	C4591001 1231 12311997	16-55	18AUG2020	54447	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311998	C4591001 1231 12311998	16-55	18AUG2020	54485	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo		
12312001	C4591001 1231 12312001	16-55	18AUG2020	54457	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12312002	C4591001 1231 12312002	16-55	18AUG2020	54456	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12312004	C4591001 1231 12312004	16-55	18AUG2020	54521	Placebo	18AUG2020/ Placebo	10SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12312005	C4591001 1231 12312005	16-55	18AUG2020	54490	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12312007	C4591001 1231 12312007	16-55	18AUG2020	54530	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12312008	C4591001 1231 12312008	16-55	18AUG2020	54496	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12312009	C4591001 1231 12312009	16-55	18AUG2020	54492	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12312010	C4591001 1231 12312010	16-55	18AUG2020	54522	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12312011	C4591001 1231 12312011	16-55	18AUG2020	54523	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12312013	C4591001 1231 12312013	16-55	18AUG2020	54587	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12312015	C4591001 1231 12312015	16-55	18AUG2020	54567	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12312019	C4591001 1231 12312019	16-55	18AUG2020	54557	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12312020	C4591001 1231 12312020	16-55	18AUG2020	54590	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12312021	C4591001 1231 12312021	16-55	18AUG2020	54582	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12312022	C4591001 1231 12312022	16-55	18AUG2020	54704	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12312024	C4591001 1231 12312024	16-55	18AUG2020	54561	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12312027	C4591001 1231 12312027	16-55	18AUG2020	54568	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12312028	C4591001 1231 12312028	16-55	18AUG2020	54728	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12312029	C4591001 1231 12312029	16-55	18AUG2020	54708	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12312030	C4591001 1231 12312030	16-55	18AUG2020	54584	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12312031	C4591001 1231 12312031	16-55	18AUG2020	54725	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12312033	C4591001 1231 12312033	16-55	18AUG2020	54703	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12312034	C4591001 1231 12312034	16-55	18AUG2020	54711	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12312035	C4591001 1231 12312035	16-55	18AUG2020	54734	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12312036	C4591001 1231 12312036	16-55	18AUG2020	54731	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12312037	C4591001 1231 12312037	16-55	18AUG2020	54812	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo		
12312038	C4591001 1231 12312038	16-55	18AUG2020	54811	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12312039	C4591001 1231 12312039	16-55	18AUG2020	54813	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12312041	C4591001 1231 12312041	16-55	18AUG2020	54943	Placebo	18AUG2020/ Placebo	07SEP2020/ Placebo		
12312042	C4591001 1231 12312042	16-55	18AUG2020	54817	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12312043	C4591001 1231 12312043	16-55	18AUG2020	55145	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12312044	C4591001 1231 12312044	16-55	18AUG2020	55104	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12312045	C4591001 1231 12312045	16-55	18AUG2020	55043	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12312046	C4591001 1231 12312046	16-55	18AUG2020	55022	Placebo	18AUG2020/ Placebo	07SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12312048	C4591001 1231 12312048	16-55	18AUG2020	55014	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12312049	C4591001 1231 12312049	16-55	18AUG2020	54944	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12312050	C4591001 1231 12312050	16-55	18AUG2020	54951	Placebo	18AUG2020/ Placebo	07SEP2020/ Placebo		
12312051	C4591001 1231 12312051	16-55	18AUG2020	55037	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12312052	C4591001 1231 12312052	16-55	18AUG2020	55244	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
12312053	C4591001 1231 12312053	16-55	18AUG2020	54948	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12312055	C4591001 1231 12312055	16-55	18AUG2020	55019	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12312056	C4591001 1231 12312056	16-55	18AUG2020	55108	Placebo	18AUG2020/ Placebo	14SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12312059	C4591001 1231 12312059	16-55	18AUG2020	55021	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12312061	C4591001 1231 12312061	16-55	18AUG2020	55047	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12312063	C4591001 1231 12312063	16-55	18AUG2020	55101	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12312064	C4591001 1231 12312064	16-55	18AUG2020	55038	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12312065	C4591001 1231 12312065	16-55	18AUG2020	55188	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12312066	C4591001 1231 12312066	16-55	18AUG2020	55149	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12312067	C4591001 1231 12312067	16-55	18AUG2020	55245	Placebo	18AUG2020/ Placebo	10SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12312068	C4591001 1231 12312068	16-55	18AUG2020	55150	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12312069	C4591001 1231 12312069	16-55	18AUG2020	55103	Placebo	18AUG2020/ Placebo	10SEP2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
12312071	C4591001 1231 12312071	16-55	18AUG2020	55152	Placebo	18AUG2020/ Placebo	10SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
12312074	C4591001 1231 12312074	16-55	18AUG2020	55171	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12312075	C4591001 1231 12312075	16-55	18AUG2020	55185	Placebo	18AUG2020/ Placebo	07SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12312076	C4591001 1231 12312076	16-55	18AUG2020	55172	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12312077	C4591001 1231 12312077	16-55	18AUG2020	55169	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
12312078	C4591001 1231 12312078	16-55	18AUG2020	55176	Placebo	18AUG2020/ Placebo	10SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12312079	C4591001 1231 12312079	16-55	18AUG2020	55204	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12312080	C4591001 1231 12312080	16-55	18AUG2020	55186	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12312086	C4591001 1231 12312086	16-55	18AUG2020	55190	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12312087	C4591001 1231 12312087	16-55	18AUG2020	55237	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12312088	C4591001 1231 12312088	16-55	18AUG2020	55195	Placebo	18AUG2020/ Placebo	10SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12312089	C4591001 1231 12312089	16-55	18AUG2020	55193	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12312090	C4591001 1231 12312090	16-55	18AUG2020	55197	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12312093	C4591001 1231 12312093	16-55	18AUG2020	55281	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12312094	C4591001 1231 12312094	16-55	18AUG2020	55229	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12312095	C4591001 1231 12312095	16-55	18AUG2020	55287	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12312096	C4591001 1231 12312096	16-55	18AUG2020	55233	Placebo	18AUG2020/ Placebo	07SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12312097	C4591001 1231 12312097	16-55	18AUG2020	55286	Placebo	18AUG2020/ Placebo	07SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12312101	C4591001 1231 12312101	16-55	18AUG2020	55235	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12312102	C4591001 1231 12312102	16-55	18AUG2020	55252	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12312103	C4591001 1231 12312103	16-55	18AUG2020	55241	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12312105	C4591001 1231 12312105	16-55	18AUG2020	55355	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12312107	C4591001 1231 12312107	16-55	18AUG2020	55360	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12312109	C4591001 1231 12312109	16-55	18AUG2020	55349	Placebo	18AUG2020/ Placebo	10SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12312110	C4591001 1231 12312110	16-55	18AUG2020	55401	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12312111	C4591001 1231 12312111	16-55	18AUG2020	55397	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12312113	C4591001 1231 12312113	16-55	18AUG2020	55352	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12312116	C4591001 1231 12312116	16-55	18AUG2020	55419	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12312117	C4591001 1231 12312117	16-55	18AUG2020	55404	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12312118	C4591001 1231 12312118	16-55	18AUG2020	55424	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12312119	C4591001 1231 12312119	16-55	18AUG2020	55405	Placebo	18AUG2020/ Placebo	07SEP2020/ Placebo		
12312120	C4591001 1231 12312120	16-55	18AUG2020	55426	Placebo	18AUG2020/ Placebo	07SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12312121	C4591001 1231 12312121	16-55	18AUG2020	55409	Placebo	18AUG2020/ Placebo	07SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	13FEB2021/ BNT162b2 (30 µg)
12312124	C4591001 1231 12312124	16-55	18AUG2020	55461	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12312125	C4591001 1231 12312125	16-55	18AUG2020	55410	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12312126	C4591001 1231 12312126	16-55	18AUG2020	55462	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12312127	C4591001 1231 12312127	16-55	18AUG2020	55414	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12312128	C4591001 1231 12312128	16-55	18AUG2020	55463	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12312129	C4591001 1231 12312129	16-55	18AUG2020	55425	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12312132	C4591001 1231 12312132	16-55	18AUG2020	55502	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12312133	C4591001 1231 12312133	16-55	18AUG2020	55429	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12312134	C4591001 1231 12312134	16-55	18AUG2020	55537	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12312135	C4591001 1231 12312135	16-55	18AUG2020	55460	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12312136	C4591001 1231 12312136	16-55	18AUG2020	55498	Placebo	18AUG2020/ Placebo	07SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12312137	C4591001 1231 12312137	16-55	18AUG2020	55542	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12312138	C4591001 1231 12312138	16-55	18AUG2020	55531	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12312139	C4591001 1231 12312139	16-55	18AUG2020	55495	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12312140	C4591001 1231 12312140	16-55	18AUG2020	55517	Placebo	18AUG2020/ Placebo	10SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12312141	C4591001 1231 12312141	16-55	18AUG2020	55529	Placebo	18AUG2020/ Placebo	07SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12312142	C4591001 1231 12312142	16-55	18AUG2020	55526	Placebo	18AUG2020/ Placebo	10SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12312149	C4591001 1231 12312149	16-55	18AUG2020	55520	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12312150	C4591001 1231 12312150	16-55	18AUG2020	55543	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12312152	C4591001 1231 12312152	16-55	18AUG2020	55550	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12312153	C4591001 1231 12312153	16-55	18AUG2020	55534	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12312154	C4591001 1231 12312154	16-55	18AUG2020	55581	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12312155	C4591001 1231 12312155	16-55	18AUG2020	55524	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12312157	C4591001 1231 12312157	16-55	18AUG2020	55504	Placebo	18AUG2020/ Placebo	07SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12312159	C4591001 1231 12312159	16-55	18AUG2020	55582	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12312160	C4591001 1231 12312160	16-55	18AUG2020	55602	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12312164	C4591001 1231 12312164	16-55	18AUG2020	55606	Placebo	18AUG2020/ Placebo	07SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12312165	C4591001 1231 12312165	16-55	18AUG2020	55578	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12312166	C4591001 1231 12312166	16-55	18AUG2020	55541	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12312167	C4591001 1231 12312167	16-55	18AUG2020	55580	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12312168	C4591001 1231 12312168	16-55	18AUG2020	55605	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12312169	C4591001 1231 12312169	16-55	19AUG2020	55721	Placebo	19AUG2020/ Placebo	19SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12312170	C4591001 1231 12312170	16-55	19AUG2020	55695	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12312171	C4591001 1231 12312171	16-55	19AUG2020	55739	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12312172	C4591001 1231 12312172	16-55	19AUG2020	55753	Placebo	19AUG2020/ Placebo	11SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12312173	C4591001 1231 12312173	16-55	19AUG2020	55668	Placebo	19AUG2020/ Placebo	11SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12312174	C4591001 1231 12312174	16-55	19AUG2020	55667	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12312175	C4591001 1231 12312175	16-55	19AUG2020	55713	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12312176	C4591001 1231 12312176	16-55	19AUG2020	55781	Placebo				

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12312177	C4591001 1231 12312177	16-55	19AUG2020	55669	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12312179	C4591001 1231 12312179	16-55	19AUG2020	55611	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12312180	C4591001 1231 12312180	16-55	19AUG2020	55751	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12312183	C4591001 1231 12312183	16-55	19AUG2020	55741	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12312184	C4591001 1231 12312184	16-55	19AUG2020	55671	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12312185	C4591001 1231 12312185	16-55	19AUG2020	55724	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12312186	C4591001 1231 12312186	16-55	19AUG2020	55717	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo		
12312187	C4591001 1231 12312187	16-55	19AUG2020	55710	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12312188	C4591001 1231 12312188	16-55	19AUG2020	55687	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12312190	C4591001 1231 12312190	16-55	19AUG2020	55743	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12312191	C4591001 1231 12312191	16-55	19AUG2020	55756	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12312192	C4591001 1231 12312192	16-55	19AUG2020	55723	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12312193	C4591001 1231 12312193	16-55	19AUG2020	55749	Placebo	19AUG2020/ Placebo	07SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12312194	C4591001 1231 12312194	16-55	19AUG2020	55691	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12312195	C4591001 1231 12312195	16-55	19AUG2020	55760	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12312196	C4591001 1231 12312196	16-55	19AUG2020	55722	Placebo	19AUG2020/ Placebo	11SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12312198	C4591001 1231 12312198	16-55	19AUG2020	55688	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12312200	C4591001 1231 12312200	16-55	19AUG2020	55738	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12312202	C4591001 1231 12312202	16-55	19AUG2020	55758	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12312203	C4591001 1231 12312203	16-55	19AUG2020	55709	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12312204	C4591001 1231 12312204	16-55	19AUG2020	55763	Placebo	19AUG2020/ Placebo	11SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12312205	C4591001 1231 12312205	16-55	19AUG2020	55766	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12312210	C4591001 1231 12312210	16-55	19AUG2020	55785	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12312211	C4591001 1231 12312211	16-55	19AUG2020	55786	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12312212	C4591001 1231 12312212	16-55	19AUG2020	55792	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12312213	C4591001 1231 12312213	16-55	19AUG2020	55890	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12312214	C4591001 1231 12312214	16-55	19AUG2020	55895	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12312216	C4591001 1231 12312216	16-55	19AUG2020	55942	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12312218	C4591001 1231 12312218	16-55	19AUG2020	55892	Placebo	19AUG2020/ Placebo	07SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
12312219	C4591001 1231 12312219	16-55	19AUG2020	55937	Placebo	19AUG2020/ Placebo	08SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12312221	C4591001 1231 12312221	16-55	19AUG2020	55979	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
12312224	C4591001 1231 12312224	16-55	19AUG2020	55948	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
12312225	C4591001 1231 12312225	16-55	19AUG2020	55975	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12312226	C4591001 1231 12312226	16-55	19AUG2020	55946	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12312227	C4591001 1231 12312227	16-55	19AUG2020	55977	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12312228	C4591001 1231 12312228	16-55	19AUG2020	55984	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12312236	C4591001 1231 12312236	16-55	19AUG2020	56015	Placebo	19AUG2020/ Placebo	11SEP2020/ Placebo		
12312239	C4591001 1231 12312239	16-55	19AUG2020	56010	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12312242	C4591001 1231 12312242	16-55	19AUG2020	56013	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12312243	C4591001 1231 12312243	16-55	19AUG2020	56020	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12312244	C4591001 1231 12312244	16-55	19AUG2020	56093	Placebo	19AUG2020/ Placebo		24FEB2021/ BNT162b2 (30 µg)	
12312245	C4591001 1231 12312245	16-55	19AUG2020	56177	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
12312247	C4591001 1231 12312247	16-55	19AUG2020	56094	Placebo	19AUG2020/ Placebo	11SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
12312249	C4591001 1231 12312249	16-55	19AUG2020	56101	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12312251	C4591001 1231 12312251	16-55	19AUG2020	56184	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12312252	C4591001 1231 12312252	16-55	19AUG2020	57108	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12312254	C4591001 1231 12312254	16-55	19AUG2020	56102	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12312255	C4591001 1231 12312255	16-55	19AUG2020	56182	Placebo	19AUG2020/ Placebo	08SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12312257	C4591001 1231 12312257	16-55	19AUG2020	56396	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12312258	C4591001 1231 12312258	16-55	19AUG2020	56258	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12312259	C4591001 1231 12312259	16-55	19AUG2020	56253	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12312260	C4591001 1231 12312260	16-55	19AUG2020	56304	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
12312263	C4591001 1231 12312263	16-55	19AUG2020	56249	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12312264	C4591001 1231 12312264	16-55	19AUG2020	56186	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12312266	C4591001 1231 12312266	16-55	19AUG2020	56259	Placebo	19AUG2020/ Placebo	08SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12312267	C4591001 1231 12312267	16-55	19AUG2020	56300	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12312268	C4591001 1231 12312268	16-55	19AUG2020	56301	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12312269	C4591001 1231 12312269	16-55	19AUG2020	56418	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12312270	C4591001 1231 12312270	16-55	19AUG2020	56394	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12312271	C4591001 1231 12312271	16-55	19AUG2020	56425	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12312272	C4591001 1231 12312272	16-55	19AUG2020	56402	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12312274	C4591001 1231 12312274	16-55	19AUG2020	56397	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12312275	C4591001 1231 12312275	16-55	19AUG2020	56307	Placebo	19AUG2020/ Placebo	08SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
12312276	C4591001 1231 12312276	16-55	19AUG2020	56861	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12312281	C4591001 1231 12312281	16-55	19AUG2020	56426	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12312282	C4591001 1231 12312282	16-55	19AUG2020	56534	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12312283	C4591001 1231 12312283	16-55	19AUG2020	56571	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12312284	C4591001 1231 12312284	16-55	19AUG2020	56502	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)			
12312286	C4591001 1231 12312286	16-55	19AUG2020	56508	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12312287	C4591001 1231 12312287	16-55	19AUG2020	56512	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12312288	C4591001 1231 12312288	16-55	19AUG2020	56427	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
12312289	C4591001 1231 12312289	16-55	19AUG2020	56528	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12312291	C4591001 1231 12312291	16-55	19AUG2020	56567	Placebo	19AUG2020/ Placebo	08SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12312292	C4591001 1231 12312292	16-55	19AUG2020	56527	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12312295	C4591001 1231 12312295	16-55	19AUG2020	56546	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12312296	C4591001 1231 12312296	16-55	19AUG2020	56509	Placebo	19AUG2020/ Placebo	11SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12312297	C4591001 1231 12312297	16-55	19AUG2020	56536	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12312298	C4591001 1231 12312298	16-55	19AUG2020	56539	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12312299	C4591001 1231 12312299	16-55	19AUG2020	56544	Placebo	19AUG2020/ Placebo	08SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12312300	C4591001 1231 12312300	16-55	19AUG2020	56611	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12312302	C4591001 1231 12312302	16-55	19AUG2020	56572	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12312303	C4591001 1231 12312303	16-55	19AUG2020	56545	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12312304	C4591001 1231 12312304	16-55	19AUG2020	56617	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12312305	C4591001 1231 12312305	16-55	19AUG2020	56564	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12312306	C4591001 1231 12312306	16-55	19AUG2020	56632	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12312307	C4591001 1231 12312307	16-55	19AUG2020	56613	Placebo	19AUG2020/ Placebo	11SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12312308	C4591001 1231 12312308	16-55	19AUG2020	56650	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12312309	C4591001 1231 12312309	16-55	19AUG2020	56630	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12312310	C4591001 1231 12312310	16-55	19AUG2020	56612	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12312311	C4591001 1231 12312311	16-55	19AUG2020	56621	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12312312	C4591001 1231 12312312	16-55	19AUG2020	56628	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12312313	C4591001 1231 12312313	16-55	19AUG2020	56686	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12312315	C4591001 1231 12312315	16-55	19AUG2020	56760	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12312316	C4591001 1231 12312316	16-55	19AUG2020	56687	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12312317	C4591001 1231 12312317	16-55	19AUG2020	56651	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12312319	C4591001 1231 12312319	16-55	19AUG2020	56646	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12312320	C4591001 1231 12312320	16-55	19AUG2020	56706	Placebo	19AUG2020/ Placebo		24FEB2021/ BNT162b2 (30 µg)	
12312321	C4591001 1231 12312321	16-55	19AUG2020	56653	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12312323	C4591001 1231 12312323	16-55	19AUG2020	56689	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12312324	C4591001 1231 12312324	16-55	19AUG2020	56707	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12312326	C4591001 1231 12312326	16-55	19AUG2020	56711	Placebo	19AUG2020/ Placebo		03MAR2021/ BNT162b2 (30 µg)	
12312327	C4591001 1231 12312327	16-55	19AUG2020	56692	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
12312329	C4591001 1231 12312329	16-55	19AUG2020	56705	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12312330	C4591001 1231 12312330	16-55	19AUG2020	56763	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo		
12312331	C4591001 1231 12312331	16-55	19AUG2020	56759	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12312333	C4591001 1231 12312333	16-55	19AUG2020	56761	Placebo	19AUG2020/ Placebo	07SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12312334	C4591001 1231 12312334	16-55	19AUG2020	57196	Placebo	19AUG2020/ Placebo			
12312335	C4591001 1231 12312335	16-55	19AUG2020	57234	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12312336	C4591001 1231 12312336	16-55	19AUG2020	57235	Placebo	19AUG2020/ Placebo	08SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12312338	C4591001 1231 12312338	16-55	19AUG2020	57243	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12312339	C4591001 1231 12312339	16-55	19AUG2020	56887	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)			
12312340	C4591001 1231 12312340	16-55	19AUG2020	56866	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12312341	C4591001 1231 12312341	16-55	19AUG2020	56862	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12312342	C4591001 1231 12312342	16-55	19AUG2020	56865	Placebo	19AUG2020/ Placebo	08SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12312343	C4591001 1231 12312343	16-55	19AUG2020	57242	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12312344	C4591001 1231 12312344	16-55	19AUG2020	56889	Placebo	19AUG2020/ Placebo	24SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12312346	C4591001 1231 12312346	16-55	19AUG2020	57282	Placebo	19AUG2020/ Placebo	07SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12312348	C4591001 1231 12312348	16-55	19AUG2020	56925	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12312349	C4591001 1231 12312349	16-55	19AUG2020	56886	Placebo	19AUG2020/ Placebo	08SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12312350	C4591001 1231 12312350	16-55	19AUG2020	56958	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12312351	C4591001 1231 12312351	16-55	19AUG2020	56921	Placebo	19AUG2020/ Placebo	11SEP2020/ Placebo		
12312352	C4591001 1231 12312352	16-55	19AUG2020	56894	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12312355	C4591001 1231 12312355	16-55	19AUG2020	56922	Placebo	19AUG2020/ Placebo	11SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12312356	C4591001 1231 12312356	16-55	19AUG2020	56964	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12312357	C4591001 1231 12312357	16-55	19AUG2020	57309	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12312358	C4591001 1231 12312358	16-55	19AUG2020	57285	Placebo	19AUG2020/ Placebo	08SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12312359	C4591001 1231 12312359	16-55	19AUG2020	56928	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12312360	C4591001 1231 12312360	16-55	19AUG2020	56996	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12312361	C4591001 1231 12312361	16-55	19AUG2020	56968	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)			
12312362	C4591001 1231 12312362	16-55	19AUG2020	57307	Placebo	19AUG2020/ Placebo	08SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12312363	C4591001 1231 12312363	16-55	19AUG2020	56963	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12312364	C4591001 1231 12312364	16-55	19AUG2020	57002	Placebo	19AUG2020/ Placebo	08SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12312365	C4591001 1231 12312365	16-55	19AUG2020	57055	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)			
12312366	C4591001 1231 12312366	16-55	19AUG2020	57004	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12312367	C4591001 1231 12312367	16-55	19AUG2020	56998	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12312368	C4591001 1231 12312368	16-55	19AUG2020	57059	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12312369	C4591001 1231 12312369	16-55	19AUG2020	57056	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12312370	C4591001 1231 12312370	16-55	19AUG2020	57111	Placebo	19AUG2020/ Placebo	11SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12312371	C4591001 1231 12312371	16-55	19AUG2020	57107	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12312372	C4591001 1231 12312372	16-55	19AUG2020	57125	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12312373	C4591001 1231 12312373	16-55	19AUG2020	57058	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12312374	C4591001 1231 12312374	16-55	19AUG2020	57310	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12312375	C4591001 1231 12312375	16-55	19AUG2020	57192	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)			
12312376	C4591001 1231 12312376	16-55	19AUG2020	57128	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12312378	C4591001 1231 12312378	16-55	19AUG2020	57467	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12312379	C4591001 1231 12312379	16-55	19AUG2020	57109	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12312381	C4591001 1231 12312381	16-55	19AUG2020	57189	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12312382	C4591001 1231 12312382	16-55	19AUG2020	57131	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12312384	C4591001 1231 12312384	16-55	19AUG2020	57134	Placebo	19AUG2020/ Placebo	08SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	13FEB2021/ BNT162b2 (30 µg)
12312385	C4591001 1231 12312385	16-55	19AUG2020	57313	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12312388	C4591001 1231 12312388	16-55	19AUG2020	57187	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12312390	C4591001 1231 12312390	16-55	19AUG2020	57348	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12312391	C4591001 1231 12312391	16-55	19AUG2020	57281	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12312394	C4591001 1231 12312394	16-55	19AUG2020	57349	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12312395	C4591001 1231 12312395	16-55	19AUG2020	57286	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12312396	C4591001 1231 12312396	16-55	19AUG2020	57407	Placebo	19AUG2020/ Placebo	08SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12312397	C4591001 1231 12312397	16-55	19AUG2020	57469	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12312398	C4591001 1231 12312398	16-55	19AUG2020	57352	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
12312399	C4591001 1231 12312399	16-55	19AUG2020	57443	Placebo	19AUG2020/ Placebo	08SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12312400	C4591001 1231 12312400	16-55	19AUG2020	57461	Placebo	19AUG2020/ Placebo	11SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12312401	C4591001 1231 12312401	16-55	19AUG2020	57345	Placebo	19AUG2020/ Placebo	08SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12312402	C4591001 1231 12312402	16-55	19AUG2020	57386	Placebo	19AUG2020/ Placebo	11SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12312403	C4591001 1231 12312403	16-55	19AUG2020	57379	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)			
12312405	C4591001 1231 12312405	16-55	19AUG2020	57381	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12312406	C4591001 1231 12312406	16-55	19AUG2020	57537	Placebo	19AUG2020/ Placebo	07SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12312407	C4591001 1231 12312407	16-55	19AUG2020	57402	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12312408	C4591001 1231 12312408	16-55	19AUG2020	57439	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12312409	C4591001 1231 12312409	16-55	19AUG2020	57401	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12312410	C4591001 1231 12312410	16-55	19AUG2020	57533	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12312411	C4591001 1231 12312411	16-55	19AUG2020	57410	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12312412	C4591001 1231 12312412	16-55	19AUG2020	57388	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12312413	C4591001 1231 12312413	16-55	19AUG2020	57442	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12312414	C4591001 1231 12312414	16-55	19AUG2020	57542	Placebo	19AUG2020/ Placebo	08SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12312415	C4591001 1231 12312415	16-55	19AUG2020	57546	Placebo	19AUG2020/ Placebo	11SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12312417	C4591001 1231 12312417	16-55	19AUG2020	57445	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12312418	C4591001 1231 12312418	16-55	19AUG2020	57552	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12312419	C4591001 1231 12312419	16-55	19AUG2020	57541	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12312420	C4591001 1231 12312420	16-55	19AUG2020	57581	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12312421	C4591001 1231 12312421	16-55	19AUG2020	57470	Placebo	19AUG2020/ Placebo	08SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
12312422	C4591001 1231 12312422	16-55	19AUG2020	57582	Placebo	19AUG2020/ Placebo	08SEP2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12312424	C4591001 1231 12312424	16-55	19AUG2020	57593	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12312425	C4591001 1231 12312425	16-55	19AUG2020	57591	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12312426	C4591001 1231 12312426	16-55	19AUG2020	57595	Placebo	19AUG2020/ Placebo	02OCT2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12312427	C4591001 1231 12312427	16-55	19AUG2020	57550	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12312428	C4591001 1231 12312428	16-55	19AUG2020	57598	Placebo	19AUG2020/ Placebo	08SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12312429	C4591001 1231 12312429	16-55	19AUG2020	57556	Placebo	19AUG2020/ Placebo	08SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12312430	C4591001 1231 12312430	16-55	19AUG2020	57625	Placebo	19AUG2020/ Placebo	08SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12312433	C4591001 1231 12312433	16-55	19AUG2020	57586	Placebo	19AUG2020/ Placebo	11SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
12312434	C4591001 1231 12312434	16-55	19AUG2020	57631	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12312435	C4591001 1231 12312435	16-55	19AUG2020	57594	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12312436	C4591001 1231 12312436	16-55	19AUG2020	57633	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12312438	C4591001 1231 12312438	16-55	19AUG2020	57636	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12312439	C4591001 1231 12312439	16-55	19AUG2020	57621	Placebo	19AUG2020/ Placebo	02OCT2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12312441	C4591001 1231 12312441	16-55	19AUG2020	57628	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12312442	C4591001 1231 12312442	16-55	19AUG2020	57640	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12312443	C4591001 1231 12312443	16-55	20AUG2020	57777	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12312444	C4591001 1231 12312444	16-55	20AUG2020	57795	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12312445	C4591001 1231 12312445	16-55	20AUG2020	57774	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12312447	C4591001 1231 12312447	16-55	20AUG2020	57783	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12312448	C4591001 1231 12312448	16-55	20AUG2020	57782	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12312449	C4591001 1231 12312449	16-55	20AUG2020	57785	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12312451	C4591001 1231 12312451	16-55	20AUG2020	57793	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)			
12312452	C4591001 1231 12312452	16-55	20AUG2020	57820	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12312454	C4591001 1231 12312454	16-55	20AUG2020	57826	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
12312455	C4591001 1231 12312455	16-55	20AUG2020	57810	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo		
12312456	C4591001 1231 12312456	16-55	20AUG2020	57816	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12312457	C4591001 1231 12312457	16-55	20AUG2020	57852	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12312460	C4591001 1231 12312460	16-55	20AUG2020	57796	Placebo	20AUG2020/ Placebo	13SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12312461	C4591001 1231 12312461	16-55	20AUG2020	57823	Placebo	20AUG2020/ Placebo	11SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12312462	C4591001 1231 12312462	16-55	20AUG2020	57849	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12312464	C4591001 1231 12312464	16-55	20AUG2020	57884	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12312466	C4591001 1231 12312466	16-55	20AUG2020	57831	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12312467	C4591001 1231 12312467	16-55	20AUG2020	57922	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12312468	C4591001 1231 12312468	16-55	20AUG2020	57888	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12312469	C4591001 1231 12312469	16-55	20AUG2020	57846	Placebo	20AUG2020/ Placebo	11SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12312471	C4591001 1231 12312471	16-55	20AUG2020	57817	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12312472	C4591001 1231 12312472	16-55	20AUG2020	57919	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12312473	C4591001 1231 12312473	16-55	20AUG2020	57828	Placebo	20AUG2020/ Placebo	11SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12312474	C4591001 1231 12312474	16-55	20AUG2020	57928	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12312475	C4591001 1231 12312475	16-55	20AUG2020	57856	Placebo	20AUG2020/ Placebo	11SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12312476	C4591001 1231 12312476	16-55	20AUG2020	57930	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12312477	C4591001 1231 12312477	16-55	20AUG2020	57887	Placebo	20AUG2020/ Placebo	11SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12312478	C4591001 1231 12312478	16-55	20AUG2020	57886	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12312479	C4591001 1231 12312479	16-55	20AUG2020	57917	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12312481	C4591001 1231 12312481	16-55	20AUG2020	57931	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12312482	C4591001 1231 12312482	16-55	20AUG2020	57933	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12312483	C4591001 1231 12312483	16-55	20AUG2020	57940	Placebo				
12312486	C4591001 1231 12312486	16-55	20AUG2020	57977	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12312487	C4591001 1231 12312487	16-55	20AUG2020	58130	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12312488	C4591001 1231 12312488	16-55	20AUG2020	57978	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12312491	C4591001 1231 12312491	16-55	20AUG2020	58038	Placebo	20AUG2020/ Placebo	11SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	
12312493	C4591001 1231 12312493	16-55	20AUG2020	58037	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12312494	C4591001 1231 12312494	16-55	20AUG2020	57986	Placebo	20AUG2020/ Placebo	09SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12312499	C4591001 1231 12312499	16-55	20AUG2020	57988	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12312500	C4591001 1231 12312500	16-55	20AUG2020	58121	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12312501	C4591001 1231 12312501	16-55	20AUG2020	58127	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12312502	C4591001 1231 12312502	16-55	20AUG2020	58042	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12312503	C4591001 1231 12312503	16-55	20AUG2020	58160	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12312506	C4591001 1231 12312506	16-55	20AUG2020	58131	Placebo	20AUG2020/ Placebo	08SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12312507	C4591001 1231 12312507	16-55	20AUG2020	58134	Placebo	20AUG2020/ Placebo	08SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12312509	C4591001 1231 12312509	16-55	20AUG2020	58044	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
12312510	C4591001 1231 12312510	16-55	20AUG2020	58163	Placebo	20AUG2020/ Placebo	11SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12312512	C4591001 1231 12312512	16-55	20AUG2020	58133	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12312513	C4591001 1231 12312513	16-55	20AUG2020	58144	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12312514	C4591001 1231 12312514	16-55	20AUG2020	58189	Placebo	20AUG2020/ Placebo	08SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12312516	C4591001 1231 12312516	16-55	20AUG2020	58241	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12312517	C4591001 1231 12312517	16-55	20AUG2020	58187	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12312518	C4591001 1231 12312518	16-55	20AUG2020	58139	Placebo	20AUG2020/ Placebo	11SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
12312519	C4591001 1231 12312519	16-55	20AUG2020	58165	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12312520	C4591001 1231 12312520	16-55	20AUG2020	58157	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12312521	C4591001 1231 12312521	16-55	20AUG2020	58192	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12312522	C4591001 1231 12312522	16-55	20AUG2020	58182	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12312523	C4591001 1231 12312523	16-55	20AUG2020	58244	Placebo	20AUG2020/ Placebo	11SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12312524	C4591001 1231 12312524	16-55	20AUG2020	58251	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12312525	C4591001 1231 12312525	16-55	20AUG2020	58359	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12312528	C4591001 1231 12312528	16-55	20AUG2020	58357	Placebo	20AUG2020/ Placebo	11SEP2020/ Placebo		
12312529	C4591001 1231 12312529	16-55	20AUG2020	58350	Placebo	20AUG2020/ Placebo	11SEP2020/ Placebo		
12312531	C4591001 1231 12312531	16-55	20AUG2020	58252	Placebo	20AUG2020/ Placebo	13SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12312532	C4591001 1231 12312532	16-55	20AUG2020	58356	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12312533	C4591001 1231 12312533	16-55	20AUG2020	58415	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12312536	C4591001 1231 12312536	16-55	20AUG2020	58418	Placebo	20AUG2020/ Placebo	22SEP2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12312537	C4591001 1231 12312537	16-55	20AUG2020	58416	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12312538	C4591001 1231 12312538	16-55	20AUG2020	58413	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12312539	C4591001 1231 12312539	16-55	20AUG2020	58424	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12312540	C4591001 1231 12312540	16-55	20AUG2020	58458	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12312542	C4591001 1231 12312542	16-55	20AUG2020	58426	Placebo	20AUG2020/ Placebo	13SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
12312543	C4591001 1231 12312543	16-55	20AUG2020	58493	Placebo	20AUG2020/ Placebo	09SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12312544	C4591001 1231 12312544	16-55	20AUG2020	58464	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12312545	C4591001 1231 12312545	16-55	20AUG2020	58467	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12312546	C4591001 1231 12312546	16-55	20AUG2020	58457	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12312547	C4591001 1231 12312547	16-55	20AUG2020	58429	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12312548	C4591001 1231 12312548	16-55	20AUG2020	58608	Placebo	20AUG2020/ Placebo	11SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
12312550	C4591001 1231 12312550	16-55	20AUG2020	58533	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12312552	C4591001 1231 12312552	16-55	20AUG2020	58529	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12312553	C4591001 1231 12312553	16-55	20AUG2020	58601	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12312554	C4591001 1231 12312554	16-55	20AUG2020	58431	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo		
12312557	C4591001 1231 12312557	16-55	20AUG2020	58502	Placebo	20AUG2020/ Placebo	09SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12312559	C4591001 1231 12312559	16-55	20AUG2020	58497	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)			
12312560	C4591001 1231 12312560	16-55	20AUG2020	58499	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12312561	C4591001 1231 12312561	16-55	20AUG2020	58532	Placebo	20AUG2020/ Placebo	08SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12312562	C4591001 1231 12312562	16-55	20AUG2020	58534	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12312563	C4591001 1231 12312563	16-55	20AUG2020	58605	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12312566	C4591001 1231 12312566	16-55	20AUG2020	58609	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12312570	C4591001 1231 12312570	16-55	20AUG2020	58639	Placebo	20AUG2020/ Placebo	09SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12312572	C4591001 1231 12312572	16-55	20AUG2020	58637	Placebo	20AUG2020/ Placebo	08SEP2020/ Placebo		
12312573	C4591001 1231 12312573	16-55	20AUG2020	59047	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12312575	C4591001 1231 12312575	16-55	20AUG2020	58769	Placebo	20AUG2020/ Placebo	08SEP2020/ Placebo		
12312576	C4591001 1231 12312576	16-55	20AUG2020	58723	Placebo	20AUG2020/ Placebo	09SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12312577	C4591001 1231 12312577	16-55	20AUG2020	58799	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)			
12312578	C4591001 1231 12312578	16-55	20AUG2020	58725	Placebo	20AUG2020/ Placebo	09SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12312580	C4591001 1231 12312580	16-55	20AUG2020	58804	Placebo	20AUG2020/ Placebo	09SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12312581	C4591001 1231 12312581	16-55	20AUG2020	58724	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12312582	C4591001 1231 12312582	16-55	20AUG2020	58771	Placebo	20AUG2020/ Placebo	08SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12312583	C4591001 1231 12312583	16-55	20AUG2020	58638	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12312584	C4591001 1231 12312584	16-55	20AUG2020	58728	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12312585	C4591001 1231 12312585	16-55	20AUG2020	58798	Placebo	20AUG2020/ Placebo	09SEP2020/ Placebo	02MAR2021/ BNT162b2 (30 µg)	
12312587	C4591001 1231 12312587	16-55	20AUG2020	58640	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12312588	C4591001 1231 12312588	16-55	20AUG2020	58870	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo		
12312589	C4591001 1231 12312589	16-55	20AUG2020	58866	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12312591	C4591001 1231 12312591	16-55	20AUG2020	58775	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12312592	C4591001 1231 12312592	16-55	20AUG2020	58871	Placebo	20AUG2020/ Placebo	08SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12312593	C4591001 1231 12312593	16-55	20AUG2020	58869	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12312594	C4591001 1231 12312594	16-55	20AUG2020	58938	Placebo	20AUG2020/ Placebo			
12312596	C4591001 1231 12312596	16-55	20AUG2020	58803	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12312597	C4591001 1231 12312597	16-55	20AUG2020	58937	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12312600	C4591001 1231 12312600	16-55	20AUG2020	59028	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12312601	C4591001 1231 12312601	16-55	20AUG2020	58947	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12312602	C4591001 1231 12312602	16-55	20AUG2020	58779	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12312605	C4591001 1231 12312605	16-55	20AUG2020	58948	Placebo	20AUG2020/ Placebo	11SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12312606	C4591001 1231 12312606	16-55	20AUG2020	59054	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12312607	C4591001 1231 12312607	16-55	20AUG2020	59021	Placebo	20AUG2020/ Placebo	08SEP2020/ Placebo		
12312608	C4591001 1231 12312608	16-55	20AUG2020	59134	Placebo	20AUG2020/ Placebo	08SEP2020/ Placebo		
12312609	C4591001 1231 12312609	16-55	20AUG2020	59024	Placebo	20AUG2020/ Placebo	08SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12312610	C4591001 1231 12312610	16-55	20AUG2020	59056	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12312611	C4591001 1231 12312611	16-55	20AUG2020	59030	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12312612	C4591001 1231 12312612	16-55	20AUG2020	59067	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	13FEB2021/ BNT162b2 (30 µg)
12312613	C4591001 1231 12312613	16-55	20AUG2020	59055	Placebo	20AUG2020/ Placebo	08SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12312615	C4591001 1231 12312615	16-55	20AUG2020	59060	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12312616	C4591001 1231 12312616	16-55	20AUG2020	59138	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12312617	C4591001 1231 12312617	16-55	20AUG2020	59179	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12312618	C4591001 1231 12312618	16-55	20AUG2020	59082	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12312620	C4591001 1231 12312620	16-55	20AUG2020	59108	Placebo	20AUG2020/ Placebo	09SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12312621	C4591001 1231 12312621	16-55	20AUG2020	59105	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
12312623	C4591001 1231 12312623	16-55	20AUG2020	59058	Placebo	20AUG2020/ Placebo			
12312626	C4591001 1231 12312626	16-55	20AUG2020	59139	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12312627	C4591001 1231 12312627	16-55	20AUG2020	59068	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12312628	C4591001 1231 12312628	16-55	20AUG2020	59178	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12312629	C4591001 1231 12312629	16-55	20AUG2020	59114	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12312630	C4591001 1231 12312630	16-55	20AUG2020	59185	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12312632	C4591001 1231 12312632	16-55	20AUG2020	59202	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12312633	C4591001 1231 12312633	16-55	20AUG2020	59177	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
12312634	C4591001 1231 12312634	16-55	20AUG2020	59204	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12312636	C4591001 1231 12312636	16-55	20AUG2020	59225	Placebo	20AUG2020/ Placebo	08SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12312638	C4591001 1231 12312638	16-55	20AUG2020	59230	Placebo	20AUG2020/ Placebo	09SEP2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12312639	C4591001 1231 12312639	16-55	20AUG2020	59115	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12312640	C4591001 1231 12312640	16-55	20AUG2020	59232	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12312641	C4591001 1231 12312641	16-55	20AUG2020	59207	Placebo	20AUG2020/ Placebo	09SEP2020/ Placebo		
12312642	C4591001 1231 12312642	16-55	20AUG2020	59268	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12312644	C4591001 1231 12312644	16-55	20AUG2020	59298	Placebo	20AUG2020/ Placebo	08SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12312645	C4591001 1231 12312645	16-55	20AUG2020	59227	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12312647	C4591001 1231 12312647	16-55	20AUG2020	59209	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12312648	C4591001 1231 12312648	16-55	20AUG2020	59304	Placebo	20AUG2020/ Placebo	08SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12312649	C4591001 1231 12312649	16-55	20AUG2020	59261	Placebo	20AUG2020/ Placebo	11SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12312651	C4591001 1231 12312651	16-55	20AUG2020	59263	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12312652	C4591001 1231 12312652	16-55	20AUG2020	59361	Placebo	20AUG2020/ Placebo	13SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
12312653	C4591001 1231 12312653	16-55	20AUG2020	59305	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12312654	C4591001 1231 12312654	16-55	20AUG2020	59366	Placebo	20AUG2020/ Placebo	08SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
12312655	C4591001 1231 12312655	16-55	20AUG2020	59272	Placebo	20AUG2020/ Placebo	08SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
12312656	C4591001 1231 12312656	16-55	20AUG2020	59367	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12312658	C4591001 1231 12312658	16-55	20AUG2020	59400	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12312659	C4591001 1231 12312659	16-55	20AUG2020	59303	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12312660	C4591001 1231 12312660	16-55	20AUG2020	59403	Placebo	20AUG2020/ Placebo		20FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12312662	C4591001 1231 12312662	16-55	20AUG2020	59422	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12312663	C4591001 1231 12312663	16-55	20AUG2020	59397	Placebo	20AUG2020/ Placebo	08SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12312664	C4591001 1231 12312664	16-55	20AUG2020	59426	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12312665	C4591001 1231 12312665	16-55	20AUG2020	59468	Placebo	20AUG2020/ Placebo	09SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12312666	C4591001 1231 12312666	16-55	20AUG2020	59427	Placebo	20AUG2020/ Placebo	09SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12312669	C4591001 1231 12312669	16-55	20AUG2020	59471	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12312670	C4591001 1231 12312670	16-55	20AUG2020	59475	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12312671	C4591001 1231 12312671	16-55	20AUG2020	59402	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12312672	C4591001 1231 12312672	16-55	20AUG2020	59526	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12312673	C4591001 1231 12312673	16-55	20AUG2020	59360	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12312674	C4591001 1231 12312674	16-55	20AUG2020	59527	Placebo	20AUG2020/ Placebo	09SEP2020/ Placebo		
12312675	C4591001 1231 12312675	16-55	20AUG2020	59532	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12312676	C4591001 1231 12312676	16-55	20AUG2020	59533	Placebo	20AUG2020/ Placebo	09SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
12312677	C4591001 1231 12312677	16-55	20AUG2020	59474	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12312678	C4591001 1231 12312678	16-55	20AUG2020	59548	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12312679	C4591001 1231 12312679	16-55	20AUG2020	59423	Placebo	20AUG2020/ Placebo	11SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12312680	C4591001 1231 12312680	16-55	20AUG2020	59574	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12312681	C4591001 1231 12312681	16-55	20AUG2020	59538	Placebo	20AUG2020/ Placebo	08SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12312683	C4591001 1231 12312683	16-55	20AUG2020	59539	Placebo	20AUG2020/ Placebo	09SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12312684	C4591001 1231 12312684	16-55	20AUG2020	59577	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12312685	C4591001 1231 12312685	16-55	20AUG2020	59544	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12312686	C4591001 1231 12312686	16-55	20AUG2020	59621	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12312687	C4591001 1231 12312687	16-55	20AUG2020	59573	Placebo	20AUG2020/ Placebo	22SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12312688	C4591001 1231 12312688	16-55	20AUG2020	59622	Placebo	20AUG2020/ Placebo	09SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12312690	C4591001 1231 12312690	16-55	20AUG2020	59627	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12312693	C4591001 1231 12312693	16-55	20AUG2020	59575	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
12312695	C4591001 1231 12312695	16-55	20AUG2020	59626	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo		
12312696	C4591001 1231 12312696	16-55	20AUG2020	59670	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12312697	C4591001 1231 12312697	16-55	20AUG2020	59669	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12312702	C4591001 1231 12312702	16-55	20AUG2020	59675	Placebo	20AUG2020/ Placebo	11SEP2020/ Placebo		
12312704	C4591001 1231 12312704	16-55	20AUG2020	59706	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12312705	C4591001 1231 12312705	16-55	20AUG2020	59707	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12312708	C4591001 1231 12312708	16-55	20AUG2020	59711	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12312709	C4591001 1231 12312709	16-55	20AUG2020	59680	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12312710	C4591001 1231 12312710	16-55	20AUG2020	59732	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12312712	C4591001 1231 12312712	16-55	20AUG2020	59735	Placebo	20AUG2020/ Placebo	08SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12312713	C4591001 1231 12312713	16-55	20AUG2020	59712	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo		
12312714	C4591001 1231 12312714	16-55	20AUG2020	59757	Placebo	20AUG2020/ Placebo	09SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12312715	C4591001 1231 12312715	16-55	20AUG2020	59759	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
12312716	C4591001 1231 12312716	16-55	20AUG2020	59763	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12312717	C4591001 1231 12312717	16-55	20AUG2020	59739	Placebo	20AUG2020/ Placebo	09SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12312718	C4591001 1231 12312718	16-55	20AUG2020	59766	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12312719	C4591001 1231 12312719	16-55	20AUG2020	59733	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12312720	C4591001 1231 12312720	16-55	20AUG2020	59773	Placebo	20AUG2020/ Placebo	09SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12312721	C4591001 1231 12312721	16-55	20AUG2020	59767	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12312723	C4591001 1231 12312723	16-55	20AUG2020	59764	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
12312724	C4591001 1231 12312724	16-55	20AUG2020	59802	Placebo	20AUG2020/ Placebo	08SEP2020/ Placebo		
12312725	C4591001 1231 12312725	16-55	20AUG2020	59775	Placebo	20AUG2020/ Placebo	08SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12312727	C4591001 1231 12312727	16-55	21AUG2020	59811	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12312728	C4591001 1231 12312728	16-55	21AUG2020	59804	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12312729	C4591001 1231 12312729	16-55	21AUG2020	59930	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12312730	C4591001 1231 12312730	16-55	21AUG2020	59946	Placebo	21AUG2020/ Placebo	10SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12312731	C4591001 1231 12312731	16-55	21AUG2020	59966	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12312732	C4591001 1231 12312732	16-55	21AUG2020	59932	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12312734	C4591001 1231 12312734	16-55	21AUG2020	59936	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12312735	C4591001 1231 12312735	16-55	21AUG2020	59933	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12312737	C4591001 1231 12312737	16-55	21AUG2020	59958	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12312738	C4591001 1231 12312738	16-55	21AUG2020	59806	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12312739	C4591001 1231 12312739	16-55	21AUG2020	59942	Placebo	21AUG2020/ Placebo	09SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12312740	C4591001 1231 12312740	16-55	21AUG2020	59931	Placebo	21AUG2020/ Placebo	10SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12312741	C4591001 1231 12312741	16-55	21AUG2020	59952	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12312742	C4591001 1231 12312742	16-55	21AUG2020	59938	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12312743	C4591001 1231 12312743	16-55	21AUG2020	59948	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12312744	C4591001 1231 12312744	16-55	21AUG2020	59955	Placebo	21AUG2020/ Placebo	10SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12312746	C4591001 1231 12312746	16-55	21AUG2020	59929	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12312747	C4591001 1231 12312747	16-55	21AUG2020	59999	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
12312748	C4591001 1231 12312748	16-55	21AUG2020	59960	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12312750	C4591001 1231 12312750	16-55	21AUG2020	60038	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12312751	C4591001 1231 12312751	16-55	21AUG2020	60030	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12312752	C4591001 1231 12312752	16-55	21AUG2020	59994	Placebo	21AUG2020/ Placebo		22FEB2021/ BNT162b2 (30 µg)	
12312753	C4591001 1231 12312753	16-55	21AUG2020	60032	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12312754	C4591001 1231 12312754	16-55	21AUG2020	59964	Placebo	21AUG2020/ Placebo	10SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12312755	C4591001 1231 12312755	16-55	21AUG2020	60054	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12312757	C4591001 1231 12312757	16-55	21AUG2020	60004	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12312759	C4591001 1231 12312759	16-55	21AUG2020	60114	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12312760	C4591001 1231 12312760	16-55	21AUG2020	60040	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12312761	C4591001 1231 12312761	16-55	21AUG2020	60056	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12312762	C4591001 1231 12312762	16-55	21AUG2020	60003	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12312763	C4591001 1231 12312763	16-55	21AUG2020	60163	Placebo	21AUG2020/ Placebo		01MAR2021/ BNT162b2 (30 µg)	
12312765	C4591001 1231 12312765	16-55	21AUG2020	60077	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12312769	C4591001 1231 12312769	16-55	21AUG2020	60061	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12312770	C4591001 1231 12312770	16-55	21AUG2020	60060	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12312771	C4591001 1231 12312771	16-55	21AUG2020	60085	Placebo	21AUG2020/ Placebo	13SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12312772	C4591001 1231 12312772	16-55	21AUG2020	60081	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo		
12312773	C4591001 1231 12312773	16-55	21AUG2020	60080	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12312774	C4591001 1231 12312774	16-55	21AUG2020	60113	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12312775	C4591001 1231 12312775	16-55	21AUG2020	60172	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12312778	C4591001 1231 12312778	16-55	21AUG2020	60118	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12312779	C4591001 1231 12312779	16-55	21AUG2020	60133	Placebo	21AUG2020/ Placebo	13SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12312785	C4591001 1231 12312785	16-55	21AUG2020	60125	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12312787	C4591001 1231 12312787	16-55	21AUG2020	60186	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12312790	C4591001 1231 12312790	16-55	21AUG2020	60185	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
12312796	C4591001 1231 12312796	16-55	21AUG2020	60124	Placebo	21AUG2020/ Placebo	09SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12312797	C4591001 1231 12312797	16-55	21AUG2020	60189	Placebo	21AUG2020/ Placebo	09SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
12312798	C4591001 1231 12312798	16-55	21AUG2020	60171	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12312800	C4591001 1231 12312800	16-55	21AUG2020	60128	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12312803	C4591001 1231 12312803	16-55	21AUG2020	60164	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12312804	C4591001 1231 12312804	16-55	21AUG2020	60132	Placebo	21AUG2020/ Placebo	10SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12312805	C4591001 1231 12312805	16-55	21AUG2020	60188	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
12312807	C4591001 1231 12312807	16-55	21AUG2020	60209	Placebo	21AUG2020/ Placebo	10SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
12312810	C4591001 1231 12312810	16-55	21AUG2020	60313	Placebo	21AUG2020/ Placebo	13SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12312811	C4591001 1231 12312811	16-55	21AUG2020	60305	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12312812	C4591001 1231 12312812	16-55	21AUG2020	60259	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12312813	C4591001 1231 12312813	16-55	21AUG2020	60267	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo		
12312814	C4591001 1231 12312814	16-55	21AUG2020	60216	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12312815	C4591001 1231 12312815	16-55	21AUG2020	60215	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12312819	C4591001 1231 12312819	16-55	21AUG2020	60309	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12312822	C4591001 1231 12312822	16-55	21AUG2020	60214	Placebo	21AUG2020/ Placebo	09SEP2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12312823	C4591001 1231 12312823	16-55	21AUG2020	60258	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12312824	C4591001 1231 12312824	16-55	21AUG2020	60268	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12312825	C4591001 1231 12312825	16-55	21AUG2020	60343	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
12312826	C4591001 1231 12312826	16-55	21AUG2020	60315	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12312827	C4591001 1231 12312827	16-55	21AUG2020	60344	Placebo	21AUG2020/ Placebo	09SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12312829	C4591001 1231 12312829	16-55	21AUG2020	60345	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12312831	C4591001 1231 12312831	16-55	21AUG2020	60425	Placebo	21AUG2020/ Placebo	09SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12312833	C4591001 1231 12312833	16-55	21AUG2020	60348	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12312835	C4591001 1231 12312835	16-55	21AUG2020	60389	Placebo	21AUG2020/ Placebo	10SEP2020/ Placebo		
12312836	C4591001 1231 12312836	16-55	21AUG2020	60393	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12312838	C4591001 1231 12312838	16-55	21AUG2020	60408	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12312840	C4591001 1231 12312840	16-55	21AUG2020	60404	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12312842	C4591001 1231 12312842	16-55	21AUG2020	60431	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
12312844	C4591001 1231 12312844	16-55	21AUG2020	60391	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12312845	C4591001 1231 12312845	16-55	21AUG2020	60401	Placebo	21AUG2020/ Placebo	10SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
12312846	C4591001 1231 12312846	16-55	21AUG2020	60434	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12312847	C4591001 1231 12312847	16-55	21AUG2020	60478	Placebo	21AUG2020/ Placebo	13SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12312848	C4591001 1231 12312848	16-55	21AUG2020	60397	Placebo	21AUG2020/ Placebo			
12312849	C4591001 1231 12312849	16-55	21AUG2020	60412	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12312850	C4591001 1231 12312850	16-55	21AUG2020	60476	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12312851	C4591001 1231 12312851	16-55	21AUG2020	60499	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo		
12312852	C4591001 1231 12312852	16-55	21AUG2020	60430	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12312853	C4591001 1231 12312853	16-55	21AUG2020	60503	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12312854	C4591001 1231 12312854	16-55	21AUG2020	60480	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12312856	C4591001 1231 12312856	16-55	21AUG2020	60477	Placebo	21AUG2020/ Placebo	09SEP2020/ Placebo		
12312857	C4591001 1231 12312857	16-55	21AUG2020	60523	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12312858	C4591001 1231 12312858	16-55	21AUG2020	60557	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12312859	C4591001 1231 12312859	16-55	21AUG2020	60526	Placebo	21AUG2020/ Placebo	13SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12312860	C4591001 1231 12312860	16-55	21AUG2020	60527	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12312861	C4591001 1231 12312861	16-55	21AUG2020	60560	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12312862	C4591001 1231 12312862	16-55	21AUG2020	60497	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12312864	C4591001 1231 12312864	16-55	21AUG2020	60500	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12312865	C4591001 1231 12312865	16-55	21AUG2020	60530	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12312867	C4591001 1231 12312867	16-55	21AUG2020	60565	Placebo	21AUG2020/ Placebo	10SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	13FEB2021/ BNT162b2 (30 µg)
12312868	C4591001 1231 12312868	16-55	21AUG2020	60566	Placebo	21AUG2020/ Placebo	08OCT2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12312870	C4591001 1231 12312870	16-55	21AUG2020	60593	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12312871	C4591001 1231 12312871	16-55	21AUG2020	60595	Placebo	21AUG2020/ Placebo	09SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12312873	C4591001 1231 12312873	16-55	21AUG2020	60597	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12312874	C4591001 1231 12312874	16-55	21AUG2020	60594	Placebo	21AUG2020/ Placebo	10SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12312875	C4591001 1231 12312875	16-55	21AUG2020	60618	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12312876	C4591001 1231 12312876	16-55	21AUG2020	60659	Placebo	21AUG2020/ Placebo	09SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12312877	C4591001 1231 12312877	16-55	21AUG2020	60626	Placebo	21AUG2020/ Placebo	09SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12312879	C4591001 1231 12312879	16-55	21AUG2020	60696	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12312880	C4591001 1231 12312880	16-55	21AUG2020	60623	Placebo	21AUG2020/ Placebo	09SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12312882	C4591001 1231 12312882	16-55	21AUG2020	60619	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12312883	C4591001 1231 12312883	16-55	21AUG2020	60719	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12312884	C4591001 1231 12312884	16-55	21AUG2020	60691	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12312886	C4591001 1231 12312886	16-55	21AUG2020	60661	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12312888	C4591001 1231 12312888	16-55	21AUG2020	60663	Placebo	21AUG2020/ Placebo	10SEP2020/ Placebo		
12312889	C4591001 1231 12312889	16-55	21AUG2020	60662	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12312890	C4591001 1231 12312890	16-55	21AUG2020	60752	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12312891	C4591001 1231 12312891	16-55	21AUG2020	60723	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12312892	C4591001 1231 12312892	16-55	21AUG2020	60689	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12312894	C4591001 1231 12312894	16-55	21AUG2020	60713	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12312895	C4591001 1231 12312895	16-55	21AUG2020	60749	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12312896	C4591001 1231 12312896	16-55	21AUG2020	60694	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12312897	C4591001 1231 12312897	16-55	21AUG2020	60756	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12312899	C4591001 1231 12312899	16-55	21AUG2020	60721	Placebo	21AUG2020/ Placebo	13SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12312900	C4591001 1231 12312900	16-55	21AUG2020	60790	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12312901	C4591001 1231 12312901	16-55	21AUG2020	60754	Placebo	21AUG2020/ Placebo	10SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12312903	C4591001 1231 12312903	16-55	21AUG2020	60792	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12312904	C4591001 1231 12312904	16-55	21AUG2020	60788	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12312905	C4591001 1231 12312905	16-55	21AUG2020	60786	Placebo	21AUG2020/ Placebo	15SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12312906	C4591001 1231 12312906	16-55	21AUG2020	60838	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12312910	C4591001 1231 12312910	16-55	21AUG2020	60844	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12312911	C4591001 1231 12312911	16-55	21AUG2020	61011	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12312912	C4591001 1231 12312912	16-55	21AUG2020	60922	Placebo	21AUG2020/ Placebo	10SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12312913	C4591001 1231 12312913	16-55	21AUG2020	60961	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12312914	C4591001 1231 12312914	16-55	21AUG2020	60954	Placebo	21AUG2020/ Placebo	14SEP2020/ Placebo		
12312916	C4591001 1231 12312916	16-55	21AUG2020	60842	Placebo	21AUG2020/ Placebo		02MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12312917	C4591001 1231 12312917	16-55	21AUG2020	61008	Placebo	21AUG2020/ Placebo	10SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12312918	C4591001 1231 12312918	16-55	21AUG2020	60962	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12312919	C4591001 1231 12312919	16-55	21AUG2020	60917	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12312920	C4591001 1231 12312920	16-55	21AUG2020	61052	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12312921	C4591001 1231 12312921	16-55	21AUG2020	61005	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12312922	C4591001 1231 12312922	16-55	21AUG2020	60920	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12312923	C4591001 1231 12312923	16-55	21AUG2020	60840	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12312924	C4591001 1231 12312924	16-55	21AUG2020	61007	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12312925	C4591001 1231 12312925	16-55	21AUG2020	61028	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12312926	C4591001 1231 12312926	16-55	21AUG2020	61050	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12312927	C4591001 1231 12312927	16-55	21AUG2020	60957	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12312928	C4591001 1231 12312928	16-55	21AUG2020	61027	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
12312929	C4591001 1231 12312929	16-55	21AUG2020	61061	Placebo	21AUG2020/ Placebo	09SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12312930	C4591001 1231 12312930	16-55	21AUG2020	61036	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12312931	C4591001 1231 12312931	16-55	21AUG2020	61034	Placebo	21AUG2020/ Placebo	09SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12312932	C4591001 1231 12312932	16-55	21AUG2020	61063	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12312933	C4591001 1231 12312933	16-55	21AUG2020	60928	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12312934	C4591001 1231 12312934	16-55	21AUG2020	61087	Placebo	21AUG2020/ Placebo	09SEP2020/ Placebo		
12312936	C4591001 1231 12312936	16-55	21AUG2020	61088	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12312937	C4591001 1231 12312937	16-55	21AUG2020	61051	Placebo	21AUG2020/ Placebo	10SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12312938	C4591001 1231 12312938	16-55	21AUG2020	61089	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12312939	C4591001 1231 12312939	16-55	21AUG2020	61049	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12312941	C4591001 1231 12312941	16-55	21AUG2020	61069	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12312943	C4591001 1231 12312943	16-55	21AUG2020	61066	Placebo	21AUG2020/ Placebo	10SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	13FEB2021/ BNT162b2 (30 µg)
12312944	C4591001 1231 12312944	16-55	21AUG2020	61133	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12312946	C4591001 1231 12312946	16-55	21AUG2020	61134	Placebo	21AUG2020/ Placebo	09SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12312947	C4591001 1231 12312947	16-55	21AUG2020	61095	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12312948	C4591001 1231 12312948	16-55	21AUG2020	61135	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12312951	C4591001 1231 12312951	16-55	21AUG2020	61157	Placebo	21AUG2020/ Placebo	10SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12312952	C4591001 1231 12312952	16-55	21AUG2020	61140	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12312953	C4591001 1231 12312953	16-55	21AUG2020	61184	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12312954	C4591001 1231 12312954	16-55	21AUG2020	61160	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12312955	C4591001 1231 12312955	16-55	21AUG2020	61220	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12312956	C4591001 1231 12312956	16-55	21AUG2020	61168	Placebo	21AUG2020/ Placebo	10SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12312957	C4591001 1231 12312957	16-55	21AUG2020	61166	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12312958	C4591001 1231 12312958	16-55	21AUG2020	61186	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12312959	C4591001 1231 12312959	16-55	21AUG2020	61192	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12312960	C4591001 1231 12312960	16-55	21AUG2020	61187	Placebo	21AUG2020/ Placebo	09SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12312962	C4591001 1231 12312962	16-55	21AUG2020	61224	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12312964	C4591001 1231 12312964	16-55	21AUG2020	61266	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12312965	C4591001 1231 12312965	16-55	21AUG2020	61274	Placebo	21AUG2020/ Placebo	09SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
12312966	C4591001 1231 12312966	16-55	21AUG2020	61218	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12312968	C4591001 1231 12312968	16-55	21AUG2020	61325	Placebo	21AUG2020/ Placebo	10SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12312969	C4591001 1231 12312969	16-55	21AUG2020	61225	Placebo	21AUG2020/ Placebo	09SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12312971	C4591001 1231 12312971	16-55	21AUG2020	61310	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12312972	C4591001 1231 12312972	16-55	21AUG2020	61270	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12312974	C4591001 1231 12312974	16-55	21AUG2020	61265	Placebo	21AUG2020/ Placebo	09SEP2020/ Placebo		
12312975	C4591001 1231 12312975	16-55	21AUG2020	61304	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
12312976	C4591001 1231 12312976	16-55	21AUG2020	61302	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12312979	C4591001 1231 12312979	16-55	21AUG2020	61307	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12312982	C4591001 1231 12312982	16-55	21AUG2020	61389	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12312983	C4591001 1231 12312983	16-55	21AUG2020	61332	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12312984	C4591001 1231 12312984	16-55	21AUG2020	61365	Placebo	21AUG2020/ Placebo	10SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
12312985	C4591001 1231 12312985	16-55	21AUG2020	61386	Placebo	21AUG2020/ Placebo	02OCT2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12312986	C4591001 1231 12312986	16-55	21AUG2020	61370	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12312988	C4591001 1231 12312988	16-55	21AUG2020	61431	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12312989	C4591001 1231 12312989	16-55	21AUG2020	61327	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12312990	C4591001 1231 12312990	16-55	21AUG2020	61393	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12312991	C4591001 1231 12312991	16-55	21AUG2020	61333	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	13FEB2021/ BNT162b2 (30 µg)
12312992	C4591001 1231 12312992	16-55	21AUG2020	61372	Placebo	21AUG2020/ Placebo	10SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12312994	C4591001 1231 12312994	16-55	21AUG2020	61428	Placebo	21AUG2020/ Placebo	01OCT2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12312995	C4591001 1231 12312995	16-55	21AUG2020	61369	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12312996	C4591001 1231 12312996	16-55	21AUG2020	61429	Placebo	21AUG2020/ Placebo	10SEP2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12313001	C4591001 1231 12313001	16-55	21AUG2020	61387	Placebo	21AUG2020/ Placebo	10SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12313002	C4591001 1231 12313002	16-55	21AUG2020	61440	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12313005	C4591001 1231 12313005	16-55	21AUG2020	61441	Placebo	21AUG2020/ Placebo	09SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12313006	C4591001 1231 12313006	16-55	21AUG2020	61443	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)			
12313007	C4591001 1231 12313007	16-55	21AUG2020	61432	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12313008	C4591001 1231 12313008	16-55	21AUG2020	61458	Placebo	21AUG2020/ Placebo	09SEP2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12313009	C4591001 1231 12313009	16-55	21AUG2020	61463	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12313011	C4591001 1231 12313011	16-55	21AUG2020	61469	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12313012	C4591001 1231 12313012	16-55	21AUG2020	61468	Placebo	21AUG2020/ Placebo	10SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12313013	C4591001 1231 12313013	16-55	21AUG2020	61480	Placebo	21AUG2020/ Placebo	09SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12313014	C4591001 1231 12313014	16-55	21AUG2020	61476	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12313015	C4591001 1231 12313015	16-55	21AUG2020	61442	Placebo	21AUG2020/ Placebo	10SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12313018	C4591001 1231 12313018	16-55	21AUG2020	61509	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12313019	C4591001 1231 12313019	16-55	21AUG2020	61464	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12313020	C4591001 1231 12313020	16-55	21AUG2020	61511	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12313022	C4591001 1231 12313022	16-55	21AUG2020	61515	Placebo	21AUG2020/ Placebo	10SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12313023	C4591001 1231 12313023	16-55	21AUG2020	61479	Placebo	21AUG2020/ Placebo	09SEP2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12313025	C4591001 1231 12313025	16-55	21AUG2020	61505	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12313026	C4591001 1231 12313026	16-55	21AUG2020	61542	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12313028	C4591001 1231 12313028	16-55	21AUG2020	61543	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12313030	C4591001 1231 12313030	16-55	21AUG2020	61549	Placebo	21AUG2020/ Placebo	10SEP2020/ Placebo		
12313031	C4591001 1231 12313031	16-55	21AUG2020	61541	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12313032	C4591001 1231 12313032	16-55	22AUG2020	61637	Placebo	22AUG2020/ Placebo	10SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
12313033	C4591001 1231 12313033	16-55	22AUG2020	61640	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313034	C4591001 1231 12313034	16-55	22AUG2020	61701	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12313035	C4591001 1231 12313035	16-55	22AUG2020	61641	Placebo	22AUG2020/ Placebo	13SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12313036	C4591001 1231 12313036	16-55	22AUG2020	61643	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12313037	C4591001 1231 12313037	16-55	22AUG2020	61649	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313038	C4591001 1231 12313038	16-55	22AUG2020	61650	Placebo	22AUG2020/ Placebo	11SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12313040	C4591001 1231 12313040	16-55	22AUG2020	61665	Placebo	22AUG2020/ Placebo	14SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12313041	C4591001 1231 12313041	16-55	22AUG2020	61660	Placebo	22AUG2020/ Placebo	11SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
12313042	C4591001 1231 12313042	16-55	22AUG2020	61661	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313043	C4591001 1231 12313043	16-55	22AUG2020	61672	Placebo	22AUG2020/ Placebo	10SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
12313044	C4591001 1231 12313044	16-55	22AUG2020	61651	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12313045	C4591001 1231 12313045	16-55	22AUG2020	61688	Placebo	22AUG2020/ Placebo	13SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12313046	C4591001 1231 12313046	16-55	22AUG2020	61675	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12313047	C4591001 1231 12313047	16-55	22AUG2020	61697	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12313048	C4591001 1231 12313048	16-55	22AUG2020	61715	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12313049	C4591001 1231 12313049	16-55	22AUG2020	61676	Placebo	22AUG2020/ Placebo	11SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12313051	C4591001 1231 12313051	16-55	22AUG2020	61684	Placebo	22AUG2020/ Placebo	11SEP2020/ Placebo		
12313054	C4591001 1231 12313054	16-55	22AUG2020	61663	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12313056	C4591001 1231 12313056	16-55	22AUG2020	61677	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12313058	C4591001 1231 12313058	16-55	22AUG2020	61692	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12313059	C4591001 1231 12313059	16-55	22AUG2020	61698	Placebo	22AUG2020/ Placebo	14SEP2020/ Placebo		
12313061	C4591001 1231 12313061	16-55	22AUG2020	61686	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12313062	C4591001 1231 12313062	16-55	22AUG2020	61728	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12313063	C4591001 1231 12313063	16-55	22AUG2020	61690	Placebo	22AUG2020/ Placebo	13SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12313064	C4591001 1231 12313064	16-55	22AUG2020	61709	Placebo	22AUG2020/ Placebo	10SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	13FEB2021/ BNT162b2 (30 µg)
12313065	C4591001 1231 12313065	16-55	22AUG2020	61704	Placebo	22AUG2020/ Placebo	10SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12313066	C4591001 1231 12313066	16-55	22AUG2020	61717	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12313068	C4591001 1231 12313068	16-55	22AUG2020	61729	Placebo	22AUG2020/ Placebo		22FEB2021/ BNT162b2 (30 µg)	
12313069	C4591001 1231 12313069	16-55	22AUG2020	61732	Placebo	22AUG2020/ Placebo		01MAR2021/ BNT162b2 (30 µg)	
12313070	C4591001 1231 12313070	16-55	22AUG2020	61718	Placebo	22AUG2020/ Placebo	11SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12313071	C4591001 1231 12313071	16-55	22AUG2020	61724	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12313074	C4591001 1231 12313074	16-55	22AUG2020	61739	Placebo	22AUG2020/ Placebo	11SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12313075	C4591001 1231 12313075	16-55	22AUG2020	61734	Placebo	22AUG2020/ Placebo	14SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
12313076	C4591001 1231 12313076	16-55	22AUG2020	61740	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12313079	C4591001 1231 12313079	16-55	22AUG2020	61743	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12313080	C4591001 1231 12313080	16-55	22AUG2020	61749	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12313082	C4591001 1231 12313082	16-55	22AUG2020	61747	Placebo	22AUG2020/ Placebo	11SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12313083	C4591001 1231 12313083	16-55	22AUG2020	61746	Placebo	22AUG2020/ Placebo	10SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12313084	C4591001 1231 12313084	16-55	22AUG2020	61764	Placebo	22AUG2020/ Placebo	11SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12313085	C4591001 1231 12313085	16-55	22AUG2020	61759	Placebo	22AUG2020/ Placebo	13SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12313086	C4591001 1231 12313086	16-55	22AUG2020	61761	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12313087	C4591001 1231 12313087	16-55	22AUG2020	61808	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12313088	C4591001 1231 12313088	16-55	22AUG2020	61750	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12313091	C4591001 1231 12313091	16-55	22AUG2020	61792	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12313092	C4591001 1231 12313092	16-55	22AUG2020	61781	Placebo	22AUG2020/ Placebo	14SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12313093	C4591001 1231 12313093	16-55	22AUG2020	61782	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12313095	C4591001 1231 12313095	16-55	22AUG2020	61763	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12313096	C4591001 1231 12313096	16-55	22AUG2020	61787	Placebo	22AUG2020/ Placebo	13SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12313098	C4591001 1231 12313098	16-55	22AUG2020	61795	Placebo	22AUG2020/ Placebo	09OCT2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	
12313099	C4591001 1231 12313099	16-55	22AUG2020	61796	Placebo	22AUG2020/ Placebo	11SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12313105	C4591001 1231 12313105	16-55	22AUG2020	61793	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12313106	C4591001 1231 12313106	16-55	22AUG2020	61817	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12313107	C4591001 1231 12313107	16-55	22AUG2020	61799	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313108	C4591001 1231 12313108	16-55	22AUG2020	61829	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12313109	C4591001 1231 12313109	16-55	22AUG2020	61816	Placebo	22AUG2020/ Placebo	14SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
12313110	C4591001 1231 12313110	16-55	22AUG2020	61809	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12313111	C4591001 1231 12313111	16-55	22AUG2020	61826	Placebo	22AUG2020/ Placebo	11SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12313113	C4591001 1231 12313113	16-55	22AUG2020	61833	Placebo	22AUG2020/ Placebo	11SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
12313115	C4591001 1231 12313115	16-55	22AUG2020	61805	Placebo	22AUG2020/ Placebo		23FEB2021/ BNT162b2 (30 µg)	
12313116	C4591001 1231 12313116	16-55	22AUG2020	61819	Placebo	22AUG2020/ Placebo	11SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12313117	C4591001 1231 12313117	16-55	22AUG2020	61825	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12313120	C4591001 1231 12313120	16-55	22AUG2020	61837	Placebo	22AUG2020/ Placebo	10SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12313122	C4591001 1231 12313122	16-55	22AUG2020	61834	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12313123	C4591001 1231 12313123	16-55	22AUG2020	61841	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12313124	C4591001 1231 12313124	16-55	22AUG2020	61954	Placebo	22AUG2020/ Placebo	11SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
12313125	C4591001 1231 12313125	16-55	22AUG2020	61845	Placebo	22AUG2020/ Placebo		01MAR2021/ BNT162b2 (30 µg)	
12313127	C4591001 1231 12313127	16-55	22AUG2020	61933	Placebo	22AUG2020/ Placebo	10SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12313128	C4591001 1231 12313128	16-55	22AUG2020	61869	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313129	C4591001 1231 12313129	16-55	22AUG2020	61846	Placebo	22AUG2020/ Placebo	11SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12313130	C4591001 1231 12313130	16-55	22AUG2020	61865	Placebo	22AUG2020/ Placebo	10SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12313132	C4591001 1231 12313132	16-55	22AUG2020	61916	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313134	C4591001 1231 12313134	16-55	22AUG2020	61909	Placebo	22AUG2020/ Placebo	10SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12313136	C4591001 1231 12313136	16-55	22AUG2020	61901	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12313137	C4591001 1231 12313137	16-55	22AUG2020	61875	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12313138	C4591001 1231 12313138	16-55	22AUG2020	61873	Placebo	22AUG2020/ Placebo	13SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12313139	C4591001 1231 12313139	16-55	22AUG2020	61918	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12313140	C4591001 1231 12313140	16-55	22AUG2020	61905	Placebo	22AUG2020/ Placebo	14SEP2020/ Placebo		
12313141	C4591001 1231 12313141	16-55	22AUG2020	61924	Placebo	22AUG2020/ Placebo	13SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12313143	C4591001 1231 12313143	16-55	22AUG2020	61911	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12313145	C4591001 1231 12313145	16-55	22AUG2020	61917	Placebo	22AUG2020/ Placebo	18SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12313148	C4591001 1231 12313148	16-55	22AUG2020	61937	Placebo	22AUG2020/ Placebo	14SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12313149	C4591001 1231 12313149	16-55	22AUG2020	61927	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12313151	C4591001 1231 12313151	16-55	22AUG2020	61939	Placebo	22AUG2020/ Placebo	10SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12313152	C4591001 1231 12313152	16-55	22AUG2020	61934	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12313153	C4591001 1231 12313153	16-55	22AUG2020	61950	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313155	C4591001 1231 12313155	16-55	22AUG2020	61947	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313156	C4591001 1231 12313156	16-55	22AUG2020	61949	Placebo	22AUG2020/ Placebo	13SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12313157	C4591001 1231 12313157	16-55	22AUG2020	61936	Placebo	22AUG2020/ Placebo	11SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12313158	C4591001 1231 12313158	16-55	22AUG2020	61941	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313160	C4591001 1231 12313160	16-55	22AUG2020	61973	Placebo	22AUG2020/ Placebo	14SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12313161	C4591001 1231 12313161	16-55	22AUG2020	61976	Placebo	22AUG2020/ Placebo	10SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12313162	C4591001 1231 12313162	16-55	22AUG2020	61959	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12313163	C4591001 1231 12313163	16-55	22AUG2020	61981	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12313164	C4591001 1231 12313164	16-55	22AUG2020	61984	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12313165	C4591001 1231 12313165	16-55	22AUG2020	62022	Placebo	22AUG2020/ Placebo	13SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	13FEB2021/ BNT162b2 (30 µg)
12313166	C4591001 1231 12313166	16-55	22AUG2020	62011	Placebo	22AUG2020/ Placebo	11SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
12313167	C4591001 1231 12313167	16-55	22AUG2020	62014	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313168	C4591001 1231 12313168	16-55	22AUG2020	62016	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12313170	C4591001 1231 12313170	16-55	22AUG2020	62046	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313174	C4591001 1231 12313174	16-55	22AUG2020	62080	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313175	C4591001 1231 12313175	16-55	22AUG2020	62025	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)			
12313176	C4591001 1231 12313176	16-55	22AUG2020	62015	Placebo	22AUG2020/ Placebo	11SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
12313177	C4591001 1231 12313177	16-55	22AUG2020	62045	Placebo	22AUG2020/ Placebo	10SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	13FEB2021/ BNT162b2 (30 µg)
12313179	C4591001 1231 12313179	16-55	22AUG2020	62036	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12313180	C4591001 1231 12313180	16-55	22AUG2020	62026	Placebo	22AUG2020/ Placebo	11SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12313181	C4591001 1231 12313181	16-55	22AUG2020	62073	Placebo	22AUG2020/ Placebo	14SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
12313182	C4591001 1231 12313182	16-55	22AUG2020	62035	Placebo	22AUG2020/ Placebo	11SEP2020/ Placebo		
12313183	C4591001 1231 12313183	16-55	22AUG2020	62030	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12313184	C4591001 1231 12313184	16-55	22AUG2020	62043	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12313186	C4591001 1231 12313186	16-55	22AUG2020	62039	Placebo	22AUG2020/ Placebo	11SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12313188	C4591001 1231 12313188	16-55	22AUG2020	62070	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313189	C4591001 1231 12313189	16-55	22AUG2020	62047	Placebo	22AUG2020/ Placebo	11SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12313190	C4591001 1231 12313190	16-55	22AUG2020	62055	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12313191	C4591001 1231 12313191	16-55	22AUG2020	62068	Placebo	22AUG2020/ Placebo	14SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12313192	C4591001 1231 12313192	16-55	22AUG2020	62059	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12313193	C4591001 1231 12313193	16-55	22AUG2020	62077	Placebo	22AUG2020/ Placebo	10SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12313194	C4591001 1231 12313194	16-55	22AUG2020	62093	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12313195	C4591001 1231 12313195	16-55	22AUG2020	62062	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12313197	C4591001 1231 12313197	16-55	22AUG2020	62064	Placebo	22AUG2020/ Placebo	14SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12313198	C4591001 1231 12313198	16-55	22AUG2020	62122	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12313199	C4591001 1231 12313199	16-55	22AUG2020	62100	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313201	C4591001 1231 12313201	16-55	22AUG2020	62118	Placebo	22AUG2020/ Placebo	11SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12313202	C4591001 1231 12313202	16-55	22AUG2020	62094	Placebo	22AUG2020/ Placebo	11SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12313203	C4591001 1231 12313203	16-55	22AUG2020	62098	Placebo	22AUG2020/ Placebo	15SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12313204	C4591001 1231 12313204	16-55	22AUG2020	62121	Placebo	22AUG2020/ Placebo	11SEP2020/ Placebo		
12313205	C4591001 1231 12313205	16-55	22AUG2020	62158	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12313206	C4591001 1231 12313206	16-55	22AUG2020	62155	Placebo	22AUG2020/ Placebo	10SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12313207	C4591001 1231 12313207	16-55	22AUG2020	62154	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)			
12313209	C4591001 1231 12313209	16-55	22AUG2020	62173	Placebo	22AUG2020/ Placebo	13SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12313210	C4591001 1231 12313210	16-55	22AUG2020	62176	Placebo	22AUG2020/ Placebo	13SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
12313211	C4591001 1231 12313211	16-55	22AUG2020	62161	Placebo	22AUG2020/ Placebo			
12313212	C4591001 1231 12313212	16-55	22AUG2020	62166	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12313213	C4591001 1231 12313213	16-55	22AUG2020	62223	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12313214	C4591001 1231 12313214	16-55	22AUG2020	62199	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12313215	C4591001 1231 12313215	16-55	22AUG2020	62195	Placebo	22AUG2020/ Placebo	11SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
12313216	C4591001 1231 12313216	16-55	22AUG2020	62169	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12313218	C4591001 1231 12313218	16-55	22AUG2020	62204	Placebo	22AUG2020/ Placebo	13SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12313219	C4591001 1231 12313219	16-55	22AUG2020	62205	Placebo	22AUG2020/ Placebo	11SEP2020/ Placebo		
12313223	C4591001 1231 12313223	16-55	22AUG2020	62239	Placebo	22AUG2020/ Placebo	14SEP2020/ Placebo		
12313224	C4591001 1231 12313224	16-55	22AUG2020	62194	Placebo	22AUG2020/ Placebo	11SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12313225	C4591001 1231 12313225	16-55	22AUG2020	62219	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)			
12313226	C4591001 1231 12313226	16-55	22AUG2020	62222	Placebo	22AUG2020/ Placebo	10SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12313227	C4591001 1231 12313227	16-55	22AUG2020	62197	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12313228	C4591001 1231 12313228	16-55	22AUG2020	62212	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12313229	C4591001 1231 12313229	16-55	22AUG2020	62201	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12313231	C4591001 1231 12313231	16-55	22AUG2020	62244	Placebo	22AUG2020/ Placebo	13SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
12313232	C4591001 1231 12313232	16-55	22AUG2020	62268	Placebo	22AUG2020/ Placebo	14SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12313235	C4591001 1231 12313235	16-55	22AUG2020	62248	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313236	C4591001 1231 12313236	16-55	22AUG2020	62253	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12313237	C4591001 1231 12313237	16-55	22AUG2020	62224	Placebo	22AUG2020/ Placebo	10SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12313238	C4591001 1231 12313238	16-55	22AUG2020	62237	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12313243	C4591001 1231 12313243	16-55	22AUG2020	62254	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12313244	C4591001 1231 12313244	16-55	22AUG2020	62260	Placebo	22AUG2020/ Placebo	14SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12313245	C4591001 1231 12313245	16-55	22AUG2020	62257	Placebo	22AUG2020/ Placebo	11SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12313246	C4591001 1231 12313246	16-55	22AUG2020	62265	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313249	C4591001 1231 12313249	16-55	22AUG2020	62407	Placebo	22AUG2020/ Placebo	13SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
12313250	C4591001 1231 12313250	16-55	22AUG2020	62299	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12313251	C4591001 1231 12313251	16-55	22AUG2020	62261	Placebo	22AUG2020/ Placebo	10SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12313253	C4591001 1231 12313253	16-55	22AUG2020	62357	Placebo	22AUG2020/ Placebo	11SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12313255	C4591001 1231 12313255	16-55	22AUG2020	62297	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12313256	C4591001 1231 12313256	16-55	22AUG2020	62301	Placebo	22AUG2020/ Placebo	13SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12313257	C4591001 1231 12313257	16-55	22AUG2020	62360	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12313258	C4591001 1231 12313258	16-55	22AUG2020	62272	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12313259	C4591001 1231 12313259	16-55	22AUG2020	62308	Placebo	22AUG2020/ Placebo	10SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12313260	C4591001 1231 12313260	16-55	22AUG2020	62327	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12313263	C4591001 1231 12313263	16-55	22AUG2020	62362	Placebo	22AUG2020/ Placebo	11SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12313264	C4591001 1231 12313264	16-55	22AUG2020	62330	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12313265	C4591001 1231 12313265	16-55	22AUG2020	62413	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12313266	C4591001 1231 12313266	16-55	22AUG2020	62367	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313268	C4591001 1231 12313268	16-55	22AUG2020	62332	Placebo	22AUG2020/ Placebo	14SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12313269	C4591001 1231 12313269	16-55	22AUG2020	62331	Placebo	22AUG2020/ Placebo	13SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12313270	C4591001 1231 12313270	16-55	22AUG2020	62412	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12313271	C4591001 1231 12313271	16-55	22AUG2020	62423	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313272	C4591001 1231 12313272	16-55	22AUG2020	62414	Placebo	22AUG2020/ Placebo	10SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12313274	C4591001 1231 12313274	16-55	22AUG2020	62418	Placebo	22AUG2020/ Placebo	10SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12313276	C4591001 1231 12313276	16-55	22AUG2020	62424	Placebo	22AUG2020/ Placebo	13SEP2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
12313277	C4591001 1231 12313277	16-55	22AUG2020	62417	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12313278	C4591001 1231 12313278	16-55	22AUG2020	62433	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12313281	C4591001 1231 12313281	16-55	22AUG2020	62455	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12313282	C4591001 1231 12313282	16-55	22AUG2020	62440	Placebo	22AUG2020/ Placebo	11SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12313283	C4591001 1231 12313283	16-55	22AUG2020	62442	Placebo	22AUG2020/ Placebo	11SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12313284	C4591001 1231 12313284	16-55	22AUG2020	62448	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313285	C4591001 1231 12313285	16-55	22AUG2020	62435	Placebo	22AUG2020/ Placebo	14SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12313287	C4591001 1231 12313287	16-55	22AUG2020	62436	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12313288	C4591001 1231 12313288	16-55	22AUG2020	62453	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313289	C4591001 1231 12313289	16-55	22AUG2020	62449	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
12313290	C4591001 1231 12313290	16-55	22AUG2020	62457	Placebo	22AUG2020/ Placebo	13SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12313291	C4591001 1231 12313291	16-55	22AUG2020	62444	Placebo	22AUG2020/ Placebo	11SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12313292	C4591001 1231 12313292	16-55	22AUG2020	62460	Placebo	22AUG2020/ Placebo	11SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12313293	C4591001 1231 12313293	16-55	22AUG2020	62465	Placebo	22AUG2020/ Placebo	11SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12313296	C4591001 1231 12313296	16-55	22AUG2020	62466	Placebo	22AUG2020/ Placebo	10SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12313297	C4591001 1231 12313297	16-55	22AUG2020	62480	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12313298	C4591001 1231 12313298	16-55	22AUG2020	62472	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12313300	C4591001 1231 12313300	16-55	22AUG2020	62485	Placebo	22AUG2020/ Placebo	14SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12313301	C4591001 1231 12313301	16-55	22AUG2020	62471	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12313302	C4591001 1231 12313302	16-55	22AUG2020	62486	Placebo	22AUG2020/ Placebo	13SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12313303	C4591001 1231 12313303	16-55	22AUG2020	62502	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12313304	C4591001 1231 12313304	16-55	22AUG2020	62495	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12313306	C4591001 1231 12313306	16-55	22AUG2020	62499	Placebo	22AUG2020/ Placebo	13SEP2020/ Placebo		
12313307	C4591001 1231 12313307	16-55	22AUG2020	62507	Placebo	22AUG2020/ Placebo	10SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12313308	C4591001 1231 12313308	16-55	22AUG2020	62505	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12313310	C4591001 1231 12313310	16-55	22AUG2020	62516	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313311	C4591001 1231 12313311	16-55	22AUG2020	62493	Placebo	22AUG2020/ Placebo	13SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12313312	C4591001 1231 12313312	16-55	22AUG2020	62519	Placebo	22AUG2020/ Placebo	10SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12313313	C4591001 1231 12313313	16-55	22AUG2020	62482	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12313314	C4591001 1231 12313314	16-55	22AUG2020	62521	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12313315	C4591001 1231 12313315	16-55	22AUG2020	62497	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12313316	C4591001 1231 12313316	16-55	22AUG2020	62527	Placebo	22AUG2020/ Placebo	11SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12313317	C4591001 1231 12313317	16-55	22AUG2020	62509	Placebo	22AUG2020/ Placebo	13SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12313318	C4591001 1231 12313318	16-55	22AUG2020	62529	Placebo	22AUG2020/ Placebo	11SEP2020/ Placebo		
12313319	C4591001 1231 12313319	16-55	22AUG2020	62518	Placebo	22AUG2020/ Placebo	11SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12313321	C4591001 1231 12313321	16-55	22AUG2020	62526	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12313322	C4591001 1231 12313322	16-55	22AUG2020	62535	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12313324	C4591001 1231 12313324	16-55	23AUG2020	62549	Placebo	23AUG2020/ Placebo	13SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12313326	C4591001 1231 12313326	16-55	23AUG2020	62560	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313327	C4591001 1231 12313327	16-55	23AUG2020	62586	Placebo	23AUG2020/ Placebo	13SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12313329	C4591001 1231 12313329	16-55	23AUG2020	62552	Placebo	23AUG2020/ Placebo	13SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12313330	C4591001 1231 12313330	16-55	23AUG2020	62557	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313332	C4591001 1231 12313332	16-55	23AUG2020	62561	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313334	C4591001 1231 12313334	16-55	23AUG2020	62571	Placebo	23AUG2020/ Placebo	14SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12313335	C4591001 1231 12313335	16-55	23AUG2020	62576	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313336	C4591001 1231 12313336	16-55	23AUG2020	62568	Placebo	23AUG2020/ Placebo	13SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12313337	C4591001 1231 12313337	16-55	23AUG2020	62582	Placebo	23AUG2020/ Placebo	14SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12313338	C4591001 1231 12313338	16-55	23AUG2020	62587	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12313340	C4591001 1231 12313340	16-55	23AUG2020	62603	Placebo	23AUG2020/ Placebo	11SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12313343	C4591001 1231 12313343	16-55	23AUG2020	62563	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12313345	C4591001 1231 12313345	16-55	23AUG2020	62579	Placebo	23AUG2020/ Placebo	11SEP2020/ Placebo	12MAR2021/ BNT162b2 (30 µg)	
12313348	C4591001 1231 12313348	16-55	23AUG2020	62596	Placebo	23AUG2020/ Placebo	13SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12313349	C4591001 1231 12313349	16-55	23AUG2020	62573	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313350	C4591001 1231 12313350	16-55	23AUG2020	62598	Placebo	23AUG2020/ Placebo	15SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12313351	C4591001 1231 12313351	16-55	23AUG2020	62604	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12313353	C4591001 1231 12313353	16-55	23AUG2020	62611	Placebo	23AUG2020/ Placebo	11SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12313356	C4591001 1231 12313356	16-55	23AUG2020	62622	Placebo	23AUG2020/ Placebo	13SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12313357	C4591001 1231 12313357	16-55	23AUG2020	62592	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)			

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12313358	C4591001 1231 12313358	16-55	23AUG2020	62605	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12313360	C4591001 1231 12313360	16-55	23AUG2020	62616	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12313361	C4591001 1231 12313361	16-55	23AUG2020	62618	Placebo	23AUG2020/ Placebo	11SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
12313363	C4591001 1231 12313363	16-55	23AUG2020	62623	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313364	C4591001 1231 12313364	16-55	23AUG2020	62617	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12313365	C4591001 1231 12313365	16-55	23AUG2020	62627	Placebo	23AUG2020/ Placebo	11SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12313367	C4591001 1231 12313367	16-55	23AUG2020	62624	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12313368	C4591001 1231 12313368	16-55	23AUG2020	62640	Placebo	23AUG2020/ Placebo	13SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12313369	C4591001 1231 12313369	16-55	23AUG2020	62635	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12313370	C4591001 1231 12313370	16-55	23AUG2020	62637	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12313372	C4591001 1231 12313372	16-55	23AUG2020	62650	Placebo	23AUG2020/ Placebo	11SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12313374	C4591001 1231 12313374	16-55	23AUG2020	62638	Placebo	23AUG2020/ Placebo	13SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	
12313375	C4591001 1231 12313375	16-55	23AUG2020	62649	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12313376	C4591001 1231 12313376	16-55	23AUG2020	62657	Placebo	23AUG2020/ Placebo			
12313378	C4591001 1231 12313378	16-55	23AUG2020	62652	Placebo	23AUG2020/ Placebo	15SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	13FEB2021/ BNT162b2 (30 µg)
12313381	C4591001 1231 12313381	16-55	23AUG2020	62646	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313383	C4591001 1231 12313383	16-55	23AUG2020	62686	Placebo	23AUG2020/ Placebo	11SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12313384	C4591001 1231 12313384	16-55	23AUG2020	62658	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313385	C4591001 1231 12313385	16-55	23AUG2020	62670	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313386	C4591001 1231 12313386	16-55	23AUG2020	62666	Placebo	23AUG2020/ Placebo	11SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12313387	C4591001 1231 12313387	16-55	23AUG2020	62665	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313388	C4591001 1231 12313388	16-55	23AUG2020	62680	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12313389	C4591001 1231 12313389	16-55	23AUG2020	62683	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12313390	C4591001 1231 12313390	16-55	23AUG2020	62694	Placebo	23AUG2020/ Placebo	11SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12313393	C4591001 1231 12313393	16-55	23AUG2020	62673	Placebo	23AUG2020/ Placebo	11SEP2020/ Placebo		
12313394	C4591001 1231 12313394	16-55	23AUG2020	62688	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313395	C4591001 1231 12313395	16-55	23AUG2020	62678	Placebo	23AUG2020/ Placebo		01MAR2021/ BNT162b2 (30 µg)	
12313399	C4591001 1231 12313399	16-55	23AUG2020	62691	Placebo	23AUG2020/ Placebo	13SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12313400	C4591001 1231 12313400	16-55	23AUG2020	62710	Placebo	23AUG2020/ Placebo	13SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12313402	C4591001 1231 12313402	16-55	23AUG2020	62704	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12313404	C4591001 1231 12313404	16-55	23AUG2020	62703	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313405	C4591001 1231 12313405	16-55	23AUG2020	62695	Placebo	23AUG2020/ Placebo	15SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
12313406	C4591001 1231 12313406	16-55	23AUG2020	62714	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12313407	C4591001 1231 12313407	16-55	23AUG2020	62715	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313408	C4591001 1231 12313408	16-55	23AUG2020	62721	Placebo	23AUG2020/ Placebo	13SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12313409	C4591001 1231 12313409	16-55	23AUG2020	62716	Placebo	23AUG2020/ Placebo	11SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12313412	C4591001 1231 12313412	16-55	23AUG2020	62722	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313413	C4591001 1231 12313413	16-55	23AUG2020	62723	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12313414	C4591001 1231 12313414	16-55	23AUG2020	62756	Placebo	23AUG2020/ Placebo	13SEP2020/ Placebo		
12313415	C4591001 1231 12313415	16-55	23AUG2020	62754	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12313416	C4591001 1231 12313416	16-55	23AUG2020	62728	Placebo	23AUG2020/ Placebo	13SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12313417	C4591001 1231 12313417	16-55	23AUG2020	62787	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313419	C4591001 1231 12313419	16-55	23AUG2020	62773	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12313421	C4591001 1231 12313421	16-55	23AUG2020	62743	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12313422	C4591001 1231 12313422	16-55	23AUG2020	62741	Placebo	23AUG2020/ Placebo	15SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12313425	C4591001 1231 12313425	16-55	23AUG2020	62758	Placebo	23AUG2020/ Placebo	13SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12313427	C4591001 1231 12313427	16-55	23AUG2020	62772	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12313428	C4591001 1231 12313428	16-55	23AUG2020	62788	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)			
12313429	C4591001 1231 12313429	16-55	23AUG2020	62790	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12313430	C4591001 1231 12313430	16-55	23AUG2020	62782	Placebo	23AUG2020/ Placebo	14SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12313431	C4591001 1231 12313431	16-55	23AUG2020	62747	Placebo	23AUG2020/ Placebo	13SEP2020/ Placebo		
12313432	C4591001 1231 12313432	16-55	23AUG2020	62761	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12313433	C4591001 1231 12313433	16-55	23AUG2020	62789	Placebo	23AUG2020/ Placebo	11SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12313434	C4591001 1231 12313434	16-55	23AUG2020	62817	Placebo	23AUG2020/ Placebo	13SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12313435	C4591001 1231 12313435	16-55	23AUG2020	62770	Placebo	23AUG2020/ Placebo	13SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12313437	C4591001 1231 12313437	16-55	23AUG2020	62793	Placebo	23AUG2020/ Placebo	13SEP2020/ Placebo		
12313438	C4591001 1231 12313438	16-55	23AUG2020	62792	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
12313439	C4591001 1231 12313439	16-55	23AUG2020	62777	Placebo	23AUG2020/ Placebo	15SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12313440	C4591001 1231 12313440	16-55	23AUG2020	62750	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12313441	C4591001 1231 12313441	16-55	23AUG2020	62819	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12313442	C4591001 1231 12313442	16-55	23AUG2020	62813	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12313443	C4591001 1231 12313443	16-55	23AUG2020	62897	Placebo				
12313444	C4591001 1231 12313444	16-55	23AUG2020	62775	Placebo	23AUG2020/ Placebo	11SEP2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12313445	C4591001 1231 12313445	16-55	23AUG2020	62824	Placebo	23AUG2020/ Placebo	13SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12313448	C4591001 1231 12313448	16-55	23AUG2020	62828	Placebo	23AUG2020/ Placebo	14SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12313449	C4591001 1231 12313449	16-55	23AUG2020	62825	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)			
12313450	C4591001 1231 12313450	16-55	23AUG2020	62829	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12313452	C4591001 1231 12313452	16-55	23AUG2020	62841	Placebo	23AUG2020/ Placebo	13SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12313454	C4591001 1231 12313454	16-55	23AUG2020	62830	Placebo	23AUG2020/ Placebo			
12313456	C4591001 1231 12313456	16-55	23AUG2020	62839	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12313459	C4591001 1231 12313459	16-55	23AUG2020	62850	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)			
12313460	C4591001 1231 12313460	16-55	23AUG2020	62845	Placebo	23AUG2020/ Placebo	15SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12313462	C4591001 1231 12313462	16-55	23AUG2020	62846	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12313463	C4591001 1231 12313463	16-55	23AUG2020	62852	Placebo	23AUG2020/ Placebo	14SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
12313465	C4591001 1231 12313465	16-55	23AUG2020	62875	Placebo	23AUG2020/ Placebo	14SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12313466	C4591001 1231 12313466	16-55	23AUG2020	62857	Placebo	23AUG2020/ Placebo	14SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12313467	C4591001 1231 12313467	16-55	23AUG2020	62868	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)			
12313469	C4591001 1231 12313469	16-55	23AUG2020	62859	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)			
12313470	C4591001 1231 12313470	16-55	23AUG2020	62878	Placebo	23AUG2020/ Placebo	22SEP2020/ Placebo		
12313471	C4591001 1231 12313471	16-55	23AUG2020	62888	Placebo	23AUG2020/ Placebo	13SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12313473	C4591001 1231 12313473	16-55	23AUG2020	62866	Placebo	23AUG2020/ Placebo	11SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12313474	C4591001 1231 12313474	16-55	23AUG2020	62865	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313475	C4591001 1231 12313475	16-55	23AUG2020	62872	Placebo	23AUG2020/ Placebo	11SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12313476	C4591001 1231 12313476	16-55	23AUG2020	62906	Placebo	23AUG2020/ Placebo	14SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12313479	C4591001 1231 12313479	16-55	23AUG2020	62899	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)			
12313481	C4591001 1231 12313481	16-55	23AUG2020	62873	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12313483	C4591001 1231 12313483	16-55	23AUG2020	62902	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12313484	C4591001 1231 12313484	16-55	23AUG2020	62879	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12313486	C4591001 1231 12313486	16-55	23AUG2020	62890	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)			
12313487	C4591001 1231 12313487	16-55	23AUG2020	62909	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12313488	C4591001 1231 12313488	16-55	23AUG2020	62896	Placebo	23AUG2020/ Placebo	14SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12313489	C4591001 1231 12313489	16-55	23AUG2020	62889	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313490	C4591001 1231 12313490	16-55	23AUG2020	62914	Placebo	23AUG2020/ Placebo	11SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12313491	C4591001 1231 12313491	16-55	23AUG2020	62915	Placebo	23AUG2020/ Placebo	11SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12313492	C4591001 1231 12313492	16-55	23AUG2020	62918	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)			
12313493	C4591001 1231 12313493	16-55	23AUG2020	62956	Placebo	23AUG2020/ Placebo	13SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
12313494	C4591001 1231 12313494	16-55	23AUG2020	62928	Placebo	23AUG2020/ Placebo	14SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12313497	C4591001 1231 12313497	16-55	23AUG2020	62923	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)			
12313498	C4591001 1231 12313498	16-55	23AUG2020	62945	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)			
12313499	C4591001 1231 12313499	16-55	23AUG2020	62924	Placebo	23AUG2020/ Placebo	13SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12313500	C4591001 1231 12313500	16-55	23AUG2020	62950	Placebo	23AUG2020/ Placebo	13SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12313501	C4591001 1231 12313501	16-55	23AUG2020	62932	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12313504	C4591001 1231 12313504	16-55	23AUG2020	62966	Placebo	23AUG2020/ Placebo	13SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12313505	C4591001 1231 12313505	16-55	23AUG2020	62949	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12313506	C4591001 1231 12313506	16-55	23AUG2020	62967	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)			
12313507	C4591001 1231 12313507	16-55	23AUG2020	62959	Placebo	23AUG2020/ Placebo	13SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12313508	C4591001 1231 12313508	16-55	23AUG2020	62974	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12313509	C4591001 1231 12313509	16-55	23AUG2020	62964	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)			
12313510	C4591001 1231 12313510	16-55	23AUG2020	62976	Placebo	23AUG2020/ Placebo		24FEB2021/ BNT162b2 (30 µg)	
12313512	C4591001 1231 12313512	16-55	23AUG2020	63019	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)			

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12313513	C4591001 1231 12313513	16-55	23AUG2020	62977	Placebo	23AUG2020/ Placebo	13SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12313514	C4591001 1231 12313514	16-55	23AUG2020	62997	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)			
12313515	C4591001 1231 12313515	16-55	23AUG2020	63015	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12313516	C4591001 1231 12313516	16-55	23AUG2020	62998	Placebo	23AUG2020/ Placebo	16OCT2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12313517	C4591001 1231 12313517	16-55	23AUG2020	63003	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)			
12313518	C4591001 1231 12313518	16-55	23AUG2020	63006	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)			
12313519	C4591001 1231 12313519	16-55	23AUG2020	62978	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)			
12313520	C4591001 1231 12313520	16-55	23AUG2020	63009	Placebo	23AUG2020/ Placebo	15SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
12313521	C4591001 1231 12313521	16-55	23AUG2020	62994	Placebo	23AUG2020/ Placebo	15SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12313525	C4591001 1231 12313525	16-55	23AUG2020	63017	Placebo	23AUG2020/ Placebo	11SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12313526	C4591001 1231 12313526	16-55	23AUG2020	63028	Placebo	23AUG2020/ Placebo	14SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12313527	C4591001 1231 12313527	16-55	23AUG2020	63011	Placebo				
12313528	C4591001 1231 12313528	16-55	23AUG2020	63033	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)			
12313529	C4591001 1231 12313529	16-55	23AUG2020	63032	Placebo	23AUG2020/ Placebo	15SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12313533	C4591001 1231 12313533	16-55	23AUG2020	63021	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12313534	C4591001 1231 12313534	16-55	23AUG2020	63046	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)			
12313535	C4591001 1231 12313535	16-55	23AUG2020	63036	Placebo	23AUG2020/ Placebo	11SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12313537	C4591001 1231 12313537	16-55	23AUG2020	63037	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)			
12313539	C4591001 1231 12313539	16-55	23AUG2020	63047	Placebo	23AUG2020/ Placebo	15SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12313540	C4591001 1231 12313540	16-55	23AUG2020	63060	Placebo	23AUG2020/ Placebo	11SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12313541	C4591001 1231 12313541	16-55	23AUG2020	63041	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)			
12313542	C4591001 1231 12313542	16-55	23AUG2020	63063	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12313543	C4591001 1231 12313543	16-55	23AUG2020	63064	Placebo	23AUG2020/ Placebo	11SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12313544	C4591001 1231 12313544	16-55	23AUG2020	63073	Placebo	23AUG2020/ Placebo	13SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12313546	C4591001 1231 12313546	16-55	23AUG2020	63074	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)			
12313547	C4591001 1231 12313547	16-55	23AUG2020	63048	Placebo	23AUG2020/ Placebo	13SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12313548	C4591001 1231 12313548	16-55	23AUG2020	63077	Placebo	23AUG2020/ Placebo	13SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
12313551	C4591001 1231 12313551	16-55	23AUG2020	63057	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)			
12313553	C4591001 1231 12313553	16-55	23AUG2020	63076	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12313554	C4591001 1231 12313554	16-55	23AUG2020	63080	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)			

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12313555	C4591001 1231 12313555	16-55	23AUG2020	63069	Placebo	23AUG2020/ Placebo	13SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
12313556	C4591001 1231 12313556	16-55	23AUG2020	63086	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12313557	C4591001 1231 12313557	16-55	23AUG2020	63121	Placebo	23AUG2020/ Placebo	13SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12313558	C4591001 1231 12313558	16-55	23AUG2020	63093	Placebo	23AUG2020/ Placebo	13SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12313560	C4591001 1231 12313560	16-55	23AUG2020	63107	Placebo	23AUG2020/ Placebo	11SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12313561	C4591001 1231 12313561	16-55	23AUG2020	63088	Placebo	23AUG2020/ Placebo	15SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12313563	C4591001 1231 12313563	16-55	23AUG2020	63105	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12313564	C4591001 1231 12313564	16-55	23AUG2020	63103	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12313565	C4591001 1231 12313565	16-55	23AUG2020	63094	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12313566	C4591001 1231 12313566	16-55	23AUG2020	63108	Placebo	23AUG2020/ Placebo	11SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12313567	C4591001 1231 12313567	16-55	23AUG2020	63095	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12313569	C4591001 1231 12313569	16-55	23AUG2020	63092	Placebo	23AUG2020/ Placebo	15SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12313570	C4591001 1231 12313570	16-55	23AUG2020	63122	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313571	C4591001 1231 12313571	16-55	23AUG2020	63116	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12313572	C4591001 1231 12313572	16-55	23AUG2020	63126	Placebo	23AUG2020/ Placebo	13SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12313575	C4591001 1231 12313575	16-55	23AUG2020	63146	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313576	C4591001 1231 12313576	16-55	23AUG2020	63128	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12313578	C4591001 1231 12313578	16-55	23AUG2020	63143	Placebo	23AUG2020/ Placebo	14SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12313579	C4591001 1231 12313579	16-55	23AUG2020	63123	Placebo	23AUG2020/ Placebo	11SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12313580	C4591001 1231 12313580	16-55	23AUG2020	63145	Placebo	23AUG2020/ Placebo	13SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12313581	C4591001 1231 12313581	16-55	23AUG2020	63125	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12313583	C4591001 1231 12313583	16-55	23AUG2020	63159	Placebo	23AUG2020/ Placebo	11SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12313587	C4591001 1231 12313587	16-55	23AUG2020	63155	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313589	C4591001 1231 12313589	16-55	23AUG2020	63130	Placebo	23AUG2020/ Placebo	13SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12313590	C4591001 1231 12313590	16-55	23AUG2020	63157	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313591	C4591001 1231 12313591	16-55	23AUG2020	63148	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12313592	C4591001 1231 12313592	16-55	23AUG2020	63162	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)			
12313595	C4591001 1231 12313595	16-55	23AUG2020	63154	Placebo	23AUG2020/ Placebo	13SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
12313596	C4591001 1231 12313596	16-55	23AUG2020	63165	Placebo	23AUG2020/ Placebo	13SEP2020/ Placebo		
12313598	C4591001 1231 12313598	16-55	23AUG2020	63169	Placebo	23AUG2020/ Placebo	13SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12313601	C4591001 1231 12313601	16-55	23AUG2020	63163	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313605	C4591001 1231 12313605	16-55	23AUG2020	63173	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313606	C4591001 1231 12313606	16-55	23AUG2020	63178	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12313607	C4591001 1231 12313607	16-55	23AUG2020	63174	Placebo	23AUG2020/ Placebo	13SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12313609	C4591001 1231 12313609	16-55	23AUG2020	63176	Placebo	23AUG2020/ Placebo	13SEP2020/ Placebo		
12313612	C4591001 1231 12313612	16-55	23AUG2020	63185	Placebo	23AUG2020/ Placebo	15SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12313613	C4591001 1231 12313613	16-55	23AUG2020	63192	Placebo	23AUG2020/ Placebo	13SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12313614	C4591001 1231 12313614	16-55	23AUG2020	63187	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12313616	C4591001 1231 12313616	16-55	24AUG2020	64146	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12313617	C4591001 1231 12313617	16-55	24AUG2020	63196	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12313618	C4591001 1231 12313618	16-55	24AUG2020	64154	Placebo	24AUG2020/ Placebo	15SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	13FEB2021/ BNT162b2 (30 µg)
12313619	C4591001 1231 12313619	16-55	24AUG2020	64145	Placebo	24AUG2020/ Placebo	15SEP2020/ Placebo		
12313620	C4591001 1231 12313620	16-55	24AUG2020	64217	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313622	C4591001 1231 12313622	16-55	24AUG2020	64270	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)			
12313623	C4591001 1231 12313623	16-55	24AUG2020	64223	Placebo	24AUG2020/ Placebo	13SEP2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12313624	C4591001 1231 12313624	16-55	24AUG2020	64219	Placebo	24AUG2020/ Placebo	13SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
12313629	C4591001 1231 12313629	16-55	24AUG2020	64149	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12313630	C4591001 1231 12313630	16-55	24AUG2020	64276	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313631	C4591001 1231 12313631	16-55	24AUG2020	64273	Placebo	24AUG2020/ Placebo	13SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12313632	C4591001 1231 12313632	16-55	24AUG2020	64282	Placebo	24AUG2020/ Placebo	13SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12313633	C4591001 1231 12313633	16-55	24AUG2020	64266	Placebo	24AUG2020/ Placebo	13SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12313634	C4591001 1231 12313634	16-55	24AUG2020	64227	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313635	C4591001 1231 12313635	16-55	24AUG2020	64281	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12313636	C4591001 1231 12313636	16-55	24AUG2020	64290	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12313637	C4591001 1231 12313637	16-55	24AUG2020	64291	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313638	C4591001 1231 12313638	16-55	24AUG2020	64285	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12313639	C4591001 1231 12313639	16-55	24AUG2020	64284	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12313640	C4591001 1231 12313640	16-55	24AUG2020	64297	Placebo	24AUG2020/ Placebo	13SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
12313641	C4591001 1231 12313641	16-55	24AUG2020	219989	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313643	C4591001 1231 12313643	16-55	24AUG2020	64299	Placebo	24AUG2020/ Placebo	13SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12313644	C4591001 1231 12313644	16-55	24AUG2020	64317	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313646	C4591001 1231 12313646	16-55	24AUG2020	64318	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12313647	C4591001 1231 12313647	16-55	24AUG2020	64320	Placebo	24AUG2020/ Placebo	15SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12313653	C4591001 1231 12313653	16-55	24AUG2020	64322	Placebo	24AUG2020/ Placebo	13SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12313656	C4591001 1231 12313656	16-55	24AUG2020	64413	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12313657	C4591001 1231 12313657	16-55	24AUG2020	64375	Placebo	24AUG2020/ Placebo		25FEB2021/ BNT162b2 (30 µg)	
12313658	C4591001 1231 12313658	16-55	24AUG2020	64416	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313659	C4591001 1231 12313659	16-55	24AUG2020	64379	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313660	C4591001 1231 12313660	16-55	24AUG2020	64421	Placebo	24AUG2020/ Placebo	13SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12313661	C4591001 1231 12313661	16-55	24AUG2020	64377	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12313662	C4591001 1231 12313662	16-55	24AUG2020	64431	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)			
12313663	C4591001 1231 12313663	16-55	24AUG2020	64380	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313664	C4591001 1231 12313664	16-55	24AUG2020	64432	Placebo	24AUG2020/ Placebo	13SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12313665	C4591001 1231 12313665	16-55	24AUG2020	64415	Placebo	24AUG2020/ Placebo	13SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
12313666	C4591001 1231 12313666	16-55	24AUG2020	64448	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12313667	C4591001 1231 12313667	16-55	24AUG2020	64419	Placebo	24AUG2020/ Placebo	13SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12313668	C4591001 1231 12313668	16-55	24AUG2020	64454	Placebo	24AUG2020/ Placebo	13SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12313669	C4591001 1231 12313669	16-55	24AUG2020	64488	Placebo	24AUG2020/ Placebo	15SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12313670	C4591001 1231 12313670	16-55	24AUG2020	64491	Placebo	24AUG2020/ Placebo	13SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12313671	C4591001 1231 12313671	16-55	24AUG2020	64449	Placebo	24AUG2020/ Placebo	13SEP2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12313672	C4591001 1231 12313672	16-55	24AUG2020	64492	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12313673	C4591001 1231 12313673	16-55	24AUG2020	64428	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12313675	C4591001 1231 12313675	16-55	24AUG2020	64446	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313677	C4591001 1231 12313677	16-55	24AUG2020	64531	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313679	C4591001 1231 12313679	16-55	24AUG2020	64487	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12313680	C4591001 1231 12313680	16-55	24AUG2020	64538	Placebo	24AUG2020/ Placebo	16SEP2020/ Placebo		
12313681	C4591001 1231 12313681	16-55	24AUG2020	64535	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12313682	C4591001 1231 12313682	16-55	24AUG2020	64565	Placebo	24AUG2020/ Placebo	15SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
12313683	C4591001 1231 12313683	16-55	24AUG2020	64589	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313684	C4591001 1231 12313684	16-55	24AUG2020	64616	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12313685	C4591001 1231 12313685	16-55	24AUG2020	64536	Placebo	24AUG2020/ Placebo	13SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12313689	C4591001 1231 12313689	16-55	24AUG2020	64660	Placebo	24AUG2020/ Placebo	13SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12313693	C4591001 1231 12313693	16-55	24AUG2020	64651	Placebo	24AUG2020/ Placebo	13SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
12313694	C4591001 1231 12313694	16-55	24AUG2020	64624	Placebo	24AUG2020/ Placebo	13SEP2020/ Placebo		
12313695	C4591001 1231 12313695	16-55	24AUG2020	64615	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313696	C4591001 1231 12313696	16-55	24AUG2020	64598	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313697	C4591001 1231 12313697	16-55	24AUG2020	64592	Placebo	24AUG2020/ Placebo	15SEP2020/ Placebo		
12313698	C4591001 1231 12313698	16-55	24AUG2020	64679	Placebo	24AUG2020/ Placebo	13SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12313699	C4591001 1231 12313699	16-55	24AUG2020	64597	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo		
12313700	C4591001 1231 12313700	16-55	24AUG2020	64649	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12313701	C4591001 1231 12313701	16-55	24AUG2020	64673	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12313702	C4591001 1231 12313702	16-55	24AUG2020	64655	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12313703	C4591001 1231 12313703	16-55	24AUG2020	64622	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313704	C4591001 1231 12313704	16-55	24AUG2020	64675	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313705	C4591001 1231 12313705	16-55	24AUG2020	64684	Placebo	24AUG2020/ Placebo	13SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12313706	C4591001 1231 12313706	16-55	24AUG2020	64792	Placebo	24AUG2020/ Placebo	17SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12313707	C4591001 1231 12313707	16-55	24AUG2020	64686	Placebo	24AUG2020/ Placebo	13SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12313709	C4591001 1231 12313709	16-55	24AUG2020	64693	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)			
12313710	C4591001 1231 12313710	16-55	24AUG2020	64685	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12313711	C4591001 1231 12313711	16-55	24AUG2020	64687	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12313713	C4591001 1231 12313713	16-55	24AUG2020	64759	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313714	C4591001 1231 12313714	16-55	24AUG2020	64712	Placebo	24AUG2020/ Placebo	15SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
12313715	C4591001 1231 12313715	16-55	24AUG2020	64714	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313716	C4591001 1231 12313716	16-55	24AUG2020	64716	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12313717	C4591001 1231 12313717	16-55	24AUG2020	64709	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313718	C4591001 1231 12313718	16-55	24AUG2020	64762	Placebo	24AUG2020/ Placebo	13SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12313720	C4591001 1231 12313720	16-55	24AUG2020	64767	Placebo	24AUG2020/ Placebo	13SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12313721	C4591001 1231 12313721	16-55	24AUG2020	64781	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12313722	C4591001 1231 12313722	16-55	24AUG2020	64788	Placebo	24AUG2020/ Placebo	13SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12313724	C4591001 1231 12313724	16-55	24AUG2020	64829	Placebo	24AUG2020/ Placebo	13SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12313725	C4591001 1231 12313725	16-55	24AUG2020	64766	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313726	C4591001 1231 12313726	16-55	24AUG2020	64838	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12313727	C4591001 1231 12313727	16-55	24AUG2020	64787	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12313729	C4591001 1231 12313729	16-55	24AUG2020	64837	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313732	C4591001 1231 12313732	16-55	24AUG2020	64840	Placebo	24AUG2020/ Placebo	16SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12313733	C4591001 1231 12313733	16-55	24AUG2020	64888	Placebo	24AUG2020/ Placebo	13SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12313734	C4591001 1231 12313734	16-55	24AUG2020	64883	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12313738	C4591001 1231 12313738	16-55	24AUG2020	64885	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12313739	C4591001 1231 12313739	16-55	24AUG2020	64912	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12313742	C4591001 1231 12313742	16-55	24AUG2020	64902	Placebo	24AUG2020/ Placebo	13SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12313743	C4591001 1231 12313743	16-55	24AUG2020	64886	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12313746	C4591001 1231 12313746	16-55	24AUG2020	64906	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12313749	C4591001 1231 12313749	16-55	24AUG2020	64907	Placebo	24AUG2020/ Placebo	13SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
12313750	C4591001 1231 12313750	16-55	24AUG2020	64930	Placebo	24AUG2020/ Placebo	15SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12313752	C4591001 1231 12313752	16-55	24AUG2020	64931	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313756	C4591001 1231 12313756	16-55	24AUG2020	64991	Placebo	24AUG2020/ Placebo	13SEP2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12313758	C4591001 1231 12313758	16-55	24AUG2020	64935	Placebo	24AUG2020/ Placebo		22FEB2021/ BNT162b2 (30 µg)	
12313759	C4591001 1231 12313759	16-55	24AUG2020	64932	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12313762	C4591001 1231 12313762	16-55	24AUG2020	64949	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12313764	C4591001 1231 12313764	16-55	24AUG2020	64956	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12313765	C4591001 1231 12313765	16-55	24AUG2020	65008	Placebo	24AUG2020/ Placebo	13SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12313766	C4591001 1231 12313766	16-55	24AUG2020	64959	Placebo	24AUG2020/ Placebo	13SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12313769	C4591001 1231 12313769	16-55	24AUG2020	64985	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
12313772	C4591001 1231 12313772	16-55	24AUG2020	64958	Placebo	24AUG2020/ Placebo	13SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12313773	C4591001 1231 12313773	16-55	24AUG2020	64995	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12313777	C4591001 1231 12313777	16-55	24AUG2020	64996	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12313778	C4591001 1231 12313778	16-55	24AUG2020	64997	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313780	C4591001 1231 12313780	16-55	24AUG2020	65007	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313781	C4591001 1231 12313781	16-55	24AUG2020	65005	Placebo	24AUG2020/ Placebo	15SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12313785	C4591001 1231 12313785	16-55	25AUG2020	65089	Placebo	25AUG2020/ Placebo	14SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12313786	C4591001 1231 12313786	16-55	25AUG2020	65063	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12313788	C4591001 1231 12313788	16-55	25AUG2020	65068	Placebo	25AUG2020/ Placebo	13SEP2020/ Placebo		
12313789	C4591001 1231 12313789	16-55	25AUG2020	65081	Placebo	25AUG2020/ Placebo	13SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12313790	C4591001 1231 12313790	16-55	25AUG2020	65067	Placebo	25AUG2020/ Placebo	13SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	13FEB2021/ BNT162b2 (30 µg)
12313793	C4591001 1231 12313793	16-55	25AUG2020	65086	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313794	C4591001 1231 12313794	16-55	25AUG2020	65130	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12313795	C4591001 1231 12313795	16-55	25AUG2020	65100	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12313797	C4591001 1231 12313797	16-55	25AUG2020	65096	Placebo	25AUG2020/ Placebo	13SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12313798	C4591001 1231 12313798	16-55	25AUG2020	65162	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12313800	C4591001 1231 12313800	16-55	25AUG2020	65105	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12313801	C4591001 1231 12313801	16-55	25AUG2020	65101	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12313802	C4591001 1231 12313802	16-55	25AUG2020	65065	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313804	C4591001 1231 12313804	16-55	25AUG2020	65114	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313805	C4591001 1231 12313805	16-55	25AUG2020	65083	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313806	C4591001 1231 12313806	16-55	25AUG2020	65135	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12313808	C4591001 1231 12313808	16-55	25AUG2020	65103	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313809	C4591001 1231 12313809	16-55	25AUG2020	65131	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313810	C4591001 1231 12313810	16-55	25AUG2020	65155	Placebo	25AUG2020/ Placebo	13SEP2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12313811	C4591001 1231 12313811	16-55	25AUG2020	65132	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12313814	C4591001 1231 12313814	16-55	25AUG2020	65106	Placebo	25AUG2020/ Placebo	13SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12313815	C4591001 1231 12313815	16-55	25AUG2020	65110	Placebo	25AUG2020/ Placebo	13SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12313816	C4591001 1231 12313816	16-55	25AUG2020	65178	Placebo	25AUG2020/ Placebo	13SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12313818	C4591001 1231 12313818	16-55	25AUG2020	65185	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313819	C4591001 1231 12313819	16-55	25AUG2020	65160	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12313821	C4591001 1231 12313821	16-55	25AUG2020	65177	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12313822	C4591001 1231 12313822	16-55	25AUG2020	65159	Placebo	25AUG2020/ Placebo	13SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12313823	C4591001 1231 12313823	16-55	25AUG2020	65204	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12313824	C4591001 1231 12313824	16-55	25AUG2020	65187	Placebo	25AUG2020/ Placebo	14SEP2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12313825	C4591001 1231 12313825	16-55	25AUG2020	65205	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12313827	C4591001 1231 12313827	16-55	25AUG2020	65208	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12313830	C4591001 1231 12313830	16-55	25AUG2020	65243	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12313831	C4591001 1231 12313831	16-55	25AUG2020	65240	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12313832	C4591001 1231 12313832	16-55	25AUG2020	65211	Placebo	25AUG2020/ Placebo	13SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12313836	C4591001 1231 12313836	16-55	25AUG2020	65245	Placebo	25AUG2020/ Placebo	16SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12313837	C4591001 1231 12313837	16-55	25AUG2020	65246	Placebo	25AUG2020/ Placebo	16SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12313840	C4591001 1231 12313840	16-55	25AUG2020	65253	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12313841	C4591001 1231 12313841	16-55	25AUG2020	65249	Placebo	25AUG2020/ Placebo	13SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
12313842	C4591001 1231 12313842	16-55	25AUG2020	65277	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12313843	C4591001 1231 12313843	16-55	25AUG2020	65251	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313847	C4591001 1231 12313847	16-55	25AUG2020	65281	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12313848	C4591001 1231 12313848	16-55	25AUG2020	65282	Placebo	25AUG2020/ Placebo	16SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12313851	C4591001 1231 12313851	16-55	25AUG2020	65255	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		
12313853	C4591001 1231 12313853	16-55	25AUG2020	65283	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12313854	C4591001 1231 12313854	16-55	25AUG2020	65300	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12313856	C4591001 1231 12313856	16-55	25AUG2020	65305	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12313859	C4591001 1231 12313859	16-55	25AUG2020	65298	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313861	C4591001 1231 12313861	16-55	25AUG2020	65327	Placebo	25AUG2020/ Placebo	13SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12313862	C4591001 1231 12313862	16-55	25AUG2020	65308	Placebo	25AUG2020/ Placebo	14SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12313864	C4591001 1231 12313864	16-55	25AUG2020	65321	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
12313865	C4591001 1231 12313865	16-55	25AUG2020	65373	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12313866	C4591001 1231 12313866	16-55	25AUG2020	65332	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12313868	C4591001 1231 12313868	16-55	25AUG2020	65326	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12313869	C4591001 1231 12313869	16-55	25AUG2020	65371	BNT162b2 (30 µg)				
12313870	C4591001 1231 12313870	16-55	25AUG2020	65378	Placebo	25AUG2020/ Placebo	13SEP2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
12313871	C4591001 1231 12313871	16-55	25AUG2020	65431	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313872	C4591001 1231 12313872	16-55	25AUG2020	65380	Placebo	25AUG2020/ Placebo	13SEP2020/ Placebo		
12313873	C4591001 1231 12313873	16-55	25AUG2020	65429	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12313875	C4591001 1231 12313875	16-55	25AUG2020	65433	Placebo	25AUG2020/ Placebo	13SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12313876	C4591001 1231 12313876	16-55	25AUG2020	65436	Placebo	25AUG2020/ Placebo	14SEP2020/ Placebo		
12313877	C4591001 1231 12313877	16-55	25AUG2020	65557	Placebo	25AUG2020/ Placebo	16SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12313878	C4591001 1231 12313878	16-55	25AUG2020	65553	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12313879	C4591001 1231 12313879	16-55	25AUG2020	65638	Placebo	25AUG2020/ Placebo	13SEP2020/ Placebo		
12313881	C4591001 1231 12313881	16-55	25AUG2020	65558	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo		
12313884	C4591001 1231 12313884	16-55	25AUG2020	65560	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12313886	C4591001 1231 12313886	16-55	25AUG2020	65820	Placebo	25AUG2020/ Placebo	13SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12313888	C4591001 1231 12313888	16-55	25AUG2020	65634	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313889	C4591001 1231 12313889	16-55	25AUG2020	65641	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313892	C4591001 1231 12313892	16-55	25AUG2020	65671	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
12313893	C4591001 1231 12313893	16-55	25AUG2020	65639	Placebo	25AUG2020/ Placebo	13SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12313895	C4591001 1231 12313895	16-55	25AUG2020	65739	Placebo	25AUG2020/ Placebo	13SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12313896	C4591001 1231 12313896	16-55	25AUG2020	65687	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313900	C4591001 1231 12313900	16-55	25AUG2020	65734	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313901	C4591001 1231 12313901	16-55	25AUG2020	65670	Placebo	25AUG2020/ Placebo	13SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12313902	C4591001 1231 12313902	16-55	25AUG2020	65679	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313903	C4591001 1231 12313903	16-55	25AUG2020	65691	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12313904	C4591001 1231 12313904	16-55	25AUG2020	65686	Placebo	25AUG2020/ Placebo	13SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12313905	C4591001 1231 12313905	16-55	25AUG2020	65676	Placebo	25AUG2020/ Placebo	13SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12313906	C4591001 1231 12313906	16-55	25AUG2020	65684	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo		
12313907	C4591001 1231 12313907	16-55	25AUG2020	65736	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12313908	C4591001 1231 12313908	16-55	25AUG2020	65737	Placebo	25AUG2020/ Placebo	13SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12313909	C4591001 1231 12313909	16-55	25AUG2020	65760	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313910	C4591001 1231 12313910	16-55	25AUG2020	65763	Placebo	25AUG2020/ Placebo	14SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12313911	C4591001 1231 12313911	16-55	25AUG2020	65759	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12313913	C4591001 1231 12313913	16-55	25AUG2020	65762	Placebo	25AUG2020/ Placebo	13SEP2020/ Placebo		
12313915	C4591001 1231 12313915	16-55	25AUG2020	65819	Placebo	25AUG2020/ Placebo	13SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
12313916	C4591001 1231 12313916	16-55	25AUG2020	65823	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313917	C4591001 1231 12313917	16-55	25AUG2020	65821	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12313919	C4591001 1231 12313919	16-55	25AUG2020	65920	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313921	C4591001 1231 12313921	16-55	25AUG2020	65967	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12313922	C4591001 1231 12313922	16-55	25AUG2020	65862	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12313923	C4591001 1231 12313923	16-55	25AUG2020	65868	Placebo	25AUG2020/ Placebo	14SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
12313924	C4591001 1231 12313924	16-55	25AUG2020	65965	Placebo	25AUG2020/ Placebo	13SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12313925	C4591001 1231 12313925	16-55	25AUG2020	65912	Placebo	25AUG2020/ Placebo	13SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12313927	C4591001 1231 12313927	16-55	25AUG2020	65959	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313930	C4591001 1231 12313930	16-55	25AUG2020	65968	Placebo	25AUG2020/ Placebo	13SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
12313931	C4591001 1231 12313931	16-55	25AUG2020	65872	Placebo	25AUG2020/ Placebo	13SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	13FEB2021/ BNT162b2 (30 µg)
12313932	C4591001 1231 12313932	16-55	25AUG2020	65919	Placebo	25AUG2020/ Placebo	14SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12313934	C4591001 1231 12313934	16-55	25AUG2020	65870	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12313935	C4591001 1231 12313935	16-55	25AUG2020	65911	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12313937	C4591001 1231 12313937	16-55	25AUG2020	65997	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12313939	C4591001 1231 12313939	16-55	25AUG2020	65998	Placebo	25AUG2020/ Placebo	07OCT2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12313941	C4591001 1231 12313941	16-55	25AUG2020	66019	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12313943	C4591001 1231 12313943	16-55	25AUG2020	66003	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12313944	C4591001 1231 12313944	16-55	25AUG2020	66017	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12313945	C4591001 1231 12313945	16-55	25AUG2020	66021	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12313946	C4591001 1231 12313946	16-55	25AUG2020	66002	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12313948	C4591001 1231 12313948	16-55	25AUG2020	66089	Placebo	25AUG2020/ Placebo	13SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12313949	C4591001 1231 12313949	16-55	25AUG2020	66026	Placebo	25AUG2020/ Placebo	14SEP2020/ Placebo		
12313953	C4591001 1231 12313953	16-55	25AUG2020	66090	Placebo	25AUG2020/ Placebo	13SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12313955	C4591001 1231 12313955	16-55	25AUG2020	66093	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12313956	C4591001 1231 12313956	16-55	25AUG2020	66311	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo		
12313957	C4591001 1231 12313957	16-55	25AUG2020	66094	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12313960	C4591001 1231 12313960	16-55	25AUG2020	66316	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12313963	C4591001 1231 12313963	16-55	25AUG2020	66314	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313964	C4591001 1231 12313964	16-55	25AUG2020	66382	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12313965	C4591001 1231 12313965	16-55	25AUG2020	66308	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313966	C4591001 1231 12313966	16-55	25AUG2020	66346	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12313967	C4591001 1231 12313967	16-55	25AUG2020	66459	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
12313968	C4591001 1231 12313968	16-55	25AUG2020	66378	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313969	C4591001 1231 12313969	16-55	25AUG2020	66345	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12313970	C4591001 1231 12313970	16-55	25AUG2020	66380	Placebo	25AUG2020/ Placebo	13SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12313971	C4591001 1231 12313971	16-55	25AUG2020	66417	Placebo	25AUG2020/ Placebo	16SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
12313973	C4591001 1231 12313973	16-55	25AUG2020	66348	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12313974	C4591001 1231 12313974	16-55	25AUG2020	66418	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12313975	C4591001 1231 12313975	16-55	25AUG2020	66420	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12313977	C4591001 1231 12313977	16-55	25AUG2020	66414	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12313978	C4591001 1231 12313978	16-55	25AUG2020	66458	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12313979	C4591001 1231 12313979	16-55	25AUG2020	66352	Placebo	25AUG2020/ Placebo	13SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12313981	C4591001 1231 12313981	16-55	25AUG2020	66381	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo		
12313984	C4591001 1231 12313984	16-55	25AUG2020	66460	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12313986	C4591001 1231 12313986	16-55	25AUG2020	66512	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12313987	C4591001 1231 12313987	16-55	25AUG2020	66450	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12313988	C4591001 1231 12313988	16-55	25AUG2020	66514	Placebo	25AUG2020/ Placebo	16SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12313989	C4591001 1231 12313989	16-55	25AUG2020	66510	Placebo	25AUG2020/ Placebo	16SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12313991	C4591001 1231 12313991	16-55	25AUG2020	66516	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12313993	C4591001 1231 12313993	16-55	25AUG2020	66583	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12313994	C4591001 1231 12313994	16-55	25AUG2020	66586	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313995	C4591001 1231 12313995	16-55	25AUG2020	66617	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12313996	C4591001 1231 12313996	16-55	25AUG2020	66622	Placebo	25AUG2020/ Placebo	14SEP2020/ Placebo		
12313998	C4591001 1231 12313998	16-55	25AUG2020	66592	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12313999	C4591001 1231 12313999	16-55	25AUG2020	66588	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12314000	C4591001 1231 12314000	16-55	25AUG2020	66623	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12314002	C4591001 1231 12314002	16-55	25AUG2020	66626	Placebo	25AUG2020/ Placebo	13SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12314004	C4591001 1231 12314004	16-55	25AUG2020	66653	Placebo	25AUG2020/ Placebo	22SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12314005	C4591001 1231 12314005	16-55	25AUG2020	66679	Placebo	25AUG2020/ Placebo	13SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12314006	C4591001 1231 12314006	16-55	25AUG2020	66654	Placebo	25AUG2020/ Placebo	14SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12314007	C4591001 1231 12314007	16-55	25AUG2020	66680	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12314008	C4591001 1231 12314008	16-55	25AUG2020	66664	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12314009	C4591001 1231 12314009	16-55	25AUG2020	66659	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12314010	C4591001 1231 12314010	16-55	25AUG2020	66927	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12314011	C4591001 1231 12314011	16-55	25AUG2020	66774	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12314013	C4591001 1231 12314013	16-55	25AUG2020	66777	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12314016	C4591001 1231 12314016	16-55	25AUG2020	66750	Placebo	25AUG2020/ Placebo	13SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12314017	C4591001 1231 12314017	16-55	25AUG2020	66682	Placebo	25AUG2020/ Placebo	14SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
12314018	C4591001 1231 12314018	16-55	25AUG2020	66684	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12314020	C4591001 1231 12314020	16-55	25AUG2020	66752	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12314021	C4591001 1231 12314021	16-55	25AUG2020	66760	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12314022	C4591001 1231 12314022	16-55	25AUG2020	66759	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12314023	C4591001 1231 12314023	16-55	25AUG2020	66779	Placebo	25AUG2020/ Placebo	13SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12314028	C4591001 1231 12314028	16-55	25AUG2020	66783	Placebo	25AUG2020/ Placebo	13SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12314030	C4591001 1231 12314030	16-55	25AUG2020	66821	Placebo	25AUG2020/ Placebo	17SEP2020/ Placebo		
12314032	C4591001 1231 12314032	16-55	25AUG2020	66827	Placebo	25AUG2020/ Placebo	14SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12314033	C4591001 1231 12314033	16-55	25AUG2020	66826	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12314034	C4591001 1231 12314034	16-55	25AUG2020	66830	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12314037	C4591001 1231 12314037	16-55	25AUG2020	66918	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
12314042	C4591001 1231 12314042	16-55	25AUG2020	66921	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314043	C4591001 1231 12314043	16-55	25AUG2020	66926	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12314046	C4591001 1231 12314046	16-55	25AUG2020	66930	Placebo	25AUG2020/ Placebo	14SEP2020/ Placebo		
12314047	C4591001 1231 12314047	16-55	25AUG2020	66933	Placebo	25AUG2020/ Placebo	13SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12314049	C4591001 1231 12314049	16-55	25AUG2020	66938	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12314050	C4591001 1231 12314050	16-55	25AUG2020	66942	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12314053	C4591001 1231 12314053	16-55	25AUG2020	66937	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12314058	C4591001 1231 12314058	16-55	25AUG2020	66948	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12314059	C4591001 1231 12314059	16-55	25AUG2020	67010	Placebo	25AUG2020/ Placebo	13SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12314061	C4591001 1231 12314061	16-55	25AUG2020	66950	Placebo	25AUG2020/ Placebo	13SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12314062	C4591001 1231 12314062	16-55	25AUG2020	66977	Placebo	25AUG2020/ Placebo	13SEP2020/ Placebo		
12314066	C4591001 1231 12314066	16-55	25AUG2020	66979	Placebo	25AUG2020/ Placebo	13SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12314067	C4591001 1231 12314067	16-55	25AUG2020	66988	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12314068	C4591001 1231 12314068	16-55	25AUG2020	66984	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12314070	C4591001 1231 12314070	16-55	25AUG2020	67002	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12314071	C4591001 1231 12314071	16-55	25AUG2020	66943	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12314073	C4591001 1231 12314073	16-55	25AUG2020	67004	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12314074	C4591001 1231 12314074	16-55	26AUG2020	67113	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12314075	C4591001 1231 12314075	16-55	26AUG2020	67115	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12314076	C4591001 1231 12314076	16-55	26AUG2020	67012	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12314077	C4591001 1231 12314077	16-55	26AUG2020	67114	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12314078	C4591001 1231 12314078	16-55	26AUG2020	67116	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314080	C4591001 1231 12314080	16-55	26AUG2020	67139	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
12314084	C4591001 1231 12314084	16-55	26AUG2020	67158	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12314085	C4591001 1231 12314085	16-55	26AUG2020	67136	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12314086	C4591001 1231 12314086	16-55	26AUG2020	67171	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12314087	C4591001 1231 12314087	16-55	26AUG2020	67163	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12314088	C4591001 1231 12314088	16-55	26AUG2020	67137	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12314095	C4591001 1231 12314095	16-55	26AUG2020	67149	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12314096	C4591001 1231 12314096	16-55	26AUG2020	67167	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12314097	C4591001 1231 12314097	16-55	26AUG2020	67154	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12314098	C4591001 1231 12314098	16-55	26AUG2020	67143	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12314099	C4591001 1231 12314099	16-55	26AUG2020	67173	Placebo	26AUG2020/ Placebo	17SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12314100	C4591001 1231 12314100	16-55	26AUG2020	67155	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12314102	C4591001 1231 12314102	16-55	26AUG2020	67166	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12314104	C4591001 1231 12314104	16-55	26AUG2020	67178	Placebo	26AUG2020/ Placebo	15SEP2020/ Placebo		
12314106	C4591001 1231 12314106	16-55	26AUG2020	67146	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12314107	C4591001 1231 12314107	16-55	26AUG2020	67182	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12314108	C4591001 1231 12314108	16-55	26AUG2020	67179	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12314109	C4591001 1231 12314109	16-55	26AUG2020	67185	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12314111	C4591001 1231 12314111	16-55	26AUG2020	67192	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314112	C4591001 1231 12314112	16-55	26AUG2020	67219	Placebo	26AUG2020/ Placebo	17SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12314114	C4591001 1231 12314114	16-55	26AUG2020	67189	Placebo	26AUG2020/ Placebo	24SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12314115	C4591001 1231 12314115	16-55	26AUG2020	67283	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12314116	C4591001 1231 12314116	16-55	26AUG2020	67224	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12314117	C4591001 1231 12314117	16-55	26AUG2020	67278	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12314119	C4591001 1231 12314119	16-55	26AUG2020	67225	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12314121	C4591001 1231 12314121	16-55	26AUG2020	67289	Placebo	26AUG2020/ Placebo	15SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12314122	C4591001 1231 12314122	16-55	26AUG2020	67227	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12314123	C4591001 1231 12314123	16-55	26AUG2020	67291	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
12314124	C4591001 1231 12314124	16-55	26AUG2020	67287	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12314126	C4591001 1231 12314126	16-55	26AUG2020	67281	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12314128	C4591001 1231 12314128	16-55	26AUG2020	67327	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314129	C4591001 1231 12314129	16-55	26AUG2020	67330	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314130	C4591001 1231 12314130	16-55	26AUG2020	67294	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12314132	C4591001 1231 12314132	16-55	26AUG2020	67295	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12314133	C4591001 1231 12314133	16-55	26AUG2020	67326	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12314134	C4591001 1231 12314134	16-55	26AUG2020	67400	Placebo	26AUG2020/ Placebo			
12314135	C4591001 1231 12314135	16-55	26AUG2020	67388	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12314137	C4591001 1231 12314137	16-55	26AUG2020	67333	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12314138	C4591001 1231 12314138	16-55	26AUG2020	67387	Placebo	26AUG2020/ Placebo	15SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12314140	C4591001 1231 12314140	16-55	26AUG2020	67397	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12314141	C4591001 1231 12314141	16-55	26AUG2020	67396	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12314142	C4591001 1231 12314142	16-55	26AUG2020	67392	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12314143	C4591001 1231 12314143	16-55	26AUG2020	67398	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12314144	C4591001 1231 12314144	16-55	26AUG2020	67441	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12314145	C4591001 1231 12314145	16-55	26AUG2020	67406	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12314150	C4591001 1231 12314150	16-55	26AUG2020	67459	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12314151	C4591001 1231 12314151	16-55	26AUG2020	67434	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12314152	C4591001 1231 12314152	16-55	26AUG2020	67437	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12314154	C4591001 1231 12314154	16-55	26AUG2020	67444	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	13FEB2021/ BNT162b2 (30 µg)
12314155	C4591001 1231 12314155	16-55	26AUG2020	67463	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
12314156	C4591001 1231 12314156	16-55	26AUG2020	67465	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12314159	C4591001 1231 12314159	16-55	26AUG2020	67464	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12314160	C4591001 1231 12314160	16-55	26AUG2020	67522	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12314161	C4591001 1231 12314161	16-55	26AUG2020	67521	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12314162	C4591001 1231 12314162	16-55	26AUG2020	67523	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12314166	C4591001 1231 12314166	16-55	26AUG2020	67526	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12314167	C4591001 1231 12314167	16-55	26AUG2020	67595	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12314169	C4591001 1231 12314169	16-55	26AUG2020	67590	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12314171	C4591001 1231 12314171	16-55	26AUG2020	67654	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12314172	C4591001 1231 12314172	16-55	26AUG2020	67594	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12314173	C4591001 1231 12314173	16-55	26AUG2020	67651	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12314175	C4591001 1231 12314175	16-55	26AUG2020	67658	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12314178	C4591001 1231 12314178	16-55	26AUG2020	67598	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12314179	C4591001 1231 12314179	16-55	26AUG2020	67701	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)			
12314181	C4591001 1231 12314181	16-55	26AUG2020	67652	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12314183	C4591001 1231 12314183	16-55	26AUG2020	67703	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12314185	C4591001 1231 12314185	16-55	26AUG2020	67705	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo		
12314186	C4591001 1231 12314186	16-55	26AUG2020	67708	Placebo	26AUG2020/ Placebo	21SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12314188	C4591001 1231 12314188	16-55	26AUG2020	67745	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12314191	C4591001 1231 12314191	16-55	26AUG2020	67796	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12314192	C4591001 1231 12314192	16-55	26AUG2020	67754	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		
12314193	C4591001 1231 12314193	16-55	26AUG2020	67756	Placebo	26AUG2020/ Placebo	17SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12314195	C4591001 1231 12314195	16-55	26AUG2020	67748	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12314198	C4591001 1231 12314198	16-55	26AUG2020	68021	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12314200	C4591001 1231 12314200	16-55	26AUG2020	67869	Placebo	26AUG2020/ Placebo	17SEP2020/ Placebo		
12314202	C4591001 1231 12314202	16-55	26AUG2020	67802	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12314203	C4591001 1231 12314203	16-55	26AUG2020	67871	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12314204	C4591001 1231 12314204	16-55	26AUG2020	67803	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12314205	C4591001 1231 12314205	16-55	26AUG2020	67797	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)			
12314210	C4591001 1231 12314210	16-55	26AUG2020	67874	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12314212	C4591001 1231 12314212	16-55	26AUG2020	67873	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12314215	C4591001 1231 12314215	16-55	26AUG2020	68022	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12314217	C4591001 1231 12314217	16-55	26AUG2020	67941	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12314218	C4591001 1231 12314218	16-55	26AUG2020	67940	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314219	C4591001 1231 12314219	16-55	26AUG2020	67945	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12314223	C4591001 1231 12314223	16-55	26AUG2020	67946	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12314224	C4591001 1231 12314224	16-55	26AUG2020	68031	Placebo	26AUG2020/ Placebo	15SEP2020/ Placebo		
12314225	C4591001 1231 12314225	16-55	26AUG2020	68023	Placebo	26AUG2020/ Placebo	18SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12314229	C4591001 1231 12314229	16-55	26AUG2020	68036	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12314230	C4591001 1231 12314230	16-55	26AUG2020	68033	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12314232	C4591001 1231 12314232	16-55	26AUG2020	68035	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12314235	C4591001 1231 12314235	16-55	26AUG2020	68034	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12314236	C4591001 1231 12314236	16-55	26AUG2020	68142	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12314238	C4591001 1231 12314238	16-55	26AUG2020	68397	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12314239	C4591001 1231 12314239	16-55	26AUG2020	68355	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
12314242	C4591001 1231 12314242	16-55	26AUG2020	68350	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314243	C4591001 1231 12314243	16-55	26AUG2020	68423	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314244	C4591001 1231 12314244	16-55	26AUG2020	68356	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12314245	C4591001 1231 12314245	16-55	26AUG2020	68151	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12314246	C4591001 1231 12314246	16-55	26AUG2020	68402	Placebo	26AUG2020/ Placebo	29SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
12314247	C4591001 1231 12314247	16-55	26AUG2020	68148	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12314249	C4591001 1231 12314249	16-55	26AUG2020	68150	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12314251	C4591001 1231 12314251	16-55	26AUG2020	68351	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12314252	C4591001 1231 12314252	16-55	26AUG2020	68513	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12314256	C4591001 1231 12314256	16-55	26AUG2020	68520	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
12314259	C4591001 1231 12314259	16-55	26AUG2020	68424	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12314260	C4591001 1231 12314260	16-55	26AUG2020	68540	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12314263	C4591001 1231 12314263	16-55	26AUG2020	68401	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12314264	C4591001 1231 12314264	16-55	26AUG2020	68544	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12314265	C4591001 1231 12314265	16-55	26AUG2020	68522	Placebo	26AUG2020/ Placebo	15SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12314266	C4591001 1231 12314266	16-55	26AUG2020	68573	Placebo	26AUG2020/ Placebo			
12314267	C4591001 1231 12314267	16-55	26AUG2020	68394	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12314268	C4591001 1231 12314268	16-55	26AUG2020	68579	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12314269	C4591001 1231 12314269	16-55	26AUG2020	68417	Placebo	26AUG2020/ Placebo	18SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12314270	C4591001 1231 12314270	16-55	26AUG2020	68644	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12314271	C4591001 1231 12314271	16-55	26AUG2020	68426	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12314272	C4591001 1231 12314272	16-55	26AUG2020	68636	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12314273	C4591001 1231 12314273	16-55	26AUG2020	68524	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12314274	C4591001 1231 12314274	16-55	26AUG2020	68641	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12314276	C4591001 1231 12314276	16-55	26AUG2020	68720	Placebo	26AUG2020/ Placebo	15SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12314277	C4591001 1231 12314277	16-55	26AUG2020	68546	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
12314278	C4591001 1231 12314278	16-55	26AUG2020	68725	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12314279	C4591001 1231 12314279	16-55	26AUG2020	68576	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12314280	C4591001 1231 12314280	16-55	26AUG2020	68728	Placebo	26AUG2020/ Placebo	15SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12314283	C4591001 1231 12314283	16-55	26AUG2020	68543	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12314284	C4591001 1231 12314284	16-55	26AUG2020	68772	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12314287	C4591001 1231 12314287	16-55	26AUG2020	68584	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12314288	C4591001 1231 12314288	16-55	26AUG2020	68775	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12314290	C4591001 1231 12314290	16-55	26AUG2020	68828	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
12314291	C4591001 1231 12314291	16-55	26AUG2020	68766	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12314292	C4591001 1231 12314292	16-55	26AUG2020	68833	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12314294	C4591001 1231 12314294	16-55	26AUG2020	68836	Placebo	26AUG2020/ Placebo	15SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12314295	C4591001 1231 12314295	16-55	26AUG2020	68643	Placebo	26AUG2020/ Placebo	15SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12314296	C4591001 1231 12314296	16-55	26AUG2020	68862	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12314297	C4591001 1231 12314297	16-55	26AUG2020	68719	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12314298	C4591001 1231 12314298	16-55	26AUG2020	68868	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12314300	C4591001 1231 12314300	16-55	26AUG2020	68869	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12314302	C4591001 1231 12314302	16-55	26AUG2020	68885	Placebo	26AUG2020/ Placebo	15SEP2020/ Placebo		
12314303	C4591001 1231 12314303	16-55	26AUG2020	68776	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12314304	C4591001 1231 12314304	16-55	26AUG2020	68896	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12314305	C4591001 1231 12314305	16-55	26AUG2020	68829	Placebo	26AUG2020/ Placebo	17SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12314308	C4591001 1231 12314308	16-55	26AUG2020	68934	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo		
12314309	C4591001 1231 12314309	16-55	26AUG2020	68888	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12314310	C4591001 1231 12314310	16-55	26AUG2020	68941	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12314311	C4591001 1231 12314311	16-55	26AUG2020	68940	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12314314	C4591001 1231 12314314	16-55	26AUG2020	68958	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)			
12314317	C4591001 1231 12314317	16-55	26AUG2020	68895	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12314318	C4591001 1231 12314318	16-55	26AUG2020	68968	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12314319	C4591001 1231 12314319	16-55	26AUG2020	68870	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
12314320	C4591001 1231 12314320	16-55	26AUG2020	69008	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12314322	C4591001 1231 12314322	16-55	26AUG2020	69009	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12314324	C4591001 1231 12314324	16-55	26AUG2020	69013	Placebo	26AUG2020/ Placebo	15SEP2020/ Placebo		
12314325	C4591001 1231 12314325	16-55	26AUG2020	68942	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12314326	C4591001 1231 12314326	16-55	26AUG2020	69015	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	
12314327	C4591001 1231 12314327	16-55	26AUG2020	68960	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	13FEB2021/ BNT162b2 (30 µg)
12314328	C4591001 1231 12314328	16-55	26AUG2020	69050	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12314329	C4591001 1231 12314329	16-55	26AUG2020	68963	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12314330	C4591001 1231 12314330	16-55	26AUG2020	69052	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12314333	C4591001 1231 12314333	16-55	26AUG2020	69046	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12314334	C4591001 1231 12314334	16-55	26AUG2020	69073	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12314336	C4591001 1231 12314336	16-55	26AUG2020	69074	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12314339	C4591001 1231 12314339	16-55	26AUG2020	69066	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo		
12314340	C4591001 1231 12314340	16-55	26AUG2020	69125	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12314342	C4591001 1231 12314342	16-55	26AUG2020	69128	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314343	C4591001 1231 12314343	16-55	26AUG2020	69051	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12314346	C4591001 1231 12314346	16-55	26AUG2020	69137	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12314348	C4591001 1231 12314348	16-55	26AUG2020	69146	Placebo	26AUG2020/ Placebo	15SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12314351	C4591001 1231 12314351	16-55	26AUG2020	69075	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12314352	C4591001 1231 12314352	16-55	26AUG2020	69176	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12314353	C4591001 1231 12314353	16-55	26AUG2020	69127	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12314354	C4591001 1231 12314354	16-55	26AUG2020	69189	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12314355	C4591001 1231 12314355	16-55	26AUG2020	69130	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12314356	C4591001 1231 12314356	16-55	26AUG2020	69190	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12314357	C4591001 1231 12314357	16-55	26AUG2020	69175	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12314358	C4591001 1231 12314358	16-55	26AUG2020	69209	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
12314359	C4591001 1231 12314359	16-55	26AUG2020	69148	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12314360	C4591001 1231 12314360	16-55	26AUG2020	69186	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12314361	C4591001 1231 12314361	16-55	26AUG2020	69174	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12314362	C4591001 1231 12314362	16-55	26AUG2020	69184	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12314363	C4591001 1231 12314363	16-55	26AUG2020	69143	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12314366	C4591001 1231 12314366	16-55	26AUG2020	69191	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12314368	C4591001 1231 12314368	16-55	26AUG2020	69213	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314371	C4591001 1231 12314371	16-55	27AUG2020	69433	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12314372	C4591001 1231 12314372	16-55	27AUG2020	69403	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo		
12314373	C4591001 1231 12314373	16-55	27AUG2020	69404	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12314374	C4591001 1231 12314374	16-55	27AUG2020	69215	Placebo	27AUG2020/ Placebo	18SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12314375	C4591001 1231 12314375	16-55	27AUG2020	69554	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12314376	C4591001 1231 12314376	16-55	27AUG2020	69434	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12314379	C4591001 1231 12314379	16-55	27AUG2020	69220	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12314380	C4591001 1231 12314380	16-55	27AUG2020	69406	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314381	C4591001 1231 12314381	16-55	27AUG2020	69407	Placebo	27AUG2020/ Placebo			
12314385	C4591001 1231 12314385	16-55	27AUG2020	69435	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)			
12314387	C4591001 1231 12314387	16-55	27AUG2020	69428	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12314388	C4591001 1231 12314388	16-55	27AUG2020	69467	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12314389	C4591001 1231 12314389	16-55	27AUG2020	69455	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314391	C4591001 1231 12314391	16-55	27AUG2020	69490	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12314392	C4591001 1231 12314392	16-55	27AUG2020	69449	Placebo	27AUG2020/ Placebo	16SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12314393	C4591001 1231 12314393	16-55	27AUG2020	69453	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12314394	C4591001 1231 12314394	16-55	27AUG2020	69472	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12314395	C4591001 1231 12314395	16-55	27AUG2020	69469	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12314396	C4591001 1231 12314396	16-55	27AUG2020	69471	Placebo	27AUG2020/ Placebo	16SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
12314397	C4591001 1231 12314397	16-55	27AUG2020	69456	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12314400	C4591001 1231 12314400	16-55	27AUG2020	69491	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12314402	C4591001 1231 12314402	16-55	27AUG2020	69495	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12314404	C4591001 1231 12314404	16-55	27AUG2020	69492	Placebo	27AUG2020/ Placebo	16SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12314405	C4591001 1231 12314405	16-55	27AUG2020	69547	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12314406	C4591001 1231 12314406	16-55	27AUG2020	69549	Placebo	27AUG2020/ Placebo	16SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12314407	C4591001 1231 12314407	16-55	27AUG2020	69574	Placebo	27AUG2020/ Placebo	16SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
12314408	C4591001 1231 12314408	16-55	27AUG2020	69550	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
12314416	C4591001 1231 12314416	16-55	27AUG2020	69609	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
12314417	C4591001 1231 12314417	16-55	27AUG2020	69575	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314418	C4591001 1231 12314418	16-55	27AUG2020	69612	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12314419	C4591001 1231 12314419	16-55	27AUG2020	69569	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12314421	C4591001 1231 12314421	16-55	27AUG2020	69628	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12314422	C4591001 1231 12314422	16-55	27AUG2020	69605	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12314423	C4591001 1231 12314423	16-55	27AUG2020	69618	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12314424	C4591001 1231 12314424	16-55	27AUG2020	69620	Placebo	27AUG2020/ Placebo	16SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12314425	C4591001 1231 12314425	16-55	27AUG2020	69577	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12314427	C4591001 1231 12314427	16-55	27AUG2020	69643	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314429	C4591001 1231 12314429	16-55	27AUG2020	69610	Placebo	27AUG2020/ Placebo	18SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
12314430	C4591001 1231 12314430	16-55	27AUG2020	69627	Placebo	27AUG2020/ Placebo	18SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12314433	C4591001 1231 12314433	16-55	27AUG2020	69645	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12314434	C4591001 1231 12314434	16-55	27AUG2020	69650	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12314435	C4591001 1231 12314435	16-55	27AUG2020	69652	Placebo	27AUG2020/ Placebo	16SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
12314436	C4591001 1231 12314436	16-55	27AUG2020	69755	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12314440	C4591001 1231 12314440	16-55	27AUG2020	69752	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12314442	C4591001 1231 12314442	16-55	27AUG2020	69756	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314444	C4591001 1231 12314444	16-55	27AUG2020	69826	Placebo	27AUG2020/ Placebo	18SEP2020/ Placebo		
12314445	C4591001 1231 12314445	16-55	27AUG2020	69824	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12314447	C4591001 1231 12314447	16-55	27AUG2020	69758	Placebo	27AUG2020/ Placebo	16SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12314449	C4591001 1231 12314449	16-55	27AUG2020	69828	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314450	C4591001 1231 12314450	16-55	27AUG2020	69893	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
12314451	C4591001 1231 12314451	16-55	27AUG2020	69831	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12314452	C4591001 1231 12314452	16-55	27AUG2020	69894	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
12314454	C4591001 1231 12314454	16-55	27AUG2020	69935	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12314457	C4591001 1231 12314457	16-55	27AUG2020	69897	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12314459	C4591001 1231 12314459	16-55	27AUG2020	69932	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12314461	C4591001 1231 12314461	16-55	27AUG2020	69982	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314462	C4591001 1231 12314462	16-55	27AUG2020	69903	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12314463	C4591001 1231 12314463	16-55	27AUG2020	69940	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
12314464	C4591001 1231 12314464	16-55	27AUG2020	69981	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314466	C4591001 1231 12314466	16-55	27AUG2020	70001	Placebo	27AUG2020/ Placebo	18SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12314467	C4591001 1231 12314467	16-55	27AUG2020	69986	Placebo	27AUG2020/ Placebo	16SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12314468	C4591001 1231 12314468	16-55	27AUG2020	69939	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12314470	C4591001 1231 12314470	16-55	27AUG2020	69983	Placebo	27AUG2020/ Placebo	18SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12314471	C4591001 1231 12314471	16-55	27AUG2020	70012	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12314474	C4591001 1231 12314474	16-55	27AUG2020	70050	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314475	C4591001 1231 12314475	16-55	27AUG2020	70009	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12314477	C4591001 1231 12314477	16-55	27AUG2020	70054	Placebo	27AUG2020/ Placebo	18SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12314478	C4591001 1231 12314478	16-55	27AUG2020	70004	Placebo	27AUG2020/ Placebo	16SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12314479	C4591001 1231 12314479	16-55	27AUG2020	70056	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12314480	C4591001 1231 12314480	16-55	27AUG2020	70133	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12314482	C4591001 1231 12314482	16-55	27AUG2020	70055	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12314486	C4591001 1231 12314486	16-55	27AUG2020	70137	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12314489	C4591001 1231 12314489	16-55	27AUG2020	70144	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12314490	C4591001 1231 12314490	16-55	27AUG2020	70192	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12314491	C4591001 1231 12314491	16-55	27AUG2020	70143	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12314492	C4591001 1231 12314492	16-55	27AUG2020	70185	Placebo	27AUG2020/ Placebo			
12314494	C4591001 1231 12314494	16-55	27AUG2020	70181	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314496	C4591001 1231 12314496	16-55	27AUG2020	70182	Placebo	27AUG2020/ Placebo	16SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12314497	C4591001 1231 12314497	16-55	27AUG2020	70250	Placebo	27AUG2020/ Placebo	16SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12314499	C4591001 1231 12314499	16-55	27AUG2020	70280	Placebo	27AUG2020/ Placebo	16SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12314500	C4591001 1231 12314500	16-55	27AUG2020	70248	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12314501	C4591001 1231 12314501	16-55	27AUG2020	70297	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314502	C4591001 1231 12314502	16-55	27AUG2020	70285	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12314503	C4591001 1231 12314503	16-55	27AUG2020	70244	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12314505	C4591001 1231 12314505	16-55	27AUG2020	70298	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
12314506	C4591001 1231 12314506	16-55	27AUG2020	70373	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12314508	C4591001 1231 12314508	16-55	27AUG2020	70281	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12314509	C4591001 1231 12314509	16-55	27AUG2020	70349	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12314510	C4591001 1231 12314510	16-55	27AUG2020	70377	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12314511	C4591001 1231 12314511	16-55	27AUG2020	70299	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
12314512	C4591001 1231 12314512	16-55	27AUG2020	70277	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12314513	C4591001 1231 12314513	16-55	27AUG2020	70251	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12314515	C4591001 1231 12314515	16-55	27AUG2020	70291	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12314516	C4591001 1231 12314516	16-55	27AUG2020	70354	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12314517	C4591001 1231 12314517	16-55	27AUG2020	70376	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12314519	C4591001 1231 12314519	16-55	27AUG2020	70351	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12314520	C4591001 1231 12314520	16-55	27AUG2020	70412	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12314521	C4591001 1231 12314521	16-55	27AUG2020	70379	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12314522	C4591001 1231 12314522	16-55	27AUG2020	70409	Placebo	27AUG2020/ Placebo	16SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12314523	C4591001 1231 12314523	16-55	27AUG2020	70352	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12314525	C4591001 1231 12314525	16-55	27AUG2020	70419	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12314526	C4591001 1231 12314526	16-55	27AUG2020	70413	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12314528	C4591001 1231 12314528	16-55	27AUG2020	70469	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12314529	C4591001 1231 12314529	16-55	27AUG2020	70472	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314530	C4591001 1231 12314530	16-55	27AUG2020	70583	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12314531	C4591001 1231 12314531	16-55	27AUG2020	70475	Placebo	27AUG2020/ Placebo	28SEP2020/ Placebo		
12314534	C4591001 1231 12314534	16-55	27AUG2020	70479	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12314535	C4591001 1231 12314535	16-55	27AUG2020	70586	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12314537	C4591001 1231 12314537	16-55	27AUG2020	70621	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12314541	C4591001 1231 12314541	16-55	27AUG2020	70580	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12314542	C4591001 1231 12314542	16-55	27AUG2020	70585	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12314547	C4591001 1231 12314547	16-55	27AUG2020	70615	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12314548	C4591001 1231 12314548	16-55	27AUG2020	70619	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12314550	C4591001 1231 12314550	16-55	27AUG2020	70665	Placebo	27AUG2020/ Placebo	16SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12314552	C4591001 1231 12314552	16-55	27AUG2020	70620	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12314553	C4591001 1231 12314553	16-55	27AUG2020	70666	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12314554	C4591001 1231 12314554	16-55	27AUG2020	70671	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314555	C4591001 1231 12314555	16-55	27AUG2020	70742	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12314557	C4591001 1231 12314557	16-55	27AUG2020	70672	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12314559	C4591001 1231 12314559	16-55	27AUG2020	70738	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314560	C4591001 1231 12314560	16-55	27AUG2020	70735	Placebo	27AUG2020/ Placebo	16SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12314562	C4591001 1231 12314562	16-55	27AUG2020	70739	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314564	C4591001 1231 12314564	16-55	27AUG2020	70760	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12314565	C4591001 1231 12314565	16-55	27AUG2020	70798	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12314566	C4591001 1231 12314566	16-55	27AUG2020	70762	Placebo	27AUG2020/ Placebo	24SEP2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12314568	C4591001 1231 12314568	16-55	27AUG2020	70766	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	
12314571	C4591001 1231 12314571	16-55	27AUG2020	70767	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314573	C4591001 1231 12314573	16-55	27AUG2020	70794	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12314574	C4591001 1231 12314574	16-55	27AUG2020	70804	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12314575	C4591001 1231 12314575	16-55	27AUG2020	70867	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
12314576	C4591001 1231 12314576	16-55	27AUG2020	70799	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12314577	C4591001 1231 12314577	16-55	27AUG2020	70914	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12314580	C4591001 1231 12314580	16-55	27AUG2020	70870	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)			
12314582	C4591001 1231 12314582	16-55	27AUG2020	70873	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12314583	C4591001 1231 12314583	16-55	27AUG2020	70872	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12314585	C4591001 1231 12314585	16-55	27AUG2020	70918	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12314586	C4591001 1231 12314586	16-55	27AUG2020	70984	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12314589	C4591001 1231 12314589	16-55	27AUG2020	70919	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12314590	C4591001 1231 12314590	16-55	27AUG2020	71023	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)			
12314591	C4591001 1231 12314591	16-55	27AUG2020	70924	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12314595	C4591001 1231 12314595	16-55	27AUG2020	70978	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12314596	C4591001 1231 12314596	16-55	27AUG2020	71032	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12314597	C4591001 1231 12314597	16-55	27AUG2020	70979	Placebo	27AUG2020/ Placebo	18SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12314599	C4591001 1231 12314599	16-55	27AUG2020	71028	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12314601	C4591001 1231 12314601	16-55	27AUG2020	70983	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12314602	C4591001 1231 12314602	16-55	27AUG2020	71109	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12314603	C4591001 1231 12314603	16-55	27AUG2020	71029	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
12314604	C4591001 1231 12314604	16-55	27AUG2020	71113	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12314606	C4591001 1231 12314606	16-55	27AUG2020	71154	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12314607	C4591001 1231 12314607	16-55	27AUG2020	71090	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12314610	C4591001 1231 12314610	16-55	27AUG2020	71162	Placebo	27AUG2020/ Placebo	16SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12314615	C4591001 1231 12314615	16-55	27AUG2020	71087	Placebo	27AUG2020/ Placebo	16SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12314616	C4591001 1231 12314616	16-55	27AUG2020	71164	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12314620	C4591001 1231 12314620	16-55	27AUG2020	71202	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12314621	C4591001 1231 12314621	16-55	27AUG2020	71085	Placebo	27AUG2020/ Placebo	16SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12314622	C4591001 1231 12314622	16-55	27AUG2020	71203	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo		
12314625	C4591001 1231 12314625	16-55	27AUG2020	71086	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314627	C4591001 1231 12314627	16-55	27AUG2020	71107	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12314628	C4591001 1231 12314628	16-55	27AUG2020	71242	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12314629	C4591001 1231 12314629	16-55	27AUG2020	71111	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12314630	C4591001 1231 12314630	16-55	27AUG2020	71246	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12314633	C4591001 1231 12314633	16-55	27AUG2020	71158	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12314635	C4591001 1231 12314635	16-55	27AUG2020	71210	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12314637	C4591001 1231 12314637	16-55	27AUG2020	71204	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314638	C4591001 1231 12314638	16-55	27AUG2020	71285	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12314639	C4591001 1231 12314639	16-55	27AUG2020	71238	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12314640	C4591001 1231 12314640	16-55	27AUG2020	71286	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12314641	C4591001 1231 12314641	16-55	27AUG2020	71243	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
12314642	C4591001 1231 12314642	16-55	27AUG2020	71289	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12314643	C4591001 1231 12314643	16-55	27AUG2020	71261	Placebo	27AUG2020/ Placebo	18SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
12314644	C4591001 1231 12314644	16-55	27AUG2020	71322	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12314645	C4591001 1231 12314645	16-55	27AUG2020	71262	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12314646	C4591001 1231 12314646	16-55	27AUG2020	71327	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12314647	C4591001 1231 12314647	16-55	27AUG2020	71267	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	13FEB2021/ BNT162b2 (30 µg)
12314648	C4591001 1231 12314648	16-55	27AUG2020	71330	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12314649	C4591001 1231 12314649	16-55	27AUG2020	71263	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12314650	C4591001 1231 12314650	16-55	27AUG2020	71331	Placebo	27AUG2020/ Placebo	18SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12314654	C4591001 1231 12314654	16-55	27AUG2020	71361	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314655	C4591001 1231 12314655	16-55	27AUG2020	71290	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12314656	C4591001 1231 12314656	16-55	27AUG2020	71364	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12314665	C4591001 1231 12314665	16-55	28AUG2020	71509	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12314666	C4591001 1231 12314666	16-55	28AUG2020	71365	Placebo	28AUG2020/ Placebo	17SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12314667	C4591001 1231 12314667	16-55	28AUG2020	71366	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12314670	C4591001 1231 12314670	16-55	28AUG2020	71484	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12314671	C4591001 1231 12314671	16-55	28AUG2020	71487	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12314672	C4591001 1231 12314672	16-55	28AUG2020	71478	Placebo	28AUG2020/ Placebo	17SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12314674	C4591001 1231 12314674	16-55	28AUG2020	71518	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314677	C4591001 1231 12314677	16-55	28AUG2020	71522	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314678	C4591001 1231 12314678	16-55	28AUG2020	71510	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12314679	C4591001 1231 12314679	16-55	28AUG2020	71524	Placebo	28AUG2020/ Placebo	04NOV2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12314680	C4591001 1231 12314680	16-55	28AUG2020	71481	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12314682	C4591001 1231 12314682	16-55	28AUG2020	71508	Placebo	28AUG2020/ Placebo	17SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12314684	C4591001 1231 12314684	16-55	28AUG2020	71507	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314685	C4591001 1231 12314685	16-55	28AUG2020	71525	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314686	C4591001 1231 12314686	16-55	28AUG2020	71560	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12314688	C4591001 1231 12314688	16-55	28AUG2020	71536	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
12314689	C4591001 1231 12314689	16-55	28AUG2020	71528	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314691	C4591001 1231 12314691	16-55	28AUG2020	71558	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314693	C4591001 1231 12314693	16-55	28AUG2020	71523	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12314694	C4591001 1231 12314694	16-55	28AUG2020	71589	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12314695	C4591001 1231 12314695	16-55	28AUG2020	71535	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12314697	C4591001 1231 12314697	16-55	28AUG2020	71550	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12314698	C4591001 1231 12314698	16-55	28AUG2020	71575	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12314699	C4591001 1231 12314699	16-55	28AUG2020	71573	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12314700	C4591001 1231 12314700	16-55	28AUG2020	71557	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)			
12314701	C4591001 1231 12314701	16-55	28AUG2020	71583	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12314703	C4591001 1231 12314703	16-55	28AUG2020	71578	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314705	C4591001 1231 12314705	16-55	28AUG2020	71590	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314706	C4591001 1231 12314706	16-55	28AUG2020	71613	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12314708	C4591001 1231 12314708	16-55	28AUG2020	71591	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12314709	C4591001 1231 12314709	16-55	28AUG2020	71592	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12314710	C4591001 1231 12314710	16-55	28AUG2020	71611	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	13FEB2021/ BNT162b2 (30 µg)
12314712	C4591001 1231 12314712	16-55	28AUG2020	71616	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314713	C4591001 1231 12314713	16-55	28AUG2020	71614	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)			
12314714	C4591001 1231 12314714	16-55	28AUG2020	71625	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314715	C4591001 1231 12314715	16-55	28AUG2020	71647	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314716	C4591001 1231 12314716	16-55	28AUG2020	71648	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314717	C4591001 1231 12314717	16-55	28AUG2020	71655	Placebo	28AUG2020/ Placebo	17SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12314718	C4591001 1231 12314718	16-55	28AUG2020	71623	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314719	C4591001 1231 12314719	16-55	28AUG2020	71626	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12314721	C4591001 1231 12314721	16-55	28AUG2020	71622	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12314722	C4591001 1231 12314722	16-55	28AUG2020	71677	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314723	C4591001 1231 12314723	16-55	28AUG2020	71651	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
12314727	C4591001 1231 12314727	16-55	28AUG2020	71803	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12314730	C4591001 1231 12314730	16-55	28AUG2020	71750	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314731	C4591001 1231 12314731	16-55	28AUG2020	71672	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314734	C4591001 1231 12314734	16-55	28AUG2020	71680	Placebo	28AUG2020/ Placebo	17SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12314735	C4591001 1231 12314735	16-55	28AUG2020	71678	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12314738	C4591001 1231 12314738	16-55	28AUG2020	71749	Placebo				
12314739	C4591001 1231 12314739	16-55	28AUG2020	71762	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12314740	C4591001 1231 12314740	16-55	28AUG2020	71751	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12314742	C4591001 1231 12314742	16-55	28AUG2020	71761	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12314743	C4591001 1231 12314743	16-55	28AUG2020	71745	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12314744	C4591001 1231 12314744	16-55	28AUG2020	71793	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314745	C4591001 1231 12314745	16-55	28AUG2020	71758	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12314746	C4591001 1231 12314746	16-55	28AUG2020	71790	Placebo	28AUG2020/ Placebo	17SEP2020/ Placebo		
12314749	C4591001 1231 12314749	16-55	28AUG2020	71816	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12314750	C4591001 1231 12314750	16-55	28AUG2020	71792	Placebo	28AUG2020/ Placebo	17SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12314751	C4591001 1231 12314751	16-55	28AUG2020	71815	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12314752	C4591001 1231 12314752	16-55	28AUG2020	71764	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12314754	C4591001 1231 12314754	16-55	28AUG2020	71794	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12314756	C4591001 1231 12314756	16-55	28AUG2020	71805	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314757	C4591001 1231 12314757	16-55	28AUG2020	71814	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12314760	C4591001 1231 12314760	16-55	28AUG2020	71806	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12314761	C4591001 1231 12314761	16-55	28AUG2020	71819	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
12314764	C4591001 1231 12314764	16-55	28AUG2020	71809	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314768	C4591001 1231 12314768	16-55	28AUG2020	71873	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12314771	C4591001 1231 12314771	16-55	28AUG2020	71882	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314772	C4591001 1231 12314772	16-55	28AUG2020	71884	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo		
12314774	C4591001 1231 12314774	16-55	28AUG2020	71874	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
12314776	C4591001 1231 12314776	16-55	28AUG2020	71933	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12314777	C4591001 1231 12314777	16-55	28AUG2020	71985	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12314781	C4591001 1231 12314781	16-55	28AUG2020	71934	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12314782	C4591001 1231 12314782	16-55	28AUG2020	71942	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12314783	C4591001 1231 12314783	16-55	28AUG2020	71936	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314787	C4591001 1231 12314787	16-55	28AUG2020	71986	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12314788	C4591001 1231 12314788	16-55	28AUG2020	71988	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12314789	C4591001 1231 12314789	16-55	28AUG2020	72066	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314790	C4591001 1231 12314790	16-55	28AUG2020	71991	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12314792	C4591001 1231 12314792	16-55	28AUG2020	72067	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12314794	C4591001 1231 12314794	16-55	28AUG2020	72071	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12314796	C4591001 1231 12314796	16-55	28AUG2020	72076	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12314797	C4591001 1231 12314797	16-55	28AUG2020	72119	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314798	C4591001 1231 12314798	16-55	28AUG2020	72095	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12314800	C4591001 1231 12314800	16-55	28AUG2020	72096	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12314801	C4591001 1231 12314801	16-55	28AUG2020	72091	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314803	C4591001 1231 12314803	16-55	28AUG2020	72117	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12314804	C4591001 1231 12314804	16-55	28AUG2020	72118	Placebo	28AUG2020/ Placebo	02OCT2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12314806	C4591001 1231 12314806	16-55	28AUG2020	72100	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314809	C4591001 1231 12314809	16-55	28AUG2020	72152	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314813	C4591001 1231 12314813	16-55	28AUG2020	72154	Placebo	28AUG2020/ Placebo	17SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12314814	C4591001 1231 12314814	16-55	28AUG2020	72149	Placebo	28AUG2020/ Placebo	17SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12314815	C4591001 1231 12314815	16-55	28AUG2020	72122	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12314816	C4591001 1231 12314816	16-55	28AUG2020	72176	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12314817	C4591001 1231 12314817	16-55	28AUG2020	72153	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314818	C4591001 1231 12314818	16-55	28AUG2020	72182	Placebo	28AUG2020/ Placebo	17SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12314819	C4591001 1231 12314819	16-55	28AUG2020	72234	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314824	C4591001 1231 12314824	16-55	28AUG2020	72183	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12314826	C4591001 1231 12314826	16-55	28AUG2020	72184	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314832	C4591001 1231 12314832	16-55	28AUG2020	72237	Placebo	28AUG2020/ Placebo	17SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12314833	C4591001 1231 12314833	16-55	28AUG2020	72235	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12314834	C4591001 1231 12314834	16-55	28AUG2020	72286	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12314835	C4591001 1231 12314835	16-55	28AUG2020	72283	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314836	C4591001 1231 12314836	16-55	28AUG2020	72291	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12314838	C4591001 1231 12314838	16-55	28AUG2020	72289	Placebo	28AUG2020/ Placebo	17SEP2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12314840	C4591001 1231 12314840	16-55	28AUG2020	72240	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12314842	C4591001 1231 12314842	16-55	28AUG2020	72313	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314843	C4591001 1231 12314843	16-55	28AUG2020	72312	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314844	C4591001 1231 12314844	16-55	28AUG2020	72316	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12314845	C4591001 1231 12314845	16-55	28AUG2020	72315	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
12314846	C4591001 1231 12314846	16-55	28AUG2020	72401	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12314847	C4591001 1231 12314847	16-55	28AUG2020	72403	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
12314848	C4591001 1231 12314848	16-55	28AUG2020	72405	Placebo	28AUG2020/ Placebo			
12314851	C4591001 1231 12314851	16-55	28AUG2020	72595	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12314852	C4591001 1231 12314852	16-55	28AUG2020	72539	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314853	C4591001 1231 12314853	16-55	28AUG2020	72537	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314854	C4591001 1231 12314854	16-55	28AUG2020	72540	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12314855	C4591001 1231 12314855	16-55	28AUG2020	72603	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314857	C4591001 1231 12314857	16-55	28AUG2020	72728	Placebo	28AUG2020/ Placebo	16OCT2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12314858	C4591001 1231 12314858	16-55	28AUG2020	72409	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314859	C4591001 1231 12314859	16-55	28AUG2020	72544	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12314862	C4591001 1231 12314862	16-55	28AUG2020	72698	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12314864	C4591001 1231 12314864	16-55	28AUG2020	72639	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314866	C4591001 1231 12314866	16-55	28AUG2020	72730	Placebo	28AUG2020/ Placebo	17SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12314868	C4591001 1231 12314868	16-55	28AUG2020	72604	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12314869	C4591001 1231 12314869	16-55	28AUG2020	72732	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12314870	C4591001 1231 12314870	16-55	28AUG2020	72637	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12314872	C4591001 1231 12314872	16-55	28AUG2020	72690	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314873	C4591001 1231 12314873	16-55	28AUG2020	72736	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12314874	C4591001 1231 12314874	16-55	28AUG2020	72630	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12314876	C4591001 1231 12314876	16-55	28AUG2020	72596	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12314877	C4591001 1231 12314877	16-55	28AUG2020	72696	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314878	C4591001 1231 12314878	16-55	28AUG2020	72694	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12314880	C4591001 1231 12314880	16-55	28AUG2020	72638	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12314883	C4591001 1231 12314883	16-55	28AUG2020	72800	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
12314884	C4591001 1231 12314884	16-55	28AUG2020	72797	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
12314885	C4591001 1231 12314885	16-55	28AUG2020	72806	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314886	C4591001 1231 12314886	16-55	28AUG2020	72805	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314889	C4591001 1231 12314889	16-55	28AUG2020	72812	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12314890	C4591001 1231 12314890	16-55	28AUG2020	72815	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12314892	C4591001 1231 12314892	16-55	28AUG2020	72920	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12314893	C4591001 1231 12314893	16-55	28AUG2020	72868	Placebo	28AUG2020/ Placebo	25SEP2020/ Placebo		
12314894	C4591001 1231 12314894	16-55	28AUG2020	72865	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12314895	C4591001 1231 12314895	16-55	28AUG2020	72820	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12314896	C4591001 1231 12314896	16-55	28AUG2020	72816	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12314899	C4591001 1231 12314899	16-55	28AUG2020	72867	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12314900	C4591001 1231 12314900	16-55	28AUG2020	72915	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12314901	C4591001 1231 12314901	16-55	28AUG2020	72863	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314903	C4591001 1231 12314903	16-55	28AUG2020	72906	Placebo	28AUG2020/ Placebo	17SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12314905	C4591001 1231 12314905	16-55	28AUG2020	72875	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314907	C4591001 1231 12314907	16-55	28AUG2020	72945	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12314908	C4591001 1231 12314908	16-55	28AUG2020	72947	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314909	C4591001 1231 12314909	16-55	28AUG2020	72869	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12314910	C4591001 1231 12314910	16-55	28AUG2020	72872	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12314912	C4591001 1231 12314912	16-55	28AUG2020	72977	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12314913	C4591001 1231 12314913	16-55	28AUG2020	72918	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12314914	C4591001 1231 12314914	16-55	28AUG2020	72978	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
12314917	C4591001 1231 12314917	16-55	28AUG2020	72925	Placebo	28AUG2020/ Placebo	17SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
12314918	C4591001 1231 12314918	16-55	28AUG2020	72873	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12314919	C4591001 1231 12314919	16-55	28AUG2020	72914	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12314921	C4591001 1231 12314921	16-55	28AUG2020	72919	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12314922	C4591001 1231 12314922	16-55	28AUG2020	72984	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
12314923	C4591001 1231 12314923	16-55	28AUG2020	72910	Placebo	28AUG2020/ Placebo			
12314924	C4591001 1231 12314924	16-55	28AUG2020	72951	Placebo	28AUG2020/ Placebo	17SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	13FEB2021/ BNT162b2 (30 µg)
12314925	C4591001 1231 12314925	16-55	28AUG2020	72943	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314928	C4591001 1231 12314928	16-55	28AUG2020	72985	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314929	C4591001 1231 12314929	16-55	28AUG2020	72990	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314930	C4591001 1231 12314930	16-55	28AUG2020	72989	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12314931	C4591001 1231 12314931	16-55	28AUG2020	73025	Placebo	28AUG2020/ Placebo	17SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12314934	C4591001 1231 12314934	16-55	28AUG2020	72998	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12314935	C4591001 1231 12314935	16-55	28AUG2020	73028	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12314936	C4591001 1231 12314936	16-55	28AUG2020	73039	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
12314937	C4591001 1231 12314937	16-55	28AUG2020	72996	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314939	C4591001 1231 12314939	16-55	28AUG2020	73052	Placebo	28AUG2020/ Placebo	17SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12314940	C4591001 1231 12314940	16-55	28AUG2020	73030	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314943	C4591001 1231 12314943	16-55	28AUG2020	73047	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12314944	C4591001 1231 12314944	16-55	28AUG2020	73046	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314945	C4591001 1231 12314945	16-55	28AUG2020	73042	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12314946	C4591001 1231 12314946	16-55	28AUG2020	73054	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12314947	C4591001 1231 12314947	16-55	28AUG2020	73032	Placebo	28AUG2020/ Placebo	17SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12314948	C4591001 1231 12314948	16-55	28AUG2020	73060	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12314954	C4591001 1231 12314954	16-55	28AUG2020	73051	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314955	C4591001 1231 12314955	16-55	28AUG2020	73063	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
12314959	C4591001 1231 12314959	16-55	28AUG2020	73064	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12314962	C4591001 1231 12314962	16-55	28AUG2020	73066	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12314964	C4591001 1231 12314964	16-55	28AUG2020	73072	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12314967	C4591001 1231 12314967	16-55	28AUG2020	73138	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314968	C4591001 1231 12314968	16-55	28AUG2020	73136	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12314970	C4591001 1231 12314970	16-55	28AUG2020	73145	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
12314974	C4591001 1231 12314974	16-55	28AUG2020	73139	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo		
12314977	C4591001 1231 12314977	16-55	28AUG2020	73156	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12314980	C4591001 1231 12314980	16-55	28AUG2020	73149	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314983	C4591001 1231 12314983	16-55	28AUG2020	73141	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314984	C4591001 1231 12314984	16-55	28AUG2020	73152	Placebo	28AUG2020/ Placebo			
12314986	C4591001 1231 12314986	16-55	28AUG2020	73160	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314987	C4591001 1231 12314987	16-55	28AUG2020	73181	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo		
12314992	C4591001 1231 12314992	16-55	28AUG2020	73166	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12314995	C4591001 1231 12314995	16-55	28AUG2020	73187	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314996	C4591001 1231 12314996	16-55	28AUG2020	73185	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314998	C4591001 1231 12314998	16-55	28AUG2020	73191	Placebo	28AUG2020/ Placebo	17SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12314999	C4591001 1231 12314999	16-55	28AUG2020	73165	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12315001	C4591001 1231 12315001	16-55	28AUG2020	73167	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo		
12315005	C4591001 1231 12315005	16-55	28AUG2020	73197	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12315009	C4591001 1231 12315009	16-55	28AUG2020	73199	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12315012	C4591001 1231 12315012	16-55	28AUG2020	73204	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12315013	C4591001 1231 12315013	16-55	28AUG2020	73200	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12315014	C4591001 1231 12315014	16-55	28AUG2020	73218	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12315015	C4591001 1231 12315015	16-55	28AUG2020	73220	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12315021	C4591001 1231 12315021	16-55	28AUG2020	73222	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12315026	C4591001 1231 12315026	16-55	28AUG2020	73249	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12315027	C4591001 1231 12315027	16-55	28AUG2020	73233	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12315031	C4591001 1231 12315031	16-55	28AUG2020	73226	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12315036	C4591001 1231 12315036	16-55	28AUG2020	73250	Placebo	28AUG2020/ Placebo	17SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12315039	C4591001 1231 12315039	16-55	28AUG2020	73240	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12315043	C4591001 1231 12315043	16-55	28AUG2020	73234	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12315045	C4591001 1231 12315045	16-55	28AUG2020	73248	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12315047	C4591001 1231 12315047	16-55	28AUG2020	73239	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12315048	C4591001 1231 12315048	16-55	28AUG2020	73271	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12315052	C4591001 1231 12315052	16-55	28AUG2020	73272	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12315053	C4591001 1231 12315053	16-55	28AUG2020	73243	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12315054	C4591001 1231 12315054	16-55	28AUG2020	73273	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12315055	C4591001 1231 12315055	16-55	29AUG2020	73274	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12315056	C4591001 1231 12315056	16-55	29AUG2020	73277	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12315057	C4591001 1231 12315057	16-55	29AUG2020	73278	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12315059	C4591001 1231 12315059	16-55	29AUG2020	73304	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12315060	C4591001 1231 12315060	16-55	29AUG2020	73282	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12315061	C4591001 1231 12315061	16-55	29AUG2020	73339	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12315062	C4591001 1231 12315062	16-55	29AUG2020	73288	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12315063	C4591001 1231 12315063	16-55	29AUG2020	73330	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12315064	C4591001 1231 12315064	16-55	29AUG2020	73306	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
12315065	C4591001 1231 12315065	16-55	29AUG2020	73307	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12315066	C4591001 1231 12315066	16-55	29AUG2020	73371	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12315067	C4591001 1231 12315067	16-55	29AUG2020	73316	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12315068	C4591001 1231 12315068	16-55	29AUG2020	73318	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12315070	C4591001 1231 12315070	16-55	29AUG2020	73321	Placebo	29AUG2020/ Placebo	18SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12315071	C4591001 1231 12315071	16-55	29AUG2020	73333	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo		
12315072	C4591001 1231 12315072	16-55	29AUG2020	73311	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12315073	C4591001 1231 12315073	16-55	29AUG2020	73332	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12315074	C4591001 1231 12315074	16-55	29AUG2020	73341	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo		
12315076	C4591001 1231 12315076	16-55	29AUG2020	73350	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
12315078	C4591001 1231 12315078	16-55	29AUG2020	73348	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12315079	C4591001 1231 12315079	16-55	29AUG2020	73366	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12315080	C4591001 1231 12315080	16-55	29AUG2020	73337	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12315082	C4591001 1231 12315082	16-55	29AUG2020	73323	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12315083	C4591001 1231 12315083	16-55	29AUG2020	73352	Placebo	29AUG2020/ Placebo	19SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12315084	C4591001 1231 12315084	16-55	29AUG2020	73331	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12315085	C4591001 1231 12315085	16-55	29AUG2020	73353	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12315087	C4591001 1231 12315087	16-55	29AUG2020	73363	Placebo	29AUG2020/ Placebo	18SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12315088	C4591001 1231 12315088	16-55	29AUG2020	73354	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12315089	C4591001 1231 12315089	16-55	29AUG2020	73361	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12315090	C4591001 1231 12315090	16-55	29AUG2020	73390	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12315091	C4591001 1231 12315091	16-55	29AUG2020	73384	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12315092	C4591001 1231 12315092	16-55	29AUG2020	73375	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		
12315093	C4591001 1231 12315093	16-55	29AUG2020	73374	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12315094	C4591001 1231 12315094	16-55	29AUG2020	73373	Placebo	29AUG2020/ Placebo	18SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12315095	C4591001 1231 12315095	16-55	29AUG2020	73391	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
12315098	C4591001 1231 12315098	16-55	29AUG2020	73394	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12315099	C4591001 1231 12315099	16-55	29AUG2020	73397	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12315100	C4591001 1231 12315100	16-55	29AUG2020	73423	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12315101	C4591001 1231 12315101	16-55	29AUG2020	73408	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12315102	C4591001 1231 12315102	16-55	29AUG2020	73393	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12315103	C4591001 1231 12315103	16-55	29AUG2020	73424	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12315104	C4591001 1231 12315104	16-55	29AUG2020	73400	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12315105	C4591001 1231 12315105	16-55	29AUG2020	73428	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		
12315112	C4591001 1231 12315112	16-55	29AUG2020	73402	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12315114	C4591001 1231 12315114	16-55	29AUG2020	73441	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12315115	C4591001 1231 12315115	16-55	29AUG2020	73437	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12315124	C4591001 1231 12315124	16-55	29AUG2020	73432	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12315136	C4591001 1231 12315136	16-55	29AUG2020	73501	Placebo	29AUG2020/ Placebo	18SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12315139	C4591001 1231 12315139	16-55	29AUG2020	73438	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo		
12315140	C4591001 1231 12315140	16-55	29AUG2020	73444	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12315142	C4591001 1231 12315142	16-55	29AUG2020	73481	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12315149	C4591001 1231 12315149	16-55	29AUG2020	73482	Placebo	29AUG2020/ Placebo	19SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12315150	C4591001 1231 12315150	16-55	29AUG2020	73512	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12315154	C4591001 1231 12315154	16-55	29AUG2020	73485	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12315155	C4591001 1231 12315155	16-55	29AUG2020	73484	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		
12315164	C4591001 1231 12315164	16-55	29AUG2020	73508	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12315165	C4591001 1231 12315165	16-55	29AUG2020	73507	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12315166	C4591001 1231 12315166	16-55	29AUG2020	73513	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12315167	C4591001 1231 12315167	16-55	29AUG2020	73503	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12315168	C4591001 1231 12315168	16-55	29AUG2020	73518	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12315169	C4591001 1231 12315169	16-55	29AUG2020	73497	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12315171	C4591001 1231 12315171	16-55	29AUG2020	73499	Placebo	29AUG2020/ Placebo	19SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12315172	C4591001 1231 12315172	16-55	29AUG2020	73523	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
12315175	C4591001 1231 12315175	16-55	29AUG2020	73525	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12315176	C4591001 1231 12315176	16-55	29AUG2020	73533	Placebo	29AUG2020/ Placebo	18SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12315177	C4591001 1231 12315177	16-55	29AUG2020	73530	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12315178	C4591001 1231 12315178	16-55	29AUG2020	73528	Placebo	29AUG2020/ Placebo	18SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12315180	C4591001 1231 12315180	16-55	29AUG2020	73571	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12315182	C4591001 1231 12315182	16-55	29AUG2020	73536	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12315183	C4591001 1231 12315183	16-55	29AUG2020	73572	Placebo	29AUG2020/ Placebo	19SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12315185	C4591001 1231 12315185	16-55	29AUG2020	73531	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12315186	C4591001 1231 12315186	16-55	29AUG2020	73569	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12315187	C4591001 1231 12315187	16-55	29AUG2020	73573	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12315189	C4591001 1231 12315189	16-55	29AUG2020	73546	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
12315190	C4591001 1231 12315190	16-55	29AUG2020	73548	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12315191	C4591001 1231 12315191	16-55	29AUG2020	73589	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
12315194	C4591001 1231 12315194	16-55	29AUG2020	73588	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12315195	C4591001 1231 12315195	16-55	29AUG2020	73552	Placebo	29AUG2020/ Placebo	18SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12315196	C4591001 1231 12315196	16-55	29AUG2020	73579	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12315197	C4591001 1231 12315197	16-55	29AUG2020	73545	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12315198	C4591001 1231 12315198	16-55	29AUG2020	73592	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12315200	C4591001 1231 12315200	16-55	29AUG2020	73583	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12315201	C4591001 1231 12315201	16-55	29AUG2020	73590	Placebo	29AUG2020/ Placebo	21SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12315202	C4591001 1231 12315202	16-55	29AUG2020	73602	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
12315203	C4591001 1231 12315203	16-55	29AUG2020	73586	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12315204	C4591001 1231 12315204	16-55	29AUG2020	73594	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)		
12315205	C4591001 1231 12315205	16-55	29AUG2020	73618	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12315206	C4591001 1231 12315206	16-55	29AUG2020	73610	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12315208	C4591001 1231 12315208	16-55	29AUG2020	73616	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12315209	C4591001 1231 12315209	16-55	29AUG2020	73619	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12315211	C4591001 1231 12315211	16-55	29AUG2020	73611	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo		
12315213	C4591001 1231 12315213	16-55	29AUG2020	73609	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo		
12315214	C4591001 1231 12315214	16-55	29AUG2020	73637	Placebo	29AUG2020/ Placebo	19SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12315215	C4591001 1231 12315215	16-55	29AUG2020	73641	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12315216	C4591001 1231 12315216	16-55	29AUG2020	73620	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12315219	C4591001 1231 12315219	16-55	29AUG2020	73643	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12315220	C4591001 1231 12315220	16-55	29AUG2020	73681	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12315222	C4591001 1231 12315222	16-55	29AUG2020	73642	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12315223	C4591001 1231 12315223	16-55	29AUG2020	73676	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
12315224	C4591001 1231 12315224	16-55	29AUG2020	73725	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12315225	C4591001 1231 12315225	16-55	29AUG2020	73710	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
12315226	C4591001 1231 12315226	16-55	29AUG2020	73674	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12315228	C4591001 1231 12315228	16-55	29AUG2020	73709	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12315229	C4591001 1231 12315229	16-55	29AUG2020	73682	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12315230	C4591001 1231 12315230	16-55	29AUG2020	73713	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12315231	C4591001 1231 12315231	16-55	29AUG2020	73717	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12315234	C4591001 1231 12315234	16-55	29AUG2020	73726	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12315238	C4591001 1231 12315238	16-55	29AUG2020	73731	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		
12315239	C4591001 1231 12315239	16-55	29AUG2020	73763	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12315241	C4591001 1231 12315241	16-55	29AUG2020	73764	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12315242	C4591001 1231 12315242	16-55	29AUG2020	73732	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12315247	C4591001 1231 12315247	16-55	29AUG2020	73779	Placebo	29AUG2020/ Placebo	18SEP2020/ Placebo		
12315248	C4591001 1231 12315248	16-55	29AUG2020	73774	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12315249	C4591001 1231 12315249	16-55	29AUG2020	73761	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12315252	C4591001 1231 12315252	16-55	29AUG2020	73765	Placebo	29AUG2020/ Placebo	18SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
12315253	C4591001 1231 12315253	16-55	29AUG2020	73769	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12315257	C4591001 1231 12315257	16-55	29AUG2020	73780	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		
12315258	C4591001 1231 12315258	16-55	29AUG2020	73807	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12315259	C4591001 1231 12315259	16-55	29AUG2020	73809	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12315263	C4591001 1231 12315263	16-55	29AUG2020	73813	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12315264	C4591001 1231 12315264	16-55	29AUG2020	73973	Placebo	29AUG2020/ Placebo	19SEP2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
12315265	C4591001 1231 12315265	16-55	29AUG2020	73815	Placebo	29AUG2020/ Placebo	29SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12315268	C4591001 1231 12315268	16-55	29AUG2020	74007	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12315269	C4591001 1231 12315269	16-55	29AUG2020	73975	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)			
12315270	C4591001 1231 12315270	16-55	29AUG2020	73919	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		
12315271	C4591001 1231 12315271	16-55	29AUG2020	73917	Placebo	29AUG2020/ Placebo	18SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12315272	C4591001 1231 12315272	16-55	29AUG2020	73924	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12315275	C4591001 1231 12315275	16-55	29AUG2020	73921	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12315276	C4591001 1231 12315276	16-55	29AUG2020	73994	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12315277	C4591001 1231 12315277	16-55	29AUG2020	73982	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12315278	C4591001 1231 12315278	16-55	29AUG2020	73941	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12315279	C4591001 1231 12315279	16-55	29AUG2020	73954	Placebo	29AUG2020/ Placebo	18SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12315280	C4591001 1231 12315280	16-55	29AUG2020	73952	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12315281	C4591001 1231 12315281	16-55	29AUG2020	73938	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12315282	C4591001 1231 12315282	16-55	29AUG2020	73947	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo		
12315283	C4591001 1231 12315283	16-55	29AUG2020	73959	Placebo	29AUG2020/ Placebo	18SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12315284	C4591001 1231 12315284	16-55	29AUG2020	73958	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12315285	C4591001 1231 12315285	16-55	29AUG2020	73945	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12315286	C4591001 1231 12315286	16-55	29AUG2020	74000	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		
12315287	C4591001 1231 12315287	16-55	29AUG2020	73974	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12315288	C4591001 1231 12315288	16-55	29AUG2020	74008	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
12315289	C4591001 1231 12315289	16-55	29AUG2020	73990	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
12315291	C4591001 1231 12315291	16-55	29AUG2020	73991	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12315292	C4591001 1231 12315292	16-55	29AUG2020	74022	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12315294	C4591001 1231 12315294	16-55	29AUG2020	74030	Placebo	29AUG2020/ Placebo	19SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12315295	C4591001 1231 12315295	16-55	29AUG2020	73995	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo		
12315296	C4591001 1231 12315296	16-55	29AUG2020	74046	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12315297	C4591001 1231 12315297	16-55	29AUG2020	74003	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12315298	C4591001 1231 12315298	16-55	29AUG2020	74049	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12315299	C4591001 1231 12315299	16-55	29AUG2020	74027	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12315300	C4591001 1231 12315300	16-55	29AUG2020	74057	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12315302	C4591001 1231 12315302	16-55	29AUG2020	74058	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12315304	C4591001 1231 12315304	16-55	29AUG2020	74060	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		
12315306	C4591001 1231 12315306	16-55	29AUG2020	74098	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
12315307	C4591001 1231 12315307	16-55	29AUG2020	74099	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12315308	C4591001 1231 12315308	16-55	29AUG2020	74100	BNT162b2 (30 µg)				
12315309	C4591001 1231 12315309	16-55	29AUG2020	74026	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12315310	C4591001 1231 12315310	16-55	29AUG2020	74107	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12315311	C4591001 1231 12315311	16-55	29AUG2020	74047	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12315312	C4591001 1231 12315312	16-55	29AUG2020	74110	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12315313	C4591001 1231 12315313	16-55	29AUG2020	74045	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12315316	C4591001 1231 12315316	16-55	29AUG2020	74115	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12315317	C4591001 1231 12315317	16-55	29AUG2020	74064	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12315318	C4591001 1231 12315318	16-55	29AUG2020	74123	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12315319	C4591001 1231 12315319	16-55	29AUG2020	74104	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12315320	C4591001 1231 12315320	16-55	29AUG2020	74126	Placebo	29AUG2020/ Placebo	19SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12315322	C4591001 1231 12315322	16-55	29AUG2020	74130	Placebo	29AUG2020/ Placebo	23OCT2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12315325	C4591001 1231 12315325	16-55	29AUG2020	74118	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12315326	C4591001 1231 12315326	16-55	29AUG2020	74132	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12315329	C4591001 1231 12315329	16-55	29AUG2020	74114	Placebo	29AUG2020/ Placebo	01OCT2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12315330	C4591001 1231 12315330	16-55	29AUG2020	74134	Placebo	29AUG2020/ Placebo	18SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12315333	C4591001 1231 12315333	16-55	29AUG2020	74127	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12315334	C4591001 1231 12315334	16-55	29AUG2020	74156	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12315337	C4591001 1231 12315337	16-55	29AUG2020	74153	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12315338	C4591001 1231 12315338	16-55	29AUG2020	74160	Placebo	29AUG2020/ Placebo	18SEP2020/ Placebo		
12315340	C4591001 1231 12315340	16-55	29AUG2020	74138	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12315342	C4591001 1231 12315342	16-55	29AUG2020	74163	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12315343	C4591001 1231 12315343	16-55	29AUG2020	74173	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12315347	C4591001 1231 12315347	16-55	29AUG2020	74176	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12315348	C4591001 1231 12315348	16-55	29AUG2020	74175	Placebo	29AUG2020/ Placebo	18SEP2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12315349	C4591001 1231 12315349	16-55	29AUG2020	74177	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12315351	C4591001 1231 12315351	16-55	29AUG2020	74180	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12315352	C4591001 1231 12315352	16-55	29AUG2020	74171	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12315353	C4591001 1231 12315353	16-55	29AUG2020	74195	Placebo	29AUG2020/ Placebo	06OCT2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12315355	C4591001 1231 12315355	16-55	29AUG2020	74192	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12315357	C4591001 1231 12315357	16-55	29AUG2020	74189	Placebo	29AUG2020/ Placebo			
12315358	C4591001 1231 12315358	16-55	29AUG2020	74186	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
12315359	C4591001 1231 12315359	16-55	29AUG2020	74183	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12315361	C4591001 1231 12315361	16-55	29AUG2020	74202	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12315362	C4591001 1231 12315362	16-55	29AUG2020	74196	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12315363	C4591001 1231 12315363	16-55	29AUG2020	74212	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12315364	C4591001 1231 12315364	16-55	29AUG2020	74206	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo		
12315365	C4591001 1231 12315365	16-55	29AUG2020	74204	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12315368	C4591001 1231 12315368	16-55	29AUG2020	74216	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12315369	C4591001 1231 12315369	16-55	29AUG2020	74213	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12315370	C4591001 1231 12315370	16-55	29AUG2020	74228	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12315371	C4591001 1231 12315371	16-55	29AUG2020	74231	Placebo	29AUG2020/ Placebo	18SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12315372	C4591001 1231 12315372	16-55	29AUG2020	74234	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12315373	C4591001 1231 12315373	16-55	29AUG2020	74218	Placebo	29AUG2020/ Placebo	18SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12315374	C4591001 1231 12315374	16-55	29AUG2020	74240	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12315375	C4591001 1231 12315375	16-55	29AUG2020	74223	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12315376	C4591001 1231 12315376	16-55	29AUG2020	74245	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12315377	C4591001 1231 12315377	16-55	29AUG2020	74229	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12315378	C4591001 1231 12315378	16-55	29AUG2020	74248	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12315380	C4591001 1231 12315380	16-55	29AUG2020	74262	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12315381	C4591001 1231 12315381	16-55	29AUG2020	74247	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12315386	C4591001 1231 12315386	16-55	30AUG2020	74264	Placebo	30AUG2020/ Placebo	18SEP2020/ Placebo		
12315391	C4591001 1231 12315391	16-55	30AUG2020	74329	BNT162b2 (30 µg)	30AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12315393	C4591001 1231 12315393	16-55	30AUG2020	74318	Placebo	30AUG2020/ Placebo	22SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12315394	C4591001 1231 12315394	16-55	30AUG2020	74300	BNT162b2 (30 µg)	30AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12315397	C4591001 1231 12315397	16-55	30AUG2020	74303	Placebo	30AUG2020/ Placebo	19SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12315400	C4591001 1231 12315400	16-55	30AUG2020	74266	BNT162b2 (30 µg)	30AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		
12315401	C4591001 1231 12315401	16-55	30AUG2020	74271	Placebo	30AUG2020/ Placebo	19SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12315402	C4591001 1231 12315402	16-55	30AUG2020	74326	BNT162b2 (30 µg)	30AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		
12315406	C4591001 1231 12315406	16-55	30AUG2020	74307	Placebo	30AUG2020/ Placebo	18SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12315407	C4591001 1231 12315407	16-55	30AUG2020	74309	BNT162b2 (30 µg)	30AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12315408	C4591001 1231 12315408	16-55	30AUG2020	74301	BNT162b2 (30 µg)	30AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12315409	C4591001 1231 12315409	16-55	30AUG2020	74344	BNT162b2 (30 µg)	30AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12315412	C4591001 1231 12315412	16-55	30AUG2020	74349	BNT162b2 (30 µg)	30AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		
12315413	C4591001 1231 12315413	16-55	30AUG2020	74330	Placebo	30AUG2020/ Placebo	18SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12315414	C4591001 1231 12315414	16-55	30AUG2020	74333	BNT162b2 (30 µg)	30AUG2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
12315415	C4591001 1231 12315415	16-55	30AUG2020	74323	Placebo	30AUG2020/ Placebo	18SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12315416	C4591001 1231 12315416	16-55	30AUG2020	74313	Placebo	30AUG2020/ Placebo	18SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
12315418	C4591001 1231 12315418	16-55	30AUG2020	74315	BNT162b2 (30 µg)	30AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
12315419	C4591001 1231 12315419	16-55	30AUG2020	74354	BNT162b2 (30 µg)	30AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12315420	C4591001 1231 12315420	16-55	30AUG2020	74353	Placebo	30AUG2020/ Placebo	18SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12315421	C4591001 1231 12315421	16-55	30AUG2020	74336	Placebo	30AUG2020/ Placebo	18SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12315422	C4591001 1231 12315422	16-55	30AUG2020	74339	Placebo	30AUG2020/ Placebo	18SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12315424	C4591001 1231 12315424	16-55	30AUG2020	74360	BNT162b2 (30 µg)	30AUG2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
12315426	C4591001 1231 12315426	16-55	30AUG2020	74347	Placebo	30AUG2020/ Placebo	19SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12315427	C4591001 1231 12315427	16-55	30AUG2020	74365	Placebo	30AUG2020/ Placebo	18SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12315429	C4591001 1231 12315429	16-55	30AUG2020	74367	BNT162b2 (30 µg)	30AUG2020/ BNT162b2 (30 µg)			
12315430	C4591001 1231 12315430	16-55	30AUG2020	74368	Placebo	30AUG2020/ Placebo	19SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
12315435	C4591001 1231 12315435	16-55	30AUG2020	74369	Placebo	30AUG2020/ Placebo	18SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	13FEB2021/ BNT162b2 (30 µg)
12315436	C4591001 1231 12315436	16-55	30AUG2020	74375	Placebo	30AUG2020/ Placebo	18SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12315437	C4591001 1231 12315437	16-55	30AUG2020	74372	BNT162b2 (30 µg)	30AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		
12315440	C4591001 1231 12315440	16-55	30AUG2020	74377	BNT162b2 (30 µg)	30AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12315441	C4591001 1231 12315441	16-55	30AUG2020	74386	BNT162b2 (30 µg)	30AUG2020/ BNT162b2 (30 µg)			
12315445	C4591001 1231 12315445	16-55	30AUG2020	74384	Placebo	30AUG2020/ Placebo	19SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12315446	C4591001 1231 12315446	16-55	30AUG2020	74397	Placebo	30AUG2020/ Placebo	19SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12315448	C4591001 1231 12315448	16-55	30AUG2020	74398	BNT162b2 (30 µg)	30AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12315449	C4591001 1231 12315449	16-55	30AUG2020	74387	BNT162b2 (30 µg)	30AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12315450	C4591001 1231 12315450	16-55	30AUG2020	74415	Placebo	30AUG2020/ Placebo	22SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12315451	C4591001 1231 12315451	16-55	30AUG2020	74396	Placebo	30AUG2020/ Placebo	19SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12315453	C4591001 1231 12315453	16-55	30AUG2020	74404	BNT162b2 (30 µg)	30AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		
12315454	C4591001 1231 12315454	16-55	30AUG2020	74388	Placebo	30AUG2020/ Placebo	18SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12315457	C4591001 1231 12315457	16-55	30AUG2020	74412	BNT162b2 (30 µg)	30AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		
12315459	C4591001 1231 12315459	16-55	30AUG2020	74421	BNT162b2 (30 µg)	30AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12315460	C4591001 1231 12315460	16-55	30AUG2020	74414	Placebo	30AUG2020/ Placebo	19SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12315461	C4591001 1231 12315461	16-55	30AUG2020	74410	BNT162b2 (30 µg)	30AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12315462	C4591001 1231 12315462	16-55	30AUG2020	74419	BNT162b2 (30 µg)	30AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12315463	C4591001 1231 12315463	16-55	30AUG2020	74417	Placebo	30AUG2020/ Placebo	18SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12315464	C4591001 1231 12315464	16-55	30AUG2020	74440	BNT162b2 (30 µg)	30AUG2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
12315465	C4591001 1231 12315465	16-55	30AUG2020	74443	Placebo	30AUG2020/ Placebo	18SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12315466	C4591001 1231 12315466	16-55	30AUG2020	74431	Placebo	30AUG2020/ Placebo	19SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12315467	C4591001 1231 12315467	16-55	30AUG2020	74451	Placebo	30AUG2020/ Placebo	19SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12315469	C4591001 1231 12315469	16-55	30AUG2020	74429	BNT162b2 (30 µg)	30AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12315470	C4591001 1231 12315470	16-55	30AUG2020	74448	BNT162b2 (30 µg)	30AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12315471	C4591001 1231 12315471	16-55	30AUG2020	74435	Placebo	30AUG2020/ Placebo	18SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12315472	C4591001 1231 12315472	16-55	30AUG2020	74423	Placebo	30AUG2020/ Placebo	18SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12315473	C4591001 1231 12315473	16-55	30AUG2020	74444	BNT162b2 (30 µg)	30AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		
12315474	C4591001 1231 12315474	16-55	30AUG2020	74453	BNT162b2 (30 µg)	30AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12315475	C4591001 1231 12315475	16-55	30AUG2020	74458	Placebo	30AUG2020/ Placebo	19SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12315477	C4591001 1231 12315477	16-55	30AUG2020	74468	Placebo	30AUG2020/ Placebo	18SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
12315478	C4591001 1231 12315478	16-55	30AUG2020	74463	Placebo	30AUG2020/ Placebo	18SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12315479	C4591001 1231 12315479	16-55	30AUG2020	74465	BNT162b2 (30 µg)	30AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		
12315480	C4591001 1231 12315480	16-55	30AUG2020	74462	BNT162b2 (30 µg)	30AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12315481	C4591001 1231 12315481	16-55	30AUG2020	74471	Placebo	30AUG2020/ Placebo	18SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12315484	C4591001 1231 12315484	16-55	30AUG2020	74467	BNT162b2 (30 µg)	30AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12315487	C4591001 1231 12315487	16-55	30AUG2020	74477	Placebo	30AUG2020/ Placebo	21SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12315489	C4591001 1231 12315489	16-55	30AUG2020	74483	Placebo	30AUG2020/ Placebo	18SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12315491	C4591001 1231 12315491	16-55	30AUG2020	74481	BNT162b2 (30 µg)	30AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12315492	C4591001 1231 12315492	16-55	30AUG2020	74482	BNT162b2 (30 µg)	30AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12315493	C4591001 1231 12315493	16-55	30AUG2020	74500	Placebo	30AUG2020/ Placebo	18SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12315494	C4591001 1231 12315494	16-55	30AUG2020	74497	BNT162b2 (30 µg)	30AUG2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
12315495	C4591001 1231 12315495	16-55	30AUG2020	74490	BNT162b2 (30 µg)	30AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12315496	C4591001 1231 12315496	16-55	30AUG2020	74503	Placebo	30AUG2020/ Placebo	18SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12315497	C4591001 1231 12315497	16-55	30AUG2020	74532	Placebo	30AUG2020/ Placebo	18SEP2020/ Placebo	12MAR2021/ BNT162b2 (30 µg)	
12315498	C4591001 1231 12315498	16-55	30AUG2020	74489	Placebo	30AUG2020/ Placebo	19SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12315499	C4591001 1231 12315499	16-55	30AUG2020	74557	BNT162b2 (30 µg)	30AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12315502	C4591001 1231 12315502	16-55	30AUG2020	74505	BNT162b2 (30 µg)	30AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12315504	C4591001 1231 12315504	16-55	30AUG2020	74509	BNT162b2 (30 µg)	30AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12315505	C4591001 1231 12315505	16-55	30AUG2020	74531	Placebo	30AUG2020/ Placebo	22SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
12315506	C4591001 1231 12315506	16-55	30AUG2020	74522	Placebo	30AUG2020/ Placebo	18SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12315511	C4591001 1231 12315511	16-55	30AUG2020	74502	Placebo	30AUG2020/ Placebo	19SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12315512	C4591001 1231 12315512	16-55	30AUG2020	74517	BNT162b2 (30 µg)	30AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		
12315513	C4591001 1231 12315513	16-55	30AUG2020	74515	Placebo	30AUG2020/ Placebo	18SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12315514	C4591001 1231 12315514	16-55	30AUG2020	74542	BNT162b2 (30 µg)	30AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12315516	C4591001 1231 12315516	16-55	30AUG2020	74540	Placebo	30AUG2020/ Placebo	18SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12315517	C4591001 1231 12315517	16-55	30AUG2020	74519	BNT162b2 (30 µg)	30AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12315518	C4591001 1231 12315518	16-55	30AUG2020	74526	BNT162b2 (30 µg)	30AUG2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
12315519	C4591001 1231 12315519	16-55	30AUG2020	74543	BNT162b2 (30 µg)	30AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		
12315521	C4591001 1231 12315521	16-55	30AUG2020	74525	BNT162b2 (30 µg)	30AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12315525	C4591001 1231 12315525	16-55	30AUG2020	74548	Placebo	30AUG2020/ Placebo	18SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
12315526	C4591001 1231 12315526	16-55	30AUG2020	74558	BNT162b2 (30 µg)	30AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		
12315527	C4591001 1231 12315527	16-55	30AUG2020	74550	Placebo	30AUG2020/ Placebo	19SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12315528	C4591001 1231 12315528	16-55	30AUG2020	74561	Placebo	30AUG2020/ Placebo	28SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12315529	C4591001 1231 12315529	16-55	30AUG2020	74581	BNT162b2 (30 µg)	30AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12315532	C4591001 1231 12315532	16-55	30AUG2020	74552	Placebo	30AUG2020/ Placebo	19SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12315533	C4591001 1231 12315533	16-55	30AUG2020	74563	Placebo	30AUG2020/ Placebo	22SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12315534	C4591001 1231 12315534	16-55	30AUG2020	74564	BNT162b2 (30 µg)	30AUG2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
12315535	C4591001 1231 12315535	16-55	30AUG2020	74577	Placebo	30AUG2020/ Placebo	21SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12315537	C4591001 1231 12315537	16-55	30AUG2020	74569	BNT162b2 (30 µg)	30AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12315538	C4591001 1231 12315538	16-55	30AUG2020	74578	Placebo	30AUG2020/ Placebo	18SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12315540	C4591001 1231 12315540	16-55	31AUG2020	74599	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		
12315541	C4591001 1231 12315541	16-55	31AUG2020	74583	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		
12315542	C4591001 1231 12315542	16-55	31AUG2020	74605	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		
12315543	C4591001 1231 12315543	16-55	31AUG2020	74603	Placebo	31AUG2020/ Placebo	19SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12315544	C4591001 1231 12315544	16-55	31AUG2020	74643	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
12315545	C4591001 1231 12315545	16-55	31AUG2020	74608	Placebo	31AUG2020/ Placebo	19SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12315546	C4591001 1231 12315546	16-55	31AUG2020	74639	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		
12315547	C4591001 1231 12315547	16-55	31AUG2020	74614	Placebo	31AUG2020/ Placebo	28SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12315550	C4591001 1231 12315550	16-55	31AUG2020	74619	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
12315551	C4591001 1231 12315551	16-55	31AUG2020	74610	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		
12315552	C4591001 1231 12315552	16-55	31AUG2020	74640	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		
12315553	C4591001 1231 12315553	16-55	31AUG2020	74618	Placebo	31AUG2020/ Placebo	19SEP2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12315554	C4591001 1231 12315554	16-55	31AUG2020	74637	Placebo	31AUG2020/ Placebo	19SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12315558	C4591001 1231 12315558	16-55	31AUG2020	74687	Placebo	31AUG2020/ Placebo	19SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
12315559	C4591001 1231 12315559	16-55	31AUG2020	74692	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		
12315560	C4591001 1231 12315560	16-55	31AUG2020	74684	Placebo	31AUG2020/ Placebo	19SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12315561	C4591001 1231 12315561	16-55	31AUG2020	74691	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
12315563	C4591001 1231 12315563	16-55	31AUG2020	74706	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		
12315566	C4591001 1231 12315566	16-55	31AUG2020	74709	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		
12315567	C4591001 1231 12315567	16-55	31AUG2020	219995	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		
12315568	C4591001 1231 12315568	16-55	31AUG2020	74710	Placebo	31AUG2020/ Placebo	19SEP2020/ Placebo		
12315572	C4591001 1231 12315572	16-55	31AUG2020	74711	Placebo	31AUG2020/ Placebo	19SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12315575	C4591001 1231 12315575	16-55	31AUG2020	74827	Placebo	31AUG2020/ Placebo	19SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12315576	C4591001 1231 12315576	16-55	31AUG2020	74828	Placebo	31AUG2020/ Placebo	19SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12315577	C4591001 1231 12315577	16-55	31AUG2020	74835	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		
12315578	C4591001 1231 12315578	16-55	31AUG2020	74832	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12315580	C4591001 1231 12315580	16-55	31AUG2020	74876	Placebo	31AUG2020/ Placebo	19SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
12315581	C4591001 1231 12315581	16-55	31AUG2020	74875	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		
12315583	C4591001 1231 12315583	16-55	31AUG2020	74880	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		
12315585	C4591001 1231 12315585	16-55	31AUG2020	74882	Placebo	31AUG2020/ Placebo	19SEP2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
12315586	C4591001 1231 12315586	16-55	31AUG2020	74897	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		
12315590	C4591001 1231 12315590	16-55	31AUG2020	74901	Placebo	31AUG2020/ Placebo	19SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12315591	C4591001 1231 12315591	16-55	31AUG2020	74900	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		
12315595	C4591001 1231 12315595	16-55	31AUG2020	74993	Placebo	31AUG2020/ Placebo	19SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
12315596	C4591001 1231 12315596	16-55	31AUG2020	74902	Placebo	31AUG2020/ Placebo	19SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12315599	C4591001 1231 12315599	16-55	31AUG2020	74997	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12315600	C4591001 1231 12315600	16-55	31AUG2020	74998	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)			
12315601	C4591001 1231 12315601	16-55	31AUG2020	75077	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
12315603	C4591001 1231 12315603	16-55	31AUG2020	75078	Placebo	31AUG2020/ Placebo	19SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12315605	C4591001 1231 12315605	16-55	31AUG2020	75002	Placebo	31AUG2020/ Placebo	19SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12315609	C4591001 1231 12315609	16-55	31AUG2020	75081	Placebo	31AUG2020/ Placebo	19SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12315613	C4591001 1231 12315613	16-55	31AUG2020	75084	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		
12315615	C4591001 1231 12315615	16-55	31AUG2020	75428	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		
12315616	C4591001 1231 12315616	16-55	31AUG2020	75425	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		
12315618	C4591001 1231 12315618	16-55	31AUG2020	75435	Placebo	31AUG2020/ Placebo	22SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	13FEB2021/ BNT162b2 (30 µg)
12315621	C4591001 1231 12315621	16-55	31AUG2020	75436	Placebo	31AUG2020/ Placebo	19SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12315622	C4591001 1231 12315622	16-55	31AUG2020	75546	Placebo	31AUG2020/ Placebo	19SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12315623	C4591001 1231 12315623	16-55	31AUG2020	75668	Placebo	31AUG2020/ Placebo	19SEP2020/ Placebo		
12315624	C4591001 1231 12315624	16-55	31AUG2020	75550	Placebo	31AUG2020/ Placebo	22SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12315626	C4591001 1231 12315626	16-55	31AUG2020	75671	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		
12315627	C4591001 1231 12315627	16-55	31AUG2020	75757	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		
12315628	C4591001 1231 12315628	16-55	31AUG2020	75665	Placebo	31AUG2020/ Placebo	19SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12315629	C4591001 1231 12315629	16-55	31AUG2020	75705	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		
12315630	C4591001 1231 12315630	16-55	31AUG2020	75551	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		
12315633	C4591001 1231 12315633	16-55	31AUG2020	75673	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		
12315635	C4591001 1231 12315635	16-55	31AUG2020	75791	Placebo	31AUG2020/ Placebo	22SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12315636	C4591001 1231 12315636	16-55	31AUG2020	75704	Placebo	31AUG2020/ Placebo	19SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12315637	C4591001 1231 12315637	16-55	31AUG2020	75711	Placebo	31AUG2020/ Placebo	19SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12315638	C4591001 1231 12315638	16-55	31AUG2020	75713	Placebo	31AUG2020/ Placebo	19SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12315639	C4591001 1231 12315639	16-55	31AUG2020	75553	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		
12315641	C4591001 1231 12315641	16-55	31AUG2020	75716	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
12315642	C4591001 1231 12315642	16-55	31AUG2020	75720	Placebo	31AUG2020/ Placebo	19SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12315643	C4591001 1231 12315643	16-55	31AUG2020	75724	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		
12315644	C4591001 1231 12315644	16-55	31AUG2020	75706	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		
12315645	C4591001 1231 12315645	16-55	31AUG2020	75758	Placebo	31AUG2020/ Placebo	19SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12315646	C4591001 1231 12315646	16-55	31AUG2020	75752	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12315647	C4591001 1231 12315647	16-55	31AUG2020	75759	Placebo	31AUG2020/ Placebo	19SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12315648	C4591001 1231 12315648	16-55	31AUG2020	75789	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		
12315649	C4591001 1231 12315649	16-55	31AUG2020	75785	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		
12315650	C4591001 1231 12315650	16-55	31AUG2020	75790	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12315651	C4591001 1231 12315651	16-55	31AUG2020	75839	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		
12315652	C4591001 1231 12315652	16-55	31AUG2020	75835	Placebo	31AUG2020/ Placebo	19SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
12315659	C4591001 1231 12315659	16-55	31AUG2020	75843	Placebo	31AUG2020/ Placebo	19SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12315663	C4591001 1231 12315663	16-55	31AUG2020	75844	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
12315666	C4591001 1231 12315666	16-55	31AUG2020	76014	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		
12315667	C4591001 1231 12315667	16-55	31AUG2020	76018	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12315673	C4591001 1231 12315673	16-55	31AUG2020	76024	Placebo	31AUG2020/ Placebo	19SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12315674	C4591001 1231 12315674	16-55	31AUG2020	76020	Placebo	31AUG2020/ Placebo	19SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12315676	C4591001 1231 12315676	16-55	31AUG2020	76067	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		
12315677	C4591001 1231 12315677	16-55	31AUG2020	76056	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		
12315678	C4591001 1231 12315678	16-55	31AUG2020	76055	Placebo	31AUG2020/ Placebo	19SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12315680	C4591001 1231 12315680	16-55	31AUG2020	76060	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
12315681	C4591001 1231 12315681	16-55	31AUG2020	76057	Placebo	31AUG2020/ Placebo	22OCT2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12315682	C4591001 1231 12315682	16-55	31AUG2020	76071	Placebo	31AUG2020/ Placebo	19SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12315684	C4591001 1231 12315684	16-55	31AUG2020	76070	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		
12321027	C4591001 1232 12321027	16-55	17AUG2020	50699	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12321028	C4591001 1232 12321028	16-55	17AUG2020	50701	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12321030	C4591001 1232 12321030	16-55	17AUG2020	50703	Placebo	17AUG2020/ Placebo	10SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12321033	C4591001 1232 12321033	16-55	17AUG2020	53190	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	21DEC2020/ BNT162b2 (30 µg)		
12321036	C4591001 1232 12321036	16-55	18AUG2020	53193	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
12321037	C4591001 1232 12321037	16-55	18AUG2020	53200	BNT162b2 (30 µg)				
12321038	C4591001 1232 12321038	16-55	18AUG2020	53195	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
12321040	C4591001 1232 12321040	16-55	18AUG2020	54571	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12321042	C4591001 1232 12321042	16-55	18AUG2020	54572	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12321043	C4591001 1232 12321043	16-55	18AUG2020	54577	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12321044	C4591001 1232 12321044	16-55	19AUG2020	54579	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12321045	C4591001 1232 12321045	16-55	19AUG2020	55818	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12321046	C4591001 1232 12321046	16-55	19AUG2020	55821	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
12321048	C4591001 1232 12321048	16-55	19AUG2020	55827	Placebo	19AUG2020/ Placebo	08SEP2020/ Placebo		
12321049	C4591001 1232 12321049	16-55	19AUG2020	55828	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12321052	C4591001 1232 12321052	16-55	19AUG2020	56465	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
12321053	C4591001 1232 12321053	16-55	19AUG2020	56469	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12321054	C4591001 1232 12321054	16-55	19AUG2020	56472	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo		
12321055	C4591001 1232 12321055	16-55	19AUG2020	56476	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12321056	C4591001 1232 12321056	16-55	19AUG2020	56549	Placebo	19AUG2020/ Placebo	23SEP2020/ Placebo		
12321057	C4591001 1232 12321057	16-55	19AUG2020	56553	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12321060	C4591001 1232 12321060	16-55	19AUG2020	56554	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12321061	C4591001 1232 12321061	16-55	19AUG2020	56559	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12321066	C4591001 1232 12321066	16-55	20AUG2020	58385	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12321068	C4591001 1232 12321068	16-55	20AUG2020	58389	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12321069	C4591001 1232 12321069	16-55	24AUG2020	58393	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
12321070	C4591001 1232 12321070	16-55	24AUG2020	58394	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo		
12321071	C4591001 1232 12321071	16-55	24AUG2020	63296	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12321072	C4591001 1232 12321072	16-55	24AUG2020	63353	Placebo	24AUG2020/ Placebo	16SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12321074	C4591001 1232 12321074	16-55	24AUG2020	63359	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12321079	C4591001 1232 12321079	16-55	24AUG2020	63361	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12321080	C4591001 1232 12321080	16-55	24AUG2020	63362	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12321084	C4591001 1232 12321084	16-55	25AUG2020	63776	Placebo	25AUG2020/ Placebo	14SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12321086	C4591001 1232 12321086	16-55	25AUG2020	63777	Placebo	25AUG2020/ Placebo	14SEP2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
12321087	C4591001 1232 12321087	16-55	25AUG2020	63778	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
12321089	C4591001 1232 12321089	16-55	25AUG2020	65525	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12321090	C4591001 1232 12321090	16-55	25AUG2020	65526	Placebo	25AUG2020/ Placebo	16SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
12321091	C4591001 1232 12321091	16-55	25AUG2020	65527	Placebo	25AUG2020/ Placebo	25SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
12321092	C4591001 1232 12321092	16-55	25AUG2020	65535	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12321093	C4591001 1232 12321093	16-55	25AUG2020	65767	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo		
12321094	C4591001 1232 12321094	16-55	25AUG2020	65829	Placebo	25AUG2020/ Placebo	17SEP2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12321095	C4591001 1232 12321095	16-55	26AUG2020	65830	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12321098	C4591001 1232 12321098	16-55	26AUG2020	65833	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12321099	C4591001 1232 12321099	16-55	26AUG2020	65834	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12321100	C4591001 1232 12321100	16-55	26AUG2020	67541	Placebo	26AUG2020/ Placebo		16FEB2021/ BNT162b2 (30 µg)	
12321101	C4591001 1232 12321101	16-55	26AUG2020	67543	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)			
12321104	C4591001 1232 12321104	16-55	26AUG2020	67547	Placebo	26AUG2020/ Placebo	18SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12321108	C4591001 1232 12321108	16-55	26AUG2020	67552	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12321111	C4591001 1232 12321111	16-55	26AUG2020	68802	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12321112	C4591001 1232 12321112	16-55	26AUG2020	68803	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	02MAR2021/ BNT162b2 (30 µg)	
12321114	C4591001 1232 12321114	16-55	26AUG2020	68809	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12321116	C4591001 1232 12321116	16-55	27AUG2020	68811	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo		
12321119	C4591001 1232 12321119	16-55	27AUG2020	69665	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12321120	C4591001 1232 12321120	16-55	27AUG2020	69667	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12321121	C4591001 1232 12321121	16-55	27AUG2020	69668	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12321122	C4591001 1232 12321122	16-55	27AUG2020	69671	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12321123	C4591001 1232 12321123	16-55	27AUG2020	69859	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12321124	C4591001 1232 12321124	16-55	27AUG2020	69861	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
12321130	C4591001 1232 12321130	16-55	27AUG2020	69862	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	11MAR2021/ BNT162b2 (30 µg)	
12321132	C4591001 1232 12321132	16-55	31AUG2020	69863	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
12321135	C4591001 1232 12321135	16-55	31AUG2020	74935	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12321139	C4591001 1232 12321139	16-55	31AUG2020	74939	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
12321140	C4591001 1232 12321140	16-55	31AUG2020	74943	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)
12321141	C4591001 1232 12321141	16-55	31AUG2020	75598	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
12321142	C4591001 1232 12321142	16-55	31AUG2020	74944	Placebo	31AUG2020/ Placebo		09FEB2021/ BNT162b2 (30 µg)	
12321145	C4591001 1232 12321145	16-55	01SEP2020	75600	Placebo	01SEP2020/ Placebo	21SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
12321146	C4591001 1232 12321146	16-55	01SEP2020	75601	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
12321147	C4591001 1232 12321147	16-55	01SEP2020	75604	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
12321151	C4591001 1232 12321151	16-55	01SEP2020	76554	Placebo	01SEP2020/ Placebo	21SEP2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12321155	C4591001 1232 12321155	16-55	01SEP2020	76555	Placebo	01SEP2020/ Placebo	21SEP2020/ Placebo		
12321158	C4591001 1232 12321158	16-55	01SEP2020	76557	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12321159	C4591001 1232 12321159	16-55	02SEP2020	76558	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
12321160	C4591001 1232 12321160	16-55	02SEP2020	77849	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
12321163	C4591001 1232 12321163	16-55	02SEP2020	77850	Placebo	02SEP2020/ Placebo	21SEP2020/ Placebo		
12321164	C4591001 1232 12321164	16-55	02SEP2020	77853	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
12321167	C4591001 1232 12321167	16-55	02SEP2020	77856	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
12321168	C4591001 1232 12321168	16-55	02SEP2020	78151	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
12321169	C4591001 1232 12321169	16-55	02SEP2020	78152	Placebo	02SEP2020/ Placebo	21SEP2020/ Placebo		
12321172	C4591001 1232 12321172	16-55	02SEP2020	78156	Placebo	02SEP2020/ Placebo	22SEP2020/ Placebo		
12321173	C4591001 1232 12321173	16-55	02SEP2020	78158	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
12321174	C4591001 1232 12321174	16-55	03SEP2020	79553	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12321175	C4591001 1232 12321175	16-55	03SEP2020	79556	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)			
12321177	C4591001 1232 12321177	16-55	03SEP2020	79557	Placebo	03SEP2020/ Placebo	22SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12321179	C4591001 1232 12321179	16-55	03SEP2020	79560	Placebo	03SEP2020/ Placebo	22SEP2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12321180	C4591001 1232 12321180	16-55	03SEP2020	79735	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
12321181	C4591001 1232 12321181	16-55	03SEP2020	79736	Placebo	03SEP2020/ Placebo	23SEP2020/ Placebo		
12321183	C4591001 1232 12321183	16-55	03SEP2020	79738	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
12321185	C4591001 1232 12321185	16-55	03SEP2020	79743	Placebo	03SEP2020/ Placebo	22SEP2020/ Placebo		
12321186	C4591001 1232 12321186	16-55	03SEP2020	80038	Placebo	03SEP2020/ Placebo	22SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12321189	C4591001 1232 12321189	16-55	03SEP2020	80039	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
12321190	C4591001 1232 12321190	16-55	03SEP2020	80040	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12321193	C4591001 1232 12321193	16-55	08SEP2020	80044	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo		
12321195	C4591001 1232 12321195	16-55	08SEP2020	83429	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
12321198	C4591001 1232 12321198	16-55	08SEP2020	83431	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
12321202	C4591001 1232 12321202	16-55	08SEP2020	83436	Placebo	08SEP2020/ Placebo	01OCT2020/ Placebo		
12321204	C4591001 1232 12321204	16-55	08SEP2020	83438	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
12321206	C4591001 1232 12321206	16-55	09SEP2020	84838	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
12321207	C4591001 1232 12321207	16-55	09SEP2020	84840	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
12321208	C4591001 1232 12321208	16-55	09SEP2020	84843	Placebo	09SEP2020/ Placebo	28SEP2020/ Placebo		
12321209	C4591001 1232 12321209	16-55	09SEP2020	84844	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo		
12321210	C4591001 1232 12321210	16-55	09SEP2020	84977	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
12321211	C4591001 1232 12321211	16-55	09SEP2020	84981	Placebo	09SEP2020/ Placebo	28SEP2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12321213	C4591001 1232 12321213	16-55	09SEP2020	84986	Placebo	09SEP2020/ Placebo			
12321214	C4591001 1232 12321214	16-55	09SEP2020	84988	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
12321216	C4591001 1232 12321216	16-55	09SEP2020	85241	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		
12321219	C4591001 1232 12321219	16-55	10SEP2020	85244	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	24NOV2020/ BNT162b2 (30 µg)		
12321220	C4591001 1232 12321220	16-55	10SEP2020	85245	Placebo	10SEP2020/ Placebo	24NOV2020/ Placebo		
12321221	C4591001 1232 12321221	16-55	10SEP2020	85249	Placebo	10SEP2020/ Placebo	29SEP2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
12321223	C4591001 1232 12321223	16-55	10SEP2020	86525	Placebo	10SEP2020/ Placebo	30SEP2020/ Placebo		
12321224	C4591001 1232 12321224	16-55	10SEP2020	86529	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
12321225	C4591001 1232 12321225	16-55	10SEP2020	86531	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
12321226	C4591001 1232 12321226	16-55	10SEP2020	86534	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12321229	C4591001 1232 12321229	16-55	10SEP2020	86755	Placebo	10SEP2020/ Placebo	30SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
12321231	C4591001 1232 12321231	16-55	10SEP2020	86760	Placebo	10SEP2020/ Placebo	29SEP2020/ Placebo		
12321232	C4591001 1232 12321232	16-55	10SEP2020	86762	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
12321233	C4591001 1232 12321233	16-55	10SEP2020	86763	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)			
12321236	C4591001 1232 12321236	16-55	11SEP2020	256838	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
12321238	C4591001 1232 12321238	16-55	11SEP2020	87773	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
12321241	C4591001 1232 12321241	16-55	11SEP2020	87776	Placebo	11SEP2020/ Placebo	30SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12321243	C4591001 1232 12321243	16-55	11SEP2020	87783	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
12321244	C4591001 1232 12321244	16-55	11SEP2020	87784	Placebo	11SEP2020/ Placebo			
12321246	C4591001 1232 12321246	16-55	11SEP2020	88157	Placebo	11SEP2020/ Placebo	01OCT2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12321247	C4591001 1232 12321247	16-55	11SEP2020	88162	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
12321248	C4591001 1232 12321248	16-55	11SEP2020	88163	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
12321249	C4591001 1232 12321249	16-55	11SEP2020	88164	Placebo	11SEP2020/ Placebo	14OCT2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
12321250	C4591001 1232 12321250	16-55	11SEP2020	88278	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
12321253	C4591001 1232 12321253	16-55	11SEP2020	88282	Placebo	11SEP2020/ Placebo	30SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12321255	C4591001 1232 12321255	16-55	21SEP2020	88285	Placebo	21SEP2020/ Placebo	13OCT2020/ Placebo		
12321260	C4591001 1232 12321260	16-55	22SEP2020	88288	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
12321262	C4591001 1232 12321262	16-55	22SEP2020	96320	Placebo	22SEP2020/ Placebo	14OCT2020/ Placebo		
12321263	C4591001 1232 12321263	16-55	23SEP2020	96322	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
12321264	C4591001 1232 12321264	16-55	23SEP2020	96325	Placebo	23SEP2020/ Placebo	12OCT2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12321265	C4591001 1232 12321265	16-55	23SEP2020	96327	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
12321266	C4591001 1232 12321266	16-55	23SEP2020	97457	Placebo	23SEP2020/ Placebo	15OCT2020/ Placebo		
12321267	C4591001 1232 12321267	16-55	23SEP2020	97459	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
12321268	C4591001 1232 12321268	16-55	23SEP2020	97460	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
12321271	C4591001 1232 12321271	16-55	24SEP2020	97468	Placebo	24SEP2020/ Placebo	13OCT2020/ Placebo		
12321272	C4591001 1232 12321272	16-55	24SEP2020	98609	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
12321274	C4591001 1232 12321274	16-55	24SEP2020	98614	Placebo	24SEP2020/ Placebo	19OCT2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
12321278	C4591001 1232 12321278	16-55	28SEP2020	98615	Placebo	28SEP2020/ Placebo	21OCT2020/ Placebo		
12321279	C4591001 1232 12321279	16-55	28SEP2020	98618	BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		
12321280	C4591001 1232 12321280	16-55	28SEP2020	101382	BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12321282	C4591001 1232 12321282	16-55	29SEP2020	101385	Placebo	29SEP2020/ Placebo	20OCT2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12321283	C4591001 1232 12321283	16-55	29SEP2020	101389	Placebo	29SEP2020/ Placebo	21OCT2020/ Placebo		
12321285	C4591001 1232 12321285	16-55	30SEP2020	101392	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		
12321287	C4591001 1232 12321287	16-55	01OCT2020	102739	Placebo	01OCT2020/ Placebo			
12321288	C4591001 1232 12321288	16-55	01OCT2020	102745	BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		
12321289	C4591001 1232 12321289	16-55	01OCT2020	102746	BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		
12321291	C4591001 1232 12321291	16-55	01OCT2020	102747	Placebo	01OCT2020/ Placebo	22OCT2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12321292	C4591001 1232 12321292	16-55	01OCT2020	102835	Placebo	01OCT2020/ Placebo	22OCT2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12321293	C4591001 1232 12321293	16-55	01OCT2020	102837	BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)			
12321294	C4591001 1232 12321294	16-55	02OCT2020	102839	BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12321296	C4591001 1232 12321296	16-55	05OCT2020	103757	Placebo	05OCT2020/ Placebo	26OCT2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
12321297	C4591001 1232 12321297	16-55	05OCT2020	102842	Placebo	05OCT2020/ Placebo	26OCT2020/ Placebo		
12321299	C4591001 1232 12321299	16-55	06OCT2020	103758	BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)			
12321301	C4591001 1232 12321301	16-55	06OCT2020	103763	Placebo	06OCT2020/ Placebo	26OCT2020/ Placebo	02MAR2021/ BNT162b2 (30 µg)	
12321302	C4591001 1232 12321302	16-55	06OCT2020	104237	BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)		
12321305	C4591001 1232 12321305	16-55	07OCT2020	104240	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	02DEC2020/ BNT162b2 (30 µg)		
12321307	C4591001 1232 12321307	16-55	07OCT2020	104242	Placebo	07OCT2020/ Placebo	26OCT2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
12321308	C4591001 1232 12321308	16-55	07OCT2020	104244	Placebo	07OCT2020/ Placebo	26OCT2020/ Placebo		
12321310	C4591001 1232 12321310	16-55	07OCT2020	104852	Placebo	07OCT2020/ Placebo	25NOV2020/ Placebo		
12321311	C4591001 1232 12321311	16-55	08OCT2020	104857	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12321312	C4591001 1232 12321312	16-55	08OCT2020	104854	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)		
12321313	C4591001 1232 12321313	16-55	08OCT2020	104853	Placebo	08OCT2020/ Placebo	30OCT2020/ Placebo		
12321316	C4591001 1232 12321316	16-55	12OCT2020	106343	BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		
12321317	C4591001 1232 12321317	16-55	12OCT2020	106345	Placebo	12OCT2020/ Placebo	02NOV2020/ Placebo		
12321318	C4591001 1232 12321318	16-55	12OCT2020	106347	Placebo	12OCT2020/ Placebo	11NOV2020/ Placebo		
12321319	C4591001 1232 12321319	16-55	12OCT2020	106348	BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		
12321320	C4591001 1232 12321320	16-55	12OCT2020	106434	BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		
12321321	C4591001 1232 12321321	16-55	12OCT2020	106441	Placebo	12OCT2020/ Placebo	03NOV2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
12321324	C4591001 1232 12321324	16-55	12OCT2020	106442	Placebo	12OCT2020/ Placebo	03NOV2020/ Placebo		
12321327	C4591001 1232 12321327	16-55	13OCT2020	106443	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
12321328	C4591001 1232 12321328	16-55	13OCT2020	106842	Placebo	13OCT2020/ Placebo	03NOV2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12321329	C4591001 1232 12321329	16-55	13OCT2020	106843	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
12321330	C4591001 1232 12321330	16-55	13OCT2020	106849	Placebo	13OCT2020/ Placebo	06NOV2020/ Placebo		
12321331	C4591001 1232 12321331	16-55	13OCT2020	106851	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
12321332	C4591001 1232 12321332	16-55	13OCT2020	106998	Placebo	13OCT2020/ Placebo	05NOV2020/ Placebo		
12321333	C4591001 1232 12321333	16-55	13OCT2020	107000	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
12321335	C4591001 1232 12321335	16-55	14OCT2020	107003	Placebo	14OCT2020/ Placebo	02NOV2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12321336	C4591001 1232 12321336	16-55	14OCT2020	107393	Placebo	14OCT2020/ Placebo	02NOV2020/ Placebo		
12321337	C4591001 1232 12321337	16-55	14OCT2020	107005	BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
12321338	C4591001 1232 12321338	16-55	14OCT2020	107396	Placebo	14OCT2020/ Placebo	02NOV2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
12321339	C4591001 1232 12321339	16-55	14OCT2020	107397	BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12321341	C4591001 1232 12321341	16-55	14OCT2020	107403	BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
12321343	C4591001 1232 12321343	16-55	14OCT2020	107502	Placebo	14OCT2020/ Placebo	05NOV2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12321344	C4591001 1232 12321344	16-55	14OCT2020	107503	Placebo	14OCT2020/ Placebo	05NOV2020/ Placebo		
12321346	C4591001 1232 12321346	16-55	14OCT2020	107504	BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		
12321347	C4591001 1232 12321347	16-55	14OCT2020	107510	BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		
12321348	C4591001 1232 12321348	16-55	14OCT2020	107585	BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
12321350	C4591001 1232 12321350	16-55	15OCT2020	107590	Placebo	15OCT2020/ Placebo	03NOV2020/ Placebo		
12321351	C4591001 1232 12321351	16-55	15OCT2020	107595	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
12321352	C4591001 1232 12321352	16-55	15OCT2020	107591	Placebo	15OCT2020/ Placebo	06NOV2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
12321353	C4591001 1232 12321353	16-55	15OCT2020	108102	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12321354	C4591001 1232 12321354	16-55	15OCT2020	108104	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
12321355	C4591001 1232 12321355	16-55	15OCT2020	108112	Placebo	15OCT2020/ Placebo	03NOV2020/ Placebo		
12321356	C4591001 1232 12321356	16-55	15OCT2020	108107	Placebo	15OCT2020/ Placebo	03NOV2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
12321358	C4591001 1232 12321358	16-55	15OCT2020	108213	Placebo	15OCT2020/ Placebo	03NOV2020/ Placebo		
12321359	C4591001 1232 12321359	16-55	19OCT2020	108217	Placebo	19OCT2020/ Placebo	11NOV2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
12321361	C4591001 1232 12321361	16-55	19OCT2020	108215	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)			
12321362	C4591001 1232 12321362	16-55	19OCT2020	108219	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
12321364	C4591001 1232 12321364	16-55	19OCT2020	110142	Placebo	19OCT2020/ Placebo	09NOV2020/ Placebo		
12321366	C4591001 1232 12321366	16-55	19OCT2020	110147	Placebo	19OCT2020/ Placebo	10NOV2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12321370	C4591001 1232 12321370	16-55	20OCT2020	110148	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12321371	C4591001 1232 12321371	16-55	20OCT2020	110149	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		
12321373	C4591001 1232 12321373	16-55	21OCT2020	111365	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
12321374	C4591001 1232 12321374	16-55	21OCT2020	111366	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		
12321376	C4591001 1232 12321376	16-55	21OCT2020	111371	Placebo	21OCT2020/ Placebo	10NOV2020/ Placebo		
12321377	C4591001 1232 12321377	16-55	22OCT2020	111376	Placebo	22OCT2020/ Placebo	24NOV2020/ Placebo		
12321378	C4591001 1232 12321378	16-55	22OCT2020	112122	Placebo	22OCT2020/ Placebo	28DEC2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
12321380	C4591001 1232 12321380	16-55	22OCT2020	112126	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
12321382	C4591001 1232 12321382	16-55	22OCT2020	112129	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
12321384	C4591001 1232 12321384	16-55	23OCT2020	112131	Placebo	23OCT2020/ Placebo	11NOV2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	
12321385	C4591001 1232 12321385	16-55	23OCT2020	112747	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12321386	C4591001 1232 12321386	16-55	23OCT2020	112748	Placebo	23OCT2020/ Placebo	12NOV2020/ Placebo		
12321391	C4591001 1232 12321391	16-55	23OCT2020	112749	Placebo	23OCT2020/ Placebo	12NOV2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12321393	C4591001 1232 12321393	16-55	23OCT2020	112952	Placebo	23OCT2020/ Placebo	13NOV2020/ Placebo		
12321394	C4591001 1232 12321394	16-55	23OCT2020	112754	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
12321395	C4591001 1232 12321395	16-55	23OCT2020	112953	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
12321396	C4591001 1232 12321396	16-55	23OCT2020	112960	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)			
12321397	C4591001 1232 12321397	16-55	23OCT2020	112958	Placebo	23OCT2020/ Placebo	13NOV2020/ Placebo		
12321400	C4591001 1232 12321400	16-55	23OCT2020	113010	Placebo	23OCT2020/ Placebo			
12321401	C4591001 1232 12321401	16-55	23OCT2020	113012	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	24NOV2020/ BNT162b2 (30 µg)		
12321402	C4591001 1232 12321402	16-55	26OCT2020	113013	Placebo	26OCT2020/ Placebo	27NOV2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
12321404	C4591001 1232 12321404	16-55	26OCT2020	113015	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	23NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12321406	C4591001 1232 12321406	16-55	26OCT2020	113603	Placebo	26OCT2020/ Placebo	23NOV2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12321408	C4591001 1232 12321408	16-55	26OCT2020	113604	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	25NOV2020/ BNT162b2 (30 µg)		
12321412	C4591001 1232 12321412	16-55	27OCT2020	113605	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)			
12321413	C4591001 1232 12321413	16-55	27OCT2020	114054	Placebo	27OCT2020/ Placebo	24NOV2020/ Placebo		
12321414	C4591001 1232 12321414	16-55	27OCT2020	113608	Placebo	27OCT2020/ Placebo	24NOV2020/ Placebo		
12321415	C4591001 1232 12321415	16-55	27OCT2020	114056	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)		
12321416	C4591001 1232 12321416	16-55	27OCT2020	114064	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	24NOV2020/ BNT162b2 (30 µg)		
12321417	C4591001 1232 12321417	16-55	27OCT2020	114061	Placebo	27OCT2020/ Placebo	19NOV2020/ Placebo	02MAR2021/ BNT162b2 (30 µg)	
12321419	C4591001 1232 12321419	16-55	27OCT2020	114114	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)			
12321420	C4591001 1232 12321420	16-55	27OCT2020	114118	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	02DEC2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12321421	C4591001 1232 12321421	16-55	27OCT2020	114121	Placebo	27OCT2020/ Placebo	24NOV2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	
12321422	C4591001 1232 12321422	16-55	27OCT2020	114123	Placebo	27OCT2020/ Placebo	30NOV2020/ Placebo		
12321423	C4591001 1232 12321423	16-55	27OCT2020	114175	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	24NOV2020/ BNT162b2 (30 µg)		
12321424	C4591001 1232 12321424	16-55	27OCT2020	114176	Placebo	27OCT2020/ Placebo	25NOV2020/ Placebo		
12321425	C4591001 1232 12321425	16-55	28OCT2020	114178	BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)			
12321426	C4591001 1232 12321426	16-55	28OCT2020	114180	Placebo	28OCT2020/ Placebo	24NOV2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12321427	C4591001 1232 12321427	16-55	28OCT2020	114342	BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)	24NOV2020/ BNT162b2 (30 µg)		
12321428	C4591001 1232 12321428	16-55	28OCT2020	114347	BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)	23NOV2020/ BNT162b2 (30 µg)		
12321429	C4591001 1232 12321429	16-55	28OCT2020	114348	Placebo	28OCT2020/ Placebo			
12321430	C4591001 1232 12321430	16-55	28OCT2020	114350	Placebo	28OCT2020/ Placebo	25NOV2020/ Placebo		
12321431	C4591001 1232 12321431	16-55	28OCT2020	114437	BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)	24NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12321433	C4591001 1232 12321433	16-55	29OCT2020	114438	Placebo	29OCT2020/ Placebo	25NOV2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12321434	C4591001 1232 12321434	16-55	29OCT2020	114439	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)		
12321435	C4591001 1232 12321435	16-55	29OCT2020	114447	Placebo	29OCT2020/ Placebo	24NOV2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
12351003	C4591001 1235 12351003	16-55	03SEP2020	79709	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
12351004	C4591001 1235 12351004	16-55	03SEP2020	79716	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
12351005	C4591001 1235 12351005	16-55	03SEP2020	79715	Placebo	03SEP2020/ Placebo	23SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
12351006	C4591001 1235 12351006	16-55	03SEP2020	79719	Placebo	03SEP2020/ Placebo	25SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
12351007	C4591001 1235 12351007	16-55	03SEP2020	80381	Placebo	03SEP2020/ Placebo	22SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
12351008	C4591001 1235 12351008	16-55	03SEP2020	80383	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
12351009	C4591001 1235 12351009	16-55	03SEP2020	80388	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	06JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12351011	C4591001 1235 12351011	16-55	04SEP2020	80392	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
12351013	C4591001 1235 12351013	16-55	04SEP2020	81641	Placebo	04SEP2020/ Placebo	23SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
12351014	C4591001 1235 12351014	16-55	04SEP2020	81644	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
12351015	C4591001 1235 12351015	16-55	04SEP2020	81648	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
12351016	C4591001 1235 12351016	16-55	04SEP2020	81651	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12351017	C4591001 1235 12351017	16-55	04SEP2020	82279	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
12351019	C4591001 1235 12351019	16-55	04SEP2020	253364	Placebo	04SEP2020/ Placebo	23SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
12351020	C4591001 1235 12351020	16-55	05SEP2020	82282	Placebo	05SEP2020/ Placebo	25SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
12351023	C4591001 1235 12351023	16-55	05SEP2020	82283	BNT162b2 (30 µg)	05SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
12351024	C4591001 1235 12351024	16-55	05SEP2020	82288	Placebo	05SEP2020/ Placebo	25SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12351025	C4591001 1235 12351025	16-55	05SEP2020	82889	Placebo	05SEP2020/ Placebo	24SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
12351026	C4591001 1235 12351026	16-55	05SEP2020	82893	BNT162b2 (30 µg)	05SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
12351027	C4591001 1235 12351027	16-55	06SEP2020	82897	Placebo	06SEP2020/ Placebo		17DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
12351028	C4591001 1235 12351028	16-55	06SEP2020	82898	BNT162b2 (30 µg)	06SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
12351029	C4591001 1235 12351029	16-55	06SEP2020	83011	Placebo	06SEP2020/ Placebo	28SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	04JAN2021/ BNT162b2 (30 µg)
12351030	C4591001 1235 12351030	16-55	06SEP2020	83015	Placebo	06SEP2020/ Placebo	28SEP2020/ Placebo	06JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
12351033	C4591001 1235 12351033	16-55	07SEP2020	83017	BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
12351034	C4591001 1235 12351034	16-55	08SEP2020	84296	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
12351035	C4591001 1235 12351035	16-55	07SEP2020	83019	BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
12351036	C4591001 1235 12351036	16-55	07SEP2020	83227	Placebo	07SEP2020/ Placebo	29SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12351037	C4591001 1235 12351037	16-55	08SEP2020	83228	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
12351038	C4591001 1235 12351038	16-55	08SEP2020	83230	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
12351040	C4591001 1235 12351040	16-55	08SEP2020	83235	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
12351041	C4591001 1235 12351041	16-55	08SEP2020	84299	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
12351044	C4591001 1235 12351044	16-55	09SEP2020	84300	Placebo	09SEP2020/ Placebo	28SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
12351045	C4591001 1235 12351045	16-55	09SEP2020	84302	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
12351048	C4591001 1235 12351048	16-55	09SEP2020	85796	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
12351049	C4591001 1235 12351049	16-55	09SEP2020	85797	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
12351050	C4591001 1235 12351050	16-55	09SEP2020	85798	Placebo	09SEP2020/ Placebo	29SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
12351052	C4591001 1235 12351052	16-55	10SEP2020	85802	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12351053	C4591001 1235 12351053	16-55	10SEP2020	86705	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
12351054	C4591001 1235 12351054	16-55	10SEP2020	86715	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
12351055	C4591001 1235 12351055	16-55	10SEP2020	86708	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
12351057	C4591001 1235 12351057	16-55	10SEP2020	86712	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
12351058	C4591001 1235 12351058	16-55	11SEP2020	87870	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
12351059	C4591001 1235 12351059	16-55	11SEP2020	87872	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
12351060	C4591001 1235 12351060	16-55	11SEP2020	87876	Placebo	11SEP2020/ Placebo	30SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
12351061	C4591001 1235 12351061	16-55	11SEP2020	87877	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12351063	C4591001 1235 12351063	16-55	11SEP2020	88374	Placebo	11SEP2020/ Placebo	30SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
12351064	C4591001 1235 12351064	16-55	11SEP2020	88378	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12351065	C4591001 1235 12351065	16-55	11SEP2020	88379	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
12351066	C4591001 1235 12351066	16-55	11SEP2020	88381	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
12351067	C4591001 1235 12351067	16-55	11SEP2020	88818	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
12351068	C4591001 1235 12351068	16-55	12SEP2020	88821	Placebo	12SEP2020/ Placebo	02OCT2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
12351070	C4591001 1235 12351070	16-55	14SEP2020	88822	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
12351071	C4591001 1235 12351071	16-55	14SEP2020	88827	Placebo	14SEP2020/ Placebo		18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
12351072	C4591001 1235 12351072	16-55	14SEP2020	89562	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
12351073	C4591001 1235 12351073	16-55	14SEP2020	89563	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
12351074	C4591001 1235 12351074	16-55	14SEP2020	89571	Placebo	14SEP2020/ Placebo	06OCT2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12351079	C4591001 1235 12351079	16-55	15SEP2020	89572	Placebo	15SEP2020/ Placebo	05OCT2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	20JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12351083	C4591001 1235 12351083	16-55	15SEP2020	90462	Placebo	15SEP2020/ Placebo	06OCT2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12351084	C4591001 1235 12351084	16-55	15SEP2020	90463	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
12351088	C4591001 1235 12351088	16-55	16SEP2020	90464	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
12351089	C4591001 1235 12351089	16-55	16SEP2020	90466	Placebo	16SEP2020/ Placebo	08OCT2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	04JAN2021/ BNT162b2 (30 µg)
12351090	C4591001 1235 12351090	16-55	16SEP2020	91349	Placebo	16SEP2020/ Placebo	05OCT2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12351092	C4591001 1235 12351092	16-55	16SEP2020	91353	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
12351093	C4591001 1235 12351093	16-55	16SEP2020	91357	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
12351097	C4591001 1235 12351097	16-55	17SEP2020	91358	Placebo	17SEP2020/ Placebo	09OCT2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
12351098	C4591001 1235 12351098	16-55	17SEP2020	92129	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
12351100	C4591001 1235 12351100	16-55	17SEP2020	92132	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12351101	C4591001 1235 12351101	16-55	17SEP2020	92139	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12351103	C4591001 1235 12351103	16-55	17SEP2020	92140	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12351105	C4591001 1235 12351105	16-55	17SEP2020	92888	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
12351106	C4591001 1235 12351106	16-55	17SEP2020	92890	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
12351108	C4591001 1235 12351108	16-55	18SEP2020	92896	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
12351109	C4591001 1235 12351109	16-55	18SEP2020	92892	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12351110	C4591001 1235 12351110	16-55	18SEP2020	93548	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
12351112	C4591001 1235 12351112	16-55	18SEP2020	93550	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
12351115	C4591001 1235 12351115	16-55	18SEP2020	93552	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
12351116	C4591001 1235 12351116	16-55	18SEP2020	93553	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	15DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12351119	C4591001 1235 12351119	16-55	18SEP2020	94122	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
12351121	C4591001 1235 12351121	16-55	18SEP2020	94123	Placebo	18SEP2020/ Placebo	08OCT2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12351124	C4591001 1235 12351124	16-55	21SEP2020	94126	Placebo	21SEP2020/ Placebo	13OCT2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
12351125	C4591001 1235 12351125	16-55	21SEP2020	94129	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
12351126	C4591001 1235 12351126	16-55	28SEP2020	99706	BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)		
12351127	C4591001 1235 12351127	16-55	21SEP2020	95201	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	04JAN2021/ BNT162b2 (30 µg)
12351128	C4591001 1235 12351128	16-55	21SEP2020	95202	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
12351130	C4591001 1235 12351130	16-55	21SEP2020	95203	Placebo	21SEP2020/ Placebo	13OCT2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
12351131	C4591001 1235 12351131	16-55	21SEP2020	95206	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
12351133	C4591001 1235 12351133	16-55	22SEP2020	96043	Placebo	22SEP2020/ Placebo	14OCT2020/ Placebo	15DEC2020/ BNT162b2 (30 µg)	04JAN2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12351134	C4591001 1235 12351134	16-55	22SEP2020	96046	Placebo	22SEP2020/ Placebo	13OCT2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
12351137	C4591001 1235 12351137	16-55	22SEP2020	96047	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
12351138	C4591001 1235 12351138	16-55	22SEP2020	96052	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
12351141	C4591001 1235 12351141	16-55	23SEP2020	97640	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12351142	C4591001 1235 12351142	16-55	23SEP2020	97644	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
12351143	C4591001 1235 12351143	16-55	23SEP2020	97645	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
12351144	C4591001 1235 12351144	16-55	23SEP2020	97647	Placebo	23SEP2020/ Placebo	12OCT2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
12351145	C4591001 1235 12351145	16-55	23SEP2020	97962	Placebo	23SEP2020/ Placebo	12OCT2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
12351146	C4591001 1235 12351146	16-55	23SEP2020	97963	Placebo	23SEP2020/ Placebo	12OCT2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	04JAN2021/ BNT162b2 (30 µg)
12351149	C4591001 1235 12351149	16-55	24SEP2020	97968	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12351151	C4591001 1235 12351151	16-55	25SEP2020	97969	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
12351152	C4591001 1235 12351152	16-55	25SEP2020	99701	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
12351153	C4591001 1235 12351153	16-55	25SEP2020	99702	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
12351155	C4591001 1235 12351155	16-55	28SEP2020	99703	Placebo	28SEP2020/ Placebo	20OCT2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
12351156	C4591001 1235 12351156	16-55	28SEP2020	101405	Placebo	28SEP2020/ Placebo	21OCT2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12351157	C4591001 1235 12351157	16-55	01OCT2020	101407	BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)		
12351158	C4591001 1235 12351158	16-55	02OCT2020	101408	Placebo	02OCT2020/ Placebo	21OCT2020/ Placebo		
12351159	C4591001 1235 12351159	16-55	02OCT2020	101414	BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)		
12351161	C4591001 1235 12351161	16-55	02OCT2020	103223	BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)		
12351162	C4591001 1235 12351162	16-55	02OCT2020	103224	Placebo	02OCT2020/ Placebo	23OCT2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12351165	C4591001 1235 12351165	16-55	08OCT2020	103225	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		
12351166	C4591001 1235 12351166	16-55	08OCT2020	103226	Placebo	08OCT2020/ Placebo	29OCT2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12351167	C4591001 1235 12351167	16-55	09OCT2020	105934	Placebo				
12351168	C4591001 1235 12351168	16-55	09OCT2020	105936	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)		
12351169	C4591001 1235 12351169	16-55	21OCT2020	110397	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
12351170	C4591001 1235 12351170	16-55	09OCT2020	105937	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)		
12351171	C4591001 1235 12351171	16-55	09OCT2020	105940	Placebo	09OCT2020/ Placebo	29OCT2020/ Placebo	06JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)
12351172	C4591001 1235 12351172	16-55	09OCT2020	106181	Placebo	09OCT2020/ Placebo	28OCT2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
12351173	C4591001 1235 12351173	16-55	13OCT2020	106184	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		
12351174	C4591001 1235 12351174	16-55	13OCT2020	106191	Placebo	13OCT2020/ Placebo	05NOV2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12351175	C4591001 1235 12351175	16-55	14OCT2020	106192	BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
12351180	C4591001 1235 12351180	16-55	15OCT2020	107998	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
12351181	C4591001 1235 12351181	16-55	15OCT2020	107999	Placebo	15OCT2020/ Placebo	04NOV2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
12351186	C4591001 1235 12351186	16-55	15OCT2020	108003	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
12351187	C4591001 1235 12351187	16-55	16OCT2020	108004	Placebo	16OCT2020/ Placebo		25JAN2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12351188	C4591001 1235 12351188	16-55	16OCT2020	108905	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)			
12351189	C4591001 1235 12351189	16-55	16OCT2020	108911	Placebo	16OCT2020/ Placebo	06NOV2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
12351190	C4591001 1235 12351190	16-55	16OCT2020	108912	Placebo	16OCT2020/ Placebo	05NOV2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
12351191	C4591001 1235 12351191	16-55	16OCT2020	108914	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
12351192	C4591001 1235 12351192	16-55	16OCT2020	109265	Placebo	16OCT2020/ Placebo	06NOV2020/ Placebo	15DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12351193	C4591001 1235 12351193	16-55	19OCT2020	109267	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
12351195	C4591001 1235 12351195	16-55	19OCT2020	109270	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
12351196	C4591001 1235 12351196	16-55	19OCT2020	109272	Placebo	19OCT2020/ Placebo	09NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12351197	C4591001 1235 12351197	16-55	19OCT2020	110393	Placebo	19OCT2020/ Placebo	10NOV2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
12351200	C4591001 1235 12351200	16-55	20OCT2020	110396	Placebo	20OCT2020/ Placebo	10NOV2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
12351207	C4591001 1235 12351207	16-55	21OCT2020	110399	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
12351208	C4591001 1235 12351208	16-55	21OCT2020	111582	Placebo	21OCT2020/ Placebo	11NOV2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
12351209	C4591001 1235 12351209	16-55	21OCT2020	111584	Placebo	21OCT2020/ Placebo	09NOV2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
12351212	C4591001 1235 12351212	16-55	21OCT2020	111587	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
12351214	C4591001 1235 12351214	16-55	22OCT2020	111590	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12351215	C4591001 1235 12351215	16-55	22OCT2020	112422	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		
12351217	C4591001 1235 12351217	16-55	23OCT2020	112425	Placebo	23OCT2020/ Placebo	13NOV2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12351218	C4591001 1235 12351218	16-55	23OCT2020	112426	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
12351219	C4591001 1235 12351219	16-55	23OCT2020	112430	Placebo	23OCT2020/ Placebo	13NOV2020/ Placebo		
12351222	C4591001 1235 12351222	16-55	23OCT2020	113129	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
12351223	C4591001 1235 12351223	16-55	23OCT2020	113132	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
12351224	C4591001 1235 12351224	16-55	26OCT2020	113137	Placebo	26OCT2020/ Placebo	16NOV2020/ Placebo	15DEC2020/ BNT162b2 (30 µg)	04JAN2021/ BNT162b2 (30 µg)
12351225	C4591001 1235 12351225	16-55	29OCT2020	113138	Placebo	29OCT2020/ Placebo	17NOV2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12351226	C4591001 1235 12351226	16-55	29OCT2020	114683	Placebo	29OCT2020/ Placebo	17NOV2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12351228	C4591001 1235 12351228	16-55	02NOV2020	114686	Placebo	02NOV2020/ Placebo	23NOV2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	20JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12351230	C4591001 1235 12351230	16-55	03NOV2020	114687	BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)	23NOV2020/ BNT162b2 (30 µg)		
12351231	C4591001 1235 12351231	16-55	03NOV2020	114688	BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)	23NOV2020/ BNT162b2 (30 µg)		
12351237	C4591001 1235 12351237	16-55	07DEC2020	117653	BNT162b2 (30 µg)	07DEC2020/ BNT162b2 (30 µg)	28DEC2020/ BNT162b2 (30 µg)		
12351240	C4591001 1235 12351240	16-55	07DEC2020	117654	Placebo	07DEC2020/ Placebo	30DEC2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
12351241	C4591001 1235 12351241	16-55	07DEC2020	117659	BNT162b2 (30 µg)	07DEC2020/ BNT162b2 (30 µg)	28DEC2020/ BNT162b2 (30 µg)		
12411126	C4591001 1241 12411126	16-55	14AUG2020	50324	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12411132	C4591001 1241 12411132	16-55	14AUG2020	50482	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	17DEC2020/ BNT162b2 (30 µg)		
12411134	C4591001 1241 12411134	16-55	14AUG2020	50538	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12411135	C4591001 1241 12411135	16-55	14AUG2020	50542	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
12411140	C4591001 1241 12411140	16-55	14AUG2020	50672	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12411142	C4591001 1241 12411142	16-55	17AUG2020	52121	Placebo	17AUG2020/ Placebo	14SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12411143	C4591001 1241 12411143	16-55	17AUG2020	52123	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12411144	C4591001 1241 12411144	16-55	17AUG2020	52125	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	18DEC2020/ BNT162b2 (30 µg)		
12411145	C4591001 1241 12411145	16-55	17AUG2020	52126	Placebo	17AUG2020/ Placebo	09SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12411146	C4591001 1241 12411146	16-55	17AUG2020	52136	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12411148	C4591001 1241 12411148	16-55	17AUG2020	52137	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12411149	C4591001 1241 12411149	16-55	17AUG2020	52140	Placebo	17AUG2020/ Placebo	14SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12411150	C4591001 1241 12411150	16-55	17AUG2020	52142	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
12411152	C4591001 1241 12411152	16-55	17AUG2020	52185	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12411153	C4591001 1241 12411153	16-55	17AUG2020	52186	Placebo	17AUG2020/ Placebo	14SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12411154	C4591001 1241 12411154	16-55	17AUG2020	52188	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12411155	C4591001 1241 12411155	16-55	17AUG2020	52192	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12411156	C4591001 1241 12411156	16-55	17AUG2020	52253	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12411157	C4591001 1241 12411157	16-55	17AUG2020	52256	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12411158	C4591001 1241 12411158	16-55	17AUG2020	52259	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12411159	C4591001 1241 12411159	16-55	17AUG2020	52262	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12411161	C4591001 1241 12411161	16-55	17AUG2020	52388	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12411163	C4591001 1241 12411163	16-55	17AUG2020	52389	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12411164	C4591001 1241 12411164	16-55	17AUG2020	52390	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12411165	C4591001 1241 12411165	16-55	17AUG2020	52393	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12411166	C4591001 1241 12411166	16-55	17AUG2020	52747	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12411167	C4591001 1241 12411167	16-55	17AUG2020	52748	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12411168	C4591001 1241 12411168	16-55	17AUG2020	52750	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12411170	C4591001 1241 12411170	16-55	17AUG2020	52756	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12411171	C4591001 1241 12411171	16-55	17AUG2020	53071	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12411175	C4591001 1241 12411175	16-55	17AUG2020	53073	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12411177	C4591001 1241 12411177	16-55	17AUG2020	53076	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12411178	C4591001 1241 12411178	16-55	17AUG2020	53077	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12411179	C4591001 1241 12411179	16-55	17AUG2020	53361	Placebo	17AUG2020/ Placebo	23SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12411180	C4591001 1241 12411180	16-55	17AUG2020	53363	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12411181	C4591001 1241 12411181	16-55	17AUG2020	53364	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12411183	C4591001 1241 12411183	16-55	17AUG2020	53367	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12411184	C4591001 1241 12411184	16-55	17AUG2020	53478	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12411185	C4591001 1241 12411185	16-55	17AUG2020	53480	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12411186	C4591001 1241 12411186	16-55	17AUG2020	53482	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12411188	C4591001 1241 12411188	16-55	17AUG2020	53488	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12411189	C4591001 1241 12411189	16-55	17AUG2020	53563	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12411190	C4591001 1241 12411190	16-55	17AUG2020	53570	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12411194	C4591001 1241 12411194	16-55	17AUG2020	53571	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12411195	C4591001 1241 12411195	16-55	17AUG2020	53572	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12411197	C4591001 1241 12411197	16-55	17AUG2020	53662	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12411198	C4591001 1241 12411198	16-55	17AUG2020	53664	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12411203	C4591001 1241 12411203	16-55	18AUG2020	53667	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12411204	C4591001 1241 12411204	16-55	18AUG2020	53668	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12411205	C4591001 1241 12411205	16-55	18AUG2020	53754	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
12411206	C4591001 1241 12411206	16-55	18AUG2020	53756	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12411207	C4591001 1241 12411207	16-55	18AUG2020	53761	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12411208	C4591001 1241 12411208	16-55	18AUG2020	53762	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	
12411209	C4591001 1241 12411209	16-55	18AUG2020	53778	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12411210	C4591001 1241 12411210	16-55	18AUG2020	53781	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12411211	C4591001 1241 12411211	16-55	18AUG2020	53782	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo		
12411212	C4591001 1241 12411212	16-55	18AUG2020	53784	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12411213	C4591001 1241 12411213	16-55	18AUG2020	53910	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12411214	C4591001 1241 12411214	16-55	18AUG2020	53911	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12411215	C4591001 1241 12411215	16-55	18AUG2020	53918	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12411216	C4591001 1241 12411216	16-55	18AUG2020	53920	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12411217	C4591001 1241 12411217	16-55	18AUG2020	54066	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12411219	C4591001 1241 12411219	16-55	18AUG2020	54072	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12411220	C4591001 1241 12411220	16-55	18AUG2020	54074	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12411221	C4591001 1241 12411221	16-55	18AUG2020	54076	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12411222	C4591001 1241 12411222	16-55	18AUG2020	54197	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12411223	C4591001 1241 12411223	16-55	18AUG2020	54200	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12411224	C4591001 1241 12411224	16-55	18AUG2020	54204	Placebo	18AUG2020/ Placebo	18SEP2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12411225	C4591001 1241 12411225	16-55	18AUG2020	54205	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12411226	C4591001 1241 12411226	16-55	18AUG2020	54609	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
12411227	C4591001 1241 12411227	16-55	18AUG2020	54611	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12411228	C4591001 1241 12411228	16-55	18AUG2020	54615	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12411229	C4591001 1241 12411229	16-55	18AUG2020	54616	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12411230	C4591001 1241 12411230	16-55	18AUG2020	54689	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12411231	C4591001 1241 12411231	16-55	18AUG2020	54691	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12411232	C4591001 1241 12411232	16-55	18AUG2020	54693	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12411233	C4591001 1241 12411233	16-55	18AUG2020	54700	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12411234	C4591001 1241 12411234	16-55	18AUG2020	54905	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
12411236	C4591001 1241 12411236	16-55	18AUG2020	54907	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12411237	C4591001 1241 12411237	16-55	18AUG2020	54909	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12411239	C4591001 1241 12411239	16-55	18AUG2020	54913	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12411240	C4591001 1241 12411240	16-55	18AUG2020	55135	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12411242	C4591001 1241 12411242	16-55	18AUG2020	55137	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12411243	C4591001 1241 12411243	16-55	18AUG2020	55140	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12411245	C4591001 1241 12411245	16-55	18AUG2020	55144	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12411248	C4591001 1241 12411248	16-55	18AUG2020	55278	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12411250	C4591001 1241 12411250	16-55	18AUG2020	55386	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12411251	C4591001 1241 12411251	16-55	18AUG2020	55394	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12411253	C4591001 1241 12411253	16-55	18AUG2020	55395	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12411255	C4591001 1241 12411255	16-55	18AUG2020	55396	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12411256	C4591001 1241 12411256	16-55	18AUG2020	55469	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12411257	C4591001 1241 12411257	16-55	19AUG2020	55470	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12411258	C4591001 1241 12411258	16-55	19AUG2020	55471	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12411260	C4591001 1241 12411260	16-55	19AUG2020	55478	Placebo	19AUG2020/ Placebo		02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12411261	C4591001 1241 12411261	16-55	19AUG2020	55625	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12411262	C4591001 1241 12411262	16-55	19AUG2020	55627	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12411263	C4591001 1241 12411263	16-55	19AUG2020	55629	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12411264	C4591001 1241 12411264	16-55	19AUG2020	55632	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12411265	C4591001 1241 12411265	16-55	19AUG2020	55676	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12411266	C4591001 1241 12411266	16-55	19AUG2020	55677	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12411267	C4591001 1241 12411267	16-55	19AUG2020	55680	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12411268	C4591001 1241 12411268	16-55	19AUG2020	55682	Placebo	19AUG2020/ Placebo	11SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12411269	C4591001 1241 12411269	16-55	19AUG2020	55770	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12411270	C4591001 1241 12411270	16-55	19AUG2020	55771	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12411271	C4591001 1241 12411271	16-55	19AUG2020	55772	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12411272	C4591001 1241 12411272	16-55	19AUG2020	55780	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12411273	C4591001 1241 12411273	16-55	19AUG2020	55889	Placebo	19AUG2020/ Placebo	23OCT2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12411274	C4591001 1241 12411274	16-55	19AUG2020	55914	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12411275	C4591001 1241 12411275	16-55	19AUG2020	55918	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12411276	C4591001 1241 12411276	16-55	19AUG2020	55919	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12411277	C4591001 1241 12411277	16-55	19AUG2020	55924	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12411278	C4591001 1241 12411278	16-55	19AUG2020	56033	Placebo	19AUG2020/ Placebo	08SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12411279	C4591001 1241 12411279	16-55	19AUG2020	56038	Placebo	19AUG2020/ Placebo		16FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
12411280	C4591001 1241 12411280	16-55	19AUG2020	56039	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12411281	C4591001 1241 12411281	16-55	19AUG2020	56043	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12411282	C4591001 1241 12411282	16-55	19AUG2020	56153	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12411283	C4591001 1241 12411283	16-55	19AUG2020	56155	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12411284	C4591001 1241 12411284	16-55	19AUG2020	56159	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12411285	C4591001 1241 12411285	16-55	19AUG2020	56160	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12411286	C4591001 1241 12411286	16-55	19AUG2020	56226	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12411287	C4591001 1241 12411287	16-55	19AUG2020	56230	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12411288	C4591001 1241 12411288	16-55	19AUG2020	56233	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12411289	C4591001 1241 12411289	16-55	19AUG2020	56236	Placebo	19AUG2020/ Placebo	11SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12411290	C4591001 1241 12411290	16-55	19AUG2020	56477	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
12411291	C4591001 1241 12411291	16-55	19AUG2020	56478	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12411292	C4591001 1241 12411292	16-55	19AUG2020	56485	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12411293	C4591001 1241 12411293	16-55	19AUG2020	56488	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12411294	C4591001 1241 12411294	16-55	19AUG2020	56696	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12411295	C4591001 1241 12411295	16-55	19AUG2020	56697	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
12411296	C4591001 1241 12411296	16-55	19AUG2020	56698	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12411297	C4591001 1241 12411297	16-55	19AUG2020	56703	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12411298	C4591001 1241 12411298	16-55	19AUG2020	56765	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12411299	C4591001 1241 12411299	16-55	19AUG2020	56766	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12411300	C4591001 1241 12411300	16-55	19AUG2020	56775	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12411301	C4591001 1241 12411301	16-55	19AUG2020	56776	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12411302	C4591001 1241 12411302	16-55	19AUG2020	56874	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12411303	C4591001 1241 12411303	16-55	19AUG2020	56875	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12411305	C4591001 1241 12411305	16-55	19AUG2020	56876	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12411307	C4591001 1241 12411307	16-55	19AUG2020	56880	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12411308	C4591001 1241 12411308	16-55	19AUG2020	57152	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12411309	C4591001 1241 12411309	16-55	19AUG2020	57153	Placebo	19AUG2020/ Placebo	08SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12411310	C4591001 1241 12411310	16-55	19AUG2020	57154	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12411311	C4591001 1241 12411311	16-55	19AUG2020	57158	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12411312	C4591001 1241 12411312	16-55	19AUG2020	57272	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12411313	C4591001 1241 12411313	16-55	19AUG2020	57275	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12411314	C4591001 1241 12411314	16-55	19AUG2020	57276	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12411315	C4591001 1241 12411315	16-55	19AUG2020	57280	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12411316	C4591001 1241 12411316	16-55	19AUG2020	57474	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12411317	C4591001 1241 12411317	16-55	19AUG2020	57475	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12411318	C4591001 1241 12411318	16-55	19AUG2020	57479	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12411319	C4591001 1241 12411319	16-55	19AUG2020	57483	Placebo	19AUG2020/ Placebo	11SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12411323	C4591001 1241 12411323	16-55	20AUG2020	57754	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12411324	C4591001 1241 12411324	16-55	20AUG2020	57756	Placebo	20AUG2020/ Placebo	09SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12411326	C4591001 1241 12411326	16-55	20AUG2020	57758	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12411327	C4591001 1241 12411327	16-55	20AUG2020	57760	Placebo	20AUG2020/ Placebo	08SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12411328	C4591001 1241 12411328	16-55	20AUG2020	57762	Placebo	20AUG2020/ Placebo	09SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12411329	C4591001 1241 12411329	16-55	20AUG2020	57765	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12411330	C4591001 1241 12411330	16-55	20AUG2020	57767	Placebo	20AUG2020/ Placebo	11SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12411331	C4591001 1241 12411331	16-55	20AUG2020	57769	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12411332	C4591001 1241 12411332	16-55	20AUG2020	57833	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12411333	C4591001 1241 12411333	16-55	20AUG2020	57839	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12411334	C4591001 1241 12411334	16-55	20AUG2020	57841	Placebo	20AUG2020/ Placebo	11SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12411335	C4591001 1241 12411335	16-55	20AUG2020	57844	Placebo	20AUG2020/ Placebo	11SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12411336	C4591001 1241 12411336	16-55	20AUG2020	57944	Placebo	20AUG2020/ Placebo	11SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12411337	C4591001 1241 12411337	16-55	20AUG2020	57945	Placebo	20AUG2020/ Placebo	11SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12411338	C4591001 1241 12411338	16-55	20AUG2020	57948	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12411339	C4591001 1241 12411339	16-55	20AUG2020	57949	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12411341	C4591001 1241 12411341	16-55	20AUG2020	58111	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12411342	C4591001 1241 12411342	16-55	20AUG2020	58117	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12411343	C4591001 1241 12411343	16-55	20AUG2020	58119	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12411344	C4591001 1241 12411344	16-55	20AUG2020	58120	Placebo	20AUG2020/ Placebo	11SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12411345	C4591001 1241 12411345	16-55	20AUG2020	58277	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12411346	C4591001 1241 12411346	16-55	20AUG2020	58283	Placebo	20AUG2020/ Placebo	11SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12411347	C4591001 1241 12411347	16-55	20AUG2020	58286	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12411348	C4591001 1241 12411348	16-55	20AUG2020	58288	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12411349	C4591001 1241 12411349	16-55	20AUG2020	58378	Placebo	20AUG2020/ Placebo	11SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12411350	C4591001 1241 12411350	16-55	20AUG2020	58380	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12411351	C4591001 1241 12411351	16-55	20AUG2020	58381	Placebo	20AUG2020/ Placebo	11SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12411353	C4591001 1241 12411353	16-55	20AUG2020	58382	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12411354	C4591001 1241 12411354	16-55	20AUG2020	58740	Placebo	20AUG2020/ Placebo	11SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12411355	C4591001 1241 12411355	16-55	20AUG2020	58741	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12411356	C4591001 1241 12411356	16-55	20AUG2020	58743	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12411357	C4591001 1241 12411357	16-55	20AUG2020	58744	Placebo	20AUG2020/ Placebo	11SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12411358	C4591001 1241 12411358	16-55	20AUG2020	58889	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12411359	C4591001 1241 12411359	16-55	20AUG2020	58897	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12411360	C4591001 1241 12411360	16-55	20AUG2020	58898	Placebo	20AUG2020/ Placebo	09SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12411361	C4591001 1241 12411361	16-55	20AUG2020	58899	Placebo	20AUG2020/ Placebo	11SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12411362	C4591001 1241 12411362	16-55	20AUG2020	58989	Placebo	20AUG2020/ Placebo	11SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12411363	C4591001 1241 12411363	16-55	20AUG2020	58990	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
12411365	C4591001 1241 12411365	16-55	20AUG2020	58992	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12411366	C4591001 1241 12411366	16-55	20AUG2020	58995	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12411367	C4591001 1241 12411367	16-55	20AUG2020	59121	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12411368	C4591001 1241 12411368	16-55	20AUG2020	59122	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12411369	C4591001 1241 12411369	16-55	20AUG2020	59124	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12411370	C4591001 1241 12411370	16-55	20AUG2020	59128	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12411372	C4591001 1241 12411372	16-55	20AUG2020	59241	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12411373	C4591001 1241 12411373	16-55	20AUG2020	59242	Placebo	20AUG2020/ Placebo	09SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
12411374	C4591001 1241 12411374	16-55	20AUG2020	59247	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12411375	C4591001 1241 12411375	16-55	20AUG2020	59345	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12411376	C4591001 1241 12411376	16-55	20AUG2020	59347	Placebo	20AUG2020/ Placebo	11SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
12411377	C4591001 1241 12411377	16-55	20AUG2020	59348	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12411378	C4591001 1241 12411378	16-55	20AUG2020	59351	Placebo	20AUG2020/ Placebo	08SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12411379	C4591001 1241 12411379	16-55	20AUG2020	59489	Placebo	20AUG2020/ Placebo	08SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12411380	C4591001 1241 12411380	16-55	20AUG2020	59492	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12411381	C4591001 1241 12411381	16-55	20AUG2020	59495	Placebo	20AUG2020/ Placebo	09SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12411382	C4591001 1241 12411382	16-55	20AUG2020	59500	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12411383	C4591001 1241 12411383	16-55	20AUG2020	59587	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12411384	C4591001 1241 12411384	16-55	20AUG2020	59588	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12411385	C4591001 1241 12411385	16-55	20AUG2020	59589	Placebo	20AUG2020/ Placebo	09SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12411386	C4591001 1241 12411386	16-55	20AUG2020	59593	Placebo	20AUG2020/ Placebo	11SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12411387	C4591001 1241 12411387	16-55	20AUG2020	59693	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12411388	C4591001 1241 12411388	16-55	20AUG2020	59695	Placebo	20AUG2020/ Placebo	11SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
12411389	C4591001 1241 12411389	16-55	20AUG2020	59699	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12411390	C4591001 1241 12411390	16-55	20AUG2020	59702	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12411393	C4591001 1241 12411393	16-55	21AUG2020	59886	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12411395	C4591001 1241 12411395	16-55	21AUG2020	59887	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12411396	C4591001 1241 12411396	16-55	21AUG2020	59890	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12411398	C4591001 1241 12411398	16-55	21AUG2020	59893	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12411399	C4591001 1241 12411399	16-55	21AUG2020	60066	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
12411400	C4591001 1241 12411400	16-55	21AUG2020	60067	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12411401	C4591001 1241 12411401	16-55	21AUG2020	60069	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
12411402	C4591001 1241 12411402	16-55	21AUG2020	60075	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12411403	C4591001 1241 12411403	16-55	21AUG2020	60198	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12411407	C4591001 1241 12411407	16-55	21AUG2020	60200	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12411408	C4591001 1241 12411408	16-55	24AUG2020	60203	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12411409	C4591001 1241 12411409	16-55	24AUG2020	60206	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12411410	C4591001 1241 12411410	16-55	24AUG2020	63197	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
12411411	C4591001 1241 12411411	16-55	24AUG2020	63199	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12411412	C4591001 1241 12411412	16-55	24AUG2020	63201	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12411413	C4591001 1241 12411413	16-55	24AUG2020	63203	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12411414	C4591001 1241 12411414	16-55	24AUG2020	63212	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12411415	C4591001 1241 12411415	16-55	24AUG2020	63214	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12411416	C4591001 1241 12411416	16-55	24AUG2020	63215	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12411417	C4591001 1241 12411417	16-55	24AUG2020	63220	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
12411418	C4591001 1241 12411418	16-55	24AUG2020	63246	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12411419	C4591001 1241 12411419	16-55	24AUG2020	63248	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12411420	C4591001 1241 12411420	16-55	24AUG2020	63252	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
12411421	C4591001 1241 12411421	16-55	24AUG2020	63253	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
12411422	C4591001 1241 12411422	16-55	24AUG2020	63269	Placebo	24AUG2020/ Placebo	15SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
12411423	C4591001 1241 12411423	16-55	24AUG2020	63274	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12411424	C4591001 1241 12411424	16-55	24AUG2020	63277	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12411426	C4591001 1241 12411426	16-55	24AUG2020	63279	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
12411427	C4591001 1241 12411427	16-55	24AUG2020	63341	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12411431	C4591001 1241 12411431	16-55	24AUG2020	63342	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12411432	C4591001 1241 12411432	16-55	24AUG2020	63349	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12411433	C4591001 1241 12411433	16-55	24AUG2020	63352	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12411435	C4591001 1241 12411435	16-55	24AUG2020	63606	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12411436	C4591001 1241 12411436	16-55	24AUG2020	63607	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12411437	C4591001 1241 12411437	16-55	24AUG2020	63613	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12411438	C4591001 1241 12411438	16-55	24AUG2020	63614	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12411439	C4591001 1241 12411439	16-55	24AUG2020	63967	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12411440	C4591001 1241 12411440	16-55	24AUG2020	63970	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12411441	C4591001 1241 12411441	16-55	24AUG2020	63973	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
12411442	C4591001 1241 12411442	16-55	24AUG2020	63975	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12411443	C4591001 1241 12411443	16-55	24AUG2020	64016	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12411444	C4591001 1241 12411444	16-55	24AUG2020	64018	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12411445	C4591001 1241 12411445	16-55	24AUG2020	64021	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
12411446	C4591001 1241 12411446	16-55	24AUG2020	64024	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12411447	C4591001 1241 12411447	16-55	24AUG2020	64195	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12411449	C4591001 1241 12411449	16-55	24AUG2020	64198	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo		
12411450	C4591001 1241 12411450	16-55	24AUG2020	64199	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12411451	C4591001 1241 12411451	16-55	24AUG2020	64203	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12411452	C4591001 1241 12411452	16-55	24AUG2020	64463	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12411453	C4591001 1241 12411453	16-55	24AUG2020	64464	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12411454	C4591001 1241 12411454	16-55	24AUG2020	64467	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12411455	C4591001 1241 12411455	16-55	24AUG2020	64468	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
12411456	C4591001 1241 12411456	16-55	24AUG2020	64567	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12411457	C4591001 1241 12411457	16-55	24AUG2020	64571	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
12411458	C4591001 1241 12411458	16-55	24AUG2020	64576	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12411459	C4591001 1241 12411459	16-55	24AUG2020	64640	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12411460	C4591001 1241 12411460	16-55	24AUG2020	64643	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12411461	C4591001 1241 12411461	16-55	24AUG2020	64644	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12411462	C4591001 1241 12411462	16-55	24AUG2020	64646	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12411463	C4591001 1241 12411463	16-55	24AUG2020	64722	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12411464	C4591001 1241 12411464	16-55	24AUG2020	64723	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12411465	C4591001 1241 12411465	16-55	24AUG2020	64730	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12411466	C4591001 1241 12411466	16-55	24AUG2020	64731	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
12411467	C4591001 1241 12411467	16-55	24AUG2020	64866	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12411468	C4591001 1241 12411468	16-55	25AUG2020	64867	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
12411469	C4591001 1241 12411469	16-55	25AUG2020	64871	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12411470	C4591001 1241 12411470	16-55	25AUG2020	64873	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12411471	C4591001 1241 12411471	16-55	25AUG2020	65073	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12411472	C4591001 1241 12411472	16-55	25AUG2020	65074	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
12411473	C4591001 1241 12411473	16-55	25AUG2020	65076	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12411474	C4591001 1241 12411474	16-55	25AUG2020	65080	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12411475	C4591001 1241 12411475	16-55	25AUG2020	65191	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12411476	C4591001 1241 12411476	16-55	25AUG2020	65192	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12411477	C4591001 1241 12411477	16-55	25AUG2020	65195	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12411478	C4591001 1241 12411478	16-55	25AUG2020	65199	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12411480	C4591001 1241 12411480	16-55	25AUG2020	65263	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
12411481	C4591001 1241 12411481	16-55	25AUG2020	65264	Placebo	25AUG2020/ Placebo	16SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
12411482	C4591001 1241 12411482	16-55	25AUG2020	65266	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)			
12411483	C4591001 1241 12411483	16-55	25AUG2020	65267	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12411484	C4591001 1241 12411484	16-55	25AUG2020	65395	Placebo	25AUG2020/ Placebo	17SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12411486	C4591001 1241 12411486	16-55	25AUG2020	65399	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12411487	C4591001 1241 12411487	16-55	25AUG2020	65401	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12411488	C4591001 1241 12411488	16-55	25AUG2020	65402	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12411489	C4591001 1241 12411489	16-55	25AUG2020	65935	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
12411490	C4591001 1241 12411490	16-55	25AUG2020	65936	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
12411491	C4591001 1241 12411491	16-55	25AUG2020	65938	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12411492	C4591001 1241 12411492	16-55	25AUG2020	65943	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12411493	C4591001 1241 12411493	16-55	25AUG2020	66197	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
12411494	C4591001 1241 12411494	16-55	25AUG2020	66201	Placebo	25AUG2020/ Placebo	14SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	
12411495	C4591001 1241 12411495	16-55	25AUG2020	66204	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12411497	C4591001 1241 12411497	16-55	25AUG2020	66205	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12411499	C4591001 1241 12411499	16-55	25AUG2020	66557	Placebo	25AUG2020/ Placebo	14SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12411500	C4591001 1241 12411500	16-55	25AUG2020	66561	Placebo	25AUG2020/ Placebo	16SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12411501	C4591001 1241 12411501	16-55	25AUG2020	66563	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12411502	C4591001 1241 12411502	16-55	25AUG2020	66567	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12411503	C4591001 1241 12411503	16-55	25AUG2020	66870	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12411504	C4591001 1241 12411504	16-55	25AUG2020	66872	Placebo	25AUG2020/ Placebo	16SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
12411505	C4591001 1241 12411505	16-55	25AUG2020	66873	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12411506	C4591001 1241 12411506	16-55	01SEP2020	66877	Placebo	01SEP2020/ Placebo	23SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12411507	C4591001 1241 12411507	16-55	01SEP2020	76854	Placebo	01SEP2020/ Placebo	24SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12411508	C4591001 1241 12411508	16-55	01SEP2020	76859	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12411509	C4591001 1241 12411509	16-55	01SEP2020	76860	Placebo	01SEP2020/ Placebo	23SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
12411510	C4591001 1241 12411510	16-55	01SEP2020	76862	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
12411511	C4591001 1241 12411511	16-55	01SEP2020	77057	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
12411512	C4591001 1241 12411512	16-55	01SEP2020	77058	Placebo	01SEP2020/ Placebo	23SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12411513	C4591001 1241 12411513	16-55	01SEP2020	77062	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
12411514	C4591001 1241 12411514	16-55	01SEP2020	77063	Placebo	01SEP2020/ Placebo	23SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	
12411515	C4591001 1241 12411515	16-55	01SEP2020	77216	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
12411516	C4591001 1241 12411516	16-55	01SEP2020	77218	Placebo	01SEP2020/ Placebo	21SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12411517	C4591001 1241 12411517	16-55	01SEP2020	77221	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
12411518	C4591001 1241 12411518	16-55	01SEP2020	77224	Placebo	01SEP2020/ Placebo	23SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12411519	C4591001 1241 12411519	16-55	01SEP2020	77322	Placebo	01SEP2020/ Placebo	21SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12411520	C4591001 1241 12411520	16-55	01SEP2020	77324	Placebo	01SEP2020/ Placebo	23SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12411522	C4591001 1241 12411522	16-55	01SEP2020	77329	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
12411524	C4591001 1241 12411524	16-55	01SEP2020	77331	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
12411526	C4591001 1241 12411526	16-55	01SEP2020	77597	Placebo	01SEP2020/ Placebo	23SEP2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	
12411527	C4591001 1241 12411527	16-55	01SEP2020	77598	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
12411528	C4591001 1241 12411528	16-55	01SEP2020	77604	Placebo	01SEP2020/ Placebo	28SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12411530	C4591001 1241 12411530	16-55	01SEP2020	77607	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
12411531	C4591001 1241 12411531	16-55	01SEP2020	77718	Placebo	01SEP2020/ Placebo	23SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12411532	C4591001 1241 12411532	16-55	01SEP2020	77720	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12411535	C4591001 1241 12411535	16-55	02SEP2020	77721	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
12411536	C4591001 1241 12411536	16-55	02SEP2020	77726	Placebo	02SEP2020/ Placebo	22SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12411537	C4591001 1241 12411537	16-55	02SEP2020	78401	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
12411538	C4591001 1241 12411538	16-55	02SEP2020	78404	Placebo	02SEP2020/ Placebo	22SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12411539	C4591001 1241 12411539	16-55	02SEP2020	78405	Placebo	02SEP2020/ Placebo	22SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12411540	C4591001 1241 12411540	16-55	02SEP2020	78410	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
12411541	C4591001 1241 12411541	16-55	02SEP2020	78461	Placebo	02SEP2020/ Placebo	22SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12411542	C4591001 1241 12411542	16-55	02SEP2020	78470	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
12411543	C4591001 1241 12411543	16-55	02SEP2020	78463	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
12411544	C4591001 1241 12411544	16-55	02SEP2020	78472	Placebo	02SEP2020/ Placebo	22SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12411546	C4591001 1241 12411546	16-55	02SEP2020	78618	Placebo	02SEP2020/ Placebo	22SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12411547	C4591001 1241 12411547	16-55	02SEP2020	78620	Placebo	02SEP2020/ Placebo	22SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
12411548	C4591001 1241 12411548	16-55	02SEP2020	78622	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
12411549	C4591001 1241 12411549	16-55	02SEP2020	78623	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
12411552	C4591001 1241 12411552	16-55	02SEP2020	78750	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12411553	C4591001 1241 12411553	16-55	02SEP2020	78752	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
12411555	C4591001 1241 12411555	16-55	02SEP2020	78754	Placebo	02SEP2020/ Placebo	22SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12411556	C4591001 1241 12411556	16-55	02SEP2020	78759	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
12411557	C4591001 1241 12411557	16-55	02SEP2020	78941	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
12411558	C4591001 1241 12411558	16-55	02SEP2020	78944	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12411561	C4591001 1241 12411561	16-55	02SEP2020	78945	Placebo	02SEP2020/ Placebo	22SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12411562	C4591001 1241 12411562	16-55	02SEP2020	78950	Placebo	02SEP2020/ Placebo	22SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
12411563	C4591001 1241 12411563	16-55	02SEP2020	79109	Placebo	02SEP2020/ Placebo	22SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12411564	C4591001 1241 12411564	16-55	02SEP2020	79114	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
12411565	C4591001 1241 12411565	16-55	02SEP2020	79115	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
12411566	C4591001 1241 12411566	16-55	02SEP2020	79117	Placebo	02SEP2020/ Placebo	22SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12411567	C4591001 1241 12411567	16-55	02SEP2020	79230	Placebo	02SEP2020/ Placebo	22SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12411568	C4591001 1241 12411568	16-55	02SEP2020	79233	Placebo	02SEP2020/ Placebo	22SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12411569	C4591001 1241 12411569	16-55	02SEP2020	79235	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
12411570	C4591001 1241 12411570	16-55	02SEP2020	79237	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12411572	C4591001 1241 12411572	16-55	03SEP2020	79798	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
12411573	C4591001 1241 12411573	16-55	03SEP2020	79801	Placebo	03SEP2020/ Placebo	22SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12411574	C4591001 1241 12411574	16-55	03SEP2020	79802	Placebo	03SEP2020/ Placebo	22SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12411575	C4591001 1241 12411575	16-55	03SEP2020	79804	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
12411576	C4591001 1241 12411576	16-55	03SEP2020	80045	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
12411577	C4591001 1241 12411577	16-55	03SEP2020	80047	Placebo	03SEP2020/ Placebo	08OCT2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12411578	C4591001 1241 12411578	16-55	03SEP2020	80048	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
12411579	C4591001 1241 12411579	16-55	03SEP2020	80053	Placebo	03SEP2020/ Placebo	22SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12411580	C4591001 1241 12411580	16-55	03SEP2020	80117	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
12411581	C4591001 1241 12411581	16-55	03SEP2020	80118	Placebo	03SEP2020/ Placebo	22SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12411582	C4591001 1241 12411582	16-55	03SEP2020	80119	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
12411583	C4591001 1241 12411583	16-55	03SEP2020	80122	Placebo	03SEP2020/ Placebo	23SEP2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
12411584	C4591001 1241 12411584	16-55	03SEP2020	80262	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
12411586	C4591001 1241 12411586	16-55	03SEP2020	80264	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
12411587	C4591001 1241 12411587	16-55	03SEP2020	80267	Placebo	03SEP2020/ Placebo	23SEP2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
12411588	C4591001 1241 12411588	16-55	03SEP2020	80541	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
12411589	C4591001 1241 12411589	16-55	03SEP2020	80272	Placebo	03SEP2020/ Placebo	23SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12411590	C4591001 1241 12411590	16-55	03SEP2020	80543	Placebo	03SEP2020/ Placebo	23SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12411592	C4591001 1241 12411592	16-55	03SEP2020	80544	Placebo	03SEP2020/ Placebo	22SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12411593	C4591001 1241 12411593	16-55	03SEP2020	80548	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12411594	C4591001 1241 12411594	16-55	03SEP2020	80609	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
12411595	C4591001 1241 12411595	16-55	03SEP2020	80610	Placebo	03SEP2020/ Placebo	22SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12411596	C4591001 1241 12411596	16-55	03SEP2020	80612	Placebo	03SEP2020/ Placebo	22SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12411598	C4591001 1241 12411598	16-55	03SEP2020	80613	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
12411599	C4591001 1241 12411599	16-55	03SEP2020	80733	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
12411600	C4591001 1241 12411600	16-55	03SEP2020	80737	Placebo	03SEP2020/ Placebo	25SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12411601	C4591001 1241 12411601	16-55	03SEP2020	80739	Placebo	03SEP2020/ Placebo	22SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
12411602	C4591001 1241 12411602	16-55	03SEP2020	80740	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
12411603	C4591001 1241 12411603	16-55	03SEP2020	80816	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
12411604	C4591001 1241 12411604	16-55	03SEP2020	80819	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12411605	C4591001 1241 12411605	16-55	03SEP2020	80822	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12411606	C4591001 1241 12411606	16-55	03SEP2020	80824	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
12411607	C4591001 1241 12411607	16-55	03SEP2020	80993	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
12411608	C4591001 1241 12411608	16-55	03SEP2020	81000	Placebo	03SEP2020/ Placebo	22SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12411609	C4591001 1241 12411609	16-55	03SEP2020	81002	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
12411610	C4591001 1241 12411610	16-55	03SEP2020	81003	Placebo	03SEP2020/ Placebo	22SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12411611	C4591001 1241 12411611	16-55	04SEP2020	81234	Placebo	04SEP2020/ Placebo	23SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12411613	C4591001 1241 12411613	16-55	04SEP2020	81240	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
12411616	C4591001 1241 12411616	16-55	04SEP2020	81241	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
12411617	C4591001 1241 12411617	16-55	04SEP2020	81242	Placebo	04SEP2020/ Placebo	23SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12411619	C4591001 1241 12411619	16-55	04SEP2020	81629	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
12411624	C4591001 1241 12411624	16-55	04SEP2020	81632	Placebo	04SEP2020/ Placebo	23SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12411625	C4591001 1241 12411625	16-55	04SEP2020	81635	Placebo	04SEP2020/ Placebo	23SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12411626	C4591001 1241 12411626	16-55	04SEP2020	81639	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
12411629	C4591001 1241 12411629	16-55	04SEP2020	81990	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
12411630	C4591001 1241 12411630	16-55	04SEP2020	81995	Placebo	04SEP2020/ Placebo	24SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
12411631	C4591001 1241 12411631	16-55	04SEP2020	81998	Placebo	04SEP2020/ Placebo	24SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12411632	C4591001 1241 12411632	16-55	04SEP2020	81999	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
12411633	C4591001 1241 12411633	16-55	04SEP2020	82110	Placebo	04SEP2020/ Placebo	24SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12411634	C4591001 1241 12411634	16-55	04SEP2020	82113	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12411635	C4591001 1241 12411635	16-55	04SEP2020	82116	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12411636	C4591001 1241 12411636	16-55	04SEP2020	82117	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
12411637	C4591001 1241 12411637	16-55	04SEP2020	82254	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
12411638	C4591001 1241 12411638	16-55	04SEP2020	82255	Placebo	04SEP2020/ Placebo	24SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12411639	C4591001 1241 12411639	16-55	04SEP2020	82258	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
12411640	C4591001 1241 12411640	16-55	04SEP2020	82263	Placebo	04SEP2020/ Placebo	24SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12411641	C4591001 1241 12411641	16-55	04SEP2020	82398	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
12411645	C4591001 1241 12411645	16-55	04SEP2020	82448	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
12411646	C4591001 1241 12411646	16-55	04SEP2020	82451	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12411647	C4591001 1241 12411647	16-55	04SEP2020	82452	Placebo	04SEP2020/ Placebo	24SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12411648	C4591001 1241 12411648	16-55	04SEP2020	82455	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
12411649	C4591001 1241 12411649	16-55	04SEP2020	82521	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
12411650	C4591001 1241 12411650	16-55	04SEP2020	82524	Placebo	04SEP2020/ Placebo	24SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12411651	C4591001 1241 12411651	16-55	04SEP2020	82525	Placebo	04SEP2020/ Placebo	02OCT2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12411653	C4591001 1241 12411653	16-55	08SEP2020	82528	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
12411654	C4591001 1241 12411654	16-55	09SEP2020	85076	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
12411655	C4591001 1241 12411655	16-55	09SEP2020	85077	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12411656	C4591001 1241 12411656	16-55	10SEP2020	85081	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
12411657	C4591001 1241 12411657	16-55	10SEP2020	85082	Placebo	10SEP2020/ Placebo	29SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12411658	C4591001 1241 12411658	16-55	10SEP2020	86730	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12411659	C4591001 1241 12411659	16-55	10SEP2020	86731	Placebo	10SEP2020/ Placebo	29SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12411660	C4591001 1241 12411660	16-55	10SEP2020	86738	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
12411661	C4591001 1241 12411661	16-55	10SEP2020	86740	Placebo	10SEP2020/ Placebo	29SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12411662	C4591001 1241 12411662	16-55	10SEP2020	87058	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
12411663	C4591001 1241 12411663	16-55	10SEP2020	87055	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
12411664	C4591001 1241 12411664	16-55	10SEP2020	87062	Placebo	10SEP2020/ Placebo	29SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12411665	C4591001 1241 12411665	16-55	10SEP2020	87063	Placebo	10SEP2020/ Placebo	29SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12411666	C4591001 1241 12411666	16-55	10SEP2020	87354	Placebo	10SEP2020/ Placebo	29SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12411667	C4591001 1241 12411667	16-55	10SEP2020	87357	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
12411668	C4591001 1241 12411668	16-55	10SEP2020	87361	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12411672	C4591001 1241 12411672	16-55	14SEP2020	87364	Placebo	14SEP2020/ Placebo	06OCT2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12411673	C4591001 1241 12411673	16-55	14SEP2020	89372	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12411674	C4591001 1241 12411674	16-55	14SEP2020	89370	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
12411677	C4591001 1241 12411677	16-55	14SEP2020	89375	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12411678	C4591001 1241 12411678	16-55	14SEP2020	89376	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
12411679	C4591001 1241 12411679	16-55	14SEP2020	89645	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo		
12411680	C4591001 1241 12411680	16-55	15SEP2020	89646	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
12411681	C4591001 1241 12411681	16-55	15SEP2020	89647	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
12411683	C4591001 1241 12411683	16-55	15SEP2020	89648	Placebo	15SEP2020/ Placebo	05OCT2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12411684	C4591001 1241 12411684	16-55	15SEP2020	90487	Placebo	15SEP2020/ Placebo	05OCT2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12411685	C4591001 1241 12411685	16-55	15SEP2020	90490	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
12411686	C4591001 1241 12411686	16-55	15SEP2020	90491	Placebo	15SEP2020/ Placebo	05OCT2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12411687	C4591001 1241 12411687	16-55	15SEP2020	90492	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
12411688	C4591001 1241 12411688	16-55	15SEP2020	90534	Placebo	15SEP2020/ Placebo		02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12411689	C4591001 1241 12411689	16-55	15SEP2020	90540	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
12411690	C4591001 1241 12411690	16-55	15SEP2020	90542	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
12411692	C4591001 1241 12411692	16-55	15SEP2020	90544	Placebo	15SEP2020/ Placebo	05OCT2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12411693	C4591001 1241 12411693	16-55	15SEP2020	90569	Placebo	15SEP2020/ Placebo	05OCT2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12411694	C4591001 1241 12411694	16-55	15SEP2020	90570	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
12411695	C4591001 1241 12411695	16-55	15SEP2020	90574	Placebo	15SEP2020/ Placebo		29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12411696	C4591001 1241 12411696	16-55	15SEP2020	90578	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
12411697	C4591001 1241 12411697	16-55	15SEP2020	90644	Placebo	15SEP2020/ Placebo	07OCT2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12411698	C4591001 1241 12411698	16-55	15SEP2020	90645	Placebo	15SEP2020/ Placebo	05OCT2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12411699	C4591001 1241 12411699	16-55	15SEP2020	90650	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
12411700	C4591001 1241 12411700	16-55	15SEP2020	90652	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
12411701	C4591001 1241 12411701	16-55	15SEP2020	90693	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
12411702	C4591001 1241 12411702	16-55	15SEP2020	90696	Placebo	15SEP2020/ Placebo	05OCT2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12411703	C4591001 1241 12411703	16-55	15SEP2020	90697	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
12411706	C4591001 1241 12411706	16-55	15SEP2020	90699	Placebo	15SEP2020/ Placebo	05OCT2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12411707	C4591001 1241 12411707	16-55	16SEP2020	90862	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12411708	C4591001 1241 12411708	16-55	16SEP2020	90865	Placebo	16SEP2020/ Placebo	06OCT2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12411709	C4591001 1241 12411709	16-55	16SEP2020	90866	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
12411710	C4591001 1241 12411710	16-55	16SEP2020	90867	Placebo	16SEP2020/ Placebo	06OCT2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12411712	C4591001 1241 12411712	16-55	16SEP2020	90882	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
12411713	C4591001 1241 12411713	16-55	16SEP2020	90884	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
12411714	C4591001 1241 12411714	16-55	16SEP2020	90887	Placebo	16SEP2020/ Placebo	05OCT2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12411715	C4591001 1241 12411715	16-55	16SEP2020	90890	Placebo	16SEP2020/ Placebo	05OCT2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12411716	C4591001 1241 12411716	16-55	16SEP2020	90911	Placebo	16SEP2020/ Placebo	05OCT2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12411717	C4591001 1241 12411717	16-55	16SEP2020	90912	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
12411718	C4591001 1241 12411718	16-55	16SEP2020	90914	Placebo	16SEP2020/ Placebo	05OCT2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12411719	C4591001 1241 12411719	16-55	16SEP2020	90916	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
12411720	C4591001 1241 12411720	16-55	16SEP2020	90958	Placebo	16SEP2020/ Placebo	05OCT2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12411723	C4591001 1241 12411723	16-55	16SEP2020	90960	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
12411724	C4591001 1241 12411724	16-55	16SEP2020	90961	Placebo	16SEP2020/ Placebo	05OCT2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12411725	C4591001 1241 12411725	16-55	16SEP2020	90962	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
12411726	C4591001 1241 12411726	16-55	16SEP2020	91064	Placebo	16SEP2020/ Placebo	05OCT2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12411727	C4591001 1241 12411727	16-55	16SEP2020	91066	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
12411729	C4591001 1241 12411729	16-55	16SEP2020	91067	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
12411730	C4591001 1241 12411730	16-55	16SEP2020	91070	Placebo	16SEP2020/ Placebo	05OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
12411731	C4591001 1241 12411731	16-55	16SEP2020	91229	Placebo	16SEP2020/ Placebo	05OCT2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12411733	C4591001 1241 12411733	16-55	16SEP2020	91230	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
12411734	C4591001 1241 12411734	16-55	16SEP2020	91235	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
12411735	C4591001 1241 12411735	16-55	16SEP2020	91239	Placebo	16SEP2020/ Placebo	07OCT2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12411736	C4591001 1241 12411736	16-55	16SEP2020	91337	Placebo	16SEP2020/ Placebo	05OCT2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12411740	C4591001 1241 12411740	16-55	16SEP2020	91340	Placebo	16SEP2020/ Placebo	06OCT2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12411741	C4591001 1241 12411741	16-55	16SEP2020	91345	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
12411742	C4591001 1241 12411742	16-55	16SEP2020	91348	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
12411743	C4591001 1241 12411743	16-55	16SEP2020	91388	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
12411744	C4591001 1241 12411744	16-55	16SEP2020	91389	Placebo	16SEP2020/ Placebo	06OCT2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12411745	C4591001 1241 12411745	16-55	16SEP2020	91390	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12411747	C4591001 1241 12411747	16-55	16SEP2020	91396	Placebo	16SEP2020/ Placebo	06OCT2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12411749	C4591001 1241 12411749	16-55	16SEP2020	91471	Placebo	16SEP2020/ Placebo	06OCT2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
12411750	C4591001 1241 12411750	16-55	16SEP2020	91472	Placebo	16SEP2020/ Placebo	06OCT2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12411754	C4591001 1241 12411754	16-55	16SEP2020	91474	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
12411756	C4591001 1241 12411756	16-55	16SEP2020	91480	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
12411757	C4591001 1241 12411757	16-55	16SEP2020	91592	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
12411758	C4591001 1241 12411758	16-55	16SEP2020	91594	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
12411760	C4591001 1241 12411760	16-55	16SEP2020	91599	Placebo	16SEP2020/ Placebo	07OCT2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12411762	C4591001 1241 12411762	16-55	16SEP2020	91600	Placebo	16SEP2020/ Placebo	07OCT2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12411763	C4591001 1241 12411763	16-55	16SEP2020	91677	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12411764	C4591001 1241 12411764	16-55	16SEP2020	91678	Placebo	16SEP2020/ Placebo	06OCT2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12411765	C4591001 1241 12411765	16-55	16SEP2020	91679	Placebo	16SEP2020/ Placebo	06OCT2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
12411766	C4591001 1241 12411766	16-55	16SEP2020	91683	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)			
12411767	C4591001 1241 12411767	16-55	16SEP2020	91781	Placebo	16SEP2020/ Placebo	06OCT2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
12411768	C4591001 1241 12411768	16-55	16SEP2020	91785	Placebo	16SEP2020/ Placebo	06OCT2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12411769	C4591001 1241 12411769	16-55	16SEP2020	91788	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
12411771	C4591001 1241 12411771	16-55	16SEP2020	91789	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
12411772	C4591001 1241 12411772	16-55	16SEP2020	91818	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
12411773	C4591001 1241 12411773	16-55	16SEP2020	91819	Placebo	16SEP2020/ Placebo	06OCT2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12411774	C4591001 1241 12411774	16-55	16SEP2020	91824	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12411775	C4591001 1241 12411775	16-55	16SEP2020	91828	Placebo	16SEP2020/ Placebo	07OCT2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12411776	C4591001 1241 12411776	16-55	16SEP2020	91830	Placebo	16SEP2020/ Placebo	07OCT2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
12411777	C4591001 1241 12411777	16-55	16SEP2020	91832	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
12411778	C4591001 1241 12411778	16-55	16SEP2020	91837	Placebo	16SEP2020/ Placebo	07OCT2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12411779	C4591001 1241 12411779	16-55	16SEP2020	91839	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
12411780	C4591001 1241 12411780	16-55	16SEP2020	91867	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
12411781	C4591001 1241 12411781	16-55	16SEP2020	91869	Placebo	16SEP2020/ Placebo	08OCT2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
12411782	C4591001 1241 12411782	16-55	16SEP2020	91873	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
12411784	C4591001 1241 12411784	16-55	16SEP2020	91876	Placebo	16SEP2020/ Placebo	09OCT2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12411785	C4591001 1241 12411785	16-55	16SEP2020	91892	Placebo	16SEP2020/ Placebo	07OCT2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12411786	C4591001 1241 12411786	16-55	16SEP2020	91893	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
12411787	C4591001 1241 12411787	16-55	16SEP2020	91895	Placebo	16SEP2020/ Placebo	09OCT2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12411790	C4591001 1241 12411790	16-55	17SEP2020	91898	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
12411791	C4591001 1241 12411791	16-55	17SEP2020	91929	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12411792	C4591001 1241 12411792	16-55	17SEP2020	91930	Placebo	17SEP2020/ Placebo	20OCT2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12411793	C4591001 1241 12411793	16-55	17SEP2020	91933	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
12411797	C4591001 1241 12411797	16-55	17SEP2020	91935	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
12411798	C4591001 1241 12411798	16-55	17SEP2020	91985	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12411799	C4591001 1241 12411799	16-55	17SEP2020	91991	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
12411800	C4591001 1241 12411800	16-55	17SEP2020	91992	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12411801	C4591001 1241 12411801	16-55	17SEP2020	91996	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12411802	C4591001 1241 12411802	16-55	17SEP2020	92084	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
12411803	C4591001 1241 12411803	16-55	17SEP2020	92087	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
12411804	C4591001 1241 12411804	16-55	17SEP2020	92090	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12411805	C4591001 1241 12411805	16-55	17SEP2020	92145	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
12411806	C4591001 1241 12411806	16-55	17SEP2020	92148	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
12411807	C4591001 1241 12411807	16-55	17SEP2020	92149	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
12411808	C4591001 1241 12411808	16-55	17SEP2020	92151	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12411809	C4591001 1241 12411809	16-55	17SEP2020	92082	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
12411810	C4591001 1241 12411810	16-55	17SEP2020	92273	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12411812	C4591001 1241 12411812	16-55	17SEP2020	92276	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
12411813	C4591001 1241 12411813	16-55	17SEP2020	92281	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
12411814	C4591001 1241 12411814	16-55	17SEP2020	92284	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12411815	C4591001 1241 12411815	16-55	17SEP2020	92393	Placebo	17SEP2020/ Placebo	07OCT2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12411816	C4591001 1241 12411816	16-55	17SEP2020	92397	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12411817	C4591001 1241 12411817	16-55	17SEP2020	92398	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
12411818	C4591001 1241 12411818	16-55	17SEP2020	92403	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
12411819	C4591001 1241 12411819	16-55	17SEP2020	92477	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
12411820	C4591001 1241 12411820	16-55	17SEP2020	92478	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12411823	C4591001 1241 12411823	16-55	17SEP2020	92481	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12411824	C4591001 1241 12411824	16-55	17SEP2020	92483	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
12411826	C4591001 1241 12411826	16-55	17SEP2020	92622	Placebo	17SEP2020/ Placebo	07OCT2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12411827	C4591001 1241 12411827	16-55	17SEP2020	92626	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
12411828	C4591001 1241 12411828	16-55	17SEP2020	92630	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
12411830	C4591001 1241 12411830	16-55	17SEP2020	92631	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
12411832	C4591001 1241 12411832	16-55	17SEP2020	92754	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
12411833	C4591001 1241 12411833	16-55	17SEP2020	92759	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12411834	C4591001 1241 12411834	16-55	17SEP2020	92761	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
12411835	C4591001 1241 12411835	16-55	17SEP2020	92764	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12411836	C4591001 1241 12411836	16-55	17SEP2020	92804	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12411837	C4591001 1241 12411837	16-55	17SEP2020	92805	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
12411839	C4591001 1241 12411839	16-55	17SEP2020	92810	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
12411840	C4591001 1241 12411840	16-55	17SEP2020	92812	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12411841	C4591001 1241 12411841	16-55	17SEP2020	92854	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
12411842	C4591001 1241 12411842	16-55	17SEP2020	92855	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
12411843	C4591001 1241 12411843	16-55	17SEP2020	92858	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12411845	C4591001 1241 12411845	16-55	17SEP2020	92859	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12411846	C4591001 1241 12411846	16-55	17SEP2020	92946	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12411847	C4591001 1241 12411847	16-55	17SEP2020	92949	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12411848	C4591001 1241 12411848	16-55	17SEP2020	92950	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12411849	C4591001 1241 12411849	16-55	17SEP2020	92951	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
12411850	C4591001 1241 12411850	16-55	17SEP2020	93005	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
12411851	C4591001 1241 12411851	16-55	17SEP2020	93006	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12411854	C4591001 1241 12411854	16-55	17SEP2020	93010	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
12411855	C4591001 1241 12411855	16-55	17SEP2020	93013	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12411856	C4591001 1241 12411856	16-55	17SEP2020	93053	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
12411857	C4591001 1241 12411857	16-55	17SEP2020	93058	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
12411858	C4591001 1241 12411858	16-55	17SEP2020	93059	Placebo	17SEP2020/ Placebo	06OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
12411859	C4591001 1241 12411859	16-55	17SEP2020	93061	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12411860	C4591001 1241 12411860	16-55	17SEP2020	93092	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12411861	C4591001 1241 12411861	16-55	17SEP2020	93093	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
12411862	C4591001 1241 12411862	16-55	17SEP2020	93099	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
12411863	C4591001 1241 12411863	16-55	17SEP2020	93129	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
12411864	C4591001 1241 12411864	16-55	17SEP2020	93100	Placebo	17SEP2020/ Placebo	06OCT2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12411865	C4591001 1241 12411865	16-55	17SEP2020	93131	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12411866	C4591001 1241 12411866	16-55	17SEP2020	93132	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
12411867	C4591001 1241 12411867	16-55	17SEP2020	93133	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12411868	C4591001 1241 12411868	16-55	17SEP2020	93137	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12411869	C4591001 1241 12411869	16-55	17SEP2020	93139	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
12411870	C4591001 1241 12411870	16-55	17SEP2020	93149	Placebo	17SEP2020/ Placebo	06OCT2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12411871	C4591001 1241 12411871	16-55	17SEP2020	93142	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
12411872	C4591001 1241 12411872	16-55	17SEP2020	93153	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
12411873	C4591001 1241 12411873	16-55	17SEP2020	93145	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12411874	C4591001 1241 12411874	16-55	17SEP2020	93158	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
12411875	C4591001 1241 12411875	16-55	17SEP2020	93152	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
12411877	C4591001 1241 12411877	16-55	18SEP2020	93162	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12411878	C4591001 1241 12411878	16-55	18SEP2020	93163	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12411879	C4591001 1241 12411879	16-55	18SEP2020	93166	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
12411880	C4591001 1241 12411880	16-55	18SEP2020	93168	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
12411881	C4591001 1241 12411881	16-55	18SEP2020	93225	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12411882	C4591001 1241 12411882	16-55	18SEP2020	93226	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
12411884	C4591001 1241 12411884	16-55	18SEP2020	93228	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
12411885	C4591001 1241 12411885	16-55	18SEP2020	93229	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
12411886	C4591001 1241 12411886	16-55	18SEP2020	93284	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
12411887	C4591001 1241 12411887	16-55	18SEP2020	93311	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
12411888	C4591001 1241 12411888	16-55	18SEP2020	93312	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
12411889	C4591001 1241 12411889	16-55	18SEP2020	93313	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
12411892	C4591001 1241 12411892	16-55	18SEP2020	93315	Placebo	18SEP2020/ Placebo	08OCT2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12411893	C4591001 1241 12411893	16-55	18SEP2020	93391	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
12411894	C4591001 1241 12411894	16-55	18SEP2020	93398	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12411895	C4591001 1241 12411895	16-55	18SEP2020	93399	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
12411897	C4591001 1241 12411897	16-55	18SEP2020	93400	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
12411898	C4591001 1241 12411898	16-55	18SEP2020	93437	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
12411899	C4591001 1241 12411899	16-55	18SEP2020	93440	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
12411900	C4591001 1241 12411900	16-55	18SEP2020	93441	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12411901	C4591001 1241 12411901	16-55	18SEP2020	93448	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12411903	C4591001 1241 12411903	16-55	18SEP2020	93498	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12411904	C4591001 1241 12411904	16-55	18SEP2020	93502	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
12411905	C4591001 1241 12411905	16-55	18SEP2020	93503	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
12411906	C4591001 1241 12411906	16-55	18SEP2020	93505	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12411907	C4591001 1241 12411907	16-55	18SEP2020	93775	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12411908	C4591001 1241 12411908	16-55	18SEP2020	93776	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
12411909	C4591001 1241 12411909	16-55	18SEP2020	93778	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
12411911	C4591001 1241 12411911	16-55	18SEP2020	93784	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12411912	C4591001 1241 12411912	16-55	18SEP2020	93869	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12411913	C4591001 1241 12411913	16-55	18SEP2020	93874	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
12411914	C4591001 1241 12411914	16-55	18SEP2020	93876	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12411915	C4591001 1241 12411915	16-55	18SEP2020	93880	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
12411917	C4591001 1241 12411917	16-55	18SEP2020	93930	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12411919	C4591001 1241 12411919	16-55	18SEP2020	93931	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12411920	C4591001 1241 12411920	16-55	18SEP2020	93936	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
12411921	C4591001 1241 12411921	16-55	18SEP2020	93939	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
12411924	C4591001 1241 12411924	16-55	18SEP2020	94014	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
12411925	C4591001 1241 12411925	16-55	18SEP2020	94015	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12411926	C4591001 1241 12411926	16-55	18SEP2020	94018	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12411927	C4591001 1241 12411927	16-55	18SEP2020	94020	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
12411929	C4591001 1241 12411929	16-55	18SEP2020	94149	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
12411930	C4591001 1241 12411930	16-55	18SEP2020	94152	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
12411931	C4591001 1241 12411931	16-55	18SEP2020	94153	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
12411932	C4591001 1241 12411932	16-55	18SEP2020	94154	Placebo	18SEP2020/ Placebo	07OCT2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12411935	C4591001 1241 12411935	16-55	18SEP2020	94217	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12411936	C4591001 1241 12411936	16-55	18SEP2020	94219	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
12411937	C4591001 1241 12411937	16-55	18SEP2020	94223	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
12411939	C4591001 1241 12411939	16-55	18SEP2020	94225	Placebo	18SEP2020/ Placebo	07OCT2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12411940	C4591001 1241 12411940	16-55	18SEP2020	94233	Placebo	18SEP2020/ Placebo	07OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
12411942	C4591001 1241 12411942	16-55	18SEP2020	94234	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
12411943	C4591001 1241 12411943	16-55	18SEP2020	94237	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
12411944	C4591001 1241 12411944	16-55	18SEP2020	94239	Placebo	18SEP2020/ Placebo	07OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
12411945	C4591001 1241 12411945	16-55	18SEP2020	94265	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
12411947	C4591001 1241 12411947	16-55	18SEP2020	94267	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12411948	C4591001 1241 12411948	16-55	18SEP2020	94270	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
12411949	C4591001 1241 12411949	16-55	18SEP2020	94274	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
12411950	C4591001 1241 12411950	16-55	18SEP2020	94306	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
12411951	C4591001 1241 12411951	16-55	18SEP2020	94307	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
12411952	C4591001 1241 12411952	16-55	18SEP2020	94309	Placebo	18SEP2020/ Placebo	07OCT2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12411953	C4591001 1241 12411953	16-55	18SEP2020	94310	Placebo	18SEP2020/ Placebo	08OCT2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12411954	C4591001 1241 12411954	16-55	18SEP2020	94349	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
12411955	C4591001 1241 12411955	16-55	18SEP2020	94350	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12411956	C4591001 1241 12411956	16-55	18SEP2020	94354	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
12411957	C4591001 1241 12411957	16-55	18SEP2020	94358	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12411958	C4591001 1241 12411958	16-55	18SEP2020	94362	Placebo	18SEP2020/ Placebo	07OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12411960	C4591001 1241 12411960	16-55	18SEP2020	94365	Placebo	18SEP2020/ Placebo	07OCT2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12411961	C4591001 1241 12411961	16-55	18SEP2020	94366	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
12411962	C4591001 1241 12411962	16-55	18SEP2020	94371	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
12411963	C4591001 1241 12411963	16-55	18SEP2020	94375	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
12411965	C4591001 1241 12411965	16-55	21SEP2020	94377	Placebo	21SEP2020/ Placebo	22OCT2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12411967	C4591001 1241 12411967	16-55	21SEP2020	94379	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
12411968	C4591001 1241 12411968	16-55	21SEP2020	94382	Placebo	21SEP2020/ Placebo	13OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
12411969	C4591001 1241 12411969	16-55	21SEP2020	94601	Placebo	21SEP2020/ Placebo	13OCT2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12411970	C4591001 1241 12411970	16-55	21SEP2020	94604	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12411971	C4591001 1241 12411971	16-55	21SEP2020	94605	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
12411972	C4591001 1241 12411972	16-55	21SEP2020	94611	Placebo	21SEP2020/ Placebo	13OCT2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12411973	C4591001 1241 12411973	16-55	21SEP2020	94637	Placebo	21SEP2020/ Placebo	13OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12411974	C4591001 1241 12411974	16-55	21SEP2020	94640	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
12411975	C4591001 1241 12411975	16-55	21SEP2020	94642	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
12411977	C4591001 1241 12411977	16-55	21SEP2020	94645	Placebo	21SEP2020/ Placebo	13OCT2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12411978	C4591001 1241 12411978	16-55	21SEP2020	94649	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
12411980	C4591001 1241 12411980	16-55	21SEP2020	94653	Placebo	21SEP2020/ Placebo	13OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
12411981	C4591001 1241 12411981	16-55	21SEP2020	94655	Placebo	21SEP2020/ Placebo	13OCT2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12411982	C4591001 1241 12411982	16-55	21SEP2020	94660	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12411983	C4591001 1241 12411983	16-55	21SEP2020	94746	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
12411984	C4591001 1241 12411984	16-55	21SEP2020	94752	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
12411985	C4591001 1241 12411985	16-55	21SEP2020	94755	Placebo	21SEP2020/ Placebo	13OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
12411986	C4591001 1241 12411986	16-55	21SEP2020	94756	Placebo	21SEP2020/ Placebo	13OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
12411987	C4591001 1241 12411987	16-55	21SEP2020	94795	Placebo	21SEP2020/ Placebo	13OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
12411988	C4591001 1241 12411988	16-55	21SEP2020	94797	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
12411990	C4591001 1241 12411990	16-55	21SEP2020	94802	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
12411991	C4591001 1241 12411991	16-55	21SEP2020	94803	Placebo	21SEP2020/ Placebo	13OCT2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
12411992	C4591001 1241 12411992	16-55	21SEP2020	95158	Placebo	21SEP2020/ Placebo	13OCT2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12411993	C4591001 1241 12411993	16-55	21SEP2020	95161	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12411994	C4591001 1241 12411994	16-55	21SEP2020	95162	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
12411995	C4591001 1241 12411995	16-55	21SEP2020	95164	Placebo	21SEP2020/ Placebo	14OCT2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12411996	C4591001 1241 12411996	16-55	21SEP2020	95179	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
12411997	C4591001 1241 12411997	16-55	21SEP2020	95182	Placebo	21SEP2020/ Placebo	13OCT2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12411998	C4591001 1241 12411998	16-55	21SEP2020	95185	Placebo	21SEP2020/ Placebo	13OCT2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12411999	C4591001 1241 12411999	16-55	21SEP2020	95186	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
12412001	C4591001 1241 12412001	16-55	21SEP2020	95249	Placebo	21SEP2020/ Placebo	13OCT2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12412002	C4591001 1241 12412002	16-55	21SEP2020	95250	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
12412003	C4591001 1241 12412003	16-55	21SEP2020	95256	Placebo	21SEP2020/ Placebo	13OCT2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12412004	C4591001 1241 12412004	16-55	21SEP2020	95257	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12412006	C4591001 1241 12412006	16-55	21SEP2020	95418	Placebo	21SEP2020/ Placebo	13OCT2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12412007	C4591001 1241 12412007	16-55	21SEP2020	95423	Placebo	21SEP2020/ Placebo	13OCT2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12412008	C4591001 1241 12412008	16-55	21SEP2020	95426	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
12412009	C4591001 1241 12412009	16-55	21SEP2020	95427	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
12412010	C4591001 1241 12412010	16-55	21SEP2020	95573	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
12412012	C4591001 1241 12412012	16-55	21SEP2020	95576	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
12412013	C4591001 1241 12412013	16-55	21SEP2020	95579	Placebo	21SEP2020/ Placebo	13OCT2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12412014	C4591001 1241 12412014	16-55	21SEP2020	95582	Placebo	21SEP2020/ Placebo	14OCT2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12412015	C4591001 1241 12412015	16-55	28SEP2020	101453	Placebo	28SEP2020/ Placebo	21OCT2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12412016	C4591001 1241 12412016	16-55	28SEP2020	101456	BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12412018	C4591001 1241 12412018	16-55	28SEP2020	101459	Placebo	28SEP2020/ Placebo	21OCT2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12412019	C4591001 1241 12412019	16-55	28SEP2020	101463	BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		
12412020	C4591001 1241 12412020	16-55	28SEP2020	101516	BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)		
12412022	C4591001 1241 12412022	16-55	29SEP2020	101520	Placebo	29SEP2020/ Placebo	22OCT2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12412023	C4591001 1241 12412023	16-55	29SEP2020	101521	Placebo	29SEP2020/ Placebo	22OCT2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12412024	C4591001 1241 12412024	16-55	29SEP2020	101523	BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)		
12412025	C4591001 1241 12412025	16-55	29SEP2020	101935	Placebo	29SEP2020/ Placebo	21OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
12412026	C4591001 1241 12412026	16-55	29SEP2020	101937	Placebo	29SEP2020/ Placebo	10NOV2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12412027	C4591001 1241 12412027	16-55	30SEP2020	101939	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)		
12412028	C4591001 1241 12412028	16-55	30SEP2020	101942	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12412029	C4591001 1241 12412029	16-55	30SEP2020	102150	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		
12412031	C4591001 1241 12412031	16-55	30SEP2020	102153	Placebo	30SEP2020/ Placebo	21OCT2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12412032	C4591001 1241 12412032	16-55	30SEP2020	102157	Placebo	30SEP2020/ Placebo	19OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12412034	C4591001 1241 12412034	16-55	30SEP2020	102160	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)		
12412035	C4591001 1241 12412035	16-55	30SEP2020	102185	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)		
12412036	C4591001 1241 12412036	16-55	30SEP2020	102188	Placebo	30SEP2020/ Placebo	23OCT2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
12412037	C4591001 1241 12412037	16-55	30SEP2020	102190	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		
12412038	C4591001 1241 12412038	16-55	30SEP2020	102193	Placebo	30SEP2020/ Placebo	23OCT2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12412039	C4591001 1241 12412039	16-55	30SEP2020	102211	Placebo	30SEP2020/ Placebo	21OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12412041	C4591001 1241 12412041	16-55	30SEP2020	102213	Placebo	30SEP2020/ Placebo	21OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12412043	C4591001 1241 12412043	16-55	30SEP2020	102215	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)		
12412044	C4591001 1241 12412044	16-55	30SEP2020	102220	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)		
12412045	C4591001 1241 12412045	16-55	30SEP2020	102294	Placebo	30SEP2020/ Placebo	21OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12412046	C4591001 1241 12412046	16-55	30SEP2020	102297	Placebo	30SEP2020/ Placebo	22OCT2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12412048	C4591001 1241 12412048	16-55	30SEP2020	102303	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		
12412049	C4591001 1241 12412049	16-55	30SEP2020	102304	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		
12412050	C4591001 1241 12412050	16-55	30SEP2020	102404	Placebo	30SEP2020/ Placebo	21OCT2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12412051	C4591001 1241 12412051	16-55	30SEP2020	102407	Placebo	30SEP2020/ Placebo	21OCT2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12412052	C4591001 1241 12412052	16-55	30SEP2020	102411	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		
12412053	C4591001 1241 12412053	16-55	30SEP2020	102412	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12412054	C4591001 1241 12412054	16-55	30SEP2020	102426	Placebo	30SEP2020/ Placebo	23OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
12412055	C4591001 1241 12412055	16-55	30SEP2020	102431	Placebo	30SEP2020/ Placebo	23OCT2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12412056	C4591001 1241 12412056	16-55	30SEP2020	102434	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)		
12412057	C4591001 1241 12412057	16-55	30SEP2020	102436	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		
12412058	C4591001 1241 12412058	16-55	30SEP2020	102453	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)		
12412059	C4591001 1241 12412059	16-55	30SEP2020	102455	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)		
12412060	C4591001 1241 12412060	16-55	30SEP2020	102457	Placebo	30SEP2020/ Placebo	21OCT2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12412061	C4591001 1241 12412061	16-55	30SEP2020	102459	Placebo	30SEP2020/ Placebo	23OCT2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12412062	C4591001 1241 12412062	16-55	30SEP2020	102475	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)		
12412063	C4591001 1241 12412063	16-55	30SEP2020	102476	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12412064	C4591001 1241 12412064	16-55	30SEP2020	102478	Placebo	30SEP2020/ Placebo	20OCT2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12412065	C4591001 1241 12412065	16-55	30SEP2020	102480	Placebo	30SEP2020/ Placebo	19OCT2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12412066	C4591001 1241 12412066	16-55	30SEP2020	102497	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		
12412067	C4591001 1241 12412067	16-55	30SEP2020	102499	Placebo	30SEP2020/ Placebo	22OCT2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
12412069	C4591001 1241 12412069	16-55	01OCT2020	102501	Placebo	01OCT2020/ Placebo	22OCT2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
12412070	C4591001 1241 12412070	16-55	01OCT2020	102508	BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		
12412071	C4591001 1241 12412071	16-55	01OCT2020	102641	Placebo	01OCT2020/ Placebo	22OCT2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12412072	C4591001 1241 12412072	16-55	01OCT2020	102643	Placebo	01OCT2020/ Placebo	22OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
12412073	C4591001 1241 12412073	16-55	01OCT2020	102646	BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)		
12412074	C4591001 1241 12412074	16-55	01OCT2020	102652	BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12412078	C4591001 1241 12412078	16-55	01OCT2020	102716	BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		
12412080	C4591001 1241 12412080	16-55	01OCT2020	102717	Placebo	01OCT2020/ Placebo	22OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
12412081	C4591001 1241 12412081	16-55	01OCT2020	102719	BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)		
12412082	C4591001 1241 12412082†	16-55	01OCT2020	102722	Placebo	01OCT2020/ Placebo	22OCT2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
12412083	C4591001 1241 12412083	16-55	01OCT2020	102872	BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)		
12412084	C4591001 1241 12412084	16-55	01OCT2020	102873	BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)		
12412086	C4591001 1241 12412086	16-55	01OCT2020	102878	Placebo	01OCT2020/ Placebo	20OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
12412087	C4591001 1241 12412087	16-55	01OCT2020	102880	Placebo	01OCT2020/ Placebo	22OCT2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
12412088	C4591001 1241 12412088	16-55	01OCT2020	102905	Placebo	01OCT2020/ Placebo	20OCT2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12412089	C4591001 1241 12412089	16-55	01OCT2020	102913	BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12412090	C4591001 1241 12412090	16-55	01OCT2020	102915	BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)		
12412091	C4591001 1241 12412091	16-55	01OCT2020	102916	Placebo	01OCT2020/ Placebo	22OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
12412092	C4591001 1241 12412092	16-55	01OCT2020	102942	BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)		
12412093	C4591001 1241 12412093	16-55	01OCT2020	102943	Placebo	01OCT2020/ Placebo	22OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
12412094	C4591001 1241 12412094	16-55	01OCT2020	102945	BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		
12412095	C4591001 1241 12412095	16-55	01OCT2020	102951	Placebo	01OCT2020/ Placebo	22OCT2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12412096	C4591001 1241 12412096	16-55	01OCT2020	102966	BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)		
12412097	C4591001 1241 12412097	16-55	01OCT2020	102967	Placebo	01OCT2020/ Placebo	22OCT2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
12412098	C4591001 1241 12412098	16-55	01OCT2020	102969	BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)		
12412099	C4591001 1241 12412099	16-55	01OCT2020	102976	Placebo	01OCT2020/ Placebo	22OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12412100	C4591001 1241 12412100	16-55	01OCT2020	102977	BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)		
12412101	C4591001 1241 12412101	16-55	01OCT2020	102978	Placebo	01OCT2020/ Placebo	22OCT2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12412102	C4591001 1241 12412102	16-55	02OCT2020	102982	BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		
12412103	C4591001 1241 12412103	16-55	02OCT2020	102987	Placebo	02OCT2020/ Placebo	21OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
12412104	C4591001 1241 12412104	16-55	02OCT2020	103063	BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		
12412105	C4591001 1241 12412105	16-55	02OCT2020	103064	BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		
12412106	C4591001 1241 12412106	16-55	02OCT2020	103065	Placebo	02OCT2020/ Placebo	21OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
12412107	C4591001 1241 12412107	16-55	02OCT2020	103067	Placebo	02OCT2020/ Placebo	21OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12412108	C4591001 1241 12412108	16-55	02OCT2020	103074	Placebo	02OCT2020/ Placebo	21OCT2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12412109	C4591001 1241 12412109	16-55	02OCT2020	103077	BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12412110	C4591001 1241 12412110	16-55	02OCT2020	103082	BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
12412111	C4591001 1241 12412111	16-55	02OCT2020	103083	Placebo	02OCT2020/ Placebo	21OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
12412112	C4591001 1241 12412112	16-55	02OCT2020	103123	BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		
12412113	C4591001 1241 12412113	16-55	02OCT2020	103125	Placebo	02OCT2020/ Placebo	21OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12412114	C4591001 1241 12412114	16-55	02OCT2020	103129	Placebo	02OCT2020/ Placebo	22OCT2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
12412117	C4591001 1241 12412117	16-55	02OCT2020	103131	BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		
12412118	C4591001 1241 12412118	16-55	02OCT2020	103146	BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		
12412119	C4591001 1241 12412119	16-55	02OCT2020	103151	Placebo	02OCT2020/ Placebo	22OCT2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12412120	C4591001 1241 12412120	16-55	02OCT2020	103152	Placebo	02OCT2020/ Placebo	21OCT2020/ Placebo		
12412121	C4591001 1241 12412121	16-55	02OCT2020	103154	BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12412122	C4591001 1241 12412122	16-55	02OCT2020	103171	Placebo	02OCT2020/ Placebo	21OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12412123	C4591001 1241 12412123	16-55	02OCT2020	103173	Placebo	02OCT2020/ Placebo	21OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12412124	C4591001 1241 12412124	16-55	02OCT2020	103178	BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		
12412126	C4591001 1241 12412126	16-55	02OCT2020	103179	BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		
12412127	C4591001 1241 12412127	16-55	02OCT2020	103255	Placebo	02OCT2020/ Placebo	21OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
12412128	C4591001 1241 12412128	16-55	02OCT2020	103257	Placebo	02OCT2020/ Placebo	21OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
12412130	C4591001 1241 12412130	16-55	02OCT2020	103260	BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		
12412131	C4591001 1241 12412131	16-55	02OCT2020	103263	BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		
12412132	C4591001 1241 12412132	16-55	02OCT2020	103301	Placebo	02OCT2020/ Placebo	21OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
12412133	C4591001 1241 12412133	16-55	02OCT2020	103305	BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12412134	C4591001 1241 12412134	16-55	02OCT2020	103306	Placebo	02OCT2020/ Placebo	23OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12412135	C4591001 1241 12412135	16-55	02OCT2020	103311	BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		
12412136	C4591001 1241 12412136	16-55	02OCT2020	103376	Placebo	02OCT2020/ Placebo	21OCT2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
12412137	C4591001 1241 12412137	16-55	05OCT2020	103377	BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
12412138	C4591001 1241 12412138	16-55	05OCT2020	103382	Placebo	05OCT2020/ Placebo	26OCT2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12412139	C4591001 1241 12412139	16-55	05OCT2020	103384	BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
12412140	C4591001 1241 12412140	16-55	06OCT2020	104192	Placebo	06OCT2020/ Placebo	26OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
12412141	C4591001 1241 12412141	16-55	06OCT2020	104195	Placebo	06OCT2020/ Placebo	26OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
12412142	C4591001 1241 12412142	16-55	06OCT2020	104198	BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
12412143	C4591001 1241 12412143	16-55	06OCT2020	104200	BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12412148	C4591001 1241 12412148	16-55	07OCT2020	104719	Placebo	07OCT2020/ Placebo	28OCT2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12412149	C4591001 1241 12412149	16-55	07OCT2020	104724	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
12412150	C4591001 1241 12412150	16-55	07OCT2020	104726	Placebo	07OCT2020/ Placebo	28OCT2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12412151	C4591001 1241 12412151	16-55	07OCT2020	104728	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
12412152	C4591001 1241 12412152	16-55	07OCT2020	104993	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)		
12412153	C4591001 1241 12412153	16-55	07OCT2020	104994	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
12412154	C4591001 1241 12412154	16-55	07OCT2020	105001	Placebo	07OCT2020/ Placebo	26OCT2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12412155	C4591001 1241 12412155	16-55	07OCT2020	104997	Placebo	07OCT2020/ Placebo	29OCT2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12412156	C4591001 1241 12412156	16-55	07OCT2020	105011	Placebo	07OCT2020/ Placebo	29OCT2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12412157	C4591001 1241 12412157	16-55	07OCT2020	105013	Placebo	07OCT2020/ Placebo	29OCT2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12412158	C4591001 1241 12412158	16-55	07OCT2020	105014	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)		
12412159	C4591001 1241 12412159	16-55	07OCT2020	105019	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)		
12412160	C4591001 1241 12412160	16-55	07OCT2020	105015	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)		
12412161	C4591001 1241 12412161	16-55	07OCT2020	105020	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)		
12412162	C4591001 1241 12412162	16-55	07OCT2020	105022	Placebo	07OCT2020/ Placebo	30OCT2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12412163	C4591001 1241 12412163	16-55	08OCT2020	105026	Placebo	08OCT2020/ Placebo	30OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
12412165	C4591001 1241 12412165	16-55	09OCT2020	106075	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
12412166	C4591001 1241 12412166	16-55	13OCT2020	106077	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
12412167	C4591001 1241 12412167	16-55	13OCT2020	106081	Placebo	13OCT2020/ Placebo	03NOV2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12412168	C4591001 1241 12412168	16-55	13OCT2020	106082	Placebo	13OCT2020/ Placebo	03NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12412169	C4591001 1241 12412169	16-55	13OCT2020	107131	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
12412170	C4591001 1241 12412170	16-55	13OCT2020	107132	Placebo	13OCT2020/ Placebo	03NOV2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12412171	C4591001 1241 12412171	16-55	13OCT2020	107135	Placebo	13OCT2020/ Placebo	03NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12412172	C4591001 1241 12412172	16-55	13OCT2020	107138	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
12412173	C4591001 1241 12412173	16-55	13OCT2020	107179	Placebo	13OCT2020/ Placebo	03NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12412174	C4591001 1241 12412174	16-55	14OCT2020	107183	BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		
12412175	C4591001 1241 12412175	16-55	14OCT2020	107185	Placebo	14OCT2020/ Placebo	04NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12412176	C4591001 1241 12412176	16-55	14OCT2020	107187	BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
12412177	C4591001 1241 12412177	16-55	14OCT2020	107333	Placebo	14OCT2020/ Placebo	04NOV2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12412179	C4591001 1241 12412179	16-55	14OCT2020	107334	BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12412180	C4591001 1241 12412180	16-55	14OCT2020	107340	Placebo	14OCT2020/ Placebo	04NOV2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12412181	C4591001 1241 12412181	16-55	14OCT2020	107343	BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
12412182	C4591001 1241 12412182	16-55	14OCT2020	107429	Placebo	14OCT2020/ Placebo	04NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12412183	C4591001 1241 12412183	16-55	14OCT2020	107431	Placebo	14OCT2020/ Placebo	04NOV2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12412186	C4591001 1241 12412186	16-55	14OCT2020	107433	BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
12412187	C4591001 1241 12412187	16-55	14OCT2020	107436	BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
12412188	C4591001 1241 12412188	16-55	14OCT2020	107633	BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
12412190	C4591001 1241 12412190	16-55	14OCT2020	107634	BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
12412192	C4591001 1241 12412192	16-55	15OCT2020	107638	Placebo	15OCT2020/ Placebo	06NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
12412193	C4591001 1241 12412193	16-55	15OCT2020	107644	Placebo	15OCT2020/ Placebo	06NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12412194	C4591001 1241 12412194	16-55	15OCT2020	108262	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
12412195	C4591001 1241 12412195	16-55	15OCT2020	108265	Placebo	15OCT2020/ Placebo	05NOV2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12412197	C4591001 1241 12412197	16-55	15OCT2020	108267	Placebo	15OCT2020/ Placebo	05NOV2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12412198	C4591001 1241 12412198	16-55	15OCT2020	108268	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	24NOV2020/ BNT162b2 (30 µg)		
12412199	C4591001 1241 12412199	16-55	15OCT2020	108284	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
12412201	C4591001 1241 12412201	16-55	15OCT2020	108286	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
12412202	C4591001 1241 12412202	16-55	15OCT2020	108287	Placebo	15OCT2020/ Placebo	05NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12412203	C4591001 1241 12412203	16-55	15OCT2020	108290	Placebo	15OCT2020/ Placebo	04NOV2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12412204	C4591001 1241 12412204	16-55	15OCT2020	108356	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
12412206	C4591001 1241 12412206	16-55	15OCT2020	108357	Placebo	15OCT2020/ Placebo	05NOV2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12412207	C4591001 1241 12412207	16-55	15OCT2020	108361	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
12412208	C4591001 1241 12412208	16-55	15OCT2020	108362	Placebo	15OCT2020/ Placebo	05NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12412209	C4591001 1241 12412209	16-55	15OCT2020	108404	Placebo	15OCT2020/ Placebo	05NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12412210	C4591001 1241 12412210	16-55	15OCT2020	108406	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
12412211	C4591001 1241 12412211	16-55	15OCT2020	108407	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
12412212	C4591001 1241 12412212	16-55	15OCT2020	108412	Placebo	15OCT2020/ Placebo	05NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12412213	C4591001 1241 12412213	16-55	15OCT2020	108437	Placebo	15OCT2020/ Placebo	06NOV2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12412214	C4591001 1241 12412214	16-55	15OCT2020	108441	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
12412215	C4591001 1241 12412215	16-55	15OCT2020	108443	Placebo	15OCT2020/ Placebo	04NOV2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12412216	C4591001 1241 12412216	16-55	15OCT2020	108445	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12412217	C4591001 1241 12412217	16-55	15OCT2020	108523	Placebo	15OCT2020/ Placebo	06NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12412218	C4591001 1241 12412218	16-55	15OCT2020	108524	Placebo	15OCT2020/ Placebo	06NOV2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12412221	C4591001 1241 12412221	16-55	15OCT2020	108525	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
12412222	C4591001 1241 12412222	16-55	16OCT2020	108531	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
12412223	C4591001 1241 12412223	16-55	16OCT2020	108665	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
12412225	C4591001 1241 12412225	16-55	16OCT2020	108668	Placebo	16OCT2020/ Placebo	06NOV2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12412226	C4591001 1241 12412226	16-55	16OCT2020	108670	Placebo	16OCT2020/ Placebo	05NOV2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12412227	C4591001 1241 12412227	16-55	16OCT2020	108676	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
12412228	C4591001 1241 12412228	16-55	16OCT2020	108680	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
12412229	C4591001 1241 12412229	16-55	16OCT2020	108682	Placebo	16OCT2020/ Placebo	05NOV2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12412232	C4591001 1241 12412232	16-55	16OCT2020	108683	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
12412233	C4591001 1241 12412233	16-55	16OCT2020	108688	Placebo	16OCT2020/ Placebo	05NOV2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12412235	C4591001 1241 12412235	16-55	16OCT2020	108718	Placebo	16OCT2020/ Placebo	05NOV2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12412236	C4591001 1241 12412236	16-55	16OCT2020	108720	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
12412237	C4591001 1241 12412237	16-55	16OCT2020	108721	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
12412239	C4591001 1241 12412239	16-55	16OCT2020	108722	Placebo	16OCT2020/ Placebo	05NOV2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12412240	C4591001 1241 12412240	16-55	16OCT2020	108778	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
12412243	C4591001 1241 12412243	16-55	16OCT2020	108781	Placebo	16OCT2020/ Placebo	05NOV2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12412244	C4591001 1241 12412244	16-55	16OCT2020	108783	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
12412245	C4591001 1241 12412245	16-55	16OCT2020	108784	Placebo	16OCT2020/ Placebo	06NOV2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12412246	C4591001 1241 12412246	16-55	16OCT2020	108799	Placebo	16OCT2020/ Placebo	05NOV2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12412247	C4591001 1241 12412247	16-55	16OCT2020	108802	Placebo	16OCT2020/ Placebo	05NOV2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
12412248	C4591001 1241 12412248	16-55	16OCT2020	108806	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
12412249	C4591001 1241 12412249	16-55	16OCT2020	108808	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
12412252	C4591001 1241 12412252	16-55	16OCT2020	108859	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
12412253	C4591001 1241 12412253	16-55	16OCT2020	108861	Placebo	16OCT2020/ Placebo	06NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
12412254	C4591001 1241 12412254	16-55	16OCT2020	108863	Placebo	16OCT2020/ Placebo	06NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
12412255	C4591001 1241 12412255	16-55	16OCT2020	108868	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
12412256	C4591001 1241 12412256	16-55	16OCT2020	108881	Placebo	16OCT2020/ Placebo	05NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12412257	C4591001 1241 12412257	16-55	16OCT2020	108882	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12412258	C4591001 1241 12412258	16-55	16OCT2020	108886	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
12412259	C4591001 1241 12412259	16-55	16OCT2020	108887	Placebo	16OCT2020/ Placebo	05NOV2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12412260	C4591001 1241 12412260	16-55	16OCT2020	108929	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
12412261	C4591001 1241 12412261	16-55	16OCT2020	108930	Placebo	16OCT2020/ Placebo	06NOV2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12412262	C4591001 1241 12412262	16-55	16OCT2020	108931	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
12412264	C4591001 1241 12412264	16-55	16OCT2020	108939	Placebo	16OCT2020/ Placebo	06NOV2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12412267	C4591001 1241 12412267	16-55	16OCT2020	109097	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
12412268	C4591001 1241 12412268	16-55	16OCT2020	109100	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
12412269	C4591001 1241 12412269	16-55	16OCT2020	109102	Placebo	16OCT2020/ Placebo	06NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12412270	C4591001 1241 12412270	16-55	16OCT2020	109105	Placebo	16OCT2020/ Placebo	05NOV2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12412271	C4591001 1241 12412271	16-55	16OCT2020	109133	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
12412274	C4591001 1241 12412274	16-55	16OCT2020	109134	Placebo	16OCT2020/ Placebo	06NOV2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12412275	C4591001 1241 12412275	16-55	16OCT2020	109138	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
12412276	C4591001 1241 12412276	16-55	16OCT2020	109144	Placebo	16OCT2020/ Placebo	05NOV2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12412277	C4591001 1241 12412277	16-55	16OCT2020	109230	Placebo	16OCT2020/ Placebo	05NOV2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12412278	C4591001 1241 12412278	16-55	16OCT2020	109237	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
12412279	C4591001 1241 12412279	16-55	16OCT2020	109238	Placebo	16OCT2020/ Placebo	05NOV2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
12412280	C4591001 1241 12412280	16-55	16OCT2020	109239	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
12412281	C4591001 1241 12412281	16-55	16OCT2020	109253	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
12412282	C4591001 1241 12412282	16-55	16OCT2020	109255	Placebo	16OCT2020/ Placebo	10NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12412283	C4591001 1241 12412283	16-55	16OCT2020	109256	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
12412284	C4591001 1241 12412284	16-55	16OCT2020	109260	Placebo	16OCT2020/ Placebo	06NOV2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12412285	C4591001 1241 12412285	16-55	16OCT2020	109289	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
12412288	C4591001 1241 12412288	16-55	16OCT2020	109292	Placebo	16OCT2020/ Placebo	05NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12412289	C4591001 1241 12412289	16-55	16OCT2020	109293	Placebo	16OCT2020/ Placebo	06NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12412290	C4591001 1241 12412290	16-55	16OCT2020	109300	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
12412291	C4591001 1241 12412291	16-55	16OCT2020	109325	Placebo	16OCT2020/ Placebo	05NOV2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12412293	C4591001 1241 12412293	16-55	16OCT2020	109328	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
12412294	C4591001 1241 12412294	16-55	16OCT2020	109333	Placebo	16OCT2020/ Placebo	05NOV2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12412295	C4591001 1241 12412295	16-55	16OCT2020	109336	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12412296	C4591001 1241 12412296	16-55	16OCT2020	109356	Placebo	16OCT2020/ Placebo	05NOV2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12412299	C4591001 1241 12412299	16-55	16OCT2020	109358	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
12412301	C4591001 1241 12412301	16-55	16OCT2020	109359	Placebo	16OCT2020/ Placebo	05NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12412303	C4591001 1241 12412303	16-55	19OCT2020	109360	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
12412304	C4591001 1241 12412304	16-55	19OCT2020	109805	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
12412306	C4591001 1241 12412306	16-55	19OCT2020	109812	Placebo	19OCT2020/ Placebo	09NOV2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12412307	C4591001 1241 12412307	16-55	19OCT2020	109813	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
12412308	C4591001 1241 12412308	16-55	19OCT2020	109814	Placebo	19OCT2020/ Placebo	09NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
12412311	C4591001 1241 12412311	16-55	19OCT2020	109843	Placebo	19OCT2020/ Placebo	09NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12412312	C4591001 1241 12412312	16-55	19OCT2020	109844	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12412313	C4591001 1241 12412313	16-55	19OCT2020	109845	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
12412314	C4591001 1241 12412314	16-55	19OCT2020	109846	Placebo	19OCT2020/ Placebo	09NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12412315	C4591001 1241 12412315	16-55	19OCT2020	109903	Placebo	19OCT2020/ Placebo	09NOV2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12412317	C4591001 1241 12412317	16-55	19OCT2020	109907	Placebo	19OCT2020/ Placebo	09NOV2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12412320	C4591001 1241 12412320	16-55	19OCT2020	109908	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
12412321	C4591001 1241 12412321	16-55	19OCT2020	109910	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
12412322	C4591001 1241 12412322	16-55	19OCT2020	109988	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
12412323	C4591001 1241 12412323	16-55	19OCT2020	109989	Placebo	19OCT2020/ Placebo	09NOV2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12412324	C4591001 1241 12412324	16-55	19OCT2020	109990	Placebo	19OCT2020/ Placebo	11NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12412327	C4591001 1241 12412327	16-55	19OCT2020	109991	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12412328	C4591001 1241 12412328	16-55	19OCT2020	110023	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
12412329	C4591001 1241 12412329	16-55	19OCT2020	110025	Placebo	19OCT2020/ Placebo	09NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12412330	C4591001 1241 12412330	16-55	19OCT2020	110029	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
12412331	C4591001 1241 12412331	16-55	19OCT2020	110030	Placebo	19OCT2020/ Placebo	11NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12412332	C4591001 1241 12412332	16-55	19OCT2020	110070	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
12412333	C4591001 1241 12412333	16-55	19OCT2020	110074	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
12412334	C4591001 1241 12412334	16-55	19OCT2020	110075	Placebo	19OCT2020/ Placebo	09NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
12412335	C4591001 1241 12412335	16-55	19OCT2020	110078	Placebo	19OCT2020/ Placebo	09NOV2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12412336	C4591001 1241 12412336	16-55	19OCT2020	110165	Placebo	19OCT2020/ Placebo	09NOV2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12412337	C4591001 1241 12412337	16-55	19OCT2020	110169	Placebo	19OCT2020/ Placebo	09NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12412338	C4591001 1241 12412338	16-55	19OCT2020	110171	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
12412339	C4591001 1241 12412339	16-55	19OCT2020	110174	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
12412341	C4591001 1241 12412341	16-55	19OCT2020	110288	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
12412342	C4591001 1241 12412342	16-55	19OCT2020	110290	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
12412343	C4591001 1241 12412343	16-55	19OCT2020	110293	Placebo	19OCT2020/ Placebo	09NOV2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12412344	C4591001 1241 12412344	16-55	19OCT2020	110294	Placebo	19OCT2020/ Placebo	09NOV2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12412345	C4591001 1241 12412345	16-55	19OCT2020	110325	Placebo	19OCT2020/ Placebo	09NOV2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12412346	C4591001 1241 12412346	16-55	19OCT2020	110329	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
12412347	C4591001 1241 12412347	16-55	19OCT2020	110330	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
12412348	C4591001 1241 12412348	16-55	19OCT2020	110331	Placebo	19OCT2020/ Placebo	16NOV2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12412350	C4591001 1241 12412350	16-55	19OCT2020	110346	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
12412351	C4591001 1241 12412351	16-55	19OCT2020	110349	Placebo	19OCT2020/ Placebo	09NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12412352	C4591001 1241 12412352	16-55	19OCT2020	110350	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
12412353	C4591001 1241 12412353	16-55	19OCT2020	110352	Placebo	19OCT2020/ Placebo	09NOV2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
12412354	C4591001 1241 12412354	16-55	19OCT2020	110360	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
12412355	C4591001 1241 12412355	16-55	19OCT2020	110362	Placebo	19OCT2020/ Placebo		08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12412357	C4591001 1241 12412357	16-55	19OCT2020	110365	Placebo	19OCT2020/ Placebo	10NOV2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12412358	C4591001 1241 12412358	16-55	19OCT2020	110368	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
12412360	C4591001 1241 12412360	16-55	19OCT2020	110422	Placebo	19OCT2020/ Placebo	09NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12412361	C4591001 1241 12412361	16-55	19OCT2020	110423	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12412362	C4591001 1241 12412362	16-55	19OCT2020	110424	Placebo	19OCT2020/ Placebo	09NOV2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12412363	C4591001 1241 12412363	16-55	19OCT2020	110428	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
12412364	C4591001 1241 12412364	16-55	19OCT2020	110453	Placebo	19OCT2020/ Placebo	09NOV2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
12412365	C4591001 1241 12412365	16-55	19OCT2020	110454	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
12412366	C4591001 1241 12412366	16-55	19OCT2020	110462	Placebo	19OCT2020/ Placebo	10NOV2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
12412367	C4591001 1241 12412367	16-55	19OCT2020	110464	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
12412368	C4591001 1241 12412368	16-55	19OCT2020	110477	Placebo	19OCT2020/ Placebo	10NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12412369	C4591001 1241 12412369	16-55	19OCT2020	110481	Placebo	19OCT2020/ Placebo	11NOV2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	
12412370	C4591001 1241 12412370	16-55	19OCT2020	110486	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
12412371	C4591001 1241 12412371	16-55	19OCT2020	110488	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12412373	C4591001 1241 12412373	16-55	19OCT2020	110515	Placebo	19OCT2020/ Placebo	09NOV2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12412374	C4591001 1241 12412374	16-55	19OCT2020	110520	Placebo	19OCT2020/ Placebo	09NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12412375	C4591001 1241 12412375	16-55	19OCT2020	110521	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
12412377	C4591001 1241 12412377	16-55	19OCT2020	110523	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		
12412378	C4591001 1241 12412378	16-55	19OCT2020	110597	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
12412379	C4591001 1241 12412379	16-55	19OCT2020	110601	Placebo	19OCT2020/ Placebo	09NOV2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12412380	C4591001 1241 12412380	16-55	20OCT2020	110603	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		
12412381	C4591001 1241 12412381	16-55	20OCT2020	110605	Placebo	20OCT2020/ Placebo	10NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12412382	C4591001 1241 12412382	16-55	20OCT2020	110669	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	15DEC2020/ BNT162b2 (30 µg)		
12412383	C4591001 1241 12412383	16-55	20OCT2020	110672	Placebo	20OCT2020/ Placebo	10NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12412385	C4591001 1241 12412385	16-55	20OCT2020	110677	Placebo	20OCT2020/ Placebo	10NOV2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12412386	C4591001 1241 12412386	16-55	20OCT2020	110680	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		
12412387	C4591001 1241 12412387	16-55	20OCT2020	110813	Placebo	20OCT2020/ Placebo	10NOV2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12412389	C4591001 1241 12412389	16-55	20OCT2020	110814	Placebo	20OCT2020/ Placebo	10NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12412390	C4591001 1241 12412390	16-55	20OCT2020	110816	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		
12412391	C4591001 1241 12412391	16-55	20OCT2020	110820	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
12412392	C4591001 1241 12412392	16-55	20OCT2020	110947	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		
12412393	C4591001 1241 12412393	16-55	20OCT2020	110950	Placebo	20OCT2020/ Placebo	10NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
12412394	C4591001 1241 12412394	16-55	20OCT2020	110951	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		
12412395	C4591001 1241 12412395	16-55	20OCT2020	110953	Placebo	20OCT2020/ Placebo	10NOV2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12412396	C4591001 1241 12412396	16-55	20OCT2020	110994	Placebo	20OCT2020/ Placebo	10NOV2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12412397	C4591001 1241 12412397	16-55	20OCT2020	110996	Placebo	20OCT2020/ Placebo	10NOV2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12412398	C4591001 1241 12412398	16-55	20OCT2020	110999	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		
12412399	C4591001 1241 12412399	16-55	20OCT2020	111000	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		
12412400	C4591001 1241 12412400	16-55	20OCT2020	111041	Placebo	20OCT2020/ Placebo	10NOV2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
12412401	C4591001 1241 12412401	16-55	20OCT2020	111044	Placebo	20OCT2020/ Placebo	10NOV2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
12412402	C4591001 1241 12412402	16-55	20OCT2020	111045	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		
12412403	C4591001 1241 12412403	16-55	20OCT2020	111050	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
12412404	C4591001 1241 12412404	16-55	20OCT2020	111066	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		
12412405	C4591001 1241 12412405	16-55	20OCT2020	111067	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12412406	C4591001 1241 12412406	16-55	20OCT2020	111069	Placebo	20OCT2020/ Placebo	10NOV2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12412407	C4591001 1241 12412407	16-55	20OCT2020	111075	Placebo	20OCT2020/ Placebo	10NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12412409	C4591001 1241 12412409	16-55	20OCT2020	111117	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		
12412410	C4591001 1241 12412410	16-55	20OCT2020	111120	Placebo	20OCT2020/ Placebo	10NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12412411	C4591001 1241 12412411	16-55	20OCT2020	111122	Placebo	20OCT2020/ Placebo	10NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	
12412412	C4591001 1241 12412412	16-55	20OCT2020	111123	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		
12412413	C4591001 1241 12412413	16-55	20OCT2020	111151	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		
12412414	C4591001 1241 12412414	16-55	20OCT2020	111152	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		
12412415	C4591001 1241 12412415	16-55	20OCT2020	111153	Placebo	20OCT2020/ Placebo	10NOV2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12412416	C4591001 1241 12412416	16-55	20OCT2020	111155	Placebo	20OCT2020/ Placebo	10NOV2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12412417	C4591001 1241 12412417	16-55	20OCT2020	111173	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		
12412418	C4591001 1241 12412418	16-55	20OCT2020	111178	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		
12412419	C4591001 1241 12412419	16-55	20OCT2020	111183	Placebo	20OCT2020/ Placebo	10NOV2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12412420	C4591001 1241 12412420	16-55	21OCT2020	111184	Placebo	21OCT2020/ Placebo	11NOV2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12412421	C4591001 1241 12412421	16-55	21OCT2020	111475	Placebo	21OCT2020/ Placebo	11NOV2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12412422	C4591001 1241 12412422	16-55	21OCT2020	111481	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
12412423	C4591001 1241 12412423	16-55	21OCT2020	111479	Placebo	21OCT2020/ Placebo	11NOV2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12412424	C4591001 1241 12412424	16-55	21OCT2020	111482	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
12412425	C4591001 1241 12412425	16-55	21OCT2020	111679	Placebo	21OCT2020/ Placebo	11NOV2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12412426	C4591001 1241 12412426	16-55	21OCT2020	111680	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12412427	C4591001 1241 12412427	16-55	21OCT2020	111682	Placebo	21OCT2020/ Placebo	11NOV2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12412428	C4591001 1241 12412428	16-55	21OCT2020	111688	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
12412429	C4591001 1241 12412429	16-55	21OCT2020	111702	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
12412430	C4591001 1241 12412430	16-55	21OCT2020	111706	Placebo	21OCT2020/ Placebo	11NOV2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12412431	C4591001 1241 12412431	16-55	21OCT2020	111711	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
12412432	C4591001 1241 12412432	16-55	21OCT2020	111712	Placebo	21OCT2020/ Placebo	11NOV2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12412433	C4591001 1241 12412433	16-55	21OCT2020	111773	Placebo	21OCT2020/ Placebo	11NOV2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12412434	C4591001 1241 12412434	16-55	21OCT2020	111776	Placebo	21OCT2020/ Placebo	11NOV2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12412435	C4591001 1241 12412435	16-55	21OCT2020	111779	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
12412436	C4591001 1241 12412436	16-55	22OCT2020	111783	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12412437	C4591001 1241 12412437	16-55	22OCT2020	112025	Placebo	22OCT2020/ Placebo	11NOV2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
12412438	C4591001 1241 12412438	16-55	22OCT2020	112026	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
12412439	C4591001 1241 12412439	16-55	22OCT2020	112033	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
12412440	C4591001 1241 12412440	16-55	22OCT2020	112036	Placebo	22OCT2020/ Placebo	11NOV2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
12412441	C4591001 1241 12412441	16-55	22OCT2020	112163	Placebo	22OCT2020/ Placebo	11NOV2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12412442	C4591001 1241 12412442	16-55	22OCT2020	112166	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
12412443	C4591001 1241 12412443	16-55	22OCT2020	112167	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
12412444	C4591001 1241 12412444	16-55	22OCT2020	112168	Placebo	22OCT2020/ Placebo	11NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
12412445	C4591001 1241 12412445	16-55	22OCT2020	112277	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
12412447	C4591001 1241 12412447	16-55	22OCT2020	112283	Placebo	22OCT2020/ Placebo	11NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12412448	C4591001 1241 12412448	16-55	22OCT2020	112284	Placebo	22OCT2020/ Placebo	11NOV2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12412449	C4591001 1241 12412449	16-55	22OCT2020	112285	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
12412450	C4591001 1241 12412450	16-55	22OCT2020	112318	Placebo	22OCT2020/ Placebo	11NOV2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12412451	C4591001 1241 12412451	16-55	22OCT2020	112320	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
12412452	C4591001 1241 12412452	16-55	22OCT2020	112321	Placebo	22OCT2020/ Placebo	11NOV2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12412453	C4591001 1241 12412453	16-55	22OCT2020	112322	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
12412454	C4591001 1241 12412454	16-55	22OCT2020	112385	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
12412455	C4591001 1241 12412455	16-55	22OCT2020	112386	Placebo	22OCT2020/ Placebo	11NOV2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
12412456	C4591001 1241 12412456	16-55	22OCT2020	112388	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
12412457	C4591001 1241 12412457	16-55	22OCT2020	112395	Placebo	22OCT2020/ Placebo	11NOV2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12412458	C4591001 1241 12412458	16-55	22OCT2020	112434	Placebo	22OCT2020/ Placebo	11NOV2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12412459	C4591001 1241 12412459	16-55	22OCT2020	112439	Placebo	22OCT2020/ Placebo	11NOV2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12412460	C4591001 1241 12412460	16-55	22OCT2020	112440	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
12412461	C4591001 1241 12412461	16-55	22OCT2020	112441	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
12412462	C4591001 1241 12412462	16-55	22OCT2020	112494	Placebo	22OCT2020/ Placebo	11NOV2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
12412463	C4591001 1241 12412463	16-55	22OCT2020	112500	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
12412464	C4591001 1241 12412464	16-55	22OCT2020	112504	Placebo	22OCT2020/ Placebo	11NOV2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12412465	C4591001 1241 12412465	16-55	22OCT2020	112496	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
12412466	C4591001 1241 12412466	16-55	22OCT2020	112541	Placebo	22OCT2020/ Placebo	12NOV2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12412467	C4591001 1241 12412467	16-55	22OCT2020	112547	Placebo	22OCT2020/ Placebo	11NOV2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12412468	C4591001 1241 12412468	16-55	22OCT2020	112548	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
12412470	C4591001 1241 12412470	16-55	22OCT2020	112549	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
12412471	C4591001 1241 12412471	16-55	22OCT2020	112554	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
12412472	C4591001 1241 12412472	16-55	22OCT2020	112557	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
12412473	C4591001 1241 12412473	16-55	22OCT2020	112556	Placebo	22OCT2020/ Placebo	12NOV2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12412475	C4591001 1241 12412475	16-55	22OCT2020	112564	Placebo	22OCT2020/ Placebo	11NOV2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
12412476	C4591001 1241 12412476	16-55	22OCT2020	112605	Placebo	22OCT2020/ Placebo	20NOV2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12412477	C4591001 1241 12412477	16-55	22OCT2020	112608	Placebo	22OCT2020/ Placebo	11NOV2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12412478	C4591001 1241 12412478	16-55	22OCT2020	112610	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
12412479	C4591001 1241 12412479	16-55	22OCT2020	112612	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12412480	C4591001 1241 12412480	16-55	22OCT2020	112617	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
12412482	C4591001 1241 12412482	16-55	23OCT2020	112619	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
12412485	C4591001 1241 12412485	16-55	23OCT2020	112620	Placebo	23OCT2020/ Placebo	12NOV2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12412486	C4591001 1241 12412486	16-55	23OCT2020	112621	Placebo	23OCT2020/ Placebo	12NOV2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12412490	C4591001 1241 12412490	16-55	23OCT2020	112699	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
12412491	C4591001 1241 12412491	16-55	23OCT2020	112700	Placebo	23OCT2020/ Placebo	12NOV2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12412493	C4591001 1241 12412493	16-55	23OCT2020	112701	Placebo	23OCT2020/ Placebo	12NOV2020/ Placebo		
12412494	C4591001 1241 12412494	16-55	23OCT2020	112708	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
12412495	C4591001 1241 12412495	16-55	23OCT2020	112736	Placebo	23OCT2020/ Placebo	12NOV2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12412498	C4591001 1241 12412498	16-55	23OCT2020	112739	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12412500	C4591001 1241 12412500	16-55	23OCT2020	112740	Placebo	23OCT2020/ Placebo	12NOV2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12412501	C4591001 1241 12412501	16-55	23OCT2020	112741	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
12412502	C4591001 1241 12412502	16-55	23OCT2020	112781	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
12412504	C4591001 1241 12412504	16-55	23OCT2020	112783	Placebo	23OCT2020/ Placebo	12NOV2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12412505	C4591001 1241 12412505	16-55	23OCT2020	112784	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
12412506	C4591001 1241 12412506	16-55	23OCT2020	112786	Placebo	23OCT2020/ Placebo	11NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12412507	C4591001 1241 12412507	16-55	23OCT2020	112842	Placebo	23OCT2020/ Placebo	13NOV2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12412508	C4591001 1241 12412508	16-55	23OCT2020	112846	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
12412509	C4591001 1241 12412509	16-55	23OCT2020	112848	Placebo	23OCT2020/ Placebo	12NOV2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12412510	C4591001 1241 12412510	16-55	23OCT2020	112852	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12412512	C4591001 1241 12412512	16-55	23OCT2020	112942	Placebo	23OCT2020/ Placebo	12NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12412513	C4591001 1241 12412513	16-55	23OCT2020	112943	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
12412515	C4591001 1241 12412515	16-55	23OCT2020	112946	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
12412516	C4591001 1241 12412516	16-55	23OCT2020	112962	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
12412517	C4591001 1241 12412517	16-55	23OCT2020	112964	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
12412518	C4591001 1241 12412518	16-55	23OCT2020	112965	Placebo	23OCT2020/ Placebo	19NOV2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12412519	C4591001 1241 12412519	16-55	23OCT2020	112937	Placebo	23OCT2020/ Placebo	13NOV2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12412523	C4591001 1241 12412523	16-55	23OCT2020	112968	Placebo	23OCT2020/ Placebo	12NOV2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12412525	C4591001 1241 12412525	16-55	23OCT2020	113035	Placebo	23OCT2020/ Placebo	12NOV2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12412527	C4591001 1241 12412527	16-55	23OCT2020	113036	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12412528	C4591001 1241 12412528	16-55	23OCT2020	113040	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
12412529	C4591001 1241 12412529	16-55	23OCT2020	113041	Placebo	23OCT2020/ Placebo	12NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
12412530	C4591001 1241 12412530	16-55	23OCT2020	113058	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
12412532	C4591001 1241 12412532	16-55	23OCT2020	113060	Placebo	23OCT2020/ Placebo	12NOV2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12412534	C4591001 1241 12412534	16-55	23OCT2020	113066	Placebo	23OCT2020/ Placebo	19NOV2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
12412535	C4591001 1241 12412535	16-55	23OCT2020	113067	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
12412537	C4591001 1241 12412537	16-55	23OCT2020	113120	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
12412539	C4591001 1241 12412539	16-55	23OCT2020	113123	Placebo	23OCT2020/ Placebo	12NOV2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12412540	C4591001 1241 12412540	16-55	23OCT2020	113126	Placebo	23OCT2020/ Placebo	11NOV2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12412543	C4591001 1241 12412543	16-55	23OCT2020	113127	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12412544	C4591001 1241 12412544	16-55	23OCT2020	113141	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
12412546	C4591001 1241 12412546	16-55	23OCT2020	113143	Placebo	23OCT2020/ Placebo	12NOV2020/ Placebo		
12412547	C4591001 1241 12412547	16-55	23OCT2020	113144	Placebo	23OCT2020/ Placebo	12NOV2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12412548	C4591001 1241 12412548	16-55	23OCT2020	113148	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
12412549	C4591001 1241 12412549	16-55	23OCT2020	113154	Placebo	23OCT2020/ Placebo	12NOV2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12412550	C4591001 1241 12412550	16-55	23OCT2020	113156	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
12412551	C4591001 1241 12412551	16-55	23OCT2020	113158	Placebo	23OCT2020/ Placebo	12NOV2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12412552	C4591001 1241 12412552	16-55	23OCT2020	113163	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
12412553	C4591001 1241 12412553	16-55	23OCT2020	113180	Placebo	23OCT2020/ Placebo	12NOV2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12412554	C4591001 1241 12412554	16-55	23OCT2020	113183	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12412556	C4591001 1241 12412556	16-55	23OCT2020	113184	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
12412557	C4591001 1241 12412557	16-55	23OCT2020	113186	Placebo	23OCT2020/ Placebo	12NOV2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12412558	C4591001 1241 12412558	16-55	23OCT2020	113229	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
12412559	C4591001 1241 12412559	16-55	23OCT2020	113232	Placebo	23OCT2020/ Placebo	12NOV2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12412560	C4591001 1241 12412560	16-55	23OCT2020	113233	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
12412561	C4591001 1241 12412561	16-55	23OCT2020	113236	Placebo	23OCT2020/ Placebo	12NOV2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12412562	C4591001 1241 12412562	16-55	23OCT2020	113237	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
12412563	C4591001 1241 12412563	16-55	23OCT2020	113243	Placebo	23OCT2020/ Placebo	12NOV2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12412564	C4591001 1241 12412564	16-55	23OCT2020	113244	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
12412565	C4591001 1241 12412565	16-55	23OCT2020	113248	Placebo	23OCT2020/ Placebo	11NOV2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12412566	C4591001 1241 12412566†	16-55	04NOV2020	115625	Placebo	04NOV2020/ Placebo	23NOV2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12461002	C4591001 1246 12461002	16-55	24SEP2020	98465	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
12461004	C4591001 1246 12461004	16-55	24SEP2020	98468	Placebo	24SEP2020/ Placebo	15OCT2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
12461005	C4591001 1246 12461005	16-55	25SEP2020	98469	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12461006	C4591001 1246 12461006	16-55	25SEP2020	98470	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
12461007	C4591001 1246 12461007	16-55	25SEP2020	99199	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12461008	C4591001 1246 12461008	16-55	25SEP2020	99200	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
12461009	C4591001 1246 12461009	16-55	25SEP2020	99201	Placebo	25SEP2020/ Placebo	15OCT2020/ Placebo		
12461010	C4591001 1246 12461010	16-55	25SEP2020	99207	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)		
12461011	C4591001 1246 12461011	16-55	25SEP2020	99257	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12461012	C4591001 1246 12461012	16-55	25SEP2020	99260	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12461014	C4591001 1246 12461014	16-55	26SEP2020	99262	Placebo	26SEP2020/ Placebo	17OCT2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12461015	C4591001 1246 12461015	16-55	26SEP2020	99263	BNT162b2 (30 µg)	26SEP2020/ BNT162b2 (30 µg)	17OCT2020/ BNT162b2 (30 µg)		
12461017	C4591001 1246 12461017	16-55	27SEP2020	100616	Placebo	27SEP2020/ Placebo	17OCT2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
12461018	C4591001 1246 12461018	16-55	27SEP2020	100617	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	17OCT2020/ BNT162b2 (30 µg)		
12461019	C4591001 1246 12461019	16-55	27SEP2020	100618	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	17OCT2020/ BNT162b2 (30 µg)		
12461020	C4591001 1246 12461020	16-55	27SEP2020	100619	Placebo	27SEP2020/ Placebo	17OCT2020/ Placebo	27FEB2021/ BNT162b2 (30 µg)	
12461021	C4591001 1246 12461021	16-55	27SEP2020	100627	Placebo	27SEP2020/ Placebo	16OCT2020/ Placebo		
12461022	C4591001 1246 12461022	16-55	28SEP2020	100629	BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)		
12461023	C4591001 1246 12461023	16-55	28SEP2020	100631	BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12461024	C4591001 1246 12461024	16-55	28SEP2020	100636	Placebo	28SEP2020/ Placebo	21OCT2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
12461025	C4591001 1246 12461025	16-55	28SEP2020	101166	BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)			
12461026	C4591001 1246 12461026	16-55	28SEP2020	101171	Placebo	28SEP2020/ Placebo	19OCT2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
12461028	C4591001 1246 12461028	16-55	28SEP2020	101172	Placebo	28SEP2020/ Placebo	19OCT2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
12461029	C4591001 1246 12461029	16-55	28SEP2020	101173	BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)		
12461030	C4591001 1246 12461030	16-55	28SEP2020	101206	Placebo	28SEP2020/ Placebo	19OCT2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
12461031	C4591001 1246 12461031	16-55	28SEP2020	101207	BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)		
12461032	C4591001 1246 12461032	16-55	28SEP2020	101210	BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		
12461033	C4591001 1246 12461033	16-55	28SEP2020	101212	Placebo	28SEP2020/ Placebo	19OCT2020/ Placebo		
12461034	C4591001 1246 12461034	16-55	29SEP2020	101659	BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12461036	C4591001 1246 12461036	16-55	29SEP2020	101660	Placebo	29SEP2020/ Placebo	20OCT2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12461037	C4591001 1246 12461037	16-55	29SEP2020	101661	Placebo	29SEP2020/ Placebo	20OCT2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12461038	C4591001 1246 12461038	16-55	29SEP2020	101664	BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		
12461039	C4591001 1246 12461039	16-55	29SEP2020	101804	Placebo	29SEP2020/ Placebo	20OCT2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	
12461041	C4591001 1246 12461041	16-55	30SEP2020	101806	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		
12461043	C4591001 1246 12461043	16-55	30SEP2020	101810	Placebo	30SEP2020/ Placebo	21OCT2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
12461044	C4591001 1246 12461044	16-55	30SEP2020	101808	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		
12461045	C4591001 1246 12461045	16-55	30SEP2020	102069	Placebo	30SEP2020/ Placebo	21OCT2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
12461046	C4591001 1246 12461046	16-55	30SEP2020	102070	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		
12461047	C4591001 1246 12461047	16-55	30SEP2020	102072	Placebo	30SEP2020/ Placebo	21OCT2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12461049	C4591001 1246 12461049†	16-55	01OCT2020	102578	Placebo	01OCT2020/ Placebo	22OCT2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12461050	C4591001 1246 12461050	16-55	01OCT2020	102076	BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)		
12461052	C4591001 1246 12461052	16-55	01OCT2020	102569	BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)		
12461053	C4591001 1246 12461053	16-55	01OCT2020	102572	BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)		
12461055	C4591001 1246 12461055†	16-55	02OCT2020	103018	Placebo	02OCT2020/ Placebo	23OCT2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
12461057	C4591001 1246 12461057	16-55	01OCT2020	102579	Placebo	01OCT2020/ Placebo	21OCT2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12461058	C4591001 1246 12461058	16-55	01OCT2020	102666	BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)		
12461059	C4591001 1246 12461059	16-55	01OCT2020	102667	BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)		
12461060	C4591001 1246 12461060	16-55	02OCT2020	102668	Placebo	02OCT2020/ Placebo	23OCT2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12461061	C4591001 1246 12461061	16-55	02OCT2020	102672	Placebo	02OCT2020/ Placebo	23OCT2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12461065	C4591001 1246 12461065	16-55	02OCT2020	103021	Placebo	02OCT2020/ Placebo	23OCT2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
12461066	C4591001 1246 12461066	16-55	02OCT2020	103022	BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)		
12461067	C4591001 1246 12461067	16-55	02OCT2020	103023	BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)		
12461068	C4591001 1246 12461068	16-55	02OCT2020	103089	BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)		
12461069	C4591001 1246 12461069	16-55	02OCT2020	103090	BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)		
12461070	C4591001 1246 12461070	16-55	03OCT2020	103401	BNT162b2 (30 µg)	03OCT2020/ BNT162b2 (30 µg)	24OCT2020/ BNT162b2 (30 µg)		
12461071	C4591001 1246 12461071	16-55	03OCT2020	103092	Placebo	03OCT2020/ Placebo	24OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
12461072	C4591001 1246 12461072	16-55	03OCT2020	103096	Placebo	03OCT2020/ Placebo	23OCT2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12461073	C4591001 1246 12461073†	16-55	05OCT2020	103407	BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
12461074	C4591001 1246 12461074	16-55	03OCT2020	103402	Placebo	03OCT2020/ Placebo	23OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12461075	C4591001 1246 12461075	16-55	03OCT2020	103406	Placebo	03OCT2020/ Placebo	23OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
12461076	C4591001 1246 12461076	16-55	05OCT2020	266950	Placebo	05OCT2020/ Placebo	26OCT2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
12461078	C4591001 1246 12461078	16-55	05OCT2020	103529	Placebo	05OCT2020/ Placebo	26OCT2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
12461079	C4591001 1246 12461079	16-55	05OCT2020	103530	BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
12461080	C4591001 1246 12461080	16-55	05OCT2020	103532	BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
12461081	C4591001 1246 12461081	16-55	05OCT2020	103540	Placebo	05OCT2020/ Placebo	24OCT2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
12461082	C4591001 1246 12461082	16-55	05OCT2020	103579	Placebo	05OCT2020/ Placebo	24OCT2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
12461084	C4591001 1246 12461084	16-55	05OCT2020	103580	Placebo	05OCT2020/ Placebo	26OCT2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
12461085	C4591001 1246 12461085	16-55	05OCT2020	103581	BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
12461086	C4591001 1246 12461086	16-55	05OCT2020	103585	BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12461087	C4591001 1246 12461087	16-55	06OCT2020	104014	Placebo	06OCT2020/ Placebo	27OCT2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
12461088	C4591001 1246 12461088	16-55	06OCT2020	104016	Placebo	06OCT2020/ Placebo	27OCT2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
12461089	C4591001 1246 12461089	16-55	06OCT2020	104018	BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		
12461090	C4591001 1246 12461090	16-55	06OCT2020	104019	BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		
12461092	C4591001 1246 12461092	16-55	06OCT2020	104045	Placebo	06OCT2020/ Placebo	27OCT2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
12461093	C4591001 1246 12461093	16-55	06OCT2020	104046	BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		
12461094	C4591001 1246 12461094	16-55	06OCT2020	104050	Placebo	06OCT2020/ Placebo	27OCT2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
12461095	C4591001 1246 12461095	16-55	06OCT2020	104055	BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
12461097	C4591001 1246 12461097	16-55	06OCT2020	104117	BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		
12461098	C4591001 1246 12461098	16-55	06OCT2020	104120	Placebo	06OCT2020/ Placebo	27OCT2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12461099	C4591001 1246 12461099	16-55	06OCT2020	104124	Placebo	06OCT2020/ Placebo	27OCT2020/ Placebo		
12461100	C4591001 1246 12461100	16-55	06OCT2020	104128	BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		
12461103	C4591001 1246 12461103	16-55	07OCT2020	104492	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
12461104	C4591001 1246 12461104	16-55	07OCT2020	104493	Placebo	07OCT2020/ Placebo	28OCT2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
12461105	C4591001 1246 12461105	16-55	07OCT2020	104495	Placebo	07OCT2020/ Placebo	28OCT2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
12461106	C4591001 1246 12461106	16-55	07OCT2020	104497	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
12461107	C4591001 1246 12461107	16-55	07OCT2020	104527	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
12461108	C4591001 1246 12461108	16-55	07OCT2020	104528	Placebo	07OCT2020/ Placebo	28OCT2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
12461109	C4591001 1246 12461109	16-55	07OCT2020	104533	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
12461110	C4591001 1246 12461110	16-55	07OCT2020	104534	Placebo	07OCT2020/ Placebo	28OCT2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12461111	C4591001 1246 12461111	16-55	08OCT2020	105054	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)		
12461112	C4591001 1246 12461112	16-55	08OCT2020	105058	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)		
12461113	C4591001 1246 12461113	16-55	08OCT2020	105063	Placebo	08OCT2020/ Placebo	31OCT2020/ Placebo	27FEB2021/ BNT162b2 (30 µg)	
12461114	C4591001 1246 12461114	16-55	08OCT2020	105064	Placebo	08OCT2020/ Placebo	29OCT2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
12461115	C4591001 1246 12461115	16-55	08OCT2020	105102	Placebo	08OCT2020/ Placebo	28OCT2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
12461116	C4591001 1246 12461116	16-55	08OCT2020	105106	Placebo	08OCT2020/ Placebo	28OCT2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
12461117	C4591001 1246 12461117	16-55	08OCT2020	105107	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
12461118	C4591001 1246 12461118	16-55	08OCT2020	105110	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
12461119	C4591001 1246 12461119	16-55	08OCT2020	105163	Placebo	08OCT2020/ Placebo	29OCT2020/ Placebo	27FEB2021/ BNT162b2 (30 µg)	
12461120	C4591001 1246 12461120	16-55	08OCT2020	105167	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12461121	C4591001 1246 12461121	16-55	09OCT2020	105168	Placebo	09OCT2020/ Placebo	30OCT2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
12461122	C4591001 1246 12461122	16-55	09OCT2020	105169	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)		
12461123	C4591001 1246 12461123	16-55	09OCT2020	105617	Placebo	09OCT2020/ Placebo	30OCT2020/ Placebo		
12461126	C4591001 1246 12461126	16-55	09OCT2020	105620	Placebo	09OCT2020/ Placebo	30OCT2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
12461127	C4591001 1246 12461127	16-55	09OCT2020	105623	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)		
12461128	C4591001 1246 12461128	16-55	09OCT2020	105624	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	31OCT2020/ BNT162b2 (30 µg)		
12461129	C4591001 1246 12461129	16-55	09OCT2020	105785	Placebo	09OCT2020/ Placebo	30OCT2020/ Placebo		
12461130	C4591001 1246 12461130	16-55	10OCT2020	105786	BNT162b2 (30 µg)	10OCT2020/ BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)		
12461131	C4591001 1246 12461131	16-55	10OCT2020	105789	Placebo	10OCT2020/ Placebo	31OCT2020/ Placebo	27FEB2021/ BNT162b2 (30 µg)	
12461133	C4591001 1246 12461133	16-55	10OCT2020	105791	BNT162b2 (30 µg)	10OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12461134	C4591001 1246 12461134	16-55	10OCT2020	106234	Placebo	10OCT2020/ Placebo	30OCT2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
12461135	C4591001 1246 12461135	16-55	10OCT2020	106236	BNT162b2 (30 µg)	10OCT2020/ BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)		
12461136	C4591001 1246 12461136	16-55	10OCT2020	106237	Placebo	10OCT2020/ Placebo	30OCT2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
12461137	C4591001 1246 12461137	16-55	10OCT2020	106238	BNT162b2 (30 µg)	10OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		
12461138	C4591001 1246 12461138	16-55	12OCT2020	106256	BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		
12461139	C4591001 1246 12461139	16-55	12OCT2020	106258	Placebo	12OCT2020/ Placebo	02NOV2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
12461140	C4591001 1246 12461140	16-55	12OCT2020	106262	BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		
12461142	C4591001 1246 12461142	16-55	12OCT2020	106264	Placebo	12OCT2020/ Placebo	02NOV2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
12471002	C4591001 1247 12471002	16-55	23SEP2020	97158	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo		
12471003	C4591001 1247 12471003	16-55	23SEP2020	97167	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12471004	C4591001 1247 12471004	16-55	23SEP2020	97160	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
12471006	C4591001 1247 12471006	16-55	23SEP2020	97164	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
12471009	C4591001 1247 12471009	16-55	23SEP2020	97186	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
12471010	C4591001 1247 12471010	16-55	23SEP2020	97187	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12471011	C4591001 1247 12471011	16-55	24SEP2020	97189	Placebo	24SEP2020/ Placebo	14OCT2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
12471012	C4591001 1247 12471012	16-55	24SEP2020	97191	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
12471013	C4591001 1247 12471013	16-55	24SEP2020	98441	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
12471014	C4591001 1247 12471014	16-55	24SEP2020	98444	Placebo	24SEP2020/ Placebo	14OCT2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
12471015	C4591001 1247 12471015	16-55	24SEP2020	98447	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
12471016	C4591001 1247 12471016	16-55	24SEP2020	98450	Placebo	24SEP2020/ Placebo	14OCT2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12471017	C4591001 1247 12471017	16-55	24SEP2020	98453	Placebo	24SEP2020/ Placebo	14OCT2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
12471018	C4591001 1247 12471018	16-55	24SEP2020	98458	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
12471019	C4591001 1247 12471019	16-55	24SEP2020	98459	Placebo	24SEP2020/ Placebo	15OCT2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
12471020	C4591001 1247 12471020	16-55	24SEP2020	98460	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
12471021	C4591001 1247 12471021	16-55	24SEP2020	98479	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
12471022	C4591001 1247 12471022	16-55	24SEP2020	98481	Placebo	24SEP2020/ Placebo	15OCT2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12471023	C4591001 1247 12471023	16-55	24SEP2020	98484	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
12471025	C4591001 1247 12471025	16-55	24SEP2020	98488	Placebo	24SEP2020/ Placebo	15OCT2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12471026	C4591001 1247 12471026	16-55	24SEP2020	98490	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
12471027	C4591001 1247 12471027	16-55	24SEP2020	98491	Placebo	24SEP2020/ Placebo	15OCT2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12471028	C4591001 1247 12471028	16-55	24SEP2020	98495	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
12471029	C4591001 1247 12471029	16-55	24SEP2020	98497	Placebo	24SEP2020/ Placebo	15OCT2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	
12471030	C4591001 1247 12471030	16-55	24SEP2020	98514	Placebo	24SEP2020/ Placebo	15OCT2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
12471031	C4591001 1247 12471031	16-55	24SEP2020	98516	Placebo	24SEP2020/ Placebo	15OCT2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
12471032	C4591001 1247 12471032	16-55	24SEP2020	98518	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
12471033	C4591001 1247 12471033	16-55	24SEP2020	98524	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
12471034	C4591001 1247 12471034	16-55	24SEP2020	98530	Placebo	24SEP2020/ Placebo	15OCT2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12471035	C4591001 1247 12471035	16-55	24SEP2020	98531	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
12471036	C4591001 1247 12471036	16-55	24SEP2020	98533	Placebo	24SEP2020/ Placebo	15OCT2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	
12471037	C4591001 1247 12471037	16-55	24SEP2020	98535	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12471038	C4591001 1247 12471038	16-55	24SEP2020	98539	Placebo	24SEP2020/ Placebo	15OCT2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
12471040	C4591001 1247 12471040	16-55	25SEP2020	98548	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
12471043	C4591001 1247 12471043	16-55	25SEP2020	98541	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
12471044	C4591001 1247 12471044	16-55	25SEP2020	98543	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo		
12471045	C4591001 1247 12471045	16-55	25SEP2020	99173	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
12471046	C4591001 1247 12471046	16-55	25SEP2020	99178	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
12471048	C4591001 1247 12471048	16-55	25SEP2020	99180	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12471050	C4591001 1247 12471050	16-55	25SEP2020	99181	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
12471051	C4591001 1247 12471051	16-55	25SEP2020	99211	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
12471052	C4591001 1247 12471052	16-55	25SEP2020	99217	Placebo	25SEP2020/ Placebo	14OCT2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12471053	C4591001 1247 12471053	16-55	25SEP2020	99218	Placebo	25SEP2020/ Placebo	15OCT2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12471054	C4591001 1247 12471054	16-55	29SEP2020	101631	BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
12471055	C4591001 1247 12471055	16-55	25SEP2020	99220	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
12471057	C4591001 1247 12471057	16-55	25SEP2020	99245	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
12471058	C4591001 1247 12471058	16-55	25SEP2020	99248	Placebo	25SEP2020/ Placebo	15OCT2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
12471059	C4591001 1247 12471059	16-55	25SEP2020	99255	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
12471060	C4591001 1247 12471060	16-55	25SEP2020	99256	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
12471061	C4591001 1247 12471061	16-55	25SEP2020	99307	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
12471062	C4591001 1247 12471062	16-55	29SEP2020	101616	BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		
12471064	C4591001 1247 12471064	16-55	29SEP2020	101308	Placebo	29SEP2020/ Placebo	19OCT2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12471069	C4591001 1247 12471069	16-55	28SEP2020	99309	Placebo	28SEP2020/ Placebo	19OCT2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12471071	C4591001 1247 12471071	16-55	28SEP2020	99310	BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)		
12471073	C4591001 1247 12471073	16-55	29SEP2020	101627	Placebo	29SEP2020/ Placebo	19OCT2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12471074	C4591001 1247 12471074	16-55	29SEP2020	101626	BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)		
12471075	C4591001 1247 12471075	16-55	28SEP2020	101298	BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)		
12471076	C4591001 1247 12471076	16-55	29SEP2020	101620	BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		
12471077	C4591001 1247 12471077	16-55	29SEP2020	101615	Placebo	29SEP2020/ Placebo	19OCT2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
12471078	C4591001 1247 12471078	16-55	28SEP2020	101303	Placebo	28SEP2020/ Placebo	20OCT2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
12471079	C4591001 1247 12471079	16-55	28SEP2020	101256	BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)		
12471080	C4591001 1247 12471080	16-55	29SEP2020	101632	Placebo	29SEP2020/ Placebo	19OCT2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12471081	C4591001 1247 12471081	16-55	29SEP2020	101640	BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		
12471082	C4591001 1247 12471082	16-55	28SEP2020	101259	Placebo	28SEP2020/ Placebo	19OCT2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
12471084	C4591001 1247 12471084	16-55	28SEP2020	101307	BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)		
12471085	C4591001 1247 12471085	16-55	28SEP2020	101255	Placebo	28SEP2020/ Placebo	19OCT2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12471086	C4591001 1247 12471086	16-55	29SEP2020	101610	Placebo	29SEP2020/ Placebo	21OCT2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
12471087	C4591001 1247 12471087	16-55	28SEP2020	99312	Placebo	28SEP2020/ Placebo	19OCT2020/ Placebo	03MAR2021/ BNT162b2 (30 µg)	
12471088	C4591001 1247 12471088	16-55	28SEP2020	101252	BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)		
12471089	C4591001 1247 12471089	16-55	29SEP2020	101634	BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		
12471090	C4591001 1247 12471090	16-55	29SEP2020	101636	Placebo	29SEP2020/ Placebo	20OCT2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12471091	C4591001 1247 12471091	16-55	29SEP2020	101643	Placebo	29SEP2020/ Placebo	20OCT2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12471092	C4591001 1247 12471092	16-55	29SEP2020	101646	Placebo	29SEP2020/ Placebo	29OCT2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12471096	C4591001 1247 12471096	16-55	29SEP2020	101650	BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		
12471099	C4591001 1247 12471099	16-55	29SEP2020	101653	BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		
12471100	C4591001 1247 12471100	16-55	29SEP2020	101656	Placebo	29SEP2020/ Placebo	20OCT2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
12471101	C4591001 1247 12471101	16-55	29SEP2020	101705	Placebo	29SEP2020/ Placebo	20OCT2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
12471102	C4591001 1247 12471102	16-55	29SEP2020	101712	BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		
12471103	C4591001 1247 12471103	16-55	29SEP2020	101714	Placebo	29SEP2020/ Placebo	20OCT2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
12471106	C4591001 1247 12471106	16-55	29SEP2020	101716	BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		
12471107	C4591001 1247 12471107	16-55	29SEP2020	101729	Placebo	29SEP2020/ Placebo	20OCT2020/ Placebo		
12471108	C4591001 1247 12471108	16-55	29SEP2020	101735	BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12471109	C4591001 1247 12471109	16-55	30SEP2020	101736	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		
12471111	C4591001 1247 12471111	16-55	30SEP2020	101740	Placebo	30SEP2020/ Placebo	21OCT2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
12471112	C4591001 1247 12471112	16-55	30SEP2020	102032	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		
12471113	C4591001 1247 12471113	16-55	30SEP2020	102033	Placebo	30SEP2020/ Placebo	21OCT2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12471114	C4591001 1247 12471114	16-55	30SEP2020	102036	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		
12471115	C4591001 1247 12471115	16-55	30SEP2020	102039	Placebo	30SEP2020/ Placebo	21OCT2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12471118	C4591001 1247 12471118	16-55	30SEP2020	102044	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		
12471120	C4591001 1247 12471120	16-55	30SEP2020	102045	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		
12471121	C4591001 1247 12471121	16-55	30SEP2020	102046	Placebo	30SEP2020/ Placebo	21OCT2020/ Placebo		
12471122	C4591001 1247 12471122	16-55	30SEP2020	102052	Placebo	30SEP2020/ Placebo	21OCT2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12471123	C4591001 1247 12471123	16-55	30SEP2020	102058	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		
12471124	C4591001 1247 12471124	16-55	30SEP2020	102057	Placebo	30SEP2020/ Placebo	21OCT2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
12471125	C4591001 1247 12471125	16-55	30SEP2020	102053	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		
12471126	C4591001 1247 12471126†	16-55	01OCT2020	102680	Placebo	01OCT2020/ Placebo	22OCT2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
12471127	C4591001 1247 12471127	16-55	30SEP2020	102059	Placebo	30SEP2020/ Placebo	21OCT2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
12471128	C4591001 1247 12471128	16-55	30SEP2020	102090	Placebo	30SEP2020/ Placebo	20OCT2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
12471130	C4591001 1247 12471130	16-55	30SEP2020	102138	Placebo	30SEP2020/ Placebo	21OCT2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12471131	C4591001 1247 12471131	16-55	30SEP2020	102091	Placebo	30SEP2020/ Placebo	21OCT2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12471132	C4591001 1247 12471132	16-55	30SEP2020	102092	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		
12471133	C4591001 1247 12471133	16-55	30SEP2020	102093	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12471136	C4591001 1247 12471136	16-55	30SEP2020	102140	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		
12471137	C4591001 1247 12471137	16-55	30SEP2020	102142	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		
12471139	C4591001 1247 12471139	16-55	30SEP2020	102146	Placebo	30SEP2020/ Placebo	21OCT2020/ Placebo		
12471140	C4591001 1247 12471140	16-55	01OCT2020	102547	Placebo	01OCT2020/ Placebo	22OCT2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12471141	C4591001 1247 12471141	16-55	01OCT2020	102551	Placebo	01OCT2020/ Placebo	22OCT2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12471142	C4591001 1247 12471142	16-55	01OCT2020	102555	BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)		
12471143	C4591001 1247 12471143	16-55	01OCT2020	102562	BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)		
12471144	C4591001 1247 12471144	16-55	01OCT2020	102556	BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)		
12471145	C4591001 1247 12471145	16-55	01OCT2020	102560	Placebo	01OCT2020/ Placebo	22OCT2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
12471147	C4591001 1247 12471147	16-55	01OCT2020	102568	Placebo	01OCT2020/ Placebo	22OCT2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12471148	C4591001 1247 12471148	16-55	01OCT2020	102586	Placebo	01OCT2020/ Placebo	03NOV2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12471149	C4591001 1247 12471149	16-55	01OCT2020	102565	BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)			
12471150	C4591001 1247 12471150	16-55	01OCT2020	102589	BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)		
12471151	C4591001 1247 12471151	16-55	01OCT2020	102590	BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)			
12471152	C4591001 1247 12471152	16-55	01OCT2020	102621	Placebo	01OCT2020/ Placebo	26OCT2020/ Placebo	11MAR2021/ BNT162b2 (30 µg)	
12471153	C4591001 1247 12471153	16-55	01OCT2020	102592	Placebo	01OCT2020/ Placebo	22OCT2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
12471154	C4591001 1247 12471154	16-55	01OCT2020	102620	Placebo	01OCT2020/ Placebo	20OCT2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
12471155	C4591001 1247 12471155	16-55	01OCT2020	102623	BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)		
12471156	C4591001 1247 12471156	16-55	01OCT2020	102627	BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)		
12471158	C4591001 1247 12471158	16-55	05OCT2020	102682	BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12471159	C4591001 1247 12471159	16-55	05OCT2020	102685	BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
12471161	C4591001 1247 12471161	16-55	05OCT2020	102686	Placebo	05OCT2020/ Placebo	26OCT2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12471162	C4591001 1247 12471162	16-55	05OCT2020	103569	Placebo	05OCT2020/ Placebo	26OCT2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	
12471164	C4591001 1247 12471164	16-55	05OCT2020	103572	BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
12471165	C4591001 1247 12471165	16-55	05OCT2020	103575	BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
12471167	C4591001 1247 12471167†	16-55	06OCT2020	104087	Placebo	06OCT2020/ Placebo	27OCT2020/ Placebo		
12471168	C4591001 1247 12471168	16-55	05OCT2020	103576	Placebo	05OCT2020/ Placebo	26OCT2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12471171	C4591001 1247 12471171	16-55	05OCT2020	103602	Placebo	05OCT2020/ Placebo	26OCT2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
12471172	C4591001 1247 12471172	16-55	05OCT2020	103606	BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
12471173	C4591001 1247 12471173	16-55	05OCT2020	103608	Placebo	05OCT2020/ Placebo	26OCT2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12471174	C4591001 1247 12471174	16-55	05OCT2020	103609	BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
12471175	C4591001 1247 12471175	16-55	05OCT2020	103641	BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
12471176	C4591001 1247 12471176	16-55	05OCT2020	103642	Placebo	05OCT2020/ Placebo	26OCT2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12471177	C4591001 1247 12471177	16-55	05OCT2020	103648	Placebo	05OCT2020/ Placebo	26OCT2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
12471178	C4591001 1247 12471178	16-55	05OCT2020	103645	BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
12471179	C4591001 1247 12471179	16-55	05OCT2020	103652	BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
12471181	C4591001 1247 12471181	16-55	06OCT2020	103659	Placebo	06OCT2020/ Placebo	27OCT2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12471182	C4591001 1247 12471182	16-55	06OCT2020	103653	Placebo	06OCT2020/ Placebo	27OCT2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12471183	C4591001 1247 12471183	16-55	06OCT2020	103655	BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		
12471184	C4591001 1247 12471184	16-55	06OCT2020	103998	BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12471185	C4591001 1247 12471185	16-55	06OCT2020	104001	BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		
12471186	C4591001 1247 12471186	16-55	06OCT2020	104006	Placebo	06OCT2020/ Placebo	26OCT2020/ Placebo	11MAR2021/ BNT162b2 (30 µg)	
12471189	C4591001 1247 12471189	16-55	06OCT2020	104007	Placebo	06OCT2020/ Placebo	27OCT2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
12471190	C4591001 1247 12471190	16-55	06OCT2020	104035	BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		
12471193	C4591001 1247 12471193	16-55	06OCT2020	104036	Placebo	06OCT2020/ Placebo	27OCT2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12471196	C4591001 1247 12471196	16-55	06OCT2020	104040	BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		
12471197	C4591001 1247 12471197	16-55	06OCT2020	104042	Placebo	06OCT2020/ Placebo	27OCT2020/ Placebo		
12471198	C4591001 1247 12471198	16-55	06OCT2020	104083	Placebo	06OCT2020/ Placebo	27OCT2020/ Placebo		
12471199	C4591001 1247 12471199	16-55	06OCT2020	104084	BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
12471200	C4591001 1247 12471200	16-55	06OCT2020	104086	BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12471201	C4591001 1247 12471201	16-55	07OCT2020	104477	Placebo	07OCT2020/ Placebo	28OCT2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
12471202	C4591001 1247 12471202	16-55	07OCT2020	104482	Placebo	07OCT2020/ Placebo	28OCT2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
12471203	C4591001 1247 12471203	16-55	07OCT2020	104486	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
12471204	C4591001 1247 12471204†	16-55	07OCT2020	104575	Placebo	07OCT2020/ Placebo	28OCT2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	
12471205	C4591001 1247 12471205	16-55	07OCT2020	104487	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
12471206	C4591001 1247 12471206	16-55	07OCT2020	104502	Placebo	07OCT2020/ Placebo	28OCT2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
12471208	C4591001 1247 12471208	16-55	07OCT2020	104506	Placebo	07OCT2020/ Placebo	29OCT2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12471209	C4591001 1247 12471209	16-55	07OCT2020	104511	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
12471211	C4591001 1247 12471211	16-55	07OCT2020	104508	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
12471212	C4591001 1247 12471212	16-55	07OCT2020	104578	Placebo	07OCT2020/ Placebo	28OCT2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12471213	C4591001 1247 12471213	16-55	07OCT2020	104583	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
12471214	C4591001 1247 12471214	16-55	07OCT2020	104584	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
12471215	C4591001 1247 12471215	16-55	12OCT2020	105719	Placebo	12OCT2020/ Placebo	03NOV2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
12471217	C4591001 1247 12471217	16-55	07OCT2020	104586	Placebo	07OCT2020/ Placebo	28OCT2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12471218	C4591001 1247 12471218	16-55	08OCT2020	104588	Placebo	08OCT2020/ Placebo	28OCT2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
12471220	C4591001 1247 12471220	16-55	08OCT2020	104594	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
12471221	C4591001 1247 12471221	16-55	08OCT2020	104589	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)		
12471222	C4591001 1247 12471222	16-55	08OCT2020	105041	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)		
12471223	C4591001 1247 12471223	16-55	08OCT2020	105047	Placebo	08OCT2020/ Placebo	30OCT2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12471224	C4591001 1247 12471224	16-55	08OCT2020	105068	Placebo	08OCT2020/ Placebo	29OCT2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12471225	C4591001 1247 12471225	16-55	08OCT2020	105048	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)		
12471226	C4591001 1247 12471226	16-55	08OCT2020	105052	Placebo	08OCT2020/ Placebo	30OCT2020/ Placebo		
12471230	C4591001 1247 12471230	16-55	08OCT2020	105072	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		
12471231	C4591001 1247 12471231	16-55	08OCT2020	105074	Placebo	08OCT2020/ Placebo	29OCT2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
12471232	C4591001 1247 12471232	16-55	08OCT2020	105080	Placebo	08OCT2020/ Placebo	29OCT2020/ Placebo		
12471233	C4591001 1247 12471233	16-55	08OCT2020	105081	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)		
12471236	C4591001 1247 12471236	16-55	08OCT2020	105088	Placebo	08OCT2020/ Placebo	30OCT2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12471237	C4591001 1247 12471237	16-55	08OCT2020	105138	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)		
12471239	C4591001 1247 12471239	16-55	09OCT2020	105146	Placebo	09OCT2020/ Placebo	29OCT2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12471240	C4591001 1247 12471240	16-55	08OCT2020	105140	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12471241	C4591001 1247 12471241	16-55	09OCT2020	105605	Placebo	09OCT2020/ Placebo	29OCT2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12471242	C4591001 1247 12471242	16-55	09OCT2020	105613	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)		
12471244	C4591001 1247 12471244	16-55	09OCT2020	105614	Placebo	09OCT2020/ Placebo	29OCT2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	
12471245	C4591001 1247 12471245	16-55	09OCT2020	105616	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)		
12471246	C4591001 1247 12471246	16-55	09OCT2020	105641	Placebo	09OCT2020/ Placebo	29OCT2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
12471247	C4591001 1247 12471247	16-55	09OCT2020	105646	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)		
12471248	C4591001 1247 12471248	16-55	09OCT2020	105647	Placebo	09OCT2020/ Placebo	30OCT2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
12471250	C4591001 1247 12471250	16-55	09OCT2020	105652	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)		
12471251	C4591001 1247 12471251	16-55	09OCT2020	105687	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)		
12471252	C4591001 1247 12471252	16-55	09OCT2020	105681	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12471253	C4591001 1247 12471253	16-55	09OCT2020	105684	Placebo	09OCT2020/ Placebo	30OCT2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12471254	C4591001 1247 12471254	16-55	09OCT2020	105686	Placebo	09OCT2020/ Placebo	30OCT2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12471255	C4591001 1247 12471255	16-55	09OCT2020	105702	Placebo	09OCT2020/ Placebo	30OCT2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
12471256	C4591001 1247 12471256	16-55	09OCT2020	105703	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)		
12471257	C4591001 1247 12471257	16-55	09OCT2020	105706	Placebo	09OCT2020/ Placebo	30OCT2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12471258	C4591001 1247 12471258	16-55	09OCT2020	105710	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)		
12471260	C4591001 1247 12471260	16-55	09OCT2020	105715	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)		
12481001	C4591001 1248 12481001	16-55	26AUG2020	68729	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12481004	C4591001 1248 12481004	16-55	26AUG2020	68730	Placebo	26AUG2020/ Placebo	15SEP2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
12481005	C4591001 1248 12481005	16-55	26AUG2020	68732	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12481007	C4591001 1248 12481007	16-55	27AUG2020	68735	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
12481009	C4591001 1248 12481009	16-55	27AUG2020	70122	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12481010	C4591001 1248 12481010	16-55	27AUG2020	70123	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12481011	C4591001 1248 12481011	16-55	27AUG2020	70127	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
12481012	C4591001 1248 12481012	16-55	27AUG2020	70132	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo		
12481013	C4591001 1248 12481013	16-55	27AUG2020	70950	Placebo	27AUG2020/ Placebo	16SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12481014	C4591001 1248 12481014	16-55	27AUG2020	70951	Placebo	28AUG2020/ Placebo	17SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12481016	C4591001 1248 12481016	16-55	28AUG2020	70952	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12481017	C4591001 1248 12481017	16-55	28AUG2020	70958	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12481018	C4591001 1248 12481018	16-55	28AUG2020	71862	Placebo				

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12481019	C4591001 1248 12481019	16-55	28AUG2020	71864	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12481022	C4591001 1248 12481022	16-55	28AUG2020	71868	Placebo	28AUG2020/ Placebo	17SEP2020/ Placebo	11MAR2021/ BNT162b2 (30 µg)	
12481023	C4591001 1248 12481023	16-55	28AUG2020	71870	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12481024	C4591001 1248 12481024	16-55	29AUG2020	73290	Placebo	29AUG2020/ Placebo	18SEP2020/ Placebo	03MAR2021/ BNT162b2 (30 µg)	
12481025	C4591001 1248 12481025	16-55	29AUG2020	73294	BNT162b2 (30 µg)				
12481031	C4591001 1248 12481031	16-55	29AUG2020	73295	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	20SEP2020/ BNT162b2 (30 µg)		
12481032	C4591001 1248 12481032	16-55	29AUG2020	73300	Placebo	29AUG2020/ Placebo	18SEP2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	28JAN2021/ BNT162b2 (30 µg)
12481033	C4591001 1248 12481033	16-55	29AUG2020	73889	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	20SEP2020/ BNT162b2 (30 µg)		
12481034	C4591001 1248 12481034	16-55	30AUG2020	73892	Placebo	30AUG2020/ Placebo	20SEP2020/ Placebo	03MAR2021/ BNT162b2 (30 µg)	
12481035	C4591001 1248 12481035	16-55	30AUG2020	73893	Placebo	30AUG2020/ Placebo	18SEP2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12481036	C4591001 1248 12481036	16-55	30AUG2020	73898	BNT162b2 (30 µg)	30AUG2020/ BNT162b2 (30 µg)	20SEP2020/ BNT162b2 (30 µg)		
12481037	C4591001 1248 12481037	16-55	30AUG2020	74586	Placebo	30AUG2020/ Placebo	20SEP2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
12481038	C4591001 1248 12481038	16-55	30AUG2020	74587	BNT162b2 (30 µg)	30AUG2020/ BNT162b2 (30 µg)	20SEP2020/ BNT162b2 (30 µg)		
12481046	C4591001 1248 12481046	16-55	31AUG2020	74590	Placebo	31AUG2020/ Placebo			
12481048	C4591001 1248 12481048	16-55	31AUG2020	74591	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)			
12481051	C4591001 1248 12481051	16-55	31AUG2020	75931	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	28JAN2021/ BNT162b2 (30 µg)
12481054	C4591001 1248 12481054	16-55	31AUG2020	75934	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
12481055	C4591001 1248 12481055	16-55	31AUG2020	75937	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	20SEP2020/ BNT162b2 (30 µg)		
12481056	C4591001 1248 12481056	16-55	01SEP2020	75940	Placebo	01SEP2020/ Placebo	20SEP2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
12481060	C4591001 1248 12481060	16-55	02SEP2020	78222	Placebo				

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12481061	C4591001 1248 12481061	16-55	02SEP2020	78223	Placebo	02SEP2020/ Placebo	24SEP2020/ Placebo		
12481062	C4591001 1248 12481062	16-55	02SEP2020	78224	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
12481063	C4591001 1248 12481063	16-55	02SEP2020	78488	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
12481065	C4591001 1248 12481065	16-55	04SEP2020	78489	Placebo	04SEP2020/ Placebo	24SEP2020/ Placebo		
12481066	C4591001 1248 12481066	16-55	05SEP2020	78490	Placebo	05SEP2020/ Placebo	25SEP2020/ Placebo	09JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)
12481067	C4591001 1248 12481067	16-55	05SEP2020	78496	BNT162b2 (30 µg)	05SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
12481068	C4591001 1248 12481068	16-55	05SEP2020	82817	Placebo	05SEP2020/ Placebo	26SEP2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)
12481069	C4591001 1248 12481069	16-55	05SEP2020	82822	Placebo	05SEP2020/ Placebo	27SEP2020/ Placebo	03MAR2021/ BNT162b2 (30 µg)	
12481075	C4591001 1248 12481075	16-55	05SEP2020	82913	BNT162b2 (30 µg)	05SEP2020/ BNT162b2 (30 µg)	26SEP2020/ BNT162b2 (30 µg)		
12481076	C4591001 1248 12481076	16-55	05SEP2020	82825	BNT162b2 (30 µg)	05SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12481077	C4591001 1248 12481077	16-55	05SEP2020	82826	BNT162b2 (30 µg)	05SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
12481081	C4591001 1248 12481081	16-55	05SEP2020	82917	BNT162b2 (30 µg)	05SEP2020/ BNT162b2 (30 µg)	26SEP2020/ BNT162b2 (30 µg)		
12481082	C4591001 1248 12481082	16-55	05SEP2020	82920	Placebo	05SEP2020/ Placebo	25SEP2020/ Placebo		
12481085	C4591001 1248 12481085	16-55	05SEP2020	82923	Placebo	05SEP2020/ Placebo	24SEP2020/ Placebo		
12481086	C4591001 1248 12481086	16-55	05SEP2020	82964	Placebo	05SEP2020/ Placebo	24SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
12481087	C4591001 1248 12481087	16-55	05SEP2020	82966	BNT162b2 (30 µg)	05SEP2020/ BNT162b2 (30 µg)	26SEP2020/ BNT162b2 (30 µg)		
12481088	C4591001 1248 12481088	16-55	06SEP2020	82970	BNT162b2 (30 µg)	06SEP2020/ BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)		
12481089	C4591001 1248 12481089	16-55	06SEP2020	82972	Placebo	06SEP2020/ Placebo	25SEP2020/ Placebo		
12481091	C4591001 1248 12481091	16-55	06SEP2020	83000	Placebo	06SEP2020/ Placebo	25SEP2020/ Placebo		
12481092	C4591001 1248 12481092	16-55	06SEP2020	82998	BNT162b2 (30 µg)	06SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
12481093	C4591001 1248 12481093	16-55	06SEP2020	83004	BNT162b2 (30 µg)	06SEP2020/ BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12481094	C4591001 1248 12481094	16-55	06SEP2020	83006	Placebo	06SEP2020/ Placebo	03OCT2020/ Placebo		
12481097	C4591001 1248 12481097	16-55	06SEP2020	83026	BNT162b2 (30 µg)	06SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
12481098	C4591001 1248 12481098	16-55	08SEP2020	83028	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
12481099	C4591001 1248 12481099	16-55	08SEP2020	83030	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12481102	C4591001 1248 12481102	16-55	08SEP2020	83032	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo		
12481103	C4591001 1248 12481103	16-55	08SEP2020	84414	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)		
12481104	C4591001 1248 12481104	16-55	08SEP2020	84415	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
12481106	C4591001 1248 12481106	16-55	09SEP2020	84418	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
12481110	C4591001 1248 12481110	16-55	09SEP2020	84420	Placebo	09SEP2020/ Placebo			
12481114	C4591001 1248 12481114	16-55	10SEP2020	86334	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12481118	C4591001 1248 12481118	16-55	11SEP2020	86335	Placebo	11SEP2020/ Placebo	01OCT2020/ Placebo	02MAR2021/ BNT162b2 (30 µg)	
12481121	C4591001 1248 12481121	16-55	11SEP2020	86342	Placebo	11SEP2020/ Placebo	12OCT2020/ Placebo	03MAR2021/ BNT162b2 (30 µg)	
12481122	C4591001 1248 12481122	16-55	12SEP2020	86343	BNT162b2 (30 µg)	12SEP2020/ BNT162b2 (30 µg)	03OCT2020/ BNT162b2 (30 µg)		
12481123	C4591001 1248 12481123	16-55	12SEP2020	89093	Placebo	12SEP2020/ Placebo	03OCT2020/ Placebo	19DEC2020/ BNT162b2 (30 µg)	09JAN2021/ BNT162b2 (30 µg)
12481125	C4591001 1248 12481125	16-55	12SEP2020	89094	BNT162b2 (30 µg)	12SEP2020/ BNT162b2 (30 µg)	03OCT2020/ BNT162b2 (30 µg)		
12481126	C4591001 1248 12481126	16-55	12SEP2020	89097	BNT162b2 (30 µg)	12SEP2020/ BNT162b2 (30 µg)	03OCT2020/ BNT162b2 (30 µg)		
12481130	C4591001 1248 12481130	16-55	12SEP2020	89100	Placebo	12SEP2020/ Placebo	03OCT2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	27FEB2021/ BNT162b2 (30 µg)
12481131	C4591001 1248 12481131	16-55	12SEP2020	89166	Placebo	12SEP2020/ Placebo	03OCT2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)
12481134	C4591001 1248 12481134	16-55	12SEP2020	89170	BNT162b2 (30 µg)	12SEP2020/ BNT162b2 (30 µg)	03OCT2020/ BNT162b2 (30 µg)		
12481135	C4591001 1248 12481135	16-55	12SEP2020	89171	Placebo	12SEP2020/ Placebo	05OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12481138	C4591001 1248 12481138	16-55	12SEP2020	89174	BNT162b2 (30 µg)	12SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
12481144	C4591001 1248 12481144	16-55	13SEP2020	89262	Placebo	13SEP2020/ Placebo	02OCT2020/ Placebo		
12481145	C4591001 1248 12481145	16-55	13SEP2020	89264	BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
12481146	C4591001 1248 12481146	16-55	13SEP2020	89265	Placebo	13SEP2020/ Placebo	03OCT2020/ Placebo	19DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
12481147	C4591001 1248 12481147	16-55	13SEP2020	89269	BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)	03OCT2020/ BNT162b2 (30 µg)		
12481150	C4591001 1248 12481150	16-55	13SEP2020	89274	BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)	03OCT2020/ BNT162b2 (30 µg)		
12481151	C4591001 1248 12481151	16-55	13SEP2020	89282	BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)	03OCT2020/ BNT162b2 (30 µg)		
12481153	C4591001 1248 12481153	16-55	13SEP2020	89283	Placebo	13SEP2020/ Placebo	03OCT2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12481154	C4591001 1248 12481154	16-55	13SEP2020	89284	Placebo	13SEP2020/ Placebo	03OCT2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
12481156	C4591001 1248 12481156	16-55	14SEP2020	89766	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12481158	C4591001 1248 12481158	16-55	14SEP2020	89767	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
12481159	C4591001 1248 12481159	16-55	14SEP2020	89772	Placebo	14SEP2020/ Placebo	10OCT2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
12481161	C4591001 1248 12481161	16-55	14SEP2020	89773	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
12481162	C4591001 1248 12481162	16-55	14SEP2020	89912	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
12481164	C4591001 1248 12481164	16-55	14SEP2020	89916	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	27FEB2021/ BNT162b2 (30 µg)
12481165	C4591001 1248 12481165	16-55	14SEP2020	89918	Placebo	14SEP2020/ Placebo	06OCT2020/ Placebo		
12481166	C4591001 1248 12481166	16-55	14SEP2020	89919	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
12481169	C4591001 1248 12481169	16-55	15SEP2020	90550	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		
12481170	C4591001 1248 12481170	16-55	15SEP2020	90549	Placebo	15SEP2020/ Placebo	03OCT2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
12481171	C4591001 1248 12481171	16-55	15SEP2020	90552	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12481172	C4591001 1248 12481172	16-55	15SEP2020	90553	Placebo	15SEP2020/ Placebo	05OCT2020/ Placebo		
12481173	C4591001 1248 12481173	16-55	15SEP2020	90654	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
12481175	C4591001 1248 12481175	16-55	15SEP2020	90659	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)			
12481176	C4591001 1248 12481176	16-55	15SEP2020	90662	Placebo	15SEP2020/ Placebo	14OCT2020/ Placebo		
12481177	C4591001 1248 12481177	16-55	15SEP2020	90663	Placebo	15SEP2020/ Placebo	07OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
12481178	C4591001 1248 12481178	16-55	15SEP2020	90822	Placebo	15SEP2020/ Placebo	06OCT2020/ Placebo		
12481179	C4591001 1248 12481179	16-55	16SEP2020	90826	Placebo	16SEP2020/ Placebo	09OCT2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	27FEB2021/ BNT162b2 (30 µg)
12481185	C4591001 1248 12481185	16-55	16SEP2020	90830	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
12481186	C4591001 1248 12481186	16-55	16SEP2020	90832	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
12481187	C4591001 1248 12481187	16-55	16SEP2020	91709	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12481188	C4591001 1248 12481188	16-55	16SEP2020	91711	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
12481189	C4591001 1248 12481189	16-55	16SEP2020	91716	Placebo	16SEP2020/ Placebo	06OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
12481190	C4591001 1248 12481190	16-55	16SEP2020	91717	Placebo	16SEP2020/ Placebo	06OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
12481191	C4591001 1248 12481191	16-55	17SEP2020	91965	Placebo	17SEP2020/ Placebo	06OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	27FEB2021/ BNT162b2 (30 µg)
12481192	C4591001 1248 12481192	16-55	17SEP2020	91970	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
12481193	C4591001 1248 12481193	16-55	17SEP2020	91971	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
12481194	C4591001 1248 12481194	16-55	17SEP2020	91967	Placebo	17SEP2020/ Placebo	19OCT2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
12481195	C4591001 1248 12481195	16-55	17SEP2020	92093	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
12481198	C4591001 1248 12481198	16-55	17SEP2020	92095	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
12481199	C4591001 1248 12481199	16-55	17SEP2020	92103	Placebo	17SEP2020/ Placebo			

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12481200	C4591001 1248 12481200	16-55	17SEP2020	92104	Placebo	17SEP2020/ Placebo	10OCT2020/ Placebo		
12481201	C4591001 1248 12481201	16-55	17SEP2020	92700	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
12481202	C4591001 1248 12481202	16-55	17SEP2020	92701	Placebo	17SEP2020/ Placebo	06OCT2020/ Placebo		
12481204	C4591001 1248 12481204	16-55	18SEP2020	92702	Placebo	18SEP2020/ Placebo	07OCT2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
12481205	C4591001 1248 12481205	16-55	18SEP2020	92703	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
12481206	C4591001 1248 12481206	16-55	18SEP2020	93859	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
12481208	C4591001 1248 12481208	16-55	18SEP2020	93860	Placebo	18SEP2020/ Placebo	10OCT2020/ Placebo	02MAR2021/ BNT162b2 (30 µg)	
12481210	C4591001 1248 12481210	16-55	18SEP2020	93866	Placebo	18SEP2020/ Placebo	08OCT2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
12481211	C4591001 1248 12481211	16-55	18SEP2020	93863	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
12481212	C4591001 1248 12481212	16-55	18SEP2020	94186	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12481213	C4591001 1248 12481213	16-55	18SEP2020	94181	Placebo	18SEP2020/ Placebo	07OCT2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
12481215	C4591001 1248 12481215	16-55	20SEP2020	94187	Placebo	20SEP2020/ Placebo	12OCT2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
12481216	C4591001 1248 12481216	16-55	20SEP2020	94188	BNT162b2 (30 µg)	20SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
12481217	C4591001 1248 12481217	16-55	20SEP2020	94577	BNT162b2 (30 µg)	20SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
12481218	C4591001 1248 12481218	16-55	20SEP2020	94580	Placebo				
12481219	C4591001 1248 12481219	16-55	20SEP2020	94581	BNT162b2 (30 µg)	20SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
12481220	C4591001 1248 12481220	16-55	20SEP2020	94587	Placebo	20SEP2020/ Placebo	09OCT2020/ Placebo	27FEB2021/ BNT162b2 (30 µg)	
12481221	C4591001 1248 12481221	16-55	20SEP2020	94591	Placebo	20SEP2020/ Placebo	10OCT2020/ Placebo		
12481224	C4591001 1248 12481224	16-55	22SEP2020	94592	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
12481227	C4591001 1248 12481227	16-55	22SEP2020	94596	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12481228	C4591001 1248 12481228	16-55	22SEP2020	94597	Placebo	22SEP2020/ Placebo	12OCT2020/ Placebo	02MAR2021/ BNT162b2 (30 µg)	
12481229	C4591001 1248 12481229	16-55	22SEP2020	96269	Placebo	22SEP2020/ Placebo	11OCT2020/ Placebo	11MAR2021/ BNT162b2 (30 µg)	
12481230	C4591001 1248 12481230	16-55	22SEP2020	96271	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
12481231	C4591001 1248 12481231	16-55	22SEP2020	96272	Placebo	22SEP2020/ Placebo	12OCT2020/ Placebo	03MAR2021/ BNT162b2 (30 µg)	
12481232	C4591001 1248 12481232	16-55	22SEP2020	96279	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
12481233	C4591001 1248 12481233	16-55	22SEP2020	96487	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
12481234	C4591001 1248 12481234	16-55	22SEP2020	96488	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
12481235	C4591001 1248 12481235	16-55	22SEP2020	96493	Placebo	22SEP2020/ Placebo	14OCT2020/ Placebo	19DEC2020/ BNT162b2 (30 µg)	09JAN2021/ BNT162b2 (30 µg)
12481240	C4591001 1248 12481240	16-55	22SEP2020	96496	Placebo	22SEP2020/ Placebo	13OCT2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
12481243	C4591001 1248 12481243	16-55	22SEP2020	97004	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12481244	C4591001 1248 12481244	16-55	24SEP2020	97006	Placebo	24SEP2020/ Placebo	15OCT2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)
12481245	C4591001 1248 12481245	16-55	05OCT2020	97007	Placebo	05OCT2020/ Placebo	26OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
12481246	C4591001 1248 12481246	16-55	05OCT2020	97012	BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)	24OCT2020/ BNT162b2 (30 µg)		
12481247	C4591001 1248 12481247	16-55	05OCT2020	103810	Placebo	05OCT2020/ Placebo	26OCT2020/ Placebo		
12481252	C4591001 1248 12481252	16-55	20OCT2020	103811	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		
12481253	C4591001 1248 12481253	16-55	24OCT2020	103813	BNT162b2 (30 µg)	24OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
12511003	C4591001 1251 12511003	16-55	18AUG2020	55062	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
12511005	C4591001 1251 12511005	16-55	19AUG2020	55066	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12511007	C4591001 1251 12511007	16-55	19AUG2020	55063	Placebo	19AUG2020/ Placebo	12SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12511013	C4591001 1251 12511013	16-55	20AUG2020	55070	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12511016	C4591001 1251 12511016	16-55	20AUG2020	59165	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12511021	C4591001 1251 12511021	16-55	20AUG2020	59168	Placebo	20AUG2020/ Placebo	09SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
12511022	C4591001 1251 12511022	16-55	21AUG2020	59174	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	12SEP2020/ BNT162b2 (30 µg)		
12511025	C4591001 1251 12511025	16-55	21AUG2020	59175	Placebo	21AUG2020/ Placebo	10SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
12511027	C4591001 1251 12511027	16-55	21AUG2020	61099	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12511030	C4591001 1251 12511030	16-55	22AUG2020	61103	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12511031	C4591001 1251 12511031	16-55	22AUG2020	61102	Placebo	22AUG2020/ Placebo	11SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
12511032	C4591001 1251 12511032	16-55	22AUG2020	61107	Placebo	22AUG2020/ Placebo	11SEP2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
12511033	C4591001 1251 12511033	16-55	22AUG2020	61965	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12511037	C4591001 1251 12511037	16-55	22AUG2020	61970	Placebo	22AUG2020/ Placebo	11SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12511039	C4591001 1251 12511039	16-55	22AUG2020	61969	Placebo	22AUG2020/ Placebo	11SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12511040	C4591001 1251 12511040	16-55	22AUG2020	61971	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12511041	C4591001 1251 12511041	16-55	24AUG2020	63534	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo		
12511044	C4591001 1251 12511044	16-55	24AUG2020	63544	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12511045	C4591001 1251 12511045	16-55	24AUG2020	63537	Placebo	24AUG2020/ Placebo	15SEP2020/ Placebo	03MAR2021/ BNT162b2 (30 µg)	
12511046	C4591001 1251 12511046	16-55	24AUG2020	63541	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12511049	C4591001 1251 12511049	16-55	24AUG2020	64554	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo		
12511051	C4591001 1251 12511051	16-55	25AUG2020	64555	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12511058	C4591001 1251 12511058	16-55	26AUG2020	64556	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12511059	C4591001 1251 12511059	16-55	26AUG2020	64563	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12511060	C4591001 1251 12511060	16-55	26AUG2020	68849	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12511061	C4591001 1251 12511061	16-55	27AUG2020	68850	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12511062	C4591001 1251 12511062	16-55	27AUG2020	68853	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
12511065	C4591001 1251 12511065	16-55	28AUG2020	68855	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12511066	C4591001 1251 12511066	16-55	28AUG2020	72187	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12511068	C4591001 1251 12511068	16-55	28AUG2020	72189	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12511070	C4591001 1251 12511070	16-55	28AUG2020	72191	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo		
12511074	C4591001 1251 12511074	16-55	29AUG2020	72194	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12511075	C4591001 1251 12511075	16-55	29AUG2020	73748	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12511077	C4591001 1251 12511077	16-55	29AUG2020	73747	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12511079	C4591001 1251 12511079	16-55	29AUG2020	73754	Placebo	29AUG2020/ Placebo	21SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
12511080	C4591001 1251 12511080	16-55	31AUG2020	73755	Placebo	31AUG2020/ Placebo	22SEP2020/ Placebo		
12511081	C4591001 1251 12511081	16-55	31AUG2020	75199	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
12511082	C4591001 1251 12511082	16-55	31AUG2020	75200	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
12511083	C4591001 1251 12511083	16-55	31AUG2020	75202	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12511084	C4591001 1251 12511084	16-55	31AUG2020	75204	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12511089	C4591001 1251 12511089	16-55	01SEP2020	76351	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
12511091	C4591001 1251 12511091	16-55	01SEP2020	76352	Placebo	01SEP2020/ Placebo	21SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
12511093	C4591001 1251 12511093	16-55	01SEP2020	76354	Placebo	01SEP2020/ Placebo	24SEP2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
12511094	C4591001 1251 12511094	16-55	01SEP2020	76358	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12511095	C4591001 1251 12511095	16-55	01SEP2020	77526	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)			
12511096	C4591001 1251 12511096	16-55	02SEP2020	77534	Placebo	02SEP2020/ Placebo	21SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12511097	C4591001 1251 12511097	16-55	02SEP2020	77535	Placebo	02SEP2020/ Placebo	25SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
12511098	C4591001 1251 12511098	16-55	02SEP2020	77536	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
12511099	C4591001 1251 12511099	16-55	02SEP2020	78257	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
12511101	C4591001 1251 12511101	16-55	02SEP2020	78259	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
12511103	C4591001 1251 12511103	16-55	02SEP2020	78264	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
12511104	C4591001 1251 12511104	16-55	02SEP2020	78266	Placebo	02SEP2020/ Placebo	21SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12511108	C4591001 1251 12511108	16-55	02SEP2020	79196	Placebo	02SEP2020/ Placebo	22SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
12511109	C4591001 1251 12511109	16-55	03SEP2020	79197	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12511112	C4591001 1251 12511112	16-55	03SEP2020	79199	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
12511113	C4591001 1251 12511113	16-55	03SEP2020	79204	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
12511114	C4591001 1251 12511114	16-55	03SEP2020	80599	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
12511115	C4591001 1251 12511115	16-55	03SEP2020	80600	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
12511117	C4591001 1251 12511117	16-55	03SEP2020	80601	Placebo	03SEP2020/ Placebo	22SEP2020/ Placebo		
12511119	C4591001 1251 12511119	16-55	03SEP2020	80602	Placebo	03SEP2020/ Placebo	25SEP2020/ Placebo		
12511121	C4591001 1251 12511121	16-55	04SEP2020	81803	Placebo	04SEP2020/ Placebo	23SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12511122	C4591001 1251 12511122	16-55	04SEP2020	81798	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
12511123	C4591001 1251 12511123	16-55	04SEP2020	81799	Placebo	04SEP2020/ Placebo	28SEP2020/ Placebo		
12511124	C4591001 1251 12511124	16-55	04SEP2020	81805	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12511127	C4591001 1251 12511127	16-55	08SEP2020	83458	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12511128	C4591001 1251 12511128	16-55	08SEP2020	83460	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
12511129	C4591001 1251 12511129	16-55	08SEP2020	83463	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
12511130	C4591001 1251 12511130	16-55	08SEP2020	83461	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo		
12511131	C4591001 1251 12511131	16-55	08SEP2020	83819	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
12511135	C4591001 1251 12511135	16-55	08SEP2020	83820	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
12511137	C4591001 1251 12511137	16-55	09SEP2020	83822	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12511138	C4591001 1251 12511138	16-55	09SEP2020	83823	Placebo	09SEP2020/ Placebo	29SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12511139	C4591001 1251 12511139	16-55	09SEP2020	85318	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
12511140	C4591001 1251 12511140	16-55	09SEP2020	85323	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12511141	C4591001 1251 12511141	16-55	09SEP2020	85322	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
12511143	C4591001 1251 12511143	16-55	10SEP2020	85324	Placebo	10SEP2020/ Placebo	02OCT2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	
12511146	C4591001 1251 12511146	16-55	10SEP2020	86623	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
12511147	C4591001 1251 12511147	16-55	10SEP2020	86626	Placebo	10SEP2020/ Placebo	06OCT2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12511148	C4591001 1251 12511148	16-55	10SEP2020	86632	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
12511149	C4591001 1251 12511149	16-55	10SEP2020	86629	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12511150	C4591001 1251 12511150	16-55	10SEP2020	87127	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
12511153	C4591001 1251 12511153	16-55	10SEP2020	87129	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12511154	C4591001 1251 12511154	16-55	11SEP2020	87132	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12511155	C4591001 1251 12511155	16-55	11SEP2020	87135	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12511156	C4591001 1251 12511156	16-55	11SEP2020	88493	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12511157	C4591001 1251 12511157	16-55	11SEP2020	88497	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
12511159	C4591001 1251 12511159	16-55	11SEP2020	88498	Placebo	11SEP2020/ Placebo	01OCT2020/ Placebo		
12511161	C4591001 1251 12511161	16-55	14SEP2020	88500	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
12511162	C4591001 1251 12511162	16-55	14SEP2020	89694	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
12511163	C4591001 1251 12511163	16-55	14SEP2020	89696	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12511165	C4591001 1251 12511165	16-55	14SEP2020	89699	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12511166	C4591001 1251 12511166	16-55	14SEP2020	89702	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
12511168	C4591001 1251 12511168	16-55	14SEP2020	90041	Placebo	14SEP2020/ Placebo	06OCT2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12511171	C4591001 1251 12511171	16-55	15SEP2020	90042	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12511173	C4591001 1251 12511173	16-55	15SEP2020	90043	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
12511175	C4591001 1251 12511175	16-55	15SEP2020	90739	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
12511176	C4591001 1251 12511176	16-55	15SEP2020	90044	Placebo	15SEP2020/ Placebo	06OCT2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
12511178	C4591001 1251 12511178	16-55	16SEP2020	90741	Placebo	16SEP2020/ Placebo	06OCT2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
12511179	C4591001 1251 12511179	16-55	16SEP2020	90744	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
12511180	C4591001 1251 12511180	16-55	16SEP2020	90745	Placebo	16SEP2020/ Placebo	08OCT2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
12511183	C4591001 1251 12511183	16-55	17SEP2020	92922	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
12511184	C4591001 1251 12511184	16-55	18SEP2020	92924	Placebo	18SEP2020/ Placebo	12OCT2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12511185	C4591001 1251 12511185	16-55	18SEP2020	92927	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
12511187	C4591001 1251 12511187	16-55	18SEP2020	92930	Placebo	18SEP2020/ Placebo	07OCT2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12511188	C4591001 1251 12511188	16-55	18SEP2020	94206	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo		
12511191	C4591001 1251 12511191	16-55	21SEP2020	94208	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
12511194	C4591001 1251 12511194	16-55	22SEP2020	94209	Placebo	22SEP2020/ Placebo	12OCT2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
12511195	C4591001 1251 12511195	16-55	22SEP2020	94212	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
12511196	C4591001 1251 12511196	16-55	22SEP2020	96548	Placebo	22SEP2020/ Placebo	13OCT2020/ Placebo		
12511197	C4591001 1251 12511197	16-55	22SEP2020	96555	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
12511198	C4591001 1251 12511198	16-55	22SEP2020	96552	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
12511201	C4591001 1251 12511201	16-55	23SEP2020	96556	Placebo	23SEP2020/ Placebo	12OCT2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12511204	C4591001 1251 12511204	16-55	23SEP2020	97897	BNT162b2 (30 µg)				
12511205	C4591001 1251 12511205	16-55	23SEP2020	97891	Placebo	23SEP2020/ Placebo	12OCT2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12511207	C4591001 1251 12511207	16-55	23SEP2020	97898	Placebo	23SEP2020/ Placebo		20FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12511208	C4591001 1251 12511208	16-55	24SEP2020	97900	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
12511212	C4591001 1251 12511212	16-55	24SEP2020	99033	Placebo	24SEP2020/ Placebo	13OCT2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
12511214	C4591001 1251 12511214	16-55	25SEP2020	99034	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
12511215	C4591001 1251 12511215	16-55	25SEP2020	99037	Placebo	25SEP2020/ Placebo	14OCT2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
12511216	C4591001 1251 12511216	16-55	25SEP2020	99040	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
12511217	C4591001 1251 12511217	16-55	25SEP2020	100253	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
12511218	C4591001 1251 12511218	16-55	25SEP2020	100259	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
12511219	C4591001 1251 12511219	16-55	25SEP2020	100262	Placebo	25SEP2020/ Placebo	15OCT2020/ Placebo		
12511220	C4591001 1251 12511220	16-55	28SEP2020	100263	Placebo	28SEP2020/ Placebo	19OCT2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12511221	C4591001 1251 12511221	16-55	29SEP2020	101885	BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)		
12511223	C4591001 1251 12511223	16-55	30SEP2020	101891	Placebo	30SEP2020/ Placebo	21OCT2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12511224	C4591001 1251 12511224	16-55	30SEP2020	101889	Placebo	30SEP2020/ Placebo	21OCT2020/ Placebo		
12511226	C4591001 1251 12511226	16-55	01OCT2020	101894	BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		
12511228	C4591001 1251 12511228	16-55	05OCT2020	103856	Placebo	05OCT2020/ Placebo	26OCT2020/ Placebo		
12511229	C4591001 1251 12511229	16-55	06OCT2020	103857	BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
12511231	C4591001 1251 12511231	16-55	06OCT2020	103860	Placebo	06OCT2020/ Placebo	26OCT2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12511232	C4591001 1251 12511232	16-55	07OCT2020	103863	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
12511233	C4591001 1251 12511233	16-55	07OCT2020	104731	Placebo	07OCT2020/ Placebo	27OCT2020/ Placebo		
12511234	C4591001 1251 12511234	16-55	07OCT2020	104733	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12511238	C4591001 1251 12511238	16-55	08OCT2020	104738	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		
12511239	C4591001 1251 12511239	16-55	13OCT2020	106973	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		
12511240	C4591001 1251 12511240	16-55	13OCT2020	104739	Placebo	13OCT2020/ Placebo	02NOV2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12511241	C4591001 1251 12511241	16-55	14OCT2020	106974	Placebo	14OCT2020/ Placebo	06NOV2020/ Placebo		
12511242	C4591001 1251 12511242	16-55	14OCT2020	106975	Placebo	14OCT2020/ Placebo	05NOV2020/ Placebo	11MAR2021/ BNT162b2 (30 µg)	
12511245	C4591001 1251 12511245	16-55	15OCT2020	108390	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
12511246	C4591001 1251 12511246	16-55	15OCT2020	106984	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
12511247	C4591001 1251 12511247	16-55	16OCT2020	108391	Placebo	16OCT2020/ Placebo	05NOV2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12511252	C4591001 1251 12511252	16-55	20OCT2020	108393	Placebo	20OCT2020/ Placebo	11NOV2020/ Placebo		
12511253	C4591001 1251 12511253	16-55	20OCT2020	108395	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12511254	C4591001 1251 12511254	16-55	20OCT2020	110923	Placebo	20OCT2020/ Placebo	30NOV2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12511255	C4591001 1251 12511255	16-55	21OCT2020	110928	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
12511256	C4591001 1251 12511256	16-55	21OCT2020	110929	Placebo	21OCT2020/ Placebo	11NOV2020/ Placebo		
12511259	C4591001 1251 12511259	16-55	26OCT2020	110931	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	18NOV2020/ BNT162b2 (30 µg)		
12511262	C4591001 1251 12511262	16-55	27OCT2020	114126	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
12521016	C4591001 1252 12521016	16-55	18AUG2020	47655	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12521019	C4591001 1252 12521019	16-55	20AUG2020	58232	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12521020	C4591001 1252 12521020	16-55	20AUG2020	58233	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
12521021	C4591001 1252 12521021	16-55	20AUG2020	231123	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12521023	C4591001 1252 12521023	16-55	21AUG2020	58234	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12521024	C4591001 1252 12521024	16-55	21AUG2020	58240	Placebo	21AUG2020/ Placebo	10SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12521029	C4591001 1252 12521029	16-55	27AUG2020	69474	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12521034	C4591001 1252 12521034	16-55	31AUG2020	69476	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
12521035	C4591001 1252 12521035	16-55	04SEP2020	69477	Placebo	04SEP2020/ Placebo	23SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12521036	C4591001 1252 12521036	16-55	08SEP2020	69478	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
12521039	C4591001 1252 12521039	16-55	16SEP2020	91421	Placebo	16SEP2020/ Placebo	07OCT2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
12521041	C4591001 1252 12521041	16-55	22SEP2020	91422	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
12541003	C4591001 1254 12541003	16-55	26AUG2020	68237	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	20FEB2021/ BNT162b2 (30 µg)
12541005	C4591001 1254 12541005	16-55	26AUG2020	68240	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12541007	C4591001 1254 12541007	16-55	26AUG2020	68241	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12541008	C4591001 1254 12541008	16-55	26AUG2020	68244	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12541020	C4591001 1254 12541020	16-55	28AUG2020	73088	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
12541023	C4591001 1254 12541023	16-55	28AUG2020	73091	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)			
12541027	C4591001 1254 12541027	16-55	29AUG2020	73094	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		
12541029	C4591001 1254 12541029	16-55	29AUG2020	73905	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		
12541030	C4591001 1254 12541030	16-55	29AUG2020	73909	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		
12541031	C4591001 1254 12541031	16-55	29AUG2020	73910	Placebo	29AUG2020/ Placebo	19SEP2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)
12541032	C4591001 1254 12541032	16-55	29AUG2020	73912	Placebo	29AUG2020/ Placebo	19SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12541033	C4591001 1254 12541033	16-55	29AUG2020	74251	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		
12541034	C4591001 1254 12541034	16-55	29AUG2020	74252	Placebo	29AUG2020/ Placebo	18SEP2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	20JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12541035	C4591001 1254 12541035	16-55	29AUG2020	74256	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
12541036	C4591001 1254 12541036	16-55	29AUG2020	74258	Placebo	29AUG2020/ Placebo	19SEP2020/ Placebo	30JAN2021/ BNT162b2 (30 µg)	20FEB2021/ BNT162b2 (30 µg)
12541038	C4591001 1254 12541038	16-55	29AUG2020	74288	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		
12541039	C4591001 1254 12541039	16-55	29AUG2020	74289	Placebo	29AUG2020/ Placebo	19SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
12541040	C4591001 1254 12541040	16-55	29AUG2020	74292	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		
12541041	C4591001 1254 12541041	16-55	31AUG2020	74295	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
12541042	C4591001 1254 12541042	16-55	31AUG2020	245929	Placebo	31AUG2020/ Placebo	19SEP2020/ Placebo	19DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
12541044	C4591001 1254 12541044	16-55	31AUG2020	75438	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
12541046	C4591001 1254 12541046	16-55	31AUG2020	75444	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
12541049	C4591001 1254 12541049	16-55	31AUG2020	75445	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	23JAN2021/ BNT162b2 (30 µg)	13FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12541050	C4591001 1254 12541050	16-55	31AUG2020	75448	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)
12541051	C4591001 1254 12541051	16-55	31AUG2020	76157	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
12541052	C4591001 1254 12541052	16-55	31AUG2020	76159	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12541053	C4591001 1254 12541053	16-55	31AUG2020	76162	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
12541054	C4591001 1254 12541054	16-55	31AUG2020	76166	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12541055	C4591001 1254 12541055	16-55	31AUG2020	76254	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
12541056	C4591001 1254 12541056	16-55	31AUG2020	76257	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
12541057	C4591001 1254 12541057	16-55	31AUG2020	76258	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
12541058	C4591001 1254 12541058	16-55	31AUG2020	76260	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12541061	C4591001 1254 12541061	16-55	01SEP2020	77658	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12541062	C4591001 1254 12541062	16-55	01SEP2020	77660	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
12541063	C4591001 1254 12541063	16-55	01SEP2020	77664	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
12541064	C4591001 1254 12541064	16-55	02SEP2020	77666	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	19DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
12541066	C4591001 1254 12541066	16-55	02SEP2020	78546	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12541067	C4591001 1254 12541067	16-55	02SEP2020	78548	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
12541068	C4591001 1254 12541068	16-55	02SEP2020	78555	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
12541069	C4591001 1254 12541069	16-55	02SEP2020	78556	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12541071	C4591001 1254 12541071	16-55	02SEP2020	79445	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	30JAN2021/ BNT162b2 (30 µg)	20FEB2021/ BNT162b2 (30 µg)
12541072	C4591001 1254 12541072	16-55	02SEP2020	79447	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
12541073	C4591001 1254 12541073	16-55	02SEP2020	79455	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12541075	C4591001 1254 12541075	16-55	02SEP2020	79454	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
12541077	C4591001 1254 12541077	16-55	02SEP2020	79505	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
12541079	C4591001 1254 12541079	16-55	03SEP2020	79509	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	20JAN2021/ BNT162b2 (30 µg)
12541080	C4591001 1254 12541080	16-55	03SEP2020	79512	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
12541081	C4591001 1254 12541081	16-55	03SEP2020	80467	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
12541082	C4591001 1254 12541082	16-55	03SEP2020	80473	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
12541083	C4591001 1254 12541083	16-55	03SEP2020	80474	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
12541084	C4591001 1254 12541084	16-55	03SEP2020	80475	Placebo	03SEP2020/ Placebo	26SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12541086	C4591001 1254 12541086	16-55	03SEP2020	81101	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
12541087	C4591001 1254 12541087	16-55	03SEP2020	81104	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12541089	C4591001 1254 12541089	16-55	03SEP2020	81108	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
12541090	C4591001 1254 12541090	16-55	04SEP2020	81109	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
12541091	C4591001 1254 12541091	16-55	04SEP2020	81871	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	20FEB2021/ BNT162b2 (30 µg)
12541094	C4591001 1254 12541094	16-55	04SEP2020	81872	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	26SEP2020/ BNT162b2 (30 µg)		
12541099	C4591001 1254 12541099	16-55	04SEP2020	81878	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
12541100	C4591001 1254 12541100	16-55	04SEP2020	81880	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
12541101	C4591001 1254 12541101	16-55	04SEP2020	82614	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12541102	C4591001 1254 12541102	16-55	05SEP2020	82615	BNT162b2 (30 µg)	05SEP2020/ BNT162b2 (30 µg)	26SEP2020/ BNT162b2 (30 µg)		
12541104	C4591001 1254 12541104	16-55	05SEP2020	82616	Placebo	05SEP2020/ Placebo	26SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	09JAN2021/ BNT162b2 (30 µg)
12541105	C4591001 1254 12541105	16-55	08SEP2020	82621	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12541107	C4591001 1254 12541107	16-55	08SEP2020	84054	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
12541109	C4591001 1254 12541109	16-55	08SEP2020	84056	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo	30JAN2021/ BNT162b2 (30 µg)	20FEB2021/ BNT162b2 (30 µg)
12541110	C4591001 1254 12541110	16-55	08SEP2020	84058	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
12541111	C4591001 1254 12541111	16-55	08SEP2020	84062	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
12541112	C4591001 1254 12541112	16-55	08SEP2020	84677	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12541113	C4591001 1254 12541113	16-55	08SEP2020	84682	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
12541114	C4591001 1254 12541114	16-55	08SEP2020	84687	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
12541115	C4591001 1254 12541115	16-55	09SEP2020	84688	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
12541116	C4591001 1254 12541116	16-55	09SEP2020	85457	Placebo	09SEP2020/ Placebo			
12541117	C4591001 1254 12541117	16-55	10SEP2020	85459	Placebo	10SEP2020/ Placebo	30SEP2020/ Placebo	23JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12541119	C4591001 1254 12541119	16-55	10SEP2020	85460	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
12541120	C4591001 1254 12541120	16-55	10SEP2020	85462	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
12541121	C4591001 1254 12541121	16-55	10SEP2020	87692	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
12541123	C4591001 1254 12541123	16-55	19SEP2020	94531	Placebo	19SEP2020/ Placebo	10OCT2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12541124	C4591001 1254 12541124	16-55	19SEP2020	94532	BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)	10OCT2020/ BNT162b2 (30 µg)		
12541126	C4591001 1254 12541126	16-55	11SEP2020	87694	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
12541131	C4591001 1254 12541131	16-55	11SEP2020	87693	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12541133	C4591001 1254 12541133	16-55	11SEP2020	88985	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	27FEB2021/ BNT162b2 (30 µg)
12541134	C4591001 1254 12541134	16-55	11SEP2020	87696	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	20FEB2021/ BNT162b2 (30 µg)
12541135	C4591001 1254 12541135	16-55	11SEP2020	88988	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12541139	C4591001 1254 12541139	16-55	11SEP2020	88990	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	03OCT2020/ BNT162b2 (30 µg)		
12541140	C4591001 1254 12541140	16-55	12SEP2020	88992	BNT162b2 (30 µg)	12SEP2020/ BNT162b2 (30 µg)	03OCT2020/ BNT162b2 (30 µg)		
12541142	C4591001 1254 12541142	16-55	12SEP2020	89228	BNT162b2 (30 µg)	12SEP2020/ BNT162b2 (30 µg)			
12541144	C4591001 1254 12541144	16-55	12SEP2020	89231	BNT162b2 (30 µg)	12SEP2020/ BNT162b2 (30 µg)	03OCT2020/ BNT162b2 (30 µg)		
12541145	C4591001 1254 12541145	16-55	12SEP2020	89232	Placebo	12SEP2020/ Placebo	02OCT2020/ Placebo		
12541147	C4591001 1254 12541147	16-55	12SEP2020	89234	Placebo	12SEP2020/ Placebo	03OCT2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	20FEB2021/ BNT162b2 (30 µg)
12541148	C4591001 1254 12541148	16-55	12SEP2020	89249	Placebo	12SEP2020/ Placebo	03OCT2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	06MAR2021/ BNT162b2 (30 µg)
12541150	C4591001 1254 12541150	16-55	14SEP2020	89250	Placebo	14SEP2020/ Placebo	06OCT2020/ Placebo	27FEB2021/ BNT162b2 (30 µg)	
12541151	C4591001 1254 12541151	16-55	14SEP2020	89257	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	03OCT2020/ BNT162b2 (30 µg)		
12541152	C4591001 1254 12541152	16-55	14SEP2020	89260	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12541153	C4591001 1254 12541153	16-55	14SEP2020	90056	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
12541154	C4591001 1254 12541154	16-55	14SEP2020	90057	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)			
12541155	C4591001 1254 12541155	16-55	16SEP2020	90058	Placebo	16SEP2020/ Placebo	07OCT2020/ Placebo	16JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
12541157	C4591001 1254 12541157	16-55	16SEP2020	90061	Placebo	16SEP2020/ Placebo	07OCT2020/ Placebo	13FEB2021/ BNT162b2 (30 µg)	06MAR2021/ BNT162b2 (30 µg)
12541158	C4591001 1254 12541158	16-55	16SEP2020	91901	Placebo	16SEP2020/ Placebo	07OCT2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	20JAN2021/ BNT162b2 (30 µg)
12541159	C4591001 1254 12541159	16-55	16SEP2020	91904	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
12541162	C4591001 1254 12541162	16-55	18SEP2020	91905	Placebo	18SEP2020/ Placebo	07OCT2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12541163	C4591001 1254 12541163	16-55	18SEP2020	91908	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
12541164	C4591001 1254 12541164	16-55	19SEP2020	94530	Placebo	19SEP2020/ Placebo	10OCT2020/ Placebo	19DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
12541165	C4591001 1254 12541165	16-55	19SEP2020	94538	BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)	10OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12541166	C4591001 1254 12541166	16-55	19SEP2020	94567	BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)	10OCT2020/ BNT162b2 (30 µg)		
12541167	C4591001 1254 12541167	16-55	21SEP2020	94571	Placebo	21SEP2020/ Placebo	13OCT2020/ Placebo		
12541168	C4591001 1254 12541168†	16-55	22SEP2020	94574	Placebo	22SEP2020/ Placebo	15OCT2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12541169	C4591001 1254 12541169	16-55	24SEP2020	98440	Placebo	24SEP2020/ Placebo	15OCT2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
12541170	C4591001 1254 12541170	16-55	23SEP2020	94576	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
12541171	C4591001 1254 12541171	16-55	23SEP2020	98117	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
12541172	C4591001 1254 12541172	16-55	23SEP2020	98120	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
12541173	C4591001 1254 12541173	16-55	23SEP2020	98122	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
12541174	C4591001 1254 12541174	16-55	23SEP2020	98125	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
12541175	C4591001 1254 12541175	16-55	23SEP2020	98434	Placebo	23SEP2020/ Placebo	16OCT2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12541176	C4591001 1254 12541176	16-55	23SEP2020	98439	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
12541177	C4591001 1254 12541177	16-55	23SEP2020	98430	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
12541178	C4591001 1254 12541178	16-55	25SEP2020	100171	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
12541179	C4591001 1254 12541179	16-55	25SEP2020	100173	Placebo	25SEP2020/ Placebo	17OCT2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	30JAN2021/ BNT162b2 (30 µg)
12541180	C4591001 1254 12541180	16-55	25SEP2020	100174	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
12541181	C4591001 1254 12541181	16-55	25SEP2020	100179	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12541182	C4591001 1254 12541182	16-55	25SEP2020	100567	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	17OCT2020/ BNT162b2 (30 µg)		
12541183	C4591001 1254 12541183	16-55	26SEP2020	100569	BNT162b2 (30 µg)	26SEP2020/ BNT162b2 (30 µg)	17OCT2020/ BNT162b2 (30 µg)		
12541184	C4591001 1254 12541184	16-55	26SEP2020	100573	Placebo	26SEP2020/ Placebo	17OCT2020/ Placebo	27FEB2021/ BNT162b2 (30 µg)	
12541185	C4591001 1254 12541185	16-55	14OCT2020	100576	Placebo	14OCT2020/ Placebo	04NOV2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12541187	C4591001 1254 12541187	16-55	15OCT2020	108559	Placebo	15OCT2020/ Placebo	05NOV2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
12541188	C4591001 1254 12541188	16-55	15OCT2020	108565	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
12541189	C4591001 1254 12541189	16-55	15OCT2020	108566	Placebo	15OCT2020/ Placebo	06NOV2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12541190	C4591001 1254 12541190	16-55	15OCT2020	108567	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
12541193	C4591001 1254 12541193	16-55	17OCT2020	109678	BNT162b2 (30 µg)	17OCT2020/ BNT162b2 (30 µg)	07NOV2020/ BNT162b2 (30 µg)		
12541194	C4591001 1254 12541194	16-55	17OCT2020	109682	Placebo	17OCT2020/ Placebo	06NOV2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
12541199	C4591001 1254 12541199	16-55	21OCT2020	109683	Placebo	21OCT2020/ Placebo	01DEC2020/ Placebo		
12541201	C4591001 1254 12541201	16-55	21OCT2020	109684	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
12541202	C4591001 1254 12541202	16-55	24OCT2020	113297	BNT162b2 (30 µg)	24OCT2020/ BNT162b2 (30 µg)	14NOV2020/ BNT162b2 (30 µg)		
12541204	C4591001 1254 12541204	16-55	24OCT2020	113298	Placebo	24OCT2020/ Placebo	14NOV2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12541208	C4591001 1254 12541208	16-55	24OCT2020	113303	Placebo	24OCT2020/ Placebo	12NOV2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12541210	C4591001 1254 12541210	16-55	24OCT2020	113304	BNT162b2 (30 µg)	24OCT2020/ BNT162b2 (30 µg)	14NOV2020/ BNT162b2 (30 µg)		
12541211	C4591001 1254 12541211	16-55	24OCT2020	113309	Placebo	24OCT2020/ Placebo	12NOV2020/ Placebo	30JAN2021/ BNT162b2 (30 µg)	20FEB2021/ BNT162b2 (30 µg)
12581001	C4591001 1258 12581001	16-55	27AUG2020	69737	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12581002	C4591001 1258 12581002	16-55	27AUG2020	69743	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12581004	C4591001 1258 12581004	16-55	27AUG2020	69747	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12581007	C4591001 1258 12581007	16-55	31AUG2020	69748	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12581008	C4591001 1258 12581008	16-55	31AUG2020	75417	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
12581009	C4591001 1258 12581009	16-55	01SEP2020	75421	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
12581013	C4591001 1258 12581013	16-55	02SEP2020	75423	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12581014	C4591001 1258 12581014	16-55	03SEP2020	75424	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
12581016	C4591001 1258 12581016	16-55	03SEP2020	80350	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
12581018	C4591001 1258 12581018	16-55	04SEP2020	80353	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12581022	C4591001 1258 12581022	16-55	09SEP2020	80355	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
12581023	C4591001 1258 12581023	16-55	09SEP2020	80356	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
12581026	C4591001 1258 12581026	16-55	11SEP2020	87761	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
12581027	C4591001 1258 12581027	16-55	11SEP2020	87763	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
12581033	C4591001 1258 12581033	16-55	17SEP2020	87768	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
12581034	C4591001 1258 12581034	16-55	18SEP2020	87769	Placebo	18SEP2020/ Placebo	13OCT2020/ Placebo		
12581035	C4591001 1258 12581035	16-55	21SEP2020	94617	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12581036	C4591001 1258 12581036	16-55	21SEP2020	94619	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
12581037	C4591001 1258 12581037	16-55	21SEP2020	94621	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo		
12581038	C4591001 1258 12581038	16-55	21SEP2020	94623	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
12581039	C4591001 1258 12581039	16-55	21SEP2020	95225	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo		
12581040	C4591001 1258 12581040	16-55	21SEP2020	95234	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
12581043	C4591001 1258 12581043	16-55	22SEP2020	95235	Placebo	22SEP2020/ Placebo	14OCT2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
12581044	C4591001 1258 12581044	16-55	24SEP2020	95236	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
12581045	C4591001 1258 12581045	16-55	24SEP2020	98718	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)		
12581046	C4591001 1258 12581046	16-55	28SEP2020	98719	Placebo	28SEP2020/ Placebo	19OCT2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
12581047	C4591001 1258 12581047	16-55	29SEP2020	98720	BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12581048	C4591001 1258 12581048	16-55	30SEP2020	98723	Placebo	30SEP2020/ Placebo	20OCT2020/ Placebo		
12581049	C4591001 1258 12581049	16-55	30SEP2020	102271	Placebo	30SEP2020/ Placebo	20OCT2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	
12581050	C4591001 1258 12581050	16-55	02OCT2020	102273	BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		
12581053	C4591001 1258 12581053	16-55	05OCT2020	102275	BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)		
12581054	C4591001 1258 12581054	16-55	06OCT2020	102276	Placebo	06OCT2020/ Placebo	28OCT2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
12581055	C4591001 1258 12581055	16-55	06OCT2020	104262	Placebo	06OCT2020/ Placebo	02NOV2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12581058	C4591001 1258 12581058	16-55	08OCT2020	104263	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)		
12581059	C4591001 1258 12581059	16-55	09OCT2020	104264	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		
12581060	C4591001 1258 12581060	16-55	09OCT2020	104268	Placebo	09OCT2020/ Placebo	02NOV2020/ Placebo		
12581061	C4591001 1258 12581061	16-55	12OCT2020	106325	BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12581062	C4591001 1258 12581062	16-55	13OCT2020	106329	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
12581063	C4591001 1258 12581063	16-55	13OCT2020	106331	Placebo	13OCT2020/ Placebo	04NOV2020/ Placebo		
12581064	C4591001 1258 12581064	16-55	14OCT2020	106334	Placebo	14OCT2020/ Placebo	04NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12581065	C4591001 1258 12581065	16-55	19OCT2020	110214	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
12581066	C4591001 1258 12581066	16-55	19OCT2020	110218	Placebo	19OCT2020/ Placebo	10NOV2020/ Placebo		
12581067	C4591001 1258 12581067	16-55	19OCT2020	110219	Placebo	19OCT2020/ Placebo	10NOV2020/ Placebo		
12581069	C4591001 1258 12581069	16-55	20OCT2020	110223	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
12581070	C4591001 1258 12581070	16-55	26OCT2020	113454	Placebo	26OCT2020/ Placebo	16NOV2020/ Placebo		
12581071	C4591001 1258 12581071	16-55	27OCT2020	113456	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
12581072	C4591001 1258 12581072	16-55	27OCT2020	113459	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	18NOV2020/ BNT162b2 (30 µg)		
12581073	C4591001 1258 12581073	16-55	28OCT2020	113462	Placebo	28OCT2020/ Placebo	18NOV2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12581074	C4591001 1258 12581074	16-55	28OCT2020	114427	Placebo	28OCT2020/ Placebo	18NOV2020/ Placebo		
12581075	C4591001 1258 12581075	16-55	29OCT2020	114429	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)		
12601001	C4591001 1260 12601001	16-55	26AUG2020	67229	Placebo	26AUG2020/ Placebo	15SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12601002	C4591001 1260 12601002	16-55	26AUG2020	67232	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12601004	C4591001 1260 12601004	16-55	26AUG2020	67234	Placebo	26AUG2020/ Placebo	17SEP2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	27JAN2021/ BNT162b2 (30 µg)
12601005	C4591001 1260 12601005	16-55	26AUG2020	67237	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12601006	C4591001 1260 12601006	16-55	26AUG2020	68646	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12601007	C4591001 1260 12601007	16-55	26AUG2020	68647	Placebo	26AUG2020/ Placebo	15SEP2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)
12601009	C4591001 1260 12601009	16-55	27AUG2020	68648	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12601010	C4591001 1260 12601010	16-55	27AUG2020	68652	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12601011	C4591001 1260 12601011	16-55	27AUG2020	69920	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
12601012	C4591001 1260 12601012	16-55	27AUG2020	69922	Placebo	27AUG2020/ Placebo	18SEP2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
12601013	C4591001 1260 12601013	16-55	28AUG2020	69923	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12601014	C4591001 1260 12601014	16-55	28AUG2020	69924	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12601016	C4591001 1260 12601016	16-55	28AUG2020	72246	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12601017	C4591001 1260 12601017	16-55	28AUG2020	72252	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12601018	C4591001 1260 12601018	16-55	28AUG2020	72251	Placebo	28AUG2020/ Placebo	17SEP2020/ Placebo	31DEC2020/ BNT162b2 (30 µg)	22JAN2021/ BNT162b2 (30 µg)
12601022	C4591001 1260 12601022	16-55	28AUG2020	72255	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
12601023	C4591001 1260 12601023	16-55	31AUG2020	74748	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
12601024	C4591001 1260 12601024	16-55	31AUG2020	74746	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12601029	C4591001 1260 12601029	16-55	31AUG2020	74749	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
12601032	C4591001 1260 12601032	16-55	31AUG2020	74752	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
12601034	C4591001 1260 12601034	16-55	31AUG2020	75308	Placebo	31AUG2020/ Placebo	22SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
12601036	C4591001 1260 12601036	16-55	31AUG2020	75309	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
12601038	C4591001 1260 12601038	16-55	01SEP2020	75312	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
12601042	C4591001 1260 12601042	16-55	01SEP2020	75314	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
12601044	C4591001 1260 12601044	16-55	01SEP2020	77023	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
12601045	C4591001 1260 12601045	16-55	01SEP2020	77025	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
12601047	C4591001 1260 12601047	16-55	01SEP2020	77026	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
12601048	C4591001 1260 12601048	16-55	01SEP2020	77027	Placebo	01SEP2020/ Placebo	23SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12601049	C4591001 1260 12601049	16-55	02SEP2020	77911	BNT162b2 (30 µg)				
12601050	C4591001 1260 12601050	16-55	02SEP2020	77914	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
12601055	C4591001 1260 12601055	16-55	02SEP2020	77917	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
12601058	C4591001 1260 12601058	16-55	04SEP2020	81517	Placebo	04SEP2020/ Placebo	24SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
12601061	C4591001 1260 12601061	16-55	04SEP2020	77918	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12601063	C4591001 1260 12601063	16-55	04SEP2020	81511	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
12601065	C4591001 1260 12601065	16-55	04SEP2020	81513	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12601067	C4591001 1260 12601067	16-55	04SEP2020	252978	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
12601068	C4591001 1260 12601068	16-55	04SEP2020	81519	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
12601070	C4591001 1260 12601070	16-55	04SEP2020	82217	Placebo				

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12601074	C4591001 1260 12601074	16-55	08SEP2020	82221	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
12601075	C4591001 1260 12601075	16-55	08SEP2020	82226	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
12601076	C4591001 1260 12601076	16-55	08SEP2020	82227	Placebo	08SEP2020/ Placebo	01OCT2020/ Placebo	31DEC2020/ BNT162b2 (30 µg)	22JAN2021/ BNT162b2 (30 µg)
12601077	C4591001 1260 12601077	16-55	08SEP2020	83564	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
12601082	C4591001 1260 12601082	16-55	08SEP2020	83566	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
12601084	C4591001 1260 12601084	16-55	08SEP2020	83567	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	15JAN2021/ BNT162b2 (30 µg)
12601085	C4591001 1260 12601085	16-55	08SEP2020	83568	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
12601086	C4591001 1260 12601086	16-55	09SEP2020	84816	Placebo	09SEP2020/ Placebo	28SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
12601091	C4591001 1260 12601091	16-55	09SEP2020	84817	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
12601092	C4591001 1260 12601092	16-55	09SEP2020	84819	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12601094	C4591001 1260 12601094	16-55	09SEP2020	84820	Placebo	09SEP2020/ Placebo	28SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12601097	C4591001 1260 12601097	16-55	09SEP2020	85925	Placebo	09SEP2020/ Placebo	28SEP2020/ Placebo		
12601098	C4591001 1260 12601098	16-55	09SEP2020	85933	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
12601099	C4591001 1260 12601099	16-55	10SEP2020	85935	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
12601100	C4591001 1260 12601100	16-55	10SEP2020	85936	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
12601104	C4591001 1260 12601104	16-55	10SEP2020	86826	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
12601106	C4591001 1260 12601106	16-55	10SEP2020	86827	Placebo	10SEP2020/ Placebo	30SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	14JAN2021/ BNT162b2 (30 µg)
12601107	C4591001 1260 12601107	16-55	10SEP2020	86833	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
12601108	C4591001 1260 12601108	16-55	10SEP2020	86836	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
12601110	C4591001 1260 12601110	16-55	10SEP2020	87116	Placebo	10SEP2020/ Placebo	02OCT2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12601111	C4591001 1260 12601111	16-55	10SEP2020	87117	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12601112	C4591001 1260 12601112	16-55	10SEP2020	87121	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
12601114	C4591001 1260 12601114	16-55	10SEP2020	87122	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
12601115	C4591001 1260 12601115	16-55	10SEP2020	87488	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
12601116	C4591001 1260 12601116	16-55	11SEP2020	87492	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
12601117	C4591001 1260 12601117	16-55	11SEP2020	87493	Placebo	11SEP2020/ Placebo	06OCT2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)
12601118	C4591001 1260 12601118	16-55	11SEP2020	87495	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
12601119	C4591001 1260 12601119	16-55	11SEP2020	88806	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
12601120	C4591001 1260 12601120	16-55	11SEP2020	88807	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
12601123	C4591001 1260 12601123	16-55	15SEP2020	88808	Placebo	15SEP2020/ Placebo	07OCT2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12601125	C4591001 1260 12601125	16-55	16SEP2020	88816	Placebo	16SEP2020/ Placebo	14OCT2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
12601126	C4591001 1260 12601126	16-55	17SEP2020	92117	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
12601127	C4591001 1260 12601127	16-55	17SEP2020	92119	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
12601128	C4591001 1260 12601128	16-55	17SEP2020	92120	Placebo	17SEP2020/ Placebo	06OCT2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
12601129	C4591001 1260 12601129	16-55	18SEP2020	92122	Placebo	18SEP2020/ Placebo	07OCT2020/ Placebo		
12601130	C4591001 1260 12601130	16-55	18SEP2020	93595	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
12601132	C4591001 1260 12601132	16-55	18SEP2020	93598	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
12611001	C4591001 1261 12611001	16-55	26AUG2020	67806	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12611002	C4591001 1261 12611002	16-55	26AUG2020	68441	Placebo	26AUG2020/ Placebo	17SEP2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
12611005	C4591001 1261 12611005	16-55	27AUG2020	68444	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12611006	C4591001 1261 12611006	16-55	27AUG2020	68448	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12611007	C4591001 1261 12611007	16-55	27AUG2020	68452	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	20JAN2021/ BNT162b2 (30 µg)
12611008	C4591001 1261 12611008	16-55	28AUG2020	72214	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12611009	C4591001 1261 12611009	16-55	28AUG2020	72215	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	28JAN2021/ BNT162b2 (30 µg)
12611010	C4591001 1261 12611010	16-55	28AUG2020	72218	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12611011	C4591001 1261 12611011	16-55	28AUG2020	72219	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	06JAN2021/ BNT162b2 (30 µg)	27JAN2021/ BNT162b2 (30 µg)
12611013	C4591001 1261 12611013	16-55	31AUG2020	75342	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
12611016	C4591001 1261 12611016	16-55	31AUG2020	75343	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
12611017	C4591001 1261 12611017	16-55	01SEP2020	75346	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
12611020	C4591001 1261 12611020	16-55	01SEP2020	75351	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12611022	C4591001 1261 12611022	16-55	01SEP2020	77515	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
12611023	C4591001 1261 12611023	16-55	01SEP2020	77517	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)
12611024	C4591001 1261 12611024	16-55	01SEP2020	77520	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)
12611025	C4591001 1261 12611025	16-55	02SEP2020	77521	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
12611026	C4591001 1261 12611026	16-55	02SEP2020	78281	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
12611027	C4591001 1261 12611027	16-55	02SEP2020	78288	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
12611028	C4591001 1261 12611028	16-55	02SEP2020	78289	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
12611029	C4591001 1261 12611029	16-55	02SEP2020	78292	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
12611030	C4591001 1261 12611030	16-55	02SEP2020	79325	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
12611031	C4591001 1261 12611031	16-55	02SEP2020	79328	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12611032	C4591001 1261 12611032	16-55	03SEP2020	79329	Placebo	03SEP2020/ Placebo	23SEP2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
12611033	C4591001 1261 12611033	16-55	03SEP2020	79334	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)
12611034	C4591001 1261 12611034	16-55	03SEP2020	80359	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
12611035	C4591001 1261 12611035	16-55	03SEP2020	80362	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
12611036	C4591001 1261 12611036	16-55	03SEP2020	80364	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	14JAN2021/ BNT162b2 (30 µg)
12611038	C4591001 1261 12611038	16-55	03SEP2020	80367	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
12611039	C4591001 1261 12611039	16-55	03SEP2020	81116	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
12611041	C4591001 1261 12611041	16-55	04SEP2020	81117	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
12611042	C4591001 1261 12611042	16-55	04SEP2020	81120	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
12611043	C4591001 1261 12611043	16-55	04SEP2020	81122	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12611046	C4591001 1261 12611046	16-55	04SEP2020	82543	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
12611047	C4591001 1261 12611047	16-55	04SEP2020	82544	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
12611049	C4591001 1261 12611049	16-55	08SEP2020	82546	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
12611050	C4591001 1261 12611050	16-55	08SEP2020	82552	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
12611051	C4591001 1261 12611051	16-55	08SEP2020	84187	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
12611052	C4591001 1261 12611052	16-55	08SEP2020	84188	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
12611053	C4591001 1261 12611053	16-55	08SEP2020	84192	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
12611054	C4591001 1261 12611054	16-55	08SEP2020	84193	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
12611056	C4591001 1261 12611056	16-55	09SEP2020	85183	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	24DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
12611057	C4591001 1261 12611057	16-55	09SEP2020	85186	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	06JAN2021/ BNT162b2 (30 µg)	27JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12611058	C4591001 1261 12611058	16-55	09SEP2020	85187	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
12611059	C4591001 1261 12611059	16-55	09SEP2020	85190	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
12611060	C4591001 1261 12611060	16-55	09SEP2020	85943	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
12611062	C4591001 1261 12611062	16-55	09SEP2020	85944	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
12611063	C4591001 1261 12611063	16-55	10SEP2020	85945	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
12611064	C4591001 1261 12611064	16-55	10SEP2020	85947	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
12611065	C4591001 1261 12611065	16-55	10SEP2020	86897	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
12611067	C4591001 1261 12611067	16-55	10SEP2020	86899	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	21JAN2021/ BNT162b2 (30 µg)
12611070	C4591001 1261 12611070	16-55	10SEP2020	86902	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	20JAN2021/ BNT162b2 (30 µg)
12611071	C4591001 1261 12611071	16-55	11SEP2020	86906	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12611074	C4591001 1261 12611074	16-55	11SEP2020	88649	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
12611077	C4591001 1261 12611077	16-55	11SEP2020	88654	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
12611078	C4591001 1261 12611078	16-55	14SEP2020	88658	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	04JAN2021/ BNT162b2 (30 µg)
12611082	C4591001 1261 12611082	16-55	14SEP2020	88659	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
12641001	C4591001 1264 12641001	16-55	20AUG2020	58806	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12641002	C4591001 1264 12641002	16-55	20AUG2020	58807	Placebo	20AUG2020/ Placebo	12SEP2020/ Placebo	15DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
12641003	C4591001 1264 12641003	16-55	20AUG2020	58811	Placebo	20AUG2020/ Placebo	12SEP2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
12641004	C4591001 1264 12641004	16-55	20AUG2020	58813	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12641005	C4591001 1264 12641005	16-55	20AUG2020	58974	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12641006	C4591001 1264 12641006	16-55	20AUG2020	58975	Placebo	20AUG2020/ Placebo	12SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12641008	C4591001 1264 12641008	16-55	21AUG2020	58976	Placebo	21AUG2020/ Placebo	13SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
12641009	C4591001 1264 12641009	16-55	21AUG2020	58982	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	12SEP2020/ BNT162b2 (30 µg)		
12641011	C4591001 1264 12641011	16-55	21AUG2020	60907	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	12SEP2020/ BNT162b2 (30 µg)		
12641012	C4591001 1264 12641012	16-55	21AUG2020	60908	Placebo	21AUG2020/ Placebo	10SEP2020/ Placebo	15DEC2020/ BNT162b2 (30 µg)	04JAN2021/ BNT162b2 (30 µg)
12641013	C4591001 1264 12641013	16-55	21AUG2020	60914	Placebo	21AUG2020/ Placebo	12SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
12641014	C4591001 1264 12641014	16-55	21AUG2020	60916	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	12SEP2020/ BNT162b2 (30 µg)		
12641015	C4591001 1264 12641015	16-55	21AUG2020	61340	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12641017	C4591001 1264 12641017	16-55	22AUG2020	61342	Placebo	22AUG2020/ Placebo	12SEP2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
12641018	C4591001 1264 12641018	16-55	22AUG2020	61346	Placebo				
12641020	C4591001 1264 12641020	16-55	22AUG2020	61348	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	12SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12641021	C4591001 1264 12641021	16-55	22AUG2020	62135	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	12SEP2020/ BNT162b2 (30 µg)		
12641022	C4591001 1264 12641022	16-55	22AUG2020	62131	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12641023	C4591001 1264 12641023	16-55	22AUG2020	62136	Placebo	22AUG2020/ Placebo	12SEP2020/ Placebo	15DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
12641024	C4591001 1264 12641024	16-55	22AUG2020	62139	Placebo	22AUG2020/ Placebo	12SEP2020/ Placebo	15DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
12641025	C4591001 1264 12641025	16-55	23AUG2020	62805	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)	12SEP2020/ BNT162b2 (30 µg)		
12641026	C4591001 1264 12641026	16-55	23AUG2020	62807	Placebo	23AUG2020/ Placebo	13SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12641028	C4591001 1264 12641028	16-55	23AUG2020	62808	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12641029	C4591001 1264 12641029	16-55	23AUG2020	62810	Placebo	23AUG2020/ Placebo	13SEP2020/ Placebo	15DEC2020/ BNT162b2 (30 µg)	04JAN2021/ BNT162b2 (30 µg)
12641032	C4591001 1264 12641032	16-55	23AUG2020	62987	Placebo	23AUG2020/ Placebo	13SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
12641033	C4591001 1264 12641033	16-55	24AUG2020	62989	Placebo	24AUG2020/ Placebo	13SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	04JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12641034	C4591001 1264 12641034	16-55	24AUG2020	62992	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	12SEP2020/ BNT162b2 (30 µg)		
12641035	C4591001 1264 12641035	16-55	24AUG2020	62991	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12641036	C4591001 1264 12641036	16-55	24AUG2020	63857	Placebo	24AUG2020/ Placebo	13SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12641037	C4591001 1264 12641037	16-55	24AUG2020	63862	Placebo	24AUG2020/ Placebo	12SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12641041	C4591001 1264 12641041	16-55	24AUG2020	63864	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12641042	C4591001 1264 12641042	16-55	24AUG2020	63868	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	12SEP2020/ BNT162b2 (30 µg)		
12641043	C4591001 1264 12641043	16-55	25AUG2020	65777	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12641046	C4591001 1264 12641046	16-55	25AUG2020	65784	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12641047	C4591001 1264 12641047	16-55	25AUG2020	65788	Placebo	25AUG2020/ Placebo	13SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12641048	C4591001 1264 12641048	16-55	25AUG2020	65787	Placebo	25AUG2020/ Placebo	14SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12641049	C4591001 1264 12641049	16-55	25AUG2020	66503	Placebo	25AUG2020/ Placebo	14SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12641050	C4591001 1264 12641050	16-55	25AUG2020	66506	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12641051	C4591001 1264 12641051	16-55	26AUG2020	66507	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12641052	C4591001 1264 12641052	16-55	26AUG2020	66508	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	15DEC2020/ BNT162b2 (30 µg)	04JAN2021/ BNT162b2 (30 µg)
12641053	C4591001 1264 12641053	16-55	26AUG2020	67857	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12641055	C4591001 1264 12641055	16-55	26AUG2020	67858	Placebo	26AUG2020/ Placebo	18SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
12641056	C4591001 1264 12641056	16-55	26AUG2020	67861	Placebo	26AUG2020/ Placebo	17SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12641058	C4591001 1264 12641058	16-55	26AUG2020	67864	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12641060	C4591001 1264 12641060	16-55	27AUG2020	70029	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12641062	C4591001 1264 12641062	16-55	27AUG2020	70031	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	04JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12641064	C4591001 1264 12641064	16-55	27AUG2020	70032	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12641065	C4591001 1264 12641065	16-55	27AUG2020	70035	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12641066	C4591001 1264 12641066	16-55	27AUG2020	70783	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12641069	C4591001 1264 12641069	16-55	27AUG2020	70784	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12641070	C4591001 1264 12641070	16-55	27AUG2020	70785	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
12641071	C4591001 1264 12641071	16-55	28AUG2020	70786	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12641072	C4591001 1264 12641072	16-55	28AUG2020	72126	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12641073	C4591001 1264 12641073	16-55	28AUG2020	72128	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	15DEC2020/ BNT162b2 (30 µg)	04JAN2021/ BNT162b2 (30 µg)
12641075	C4591001 1264 12641075	16-55	28AUG2020	72134	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12641078	C4591001 1264 12641078	16-55	28AUG2020	72135	Placebo	28AUG2020/ Placebo	17SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12641081	C4591001 1264 12641081	16-55	31AUG2020	75129	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
12641082	C4591001 1264 12641082	16-55	31AUG2020	75130	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
12641083	C4591001 1264 12641083	16-55	31AUG2020	75132	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
12641084	C4591001 1264 12641084	16-55	31AUG2020	75136	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12641086	C4591001 1264 12641086	16-55	31AUG2020	75581	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
12641087	C4591001 1264 12641087	16-55	01SEP2020	75586	Placebo	01SEP2020/ Placebo	21SEP2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
12641088	C4591001 1264 12641088	16-55	01SEP2020	75582	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
12641089	C4591001 1264 12641089	16-55	01SEP2020	75587	Placebo	01SEP2020/ Placebo	21SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
12641090	C4591001 1264 12641090	16-55	01SEP2020	76772	Placebo	01SEP2020/ Placebo	21SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
12641091	C4591001 1264 12641091	16-55	01SEP2020	76775	Placebo	01SEP2020/ Placebo	21SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12641092	C4591001 1264 12641092	16-55	01SEP2020	76776	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
12641093	C4591001 1264 12641093	16-55	01SEP2020	76778	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
12641094	C4591001 1264 12641094	16-55	01SEP2020	77253	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
12641095	C4591001 1264 12641095	16-55	02SEP2020	77258	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
12641096	C4591001 1264 12641096	16-55	02SEP2020	77260	Placebo	02SEP2020/ Placebo	24SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12641100	C4591001 1264 12641100	16-55	02SEP2020	78737	Placebo	02SEP2020/ Placebo	25SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12641101	C4591001 1264 12641101	16-55	02SEP2020	78738	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
12641103	C4591001 1264 12641103	16-55	03SEP2020	78739	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
12641104	C4591001 1264 12641104	16-55	03SEP2020	78743	Placebo	03SEP2020/ Placebo	09OCT2020/ Placebo	15DEC2020/ BNT162b2 (30 µg)	04JAN2021/ BNT162b2 (30 µg)
12641105	C4591001 1264 12641105	16-55	03SEP2020	80060	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12641106	C4591001 1264 12641106	16-55	03SEP2020	80062	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12641108	C4591001 1264 12641108	16-55	03SEP2020	80063	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
12641109	C4591001 1264 12641109	16-55	03SEP2020	80068	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12641110	C4591001 1264 12641110	16-55	03SEP2020	80671	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12641113	C4591001 1264 12641113	16-55	04SEP2020	80677	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
12641115	C4591001 1264 12641115	16-55	04SEP2020	80679	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12641116	C4591001 1264 12641116	16-55	04SEP2020	80680	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
12641118	C4591001 1264 12641118	16-55	04SEP2020	82194	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
12641119	C4591001 1264 12641119	16-55	08SEP2020	82197	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
12641120	C4591001 1264 12641120	16-55	08SEP2020	83766	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12641122	C4591001 1264 12641122	16-55	08SEP2020	82198	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
12641123	C4591001 1264 12641123	16-55	08SEP2020	82203	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
12641124	C4591001 1264 12641124	16-55	08SEP2020	83768	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
12641125	C4591001 1264 12641125	16-55	08SEP2020	83770	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12641126	C4591001 1264 12641126	16-55	08SEP2020	83774	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12641127	C4591001 1264 12641127	16-55	08SEP2020	84091	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
12641129	C4591001 1264 12641129	16-55	09SEP2020	84093	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
12641131	C4591001 1264 12641131	16-55	09SEP2020	84095	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
12641132	C4591001 1264 12641132	16-55	09SEP2020	84096	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	15DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
12641135	C4591001 1264 12641135	16-55	09SEP2020	85721	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12641140	C4591001 1264 12641140	16-55	10SEP2020	85729	Placebo	10SEP2020/ Placebo	29SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12641141	C4591001 1264 12641141	16-55	10SEP2020	85728	Placebo	10SEP2020/ Placebo	29SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
12641142	C4591001 1264 12641142	16-55	10SEP2020	85724	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
12641143	C4591001 1264 12641143	16-55	10SEP2020	87090	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
12641144	C4591001 1264 12641144	16-55	10SEP2020	87093	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
12641145	C4591001 1264 12641145	16-55	10SEP2020	87098	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
12641146	C4591001 1264 12641146	16-55	10SEP2020	87099	Placebo	10SEP2020/ Placebo	30SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12641147	C4591001 1264 12641147	16-55	10SEP2020	87415	Placebo	10SEP2020/ Placebo	29SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12641148	C4591001 1264 12641148	16-55	11SEP2020	87416	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
12641150	C4591001 1264 12641150	16-55	11SEP2020	87420	Placebo	11SEP2020/ Placebo	30SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12641151	C4591001 1264 12641151	16-55	11SEP2020	87421	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
12641152	C4591001 1264 12641152	16-55	11SEP2020	88531	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12641153	C4591001 1264 12641153	16-55	11SEP2020	88534	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	15DEC2020/ BNT162b2 (30 µg)	04JAN2021/ BNT162b2 (30 µg)
12641154	C4591001 1264 12641154	16-55	11SEP2020	88537	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
12641156	C4591001 1264 12641156	16-55	11SEP2020	88538	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
12641157	C4591001 1264 12641157	16-55	16SEP2020	91379	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
12641158	C4591001 1264 12641158	16-55	16SEP2020	91382	Placebo	16SEP2020/ Placebo	07OCT2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12641159	C4591001 1264 12641159	16-55	16SEP2020	91384	Placebo	16SEP2020/ Placebo	06OCT2020/ Placebo		
12641160	C4591001 1264 12641160	16-55	16SEP2020	91541	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
12641162	C4591001 1264 12641162	16-55	16SEP2020	91542	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12641165	C4591001 1264 12641165	16-55	16SEP2020	91545	Placebo	16SEP2020/ Placebo	06OCT2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12641166	C4591001 1264 12641166	16-55	16SEP2020	91549	Placebo	16SEP2020/ Placebo	08OCT2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12641167	C4591001 1264 12641167	16-55	16SEP2020	91878	Placebo	16SEP2020/ Placebo	08OCT2020/ Placebo	15DEC2020/ BNT162b2 (30 µg)	04JAN2021/ BNT162b2 (30 µg)
12641168	C4591001 1264 12641168	16-55	16SEP2020	91877	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
12641171	C4591001 1264 12641171	16-55	17SEP2020	91885	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
12641172	C4591001 1264 12641172	16-55	17SEP2020	91886	Placebo	17SEP2020/ Placebo	06OCT2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12641173	C4591001 1264 12641173	16-55	17SEP2020	93067	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
12641175	C4591001 1264 12641175	16-55	17SEP2020	93070	Placebo	17SEP2020/ Placebo	09OCT2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12641176	C4591001 1264 12641176	16-55	17SEP2020	93072	Placebo	17SEP2020/ Placebo	09OCT2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12641177	C4591001 1264 12641177	16-55	18SEP2020	93074	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12641179	C4591001 1264 12641179	16-55	18SEP2020	94279	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
12641181	C4591001 1264 12641181	16-55	21SEP2020	94281	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
12641183	C4591001 1264 12641183	16-55	21SEP2020	94282	Placebo	21SEP2020/ Placebo	14OCT2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
12641184	C4591001 1264 12641184	16-55	21SEP2020	94288	Placebo	21SEP2020/ Placebo	14OCT2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
12641185	C4591001 1264 12641185	16-55	21SEP2020	95705	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
12641186	C4591001 1264 12641186	16-55	21SEP2020	95712	Placebo	21SEP2020/ Placebo	14OCT2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12641187	C4591001 1264 12641187	16-55	22SEP2020	95713	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
12641188	C4591001 1264 12641188	16-55	22SEP2020	95715	Placebo	22SEP2020/ Placebo	12OCT2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12641189	C4591001 1264 12641189	16-55	22SEP2020	96522	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
12641190	C4591001 1264 12641190	16-55	22SEP2020	96524	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12641191	C4591001 1264 12641191	16-55	22SEP2020	96527	Placebo	22SEP2020/ Placebo	12OCT2020/ Placebo	15DEC2020/ BNT162b2 (30 µg)	04JAN2021/ BNT162b2 (30 µg)
12641192	C4591001 1264 12641192	16-55	22SEP2020	96530	Placebo	22SEP2020/ Placebo	12OCT2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
12641193	C4591001 1264 12641193	16-55	22SEP2020	96942	Placebo	22SEP2020/ Placebo	14OCT2020/ Placebo	15DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
12641197	C4591001 1264 12641197	16-55	22SEP2020	96947	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
12641200	C4591001 1264 12641200	16-55	23SEP2020	96948	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
12641201	C4591001 1264 12641201	16-55	23SEP2020	96949	Placebo	23SEP2020/ Placebo	12OCT2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
12641202	C4591001 1264 12641202	16-55	23SEP2020	97853	Placebo	23SEP2020/ Placebo	16OCT2020/ Placebo	15DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
12641203	C4591001 1264 12641203	16-55	23SEP2020	97855	Placebo	23SEP2020/ Placebo	12OCT2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12641204	C4591001 1264 12641204	16-55	23SEP2020	97857	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
12641206	C4591001 1264 12641206	16-55	23SEP2020	97858	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12641208	C4591001 1264 12641208	16-55	23SEP2020	98418	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
12641209	C4591001 1264 12641209	16-55	21OCT2020	98423	Placebo	21OCT2020/ Placebo	09NOV2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12641210	C4591001 1264 12641210	16-55	21OCT2020	98424	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
12641211	C4591001 1264 12641211	16-55	21OCT2020	98428	Placebo	21OCT2020/ Placebo	09NOV2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
12641212	C4591001 1264 12641212	16-55	21OCT2020	111593	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
12641213	C4591001 1264 12641213	16-55	21OCT2020	111597	Placebo	21OCT2020/ Placebo	09NOV2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
12641215	C4591001 1264 12641215	16-55	21OCT2020	111598	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
12641216	C4591001 1264 12641216	16-55	21OCT2020	111603	Placebo	21OCT2020/ Placebo	13NOV2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
12641218	C4591001 1264 12641218	16-55	21OCT2020	111848	Placebo	21OCT2020/ Placebo	09NOV2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
12641221	C4591001 1264 12641221	16-55	23OCT2020	111850	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12641225	C4591001 1264 12641225	16-55	23OCT2020	111851	Placebo	23OCT2020/ Placebo	13NOV2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12641226	C4591001 1264 12641226	16-55	23OCT2020	111853	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
12641227	C4591001 1264 12641227	16-55	26OCT2020	113611	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
12641228	C4591001 1264 12641228	16-55	26OCT2020	113612	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
12651003	C4591001 1265 12651003	16-55	24AUG2020	64913	Placebo	24AUG2020/ Placebo	16SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
12651004	C4591001 1265 12651004	16-55	25AUG2020	64916	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12651006	C4591001 1265 12651006	16-55	25AUG2020	64921	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12651007	C4591001 1265 12651007	16-55	26AUG2020	64924	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
12651010	C4591001 1265 12651010	16-55	27AUG2020	70254	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
12651013	C4591001 1265 12651013	16-55	27AUG2020	70255	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12651016	C4591001 1265 12651016	16-55	27AUG2020	70258	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	02MAR2021/ BNT162b2 (30 µg)	
12651020	C4591001 1265 12651020	16-55	28AUG2020	70264	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
12651021	C4591001 1265 12651021	16-55	28AUG2020	72966	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo		
12651022	C4591001 1265 12651022	16-55	28AUG2020	72969	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12651024	C4591001 1265 12651024	16-55	31AUG2020	72972	Placebo	31AUG2020/ Placebo	22SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
12651025	C4591001 1265 12651025	16-55	31AUG2020	72974	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
12651027	C4591001 1265 12651027	16-55	31AUG2020	75968	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
12651029	C4591001 1265 12651029	16-55	31AUG2020	75972	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
12651030	C4591001 1265 12651030	16-55	31AUG2020	75973	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
12651031	C4591001 1265 12651031	16-55	31AUG2020	75975	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12651032	C4591001 1265 12651032	16-55	01SEP2020	76747	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
12651035	C4591001 1265 12651035	16-55	01SEP2020	76748	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
12651037	C4591001 1265 12651037	16-55	01SEP2020	76752	Placebo	01SEP2020/ Placebo	25SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12651040	C4591001 1265 12651040	16-55	02SEP2020	76753	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
12651041	C4591001 1265 12651041	16-55	02SEP2020	78631	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
12651042	C4591001 1265 12651042	16-55	02SEP2020	78633	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
12651043	C4591001 1265 12651043	16-55	02SEP2020	78634	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
12651044	C4591001 1265 12651044	16-55	02SEP2020	78636	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
12651047	C4591001 1265 12651047	16-55	03SEP2020	79997	Placebo	03SEP2020/ Placebo	25SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
12651049	C4591001 1265 12651049	16-55	03SEP2020	79998	Placebo	03SEP2020/ Placebo	22SEP2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12651053	C4591001 1265 12651053	16-55	03SEP2020	80000	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
12651055	C4591001 1265 12651055	16-55	03SEP2020	80004	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
12651058	C4591001 1265 12651058	16-55	04SEP2020	81905	Placebo	04SEP2020/ Placebo	23SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12651059	C4591001 1265 12651059	16-55	04SEP2020	81907	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
12651060	C4591001 1265 12651060	16-55	04SEP2020	81910	Placebo	04SEP2020/ Placebo	23SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
12651061	C4591001 1265 12651061	16-55	04SEP2020	81915	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
12651062	C4591001 1265 12651062	16-55	04SEP2020	82481	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
12651063	C4591001 1265 12651063	16-55	04SEP2020	82485	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
12651064	C4591001 1265 12651064	16-55	04SEP2020	82488	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
12651065	C4591001 1265 12651065	16-55	08SEP2020	82491	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12651066	C4591001 1265 12651066	16-55	08SEP2020	83780	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
12651067	C4591001 1265 12651067	16-55	08SEP2020	83782	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
12651072	C4591001 1265 12651072	16-55	08SEP2020	83783	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
12651073	C4591001 1265 12651073	16-55	08SEP2020	83785	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
12651076	C4591001 1265 12651076	16-55	09SEP2020	85361	Placebo	09SEP2020/ Placebo	28SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
12651079	C4591001 1265 12651079	16-55	09SEP2020	85367	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
12651081	C4591001 1265 12651081	16-55	09SEP2020	85369	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
12651082	C4591001 1265 12651082	16-55	09SEP2020	85370	Placebo	09SEP2020/ Placebo	28SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
12651083	C4591001 1265 12651083	16-55	09SEP2020	86141	Placebo	09SEP2020/ Placebo	29SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12651084	C4591001 1265 12651084	16-55	09SEP2020	86148	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12651086	C4591001 1265 12651086	16-55	10SEP2020	86149	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
12651089	C4591001 1265 12651089	16-55	10SEP2020	86152	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
12651090	C4591001 1265 12651090	16-55	10SEP2020	87197	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
12651093	C4591001 1265 12651093	16-55	10SEP2020	87202	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
12651096	C4591001 1265 12651096	16-55	10SEP2020	87203	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
12651097	C4591001 1265 12651097	16-55	10SEP2020	87206	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
12651098	C4591001 1265 12651098	16-55	11SEP2020	88266	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
12651099	C4591001 1265 12651099	16-55	11SEP2020	88269	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
12651101	C4591001 1265 12651101	16-55	11SEP2020	88271	Placebo	11SEP2020/ Placebo	30SEP2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
12651104	C4591001 1265 12651104	16-55	11SEP2020	88272	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12651106	C4591001 1265 12651106	16-55	14SEP2020	89670	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
12651108	C4591001 1265 12651108	16-55	14SEP2020	89672	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
12651110	C4591001 1265 12651110	16-55	14SEP2020	89673	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
12651111	C4591001 1265 12651111	16-55	14SEP2020	89680	Placebo	14SEP2020/ Placebo	07OCT2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12651114	C4591001 1265 12651114	16-55	14SEP2020	90101	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
12651124	C4591001 1265 12651124	16-55	16SEP2020	90105	Placebo	16SEP2020/ Placebo	08OCT2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
12651126	C4591001 1265 12651126	16-55	16SEP2020	90106	Placebo	16SEP2020/ Placebo	07OCT2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
12651128	C4591001 1265 12651128	16-55	16SEP2020	90111	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
12651134	C4591001 1265 12651134	16-55	17SEP2020	92958	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
12651136	C4591001 1265 12651136	16-55	17SEP2020	92959	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12651138	C4591001 1265 12651138	16-55	17SEP2020	92962	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
12651139	C4591001 1265 12651139†	16-55	18SEP2020	92964	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
12651142	C4591001 1265 12651142	16-55	18SEP2020	93954	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
12651143	C4591001 1265 12651143†	16-55	18SEP2020	93955	Placebo	18SEP2020/ Placebo	07OCT2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12651144	C4591001 1265 12651144	16-55	18SEP2020	93960	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
12651145	C4591001 1265 12651145	16-55	18SEP2020	93963	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
12651146	C4591001 1265 12651146	16-55	18SEP2020	94342	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
12651147	C4591001 1265 12651147	16-55	18SEP2020	94343	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
12651148	C4591001 1265 12651148	16-55	21SEP2020	94344	Placebo	21SEP2020/ Placebo	13OCT2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12651149	C4591001 1265 12651149	16-55	21SEP2020	94345	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12651151	C4591001 1265 12651151	16-55	21SEP2020	95586	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
12651153	C4591001 1265 12651153	16-55	21SEP2020	95590	Placebo	21SEP2020/ Placebo	13OCT2020/ Placebo		
12651155	C4591001 1265 12651155	16-55	22SEP2020	95594	Placebo	22SEP2020/ Placebo	12OCT2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
12651159	C4591001 1265 12651159†	16-55	22SEP2020	95595	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
12651161	C4591001 1265 12651161	16-55	22SEP2020	97075	Placebo	22SEP2020/ Placebo	14OCT2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
12651162	C4591001 1265 12651162	16-55	23SEP2020	97078	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
12651164	C4591001 1265 12651164†	16-55	23SEP2020	97079	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
12651165	C4591001 1265 12651165	16-55	23SEP2020	97083	Placebo	23SEP2020/ Placebo	12OCT2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
12651166	C4591001 1265 12651166	16-55	23SEP2020	97974	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
12651167	C4591001 1265 12651167	16-55	23SEP2020	97977	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12651168	C4591001 1265 12651168	16-55	23SEP2020	97978	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
12651170	C4591001 1265 12651170	16-55	24SEP2020	97981	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
12651173	C4591001 1265 12651173	16-55	24SEP2020	98861	Placebo	24SEP2020/ Placebo	13OCT2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
12651174	C4591001 1265 12651174	16-55	24SEP2020	98864	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
12651175	C4591001 1265 12651175	16-55	24SEP2020	98865	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
12651177	C4591001 1265 12651177	16-55	24SEP2020	98870	Placebo	24SEP2020/ Placebo	16OCT2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
12651180	C4591001 1265 12651180	16-55	25SEP2020	99907	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
12651182	C4591001 1265 12651182†	16-55	25SEP2020	99911	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
12651186	C4591001 1265 12651186†	16-55	25SEP2020	99912	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
12691001	C4591001 1269 12691001	16-55	17AUG2020	53227	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	23JAN2021/ BNT162b2 (30 µg)	13FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12691002	C4591001 1269 12691002	16-55	17AUG2020	53228	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12691004	C4591001 1269 12691004	16-55	17AUG2020	53231	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12691006	C4591001 1269 12691006	16-55	19AUG2020	53236	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12691007	C4591001 1269 12691007	16-55	19AUG2020	57162	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo		
12691010	C4591001 1269 12691010	16-55	20AUG2020	57163	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12691011	C4591001 1269 12691011	16-55	20AUG2020	57164	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12691013	C4591001 1269 12691013	16-55	20AUG2020	59504	Placebo	20AUG2020/ Placebo	09SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12691014	C4591001 1269 12691014	16-55	20AUG2020	57171	Placebo	20AUG2020/ Placebo	09SEP2020/ Placebo		
12691016	C4591001 1269 12691016	16-55	20AUG2020	59506	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12691018	C4591001 1269 12691018	16-55	20AUG2020	59507	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12691020	C4591001 1269 12691020	16-55	20AUG2020	59511	Placebo	20AUG2020/ Placebo	09SEP2020/ Placebo	23JAN2021/ BNT162b2 (30 µg)	13FEB2021/ BNT162b2 (30 µg)
12691022	C4591001 1269 12691022	16-55	21AUG2020	60894	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12691025	C4591001 1269 12691025	16-55	21AUG2020	60896	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12691026	C4591001 1269 12691026	16-55	21AUG2020	60901	Placebo	21AUG2020/ Placebo	10SEP2020/ Placebo		
12691027	C4591001 1269 12691027	16-55	21AUG2020	60902	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12691029	C4591001 1269 12691029	16-55	21AUG2020	61553	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo		
12691030	C4591001 1269 12691030	16-55	21AUG2020	61554	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12691031	C4591001 1269 12691031	16-55	22AUG2020	61560	Placebo	22AUG2020/ Placebo	11SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12691032	C4591001 1269 12691032	16-55	22AUG2020	61564	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	12SEP2020/ BNT162b2 (30 µg)		
12691033	C4591001 1269 12691033	16-55	22AUG2020	62141	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12691034	C4591001 1269 12691034	16-55	22AUG2020	62142	Placebo	22AUG2020/ Placebo	10SEP2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	14JAN2021/ BNT162b2 (30 µg)
12691037	C4591001 1269 12691037	16-55	22AUG2020	62150	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12691039	C4591001 1269 12691039	16-55	22AUG2020	62152	Placebo	22AUG2020/ Placebo	12SEP2020/ Placebo	19DEC2020/ BNT162b2 (30 µg)	09JAN2021/ BNT162b2 (30 µg)
12691041	C4591001 1269 12691041	16-55	22AUG2020	62538	Placebo	22AUG2020/ Placebo	12SEP2020/ Placebo	24DEC2020/ BNT162b2 (30 µg)	16JAN2021/ BNT162b2 (30 µg)
12691042	C4591001 1269 12691042	16-55	24AUG2020	62540	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12691045	C4591001 1269 12691045	16-55	24AUG2020	62542	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12691047	C4591001 1269 12691047	16-55	25AUG2020	62548	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo		
12691048	C4591001 1269 12691048	16-55	25AUG2020	66054	Placebo	25AUG2020/ Placebo	14SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
12691050	C4591001 1269 12691050	16-55	25AUG2020	66059	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	23JAN2021/ BNT162b2 (30 µg)	13FEB2021/ BNT162b2 (30 µg)
12691051	C4591001 1269 12691051	16-55	25AUG2020	66061	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12691055	C4591001 1269 12691055	16-55	25AUG2020	67027	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12691056	C4591001 1269 12691056	16-55	25AUG2020	66064	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12691057	C4591001 1269 12691057	16-55	26AUG2020	67030	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12691058	C4591001 1269 12691058	16-55	26AUG2020	67032	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12691059	C4591001 1269 12691059	16-55	26AUG2020	67036	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12691060	C4591001 1269 12691060	16-55	26AUG2020	68705	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
12691062	C4591001 1269 12691062	16-55	26AUG2020	68706	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
12691063	C4591001 1269 12691063	16-55	27AUG2020	68713	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12691064	C4591001 1269 12691064	16-55	27AUG2020	70928	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12691065	C4591001 1269 12691065	16-55	27AUG2020	68716	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12691072	C4591001 1269 12691072	16-55	28AUG2020	70932	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
12691073	C4591001 1269 12691073	16-55	28AUG2020	70933	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12691074	C4591001 1269 12691074	16-55	28AUG2020	70936	Placebo	28AUG2020/ Placebo	20SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
12691075	C4591001 1269 12691075	16-55	28AUG2020	72756	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12691076	C4591001 1269 12691076	16-55	28AUG2020	72754	Placebo	28AUG2020/ Placebo	17SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12691078	C4591001 1269 12691078	16-55	28AUG2020	72757	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12691081	C4591001 1269 12691081	16-55	28AUG2020	72760	Placebo	28AUG2020/ Placebo	14SEP2020/ Placebo		
12691084	C4591001 1269 12691084	16-55	31AUG2020	75379	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
12691087	C4591001 1269 12691087	16-55	31AUG2020	75383	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12691088	C4591001 1269 12691088	16-55	31AUG2020	75385	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12691089	C4591001 1269 12691089	16-55	31AUG2020	75388	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
12691091	C4591001 1269 12691091	16-55	01SEP2020	77011	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
12691093	C4591001 1269 12691093	16-55	01SEP2020	77013	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
12691094	C4591001 1269 12691094	16-55	01SEP2020	77015	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
12691095	C4591001 1269 12691095	16-55	01SEP2020	77020	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12691096	C4591001 1269 12691096	16-55	01SEP2020	77553	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
12691097	C4591001 1269 12691097	16-55	01SEP2020	77554	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12691099	C4591001 1269 12691099	16-55	02SEP2020	77559	Placebo	02SEP2020/ Placebo	24SEP2020/ Placebo	23JAN2021/ BNT162b2 (30 µg)	13FEB2021/ BNT162b2 (30 µg)
12691103	C4591001 1269 12691103	16-55	02SEP2020	77560	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
12691104	C4591001 1269 12691104	16-55	02SEP2020	79376	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12691105	C4591001 1269 12691105	16-55	02SEP2020	79379	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
12691106	C4591001 1269 12691106	16-55	02SEP2020	79380	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
12691107	C4591001 1269 12691107	16-55	02SEP2020	79377	Placebo	02SEP2020/ Placebo	24SEP2020/ Placebo		
12691108	C4591001 1269 12691108	16-55	03SEP2020	80155	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
12691110	C4591001 1269 12691110	16-55	03SEP2020	80633	Placebo	03SEP2020/ Placebo	25SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12691113	C4591001 1269 12691113	16-55	03SEP2020	80634	Placebo	03SEP2020/ Placebo	25SEP2020/ Placebo	23JAN2021/ BNT162b2 (30 µg)	13FEB2021/ BNT162b2 (30 µg)
12691115	C4591001 1269 12691115	16-55	03SEP2020	80639	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
12691116	C4591001 1269 12691116	16-55	04SEP2020	80640	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
12691117	C4591001 1269 12691117	16-55	04SEP2020	82289	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
12691119	C4591001 1269 12691119	16-55	04SEP2020	82292	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12691121	C4591001 1269 12691121	16-55	08SEP2020	82293	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
12691122	C4591001 1269 12691122	16-55	08SEP2020	82298	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12691123	C4591001 1269 12691123	16-55	08SEP2020	84017	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
12691125	C4591001 1269 12691125	16-55	08SEP2020	84023	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
12691126	C4591001 1269 12691126	16-55	09SEP2020	84024	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12691127	C4591001 1269 12691127	16-55	09SEP2020	84028	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
12691129	C4591001 1269 12691129	16-55	09SEP2020	85877	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12691130	C4591001 1269 12691130	16-55	09SEP2020	85879	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
12691133	C4591001 1269 12691133	16-55	10SEP2020	85882	Placebo	10SEP2020/ Placebo	29SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12691136	C4591001 1269 12691136	16-55	10SEP2020	85888	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12691140	C4591001 1269 12691140	16-55	17SEP2020	92609	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	16JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
12691143	C4591001 1269 12691143	16-55	21SEP2020	92614	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
12701003	C4591001 1270 12701003	16-55	25AUG2020	66116	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12701004	C4591001 1270 12701004	16-55	25AUG2020	66115	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12701007	C4591001 1270 12701007	16-55	26AUG2020	66117	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12701008	C4591001 1270 12701008	16-55	26AUG2020	66119	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo		
12701010	C4591001 1270 12701010	16-55	26AUG2020	68674	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
12701011	C4591001 1270 12701011	16-55	26AUG2020	68675	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12701013	C4591001 1270 12701013	16-55	27AUG2020	68680	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12701014	C4591001 1270 12701014	16-55	27AUG2020	68676	Placebo	27AUG2020/ Placebo	16SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12701015	C4591001 1270 12701015	16-55	27AUG2020	70193	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12701018	C4591001 1270 12701018	16-55	27AUG2020	70196	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12701020	C4591001 1270 12701020	16-55	27AUG2020	70199	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
12701021	C4591001 1270 12701021	16-55	27AUG2020	70200	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	14JAN2021/ BNT162b2 (30 µg)
12701022	C4591001 1270 12701022	16-55	28AUG2020	72077	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12701023	C4591001 1270 12701023	16-55	28AUG2020	72079	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12701025	C4591001 1270 12701025	16-55	28AUG2020	72080	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12701030	C4591001 1270 12701030	16-55	31AUG2020	72082	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
12701033	C4591001 1270 12701033	16-55	31AUG2020	75906	Placebo	31AUG2020/ Placebo	22SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12701034	C4591001 1270 12701034	16-55	31AUG2020	76139	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12701035	C4591001 1270 12701035	16-55	31AUG2020	76140	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12701037	C4591001 1270 12701037	16-55	01SEP2020	76142	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
12701041	C4591001 1270 12701041	16-55	01SEP2020	76143	Placebo	01SEP2020/ Placebo	21SEP2020/ Placebo		
12701045	C4591001 1270 12701045	16-55	01SEP2020	77693	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
12701046	C4591001 1270 12701046	16-55	02SEP2020	77701	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
12701048	C4591001 1270 12701048	16-55	02SEP2020	77702	Placebo	02SEP2020/ Placebo	25SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
12701051	C4591001 1270 12701051	16-55	02SEP2020	77704	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
12701056	C4591001 1270 12701056	16-55	03SEP2020	80309	Placebo	03SEP2020/ Placebo	02NOV2020/ Placebo		
12701064	C4591001 1270 12701064	16-55	04SEP2020	80311	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
12701065	C4591001 1270 12701065	16-55	04SEP2020	80313	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12701068	C4591001 1270 12701068	16-55	04SEP2020	80317	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
12701069	C4591001 1270 12701069	16-55	04SEP2020	82068	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
12701071	C4591001 1270 12701071	16-55	08SEP2020	82069	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12701074	C4591001 1270 12701074	16-55	08SEP2020	82070	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12701076	C4591001 1270 12701076	16-55	08SEP2020	82072	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
12701082	C4591001 1270 12701082	16-55	09SEP2020	85916	Placebo	09SEP2020/ Placebo	01OCT2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)
12701084	C4591001 1270 12701084	16-55	09SEP2020	85918	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
12701085	C4591001 1270 12701085	16-55	10SEP2020	85920	Placebo	10SEP2020/ Placebo	29SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
12701086	C4591001 1270 12701086	16-55	10SEP2020	85921	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
12701087	C4591001 1270 12701087	16-55	10SEP2020	86981	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo	31DEC2020/ BNT162b2 (30 µg)	21JAN2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12701088	C4591001 1270 12701088	16-55	10SEP2020	86982	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
12701089	C4591001 1270 12701089	16-55	10SEP2020	86985	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
12701090	C4591001 1270 12701090	16-55	10SEP2020	86986	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
12701091	C4591001 1270 12701091	16-55	10SEP2020	87655	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
12701097	C4591001 1270 12701097	16-55	11SEP2020	87656	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
12701098	C4591001 1270 12701098	16-55	11SEP2020	87661	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
12701099	C4591001 1270 12701099	16-55	11SEP2020	87664	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12701100	C4591001 1270 12701100	16-55	11SEP2020	88961	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
12701107	C4591001 1270 12701107	16-55	15SEP2020	88964	Placebo	15SEP2020/ Placebo	05OCT2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
12701118	C4591001 1270 12701118	16-55	16SEP2020	88965	Placebo	16SEP2020/ Placebo	07OCT2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12701119	C4591001 1270 12701119	16-55	16SEP2020	88970	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
12701121	C4591001 1270 12701121	16-55	17SEP2020	92357	Placebo	17SEP2020/ Placebo	15OCT2020/ Placebo		
12701122	C4591001 1270 12701122	16-55	17SEP2020	92361	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
12701123	C4591001 1270 12701123	16-55	17SEP2020	92363	Placebo	17SEP2020/ Placebo	07OCT2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
12701124	C4591001 1270 12701124	16-55	17SEP2020	92365	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
12701125	C4591001 1270 12701125	16-55	17SEP2020	93029	Placebo	17SEP2020/ Placebo	07OCT2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
12701128	C4591001 1270 12701128	16-55	18SEP2020	93030	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
12701129	C4591001 1270 12701129	16-55	18SEP2020	93032	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
12701131	C4591001 1270 12701131	16-55	18SEP2020	93036	Placebo	18SEP2020/ Placebo	08OCT2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
12701132	C4591001 1270 12701132	16-55	18SEP2020	94169	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12701133	C4591001 1270 12701133	16-55	18SEP2020	94174	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
12701134	C4591001 1270 12701134	16-55	18SEP2020	94178	Placebo	18SEP2020/ Placebo	07OCT2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
12701135	C4591001 1270 12701135	16-55	18SEP2020	94179	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)		
12701136	C4591001 1270 12701136	16-55	21SEP2020	94913	Placebo	21SEP2020/ Placebo	13OCT2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
12701137	C4591001 1270 12701137	16-55	21SEP2020	94914	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
12701141	C4591001 1270 12701141	16-55	21SEP2020	94915	Placebo	21SEP2020/ Placebo	13OCT2020/ Placebo	24DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
12701142	C4591001 1270 12701142	16-55	21SEP2020	94919	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
12701146	C4591001 1270 12701146	16-55	04NOV2020	115666	Placebo	04NOV2020/ Placebo	23NOV2020/ Placebo		
12701147	C4591001 1270 12701147	16-55	04NOV2020	115667	Placebo	04NOV2020/ Placebo	25NOV2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12701148	C4591001 1270 12701148	16-55	05NOV2020	115668	BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)	24NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12701149	C4591001 1270 12701149	16-55	06NOV2020	115669	BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)	25NOV2020/ BNT162b2 (30 µg)		
12701150	C4591001 1270 12701150	16-55	06NOV2020	115928	Placebo	06NOV2020/ Placebo	25NOV2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12701151	C4591001 1270 12701151	16-55	11NOV2020	115932	BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)	02DEC2020/ BNT162b2 (30 µg)		
12701152	C4591001 1270 12701152	16-55	11NOV2020	115933	Placebo	11NOV2020/ Placebo	02DEC2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12701153	C4591001 1270 12701153	16-55	12NOV2020	115934	BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)	02DEC2020/ BNT162b2 (30 µg)		
12701154	C4591001 1270 12701154	16-55	16NOV2020	116312	Placebo	16NOV2020/ Placebo	07DEC2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12701155	C4591001 1270 12701155	16-55	16NOV2020	116313	Placebo	16NOV2020/ Placebo	07DEC2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
12701156	C4591001 1270 12701156	16-55	18NOV2020	116316	BNT162b2 (30 µg)	18NOV2020/ BNT162b2 (30 µg)	09DEC2020/ BNT162b2 (30 µg)		
12701157	C4591001 1270 12701157	16-55	18NOV2020	116320	BNT162b2 (30 µg)	18NOV2020/ BNT162b2 (30 µg)	10DEC2020/ BNT162b2 (30 µg)		
12701158	C4591001 1270 12701158	16-55	19NOV2020	116526	BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)	10DEC2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12701159	C4591001 1270 12701159	16-55	19NOV2020	116527	Placebo	19NOV2020/ Placebo	10DEC2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12701160	C4591001 1270 12701160	16-55	19NOV2020	116532	Placebo	19NOV2020/ Placebo	08DEC2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
12701161	C4591001 1270 12701161	16-55	20NOV2020	116536	BNT162b2 (30 µg)	20NOV2020/ BNT162b2 (30 µg)	09DEC2020/ BNT162b2 (30 µg)		
12701162	C4591001 1270 12701162	16-55	20NOV2020	116634	Placebo	20NOV2020/ Placebo	11DEC2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12701163	C4591001 1270 12701163	16-55	23NOV2020	116638	BNT162b2 (30 µg)	23NOV2020/ BNT162b2 (30 µg)	14DEC2020/ BNT162b2 (30 µg)		
12701164	C4591001 1270 12701164	16-55	23NOV2020	116640	Placebo	23NOV2020/ Placebo	14DEC2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12701165	C4591001 1270 12701165	16-55	23NOV2020	116643	BNT162b2 (30 µg)	23NOV2020/ BNT162b2 (30 µg)	15DEC2020/ BNT162b2 (30 µg)		
12701166	C4591001 1270 12701166	16-55	24NOV2020	116840	Placebo	24NOV2020/ Placebo	14DEC2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12701167	C4591001 1270 12701167	16-55	24NOV2020	116844	Placebo	24NOV2020/ Placebo	14DEC2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12701168	C4591001 1270 12701168	16-55	24NOV2020	116847	BNT162b2 (30 µg)	24NOV2020/ BNT162b2 (30 µg)	16DEC2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12701169	C4591001 1270 12701169	16-55	24NOV2020	116848	BNT162b2 (30 µg)	24NOV2020/ BNT162b2 (30 µg)	16DEC2020/ BNT162b2 (30 µg)		
12701170	C4591001 1270 12701170	16-55	25NOV2020	116945	Placebo	25NOV2020/ Placebo	12JAN2021/ Placebo	09FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12701171	C4591001 1270 12701171	16-55	25NOV2020	116947	Placebo	25NOV2020/ Placebo	18DEC2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12701172	C4591001 1270 12701172	16-55	25NOV2020	116950	BNT162b2 (30 µg)	25NOV2020/ BNT162b2 (30 µg)	18DEC2020/ BNT162b2 (30 µg)		
12701175	C4591001 1270 12701175	16-55	01DEC2020	116952	BNT162b2 (30 µg)	01DEC2020/ BNT162b2 (30 µg)	21DEC2020/ BNT162b2 (30 µg)		
12701176	C4591001 1270 12701176	16-55	01DEC2020	117139	BNT162b2 (30 µg)	01DEC2020/ BNT162b2 (30 µg)	21DEC2020/ BNT162b2 (30 µg)		
12701178	C4591001 1270 12701178	16-55	01DEC2020	117141	Placebo	01DEC2020/ Placebo	22DEC2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12701179	C4591001 1270 12701179	16-55	02DEC2020	117146	BNT162b2 (30 µg)	02DEC2020/ BNT162b2 (30 µg)	23DEC2020/ BNT162b2 (30 µg)		
12701182	C4591001 1270 12701182	16-55	02DEC2020	117147	Placebo	02DEC2020/ Placebo	23DEC2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12701183	C4591001 1270 12701183	16-55	02DEC2020	117270	Placebo	02DEC2020/ Placebo	23DEC2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12701185	C4591001 1270 12701185	16-55	02DEC2020	117273	BNT162b2 (30 µg)	02DEC2020/ BNT162b2 (30 µg)	23DEC2020/ BNT162b2 (30 µg)		
12701186	C4591001 1270 12701186	16-55	03DEC2020	117274	BNT162b2 (30 µg)	03DEC2020/ BNT162b2 (30 µg)	22DEC2020/ BNT162b2 (30 µg)		
12701190	C4591001 1270 12701190	16-55	03DEC2020	117277	Placebo	03DEC2020/ Placebo	23DEC2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12701193	C4591001 1270 12701193	16-55	04DEC2020	117619	BNT162b2 (30 µg)	04DEC2020/ BNT162b2 (30 µg)	23DEC2020/ BNT162b2 (30 µg)		
12701195	C4591001 1270 12701195	16-55	04DEC2020	117624	BNT162b2 (30 µg)	04DEC2020/ BNT162b2 (30 µg)	24DEC2020/ BNT162b2 (30 µg)		
12701196	C4591001 1270 12701196	16-55	04DEC2020	117625	Placebo	04DEC2020/ Placebo	24DEC2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12701197	C4591001 1270 12701197	16-55	07DEC2020	117626	Placebo	07DEC2020/ Placebo	29DEC2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
44441003	C4591001 4444 44441003	16-55	21SEP2020	94871	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
44441004	C4591001 4444 44441004	16-55	21SEP2020	94858	Placebo	21SEP2020/ Placebo	13OCT2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
44441007	C4591001 4444 44441007	16-55	21SEP2020	94872	Placebo	21SEP2020/ Placebo	04NOV2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
44441008	C4591001 4444 44441008	16-55	21SEP2020	94856	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
44441012	C4591001 4444 44441012	16-55	21SEP2020	94853	Placebo	21SEP2020/ Placebo	13OCT2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
44441014	C4591001 4444 44441014	16-55	21SEP2020	95152	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
44441015	C4591001 4444 44441015	16-55	21SEP2020	94996	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
44441016	C4591001 4444 44441016	16-55	21SEP2020	94859	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
44441017	C4591001 4444 44441017	16-55	21SEP2020	94866	Placebo	21SEP2020/ Placebo	13OCT2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
44441019	C4591001 4444 44441019	16-55	21SEP2020	94904	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
44441020	C4591001 4444 44441020	16-55	21SEP2020	94873	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
44441023	C4591001 4444 44441023	16-55	21SEP2020	94905	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
44441024	C4591001 4444 44441024	16-55	21SEP2020	94998	Placebo	21SEP2020/ Placebo	13OCT2020/ Placebo		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
44441025	C4591001 4444 44441025	16-55	21SEP2020	94909	Placebo	21SEP2020/ Placebo		24FEB2021/ BNT162b2 (30 µg)	
44441026	C4591001 4444 44441026	16-55	21SEP2020	94993	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
44441027	C4591001 4444 44441027	16-55	21SEP2020	94912	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
44441028	C4591001 4444 44441028	16-55	21SEP2020	95021	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
44441031	C4591001 4444 44441031	16-55	21SEP2020	94987	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
44441033	C4591001 4444 44441033	16-55	21SEP2020	94991	Placebo	21SEP2020/ Placebo	13OCT2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
44441034	C4591001 4444 44441034	16-55	21SEP2020	95001	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
44441037	C4591001 4444 44441037	16-55	21SEP2020	94999	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
44441038	C4591001 4444 44441038	16-55	21SEP2020	95008	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
44441040	C4591001 4444 44441040	16-55	21SEP2020	95026	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
44441043	C4591001 4444 44441043	16-55	21SEP2020	95107	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)			
44441044	C4591001 4444 44441044	16-55	21SEP2020	95028	Placebo	21SEP2020/ Placebo		24FEB2021/ BNT162b2 (30 µg)	
44441045	C4591001 4444 44441045	16-55	21SEP2020	95032	Placebo	21SEP2020/ Placebo	13OCT2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
44441048	C4591001 4444 44441048	16-55	21SEP2020	95108	Placebo	21SEP2020/ Placebo			
44441055	C4591001 4444 44441055	16-55	21SEP2020	95110	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
44441056	C4591001 4444 44441056	16-55	21SEP2020	95115	Placebo	21SEP2020/ Placebo	13OCT2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
44441060	C4591001 4444 44441060	16-55	21SEP2020	95215	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
44441063	C4591001 4444 44441063	16-55	21SEP2020	95142	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
44441064	C4591001 4444 44441064	16-55	21SEP2020	95143	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
44441065	C4591001 4444 44441065	16-55	21SEP2020	95213	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
44441066	C4591001 4444 44441066	16-55	21SEP2020	95145	Placebo	21SEP2020/ Placebo	13OCT2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
44441068	C4591001 4444 44441068	16-55	21SEP2020	95351	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
44441069	C4591001 4444 44441069	16-55	21SEP2020	95238	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
44441071	C4591001 4444 44441071	16-55	21SEP2020	95219	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)		
44441072	C4591001 4444 44441072	16-55	21SEP2020	95265	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
44441073	C4591001 4444 44441073	16-55	21SEP2020	95216	Placebo	21SEP2020/ Placebo	13OCT2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
44441075	C4591001 4444 44441075	16-55	21SEP2020	95241	Placebo	21SEP2020/ Placebo	13OCT2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
44441076	C4591001 4444 44441076	16-55	21SEP2020	95269	Placebo	21SEP2020/ Placebo	13OCT2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
44441077	C4591001 4444 44441077	16-55	21SEP2020	95239	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
44441079	C4591001 4444 44441079	16-55	21SEP2020	95246	Placebo	21SEP2020/ Placebo			

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
44441081	C4591001 4444 44441081	16-55	21SEP2020	95262	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
44441084	C4591001 4444 44441084	16-55	21SEP2020	95345	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
44441086	C4591001 4444 44441086	16-55	21SEP2020	95353	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
44441087	C4591001 4444 44441087	16-55	21SEP2020	95267	Placebo	21SEP2020/ Placebo	13OCT2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	13FEB2021/ BNT162b2 (30 µg)
44441094	C4591001 4444 44441094	16-55	21SEP2020	95390	Placebo	21SEP2020/ Placebo	13OCT2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
44441095	C4591001 4444 44441095	16-55	21SEP2020	95354	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
44441100	C4591001 4444 44441100	16-55	21SEP2020	95400	Placebo	21SEP2020/ Placebo	13OCT2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
44441101	C4591001 4444 44441101	16-55	21SEP2020	95383	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44441102	C4591001 4444 44441102	16-55	21SEP2020	95395	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
44441103	C4591001 4444 44441103	16-55	21SEP2020	95448	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
44441105	C4591001 4444 44441105	16-55	21SEP2020	95384	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
44441106	C4591001 4444 44441106	16-55	21SEP2020	95398	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
44441108	C4591001 4444 44441108	16-55	21SEP2020	95389	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
44441110	C4591001 4444 44441110	16-55	21SEP2020	95393	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44441113	C4591001 4444 44441113	16-55	21SEP2020	95447	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44441115	C4591001 4444 44441115	16-55	21SEP2020	95445	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
44441120	C4591001 4444 44441120	16-55	21SEP2020	95466	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
44441121	C4591001 4444 44441121	16-55	21SEP2020	95468	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
44441123	C4591001 4444 44441123	16-55	21SEP2020	95475	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
44441125	C4591001 4444 44441125	16-55	21SEP2020	95451	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
44441126	C4591001 4444 44441126	16-55	21SEP2020	95474	Placebo	21SEP2020/ Placebo	13OCT2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
44441134	C4591001 4444 44441134	16-55	21SEP2020	95548	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
44441135	C4591001 4444 44441135	16-55	21SEP2020	95546	BNT162b2 (30 µg)				
44441138	C4591001 4444 44441138	16-55	21SEP2020	95610	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
44441139	C4591001 4444 44441139	16-55	21SEP2020	95545	Placebo	21SEP2020/ Placebo	13OCT2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
44441142	C4591001 4444 44441142	16-55	21SEP2020	95634	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
44441143	C4591001 4444 44441143	16-55	21SEP2020	95538	Placebo	21SEP2020/ Placebo	14OCT2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
44441144	C4591001 4444 44441144	16-55	21SEP2020	95650	Placebo	21SEP2020/ Placebo	13OCT2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
44441147	C4591001 4444 44441147	16-55	21SEP2020	95620	Placebo	21SEP2020/ Placebo	13OCT2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
44441149	C4591001 4444 44441149	16-55	21SEP2020	95611	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
44441150	C4591001 4444 44441150	16-55	21SEP2020	95662	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
44441154	C4591001 4444 44441154	16-55	21SEP2020	95681	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44441155	C4591001 4444 44441155	16-55	21SEP2020	95638	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
44441156	C4591001 4444 44441156	16-55	21SEP2020	95683	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo		
44441157	C4591001 4444 44441157	16-55	21SEP2020	95655	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo		
44441159	C4591001 4444 44441159	16-55	21SEP2020	95633	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
44441160	C4591001 4444 44441160	16-55	21SEP2020	95653	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
44441162	C4591001 4444 44441162	16-55	21SEP2020	95657	Placebo	21SEP2020/ Placebo	13OCT2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
44441163	C4591001 4444 44441163	16-55	21SEP2020	95635	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)		
44441166	C4591001 4444 44441166	16-55	21SEP2020	95693	Placebo	21SEP2020/ Placebo	13OCT2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
44441169	C4591001 4444 44441169	16-55	21SEP2020	95647	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
44441170	C4591001 4444 44441170	16-55	21SEP2020	95696	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
44441171	C4591001 4444 44441171	16-55	21SEP2020	95692	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
44441172	C4591001 4444 44441172	16-55	21SEP2020	95614	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
44441173	C4591001 4444 44441173	16-55	21SEP2020	95665	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
44441175	C4591001 4444 44441175	16-55	21SEP2020	95663	Placebo	21SEP2020/ Placebo	13OCT2020/ Placebo		
44441176	C4591001 4444 44441176	16-55	21SEP2020	95719	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44441177	C4591001 4444 44441177	16-55	21SEP2020	95695	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
44441179	C4591001 4444 44441179	16-55	21SEP2020	95686	Placebo	21SEP2020/ Placebo			
44441180	C4591001 4444 44441180	16-55	21SEP2020	95747	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
44441184	C4591001 4444 44441184	16-55	21SEP2020	95742	Placebo	21SEP2020/ Placebo	13OCT2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
44441187	C4591001 4444 44441187	16-55	21SEP2020	95720	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
44441190	C4591001 4444 44441190	16-55	21SEP2020	95744	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44441191	C4591001 4444 44441191	16-55	21SEP2020	95698	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
44441192	C4591001 4444 44441192	16-55	21SEP2020	95779	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
44441194	C4591001 4444 44441194	16-55	21SEP2020	95756	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
44441197	C4591001 4444 44441197	16-55	21SEP2020	95723	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
44441198	C4591001 4444 44441198	16-55	21SEP2020	95781	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
44441199	C4591001 4444 44441199	16-55	21SEP2020	95743	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo		
44441201	C4591001 4444 44441201	16-55	21SEP2020	95753	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
44441203	C4591001 4444 44441203	16-55	21SEP2020	95755	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
44441205	C4591001 4444 44441205	16-55	21SEP2020	95787	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
44441206	C4591001 4444 44441206	16-55	21SEP2020	95788	Placebo	21SEP2020/ Placebo	14OCT2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
44441207	C4591001 4444 44441207	16-55	21SEP2020	95725	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
44441209	C4591001 4444 44441209	16-55	21SEP2020	95791	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)		
44441211	C4591001 4444 44441211	16-55	21SEP2020	95759	Placebo	21SEP2020/ Placebo	13OCT2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
44441212	C4591001 4444 44441212	16-55	21SEP2020	95827	Placebo	21SEP2020/ Placebo	13OCT2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
44441213	C4591001 4444 44441213	16-55	21SEP2020	95795	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
44441218	C4591001 4444 44441218	16-55	21SEP2020	95849	Placebo	21SEP2020/ Placebo	14OCT2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	13FEB2021/ BNT162b2 (30 µg)
44441219	C4591001 4444 44441219	16-55	21SEP2020	95796	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
44441220	C4591001 4444 44441220	16-55	21SEP2020	95855	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
44441223	C4591001 4444 44441223	16-55	21SEP2020	95797	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
44441224	C4591001 4444 44441224	16-55	21SEP2020	95864	Placebo	21SEP2020/ Placebo	13OCT2020/ Placebo		
44441225	C4591001 4444 44441225	16-55	21SEP2020	95833	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
44441232	C4591001 4444 44441232	16-55	21SEP2020	95873	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
44441234	C4591001 4444 44441234	16-55	21SEP2020	95886	Placebo	21SEP2020/ Placebo	14OCT2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
44441236	C4591001 4444 44441236	16-55	21SEP2020	95865	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
44441237	C4591001 4444 44441237	16-55	21SEP2020	95834	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
44441238	C4591001 4444 44441238	16-55	21SEP2020	95891	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
44441243	C4591001 4444 44441243	16-55	21SEP2020	95835	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
44441245	C4591001 4444 44441245	16-55	21SEP2020	95862	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44441247	C4591001 4444 44441247	16-55	21SEP2020	95881	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
44441248	C4591001 4444 44441248	16-55	21SEP2020	95902	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
44441249	C4591001 4444 44441249	16-55	21SEP2020	95857	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
44441252	C4591001 4444 44441252	16-55	21SEP2020	95897	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
44441253	C4591001 4444 44441253	16-55	21SEP2020	95856	Placebo	21SEP2020/ Placebo	22OCT2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
44441255	C4591001 4444 44441255	16-55	21SEP2020	95880	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
44441257	C4591001 4444 44441257	16-55	21SEP2020	95867	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
44441260	C4591001 4444 44441260	16-55	21SEP2020	95910	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
44441261	C4591001 4444 44441261	16-55	21SEP2020	95892	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
44441262	C4591001 4444 44441262	16-55	21SEP2020	95904	Placebo	21SEP2020/ Placebo	13OCT2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
44441263	C4591001 4444 44441263	16-55	21SEP2020	95874	Placebo	21SEP2020/ Placebo	13OCT2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
44441265	C4591001 4444 44441265	16-55	21SEP2020	95900	Placebo	21SEP2020/ Placebo	14OCT2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
44441267	C4591001 4444 44441267	16-55	21SEP2020	95894	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
44441268	C4591001 4444 44441268	16-55	21SEP2020	95912	Placebo	21SEP2020/ Placebo	23OCT2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
44441271	C4591001 4444 44441271	16-55	22SEP2020	95915	Placebo	22SEP2020/ Placebo	12OCT2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
44441272	C4591001 4444 44441272	16-55	22SEP2020	95938	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
44441273	C4591001 4444 44441273	16-55	22SEP2020	95939	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)			
44441275	C4591001 4444 44441275	16-55	22SEP2020	95920	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
44441277	C4591001 4444 44441277	16-55	22SEP2020	95945	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
44441278	C4591001 4444 44441278	16-55	22SEP2020	95947	Placebo	22SEP2020/ Placebo	12OCT2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
44441279	C4591001 4444 44441279	16-55	22SEP2020	95955	Placebo	22SEP2020/ Placebo	13OCT2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
44441280	C4591001 4444 44441280	16-55	22SEP2020	95940	Placebo	22SEP2020/ Placebo	12OCT2020/ Placebo		
44441284	C4591001 4444 44441284	16-55	22SEP2020	95954	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
44441285	C4591001 4444 44441285	16-55	22SEP2020	95962	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
44441286	C4591001 4444 44441286	16-55	22SEP2020	95944	Placebo	22SEP2020/ Placebo	13OCT2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
44441288	C4591001 4444 44441288	16-55	22SEP2020	95965	Placebo	22SEP2020/ Placebo	12OCT2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
44441289	C4591001 4444 44441289	16-55	22SEP2020	95966	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
44441293	C4591001 4444 44441293	16-55	22SEP2020	95969	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
44441294	C4591001 4444 44441294	16-55	22SEP2020	95997	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
44441296	C4591001 4444 44441296	16-55	22SEP2020	95970	Placebo	22SEP2020/ Placebo	12OCT2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
44441297	C4591001 4444 44441297	16-55	22SEP2020	95973	Placebo	22SEP2020/ Placebo	12OCT2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
44441298	C4591001 4444 44441298	16-55	22SEP2020	96007	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
44441300	C4591001 4444 44441300	16-55	22SEP2020	95974	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
44441301	C4591001 4444 44441301	16-55	22SEP2020	95967	Placebo	22SEP2020/ Placebo	13OCT2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
44441302	C4591001 4444 44441302	16-55	22SEP2020	95995	Placebo	22SEP2020/ Placebo	13OCT2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
44441304	C4591001 4444 44441304	16-55	22SEP2020	95996	Placebo	22SEP2020/ Placebo	12OCT2020/ Placebo		
44441310	C4591001 4444 44441310	16-55	22SEP2020	96005	Placebo	22SEP2020/ Placebo	13OCT2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
44441311	C4591001 4444 44441311	16-55	22SEP2020	96004	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
44441315	C4591001 4444 44441315	16-55	22SEP2020	96008	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
44441317	C4591001 4444 44441317	16-55	22SEP2020	96035	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
44441319	C4591001 4444 44441319	16-55	22SEP2020	96010	Placebo	22SEP2020/ Placebo	12OCT2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
44441321	C4591001 4444 44441321	16-55	22SEP2020	96085	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
44441323	C4591001 4444 44441323	16-55	22SEP2020	96031	Placebo	22SEP2020/ Placebo	12OCT2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
44441324	C4591001 4444 44441324	16-55	22SEP2020	96037	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
44441325	C4591001 4444 44441325	16-55	22SEP2020	96056	Placebo	22SEP2020/ Placebo	14OCT2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
44441326	C4591001 4444 44441326	16-55	22SEP2020	96088	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
44441327	C4591001 4444 44441327	16-55	22SEP2020	96078	Placebo	22SEP2020/ Placebo	14OCT2020/ Placebo		
44441329	C4591001 4444 44441329	16-55	22SEP2020	96030	Placebo	22SEP2020/ Placebo	12OCT2020/ Placebo		
44441330	C4591001 4444 44441330	16-55	22SEP2020	96110	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
44441334	C4591001 4444 44441334	16-55	22SEP2020	96060	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44441335	C4591001 4444 44441335	16-55	22SEP2020	96062	Placebo	22SEP2020/ Placebo	13OCT2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
44441336	C4591001 4444 44441336	16-55	22SEP2020	96105	Placebo	22SEP2020/ Placebo	12OCT2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
44441337	C4591001 4444 44441337	16-55	22SEP2020	96083	Placebo	22SEP2020/ Placebo	13OCT2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
44441341	C4591001 4444 44441341	16-55	22SEP2020	96054	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44441345	C4591001 4444 44441345	16-55	22SEP2020	96106	Placebo	22SEP2020/ Placebo	13OCT2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
44441346	C4591001 4444 44441346	16-55	22SEP2020	263497	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
44441347	C4591001 4444 44441347	16-55	22SEP2020	96152	Placebo	22SEP2020/ Placebo	13OCT2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	13FEB2021/ BNT162b2 (30 µg)
44441348	C4591001 4444 44441348	16-55	22SEP2020	96111	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
44441351	C4591001 4444 44441351	16-55	22SEP2020	96151	Placebo	22SEP2020/ Placebo	13OCT2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
44441352	C4591001 4444 44441352	16-55	22SEP2020	96154	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
44441353	C4591001 4444 44441353	16-55	22SEP2020	96157	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
44441357	C4591001 4444 44441357	16-55	22SEP2020	96228	Placebo	22SEP2020/ Placebo	13OCT2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
44441358	C4591001 4444 44441358	16-55	22SEP2020	96180	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
44441359	C4591001 4444 44441359	16-55	22SEP2020	96183	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
44441360	C4591001 4444 44441360	16-55	22SEP2020	96173	Placebo	22SEP2020/ Placebo	13OCT2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
44441361	C4591001 4444 44441361	16-55	22SEP2020	96181	Placebo	22SEP2020/ Placebo	12OCT2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
44441365	C4591001 4444 44441365	16-55	22SEP2020	96224	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44441366	C4591001 4444 44441366	16-55	22SEP2020	96222	Placebo	22SEP2020/ Placebo	12OCT2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
44441376	C4591001 4444 44441376	16-55	22SEP2020	96309	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
44441377	C4591001 4444 44441377	16-55	22SEP2020	96246	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44441378	C4591001 4444 44441378	16-55	22SEP2020	96231	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
44441379	C4591001 4444 44441379	16-55	22SEP2020	96307	Placebo	22SEP2020/ Placebo	13OCT2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
44441380	C4591001 4444 44441380	16-55	22SEP2020	96253	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
44441384	C4591001 4444 44441384	16-55	22SEP2020	96255	Placebo	22SEP2020/ Placebo	29OCT2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
44441386	C4591001 4444 44441386	16-55	22SEP2020	96254	Placebo	22SEP2020/ Placebo	13OCT2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
44441387	C4591001 4444 44441387	16-55	22SEP2020	96467	Placebo	22SEP2020/ Placebo	12OCT2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
44441388	C4591001 4444 44441388	16-55	22SEP2020	96464	Placebo	22SEP2020/ Placebo	13OCT2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
44441390	C4591001 4444 44441390	16-55	22SEP2020	96312	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
44441395	C4591001 4444 44441395	16-55	22SEP2020	96401	Placebo	22SEP2020/ Placebo	14OCT2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
44441396	C4591001 4444 44441396	16-55	22SEP2020	96313	Placebo	22SEP2020/ Placebo	14OCT2020/ Placebo		
44441398	C4591001 4444 44441398	16-55	22SEP2020	96500	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
44441400	C4591001 4444 44441400	16-55	22SEP2020	96406	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
44441401	C4591001 4444 44441401	16-55	22SEP2020	96405	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
44441402	C4591001 4444 44441402	16-55	22SEP2020	96411	Placebo	22SEP2020/ Placebo	14OCT2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
44441404	C4591001 4444 44441404	16-55	22SEP2020	96537	Placebo	22SEP2020/ Placebo	12OCT2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
44441405	C4591001 4444 44441405†	16-55	22SEP2020	96465	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
44441407	C4591001 4444 44441407	16-55	22SEP2020	96501	Placebo	22SEP2020/ Placebo	12OCT2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
44441408	C4591001 4444 44441408	16-55	22SEP2020	96499	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
44441412	C4591001 4444 44441412	16-55	22SEP2020	96462	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
44441413	C4591001 4444 44441413	16-55	22SEP2020	96535	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44441419	C4591001 4444 44441419	16-55	22SEP2020	96503	Placebo	22SEP2020/ Placebo	13OCT2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
44441425	C4591001 4444 44441425	16-55	22SEP2020	96599	Placebo	22SEP2020/ Placebo	12OCT2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
44441428	C4591001 4444 44441428	16-55	22SEP2020	96540	Placebo	22SEP2020/ Placebo	12OCT2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
44441432	C4591001 4444 44441432	16-55	22SEP2020	96602	Placebo	22SEP2020/ Placebo	13OCT2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	
44441433	C4591001 4444 44441433	16-55	22SEP2020	96601	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
44441435	C4591001 4444 44441435	16-55	22SEP2020	96697	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44441436	C4591001 4444 44441436	16-55	22SEP2020	96543	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
44441437	C4591001 4444 44441437	16-55	22SEP2020	96668	Placebo	22SEP2020/ Placebo	13OCT2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
44441438	C4591001 4444 44441438	16-55	22SEP2020	96597	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
44441440	C4591001 4444 44441440	16-55	22SEP2020	96642	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
44441442	C4591001 4444 44441442	16-55	22SEP2020	96646	Placebo	22SEP2020/ Placebo	13OCT2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
44441443	C4591001 4444 44441443	16-55	22SEP2020	96714	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
44441444	C4591001 4444 44441444	16-55	22SEP2020	96692	Placebo	22SEP2020/ Placebo	12OCT2020/ Placebo		
44441445	C4591001 4444 44441445	16-55	22SEP2020	96670	Placebo	22SEP2020/ Placebo	13OCT2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
44441446	C4591001 4444 44441446	16-55	22SEP2020	96672	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
44441450	C4591001 4444 44441450	16-55	22SEP2020	96649	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
44441452	C4591001 4444 44441452	16-55	22SEP2020	96713	Placebo	22SEP2020/ Placebo	13OCT2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
44441453	C4591001 4444 44441453	16-55	22SEP2020	96673	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
44441457	C4591001 4444 44441457	16-55	22SEP2020	96689	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
44441458	C4591001 4444 44441458	16-55	22SEP2020	96695	Placebo	22SEP2020/ Placebo	12OCT2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
44441459	C4591001 4444 44441459	16-55	22SEP2020	96651	Placebo	22SEP2020/ Placebo	13OCT2020/ Placebo		
44441460	C4591001 4444 44441460	16-55	22SEP2020	96740	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
44441461	C4591001 4444 44441461	16-55	22SEP2020	96721	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44441464	C4591001 4444 44441464	16-55	22SEP2020	96716	Placebo	22SEP2020/ Placebo	14OCT2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
44441469	C4591001 4444 44441469	16-55	22SEP2020	96737	Placebo	22SEP2020/ Placebo	13OCT2020/ Placebo		
44441472	C4591001 4444 44441472	16-55	22SEP2020	96741	Placebo	22SEP2020/ Placebo	14OCT2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
44441474	C4591001 4444 44441474	16-55	22SEP2020	96782	Placebo	22SEP2020/ Placebo	12OCT2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
44441476	C4591001 4444 44441476	16-55	22SEP2020	96773	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
44441477	C4591001 4444 44441477	16-55	22SEP2020	96744	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
44441478	C4591001 4444 44441478	16-55	22SEP2020	96776	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
44441482	C4591001 4444 44441482	16-55	22SEP2020	96833	Placebo	22SEP2020/ Placebo	12OCT2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
44441483	C4591001 4444 44441483	16-55	22SEP2020	96850	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
44441485	C4591001 4444 44441485	16-55	22SEP2020	96843	Placebo	22SEP2020/ Placebo	13OCT2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
44441486	C4591001 4444 44441486	16-55	22SEP2020	96809	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
44441487	C4591001 4444 44441487	16-55	22SEP2020	96835	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
44441488	C4591001 4444 44441488	16-55	22SEP2020	96783	Placebo	22SEP2020/ Placebo	13OCT2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	13FEB2021/ BNT162b2 (30 µg)
44441490	C4591001 4444 44441490	16-55	22SEP2020	96811	Placebo	22SEP2020/ Placebo	12OCT2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	13FEB2021/ BNT162b2 (30 µg)
44441491	C4591001 4444 44441491	16-55	22SEP2020	96819	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44441494	C4591001 4444 44441494	16-55	22SEP2020	96817	Placebo	22SEP2020/ Placebo	13OCT2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
44441498	C4591001 4444 44441498	16-55	22SEP2020	96845	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
44441499	C4591001 4444 44441499	16-55	22SEP2020	96841	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44441500	C4591001 4444 44441500	16-55	22SEP2020	96851	Placebo	22SEP2020/ Placebo	12OCT2020/ Placebo		
44441501	C4591001 4444 44441501	16-55	22SEP2020	96872	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
44441502	C4591001 4444 44441502	16-55	22SEP2020	96869	Placebo	22SEP2020/ Placebo	13OCT2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
44441503	C4591001 4444 44441503	16-55	22SEP2020	96853	Placebo	22SEP2020/ Placebo	14OCT2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
44441505	C4591001 4444 44441505	16-55	22SEP2020	96878	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
44441506	C4591001 4444 44441506	16-55	22SEP2020	96879	Placebo	22SEP2020/ Placebo	13OCT2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
44441510	C4591001 4444 44441510	16-55	22SEP2020	96921	Placebo	22SEP2020/ Placebo	12OCT2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
44441511	C4591001 4444 44441511	16-55	22SEP2020	96881	Placebo	22SEP2020/ Placebo	14OCT2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
44441514	C4591001 4444 44441514	16-55	22SEP2020	96882	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
44441515	C4591001 4444 44441515	16-55	22SEP2020	96925	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
44441516	C4591001 4444 44441516	16-55	22SEP2020	96977	Placebo	22SEP2020/ Placebo	12OCT2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
44441518	C4591001 4444 44441518	16-55	22SEP2020	96923	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
44441520	C4591001 4444 44441520	16-55	22SEP2020	96883	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
44441521	C4591001 4444 44441521	16-55	22SEP2020	96887	Placebo	22SEP2020/ Placebo	12OCT2020/ Placebo		
44441522	C4591001 4444 44441522	16-55	22SEP2020	96928	Placebo	22SEP2020/ Placebo			
44441523	C4591001 4444 44441523	16-55	22SEP2020	96955	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44441524	C4591001 4444 44441524	16-55	22SEP2020	96954	Placebo	22SEP2020/ Placebo	14OCT2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
44441525	C4591001 4444 44441525	16-55	22SEP2020	96981	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
44441526	C4591001 4444 44441526	16-55	22SEP2020	96962	Placebo	22SEP2020/ Placebo	13OCT2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
44441527	C4591001 4444 44441527	16-55	22SEP2020	96958	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
44441528	C4591001 4444 44441528	16-55	22SEP2020	96989	Placebo	22SEP2020/ Placebo	13OCT2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
44441530	C4591001 4444 44441530	16-55	22SEP2020	96982	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
44441531	C4591001 4444 44441531	16-55	22SEP2020	96990	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44441532	C4591001 4444 44441532	16-55	22SEP2020	96986	Placebo	22SEP2020/ Placebo	13OCT2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
44441534	C4591001 4444 44441534	16-55	22SEP2020	96994	Placebo	22SEP2020/ Placebo	13OCT2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
44441536	C4591001 4444 44441536	16-55	22SEP2020	96997	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
44441538	C4591001 4444 44441538	16-55	23SEP2020	97197	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
44441539	C4591001 4444 44441539	16-55	23SEP2020	97252	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
44441541	C4591001 4444 44441541	16-55	23SEP2020	97216	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
44441542	C4591001 4444 44441542	16-55	23SEP2020	97273	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
44441544	C4591001 4444 44441544	16-55	23SEP2020	97194	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
44441546	C4591001 4444 44441546	16-55	23SEP2020	97205	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
44441549	C4591001 4444 44441549	16-55	23SEP2020	97289	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44441550	C4591001 4444 44441550	16-55	23SEP2020	97257	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
44441553	C4591001 4444 44441553	16-55	23SEP2020	97250	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44441554	C4591001 4444 44441554	16-55	23SEP2020	97213	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
44441555	C4591001 4444 44441555	16-55	23SEP2020	97201	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44441556	C4591001 4444 44441556	16-55	23SEP2020	97199	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
44441557	C4591001 4444 44441557	16-55	23SEP2020	97208	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
44441558	C4591001 4444 44441558	16-55	23SEP2020	97221	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44441559	C4591001 4444 44441559	16-55	23SEP2020	97258	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
44441560	C4591001 4444 44441560	16-55	23SEP2020	97276	Placebo	23SEP2020/ Placebo		05MAR2021/ BNT162b2 (30 µg)	
44441561	C4591001 4444 44441561	16-55	23SEP2020	97269	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44441562	C4591001 4444 44441562	16-55	23SEP2020	97225	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
44441563	C4591001 4444 44441563	16-55	23SEP2020	97243	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
44441564	C4591001 4444 44441564	16-55	23SEP2020	97261	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
44441565	C4591001 4444 44441565	16-55	23SEP2020	97223	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
44441566	C4591001 4444 44441566	16-55	23SEP2020	97227	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
44441567	C4591001 4444 44441567	16-55	23SEP2020	97284	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44441569	C4591001 4444 44441569	16-55	23SEP2020	97274	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)			
44441570	C4591001 4444 44441570	16-55	23SEP2020	97251	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
44441572	C4591001 4444 44441572	16-55	23SEP2020	97262	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)			
44441573	C4591001 4444 44441573	16-55	23SEP2020	97282	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
44441574	C4591001 4444 44441574	16-55	23SEP2020	97309	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
44441576	C4591001 4444 44441576	16-55	23SEP2020	97290	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
44441577	C4591001 4444 44441577	16-55	23SEP2020	97291	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
44441578	C4591001 4444 44441578	16-55	23SEP2020	97280	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44441581	C4591001 4444 44441581	16-55	23SEP2020	97308	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
44441582	C4591001 4444 44441582	16-55	23SEP2020	97283	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
44441583	C4591001 4444 44441583	16-55	23SEP2020	97305	Placebo	23SEP2020/ Placebo	12OCT2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
44441585	C4591001 4444 44441585	16-55	23SEP2020	97298	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
44441586	C4591001 4444 44441586	16-55	23SEP2020	97322	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo		
44441587	C4591001 4444 44441587	16-55	23SEP2020	97311	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44441589	C4591001 4444 44441589	16-55	23SEP2020	97319	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
44441590	C4591001 4444 44441590	16-55	23SEP2020	97363	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44441591	C4591001 4444 44441591	16-55	23SEP2020	97320	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
44441593	C4591001 4444 44441593	16-55	23SEP2020	97364	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
44441594	C4591001 4444 44441594	16-55	23SEP2020	97351	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
44441596	C4591001 4444 44441596	16-55	23SEP2020	97360	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
44441597	C4591001 4444 44441597	16-55	23SEP2020	97375	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
44441599	C4591001 4444 44441599	16-55	23SEP2020	97349	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
44441601	C4591001 4444 44441601	16-55	23SEP2020	97318	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
44441603	C4591001 4444 44441603	16-55	23SEP2020	97397	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
44441604	C4591001 4444 44441604	16-55	23SEP2020	97367	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44441605	C4591001 4444 44441605	16-55	23SEP2020	97369	Placebo	23SEP2020/ Placebo	13OCT2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
44441606	C4591001 4444 44441606	16-55	23SEP2020	97383	Placebo	23SEP2020/ Placebo	15OCT2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
44441608	C4591001 4444 44441608	16-55	23SEP2020	97384	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44441610	C4591001 4444 44441610	16-55	23SEP2020	97409	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
44441611	C4591001 4444 44441611	16-55	23SEP2020	97356	Placebo	23SEP2020/ Placebo	15OCT2020/ Placebo		
44441612	C4591001 4444 44441612	16-55	23SEP2020	97376	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
44441614	C4591001 4444 44441614	16-55	23SEP2020	97414	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44441615	C4591001 4444 44441615	16-55	23SEP2020	97400	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44441616	C4591001 4444 44441616	16-55	23SEP2020	97429	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
44441617	C4591001 4444 44441617	16-55	23SEP2020	97407	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44441618	C4591001 4444 44441618	16-55	23SEP2020	97401	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
44441619	C4591001 4444 44441619	16-55	23SEP2020	97411	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
44441623	C4591001 4444 44441623	16-55	23SEP2020	97419	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
44441624	C4591001 4444 44441624	16-55	23SEP2020	97431	Placebo	23SEP2020/ Placebo	30OCT2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
44441628	C4591001 4444 44441628	16-55	23SEP2020	97546	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44441629	C4591001 4444 44441629	16-55	23SEP2020	97430	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
44441632	C4591001 4444 44441632	16-55	23SEP2020	97432	Placebo	23SEP2020/ Placebo	13OCT2020/ Placebo		
44441633	C4591001 4444 44441633	16-55	23SEP2020	97549	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44441634	C4591001 4444 44441634	16-55	23SEP2020	97500	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44441636	C4591001 4444 44441636	16-55	23SEP2020	97502	Placebo	23SEP2020/ Placebo	13OCT2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
44441638	C4591001 4444 44441638	16-55	23SEP2020	97504	Placebo	23SEP2020/ Placebo	15OCT2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
44441639	C4591001 4444 44441639	16-55	23SEP2020	97541	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
44441640	C4591001 4444 44441640	16-55	23SEP2020	97614	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)		
44441643	C4591001 4444 44441643	16-55	23SEP2020	97618	Placebo	23SEP2020/ Placebo	16OCT2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
44441644	C4591001 4444 44441644	16-55	23SEP2020	97550	Placebo	23SEP2020/ Placebo	15OCT2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
44441649	C4591001 4444 44441649	16-55	23SEP2020	97617	Placebo	23SEP2020/ Placebo	13OCT2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
44441650	C4591001 4444 44441650	16-55	23SEP2020	97623	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
44441652	C4591001 4444 44441652	16-55	23SEP2020	97805	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
44441654	C4591001 4444 44441654	16-55	23SEP2020	97633	Placebo	23SEP2020/ Placebo	15OCT2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
44441658	C4591001 4444 44441658	16-55	23SEP2020	97654	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
44441659	C4591001 4444 44441659	16-55	23SEP2020	97630	Placebo	23SEP2020/ Placebo	13OCT2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
44441660	C4591001 4444 44441660	16-55	23SEP2020	97625	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
44441662	C4591001 4444 44441662	16-55	23SEP2020	97632	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
44441663	C4591001 4444 44441663	16-55	23SEP2020	97652	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
44441664	C4591001 4444 44441664	16-55	23SEP2020	97665	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
44441668	C4591001 4444 44441668	16-55	23SEP2020	97649	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44441669	C4591001 4444 44441669	16-55	23SEP2020	97713	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
44441670	C4591001 4444 44441670	16-55	23SEP2020	97657	Placebo	23SEP2020/ Placebo	13OCT2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
44441672	C4591001 4444 44441672	16-55	23SEP2020	97686	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44441673	C4591001 4444 44441673	16-55	23SEP2020	97672	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44441675	C4591001 4444 44441675	16-55	23SEP2020	97662	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
44441676	C4591001 4444 44441676	16-55	23SEP2020	97693	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
44441677	C4591001 4444 44441677	16-55	23SEP2020	97690	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
44441678	C4591001 4444 44441678	16-55	23SEP2020	97718	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
44441679	C4591001 4444 44441679	16-55	23SEP2020	97720	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44441680	C4591001 4444 44441680	16-55	23SEP2020	97692	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44441681	C4591001 4444 44441681	16-55	23SEP2020	97671	Placebo	23SEP2020/ Placebo	13OCT2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
44441682	C4591001 4444 44441682	16-55	23SEP2020	97732	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
44441683	C4591001 4444 44441683	16-55	23SEP2020	97717	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
44441685	C4591001 4444 44441685	16-55	23SEP2020	97730	Placebo	23SEP2020/ Placebo	15OCT2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
44441686	C4591001 4444 44441686	16-55	23SEP2020	97726	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
44441688	C4591001 4444 44441688	16-55	23SEP2020	97731	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
44441694	C4591001 4444 44441694	16-55	23SEP2020	97807	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
44441695	C4591001 4444 44441695	16-55	23SEP2020	98038	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
44441696	C4591001 4444 44441696	16-55	23SEP2020	97935	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
44441699	C4591001 4444 44441699	16-55	23SEP2020	97945	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
44441700	C4591001 4444 44441700	16-55	23SEP2020	97926	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44441705	C4591001 4444 44441705	16-55	23SEP2020	97816	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
44441707	C4591001 4444 44441707	16-55	23SEP2020	97813	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44441710	C4591001 4444 44441710	16-55	23SEP2020	97929	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo		
44441711	C4591001 4444 44441711	16-55	23SEP2020	97940	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
44441712	C4591001 4444 44441712	16-55	23SEP2020	97937	Placebo	23SEP2020/ Placebo	13OCT2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
44441715	C4591001 4444 44441715	16-55	23SEP2020	97949	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
44441716	C4591001 4444 44441716	16-55	23SEP2020	98043	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
44441717	C4591001 4444 44441717	16-55	23SEP2020	97927	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
44441719	C4591001 4444 44441719	16-55	23SEP2020	97958	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
44441721	C4591001 4444 44441721	16-55	23SEP2020	97952	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44441722	C4591001 4444 44441722	16-55	23SEP2020	97948	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
44441724	C4591001 4444 44441724	16-55	23SEP2020	97953	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44441725	C4591001 4444 44441725	16-55	23SEP2020	98044	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
44441726	C4591001 4444 44441726	16-55	23SEP2020	98045	Placebo	23SEP2020/ Placebo	12OCT2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
44441728	C4591001 4444 44441728	16-55	23SEP2020	98035	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
44441729	C4591001 4444 44441729	16-55	23SEP2020	98094	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
44441731	C4591001 4444 44441731	16-55	23SEP2020	98050	Placebo	23SEP2020/ Placebo	13OCT2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
44441733	C4591001 4444 44441733	16-55	23SEP2020	98048	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44441735	C4591001 4444 44441735	16-55	23SEP2020	98095	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
44441738	C4591001 4444 44441738	16-55	23SEP2020	98099	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
44441739	C4591001 4444 44441739	16-55	23SEP2020	98049	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44441741	C4591001 4444 44441741	16-55	23SEP2020	98138	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
44441744	C4591001 4444 44441744	16-55	23SEP2020	98102	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
44441745	C4591001 4444 44441745	16-55	23SEP2020	98167	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
44441746	C4591001 4444 44441746	16-55	23SEP2020	98255	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44441747	C4591001 4444 44441747	16-55	23SEP2020	98201	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
44441748	C4591001 4444 44441748	16-55	23SEP2020	98137	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
44441750	C4591001 4444 44441750	16-55	23SEP2020	98258	Placebo	23SEP2020/ Placebo	13OCT2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
44441751	C4591001 4444 44441751	16-55	23SEP2020	98171	Placebo	23SEP2020/ Placebo	15OCT2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
44441752	C4591001 4444 44441752	16-55	23SEP2020	98139	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
44441753	C4591001 4444 44441753	16-55	23SEP2020	98208	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
44441754	C4591001 4444 44441754	16-55	23SEP2020	98133	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44441755	C4591001 4444 44441755	16-55	23SEP2020	98174	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44441756	C4591001 4444 44441756	16-55	23SEP2020	98169	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
44441758	C4591001 4444 44441758	16-55	23SEP2020	98274	Placebo	23SEP2020/ Placebo	13OCT2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
44441760	C4591001 4444 44441760	16-55	23SEP2020	98260	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44441761	C4591001 4444 44441761	16-55	23SEP2020	98202	Placebo	23SEP2020/ Placebo	16OCT2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
44441763	C4591001 4444 44441763	16-55	23SEP2020	98212	Placebo	23SEP2020/ Placebo	13OCT2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
44441764	C4591001 4444 44441764	16-55	23SEP2020	98327	Placebo	23SEP2020/ Placebo	13OCT2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
44441765	C4591001 4444 44441765	16-55	23SEP2020	98259	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
44441766	C4591001 4444 44441766	16-55	23SEP2020	98280	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
44441767	C4591001 4444 44441767	16-55	23SEP2020	98284	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44441768	C4591001 4444 44441768	16-55	23SEP2020	98323	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo		
44441769	C4591001 4444 44441769	16-55	23SEP2020	98283	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44441770	C4591001 4444 44441770	16-55	23SEP2020	98338	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
44441771	C4591001 4444 44441771	16-55	23SEP2020	98369	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
44441772	C4591001 4444 44441772	16-55	23SEP2020	98360	Placebo	23SEP2020/ Placebo	15OCT2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
44441773	C4591001 4444 44441773	16-55	23SEP2020	98336	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
44441776	C4591001 4444 44441776	16-55	23SEP2020	98325	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
44441777	C4591001 4444 44441777	16-55	23SEP2020	98370	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44441778	C4591001 4444 44441778	16-55	23SEP2020	98332	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)		
44441779	C4591001 4444 44441779	16-55	23SEP2020	98356	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44441780	C4591001 4444 44441780	16-55	23SEP2020	98334	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
44441781	C4591001 4444 44441781	16-55	23SEP2020	98340	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo		
44441782	C4591001 4444 44441782	16-55	23SEP2020	98346	Placebo	23SEP2020/ Placebo	15OCT2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
44441783	C4591001 4444 44441783	16-55	23SEP2020	98362	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
44441784	C4591001 4444 44441784	16-55	23SEP2020	98355	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
44441785	C4591001 4444 44441785	16-55	23SEP2020	98345	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44441786	C4591001 4444 44441786	16-55	23SEP2020	98386	Placebo	23SEP2020/ Placebo	12OCT2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
44441788	C4591001 4444 44441788	16-55	23SEP2020	98358	Placebo	23SEP2020/ Placebo	13OCT2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
44441789	C4591001 4444 44441789	16-55	23SEP2020	98379	Placebo	23SEP2020/ Placebo	22OCT2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
44441791	C4591001 4444 44441791	16-55	23SEP2020	98367	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44441793	C4591001 4444 44441793	16-55	23SEP2020	98380	Placebo	23SEP2020/ Placebo	12OCT2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
44441795	C4591001 4444 44441795	16-55	23SEP2020	98387	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44441796	C4591001 4444 44441796	16-55	23SEP2020	98389	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
44441797	C4591001 4444 44441797	16-55	25SEP2020	99269	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
44441798	C4591001 4444 44441798	16-55	25SEP2020	99271	Placebo	25SEP2020/ Placebo	15OCT2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
44441799	C4591001 4444 44441799	16-55	25SEP2020	98392	Placebo	25SEP2020/ Placebo	14OCT2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
44441800	C4591001 4444 44441800	16-55	25SEP2020	99273	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
44441801	C4591001 4444 44441801	16-55	25SEP2020	99357	Placebo	25SEP2020/ Placebo	14OCT2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
44441804	C4591001 4444 44441804	16-55	25SEP2020	99278	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
44441805	C4591001 4444 44441805	16-55	25SEP2020	99324	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
44441806	C4591001 4444 44441806	16-55	25SEP2020	99318	Placebo	25SEP2020/ Placebo	15OCT2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
44441807	C4591001 4444 44441807	16-55	25SEP2020	99320	Placebo	25SEP2020/ Placebo	15OCT2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
44441808	C4591001 4444 44441808	16-55	25SEP2020	99340	Placebo	25SEP2020/ Placebo	15OCT2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
44441810	C4591001 4444 44441810	16-55	25SEP2020	99334	Placebo	25SEP2020/ Placebo	15OCT2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
44441815	C4591001 4444 44441815	16-55	25SEP2020	99345	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
44441817	C4591001 4444 44441817	16-55	25SEP2020	99341	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
44441818	C4591001 4444 44441818	16-55	25SEP2020	99322	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)			
44441819	C4591001 4444 44441819	16-55	25SEP2020	99361	Placebo	25SEP2020/ Placebo	15OCT2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
44441823	C4591001 4444 44441823	16-55	25SEP2020	99333	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
44441824	C4591001 4444 44441824	16-55	25SEP2020	99330	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44441825	C4591001 4444 44441825	16-55	25SEP2020	99369	Placebo	25SEP2020/ Placebo	29OCT2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
44441826	C4591001 4444 44441826	16-55	25SEP2020	99372	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44441827	C4591001 4444 44441827	16-55	25SEP2020	99362	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44441828	C4591001 4444 44441828	16-55	25SEP2020	99342	Placebo	25SEP2020/ Placebo	15OCT2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
44441830	C4591001 4444 44441830	16-55	25SEP2020	99348	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
44441832	C4591001 4444 44441832	16-55	25SEP2020	99356	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)		
44441833	C4591001 4444 44441833	16-55	25SEP2020	99368	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
44441835	C4591001 4444 44441835	16-55	25SEP2020	99371	Placebo	25SEP2020/ Placebo	15OCT2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
44441837	C4591001 4444 44441837	16-55	25SEP2020	99387	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
44441839	C4591001 4444 44441839	16-55	25SEP2020	99383	Placebo	25SEP2020/ Placebo	14OCT2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
44441840	C4591001 4444 44441840	16-55	25SEP2020	99381	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
44441841	C4591001 4444 44441841	16-55	25SEP2020	99402	Placebo	25SEP2020/ Placebo	14OCT2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
44441842	C4591001 4444 44441842	16-55	25SEP2020	99388	Placebo	25SEP2020/ Placebo	14OCT2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
44441843	C4591001 4444 44441843	16-55	25SEP2020	99413	Placebo	25SEP2020/ Placebo	15OCT2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
44441849	C4591001 4444 44441849	16-55	25SEP2020	99409	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
44441850	C4591001 4444 44441850	16-55	25SEP2020	99408	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
44441851	C4591001 4444 44441851	16-55	25SEP2020	99417	Placebo	25SEP2020/ Placebo	15OCT2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
44441852	C4591001 4444 44441852	16-55	25SEP2020	99411	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
44441854	C4591001 4444 44441854	16-55	25SEP2020	99486	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
44441855	C4591001 4444 44441855†	16-55	25SEP2020	99488	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44441857	C4591001 4444 44441857	16-55	25SEP2020	99525	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44441859	C4591001 4444 44441859	16-55	25SEP2020	99446	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
44441860	C4591001 4444 44441860	16-55	25SEP2020	99437	Placebo	25SEP2020/ Placebo	06NOV2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
44441861	C4591001 4444 44441861	16-55	25SEP2020	99440	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
44441862	C4591001 4444 44441862	16-55	25SEP2020	99445	Placebo	25SEP2020/ Placebo	15OCT2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
44441863	C4591001 4444 44441863	16-55	25SEP2020	99422	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44441864	C4591001 4444 44441864	16-55	25SEP2020	99415	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
44441868	C4591001 4444 44441868	16-55	25SEP2020	99539	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
44441870	C4591001 4444 44441870	16-55	25SEP2020	99522	Placebo	25SEP2020/ Placebo	14OCT2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
44441871	C4591001 4444 44441871	16-55	25SEP2020	99491	Placebo	25SEP2020/ Placebo	14OCT2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
44441872	C4591001 4444 44441872	16-55	25SEP2020	99492	Placebo	25SEP2020/ Placebo	14OCT2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
44441874	C4591001 4444 44441874	16-55	25SEP2020	99527	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44441875	C4591001 4444 44441875	16-55	25SEP2020	99541	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
44441877	C4591001 4444 44441877	16-55	25SEP2020	99537	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
44441878	C4591001 4444 44441878	16-55	25SEP2020	99528	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
44441881	C4591001 4444 44441881	16-55	25SEP2020	99597	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44441883	C4591001 4444 44441883	16-55	25SEP2020	99543	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
44441885	C4591001 4444 44441885	16-55	25SEP2020	99596	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
44441886	C4591001 4444 44441886	16-55	25SEP2020	99607	Placebo	25SEP2020/ Placebo	15OCT2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
44441887	C4591001 4444 44441887†	16-55	25SEP2020	99797	Placebo	25SEP2020/ Placebo	14OCT2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
44441888	C4591001 4444 44441888	16-55	25SEP2020	99593	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
44441889	C4591001 4444 44441889	16-55	25SEP2020	99605	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44441891	C4591001 4444 44441891	16-55	25SEP2020	99612	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
44441893	C4591001 4444 44441893	16-55	25SEP2020	99603	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
44441895	C4591001 4444 44441895	16-55	25SEP2020	99614	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
44441896	C4591001 4444 44441896	16-55	25SEP2020	99642	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
44441898	C4591001 4444 44441898	16-55	25SEP2020	99651	Placebo	25SEP2020/ Placebo	14OCT2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
44441900	C4591001 4444 44441900	16-55	25SEP2020	99693	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
44441903	C4591001 4444 44441903	16-55	25SEP2020	99641	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
44441904	C4591001 4444 44441904	16-55	25SEP2020	99643	Placebo	25SEP2020/ Placebo	14OCT2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
44441907	C4591001 4444 44441907	16-55	25SEP2020	99689	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44441909	C4591001 4444 44441909	16-55	25SEP2020	99740	Placebo	25SEP2020/ Placebo	14OCT2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
44441910	C4591001 4444 44441910	16-55	25SEP2020	99739	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
44441912	C4591001 4444 44441912	16-55	25SEP2020	99691	Placebo	25SEP2020/ Placebo	13OCT2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
44441913	C4591001 4444 44441913	16-55	25SEP2020	99690	Placebo	25SEP2020/ Placebo	15OCT2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
44441915	C4591001 4444 44441915	16-55	25SEP2020	99744	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44441916	C4591001 4444 44441916	16-55	25SEP2020	99742	Placebo	25SEP2020/ Placebo	14OCT2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
44441917	C4591001 4444 44441917	16-55	25SEP2020	99761	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44441918	C4591001 4444 44441918	16-55	25SEP2020	99762	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	13FEB2021/ BNT162b2 (30 µg)
44441921	C4591001 4444 44441921	16-55	25SEP2020	99802	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44441923	C4591001 4444 44441923	16-55	25SEP2020	99808	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
44441924	C4591001 4444 44441924	16-55	25SEP2020	99769	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44441925	C4591001 4444 44441925	16-55	25SEP2020	99787	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
44441928	C4591001 4444 44441928	16-55	25SEP2020	99771	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo		
44441929	C4591001 4444 44441929	16-55	25SEP2020	99833	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
44441931	C4591001 4444 44441931	16-55	25SEP2020	99827	Placebo	25SEP2020/ Placebo			
44441933	C4591001 4444 44441933	16-55	25SEP2020	99843	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
44441934	C4591001 4444 44441934	16-55	25SEP2020	99826	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
44441935	C4591001 4444 44441935	16-55	25SEP2020	99804	Placebo	25SEP2020/ Placebo	14OCT2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
44441937	C4591001 4444 44441937	16-55	25SEP2020	99821	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44441938	C4591001 4444 44441938	16-55	25SEP2020	99831	Placebo	25SEP2020/ Placebo	13OCT2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
44441939	C4591001 4444 44441939	16-55	25SEP2020	99837	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
44441940	C4591001 4444 44441940	16-55	25SEP2020	99883	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
44441945	C4591001 4444 44441945	16-55	25SEP2020	99884	Placebo	25SEP2020/ Placebo	14OCT2020/ Placebo		
44441946	C4591001 4444 44441946	16-55	25SEP2020	99836	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
44441949	C4591001 4444 44441949	16-55	25SEP2020	100191	Placebo	25SEP2020/ Placebo	14OCT2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
44441950	C4591001 4444 44441950	16-55	25SEP2020	99881	Placebo	25SEP2020/ Placebo	15OCT2020/ Placebo		
44441951	C4591001 4444 44441951	16-55	25SEP2020	99886	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)			
44441952	C4591001 4444 44441952	16-55	25SEP2020	100047	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44441953	C4591001 4444 44441953	16-55	25SEP2020	100041	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44441954	C4591001 4444 44441954	16-55	25SEP2020	100039	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
44441955	C4591001 4444 44441955	16-55	25SEP2020	100045	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
44441956	C4591001 4444 44441956	16-55	25SEP2020	100092	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
44441957	C4591001 4444 44441957	16-55	25SEP2020	100111	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44441958	C4591001 4444 44441958	16-55	25SEP2020	100053	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
44441959	C4591001 4444 44441959	16-55	25SEP2020	100055	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
44441961	C4591001 4444 44441961	16-55	25SEP2020	100057	Placebo	25SEP2020/ Placebo	15OCT2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
44441962	C4591001 4444 44441962	16-55	25SEP2020	100115	Placebo	25SEP2020/ Placebo	15OCT2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
44441963	C4591001 4444 44441963	16-55	25SEP2020	100091	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
44441964	C4591001 4444 44441964	16-55	25SEP2020	100095	Placebo	25SEP2020/ Placebo	29OCT2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
44441965	C4591001 4444 44441965	16-55	25SEP2020	100166	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
44441966	C4591001 4444 44441966	16-55	25SEP2020	100056	Placebo	25SEP2020/ Placebo	15OCT2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
44441967	C4591001 4444 44441967	16-55	25SEP2020	100159	Placebo	25SEP2020/ Placebo	14OCT2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
44441969	C4591001 4444 44441969	16-55	25SEP2020	100246	Placebo	25SEP2020/ Placebo	14OCT2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
44441970	C4591001 4444 44441970	16-55	25SEP2020	100094	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
44441971	C4591001 4444 44441971	16-55	25SEP2020	100112	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44441972	C4591001 4444 44441972	16-55	25SEP2020	100202	Placebo	25SEP2020/ Placebo	14OCT2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
44441973	C4591001 4444 44441973	16-55	25SEP2020	100158	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)		
44441974	C4591001 4444 44441974	16-55	25SEP2020	100120	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
44441975	C4591001 4444 44441975	16-55	25SEP2020	100194	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
44441976	C4591001 4444 44441976	16-55	25SEP2020	100193	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
44441977	C4591001 4444 44441977	16-55	25SEP2020	100181	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
44441979	C4591001 4444 44441979	16-55	25SEP2020	100195	Placebo	25SEP2020/ Placebo			
44441980	C4591001 4444 44441980	16-55	25SEP2020	100182	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
44441982	C4591001 4444 44441982	16-55	25SEP2020	100209	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
44441983	C4591001 4444 44441983	16-55	25SEP2020	100163	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
44441984	C4591001 4444 44441984	16-55	25SEP2020	100186	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
44441985	C4591001 4444 44441985	16-55	25SEP2020	100205	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
44441986	C4591001 4444 44441986	16-55	25SEP2020	100208	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
44441988	C4591001 4444 44441988	16-55	25SEP2020	100225	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
44441990	C4591001 4444 44441990	16-55	25SEP2020	100244	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
44441991	C4591001 4444 44441991	16-55	25SEP2020	100248	Placebo	25SEP2020/ Placebo	14OCT2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
44441992	C4591001 4444 44441992	16-55	25SEP2020	100216	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
44441994	C4591001 4444 44441994	16-55	25SEP2020	100218	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
44441995	C4591001 4444 44441995	16-55	25SEP2020	100220	Placebo	25SEP2020/ Placebo	15OCT2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
44441996	C4591001 4444 44441996	16-55	25SEP2020	100228	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44441997	C4591001 4444 44441997	16-55	25SEP2020	100271	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
44442000	C4591001 4444 44442000	16-55	25SEP2020	100275	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
44442001	C4591001 4444 44442001	16-55	25SEP2020	100269	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo		
44442003	C4591001 4444 44442003	16-55	25SEP2020	100276	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
44442004	C4591001 4444 44442004	16-55	25SEP2020	100251	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
44442005	C4591001 4444 44442005	16-55	25SEP2020	100303	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
44442006	C4591001 4444 44442006	16-55	25SEP2020	100304	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44442007	C4591001 4444 44442007	16-55	25SEP2020	100302	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
44442008	C4591001 4444 44442008	16-55	25SEP2020	100347	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
44442009	C4591001 4444 44442009	16-55	25SEP2020	100312	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44442011	C4591001 4444 44442011	16-55	25SEP2020	100341	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44442013	C4591001 4444 44442013	16-55	25SEP2020	100356	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
44442014	C4591001 4444 44442014	16-55	25SEP2020	100350	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
44442015	C4591001 4444 44442015	16-55	25SEP2020	100340	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo		
44442016	C4591001 4444 44442016	16-55	25SEP2020	100360	Placebo	25SEP2020/ Placebo	19OCT2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	13FEB2021/ BNT162b2 (30 µg)
44442018	C4591001 4444 44442018	16-55	25SEP2020	100352	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
44442019	C4591001 4444 44442019	16-55	25SEP2020	100346	Placebo	25SEP2020/ Placebo	14OCT2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
44442021	C4591001 4444 44442021	16-55	25SEP2020	100399	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
44442022	C4591001 4444 44442022	16-55	25SEP2020	100398	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
44442024	C4591001 4444 44442024	16-55	25SEP2020	100388	Placebo	25SEP2020/ Placebo	14OCT2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
44442025	C4591001 4444 44442025	16-55	25SEP2020	100433	Placebo	25SEP2020/ Placebo	14OCT2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
44442026	C4591001 4444 44442026	16-55	25SEP2020	100385	Placebo	25SEP2020/ Placebo	14OCT2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
44442028	C4591001 4444 44442028	16-55	25SEP2020	100389	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44442029	C4591001 4444 44442029	16-55	25SEP2020	100404	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44442030	C4591001 4444 44442030†	16-55	25SEP2020	100448	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)		
44442032	C4591001 4444 44442032	16-55	25SEP2020	100401	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
44442033	C4591001 4444 44442033	16-55	25SEP2020	100392	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
44442034	C4591001 4444 44442034	16-55	25SEP2020	100436	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
44442035	C4591001 4444 44442035	16-55	25SEP2020	100447	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
44442037	C4591001 4444 44442037	16-55	25SEP2020	100472	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
44442039	C4591001 4444 44442039	16-55	25SEP2020	100473	Placebo	25SEP2020/ Placebo	14OCT2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
44442040	C4591001 4444 44442040	16-55	25SEP2020	100443	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
44442041	C4591001 4444 44442041	16-55	25SEP2020	100478	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
44442043	C4591001 4444 44442043	16-55	25SEP2020	100456	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
44442044	C4591001 4444 44442044	16-55	25SEP2020	100441	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
44442045	C4591001 4444 44442045	16-55	25SEP2020	100470	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
44442047	C4591001 4444 44442047	16-55	25SEP2020	100486	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
44442048	C4591001 4444 44442048	16-55	25SEP2020	100485	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44442049	C4591001 4444 44442049	16-55	25SEP2020	100452	Placebo	25SEP2020/ Placebo	15OCT2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
44442050	C4591001 4444 44442050	16-55	25SEP2020	100493	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
44442051	C4591001 4444 44442051	16-55	25SEP2020	100494	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44442052	C4591001 4444 44442052	16-55	25SEP2020	100500	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo		
44442053	C4591001 4444 44442053	16-55	25SEP2020	100489	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
44442054	C4591001 4444 44442054	16-55	25SEP2020	100487	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
44442055	C4591001 4444 44442055	16-55	25SEP2020	100503	Placebo	25SEP2020/ Placebo	14OCT2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	13FEB2021/ BNT162b2 (30 µg)
44442058	C4591001 4444 44442058	16-55	27SEP2020	100641	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
44442059	C4591001 4444 44442059	16-55	27SEP2020	100643	Placebo	27SEP2020/ Placebo	15OCT2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
44442060	C4591001 4444 44442060	16-55	27SEP2020	100649	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
44442062	C4591001 4444 44442062	16-55	27SEP2020	100661	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
44442064	C4591001 4444 44442064	16-55	27SEP2020	100658	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
44442065	C4591001 4444 44442065	16-55	27SEP2020	100647	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
44442068	C4591001 4444 44442068	16-55	27SEP2020	100656	Placebo	27SEP2020/ Placebo	16OCT2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
44442069	C4591001 4444 44442069	16-55	27SEP2020	100670	Placebo	27SEP2020/ Placebo	15OCT2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
44442070	C4591001 4444 44442070	16-55	27SEP2020	100687	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
44442071	C4591001 4444 44442071	16-55	27SEP2020	100655	Placebo	27SEP2020/ Placebo	11NOV2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
44442072	C4591001 4444 44442072	16-55	27SEP2020	100637	Placebo	27SEP2020/ Placebo	15OCT2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
44442073	C4591001 4444 44442073	16-55	27SEP2020	100692	Placebo	27SEP2020/ Placebo	16OCT2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
44442077	C4591001 4444 44442077	16-55	27SEP2020	100665	Placebo	27SEP2020/ Placebo	15OCT2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
44442080	C4591001 4444 44442080	16-55	27SEP2020	100675	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
44442081	C4591001 4444 44442081	16-55	27SEP2020	100681	Placebo	27SEP2020/ Placebo	15OCT2020/ Placebo		
44442084	C4591001 4444 44442084	16-55	27SEP2020	100667	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
44442085	C4591001 4444 44442085	16-55	27SEP2020	100676	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
44442086	C4591001 4444 44442086	16-55	27SEP2020	100703	Placebo	27SEP2020/ Placebo	15OCT2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
44442087	C4591001 4444 44442087	16-55	27SEP2020	100686	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
44442088	C4591001 4444 44442088	16-55	27SEP2020	100701	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
44442090	C4591001 4444 44442090	16-55	27SEP2020	100685	Placebo	27SEP2020/ Placebo	15OCT2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
44442091	C4591001 4444 44442091	16-55	27SEP2020	100680	Placebo	27SEP2020/ Placebo	15OCT2020/ Placebo		
44442093	C4591001 4444 44442093	16-55	27SEP2020	100705	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
44442094	C4591001 4444 44442094	16-55	27SEP2020	100709	Placebo	27SEP2020/ Placebo	16OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
44442095	C4591001 4444 44442095	16-55	27SEP2020	100707	Placebo	27SEP2020/ Placebo	15OCT2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
44442100	C4591001 4444 44442100	16-55	27SEP2020	100760	Placebo	27SEP2020/ Placebo	15OCT2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
44442101	C4591001 4444 44442101	16-55	27SEP2020	100720	Placebo	27SEP2020/ Placebo	15OCT2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
44442102	C4591001 4444 44442102	16-55	27SEP2020	100712	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
44442104	C4591001 4444 44442104	16-55	27SEP2020	100725	Placebo	27SEP2020/ Placebo	16OCT2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
44442105	C4591001 4444 44442105	16-55	27SEP2020	100735	Placebo	27SEP2020/ Placebo	15OCT2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
44442106	C4591001 4444 44442106	16-55	27SEP2020	100710	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
44442107	C4591001 4444 44442107	16-55	27SEP2020	100749	Placebo	27SEP2020/ Placebo			
44442109	C4591001 4444 44442109	16-55	27SEP2020	100733	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
44442113	C4591001 4444 44442113	16-55	27SEP2020	100729	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
44442114	C4591001 4444 44442114	16-55	27SEP2020	100726	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
44442115	C4591001 4444 44442115	16-55	27SEP2020	100737	Placebo	27SEP2020/ Placebo	15OCT2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
44442117	C4591001 4444 44442117	16-55	27SEP2020	100732	Placebo	27SEP2020/ Placebo	15OCT2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
44442118	C4591001 4444 44442118	16-55	27SEP2020	100755	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
44442119	C4591001 4444 44442119	16-55	27SEP2020	100756	Placebo	27SEP2020/ Placebo	15OCT2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
44442122	C4591001 4444 44442122	16-55	27SEP2020	100763	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
44442123	C4591001 4444 44442123	16-55	27SEP2020	100751	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
44442124	C4591001 4444 44442124	16-55	27SEP2020	100738	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
44442129	C4591001 4444 44442129	16-55	27SEP2020	100770	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
44442131	C4591001 4444 44442131	16-55	27SEP2020	100757	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
44442133	C4591001 4444 44442133	16-55	27SEP2020	100764	Placebo	27SEP2020/ Placebo	16OCT2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
44442135	C4591001 4444 44442135	16-55	27SEP2020	100777	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
44442138	C4591001 4444 44442138	16-55	27SEP2020	100785	Placebo	27SEP2020/ Placebo	16OCT2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
44442140	C4591001 4444 44442140	16-55	27SEP2020	100775	Placebo	27SEP2020/ Placebo	15OCT2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
44442142	C4591001 4444 44442142	16-55	27SEP2020	100791	Placebo	27SEP2020/ Placebo	15OCT2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
44442146	C4591001 4444 44442146	16-55	27SEP2020	100825	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
44442147	C4591001 4444 44442147	16-55	27SEP2020	100794	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
44442148	C4591001 4444 44442148	16-55	27SEP2020	100783	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
44442151	C4591001 4444 44442151	16-55	27SEP2020	100801	Placebo	27SEP2020/ Placebo	15OCT2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
44442152	C4591001 4444 44442152	16-55	27SEP2020	100855	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
44442154	C4591001 4444 44442154	16-55	27SEP2020	100788	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
44442155	C4591001 4444 44442155	16-55	27SEP2020	100796	Placebo	27SEP2020/ Placebo	16OCT2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
44442156	C4591001 4444 44442156	16-55	27SEP2020	100809	Placebo	27SEP2020/ Placebo	15OCT2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
44442157	C4591001 4444 44442157	16-55	27SEP2020	100793	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	14NOV2020/ BNT162b2 (30 µg)		
44442158	C4591001 4444 44442158	16-55	27SEP2020	100834	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
44442159	C4591001 4444 44442159	16-55	27SEP2020	100812	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
44442160	C4591001 4444 44442160	16-55	27SEP2020	100823	Placebo	27SEP2020/ Placebo	15OCT2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	
44442161	C4591001 4444 44442161	16-55	27SEP2020	100829	Placebo	27SEP2020/ Placebo	15OCT2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
44442162	C4591001 4444 44442162	16-55	27SEP2020	100832	Placebo	27SEP2020/ Placebo	15OCT2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
44442163	C4591001 4444 44442163	16-55	27SEP2020	100827	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
44442165	C4591001 4444 44442165	16-55	27SEP2020	100826	Placebo	27SEP2020/ Placebo	15OCT2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
44442167	C4591001 4444 44442167	16-55	27SEP2020	100839	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
44442168	C4591001 4444 44442168	16-55	27SEP2020	100814	Placebo	27SEP2020/ Placebo	15OCT2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
44442170	C4591001 4444 44442170	16-55	27SEP2020	100852	Placebo	27SEP2020/ Placebo	15OCT2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
44442171	C4591001 4444 44442171	16-55	27SEP2020	100816	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
44442172	C4591001 4444 44442172	16-55	27SEP2020	100843	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
44442173	C4591001 4444 44442173	16-55	27SEP2020	100850	Placebo	27SEP2020/ Placebo	16OCT2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
44442174	C4591001 4444 44442174	16-55	27SEP2020	100844	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
44442177	C4591001 4444 44442177	16-55	27SEP2020	100860	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
44442180	C4591001 4444 44442180	16-55	27SEP2020	100859	Placebo	27SEP2020/ Placebo	16OCT2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
44442181	C4591001 4444 44442181	16-55	27SEP2020	100864	Placebo	27SEP2020/ Placebo	16OCT2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
44442182	C4591001 4444 44442182	16-55	27SEP2020	100869	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
44442186	C4591001 4444 44442186	16-55	27SEP2020	100868	Placebo	27SEP2020/ Placebo	16OCT2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
44442188	C4591001 4444 44442188	16-55	27SEP2020	100867	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
44442189	C4591001 4444 44442189	16-55	27SEP2020	100872	Placebo	27SEP2020/ Placebo	16OCT2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
44442190	C4591001 4444 44442190	16-55	27SEP2020	100893	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
44442193	C4591001 4444 44442193	16-55	27SEP2020	100890	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
44442194	C4591001 4444 44442194	16-55	27SEP2020	100881	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)			
44442195	C4591001 4444 44442195	16-55	27SEP2020	100879	Placebo	27SEP2020/ Placebo	16OCT2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
44442196	C4591001 4444 44442196	16-55	27SEP2020	100889	Placebo	27SEP2020/ Placebo	15OCT2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
44442197	C4591001 4444 44442197	16-55	27SEP2020	100915	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
44442198	C4591001 4444 44442198	16-55	27SEP2020	100907	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)		
44442199	C4591001 4444 44442199	16-55	27SEP2020	100883	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
44442200	C4591001 4444 44442200	16-55	27SEP2020	100901	Placebo	27SEP2020/ Placebo	16OCT2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
44442201	C4591001 4444 44442201	16-55	27SEP2020	100885	Placebo	27SEP2020/ Placebo	16OCT2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
44442202	C4591001 4444 44442202	16-55	27SEP2020	100912	Placebo	27SEP2020/ Placebo	22OCT2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
44442203	C4591001 4444 44442203	16-55	27SEP2020	100904	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
44442205	C4591001 4444 44442205	16-55	27SEP2020	100891	Placebo	27SEP2020/ Placebo	15OCT2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
44442209	C4591001 4444 44442209	16-55	27SEP2020	100919	Placebo	27SEP2020/ Placebo	16OCT2020/ Placebo		
44442210	C4591001 4444 44442210	16-55	27SEP2020	100920	Placebo	27SEP2020/ Placebo	16OCT2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
44442211	C4591001 4444 44442211	16-55	27SEP2020	100922	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
44442212	C4591001 4444 44442212	16-55	27SEP2020	100945	Placebo	27SEP2020/ Placebo	15OCT2020/ Placebo		
44442214	C4591001 4444 44442214	16-55	27SEP2020	100930	Placebo	27SEP2020/ Placebo	16OCT2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
44442215	C4591001 4444 44442215	16-55	27SEP2020	100949	Placebo	27SEP2020/ Placebo	15OCT2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
44442216	C4591001 4444 44442216	16-55	27SEP2020	100935	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
44442217	C4591001 4444 44442217	16-55	27SEP2020	100932	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
44442218	C4591001 4444 44442218	16-55	27SEP2020	100950	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)		
44442219	C4591001 4444 44442219	16-55	27SEP2020	100947	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
44442220	C4591001 4444 44442220	16-55	27SEP2020	100941	Placebo	27SEP2020/ Placebo	16OCT2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
44442221	C4591001 4444 44442221	16-55	27SEP2020	100979	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
44442222	C4591001 4444 44442222	16-55	27SEP2020	100936	Placebo	27SEP2020/ Placebo	16OCT2020/ Placebo		
44442224	C4591001 4444 44442224	16-55	27SEP2020	100960	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
44442226	C4591001 4444 44442226	16-55	27SEP2020	100986	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
44442227	C4591001 4444 44442227	16-55	27SEP2020	100974	Placebo	27SEP2020/ Placebo	29OCT2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
44442229	C4591001 4444 44442229	16-55	27SEP2020	100959	Placebo	27SEP2020/ Placebo	16OCT2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
44442230	C4591001 4444 44442230	16-55	27SEP2020	100948	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
44442232	C4591001 4444 44442232	16-55	27SEP2020	100978	Placebo	27SEP2020/ Placebo	11NOV2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
44442233	C4591001 4444 44442233	16-55	27SEP2020	100961	Placebo	27SEP2020/ Placebo	15OCT2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
44442234	C4591001 4444 44442234	16-55	27SEP2020	100963	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
44442235	C4591001 4444 44442235	16-55	27SEP2020	100967	Placebo	27SEP2020/ Placebo	16OCT2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
44442236	C4591001 4444 44442236	16-55	27SEP2020	100975	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
44442237	C4591001 4444 44442237	16-55	27SEP2020	100991	Placebo	27SEP2020/ Placebo	15OCT2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
44442238	C4591001 4444 44442238	16-55	27SEP2020	100971	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
44442241	C4591001 4444 44442241	16-55	27SEP2020	101005	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
44442245	C4591001 4444 44442245	16-55	27SEP2020	100985	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
44442248	C4591001 4444 44442248	16-55	27SEP2020	101003	Placebo	27SEP2020/ Placebo	30OCT2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
44442249	C4591001 4444 44442249	16-55	27SEP2020	100994	Placebo	27SEP2020/ Placebo	15OCT2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
44442250	C4591001 4444 44442250	16-55	27SEP2020	100999	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
44442252	C4591001 4444 44442252	16-55	27SEP2020	101025	Placebo	27SEP2020/ Placebo	16OCT2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
44442253	C4591001 4444 44442253	16-55	27SEP2020	101016	Placebo	27SEP2020/ Placebo	15OCT2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
44442254	C4591001 4444 44442254	16-55	27SEP2020	101006	Placebo	27SEP2020/ Placebo	16OCT2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
44442255	C4591001 4444 44442255	16-55	27SEP2020	101011	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
44442256	C4591001 4444 44442256	16-55	27SEP2020	101020	Placebo	27SEP2020/ Placebo	15OCT2020/ Placebo		
44442258	C4591001 4444 44442258	16-55	27SEP2020	101040	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
44442260	C4591001 4444 44442260	16-55	27SEP2020	101035	Placebo	27SEP2020/ Placebo	16OCT2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
44442261	C4591001 4444 44442261	16-55	27SEP2020	101029	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
44442262	C4591001 4444 44442262	16-55	27SEP2020	101017	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
44442263	C4591001 4444 44442263	16-55	27SEP2020	101027	Placebo	27SEP2020/ Placebo			
44442268	C4591001 4444 44442268	16-55	27SEP2020	101023	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
44442269	C4591001 4444 44442269	16-55	27SEP2020	101044	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	14NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
44442270	C4591001 4444 44442270	16-55	27SEP2020	101062	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
44442273	C4591001 4444 44442273	16-55	27SEP2020	101052	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
44442274	C4591001 4444 44442274	16-55	27SEP2020	101033	Placebo	27SEP2020/ Placebo	11NOV2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
44442275	C4591001 4444 44442275	16-55	27SEP2020	101066	Placebo	27SEP2020/ Placebo	16OCT2020/ Placebo		
44442277	C4591001 4444 44442277	16-55	27SEP2020	101055	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
44442278	C4591001 4444 44442278	16-55	27SEP2020	101061	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
44442279	C4591001 4444 44442279	16-55	27SEP2020	101053	Placebo	27SEP2020/ Placebo	15OCT2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
44442280	C4591001 4444 44442280	16-55	27SEP2020	101063	Placebo	27SEP2020/ Placebo	16OCT2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
44442281	C4591001 4444 44442281	16-55	27SEP2020	101056	Placebo	27SEP2020/ Placebo	15OCT2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
44442283	C4591001 4444 44442283	16-55	27SEP2020	101078	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
44442284	C4591001 4444 44442284	16-55	27SEP2020	101074	Placebo	27SEP2020/ Placebo	15OCT2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
44442285	C4591001 4444 44442285	16-55	27SEP2020	101075	Placebo	27SEP2020/ Placebo	15OCT2020/ Placebo		
44442286	C4591001 4444 44442286	16-55	27SEP2020	101076	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
44442287	C4591001 4444 44442287	16-55	27SEP2020	101118	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
44442288	C4591001 4444 44442288	16-55	27SEP2020	101081	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
44442291	C4591001 4444 44442291	16-55	27SEP2020	101083	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)		
44442292	C4591001 4444 44442292	16-55	27SEP2020	101121	Placebo	27SEP2020/ Placebo	15OCT2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
44442293	C4591001 4444 44442293	16-55	27SEP2020	101090	Placebo	27SEP2020/ Placebo			
44442294	C4591001 4444 44442294	16-55	27SEP2020	101085	Placebo	27SEP2020/ Placebo	15OCT2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
44442297	C4591001 4444 44442297	16-55	27SEP2020	101100	Placebo	27SEP2020/ Placebo	15OCT2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
44442298	C4591001 4444 44442298	16-55	27SEP2020	101094	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
44442299	C4591001 4444 44442299	16-55	27SEP2020	101095	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
44442300	C4591001 4444 44442300	16-55	27SEP2020	101105	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
44442301	C4591001 4444 44442301	16-55	27SEP2020	101107	Placebo	27SEP2020/ Placebo	15OCT2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
44442303	C4591001 4444 44442303	16-55	27SEP2020	101128	Placebo	27SEP2020/ Placebo	15OCT2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
44442304	C4591001 4444 44442304	16-55	27SEP2020	101104	Placebo	27SEP2020/ Placebo	15OCT2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
44442305	C4591001 4444 44442305	16-55	27SEP2020	101113	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
44442306	C4591001 4444 44442306	16-55	27SEP2020	101141	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
44442307	C4591001 4444 44442307	16-55	27SEP2020	101133	Placebo	27SEP2020/ Placebo	15OCT2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
44442308	C4591001 4444 44442308	16-55	27SEP2020	101111	Placebo	27SEP2020/ Placebo	15OCT2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
44442310	C4591001 4444 44442310	16-55	27SEP2020	101160	Placebo	27SEP2020/ Placebo	15OCT2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
44442311	C4591001 4444 44442311	16-55	27SEP2020	101123	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)		
44442312	C4591001 4444 44442312	16-55	27SEP2020	101131	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
44442313	C4591001 4444 44442313	16-55	27SEP2020	101130	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
44442314	C4591001 4444 44442314	16-55	27SEP2020	101155	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
44442315	C4591001 4444 44442315	16-55	27SEP2020	101147	Placebo	27SEP2020/ Placebo	15OCT2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
44442317	C4591001 4444 44442317	16-55	27SEP2020	101154	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
44442318	C4591001 4444 44442318	16-55	27SEP2020	101139	Placebo	27SEP2020/ Placebo	16OCT2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
44442319	C4591001 4444 44442319	16-55	27SEP2020	101142	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)			
44442321	C4591001 4444 44442321	16-55	27SEP2020	101152	Placebo	27SEP2020/ Placebo	16OCT2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
44442322	C4591001 4444 44442322	16-55	27SEP2020	101161	Placebo	27SEP2020/ Placebo	15OCT2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	

Note: † = Human immunodeficiency virus (HIV)-positive subject.  
a. Subject Study Identifier = the current study 4-digit site number followed by the unique 4-digit subject identifier.  
PFIZER CONFIDENTIAL SDTM Creation: 25MAR2021 (23:24) Source Data: adsl Table Generation: 29MAR2021 (23:11)  
(Cutoff Date: 13MAR2021, Snapshot Date: 25MAR2021) Output File: ./nda2\_unblinded/C4591001\_EUA\_1655/adsl\_1003\_1655